PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hoskins, EE; Gunawardena, RW; Habash, KB; Wise-Draper, TM; Jansen, M; Knudsen, ES; Wells, SI				Hoskins, E. E.; Gunawardena, R. W.; Habash, K. B.; Wise-Draper, T. M.; Jansen, M.; Knudsen, E. S.; Wells, S. I.			Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway	ONCOGENE			English	Article						Fanconi anemia; Rb protein family; E2F; transcription	CERVICAL-CARCINOMA CELLS; HUMAN-PAPILLOMAVIRUS E7; OVARIAN-CANCER; DNA-REPLICATION; POCKET PROTEINS; MESSENGER-RNA; FA PATHWAY; IN-VIVO; BRCA1; TUMOR	Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and neck, anogenital region and skin. Thirteen complementation groups and the corresponding FA genes have been identified, and their protein products assemble into nuclear core complexes during DNA-damage responses. Much progress has been made in our understanding of post-translational FA protein modi. cations and physical interactions. By contrast, little is known about the control of protein availability at the level of transcription. We report here that multiple FA proteins were downregulated during the proliferative arrest of primary human keratinocytes and HeLa cells, and that the observed regulation was at a transcriptional level. Proliferative stimuli such as expression of HPV16 E7 as well as E2F1 overexpression in primary cells resulted in coordinate FA upregulation. To de. ne the underlying mechanism, we examined the endogenous FANCD2 promoter, and detected regulated binding of members of the E2F/Rb family in chromatin immunoprecipitation assays. Finally, a 1 kb promoter fragment was sufficient to confer E2F/Rb regulation in reporter assays. Taken together, our data demonstrate FA gene co-regulation in synchrony with the cell cycle and suggest that deregulated expression of individual FA genes-in addition to FA gene mutation-may promote FA-related human cancer.	[Hoskins, E. E.; Habash, K. B.; Wise-Draper, T. M.; Wells, S. I.] Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Gunawardena, R. W.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Jansen, M.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Jefferson University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wells, SI (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, 3333 Burnet Ave,TCHRF Room S7-206, Cincinnati, OH 45229 USA.	Susanne.Wells@cchmc.org		Wise-Draper, Trisha/0000-0002-7279-4028	NATIONAL CANCER INSTITUTE [R01CA116316, R01CA104213, R01CA102357] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116316-01A1, R01 CA102357-01A1, CA104213, R01 CA102357, R01 CA116316, CA102357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chang YJE, 2002, J VIROL, V76, P8864, DOI 10.1128/JVI.76.17.8864-8874.2002; Chen CC, 2007, J MOL MED, V85, P497, DOI 10.1007/s00109-006-0153-2; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dhillon VS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-33; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Gurtan AM, 2006, DNA REPAIR, V5, P1119, DOI 10.1016/j.dnarep.2006.05.009; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kobayashi Teruaki, 1994, Journal of Dermatological Science, V8, P171, DOI 10.1016/0923-1811(94)90050-7; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leveille F, 2006, DNA REPAIR, V5, P556, DOI 10.1016/j.dnarep.2006.01.005; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meijer GA, 2007, CELL ONCOL, V29, P181; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Pejovic T, 2006, CANCER RES, V66, P9017, DOI 10.1158/0008-5472.CAN-06-0222; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Tategu M, 2007, GENE REGUL SYST BIO, V1, P1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942	59	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4798	4808		10.1038/onc.2008.121	http://dx.doi.org/10.1038/onc.2008.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438432	Green Accepted			2022-12-25	WOS:000258445100005
J	Hintzen, C; Evers, C; Lippok, BE; Volkmer, R; Heinrich, PC; Radtke, S; Hermanns, HM				Hintzen, Christoph; Evers, Christina; Lippok, Barbara E.; Volkmer, Rudolf; Heinrich, Peter C.; Radtke, Simone; Hermanns, Heike M.			Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; TYROSINE KINASE; GROWTH-FACTOR; DIFFERENTIAL ACTIVATION; GENE-EXPRESSION; PATHWAY; PROTEIN; JAK2	Human and murine oncostatin M (OSM) induce their bioactivities through a heterodimeric receptor complex consisting of gp130 and the OSM receptor (OSMR), which initiates a signaling pathway involving Janus kinases (JAKs) and transcription factors of the signal transducers and activators of transcription (STAT) family. In contrast to the signal transducing receptor subunit gp130, the OSMR allows strong activation of STAT5B. The underlying molecular mechanism, however, remained unclear. Here we demonstrate that the human and murine OSM receptors use distinct mechanisms for STAT5B activation. The human receptor contains a STAT5B recruiting tyrosine motif (Tyr(837)/Tyr(839)) C-terminal to the box 1/2 region, which is absent in the mouse receptor. In contrast, the murine receptor initiates STAT5 activation directly via the receptor bound Janus kinases. Intriguingly, the murine receptor preferentially recruits JAK2, whereas the human receptor seems to have a higher affinity for JAK1. We identify a single amino acid (Phe(820)) in the human receptor that is responsible for this preference. Exchange by the murine counterpart (Cys(815)) allows recruitment of JAK2 by the human receptor and consequently activation of STAT5B independently of receptor tyrosine motifs. STAT5B interacts directly with JAK2 only in response to activation of the murine OSMR or the mutated human OSMR. Additionally, we show that OSM-induced STAT1 phosphorylation occurs independently of receptor tyrosine motifs and is mediated directly by Janus kinases, whereas the two C-terminally located tyrosine residues Tyr(917)/Tyr(945) of the OSMR are crucial for STAT3 activation.	[Hintzen, Christoph; Evers, Christina; Lippok, Barbara E.; Heinrich, Peter C.; Radtke, Simone; Hermanns, Heike M.] Univ Klinikum RWTH Aachen, Inst Biochem, D-52074 Aachen, Germany; [Volkmer, Rudolf] Humboldt Univ, Inst Med Immunol, Univ Klinikum Charite, D-10117 Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hermanns, HM (corresponding author), Univ Wurzburg, Rudolf Virchow Zentrum, Versbacher Str 9, D-97080 Wurzburg, Germany.	heike.hermanns@virchow.uni-wuerzburg.de		Volkmer, Rudolf/0000-0003-4710-1143				Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Bonifati C, 1998, ARCH DERMATOL RES, V290, P9, DOI 10.1007/s004030050269; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Cross A, 2004, ARTHRITIS RHEUM-US, V50, P1430, DOI 10.1002/art.20166; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Derouet D, 2004, P NATL ACAD SCI USA, V101, P4827, DOI 10.1073/pnas.0306178101; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gatsios P, 1996, EUR J BIOCHEM, V241, P56, DOI 10.1111/j.1432-1033.1996.0056t.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan S, 2005, CELL SIGNAL, V17, P1542, DOI 10.1016/j.cellsig.2005.03.010; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hui W, 2005, ARTHRITIS RES THER, V7, pR57, DOI 10.1186/ar1460; Ichihara M, 1997, BLOOD, V90, P165; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002-9440(10)64634-2; Li WQ, 1998, J IMMUNOL, V161, P5000; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stevenson NJ, 2004, J IMMUNOL, V173, P3243, DOI 10.4049/jimmunol.173.5.3243; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200	54	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19465	19477		10.1074/jbc.M710157200	http://dx.doi.org/10.1074/jbc.M710157200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18430728	hybrid			2022-12-25	WOS:000257387600033
J	Komiya, Y; Kurabe, N; Katagiri, K; Ogawa, M; Sugiyama, A; Kawasaki, Y; Tashiro, F				Komiya, Yuko; Kurabe, Nobuya; Katagiri, Kumiko; Ogawa, Makiko; Sugiyama, Akinori; Kawasaki, Yasushi; Tashiro, Fumio			A novel binding factor of 14-3-3 beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; PROTEIN; CANCER; PHOSPHORYLATION; MECHANISMS; EXPRESSION; TUMOR; GENE; METALLOPROTEINASES; DIFFERENTIATION	The 14-3-3 proteins form a highly conserved family of dimeric proteins that interact with various signal transduction proteins and regulate cell cycle, apoptosis, stress response, and malignant transformation. We previously demonstrated that the beta isoform of 14-3-3 proteins promotes tumorigenicity and angiogenesis of rat hepatoma K2 cells. In this study, to analyze the mechanism of 14-3-3 beta-induced malignant transformation, yeast two-hybrid screening was performed, and a novel 14-33 beta-binding factor, FBI1 (fourteen-three-three beta interactant 1), was identified. In vitro binding and co-immunoprecipitation analyses verified specific interaction of 14-3-3 beta with FBI1. The strong expression of FBI1 was observed in several tumor cell lines but not in non-tumor cell lines. Forced expression of antisense FBI1 in K2 cells inhibited anchorage-independent growth but had no significant effect on cell proliferation in monolayer culture. Down-regulation of FBI1 also inhibited tumorigenicity and metastasis accompanying a decrease in MMP-9 ( matrix metalloproteinase-9) expression. In addition, the duration of ERK1/2 activation was curtailed in antisense FBI1-expressing K2 cells. A luciferase reporter assay revealed that the FBI1-14-3-3 beta complex could act as a transcriptional silencer, and MKP-1 (MAPK phosphatase-1) was one of the target genes of the FBI1-14-3-3 beta complex. Moreover, chromatin immunoprecipitation analysis demonstrated that FBI1 and 14-3-3 beta were presented on the MKP-1 promoter. These results indicate that FBI1 promotes sustained ERK1/2 activation through repression of MKP-1 transcription, resulting in promotion of tumorigenicity and metastasis.	[Komiya, Yuko; Kurabe, Nobuya; Katagiri, Kumiko; Ogawa, Makiko; Sugiyama, Akinori; Kawasaki, Yasushi; Tashiro, Fumio] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Yamazaki 2641, Noda, Chiba 2788510, Japan.	ftashir@rs.noda.tus.ac.jp						Aitken A, 2002, PLANT MOL BIOL, V50, P993, DOI 10.1023/A:1021261931561; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Akiyama H, 2003, J BIOL CHEM, V278, P10752, DOI 10.1074/jbc.M209856200; Baccarini M, 2005, FEBS LETT, V579, P3271, DOI 10.1016/j.febslet.2005.03.024; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; BOS JL, 1989, CANCER RES, V49, P4682; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dramsi S, 2002, J BIOL CHEM, V277, P6399, DOI 10.1074/jbc.M109990200; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MORIMURA S, 1990, CHEM PHARM BULL, V38, P460, DOI 10.1248/cpb.38.460; Muda M, 1996, J BIOL CHEM, V271, P4319; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Ryser S, 2004, BIOCHEM J, V378, P473, DOI 10.1042/BJ20031022; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shoji Masahiro, 1994, Human Antibodies and Hybridomas, V5, P123; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; TAKAI R, 1995, J BIOCHEM, V118, P1045, DOI 10.1093/jb/118.5.1045; Takihara Y, 2000, CARCINOGENESIS, V21, P2073, DOI 10.1093/carcin/21.11.2073; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Urano Y, 2006, J BIOL CHEM, V281, P7498, DOI 10.1074/jbc.M510881200; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151	47	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18753	18764		10.1074/jbc.M802530200	http://dx.doi.org/10.1074/jbc.M802530200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460465	hybrid			2022-12-25	WOS:000257165600032
J	Simonetti, M; Giniatullin, R; Fabbretti, E				Simonetti, Manuela; Giniatullin, Rashid; Fabbretti, Elsa			Mechanisms mediating the enhanced gene transcription of P2X(3) receptor by calcitonin gene-related peptide in trigeminal sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-MODIFYING PROTEIN-1; ELEMENT-BINDING PROTEIN; NITRIC-OXIDE; DEPENDENT TRANSCRIPTION; ANTAGONIST BIBN4096BS; NEUROTROPHIC FACTOR; BLOOD-FLOW; C-FOS; CREB; MIGRAINE	The molecular mechanisms underlying migraine pain remain unclear and probably require sustained facilitation in pain-sensing P2X(3) receptors gated by extracellular ATP in nociceptive sensory neurons. The major migraine mediator calcitonin gene-related peptide ( CGRP) is known to sensitize P2X3 receptors to increase impulse flow to brainstem trigeminal nuclei. This process is mediated via changes in the expression and function of P2X3 receptors initially through enhanced trafficking and, later, perhaps through augmented synthesis of P2X3 receptors. To clarify the mechanisms responsible for CGRP-evoked long lasting alterations in P2X3 receptors, we used as a model mouse trigeminal ganglion neurons in culture. CGRP activated Ca2+-calmodulin- dependent kinase II, which became localized to the perimembrane region and neuronal processes, a phenomenon already apparent after 30 min and accompanied by a parallel increase in cAMP-response element-binding protein ( CREB) phosphorylation and nuclear translocation. These effects triggered increased P2X3 receptor transcription and were prevented by expressing a dominant negative form of CREB. Increased P2X3 receptor synthesis was partly mediated by endogenous brain-derived neurotrophic factor ( BDNF) because of its block by anti-BDNF antibodies and mimicry by exogenous BDNF. Immunocytochemistry experiments indicated distinct subpopulations of BDNF- or CGRP-sensitive trigeminal neurons with only partial overlap. The present data indicate a novel mechanism for enhancing P2X3 receptor expression and function in trigeminal sensory neurons by CGRP via CREB phosphorylation. BDNF was an intermediate to extend the sensitizing effect of CGRP also to CGRP-insensitive neurons. This combinatorial action could serve as a powerful process to amplify and prolong pain mediated by P2X3 receptors.	[Simonetti, Manuela; Giniatullin, Rashid; Fabbretti, Elsa] SISSA, Neurobiol Sector, I-34014 Trieste, Italy; [Simonetti, Manuela; Giniatullin, Rashid; Fabbretti, Elsa] SISSA, Italian Inst Technol Unit, I-34014 Trieste, Italy; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland	International School for Advanced Studies (SISSA); International School for Advanced Studies (SISSA); Istituto Italiano di Tecnologia - IIT; University of Eastern Finland	Fabbretti, E (corresponding author), SISSA, Neurobiol Sector, Beirut 2-4, I-34014 Trieste, Italy.	fabbre@sissa.it	Giniatullin, Rashid/Y-9687-2018	Giniatullin, Rashid/0000-0002-1580-6280	Telethon [GGP07032] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Anderson LE, 2004, J NEUROCHEM, V91, P1417, DOI 10.1111/j.1471-4159.2004.02833.x; Arulmani U, 2004, EUR J PHARMACOL, V500, P315, DOI 10.1016/j.ejphar.2004.07.035; Blandini F, 2006, CEPHALALGIA, V26, P136, DOI 10.1111/j.1468-2982.2005.01006.x; Buldyrev I, 2006, J NEUROCHEM, V99, P1338, DOI 10.1111/j.1471-4159.2006.04161.x; Chawla S, 2002, EUR J PHARMACOL, V447, P131, DOI 10.1016/S0014-2999(02)01837-X; Chen MJ, 2007, LIFE SCI, V81, P1280, DOI 10.1016/j.lfs.2007.09.003; COCKAYNE DA, 2002, J PHYSL, V567, P621; Cohen JE, 2006, CELL CALCIUM, V39, P445, DOI 10.1016/j.ceca.2006.01.005; Cottrell GS, 2005, J COMP NEUROL, V490, P239, DOI 10.1002/cne.20669; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; D'Arco M, 2007, J NEUROSCI, V27, P8190, DOI 10.1523/JNEUROSCI.0713-07.2007; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; Drissi H, 1999, CYTOKINE, V11, P200, DOI 10.1006/cyto.1998.0415; Durham PL, 2006, HEADACHE, V46, pS3, DOI 10.1111/j.1526-4610.2006.00483.x; Edvinsson L, 2005, CNS DRUG REV, V11, P69; Fabbretti E, 2006, J NEUROSCI, V26, P6163, DOI 10.1523/JNEUROSCI.0647-06.2006; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GALLAI V, 1995, CEPHALALGIA, V15, P384, DOI 10.1046/j.1468-2982.1995.1505384.x; Giachino C, 2005, J NEUROSCI, V25, P10105, DOI 10.1523/JNEUROSCI.3512-05.2005; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Goadsby PJ, 2005, DRUGS, V65, P2557, DOI 10.2165/00003495-200565180-00002; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gozalov A, 2007, CEPHALALGIA, V27, P1120, DOI 10.1111/j.1468-2982.2007.01409.x; Groth RD, 2007, J NEUROCHEM, V102, P1162, DOI 10.1111/j.1471-4159.2007.04632.x; Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361-9230(97)00277-3; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Iovino M, 2004, CEPHALALGIA, V24, P645, DOI 10.1111/j.1468-2982.2004.00726.x; Jarvis MF, 2002, P NATL ACAD SCI USA, V99, P17179, DOI 10.1073/pnas.252537299; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LaCroix-Fralish ML, 2007, PAIN, V131, DOI 10.1016/j.pain.2007.04.041; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mandolesi G, 2002, FEBS LETT, V510, P50, DOI 10.1016/S0014-5793(01)03227-6; Messlinger K, 2000, BRIT J PHARMACOL, V129, P1397, DOI 10.1038/sj.bjp.0703220; Miletic G, 2004, NEUROSCI LETT, V361, P269, DOI 10.1016/j.neulet.2003.12.029; Miyabe T, 2005, NEUROSCI LETT, V381, P80, DOI 10.1016/j.neulet.2005.02.001; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Mogil JS, 2000, J PAIN, V1, P66, DOI 10.1054/jpai.2000.9821; North R Alan, 2003, Curr Opin Investig Drugs, V4, P833; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Riccio A, 2006, MOL CELL, V21, P283, DOI 10.1016/j.molcel.2005.12.006; RUBINSTEIN C, 1993, CLIN EXP PHARMACOL P, V20, P477, DOI 10.1111/j.1440-1681.1993.tb01728.x; Sarchielli P, 2007, J PAIN, V8, P737, DOI 10.1016/j.jpain.2007.05.002; Schwenger N, 2007, CEPHALALGIA, V27, P481, DOI 10.1111/j.1468-2982.2007.01321.x; Seybold VS, 2006, J NEUROCHEM, V97, P397, DOI 10.1111/j.1471-4159.2006.03744.x; Seybold VS, 2003, J NEUROSCI, V23, P1816; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Simonetti M, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-11; Sjostrand C, 2006, HEADACHE, V46, P1518, DOI 10.1111/j.1526-4610.2006.00611.x; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Souslova V, 1997, GENE, V195, P101, DOI 10.1016/S0378-1119(97)00225-4; Ulmann L, 2007, EUR J NEUROSCI, V26, P113, DOI 10.1111/j.1460-9568.2007.05649.x; Wang HM, 2006, PROG NEUROBIOL, V79, P123, DOI 10.1016/j.pneurobio.2006.06.004; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003-4819-140-8-200404200-00010; Zhang ZM, 2007, J NEUROSCI, V27, P2693, DOI 10.1523/JNEUROSCI.4542-06.2007; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6	61	77	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18743	18752		10.1074/jbc.M800296200	http://dx.doi.org/10.1074/jbc.M800296200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460469	hybrid			2022-12-25	WOS:000257165600031
J	Chen, YP; Shi, L; Zhang, LR; Li, RF; Liang, J; Yu, WH; Sun, LY; Yang, XH; Wang, Y; Zhang, Y; Shang, YF				Chen, Yupeng; Shi, Lei; Zhang, Lirong; Li, Ruifang; Liang, Jing; Yu, Wenhua; Sun, Luyang; Yang, Xiaohan; Wang, Yan; Zhang, Yu; Shang, Yongfeng			The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-REGULATED TRANSCRIPTION; EMBRYONIC STEM-CELLS; CYCLIN D1; BETA-CATENIN; ENDOMETRIAL CARCINOGENESIS; PROTEIN; EXPRESSION; CARCINOMA; ESTROGEN; FAMILY	SOX genes encode a family of high-mobility group transcription factors that play critical roles in organogenesis. The functional specificity of different SOX proteins and the tissue specificity of a particular SOX factor are largely determined by the differential partnership of SOX transcription factors with other transcription regulators, many of which have not yet been discovered. Virtually all members of the SOX family have been found to be deregulated in a wide variety of tumors. However, little is known about the cellular and molecular behaviors involved in the oncogenic potential of SOX proteins. Using cell culture experiments, tissue analysis, molecular profiling, and animal studies, we report here that SOX2 promotes cell proliferation and tumorigenesis by facilitating the G(1)/S transition and through its transcription regulation of the CCND1 gene in breast cancer cells. In addition, we identified beta-catenin as the transcription partner for SOX2 and demonstrated that SOX2 and beta-catenin act in synergy in the transcription regulation of CCND1 in breast cancer cells. Our experiments not only determined a role for SOX2 in mammary tumorigenesis but also revealed another activity of the multifunctional protein, beta-catenin.	[Chen, Yupeng; Shi, Lei; Zhang, Lirong; Li, Ruifang; Liang, Jing; Yu, Wenhua; Sun, Luyang; Yang, Xiaohan; Wang, Yan; Zhang, Yu; Shang, Yongfeng] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Shang, YF (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	yshang@hsc.pku.edu.cn	Zhang, Li/GWM-7501-2022; Chen, Yupeng/T-5275-2019	Chen, Yupeng/0000-0001-8887-9547				Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Comtesse N, 2005, P NATL ACAD SCI USA, V102, P9601, DOI 10.1073/pnas.0500404102; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; FANTL V, 1993, CANCER SURV, V18, P77; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; GILLETT C, 1994, CANCER RES, V54, P1812; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Li XL, 2004, INT J ONCOL, V24, P257; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matsumata M, 2005, DEV BIOL, V286, P601, DOI 10.1016/j.ydbio.2005.08.005; RODRIGUEZPINILL.SM, 2007, DOD PATHOL, V20, P474; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xia Y, 2000, CANCER RES, V60, P6303; Yeo S, 2007, BIOCHEM BIOPH RES CO, V359, P536, DOI 10.1016/j.bbrc.2007.05.120; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang C, 2003, DEVELOPMENT, V130, P5609, DOI 10.1242/dev.00798; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zhang Y, 2007, EMBO J, V26, P2645, DOI 10.1038/sj.emboj.7601710; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	45	287	309	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17969	17978		10.1074/jbc.M802917200	http://dx.doi.org/10.1074/jbc.M802917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18456656	hybrid			2022-12-25	WOS:000256949200026
J	Balogh, LM; Roberts, AG; Shireman, LM; Greene, RJ; Atkins, WM				Balogh, Larissa M.; Roberts, Arthur G.; Shireman, Laura M.; Greene, Robert J.; Atkins, William M.			The stereochemical course of 4-hydroxy-2-nonenal metabolism by glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH CATALYTIC EFFICIENCY; LIPID-PEROXIDATION PRODUCT; OXIDATIVE STRESS; DRUG-ACTION; 4-HYDROXY-2(E)-NONENAL ENANTIOMERS; 4-HYDROXY-TRANS-2-NONENAL HNE; ENANTIOSELECTIVE METABOLISM; MASS-SPECTROMETRY; PROTEIN; ACID	4-Hydroxy-2-nonenal (HNE) is a toxic aldehyde generated during lipid peroxidation and has been implicated in a variety of pathological states associated with oxidative stress. Glutathione S-transferase (GST) A4-4 is recognized as one of the predominant enzymes responsible for the metabolism of HNE. However, substrate and product stereoselectivity remain to be fully explored. The results from a product formation assay indicate that hGSTA4-4 exhibits a modest preference for the biotransformation of S-HNE in the presence of both enantiomers. Liquid chromatography mass spectrometry analyses using the racemic and enantioisomeric HNE substrates explicitly demonstrate that hGSTA4-4 conjugates glutathione to both HNE enantiomers in a completely stereoselective manner that is not maintained in the spontaneous reaction. Compared with other hGST isoforms, hGSTA4-4 shows the highest degree of stereoselectivity. NMR experiments in combination with simulated annealing structure determinations enabled the determination of stereochemical configurations for the GSHNE diastereomers and are consistent with an hGSTA4-4-catalyzed nucleophilic attack that produces only the S-configuration at the site of conjugation, regardless of substrate chirality. In total these results indicate that hGSTA4-4 exhibits an intriguing combination of low substrate stereoselectivity with strict product stereoselectivity. This behavior allows for the detoxification of both HNE enantiomers while generating only a select set of GSHNE diastereomers with potential stereochemical implications concerning their effects and fates in biological tissues.	[Balogh, Larissa M.; Roberts, Arthur G.; Shireman, Laura M.; Atkins, William M.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; [Greene, Robert J.] Amgen Inc, Dept Pharmacokinet & Drug Metab, Seattle, WA 98119 USA	University of Washington; University of Washington Seattle; Amgen	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	winky@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alary J, 1998, CHEM RES TOXICOL, V11, P130, DOI 10.1021/tx970139w; Alary Jacques, 2003, Molecular Aspects of Medicine, V24, P177, DOI 10.1016/S0098-2997(03)00012-8; Aldini G, 2002, BIOCHEM BIOPH RES CO, V298, P699, DOI 10.1016/S0006-291X(02)02545-7; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Awasthi YC, 2005, METHOD ENZYMOL, V401, P379, DOI 10.1016/S0076-6879(05)01024-4; Beretta G, 2007, CHEM RES TOXICOL, V20, P1309, DOI 10.1021/tx700185s; Board PG, 1998, BIOCHEM J, V330, P827; Boon PJM, 1999, TOXICOL APPL PHARM, V159, P214, DOI 10.1006/taap.1999.8742; Brichac J, 2007, CHEM RES TOXICOL, V20, P887, DOI 10.1021/tx7000509; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Burke D, 2002, BRIT J ANAESTH, V88, P563, DOI 10.1093/bja/88.4.563; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Carini M, 2004, MASS SPECTROM REV, V23, P281, DOI 10.1002/mas.10076; EICHELBAUM M, 1996, ADV DRUG RES, V28, P1; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gueraud F, 2005, BIOFACTORS, V24, P97, DOI 10.1002/biof.5520240111; Hashimoto M, 2003, J BIOL CHEM, V278, P5044, DOI 10.1074/jbc.M210129200; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hiratsuka A, 2000, BIOCHEM J, V349, P729, DOI 10.1042/bj3490729; Hiratsuka A, 2001, BIOCHEM J, V355, P237, DOI 10.1042/0264-6021:3550237; Honzatko A, 2005, FREE RADICAL BIO MED, V39, P913, DOI 10.1016/j.freeradbiomed.2005.05.010; Hou L, 2007, J BIOL CHEM, V282, P23264, DOI 10.1074/jbc.M700868200; Hu WW, 2002, CARCINOGENESIS, V23, P1781, DOI 10.1093/carcin/23.11.1781; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; JAMALI F, 1989, J PHARM SCI-US, V78, P695, DOI 10.1002/jps.2600780902; Ji B, 2002, FREE RADICAL BIO MED, V33, P370, DOI 10.1016/S0891-5849(02)00906-1; Lu WD, 2004, BIOCHEMISTRY-US, V43, P12761, DOI 10.1021/bi049217m; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Ramana KV, 2006, J BIOL CHEM, V281, P17652, DOI 10.1074/jbc.M600270200; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; SASHIDHAR RB, 1994, J IMMUNOL METHODS, V167, P121, DOI 10.1016/0022-1759(94)90081-7; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Sharma R, 2002, ACTA BIOCHIM POL, V49, P693; Siegel SJ, 2007, BIOCHEMISTRY-US, V46, P1503, DOI 10.1021/bi061853s; SINGHAL SS, 1994, ARCH BIOCHEM BIOPHYS, V311, P242, DOI 10.1006/abbi.1994.1233; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH DF, 1989, PHARMACOL TOXICOL, V65, P321, DOI 10.1111/j.1600-0773.1989.tb01182.x; TESTA B, 1986, TRENDS PHARMACOL SCI, V7, P60, DOI 10.1016/0165-6147(86)90255-5; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Volkel W, 2006, NEUROCHEM INT, V48, P679, DOI 10.1016/j.neuint.2005.12.003; WALLE T, 1986, TRENDS PHARMACOL SCI, V7, P155, DOI 10.1016/0165-6147(86)90294-4; West JD, 2005, CHEM RES TOXICOL, V18, P1642, DOI 10.1021/tx050211n; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yang YS, 2003, ACTA BIOCHIM POL, V50, P319; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	50	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16702	16710		10.1074/jbc.M801725200	http://dx.doi.org/10.1074/jbc.M801725200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424441	Green Published, hybrid			2022-12-25	WOS:000256497100047
J	Kohlmann, S; Schafer, A; Wolf, DH				Kohlmann, Sonja; Schaefer, Antje; Wolf, Dieter H.			Ubiquitin ligase Hul5 is required for fragment-specific substrate degradation in endoplasmic reticulum-associated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; UNFOLDED-PROTEIN RESPONSE; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; SACCHAROMYCES-CEREVISIAE; PROTEOLYTIC PATHWAY; PROTEASOME PATHWAY; IDENTIFIES YOS9P; COMPLEX; MEMBRANE	To identify new components of the protein quality control and degradation pathway of the endoplasmic reticulum (ER), we performed a growth-based genome-wide screen of about 5000 viable deletion mutants of the yeast Saccharomyces cerevisiae. As substrates we used two misfolded ER membrane proteins, CTL* and Sec61-2L, chimeric derivatives of the classical ER degradation substrates CPY* and Sec61-2. Both substrates contain a cytosolic Leu2 protein fusion, and stabilization of these substrates in ER-associated degradation-deficient strains enables a restored growth of the transformed LEU2-deficient deletion mutants. We identified the strain deleted for the ubiquitin chain elongating ligase Hul5 among the mutant strains with a strong growth phenotype. Here we show that Hul5 is necessary for the degradation of two misfolded ER membrane substrates. Although the degradation of their N-terminal parts is Hul5-independent, the breakdown of their C-terminal fragments requires the ubiquitin chain elongating ligase activity of Hul5. In the absence of Hul5, a truncated form of CTL* myc remains to a large extent embedded in the ER membrane. Hul5 activity promotes the interaction of this truncated CTL* myc with the AAA-ATPase Cdc48, which is known to pull proteins out of the ER membrane. This study unravels the stepwise elimination of the ER membrane-localized CTL* myc substrate. First, N-terminal, lumenal CPY* is transferred to the cytoplasm and degraded by the proteasome. Subsequently, the remaining C-terminal membrane-anchored part requires Hul5 for its effective extraction out of the endoplasmic reticulum and proteasomal degradation.	[Kohlmann, Sonja; Schaefer, Antje; Wolf, Dieter H.] Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany	University of Stuttgart	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	dieter.wolf@ibc.uni-stuttgart.de						Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Buschhorn BA, 2004, FEBS LETT, V577, P422, DOI 10.1016/j.febslet.2004.10.039; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Crosas B, 2006, CELL, V127, P1401, DOI 10.1016/j.cell.2006.09.051; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Gauss R, 2006, NAT CELL BIOL, V8, P849, DOI 10.1038/ncb1445; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUTHRIE C, 1991, METHODS ENZYMOLOGY G, V350; GUTHRIE C, 1991, METHODS ENZYMOLOGY G, V351; Hanna J, 2007, FEBS LETT, V581, P2854, DOI 10.1016/j.febslet.2007.03.053; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kraut DA, 2007, TRENDS CELL BIOL, V17, P419, DOI 10.1016/j.tcb.2007.06.008; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Nakatsukasa K, 2008, CELL, V132, P101, DOI 10.1016/j.cell.2007.11.023; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Raasi S, 2007, SEMIN CELL DEV BIOL, V18, P780, DOI 10.1016/j.semcdb.2007.09.008; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schafer A, 2005, METHOD ENZYMOL, V399, P459, DOI 10.1016/S0076-6879(05)99031-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	56	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16374	16383		10.1074/jbc.M801702200	http://dx.doi.org/10.1074/jbc.M801702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18436532	hybrid			2022-12-25	WOS:000256497100013
J	Liu, SW; Rajagopal, V; Patel, SS; Kiledjian, M				Liu, Shin-Wu; Rajagopal, Vaishnavi; Patel, Smita S.; Kiledjian, Megerditch			Mechanistic and kinetic analysis of the DcpS scavenger decapping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; M(7)GPPPX PYROPHOSPHATASE ACTIVITY; HISTIDINE TRIAD SUPERFAMILY; PROTEIN; YEAST; TURNOVER; COMPLEX; EXOSOME; DEGRADATION; REQUIRES	Decapping is an important process in the control of eukaryotic mRNA degradation. The scavenger decapping enzyme DcpS functions to clear the cell of cap structure following decay of the RNA body by catalyzing the hydrolysis of m(7)GpppN to m(7)Gp and ppN. Structural analysis has revealed that DcpS is a dimeric protein with a domain-swapped amino terminus. The protein dimer contains two cap binding/hydrolysis sites and displays a symmetric structure with both binding sites in the open conformation in the ligand-free state and an asymmetric conformation with one site open and one site closed in the ligand-bound state. The structural data are suggestive of a dynamic decapping mechanism where each monomer could alternate between an open and closed state. Using transient state kinetic studies, we show that both the rate-limiting step and rate of decapping are regulated by cap substrate. A regulatory mechanism is established by the intrinsic domain-swapped structure of the DcpS dimer such that the decapping reaction is very efficient at low cap substrate concentrations yet regulated with excess cap substrate. These data provide biochemical evidence to verify experimentally a dynamic and mutually exclusive cap hydrolysis activity of the two cap binding sites of DcpS and provide key insights into its regulation.	[Liu, Shin-Wu; Kiledjian, Megerditch] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Rajagopal, Vaishnavi; Patel, Smita S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kiledjian, M (corresponding author), 604 Allison Rd, Piscataway, NJ 08854 USA.	kiledjian@biology.rutgers.edu	Rajagopal, Vaishnavi/E-5272-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067005] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55310, GM67005] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Chen N, 2005, J MOL BIOL, V347, P707, DOI 10.1016/j.jmb.2005.01.062; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Fenger-Gron M, 2005, MOL CELL, V20, P905, DOI 10.1016/j.molcel.2005.10.031; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gu MG, 2004, MOL CELL, V14, P67, DOI 10.1016/S1097-2765(04)00180-7; Guranowski A, 1996, PROTEIN EXPRES PURIF, V8, P416, DOI 10.1006/prep.1996.0119; Han GW, 2005, PROTEINS, V60, P797, DOI 10.1002/prot.20467; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Liu H, 2006, BIOCHEM SOC T, V34, P35, DOI 10.1042/BST0340035; Liu HD, 2005, MOL CELL BIOL, V25, P9764, DOI 10.1128/MCB.25.22.9764-9772.2005; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Liu SW, 2004, RNA, V10, P1412, DOI 10.1261/rna.7660804; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Malys N, 2004, NUCLEIC ACIDS RES, V32, P3590, DOI 10.1093/nar/gkh687; Malys N, 2006, J MOL BIOL, V363, P370, DOI 10.1016/j.jmb.2006.08.015; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Mullen TE, 2008, GENE DEV, V22, P50, DOI 10.1101/gad.1622708; Murray EL, 2007, MOL CELL BIOL, V27, P2791, DOI 10.1128/MCB.01445-06; Pentikainen U, 2008, PROTEINS, V70, P498, DOI 10.1002/prot.21540; Rodgers ND, 2002, RNA, V8, P1526, DOI 10.1017/S1355838202029035; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; van Dijk E, 2003, P NATL ACAD SCI USA, V100, P12081, DOI 10.1073/pnas.1635192100; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X	32	20	21	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16427	16436		10.1074/jbc.M800341200	http://dx.doi.org/10.1074/jbc.M800341200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18441014	Green Published			2022-12-25	WOS:000256497100019
J	Jensen, TE; Schjerling, P; Viollet, B; Wojtaszewski, JFP; Richter, EA				Jensen, Thomas E.; Schjerling, Peter; Viollet, Benoit; Wojtaszewski, Jorgen F. P.; Richter, Erik A.			AMPK alpha(1) Activation Is Required for Stimulation of Glucose Uptake by Twitch Contraction, but Not by H2O2, in Mouse Skeletal Muscle	PLOS ONE			English	Article							5'-AMP-ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; AS160 PHOSPHORYLATION; GLYCOGEN-SYNTHESIS; TRANSPORT; INSULIN; EXPRESSION; INHIBITION; GLUT1; GLUCOSE-TRANSPORTER-4	Background: AMPK is a promising pharmacological target in relation to metabolic disorders partly due to its non-insulin dependent glucose uptake promoting role in skeletal muscle. Of the 2 catalytic alpha-AMPK isoforms, alpha(2) AMPK is clearly required for stimulation of glucose transport into muscle by certain stimuli. In contrast, no clear function has yet been determined for alpha(1) AMPK in skeletal muscle, possibly due to alpha-AMPK isoform signaling redundancy. By applying low-intensity twitch-contraction and H2O2 stimulation to activate alpha(1) AMPK, but not alpha(2) AMPK, in wildtype and alpha-AMPK transgenic mouse muscles, this study aimed to define conditions where alpha(1) AMPK is required to increase muscle glucose uptake. Methodology/Principal Findings: Following stimulation with H2O2 (3 mM, 20 min) or twitch-contraction (0.1 ms pulse, 2 Hz, 2 min), signaling and 2-deoxyglucose uptake were measured in incubated soleus muscles from wildtype and muscle-specific kinase-dead AMPK (KD), alpha(1) AMPK knockout or alpha(2) AMPK knockout mice. H2O2 increased the activity of both alpha(1) and alpha(2) AMPK in addition to Akt phosphorylation, and H2O2-stimulated glucose uptake was not reduced in any of the AMPK transgenic mouse models compared with wild type. In contrast, twitch-contraction increased the activity of alpha(1) AMPK, but not alpha(2) AMPK activity nor Akt or AS160 phosphorylation. Glucose uptake was markedly lower in alpha(1) AMPK knockout and KD AMPK muscles, but not in alpha(2) AMPK knockout muscles, following twitch stimulation. Conclusions/Significance: These results provide strong genetic evidence that alpha(1) AMPK, but not alpha(2) AMPK, Akt or AS160, is necessary for regulation of twitch-contraction stimulated glucose uptake. To our knowledge, this is the first report to show a major and essential role of alpha(1) AMPK in regulating a physiological endpoint in skeletal muscle. In contrast, AMPK is not essential for H2O2-stimulated muscle glucose uptake, as proposed by recent studies.	[Jensen, Thomas E.; Wojtaszewski, Jorgen F. P.; Richter, Erik A.] Univ Copenhagen, Copenhagen Muscle Res Ctr, Dept Exercise & Sport Sci, Mol Physiol Grp,Sect Human Physiol, Copenhagen, Denmark; [Schjerling, Peter] Rigshospitalet, Dept Mol Muscle Biol, Copenhagen Muscle Res Ctr, Copenhagen, Denmark; [Schjerling, Peter] Univ Copenhagen, Dept Biomed Sci, Med Muscle Res Cluster, Mol Muscle Biol, Copenhagen, Denmark; [Viollet, Benoit] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France; [Viollet, Benoit] Inserm, U567, Paris, France	University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jensen, TE (corresponding author), Univ Copenhagen, Copenhagen Muscle Res Ctr, Dept Exercise & Sport Sci, Mol Physiol Grp,Sect Human Physiol, Copenhagen, Denmark.	ERichter@ifi.ku.dk	Schjerling, Peter/F-6194-2011; Jensen, Thomas/E-1215-2015; Viollet, Benoit/O-6927-2017; Richter, Erik A./Y-8131-2019; Wojtaszewski, Jørgen FP/P-6583-2014	Schjerling, Peter/0000-0001-7138-3211; Jensen, Thomas/0000-0001-6139-8268; Viollet, Benoit/0000-0002-0121-0224; Richter, Erik A./0000-0002-6850-3056; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; wojtaszewski, jorgen/0000-0001-8185-3408	Novo Nordisk Research Foundation [Hallas Moller Fellowship]; Danish Diabetes Association; European Commission [LSHM-CT-2004-005272]; The Lundbeck Foundation; The Copenhagen Muscle Research Centre; The Danish Medical and Natural Sciences Research Councils	Novo Nordisk Research Foundation(Novo Nordisk Foundation); Danish Diabetes Association; European Commission(European CommissionEuropean Commission Joint Research Centre); The Lundbeck Foundation(Lundbeckfonden); The Copenhagen Muscle Research Centre; The Danish Medical and Natural Sciences Research Councils	The study was supported by the Novo Nordisk Research Foundation, The Danish Diabetes Association, an Integrated Project (LSHM-CT-2004-005272) funded by the European Commission, The Lundbeck Foundation, The Copenhagen Muscle Research Centre and The Danish Medical and Natural Sciences Research Councils. Jorgen F. P. Wojtaszewski was supported by a Hallas Moller Fellowship from The Novo Nordisk Foundation.	Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Andrade FH, 2001, FASEB J, V15, P309; Barnes K, 2002, J CELL SCI, V115, P2433; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; Cartee GD, 2007, APPL PHYSIOL NUTR ME, V32, P557, DOI 10.1139/H07-026; Daugaard JR, 2004, PFLUG ARCH EUR J PHY, V447, P452, DOI 10.1007/s00424-003-1195-8; Derave W, 2006, AM J PHYSIOL-ENDOC M, V291, pE1250, DOI 10.1152/ajpendo.00060.2006; Frosig C, 2004, AM J PHYSIOL-ENDOC M, V286, pE411, DOI 10.1152/ajpendo.00317.2003; Fujii N, 2005, J BIOL CHEM, V280, P39033, DOI 10.1074/jbc.M504208200; FUJII N, 2005, J BIOL CHEM; Geraghty KM, 2007, BIOCHEM J, V407, P231, DOI 10.1042/BJ20070649; HIDALGO C, 2006, J BIOL CHEM; HIGAKI Y, 2008, AM J PHYSL ENDOCRINO; Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V292, pE1308, DOI 10.1152/ajpendo.00456.2006; Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V293, pE286, DOI 10.1152/ajpendo.00693.2006; Jing M, 2006, AM J PHYSIOL-CELL PH, V290, pC484, DOI 10.1152/ajpcell.00321.2005; Jing M, 2007, AM J PHYSIOL-CELL PH, V292, pC477, DOI 10.1152/ajpcell.00196.2006; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; Kim JS, 2006, FREE RADICAL BIO MED, V41, P818, DOI 10.1016/j.freeradbiomed.2006.05.031; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Putman CT, 2007, AM J PHYSIOL-REG I, V293, pR1325, DOI 10.1152/ajpregu.00609.2006; RANEY MA, 2008, J APPL PHYSL; RHEE SG, 2000, SCI STKE, pE1; Rubin D, 2004, ARCH BIOCHEM BIOPHYS, V431, P224, DOI 10.1016/j.abb.2004.08.007; Rubin D, 2003, AM J PHYSIOL-CELL PH, V285, pC377, DOI 10.1152/ajpcell.00060.2003; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; Sakamoto K, 2002, J BIOL CHEM, V277, P11910, DOI 10.1074/jbc.M112410200; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sandstrom ME, 2006, J PHYSIOL-LONDON, V575, P251, DOI 10.1113/jphysiol.2006.110601; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; TAYLOR EB, 2008, J BIOL CHEM; Toyoda T, 2006, AM J PHYSIOL-ENDOC M, V290, pE583, DOI 10.1152/ajpendo.00395.2005; Toyoda T, 2004, AM J PHYSIOL-ENDOC M, V287, pE166, DOI 10.1152/ajpendo.00487.2003; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	41	69	71	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2102	10.1371/journal.pone.0002102	http://dx.doi.org/10.1371/journal.pone.0002102			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461163	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400024
J	Tsirigotis, M; Baldwin, RM; Tang, MY; Lorimer, IAJ; Gray, DA				Tsirigotis, Maria; Baldwin, R. Mitchell; Tang, Matthew Y.; Lorimer, Ian A. J.; Gray, Douglas A.			Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced Cytotoxicity	PLOS ONE			English	Article							PROTEIN-KINASE INHIBITOR; SIGNAL-REGULATED KINASE; HUNTINGTONS-DISEASE; MOUSE MODEL; CELL-DEATH; MUTANT HUNTINGTIN; TRANSGENIC MICE; SPINOCEREBELLAR ATAXIA; MEDIATED TRANSCRIPTION; HIPPOCAMPAL-NEURONS	Background: The signaling pathways that may modulate the pathogenesis of diseases induced by expanded polyglutamine proteins are not well understood. Methodologies/Principal Findings: Herein we demonstrate that expanded polyglutamine protein cytotoxicity is mediated primarily through activation of p38MAPK and that the atypical PKC iota ( PKC iota) enzyme antagonizes polyglutamine-induced cell death through induction of the ERK signaling pathway. We show that pharmacological blockade of p38MAPK rescues cells from polyglutamine-induced cell death whereas inhibition of ERK recapitulates the sensitivity observed in cells depleted of PKCi by RNA interference. We provide evidence that two unrelated proteins with expanded polyglutamine repeats induce p38MAPK in cultured cells, and demonstrate induction of p38MAPK in an in vivo model of neurodegeneration (spinocerebellar ataxia 1, or SCA-1). Conclusions/Significance: Taken together, our data implicate activated p38MAPK in disease progression and suggest that its inhibition may represent a rational strategy for therapeutic intervention in the polyglutamine disorders.	[Tsirigotis, Maria; Baldwin, R. Mitchell; Tang, Matthew Y.; Lorimer, Ian A. J.; Gray, Douglas A.] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Baldwin, R. Mitchell; Tang, Matthew Y.; Lorimer, Ian A. J.; Gray, Douglas A.] Univ Ottawa, Dept Biochem, Microbiol & Immunol, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Tsirigotis, M (corresponding author), Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada.	dgray@ohri.ca	/U-3554-2018	/0000-0002-8634-4984	Canadian Institutes of Health Research [57737, 62797]; National Cancer Institute of Canada [015343]; Ontario Graduate Scholarship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Ontario Graduate Scholarship(Ontario Graduate Scholarship)	The work was funded by Canadian Institutes of Health Research (grant number 57737 and 62797 awarded DAG and IAJL respectively) and the National Cancer Institute of Canada (grant number 015343 awarded IAJL). RMB is a Research Student of The Terry Fox Foundation through an award from the National Cancer Institute of Canada. MYT is the recipient of an Ontario Graduate Scholarship.	Ackerley S, 2004, MOL CELL NEUROSCI, V26, P354, DOI 10.1016/j.mcn.2004.02.009; Apostol BL, 2006, HUM MOL GENET, V15, P273, DOI 10.1093/hmg/ddi443; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bodles AM, 2005, NEUROBIOL AGING, V26, P9, DOI 10.1016/j.neurobiolaging.2004.02.022; Branger J, 2002, J IMMUNOL, V168, P4070, DOI 10.4049/jimmunol.168.8.4070; Branger J, 2003, BLOOD, V101, P4446, DOI 10.1182/blood-2002-11-3338; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Campbell CSG, 2004, LIFE SCI, V76, P57, DOI 10.1016/j.lfs.2004.06.017; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Charroux B, 2006, DEV BIOL, V291, P278, DOI 10.1016/j.ydbio.2005.12.012; Cheung Eric C C, 2004, Sci STKE, V2004, pPE45; Chiang MC, 2005, J BIOL CHEM, V280, P14331, DOI 10.1074/jbc.M413279200; Colognato R, 2006, CLIN NUTR, V25, P135, DOI 10.1016/j.clnu.2005.10.005; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Cong SY, 2005, MOL CELL NEUROSCI, V30, P12, DOI 10.1016/j.mcn.2005.05.003; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Guo Q, 2001, J BIOL CHEM, V276, P16040, DOI 10.1074/jbc.M010996200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Holasek SS, 2005, BRAIN RES, V1045, P185, DOI 10.1016/j.brainres.2005.03.037; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jana NR, 2003, J CHEM NEUROANAT, V26, P95, DOI 10.1016/S0891-0618(03)00029-2; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kariya S, 2006, NEUROSCI LETT, V392, P213, DOI 10.1016/j.neulet.2005.09.019; Kaytor MD, 2005, HUM MOL GENET, V14, P1095, DOI 10.1093/hmg/ddi122; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kuida K, 2004, J BIOCHEM, V135, P653, DOI 10.1093/jb/mvh078; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Laurino L, 2005, J CELL SCI, V118, P3653, DOI 10.1242/jcs.02490; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Li SH, 1999, J NEUROSCI, V19, P5159; Lievens JC, 2005, HUM MOL GENET, V14, P713, DOI 10.1093/hmg/ddi067; Lipinski MM, 2004, CURR OPIN PHARMACOL, V4, P85, DOI 10.1016/j.coph.2003.09.008; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; Miyashita T, 2005, BIOCHEM BIOPH RES CO, V333, P1241, DOI 10.1016/j.bbrc.2005.06.032; Monteiro FA, 2006, J NEUROCHEM, V97, P151, DOI 10.1111/j.1471-4159.2006.03716.x; Muscella A, 2004, J CELL PHYSIOL, V200, P428, DOI 10.1002/jcp.20033; Nakazawa T, 2003, CURR EYE RES, V26, P55, DOI 10.1076/ceyr.26.1.55.14254; Nolan Y, 2003, EXP NEUROL, V184, P794, DOI 10.1016/S0014-4886(03)00301-7; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Orr HT, 2000, NEUROBIOL DIS, V7, P129, DOI 10.1006/nbdi.2000.0305; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x; Rangone H, 2005, J BIOL CHEM, V280, P22021, DOI 10.1074/jbc.M407528200; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Rouaux C, 2004, BIOCHEM PHARMACOL, V68, P1157, DOI 10.1016/j.bcp.2004.05.035; Sahara N, 2004, J NEUROCHEM, V90, P829, DOI 10.1111/j.1471-4159.2004.02558.x; Senut MC, 2000, J NEUROSCI, V20, P219, DOI 10.1523/JNEUROSCI.20-01-00219.2000; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Silva RM, 2005, MOVEMENT DISORD, V20, P653, DOI 10.1002/mds.20390; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; Song C, 2002, J BIOL CHEM, V277, P6703, DOI 10.1074/jbc.M110338200; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; Sugars KL, 2004, J BIOL CHEM, V279, P4988, DOI 10.1074/jbc.M310226200; Swayne LA, 2005, MOL CELL NEUROSCI, V30, P339, DOI 10.1016/j.mcn.2005.07.016; Tamagno E, 2003, EXP NEUROL, V180, P144, DOI 10.1016/S0014-4886(02)00059-6; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Tortarolo M, 2003, MOL CELL NEUROSCI, V23, P180, DOI 10.1016/S1044-7431(03)00022-8; Tsirigotis M, 2006, NEUROPATH APPL NEURO, V32, P26, DOI 10.1111/j.1365-2990.2005.00694.x; van de Warrenburg BPC, 2003, NEUROLOGY, V61, P1760, DOI 10.1212/01.WNL.0000098883.79421.73; Van den Blink B, 2004, J CLIN IMMUNOL, V24, P37, DOI 10.1023/B:JOCI.0000018061.58504.75; Vig PJS, 2006, BRAIN RES BULL, V69, P573, DOI 10.1016/j.brainresbull.2006.02.020; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Warby SC, 2005, HUM MOL GENET, V14, P1569, DOI 10.1093/hmg/ddi165; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xie J, 2005, J BIOL CHEM, V280, P13824, DOI 10.1074/jbc.M411933200; Xie J, 2000, MOL BRAIN RES, V82, P107, DOI 10.1016/S0169-328X(00)00187-X; Xie J, 2001, BRAIN RES, V915, P1, DOI 10.1016/S0006-8993(01)02803-7; Yu XR, 2006, ACTA BIOCH BIOPH SIN, V38, P241, DOI 10.1111/j.1745-7270.2006.00152.x; Zheng WH, 2004, J NEUROCHEM, V89, P844, DOI 10.1111/j.1471-4159.2004.02350.x; Zwerina J, 2006, ARTHRITIS RHEUM-US, V54, P463, DOI 10.1002/art.21626	89	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2130	10.1371/journal.pone.0002130	http://dx.doi.org/10.1371/journal.pone.0002130			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461158	gold, Green Submitted, Green Published			2022-12-25	WOS:000261642400051
J	Alboresi, A; Caffarri, S; Nogue, F; Bassi, R; Morosinotto, T				Alboresi, Alessandro; Caffarri, Stefano; Nogue, Fabien; Bassi, Roberto; Morosinotto, Tomas			In Silico and Biochemical Analysis of Physcomitrella patens Photosynthetic Antenna: Identification of Subunits which Evolved upon Land Adaptation	PLOS ONE			English	Article							LIGHT-HARVESTING COMPLEX; PHOTOSYSTEM-I; HIGHER-PLANTS; SUPRAMOLECULAR ORGANIZATION; CHLAMYDOMONAS-REINHARDTII; CHLOROPHYLL FLUORESCENCE; ARABIDOPSIS-THALIANA; THYLAKOID MEMBRANES; OSTREOCOCCUS-TAURI; MESOSTIGMA-VIRIDE	Background: In eukaryotes the photosynthetic antenna system is composed of subunits encoded by the light harvesting complex (Lhc) multigene family. These proteins play a key role in photosynthesis and are involved in both light harvesting and photoprotection. The moss Physcomitrella patens is a member of a lineage that diverged from seed plants early after land colonization and therefore by studying this organism, we may gain insight into adaptations to the aerial environment. Principal Findings: In this study, we characterized the antenna protein multigene family in Physcomitrella patens, by sequence analysis as well as biochemical and functional investigations. Sequence identification and analysis showed that some antenna polypeptides, such as Lhcb3 and Lhcb6, are present only in land organisms, suggesting they play a role in adaptation to the sub-aerial environment. Our functional analysis which showed that photo-protective mechanisms in Physcomitrella patens are very similar to those in seed plants fits with this hypothesis. In particular, Physcomitrella patens also activates Non Photochemical Quenching upon illumination, consistent with the detection of an ortholog of the PsbS protein. As a further adaptation to terrestrial conditions, the content of Photosystem I low energy absorbing chlorophylls also increased, as demonstrated by differences in Lhca3 and Lhca4 polypeptide sequences, in vitro reconstitution experiments and low temperature fluorescence spectra. Conclusions: This study highlights the role of Lhc family members in environmental adaptation and allowed proteins associated with mechanisms of stress resistance to be identified within this large family.	[Alboresi, Alessandro; Caffarri, Stefano; Morosinotto, Tomas] Univ Mediterranee, CNRS, CEA, Lab Genet & Biophys Plantes,UMR 6191, Marseille, France; [Nogue, Fabien] IJPB, INRA, Stn Genet Ameliorat Plantes, Versailles, France; [Bassi, Roberto] Univ Verona, Dipartimento Sci Tecnol, Verona, Italy; [Morosinotto, Tomas] Univ Padua, Dipartimento Biol, Padua, Italy	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Verona; University of Padua	Alboresi, A (corresponding author), Univ Mediterranee, CNRS, CEA, Lab Genet & Biophys Plantes,UMR 6191, Marseille, France.	tomas.morosinotto@unipd.it	Morosinotto, Tomas/AAC-3188-2019; Alboresi, Alessandro/B-5080-2010; Alboresi, Alessandro/Z-1220-2019; Caffarri, Stefano/AAX-8913-2021	Morosinotto, Tomas/0000-0002-0803-7591; Alboresi, Alessandro/0000-0003-4818-7778; Caffarri, Stefano/0000-0002-4729-7679; bassi, roberto/0000-0002-4140-8446; Nogue, Fabien/0000-0003-0619-4638	European Community's Human Potential Program [HPRN-CT-2002-00248]; CEA [fellowship]	European Community's Human Potential Program; CEA(French Atomic Energy Commission)	AA was supported by the European Community's Human Potential Program contract HPRN-CT-2002-00248 (PSICO) and by a CEA fellowship. We thank the FISR grants Idrobio for financial support.	ASHTON NW, 1979, PLANTA, V144, P427, DOI 10.1007/BF00380118; Ballottari M, 2004, EUR J BIOCHEM, V271, P4659, DOI 10.1111/j.1432-1033.2004.04426.x; Ballottari M, 2007, J BIOL CHEM, V282, P8947, DOI 10.1074/jbc.M606417200; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BASSI R, 1992, J BIOL CHEM, V267, P25714; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Caffarri S, 2005, PROTEOMICS, V5, P758, DOI 10.1002/pmic.200402008; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Carbonera D, 2005, BIOCHEMISTRY-US, V44, P8337, DOI 10.1021/bi050260z; COURTIES C, 1994, NATURE, V370, P255, DOI 10.1038/370255a0; Courties C, 1998, J PHYCOL, V34, P844, DOI 10.1046/j.1529-8817.1998.340844.x; Cove D, 2005, ANNU REV GENET, V39, P339, DOI 10.1146/annurev.genet.39.073003.110214; Cove DJ, 1997, TRENDS PLANT SCI, V2, P99, DOI 10.1016/S1360-1385(96)10056-X; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Croce R, 2007, BIOCHEMISTRY-US, V46, P3846, DOI 10.1021/bi602531k; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, PHYSIOL PLANTARUM, V98, P253, DOI 10.1034/j.1399-3054.1996.980206.x; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Elrad D, 2004, CURR GENET, V45, P61, DOI 10.1007/s00294-003-0460-x; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Falkowski PG, 2006, SCIENCE, V311, P1724, DOI 10.1126/science.1125937; Finazzi G, 2006, BIOCHEMISTRY-US, V45, P1490, DOI 10.1021/bi0521588; Frigerio S, 2007, J BIOL CHEM, V282, P29457, DOI 10.1074/jbc.M705132200; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Gunning BES, 1999, AUST J PLANT PHYSIOL, V26, P695, DOI 10.1071/PP99076; Harrer R, 2003, PHOTOSYNTH RES, V75, P249, DOI 10.1023/A:1023952832255; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Hofmann AH, 1999, MOL GEN GENET, V261, P92, DOI 10.1007/s004380050945; Horton P, 2005, J EXP BOT, V56, P365, DOI 10.1093/jxb/eri023; Hutin C, 2003, P NATL ACAD SCI USA, V100, P4921, DOI 10.1073/pnas.0736939100; Jansson S, 1999, PLANT MOL BIOL REP, V17, P221, DOI 10.1023/A:1007620508007; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Kargul J, 2003, J BIOL CHEM, V278, P16135, DOI 10.1074/jbc.M300262200; Klimmek F, 2006, PLANT PHYSIOL, V140, P793, DOI 10.1104/pp.105.073304; Kovacs L, 2006, PLANT CELL, V18, P3106, DOI 10.1105/tpc.106.045641; KOZIOL AG, 2007, PLANT PHYSL; Kulheim C, 2002, SCIENCE, V297, P91, DOI 10.1126/science.1072359; Larkum AWD, 2003, ADV PHOTO RESPIRAT, V14, P11; LAROCHE J, 1991, PLANT PHYSIOL, V97, P147, DOI 10.1104/pp.97.1.147; Lemieux C, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-2; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Markmann-Mulisch U, 2002, P NATL ACAD SCI USA, V99, P2959, DOI 10.1073/pnas.032668199; Matsubara S, 2007, PLANT PHYSIOL, V144, P926, DOI 10.1104/pp.107.099077; Morosinotto T, 2005, J BIOL CHEM, V280, P31050, DOI 10.1074/jbc.M502935200; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Morosinotto T, 2006, FEBS J, V273, P4616, DOI 10.1111/j.1742-4658.2006.05465.x; Nedelcu AM, 2006, MOL BIOL EVOL, V23, P1011, DOI 10.1093/molbev/msj108; Nelson N, 2005, BIOESSAYS, V27, P914, DOI 10.1002/bies.20278; Nishiyama T, 2003, P NATL ACAD SCI USA, V100, P8007, DOI 10.1073/pnas.0932694100; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; Peers G, 2007, PHOTOSYNTH RES, V91, P250; PETER GF, 1991, J BIOL CHEM, V266, P16745; Quatrano RS, 2007, CURR OPIN PLANT BIOL, V10, P182, DOI 10.1016/j.pbi.2007.01.005; Rensing SA, 2008, SCIENCE, V319, P64, DOI 10.1126/science.1150646; RHIEL E, 1993, MOL GEN GENET, V240, P403, DOI 10.1007/BF00280392; Richard C, 2000, PLANT MOL BIOL, V42, P303, DOI 10.1023/A:1006340308077; Rivadossi A, 1999, PHOTOSYNTH RES, V60, P209, DOI 10.1023/A:1006236829711; Rodriguez-Ezpeleta N, 2007, MOL BIOL EVOL, V24, P723, DOI 10.1093/molbev/msl200; Rossini S, 2006, PLANT PHYSIOL, V141, P1264, DOI 10.1104/pp.106.083055; Six C, 2005, MOL BIOL EVOL, V22, P2217, DOI 10.1093/molbev/msi220; Standfuss J, 2004, J BIOL CHEM, V279, P36884, DOI 10.1074/jbc.M402348200; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; TRISSL HW, 1993, TRENDS BIOCHEM SCI, V18, P415, DOI 10.1016/0968-0004(93)90136-B; Trouiller B, 2006, NUCLEIC ACIDS RES, V34, P232, DOI 10.1093/nar/gkj423; Turmel M, 2002, MOL BIOL EVOL, V19, P24, DOI 10.1093/oxfordjournals.molbev.a003979; Tzvetkova-Chevolleau T, 2007, PLANT J, V50, P795, DOI 10.1111/j.1365-313X.2007.03090.x; Walters RG, 2005, J EXP BOT, V56, P435, DOI 10.1093/jxb/eri060	80	104	106	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2033	10.1371/journal.pone.0002033	http://dx.doi.org/10.1371/journal.pone.0002033			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446222	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300006
J	Curtin, JF; Candolfi, M; Fakhouri, TM; Liu, CY; Alden, A; Edwards, M; Lowenstein, PR; Castro, MG				Curtin, James F.; Candolfi, Marianela; Fakhouri, Tamer M.; Liu, Chunyan; Alden, Anderson; Edwards, Matthew; Lowenstein, Pedro R.; Castro, Maria G.			Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials	PLOS ONE			English	Article								Background: Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to mediate GBM regression in preclinical models of brain tumors. Clinical trials that combine Treg depletion with tumor vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and improve long term survival in cancer patients. Findings: Using a syngeneic intracrabial glioblastoma (GBM) mouse model we show that systemic depletion of Tregs 15 days after tumor implantation using PC61 resulted in a decrease in Tregs present in tumors, draining lymph nodes and spleen and improved long-term survival (50% of mice survived > 150 days). No improvement in survival was observed when Tregs were depleted 24 days after tumor implantation, suggesting that tumor burden is an important factor for determining efficacy of Treg depletion in clinical trials. In a T cell dependent model of brain tumor regression elicited by intratumoral delivery of adenoviral vectors (Ad) expressing Fms-like Tyrosine Kinase 3 ligand (Flt3L) and Herpes Simplex Type 1-Thymidine Kinase (TK) with ganciclovir (GCV), we demonstrate that administration of PC61 24 days after tumor implantation (7 days after treatment) inhibited T cell dependent tumor regression and long term survival. Further, depletion with PC61 completely inhibited clonal expansion of tumor antigen-specific T lymphocytes in response to the treatment. Conclusions: Our data demonstrate for the first time, that although Treg depletion inhibits the progression/eliminates GBM tumors, its efficacy is dependent on tumor burden. We conclude that this approach will be useful in a setting of minimal residual disease. Further, we also demonstrate that Treg depletion, using PC61 in combination with immunotherapy, inhibits clonal expansion of tumor antigen-specific T cells, suggesting that new, more specific targets to block Tregs will be necessary when used in combination with therapies that activate anti-tumor immunity.	[Curtin, James F.; Candolfi, Marianela; Fakhouri, Tamer M.; Liu, Chunyan; Alden, Anderson; Edwards, Matthew; Lowenstein, Pedro R.; Castro, Maria G.] Cedars Sinai Med Ctr, Dept Biomed Sci, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; [Curtin, James F.; Candolfi, Marianela; Liu, Chunyan; Lowenstein, Pedro R.; Castro, Maria G.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehensive Canc Ctr, Brain Res Inst, Dept Med, Los Angeles, CA USA; [Curtin, James F.; Candolfi, Marianela; Liu, Chunyan; Lowenstein, Pedro R.; Castro, Maria G.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehensive Canc Ctr, Brain Res Inst, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Cedars Sinai Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Castro, MG (corresponding author), Cedars Sinai Med Ctr, Dept Biomed Sci, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA.	castromg@cshs.org	Curtin, James/B-1669-2008; Castro, Maria/ABC-5182-2021	Curtin, James/0000-0002-9320-9254; Castro, Maria/0000-0003-2237-2756; Edwards, Matthew/0000-0002-9701-0736	National Institutes of Health/National Institute of Neurological Disorders & Stroke (NIH/NINDS) [1R01 NS44556.01, NS445561.01, 1R21-NSO54143.01, 1UO1 NS052465.01, 1 RO3 TW006273-01, 1 RO1 NS 054193.01, RO1 NS 42893.01, U54 NS045309-01, 1R21 NS047298-01, 1F32 NS058156.01]; The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics; The Linda Tallen & David Paul Kane Foundation Annual Fellowship; Board of Governors at CSMC; FOGARTY INTERNATIONAL CENTER [R03TW006273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS058156, R01NS044556, U54NS045309, R01NS054193, R21NS047298, U01NS052465, R01NS042893] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Neurological Disorders & Stroke (NIH/NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics; The Linda Tallen & David Paul Kane Foundation Annual Fellowship; Board of Governors at CSMC; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by National Institutes of Health/National Institute of Neurological Disorders & Stroke (NIH/NINDS) Grant 1R01 NS44556.01, Minority Supplement NS445561.01; 1R21-NSO54143.01; 1UO1 NS052465.01, 1 RO3 TW006273-01 to M.G.C.; NIH/NINDS Grants 1 RO1 NS 054193.01; RO1 NS 42893.01, U54 NS045309-01 and 1R21 NS047298-01 to P.R.L. The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics to PRL and MGC, respectively, The Linda Tallen & David Paul Kane Foundation Annual Fellowship and the Board of Governors at CSMC. M.C is supported by NIH/NINDS 1F32 NS058156.01.	Alegre ML, 1998, J IMMUNOL, V161, P3347; Ali S, 2004, MOL THER, V10, P1071, DOI 10.1016/j.ymthe.2004.08.025; Ali S, 2005, CANCER RES, V65, P7194, DOI 10.1158/0008-5472.CAN-04-3434; Barao I, 2006, P NATL ACAD SCI USA, V103, P5460, DOI 10.1073/pnas.0509249103; Barzon L, 2006, CANCER GENE THER, V13, P539, DOI 10.1038/sj.cgt.7700930; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Curtin JF, 2006, J IMMUNOL, V176, P3566, DOI 10.4049/jimmunol.176.6.3566; Curtin JF, 2005, CURR TOP MED CHEM, V5, P1151, DOI 10.2174/156802605774370856; Dewey RA, 1999, NAT MED, V5, P1256, DOI 10.1038/15207; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; El Andaloussi A, 2006, NEURO-ONCOLOGY, V8, P234, DOI 10.1215/15228517-2006-006; El Andaloussi A, 2007, J NEURO-ONCOL, V83, P145, DOI 10.1007/s11060-006-9314-y; El Andaloussi A, 2006, J NEUROSURG, V105, P430, DOI 10.3171/jns.2006.105.3.430; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Fecci PE, 2007, CLIN CANCER RES, V13, P2158, DOI 10.1158/1078-0432.CCR-06-2070; Fecci PE, 2006, CLIN CANCER RES, V12, P4294, DOI 10.1158/1078-0432.CCR-06-0053; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Ghiringhelli F, 2006, IMMUNOL REV, V214, P229, DOI 10.1111/j.1600-065X.2006.00445.x; Gomez GG, 2006, GENE THER MOL BIOL, V10A, P133; Grauer OM, 2007, INT J CANCER, V121, P95, DOI 10.1002/ijc.22607; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnson BD, 2007, J IMMUNOTHER, V30, P203, DOI 10.1097/01.cji.0000211336.91513.dd; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; King GD, 2005, CURR GENE THER, V5, P535, DOI 10.2174/156652305774964631; KING GD, 2007, NEUROONCOL; Liau LM, 2005, CLIN CANCER RES, V11, P5515, DOI 10.1158/1078-0432.CCR-05-0464; Lowenstein PR, 2002, TRENDS IMMUNOL, V23, P23, DOI 10.1016/S1471-4906(01)02063-4; LOWENTHAL JW, 1985, NATURE, V315, P669, DOI 10.1038/315669a0; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; McLendon RE, 2003, CANCER-AM CANCER SOC, V98, P1745, DOI 10.1002/cncr.11666; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Onizuka S, 1999, CANCER RES, V59, P3128; Prins RM, 2004, FRONT BIOSCI-LANDMRK, V9, P3124, DOI 10.2741/1465; Qu YY, 2007, INT REV IMMUNOL, V26, P145, DOI 10.1080/08830180701365917; Skog J, 2006, EXPERT REV VACCINES, V5, P793, DOI 10.1586/14760584.5.6.793; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Sun Z, 2006, AM J TRANSPLANT, V6, P2841, DOI 10.1111/j.1600-6143.2006.01549.x; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Tang J, 2005, CLIN CANCER RES, V11, P5292, DOI 10.1158/1078-0432.CCR-05-0545; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Whiteside TL, 2006, SEMIN CANCER BIOL, V16, P3, DOI 10.1016/j.semcancer.2005.07.008; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Yamanaka R, 2003, BRIT J CANCER, V89, P1172, DOI 10.1038/sj.bjc.6601268; Yi HF, 2006, CELL MOL IMMUNOL, V3, P189	50	99	105	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1983	10.1371/journal.pone.0001983	http://dx.doi.org/10.1371/journal.pone.0001983			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431473	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700008
J	Gentilella, A; Passiatore, G; Deshmane, S; Turco, MC; Khalili, K				Gentilella, A.; Passiatore, G.; Deshmane, S.; Turco, M. C.; Khalili, K.			Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells	ONCOGENE			English	Article						BAG3; Egr-1; neuron/neuronal	FIBROBLAST GROWTH FACTOR-2; TRANSCRIPTION FACTOR EGR-1; SMOOTH-MUSCLE-CELLS; BCL-2-BINDING PROTEIN; REACTIVE ASTROCYTES; APOPTOSIS; GENE; SURVIVAL; FAMILY; BRAIN	The co-chaperone protein, BAG3, which belongs to the BAG protein family, has an established antiapoptotic function in different tumor cell lines. Here we demonstrated that treatment of the human neuroblastoma cell line, SK-N-MC, with. broblast growth factor-2 (FGF-2) results in induction of BAG3 expression. Induction of BAG3 protein by FGF-2 occurs at the transcriptional level; it requires the extracellular regulated kinase1/2 pathway and is dependent on the activity of Egr-1 upon the BAG3 promoter. Targeted suppression of BAG3 by small-interfering RNA results in dysregulation of cell-cycle progression most notably at S and G(2) phases, which corroborates the decreased level of cyclin B1 expression. These observations suggest a new role for BAG3 in regulation of the cell cycle.	[Gentilella, A.; Passiatore, G.; Deshmane, S.; Khalili, K.] Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Turco, M. C.] Univ Salerno, Dept Pharmaceut Sci, I-84100 Salerno, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Salerno	Khalili, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu	TURCO, Maria Caterina/AAC-5282-2022; Gentilella, Antonio/AAA-9864-2020	TURCO, Maria Caterina/0000-0002-7835-359X; 	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank past and present members of the Department of Neuroscience and Center for Neurovirology for sharing of ideas and reagents, and their encouragement throughout this study. We also thank Dr Francesca Peruzzi, Dr Davide Eletto and Dr Thersa M Sweet for their advices, William Yen and Jessica Otte for their technical support, Dr Martyn White for his time and assistance in the preparation of the manuscript and C Schriver for editorial assistance. This study is dedicated to our friend and colleague, Dr Arturo Leone. This work was made possible by grants awarded by NIH to KK.	Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Gremo F, 2000, INT J DEV NEUROSCI, V18, P271, DOI 10.1016/S0736-5748(99)00095-7; Gritti A, 1996, J NEUROSCI, V16, P1091; Her S, 2004, MOL BRAIN RES, V126, P157, DOI 10.1016/j.molbrainres.2004.04.002; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Issa Razao, 2005, Angiogenesis, V8, P53, DOI 10.1007/s10456-005-5613-8; Kim MS, 2004, J PATHOL, V202, P103, DOI 10.1002/path.1497; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Lee MY, 2002, EXP MOL MED, V34, P167, DOI 10.1038/emm.2002.24; Lee MY, 2002, EXP NEUROL, V175, P338, DOI 10.1006/exnr.2002.7903; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liman J, 2005, MOL CELL BIOL, V25, P3715, DOI 10.1128/MCB.25.9.3715-3725.2005; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Midgley VC, 2004, J BIOL CHEM, V279, P40289, DOI 10.1074/jbc.M406063200; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; Rossler OG, 2004, AM J PHYSIOL-CELL PH, V286, pC1118, DOI 10.1152/ajpcell.00301.2003; Russo VC, 2004, J CELL PHYSIOL, V199, P371, DOI 10.1002/jcp.10416; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Vogel S, 2006, J CELL PHYSIOL, V206, P25, DOI 10.1002/jcp.20437; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	41	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5011	5018		10.1038/onc.2008.142	http://dx.doi.org/10.1038/onc.2008.142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469860				2022-12-25	WOS:000258914800004
J	Jia, JM; Chen, Q; Zhou, Y; Miao, S; Zheng, J; Zhang, C; Xiong, ZQ				Jia, Jie-Min; Chen, Qian; Zhou, Yang; Miao, Sheng; Zheng, Jing; Zhang, Chi; Xiong, Zhi-Qi			Brain-derived neurotrophic factor-tropomyosin-related kinase B signaling contributes to activity-dependent changes in synaptic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; DEGRADATION; BDNF; CREB; MODULATION; EXPRESSION; PLASTICITY; RECEPTORS	The ability of synapses to undergo changes in structure and function in response to alterations of neuronal activity is an essential property of neural circuits. One way that this is achieved is through global changes in the molecular composition of the synapse; however, it is not clear how these changes are coupled to the dynamics of neuronal activity. Here we found that, in cultured rat cortical neurons, bidirectional changes of neuronal activity led to corresponding alterations in the expression of brain-derived neurotrophic factor (BDNF) and phosphorylation of its receptor tropomyosin-related kinase B (TrkB), as well as in the level of synaptic proteins. Exogenous BDNF reversed changes in synaptic proteins induced by chronic activity blockade, while inhibiting Trk kinase activity or depleting endogenous BDNF abolished the concentration changes induced by chronic activity elevation. Both tetrodotoxin and bicuculline had significant, but opposite, effects on synaptic protein ubiquitination in a time-dependent manner. Furthermore, exogenous BDNF was sufficient to increase ubiquitination of synaptic proteins, whereas scavenging endogenous BDNF or inhibiting Trk kinase activity prevented the ubiquitination of synaptic proteins induced by chronic elevation of neuronal activity. Inhibiting the proteasome or blocking protein polyubiquitination mimicked the effect of tetrodotoxin on the levels of synaptic proteins and canceled the effects of BDNF. Our study indicates that BDNF-TrkB signaling acts upstream of the ubiquitin proteasome system, linking neuronal activity to protein turnover at the synapse.	[Xiong, Zhi-Qi] Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Neurosci, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Xiong, ZQ (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	xiongzhiqi@ion.ac.cn	Zhang, Chi/ABB-1176-2021; Jia, Jie-Min/O-1150-2013; Chen, Qian/B-7405-2013	Zhang, Chi/0000-0003-4866-1441; Jia, Jie-Min/0000-0001-8446-3819; 				Aamodt S M, 1999, Adv Neurol, V79, P133; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; BOZZI Y, 1995, NEUROSCIENCE, V69, P1133, DOI 10.1016/0306-4522(95)00321-9; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chen Q, 2007, J NEUROSCI, V27, P542, DOI 10.1523/JNEUROSCI.3607-06.2007; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; He XP, 2004, NEURON, V43, P31, DOI 10.1016/j.neuron.2004.06.019; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; LESSMANN V, 1994, NEUROREPORT, V6, P21; Liu CL, 2004, J CEREBR BLOOD F MET, V24, P1219, DOI 10.1097/01.WCB.0000136706.77918.21; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lu B, 2004, PROG BRAIN RES, V146, P137, DOI 10.1016/S0079-6123(03)46010-X; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Mayer RJ, 2003, DRUG NEWS PERSPECT, V16, P103, DOI 10.1358/dnp.2003.16.2.829327; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Patil S, 2005, CELL METAB, V2, P210, DOI 10.1016/j.cmet.2005.09.007; Patrick GN, 2003, CURR BIOL, V13, P2073, DOI 10.1016/j.cub.2003.10.028; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Speese SD, 2003, CURR BIOL, V13, P899, DOI 10.1016/S0960-9822(03)00338-5; Spencer ML, 2004, J BIOL CHEM, V279, P37069, DOI 10.1074/jbc.M402507200; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Wu H, 2007, FEBS J, V274, P3218, DOI 10.1111/j.1742-4658.2007.05891.x; Yeo GSH, 2004, NAT NEUROSCI, V7, P1187, DOI 10.1038/nn1336; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016	45	36	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					21242	21250		10.1074/jbc.M800282200	http://dx.doi.org/10.1074/jbc.M800282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18474605	Green Published, hybrid			2022-12-25	WOS:000257746100066
J	Heyd, F; Carmo-Fonseca, M; Moroy, T				Heyd, Florian; Carmo-Fonseca, Maria; Moroy, Tarik			Differential isoform expression and interaction with the P32 regulatory protein controls the subcellular localization of the splicing factor U2AF26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; FACTOR U2AF(35); SR PROTEINS; SITE AG; BINDING; NUCLEUS; VIRUS; KINASE; IDENTIFICATION; RECOGNITION	The U2 auxiliary factor (U2AF) is an integral part of the spliceosome that is important for the recognition of the 3' splice site. U2AF consists of a large and a small subunit, the prototypes of which are U2AF65 and U2AF35. Recent evidence suggests that several homologs of both U2AF subunits exist that are able to regulate alternative splicing. Here we have investigated the expression, intracellular localization, and nucleo-cytoplasmic shuttling of one homolog of the small U2AF subunit, U2AF26, and a splice variant lacking exon 7, U2AF26 Delta E7. In contrast to the nuclear U2AF26, which displays active nucleo-cytoplasmic shuttling, U2AF26 Delta E7 is localized in the cytoplasm. Our studies reveal a nuclear localization sequence in the C-terminal exons 7 and 8 of U2AF26 that differs from the known nuclear localization sequence in U2AF35. In addition, we could identify P32 as a protein that is able to interact with U2AF26 through this domain, and we demonstrate that this interaction is required for the nuclear translocation of U2AF26. Our results suggest the existence of two distinct nuclear import pathways for U2AF26 and U2AF35 that could independently control their intracellular distribution and availability to the splicing machinery. Such a mechanism could work in addition to the differential expression of U2AF homologs to contribute to the regulation of alternative splicing.	[Heyd, Florian; Moroy, Tarik] Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; [Moroy, Tarik] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H2W 1R7, Canada; [Carmo-Fonseca, Maria] Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universidade de Lisboa	Moroy, T (corresponding author), Univ Montreal, Inst Rech Clin Montreal, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	Tarik.Moroy@ircm.qc.ca	Moroy, Tarik/D-9923-2011	Carmo-Fonseca, Maria/0000-0002-3402-7143				Berro R, 2006, J VIROL, V80, P3189, DOI 10.1128/JVI.80.7.3189-3204.2006; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blanchette M, 2004, MOL CELL, V14, P775, DOI 10.1016/j.molcel.2004.06.012; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Brokstad KA, 2001, BIOCHEM BIOPH RES CO, V281, P1161, DOI 10.1006/bbrc.2001.4473; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Gama-Carvalho M, 2001, J BIOL CHEM, V276, P13104, DOI 10.1074/jbc.M008759200; Gama-Carvalho M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-11-r113; Ghebrehiwet B, 2004, MOL IMMUNOL, V41, P173, DOI 10.1016/j.molimm.2004.03.014; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hastings ML, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000538; Heyd F, 2006, NAT IMMUNOL, V7, P859, DOI 10.1038/ni1361; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Majumdar M, 2002, BIOCHEM BIOPH RES CO, V291, P829, DOI 10.1006/bbrc.2002.6491; Marschall M, 2005, J BIOL CHEM, V280, P33357, DOI 10.1074/jbc.M502672200; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Mollet I, 2006, FEBS J, V273, P4807, DOI 10.1111/j.1742-4658.2006.05502.x; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Pacheco TR, 2004, J BIOL CHEM, V279, P27039, DOI 10.1074/jbc.M402136200; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Robles-Flores M, 2002, J BIOL CHEM, V277, P5247, DOI 10.1074/jbc.M109333200; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Shepard J, 2002, MOL CELL BIOL, V22, P221, DOI 10.1128/MCB.22.1.221-230.2002; SHEPARD J, 2004, THESIS U TEXAS SW ME; Shoya Y, 1998, J VIROL, V72, P9755, DOI 10.1128/JVI.72.12.9755-9762.1998; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zheng YH, 2003, NAT CELL BIOL, V5, P611, DOI 10.1038/ncb1000; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	35	14	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19637	19645		10.1074/jbc.M801014200	http://dx.doi.org/10.1074/jbc.M801014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18460468	hybrid			2022-12-25	WOS:000257387600049
J	Nabavi, N; Urukova, Y; Cardelli, M; Aubin, JE; Harrison, RE				Nabavi, Noushin; Urukova, Yulia; Cardelli, Marco; Aubin, Jane E.; Harrison, Rene E.			Lysosome dispersion in osteoblasts accommodates enhanced collagen production during differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; SECRETORY GRANULES; LUNG FIBROBLASTS; PLASMA-MEMBRANE; MC3T3-E1 CELLS; LATE ENDOSOMES; GOLGI-COMPLEX; PROTEIN RILP; TRANSPORT; MICROTUBULES	Lysosomes are essential organelles for intracellular degradation and are generally sequestered near the cell center to receive vesicles with contents targeted for destruction. During ascorbic acid (AA)-induced differentiation of osteogenic cells (Beck, G. R., Jr., Zerler, B., and Moran, E. (2001) Cell Growth Differ. 12, 61 -83), we saw a marked increase in total lysosome organelles in osteoblastic cells, in addition to an enhanced endocytic rate. Interestingly, lysosomes were dispersed toward the cell periphery in differentiating osteoblasts. We determined that lysosome dispersion in differentiated osteoblasts required intact microtubules for long range transport and was dependent on kinesin motors but did not involve cytosolic acidification. Impairment of lysosome dispersion markedly reduced AA-induced osteoblast differentiation. Lysosomes were not secreted in differentiated osteoblasts, implicating them instead in intracellular degradation. We assayed the degradative capacity and saw a significant increase in DQ-ovalbumin fluorescence in differentiated osteogenic cells compared with undifferentiated control cells. Osteogenic cells are specialized for type I collagen production, and we noted enhanced secreted and intracellular collagen in AA-differentiated osteoblasts versus control cells. Importantly, osteoblasts displayed procollagen-containing vesicles that were distributed throughout the cytoplasm, a portion of which colocalized with lysosomes. Treatment of cells with 2,2'-dipyridyl to inhibit procollagen trimerization enhanced colocalization of lysosomes with procollagen-containing organelles, implicating dispersed lysosomes in collagen processing in osteogenic cells.	[Nabavi, Noushin; Harrison, Rene E.] Univ Toronto Scarborough, Fac Med, Dept Cell & Syst Biol, Toronto, ON M1C 1A4, Canada; [Nabavi, Noushin; Urukova, Yulia; Harrison, Rene E.] Univ Toronto Scarborough, Fac Med, Dept Biol Sci, Toronto, ON M1C 1A4, Canada; [Cardelli, Marco; Aubin, Jane E.] Univ Toronto Scarborough, Fac Med, Dept Med Biophys, Toronto, ON M1C 1A4, Canada; [Aubin, Jane E.] Univ Toronto Scarborough, Fac Med, Dept Mol Genet, Toronto, ON M1C 1A4, Canada	University of Toronto; University Toronto Scarborough; University of Toronto; University Toronto Scarborough; University of Toronto; University Toronto Scarborough; University of Toronto; University Toronto Scarborough	Harrison, RE (corresponding author), Univ Toronto Scarborough, Fac Med, Dept Cell & Syst Biol, Toronto, ON M1C 1A4, Canada.	harrison@utsc.utoronto.ca		Nabavi, Noushin/0000-0002-5471-6229; Aubin, Jane E./0000-0002-7268-5235				Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110; AUBIN JE, 1995, BONE, V17, P77; BARILE FA, 1990, ARCH BIOCHEM BIOPHYS, V276, P125, DOI 10.1016/0003-9861(90)90018-T; Beck GR, 2001, CELL GROWTH DIFFER, V12, P61; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BERG RA, 1983, ARCH BIOCHEM BIOPHYS, V226, P681, DOI 10.1016/0003-9861(83)90338-7; BIENKOWSKI RS, 1984, J CELL PHYSIOL, V121, P152, DOI 10.1002/jcp.1041210119; Billiard J, 2003, J CELL BIOCHEM, V89, P389, DOI 10.1002/jcb.10514; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; CARMOFONSECA M, 1990, ELECTRON MICROSC REV, V3, P115, DOI 10.1016/0892-0354(90)90017-M; Caviston JP, 2006, TRENDS CELL BIOL, V16, P530, DOI 10.1016/j.tcb.2006.08.002; CECH S, 1983, CELL TISSUE RES, V230, P661, DOI 10.1007/BF00216209; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DIEGELMA.RF, 1972, P NATL ACAD SCI USA, V69, P892, DOI 10.1073/pnas.69.4.892; Eng EW, 2007, MOL BIOL CELL, V18, P2389, DOI 10.1091/mbc.e06-12-1128; FRANCESCHI RT, 1995, AM J PHYSIOL-CELL PH, V268, pC1430, DOI 10.1152/ajpcell.1995.268.6.C1430; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; Harrison RE, 2004, MOL BIOL CELL, V15, P3146, DOI 10.1091/mbc.E04-02-0092; Harrison RE, 2003, MOL CELL BIOL, V23, P6494, DOI 10.1128/MCB.23.18.6494-6506.2003; HARWOOD R, 1976, BIOCHEM J, V156, P81, DOI 10.1042/bj1560081; HELSETH DL, 1984, P NATL ACAD SCI-BIOL, V81, P3302, DOI 10.1073/pnas.81.11.3302; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Holt OJ, 2006, J BIOCHEM, V140, P7, DOI 10.1093/jb/mvj126; Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; Khumalo H, 1998, CLIN CHEM, V44, P1573; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; Lee HJ, 2006, MOL BIOL CELL, V17, P4812, DOI 10.1091/mbc.E06-06-0486; LIN SXH, 1992, J CELL SCI, V101, P125; Lu ZM, 2001, MOL BIOL CELL, V12, P795, DOI 10.1091/mbc.12.4.795; Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074; Martinez-Vicente M, 2007, LANCET NEUROL, V6, P352, DOI 10.1016/S1474-4422(07)70076-5; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; Ripley CR, 1997, EXP CELL RES, V236, P147, DOI 10.1006/excr.1997.3707; Rockel TD, 2005, J CELL SCI, V118, P5231, DOI 10.1242/jcs.02642; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rudolf R, 2001, MOL BIOL CELL, V12, P1353, DOI 10.1091/mbc.12.5.1353; Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200; Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097-4644(19991001)75:1<22::AID-JCB3>3.0.CO;2-6; Stains JP, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-222; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1992, J CELL SCI, V103, P201; Tullberg-Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wada M, 2004, CURR OPIN PLANT BIOL, V7, P626, DOI 10.1016/j.pbi.2004.09.005; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097-4644(20001101)79:2<301::AID-JCB130>3.0.CO;2-0; Zhang YR, 2004, BIOPHYS J, V87, P1795, DOI 10.1529/biophysj.104.039842; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	57	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19678	19690		10.1074/jbc.M802517200	http://dx.doi.org/10.1074/jbc.M802517200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18463099	hybrid			2022-12-25	WOS:000257387600053
J	Prickett, TD; Ninomiya-Tsuji, J; Broglie, P; Muratore-Schroeder, TL; Shabanowitz, J; Hunt, DF; Brautigan, DL				Prickett, Todd D.; Ninomiya-Tsuji, Jun; Broglie, Peter; Muratore-Schroeder, Tara L.; Shabanowitz, Jeffrey; Hunt, Donald F.; Brautigan, David L.			TAB4 stimulates TAK1-TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATASE 2A; TOR PROTEINS; TAK1 MAPKKK; UBIQUITIN; PATHWAYS; TRAF6; TAP42; IKK; INHIBITOR	Responses to transforming growth factor beta and multiple cytokines involve activation of transforming growth factor beta-activated kinase-1 (TAK1) kinase, which activates kinases I kappa B kinase (IKK) and MKK3/6, leading to the parallel activation of NF-kappa B and p38 MAPK. Activation of TAK1 by autophosphorylation is known to involve three different TAK1-binding proteins (TABs). Here we report a protein phosphatase subunit known as type 2A phosphatase-interacting protein (TIP) that also acts as a TAB because it co-precipitates with and directly binds to TAK1, enhances TAK1 autophosphorylation at unique sites, and promotes TAK1 phosphorylation of IKK beta and signaling to NF-kappa B. Mass spectrometry demonstrated that co-expression of TAB4 protein significantly increased phosphorylation of four sites in TAK1, in a linker region between the kinase and TAB2/3 binding domains, and two sites in TAB1. Recombinant GST-TAB4 bound in an overlay assay directly to inactive TAK1 and activated TAK1 but not TAK1 phosphorylated in the linker sites, suggesting a bind and release mechanism. In kinase assays using TAK1 immune complexes, added GST-TAB4 selectively stimulated IKK phosphorylation. TAB4 co-precipitated polyubiquitinated proteins dependent on a Phe-Pro motif that was required to enhance phosphorylation of TAK1. TAB4 mutated at Phe-Pro dominantly interfered with IL-1 beta activation of NF-kappa B involving IKK-dependent but not p38 MAPK-dependent signaling. The results show that TAB4 binds TAK1 and polyubiquitin chains to promote specific sites of phosphorylation in TAK1-TAB1, which activates IKK signaling to NF-kappa B.	[Brautigan, David L.] Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Ninomiya-Tsuji, Jun; Broglie, Peter] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Muratore-Schroeder, Tara L.; Shabanowitz, Jeffrey; Hunt, Donald F.] Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of North Carolina; North Carolina State University; University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Box 800577,W Complex,Rm 7225,1400 Jefferson Ave, Charlottesville, VA 22908 USA.	db8g@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NCI NIH HHS [CA77584] Funding Source: Medline; NIGMS NIH HHS [GM068812, R01 GM037537, GM-37537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812, R01GM037537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Crosetto N, 2006, MOL CANCER RES, V4, P899, DOI 10.1158/1541-7786.MCR-06-0328; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Duvel K, 2003, CURR TOP MICROBIOL, V279, P19; Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; McConnell JL, 2007, ONCOGENE, V26, P6021, DOI 10.1038/sj.onc.1210406; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Schroeder MJ, 2005, J PROTEOME RES, V4, P1832, DOI 10.1021/pr0502020; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Stefansson B, 2006, J BIOL CHEM, V281, P22624, DOI 10.1074/jbc.M601772200; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597	35	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19245	19254		10.1074/jbc.M800943200	http://dx.doi.org/10.1074/jbc.M800943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18456659	hybrid, Green Published			2022-12-25	WOS:000257387600010
J	Matsushima-Nishiwaki, R; Takai, S; Adachi, S; Minamitani, C; Yasuda, E; Noda, T; Kato, K; Toyoda, H; Kaneoka, Y; Yamaguchi, A; Kumada, T; Kozawa, O				Matsushima-Nishiwaki, Rie; Takai, Shinji; Adachi, Seiji; Minamitani, Chiho; Yasuda, Eisuke; Noda, Takahiro; Kato, Kanefusa; Toyoda, Hidenori; Kaneoka, Yuji; Yamaguchi, Akihiro; Kumada, Takashi; Kozawa, Osamu			Phosphorylated heat shock protein 27 represses growth of hepatocellular carcinoma via inhibition of extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; INDUCED CELL-DEATH; TUMOR PROGRESSION; KAPPA-B; GENE-EXPRESSION; ACTIVATION; PATHWAY; ALPHA; STRESS; HSP27	Heat shock protein 27, one of the low molecular weight stress proteins, is recognized as a molecular chaperone; however, other functions have not yet been well established. Phosphorylated heat shock protein 27 levels inversely correlate with the progression of human hepatocellular carcinoma. This study shows that phosphorylated heat shock protein 27 interferes with cell growth of the hepatocellular carcinoma-derived HuH7 cells in the presence of the proinflammatory cytokine, tumor necrosis factor-alpha, via inhibition of the sustained activation of the extracellular signal-regulated kinase signal pathway. The activities of Raf/extracellular signal-regulated kinase and subsequent activator protein-1 transactivation and the induction levels of cyclin D1 were lower in HuH7 cells transfected with phosphorylated heat shock protein 27 than those with unphosphorylated heat shock protein 27. Moreover, phosphorylated heat shock protein 27 up-regulated the levels of p38 mitogen-activated protein kinase and mitogen-activated protein kinase phosphatase-1, an inhibitory protein of extracellular signal-regulated kinase. These results indicate that phosphorylated heat shock protein 27 might suppress the extracellular signal-regulated kinase activity in the hepatocellular carcinoma cells via two separate pathways in an inflammatory state. The extracellular signal-regulated kinase activity is inversely correlated with phosphorylated heat shock protein 27 at serine 15 and also in human hepatocellular carcinoma tissues in vivo. Because the extracellular signal-regulated kinase signal pathway is a major proliferation signal of hepatocellular carcinoma, activator protein-1 activation is an early event in hepatocarcinogenesis. These findings strongly suggest that the control of the phosphorylated heat shock protein 27 levels could be a new therapeutic strategy especially to counter the recurrence of hepatocellular carcinoma.	[Matsushima-Nishiwaki, Rie; Takai, Shinji; Adachi, Seiji; Minamitani, Chiho; Yasuda, Eisuke; Noda, Takahiro; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan; [Yasuda, Eisuke; Noda, Takahiro; Toyoda, Hidenori; Kumada, Takashi] Ogaki Municipal Hosp, Dept Gastroenterol, Gifu 5038502, Japan; [Kaneoka, Yuji; Yamaguchi, Akihiro] Ogaki Municipal Hosp, Dept Surg, Gifu 5038502, Japan; [Kato, Kanefusa] Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan	Gifu University; Ogaki Municipal Hospital; Ogaki Municipal Hospital	Kozawa, O (corresponding author), Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan.	okozawa@gifu-u.ac.jp						Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; Alford KA, 2007, J BIOL CHEM, V282, P6232, DOI 10.1074/jbc.M610987200; ATASEVEN H, 2006, MEDIAT INFLAMM, P1; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cho HN, 2002, CELL DEATH DIFFER, V9, P448, DOI 10.1038/sj.cdd.4400979; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Haddad JJ, 2002, BRIT J PHARMACOL, V135, P520, DOI 10.1038/sj.bjp.0704467; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Kim SK, 2005, BIOCHEM PHARMACOL, V70, P1785, DOI 10.1016/j.bcp.2005.07.019; Kojima S, 2004, INT J ONCOL, V24, P797; Kubisch C, 2004, GASTROENTEROLOGY, V127, P275, DOI 10.1053/j.gastro.2004.04.005; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee KH, 2005, J BIOL CHEM, V280, P13179, DOI 10.1074/jbc.M410059200; Lee YJ, 2004, FREE RADICAL BIO MED, V36, P429, DOI 10.1016/j.freeradbiomed.2003.11.009; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Noda T, 2007, ONCOL REP, V17, P1309; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sun XK, 2006, CELL STRESS CHAPERON, V11, P61, DOI 10.1379/CSC-149R.1; Takai S, 2007, LIFE SCI, V81, P585, DOI 10.1016/j.lfs.2007.06.018; Taylor RP, 2005, J MOL CELL CARDIOL, V38, P433, DOI 10.1016/j.yjmcc.2004.12.014; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Wang XX, 2007, CELL SIGNAL, V19, P1372, DOI 10.1016/j.cellsig.2007.03.013; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wullaert A, 2007, ENDOCR REV, V28, P365, DOI 10.1210/er.2006-0031; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yasuda E, 2005, BIOCHEM BIOPH RES CO, V337, P337, DOI 10.1016/j.bbrc.2005.08.273	45	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18852	18860		10.1074/jbc.M801301200	http://dx.doi.org/10.1074/jbc.M801301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18477563	hybrid			2022-12-25	WOS:000257165600042
J	Saliba, RS; Pangalos, M; Moss, SJ				Saliba, Richard S.; Pangalos, Menelas; Moss, Stephen J.			The ubiquitin-like protein Plic-1 enhances the membrane insertion of GABA(A) receptors by increasing their stability within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCANS; BETA SUBUNITS; HIPPOCAMPAL-NEURONS; SYNAPTIC INHIBITION; TRAFFICKING; PHOSPHORYLATION; PROTEASOME; GAMMA; IDENTIFICATION; MODULATION	gamma-Aminobutyric acid receptors (GABA(A)R) are the major sites of fast inhibitory neurotransmission in the brain, and a critical determinant for the efficacy of neuronal inhibition is the number of these receptors that are expressed on the neuronal cell surface. GABA(A)Rs are heteropentamers that can be constructed from seven subunit classes with multiple members; alpha, beta, gamma(1-3), delta, epsilon(1-3), theta, and pi. Receptor assembly occurs within the endoplasmic reticulum, and it is evident that transport-competent combinations exiting this organelle can access the cell surface, whereas unassembled subunits are ubiquitinated and subject to proteasomal degradation. In a previous report the ubiquitin-like protein Plic-1 was shown to directly interact with GABA(A)Rs and promote their accumulation at the cell surface. In this study we explore the mechanisms by which Plic-1 regulates the membrane trafficking of GABA(A)Rs. Using both recombinant and neuronal preparations it was apparent that Plic-1 increased the stability of endoplasmic reticulum resident GABA(A)Rs together with an increase in the abundance of poly-ubiquitinated receptor subunits. Furthermore, Plic-1 elevated cell surface expression levels by selectively increasing their rates of membrane insertion. Thus, Plic-1 may play a significant role in regulating the strength of synaptic inhibition by increasing the stability of GABA(A)Rs within the secretory pathway and thereby promoting their insertion into the neuronal plasma membrane.	[Saliba, Richard S.; Moss, Stephen J.] Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; [Saliba, Richard S.; Moss, Stephen J.] UCL, Dept Neurosci Pharmacol & Physiol, London WC1E 6BT, England; [Pangalos, Menelas] Wyeth Ayerst Res, Princeton, NJ 08852 USA	University of Pennsylvania; University of London; University College London; Pfizer	Moss, SJ (corresponding author), Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056359, R01NS046478, R01NS051195, P01NS054900, R01NS048045] Funding Source: NIH RePORTER; Medical Research Council Funding Source: Medline; NINDS NIH HHS [NS051195, NS048045, R01 NS051195, NS056359, P01NS054900, R01 NS056359, NS046478, P01 NS054900] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bogdanov Y, 2006, EMBO J, V25, P4381, DOI 10.1038/sj.emboj.7601309; Brandon NJ, 2003, MOL CELL NEUROSCI, V22, P87, DOI 10.1016/S1044-7431(02)00017-9; BUCHSTALLER A, 1991, NEUROSCI LETT, V129, P237, DOI 10.1016/0304-3940(91)90470-E; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Heir R, 2006, EMBO REP, V7, P1252, DOI 10.1038/sj.embor.7400823; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; HUH KH, 1995, MOL PHARMACOL, V48, P666; Jacob TC, 2005, J NEUROSCI, V25, P10469, DOI 10.1523/JNEUROSCI.2267-05.2005; Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370; Jovanovic JN, 2004, J NEUROSCI, V24, P522, DOI 10.1523/JNEUROSCI.3606-03.2004; Kittler JT, 2000, MOL CELL NEUROSCI, V16, P440, DOI 10.1006/mcne.2000.0882; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Kittler JT, 2000, J NEUROSCI, V20, P7972; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Luscher B, 2001, NAT CELL BIOL, V3, pE232, DOI 10.1038/ncb1001-e232; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; N'Diaye EN, 2008, MOL BIOL CELL, V19, P1252, DOI 10.1091/mbc.E07-08-0775; N'Diaye EN, 2003, J CELL BIOL, V163, P1157, DOI 10.1083/jcb.200307155; Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429; Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003; Saliba RS, 2007, J NEUROSCI, V27, P13341, DOI 10.1523/JNEUROSCI.3277-07.2007; Sekine-Aizawa Y, 2004, P NATL ACAD SCI USA, V101, P17114, DOI 10.1073/pnas.0407563101; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9	38	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18538	18544		10.1074/jbc.M802077200	http://dx.doi.org/10.1074/jbc.M802077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18467327	Green Published, hybrid			2022-12-25	WOS:000257165600009
J	Stumpf, T; Zhang, Q; Hirnet, D; Lewandrowski, U; Sickmann, A; Wissenbach, U; Dorr, J; Lohr, C; Deitmer, JW; Fecher-Trost, C				Stumpf, Tobias; Zhang, Qi; Hirnet, Daniela; Lewandrowski, Urs; Sickmann, Albert; Wissenbach, Ulrich; Doerr, Janka; Lohr, Christian; Deitmer, Joachim W.; Fecher-Trost, Claudia			The human TRPV6 channel protein is associated with cyclophilin B in human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PEPTIDYL-PROLYL ISOMERASE; CALCIUM-CHANNELS; CA2+ ENTRY; TROPHOBLAST CELLS; PLASMA-MEMBRANES; BINDING-PROTEIN; CAT-LIKE; EXPRESSION; RELEASE	Transcellular calcium transport in the kidney, pancreas, small intestine, and placenta is partly mediated by transient receptor potential (TRP) channels. The highly selective TRPV6 calcium channel protein is most likely important for the calcium transfer in different specialized epithelial cells. In the human placenta the protein is expressed in trophoblast tissue, where it is implicated in the transepithelial calcium transfer from mother to the fetus. We enriched the TRPV6 channel protein endogenously expressed in placenta together with annexin A2 and cyclophilin B (CypB), which is a member of the huge immunophilin family. In the human placenta TRPV6 and CypB are mainly located intracellularly in the syncytiotrophoblast layer, but a small amount of the mature glycosylated TRPV6 channel protein and CypB is also expressed in microvilli apical membranes, the fetomaternal barrier. To understand the role of CypB on the TRPV6 channel function, we evaluated the effect of CypB co-expression on TRPV6-mediated calcium uptake into Xenopus laevis oocytes expressing TRPV6. A significant increase of TRPV6-mediated calcium uptake was observed after CypB/TRPV6 coexpression. This stimulatory effect of CypB was reversed by the immunosuppressive drug cyclosporin A, which inhibits the enzymatic activity of CypB. Cyclosporin A had no significant effect on TRPV6 and CypB protein expression levels in the oocytes. In summary, our results establish CypB as a new TRPV6 accessory protein with potential involvement in TRPV6 channel activation through its peptidyl-prolyl cis/trans isomerase activity.	[Stumpf, Tobias; Zhang, Qi; Hirnet, Daniela; Doerr, Janka; Fecher-Trost, Claudia] Tech Univ Kaiserslautern, Abt Prot Funkt Prote & Allgemeine Zool Fachbereic, D-67663 Kaiserslautern, Germany; [Lewandrowski, Urs; Sickmann, Albert] Univ Saarland, D-66421 Homburg, Germany; [Lohr, Christian; Deitmer, Joachim W.] Univ Wurzburg, Deutsch Forschungsgemeinschaft Res Ctr Expt Biome, Rudolf Virchow Ctr, D-9707 Wurzburg, Germany	University of Kaiserslautern; Saarland University; University of Wurzburg	Fecher-Trost, C (corresponding author), Tech Univ Kaiserslautern, Abt Prot Funkt Prote & Allgemeine Zool Fachbereic, POB 3049, D-67663 Kaiserslautern, Germany.	fecher@biologie.uni-kl.de	Lohr, Christian/F-2968-2011; Sickmann, Albert/A-1010-2011	Lohr, Christian/0000-0001-6518-6422; Sickmann, Albert/0000-0002-2388-5265				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; Becker HM, 2005, J BIOL CHEM, V280, P39882, DOI 10.1074/jbc.M503081200; Belkacemi L, 2005, CELL CALCIUM, V37, P1, DOI 10.1016/j.ceca.2004.06.010; Bernucci L, 2006, PLACENTA, V27, P1082, DOI 10.1016/j.placenta.2005.12.007; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Cemerikic B, 1998, J MOL NEUROSCI, V10, P261, DOI 10.1007/BF02761779; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clarson LH, 2003, J PHYSIOL-LONDON, V550, P515, DOI 10.1113/jphysiol.2003.044149; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Gkika D, 2006, AM J PHYSIOL-RENAL, V290, pF1253, DOI 10.1152/ajprenal.00298.2005; Goel M, 2001, J BIOL CHEM, V276, P38762, DOI 10.1074/jbc.M104125200; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Jiang Y, 2007, AM J PHYSIOL-RENAL, V292, pF545, DOI 10.1152/ajprenal.00187.2006; Jimenez V, 2004, PLACENTA, V25, P422, DOI 10.1016/j.placenta.2003.10.013; Kristoffersen EK, 1996, AM J REPROD IMMUNOL, V36, P141; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MEURIS S, 1994, BBA-MOL CELL RES, V1220, P101, DOI 10.1016/0167-4889(94)90124-4; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Moreau R, 2002, BBA-BIOMEMBRANES, V1564, P325, DOI 10.1016/S0005-2736(02)00466-2; Moreau R, 2002, BIOL REPROD, V67, P1473, DOI 10.1095/biolreprod.102.005397; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Obata Y, 2005, J BIOL CHEM, V280, P18355, DOI 10.1074/jbc.M501684200; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; PETIT A, 1993, J CLIN ENDOCR METAB, V77, P670, DOI 10.1210/jc.77.3.670; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Schindler J, 2006, MOL CELL PROTEOMICS, V5, P390, DOI 10.1074/mcp.T500017-MCP200; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Sinkins WG, 2004, J BIOL CHEM, V279, P34521, DOI 10.1074/jbc.M401156200; TIETZ NW, 1976, FUNDAMENTAL CLIN CHE, P52; Trius A, 1996, CRIT REV FOOD SCI, V36, P69, DOI 10.1080/10408399609527719; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	53	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18086	18098		10.1074/jbc.M801821200	http://dx.doi.org/10.1074/jbc.M801821200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18445599	hybrid			2022-12-25	WOS:000256949200038
J	Bauerschmitt, H; Funes, S; Herrmann, JM				Bauerschmitt, Heike; Funes, Soledad; Herrmann, Johannes M.			The membrane-bound GTPase Guf1 promotes mitochondrial protein synthesis under suboptimal conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; EXPORT MACHINERY; LEP OPERON; RIBOSOME; GENE; COMPONENT; SUBUNIT; DNA	Recently, the bacterial elongation factor LepA was identified as critical for the accuracy of in vitro translation reactions. Extremely well conserved homologues of LepA are present throughout bacteria and eukaryotes, but the physiological relevance of these proteins is unclear. Here we show that the yeast counterpart of LepA, Guf1, is located in the mitochondrial matrix and tightly associated with the inner membrane. It binds to mitochondrial ribosomes in a GTP-dependent manner. Mutants lacking Guf1 show cold- and heat-sensitive growth defects on non-fermentable carbon sources that are especially pronounced under nutrient-limiting conditions. The cold sensitivity is explained by diminished rates of protein synthesis at low temperatures. At elevated temperatures, Guf1-deficient mutants exhibit defects in the assembly of cytochrome oxidase, suggesting that the polypeptides produced are not functional. Moreover, Guf1 mutants exhibit synthetic growth defects with mutations of the protein insertase Oxa1. These observations show a critical role for Guf1 in vivo. The observed defects in Guf1-deficient mitochondria are consistent with a function of Guf1 as a fidelity factor of mitochondrial protein synthesis.	[Bauerschmitt, Heike; Herrmann, Johannes M.] Univ Kaiserslautern, Dept Cell Biol, D-67663 Kaiserslautern, Germany; [Bauerschmitt, Heike; Funes, Soledad] Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Kaiserslautern; University of Munich	Herrmann, JM (corresponding author), Univ Kaiserslautern, Dept Cell Biol, Erwin Schroedingerstr 13, D-67663 Kaiserslautern, Germany.	hannes.herrmann@biologie.uni-kl.de	Funes, Soledad/A-1278-2010	Funes, Soledad/0000-0003-1815-1977				BORST P, 1978, CELL, V15, P705, DOI 10.1016/0092-8674(78)90257-X; BORST P, 1977, TRENDS BIOCHEM SCI, V2, P31, DOI 10.1016/0968-0004(77)90252-3; Brachmann CB, 1998, YEAST, V14, P115; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; DEKKER PJT, 1993, CURR GENET, V23, P22, DOI 10.1007/BF00336745; DIBB NJ, 1986, J BACTERIOL, V166, P83, DOI 10.1128/jb.166.1.83-87.1986; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FOX TD, 1996, TRANSLATIONAL CONTRO, P733; Frazier AE, 2006, J CELL BIOL, V172, P553, DOI 10.1083/jcb.200505060; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; LUZIKOV VN, 1989, RBC-CELL BIOL REV, V21, P491; MARCH PE, 1985, J BIOL CHEM, V260, P7206; MARCH PE, 1992, MOL MICROBIOL, V6, P1253, DOI 10.1111/j.1365-2958.1992.tb00845.x; MARCH PE, 1985, P NATL ACAD SCI USA, V82, P7500, DOI 10.1073/pnas.82.22.7500; Margus T, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-15; Meier S, 2005, J BIOL CHEM, V280, P7777, DOI 10.1074/jbc.M412158200; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; Ott M, 2006, EMBO J, V25, P1603, DOI 10.1038/sj.emboj.7601070; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Qin Y, 2006, CELL, V127, P721, DOI 10.1016/j.cell.2006.09.037; RASMUSSEN SW, 1995, YEAST, V11, P873, DOI 10.1002/yea.320110909; ROSENTHAL LP, 1987, J BIOL CHEM, V262, P10955; RUUSALA T, 1984, EMBO J, V3, P2575, DOI 10.1002/j.1460-2075.1984.tb02176.x; Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Youngman EM, 2007, CURR BIOL, V17, pR136, DOI 10.1016/j.cub.2006.12.029; Zambrano A, 2007, MOL BIOL CELL, V18, P523, DOI 10.1091/mbc.E06-09-0803	40	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17139	17146		10.1074/jbc.M710037200	http://dx.doi.org/10.1074/jbc.M710037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442968	hybrid			2022-12-25	WOS:000256720600022
J	Burman, JD; Leung, E; Atkins, KL; O'Seaghdha, MN; Lango, L; Bernado, P; Bagby, S; Svergun, DI; Foster, TJ; Isenman, DE; van den Elsen, JMH				Burman, Julia D.; Leung, Elisa; Atkins, Karen L.; O'Seaghdha, Maghnus N.; Lango, Lea; Bernado, Pau; Bagby, Stefan; Svergun, Dmitri I.; Foster, Timothy J.; Isenman, David E.; van den Elsen, Jean M. H.			Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein - Indications of a novel mechanism of complement evasion by Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; RAY CRYSTAL-STRUCTURE; CELL-SURFACE; CONFORMATIONAL-CHANGES; INHIBITORY PROTEIN; IMMUNE EVASION; 3RD COMPONENT; C3; IGG; IDENTIFICATION	Staphylococcal immunoglobulin-binding protein, Sbi, is a 436-residue protein produced by many strains of Staphylococcus aureus. It was previously characterized as being cell surface-associated and having binding capacity for human IgG and beta 2-glycoprotein I. Here we show using small angle x-ray scattering that the proposed extracellular region of Sbi (Sbi-E) is an elongated molecule consisting of four globular domains, two immunoglobulin-binding domains (I and II) and two novel domains (III and IV). We further show that together domains III and IV (Sbi-III-IV), as well as domain IV on its own (Sbi-IV), bind complement component C3 via contacts involving both the C3dg fragment and the C3a anaphylatoxin domain. Preincubation of human serum with either Sbi-E or Sbi-III-IV is inhibitory to all complement pathways, whereas domain IV specifically inhibits the alternative pathway. Monitoring C3 activation in serum incubated with Sbi fragments reveals that Sbi-E and Sbi-III-IV both activate the alternative pathway, leading to consumption of C3. By contrast, inhibition of this pathway by Sbi-IV does not involve C3 consumption. The observation that Sbi-E activates the alternative pathway is counterintuitive to intact Sbi being cell wall-associated, as recruiting complement to the surface of S. aureus would be deleterious to the bacterium. Upon re-examination of this issue, we found that Sbi was not associated with the cell wall fraction, but rather was found in the growth medium, consistent with it being an excreted protein. As such, our data suggest that Sbi helps mediate bacterial evasion of complement via a novel mechanism, namely futile fluid-phase consumption.	[Leung, Elisa; Isenman, David E.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; [Burman, Julia D.; Atkins, Karen L.; Lango, Lea; Bagby, Stefan; van den Elsen, Jean M. H.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [O'Seaghdha, Maghnus N.; Foster, Timothy J.] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; [Bernado, Pau; Svergun, Dmitri I.] Hamburg Outstn, EMBL, D-22603 Hamburg, Germany; [Svergun, Dmitri I.] Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	University of Toronto; University of Bath; Trinity College Dublin; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Isenman, DE (corresponding author), Univ Toronto, Dept Biochem, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	d.isenman@utoronto.ca; bssjmhve@bath.ac.uk	van den Elsen, Jean/D-9274-2011; Bernado, Pau/F-9643-2013	Bernado, Pau/0000-0001-7395-5922; Bagby, Stefan/0000-0003-2302-9511; Svergun, Dmitri/0000-0003-0830-5696; O'Seaghdha, Maghnus/0000-0002-0232-0556; van den Elsen, Jean/0000-0002-0367-1956	Biotechnology and Biological Sciences Research Council [BBS/B/12121] Funding Source: Medline; Wellcome Trust [076124] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Atkins KL, 2008, MOL IMMUNOL, V45, P1600, DOI 10.1016/j.molimm.2007.10.021; BECHERER JD, 1988, J BIOL CHEM, V263, P14586; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Clemenza L, 2000, J IMMUNOL, V165, P3839, DOI 10.4049/jimmunol.165.7.3839; COLE FS, 1985, J IMMUNOL, V134, P2610; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Downer R, 2002, J BIOL CHEM, V277, P243, DOI 10.1074/jbc.M107621200; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; GOWARD CR, 1993, TRENDS BIOCHEM SCI, V18, P136, DOI 10.1016/0968-0004(93)90021-E; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Hammel M, 2007, J BIOL CHEM, V282, P30051, DOI 10.1074/jbc.M704247200; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, J BIOL CHEM, V258, P4238; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; KALLI KR, 1991, J IMMUNOL, V147, P590; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Langley R, 2005, J IMMUNOL, V174, P2926, DOI 10.4049/jimmunol.174.5.2926; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; Law SKA, 1997, PROTEIN SCI, V6, P263; Lee LYL, 2004, J BIOL CHEM, V279, P50710, DOI 10.1074/jbc.M408570200; Lutz HU, 2006, MOL IMMUNOL, V43, P2, DOI 10.1016/j.molimm.2005.06.020; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Nielsen CH, 2002, J LEUKOCYTE BIOL, V72, P249; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; Rooijakkers SHM, 2005, TRENDS MICROBIOL, V13, P596, DOI 10.1016/j.tim.2005.10.002; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; SASSO EH, 1991, J IMMUNOL, V147, P1877; Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Silverman GJ, 2005, TRANSFUSION, V45, P274, DOI 10.1111/j.1537-2995.2004.04333.x; SIM RB, 1981, BIOCHEM J, V193, P129, DOI 10.1042/bj1930129; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2003, REP PROG PHYS, V66, P1735, DOI 10.1088/0034-4885/66/10/R05; van den Elsen JMH, 2002, J MOL BIOL, V322, P1103, DOI 10.1016/S0022-2836(02)00854-9; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604; WRIGHT JF, 1988, J BIOL CHEM, V263, P11221; Zhang LH, 1999, MICROBIOL-UK, V145, P177, DOI 10.1099/13500872-145-1-177; Zhang LH, 1998, MICROBIOL-UK, V144, P985, DOI 10.1099/00221287-144-4-985; Zhang LH, 2000, FEMS IMMUNOL MED MIC, V28, P211, DOI 10.1111/j.1574-695X.2000.tb01479.x	47	103	111	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17579	17593		10.1074/jbc.M800265200	http://dx.doi.org/10.1074/jbc.M800265200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434316	Green Accepted, hybrid			2022-12-25	WOS:000256720600065
J	Chen, WY; Chang, FR; Huang, ZY; Chen, JH; Wu, YC; Wu, CC				Chen, Wen-Ying; Chang, Fang-Rong; Huang, Zih-You; Chen, Jyun-Hong; Wu, Yang-Chang; Wu, Chin-Chung			Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; MOLECULAR CHAPERONES; CYTOCHROME-C; PROTEASOMAL DEGRADATION; ANTILEUKEMIA ACTIVITY; HSP90 INHIBITORS; PROSTATE-CANCER; CARCINOMA-CELLS; WITHAFERIN-A; STRESS	Tubocapsenolide A (TA), a novel withanolide-type steroid, exhibits potent cytotoxicity against several human cancer cell lines. In the present study, we observed that treatment of human breast cancer MDA-MB-231 cells with TA led to cell cycle arrest at G(1) phase and apoptosis. The actions of TA were correlated with proteasome-dependent degradation of Cdk4, cyclin D1, Raf-1, Akt, and mutant p53, which are heat shock protein 90 (Hsp90) client proteins. TA treatment induced a transient increase in reactive oxygen species and a decrease in the intracellular glutathione contents. Nonreducing SDS-PAGE revealed that TA rapidly and selectively induced thiol oxidation and aggregation of Hsp90 and Hsp70, both in intact cells and in cell-free systems using purified recombinant proteins. Furthermore, TA inhibited the chaperone activity of Hsp90-Hsp70 complex in the luciferase refolding assay. N-Acetylcysteine, a thiol antioxidant, prevented all of the TA-induced effects, including oxidation of heat shock proteins, degradation of Hsp90 client proteins, and apoptosis. In contrast, non-thiol antioxidants (trolox and vitamin C) were ineffective to prevent Hsp90 inhibition and cell death. Taken together, our results demonstrate that the TA inhibits the activity of Hsp90-Hsp70 chaperone complex, at least in part, by a direct thiol oxidation, which in turn leads to the destabilization and depletion of Hsp90 client proteins and thus causes cell cycle arrest and apoptosis in MDA-MB-231 cells. Therefore, TA can be considered as a new type of inhibitor of Hsp90-Hsp70 chaperone complex, which has the potential to be developed as a novel strategy for cancer treatment.	[Chen, Wen-Ying; Chang, Fang-Rong; Huang, Zih-You; Chen, Jyun-Hong; Wu, Yang-Chang; Wu, Chin-Chung] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung 807, Taiwan; [Chen, Wen-Ying] Fooyin Univ, Basic Med Sci Educ Ctr, Kaohsiung 831, Taiwan	Kaohsiung Medical University; Fooyin University	Wu, YC (corresponding author), Kaohsiung Med Univ, Grad Inst Nat Prod, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	yachwu@kmu.edu.tw; ccwu@kmu.edu.tw	Wu, Chin-Chung/C-5684-2009; Wu, Yang-Chang/C-5682-2009; Chang, Fang-Rong/C-5692-2009; Wu, Yang-Chang/D-1471-2011	Wu, Yang-Chang/0000-0001-7815-2686; Wu, Chin-Chung/0000-0003-4203-4084; Chang, Fang-Rong/0000-0003-2549-4193				Abou-Douh AM, 2002, ARCH PHARM, V335, P267, DOI 10.1002/1521-4184(200208)335:6&lt;267::AID-ARDP267&gt;3.0.CO;2-E; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Bagatell R, 2004, MOL CANCER THER, V3, P1021; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Chen WY, 2005, EUR J PHARMACOL, V522, P20, DOI 10.1016/j.ejphar.2005.08.047; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fernandez C, 2004, J BIOL CHEM, V279, P3877, DOI 10.1074/jbc.M310665200; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; FUSKA J, 1984, NEOPLASMA, V31, P31; Gabai VL, 2005, ONCOGENE, V24, P3328, DOI 10.1038/sj.onc.1208495; Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002; Gorman AM, 1999, FEBS LETT, V445, P98, DOI 10.1016/S0014-5793(99)00094-0; Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hsieh PW, 2007, J NAT PROD, V70, P747, DOI 10.1021/np0605541; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu QL, 1996, J BIOL CHEM, V271, P29937, DOI 10.1074/jbc.271.47.29937; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mishra L C, 2000, Altern Med Rev, V5, P334; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; Nardai G, 2000, ARCH BIOCHEM BIOPHYS, V384, P59, DOI 10.1006/abbi.2000.2075; Neckers L, 2002, CLIN CANCER RES, V8, P962; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; Sreedhar AS, 2004, BBA-PROTEINS PROTEOM, V1697, P233, DOI 10.1016/j.bbapap.2003.11.027; Srirangam A, 2006, CLIN CANCER RES, V12, P1883, DOI 10.1158/1078-0432.CCR-05-1167; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Turbyville TJ, 2006, J NAT PROD, V69, P178, DOI 10.1021/np058095b; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Waak J, 2006, NEUROCHEM RES, V31, P1409, DOI 10.1007/s11064-006-9192-x; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wright L, 2004, CHEM BIOL, V11, P775, DOI 10.1016/j.chembiol.2004.03.033; Wu CC, 2005, MOL CANCER THER, V4, P1277, DOI 10.1158/1535-7163.MCT-05-0027; Yokota Y, 2006, BIOORG MED CHEM LETT, V16, P2603, DOI 10.1016/j.bmcl.2006.02.039; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	69	58	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17184	17193		10.1074/jbc.M709447200	http://dx.doi.org/10.1074/jbc.M709447200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442981	hybrid			2022-12-25	WOS:000256720600027
J	Czirr, E; Cottrell, BA; Leuchtenberger, S; Kukar, T; Ladd, TB; Esselmann, H; Paul, S; Schubenel, R; Torpey, JW; Pietrzik, CU; Golde, TE; Wiltfang, J; Baumann, K; Koo, EH; Weggen, S				Czirr, Eva; Cottrell, Barbara A.; Leuchtenberger, Stefanie; Kukar, Thomas; Ladd, Thomas B.; Esselmann, Hermann; Paul, Sabine; Schubenel, Robert; Torpey, Justin W.; Pietrzik, Claus U.; Golde, Todd E.; Wiltfang, Jens; Baumann, Karlheinz; Koo, Edward H.; Weggen, Sascha			Independent generation of A beta 42 and A beta 38 peptide species by gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; ALZHEIMER-DISEASE; PRESENILIN MUTATIONS; INTRAMEMBRANE CLEAVAGE; TRANSMEMBRANE DOMAIN; TALKING POINT; BETA-PROTEIN; MOUSE MODEL; MODULATION	Proteolytic processing of the amyloid precursor protein by beta- and gamma-secretase generates the amyloid-beta (A beta) peptides, which are principal drug targets in Alzheimer disease therapeutics. gamma-Secretase has imprecise cleavage specificity and generates the most abundant A beta 40 and A beta 42 species together with longer and shorter peptides such as A beta 38. Several mechanisms could explain the production of multiple A beta peptides by gamma-secretase, including sequential processing of longer into shorter A beta peptides. A novel class of gamma-secretase modulators (GSMs) that includes some non-steroidal anti-inflammatory drugs has been shown to selectively lower A beta 42 levels with out a change in A beta 40 levels. A signature of GSMs is the concomitant increase in shorter A beta peptides, such as A beta 38, leading to the suggestion that generation of A beta 42 and A beta 38 peptide species by gamma-secretase is coordinately regulated. However, no evidence for or against such a precursor-product relationship has been provided. We have previously shown that stable overexpression of aggressive presenilin-1 (PS1) mutations associated with early-onset familial Alzheimer disease attenuated the cellular response to GSMs, resulting in greatly diminished A beta 42 reductions as compared with wild type PS1. We have now used this model system to investigate whether A beta 38 production would be similarly affected indicating coupled generation of A beta 42 and A beta 38 peptides. Surprisingly, treatment with the GSM sulindac sulfide increased A beta 38 production to similar levels in four different PS1 mutant cell lines as compared with wild type PS1 cells. This was confirmed with the structurally divergent GSMs ibuprofen and indomethacin. Mass spectrometry analysis and high resolution urea gel electrophoresis further demonstrated that sulindac sulfide did not induce detectable compensatory changes in levels of other A beta peptide species. These data provide evidence that A beta 42 and A beta 38 species can be independently generated by gamma-secretase and argue against a precursor-product relationship between these peptides.	[Czirr, Eva; Leuchtenberger, Stefanie; Weggen, Sascha] Univ Dusseldorf, Dept Neuropathol, Mol Neuropathol Grp, D-40225 Dusseldorf, Germany; [Cottrell, Barbara A.; Koo, Edward H.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Torpey, Justin W.] Univ Calif San Diego, Dept Biomol Mass Spectrometry Facil, La Jolla, CA 92093 USA; [Pietrzik, Claus U.] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Mol Neurodegenerat Grp, D-55128 Mainz, Germany; [Schubenel, Robert; Baumann, Karlheinz] F Hoffmann La Roche & Co Ltd, Preclin Res CNS, Div Pharmaceut, CH-4070 Basel, Switzerland; [Kukar, Thomas; Ladd, Thomas B.; Golde, Todd E.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; [Esselmann, Hermann; Paul, Sabine; Wiltfang, Jens] Univ Duisburg Essen, Rhine State Hosp, Dept Psychiat & Psychotherapy, D-45147 Essen, Germany	Heinrich Heine University Dusseldorf; University of California System; University of California San Diego; University of California System; University of California San Diego; Johannes Gutenberg University of Mainz; Roche Holding; Mayo Clinic; University of Duisburg Essen	Weggen, S (corresponding author), Univ Dusseldorf, Dept Neuropathol, Mol Neuropathol Grp, D-40225 Dusseldorf, Germany.	sweggen@uni-duesseldorf.de	Cruz e Silva, Odete/AAH-5595-2020; Kukar, Thomas/AAW-2612-2021	Kukar, Thomas/0000-0002-3750-6262; Wiltfang, Jens/0000-0003-1492-5330				Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Czirr E, 2007, J BIOL CHEM, V282, P24504, DOI 10.1074/jbc.M700618200; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Golde TE, 2006, J NEUROCHEM, V99, P689, DOI 10.1111/j.1471-4159.2006.04211.x; Imbimbo BP, 2007, J PHARMACOL EXP THER, V323, P822, DOI 10.1124/jpet.107.129007; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Leuchtenberger S, 2006, CURR PHARM DESIGN, V12, P4337, DOI 10.2174/138161206778793029; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Narlawar R, 2007, BIOORG MED CHEM LETT, V17, P176, DOI 10.1016/j.bmcl.2006.09.061; Page RM, 2008, J BIOL CHEM, V283, P677, DOI 10.1074/jbc.M708754200; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Sato T, 2005, FEBS LETT, V579, P2907, DOI 10.1016/j.febslet.2005.04.037; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; Weggen S, 2003, J BIOL CHEM, V278, P30748, DOI 10.1074/jbc.M304824200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wilcock G, 2006, ALZHEIMERS DEMENT S1, V2, pS81; Wolfe MS, 2007, EMBO REP, V8, P136, DOI 10.1038/sj.embor.7400896; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200; Zhao GJ, 2007, J NEUROCHEM, V100, P1234, DOI 10.1111/j.1471-4159.2006.04302.x	29	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17049	17054		10.1074/jbc.M802912200	http://dx.doi.org/10.1074/jbc.M802912200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426795	hybrid			2022-12-25	WOS:000256720600011
J	Ichiyama, K; Yoshida, H; Wakabayashi, Y; Chinen, T; Saeki, K; Nakaya, M; Takaesu, G; Hori, S; Yoshimura, A; Kobayashi, T				Ichiyama, Kenji; Yoshida, Hideyuki; Wakabayashi, Yu; Chinen, Takatoshi; Saeki, Kazuko; Nakaya, Mako; Takaesu, Giichi; Hori, Shohei; Yoshimura, Akihiko; Kobayashi, Takashi			Foxp3 inhibits ROR gamma t-mediated IL-17A mRNA transcription through direct interaction with ROR gamma t	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; HELPER-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; DIFFERENTIATION; GENERATION; INDUCTION; TOLERANCE; RECEPTOR; T(H)17; IL-21	The cytokine, transforming growth factor-beta 1 (TGF-beta 1), converts naive T cells into regulatory T cells that prevent autoimmunity. However, in the presence of interleukin (IL)-6, TGF-beta 1 has also been found to promote differentiation into IL-17-producing helper T (Th17) cells that are deeply involved in autoimmunity and inflammation. However, it has not been clarified how TGF-beta 1 and IL-6 determine such a distinct fate. Here we found that a master regulator for Th17, retinoic acid-related orphan receptor gamma t (ROR gamma t), was rapidly induced by TGF-beta 1 regardless of the presence of IL-6. IL-6 reduced Foxp3 expression, and overexpression of Foxp3 in a T cell line resulted in a strong reduction of IL-17A expression. We have characterized the IL-17A promoter and found that ROR gamma t binding is sufficient for activation of the minimum promoter in the HEK 293T cells. ROR gamma t-mediated IL-17A promoter activation was suppressed by forced expression of Foxp3. Foxp3 directly interacted with ROR gamma t through exon 2 region of Foxp3. The exon 2 region and forkhead (FKH) domain of Foxp3 were necessary for the suppression of ROR gamma t-mediated IL-17A promoter activation. We propose that induction of Foxp3 is the mechanism for the suppression of Th17 and polarization into inducible Treg.	[Ichiyama, Kenji; Yoshida, Hideyuki; Chinen, Takatoshi; Saeki, Kazuko; Nakaya, Mako; Takaesu, Giichi; Yoshimura, Akihiko; Kobayashi, Takashi] Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; [Wakabayashi, Yu; Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; [Hori, Shohei] RIKEN Res Ctr Allergy & Immunol, Res Unit Immune Homeostasis, Tsurumi Ku, Kanagawa 2300045, Japan	Kyushu University; Keio University; RIKEN	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yoshimura@a6.keio.jp; takashik@bioreg.kyushu-u.ac.jp	Hori, Shohei/O-6163-2019; Yoshimura, Akihiko/K-5515-2013	Hori, Shohei/0000-0001-8770-4593; Ichiyama, Kenji/0000-0002-3340-9799; Takaesu, Giichi/0000-0002-1581-1055				Auja SJ, 2007, SEMIN IMMUNOL, V19, P377, DOI 10.1016/j.smim.2007.10.009; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Kikly K, 2006, CURR OPIN IMMUNOL, V18, P670, DOI 10.1016/j.coi.2006.09.008; Kinjyo I, 2006, J EXP MED, V203, P1021, DOI 10.1084/jem.20052333; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kottke T, 2007, CANCER RES, V67, P11970, DOI 10.1158/0008-5472.CAN-07-2259; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Takaki H, 2008, J BIOL CHEM, V283, P14955, DOI 10.1074/jbc.M801123200; Takaki H, 2006, GENES CELLS, V11, P871, DOI 10.1111/j.1365-2443.2006.00988.x; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	31	332	374	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17003	17008		10.1074/jbc.M801286200	http://dx.doi.org/10.1074/jbc.M801286200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434325	hybrid			2022-12-25	WOS:000256720600006
J	Kong, W; Weatherspoon, N; Shi, YX				Kong, Wei; Weatherspoon, Natasha; Shi, Yixin			Molecular mechanism for establishment of signal-dependent regulation in the PhoP/PhoQ system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; BACTERIAL SENSOR KINASE; ESCHERICHIA-COLI K-12; PROMOTERS IN-VIVO; SALMONELLA-ENTERICA; ANTIMICROBIAL PEPTIDES; H-NS; PHOP; IDENTIFICATION; GENES	In this report, we demonstrate that H-NS is essential for establishing the Mg2+-responsive transcriptional regulation of the PhoP regulon in Salmonella. Deletion of this regulatory gene abolished the transcriptional repression of PhoP-activated genes when bacteria were grown in high environmental Mg2+, thus stimulating expression of phoP and other PhoP regulon genes. In the absence of H-NS, transcriptional activation was PhoP-dependent for those genes only activated by PhoP, but was PhoP-independent for those genes activated by both PhoP and SlyA. The H-NS protein footprints the phoP promoter in a sequence located upstream of the PhoP box; mutation of this cis-acting factor abolished transcriptional repression of the phoP gene equivalent to the phenotype exhibited in the hns mutant. Further results showed that H-NS gel shifts other PhoP regulon promoters, indicating that a PhoP-activated gene would be transcriptionally repressed via direct H-NS binding and inhibition of its activator PhoP. Furthermore, H-NS footprints a newly identified SlyA box and the reverse PhoP box in the pagC promoter, suggesting that both SlyA and PhoP compete with this regulatory protein. Therefore, H-NS should pair with SlyA and PhoP to establish a forward regulatory loop to regulate expression of pagC, and perhaps other PhoP-and SlyA-dependent genes.	[Weatherspoon, Natasha; Shi, Yixin] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Kong, Wei; Shi, Yixin] Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Shi, YX (corresponding author), Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA.	yixin.shi@asu.edu	SHI, YIXIN/M-5751-2019		NIAID NIH HHS [AI24533] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024533] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bader MW, 2005, CELL, V122, P461, DOI 10.1016/j.cell.2005.05.030; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Castelli ME, 2003, J BIOL CHEM, V278, P23579, DOI 10.1074/jbc.M303042200; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; Dorman CJ, 2007, NAT REV MICROBIOL, V5, P157, DOI 10.1038/nrmicro1598; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hilbert F, 1999, J BACTERIOL, V181, P2158, DOI 10.1128/JB.181.7.2158-2165.1999; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; KIER LD, 1979, J BACTERIOL, V138, P155, DOI 10.1128/JB.138.1.155-161.1979; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lejona S, 2004, J BACTERIOL, V186, P2476, DOI 10.1128/JB.186.8.2476-2480.2004; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Navarre WW, 2005, MOL MICROBIOL, V56, P492, DOI 10.1111/j.1365-2958.2005.04553.x; Norte VA, 2003, J BACTERIOL, V185, P3508, DOI 10.1128/JB.185.12.3508-3514.2003; Perron-Savard P, 2005, MICROBIOL-SGM, V151, P3979, DOI 10.1099/mic.0.28236-0; Prost LR, 2008, CELL MICROBIOL, V10, P576, DOI 10.1111/j.1462-5822.2007.01111.x; Prost LR, 2007, MOL CELL, V26, P165, DOI 10.1016/j.molcel.2007.03.008; Shi YX, 2004, J BIOL CHEM, V279, P38618, DOI 10.1074/jbc.M406149200; Shin D, 2005, J BIOL CHEM, V280, P4089, DOI 10.1074/jbc.M412741200; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X	33	25	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16612	16621		10.1074/jbc.M800547200	http://dx.doi.org/10.1074/jbc.M800547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18434315	Green Published, hybrid			2022-12-25	WOS:000256497100038
J	Chen, MR; Gan, GL; Wu, Y; Wang, L; Wu, YL; Ding, J				Chen, Maorong; Gan, Geliang; Wu, Ying; Wang, Lu; Wu, Yingliang; Ding, Jiuping			Lysine-Rich Extracellular Rings Formed by h beta 2 Subunits Confer the Outward Rectification of BK Channels	PLOS ONE			English	Article							CA2+-ACTIVATED K+ CHANNELS; AUXILIARY BETA-SUBUNITS; LARGE-CONDUCTANCE; CHROMAFFIN CELLS; MOLECULAR-BASIS; CALCIUM; VOLTAGE; INACTIVATION; CA2+; COLOCALIZATION	The auxiliary beta subunits of large-conductance Ca2+-activated K+ (BK) channels greatly contribute to the diversity of BK (mSlo1 alpha) channels, which is fundamental to the adequate function in many tissues. Here we describe a functional element of the extracellular segment of h beta 2 auxiliary subunits that acts as the positively charged rings to modify the BK channel conductance. Four consecutive lysines of the h beta 2 extracellular loop, which reside sufficiently close to the extracellular entryway of the pore, constitute three positively charged rings. These rings can decrease the extracellular K+ concentration and prevent the Charybdotoxin (ChTX) from approaching the extracellular entrance of channels through electrostatic mechanism, leading to the reduction of K+ inflow or the outward rectification of BK channels. Our results demonstrate that the lysine rings formed by the h beta 2 auxiliary subunits influences the inward current of BK channels, providing a mechanism by which current can be rapidly diminished during cellular repolarization. Furthermore, this study will be helpful to understand the functional diversity of BK channels contributed by different auxiliary beta subunits.	[Chen, Maorong; Wu, Ying; Wang, Lu; Ding, Jiuping] Huazhong Univ Sci & Technol, Key Lab Mol Biophys, Minist Educ, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China; [Gan, Geliang; Wu, Yingliang] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan, Peoples R China	Huazhong University of Science & Technology; Wuhan University	Chen, MR (corresponding author), Huazhong Univ Sci & Technol, Key Lab Mol Biophys, Minist Educ, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China.	jpding@mail.hust.edu.cn	Chen, Maorong/AAF-4006-2019	Chen, Maorong/0000-0003-3744-8864	National Science Foundation of China [30770522, 30770519]	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Grants from the National Science Foundation of China (30770522, 30770519).	ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Brelidze TI, 2003, P NATL ACAD SCI USA, V100, P9017, DOI 10.1073/pnas.1532257100; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Ding JP, 1998, BIOPHYS J, V74, P268, DOI 10.1016/S0006-3495(98)77785-9; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GOLA M, 1993, NEURON, V10, P689, DOI 10.1016/0896-6273(93)90170-V; GUO ZH, 2008, BIOPHYS J IN PRESS; Haug T, 2004, J GEN PHYSIOL, V124, P173, DOI 10.1085/jgp.200308949; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Li W, 2007, J CELL PHYSIOL, V212, P348, DOI 10.1002/jcp.21007; Li ZW, 1999, J NEUROPHYSIOL, V81, P611, DOI 10.1152/jn.1999.81.2.611; Lv CX, 2008, J BIOL CHEM, V283, P2709, DOI 10.1074/jbc.M704440200; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nimigean CM, 2003, BIOCHEMISTRY-US, V42, P9263, DOI 10.1021/bi0348720; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wang YW, 2002, J NEUROSCI, V22, P1550, DOI 10.1523/JNEUROSCI.22-05-01550.2002; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xia XM, 2000, J NEUROSCI, V20, P4890; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932; Zeng XH, 2001, J GEN PHYSIOL, V117, P607, DOI 10.1085/jgp.117.6.607	25	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2114	10.1371/journal.pone.0002114	http://dx.doi.org/10.1371/journal.pone.0002114			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461166	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400036
J	McGowan, PO; Sasaki, A; Huang, TCT; Unterberger, A; Suderman, M; Ernst, C; Meaney, MJ; Turecki, G; Szyf, M				McGowan, Patrick O.; Sasaki, Aya; Huang, Tony C. T.; Unterberger, Alexander; Suderman, Matthew; Ernst, Carl; Meaney, Michael J.; Turecki, Gustavo; Szyf, Moshe			Promoter-Wide Hypermethylation of the Ribosomal RNA Gene Promoter in the Suicide Brain	PLOS ONE			English	Article								Background: Alterations in gene expression in the suicide brain have been reported and for several genes DNA methylation as an epigenetic regulator is thought to play a role. rRNA genes, that encode ribosomal RNA, are the backbone of the protein synthesis machinery and levels of rRNA gene promoter methylation determine rRNA transcription. Methodology/Principal Findings: We test here by sodium bisulfite mapping of the rRNA promoter and quantitative realtime PCR of rRNA expression the hypothesis that epigenetic differences in critical loci in the brain are involved in the pathophysiology of suicide. Suicide subjects in this study were selected for a history of early childhood neglect/abuse, which is associated with decreased hippocampal volume and cognitive impairments. rRNA was significantly hypermethylated throughout the promoter and 59 regulatory region in the brain of suicide subjects, consistent with reduced rRNA expression in the hippocampus. This difference in rRNA methylation was not evident in the cerebellum and occurred in the absence of genome-wide changes in methylation, as assessed by nearest neighbor. Conclusions/Significance: This is the first study to show aberrant regulation of the protein synthesis machinery in the suicide brain. The data implicate the epigenetic modulation of rRNA in the pathophysiology of suicide.	[McGowan, Patrick O.; Sasaki, Aya; Ernst, Carl; Meaney, Michael J.; Turecki, Gustavo] Douglas Mental Hlth Univ Inst, Dept Psychiat, Montreal, PQ, Canada; [McGowan, Patrick O.; Sasaki, Aya; Meaney, Michael J.] McGill Univ, McGill Program Study Behaviour, Genes & Env, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [McGowan, Patrick O.; Sasaki, Aya; Huang, Tony C. T.; Unterberger, Alexander; Suderman, Matthew; Meaney, Michael J.; Szyf, Moshe] McGill Univ, Sackler Program Epigenet & Psychobiol, Montreal, PQ, Canada; [Huang, Tony C. T.; Unterberger, Alexander; Szyf, Moshe] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Suderman, Matthew] McGill Univ, McGill Ctr Bioinformat, Montreal, PQ, Canada; [Ernst, Carl; Turecki, Gustavo] Douglas Mental Hlth Univ Inst, McGill Grp Suicide Stud, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	McGowan, PO (corresponding author), Douglas Mental Hlth Univ Inst, Dept Psychiat, Montreal, PQ, Canada.	gustvao.turecki@mcgill.ca; moshe.szyf@mcgill.ca	Meaney, Michael/N-5931-2019; Turecki, Gustavo/K-5100-2015	Turecki, Gustavo/0000-0003-4075-2736; Suderman, Matthew/0000-0002-2715-9930	National Cancer Institute; NICHD; HSFP; Maternal Adversity, Vulnerability and Neurodevelopment Project grant from the Canadian Institutes for Health Research (CIHR)	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); HSFP; Maternal Adversity, Vulnerability and Neurodevelopment Project grant from the Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work was funded by a grant from the National Cancer Institute to MS, NICHD to MJM and MS, HSFP to MJM and MS, the Maternal Adversity, Vulnerability and Neurodevelopment Project grant from the Canadian Institutes for Health Research (CIHR) to MJM and MS, as well as grants from CIHR to GT. Competing interests: The authors have declared that no competing interests exist.	Abdolmaleky HM, 2006, HUM MOL GENET, V15, P3132, DOI 10.1093/hmg/ddl253; BIFULCO A, 1994, J CHILD PSYCHOL PSYC, V35, P1419, DOI 10.1111/j.1469-7610.1994.tb01284.x; Bleich S, 2006, ALCOHOL CLIN EXP RES, V30, P587, DOI 10.1111/j.1530-0277.2006.00068.x; Bonsch D, 2005, NEUROREPORT, V16, P167; Brezo J, 2007, PSYCHOL MED, V37, P1563, DOI 10.1017/S003329170700058X; Brown SE, 2007, MOL CELL BIOL, V27, P4938, DOI 10.1128/MCB.01880-06; Caburet S, 2005, GENOME RES, V15, P1079, DOI 10.1101/gr.3970105; Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119; CHARBONNEAU H, 1987, NAISSANCE POPULATION; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Detich N, 2003, J BIOL CHEM, V278, P27586, DOI 10.1074/jbc.M303740200; Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200; Ding QX, 2006, NEUROCHEM RES, V31, P705, DOI 10.1007/s11064-006-9071-5; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Dong E, 2007, P NATL ACAD SCI USA, V104, P4676, DOI 10.1073/pnas.0700529104; Dumais A, 2005, AM J PSYCHIAT, V162, P2116, DOI 10.1176/appi.ajp.162.11.2116; Dwivedi Y, 2005, BIOL PSYCHIAT, V58, P315, DOI 10.1016/j.biopsych.2005.04.014; Dwivedi Y, 2006, ARCH GEN PSYCHIAT, V63, P639, DOI 10.1001/archpsyc.63.6.639; Fergusson DM, 1996, J AM ACAD CHILD PSY, V35, P1365, DOI 10.1097/00004583-199610000-00024; FIRST MB, 1995, J PERS DISORD, V9, P83, DOI 10.1521/pedi.1995.9.2.83; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grayson DR, 2005, P NATL ACAD SCI USA, V102, P9341, DOI 10.1073/pnas.0503736102; Hedges L.V., 1985, STAT METHODS META AN; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; Iwamoto K, 2005, J NEUROSCI, V25, P5376, DOI 10.1523/JNEUROSCI.0766-05.2005; Kirk RE, 2007, J STAT PLAN INFER, V137, P1634, DOI 10.1016/j.jspi.2006.09.011; Kuratomi G, 2008, MOL PSYCHIATR, V13, P429, DOI 10.1038/sj.mp.4002001; Machwe A, 2000, FASEB J, V14, P1715, DOI 10.1096/fj.99-0926com; Majumder S, 2006, J BIOL CHEM, V281, P22062, DOI 10.1074/jbc.M601155200; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; McGowan Patrick O., 2008, Environmental Health and Preventive Medicine, V13, P16, DOI 10.1007/s12199-007-0002-0; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Milutinovic S, 2007, CARCINOGENESIS, V28, P560, DOI 10.1093/carcin/bgl167; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Odagaki Y, 2001, BRAIN RES, V898, P224, DOI 10.1016/S0006-8993(01)02188-6; Ramsahoye Bernard H, 2002, Methods Mol Biol, V200, P9; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROY A, 1995, AM J PSYCHIAT, V152, P1075; ROY A, 1991, ARCH GEN PSYCHIAT, V48, P29; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Schloss P, 2004, PHARMACOL THERAPEUT, V102, P47, DOI 10.1016/j.pharmthera.2004.02.001; Seguin M, 2007, PSYCHOL MED, V37, P1575, DOI 10.1017/S0033291707000955; Sequeira A, 2007, MOL PSYCHIATR, V12, P640, DOI 10.1038/sj.mp.4001969; Sequeira A, 2006, OMICS, V10, P444, DOI 10.1089/omi.2006.10.444; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Stults DM, 2008, GENOME RES, V18, P13, DOI 10.1101/gr.6858507; Szyf M, 2008, ENVIRON MOL MUTAGEN, V49, P46, DOI 10.1002/em.20357; Tochigi M, 2008, NEUROSCI RES, V60, P184, DOI 10.1016/j.neures.2007.10.010; Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132; Turecki G, 2005, J PSYCHIATR NEUROSCI, V30, P398; Turecki G, 2001, BIPOLAR DISORD, V3, P335, DOI 10.1034/j.1399-5618.2001.30608.x; Veldic M, 2007, SCHIZOPHR RES, V91, P51, DOI 10.1016/j.schres.2006.11.029; Vythilingam M, 2002, AM J PSYCHIAT, V159, P2072, DOI 10.1176/appi.ajp.159.12.2072; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Widom CS, 2007, ARCH GEN PSYCHIAT, V64, P49; Zouk H, 2006, J AFFECT DISORDERS, V92, P195, DOI 10.1016/j.jad.2006.01.016	59	249	254	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2085	10.1371/journal.pone.0002085	http://dx.doi.org/10.1371/journal.pone.0002085			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461137	Green Submitted, gold, Green Published			2022-12-25	WOS:000261642400008
J	Yu, JKL; Tok, TS; Tsai, JJ; Chang, WS; Dzimadzi, RK; Yen, PH; Makombe, SD; Nkhata, A; Schouten, EJ; Kamoto, K; Harries, AD				Yu, Joseph Kwong-Leung; Tok, Teck-Siang; Tsai, Jih-Jin; Chang, Wu-Shou; Dzimadzi, Rose K.; Yen, Ping-Hsiang; Makombe, Simon D.; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita; Harries, Anthony D.			What Happens to Patients on Antiretroviral Therapy Who Transfer Out to Another Facility?	PLOS ONE			English	Article								Background: Long term retention of patients on antiretroviral therapy ( ART) in Africa's rapidly expanding programmes is said to be 60% at 2 years. Many reports from African ART programmes make little mention of patients who are transferred out to another facility, yet Malawi's national figures show a transfer out of 9%. There is no published information about what happens to patients who transfer-out, but this is important because if they transfer-in and stay alive in these other facilities then national retention figures will be better than previously reported. Methodology/Principal Findings: Of all patients started on ART over a three year period in Mzuzu Central Hospital, North Region, Malawi, those who transferred out were identified from the ART register and master cards. Clinic staff attempted to trace these patients to determine whether they had transferred in to a new ART facility and their outcome status. There were 805 patients (19% of the total cohort) who transferred out, of whom 737 (92%) were traced as having transferred in to a new ART facility, with a median time of 1.3 months between transferring-out and transferring-in. Survival probability was superior and deaths were lower in the transfer-out patients compared with those who did not transfer. Conclusion/Significance: In Mzuzu Central Hospital, patients who transfer-out constitute a large proportion of patients not retained on ART at their original clinic of registration. Good documentation of transfer-outs and transfer-ins are needed to keep track of national outcomes. Furthermore, the current practice of regarding transfer-outs as being double counted in national cohorts and subtracting this number from the total national registrations to get the number of new patients started on ART is correct.	[Yu, Joseph Kwong-Leung] Mzuzu Cent Hosp, Taiwan Med Mission Malawi, Mzuzu, Malawi; [Yu, Joseph Kwong-Leung; Tok, Teck-Siang; Yen, Ping-Hsiang] Pingtung Christian Hosp, Int Med Cooperat & Development Ctr, Pingtung, Taiwan; [Yu, Joseph Kwong-Leung; Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Kaohsiung Med Univ Div Infect Dis, Coll Med, Kaohsiung, Taiwan; [Yu, Joseph Kwong-Leung; Chang, Wu-Shou] Dept Hlth, Bureau Int Cooperation, Taipei, Taiwan; [Dzimadzi, Rose K.] Minist Hlth, Mzuzu Central Hosp, Office Hosp Director, Mzuzu, Malawi; [Makombe, Simon D.; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita; Harries, Anthony D.] Minist Hlth, HIV Unit, Lilongwe, Malawi; [Schouten, Erik J.] Management Sci Hlth, Lilongwe, Malawi; [Harries, Anthony D.] Family Hlth Int, Lilongwe, Malawi; [Harries, Anthony D.] London Sch Hyg & Trop Med, London, England	Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of London; London School of Hygiene & Tropical Medicine	Yu, JKL (corresponding author), Mzuzu Cent Hosp, Taiwan Med Mission Malawi, Mzuzu, Malawi.	adharries@malawi.net	TSAI, JIH-JIN/GOP-2776-2022	TSAI, JIH-JIN/0000-0003-2226-8916				Boulle A, 2007, SEX TRANSM INFECT, V83, P503, DOI 10.1136/sti.2007.027748; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062; Meijnen S, 2002, INT J TUBERC LUNG D, V6, P666; *MIN HLTH MAL HIV, 2006, ARV THER MAL 30 JUN; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Wester CW, 2005, JAIDS-J ACQ IMM DEF, V40, P336, DOI 10.1097/01.qai.0000159668.80207.5b; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	12	21	21	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2065	10.1371/journal.pone.0002065	http://dx.doi.org/10.1371/journal.pone.0002065			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446230	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300034
J	Frechet, M; Warrick, E; Vioux, C; Chevallier, O; Spatz, A; Benhamou, S; Sarasin, A; Bernerd, F; Magnaldo, T				Frechet, M.; Warrick, E.; Vioux, C.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Bernerd, F.; Magnaldo, T.			Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients	ONCOGENE			English	Article						xeroderma pigmentosum; skin; cancer; MMP1; AP-1; ROS	SQUAMOUS-CELL CARCINOMA; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; COLLAGENASE GENE; MOLECULAR-BASIS; SKIN; CANCER; INDUCTION	Xeroderma pigmentosum (XP) is a rare, recessively inherited genetic disease characterized by skin cancer proneness and premature aging in photoexposed area. The disease results from defective nucleotide excision repair of ultraviolet (UV)-induced DNA lesions. Reconstruction of group C (XP-C) skin in vitro previously suggested that patients' dermal fibroblasts might be involved in promoting skin cancer development, as they elicited microinvasions of both control and XP-C keratinocytes within dermal equivalents. Here we show that in the absence of UV exposure XP-C fibroblasts exhibit aged-like features such as an elongated and dendritic shape. We analysed the repertoire of expression of matrix metalloproteinases ( MMPs) involved in skin aging and cancer. All XP-C fibroblasts tested in this study overexpressed specifically and significantly MMP1. MMP1 expression was also found increased in the dermis of XP-C skin sections suggesting the active contribution of XP-C mesenchymal cells to skin aging and exacerbated carcinogenesis. Increased MMP1 expression in cultured XP-C fibroblasts resulted from MMP1 mRNA accumulation and enhanced transcriptional activity of the MMP1 gene promoter. Deletion analysis revealed the essential role of AP-1 activation in constitutive MMP1 overexpression in XP-C primary fibroblasts. In parallel, levels of reactive oxygen species and FOSB DNA-binding activity were found increased in XP-C fibroblasts. Altogether, these observations suggest that beyond its role in nucleotide excision repair the XPC protein may be important in cell metabolism and fate in the absence of UV.	[Frechet, M.; Warrick, E.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Magnaldo, T.] Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; [Warrick, E.; Vioux, C.; Bernerd, F.] LOreal, Life Sci Adv Res, Ctr C Zviak, F-92583 Clichy, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; L'Oreal Group	Magnaldo, T (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins, F-94805 Villejuif, France.	magnaldo@igr.fr	Benhamou, Simone/K-6554-2015; Benhamou, Simone/ABD-2590-2020; SPATZ, ALAN/B-8645-2009	SPATZ, ALAN/0000-0003-3020-1420; BENHAMOU, Simone/0000-0001-5853-8047	Association pour la Recherche sur le Cancer [3590]; Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies; Les enfants de la Lune	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Les enfants de la Lune	Dr Asselineau and Dr J Leclaire are gratefully acknowledged for continuous support and encouragements. We are indebted to V Marty, C Pierrard and Dr C Marionnet for their expert help. We are also grateful to Dr A Jalil for confocal microscopy. We thank Professor P Herrlich and Professor CE Brinckerhoff for DNA reporter constructs. Many thanks to F Duvigneau for editing English usage in the article. TM gratefully acknowledges fundings from the Association pour la Recherche sur le Cancer (no. 3590), the Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies. AS thanks the association 'Les enfants de la Lune' for its support.	Airola K, 2001, J INVEST DERMATOL, V116, P85, DOI 10.1046/j.1523-1747.2001.00223.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Arnaudeau-Begard C, 2003, HUM GENE THER, V14, P983, DOI 10.1089/104303403766682241; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Bernerd F, 2005, PHOTOCHEM PHOTOBIOL, V81, P19, DOI 10.1562/2004-07-29-IR-250.1; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Chung JH, 2001, J INVEST DERMATOL, V117, P1218, DOI 10.1046/j.0022-202x.2001.01544.x; Chung JH, 2000, J INVEST DERMATOL, V115, P177, DOI 10.1046/j.1523-1747.2000.00009.x; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; Comoglio PM, 2005, NAT MED, V11, P1156, DOI 10.1038/nm1105-1156; D'Errico M, 2006, EMBO J, V25, P4305, DOI 10.1038/sj.emboj.7601277; Del Rio M, 2002, HUM GENE THER, V13, P959, DOI 10.1089/10430340252939069; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fligiel SEG, 2003, J INVEST DERMATOL, V120, P842, DOI 10.1046/j.1523-1747.2003.12148.x; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Frechet Mathilde, 2006, Methods Mol Biol, V314, P9; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAY ST, 1992, AM J PATHOL, V141, P301; Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200; Jorissen HJMM, 2007, BIOCHEMISTRY-US, V46, P8360, DOI 10.1021/bi700494v; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kerkela E, 2002, J PATHOL, V198, P258, DOI 10.1002/path.1198; Khorramizadeh MR, 1999, MOL CELL BIOCHEM, V194, P99, DOI 10.1023/A:1006909021352; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Monhian N, 2005, ARCH FACIAL PLAST S, V7, P238, DOI 10.1001/archfaci.7.4.238; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; NISHIGORI C, 1989, J INVEST DERMATOL, V93, P506, DOI 10.1111/1523-1747.ep12284060; Otto AI, 1999, CANCER RES, V59, P1212; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhie GE, 2001, J INVEST DERMATOL, V117, P1212, DOI 10.1046/j.0022-202x.2001.01469.x; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Shimizu Y, 2003, EMBO J, V22, P164, DOI 10.1093/emboj/cdg016; Shimokawa N, 2005, J CELL PHYSIOL, V205, P77, DOI 10.1002/jcp.20369; Shin MH, 2005, J INVEST DERMATOL, V125, P221, DOI 10.1111/j.0022-202X.2005.23823.x; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Varani J, 2004, J INVEST DERMATOL, V122, P1471, DOI 10.1111/j.0022-202X.2004.22614.x; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; VUILLAUME M, 1992, CARCINOGENESIS, V13, P321, DOI 10.1093/carcin/13.3.321; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9	55	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5223	5232		10.1038/onc.2008.153	http://dx.doi.org/10.1038/onc.2008.153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469853				2022-12-25	WOS:000258915100006
J	Kowalczuk, S; Broer, A; Tietze, N; Vanslambrouck, JM; Rasko, JEJ; Broer, S				Kowalczuk, Sonja; Broeer, Angelika; Tietze, Nadine; Vanslambrouck, Jessica M.; Rasko, John E. J.; Broeer, Stefan			A protein complex in the brush-border membrane explains a Hartnup disorder allele	FASEB JOURNAL			English	Article						amino acid transport; angiotensin-converting enzyme 2; epithelial transport	AMINO-ACID TRANSPORTERS; ANGIOTENSIN-CONVERTING ENZYME-2; XENOPUS-LAEVIS OOCYTES; PROLINE TRANSPORTER; MOLECULAR-CLONING; SYSTEM; FAMILY; EXPRESSION; COLLECTRIN; INTESTINE	Protein absorption in the intestine is mediated by proteases and brush-border peptidases together with peptide and amino acid transporters. Neutral amino acids are generated by a variety of aminopeptidases and carboxypeptidases and are subsequently taken up by the amino acid transporter B(0)AT1 (SLC6A19), which is mutated in Hartnup disorder. Coexpression of B(0)AT1 together with the brush-border carboxypeptidase angiotensin-converting enzyme 2 (ACE2) in Xenopus laevis oocytes led to a dramatic increase of transporter expression at the oocyte surface. Other members of the SLC6 family were not stimulated by coexpression with ACE2. Addition of a peptide containing a carboxyterminal leucine residue to ACE2- and B(0)AT1-coexpressing oocytes caused inward currents due to Na(+)-leucine cotransport, demonstrating the formation of a metabolic complex. Coexpression of the Hartnup disorder causing mutation B(0)AT1(R240Q) showed reduced interaction with ACE2 and its renal paralogue collectrin. This would result in reduced surface expression in both kidney and intestine, thereby explaining the onset of the disorder in individuals carrying this mutation.	[Vanslambrouck, Jessica M.; Rasko, John E. J.] Univ Sydney, Centenary Inst Canc Med & Cell Biol, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [Vanslambrouck, Jessica M.; Rasko, John E. J.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; [Kowalczuk, Sonja; Broeer, Angelika; Tietze, Nadine; Broeer, Stefan] Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	University of Sydney; Centenary Institute; University of Sydney; Australian National University	Broer, S (corresponding author), Australian Natl Univ, Sch Biochem & Mol Biol, Linnaeus Way 41, Canberra, ACT 0200, Australia.	stefan.broeer@anu.edu.au	Rasko, John EJ/F-5754-2013; Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634; rasko, John/0000-0003-2975-807X				AZMANOV DN, 2008, HUM MUTAT IN PRESS; BAI JPF, 1994, PHARMACEUT RES, V11, P897, DOI 10.1023/A:1018946228432; Biber J, 2007, NAT PROTOC, V2, P1356, DOI 10.1038/nprot.2007.156; Bohmer C, 2005, BIOCHEM J, V389, P745; Broer A, 2006, BIOCHEM J, V393, P421, DOI 10.1042/BJ20051273; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer S, 2008, PHYSIOL REV, V88, P249, DOI 10.1152/physrev.00018.2006; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475; ELION EA, 2007, CURRENT PROTOCOLS IM; Guy JL, 2003, BIOCHEMISTRY-US, V42, P13185, DOI 10.1021/bi035268s; HILLMAN RE, 1986, PEDIATR RES, V20, pA265; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Kowalczuk S, 2005, BIOCHEM J, V386, P417, DOI 10.1042/BJ20050100; Lambert DW, 2008, BIOCHEM PHARMACOL, V75, P781, DOI 10.1016/j.bcp.2007.08.012; Malakauskas SM, 2007, AM J PHYSIOL-RENAL, V292, pF533, DOI 10.1152/ajprenal.00325.2006; Matthews D. M., 1991, PROTEIN ABSORPTION; O'Mara M, 2006, J MEMBRANE BIOL, V213, P111, DOI 10.1007/s00232-006-0879-3; Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCRIVER CR, 1987, AM J HUM GENET, V40, P401; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; Takanaga H, 2005, BIOCHEM BIOPH RES CO, V337, P892, DOI 10.1016/j.bbrc.2005.09.128; Takanaga H, 2005, J BIOL CHEM, V280, P8974, DOI 10.1074/jbc.M413027200; Turner AJ, 2002, CAN J PHYSIOL PHARM, V80, P346, DOI 10.1139/Y02-021; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; [No title captured]	34	129	138	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2880	2887		10.1096/fj.08-107300	http://dx.doi.org/10.1096/fj.08-107300			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424768				2022-12-25	WOS:000258089300028
J	Rehman, AO; Wang, CY				Rehman, Aasia O.; Wang, Cun-Yu			SDF-1 alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; PROINFLAMMATORY CYTOKINE EXPRESSION; GROWTH-STIMULATING FACTOR; LYMPH-NODE METASTASIS; BREAST-CANCER; CONSTITUTIVE ACTIVATION; MOLECULAR-CLONING; DOWN-REGULATION; KINASE-ALPHA; TUMOR-GROWTH	CXCL12/stromal cell-derived factor-1 alpha (SDF-1 alpha), a chemokine ligand for the G protein-coupled receptor CXCR4, plays an important role in the directed movement of cells. Many studies have documented the importance of CXCR4 in tumor progression and organ-specific metastasis. Recently, several studies have implicated a role for SDF-1 alpha in head and neck squamous cell carcinoma (HNSCC) metastasis, but currently there is little information about how SDF-1 alpha promotes HNSCC metastasis. In this report we show that the NF-kappa B signaling pathway is activated in response to SDF-1 alpha in HNSCC while primary and immortalized keratinocytes show no SDF-1 alpha-mediated NF-kappa B activity. We found that SDF-1 alpha-mediated NF-kappa B signaling is independent of phosphoinositide 3-kinase/Akt and ERK/MAPK pathways. We observed that SDF-1 alpha induces I kappa B alpha phosphorylation and degradation and the nuclear translocation of NF-kappa B in HNSCC cell lines, suggesting that SDF-1 alpha activates the classical NF-kappa B signaling pathway. Contrary to previous reports, SDF-1 alpha-induced NF-kappa B activation is not mediated by tumor necrosis factor alpha. Furthermore, blocking the NF-kappa B signaling pathway with an IKK beta inhibitor significantly reduces SDF-1 alpha-mediated HNSCC invasion. Taken together, our data suggest SDF-1 alpha/CXCR4 may promote HNSCC invasion and metastasis by activating NF-kappa B and that targeting NF-kappa B may provide therapeutic opportunities in preventing HNSCC metastasis mediated by SDF-1 alpha.	[Rehman, Aasia O.; Wang, Cun-Yu] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Mol Signalling Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Wang, CY (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Mol Signalling Lab, Los Angeles, CA 90095 USA.	cwang@dentistry.ucla.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013848, R01DE015964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 15964, DE 13848] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almofti A, 2004, INT J ONCOL, V25, P65; Andela VB, 2000, CANCER RES, V60, P6557; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bertolini F, 2002, CANCER RES, V62, P3106; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chen YC, 2003, CANCER RES, V63, P4801; Delilbasi CB, 2004, ORAL ONCOL, V40, P154, DOI 10.1016/S1368-8375(03)00144-1; Dong G, 1999, CANCER RES, V59, P3495; Duffey DC, 1999, CANCER RES, V59, P3468; Duffey DC, 2000, BRIT J CANCER, V83, P1367, DOI 10.1054/bjoc.2000.1423; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Ishikawa T, 2006, INT J ONCOL, V28, P61; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Katayama A, 2005, CLIN CANCER RES, V11, P2937, DOI 10.1158/1078-0432.CCR-04-1470; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lee BC, 2004, MOL CANCER RES, V2, P327; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Onoue T, 2006, INT J ONCOL, V29, P1133; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Patel V, 2001, CRIT REV ORAL BIOL M, V12, P55, DOI 10.1177/10454411010120010401; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Samara GJ, 2004, CANCER LETT, V214, P231, DOI 10.1016/j.canlet.2004.04.035; Scotton CJ, 2002, CANCER RES, V62, P5930; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Uchida DE, 2004, LAB INVEST, V84, P1538, DOI 10.1038/labinvest.3700190; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	47	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					19888	19894		10.1074/jbc.M710432200	http://dx.doi.org/10.1074/jbc.M710432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18448428	hybrid, Green Published			2022-12-25	WOS:000257565300003
J	Li, Y; Kovach, A; Suino-Powell, K; Martynowski, D; Xu, HE				Li, Yong; Kovach, Amanda; Suino-Powell, Kelly; Martynowski, Dariusz; Xu, H. Eric			Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; PPAR-GAMMA; TRANSCRIPTION COACTIVATORS; CRYSTAL-STRUCTURE; ALPHA; LIGAND; PGC-1; HETERODIMERIZATION; IDENTIFICATION; ROSIGLITAZONE	The functional interaction between the peroxisome proliferator-activated receptor gamma (PPAR gamma) and its coactivator PGC-1 alpha is crucial for the normal physiology of PPAR gamma and its pharmacological response to antidiabetic treatment with rosiglitazone. Here we report the crystal structure of the PPAR gamma ligand-binding domain bound to rosiglitazone and to a large PGC-1 alpha fragment that contains two LXXLL-related motifs. The structure reveals critical contacts mediated through the first LXXLL motif of PGC-1 alpha and the PPAR gamma coactivator binding site. Through a combination of biochemical and structural studies, we demonstrate that the first LXXLL motif is the most potent among all nuclear receptor coactivator motifs tested, and only this motif of the two LXXLL-related motifs in PGC-1 alpha is capable of binding to PPAR gamma. Our studies reveal that the strong interaction of PGC-1 alpha and PPAR gamma is mediated through both hydrophobic and specific polar interactions. Mutations within the context of the full-length PGC-1 alpha indicate that the first PGC-1 alpha motif is necessary and sufficient for PGC-1 alpha to coactivate PPAR gamma in the presence or absence of rosiglitazone. These results provide a molecular basis for specific recruitment and functional interplay between PPAR gamma and PGC-1 alpha in glucose homeostasis and adipocyte differentiation.	[Li, Yong; Kovach, Amanda; Suino-Powell, Kelly; Xu, H. Eric] Van Andel Res Inst, Lab Struct Sci, Grand Rapids, MI 49503 USA; [Li, Yong; Martynowski, Dariusz] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA	Van Andel Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, Y (corresponding author), 709 Salk Hall, Pittsburgh, PA 15261 USA.	yol21@pitt.edu; eric.xu@vai.org	Xu, H. Eric/ABD-7487-2021; Martynowski, Dariusz/AAU-6083-2020	Martynowski, Dariusz/0000-0001-7617-7716; Xu, H. Eric/0000-0002-6829-8144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066202, R01DK071662] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL089301] Funding Source: Medline; NIDDK NIH HHS [DK066202, DK071662] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Hall JM, 2007, MOL ENDOCRINOL, V21, P1756, DOI 10.1210/me.2007-0060; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li Y, 2005, MOL CELL, V19, P367, DOI 10.1016/j.molcel.2005.06.026; Li Y, 2003, STRUCTURE, V11, P741, DOI 10.1016/S0969-2126(03)00133-3; Li Y, 2005, MOL CELL, V17, P491, DOI 10.1016/j.molcel.2005.02.002; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012; NAVAZA J, 1992, MOL REPLACEMENT; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Suino K, 2004, MOL CELL, V16, P893, DOI 10.1016/j.molcel.2004.11.036; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Wu YF, 2003, J BIOL CHEM, V278, P8637, DOI 10.1074/jbc.M210910200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yu ST, 2007, BBA-MOL CELL BIOL L, V1771, P936, DOI 10.1016/j.bbalip.2007.01.008	32	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19132	19139		10.1074/jbc.M802040200	http://dx.doi.org/10.1074/jbc.M802040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18469005	Green Published, hybrid			2022-12-25	WOS:000257165600068
J	Tokuhiro, K; Hirose, M; Miyagawa, Y; Tsujimura, A; Irie, S; Isotani, A; Okabe, M; Toyama, Y; Ito, C; Toshimori, K; Takeda, K; Oshio, S; Tainaka, H; Tsuchida, J; Okuyama, A; Nishimune, Y; Tanaka, H				Tokuhiro, Keizo; Hirose, Mika; Miyagawa, Yasushi; Tsujimura, Akira; Irie, Shinji; Isotani, Ayako; Okabe, Masaru; Toyama, Yoshiro; Ito, Chizuru; Toshimori, Kiyotaka; Takeda, Ken; Oshio, Shigeru; Tainaka, Hitoshi; Tsuchida, Junji; Okuyama, Akihiko; Nishimune, Yoshitake; Tanaka, Hiromitsu			Meichroacidin containing the membrane occupation and recognition nexus motif is essential for spermatozoa morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACYTOPLASMIC SPERM INJECTION; OUTER DENSE FIBERS; EPIDIDYMAL OBSTRUCTION; MOLECULAR-CLONING; FIBROUS SHEATH; MOUSE SPERM; RAT SPERM; PROTEIN; FERTILITY; SPERMATOGENESIS	Meichroacidin (MCA) is a highly hydrophilic protein that contains the membrane occupation and recognition nexus motif. MCA is expressed during the stages of spermatogenesis from pachytene spermatocytes to mature sperm development and is localized in the male meiotic metaphase chromosome and sperm flagellum. MCA sequences are highly conserved in Ciona intestinalis, Cyprinus carpio, and mammals. To investigate the physiological role of MCA, we generated MCA-disrupted mutant mice; homozygous MCA mutant males were infertile, but females were not. Sperm was rarely observed in the caput epididymidis of MCA mutant males. However, little to no difference was seen in testis mass between wild-type and mutant mice. During sperm morphogenesis, elongated spermatids had retarded flagellum formation and might increase phagocytosis by Sertoli cells. Immunohistochemical analysis revealed that MCA interacts with proteins located on the outer dense fibers of the flagellum. The testicular sperm of MCA mutant mice was capable of fertilizing eggs successfully via intracytoplasmic sperm injection and generated healthy progeny. Our results suggest that MCA is essential for sperm flagellum formation and the production of functional sperm.	[Tokuhiro, Keizo; Hirose, Mika; Tainaka, Hitoshi; Tanaka, Hiromitsu] Osaka Univ, TANAKA Project, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan; [Tokuhiro, Keizo; Hirose, Mika; Isotani, Ayako; Okabe, Masaru; Tsuchida, Junji; Tanaka, Hiromitsu] Osaka Univ, Microbial Dis Res Inst, Anim Resource Ctr Infect Dis, Suita, Osaka 5650871, Japan; [Miyagawa, Yasushi; Tsujimura, Akira; Okuyama, Akihiko] Osaka Univ, Grad Sch Med, Dept Urol, Suita, Osaka 5650871, Japan; [Irie, Shinji] Toppan Printing Co Ltd, Business Incubat Ctr, Dept Life Sci, Corp Mfg Technol & Res Div,Bunkyo Ku, Tokyo 1128531, Japan; [Toyama, Yoshiro; Ito, Chizuru; Toshimori, Kiyotaka] Chiba Univ, Grad Sch Med, Dept Anat & Dev Biol, Chiba 2608670, Japan; [Takeda, Ken] Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Chiba 2788510, Japan; [Nishimune, Yoshitake] Osaka Univ, Microbial Dis Res Inst, Res Collaborat Ctr Emerging & Reemerging Infect, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Toppan Printing Co Ltd; Chiba University; Tokyo University of Science; Osaka University	Tanaka, H (corresponding author), Nagasaki Int Univ, Fac Pharmaceut Sci, Nagasaki 8593298, Japan.	h-tanaka@niu.ac.jp	Tokuhiro, Keizo/HDM-4295-2022; Isotani, Ayako/A-9929-2009; Isotani, Ayako/D-4564-2017; Okabe, Masaru/B-6917-2015	Isotani, Ayako/0000-0002-4720-2318; Isotani, Ayako/0000-0002-4720-2318; Ito, Chizuru/0000-0003-2697-0382; Okabe, Masaru/0000-0002-0803-9044				BAILLIE AH, 1962, J ANAT, V96, P335; Bannister LA, 2007, PLOS BIOL, V5, P1016, DOI 10.1371/journal.pbio.0050105; BELLVE AR, 1993, METHOD ENZYMOL, V225, P113; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; Cao WL, 2006, MOL CELL PROTEOMICS, V5, P801, DOI 10.1074/mcp.M500322-MCP200; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; de Carvalho CE, 2002, BIOL REPROD, V66, P785, DOI 10.1095/biolreprod66.3.785; De Kretser DM, 1999, J CLIN ENDOCR METAB, V84, P3443, DOI 10.1210/jc.84.10.3443; FAWCETT DW, 1975, DEV BIOL, V11, P391; Flickinger CJ, 1999, ANAT REC, V254, P76, DOI 10.1002/(SICI)1097-0185(19990101)254:1<76::AID-AR10>3.0.CO;2-#; Hart PE, 1999, GENOMICS, V60, P111, DOI 10.1006/geno.1999.5880; HIGGY NA, 1994, BIOL REPROD, V50, P1357, DOI 10.1095/biolreprod50.6.1357; HO YG, 1995, MOL REPROD DEV, V41, P232, DOI 10.1002/mrd.1080410214; Ihara M, 2005, DEV CELL, V8, P343, DOI 10.1016/j.devcel.2004.12.005; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Ju TK, 2004, BIOL REPROD, V71, P1419, DOI 10.1095/biolreprod.104.030346; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; Kotaja N, 2004, NAT METHODS, V1, P249, DOI 10.1038/nmeth1204-249; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Matsuoka Yasuhiro, 2005, Reprod Med Biol, V4, P213, DOI 10.1111/j.1447-0578.2005.00108.x; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; Moriguchi S, 2006, P NATL ACAD SCI USA, V103, P10811, DOI 10.1073/pnas.0509863103; Nishimune Y, 2006, J ANDROL, V27, P326, DOI 10.2164/jandrol.05162; OLSON GE, 1976, BIOL REPROD, V14, P517, DOI 10.1095/biolreprod14.5.517; OLSON GE, 1980, BIOL REPROD, V22, P319, DOI 10.1095/biolreprod22.2.319; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P120; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satouh Y, 2005, MOL BIOL CELL, V16, P626, DOI 10.1091/mbc.e04-09-0784; Shetty J, 2007, GENE, V396, P93, DOI 10.1016/j.gene.2007.02.031; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tanaka H, 2005, MOL CELL BIOL, V25, P7107, DOI 10.1128/MCB.25.16.7107-7119.2005; Tanaka H, 2003, BIOL REPROD, V69, P475, DOI 10.1095/biolreprod.103.015867; Tanaka H, 2003, MOL HUM REPROD, V9, P69, DOI 10.1093/molehr/gag010; Tohda A, 2002, BIOL REPROD, V66, P85, DOI 10.1095/biolreprod66.1.85; Tsuchida J, 1998, DEV BIOL, V197, P67, DOI 10.1006/dbio.1998.8885; VERA JC, 1984, J BIOL CHEM, V259, P5970; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	37	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19039	19048		10.1074/jbc.M708590200	http://dx.doi.org/10.1074/jbc.M708590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18453535	hybrid			2022-12-25	WOS:000257165600059
J	Creze, C; Castang, S; Derivery, E; Haser, R; Hugouvieux-Cotte-Pattat, N; Shevchik, VE; Gouet, P				Creze, Christophe; Castang, Sandra; Derivery, Emmanuel; Haser, Richard; Hugouvieux-Cotte-Pattat, Nicole; Shevchik, Vladimir E.; Gouet, Patrice			The crystal structure of pectate lyase PelI from soft rot pathogen Erwinia chrysanthemi in complex with its substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ELIMINATION; III DOMAIN; FIBRONECTIN; PROTEIN; BINDING; CRYSTALLIZATION; NUCLEOTIDE; CAROTOVORA; MOLSCRIPT; DISPLAYS	The crystallographic structure of the family 3 polysaccharide lyase (PL-3) PelI from Erwinia chrysanthemi has been solved to 1.45 angstrom resolution. It consists of an N-terminal domain harboring a fibronectin type III fold linked to a catalytic domain displaying a parallel beta-helix topology. The N-terminal domain is located away from the active site and is not involved in the catalytic process. After secretion in planta, the two domains are separated by E. chrysanthemi proteases. This event turns on the hypersensitive response of the host. The structure of the single catalytic domain determined to 2.1 angstrom resolution shows that the domain separation unveils a "Velcro"-like motif of asparagines, which might be recognized by a plant receptor. The structure of PelI in complex with its substrate, a tetragalacturonate, has been solved to 2.3 angstrom resolution. The sugar binds from subsites -2 to +2 in one monomer of the asymmetric unit, although it lies on subsites -1 to +3 in the other. These two "Michaelis complexes" have never been observed simultaneously before and are consistent with the dual mode of bond cleavage in this substrate. The bound sugar adopts a mixed 2(1) and 3(1) helical conformation similar to that reported in inactive mutants from families PL-1 and PL-10. However, our study suggests that the catalytic base in PelI is not a conventional arginine but a lysine as proposed in family PL-9.	[Creze, Christophe; Derivery, Emmanuel; Haser, Richard; Gouet, Patrice] CNRS, Inst Biol & Chim Prot, Lab BioCristallog, F-69367 Lyon 07, France; [Creze, Christophe; Derivery, Emmanuel; Haser, Richard; Gouet, Patrice] Univ Lyon, UMR 5086, IFR 128 BioSci Gerland Lyon Sud, F-69367 Lyon, France; [Castang, Sandra; Hugouvieux-Cotte-Pattat, Nicole; Shevchik, Vladimir E.] Univ Lyon 1, CNRS, UMR 5240, Unite Microbiol Adaptat & Pathol, F-69622 Villeurbanne, France; [Castang, Sandra; Hugouvieux-Cotte-Pattat, Nicole; Shevchik, Vladimir E.] INSA, Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National des Sciences Appliquees de Lyon - INSA Lyon	Gouet, P (corresponding author), CNRS, Inst Biol & Chim Prot, Lab BioCristallog, F-69367 Lyon 07, France.	p.gouet@ibcp.fr		Shevchik, Vladimir/0000-0002-8031-8638; gouet, patrice/0000-0001-9485-6157; COTTE-PATTAT, Nicole/0000-0002-4322-160X				Abbott DW, 2007, J BIOL CHEM, V282, P35328, DOI 10.1074/jbc.M705511200; Abbott DW, 2007, J MOL BIOL, V368, P1215, DOI 10.1016/j.jmb.2007.02.083; Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BORK P, 1993, PROTEIN SCI, V2, P1185, DOI 10.1002/pro.5560020714; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buttner D, 2003, CURR OPIN PLANT BIOL, V6, P312, DOI 10.1016/S1369-5266(03)00064-5; Castang S, 2004, ACTA CRYSTALLOGR D, V60, P190, DOI 10.1107/S0907444903026222; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; Coutinho PM, 1999, ROY SOC CH, P3; de Armas HN, 2004, ACTA CRYSTALLOGR D, V60, P999, DOI 10.1107/S090744490400602X; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Hatada Y, 2001, EXTREMOPHILES, V5, P127, DOI 10.1007/s007920100182; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; Jee JG, 2002, J BIOL CHEM, V277, P1388, DOI 10.1074/jbc.M109726200; Jenkins J, 2004, J BIOL CHEM, V279, P9139, DOI 10.1074/jbc.M311390200; Kataeva IA, 2002, APPL ENVIRON MICROB, V68, P4292, DOI 10.1128/AEM.68.9.4292-4300.2002; Kim JF, 1998, J BACTERIOL, V180, P5203, DOI 10.1128/JB.180.19.5203-5210.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIU Y, 1994, APPL ENVIRON MICROB, V60, P2545, DOI 10.1128/AEM.60.7.2545-2552.1994; Login FH, 2006, J BIOL CHEM, V281, P33152, DOI 10.1074/jbc.M606245200; Michel G, 2004, J BIOL CHEM, V279, P32882, DOI 10.1074/jbc.M403421200; Nakaniwa T, 2003, ACTA CRYSTALLOGR D, V59, P341, DOI 10.1107/S0907444902020541; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Roussel A, 1992, TURBO FRODO BIOGRAPH; Roy C, 1999, J BACTERIOL, V181, P3705, DOI 10.1128/JB.181.12.3705-3709.1999; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shevchik VE, 1998, MOL MICROBIOL, V29, P1459, DOI 10.1046/j.1365-2958.1998.01028.x; Shevchik VE, 1999, J BACTERIOL, V181, P3912, DOI 10.1128/JB.181.13.3912-3919.1999; Tardy F, 1997, J BACTERIOL, V179, P2503, DOI 10.1128/jb.179.8.2503-2511.1997; Thomas LM, 2002, ACTA CRYSTALLOGR D, V58, P1008, DOI 10.1107/S0907444902005851; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7	44	33	34	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18260	18268		10.1074/jbc.M709931200	http://dx.doi.org/10.1074/jbc.M709931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18430740	hybrid			2022-12-25	WOS:000256949200054
J	Edwards, IJ; Sun, H; Hu, Y; Berquin, IM; O'Flaherty, JT; Cline, JM; Rudel, LL; Chen, YQ				Edwards, Iris J.; Sun, Haiguo; Hu, Yunping; Berquin, Isabelle M.; O'Flaherty, Joseph T.; Cline, J. Mark; Rudel, Lawrence L.; Chen, Yong Q.			In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; PROLIFERATOR-ACTIVATED RECEPTORS; LOW-DENSITY LIPOPROTEINS; SURFACE PROTEOGLYCAN; GENE-EXPRESSION; CANCER-CELLS; PROGNOSTIC-SIGNIFICANCE; DOCOSAHEXAENOIC ACID; REDUCED EXPRESSION	Syndecan 1 is the major proteoglycan produced by epithelial cells. It is strategically localized at the plasma membrane to participate in growth factor signaling and cell-cell and cell-matrix interactions. Its expression may modulate the properties of epithelial lineage tumor cells in which it is generally down-regulated compared with nontumor progenitors. The present study examined the regulation of syndecan 1 in prostate epithelial cells by n-3 polyunsaturated fatty acids. In prostate tissue of mice, syndecan 1 immunostaining was demonstrated in epithelial cells throughout each gland. In animals fed an n-3 polyunsaturated fatty acid-enriched diet, syndecan 1 mRNA was increased in all prostate glands. In the human prostate cancer cell line, PC-3, delivery of exogenous n-3 (but not n-6) fatty acids resulted in up-regulation of syndecan 1 expression. This effect was mimicked by a peroxisome proliferator-activated receptor (PPAR)gamma agonist, troglitazone, and inhibited in the presence of a PPAR gamma antagonist and in cells transfected with dominant negative PPAR gamma cDNA. Using a luciferase gene driven either by a PPAR response element or by a DR-1 site present in the syndecan 1 promoter, reporter activation was increased by n-3 low density lipoprotein, docosahexaenoic acid, and troglitazone, whereas activity of a luciferase gene placed downstream of a mutant DR-1 site was unresponsive. These findings indicate that syndecan 1 is up-regulated by n-3 fatty acids by a transcriptional pathway involving PPAR gamma. This mechanism may contribute to the chemopreventive properties of n-3 fatty acids in prostate cancer.	[Edwards, Iris J.] Wake Forest Univ, Sch Med, Dept Pathol Tumor Biol, Winston Salem, NC 27157 USA; [Edwards, Iris J.; Sun, Haiguo; Hu, Yunping; Berquin, Isabelle M.; Cline, J. Mark; Rudel, Lawrence L.] Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; [O'Flaherty, Joseph T.] Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA; [Chen, Yong Q.] Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Edwards, IJ (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol Tumor Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	iedwards@wfubmc.edu	Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708	NCI NIH HHS [R01 CA 107668, R01 CA 114017, R01 CA 115958, P01 CA 106742, R01 CA107668] Funding Source: Medline; NHLBI NIH HHS [HL 49373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA106742, R01CA107668, R01CA115958, R01CA114017] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anisfeld AM, 2003, J BIOL CHEM, V278, P20420, DOI 10.1074/jbc.M302505200; Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berquin IM, 2005, J BIOL CHEM, V280, P36442, DOI 10.1074/jbc.M504945200; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Chen D, 2004, UROLOGY, V63, P402, DOI 10.1016/j.urology.2003.08.036; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Davis BC, 2003, AM J CLIN NUTR, V78, p640S, DOI 10.1093/ajcn/78.3.640S; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Edwards IJ, 2004, CLIN CANCER RES, V10, P8275, DOI 10.1158/1078-0432.CCR-04-1357; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Freeman VL, 2004, CANCER-AM CANCER SOC, V101, P2744, DOI 10.1002/cncr.20676; Fujiya M, 2001, JPN J CANCER RES, V92, P1074, DOI 10.1111/j.1349-7006.2001.tb01062.x; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; Hughes-Fulford M, 2006, CANCER RES, V66, P1427, DOI 10.1158/0008-5472.CAN-05-0914; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; Kaushal GP, 1999, BRIT J HAEMATOL, V104, P365, DOI 10.1046/j.1365-2141.1999.01180.x; Kiviniemi J, 2004, APMIS, V112, P89, DOI 10.1111/j.1600-0463.2004.apm1120202.x; KODA JE, 1985, J BIOL CHEM, V260, P8157; Kumar-Singh S, 1998, J PATHOL, V186, P300, DOI 10.1002/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; Leitzmann MF, 2004, AM J CLIN NUTR, V80, P204; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Mamalakis G, 2002, PROSTAG LEUKOTR ESS, V66, P467, DOI 10.1054/plef.2002.0384; Matsumoto A, 1997, INT J CANCER, V74, P482, DOI 10.1002/(SICI)1097-0215(19971021)74:5<482::AID-IJC2>3.0.CO;2-#; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Nackaerts K, 1997, INT J CANCER, V74, P335, DOI 10.1002/(SICI)1097-0215(19970620)74:3<335::AID-IJC18>3.3.CO;2-4; Narayanan NK, 2005, INT J ONCOL, V26, P785; Norrish AE, 1999, BRIT J CANCER, V81, P1238, DOI 10.1038/sj.bjc.6690835; Numa F, 2002, INT J ONCOL, V20, P39; Park Y, 2003, J LIPID RES, V44, P455, DOI 10.1194/jlr.M200282-JLR200; PARKS JS, 1991, J LIPID RES, V32, P305; Pulkkinen JO, 1997, ACTA OTO-LARYNGOL, V117, P312, DOI 10.3109/00016489709117794; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Rose DP, 1997, P SOC EXP BIOL MED, V216, P224, DOI 10.3181/00379727-216-44172; ROSE DP, 1991, PROSTATE, V18, P243, DOI 10.1002/pros.2990180306; Sakr WA, 1998, ANAL QUANT CYTOL, V20, P417; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Sprecher H, 2002, PROSTAG LEUKOTR ESS, V67, P79, DOI 10.1054/plef.2002.0402; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Sun HG, 2005, CANCER RES, V65, P4442, DOI 10.1158/0008-5472.CAN-04-4200; SUN XJ, 1989, J BIOL CHEM, V264, P11288; Terry PD, 2004, J NUTR, V134, p3412S, DOI 10.1093/jn/134.12.3412S; Wiksten JP, 2000, ANTICANCER RES, V20, P4905; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Williams CM, 2006, P NUTR SOC, V65, P42, DOI 10.1079/PNS2005473; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yang YJ, 1999, CLIN BIOCHEM, V32, P405, DOI 10.1016/S0009-9120(99)00036-3; Zellweger T, 2003, PROSTATE, V55, P20, DOI 10.1002/pros.10209; Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158	54	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18441	18449		10.1074/jbc.M802107200	http://dx.doi.org/10.1074/jbc.M802107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450755	Green Published, hybrid			2022-12-25	WOS:000256949200072
J	Kim, S; Lee, UJ; Kim, MN; Lee, EJ; Kim, JY; Lee, MY; Choung, S; Kim, YJ; Choi, YC				Kim, Seonhoe; Lee, Ui Jin; Kim, Mi Na; Lee, Eun-Ju; Kim, Ji Young; Lee, Mi Young; Choung, Sorim; Kim, Young Joo; Choi, Young-Chul			MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; HUMAN CANCER-CELLS; RNA-INTERFERENCE; DNA METHYLATION; TYROSINE KINASE; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS; DOWN-REGULATION; NUCLEAR EXPORT	MicroRNAs (miRNAs) constitute a class of small noncoding RNAs that play important roles in a variety of biological processes including development, apoptosis, proliferation, and differentiation. Here we show that the expression of miR-199a and miR-199a* (miR-199a/a*), which are processed from the same precursor, is confined to fibroblast cells among cultured cell lines. The fibroblast-specific expression pattern correlated well with methylation patterns: gene loci on chromosome 1 and 19 were fully methylated in all examined cell lines but unmethylated in fibroblasts. Transfection of miR-199a and/or -199a* mimetics into several cancer cell lines caused prominent apoptosis with miR-199a* being more pro-apoptotic. The mechanism underlying apoptosis induced by miR-199a was caspase-dependent, whereas a caspase-independent pathway was involved in apoptosis induced by miR-199a* in A549 cells. By employing microarray and immunoblotting analyses, we identified the MET proto-oncogene as a target of miR-199a*. Studies with a luciferase reporter fused to the 3'-untranslated region of the MET gene demonstrated miR-199a*-mediated down-regulation of luciferase activity through a binding site of miR-199a*. Interestingly, extracellular signal-regulated kinase 2 (ERK2) was also down-regulated by miR-199a*. Coordinated down-regulation of both MET and its downstream effector ERK2 by miR199a* may be effective in inhibiting not only cell proliferation but also motility and invasive capabilities of tumor cells.	[Kim, Young Joo] Korea Res Inst Biosci & Biotechnol, Natl Genome Informat Ctr, Taejon 306220, South Korea; [Kim, Seonhoe; Lee, Ui Jin; Kim, Mi Na; Lee, Eun-Ju; Kim, Ji Young; Lee, Mi Young; Choung, Sorim; Choi, Young-Chul] Bioneer Corp, Gene2Drug Res Ctr, Taejon 306220, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Choi, YC (corresponding author), 49-3 Munpyeong Dong, Taejon 306220, South Korea.	youcchoi@hanmail.net						Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Burgess T, 2006, CANCER RES, V66, P1721, DOI 10.1158/0008-5472.CAN-05-3329; Chakrabarty A, 2007, P NATL ACAD SCI USA, V104, P15144, DOI 10.1073/pnas.0705917104; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CORSO S, 2007, ONCOGENE, V6, P1; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fremin C, 2007, HEPATOLOGY, V45, P1035, DOI 10.1002/hep.21551; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jeyaseelan K, 2007, EXPERT OPIN THER TAR, V11, P1119, DOI 10.1517/14728222.11.8.1119; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kijima Y, 2002, ONCOLOGY-BASEL, V62, P60, DOI 10.1159/000048248; Kim JY, 2007, MOL CELLS, V24, P247; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lebedeva I, 2000, CANCER RES, V60, P6052; LEE UJ, 2007, MOL BI IN PRESS 0525; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Matsumoto K, 2008, FRONT BIOSCI-LANDMRK, V13, P1943, DOI 10.2741/2813; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Miller CT, 2006, ONCOGENE, V25, P409, DOI 10.1038/sj.onc.1209057; Muller S, 2007, IMMUNITY, V27, P1, DOI 10.1016/j.immuni.2007.07.003; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; REED JC, 1990, CANCER RES, V50, P6565; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Salvi A, 2007, INT J ONCOL, V31, P451; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Van Rooij E, 2007, J CLIN INVEST, V117, P2369, DOI 10.1172/JCI33099; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Wacheck V, 2003, OLIGONUCLEOTIDES, V13, P393, DOI 10.1089/154545703322617078; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yu SL, 2007, DNA CELL BIOL, V26, P283, DOI 10.1089/dna.2006.0555	69	185	200	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18158	18166		10.1074/jbc.M800186200	http://dx.doi.org/10.1074/jbc.M800186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18456660	hybrid			2022-12-25	WOS:000256949200044
J	Zhu, H; Xie, G; Liu, MY; Olson, JS; Fabian, M; Dooley, DM; Lei, BF				Zhu, Hui; Xie, Gang; Liu, Mengyao; Olson, John S.; Fabian, Marian; Dooley, David M.; Lei, Benfang			Pathway for heme uptake from human methemoglobin by the iron-regulated surface determinants system of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SHP; HEMOGLOBIN RECEPTOR; BINDING PROPERTIES; CRYSTAL-STRUCTURE; AFFINITY BINDING; IDENTIFICATION; ACQUISITION; ISDC; HTSA; DOMAIN	The iron-regulated surface proteins IsdA, IsdB, and IsdC and transporter IsdDEF of Staphylococcus aureus are involved in heme acquisition. To establish an experimental model of heme acquisition by this system, we have investigated hemin transfer between the various couples of human methemoglobin (metHb), IsdA, IsdB, IsdC, and IsdE by spectroscopic and kinetic analyses. The efficiencies of hemin transfer from hemin-containing donors (holo-protein) to different hemin-free acceptors (apo-protein) were examined, and the rates of the transfer reactions were compared with that of indirect loss of hemin from the relevant donor to H64Y/V68F apomyoglobin. The efficiencies, spectral changes, and kinetics of the transfer reactions demonstrate that: 1) metHb directly transfers hemin to apo-IsdB, but not to apo-IsdA, apo-IsdC, and apo-IsdE; 2) holo-IsdB directly transfers hemin to apo-IsdA and apo-IsdC, but not to apo-IsdE; 3) apo-IsdE directly acquires hemin from holo-IsdC, but not from holo-IsdB and holo-IsdA; and 4) IsdB and IsdC enhance hemin transfer from metHb to apo-IsdC and from holo-IsdB to apo-IsdE, respectively. Taken together with our recent finding that holo-IsdA directly transfers its hemin to apo-IsdC, these results provide direct experimental evidence for a model in which IsdB acquires hemin from metHb and transfers it directly or through IsdA to IsdC. Hemin is then relayed to IsdE, the lipoprotein component of the IsdDEF transporter.	[Zhu, Hui; Xie, Gang; Liu, Mengyao; Lei, Benfang] Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59718 USA; [Dooley, David M.] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59718 USA; [Olson, John S.; Fabian, Marian] Rice Univ, WM Keck Ctr Computat Biol, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Rice University	Lei, BF (corresponding author), Montana State Univ, Dept Vet Mol Biol, POB 173610, Bozeman, MT 59717 USA.	blei@montana.edu		Lei, Benfang Lei/0000-0001-8133-6021; Olson, John/0000-0002-0760-5403	NCRR NIH HHS [P20 RR020185-037582, P20 RR020185-047743, P20 RR 020185, P20 RR020185] Funding Source: Medline; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 27659] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, R01GM027659] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrade MA, 2002, GENOME BIOL, V3; Aranda R, 2007, J MOL BIOL, V374, P374, DOI 10.1016/j.jmb.2007.08.058; Ascoli F, 1981, Methods Enzymol, V76, P72; Bates CS, 2003, INFECT IMMUN, V71, P1042, DOI 10.1128/IAI.71.3.1042-1055.2003; Burkhard KA, 2007, J BIOL CHEM, V282, P15126, DOI 10.1074/jbc.M611121200; Clarke SR, 2004, MOL MICROBIOL, V51, P1509, DOI 10.1111/j.1365-2958.2003.03938.x; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Dryla A, 2003, MOL MICROBIOL, V49, P37, DOI 10.1046/j.1365-2958.2003.03542.x; Dryla A, 2007, J BACTERIOL, V189, P254, DOI 10.1128/JB.01366-06; Eichenbaum Z, 1996, INFECT IMMUN, V64, P5428, DOI 10.1128/IAI.64.12.5428-5429.1996; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Grigg JC, 2007, J BIOL CHEM, V282, P28815, DOI 10.1074/jbc.M704602200; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; Lei BF, 2003, INFECT IMMUN, V71, P5962, DOI 10.1128/IAI.71.10.5962-5969.2003; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Liu MY, 2008, J BIOL CHEM, V283, P6668, DOI 10.1074/jbc.M708372200; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Maresso AW, 2006, J BACTERIOL, V188, P8145, DOI 10.1128/JB.01011-06; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Pilpa RM, 2006, J MOL BIOL, V360, P435, DOI 10.1016/j.jmb.2006.05.019; Pluym M, 2008, J INORG BIOCHEM, V102, P480, DOI 10.1016/j.jinorgbio.2007.11.011; Pluym M, 2007, BIOCHEMISTRY-US, V46, P12777, DOI 10.1021/bi7009585; Ran YC, 2007, J BIOL CHEM, V282, P31380, DOI 10.1074/jbc.M705967200; REISBERG PI, 1980, J BIOL CHEM, V255, P4144; Reniere ML, 2007, BIOMETALS, V20, P333, DOI 10.1007/s10534-006-9032-0; Rouault TA, 2004, SCIENCE, V305, P1577, DOI 10.1126/science.1102975; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; ZHANG L, 1991, J BIOL CHEM, V266, P24698; Zhu H, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-15	42	98	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18450	18460		10.1074/jbc.M801466200	http://dx.doi.org/10.1074/jbc.M801466200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18467329	Green Published, hybrid			2022-12-25	WOS:000256949200073
J	Lindstrom, MS; Zhang, YP				Lindstrom, Mikael S.; Zhang, Yanping			Ribosomal protein S9 is a novel B23/NPM-binding protein required for normal cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; HISTONE CHAPERONE; CRYSTAL-STRUCTURE; NUCLEOPHOSMIN; B23; RNA; ARF; BINDING; DEGRADATION; MDM2	B23 (NPM/nucleophosmin) is a multifunctional nucleolar protein and a member of the nucleoplasmin superfamily of acidic histone chaperones. B23 is essential for normal embryonic development and plays an important role in genomic stability, ribosome biogenesis, and anti-apoptotic signaling. Altered protein expression or genomic mutation of B23 is encountered in many different forms of cancer. Although described as multifunctional, a genuine molecular function of B23 is not fully understood. Here we show that B23 is associated with a protein complex consisting of ribosomal proteins and ribosome-associated RNA helicases. A novel, RNA-independent interaction between ribosomal protein S9 (RPS9) and B23 was further investigated. We found that S9 binding requires an intact B23 oligomerization domain. Depletion of S9 by small interfering RNA resulted in decreased protein synthesis and G(1) cell cycle arrest, in association with induction of p53 target genes. We determined that S9 is a short-lived protein in the absence of ribosome biogenesis, and proteasomal inhibition significantly increased S9 protein level. Overexpression of B23 facilitated nucleolar storage of S9, whereas knockdown of B23 led to diminished levels of nucleolar S9. Our results suggest that B23 selectively stores, and protects ribosomal protein S9 in nucleoli and therefore could facilitate ribosome biogenesis.	[Lindstrom, Mikael S.; Zhang, Yanping] Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; [Lindstrom, Mikael S.; Zhang, Yanping] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Zhang, Yanping] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, YP (corresponding author), Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.	ypzhang@med.unc.edu	Lindström, Mikael S/AAA-1451-2019	Lindström, Mikael S/0000-0003-1148-8497	NATIONAL CANCER INSTITUTE [R01CA100302, K01CA087580] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA087580, R01 CA100302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1993, J BIOL CHEM, V268, P13930; Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Gerstner RB, 2001, BIOCHEMISTRY-US, V40, P7165, DOI 10.1021/bi010026i; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Huang N, 2005, J BIOL CHEM, V280, P5496, DOI 10.1074/jbc.M407856200; HUGLE B, 1985, J CELL BIOL, V100, P873, DOI 10.1083/jcb.100.3.873; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kim SY, 2003, NEUROCHEM RES, V28, P925, DOI 10.1023/A:1023283628454; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kruger T, 2007, J CELL BIOL, V177, P573, DOI 10.1083/jcb.200612048; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lechertier T, 2007, J CELL SCI, V120, P265, DOI 10.1242/jcs.03345; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Lindstrom MS, 2007, CELL CYCLE, V6, P434, DOI 10.4161/cc.6.4.3861; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Panic L, 2006, MOL CELL BIOL, V26, P8880, DOI 10.1128/MCB.00751-06; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; Pnueli L, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-285; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Staker BL, 2000, EMBO J, V19, P749, DOI 10.1093/emboj/19.4.749; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; Tarapore P, 2006, FEBS LETT, V580, P399, DOI 10.1016/j.febslet.2005.12.022; TSURUGI K, 1988, EXP CELL RES, V174, P177, DOI 10.1016/0014-4827(88)90153-X; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	58	88	95	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15568	15576		10.1074/jbc.M801151200	http://dx.doi.org/10.1074/jbc.M801151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18420587	Green Published, hybrid			2022-12-25	WOS:000256332500010
J	Olesen, KM; Auger, AP				Olesen, Kristin M.; Auger, Anthony P.			Dopaminergic Activation of Estrogen Receptors Induces Fos Expression within Restricted Regions of the Neonatal Female Rat Brain	PLOS ONE			English	Article								Steroid receptor activation in the developing brain influences a variety of cellular processes that endure into adulthood, altering both behavior and physiology. Recent data suggests that dopamine can regulate expression of progestin receptors within restricted regions of the developing rat brain by activating estrogen receptors in a ligand-independent manner. It is unclear whether changes in neuronal activity induced by dopaminergic activation of estrogen receptors are also region specific. To investigate this question, we examined where the dopamine D1-like receptor agonist, SKF 38393, altered Fos expression via estrogen receptor activation. We report that dopamine D1-like receptor agonist treatment increased Fos protein expression within many regions of the developing female rat brain. More importantly, prior treatment with an estrogen receptor antagonist partially reduced D1-like receptor agonist-induced Fos expression only within the bed nucleus of the stria terminalis and the central amygdala. These data suggest that dopaminergic activation of estrogen receptors alters neuronal activity within restricted regions of the developing rat brain. This implies that ligand-independent activation of estrogen receptors by dopamine might organize a unique set of behaviors during brain development in contrast to the more wide spread ligand activation of estrogen receptors by estrogen.	[Olesen, Kristin M.; Auger, Anthony P.] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Olesen, KM (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	apauger@wisc.edu			NIMH [R01MH072956, K01MH002035]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH072956, K01MH002035] Funding Source: NIH RePORTER	NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This research was funded by NIMH grants R01MH072956 and K01MH002035 to APA.	Altman J. B. S., 1995, ATLAS PRENATAL RAT B; Amateau SK, 2004, ENDOCRINOLOGY, V145, P2906, DOI 10.1210/en.2003-1363; Apostolakis EM, 2000, MOL ENDOCRINOL, V14, P1086, DOI 10.1210/me.14.7.1086; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Arrieta I, 2000, BRAIN RES, V867, P100, DOI 10.1016/S0006-8993(00)02244-7; AUGER AP, 1995, J NEUROSCI, V15, P2272, DOI 10.1523/JNEUROSCI.15-03-02272.1995; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Auger AP, 2004, HORM BEHAV, V45, P168, DOI 10.1016/j.yhbeh.2003.09.013; Auger AP, 1997, ENDOCRINOLOGY, V138, P511, DOI 10.1210/en.138.1.511; Auger AP, 2002, ENDOCRINOLOGY, V143, P3009, DOI 10.1210/en.143.8.3009; BEACH FA, 1946, J EXP ZOOL, V101, P91, DOI 10.1002/jez.1401010107; Blaustein JD, 2004, ENDOCRINOLOGY, V145, P1075, DOI 10.1210/en.2003-1485; Blaustein JD, 2002, J NEUROENDOCRINOL, V14, P109, DOI 10.1046/j.0007-1331.2001.00743.x; BOYSON SJ, 1986, J NEUROSCI, V6, P3177; CATTANEO E, 1990, EUR J PHARM-MOLEC PH, V188, P153, DOI 10.1016/0922-4106(90)90050-8; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Cushing BS, 2003, DEV BRAIN RES, V143, P129, DOI 10.1016/S0165-3806(03)00105-6; Eaton MJ, 1996, BRAIN RES, V738, P60, DOI 10.1016/0006-8993(96)00765-2; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; FEDER HH, 1966, J ENDOCRINOL, V34, P131, DOI 10.1677/joe.0.0340131; Finn PD, 2005, HORM BEHAV, V47, P123, DOI 10.1016/j.yhbeh.2004.08.008; Giannakopoulou M, 2001, NEUROENDOCRINOLOGY, V73, P387, DOI 10.1159/000054657; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006; HUANG Q, 1992, P NATL ACAD SCI USA, V89, P11988, DOI 10.1073/pnas.89.24.11988; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; INSEL TR, 1990, ENDOCRINOLOGY, V126, P1849, DOI 10.1210/endo-126-4-1849; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Lazarov NE, 1998, HISTOCHEM CELL BIOL, V109, P271, DOI 10.1007/s004180050227; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; McCarthy MM, 1997, DEV NEUROSCI-BASEL, V19, P488, DOI 10.1159/000111246; MCCARTHY MM, 1993, ENDOCRINOLOGY, V133, P433, DOI 10.1210/en.133.2.433; MEANEY MJ, 1981, PHYSIOL BEHAV, V26, P467, DOI 10.1016/0031-9384(81)90175-X; Meredith JM, 1997, J NEUROENDOCRINOL, V9, P385, DOI 10.1046/j.1365-2826.1997.00594.x; Mong JA, 1999, J NEUROBIOL, V40, P602, DOI 10.1002/(SICI)1097-4695(19990915)40:4<602::AID-NEU14>3.0.CO;2-O; Olesen KM, 2007, J NEUROENDOCRINOL, V19, P481, DOI 10.1111/j.1365-2826.2007.01554.x; Olesen KM, 2005, ENDOCRINOLOGY, V146, P3705, DOI 10.1210/en.2005-0498; Olesen KM, 2005, J NEUROENDOCRINOL, V17, P255, DOI 10.1111/j.1365-2826.2005.01302.x; OUIMET CC, 1991, BRAIN RES, V562, P85, DOI 10.1016/0006-8993(91)91190-C; Paxinos G., 1998, RAT BRAIN STEROTAXIC; Perez-Martin M, 2003, EUR J NEUROSCI, V18, P923, DOI 10.1046/j.1460-9568.2003.02830.x; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Quysner A, 2001, BRAIN RES, V921, P173, DOI 10.1016/S0006-8993(01)03116-X; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; SCHALLING M, 1990, MOL BRAIN RES, V7, P139, DOI 10.1016/0169-328X(90)90091-Q; Shearman LP, 1997, DEV BRAIN RES, V102, P105, DOI 10.1016/S0165-3806(97)00091-6; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; SOKKA TA, 1995, BIOL REPROD, V52, P1404, DOI 10.1095/biolreprod52.6.1404; STUMPF WE, 1976, J STEROID BIOCHEM, V7, P1163, DOI 10.1016/0022-4731(76)90050-9; Tsai HW, 2004, ENDOCRINOLOGY, V145, P2730, DOI 10.1210/en.2003-1470; Vagell ME, 1996, BRAIN RES BULL, V41, P121, DOI 10.1016/S0361-9230(96)00158-X; Vagell ME, 1998, HORM BEHAV, V33, P163, DOI 10.1006/hbeh.1998.1445; Vagell ME, 1997, J NEUROENDOCRINOL, V9, P797, DOI 10.1046/j.1365-2826.1997.d01-1047.x; VANDEVELDE P, 1994, J STEROID BIOCHEM, V48, P187, DOI 10.1016/0960-0760(94)90144-9; Wagner CK, 2001, J NEUROBIOL, V47, P176, DOI 10.1002/neu.1025; WEINER DM, 1991, P NATL ACAD SCI USA, V88, P1859, DOI 10.1073/pnas.88.5.1859; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; WENIGER JP, 1993, REPROD NUTR DEV, V33, P129, DOI 10.1051/rnd:19930205; WHALEN RE, 1967, ANAT RECORD, V157, P173, DOI 10.1002/ar.1091570208	60	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2177	10.1371/journal.pone.0002177	http://dx.doi.org/10.1371/journal.pone.0002177			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478050	Green Published, Green Submitted, gold			2022-12-25	WOS:000262172800042
J	Rodriguez-Cattaneo, A; Pereira, AC; Aguilera, PA; Crampton, WGR; Caputi, AA				Rodriguez-Cattaneo, Alejo; Pereira, Ana Carolina; Aguilera, Pedro A.; Crampton, William G. R.; Caputi, Angel A.			Species-Specific Diversity of a Fixed Motor Pattern: The Electric Organ Discharge of Gymnotus	PLOS ONE			English	Article							WAVE-FORM GENERATION; ELECTROMOTOR SYSTEM; FREQUENCY-RESPONSE; FISH GYMNOTOIDEI; CARAPO; ELECTRORECEPTION; ELECTROLOCATION; DISCRIMINATION; GYMNOTIFORMES; INNERVATION	Understanding fixed motor pattern diversity across related species provides a window for exploring the evolution of their underlying neural mechanisms. The electric organ discharges of weakly electric fishes offer several advantages as paradigmatic models for investigating how a neural decision is transformed into a spatiotemporal pattern of action. Here, we compared the far fields, the near fields and the electromotive force patterns generated by three species of the pulse generating New World gymnotiform genus Gymnotus. We found a common pattern in electromotive force, with the far field and near field diversity determined by variations in amplitude, duration, and the degree of synchronization of the different components of the electric organ discharges. While the rostral regions of the three species generate similar profiles of electromotive force and local fields, most of the species-specific differences are generated in the main body and tail regions of the fish. This causes that the waveform of the field is highly site dependant in all the studied species. These findings support a hypothesis of the relative separation of the electrolocation and communication carriers. The presence of early head negative waves in the rostral region, a species-dependent early positive wave at the caudal region, and the different relationship between the late negative peak and the main positive peak suggest three points of lability in the evolution of the electrogenic system: a) the variously timed neuronal inputs to different groups of electrocytes; b) the appearance of both rostrally and caudally innervated electrocytes, and c) changes in the responsiveness of the electrocyte membrane.	[Rodriguez-Cattaneo, Alejo; Pereira, Ana Carolina; Aguilera, Pedro A.; Caputi, Angel A.] Inst Invest Biol Clemente Estable, Dept Integrat & Computat Neurosci, Montevideo, Uruguay; [Crampton, William G. R.] Univ Cent Florida, Dept Biol, Orlando, FL USA	Instituto de Investigaciones Biologicas Clemente Estable Uruguay; State University System of Florida; University of Central Florida	Rodriguez-Cattaneo, A (corresponding author), Inst Invest Biol Clemente Estable, Dept Integrat & Computat Neurosci, Montevideo, Uruguay.	angel@iibce.edu.uy	Crampton, William/AAP-3608-2020		National Science Foundation [0614334]	National Science Foundation(National Science Foundation (NSF))	This research was partially supported by National Science Foundation grant 0614334: The Evolution of Species and Signal Diversity in the Neotropical Electric Fish Gymnotus (PI W. Crampton).	Aguilera PA, 2003, J EXP BIOL, V206, P989, DOI 10.1242/jeb.00198; Aguilera PA, 2001, J EXP BIOL, V204, P185; Albert James S., 2003, Zootaxa, V287, P1; Albert JS, 2005, SPR HDB AUD, V21, P360; Arnegard ME, 2006, J EXP BIOL, V209, P2182, DOI 10.1242/jeb.02239; Arnegard ME, 2003, ENVIRON BIOL FISH, V67, P321, DOI 10.1023/A:1025882914527; Assad C, 1999, J EXP BIOL, V202, P1185; BASTIAN J, 1976, J COMP PHYSIOL, V112, P165, DOI 10.1007/BF00606536; BASTIAN J, 1977, J COMP PHYSIOL, V121, P53, DOI 10.1007/BF00614180; BENNETT MVL, 1959, J GEN PHYSIOL, V42, P1067, DOI 10.1085/jgp.42.5.1067; Bennett MVL., 1971, FISH PHYSIOL, P347, DOI DOI 10.1016/S1546-5098(08)60051-5; Bullock T.H., 1986, ELECTRORECEPTION; Bullock TH, 2005, ELECTRORECEPTION; CAPUTI A, 1995, J COMPUT NEUROSCI, V2, P131, DOI 10.1007/BF00961884; CAPUTI A, 1989, J COMP PHYSIOL A, V165, P361, DOI 10.1007/BF00619355; CAPUTI A, 1993, J COMP PHYSIOL A, V173, P227; Caputi A, 1996, J COMP PHYSIOL A, V179, P827; CAPUTI A, 1994, BRAIN BEHAV EVOLUT, V44, P166, DOI 10.1159/000113588; Caputi AA, 2006, J COMP PHYSIOL A, V192, P587, DOI 10.1007/s00359-006-0100-2; Caputi AA, 1999, J EXP BIOL, V202, P1229; Caputi AA, 2004, J PHYSIOL-PARIS, V98, P81, DOI 10.1016/j.jphysparis.2004.03.002; Caputi AA, 2002, J PHYSIOLOGY-PARIS, V96, P493, DOI 10.1016/S0928-4257(03)00005-6; Caputi AA, 2005, SPR HDB AUD, V21, P410; Castello ME, 2000, J EXP BIOL, V203, P3279; Crampton W.G.R., 2006, COMMUNICATION FISHES, P647; Crampton WGR, 2005, COPEIA, P48, DOI 10.1643/CI-04-056R1; Crampton WGR, 2006, COMMUNICATION FISHES, P696; Crampton William G.R., 2003, Zootaxa, V348, P1; Fessard A, 1974, HDB SENSORY PHYSL, VIII/3; Franchina CR, 1997, J COMP PHYSIOL A, V181, P111, DOI 10.1007/s003590050098; HOPKINS CD, 1974, BEHAVIOUR, V50, P270, DOI 10.1163/156853974X00499; HOPKINS CD, 1978, BEHAV ECOL SOCIOBIOL, V3, P113, DOI 10.1007/BF00294985; HOPKINS CD, 1981, AM ZOOL, V21, P211; Hopkins CD, 1995, CURR OPIN NEUROBIOL, V5, P769, DOI 10.1016/0959-4388(95)80105-7; KEYNES RD, 1961, BIOELECTROGENESIS, P102; Keynes RD, 1961, BIOELECTROGENESIS, P14; Kirschbaum F, 2002, J PHYSIOLOGY-PARIS, V96, P557, DOI 10.1016/S0928-4257(03)00011-1; KIRSCHBAUM F, 1975, EXPERIENTIA, V31, P1290, DOI 10.1007/BF01945786; KIRSCHBAUM F, 1977, NATURWISSENSCHAFTEN, V64, P387, DOI 10.1007/BF00368748; KIRSCHBAUM F, 1983, NATURWISSENSCHAFTEN, V70, P205, DOI 10.1007/BF01047569; Kramer B., 1981, SENSORY PHYSL AQUATI, P195, DOI DOI 10.1016/B978-0-08-027352-5.50018-5; LISSMANN HW, 1958, J EXP BIOL, V35, P156; LISSMANN HW, 1958, J EXP BIOL, V35, P451; Llinas R., 2002, I VORTEX NEURONS SEL; LORENZO D, 1988, J COMP PHYSIOL A, V162, P141, DOI 10.1007/BF01342711; LORENZO D, 1990, J COMP PHYSIOL A, V167, P447; LORENZO D, 1993, J COMP PHYSIOL A, V173, P221; MACADAR O, 1989, J COMP PHYSIOL A, V165, P353, DOI 10.1007/BF00619354; Macadar O., 1993, Journal of Comparative Physiology A Sensory Neural and Behavioral Physiology, V173, P728; MEYER JH, 1982, J COMP PHYSIOL, V145, P459; MOHRES FP, 1957, NATURWISSENSCHAFTEN, V44, P431; Moller P., 1995, ELECT FISHES HIST BE; Pereira AC, 2007, J EXP BIOL, V210, P800, DOI 10.1242/jeb.000638; Scheich H., 1974, P201; Silva A, 2003, ENVIRON BIOL FISH, V66, P329, DOI 10.1023/A:1023986600069; Sullivan J.P., 1997, THESIS DUKE U DURHAM; Tinbergen N., 1963, Zeitschrift fuer Tierpsychologie, V20, P410; TRUJILLOCENOZ O, 1989, J COMP PHYSIOL A, V165, P343, DOI 10.1007/BF00619353; TRUJILLOCENOZ O, 1984, J NEUROBIOL, V15, P273, DOI 10.1002/neu.480150404; VONDEREMDE G, 1990, J COMP PHYSIOL A, V167, P413, DOI 10.1007/BF00192576	60	29	29	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2038	10.1371/journal.pone.0002038	http://dx.doi.org/10.1371/journal.pone.0002038			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461122	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400002
J	Habjan, M; Andersson, I; Klingstrom, J; Schumann, M; Martin, A; Zimmermann, P; Wagner, V; Pichlmair, A; Schneider, U; Muhlberger, E; Mirazimi, A; Weber, F				Habjan, Matthias; Andersson, Ida; Klingstrom, Jonas; Schuemann, Michael; Martin, Arnold; Zimmermann, Petra; Wagner, Valentina; Pichlmair, Andreas; Schneider, Urs; Muehlberger, Elke; Mirazimi, Ali; Weber, Friedemann			Processing of Genome 5 ' Termini as a Strategy of Negative-Strand RNA Viruses to Avoid RIG-I-Dependent Interferon Induction	PLOS ONE			English	Article								Innate immunity is critically dependent on the rapid production of interferon in response to intruding viruses. The intracellular pathogen recognition receptors RIG-I and MDA5 are essential for interferon induction by viral RNAs containing 59 triphosphates or double-stranded structures, respectively. Viruses with a negative-stranded RNA genome are an important group of pathogens causing emerging and re-emerging diseases. We investigated the ability of genomic RNAs from substantial representatives of this virus group to induce interferon via RIG-I or MDA5. RNAs isolated from particles of Ebola virus, Nipah virus, Lassa virus, and Rift Valley fever virus strongly activated the interferon-beta promoter. Knockdown experiments demonstrated that interferon induction depended on RIG-I, but not MDA5, and phosphatase treatment revealed a requirement for the RNA 59 triphosphate group. In contrast, genomic RNAs of Hantaan virus, Crimean-Congo hemorrhagic fever virus and Borna disease virus did not trigger interferon induction. Sensitivity of these RNAs to a 59 monophosphate-specific exonuclease indicates that the RIG-I-activating 59 triphosphate group was removed posttranscriptionally by a viral function. Consequently, RIG-I is unable to bind the RNAs of Hantaan virus, Crimean-Congo hemorrhagic fever virus and Borna disease virus. These results establish RIG-I as a major intracellular recognition receptor for the genome of most negative-strand RNA viruses and define the cleavage of triphosphates at the RNA 59 end as a strategy of viruses to evade the innate immune response.	[Habjan, Matthias; Martin, Arnold; Zimmermann, Petra; Wagner, Valentina; Schneider, Urs; Weber, Friedemann] Univ Freiburg, Dept Virol, Freiburg, Germany; [Andersson, Ida; Klingstrom, Jonas; Mirazimi, Ali] Karolinska Inst, Dept Microbiol, Tumor & Cell Biol, Stockholm, Sweden; [Andersson, Ida; Klingstrom, Jonas; Mirazimi, Ali] Swedish Inst Infect Dis Control, Ctr Microbiol Preparedness, Solna, Sweden; [Schuemann, Michael; Muehlberger, Elke] Univ Marburg, Dept Virol, Marburg, Germany; [Pichlmair, Andreas] London Res Inst, Canc Res UK, Immunobiol Lab, London, England	University of Freiburg; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Philipps University Marburg; Cancer Research UK	Habjan, M (corresponding author), Univ Freiburg, Dept Virol, Freiburg, Germany.	friedemann.weber@uniklinik-freiburg.de	Weber, Friedemann/AAB-3425-2019; Muhlberger, Elke/AAD-6924-2019	Weber, Friedemann/0000-0001-9737-337X; Muhlberger, Elke/0000-0003-3547-9376; Habjan, Matthias/0000-0002-3623-4496; Klingstrom, Jonas/0000-0001-9076-1441; , Ali/0000-0003-2371-6055	Deutsche Forschungsgemeinschaft; Swedish Medicine Council [K2007-56X-20349-01-3]; Swedish Society for Medical Research;  [We 2616/5-1];  [SFB 535]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Swedish Medicine Council; Swedish Society for Medical Research; ; 	Work in the authors laboratories is supported by the grants We 2616/5-1 (FW) and SFB 535 (MS, EM) from the Deutsche Forschungsgemeinschaft, by the grant K2007-56X-20349-01-3 from the Swedish Medicine Council (AM), and by the Swedish Society for Medical Research (JK).	Alff PJ, 2006, J VIROL, V80, P9676, DOI 10.1128/JVI.00508-06; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; Billecocq A, 2004, J VIROL, V78, P9798, DOI 10.1128/JVI.78.18.9798-9806.2004; Blakqori G, 2007, J VIROL, V81, P4991, DOI 10.1128/JVI.01933-06; BOWIE AG, 2007, RIG 1 TRIING DISCRIM; Brzozka K, 2005, J VIROL, V79, P7673, DOI 10.1128/JVI.79.12.7673-7681.2005; Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05; Eaton BT, 2006, NAT REV MICROBIOL, V4, P23, DOI 10.1038/nrmicro1323; Elliott R.M., 1996, BUNYAVIRIDAE; Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; GARCIN D, 1995, J VIROL, V69, P5754, DOI 10.1128/JVI.69.9.5754-5762.1995; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024; Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200; HORNUNG V, 2006, SCIENCE, P314; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jaaskelainen KM, 2007, J MED VIROL, V79, P1527, DOI 10.1002/jmv.20948; JIN H, 1993, J GEN VIROL, V74, P2293, DOI 10.1099/0022-1317-74-10-2293; Kash JC, 2006, J VIROL, V80, P3009, DOI 10.1128/JVI.80.6.3009-3020.2006; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368; Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1; Liu P, 2007, J VIROL, V81, P1401, DOI 10.1128/JVI.01740-06; Martinez-Sobrido L, 2006, J VIROL, V80, P9192, DOI 10.1128/JVI.00555-06; Meyer BJ, 2000, TRENDS MICROBIOL, V8, P61, DOI 10.1016/S0966-842X(99)01658-3; Pak J, 2007, SCIENCE, V315, P241, DOI 10.1126/science.1132839; Paladino P, 2006, J IMMUNOL, V177, P8008, DOI 10.4049/jimmunol.177.11.8008; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Prescott JB, 2007, J IMMUNOL, V179, P1796, DOI 10.4049/jimmunol.179.3.1796; Schlee M, 2007, CURR TOP MICROBIOL, V316, P207; Schneider U, 2005, P NATL ACAD SCI USA, V102, P3441, DOI 10.1073/pnas.0405965102; SCHNEIDER U, 2007, CELL MOL LIFE SCI; Shaw ML, 2005, J VIROL, V79, P6078, DOI 10.1128/JVI.79.10.6078-6088.2005; Spiropoulou CF, 2007, J VIROL, V81, P2769, DOI 10.1128/JVI.02402-06; STAUNTON D, 1989, J GEN VIROL, V70, P2811, DOI 10.1099/0022-1317-70-10-2811; Stoltz M, 2007, J VIROL, V81, P8685, DOI 10.1128/JVI.00415-07; Strahle L, 2006, VIROLOGY, V351, P101, DOI 10.1016/j.virol.2006.03.022; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Unterstab G, 2005, P NATL ACAD SCI USA, V102, P13640, DOI 10.1073/pnas.0502883102; Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200	49	238	247	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2032	10.1371/journal.pone.0002032	http://dx.doi.org/10.1371/journal.pone.0002032			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446221	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300005
J	Xu, J; Clancy, CE				Xu, Jun; Clancy, Colleen E.			Ionic Mechanisms of Endogenous Bursting in CA3 Hippocampal Pyramidal Neurons: A Model Study	PLOS ONE			English	Article								A critical property of some neurons is burst firing, which in the hippocampus plays a primary role in reliable transmission of electrical signals. However, bursting may also contribute to synchronization of electrical activity in networks of neurons, a hallmark of epilepsy. Understanding the ionic mechanisms of bursting in a single neuron, and how mutations associated with epilepsy modify these mechanisms, is an important building block for understanding the emergent network behaviors. We present a single-compartment model of a CA3 hippocampal pyramidal neuron based on recent experimental data. We then use the model to determine the roles of primary depolarizing currents in burst generation. The single compartment model incorporates accurate representations of sodium (Na+) channels (NaV1.1) and T-type calcium (Ca2+) channel subtypes (CaV3.1, CaV3.2, and CaV3.3). Our simulations predict the importance of Na+ and T-type Ca2+ channels in hippocampal pyramidal cell bursting and reveal the distinct contribution of each subtype to burst morphology. We also performed fastslow analysis in a reduced comparable model, which shows that our model burst is generated as a result of the interaction of two slow variables, the T-type Ca2+ channel activation gate and the Ca2+-dependent potassium (K+) channel activation gate. The model reproduces a range of experimentally observed phenomena including afterdepolarizing potentials, spike widening at the end of the burst, and rebound. Finally, we use the model to simulate the effects of two epilepsy-linked mutations: R1648H in NaV1.1 and C456S in CaV3.2, both of which result in increased cellular excitability.	[Xu, Jun; Clancy, Colleen E.] Cornell Univ, Weill Med Coll, Inst Computat Biomed, Dept Phys & Biophys, New York, NY 10021 USA	Cornell University	Xu, J (corresponding author), Cornell Univ, Weill Med Coll, Inst Computat Biomed, Dept Phys & Biophys, New York, NY 10021 USA.	clc7003@med.cornell.edu	Clancy, Colleen/B-2528-2010		National Institutes of Health NHLBI [RO1-HL-085592]; American Heart Association; National Epilepsy Foundation; Alfred P. Sloan Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085592] Funding Source: NIH RePORTER	National Institutes of Health NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); National Epilepsy Foundation; Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The research was supported by grants from the National Institutes of Health NHLBI RO1-HL-085592, The American Heart Association, the National Epilepsy Foundation and the Alfred P. Sloan Foundation to CEC.	ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P531, DOI 10.1113/jphysiol.1979.sp012829; Avery RB, 1996, J NEUROSCI, V16, P5567; Borg-Graham LJ, 1999, CEREBRAL CORTEX, P19; Buckmaster PS, 2001, J COMP NEUROL, V430, P264, DOI 10.1002/1096-9861(20010205)430:2<264::AID-CNE1030>3.0.CO;2-3; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Clancy CE, 2004, BIOPHYS J, V86, P2606, DOI 10.1016/S0006-3495(04)74315-5; Clancy CE, 1999, NATURE, V400, P566, DOI 10.1038/23034; Ermentrout B., 2002, SIMULATING ANAL ANIM, V14; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; Gold C, 2006, J NEUROPHYSIOL, V95, P3113, DOI 10.1152/jn.00979.2005; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Golomb D, 2006, J NEUROPHYSIOL, V96, P1912, DOI 10.1152/jn.00205.2006; HABLITZ JJ, 1981, CELL MOL NEUROBIOL, V1, P325, DOI 10.1007/BF00716267; JAFFE DB, 1994, J NEUROPHYSIOL, V71, P1065, DOI 10.1152/jn.1994.71.3.1065; Jefferys JGR, 2003, EPILEPSIA, V44, P44, DOI 10.1111/j.0013-9580.2003.12004.x; JOHNSTON D, 1980, NATURE, V286, P391, DOI 10.1038/286391a0; Kahlig KM, 2006, J NEUROSCI, V26, P10958, DOI 10.1523/JNEUROSCI.3378-06.2006; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; Lossin C, 2002, NEURON, V34, P877, DOI 10.1016/S0896-6273(02)00714-6; Ma MH, 1996, J NEUROSCI, V16, P4089; MASUKAWA LM, 1982, BRAIN RES, V242, P341, DOI 10.1016/0006-8993(82)90320-1; Metz AE, 2005, J NEUROSCI, V25, P5763, DOI 10.1523/JNEUROSCI.0624-05.2005; Migliore M, 2002, NAT REV NEUROSCI, V3, P362, DOI 10.1038/nrn810; MIGLIORE M, 1995, J NEUROPHYSIOL, V73, P1157, DOI 10.1152/jn.1995.73.3.1157; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Rhodes TH, 2005, J PHYSIOL-LONDON, V569, P433, DOI 10.1113/jphysiol.2005.094326; RINZEL J, 1998, METHODS NEURONAL MOD, P251; Rush AM, 2005, J PHYSIOL-LONDON, V564, P803, DOI 10.1113/jphysiol.2005.083089; Sabatini BL, 1997, J NEUROSCI, V17, P3425; SAH P, 1988, J GEN PHYSIOL, V91, P373, DOI 10.1085/jgp.91.3.373; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Sipila ST, 2006, EUR J NEUROSCI, V23, P2330, DOI 10.1111/j.1460-9568.2006.04757.x; Spampanato J, 2004, J NEUROPHYSIOL, V91, P2040, DOI 10.1152/jn.00982.2003; Swensen AM, 2003, J NEUROSCI, V23, P9650; Talley EM, 1999, J NEUROSCI, V19, P1895; Traub R.D., 1991, NEURONAL NETWORKS HI; TRAUB RD, 1991, J NEUROPHYSIOL, V66, P635, DOI 10.1152/jn.1991.66.2.635; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Vitko I, 2005, J NEUROSCI, V25, P4844, DOI 10.1523/JNEUROSCI.0847-05.2005; Vitko I, 2007, J NEUROSCI, V27, P322, DOI 10.1523/JNEUROSCI.1817-06.2007; WONG RKS, 1981, J NEUROPHYSIOL, V45, P86, DOI 10.1152/jn.1981.45.1.86	43	32	34	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2056	10.1371/journal.pone.0002056	http://dx.doi.org/10.1371/journal.pone.0002056			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446231	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300025
J	Kattan, Z; Marchal, S; Brunner, E; Ramacci, C; Leroux, A; Merlin, JL; Domenjoud, L; Dauca, M; Becuwe, P				Kattan, Zilal; Marchal, Sophie; Brunner, Emilie; Ramacci, Carole; Leroux, Agnes; Merlin, Jean Louis; Domenjoud, Lionel; Dauca, Michel; Becuwe, Philippe			Damaged DNA Binding Protein 2 Plays a Role in Breast Cancer Cell Growth	PLOS ONE			English	Article								The Damaged DNA binding protein 2 (DDB2), is involved in nucleotide excision repair as well as in other biological processes in normal cells, including transcription and cell cycle regulation. Loss of DDB2 function may be related to tumor susceptibility. However, hypothesis of this study was that DDB2 could play a role in breast cancer cell growth, resulting in its well known interaction with the proliferative marker E2F1 in breast neoplasia. DDB2 gene was overexpressed in estrogen receptor (ER)-positive (MCF-7 and T47D), but not in ER-negative breast cancer (MDA-MB231 and SKBR3) or normal mammary epithelial cell lines. In addition, DDB2 expression was significantly (3.0-fold) higher in ER-positive than in ER-negative tumor samples (P=0.0208) from 16 patients with breast carcinoma. Knockdown of DDB2 by small interfering RNA in MCF-7 cells caused a decrease in cancer cell growth and colony formation. Inversely, introduction of the DDB2 gene into MDA-MB231 cells stimulated growth and colony formation. Cell cycle distribution and 5 Bromodeoxyuridine incorporation by flow cytometry analysis showed that the growth-inhibiting effect of DDB2 knockdown was the consequence of a delayed G1/S transition and a slowed progression through the S phase of MCF-7 cells. These results were supported by a strong decrease in the expression of S phase markers (Proliferating Cell Nuclear Antigen, cyclin E and dihydrofolate reductase). These findings demonstrate for the first time that DDB2 can play a role as oncogene and may become a promising candidate as a predictive marker in breast cancer.	[Kattan, Zilal; Brunner, Emilie; Domenjoud, Lionel; Dauca, Michel; Becuwe, Philippe] Nancy Univ, Univ Henri Poincare, Lab Biol Cellulaire Dev, EA 3446, Vandoeuvre Les Nancy, France; [Marchal, Sophie] Nancy Univ, Univ Henri Poincare, Inst Polytech Lorraine, Ctr Alexis Vautrin, UMR 7039, CNRS, Vandoeuvre Les Nancy, France; [Ramacci, Carole; Leroux, Agnes; Merlin, Jean Louis] Nancy Univ, Unite Biol Tumeurs Ctr Alexis Vautrin, EA3452, Vandoeuvre Les Nancy, France	Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Institut de cancerologie de Lorraine (ICL); Universite de Lorraine; Universite de Lorraine	Becuwe, P (corresponding author), Nancy Univ, Univ Henri Poincare, Lab Biol Cellulaire Dev, EA 3446, Vandoeuvre Les Nancy, France.	becuwe@scbiol.uhp-nancy.fr			Ligue contre le Cancer comite Meuse; Association pour la Recherche sur le Cancer; Henri Poincare's University	Ligue contre le Cancer comite Meuse; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Henri Poincare's University	Funding from Ligue contre le Cancer comite Meuse and Meurthe et Moselle, from Association pour la Recherche sur le Cancer, and from Henri Poincare's University.	Alekseev S, 2005, CANCER RES, V65, P10298, DOI 10.1158/0008-5472.CAN-05-2295; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; ELBOUHTOURY F, 1992, J PATHOL, V166, P27, DOI 10.1002/path.1711660106; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Hartman AR, 2003, J MOL MED-JMM, V81, P700, DOI 10.1007/s00109-003-0477-0; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hu ZB, 2006, CARCINOGENESIS, V27, P1475, DOI 10.1093/carcin/bgi350; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Inoki T, 2004, BIOCHEM BIOPH RES CO, V314, P1036, DOI 10.1016/j.bbrc.2004.01.003; Itoh T, 2003, MOL CELL BIOL, V23, P7540, DOI 10.1128/MCB.23.21.7540-7553.2003; Itoh T, 2007, HUM MOL GENET, V16, P1578, DOI 10.1093/hmg/ddm107; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KATTAN Z, 2007, BREAST CANC IN PRESS; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kulaksiz G, 2005, MOL CELL BIOL, V25, P9784, DOI 10.1128/MCB.25.22.9784-9792.2005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mirjolet JF, 2002, CYTOMETRY, V48, P6, DOI 10.1002/cyto.10087; Moser J, 2005, DNA REPAIR, V4, P571, DOI 10.1016/j.dnarep.2005.01.001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OLNES MJ, 1994, BIOTECHNIQUES, V17, P828; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Prost S, 2007, ONCOGENE, V26, P3572, DOI 10.1038/sj.onc.1210151; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yoon T, 2005, ONCOGENE, V24, P469, DOI 10.1038/sj.onc.1208211; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	40	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2002	10.1371/journal.pone.0002002	http://dx.doi.org/10.1371/journal.pone.0002002			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431487	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700022
J	Blanke, ML; VanDongen, AMJ				Blanke, Marie L.; VanDongen, Antonius M. J.			Constitutive activation of the N-methyl-D-aspartate receptor via cleft-spanning disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; MOLECULAR-DYNAMICS SIMULATIONS; IONOTROPIC GLUTAMATE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; LONG-TERM POTENTIATION; PARTIAL AGONIST ACTION; NMDA RECEPTOR; INTERDOMAIN INTERACTIONS; SYNAPTIC TRANSMISSION; ALZHEIMERS-DISEASE	Although the N-methyl-D-aspartate (NMDA) receptor plays a critical role in the central nervous system, many questions remain regarding the relationship between its structure and functional properties. In particular, the involvement of ligand-binding domain closure in determining agonist efficacy, which has been reported in other glutamate receptor subtypes, remains unresolved. To address this question, we designed dual cysteine point mutations spanning the NR1 and NR2 ligand-binding clefts, aiming to stabilize these domains in closed cleft conformations. Two mutants, E522C/I691C in NR1 (EI) and K487C/N687C in NR2 (KN) were found to exhibit significant glycine- and glutamate-independent activation, respectively, and co-expression of the two subunits produced a constitutively active channel. However, both individual mutants could be activated above constitutive levels in a concentration-dependent manner, indicating that cleft closure does not completely prevent agonist association. Interestingly, whereas the NR2 KN disulfide was found to potentiate channel gating and M3 accessibility, NR1 EI exhibited the opposite phenotype, suggesting that the EI disulfide may trap the NR1 ligand-binding domain in a lower efficacy conformation. Furthermore, both mutants affected agonist sensitivity at the opposing subunit, suggesting that closed cleft stabilization may contribute to coupling between the subunits. These results support a correlation between cleft stability and receptor activation, providing compelling evidence for the Venus flytrap mechanism of glutamate receptor domain closure.	[Blanke, Marie L.; VanDongen, Antonius M. J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	VanDongen, AMJ (corresponding author), Duke NUS Grad Med Sch, Neurosci Program, 2 Jalan Bukit Merah, Singapore 169547, Singapore.	vando005@mc.duke.edu		VanDongen, Antonius/0000-0002-9923-3407	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS053030] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS 053030-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arinaminpathy Y, 2002, BIOPHYS J, V82, P676, DOI 10.1016/S0006-3495(02)75430-1; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Banke TG, 2005, J NEUROSCI, V25, P42, DOI 10.1523/JNEUROSCI.3154-04.2005; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; Chen PE, 2005, MOL PHARMACOL, V67, P1470, DOI 10.1124/mol.104.008185; Chen PE, 2008, J PHYSIOL-LONDON, V586, P227, DOI 10.1113/jphysiol.2007.143172; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Emamian ES, 2004, J NEUROSCI, V24, P1561, DOI 10.1523/JNEUROSCI.4650-03.2004; Erreger K, 2005, J NEUROSCI, V25, P7858, DOI 10.1523/JNEUROSCI.1613-05.2005; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; Erreger K, 2007, MOL PHARMACOL, V72, P907, DOI 10.1124/mol.107.037333; Furukawa H, 2005, NATURE, V438, P185, DOI 10.1038/nature04089; Grosman C, 2001, P NATL ACAD SCI USA, V98, P14102, DOI 10.1073/pnas.251402498; Hansen KB, 2005, MOL PHARMACOL, V68, P1510, DOI 10.1124/mol.105.014795; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jones KS, 2002, J NEUROSCI, V22, P2044, DOI 10.1523/JNEUROSCI.22-06-02044.2002; Kalbaugh TL, 2004, MOL PHARMACOL, V66, P209, DOI 10.1124/mol.66.2.209; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; Kaye SL, 2007, BIOCHEMISTRY-US, V46, P2136, DOI 10.1021/bi061462d; Kaye SL, 2006, J BIOL CHEM, V281, P12736, DOI 10.1074/jbc.M512728200; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LERMA J, 1990, P NATL ACAD SCI USA, V87, P2354, DOI 10.1073/pnas.87.6.2354; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Maier W, 2007, J BIOL CHEM, V282, P1863, DOI 10.1074/jbc.M608156200; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Regalado MP, 2001, NEURON, V32, P1085, DOI 10.1016/S0896-6273(01)00539-6; Robert A, 2005, J NEUROSCI, V25, P3752, DOI 10.1523/JNEUROSCI.0188-05.2005; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Tsai GE, 1999, AM J PSYCHIAT, V156, P467; Weston MC, 2006, J NEUROSCI, V26, P7650, DOI 10.1523/JNEUROSCI.1519-06.2006; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhang L, 1997, J NEUROPHYSIOL, V78, P582, DOI 10.1152/jn.1997.78.2.582; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894	47	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2008	283	31					21519	21529		10.1074/jbc.M709190200	http://dx.doi.org/10.1074/jbc.M709190200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	329VN	18450751	Green Published, hybrid			2022-12-25	WOS:000257898800025
J	Zemskova, M; Sahakian, E; Bashkirova, S; Lilly, M				Zemskova, Marina; Sahakian, Eva; Bashkirova, Svetlana; Lilly, Michael			The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GROWTH-FACTOR; INDUCED APOPTOSIS; STRESS-RESPONSE; RECEPTOR TRANSACTIVATION; TRANSIENT ACTIVATION; TARGETED INHIBITION; PROTEIN EXPRESSION; SIGNAL TRANSDUCER; OXIDATIVE STRESS	A defining characteristic of solid tumors is the capacity to divide aggressively and disseminate under conditions of nutrient deprivation, limited oxygen availability, and exposure to cytotoxic drugs or radiation. Survival pathways are activated within tumor cells to cope with these ambient stresses. We here describe a survival pathway activated by the anti-cancer drug docetaxel in prostate cancer cells. Docetaxel activates STAT3 phosphorylation and transcriptional activity, which in turns induces expression of the PIM1 gene, encoding a serine-threonine kinase activated by many cellular stresses. Expression of PIM1 improves survival of docetaxel-treated prostate cancer cells, and PIM1 knockdown or expression of a dominant-negative PIM1 protein sensitize cells to the cytotoxic effects of docetaxel. PIM1 in turn mediates docetaxel-induced activation of NF kappa B transcriptional activity, and PIM1 depends in part on RELA/p65 proteins for its prosurvival effects. The PIM1 kinase plays a critical role in this STAT3 -> 3 PIM1 -> 3 NF kappa B stress response pathway and serves as a target for intervention to enhance the therapeutic effects of cytotoxic drugs such as docetaxel.	[Zemskova, Marina; Sahakian, Eva; Bashkirova, Svetlana; Lilly, Michael] Loma Linda Univ, Sch Med, Ctr Hlth Disparties & Mol Med, Dept Med, Loma Linda, CA 92354 USA; [Zemskova, Marina; Sahakian, Eva; Bashkirova, Svetlana; Lilly, Michael] Loma Linda Univ, Sch Med, Ctr Hlth Disparties & Mol Med, Dept Microbiol, Loma Linda, CA 92354 USA; [Lilly, Michael] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92868 USA	Loma Linda University; Loma Linda University; University of California System; University of California Irvine	Lilly, M (corresponding author), Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Bldg 56,Rm 248,101 City Dr, Orange, CA 92868 USA.	mlilly@uci.edu	Sahakian, Eva/E-8838-2013	Sahakian, Eva/0000-0001-6930-2275; Zemskova, Marina/0000-0002-1454-3714				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Anderson KM, 2002, ANTICANCER RES, V22, P75; Baker SD, 2006, CLIN PHARMACOKINET, V45, P235, DOI 10.2165/00003088-200645030-00002; Beier UH, 2007, INT J ONCOL, V30, P1381; Bullock AN, 2005, J MED CHEM, V48, P7604, DOI 10.1021/jm0504858; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Burns BS, 2001, CLIN ORTHOP RELAT R, P259; Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015; Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P463, DOI 10.1080/10408440591034502; Chen CH, 2006, MOL PHARMACOL, V69, P1347, DOI 10.1124/mol.105.017558; Cusack JC, 2000, CANCER RES, V60, P2323; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452; DaSilva L, 2003, TOXICON, V41, P813, DOI 10.1016/S0041-0101(03)00035-7; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; di Palma A, 2006, MOL CANCER THER, V5, P1318, DOI 10.1158/1535-7163.MCT-05-0473; Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Fiaschi T, 2007, HEPATOLOGY, V46, P130, DOI 10.1002/hep.21643; Flynn V, 2003, INT J ONCOL, V23, P317; Frank GD, 2003, ANTIOXID REDOX SIGN, V5, P771, DOI 10.1089/152308603770380070; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Hari M, 2006, MOL CANCER THER, V5, P270, DOI 10.1158/1535-7163.MCT-05-0190; Herbst RS, 2007, CLIN CANCER RES, V13, p4641S, DOI 10.1158/1078-0432.CCR-07-0538; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Holder S, 2007, BIOORGAN MED CHEM, V15, P6463, DOI 10.1016/j.bmc.2007.06.025; Horinaga M, 2005, UROLOGY, V66, P671, DOI 10.1016/j.urology.2005.03.066; Huang HF, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-2; Kappert K, 2006, ARTERIOSCL THROM VAS, V26, P2644, DOI 10.1161/01.ATV.0000246777.30819.85; Katoh M, 2000, CANCER LETT, V161, P113, DOI 10.1016/S0304-3835(00)00601-7; Kramer G, 2006, BRIT J CANCER, V94, P1592, DOI 10.1038/sj.bjc.6603129; Kraus LA, 2003, INVEST NEW DRUG, V21, P259, DOI 10.1023/A:1025436307913; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Kyle AH, 2007, CLIN CANCER RES, V13, P2804, DOI 10.1158/1078-0432.CCR-06-1941; Lechanteur C, 2005, ONCOGENE, V24, P1788, DOI 10.1038/sj.onc.1208436; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li J, 2006, J SURG RES, V132, P112, DOI 10.1016/j.jss.2005.10.005; Liang H, 1996, ARCH BIOCHEM BIOPHYS, V330, P259, DOI 10.1006/abbi.1996.0251; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1992, ONCOGENE, V7, P727; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Liu GW, 2007, CRIT REV TOXICOL, V37, P587, DOI 10.1080/10408440701493061; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Morse DL, 2005, MOL CANCER THER, V4, P1495, DOI 10.1158/1535-7163.MCT-05-0130; Nakahara C, 2003, CLIN CANCER RES, V9, P5409; Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nozawa H, 2006, CANCER SCI, V97, P1115, DOI 10.1111/j.1349-7006.2006.00287.x; Ohta T, 2006, ENDOCRINOLOGY, V147, P1761, DOI 10.1210/en.2005-1450; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Paoletti A, 1997, J CELL SCI, V110, P2403; Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006/bbrc.2001.5058; Patterson SG, 2006, ONCOGENE, V25, P6113, DOI 10.1038/sj.onc.1209632; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pircher TJ, 2000, ONCOGENE, V19, P3684, DOI 10.1038/sj.onc.1203684; Pogacic V, 2007, CANCER RES, V67, P6916, DOI 10.1158/0008-5472.CAN-07-0320; Pu YS, 2006, BIOCHEM PHARMACOL, V71, P751, DOI 10.1016/j.bcp.2005.12.009; Qiu LH, 2005, INT J ONCOL, V27, P1441; Qiu LH, 2005, INT J ONCOL, V27, P823; Shay KP, 2005, MOL CANCER RES, V3, P170; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Stout BA, 2004, J IMMUNOL, V173, P6409, DOI 10.4049/jimmunol.173.10.6409; Takabatake D, 2007, INT J CANCER, V120, P181, DOI 10.1002/ijc.22187; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; Van Schaeybroeck S, 2006, MOL CANCER THER, V5, P1154, DOI 10.1158/1535-7163.MCT-05-0446; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Welsh SJ, 2006, SEMIN ONCOL, V33, P486, DOI 10.1053/j.seminoncol.2006.04.011; Xu Y, 2005, J SURG ONCOL, V92, P326, DOI 10.1002/jso.20325; Yan B, 2006, BRAZ J MED BIOL RES, V39, P169, DOI 10.1590/S0100-879X2006000200002; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Yang P, 2007, J TOXICOL ENV HEAL A, V70, P976, DOI 10.1080/15287390701290832	81	104	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					20635	20644		10.1074/jbc.M709479200	http://dx.doi.org/10.1074/jbc.M709479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18426800	hybrid, Green Published			2022-12-25	WOS:000257746100004
J	Greschik, H; Althage, M; Flaig, R; Sato, Y; Chavant, V; Peluso-Iltis, C; Choulier, L; Cronet, P; Rochel, N; Schule, R; Stromstedt, PE; Moras, D				Greschik, Holger; Althage, Magnus; Flaig, Ralf; Sato, Yoshiteru; Chavant, Virginie; Peluso-Iltis, Carole; Choulier, Laurence; Cronet, Philippe; Rochel, Natacha; Schuele, Roland; Stromstedt, Per-Erik; Moras, Dino			Communication between the ERR alpha homodimer interface and the PGC-1 alpha binding surface via the helix 8-9 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL COACTIVATOR PGC-1; NUCLEAR RECEPTORS; ANDROGEN RECEPTOR; STRUCTURAL DETERMINANTS; CRYSTAL-STRUCTURE; ACTIVATION; RECOGNITION; DOMAIN; SITE	Although structural studies on the ligand-binding domain (LBD) have established the general mode of nuclear receptor (NR)/coactivator interaction, determinants of binding specificity are only partially understood. The LBD of estrogen receptor alpha(ER alpha), for example, interacts only with a region of peroxisome proliferator-activated receptor coactivator (PGC)-1 alpha, which contains the canonical LXXLL motif (NR box2), whereas the LBD of estrogen-related receptor-alpha(ERR alpha) also binds efficiently an untypical, LXXYL-containing region (NR box3) of PGC-1 alpha. Surprisingly, in a previous structural study, the ER alpha LBD has been observed to bind NR box3 of transcriptional intermediary factor (TIF)-2 untypically via LXXYL, whereas the ERR alpha LBD binds this region of TIF-2 only poorly. Here we present a new crystal structure of the ERR alpha LBD in complex with a PGC-1 alpha box3 peptide. In this structure, residues N-terminal of the PGC-1 alpha LXXYL motif formed contacts with helix 4, the loop connecting helices 8 and 9, and with the C terminus of the ERR alpha LBD. Interaction studies using wild-type and mutant PGC-1 alpha and ERR alpha showed that these contacts are functionally relevant and are required for efficient ERR alpha/PGC-1 alpha interaction. Furthermore, a structure comparison between ERR alpha and ER alpha and mutation analyses provided evidence that the helix 8 -9 loop, which differs significantly in both nuclear receptors, is a major determinant of coactivator binding specificity. Finally, our results revealed that in ERR alpha the helix 8 -9 loop allosterically links the LBD homodimer interface with the coactivator cleft, thus providing a plausible explanation for distinct PGC-1 alpha binding to ERR alpha monomers and homodimers.	[Greschik, Holger; Althage, Magnus; Sato, Yoshiteru; Chavant, Virginie; Peluso-Iltis, Carole; Rochel, Natacha; Moras, Dino] Inst Genet & Biol Mol & Cellulaire, Dept Biol Genom Struct, F-67404 Illkirch Graffenstaden, France; [Althage, Magnus; Cronet, Philippe; Stromstedt, Per-Erik] AstraZeneca R&D, S-43183 Molndal, Sweden; [Greschik, Holger; Schuele, Roland] Univ Frauenklin, Zent Klin Forsch, D-79106 Freiburg, Germany; [Choulier, Laurence] Univ Strasbourg 1, Inst Gilbert Laustriat, F-67412 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; AstraZeneca; University of Freiburg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Inst Genet & Biol Mol & Cellulaire, Dept Biol Genom Struct, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Rochel, Natacha/A-5718-2016	Rochel, Natacha/0000-0002-3573-5889; Choulier, Laurence/0000-0003-1493-9775				Barry JB, 2006, MOL ENDOCRINOL, V20, P302, DOI 10.1210/me.2005-0313; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bour G, 2005, P NATL ACAD SCI USA, V102, P16608, DOI 10.1073/pnas.0505556102; Brelivet Y, 2004, EMBO REP, V5, P423, DOI 10.1038/sj.embor.7400119; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Darimont BD, 2003, CHEM BIOL, V10, P675, DOI 10.1016/S1074-5521(03)00177-7; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Gaillard S, 2007, MOL ENDOCRINOL, V21, P62, DOI 10.1210/me.2006-0179; Gearhart MD, 2003, J MOL BIOL, V327, P819, DOI 10.1016/S0022-2836(03)00183-9; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; Hentschke M, 2002, BIOCHEM BIOPH RES CO, V299, P872, DOI 10.1016/S0006-291X(02)02753-5; Horard B, 2004, J MOL ENDOCRINOL, V33, P493, DOI 10.1677/jme.1.01538; Huppunen J, 2004, BIOCHEM BIOPH RES CO, V314, P964, DOI 10.1016/j.bbrc.2003.12.194; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kallen J, 2007, J BIOL CHEM, V282, P23231, DOI 10.1074/jbc.M703337200; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li Y, 2005, P NATL ACAD SCI USA, V102, P9505, DOI 10.1073/pnas.0501204102; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Molnar F, 2005, J BIOL CHEM, V280, P26543, DOI 10.1074/jbc.M502463200; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Oldfield TJ, 2003, ACTA CRYSTALLOGR D, V59, P483, DOI 10.1107/S0907444902023570; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Suino K, 2004, MOL CELL, V16, P893, DOI 10.1016/j.molcel.2004.11.036; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Warnmark A, 2002, J BIOL CHEM, V277, P21862, DOI 10.1074/jbc.M200764200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang ZP, 2001, MOL CELL ENDOCRINOL, V172, P223, DOI 10.1016/S0303-7207(00)00372-5	51	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20220	20230		10.1074/jbc.M801920200	http://dx.doi.org/10.1074/jbc.M801920200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18441008	hybrid			2022-12-25	WOS:000257565300038
J	He, KL; Deora, AB; Xiong, HB; Ling, Q; Weksler, BB; Niesvizky, R; Hajjar, KA				He, Kai-Li; Deora, Arunkumar B.; Xiong, Huabao; Ling, Qi; Weksler, Babette B.; Niesvizky, Ruben; Hajjar, Katherine A.			Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; EPITHELIAL-CELLS; P11 PROTEIN; UBIQUITIN; PHOSPHORYLATION; CHANNEL; RECEPTOR; ASSOCIATION; COMPLEX; S100	The annexin A2 (A2) heterotetramer, consisting of two copies of A2 and two copies of S100A10/p11, promotes fibrinolytic activity on the surface of vascular endothelial cells by assembling plasminogen and tissue plasminogen activator (tPA) and accelerating the generation of plasmin. In humans, overexpression of A2 by acute promyelocytic leukemia cells is associated with excessive fibrinolysis and hemorrhage, whereas anti-A2 autoantibodies appear to accentuate the risk of thrombosis in patients with anti-phospholipid syndrome. Complete deficiency of A2 in mice leads to a lack of tPA cofactor activity, accumulation of intravascular fibrin, and failure to clear arterial thrombi. Within the endothelial cell, p11 is required for Src kinase-mediated tyrosine phosphorylation of A2, which signals translocation of both proteins to the cell surface. Here we show that p11 is expressed at very low levels in the absence of A2 both in vitro and in vivo. We demonstrate further that unpartnered p11 becomes polyubiquitinated and degraded via a proteasome-dependent mechanism. A2 stabilizes intracellular p11 through direct binding, thus masking an autonomous p11 polyubiquitination signal that triggers proteasomal degradation. This interaction requires both the p11-binding N-terminal domain of A2 and the C-terminal domain of p11. This mechanism prevents accumulation of free p11 in the endothelial cell and suggests that regulation of tPA-dependent cell surface fibrinolytic activity is precisely tuned to the intracellular level of p11.	[He, Kai-Li; Deora, Arunkumar B.; Ling, Qi; Hajjar, Katherine A.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY 10065 USA; [Weksler, Babette B.; Niesvizky, Ruben] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Xiong, Huabao] Mt Sinai Med Ctr, Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Cornell University; Cornell University; Icahn School of Medicine at Mount Sinai	Hajjar, KA (corresponding author), Weill Cornell Med Coll, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10065 USA.	khajjar@med.cornell.edu			NHLBI NIH HHS [HL42493, HL67839, HL46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL042493, P01HL067839] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beaton AR, 2002, P NATL ACAD SCI USA, V99, P13154, DOI 10.1073/pnas.192432299; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Cesarman-Maus G, 2005, BRIT J HAEMATOL, V129, P307, DOI 10.1111/j.1365-2141.2005.05444.x; Cesarman-Maus G, 2006, BLOOD, V107, P4375, DOI 10.1182/blood-2005-07-2636; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Deora AB, 2004, J BIOL CHEM, V279, P43411, DOI 10.1074/jbc.M408078200; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donier E, 2005, J BIOL CHEM, V280, P38666, DOI 10.1074/jbc.M505981200; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Gladwin MT, 2000, AM J PHYSIOL-LUNG C, V279, pL1103, DOI 10.1152/ajplung.2000.279.6.L1103; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 2006, WILLIAMS HEMATOLOGY, P2089; HAJJAR KA, 2006, WILLIAMS HEMATOLOGY, P1715; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang XL, 2003, J BIOL CHEM, V278, P9298, DOI 10.1074/jbc.M212704200; Ishii H, 2001, CIRC RES, V89, P1240, DOI 10.1161/hh2401.101066; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; Jost M, 1997, J CELL SCI, V110, P221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KUBE E, 1992, J BIOL CHEM, V267, P14175; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Peterson EA, 2003, J CELL SCI, V116, P2399, DOI 10.1242/jcs.00434; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Poon WYL, 2004, FEBS LETT, V558, P114, DOI 10.1016/S0014-5793(03)01512-6; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; Puisieux A, 1996, BIOCHEM J, V313, P51, DOI 10.1042/bj3130051; Razani B, 2001, J BIOL CHEM, V276, P38121; Renigunta V, 2006, TRAFFIC, V7, P168, DOI 10.1111/j.1600-0854.2005.00375.x; Rescher U, 2008, PFLUG ARCH EUR J PHY, V455, P575, DOI 10.1007/s00424-007-0313-4; Rety S, 1999, NAT STRUCT BIOL, V6, P89; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Svenningsson P, 2006, SCIENCE, V311, P77, DOI 10.1126/science.1117571; Tanaka Y, 2007, BRAIN RES, V1165, P135, DOI 10.1016/j.brainres.2007.06.039; THIEL C, 1992, J CELL SCI, V103, P733; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; WARD CL, 1995, CELL, V14, P725; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Xiong HB, 2005, J BIOL CHEM, V280, P23531, DOI 10.1074/jbc.M414296200; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	56	97	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19192	19200		10.1074/jbc.M800100200	http://dx.doi.org/10.1074/jbc.M800100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18434302	Green Published, hybrid			2022-12-25	WOS:000257387600004
J	Belova, L; Brickley, DR; Ky, B; Sharma, SK; Conzen, SD				Belova, Larissa; Brickley, Deanna R.; Ky, Betty; Sharma, Sanjay K.; Conzen, Suzanne D.			Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoid-regulated kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; RECEPTOR LIGAND-BINDING; PROGESTERONE-RECEPTOR; ANDROGEN RECEPTOR; MUTATIONAL ANALYSIS; CHAPERONE; DEGRADATION; HEAT-SHOCK-PROTEIN-90; INHIBITION; COMPLEX	SGK-1 (serum- and glucocorticoid-regulated kinase-1), a member of the AGC protein kinase family, plays an important role in regulating ion channel expression and contributes to malignant epithelial cell proliferation and survival. SGK-1 activity is regulated on three levels: transcriptional induction following a variety of environmental and intracellular stresses, proteasomal degradation, and phosphorylation. Here we report that phosphoinositide 3-kinase (PI3K)-dependent phosphorylation of SGK-1 requires formation of a complex between SGK-1 and heat-shock protein 90 (Hsp90). Inactivation of Hsp90 by geldanamycin led to decreased SGK-1 phosphorylation independently of increased proteasomal protein degradation, and inhibition of PI3K activity by LY294002 appeared to eliminate SGK-1 phosphorylation at the same residues as those affected by geldanamycin treatment. Interestingly, geldanamycin-targeted phosphorylation sites were not limited to the known conserved PI3K-dependent sites Thr-256 and Ser-422 in SGK-1 but included additional unknown PI3K-dependent residues. Inhibition of Hsp90 also resulted in a complete loss of SGK-1 kinase activity, suggesting that Hsp90 activity is essential for regulating the PI3K/SGK-1 pathway.	[Belova, Larissa; Brickley, Deanna R.; Ky, Betty; Sharma, Sanjay K.; Conzen, Suzanne D.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Conzen, Suzanne D.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Conzen, Suzanne D.] Univ Chicago, Ben May Dept Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Conzen, SD (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	sdconzen@uchicago.edu		Sharma, Sanjeev Kumar/0000-0002-3273-0708	NCI NIH HHS [P30CA014599-32, R01CA089208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089208, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 2000, CELL GROWTH DIFFER, V11, P355; Arteaga MF, 2007, MOL BIOL CELL, V18, P2072, DOI 10.1091/mbc.E06-10-0968; Arteaga MF, 2006, P NATL ACAD SCI USA, V103, P11178, DOI 10.1073/pnas.0604816103; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Boehmer C, 2003, CARDIOVASC RES, V57, P1079, DOI 10.1016/S0008-6363(02)00837-4; BOGUSZ A, 2006, THESIS U CHICAGO CHI; Bogusz AM, 2006, FEBS J, V273, P2913, DOI 10.1111/j.1742-4658.2006.05304.x; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brickley DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; CARSONJURICA MA, 1989, J STEROID BIOCHEM, V34, P1, DOI 10.1016/0022-4731(89)90060-5; Chene P, 2002, NAT REV DRUG DISCOV, V1, P665, DOI 10.1038/nrd894; Chiosis G, 2003, MOL CANCER THER, V2, P123; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Fliss AE, 2000, J STEROID BIOCHEM, V72, P223, DOI 10.1016/S0960-0760(00)00037-6; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Haverinen M, 2001, CELL STRESS CHAPERON, V6, P256, DOI 10.1379/1466-1268(2001)006<0256:HSPATN>2.0.CO;2; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HURD C, 1991, MOL CELL BIOCHEM, V105, P73; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103; Lamitina ST, 2005, AM J PHYSIOL-CELL PH, V288, pC467, DOI 10.1152/ajpcell.00451.2004; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; MARIVOET S, 1992, MOL CELL ENDOCRINOL, V88, P165, DOI 10.1016/0303-7207(92)90021-W; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meng X, 1996, J CELL SCI, V109, P1677; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Sahoo S, 2005, EUR J CANCER, V41, P2754, DOI 10.1016/j.ejca.2005.07.018; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284; Skach WR, 2006, CELL, V127, P673, DOI 10.1016/j.cell.2006.11.002; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; TUOHIMAA P, 1993, P NATL ACAD SCI USA, V90, P5848, DOI 10.1073/pnas.90.12.5848; Vallon V, 2005, CURR OPIN NEPHROL HY, V14, P59, DOI 10.1097/00041552-200501000-00010; van Bemmelen MX, 2004, CIRC RES, V95, P284, DOI 10.1161/01.RES.0000136816.05109.89; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Xu WP, 2003, CANCER RES, V63, P7777; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang LP, 2005, CANCER RES, V65, P457; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	72	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18821	18831		10.1074/jbc.M803289200	http://dx.doi.org/10.1074/jbc.M803289200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18456663	hybrid, Green Published			2022-12-25	WOS:000257165600039
J	Kan, QM; Jinno, S; Kobayashi, K; Yamamoto, H; Okayama, H				Kan, Qiuming; Jinno, Shigeki; Kobayashi, Kohei; Yamamoto, Hanako; Okayama, Hiroto			Cdc6 determines utilization of p21(WAF1/CIP1)-dependent damage checkpoint in S phase cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; P53; REPLICATION; INHIBITOR; P27(KIP1); ANCHORAGE; PROTEIN; CDK2	When cells traversing G(1) are irradiated with UV light, two parallel damage checkpoint pathways are activated: Chk1-Cdc25A and p53-p21(WAF1/CIP1), both targeting Cdk2, but the latter inducing a long lasting arrest. In similarly treated S phase-progressing cells, however, only the Cdc25A-dependent checkpoint is active. We have recently found that the p21-dependent checkpoint can be activated and induce a prolonged arrest if S phase cells are damaged with a base-modifying agent, such as methyl methanesulfonate (MMS) and cisplatin. But the mechanistic basis for the differential activation of the p21-dependent checkpoint by different DNA damaging agents is not understood. Here we report that treatment of S phase cells with MMS but not a comparable dose of UV light elicits proteasome-mediated degradation of Cdc6, the assembler of pre-replicative complexes, which allows induced p21 to bind Cdk2, thereby extending inactivation of Cdk2 and S phase arrest. Consistently, enforced expression of Cdc6 largely eliminates the prolonged S phase arrest and Cdk2 inactivation induced with MMS, whereas RNA interference-mediated Cdc6 knockdown not only prolongs such arrest and inactivation but also effectively activates the p21-dependent checkpoint in the UV-irradiated S phase cells.	Univ Tokyo, Dept Biochem & Mol Biol, Grad Sch, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Okayama, H (corresponding author), 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan.	okayama@m.u-tokyo.ac.jp						ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gottifredi V, 2005, SEMIN CELL DEV BIOL, V16, P355, DOI 10.1016/j.semcdb.2005.02.011; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Ji C, 1997, ONCOGENE, V15, P2749, DOI 10.1038/sj.onc.1201441; Jinno S, 2002, ONCOGENE, V21, P1777, DOI 10.1038/sj.onc.1205249; Kan QM, 2008, P NATL ACAD SCI USA, V105, P4757, DOI 10.1073/pnas.0706392105; Kan Q, 2007, FEBS LETT, V581, P5879, DOI 10.1016/j.febslet.2007.11.075; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Komarova EA, 1997, CANCER RES, V57, P5217; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; KUME K, 1992, NEW BIOL, V4, P504; Lei M, 2001, J CELL SCI, V114, P1447; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17864	17872		10.1074/jbc.M802055200	http://dx.doi.org/10.1074/jbc.M802055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18458079	hybrid			2022-12-25	WOS:000256949200014
J	Gardner, AA; Reichert, EC; Topham, MK; Stafforini, DM				Gardner, Alison A.; Reichert, Ethan C.; Topham, Matthew K.; Stafforini, Diana M.			Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; E-DEFICIENT MICE; MIDDLE-AGED MEN; PHOSPHOLIPASE A(2); HUMAN-PLASMA; PAF-AH; CARDIOVASCULAR-DISEASE; ALTERED DISTRIBUTION; HYPOLIPIDEMIC DRUGS	The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inactivates potent lipid messengers such as PAF and modified phospholipids generated in settings of oxidant stress. In humans, PAF-AH circulates in blood in fully active form and associates with high and low density lipoproteins (HDL and LDL). Several studies suggest that the location of PAF-AH affects both the catalytic efficiency and the function of the enzyme in vivo. The distribution of PAF-AH among lipoproteins varies widely among mammals. Here, we report that mouse and human PAF-AHs associate with human HDL particles of different density. We made use of this observation in the development of a binding assay to identify domains required for association of human PAF-AH with human HDL. Sequence comparisons among species combined with domain-swapping and site-directed mutagenesis studies led us to the identification of C-terminal residues necessary for the association of human PAF-AH with human HDL. Interestingly, the region identified is not conserved among PAF-AHs, suggesting that PAF-AH interacts with HDL particles in a manner that is unique to each species. These findings contribute to our understanding of the mechanisms responsible for association of human PAF-AH with HDL and may facilitate future studies aimed at precisely determining the function of PAF-AH in each lipoprotein particle.	[Gardner, Alison A.; Reichert, Ethan C.; Topham, Matthew K.; Stafforini, Diana M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Topham, Matthew K.; Stafforini, Diana M.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allison MA, 2007, J VASC SURG, V46, P500, DOI 10.1016/j.jvs.2007.04.038; Ballantyne CM, 2004, CIRCULATION, V109, P837, DOI 10.1161/01.CIR.0000116763.91992.F1; Bayes M, 2006, Methods Find Exp Clin Pharmacol, V28, P451; Bell R, 1997, BIOCHEM BIOPH RES CO, V241, P630, DOI 10.1006/bbrc.1997.7741; Blackie JA, 2002, BIOORG MED CHEM LETT, V12, P2603, DOI 10.1016/S0960-894X(02)00473-0; Blake GJ, 2001, J AM COLL CARDIOL, V38, P1302, DOI 10.1016/S0735-1097(01)01554-6; Brilakis ES, 2005, EUR HEART J, V26, P137, DOI 10.1093/eurheartj/ehi010; Carpenter KLH, 2001, FEBS LETT, V505, P357, DOI 10.1016/S0014-5793(01)02840-X; Corsetti JP, 2006, CLIN CHEM, V52, P1331, DOI 10.1373/clinchem.2006.066845; De Geest B, 2000, ARTERIOSCL THROM VAS, V20, pE68; Eisaf M, 2003, BIOCHEM PHARMACOL, V66, P2069, DOI 10.1016/S0006-2952(03)00559-8; Hakkinen T, 1999, ARTERIOSCL THROM VAS, V19, P2909, DOI 10.1161/01.ATV.19.12.2909; Iribarren C, 2005, ARTERIOSCL THROM VAS, V25, P216, DOI 10.1161/01.ATV.0000148322.89911.44; Jang Y, 2006, J CLIN ENDOCR METAB, V91, P3521, DOI 10.1210/jc.2006-0116; Karabina SAP, 1997, EUR J CLIN INVEST, V27, P595, DOI 10.1046/j.1365-2362.1997.1570706.x; Karasawa K, 2006, BBA-MOL CELL BIOL L, V1761, P1359, DOI 10.1016/j.bbalip.2006.06.017; Kardys I, 2006, ARTERIOSCL THROM VAS, V26, P631, DOI 10.1161/01.ATV.0000201289.83256.cf; Khuseyinova N, 2007, MOL DIAGN THER, V11, P203, DOI 10.1007/BF03256242; Koenig W, 2004, CIRCULATION, V110, P1903, DOI 10.1161/01.CIR.0000143377.53389.C8; Kolodgie FD, 2006, ARTERIOSCL THROM VAS, V26, P2523, DOI 10.1161/01.ATV.0000244681.72738.bc; Kriska T, 2007, J BIOL CHEM, V282, P100, DOI 10.1074/jbc.M608135200; Kujiraoka T, 2003, J LIPID RES, V44, P2006, DOI 10.1194/jlr.D300021-JLR200; Liberopoulos EN, 2004, PERITON DIALYSIS INT, V24, P580; Macphee CH, 2006, CURR OPIN PHARMACOL, V6, P154, DOI 10.1016/j.coph.2005.11.008; Macphee CH, 2005, CURR OPIN LIPIDOL, V16, P442, DOI 10.1097/01.mol.0000174155.61307.5f; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; MacRitchie AN, 2007, FASEB J, V21, P1164, DOI 10.1096/fj.06-6743com; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; Milionis HJ, 2005, THYROID, V15, P455, DOI 10.1089/thy.2005.15.455; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Noto H, 2003, ARTERIOSCL THROM VAS, V23, P829, DOI 10.1161/01.ATV.0000067701.09398.18; Oei HHS, 2005, CIRCULATION, V111, P570, DOI 10.1161/01.CIR.0000154553.12214.CD; Okamura K, 2007, CIRC J, V71, P214, DOI 10.1253/circj.71.214; OSTERMANN G, 1986, THROMB RES, V44, P303, DOI 10.1016/0049-3848(86)90005-8; Packard CJ, 2000, NEW ENGL J MED, V343, P1148, DOI 10.1056/NEJM200010193431603; Papaspyridonos M, 2006, ARTERIOSCL THROM VAS, V26, P1837, DOI 10.1161/01.ATV.0000229695.68416.76; Papavasiliou EC, 2006, NEPHROL DIAL TRANSPL, V21, P1270, DOI 10.1093/ndt/gfk043; PRITCHARD PH, 1987, BIOCHEM J, V246, P791, DOI 10.1042/bj2460791; Quarck R, 2001, CIRCULATION, V103, P2495; Rizos E, 2005, PROSTAG LEUKOTR ESS, V72, P203, DOI 10.1016/j.plefa.2004.10.021; Rufail ML, 2005, J LIPID RES, V46, P2752, DOI 10.1194/jlr.M500389-JLR200; Sabatine MS, 2007, ARTERIOSCL THROM VAS, V27, P2463, DOI 10.1161/ATVBAHA.107.151670; Stafforini DM, 2001, PHARMACOGENOMICS, V2, P163, DOI 10.1517/14622416.2.3.163; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Tambaki AP, 2004, J CARDIOVASC PHARM T, V9, P91, DOI 10.1177/107424840400900204; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; TSAOUSSIS V, 1994, J LIPID MEDIAT CELL, V9, P317; TSELEPIS AD, 1995, ARTERIOSCL THROM VAS, V15, P1764, DOI 10.1161/01.ATV.15.10.1764; Tselepis AD, 2001, J LIPID RES, V42, P1645; Tsimihodimos V, 2003, J LIPID RES, V44, P927, DOI 10.1194/jlr.M200452-JLR200; Tsimihodimos V, 2002, J LIPID RES, V43, P256; Zalewski A., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P527, DOI 10.2174/156800605774962103; Zalewski A, 2006, CLIN CHEM, V52, P1645, DOI 10.1373/clinchem.2006.070672	62	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17099	17106		10.1074/jbc.M802394200	http://dx.doi.org/10.1074/jbc.M802394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434304	Green Published, hybrid			2022-12-25	WOS:000256720600017
J	Deng, L; Cho, S; Malchiodi, EL; Kerzic, MC; Dam, J; Mariuzza, RA				Deng, Lu; Cho, Sangwoo; Malchiodi, Emilio L.; Kerzic, Melissa C.; Dam, Julie; Mariuzza, Roy A.			Molecular architecture of the major histocompatibility complex class I-binding site of Ly49 natural killer cell receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MHC; RECOGNITION; LIGAND; ACTIVATION; SPECIFICITY; ENGAGEMENT; H-2D(D); DOMAIN; NKG2D	Natural killer (NK) cells play a vital role in the detection and destruction of virally infected and tumor cells during innate immune responses. The highly polymorphic Ly49 family of NK receptors regulates NK cell function by sensing major histocompatibility complex class I (MHC-I) molecules on target cells. Despite the determination of two Ly49-MHC-I complex structures, the molecular features of Ly49 receptors that confer specificity for particular MHC-I alleles have not been identified. To understand the functional architecture of Ly49-binding sites, we determined the crystal structures of Ly49C and Ly49G and completed refinement of the Ly49C-H-2Kb complex. This information, combined with mutational analysis of Ly49A, permitted a structure-based classification of Ly49s that we used to dissect the binding site into three distinct regions, each having different roles in MHC recognition. One region, located at the center of the binding site, has a similar structure across the Ly49 family and mediates conserved interactions with MHC-I that contribute most to binding. However, the preference of individual Ly49s for particular MHC-I molecules is governed by two regions that flank the central region and are structurally more variable. One of the flanking regions divides Ly49s into those that recognize both H-2D and H-2K versus only H-2D ligands, whereas the other discriminates among H-2D or H-2K alleles. The modular design of Ly49-binding sites provides a framework for predicting the MHC- binding specificity of Ly49s that have not been characterized experimentally.	[Deng, Lu; Cho, Sangwoo; Malchiodi, Emilio L.; Kerzic, Melissa C.; Dam, Julie; Mariuzza, Roy A.] Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA; [Malchiodi, Emilio L.] Univ Buenos Aires, Fac Farm & Bioquim, Catedra Inmunol, RA-1113 Buenos Aires, DF, Argentina; [Malchiodi, Emilio L.] Univ Buenos Aires, Fac Farm & Bioquim, Inst Estudios Inmunidad Humoral, CONICET UBA, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@carb.nist.gov	Deng, Lu/AAE-1635-2021; Dam, Julie/O-1625-2018	Dam, Julie/0000-0001-6871-2678; Malchiodi, Emilio/0000-0001-7501-3330	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047990] Funding Source: NIH RePORTER; NIAID NIH HHS [AI047990, R01 AI047990-08, R01 AI047990] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P240; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Back J, 2007, P NATL ACAD SCI USA, V104, P3978, DOI 10.1073/pnas.0607418104; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dam J, 2003, NAT IMMUNOL, V4, P1213, DOI 10.1038/ni1006; Dam J, 2006, J MOL BIOL, V362, P102, DOI 10.1016/j.jmb.2006.07.005; Deng L, 2006, SEMIN IMMUNOL, V18, P159, DOI 10.1016/j.smim.2006.03.004; Desrosiers MP, 2005, NAT GENET, V37, P593, DOI 10.1038/ng1564; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; Held W, 2008, NAT REV IMMUNOL, V8, P269, DOI 10.1038/nri2278; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Ma BJ, 2003, J IMMUNOL, V171, P5337, DOI 10.4049/jimmunol.171.10.5337; McQueen KL, 2002, CURR OPIN IMMUNOL, V14, P615, DOI 10.1016/S0952-7915(02)00380-1; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moza B, 2006, P NATL ACAD SCI USA, V103, P9867, DOI 10.1073/pnas.0600220103; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Natarajan K, 2002, ANNU REV IMMUNOL, V20, P853, DOI 10.1146/annurev.immunol.20.100301.064812; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SHELDRICK GM, 2002, XPREP VERSION 6 10; Silver ET, 2002, J IMMUNOL, V169, P4752, DOI 10.4049/jimmunol.169.9.4752; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; Vivier E, 2002, CURR OPIN IMMUNOL, V14, P306, DOI 10.1016/S0952-7915(02)00337-0; Wang J, 2002, J BIOL CHEM, V277, P1433, DOI 10.1074/jbc.M110316200; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055	34	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16840	16849		10.1074/jbc.M801526200	http://dx.doi.org/10.1074/jbc.M801526200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18426793	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000256497100061
J	Irla, M; Saade, M; Kissenpfennig, A; Poulin, LF; Leserman, L; Marche, PN; Jouvin-Marche, E; Berger, F; Nguyen, C				Irla, Magali; Saade, Murielle; Kissenpfennig, Adrien; Poulin, Lionel Franz; Leserman, Lee; Marche, Patrice N.; Jouvin-Marche, Evelyne; Berger, Francois; Nguyen, Catherine			ZAP-70 Restoration in Mice by In Vivo Thymic Electroporation	PLOS ONE			English	Article							NONVIRAL GENE-TRANSFER; NEGATIVE SELECTION; THERAPY; CELLS; IMMUNODEFICIENCY; TRANSFECTION; DELIVERY; SPLEEN; ALPHA	Viral and non-viral vectors have been developed for gene therapy, but their use is associated with unresolved problems of efficacy and safety. Efficient and safe methods of DNA delivery need to be found for medical application. Here we report a new monopolar system of non-viral electro-gene transfer into the thymus in vivo that consists of the local application of electrical pulses after the introduction of the DNA. We assessed the proof of concept of this approach by correcting ZAP-70 deficient severe combined immunodeficiency ( SCID) in mice. The thymic electro-gene transfer of the pCMV-ZAP-70-IRES-EGFP vector in these mice resulted in rapid T cell differentiation in the thymus with mature lymphocytes detected by three weeks in secondary lymphoid organs. Moreover, this system resulted in the generation of long-term functional T lymphocytes. Peripheral reconstituted T cells displayed a diversified T cell receptor (TCR) repertoire, and were responsive to alloantigens in vivo. This process applied to the thymus could represent a simplified and effective alternative for gene therapy of T cell immunodeficiencies.	[Irla, Magali; Saade, Murielle; Nguyen, Catherine] Univ Mediterranee, Parc Sci Luminy, INSERM U928, Marseille, France; [Kissenpfennig, Adrien] Queens Univ Belfast, CCRCB, Belfast, Antrim, North Ireland; [Kissenpfennig, Adrien; Poulin, Lionel Franz; Leserman, Lee] Univ Mediterranee, Ctr Immunol Marseille Luminy, INSERM U631, CNRS UMR6102, Marseille, France; [Marche, Patrice N.; Jouvin-Marche, Evelyne] INSERM, U823, Grenoble, France; [Marche, Patrice N.; Jouvin-Marche, Evelyne] Univ Joseph Fourier Grenoble I, Inst Albert Bonniot, UMR S823, Grenoble, France; [Berger, Francois] INSERM U836, Grenoble, France; [Berger, Francois] Univ Joseph Fourier Grenoble I, Grenoble Inst Neurosci, UMR S836, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Queens University Belfast; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Irla, M (corresponding author), Univ Mediterranee, Parc Sci Luminy, INSERM U928, Marseille, France.	nguyen@tagc.univ-mrs.fr	JOUVIN MARCHE, Evelyne/L-8648-2013; Marche, Patrice N/K-5060-2013; IRLA, Magali/AAH-7941-2019; saade, murielle/Y-5050-2019; Nguyen, Catherine/M-4119-2016; Poulin, Lionel F. F/U-7794-2018	JOUVIN MARCHE, Evelyne/0000-0001-8616-138X; Marche, Patrice N/0000-0002-8930-9340; IRLA, Magali/0000-0001-8803-9708; saade, murielle/0000-0002-3937-4291; Nguyen, Catherine/0000-0001-9376-6360; Poulin, Lionel F. F/0000-0003-4272-4659; Kissenpfennig, Adrien/0000-0002-9633-3111	Institut National de la Sante Et de la Recherche Medicale (INSERM); Association pour la Recherche sur le Cancer (ARC) [PhD fellowship]; Association Francaise contre les Myopathies (AFM); Ligue Contre le Cancer en Isere	Institut National de la Sante Et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); Ligue Contre le Cancer en Isere	This work was supported by Institut National de la Sante Et de la Recherche Medicale (INSERM). M. Irla is supported by a PhD fellowship from the Association pour la Recherche sur le Cancer (ARC) and M. Saade is supported by a grant from the Association Francaise contre les Myopathies (AFM). We acknowledge Ligue Contre le Cancer en Isere and the ARC for their help in obtaining equipment necessary for this work.	Adjali O, 2005, P NATL ACAD SCI USA, V102, P13586, DOI 10.1073/pnas.0504268102; Adjali O, 2005, J CLIN INVEST, V115, P2287, DOI 10.1172/JCI23966; Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Berzins SP, 1999, P NATL ACAD SCI USA, V96, P9787, DOI 10.1073/pnas.96.17.9787; BILLINGHAM RE, 1951, J EXP BIOL, V28, P385; Chinen J, 2004, J ALLERGY CLIN IMMUN, V113, P595, DOI 10.1016/j.jaci.2004.01.765; Favard C, 2007, CURR GENE THER, V7, P67, DOI 10.2174/156652307779940207; Fischer A, 2002, NAT REV IMMUNOL, V2, P615, DOI 10.1038/nri859; Fischer A, 2001, LANCET, V357, P1863, DOI 10.1016/S0140-6736(00)04959-X; Gallagher M, 2001, J IMMUNOL, V167, P1447, DOI 10.4049/jimmunol.167.3.1447; Gehl J, 2003, ACTA PHYSIOL SCAND, V177, P437, DOI 10.1046/j.1365-201X.2003.01093.x; Girish V, 2004, Indian J Cancer, V41, P47; Golzio M, 2002, BBA-BIOMEMBRANES, V1563, P23, DOI 10.1016/S0005-2736(02)00369-3; Grayson MH, 2003, AM J PHYSIOL-HEART C, V284, pH2213, DOI 10.1152/ajpheart.00999.2002; Hamrouni A, 2003, J EXP MED, V197, P601, DOI 10.1084/jem.20021945; Kadlecek TA, 1998, J IMMUNOL, V161, P4688; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; Le Moine A, 1999, J IMMUNOL, V163, P3778; Maloy KJ, 2001, P NATL ACAD SCI USA, V98, P3299, DOI 10.1073/pnas.051630798; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Moylett EH, 2004, J ALLERGY CLIN IMMUN, V114, P206, DOI 10.1016/j.jaci.2004.01.782; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; Pasqual N, 2002, J EXP MED, V196, P1163, DOI 10.1084/jem.20021074; Poulin LF, 2005, EUR CYTOKINE NETW, V16, P233; Prud'homme GJ, 2006, CURR GENE THER, V6, P243, DOI 10.2174/156652306776359504; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; TAKAHASHI M, 1991, EXP HEMATOL, V19, P343; TAKAHASHI M, 1991, EXP HEMATOL, V5, P324; Tupin E, 2003, GENE THER, V10, P569, DOI 10.1038/sj.gt.3301914; Ushiki T, 1997, ARCH HISTOL CYTOL, V60, P89, DOI 10.1679/aohc.60.89; Vicat JM, 2000, HUM GENE THER, V11, P909, DOI 10.1089/10430340050015518; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Woods NB, 2006, NATURE, V440, P1123, DOI 10.1038/4401123a; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	35	12	12	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2059	10.1371/journal.pone.0002059	http://dx.doi.org/10.1371/journal.pone.0002059			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446234	Green Submitted, Green Published, gold			2022-12-25	WOS:000261572300028
J	van Beers, RJ				van Beers, Robert J.			Saccadic Eye Movements Minimize the Consequences of Motor Noise	PLOS ONE			English	Article								The durations and trajectories of our saccadic eye movements are remarkably stereotyped. We have no voluntary control over these properties but they are determined by the movement amplitude and, to a smaller extent, also by the movement direction and initial eye orientation. Here we show that the stereotyped durations and trajectories are optimal for minimizing the variability in saccade endpoints that is caused by motor noise. The optimal duration can be understood from the nature of the motor noise, which is a combination of signal-dependent noise favoring long durations, and constant noise, which prefers short durations. The different durations of horizontal vs. vertical and of centripetal vs. centrifugal saccades, and the somewhat surprising properties of saccades in oblique directions are also accurately predicted by the principle of minimizing movement variability. The simple and sensible principle of minimizing the consequences of motor noise thus explains the full stereotypy of saccadic eye movements. This suggests that saccades are so stereotyped because that is the best strategy to minimize movement errors for an open-loop motor system.	[van Beers, Robert J.] Univ Utrecht, Helmholtz Inst, Utrecht, Netherlands; [van Beers, Robert J.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands	Utrecht University; Erasmus University Rotterdam; Erasmus MC	van Beers, RJ (corresponding author), Univ Utrecht, Helmholtz Inst, Utrecht, Netherlands.	r.j.vanbeers@phys.uu.nl	van Beers, Robert J/R-7248-2018	van Beers, Robert J/0000-0003-3847-8918	Netherlands Organization for Scientific Research (NWO) [451-02-013]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	The author was supported by Netherlands Organization for Scientific Research (NWO) Grant 451-02-013.	[Anonymous], 1991, OPTIMAL CONTROL INTR; BAHILL A T, 1975, Mathematical Biosciences, V24, P191, DOI 10.1016/0025-5564(75)90075-9; BAHILL AT, 1981, INVEST OPHTH VIS SCI, V21, P116; BALOH RW, 1975, NEUROLOGY, V25, P1065, DOI 10.1212/WNL.25.11.1065; BARMACK NH, 1976, J NEUROPHYSIOL, V39, P1009, DOI 10.1152/jn.1976.39.5.1009; BECKER W, 1990, VISION RES, V30, P893, DOI 10.1016/0042-6989(90)90057-R; Becker W., 1989, NEUROBIOLOGY SACCADI, P13; BOGHEN D, 1974, INVEST OPHTH VISUAL, V13, P619; Carpenter RHS, 1988, MOVEMENTS EYES; CLARK MR, 1975, IEEE T AUTOMAT CONTR, VAC20, P345, DOI 10.1109/TAC.1975.1100955; COLLEWIJN H, 1977, J PHYSIOL-LONDON, V266, P471, DOI 10.1113/jphysiol.1977.sp011778; COLLEWIJN H, 1988, J PHYSIOL-LONDON, V404, P183, DOI 10.1113/jphysiol.1988.sp017285; COLLEWIJN H, 1988, J PHYSIOL-LONDON, V404, P157, DOI 10.1113/jphysiol.1988.sp017284; COLLEWIJN H, 1998, VISION RES PRACTICAL, P245; COLLINS CC, 1975, J PHYSIOL-LONDON, V245, P351, DOI 10.1113/jphysiol.1975.sp010850; DEMER JL, 1995, INVEST OPHTH VIS SCI, V36, P1125; ENDERLE JD, 1987, IEEE T BIO-MED ENG, V34, P43, DOI 10.1109/TBME.1987.326014; EVINGER C, 1978, J PHYSIOL-LONDON, V285, P209, DOI 10.1113/jphysiol.1978.sp012568; Feng JF, 2002, J PHYS A-MATH GEN, V35, P7287, DOI 10.1088/0305-4470/35/34/304; Frens MA, 2002, J NEUROPHYSIOL, V88, P692, DOI 10.1152/jn.00457.2001; FUCHS AF, 1967, J PHYSIOL-LONDON, V191, P609, DOI 10.1113/jphysiol.1967.sp008271; GOMEZ C, 1986, BRAIN RES, V381, P401, DOI 10.1016/0006-8993(86)90099-5; Hamilton AFD, 2004, EXP BRAIN RES, V157, P417, DOI 10.1007/s00221-004-1856-7; Harris CM, 2006, BIOL CYBERN, V95, P21, DOI 10.1007/s00422-006-0064-x; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Harris CM, 1998, J NEUROSCI METH, V83, P73, DOI 10.1016/S0165-0270(98)00063-6; HASLWANTER T, 1995, VISION RES, V35, P1727, DOI 10.1016/0042-6989(94)00257-M; HEPP K, 1995, VISION RES, V35, P3237, DOI 10.1016/0042-6989(95)00104-M; Hu XT, 2007, P NATL ACAD SCI USA, V104, P8137, DOI 10.1073/pnas.0702799104; KELLER EL, 1971, J NEUROPHYSIOL, V34, P908, DOI 10.1152/jn.1971.34.5.908; KING WM, 1986, J NEUROPHYSIOL, V56, P769, DOI 10.1152/jn.1986.56.3.769; Kirk D.E., 1998, OPTIMAL CONTROL THEO; KUBO T, 1991, ACTA OTO-LARYNGOL, P382; PASTOR AM, 1991, J NEUROPHYSIOL, V66, P2125, DOI 10.1152/jn.1991.66.6.2125; PELISSON D, 1988, VISION RES, V28, P87, DOI 10.1016/0042-6989(88)90010-7; Raphan T, 1998, J NEUROPHYSIOL, V79, P2653, DOI 10.1152/jn.1998.79.5.2653; ROBINSON DA, 1964, J PHYSIOL-LONDON, V174, P245, DOI 10.1113/jphysiol.1964.sp007485; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; SCHMIDT D, 1979, AVIAT SPACE ENVIR MD, V50, P393; SCHNABOLK C, 1994, J NEUROPHYSIOL, V71, P623, DOI 10.1152/jn.1994.71.2.623; Schutte S, 2006, VISION RES, V46, P1724, DOI 10.1016/j.visres.2005.11.022; SMIT AC, 1990, EXP BRAIN RES, V81, P325, DOI 10.1007/BF00228123; SMIT AC, 1990, EXP BRAIN RES, V81, P335, DOI 10.1007/BF00228124; STAHL JS, 1995, J NEUROPHYSIOL, V73, P1383, DOI 10.1152/jn.1995.73.4.1383; Tanaka H, 2006, J NEUROPHYSIOL, V95, P3875, DOI 10.1152/jn.00751.2005; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; TWEED D, 1987, J NEUROPHYSIOL, V58, P823; van Beers RJ, 2004, J NEUROPHYSIOL, V91, P1050, DOI 10.1152/jn.00652.2003; van Beers RJ, 2007, J NEUROSCI, V27, P8757, DOI 10.1523/JNEUROSCI.2311-07.2007; van der Geest JN, 2002, J NEUROSCI METH, V114, P185, DOI 10.1016/S0165-0270(01)00527-1; VANOPSTAL AJ, 1989, VISION RES, V29, P1183, DOI 10.1016/0042-6989(89)90064-3; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	52	46	46	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2070	10.1371/journal.pone.0002070	http://dx.doi.org/10.1371/journal.pone.0002070			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446209	gold, Green Published			2022-12-25	WOS:000261572300039
J	Gurtner, A; Fuschi, P; Magi, F; Colussi, C; Gaetano, C; Dobbelstein, M; Sacchi, A; Piaggio, G				Gurtner, Aymone; Fuschi, Paola; Magi, Fiorenza; Colussi, Claudia; Gaetano, Carlo; Dobbelstein, Matthias; Sacchi, Ada; Piaggio, Giulia			NF-Y Dependent Epigenetic Modifications Discriminate between Proliferating and Postmitotic Tissue	PLOS ONE			English	Article							CCAAT-BINDING ACTIVITY; RNA-POLYMERASE-II; CYCLIN B1 GENE; TRANSCRIPTION FACTOR; CELL-CYCLE; HISTONE ACETYLTRANSFERASES; DOWN-REGULATION; CHROMATIN; EXPRESSION; ACETYLATION	The regulation of gene transcription requires posttranslational modifications of histones that, in concert with chromatin remodeling factors, shape the structure of chromatin. It is currently under intense investigation how this structure is modulated, in particular in the context of proliferation and differentiation. Compelling evidence suggests that the transcription factor NF-Y acts as a master regulator of cell cycle progression, activating the transcription of many cell cycle regulatory genes. However, the underlying molecular mechanisms are not yet completely understood. Here we show that NF-Y exerts its effect on transcription through the modulation of the histone "code''. NF-Y colocalizes with nascent RNA, while RNA polymerase II is I phosphorylated on serine 2 of the YSPTSPS repeats within its carboxyterminal domain and histones are carrying modifications that represent activation signals of gene expression (H3K9ac and PAN-H4ac). Comparing postmitotic muscle tissue from normal mice and proliferating muscles from mdx mice, we demonstrate by chromatin immunoprecipitation (ChIP) that NF-Y DNA binding activity correlates with the accumulation of acetylated histones H3 and H4 on promoters of key cell cycle regulatory genes, and with their active transcription. Accordingly, p300 is recruited onto the chromatin of NF-Y target genes in a NF-Y-dependent manner, as demonstrated by Re-ChIP. Conversely, the loss of NF-Y binding correlates with a decrease of acetylated histones, the recruitment of HDAC1, and a repressed heterochromatic state with enrichment of histones carrying modifications known to mediate silencing of gene expression (H3K9me3, H3K27me2 and H4K20me3). As a consequence, NF-Y target genes are downregulated in this context. In conclusion, our data indicate a role of NF-Y in modulating the structure and transcriptional competence of chromatin in vivo and support a model in which NF-Y-dependent histone "code'' changes contribute to the proper discrimination between proliferating and postmitotic cells in vivo and in vitro.	[Gurtner, Aymone; Fuschi, Paola; Magi, Fiorenza; Sacchi, Ada; Piaggio, Giulia] Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy; [Colussi, Claudia; Gaetano, Carlo] Ist Ricovero Cura Carattere Sci IRCCS, Ist Dermopat Immacolata, Lab Vas Pathol, Rome, Italy; [Dobbelstein, Matthias] Gottingen Ctr Mol Biosci GZMB, Dept Mol Oncol, Gottingen, Germany; [Piaggio, Giulia] Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Expt Oncol Dept, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Gurtner, A (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy.	piaggio@ifo.it	gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/J-7214-2018; Gurtner, Aymone/J-7217-2018; Piaggio, Giulia/AAD-7336-2022; Gaetano, Carlo/P-9997-2019; Colussi, Claudia/H-8609-2019	gurtner, aymone/0000-0002-7661-9059; Piaggio, Giulia/0000-0003-2114-1892; Gurtner, Aymone/0000-0002-7661-9059; Gaetano, Carlo/0000-0002-5238-1832; Colussi, Claudia/0000-0002-7727-8911; Dobbelstein, Matthias/0000-0001-5052-3967	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero della Sanita [ICS-120.4/RA00-90, R.F.02/184]; Istituto Superiore di Sanita [N.ACC2/R7.5]; EU 6th Framework Program [UE-LHSB-CT-04-502988]; German Research Foundation (DFG); German Cancer Aid; Wilhelm Sander Stiftung; FIRB [RBLA035A4X-1-FIRB]; AIRC; AFM [MNM2-06, DdT2-06]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Sanita(Ministry of Health, Italy); Istituto Superiore di Sanita; EU 6th Framework Program(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); Wilhelm Sander Stiftung; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); AIRC(Fondazione AIRC per la ricerca sul cancro); AFM(Association Francaise contre les Myopathies)	This work has been supported by grants to GP from Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita (ICS-120.4/RA00-90; R.F.02/184) and Istituto Superiore di Sanita (N.ACC2/R7.5). MD's work was supported by the EU 6th Framework Program (Integrated Project Active p53), the German Research Foundation (DFG), the German Cancer Aid/Dr. Mildred Scheel Stiftung, and the Wilhelm Sander Stiftung. CG's work has been supported by: FIRB # RBLA035A4X-1-FIRB, AIRC regional grant, UE FP6 grant # UE-LHSB-CT-04-502988 and AFM grants # MNM2-06 and #DdT2-06.	AGGER K, 2007, NATURE          0822; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bhattacharya A, 2003, CANCER RES, V63, P8167; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cho EJ, 2007, EXP MOL MED, V39, P247, DOI 10.1038/emm.2007.28; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; de Wit E, 2007, PLOS GENET, V3, P346, DOI 10.1371/journal.pgen.0030038; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grskovic M, 2007, PLOS GENET, V3, P1524, DOI 10.1371/journal.pgen.0030145; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Gurtner A, 2003, MOL BIOL CELL, V14, P2706, DOI 10.1091/mbc.E02-09-0600; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee WR, 2006, J CELL BIOCHEM, V99, P209, DOI 10.1002/jcb.20902; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Linhart C, 2005, CELL CYCLE, V4, P1788, DOI 10.4161/cc.4.12.2173; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Okamura H, 2004, INT J ONCOL, V25, P1031; Park SH, 2007, CLIN CANCER RES, V13, P858, DOI 10.1158/1078-0432.CCR-06-1461; PENG Y, 2007, ONCOGENE        0618; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WIENCHE JK, 2007, ONCOGENE        1029; [No title captured]	61	51	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2047	10.1371/journal.pone.0002047	http://dx.doi.org/10.1371/journal.pone.0002047			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431504	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700039
J	Rands, SA; Whitney, HM				Rands, Sean A.; Whitney, Heather M.			Floral Temperature and Optimal Foraging: Is Heat a Feasible Floral Reward for Pollinators?	PLOS ONE			English	Article							WARM-UP; NECTAR; BEES; HONEYBEES; BIOLOGY; PLANT; EFFICIENCY; FLOWERS	As well as nutritional rewards, some plants also reward ectothermic pollinators with warmth. Bumble bees have some control over their temperature, but have been shown to forage at warmer flowers when given a choice, suggesting that there is some advantage to them of foraging at warm flowers (such as reducing the energy required to raise their body to flight temperature before leaving the flower). We describe a model that considers how a heat reward affects the foraging behaviour in a thermogenic central-place forager (such as a bumble bee). We show that although the pollinator should spend a longer time on individual flowers if they are warm, the increase in total visit time is likely to be small. The pollinator's net rate of energy gain will be increased by landing on warmer flowers. Therefore, if a plant provides a heat reward, it could reduce the amount of nectar it produces, whilst still providing its pollinator with the same net rate of gain. We suggest how heat rewards may link with plant life history strategies.	[Rands, Sean A.] Univ Bristol, Ctr Behav Biol, Sch Clin Vet Sci, Bristol, Avon, England; [Whitney, Heather M.] Univ Cambridge, Dept Plant Sci, Cambridge, England	University of Bristol; University of Cambridge	Rands, SA (corresponding author), Univ Bristol, Ctr Behav Biol, Sch Clin Vet Sci, Bristol, Avon, England.	sean.rands@bristol.ac.uk	Rands, Sean A/B-2243-2008	Rands, Sean A/0000-0002-7400-005X; Whitney, Heather/0000-0001-6450-8266	NERC	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	HMW was supported as a postdoctoral researcher on a NERC research grant awarded to Beverley J. Glover (University of Cambridge) and Lars Chittka (Queen Mary, University of London). The sponsors played no role in any aspect of the work described in the manuscript.	Biesmeijer JC, 2006, SCIENCE, V313, P351, DOI 10.1126/science.1127863; Bishop JA, 1999, FUNCT ECOL, V13, P711, DOI 10.1046/j.1365-2435.1999.00351.x; CASEY TM, 1992, AM ZOOL, V32, P225; CHARNOV EL, 1976, THEOR POPUL BIOL, V9, P129, DOI 10.1016/0040-5809(76)90040-X; Chittka L., 2001, ANIMAL BEHAV FLORAL; Corbet S.A., 1978, Linnean Society Symposium Series, P21; Dyer AG, 2006, NATURE, V442, P525, DOI 10.1038/442525a; GOULSON D, 2003, BUMBLEBEES BEHAVIOUR; Goulson Dave, 1999, Perspectives in Plant Ecology Evolution and Systematics, V2, P185, DOI 10.1078/1433-8319-00070; HARDER LD, 1983, OECOLOGIA, V57, P274, DOI 10.1007/BF00379591; HEINRICH B, 1975, J COMP PHYSIOL, V96, P155, DOI 10.1007/BF00706595; Heinrich B., 1993, The hot-blooded insects: strategies and mechanisms of thermoregulation.; Heinrich B., 1979, BUMBLEBEE EC; HERAN H, 1952, Z VERGL PHYSIOL, V34, P179; HERRERA CM, 1995, ECOLOGY, V76, P218, DOI 10.2307/1940644; HUBER H, 1956, PLANTA, V48, P47, DOI 10.1007/BF01911144; Ivancic A, 2008, J PLANT RES, V121, P73, DOI 10.1007/s10265-007-0129-5; JAKOBSEN HB, 1994, ANN BOT-LONDON, V74, P327, DOI 10.1006/anbo.1994.1125; KACELNIK A, 1986, BEHAV ECOL SOCIOBIOL, V19, P19, DOI 10.1007/BF00303838; Kevan P.G., 1989, International Congress Series, V871, P747; KEVAN PG, 1983, ANNU REV ENTOMOL, V28, P407, DOI 10.1146/annurev.en.28.010183.002203; Luzar N, 2001, ARCT ANTARCT ALP RES, V33, P93, DOI 10.2307/1552282; McKee J, 1998, BOT J LINN SOC, V128, P369; Memmott J, 2007, ECOL LETT, V10, P710, DOI 10.1111/j.1461-0248.2007.01061.x; NICOLSON SW, 1995, FUNCT ECOL, V9, P584, DOI 10.2307/2390148; Orueta D, 2002, ECOLOGY, V83, P3073, DOI 10.1890/0012-9658(2002)083[3073:TRBCAI]2.0.CO;2; Pacini E, 2003, PLANT SYST EVOL, V238, P7, DOI 10.1007/s00606-002-0277-y; Pellmyr Olle, 2002, P157; PYKE GH, 1991, NATURE, V350, P58, DOI 10.1038/350058a0; Rasheed SA, 1997, ANIM BEHAV, V54, P911, DOI 10.1006/anbe.1997.0487; Sapir Y, 2006, OECOLOGIA, V147, P53, DOI 10.1007/s00442-005-0246-6; SCHMIDHEMPEL P, 1987, J ANIM ECOL, V56, P219, DOI 10.2307/4811; SCHMIDHEMPEL P, 1985, BEHAV ECOL SOCIOBIOL, V17, P61, DOI 10.1007/BF00299430; SCHMIDHEMPEL P, 1987, J ANIM ECOL, V56, P209, DOI 10.2307/4810; Seymour RS, 1998, PHILOS T ROY SOC B, V353, P935, DOI 10.1098/rstb.1998.0258; Seymour RS, 2003, NATURE, V426, P243, DOI 10.1038/426243a; Seymour RS, 1997, ENDEAVOUR, V21, P125, DOI 10.1016/S0160-9327(97)80222-0; Seymour RS, 2001, BIOSCIENCE REP, V21, P223, DOI 10.1023/A:1013608627084; SMITH A P, 1975, Biotropica, V7, P284, DOI 10.2307/2989741; SOUTHWICK EE, 1984, ECOLOGY, V65, P1775, DOI 10.2307/1937773; Stephens D.W., 1986, pi; STONE GN, 1993, J EXP BIOL, V174, P299; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; Whitney HM, 2007, ARTHROPOD-PLANT INTE, V1, P147, DOI 10.1007/s11829-007-9014-3	44	49	50	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2007	10.1371/journal.pone.0002007	http://dx.doi.org/10.1371/journal.pone.0002007			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431488	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700023
J	Lee, KY; Geng, H; Ng, KM; Yu, J; van Hasselt, A; Cao, Y; Zeng, YX; Wong, AHY; Wang, X; Ying, J; Srivastava, G; Lung, ML; Wang, LD; Kwok, TT; Levi, BZ; Chan, ATC; Sung, JJY; Tao, Q				Lee, K. Y.; Geng, H.; Ng, K. M.; Yu, J.; van Hasselt, A.; Cao, Y.; Zeng, Y-X; Wong, A. H. Y.; Wang, X.; Ying, J.; Srivastava, G.; Lung, M. L.; Wang, L-D; Kwok, T. T.; Levi, B-Z; Chan, A. T. C.; Sung, J. J. Y.; Tao, Q.			Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas	ONCOGENE			English	Article						IRF8; methylation; CpG island; tumor suppressor gene; carcinoma	BINDING-PROTEIN ICSBP; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; CELL CARCINOMA; MYELOID CELLS; GENE; CANCER; APOPTOSIS; EXPRESSION; ICSBP/IRF-8	16q24 is frequently deleted in multiple tumors including cancers of nasopharynx, esophagus, breast, prostate and liver. By array comparative genomic hybridization (aCGH), we refined a 16q24 hemizygous deletion in nasopharyngeal carcinoma (NPC) cell lines. Semi-quantitative RT-PCR analysis revealed interferon regulatory factor 8 (IRF8) as the only downregulated gene within this deletion. IRF8 belongs to a family of interferon (IFN) regulatory factors that modulate various important physiologic processes including host defense, cell growth and differentiation and immune regulation. In contrast to the broad expression of IRF8 in normal adult and fetal tissues, transcriptional silencing and promoter methylation of IRF8 were frequently detected in multiple carcinoma (except for hepatocellular) cell lines (100% in NPC, 88% in esophageal and 18-78% in other carcinoma cell lines) and in a large collection of primary carcinomas (78% in NPC, 36-71% in other carcinomas). Methylation of the IRF8 promoter led to the disruption of its response to IFN-gamma stimulation. Pharmacological and genetic demethylation could restore IRF8 expression, indicating a direct epigenetic mechanism. Ectopic expression of IRF8 in tumor cells lacking its expression strongly inhibited their clonogenicity, confirming its tumor suppressor function. Thus, IRF8 was identified as a functional tumor suppressor, which is frequently silenced by epigenetic mechanism in multiple carcinomas.	[Lee, K. Y.; Geng, H.; Ng, K. M.; Wong, A. H. Y.; Wang, X.; Ying, J.; Chan, A. T. C.; Tao, Q.] Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [van Hasselt, A.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Cao, Y.] Cent S Univ, Hunan Yale Xiang Ya Sch Med, Changsha 410083, Peoples R China; [Zeng, Y-X] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lung, M. L.] Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; [Wang, L-D] Zhengzhou Univ, Coll Med, Henan Key Lab Esophageal Canc, Zhengzhou, Henan, Peoples R China; [Kwok, T. T.] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Levi, B-Z] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Central South University; Sun Yat Sen University; University of Hong Kong; Hong Kong University of Science & Technology; Zhengzhou University; Chinese University of Hong Kong; Technion Israel Institute of Technology	Tao, Q (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Sung, Joseph J. Y./R-3203-2018; Tao, Qian/T-4743-2018; Yu, Jun/D-8569-2015; Kwok, Timothy/C-3725-2008; Lung, Maria Li/C-4495-2009	Chan, Anthony Tak Cheung/0000-0002-6912-8091; Sung, Joseph J. Y./0000-0003-3125-5199; Tao, Qian/0000-0001-5383-4808; Yu, Jun/0000-0001-5008-2153; Kwok, Timothy/0000-0001-9253-3549; Wang, Xian/0000-0003-0041-7589; Lung, Maria Li/0000-0003-2559-3626	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant [CA06/07.SC03]	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant(Hong Kong Research Grants Council)	This project was supported by a Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP) Grant to QT and a Hong Kong RGC Central Allocation Grant (CA06/07.SC03, QT). We thank Drs Bert Vogelstein, George Tsao (Dolly Huang), Sun Young Rha and Kaitai Yao for some cell lines, DSMZ (German Collection of Microorganisms and Cell Cultures) for the KYSE cell lines [Shimada et al., Cancer 69: 277-284 (1992)], Dr C Langford at the Wellcome Trust Sanger Institute, Cambridge, UK for aCGH slides, and Tzer- Jing Seng (Johns Hopkins Singapore) for her valuable help in aCGH analysis.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Egwuagu CE, 2006, ONCOGENE, V25, P3670, DOI 10.1038/sj.onc.1209402; Hashmueli S, 2003, INT IMMUNOL, V15, P807, DOI 10.1093/intimm/dxg077; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu GD, 2005, CANCER RES, V65, P7403, DOI 10.1158/0008-5472.CAN-05-0583; Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanno Y, 2005, J INTERF CYTOK RES, V25, P770, DOI 10.1089/jir.2005.25.770; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Paige AJW, 2000, CANCER RES, V60, P1690; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Watson GA, 2006, NEOPLASIA, V8, P31, DOI 10.1593/neo.05559; Wong ML, 2006, INT J ONCOL, V28, P767; Yang DF, 2007, J IMMUNOL, V179, P4775, DOI 10.4049/jimmunol.179.7.4775; Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	43	61	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5267	5276		10.1038/onc.2008.147	http://dx.doi.org/10.1038/onc.2008.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469857				2022-12-25	WOS:000258915100011
J	Bourajjaj, M; Armand, AS; Martins, PADC; Weijts, B; van der Nagel, R; Heeneman, S; Wehrens, XH; De Windt, LJ				Bourajjaj, Meriem; Armand, Anne-Sophie; Martins, Paula A. da Costa; Weijts, Bart; van der Nagel, Roel; Heeneman, Sylvia; Wehrens, Xander H.; De Windt, Leon J.			NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; IN-VIVO; NUCLEAR FACTOR; TRANSCRIPTION FACTORS; TARGETED INHIBITION; DYSFUNCTION; EXPRESSION; STRESS; FAMILY; HOMEOSTASIS	One major intracellular signaling pathway involved in heart failure employs the phosphatase calcineurin and its downstream transcriptional effector nuclear factor of activated T-cells ( NFAT). In vivo evidence for the involvement ofNFATfactors in heart failure development is still ill defined. Here we reveal that nfatc2 transcripts outnumber those from other nfat genes in the unstimulated heart by severalfold. Transgenic mice with activated calcineurin in the postnatal myocardium crossbred with nfatc2-null mice revealed a significant abrogation of calcineurin-provoked cardiac growth, indicating that NFATc2 plays an important role downstream of calcineurin and validates the original hypothesis that calcineurin mediates myocyte hypertrophy through activation of NFAT transcription factors. In the absence of NFATc2, a clear protection against the geometrical, functional, and molecular deterioration of the myocardium following biomechanical stress was also evident. In contrast, physiological cardiac enlargement in response to voluntary exercise training was not affected in nfatc2-null mice. Combined, these results reveal a major role for the NFATc2 transcription factor in pathological cardiac remodeling and heart failure.	[De Windt, Leon J.] Univ Utrecht, Med Ctr, Div Heart & Lungs, Dept Med Physiol, NL-3584 CM Utrecht, Netherlands; [Bourajjaj, Meriem; Armand, Anne-Sophie; Martins, Paula A. da Costa; Weijts, Bart; van der Nagel, Roel; De Windt, Leon J.] Royal Netherlands Acad Sci, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands; [Bourajjaj, Meriem; Armand, Anne-Sophie; Martins, Paula A. da Costa; Weijts, Bart; van der Nagel, Roel; De Windt, Leon J.] Royal Netherlands Acad Sci, Interuniv Cardiol Inst Netherlands, NL-3584 CT Utrecht, Netherlands; [Heeneman, Sylvia] Univ Hosp Maastricht, Dept Pathol, NL-6229 HX Maastricht, Netherlands; [Wehrens, Xander H.] Baylor Coll Med, Houston, TX 77030 USA	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Maastricht University; Maastricht University Medical Centre (MUMC); Baylor College of Medicine	De Windt, LJ (corresponding author), Univ Utrecht, Med Ctr, Div Heart & Lungs, Dept Med Physiol, Yalelaan 50, NL-3584 CM Utrecht, Netherlands.	L.J.deWindt@umcutrecht.nl	de Windt, Leon/AAO-6395-2020; Weijts, Bart/O-7107-2019; Wehrens, Xander/AAQ-9574-2020	de Windt, Leon/0000-0002-7793-2856; Weijts, Bart/0000-0003-4843-3019; Wehrens, Xander/0000-0001-5044-672X; Armand, Anne-Sophie/0000-0002-0291-6421				Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Buitrago M, 2005, NAT MED, V11, P837, DOI 10.1038/nm1272; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; HO KKL, 1993, J AM COLL CARDIOL  S, V22, P6; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Imamura R, 1998, J IMMUNOL, V161, P3455; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Oakley D, 2001, HEART, V86, P722, DOI 10.1136/heart.86.6.722; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Perrino C, 2006, J CLIN INVEST, V116, P1547, DOI 10.1172/JCI25397; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; van Empel VPM, 2006, J AM COLL CARDIOL, V48, P824, DOI 10.1016/j.jacc.2006.02.075; van Oort RJ, 2006, CIRCULATION, V114, P298, DOI 10.1161/CIRCULATIONAHA.105.608968; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	34	116	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2008	283	32					22295	22303		10.1074/jbc.M801296200	http://dx.doi.org/10.1074/jbc.M801296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332WV	18477567	hybrid			2022-12-25	WOS:000258114700048
J	Koch, A; Scherr, M; Breyer, B; Mancini, A; Kardinal, C; Battmer, K; Eder, M; Tamura, T				Koch, A.; Scherr, M.; Breyer, B.; Mancini, A.; Kardinal, C.; Battmer, K.; Eder, M.; Tamura, T.			Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover	ONCOGENE			English	Article						TrkA and Bcr-Abl; CML; imatinib; receptor internalization; CD34+cells	CHRONIC MYELOID-LEUKEMIA; TRK NEUROTROPHIN RECEPTORS; HEMATOPOIETIC-CELLS; C-KIT; PHILADELPHIA-CHROMOSOME; 5-PHOSPHATASE SHIP2; IN-VITRO; STI 571; EXPRESSION; NGF	Receptor tyrosine kinase-mediated signaling is tightly regulated by a number of cytoplasmic signaling molecules. In this report, we show that Bcr-Abl transformed chronic myelogenous leukemia (CML) cell lines, K562 and Meg-01, express the receptor for nerve growth factor (NGF), TrkA, on the cell surface; however, the NGF-mediated signal is not particularly strong. Treatment with imatinib, a potent inhibitor of Bcr-Abl tyrosine kinase, downmodulates phosphorylation of downstream molecules. Upon stimulation with NGF, Erk and Akt are phosphorylated to a much greater degree in imatinib-treated cells than in untreated cells. Knockdown of expression of Bcr-Abl using small interfering RNA technique also enhanced NGF-mediated Akt phosphorylation, indicating that Bcr-Abl kinase modifies NGF signaling directly. Imatinib treatment also enhanced NGF signaling in rat adrenal pheochromocytoma cell line PC12 that expresses TrkA and c-Abl, suggesting that it is not only restoration of responsiveness to NGF after blocking oncoprotein activity, but also c-Abl tyrosine kinase per se may be a negative regulator of growth factor signaling. Furthermore, inhibition of Abl tyrosine kinase enhanced clearance of surface TrkA after NGF treatment and simultaneously enhanced NGF-mediated signaling, suggesting that as in neuronal cells 'signaling endosomes' are formed in hematopoietic cells. To examine the role of TrkA in CML cells, we studied cell growth or colony formation in the presence or absence of imatinib with or without NGF. We found that NGF treatment induces cell survival in imatinib-treated CML cell lines, as well as colony formation of primary CD34+ CML cells, strongly suggesting that NGF/TrkA signaling contributes to aberrant signaling in CML.	[Koch, A.; Breyer, B.; Mancini, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE 4310, D-30623 Hannover, Germany; [Scherr, M.; Battmer, K.; Eder, M.] Hannover Med Sch, OE 6860, D-30623 Hannover, Germany; [Kardinal, C.] Hannover Med Sch, OE 6780, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310, Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@MH-Hannover.de						Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Bonati A, 2000, CANCER RES, V60, P728; Bracci-Laudiero L, 2003, J NEUROIMMUNOL, V136, P130, DOI 10.1016/S0165-5728(03)00007-9; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Chen ZY, 2005, MOL BIOL CELL, V16, P5761, DOI 10.1091/mbc.E05-07-0651; CHEVALIER S, 1994, BLOOD, V83, P1479; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Giuriato S, 2002, BIOCHEM BIOPH RES CO, V296, P106, DOI 10.1016/S0006-291X(02)00787-8; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kaebisch A, 1996, BRIT J HAEMATOL, V95, P102, DOI 10.1046/j.1365-2141.1996.d01-1874.x; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Scherr M, 2005, GENE THER, V12, P12, DOI 10.1038/sj.gt.3302328; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Simone MD, 1999, HEMATOL ONCOL, V17, P1; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	46	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4678	4689		10.1038/onc.2008.107	http://dx.doi.org/10.1038/onc.2008.107			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18427551				2022-12-25	WOS:000258236300006
J	Demidenko, ZN; Kalurupalle, S; Hanko, C; Lim, CU; Broude, E; Blagosklonny, MV				Demidenko, Z. N.; Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.			Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis	ONCOGENE			English	Article						cell cycle; cancer; G1 arrest; paclitaxel; mitosis	MAMMALIAN-CELLS; MITOTIC ARREST; G(1) ARREST; P53; CHECKPOINT; TRANSCRIPTION; INHIBITORS; TAXOL; P21; REREPLICATION	Paclitaxel (PTX) and other microtubule inhibitors cause mitotic arrest. However, low concentrations of PTX (low PTX) paradoxically cause G1 arrest ( without mitotic arrest). Here, we demonstrated that unexpectedly, low PTX did not cause G1 arrest in the first cell cycle and did not prevent cells from passing through S phase and entering mitosis. Mitosis was prolonged but cells still divided, producing either two or three cells (tripolar mitosis), thus explaining a sub G1 peak caused by low PTX. Importantly, sub G1 cells were viable and non-apoptotic. Some cells fused back and then progressed to mitosis, frequently producing three cells again before becoming arrested in the next cell-cycle interphase. Thus, low PTX caused postmitotic arrest in second and even the third cell cycles. By increasing concentration of PTX, tripolar mitosis was transformed to mitotic slippage, thus eliminating a sub G1 peak. Time-lapse microscopy revealed that prolonged mitosis ensured a p53-dependent postmitotic arrest. We conclude that PTX directly affects cells only in mitosis and the duration of mitosis determines cell fate, including p53-dependent G1-like arrest.	[Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.] Ctr Canc, Ordway Res Inst, Albany, NY 12208 USA; [Demidenko, Z. N.; Blagosklonny, M. V.] Oncotarget, Ordway Res Inst, Albany, NY USA	Ordway Research Institute; Ordway Research Institute	Blagosklonny, MV (corresponding author), Ctr Canc, Ordway Res Inst, 150 New Scotland Ave, Albany, NY 12208 USA.	blagosklonny@oncotarget.com						Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broude EV, 2007, CELL CYCLE, V6, P1468; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; KESSOUS A, 1980, CANCER RES, V40, P1354; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PRESCOTT DM, 1964, PROG NUCLEIC ACID RE, V3, P33, DOI 10.1016/S0079-6603(08)60738-2; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Stark B, 2001, CANCER GENET CYTOGEN, V128, P108, DOI 10.1016/S0165-4608(01)00411-3; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	33	82	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4402	4410		10.1038/onc.2008.82	http://dx.doi.org/10.1038/onc.2008.82			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18469851				2022-12-25	WOS:000257881700003
J	Cohen, A; Ben-Abu, Y; Hen, S; Zilberberg, N				Cohen, Asi; Ben-Abu, Yuval; Hen, Shelly; Zilberberg, Noam			A novel mechanism for human K(2P)2.1 channel Gating - Facilitation of C-type gating by protonation of extracellular histidine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN K+ CHANNELS; POLYUNSATURATED FATTY-ACIDS; SHAKER POTASSIUM CHANNELS; 2-PORE DOMAIN; FUNCTIONAL EXPRESSION; MOLECULAR-BASIS; TREK-1; PORE; PH; INHIBITION	The mammalian K(2P)2.1 potassium channel (TREK-1, KCNK2) is highly expressed in excitable tissues, where it plays a key role in the cellular mechanisms of neuroprotection, anesthesia, pain perception, and depression. Here, we report that external acidification, within the physiological range, strongly inhibits the human K(2P)2.1 channel by inducing "C-type" closure. We have identified two histidine residues (i.e. His-87 and His-141), located in the first external loop of the channel, that govern the response of the channel to external pH. We demonstrate that these residues are within physical proximity to glutamate 84, homologous to Shaker Glu-418, KcsA Glu-51, and KCNK0 Glu-28 residues, all previously argued to stabilize the outer pore gate in the open conformation by forming hydrogen bonds with pore-adjacent residues. We thus propose a novel mechanism for pH sensing in which protonation of His-141 and His-87 generates a local positive charge that serves to draw Glu-84 away from its natural interactions, facilitating the collapse of the selectivity filter region. In accordance with this proposed mechanism, low pH modified K(2P)2.1 selectivity toward potassium. Moreover, the proton-mediated effect was inhibited by external potassium ions and was enhanced by a mutation (S164Y) known to accelerate C-type gating. Furthermore, proton-induced current inhibition was more pronounced at negative potentials. Thus, voltage-dependent C-type gating acceleration by protons represents a novel mechanism for K(2P)2.1 outward rectification.	[Zilberberg, Noam] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Zilberberg, N (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	noamz@bgu.ac.il	Zilberberg, Noam/F-2005-2012; Abu, Yuval Ben/AAD-1402-2020	Zilberberg, Noam/0000-0002-7848-2391				Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; Alloui A, 2006, EMBO J, V25, P2368, DOI 10.1038/sj.emboj.7601116; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Claydon TW, 2004, BIOPHYS J, V87, P2407, DOI 10.1529/biophysj.103.039073; Cohen A, 2006, J NEUROSCI METH, V153, P62, DOI 10.1016/j.jneumeth.2005.10.005; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Harinath S, 2005, EPILEPSY RES, V64, P127, DOI 10.1016/j.eplepsyres.2005.03.002; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Honore E, 2007, NAT REV NEUROSCI, V8, P251, DOI 10.1038/nrn2117; Kang D, 2005, J PHYSIOL-LONDON, V564, P103, DOI 10.1113/jphysiol.2004.081059; Kennard LE, 2005, BRIT J PHARMACOL, V144, P821, DOI 10.1038/sj.bjp.0706068; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Koh SD, 2001, J BIOL CHEM, V276, P44338, DOI 10.1074/jbc.M108125200; La JH, 2006, NEUROSCI LETT, V406, P244, DOI 10.1016/j.neulet.2006.07.039; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Meadows HJ, 2000, PFLUG ARCH EUR J PHY, V439, P714, DOI 10.1007/s004240050997; Morton MJ, 2005, P NATL ACAD SCI USA, V102, P16102, DOI 10.1073/pnas.0506870102; Mulkey DK, 2007, J NEUROSCI, V27, P14049, DOI 10.1523/JNEUROSCI.4254-07.2007; Niemeyer MI, 2007, P NATL ACAD SCI USA, V104, P666, DOI 10.1073/pnas.0606173104; Ogielska EM, 1999, J GEN PHYSIOL, V113, P347, DOI 10.1085/jgp.113.2.347; Ortega-Saenz P, 2000, J GEN PHYSIOL, V116, P181, DOI 10.1085/jgp.116.2.181; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Starkus JG, 2003, PFLUG ARCH EUR J PHY, V447, P44, DOI 10.1007/s00424-003-1121-0; Starkus JG, 1997, J GEN PHYSIOL, V110, P539, DOI 10.1085/jgp.110.5.539; Starkus JG, 1998, J GEN PHYSIOL, V112, P85, DOI 10.1085/jgp.112.1.85; Steidl JV, 1999, MOL PHARMACOL, V55, P812; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Xiong ZG, 2007, FRONT BIOSCI-LANDMRK, V12, P1376, DOI 10.2741/2154; Yuill KH, 2007, PFLUG ARCH EUR J PHY, V455, P333, DOI 10.1007/s00424-007-0282-7; Zilberberg N, 2001, NEURON, V32, P635, DOI 10.1016/S0896-6273(01)00503-7	46	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19448	19455		10.1074/jbc.M801273200	http://dx.doi.org/10.1074/jbc.M801273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474599	hybrid			2022-12-25	WOS:000257387600031
J	Handa, N; Mizohata, E; Kishishita, S; Toyama, M; Morita, S; Uchikubo-Kamo, T; Akasaka, R; Omori, K; Kotera, J; Terada, T; Shirouzu, M; Yokoyama, S				Handa, Noriko; Mizohata, Eiichi; Kishishita, Seiichiro; Toyama, Mitsutoshi; Morita, Satoshi; Uchikubo-Kamo, Tomomi; Akasaka, Ryogo; Omori, Kenji; Kotera, Jun; Terada, Takaho; Shirouzu, Mikako; Yokoyama, Shigeyuki			Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP BINDING; PDE10A; LOCALIZATION; ORGANIZATION; DIMERIZATION; INHIBITION; GENE; PDES	Cyclic nucleotide phosphodiesterases (PDEs) catalyze the degradation of the cyclic nucleotides cAMP and cGMP, which are important second messengers. Five of the 11 mammalian PDE families have tandem GAF domains at their N termini. PDE10A may be the only mammalian PDE for which cAMP is the GAF domain ligand, and it may be allosterically stimulated by cAMP. PDE10A is highly expressed in striatal medium spiny neurons. Here we report the crystal structure of the C-terminal GAF domain (GAF-B) of human PDE10A complexed with cAMP at 2.1-angstrom resolution. The conformation of the PDE10A GAF-B domain monomer closely resembles those of the GAF domains of PDE2A and the cyanobacterium Anabaena cyaB2 adenylyl cyclase, except for the helical bundle consisting of alpha 1, alpha 2, and alpha 5. The PDE10A GAF-B domain forms a dimer in the crystal and in solution. The dimerization is mainly mediated by hydrophobic interactions between the helical bundles in a parallel arrangement, with a large buried surface area. In the PDE10A GAF-B domain, cAMP tightly binds to a cNMP-binding pocket. The residues in the alpha 3 and alpha 4 helices, the alpha 6 strand, the loop between 3(10) and alpha 4, and the loop between alpha 4 and beta 5 are involved in the recognition of the phosphate and ribose moieties. This recognition mode is similar to those of the GAF domains of PDE2A and cyaB2. In contrast, the adenine base is specifically recognized by the PDE10A GAF-B domain in a unique manner, through residues in the beta 1 and beta 2 strands.	[Handa, Noriko; Mizohata, Eiichi; Kishishita, Seiichiro; Toyama, Mitsutoshi; Morita, Satoshi; Uchikubo-Kamo, Tomomi; Akasaka, Ryogo; Terada, Takaho; Shirouzu, Mikako; Yokoyama, Shigeyuki] RIKEN, Yokohama Inst, Syst & Struct Biol Ctr, Yokohama, Kanagawa 2300045, Japan; [Omori, Kenji; Kotera, Jun] Mitsubishi Tanabe Pharma Corp, Adv Med Res Lab, Saitama 3358505, Japan; [Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	RIKEN; Mitsubishi Tanabe Pharma Corporation; University of Tokyo	Yokoyama, S (corresponding author), RIKEN, Yokohama Inst, Syst & Struct Biol Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Kishishita, Seiichiro/H-1836-2011; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kishishita, Seiichiro/0000-0001-7587-2581; 				Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann M, 2007, MOL MICROBIOL, V64, P461, DOI 10.1111/j.1365-2958.2007.05669.x; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fujishige K, 1999, EUR J BIOCHEM, V266, P1118, DOI 10.1046/j.1432-1327.1999.00963.x; Fujishige K, 2000, EUR J BIOCHEM, V267, P5943, DOI 10.1046/j.1432-1327.2000.01661.x; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gross-Langenhoff M, 2006, J BIOL CHEM, V281, P2841, DOI 10.1074/jbc.M511468200; Hebb ALO, 2004, NEUROSCIENCE, V123, P967, DOI 10.1016/j.neuroscience.2003.11.009; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HURLEY JH, 2003, SCI STKE, pPE1; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; Kigawa T, 1999, Tanpakushitsu Kakusan Koso, V44, P598; Kigawa Takanori, 2004, Journal of Structural and Functional Genomics, V5, P63, DOI 10.1023/B:JSFG.0000029204.57846.7d; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Martinez Sergio E, 2002, Mol Interv, V2, P317, DOI 10.1124/mi.2.5.317; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Muradov KG, 2003, J BIOL CHEM, V278, P10594, DOI 10.1074/jbc.M208456200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Rodefer JS, 2005, EUR J NEUROSCI, V21, P1070, DOI 10.1111/j.1460-9568.2005.03937.x; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Seeger TF, 2003, BRAIN RES, V985, P113, DOI 10.1016/S0006-8993(03)02754-9; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P386, DOI 10.1016/j.neuropharm.2006.04.013; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P374, DOI 10.1016/j.neuropharm.2006.01.012; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wada T, 2003, ACTA CRYSTALLOGR D, V59, P1213, DOI 10.1107/S0907444903010515; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Xie Z, 2006, NEUROSCIENCE, V139, P597, DOI 10.1016/j.neuroscience.2005.12.042; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200	48	51	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19657	19664		10.1074/jbc.M800595200	http://dx.doi.org/10.1074/jbc.M800595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18477562	hybrid			2022-12-25	WOS:000257387600051
J	Huang, J; Shelton, JM; Richardson, JA; Kamm, KE; Stull, JT				Huang, Jian; Shelton, John M.; Richardson, James A.; Kamm, Kristine E.; Stull, James T.			Myosin regulatory light chain phosphorylation attenuates cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; SMOOTH-MUSCLE; CA2+ SENSITIVITY; Z-LINES; CALMODULIN; KINASE; KINETICS; PROTEIN; CONTRACTION; CALCIUM	Hyperphosphorylation of myosin regulatory light chain (RLC) in cardiac muscle is proposed to cause compensatory hypertrophy. We therefore investigated potential mechanisms in genetically modified mice. Transgenic (TG) mice were generated to overexpress Ca2+/calmodulin-dependent myosin light chain kinase specifically in cardiomyocytes. Phosphorylation of sarcomeric cardiac RLC and cytoplasmic nonmuscle RLC increased markedly in hearts from TG mice compared with hearts from wild-type (WT) mice. Quantitative measures of RLC phosphorylation revealed no spatial gradients. No significant hypertrophy or structural abnormalities were observed up to 6 months of age in hearts of TG mice compared with WT animals. Hearts and cardiomyocytes from WT animals subjected to voluntary running exercise and isoproterenol treatment showed hypertrophic cardiac responses, but the responses for TG mice were attenuated. Additional biochemical measurements indicated that overexpression of the Ca2+/calmodulin-binding kinase did not perturb other Ca2+/calmodulin-dependent processes involving Ca2+/calmodulin-dependent protein kinase II or the protein phosphatase calcineurin. Thus, increased myosin RLC phosphorylation per se does not cause cardiac hypertrophy and probably inhibits physiological and pathophysiological hypertrophy by contributing to enhanced contractile performance and efficiency.	[Huang, Jian; Kamm, Kristine E.; Stull, James T.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Shelton, John M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Richardson, James A.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Richardson, James A.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.stull@utsouthwestern.edu			NHLBI NIH HHS [HL06296, HL080536] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080536, P01HL006296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Buck SH, 1999, AM J PHYSIOL-HEART C, V276, pH1167, DOI 10.1152/ajpheart.1999.276.4.H1167; Chan JY, 2008, CIRC RES, V102, P571, DOI 10.1161/CIRCRESAHA.107.161687; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; Dias FAL, 2006, J MOL CELL CARDIOL, V41, P330, DOI 10.1016/j.yjmcc.2006.05.012; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Dudnakova TV, 2006, CELL MOTIL CYTOSKEL, V63, P375, DOI 10.1002/cm.20127; Epstein ND, 2006, CIRC RES, V98, P1110, DOI 10.1161/01.RES.0000223888.99864.3c; Herring BP, 2000, AM J PHYSIOL-CELL PH, V279, pC1656, DOI 10.1152/ajpcell.2000.279.5.C1656; HIGH CW, 1980, AM J PHYSIOL, V239, pH756, DOI 10.1152/ajpheart.1980.239.6.H756; Hill JA, 2008, NEW ENGL J MED, V358, P1370, DOI 10.1056/NEJMra072139; Isotani E, 2004, P NATL ACAD SCI USA, V101, P6279, DOI 10.1073/pnas.0308742101; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Maier LS, 2006, J MOL CELL CARDIOL, V41, P451, DOI 10.1016/j.yjmcc.2006.04.020; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Metrich M, 2008, CIRC RES, V102, P959, DOI 10.1161/CIRCRESAHA.107.164947; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Moss RL, 2006, CIRC RES, V99, P225, DOI 10.1161/01.RES.0000236793.88131.dc; Nart P, 2004, J COMP PATHOL, V130, P235, DOI 10.1016/j.jcpa.2003.11.002; Ni YG, 2006, CIRCULATION, V114, P1159, DOI 10.1161/CIRCULATIONAHA.106.637124; Olsson MC, 2004, AM J PHYSIOL-HEART C, V287, pH2712, DOI 10.1152/ajpheart.01067.2003; Patel JR, 1998, BIOPHYS J, V74, P360, DOI 10.1016/S0006-3495(98)77793-8; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Ryder JW, 2007, J BIOL CHEM, V282, P20447, DOI 10.1074/jbc.M702927200; SEGUCHI O, J CLIN INVESTIG, V117, P2812; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P40; SILVER PJ, 1986, J MOL CELL CARDIOL, V18, P31, DOI 10.1016/S0022-2828(86)80980-4; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1982, J MOL CELL CARDIOL, V14, P105, DOI 10.1016/0022-2828(82)90137-7; STULL JT, 1986, ENZYMES, P113; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Takeda K, 2000, CELL MOTIL CYTOSKEL, V46, P59, DOI 10.1002/(SICI)1097-0169(200005)46:1<59::AID-CM6>3.0.CO;2-Q; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; Tran QK, 2005, CELL CALCIUM, V37, P541, DOI 10.1016/j.ceca.2005.02.001; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; WALSH MP, 1979, J BIOL CHEM, V254, P2136; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; WOLF H, 1980, P NATL ACAD SCI-BIOL, V77, P5852, DOI 10.1073/pnas.77.10.5852; Woods A, 1994, LAB HISTOPATHOLOGY C; Wu X, 2007, CELL CALCIUM, V41, P353, DOI 10.1016/j.ceca.2006.07.011; Zhi G, 2005, P NATL ACAD SCI USA, V102, P17519, DOI 10.1073/pnas.0506846102; ZHI G, 1994, J BIOL CHEM, V269, P24723; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951; ZIMMERMANN B, 1995, J BIOL CHEM, V270, P23966, DOI 10.1074/jbc.270.41.23966	50	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19748	19756		10.1074/jbc.M802605200	http://dx.doi.org/10.1074/jbc.M802605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474588	hybrid, Green Published			2022-12-25	WOS:000257387600059
J	Miller, BM; Trybus, KM				Miller, Becky M.; Trybus, Kathleen M.			Functional effects of nemaline myopathy mutations on human skeletal alpha-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ACTIN; MUSCLE ACTIN; WILD-TYPE; HYPERTROPHIC CARDIOMYOPATHY; PROTEOLYTIC REMOVAL; CRYSTAL-STRUCTURE; MONOMERIC ACTIN; BETA-ACTIN; MYOSIN; POLYMERIZATION	Mutations in human alpha-skeletal actin have been implicated in causing congenital nemaline myopathy, a disease characterized histopathologically by nemaline bodies in skeletal muscle and manifested in the patient as skeletal muscle weakness. Here we investigate the functional effects of three severe nemaline myopathy mutations (V43F, A138P, and R183G) in human alpha-skeletal actin. Wild-type and mutant actins were expressed and purified from the baculovirus/insect cell expression system. The mutations are located in different subdomains of actin; Val-43 is located in a flexible loop of subdomain 2, Ala-138 is near a hydrophobic cleft in the "hinge" region between subdomains 1 and 3, and Arg-183 is near the nucleotide-binding site. None of the three mutations affected the folding of the actin monomer, the velocity at which skeletal myosin moves actin in an in vitro motility assay, or the relative average isometric force supported by F-actin. Defects in fundamental actomyosin interactions are, therefore, unlikely to account for the muscle weakness observed in affected patients. There were, however, significant changes observed in the polymerization kinetics of V43F and A138P and in the rate of nucleotide release for V43F. No detectable defect was found for R183G. If these subtle changes in polymerization observed in vitro are amplified in the context of the sarcomere, it could in principle be one of the primary insults that triggers the development of nemaline myopathy.	[Miller, Becky M.; Trybus, Kathleen M.] Univ Vermont, Dept Mol Phys & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Phys & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	trybus@physiology.med.uvm.edu			NHLBI NIH HHS [HL059408, T32 HL07647, T32 HL007944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059408, T32HL007647, T32HL007944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal PB, 2004, ANN NEUROL, V56, P86, DOI 10.1002/ana.20157; Akkari PA, 2003, BIOCHEM BIOPH RES CO, V307, P74, DOI 10.1016/S0006-291X(03)01133-1; Allingham JS, 2006, CELL MOL LIFE SCI, V63, P2119, DOI 10.1007/s00018-006-6157-9; Bathe FS, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-2; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; Bookwalter CS, 2006, J BIOL CHEM, V281, P16777, DOI 10.1074/jbc.M512935200; Brault V, 1999, MOL BIOL CELL, V10, P135, DOI 10.1091/mbc.10.1.135; Buzan J, 1999, P NATL ACAD SCI USA, V96, P2823, DOI 10.1073/pnas.96.6.2823; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; Clarkson E, 2004, J PATHOL, V204, P407, DOI 10.1002/path.1648; CONEN PE, 1963, CAN MED ASSOC J, V89, P983; Costa CF, 2004, J CELL SCI, V117, P3367, DOI 10.1242/jcs.01172; D'Amico A, 2006, NEUROMUSCULAR DISORD, V16, P548, DOI 10.1016/j.nmd.2006.07.005; Dominguez R, 2004, TRENDS BIOCHEM SCI, V29, P572, DOI 10.1016/j.tibs.2004.09.004; Dominguez R, 2003, BIOPHYS J, V85, P2073, DOI 10.1016/S0006-3495(03)74635-9; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; Fujiwara I, 2002, NAT CELL BIOL, V4, P666, DOI 10.1038/ncb841; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Ilkovski B, 2004, HUM MOL GENET, V13, P1727, DOI 10.1093/hmg/ddh185; Joel PB, 2004, BIOCHEMISTRY-US, V43, P11554, DOI 10.1021/bi048899a; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; KARPATI G, 1972, ARCH NEUROL-CHICAGO, V27, P237, DOI 10.1001/archneur.1972.00490150045008; KAWABUCHI M, 1982, J NEUROPATH EXP NEUR, V41, P298, DOI 10.1097/00005072-198205000-00005; Kim E, 2002, BIOCHEMISTRY-US, V41, P86, DOI 10.1021/bi0113824; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kudryashov DS, 2003, BIOPHYS J, V85, P2466, DOI 10.1016/S0006-3495(03)74669-4; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; Laing NG, 2005, BIOESSAYS, V27, P809, DOI 10.1002/bies.20269; Malmqvist UP, 2004, BIOCHEMISTRY-US, V43, P15058, DOI 10.1021/bi0495329; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Marston S, 2004, NEUROMUSCULAR DISORD, V14, P167, DOI 10.1016/j.nmd.2003.11.003; McKane M, 2006, J BIOL CHEM, V281, P29916, DOI 10.1074/jbc.M602251200; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; Nowak KJ, 2007, ANN NEUROL, V61, P175, DOI 10.1002/ana.21035; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Procaccio V, 2006, AM J HUM GENET, V78, P947, DOI 10.1086/504271; Rommelaere Heidi, 2004, Biol Proced Online, V6, P235, DOI 10.1251/bpo94; Rould MA, 2006, J BIOL CHEM, V281, P31909, DOI 10.1074/jbc.M601973200; Rutkevich LA, 2006, CAN J PHYSIOL PHARM, V84, P111, DOI 10.1139/Y05-140; Sanoudou D, 2001, TRENDS MOL MED, V7, P362, DOI 10.1016/S1471-4914(01)02089-5; Sanoudou D, 2006, HUM MOL GENET, V15, P2603, DOI 10.1093/hmg/ddl186; Schuler H, 2000, EUR J BIOCHEM, V267, P476, DOI 10.1046/j.1432-1327.2000.01023.x; SHY GM, 1963, BRAIN, V86, P793, DOI 10.1093/brain/86.4.793; Sparrow JC, 2003, NEUROMUSCULAR DISORD, V13, P519, DOI 10.1016/S0960-8966(03)00101-9; SPARROW JC, 1992, SYM SOC EXP BIOL, V46, P111; STRZELECKAGOLASZEWSKA H, 1995, BIOCHEM J, V307, P527, DOI 10.1042/bj3070527; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; Trybus KM, 2000, METHODS, V22, P327, DOI 10.1006/meth.2000.1085; Wang Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709; Wen KK, 2003, J BIOL CHEM, V278, P48386, DOI 10.1074/jbc.M308980200; WERTMAN KF, 1992, GENETICS, V132, P337; YAMAGUCHI M, 1982, J NEUROL SCI, V56, P35, DOI 10.1016/0022-510X(82)90059-4	61	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19379	19388		10.1074/jbc.M801963200	http://dx.doi.org/10.1074/jbc.M801963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18477565	Green Published, hybrid			2022-12-25	WOS:000257387600024
J	Mor-Cohen, R; Rosenberg, N; Landau, M; Lahav, J; Seligsohn, U				Mor-Cohen, Ronit; Rosenberg, Nurit; Landau, Meytal; Lahav, Judith; Seligsohn, Uri			Specific cysteines in beta 3 are involved in disulfide bond exchange-dependent and -independent activation of alpha IIb beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; GPIIB-IIIA; GLYCOPROTEIN-IIB; DOMAIN BINDS; EGF-LIKE; REVEALS; THROMBASTHENIA; DISRUPTION; INTEGRINS; ISOMERASE	Disulfide bond exchange among cysteine residues in epidermal growth factor (EGF)-like domains of beta 3 was suggested to be involved in activation of alpha IIb beta 3. To investigate the role of specific beta 3 cysteines in alpha IIb beta 3 expression and activation, we expressed in baby hamster kidney cells normal alpha IIb with normal beta 3 or beta 3 with single or double cysteine substitutions of nine disulfide bonds in EGF-3, EGF-4, and beta-tail domains and assessed alpha IIb beta 3 surface expression and activation state by flow cytometry using P2 or PAC-1 antibodies, respectively. Most mutants displayed reduced surface expression of alpha IIb beta 3. Disruptions of disulfide bonds in EGF-3 yielded constitutively active alpha IIb beta 3, implying that these bonds stabilize the inactive alpha IIb beta 3 conformer. Mutants of the Cys-567-Cys-581 bond in EGF-4 were inactive even after exposure to alpha IIb beta 3-activating antibodies, indicating that this bond is necessary for activating alpha IIb beta 3. Disrupting Cys-560-Cys-583 in the EGF-3/EGF-4 or Cys-608-Cys-655 in beta-tail domain resulted in alpha IIb beta 3 activation only when Cys-560 or Cys-655 of each pair was mutated but not when their partners (Cys-583, Cys-608) or both cysteines were mutated, suggesting that free sulfhydryls of Cys-583 and Cys-608 participate in alpha IIb beta 3 activation by a disulfide bond exchange-dependent mechanism. The free sulfhydryl blocker dithiobisnitrobenzoic acid inhibited 70% of anti-LIBS6 antibody-induced activation of wild-type alpha IIb beta 3 and had a smaller effect on mutants, implicating disulfide bond exchange-dependent and -independent mechanisms in alpha IIb beta 3 activation. These data suggest that different disulfide bonds in beta 3 EGF and beta-tail domains play variable structural and regulatory roles in alpha IIb beta 3.	[Seligsohn, Uri] Chaim Sheba Med Ctr, Amalia Biron Res Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Landau, Meytal] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; [Lahav, Judith] Beilinson Med Ctr, Hemostasis Lab, IL-49100 Petah Tiqwa, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Rabin Medical Center	Seligsohn, U (corresponding author), Chaim Sheba Med Ctr, Amalia Biron Res Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel.	seligson@sheba.health.gov.il	Mor-Cohen, Ronit/AAB-8657-2020; Landau, Meytal/AAF-3479-2021; Landau, Meytal/J-3075-2012	Landau, Meytal/0000-0002-1743-3430; Landau, Meytal/0000-0002-1743-3430				Ambo H, 1998, BIOCHEM BIOPH RES CO, V251, P763, DOI 10.1006/bbrc.1998.9526; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Baldock C, 2006, P NATL ACAD SCI USA, V103, P11922, DOI 10.1073/pnas.0601609103; Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Calvete JJ, 1999, P SOC EXP BIOL MED, V222, P29, DOI 10.1111/j.1525-1373.1999.09993.x; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; Chen VM, 2006, J THROMB HAEMOST, V4, P2533, DOI 10.1111/j.1538-7836.2006.02236.x; DU XP, 1993, J BIOL CHEM, V268, P23087; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2004, BIOCHEM J, V378, P1079, DOI 10.1042/BJ20031701; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Mor-Cohen R, 2007, THROMB HAEMOSTASIS, V98, P1257, DOI 10.1160/TH07-04-0248; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Robinson A, 2006, BRIT J HAEMATOL, V132, P339, DOI 10.1111/j.1365-2141.2005.05878.x; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Yatuv R, 2001, BLOOD, V98, P1063, DOI 10.1182/blood.V98.4.1063	43	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19235	19244		10.1074/jbc.M802399200	http://dx.doi.org/10.1074/jbc.M802399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18458089	hybrid			2022-12-25	WOS:000257387600009
J	Faisal, A; Saurin, A; Gregory, B; Foxwell, B; Parker, PJ				Faisal, Amir; Saurin, Adrian; Gregory, Bernard; Foxwell, Brian; Parker, Peter J.			The scaffold MyD88 acts to couple protein kinase C epsilon to toll-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNALING PATHWAY; PKC-EPSILON; MACROPHAGE ACTIVATION; REGULATORY FACTOR-3; LIPOPOLYSACCHARIDE; ALPHA; CELLS; ZETA; PHOSPHORYLATION	Mice lacking protein kinase C epsilon(PKC epsilon) are hypersensitive to both Gram-positive and Gram-negative bacterial infections; however, the mechanism of PKC epsilon coupling to the Toll-like receptors (TLRs), responsible for pathogen detection, is poorly understood. Here we sought to investigate the mechanism of PKC epsilon involvement in TLR signaling and found that PKC epsilon is recruited to TLR4 and phosphorylated on two recently identified sites in response to lipopolysaccharide (LPS) stimulation. Phosphorylation at both of these sites (Ser-346 and Ser-368) resulted in PKC epsilon binding to 14-3-3 beta. LPS-induced PKC epsilon phosphorylation, 14-3-3 beta binding, and recruitment to TLR4 were all dependent on expression of the scaffold protein MyD88. In mouse embryo fibroblasts and activated macrophages from MyD88 knock-out mice, LPS-stimulated PKC epsilon phosphorylation was reduced compared with wild type cells. Acute knockdown of MyD88 in LPS-responsive 293 cells also resulted in complete loss of Ser-346 phosphorylation and TLR4/PKC epsilon association. By contrast, MyD88 overexpression in 293 cells resulted in constitutive phosphorylation of PKC epsilon. A general role for MyD88 was evidenced by the finding that phosphorylation of PKC epsilon was induced by the activation of all TLRs tested that signal through MyD88 (i.e. all except TLR3) both in RAW cells and in primary human macrophages. Functionally, it is established that phosphorylation of PKC epsilon at these two sites is required for TLR4- and TLR2-induced NF kappa B reporter activation and I kappa B degradation in reconstituted PKC epsilon(-/-) cells. This study therefore identifies the scaffold protein MyD88 as the link coupling TLRs to PKC epsilon recruitment, phosphorylation, and downstream signaling.	[Faisal, Amir; Saurin, Adrian; Parker, Peter J.] London Res Inst, Prot Phosphorylat Lab, London WC2A 3PX, England; [Gregory, Bernard; Foxwell, Brian] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London SW7 2AZ, England; [Parker, Peter J.] Kings Coll London, Guys Hosp, Div Canc Studies, London SE1 1UL, England	Imperial College London; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Parker, PJ (corresponding author), 44 Lincolns Inn Fields, London WC2A 3PX, England.	peter.parker@cancer.org.uk	Parker, Peter j/D-5192-2013; Faisal, Amir/AAE-8992-2020	Faisal, Amir/0000-0002-7376-8286; Saurin, Adrian/0000-0001-9317-2255; parker, peter/0000-0002-6218-2933				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chano F, 2002, EUR J IMMUNOL, V32, P2897, DOI 10.1002/1521-4141(2002010)32:10<2897::AID-IMMU2897>3.0.CO;2-J; Cuschieri J, 2004, J SURG RES, V121, P76, DOI 10.1016/j.jss.2004.04.005; Dallot E, 2005, BIOCHIMIE, V87, P513, DOI 10.1016/j.biochi.2005.02.009; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Durgan J, 2008, BIOCHEM J, V411, P319, DOI [10.1042/BJ20071348, 10.1042/bj20071348]; Durgan J, 2007, FEBS LETT, V581, P3377, DOI 10.1016/j.febslet.2007.06.035; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Giroux M, 2000, J IMMUNOL, V165, P3985, DOI 10.4049/jimmunol.165.7.3985; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Johnson J, 2007, J BIOL CHEM, V282, P15022, DOI 10.1074/jbc.M700421200; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kubo-Murai M, 2007, MOL IMMUNOL, V44, P2257, DOI 10.1016/j.molimm.2006.11.005; Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; McGettrick AF, 2006, P NATL ACAD SCI USA, V103, P9196, DOI 10.1073/pnas.0600462103; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Monick MM, 1999, J IMMUNOL, V162, P3005; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Sheedy FJ, 2007, J LEUKOCYTE BIOL, V82, P196, DOI 10.1189/jlb.1206750; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Tschaikowsky K, 1998, J PHARMACOL EXP THER, V285, P800; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Xu SJ, 2005, ACTA PHARMACOL SIN, V26, P1497, DOI 10.1111/j.1745-7254.2005.00217.x; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986	43	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18591	18600		10.1074/jbc.M710330200	http://dx.doi.org/10.1074/jbc.M710330200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458086	hybrid			2022-12-25	WOS:000257165600015
J	Hawrani, A; Howe, RA; Walsh, TR; Dempsey, CE				Hawrani, Ayman; Howe, Robin A.; Walsh, Timothy R.; Dempsey, Christopher E.			Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANES; RESISTANCE; MELITTIN; MECHANISMS; ENERGETICS; EVOLUTION; PROTEINS; MAGAININ; ANALOG; SCALE	We recently described a novel antimicrobial peptide, RTA3, derived from the commensal organism Streptococcus mitis, with strong anti-Gram-negative activity, low salt sensitivity, and minimal mammalian cell toxicity in vitro and in vivo. This peptide conforms to the positively charged, amphipathic helical peptide motif, but has a positively charged amino acid (Arg-5) on the nonpolar face of the helical structure that is induced upon membrane binding. We surmised that disruption of the hydrophobic face with a positively charged residue plays a role in minimizing eukaryotic cell toxicity, and we tested this using a mutant with an R5L substitution. The greatly enhanced toxicity in the mutant peptide correlated with its ability to bind and adopt helical conformations upon interacting with neutral membranes; the wild type peptide RTA3 did not bind to neutral membranes (binding constant reduced by at least 1000-fold). Spectroscopic analysis indicates that disruption of the hydrophobic face of the parent peptide is accommodated in negatively charged membranes without partial peptide unfolding. These observations apply generally to amphipathic helical peptides of this class as we obtained similar results with a peptide and mutant pair (Chen, Y., Mant, C. T., Farmer, S. W., Hancock, R. E., Vasil, M. L., and Hodges, R. S. (2005) J. Biol. Chem. 280, 12316-12329) having similar structural properties. In contrast to previous interpretations, we demonstrate that these peptides simply do not bind well to membranes (like those of eukaryotes) with exclusively neutral lipids in their external bilayer leaflet. We highlight a significant role for tryptophan in promoting binding of amphipathic helical peptides to neutral bilayers, augmenting the arsenal of strategies to reduce mammalian toxicity in antimicrobial peptides.	[Dempsey, Christopher E.] Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; [Hawrani, Ayman] Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Howe, Robin A.] Univ Wales Hosp, Natl Publ Hlth Serv Cardiff, Cardiff CF14 4XW, S Glam, Wales; [Walsh, Timothy R.] Cardiff Univ, Dept Med Microbiol, Cardiff CF14 4XN, S Glam, Wales	University of Bristol; University of Bristol; Cardiff University; Cardiff University	Dempsey, CE (corresponding author), Univ Walk, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	c.dempsey@bris.ac.uk	Walsh, Timothy R/F-6519-2010	Walsh, Timothy/0000-0003-4315-4096; Dempsey, Christopher/0000-0002-1933-7805	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abbott A, 2005, NATURE, V436, P758, DOI 10.1038/436758a; Bergen PJ, 2006, ANTIMICROB AGENTS CH, V50, P1953, DOI 10.1128/AAC.00035-06; Bray BL, 2003, NAT REV DRUG DISCOV, V2, P587, DOI 10.1038/nrd1133; Chen YX, 2006, CHEM BIOL DRUG DES, V67, P162, DOI 10.1111/j.1747-0285.2006.00349.x; Chen YX, 2005, J BIOL CHEM, V280, P12316, DOI 10.1074/jbc.M413406200; *CLIN LAB STAND I, 2003, M7A6 CLINLAB STAND I; Dempsey CE, 2005, BIOCHEMISTRY-US, V44, P775, DOI 10.1021/bi048389g; DEMPSEY CE, 1992, BIOCHEMISTRY-US, V31, P11973, DOI 10.1021/bi00163a003; Dempsey CE, 2003, BIOCHEMISTRY-US, V42, P402, DOI 10.1021/bi026328h; Dorairaj S, 2007, P NATL ACAD SCI USA, V104, P4943, DOI 10.1073/pnas.0610470104; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Ge YG, 1999, ANTIMICROB AGENTS CH, V43, P782, DOI 10.1128/AAC.43.4.782; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; Halsall A, 1999, J MOL BIOL, V293, P901, DOI 10.1006/jmbi.1999.3194; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hornef MW, 2004, NAT IMMUNOL, V5, P836, DOI 10.1038/ni1094; Hristova K, 2001, BIOPHYS J, V80, P801, DOI 10.1016/S0006-3495(01)76059-6; HURTER P, 1970, PEDIATRICS, V46, P259; Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Ladokhin AS, 1999, J MOL BIOL, V285, P1363, DOI 10.1006/jmbi.1998.2346; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; Pereira HA, 2006, CURR PHARM BIOTECHNO, V7, P229; Perron GG, 2006, P ROY SOC B-BIOL SCI, V273, P251, DOI 10.1098/rspb.2005.3301; SHAI Y, 1999, BIOCHIM BIOPHYS ACTA, V1462, P65; Tenover FC, 2006, AM J INFECT CONTROL, V34, pS3, DOI 10.1016/j.ajic.2006.05.219; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; White SH, 1998, METHOD ENZYMOL, V295, P62; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2004, EXPERT OPIN INV DRUG, V13, P97	36	69	75	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18636	18645		10.1074/jbc.M709154200	http://dx.doi.org/10.1074/jbc.M709154200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18434320	hybrid			2022-12-25	WOS:000257165600020
J	Iijima-Ando, K; Hearn, SA; Granger, L; Shenton, C; Gatt, A; Chiang, HC; Hakker, I; Zhong, Y; Iijima, K				Iijima-Ando, Kanae; Hearn, Stephen A.; Granger, Linda; Shenton, Christopher; Gatt, Anthony; Chiang, Hsueh-Cheng; Hakker, Inessa; Zhong, Yi; Iijima, Koichi			Overexpression of neprilysin reduces Alzheimer amyloid-beta 42 (A beta 42)-induced neuron loss and intraneuronal A beta 42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; A-BETA; PLAQUE-FORMATION; TRANSGENIC MICE; DEGRADING ENDOPEPTIDASE; PRECURSOR PROTEIN; DISEASE; BRAIN; ACCUMULATION; NEURODEGENERATION	The amyloid-beta 42 (A beta 42) peptide has been suggested to play a causative role in Alzheimer disease (AD). Neprilysin (NEP) is one of the rate-limiting A beta-degrading enzymes, and its enhancement ameliorates extracellular amyloid pathology, synaptic dysfunction, and memory defects in mouse models of A beta amyloidosis. In addition to the extracellular A beta, intraneuronal A beta 42 may contribute to AD pathogenesis. However, the protective effects of neuronal NEP expression on intraneuronal A beta 42 accumulation and neurodegeneration remain elusive. In contrast, sustained NEP activation may be detrimental because NEP can degrade many physiological peptides, but its consequences in the brain are not fully understood. Using transgenic Drosophila expressing human NEP and A beta 42, we demonstrated that NEP efficiently suppressed the formation of intraneuronal A beta 42 deposits and A beta 42-induced neuron loss. However, neuronal NEP overexpression reduced cAMP-responsive element-binding protein-mediated transcription, caused age-dependent axon degeneration, and shortened the life span of the flies. Interestingly, the mRNA levels of endogenous fly NEP genes and phosphoramidon-sensitive NEP activity declined during aging in fly brains, as observed in mammals. Taken together, these data suggest both the protective and detrimental effects of chronically high NEP activity in the brain. Down-regulation of NEP activity in aging brains may be an evolutionarily conserved phenomenon, which could predispose humans to developing late-onset AD.	[Iijima-Ando, Kanae; Granger, Linda; Shenton, Christopher] Thomas Jefferson Univ, Lab Neurogenet & Pathobiol, Farber Inst Neurosciences, Philadelphia, PA 19107 USA; [Granger, Linda; Gatt, Anthony; Iijima, Koichi] Thomas Jefferson Univ, Lab Neurodegenerat Dis & Gene Discovery, Farber Inst Neurosciences, Philadelphia, PA 19107 USA; [Iijima-Ando, Kanae; Iijima, Koichi] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; [Hearn, Stephen A.; Chiang, Hsueh-Cheng; Hakker, Inessa; Zhong, Yi] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Chiang, Hsueh-Cheng] SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	Jefferson University; Jefferson University; Jefferson University; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Iijima-Ando, K (corresponding author), 900 Walnut St JHN410, Philadelphia, PA 19107 USA.	Kanae.Iijima-Ando@jefferson.edu; Koichi.Iijima@jefferson.edu		Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976; Hearn, Stephen/0000-0002-2489-2424				BARNES K, 1992, J NEUROCHEM, V58, P2088, DOI 10.1111/j.1471-4159.1992.tb10950.x; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; CARREL S, 1982, ACTA NEUROPATHOL, V57, P158, DOI 10.1007/BF00685384; Carter TL, 2006, NEUROSCI LETT, V392, P235, DOI 10.1016/j.neulet.2005.09.022; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Cataldo AM, 2004, NEUROBIOL AGING, V25, P1263, DOI 10.1016/j.neurobiolaging.2004.02.027; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Clifford PM, 2007, BRAIN RES, V1142, P223, DOI 10.1016/j.brainres.2007.01.070; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cruz JC, 2006, J NEUROSCI, V26, P10536, DOI 10.1523/JNEUROSCI.3133-06.2006; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2005, BIOCHEM SOC T, V33, P1101, DOI 10.1042/BST0331101; Farris W, 2007, AM J PATHOL, V171, P241, DOI 10.2353/ajpath.2007.070105; Finelli A, 2004, MOL CELL NEUROSCI, V26, P365, DOI 10.1016/j.mcn.2004.03.001; Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hama E, 2004, J BIOL CHEM, V279, P30259, DOI 10.1074/jbc.M401891200; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; HELLSTROMLINDAH.E, 2006, NEUROBIOL AGING; Hemming ML, 2007, PLOS MED, V4, P1405, DOI 10.1371/journal.pmed.0040262; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Iijima K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001703; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Knobloch M, 2007, NEUROBIOL AGING, V28, P1297, DOI 10.1016/j.neurobiolaging.2006.06.019; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LI CW, 1995, METHOD ENZYMOL, V248, P253; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Marr RA, 2003, J NEUROSCI, V23, P1992; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Poirier R, 2006, NEUROBIOL DIS, V24, P475, DOI 10.1016/j.nbd.2006.08.003; Rodrigo J, 2004, NEUROSCIENCE, V128, P73, DOI 10.1016/j.neuroscience.2004.06.030; Roman G, 2001, BIOESSAYS, V23, P571, DOI 10.1002/bies.1083; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Russo R, 2005, FEBS LETT, V579, P6027, DOI 10.1016/j.febslet.2005.09.054; SAITO T, 2003, SCI AGING KNOWLEDGE, pPE1; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Sudoh S, 2002, BIOCHEMISTRY-US, V41, P1091, DOI 10.1021/bi011193l; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Thomas JE, 2005, BIOCHEM J, V386, P357, DOI 10.1042/BJ20041753; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6; Turner AJ, 2007, INT REV NEUROBIOL, V82, P113, DOI 10.1016/S0074-7742(07)82006-X; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	72	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19066	19076		10.1074/jbc.M710509200	http://dx.doi.org/10.1074/jbc.M710509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18463098	Green Published, hybrid			2022-12-25	WOS:000257165600062
J	Kumar, KGS; Varghese, B; Banerjee, A; Baker, DP; Constantinescu, SN; Pellegrini, S; Fuchs, SY				Kumar, K. G. Suresh; Varghese, Bentley; Banerjee, Anamika; Baker, Darren P.; Constantinescu, Stefan N.; Pellegrini, Sandra; Fuchs, Serge Y.			Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; MONOCLONAL-ANTIBODIES; TYK2; SIGNALS; BINDING; REGION; PHOSPHORYLATION; JANUS-KINASE-2; LOCALIZATION; DEGRADATION	Linear endocytic motifs of signaling receptors as well as their ubiquitination determine the rate of ligand-induced endocytosis that mediates down-regulation of these receptors and restricts the magnitude and duration of their respective signal transduction pathways. We previously hypothesized that, in the absence of its cognate ligand, type I interferon (IFN), the IFN alpha receptor chain 1 (IFNAR1) receptor chain is protected from basal endocytosis by a hypothetical masking complex that prevents the Tyr-based endocytic motif within IFNAR1 from interacting with components of the adaptin protein complex 2 (AP2). Here we identify a member of the Janus kinase (Jak) family, Tyk2, as a component of such a masking complex. In the absence of ligand or of receptor chain ubiquitination, binding of Janus kinase Tyk2 within the proximity of the Tyr-based linear motif of IFNAR1 is required to prevent IFNAR1 internalization and to maintain its cell surface expression. Furthermore, interaction experiments revealed that Tyk2 physically shields this Tyr-based motif from the recognition by the AP50 subunit of AP2. These data delineate a long-sought ligand- and ubiquitin-independent mechanism by which Tyk2 contributes to both the regulation of total IFNAR1 levels as well as the regulation of the cell surface density of this receptor chain.	[Kumar, K. G. Suresh; Varghese, Bentley; Banerjee, Anamika; Fuchs, Serge Y.] Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; [Kumar, K. G. Suresh; Varghese, Bentley; Banerjee, Anamika; Fuchs, Serge Y.] Univ Penn, Mari Lowe Ctr Comparat Oncol Res, Philadelphia, PA 19104 USA; [Baker, Darren P.] Biogen Idec Inc, Cambridge, MA 02142 USA; [Constantinescu, Stefan N.] Ludwig Inst Canc Res, B-1200 Brussels, Belgium; [Constantinescu, Stefan N.] Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; [Pellegrini, Sandra] Inst Pasteur, CNRS, URA 1961, Unite Signalisat Cytokines, F-75724 Paris, France	University of Pennsylvania; University of Pennsylvania; Biogen; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 380 S Univ Ave,Hill 316, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; Constantinescu, Stefan N/E-5277-2012	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; 	NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI073347] Funding Source: NIH RePORTER; NCI NIH HHS [CA92900, R01 CA092900-08, R01 CA092900] Funding Source: Medline; NIAID NIH HHS [R21 AI073347, R21 AI073347-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Deng L, 2007, MOL ENDOCRINOL, V21, P1537, DOI 10.1210/me.2007-0138; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Haan C, 2006, BIOCHEM PHARMACOL, V72, P1538, DOI 10.1016/j.bcp.2006.04.013; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; He K, 2005, ENDOCRINOLOGY, V146, P4755, DOI 10.1210/en.2005-0514; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Holler D, 2004, BIOCHEM PHARMACOL, V67, P1013, DOI 10.1016/j.bcp.2004.01.003; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Jabbour H N, 1997, Rev Reprod, V2, P14; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jung N, 2007, TRAFFIC, V8, P1129, DOI 10.1111/j.1600-0854.2007.00595.x; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kumar KGS, 2007, J CELL BIOL, V179, P935, DOI 10.1083/jcb.200706034; Kumar KGS, 2003, EMBO J, V22, P5480; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Marijanovic Z, 2006, BIOCHEM J, V397, P31, DOI 10.1042/BJ20060272; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Radtke S, 2006, J BIOL CHEM, V281, P4024, DOI 10.1074/jbc.M511779200; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2001, J BIOL CHEM, V276, P30812, DOI 10.1074/jbc.M103559200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Royer Y, 2005, J BIOL CHEM, V280, P27251, DOI 10.1074/jbc.M501376200; Sheehan KCF, 2006, J INTERF CYTOK RES, V26, P804, DOI 10.1089/jir.2006.26.804; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yan H, 1996, MOL CELL BIOL, V16, P2074	41	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18566	18572		10.1074/jbc.M800991200	http://dx.doi.org/10.1074/jbc.M800991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474601	hybrid, Green Published			2022-12-25	WOS:000257165600012
J	Shibata, Y; Voss, C; Rist, JM; Hu, J; Rapoport, TA; Prinz, WA; Voeltz, GK				Shibata, Yoko; Voss, Christiane; Rist, Julia M.; Hu, Junjie; Rapoport, Tom A.; Prinz, William A.; Voeltz, Gia K.			The reticulon and DP1/Yop1p proteins form immobile oligomers in the tubular endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; ORGANIZATION; DYNAMICS; CELLS; MICROTUBULES; INHERITANCE; CURVATURE; SHEETS; NOGO; ER	We recently identified a class of membrane proteins, the reticulons and DP1/Yop1p, which shape the tubular endoplasmic reticulum ( ER) in yeast and mammalian cells. These proteins are highly enriched in the tubular portions of the ER and virtually excluded from other regions. To understand how they promote tubule formation, we characterized their behavior in cellular membranes and addressed how their localization in the ER is determined. Using fluorescence recovery after photobleaching, we found that yeast Rtn1p and Yop1p are less mobile in the membrane than normal ER proteins. Sucrose gradient centrifugation and cross-linking analyses show that they form oligomers. Mutants of yeast Rtn1p, which no longer localize exclusively to the tubular ER or are even totally inactive in inducing ER tubules, are more mobile and oligomerize less extensively. The mammalian reticulons and DP1 are also relatively immobile and can form oligomers. The conserved reticulon homology domain that includes the two membrane-embedded segments is sufficient for the localization of the reticulons to the tubular ER, as well as for their diffusional immobility and oligomerization. Finally, ATP depletion in both yeast and mammalian cells further decreases the mobilities of the reticulons and DP1. We propose that oligomerization of the reticulons and DP1/Yop1p is important for both their localization to the tubular domains of the ER and for their ability to form tubules.	[Voss, Christiane; Prinz, William A.] NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; [Shibata, Yoko; Rist, Julia M.; Hu, Junjie; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; [Shibata, Yoko; Rist, Julia M.; Hu, Junjie; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Voeltz, Gia K.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Colorado System; University of Colorado Boulder	Prinz, WA (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.	wprinz@helix.nih.gov; gia.voeltz@colorado.edu	Hu, Junjie/F-9713-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060105, ZIADK060105] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Audhya A, 2007, J CELL BIOL, V178, P1309, DOI 10.1083/jcb.20070113920070911c; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Daumke O, 2007, NATURE, V449, P923, DOI 10.1038/nature06173; De Craene JO, 2006, MOL BIOL CELL, V17, P3009, DOI 10.1091/mbc.e06-01-0080; de Martin PE, 2005, BIOCHEM CELL BIOL, V83, P752, DOI 10.1139/O05-159; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fehrenbacher KL, 2002, MOL BIOL CELL, V13, P854, DOI 10.1091/mbc.01-04-0184; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; He WX, 2007, J BIOL CHEM, V282, P29144, DOI 10.1074/jbc.M704181200; Hinshaw JE, 1999, CURR OPIN STRUC BIOL, V9, P260, DOI 10.1016/S0959-440X(99)80036-0; Hu JJ, 2008, SCIENCE, V319, P1247, DOI 10.1126/science.1153634; Hu XY, 2007, EMBO J, V26, P2755, DOI 10.1038/sj.emboj.7601707; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Kiseleva E, 2007, J STRUCT BIOL, V160, P224, DOI 10.1016/j.jsb.2007.08.005; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Shibata Y, 2006, CELL, V126, P435, DOI 10.1016/j.cell.2006.07.019; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Tolley N, 2008, TRAFFIC, V9, P94, DOI 10.1111/j.1600-0854.2007.00670.x; Voeltz GK, 2007, NAT REV MOL CELL BIO, V8, P258, DOI 10.1038/nrm2119; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Wakefield S, 2006, CELL MOL LIFE SCI, V63, P2027, DOI 10.1007/s00018-006-6142-3; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5	33	242	250	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18892	18904		10.1074/jbc.M800986200	http://dx.doi.org/10.1074/jbc.M800986200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18442980	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000257165600046
J	Suh, JY; Cai, ML; Clore, GM				Suh, Jeong-Yong; Cai, Mengli; Clore, G. Marius			Impact of phosphorylation on structure and thermodynamics of the interaction between the N-terminal domain of enzyme I and the histidine phosphocarrier protein of the bacterial phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; GLOBAL REPRESSOR MLC; ESCHERICHIA-COLI; SUGAR-TRANSPORT; CARBOHYDRATE TRANSPORTERS; SALMONELLA-TYPHIMURIUM; MANNITOL TRANSPORTER; RESOLUTION STRUCTURE; GLUCOSE-TRANSPORTER; TRANSFER COMPLEX	The structural and thermodynamic impact of phosphorylation on the interaction of the N-terminal domain of enzyme I (EIN) and the histidine phosphocarrier protein (HPr), the two common components of all branches of the bacterial phosphotransferase system, have been examined using NMR spectroscopy and isothermal titration calorimetry. His-189 is located at the interface of the alpha and alpha beta domains of EIN, resulting in rather widespread chemical shift perturbation upon phosphorylation, in contrast to the highly localized perturbations seen for HPr, where His-15 is fully exposed to solvent. Residual dipolar coupling measurements, however, demonstrate unambiguously that no significant changes in backbone conformation of either protein occur upon phosphorylation: for EIN, the relative orientation of the alpha and alpha beta domains remains unchanged; for HPr, the backbone phi/psi torsion angles of the active site residues are unperturbed within experimental error. His 3 Glu/Asp mutations of the active site histidines designed to mimic the phosphorylated states reveal binding equilibria that favor phosphoryl transfer from EIN to HPr. Although binding of phospho-EIN to phospho-HPr is reduced by a factor of similar to 21 relative to the unphosphorylated complex, residual dipolar coupling measurements reveal that the structures of the unphosphorylated and biphosphorylated complexes are the same. Hence, the phosphorylation states of EIN and HPr shift the binding equilibria predominantly by modulating intermolecular electrostatic interactions without altering either the backbone scaffold or binding interface. This facilitates highly efficient phosphoryl transfer between EIN and HPr, which is estimated to occur at a rate of similar to 850 s(-1) from exchange spectroscopy.	[Suh, Jeong-Yong; Cai, Mengli; Clore, G. Marius] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.	mariusc@mail.nih.gov	Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deutscher J, 2006, MICROBIOL MOL BIOL R, V70, P939, DOI 10.1128/MMBR.00024-06; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2996, DOI 10.1021/bi00581a014; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; Garrett DS, 1998, PROTEIN SCI, V7, P789, DOI 10.1002/pro.5560070329; GASSNER M, 1977, EUR J BIOCHEM, V75, P287, DOI 10.1111/j.1432-1033.1977.tb11528.x; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones BE, 1997, PROTEIN SCI, V6, P2107; LEE BR, 1994, ARCH BIOCHEM BIOPHYS, V312, P121, DOI 10.1006/abbi.1994.1289; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LUX R, 1995, P NATL ACAD SCI USA, V92, P11583, DOI 10.1073/pnas.92.25.11583; Lux R, 1999, MOL BIOL CELL, V10, P1133, DOI 10.1091/mbc.10.4.1133; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meadow ND, 2005, BIOCHEMISTRY-US, V44, P12790, DOI 10.1021/bi0502846; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Prestegard JH, 2004, CHEM REV, V104, P3519, DOI 10.1021/cr030419i; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Suh JY, 2007, J AM CHEM SOC, V129, P12954, DOI 10.1021/ja0760978; Suh JY, 2007, P NATL ACAD SCI USA, V104, P3153, DOI 10.1073/pnas.0609103104; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Teplyakov A, 2006, P NATL ACAD SCI USA, V103, P16218, DOI 10.1073/pnas.0607587103; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WIEGEL N, 1982, J BIOL CHEM, V257, P14499; Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200; Williams DC, 2005, J BIOL CHEM, V280, P20775, DOI 10.1074/jbc.M501986200; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200	44	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18980	18989		10.1074/jbc.M802211200	http://dx.doi.org/10.1074/jbc.M802211200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18445588	Green Published, hybrid			2022-12-25	WOS:000257165600054
J	Pinheiro, BA; Proctor, MR; Martinez-Fleites, C; Prates, JAM; Money, VA; Davies, GJ; Bayer, EA; Fontes, CMGA; Fierobe, HP; Gilbert, HJ				Pinheiro, Benedita A.; Proctor, Mark R.; Martinez-Fleites, Carlos; Prates, Jose A. M.; Money, Victoria A.; Davies, Gideon J.; Bayer, Edward A.; Fontes, Carlos M. G. A.; Fierobe, Henri-Pierre; Gilbert, Harry J.			The Clostridium cellulolyticum dockerin displays a dual binding mode for its cohesin partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCELLUM ENDOGLUCANASE CELD; SCAFFOLDING PROTEIN CIPA; CRYSTAL-STRUCTURE; CELLULOSOME; SPECIFICITY; DETERMINANTS; DEGRADATION; MOLSCRIPT; INCLUDES; INSIGHTS	The plant cell wall degrading apparatus of anaerobic bacteria includes a large multienzyme complex termed the "cellulosome." The complex assembles through the interaction of enzyme-derived dockerin modules with the multiple cohesin modules of the noncatalytic scaffolding protein. Here we report the crystal structure of the Clostridium cellulolyticum cohesin-dockerin complex in two distinct orientations. The data show that the dockerin displays structural symmetry reflected by the presence of two essentially identical cohesin binding surfaces. In one binding mode, visualized through the A16S/L17T dockerin mutant, the C-terminal helix makes extensive interactions with its cohesin partner. In the other binding mode observed through the A47S/F48T dockerin variant, the dockerin is reoriented by 180 and interacts with the cohesin primarily through the N-terminal helix. Apolar interactions dominate cohesin-dockerin recognition that is centered around a hydrophobic pocket on the surface of the cohesin, formed by Leu-87 and Leu-89, which is occupied, in the two binding modes, by the dockerin residues Phe-19 and Leu-50, respectively. Despite the structural similarity between the C. cellulolyticum and Clostridium thermocellum cohesins and dockerins, there is no cross-specificity between the protein partners from the two organisms. The crystal structure of the C. cellulolyticum complex shows that organism-specific recognition between the protomers is dictated by apolar interactions primarily between only two residues, Leu-17 in the dockerin and the cohesin amino acid Ala-129. The biological significance of the plasticity in dockerin-cohesin recognition, observed here in C. cellulolyticum and reported previously in C. thermocellum, is discussed.	[Pinheiro, Benedita A.; Prates, Jose A. M.; Fontes, Carlos M. G. A.] Univ Tecn Lisboa, Fac Med Vet, Ctr Interdisciplinar Invest Sanidade Anim, P-1300477 Lisbon, Portugal; [Proctor, Mark R.; Gilbert, Harry J.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Martinez-Fleites, Carlos; Money, Victoria A.; Davies, Gideon J.] Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; [Fierobe, Henri-Pierre] IBSM, CNRS, UPR9043, Chim Bacterienne Lab, F-13402 Marseille, France; [Bayer, Edward A.] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Universidade de Lisboa; Newcastle University - UK; University of York - UK; Centre National de la Recherche Scientifique (CNRS); Weizmann Institute of Science	Fontes, CMGA (corresponding author), Univ Tecn Lisboa, Fac Med Vet, Ctr Interdisciplinar Invest Sanidade Anim, Ave Univ Tecn, P-1300477 Lisbon, Portugal.	cafontes@fmv.utl.pt; h.j.gilbert@ncl.ac.uk	FIEROBE, Henri-Pierre/P-4372-2019; Davies, Gideon J/A-9042-2011; Martinez Fleites, Carlos/F-8526-2010; Prates, José A M/K-9934-2013; Money, Victoria/E-8851-2013; Pinheiro, Benedita A/D-2055-2013	Davies, Gideon J/0000-0002-7343-776X; Prates, José A M/0000-0003-1032-5987; Pinheiro, Benedita A/0000-0002-3045-077X; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BB/D522511/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; BAYER EA, 1985, J BACTERIOL, V163, P552, DOI 10.1128/JB.163.2.552-559.1985; Bhat MK, 2000, BIOTECHNOL ADV, V18, P355, DOI 10.1016/S0734-9750(00)00041-0; Boudet AM, 2003, TRENDS PLANT SCI, V8, P576, DOI 10.1016/j.tplants.2003.10.001; Carvalho AL, 2005, J MOL BIOL, V349, P909, DOI 10.1016/j.jmb.2005.04.037; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Ciruela A, 1998, FEBS LETT, V422, P221, DOI 10.1016/S0014-5793(97)01590-1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fierobe HP, 2005, J BIOL CHEM, V280, P16325, DOI 10.1074/jbc.M414449200; FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Gilbert HJ, 2007, MOL MICROBIOL, V63, P1568, DOI 10.1111/j.1365-2958.2007.05640.x; Hammel M, 2005, J BIOL CHEM, V280, P38562, DOI 10.1074/jbc.M503168200; Hammel M, 2004, J BIOL CHEM, V279, P55985, DOI 10.1074/jbc.M408979200; Handelsman T, 2004, FEBS LETT, V572, P195, DOI 10.1016/j.febslet.2004.07.040; HAZLEWOOD GP, 1992, J APPL BACTERIOL, V72, P244, DOI 10.1111/j.1365-2672.1992.tb01830.x; Kakiuchi M, 1998, J BACTERIOL, V180, P4303, DOI 10.1128/JB.180.16.4303-4308.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mechaly A, 2001, J BIOL CHEM, V276, P9883, DOI 10.1074/jbc.M009237200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; SALAMITOU S, 1994, J BACTERIOL, V176, P2822, DOI 10.1128/JB.176.10.2822-2827.1994; Schaeffer F, 2002, BIOCHEMISTRY-US, V41, P2106, DOI 10.1021/bi011853m; SHOSEYOV O, 1992, P NATL ACAD SCI USA, V89, P3483, DOI 10.1073/pnas.89.8.3483; Spinelli S, 2000, J MOL BIOL, V304, P189, DOI 10.1006/jmbi.2000.4191; Xu Q, 2003, J BACTERIOL, V185, P4548, DOI 10.1128/JB.185.15.4548-4557.2003; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	34	65	66	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18422	18430		10.1074/jbc.M801533200	http://dx.doi.org/10.1074/jbc.M801533200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18445585	hybrid			2022-12-25	WOS:000256949200070
J	Tourneur, L; Mistou, S; Schmitt, A; Chiocchia, G				Tourneur, Lea; Mistou, Sylvie; Schmitt, Alain; Chiocchia, Gilles			Adenosine receptors control a new pathway of Fas-associated death domain protein expression regulation by secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; LEUKEMIA-CELLS; FADD/MORT1; APOPTOSIS; FADD; RELEASE; ATP; PROLIFERATION; ACTIVATION; EXOSOMES	FADD is the key adaptor transmitting the apoptotic signal mediated by death receptors. We have previously shown that FADD protein expression could be lost in vivo in cancerous cells, in mice and humans, and be used as prognostic factor. Furthermore, loss of FADD could contribute to tumor progression and aggressiveness. However, the mechanism accounting for the loss of FADD was unknown. Using in vitro-cultured mouse organ models, we demonstrated that loss of FADD occurred through a new regulatory pathway of FADD expression by secretion. The secretion of FADD is an active release following shedding of microvesicles derived from the plasma membrane. In our experimental settings, this phenomenon was restricted to 6 of 12 FADD-expressing organs. This process is calcium-and adenosine dependent. Moreover, we identified the two receptors with low affinity to adenosine, namely A(2B) and A(3) adenosine receptors, as regulators of the FADD secretion process. Furthermore, we showed that modulating A(3) adenosine receptor can convert a nonsecreting organ into a FADD-secreting one. Finally, we reported that mouse FADD release occurred in vivo during tumor disease. These results demonstrate the existence of a new localization site ( in microvesicles) and regulatory mechanism ( by secretion) of the FADD protein, and the implication of adenosine receptors in this process. These data open a new field of investigation consisting of the possibility to regulate FADD expression via the modulation of adenosine receptors, which constitutes a therapeutic target in diseases in which FADD-mediated signaling is impaired.	[Tourneur, Lea; Mistou, Sylvie; Schmitt, Alain; Chiocchia, Gilles] Inst Cochin Genet Mol, Dept Immunol, INSERM, U567, F-75014 Paris, France; [Tourneur, Lea; Mistou, Sylvie; Schmitt, Alain; Chiocchia, Gilles] Univ Paris 05, CNRS, UMR 8104, F-75014 Paris, France; [Chiocchia, Gilles] Hop Ambroise Pare, Serv Rhumatol, F-92100 Boulogne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Chiocchia, G (corresponding author), Inst Cochin Genet Mol, Dept Immunol, INSERM, U567, Pavillon Hardy A 1Eretage,27 Rue Fbg St Jacques, F-75014 Paris, France.	gilles.chiocchia@inserm.fr	CHIOCCHIA, Gilles R/F-6287-2013	CHIOCCHIA, Gilles R/0000-0001-9973-0940				Aupeix K, 1997, J CLIN INVEST, V99, P1546, DOI 10.1172/JCI119317; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Kohno Y, 1996, BIOCHEM BIOPH RES CO, V219, P904, DOI 10.1006/bbrc.1996.0331; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Sheikh MS, 2003, CELL CYCLE, V2, P346, DOI 10.4161/cc.2.4.421; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tourneur L, 2004, CANCER RES, V64, P8101, DOI 10.1158/0008-5472.CAN-04-2361; Tourneur L, 2003, ONCOGENE, V22, P2795, DOI 10.1038/sj.onc.1206399; Tourneur Lea, 2005, Med Immunol, V4, P1, DOI 10.1186/1476-9433-4-1; Wilson HL, 2004, J IMMUNOL, V173, P1202, DOI 10.4049/jimmunol.173.2.1202; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	37	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17929	17938		10.1074/jbc.M802263200	http://dx.doi.org/10.1074/jbc.M802263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18445587	hybrid			2022-12-25	WOS:000256949200021
J	Bourguignon, LYW; Peyrollier, K; Xia, WL; Gilad, E				Bourguignon, Lilly Y. W.; Peyrollier, Karine; Xia, Weiliang; Gilad, Eli			Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN ERYTHROCYTE ANKYRIN; GROWTH-FACTOR RECEPTOR; HYALURONIC-ACID; CD44 INTERACTION; P-GLYCOPROTEIN; SIGNAL TRANSDUCER; ONCOGENE PRODUCT; HOMING RECEPTOR; DRUG-RESISTANCE; CDNA SEQUENCE	Hyaluronan (HA) is a major glycosaminoglycan in the extracellular matrix whose expression is tightly linked to multidrug resistance and tumor progression. In this study we investigated HA-induced interaction between CD44 (a HA receptor) and Nanog (an embryonic stem cell transcription factor) in both human breast tumor cells (MCF-7 cells) and human ovarian tumor cells (SK-OV-3.ipl cells). Using a specific primer pair to amplify Nanog by reverse transcriptase-PCR, we detected the expression of Nanog transcript in both tumor cell lines. In addition, our results reveal that HA binding to these tumor cells promotes Nanog protein association with CD44 followed by Nanog activation and the expression of pluripotent stem cell regulators (e. g. Rex1 and Sox2). Nanog also forms a complex with the "signal transducer and activator of transcription protein 3" (Stat-3) in the nucleus leading to Stat-3-specific transcriptional activation and multidrug transporter, MDR1 (P-glycoprotein) gene expression. Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e. g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Overexpression of Nanog by transfecting tumor cells with Nanog cDNA stimulates Stat-3 transcriptional activation, MDR1 overexpression, and multidrug resistance. Down regulation of Nanog signaling or ankyrin function (by transfecting tumor cells with Nanog small interfering RNA or ankyrin repeat domain cDNA) not only blocks HA/CD44-mediated tumor cell behaviors but also enhances chemosensitivity. Taken together, these findings suggest that targeting HA/CD44-mediated Nanog-Stat-3 signaling pathways and ankyrin/cytoskeleton function may represent a novel approach to overcome chemotherapy resistance in some breast and ovarian tumor cells displaying stem cell marker properties during tumor progression.	[Bourguignon, Lilly Y. W.] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lilly.bourguignon@ucsf.edu	XIA, WEILIANG/AEA-0835-2022; Xia, Weiliang/C-2650-2008	XIA, WEILIANG/0000-0002-0256-4219; Xia, Weiliang/0000-0002-0256-4219	NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078633, R01 CA078633-10, R01 CA066163, R01 CA066163-14, R01 CA66163, R01 CA78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR039448-190007, P01 AR39448, P01 AR039448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200; Auvinen P, 2005, HISTOPATHOLOGY, V47, P420, DOI 10.1111/j.1365-2559.2005.02220.x; Bacso Z, 2004, CYTOM PART A, V61A, P105, DOI 10.1002/cyto.a.20081; Baker EK, 2004, CANCER BIOL THER, V3, P819, DOI 10.4161/cbt.3.9.1101; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bourguignon LYW, 2007, J BIOL CHEM, V282, P19426, DOI 10.1074/jbc.M610054200; Bourguignon LYW, 2007, J BIOL CHEM, V282, P1265, DOI 10.1074/jbc.M604672200; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BOURGUIGNON LYW, 2005, HYALURONAN ITS STRUC, P305; Burger H, 2003, CLIN CANCER RES, V9, P827; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chumsri Saranya, 2007, Cancer Genomics & Proteomics, V4, P165; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DELPECH B, 1990, INT J CANCER, V46, P388, DOI 10.1002/ijc.2910460309; Do JT, 2006, E SCHERING RES FDN W, V60, P35; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HARNETT PR, 1986, J CLIN ONCOL, V4, P952, DOI 10.1200/JCO.1986.4.6.952; Haylock DN, 2006, REGEN MED, V1, P437, DOI 10.2217/17460751.1.4.437; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; HIGGINS CF, 1992, ANN REV CELL BIOL, V8, P305; Hoei-Hansen CE, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-12; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Huang EH, 2007, SURGERY, V141, P415, DOI 10.1016/j.surg.2006.12.015; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JONES LMH, 1995, CLIN EXP METASTAS, V13, P373; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kim DJ, 2007, MOL CARCINOGEN, V46, P725, DOI 10.1002/mc.20342; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; Kuh HJ, 2000, J PHARMACOL EXP THER, V293, P761; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Luciani F, 2002, BLOOD, V99, P641, DOI 10.1182/blood.V99.2.641; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Manara MC, 2004, INT J ONCOL, V24, P365; Mechetner E, 1998, CLIN CANCER RES, V4, P389; Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mollinedo F, 2005, IDRUGS, V8, P127; Muggia FM, 1997, DRUGS, V54, P22, DOI 10.2165/00003495-199700544-00006; Nishio K, 1999, ANTI-CANCER DRUG DES, V14, P133; Ohashi R, 2007, CANCER LETT, V252, P225, DOI 10.1016/j.canlet.2006.12.025; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122; Sales KM, 2007, STEM CELL REV, V3, P249, DOI 10.1007/s12015-007-9002-0; Sartor CI, 1997, CANCER RES, V57, P978; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Singh VK, 2007, CANCER RES, V67, P626, DOI 10.1158/0008-5472.CAN-06-1820; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Stern R, 2006, CHEM REV, V106, P818, DOI 10.1021/cr050247k; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; TSE WT, 1991, GENOMICS, V12, P702; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL C, 1992, J CELL SCI, V103, P293; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang SJ, 2006, ARCH OTOLARYNGOL, V132, P19, DOI 10.1001/archotol.132.1.19; Wang SJ, 2007, ARCH OTOLARYNGOL, V133, P281, DOI 10.1001/archotol.133.3.281; Wang SJ, 2006, ARCH OTOLARYNGOL, V132, P771, DOI 10.1001/archotol.132.7.771; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	103	349	372	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17635	17651		10.1074/jbc.M800109200	http://dx.doi.org/10.1074/jbc.M800109200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18441325	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000256720600070
J	Minko, IG; Harbut, MB; Kozekov, ID; Kozekova, A; Jakobs, PM; Olson, SB; Moses, RE; Harris, TM; Rizzo, CJ; Lloyd, RS				Minko, Irina G.; Harbut, Michael B.; Kozekov, Ivan D.; Kozekova, Albena; Jakobs, Petra M.; Olson, Susan B.; Moses, Robb E.; Harris, Thomas M.; Rizzo, Carmelo J.; Lloyd, R. Stephen			Role for DNA polymerase kappa in the processing of N-2-N-2-guanine interstrand cross-links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION-REPAIR; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; LESION-BYPASS; POL-KAPPA; MITOMYCIN-C; MISMATCH EXTENSION; Y-FAMILY; ADDUCT	Although there exists compelling genetic evidence for a homologous recombination-independent pathway for repair of interstrand cross-links (ICLs) involving translesion synthesis (TLS), biochemical support for this model is lacking. To identify DNA polymerases that may function in TLS past ICLs, oligodeoxynucleotides were synthesized containing site-specific ICLs in which the linkage was between N-2-guanines, similar to cross-links formed by mitomycin C and enals. Here, data are presented that mammalian cell replication of DNAs containing these lesions was similar to 97% accurate. Using a series of oligodeoxynucleotides that mimic potential intermediates in ICL repair, we demonstrate that human polymerase (pol) kappa not only catalyzed accurate incorporation opposite the cross-linked guanine but also replicated beyond the lesion, thus providing the first biochemical evidence for TLS past an ICL. The efficiency of TLS was greatly enhanced by truncation of both the 5' and 3' ends of the nontemplating strand. Further analyses showed that although yeast Rev1 could incorporate a dCTP opposite the cross-linked guanine, no evidence was found for TLS by pol zeta or a pol zeta/Rev1 combination. Because pol kappa was able to bypass these ICLs, biological evidence for a role for pol kappa in tolerating the N-2-N-2-guanine ICLs was sought; both cell survival and chromosomal stability were adversely affected in pol kappa-depleted cells following mitomycin C exposure. Thus, biochemical data and cellular studies both suggest a role for pol kappa in the processing of N-2-N-2-guanine ICLs.	[Minko, Irina G.; Harbut, Michael B.; Lloyd, R. Stephen] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA; [Jakobs, Petra M.; Olson, Susan B.; Moses, Robb E.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; [Kozekov, Ivan D.; Kozekova, Albena; Harris, Thomas M.; Rizzo, Carmelo J.] Vanderbilt Univ, Ctr Mol Toxicol, Dept Chem, Nashville, TN 37235 USA	Oregon Health & Science University; Oregon Health & Science University; Vanderbilt University	Lloyd, RS (corresponding author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	lloydst@ohsu.edu		Rizzo, Carmelo/0000-0001-9005-611X; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL CANCER INSTITUTE [P01CA160032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P01ES005355, P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA160032] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES 000267, ES 05355, P01 ES005355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acharya N, 2006, MOL CELL BIOL, V26, P9555, DOI 10.1128/MCB.01671-06; Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Broyde S, 2008, CHEM RES TOXICOL, V21, P45, DOI 10.1021/tx700193x; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Choi JY, 2006, J BIOL CHEM, V281, P21062, DOI 10.1074/jbc.M602246200; Creighton S, 1995, METHOD ENZYMOL, V262, P232; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dooley PA, 2001, J AM CHEM SOC, V123, P1730, DOI 10.1021/ja003163w; Dooley PA, 2003, J AM CHEM SOC, V125, P62, DOI 10.1021/ja0207798; Fisher LA, 2008, J BIOL CHEM, V283, P1275, DOI 10.1074/jbc.M708072200; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; Guzder SN, 2004, GENE DEV, V18, P2283, DOI 10.1101/gad.1232804; Hejna J, 2007, NUCLEIC ACIDS RES, V35, P6115, DOI 10.1093/nar/gkm530; HENRIQUES JAP, 1980, GENETICS, V95, P273; Jarosz DF, 2006, NATURE, V439, P225, DOI 10.1038/nature04318; Kanuri M, 2002, J BIOL CHEM, V277, P18257, DOI 10.1074/jbc.M112419200; Kozekov ID, 2003, J AM CHEM SOC, V125, P50, DOI 10.1021/ja020778f; Kumaresan KR, 1995, J BIOL CHEM, V270, P30709, DOI 10.1074/jbc.270.51.30709; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Lee CH, 2006, J MOL GRAPH MODEL, V25, P87, DOI 10.1016/j.jmgm.2005.10.009; Lehoczky P, 2007, FEMS MICROBIOL REV, V31, P109, DOI 10.1111/j.1574-6976.2006.00046.x; Li XR, 2005, DNA REPAIR, V4, P163, DOI 10.1016/j.dnarep.2004.08.012; Liu X, 2006, BIOCHEMISTRY-US, V45, P12898, DOI 10.1021/bi060792v; Lone S, 2007, MOL CELL, V25, P601, DOI 10.1016/j.molcel.2007.01.018; McElhinny SAN, 2006, CELL CYCLE, V5, P958, DOI 10.4161/cc.5.9.2736; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Noll DM, 2006, CHEM REV, V106, P277, DOI 10.1021/cr040478b; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Richards S, 2005, NUCLEIC ACIDS RES, V33, P5382, DOI 10.1093/nar/gki851; Sarkar S, 2006, EMBO J, V25, P1285, DOI 10.1038/sj.emboj.7600993; SASAKI MS, 1975, NATURE, V257, P501, DOI 10.1038/257501a0; Shen X, 2006, J BIOL CHEM, V281, P13869, DOI 10.1074/jbc.C600071200; TOMASZ M, 1995, CHEM BIOL, V2, P575, DOI 10.1016/1074-5521(95)90120-5; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Washington MT, 2004, MOL CELL BIOL, V24, P6900, DOI 10.1128/MCB.24.16.6900-6906.2004; Wu HI, 2004, CANCER RES, V64, P3940, DOI 10.1158/0008-5472.CAN-03-3113; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	46	109	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17075	17082		10.1074/jbc.M801238200	http://dx.doi.org/10.1074/jbc.M801238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434313	Green Published, hybrid			2022-12-25	WOS:000256720600014
J	Nakamura, K; Sakaue, H; Nishizawa, A; Matsuki, Y; Gomi, H; Watanabe, E; Hiramatsu, R; Tamamori-Adachi, M; Kitajima, S; Noda, T; Ogawa, W; Kasuga, M				Nakamura, Kyoko; Sakaue, Hiroshi; Nishizawa, Akihiko; Matsuki, Yasushi; Gomi, Hideyuki; Watanabe, Eijiro; Hiramatsu, Ryuji; Tamamori-Adachi, Mimi; Kitajima, Shigetaka; Noda, Tetsuo; Ogawa, Wataru; Kasuga, Masato			PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27(Kip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; RIBOSOMAL S6 KINASE; SIGNALING PATHWAY; PHOSPHOINOSITIDE 3-KINASE; MAMMALIAN-CELLS; CDK INHIBITORS; BREAST-CANCER; G1 PHASE; P27	PDK1 (3-phosphoinositide-dependent protein kinase 1) is a key mediator of signaling by phosphoinositide 3-kinase. To gain insight into the physiological importance of PDK1 in cell proliferation and cell cycle control, we established immortalized mouse embryonic fibroblasts (MEFs) from mice homozygous for a "floxed" allele of Pdk1 and from wild-type mice. Introduction of Cre recombinase by retrovirus-mediated gene transfer resulted in the depletion of PDK1 in Pdk1(lox/lox) MEFs but not in Pdk1(+/+) MEFs. The insulin-like growth factor-1-induced phosphorylation of various downstream effectors of PDK1, including Akt, glycogen synthase kinase 3, ribosomal protein S6, and p70 S6 kinase, was markedly inhibited in the PDK1-depleted (Pdk1-KO) MEFs. The rate of serum-induced cell proliferation was reduced; progression of the cell cycle from the G(0)-G(1) phase to the S phase was delayed, and cell cycle progression at G(2)-M phase was impaired in Pdk1-KO MEFs. These cells also manifested an increased level of p27(Kip1) expression and a reduced level of cyclin D1 expression during cell cycle progression. The defect in cell cycle progression from the G(0)-G(1) to the S phase in Pdk1-KO MEFs was rescued by forced expression of cyclin D1, whereas rescue of the defect in G(2)-M progression in these cells required both overexpression of cyclin D1 and depletion of p27(Kip1) by RNA interference. These data indicate that PDK1 plays an important role in cell proliferation and cell cycle progression by controlling the expression of both cyclin D1 and p27(Kip1).	[Nakamura, Kyoko; Sakaue, Hiroshi; Nishizawa, Akihiko; Ogawa, Wataru; Kasuga, Masato] Kobe Univ, Grad Sch Med, Div Endocrinol Diabet & Metab, Dept Internal Med, Kobe, Hyogo 6500017, Japan; [Matsuki, Yasushi; Gomi, Hideyuki; Watanabe, Eijiro; Hiramatsu, Ryuji] Sumitomo Pharmaceut Co Ltd, Genom Sci Labs, Takarazuka, Hyogo 6650051, Japan; [Tamamori-Adachi, Mimi; Kitajima, Shigetaka] Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Tokyo 1138510, Japan; [Noda, Tetsuo] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan	Kobe University; Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Sakaue, H (corresponding author), Kinki Univ, Sch Med, Div Pharmacol, 377-2 Onohigashi, Osaka 5898511, Japan.	hsakaue@med.kindai.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; Noda, Tetsuo/B-1667-2016; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; 				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bilanges B, 2005, BIOCHEM J, V388, P573, DOI 10.1042/BJ20041956; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cho KS, 2001, P NATL ACAD SCI USA, V98, P6144, DOI 10.1073/pnas.101596998; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; JIANG W, 1993, ONCOGENE, V8, P3447; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lee SR, 2005, J CELL PHYSIOL, V205, P270, DOI 10.1002/jcp.20395; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Novak M, 2004, J THEOR BIOL, V230, P563, DOI 10.1016/j.jtbi.2004.04.039; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reichert M, 2007, CANCER RES, V67, P4149, DOI 10.1158/0008-5472.CAN-06-4484; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Seki T, 2006, GENES CELLS, V11, P1051, DOI 10.1111/j.1365-2443.2006.01003.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Susaki E, 2007, MOL CELL BIOL, V27, P4626, DOI 10.1128/MCB.00862-06; Tamamori-Adachi M, 2004, J BIOL CHEM, V279, P50429, DOI 10.1074/jbc.M403084200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uchida T, 2005, NAT MED, V11, P175, DOI 10.1038/nm1187; van Duijn PW, 2006, PROSTATE, V66, P749, DOI 10.1002/pros.20398; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yu Bo, 2000, Molecular Cell Biology Research Communications, V3, P352, DOI 10.1006/mcbr.2000.0238; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	74	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17702	17711		10.1074/jbc.M802589200	http://dx.doi.org/10.1074/jbc.M802589200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430722	hybrid			2022-12-25	WOS:000256720600076
J	Travesa, A; Duch, A; Quintana, DG				Travesa, Anna; Duch, Alba; Quintana, David G.			Distinct phosphatases mediate the deactivation of the DNA damage checkpoint kinase Rad53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; S-PHASE; CHROMOSOMAL REARRANGEMENTS; PROTEIN-PHOSPHORYLATION; WIP1 PHOSPHATASE; YEAST; MEC1; POLYMERASE	The DNA damage checkpoint regulates DNA replication and arrests cell cycle progression in response to genotoxic stress. In Saccharomyces cerevisiae, the protein kinase Rad53 plays a central role in preventing genomic instability and maintaining viability in the presence of replication stress and DNA damage. Activation of Rad53 depends on phosphorylation by the upstream kinase Mec1, followed by autophosphorylation on multiple residues. Also critical for cell viability, the molecular mechanism of Rad53 deactivation remains incompletely understood. Rad53 dephosphorylation after repair of a persistent double strand break in G(2)/M has been shown to depend on the presence of the PP2C-type phosphatases Ptc2 and Ptc3. More recently, the PP2A-like protein phosphatase Pph3 has been shown to be required to dephosphorylate Rad53 after DNA methylation damage in S phase. However, we show here that Ptc2/3 are dispensable for Rad53 deactivation after replication stress or DNA methylation damage. Pph3 is also dispensable for the deactivation of Rad53 after replication stress. In addition, Rad53 kinase activity is still deactivated in pph3 null cells after DNA methylation damage, despite persistent Rad53 hyperphosphorylation. Finally, a strain in which the three phosphatases are deleted shows a severe defect in Rad53 kinase deactivation after DNA methylation damage but not after replication stress. In all, our results suggest that distinct phosphatases operate to return Rad53 to its basal state after different genotoxic stresses and that a yet unidentified phosphatase may be responsible for the deactivation of Rad53 after replication stress.	[Quintana, David G.] Univ Autonoma Barcelona, Sch Med, Dept Biochem & Mol Biol, Bellaterra 08193, Catalonia, Spain; Univ Autonoma Barcelona, Sch Med, Ctr Biophys Studies, Bellaterra 08193, Catalonia, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Quintana, DG (corresponding author), Univ Autonoma Barcelona, Sch Med, Dept Biochem & Mol Biol, Bellaterra 08193, Catalonia, Spain.	davidg.quintana@uab.es	Duch, Alba/AGI-1035-2022; Quintana, David G/M-5628-2018	Duch, Alba/0000-0001-6041-1360; Quintana, David G./0000-0002-4909-6686				Admire A, 2006, GENE DEV, V20, P159, DOI 10.1101/gad.1392506; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Brachmann CB, 1998, YEAST, V14, P115; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Cobb JA, 2005, GENE DEV, V19, P3055, DOI 10.1101/gad.361805; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Evans DRH, 1997, GENETICS, V145, P227; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Guillemain G, 2007, MOL CELL BIOL, V27, P3378, DOI 10.1128/MCB.00863-06; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heideker J, 2007, CELL CYCLE, V6, P3058, DOI 10.4161/cc.6.24.5100; Hodgson B, 2007, MOL BIOL CELL, V18, P3894, DOI 10.1091/mbc.E07-05-0500; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mantiero D, 2007, EMBO REP, V8, P380, DOI 10.1038/sj.embor.7400911; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; O'Neill BM, 2007, P NATL ACAD SCI USA, V104, P9290, DOI 10.1073/pnas.0703252104; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Rubenstein EM, 2007, EUKARYOT CELL, V6, P571, DOI 10.1128/EC.00026-07; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Smolka MB, 2005, MOL CELL PROTEOMICS, V4, P1358, DOI 10.1074/mcp.M500115-MCP200; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	52	42	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17123	17130		10.1074/jbc.M801402200	http://dx.doi.org/10.1074/jbc.M801402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18441009	hybrid			2022-12-25	WOS:000256720600020
J	Xu, JD; Weerapura, M; Ali, MK; Jackson, MF; Li, HB; Lei, G; Xue, S; Kwan, CL; Manolson, MF; Yang, K; MacDonald, JF; Yu, XM				Xu, Jindong; Weerapura, Manjula; Ali, Mohammad K.; Jackson, Michael F.; Li, Hongbin; Lei, Gang; Xue, Sheng; Kwan, Chun L.; Manolson, Morris F.; Yang, Kai; MacDonald, John F.; Yu, Xian-Min			Control of excitatory synaptic transmission by C-terminal Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HOMOLOGOUS-KINASE; TYROSINE KINASES; CSK; ACTIVATION; INDUCTION; POTENTIATION; TRAFFICKING; PHOSPHORYLATION; COMPLEXES	The induction of long-term potentiation at CA3 -CA1 synapses is caused by an N-methyl-D-aspartate (NMDA) receptor-dependent accumulation of intracellular Ca2+, followed by Src family kinase activation and a positive feedback enhancement of NMDA receptors (NMDARs). Nevertheless, the amplitude of baseline transmission remains remarkably constant even though low frequency stimulation is also associated with an NMDAR-dependent influx of Ca2+ into dendritic spines. We show here that an interaction between C-terminal Src kinase (Csk) and NMDARs controls the Src-dependent regulation of NMDAR activity. Csk associates with the NMDAR signaling complex in the adult brain, inhibiting the Src-dependent potentiation of NMDARs in CA1 neurons and attenuating the Src-dependent induction of long-term potentiation. Csk associates directly with Src-phosphorylated NR2 subunits in vitro. An inhibitory antibody for Csk disrupts this physical association, potentiates NMDAR mediated excitatory postsynaptic currents, and induces long-term potentiation at CA3 -CA1 synapses. Thus, Csk serves to maintain the constancy of baseline excitatory synaptic transmission by inhibiting Src kinase-dependent synaptic plasticity in the hippocampus.	[Weerapura, Manjula; Jackson, Michael F.; Li, Hongbin; Yang, Kai; MacDonald, John F.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Xu, Jindong; Lei, Gang; Xue, Sheng; Kwan, Chun L.; Manolson, Morris F.; Yu, Xian-Min] Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada; [Ali, Mohammad K.; Yu, Xian-Min] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA	University of Toronto; University of Toronto; State University System of Florida; Florida State University	MacDonald, JF (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	j.macdonald@utoronto.ca; xianmin.yu@med.fsu.edu	Jackson, Mike/H-5573-2012	Jackson, Mike/0000-0002-4730-201X; Manolson, Morris/0000-0001-8755-5460	NINDS NIH HHS [5R01 NS053567-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053567] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abrahamsen H, 2003, J BIOL CHEM, V278, P17170, DOI 10.1074/jbc.M211426200; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; Bloodgood BL, 2007, CURR OPIN NEUROBIOL, V17, P345, DOI 10.1016/j.conb.2007.04.003; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2006, J BIOL CHEM, V281, P32988, DOI 10.1074/jbc.M602951200; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Dineley KT, 2001, J NEUROCHEM, V77, P961, DOI 10.1046/j.1471-4159.2001.00321.x; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Gerber U, 2002, NEUROPHARMACOLOGY, V42, P587, DOI 10.1016/S0028-3908(01)00203-9; Groc L, 2006, P NATL ACAD SCI USA, V103, P18769, DOI 10.1073/pnas.0605238103; Groc L, 2006, CELL TISSUE RES, V326, P423, DOI 10.1007/s00441-006-0254-9; Hamaguchi I, 1996, BIOCHEM BIOPH RES CO, V224, P172, DOI 10.1006/bbrc.1996.1003; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; Kotecha SA, 2003, INT REV NEUROBIOL, V54, P53; Kuo SS, 1997, EUR J NEUROSCI, V9, P2383, DOI 10.1111/j.1460-9568.1997.tb01655.x; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; Lei G, 2002, EMBO J, V21, P2977, DOI 10.1093/emboj/cdf292; Lei SB, 1999, J BIOL CHEM, V274, P30617, DOI 10.1074/jbc.274.43.30617; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MACDONALD JF, 2007, BIOCHIM BIOPHYS ACTA, V1748, P941; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NEET K, 1995, MOL CELL BIOL, V15, P4908; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Petralia RS, 2005, MOL CELL NEUROSCI, V29, P436, DOI 10.1016/j.mcn.2005.03.013; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Seabold GK, 2003, J BIOL CHEM, V278, P15040, DOI 10.1074/jbc.M212825200; Sobczyk A, 2005, J NEUROSCI, V25, P6037, DOI 10.1523/JNEUROSCI.1221-05.2005; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Yaqub S, 2003, BIOCHEM J, V372, P271, DOI 10.1042/BJ20030021; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	45	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17503	17514		10.1074/jbc.M800917200	http://dx.doi.org/10.1074/jbc.M800917200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445593	Green Published, hybrid			2022-12-25	WOS:000256720600058
J	Albeanu, DF; Soucy, E; Sato, TF; Meister, M; Murthy, VN				Albeanu, Dinu F.; Soucy, Edward; Sato, Tomokazu F.; Meister, Markus; Murthy, Venkatesh N.			LED Arrays as Cost Effective and Efficient Light Sources for Widefield Microscopy	PLOS ONE			English	Article							ILLUMINATION; PROTEIN	New developments in fluorophores as well as in detection methods have fueled the rapid growth of optical imaging in the life sciences. Commercial widefield microscopes generally use arc lamps, excitation/emission filters and shutters for fluorescence imaging. These components can be expensive, difficult to maintain and preclude stable illumination. Here, we describe methods to construct inexpensive and easy-to-use light sources for optical microscopy using light-emitting diodes (LEDs). We also provide examples of its applicability to biological fluorescence imaging.	[Albeanu, Dinu F.; Meister, Markus; Murthy, Venkatesh N.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; [Albeanu, Dinu F.; Soucy, Edward; Sato, Tomokazu F.; Meister, Markus; Murthy, Venkatesh N.] Harvard Univ, Ctr Brain Sci, Cambridge, MA USA; [Sato, Tomokazu F.; Meister, Markus; Murthy, Venkatesh N.] Harvard Med Sch, Harvard Biophys Program, Boston, MA USA; [Meister, Markus; Murthy, Venkatesh N.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard Medical School; Harvard University	Albeanu, DF (corresponding author), Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA.	vnmurthy@fas.harvard.edu		Albeanu, Dinu/0000-0001-7825-7744; Meister, Markus/0000-0003-2136-6506; Murthy, Venkatesh/0000-0003-2443-4252	Harvard University	Harvard University	Support was only from start up funds provided by Harvard University to the senior authors. These funds have no restrictions and the University does not direct the research in any way.	Bormuth V, 2007, J MICROSC-OXFORD, V226, P1, DOI 10.1111/j.1365-2818.2007.01756.x; Born M, 1999, PRINCIPLES OPTICS, V461; Bozza T, 2004, NEURON, V42, P9, DOI 10.1016/S0896-6273(04)00144-8; Deisseroth K, 2006, J NEUROSCI, V26, P10380, DOI 10.1523/JNEUROSCI.3863-06.2006; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Herman P, 2001, J MICROSC-OXFORD, V203, P176, DOI 10.1046/j.1365-2818.2001.00943.x; Holman B, 2007, BIOMED INSTRUM TECHN, V41, P461; Koren P. E., 2000, FAMILY EMPOWERMENT S; Lichtman JW, 2005, NAT METHODS, V2, P910, DOI 10.1038/NMETH817; Martin G, 2005, BIOTECHNIQUES, V38, P204, DOI 10.2144/05382BM06; Meister M, 2001, J NEUROSCI, V21, P1351; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Round H.J., 1907, ELECT WORLD, V49, P309; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Salzberg BM, 2005, J NEUROSCI METH, V141, P165, DOI 10.1016/j.jneumeth.2004.06.009; Tsien RY, 2003, NAT REV MOL CELL BIO, pSS16, DOI 10.1038/nrm1196; Wachowiak M, 2001, NEURON, V32, P723, DOI 10.1016/S0896-6273(01)00506-2; Zheludev N, 2007, NAT PHOTONICS, V1, P189, DOI 10.1038/nphoton.2007.34	19	46	46	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2146	10.1371/journal.pone.0002146	http://dx.doi.org/10.1371/journal.pone.0002146			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478056	Green Accepted, Green Published, gold			2022-12-25	WOS:000262172800011
J	Krishnan, A; Giuliani, A; Zbilut, JP; Tomita, M				Krishnan, Arun; Giuliani, Alessandro; Zbilut, Joseph P.; Tomita, Masaru			Implications from a Network-Based Topological Analysis of Ubiquitin Unfolding Simulations	PLOS ONE			English	Article							MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; PRINCIPLES; TRANSITION; NUCLEATION; HELIX; COIL	Background: The architectural organization of protein structures has been the focus of intense research since it can hopefully lead to an understanding of how proteins fold. In earlier works we had attempted to identify the inherent structural organization in proteins through a study of protein topology. We obtained a modular partitioning of protein structures with the modules correlating well with experimental evidence of early folding units or "foldons". Residues that connect different modules were shown to be those that were protected during the transition phase of folding. Methodology/Principal Findings: In this work, we follow the topological path of ubiquitin through molecular dynamics unfolding simulations. We observed that the use of recurrence quantification analysis (RQA) could lead to the identification of the transition state during unfolding. Additionally, our earlier contention that the modules uncovered through our graph partitioning approach correlated well with early folding units was vindicated through our simulations. Moreover, residues identified from native structure as connector hubs and which had been shown to be those that were protected during the transition phase of folding were indeed more stable (less flexible) well beyond the transition state. Further analysis of the topological pathway suggests that the all pairs shortest path in a protein is minimized during folding. Conclusions: We observed that treating a protein native structure as a network by having amino acid residues as nodes and the non-covalent interactions among them as links allows for the rationalization of many aspects of the folding process. The possibility to derive this information directly from 3D structure opens the way to the prediction of important residues in proteins, while the confirmation of the minimization of APSP for folding allows for the establishment of a potentially useful proxy for kinetic optimality in the validation of sequence-structure predictions.	[Krishnan, Arun; Tomita, Masaru] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan; [Giuliani, Alessandro] Ist Superiore Sanita, Dept Env & Hlth, Rome, Italy; [Zbilut, Joseph P.] Rush Univ, Med Ctr, Dept Mol Biophys & Physiol, Chicago, IL USA	Keio University; Istituto Superiore di Sanita (ISS); Rush University	Krishnan, A (corresponding author), Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.	krishnan@ttck.keio.ac.jp	Giuliani, Alessandro/K-7589-2016; Giuliani, Alessandro/AAF-1740-2020	Giuliani, Alessandro/0000-0002-4640-804X; Giuliani, Alessandro/0000-0002-4640-804X				Allen MP., 1989, COMPUTER SIMULATION; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Brinda KV, 2005, BIOPHYS J, V89, P4159, DOI 10.1529/biophysj.105.064485; BRYGELSON JD, 1995, PROTEIN-STRUCT FUNCT, V21, P167; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Condamin S, 2007, NATURE, V450, P77, DOI 10.1038/nature06201; Cruz L, 2005, P NATL ACAD SCI USA, V102, P18258, DOI 10.1073/pnas.0509276102; DASTIDAR SG, 2007, PHYS REV E, V72, P1; del Sol A, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r92; DEMACKERELL A, 1998, J PHYS CHEM B, V102, P3586; DILL KA, 1995, PROTEIN SCI, V4, P561; Dokholyan NV, 2002, P NATL ACAD SCI USA, V99, P8637, DOI 10.1073/pnas.122076099; Ghosh A, 2007, P NATL ACAD SCI USA, V104, P15711, DOI 10.1073/pnas.0704459104; Giuliani A, 1998, AM J PHYSIOL-HEART C, V275, pH1455, DOI 10.1152/ajpheart.1998.275.4.H1455; Giuliani A, 2000, PROTEIN ENG, V13, P671, DOI 10.1093/protein/13.10.671; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JANIN J, 1979, B I PASTEUR, V77, P337; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Krishnan A, 2007, J PROTEOME RES, V6, P3924, DOI 10.1021/pr070162v; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LI AJ, 1994, P NATL ACAD SCI USA, V91, P10430, DOI 10.1073/pnas.91.22.10430; LIFSON S, 1961, J CHEM PHYS, V34, P1963, DOI 10.1063/1.1731802; Manetti C, 1999, PHYS REV E, V59, P992, DOI 10.1103/PhysRevE.59.992; ONUCHIE JN, 1995, ADV PROTEIN CHEM, V53, P87; PAN YQ, 1992, BIOCHEMISTRY-US, V31, P11405, DOI 10.1021/bi00161a019; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; SINGH J, 1991, ATLAS PROTEIN SIDE C; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; THOMAS H, 1990, INTRO ALGORITHMS; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEBBER CL, 1994, J APPL PHYSIOL, V76, P965, DOI 10.1152/jappl.1994.76.2.965; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Yon JM, 2002, J CELL MOL MED, V6, P307, DOI 10.1111/j.1582-4934.2002.tb00511.x; Zbilut JP, 2007, PROTEINS, V66, P621, DOI 10.1002/prot.21179; Zbilut JP, 2006, FEBS LETT, V580, P4861, DOI 10.1016/j.febslet.2006.07.076; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	40	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2149	10.1371/journal.pone.0002149	http://dx.doi.org/10.1371/journal.pone.0002149			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478068	Green Published, Green Submitted, gold			2022-12-25	WOS:000262172800014
J	Casas, J; Steinmann, T; Dangles, O				Casas, Jerome; Steinmann, Thomas; Dangles, Olivier			The Aerodynamic Signature of Running Spiders	PLOS ONE			English	Article							FORAGING MODE; CRICKET; ESCAPE; LOCOMOTION; COCKROACH; SYSTEM; HAIRS	Many predators display two foraging modes, an ambush strategy and a cruising mode. These foraging strategies have been classically studied in energetic, biomechanical and ecological terms, without considering the role of signals produced by predators and perceived by prey. Wolf spiders are a typical example; they hunt in leaf litter either using an ambush strategy or by moving at high speed, taking over unwary prey. Air flow upstream of running spiders is a source of information for escaping prey, such as crickets and cockroaches. However, air displacement by running arthropods has not been previously examined. Here we show, using digital particle image velocimetry, that running spiders are highly conspicuous aerodynamically, due to substantial air displacement detectable up to several centimetres in front of them. This study explains the bimodal distribution of spider's foraging modes in terms of sensory ecology and is consistent with the escape distances and speeds of cricket prey. These findings may be relevant to the large and diverse array of arthropod prey-predator interactions in leaf litter.	[Casas, Jerome; Steinmann, Thomas] Univ Tours, Inst Rech Biol Insecte, CNRS, UMR 6035, F-37200 Tours, France; [Dangles, Olivier] CNRS, UPR 9034, LEGS, UR 072,IRD, F-91198 Gif Sur Yvette, France; [Dangles, Olivier] Univ Paris Sud 11, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Casas, J (corresponding author), Univ Tours, Inst Rech Biol Insecte, CNRS, UMR 6035, F-37200 Tours, France.	casas@univ-tours.fr	Casas, Jérôme/D-9620-2011; Dangles, Olivier/C-4924-2009	Casas, Jérôme/0000-0003-1666-295X; Dangles, Olivier/0000-0002-1987-8433	CICADA [IST-2001-34718]; CILIA [FP6-IST-016039]; Information Society Technologies-IST Program, Future and emergent Technologies (FET)	CICADA; CILIA; Information Society Technologies-IST Program, Future and emergent Technologies (FET)	This work is part of the research conducted within the Cricket Inspired perCeption and Autonomous Decision Automata (CICADA) project (IST-2001-34718) and within the Customized Intelligent Life Inspired Arrays (CILIA) project (FP6-IST-016039). These projects are both funded by the European Community under the Information Society Technologies-IST Program, Future and emergent Technologies (FET).	Camhi JM, 1984, NEUROETHOLOGY NERVE; Cooper WE, 2005, J ZOOL, V267, P179, DOI 10.1017/S0952836905007375; Curio E., 1976, ETHOLOGY PREDATION; Dangles O, 2006, ANIM BEHAV, V72, P603, DOI 10.1016/j.anbehav.2005.11.018; Dangles O, 2006, J EXP BIOL, V209, P393, DOI 10.1242/jeb.02000; Dickinson MH, 2000, SCIENCE, V288, P100, DOI 10.1126/science.288.5463.100; EDWARDS JS, 1974, PROC R SOC SER B-BIO, V185, P83, DOI 10.1098/rspb.1974.0007; Foelix R. F., 2011, BIOL SPIDERS; FULL RJ, 1991, J EXP BIOL, V156, P215; Gnatzy W., 1996, DIGGER WASP VS CRICK; Grimaldi David, 2005, pi; HUEY RB, 1981, ECOLOGY, V62, P991, DOI 10.2307/1936998; Koehl MAR, 2001, SCIENCE, V294, P1948, DOI 10.1126/science.1063724; Kramer DL, 2001, AM ZOOL, V41, P137, DOI 10.1668/0003-1569(2001)041[0137:TBEOIL]2.0.CO;2; Kronestedt T, 2007, ZOOTAXA, P25; Labandeira Conrad C., 2002, Paleontological Society Papers, V8, P211; Lauder GV, 2008, ANNU REV PHYSIOL, V70, P143, DOI 10.1146/annurev.physiol.70.113006.100438; Nishikawa K, 2007, INTEGR COMP BIOL, V47, P16, DOI 10.1093/icb/icm024; PLUMMER MR, 1981, J COMP PHYSIOL, V142, P347, DOI 10.1007/BF00605447; Riechert Susan E., 1992, P313, DOI 10.1002/9781444314076.ch13; Rinberg D, 2003, J COMP PHYSIOL A, V189, P867, DOI 10.1007/s00359-003-0460-9; Schmitz OJ, 2008, SCIENCE, V319, P952, DOI 10.1126/science.1152355; Schmitz OJ, 2007, ECOLOGY, V88, P2415, DOI 10.1890/06-0937.1; Schoener T. W., 1971, A Rev Ecol Syst, V2, P369, DOI 10.1146/annurev.es.02.110171.002101; SHIMOZAWA T, 1984, J COMP PHYSIOL, V155, P485, DOI 10.1007/BF00611913; Shimozawa T, 2003, SENSORS AND SENSING IN BIOLOGY AND ENGINEERING, P145; Steinmann T, 2006, J EXP BIOL, V209, P4398, DOI 10.1242/jeb.02506; TAUBER E, 1995, J EXP BIOL, V198, P1895; Tautz J, 1989, MEDIENBEWEGUNG SINNE; Taylor GK, 2003, NATURE, V425, P707, DOI 10.1038/nature02000; Warrick DR, 2005, NATURE, V435, P1094, DOI 10.1038/nature03647	31	37	37	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2116	10.1371/journal.pone.0002116	http://dx.doi.org/10.1371/journal.pone.0002116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461167	Green Published, gold			2022-12-25	WOS:000261642400038
J	Chan, PK; Wai, A; Philipsen, S; Tan-Un, KC				Chan, Ping Kei; Wai, Albert; Philipsen, Sjaak; Tan-Un, Kian-Cheng			5 ' HS5 of the Human beta-globin Locus Control Region Is Dispensable for the Formation of the beta-globin Active Chromatin Hub	PLOS ONE			English	Article								Hypersensitive site 5 (5'HS5) of the beta-globin Locus Control Region functions as a developmental stage-specific border in erythroid cells. Here, we have analyzed the role of 5'HS5 in the three dimensional organization of the beta-gene locus using the Chromatin Conformation Capture (3C) technique. The results show that when 5'HS5 is deleted from the locus, both remote and internal regulatory elements are still able to interact with each other in a three-dimensional configuration termed the Active Chromatin Hub. Thus, the absence of 5'HS5 does not have an appreciable effect on the three dimensional organization of the beta-globin locus. This rules out models in which 5'HS5 nucleates interactions with remote and/or internal regulatory elements. We also determined the binding of CTCF, the only defined insulator protein in mammalian cells, to 5'HS5 by using chromatin immunoprecipitation (ChIP) assays. We detect low levels of CTCF binding to 5'HS5 in primitive erythroid cells, in which it functions as a border element. Surprisingly, we also observe binding levels of CTCF to 59HS5 in definitive erythroid cells. Thus, binding of CTCF to 59HS5 per se does not render it a functional border element. This is consistent with the previous data suggesting that CTCF has dual functionality.	[Chan, Ping Kei; Tan-Un, Kian-Cheng] Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; [Wai, Albert; Philipsen, Sjaak] Erasmus MC, Dept Cell Biol, Rotterdam, Netherlands	University of Hong Kong; Erasmus University Rotterdam; Erasmus MC	Chan, PK (corresponding author), Univ Hong Kong, Dept Zool, Kadoorie Biol Sci Bldg, Hong Kong, Hong Kong, Peoples R China.	j.philipsen@erasmusmc.nl; kctanun@hkucc.hku.hk			HKU School of Professional and Continuing Education (HKU SPACE)	HKU School of Professional and Continuing Education (HKU SPACE)	This work was supported by the HKU School of Professional and Continuing Education (HKU SPACE).	Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bungert J, 1999, MOL CELL BIOL, V19, P3062; Capelson M, 2006, EMBO J, V25, P1906, DOI 10.1038/sj.emboj.7601068; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Grosveld F, 1987, Prog Clin Biol Res, V251, P133; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Imam AMA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e65; Levings PP, 2002, EUR J BIOCHEM, V269, P1589, DOI 10.1046/j.1432-1327.2002.02797.x; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Patrinos GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/gad.289704; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; Wai AWK, 2003, EMBO J, V22, P4489, DOI 10.1093/emboj/cdg437; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Yusufzai TM, 2004, P NATL ACAD SCI USA, V101, P8620, DOI 10.1073/pnas.0402938101; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	35	7	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2134	10.1371/journal.pone.0002134	http://dx.doi.org/10.1371/journal.pone.0002134			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461170	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400055
J	Little, AC; Jones, BC; Waitt, C; Tiddeman, BP; Feinberg, DR; Perrett, DI; Apicella, CL; Marlowe, FW				Little, Anthony C.; Jones, Benedict C.; Waitt, Corri; Tiddeman, Bernard P.; Feinberg, David R.; Perrett, David I.; Apicella, Coren L.; Marlowe, Frank W.			Symmetry Is Related to Sexual Dimorphism in Faces: Data Across Culture and Species	PLOS ONE			English	Article							FLUCTUATING ASYMMETRY; DEVELOPMENTAL STABILITY; FACIAL ATTRACTIVENESS; ONE ORNAMENT; SELECTION; TESTOSTERONE; PREFERENCES; SIGNALS; APPEARANCE; ESTROGEN	Background: Many animals both display and assess multiple signals. Two prominently studied traits are symmetry and sexual dimorphism, which, for many animals, are proposed cues to heritable fitness benefits. These traits are associated with other potential benefits, such as fertility. In humans, the face has been extensively studied in terms of attractiveness. Faces have the potential to be advertisements of mate quality and both symmetry and sexual dimorphism have been linked to the attractiveness of human face shape. Methodology/Principal Findings: Here we show that measurements of symmetry and sexual dimorphism from faces are related in humans, both in Europeans and African hunter-gatherers, and in a non-human primate. Using human judges, symmetry measurements were also related to perceived sexual dimorphism. In all samples, symmetric males had more masculine facial proportions and symmetric females had more feminine facial proportions. Conclusions/Significance: Our findings support the claim that sexual dimorphism and symmetry in faces are signals advertising quality by providing evidence that there must be a biological mechanism linking the two traits during development. Such data also suggests that the signalling properties of faces are universal across human populations and are potentially phylogenetically old in primates.	[Little, Anthony C.] Univ Stirling, Sch Psychol, Stirling FK9 4LA, Scotland; [Jones, Benedict C.] Univ Aberdeen, Sch Psychol, Aberdeen, Scotland; [Waitt, Corri] Univ Oxford, Dept Zool, Oxford, England; [Tiddeman, Bernard P.] Univ St Andrews, Sch Comp Sci, St Andrews, Fife, Scotland; [Feinberg, David R.] McMaster Univ, Dept Psychol, Hamilton, ON, Canada; [Perrett, David I.] Univ St Andrews, Sch Psychol, St Andrews, Fife, Scotland; [Apicella, Coren L.] Harvard Univ, Dept Anthropol, Cambridge, MA USA; [Marlowe, Frank W.] Florida State Univ, Dept Anthropol, Tallahassee, FL USA	University of Stirling; University of Aberdeen; University of Oxford; University of St Andrews; McMaster University; University of St Andrews; Harvard University; State University System of Florida; Florida State University	Little, AC (corresponding author), Univ Stirling, Sch Psychol, Stirling FK9 4LA, Scotland.	anthony.little@stir.ac.uk	Jones, Benedict C/A-7850-2008; Little, Anthony C/B-8497-2009; Little, Anthony/W-2732-2019; Feinberg, David/C-1249-2009; Marlowe, Frank/G-9752-2012	Jones, Benedict C/0000-0001-7777-0220; Little, Anthony C/0000-0001-9100-1903; Little, Anthony/0000-0001-9100-1903; Feinberg, David/0000-0003-4179-1446; Apicella, Coren/0000-0002-9661-6998; Perrett, David/0000-0002-6025-0939; Tiddeman, Bernard/0000-0001-7570-1192	Royal Society University Research Fellowship; National Science Foundation [0650574]; Unilever research	Royal Society University Research Fellowship(Royal Society of London); National Science Foundation(National Science Foundation (NSF)); Unilever research(Unilever)	Anthony Little is supported by a Royal Society University Research Fellowship. Frank Marlowe is sponsored by the National Science Foundation grant # 0650574. David Perrett is supported by Unilever research. No funders had any role in the conduct or any other aspect of this paper.	ALEXANDER J, 1988, PARASITOL TODAY, V4, P189, DOI 10.1016/0169-4758(88)90077-4; Andersson Malte, 1994; [Anonymous], [No title captured]; BALMFORD A, 1993, NATURE, V361, P628, DOI 10.1038/361628a0; BARDIN CW, 1981, SCIENCE, V211, P1285, DOI 10.1126/science.7010603; BENSON PJ, 1993, PERCEPTION, V22, P257, DOI 10.1068/p220257; BOROD JC, 1981, CORTEX, V17, P381, DOI 10.1016/S0010-9452(81)80025-1; Candolin U, 2003, BIOL REV, V78, P575, DOI 10.1017/S1464793103006158; CHANGIZI MA, BIOL LETT IN PRESS; Darwin G., 1871, P423; Enlow D.H., 1982, HDB FACIAL GROWTH; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; ENQUIST M, 1994, NATURE, V372, P169, DOI 10.1038/372169a0; Feinberg DR, 2005, EVOL HUM BEHAV, V26, P398, DOI 10.1016/j.evolhumbehav.2005.04.001; Fisher R.A., 1930, GENETICAL THEORY NAT; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; Gangestad SW, 2003, EVOL HUM BEHAV, V24, P231, DOI 10.1016/S1090-5138(03)00017-5; Getty T, 2002, AM NAT, V159, P363, DOI 10.1086/338992; Grammer K, 2003, BIOL REV, V78, P385, DOI 10.1017/S1464793102006085; GRAMMER K, 1994, J COMP PSYCHOL, V108, P233, DOI 10.1037/0735-7036.108.3.233; Gray PB, 2002, ANN HUM BIOL, V29, P495, DOI 10.1080/03014460110112060; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; JOHNSTONE RA, 1994, NATURE, V372, P172, DOI 10.1038/372172a0; Johnstone RA, 1996, PHILOS T R SOC B, V351, P329, DOI 10.1098/rstb.1996.0026; Kanda N, 1996, CLIN EXP IMMUNOL, V106, P410, DOI 10.1046/j.1365-2249.1996.d01-842.x; Koehler N, 2004, P ROY SOC B-BIOL SCI, V271, pS233, DOI 10.1098/rsbl.2003.0146; Law-Smith MJ, 2006, P ROY SOC B-BIOL SCI, V273, P135, DOI 10.1098/rspb.2005.3296; Little AC, 2003, P ROY SOC B-BIOL SCI, V270, P1759, DOI 10.1098/rspb.2003.2445; Little AC, 2002, P ROY SOC B-BIOL SCI, V269, P1095, DOI 10.1098/rspb.2002.1984; Little AC, 2007, P ROY SOC B-BIOL SCI, V274, P3113, DOI 10.1098/rspb.2007.0895; Manning JT, 1998, EVOL HUM BEHAV, V19, P273, DOI 10.1016/S1090-5138(98)00024-5; MANNING JT, 1993, P ROY SOC B-BIOL SCI, V251, P83, DOI 10.1098/rspb.1993.0012; Mazur A, 1998, BEHAV BRAIN SCI, V21, P353, DOI 10.1017/S0140525X98001228; Moller AP, 1997, AM NAT, V149, P916, DOI 10.1086/286030; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V245, P1, DOI 10.1098/rspb.1991.0080; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; Palmer AR, 1997, J EVOLUTION BIOL, V10, P39; PARSONS PA, 1992, HEREDITY, V68, P361, DOI 10.1038/hdy.1992.51; Penton-Voak IS, 1999, NATURE, V399, P741, DOI 10.1038/21557; Penton-Voak IS, 2001, P ROY SOC B-BIOL SCI, V268, P1617, DOI 10.1098/rspb.2001.1703; Penton-Voak IS, 2004, EVOL HUM BEHAV, V25, P229, DOI 10.1016/j.evolhumbehav.2004.04.003; Perrett DI, 1998, NATURE, V394, P884, DOI 10.1038/29772; Perrett DI, 1999, EVOL HUM BEHAV, V20, P295, DOI 10.1016/S1090-5138(99)00014-8; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; RHODES G, 2003, DOES SEXUAL DIMORPHI; Roberts ML, 2004, ANIM BEHAV, V68, P227, DOI 10.1016/j.anbehav.2004.05.001; RYAN MJ, 1990, EVOLUTION, V44, P305, DOI 10.1111/j.1558-5646.1990.tb05200.x; Scheib JE, 1999, P ROY SOC B-BIOL SCI, V266, P1913, DOI 10.1098/rspb.1999.0866; Service RF, 1998, SCIENCE, V279, P1631, DOI 10.1126/science.279.5357.1631; Thornhill R, 2006, EVOL HUM BEHAV, V27, P131, DOI 10.1016/j.evolhumbehav.2005.06.001; Thornhill R, 1999, TRENDS COGN SCI, V3, P452, DOI 10.1016/S1364-6613(99)01403-5; Thornhill R, 1999, EVOL HUM BEHAV, V20, P105, DOI 10.1016/S1090-5138(98)00044-0; Tiddeman B, 2001, IEEE COMPUT GRAPH, V21, P42, DOI 10.1109/38.946630; VALEN LV, 1962, EVOLUTION, V16, P125, DOI DOI 10.2307/2406192; Waitt C, 2006, INT J PRIMATOL, V27, P133, DOI 10.1007/s10764-005-9015-y; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	56	133	141	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2106	10.1371/journal.pone.0002106	http://dx.doi.org/10.1371/journal.pone.0002106			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461131	Green Submitted, Green Published, Green Accepted, gold			2022-12-25	WOS:000261642400028
J	Todi, SV; Sivan-Loukianova, E; Jacobs, JS; Kiehart, DP; Eberl, DF				Todi, Sokol V.; Sivan-Loukianova, Elena; Jacobs, Julie S.; Kiehart, Daniel P.; Eberl, Daniel F.			Myosin VIIA, Important for Human Auditory Function, Is Necessary for Drosophila Auditory Organ Development	PLOS ONE			English	Article								Background: Myosin VIIA (MyoVIIA) is an unconventional myosin necessary for vertebrate audition [1-5]. Human auditory transduction occurs in sensory hair cells with a staircase-like arrangement of apical protrusions called stereocilia. In these hair cells, MyoVIIA maintains stereocilia organization [6]. Severe mutations in the Drosophila MyoVIIA orthologue, crinkled (ck), are semi-lethal [7] and lead to deafness by disrupting antennal auditory organ (Johnston's Organ, JO) organization [8]. ck/MyoVIIA mutations result in apical detachment of auditory transduction units (scolopidia) from the cuticle that transmits antennal vibrations as mechanical stimuli to JO. Principal Findings: Using flies expressing GFP-tagged NompA, a protein required for auditory organ organization in Drosophila, we examined the role of ck/MyoVIIA in JO development and maintenance through confocal microscopy and extracellular electrophysiology. Here we show that ck/MyoVIIA is necessary early in the developing antenna for initial apical attachment of the scolopidia to the articulating joint. ck/MyoVIIA is also necessary to maintain scolopidial attachment throughout adulthood. Moreover, in the adult JO, ck/MyoVIIA genetically interacts with the non-muscle myosin II (through its regulatory light chain protein and the myosin binding subunit of myosin II phosphatase). Such genetic interactions have not previously been observed in scolopidia. These factors are therefore candidates for modulating MyoVIIA activity in vertebrates. Conclusions: Our findings indicate that MyoVIIA plays evolutionarily conserved roles in auditory organ development and maintenance in invertebrates and vertebrates, enhancing our understanding of auditory organ development and function, as well as providing significant clues for future research.	[Todi, Sokol V.; Eberl, Daniel F.] Univ Iowa, Neurosci Grad Program, Iowa City, IA USA; [Todi, Sokol V.; Sivan-Loukianova, Elena; Jacobs, Julie S.; Eberl, Daniel F.] Univ Iowa, Dept Biol, Iowa City, IA USA; [Kiehart, Daniel P.] Duke Univ, Dept Biol, Durham, NC USA	University of Iowa; University of Iowa; Duke University	Todi, SV (corresponding author), Univ Iowa, Neurosci Grad Program, Iowa City, IA USA.	daniel-eberl@uiowa.edu	Eberl, Daniel F./AAN-3359-2020	Eberl, Daniel F./0000-0001-9982-9895; TODI, SOKOL/0000-0003-4399-5549	AHA predoctoral fellowship [0410077Z]; NIH [DC07673, DC04848]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC007673, R01DC004848] Funding Source: NIH RePORTER	AHA predoctoral fellowship(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by AHA predoctoral fellowship #0410077Z to SVT, and NIH grants #DC07673 to DPK and #DC04848 to DFE. These agencies had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Adato A, 2005, HUM MOL GENET, V14, P3921, DOI 10.1093/hmg/ddi416; Adato A, 2005, HUM MOL GENET, V14, P347, DOI 10.1093/hmg/ddi031; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung YD, 2001, NEURON, V29, P415, DOI 10.1016/S0896-6273(01)00215-X; Delprat B, 2005, HUM MOL GENET, V14, P401, DOI 10.1093/hmg/ddi036; Eberl DF, 2000, J NEUROSCI, V20, P5981, DOI 10.1523/JNEUROSCI.20-16-05981.2000; El-Amraoui A, 2005, J CELL SCI, V118, P4593, DOI 10.1242/jcs.02636; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; Franke JD, 2006, CELL MOTIL CYTOSKEL, V63, P604, DOI 10.1002/cm.20148; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Kiehart DP, 2004, GENETICS, V168, P1337, DOI 10.1534/genetics.104.026369; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Kros CJ, 2002, NAT NEUROSCI, V5, P41, DOI 10.1038/nn784; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; Kussel-Andermann P, 2000, J BIOL CHEM, V275, P29654, DOI 10.1074/jbc.M004393200; LI CL, 1995, J NEUROBIOL, V28, P363, DOI 10.1002/neu.480280309; LIENHARD MC, 1991, DEVELOPMENT, V112, P1063; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Michalski N, 2007, J NEUROSCI, V27, P6478, DOI 10.1523/JNEUROSCI.0342-07.2007; MILNER MJ, 1979, ROUX ARCH DEV BIOL, V185, P363, DOI 10.1007/BF00848522; Mizuno T, 1999, GENE, V238, P437, DOI 10.1016/S0378-1119(99)00351-0; Mizuno T, 2002, DEVELOPMENT, V129, P1215; Mlodzik M, 1999, EMBO J, V18, P6873, DOI 10.1093/emboj/18.24.6873; Self T, 1998, DEVELOPMENT, V125, P557; Senften M, 2006, J NEUROSCI, V26, P2060, DOI 10.1523/JNEUROSCI.4251-05.2006; Sokol S, 2000, NAT CELL BIOL, V2, pE124, DOI 10.1038/35017136; Tan CG, 2003, DEVELOPMENT, V130, P671, DOI 10.1242/dev.00298; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Todi SV, 2005, CURR BIOL, V15, P862, DOI 10.1016/j.cub.2005.03.050; Todi SV, 2004, MICROSC RES TECHNIQ, V63, P388, DOI 10.1002/jemt.20053; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209	40	24	26	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2115	10.1371/journal.pone.0002115	http://dx.doi.org/10.1371/journal.pone.0002115			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461180	Green Submitted, Green Published, gold			2022-12-25	WOS:000261642400037
J	Chung, W; Kwabi-Addo, B; Ittmann, M; Jelinek, J; Shen, L; Yu, YH; Issa, JPJ				Chung, Woonbok; Kwabi-Addo, Bernard; Ittmann, Michael; Jelinek, Jaroslav; Shen, Lanlan; Yu, Yinhua; Issa, Jean-Pierre J.			Identification of Novel Tumor Markers in Prostate, Colon and Breast Cancer by Unbiased Methylation Profiling	PLOS ONE			English	Article								DNA hypermethylation is a common epigenetic abnormality in cancer and may serve as a useful marker to clone cancer-related genes as well as a marker of clinical disease activity. To identify CpG islands methylated in prostate cancer, we used methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) on prostate cancer cell lines. We isolated 34 clones that corresponded to promoter CpG islands, including 5 reported targets of hypermethylation in cancer. We confirmed the data for 17 CpG islands by COBRA and/or pyrosequencing. All 17 genes were methylated in at least 2 cell lines of a 21-cancer cell line panel containing prostate cancer, colon cancer, leukemia, and breast cancer. Based on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and NSE1 are candidate biomarkers for prostate cancer (methylation range 50%-85%). The combination of NSE1 or SPOCK2 hypermethylation showed a sensitivity of 80% and specificity of 95% in differentiating cancer from normal. Similarly NKX2-5, SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%-95%) and GALR2 hypermethylation showed a sensitivity of 85% and specificity of 95%. Finally, SLC16A12, GALR2, TOX, SPOCK2, EGFR5 and DPYS are candidate biomarkers for breast cancer (methylation range 33%-79%) with the combination of EGFR5 or TOX hypermethylation showing a sensitivity of 92% and specificity of 92%. Expression analysis for eight genes that had the most hypermethylation confirmed the methylation associated silencing and reactivation with 5-aza-2'-deoxycytidine treatment. Our data identify new targets of transcriptional silencing in cancer, and provide new biomarkers that could be useful in screening for prostate cancer and other cancers.	[Chung, Woonbok; Jelinek, Jaroslav; Shen, Lanlan; Issa, Jean-Pierre J.] Baylor Coll Med, Dept Leukemia, Houston, TX 77030 USA; [Kwabi-Addo, Bernard; Ittmann, Michael] Baylor Coll Med, Dept Pathol, Houston, TX USA; [Yu, Yinhua] Baylor Coll Med, Monroe Dunaway M. D. Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Chung, W (corresponding author), Baylor Coll Med, Dept Leukemia, Houston, TX 77030 USA.	jpissa@mdanderson.org	Jelinek, Jaroslav/O-6876-2019; Kwabi-Addo, Bernard/A-6993-2016	Kwabi-Addo, Bernard/0000-0003-3692-6350; Issa, Jean-Pierre/0000-0003-2258-5030	National Institutes of Health [CA100632, CA098006]; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA098006] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health Grants CA100632 and CA098006.	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01; Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x; Estecio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Schmutte C, 1998, BIOL CHEM, V379, P377; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Singal R, 2001, CANCER RES, V61, P4820; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Toyota M, 1999, CANCER RES, V59, P2307; Webber MM, 1996, CARCINOGENESIS, V17, P1641, DOI 10.1093/carcin/17.8.1641; Wimmer K, 2002, GENE CHROMOSOME CANC, V33, P285, DOI 10.1002/gcc.10030; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamada Y, 2003, CANCER SCI, V94, P536, DOI 10.1111/j.1349-7006.2003.tb01479.x; Yamanaka M, 2003, INT J CANCER, V106, P382, DOI 10.1002/ijc.11227; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	32	100	115	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2079	10.1371/journal.pone.0002079	http://dx.doi.org/10.1371/journal.pone.0002079			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446232	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300047
J	Proell, M; Riedl, SJ; Fritz, JH; Rojas, AM; Schwarzenbacher, R				Proell, Martina; Riedl, Stefan J.; Fritz, Joerg H.; Rojas, Ana M.; Schwarzenbacher, Robert			The Nod-Like Receptor (NLR) Family: A Tale of Similarities and Differences	PLOS ONE			English	Article								Innate immunity represents an important system with a variety of vital processes at the core of many diseases. In recent years, the central role of the Nod-like receptor (NLR) protein family became increasingly appreciated in innate immune responses. NLRs are classified as part of the signal transduction ATPases with numerous domains (STAND) clade within the AAA+ ATPase family. They typically feature an N-terminal effector domain, a central nucleotide-binding domain (NACHT) and a C-terminal ligand-binding region that is composed of several leucine-rich repeats (LRRs). NLRs are believed to initiate or regulate host defense pathways through formation of signaling platforms that subsequently trigger the activation of inflammatory caspases and NF-kB. Despite their fundamental role in orchestrating key pathways in innate immunity, their mode of action in molecular terms remains largely unknown. Here we present the first comprehensive sequence and structure modeling analysis of NLR proteins, revealing that NLRs posses a domain architecture similar to the apoptotic initiator protein Apaf-1. Apaf-1 performs its cellular function by the formation of a heptameric platform, dubbed apoptosome, ultimately triggering the controlled demise of the affected cell. The mechanism of apoptosome formation by Apaf-1 potentially offers insight into the activation mechanisms of NLR proteins. Multiple sequence alignment analysis and homology modeling revealed Apaf-1-like structural features in most members of the NLR family, suggesting a similar biochemical behaviour in catalytic activity and oligomerization. Evolutionary tree comparisons substantiate the conservation of characteristic functional regions within the NLR family and are in good agreement with domain distributions found in distinct NLRs. Importantly, the analysis of LRR domains reveals surprisingly low conservation levels among putative ligand-binding motifs. The same is true for the effector domains exhibiting distinct interfaces ensuring specific interactions with downstream target proteins. All together these factors suggest specific biological functions for individual NLRs.	[Proell, Martina; Schwarzenbacher, Robert] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Riedl, Stefan J.] Burnham Inst Med Res, La Jolla, CA USA; [Fritz, Joerg H.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Rojas, Ana M.] Spanish Natl Canc Res Ctr, Structural Computat Biol Grp, Madrid, Spain	Salzburg University; Sanford Burnham Prebys Medical Discovery Institute; University of Toronto; Centro Nacional de Investigaciones Oncologicas (CNIO)	Proell, M (corresponding author), Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.	robert.schwarzenbacher@sbg.ac.at	IBIS, BIOINFORMATICA/O-1882-2015; Rojas, Ana M/C-3022-2008; Rojas, Ana M/D-5777-2011; Rojas, Ana M./I-2882-2019	Rojas, Ana M/0000-0003-0750-9099; Rojas, Ana M./0000-0003-0750-9099	Austrian Academy of Sciences [APART-fellowship]; V-foundation [fellow];  [MCEXT-033534];  [MIRG-CT-2005-016499];  [DOC-FFORTE-fellowship]	Austrian Academy of Sciences; V-foundation; ; ; 	This work was supported by MCEXT-033534 to RS and MIRG-CT-2005-016499 to AMR. MP was supported by a DOC-FFORTE-fellowship and JHF by an APART-fellowship of the Austrian Academy of Sciences. SJR is a fellow of the V-foundation.	Albrecht M, 2006, BIOCHEM BIOPH RES CO, V339, P459, DOI 10.1016/j.bbrc.2005.10.074; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ammelburg M, 2006, J STRUCT BIOL, V156, P2, DOI 10.1016/j.jsb.2006.05.002; Colonna M, 2007, NAT IMMUNOL, V8, P554, DOI 10.1038/ni0607-554; Diemand AV, 2006, J STRUCT BIOL, V156, P230, DOI 10.1016/j.jsb.2006.04.011; Duncan JA, 2007, P NATL ACAD SCI USA, V104, P8041, DOI 10.1073/pnas.0611496104; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Enkhbayar P, 2004, PROTEINS, V54, P394, DOI 10.1002/prot.10605; Faustin B, 2008, TRENDS CELL BIOL, V18, P4, DOI 10.1016/j.tcb.2007.10.004; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Kim HE, 2005, P NATL ACAD SCI USA, V102, P17545, DOI 10.1073/pnas.0507900102; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Lelpe DD, 2004, J MOL BIOL, V343, P1, DOI 10.1016/j.jmb.2004.08.023; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Lu CF, 2005, BIOCHEM BIOPH RES CO, V331, P1114, DOI 10.1016/j.bbrc.2005.04.027; Manon F, 2007, J MOL BIOL, V365, P160, DOI 10.1016/j.jmb.2006.09.067; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2007, EUR J IMMUNOL, V37, P3003, DOI 10.1002/eji.200737871; Martinon F, 2007, SEMIN IMMUNOPATHOL, V29, P213, DOI 10.1007/s00281-007-0079-y; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Natarajan A, 2006, J BIOL CHEM, V281, P31863, DOI 10.1074/jbc.M605458200; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Tattoli I, 2007, SEMIN IMMUNOPATHOL, V29, P289, DOI 10.1007/s00281-007-0083-2; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; Werts C, 2006, CELL DEATH DIFFER, V13, P798, DOI 10.1038/sj.cdd.4401890; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; YE Z, 2007, MOL CELL BIOL; Yu XC, 2006, J MOL BIOL, V355, P577, DOI 10.1016/j.jmb.2005.10.040	52	255	260	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2119	10.1371/journal.pone.0002119	http://dx.doi.org/10.1371/journal.pone.0002119			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446235	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300049
J	Rolf, HJ; Kierdorf, U; Kierdorf, H; Schulz, J; Seymour, N; Schliephake, H; Napp, J; Niebert, S; Wolfel, H; Wiese, KG				Rolf, Hans J.; Kierdorf, Uwe; Kierdorf, Horst; Schulz, Jutta; Seymour, Natascha; Schliephake, Henning; Napp, Joanna; Niebert, Sabine; Woelfel, Helmuth; Wiese, K. Guenter			Localization and Characterization of STRO-1(+) Cells in the Deer Pedicle and Regenerating Antler	PLOS ONE			English	Article							HUMAN BONE-MARROW; STEM-CELLS; GROWING TIP; POPULATION; IDENTIFICATION; PERIOSTEUM; GROWTH; KEY	The annual regeneration of deer antlers is a unique developmental event in mammals, which as a rule possess only a very limited capacity to regenerate lost appendages. Studying antler regeneration can therefore provide a deeper insight into the mechanisms that prevent limb regeneration in humans and other mammals, and, with regard to medical treatments, may possibly even show ways how to overcome these limitations. Traditionally, antler regeneration has been characterized as a process involving the formation of a blastema from de-differentiated cells. More recently it has, however, been hypothesized that antler regeneration is a stem cell-based process. Thus far, direct evidence for the presence of stem cells in primary or regenerating antlers was lacking. Here we demonstrate the presence of cells positive for the mesenchymal stem cell marker STRO-1 in the chondrogenic growth zone and the perivascular tissue of the cartilaginous zone in primary and regenerating antlers as well as in the pedicle of fallow deer (Dama dama). In addition, cells positive for the stem cell/progenitor cell markers STRO-1, CD133 and CD271 (LNGFR) were isolated from the growth zones of regenerating fallow deer antlers as well as the pedicle periosteum and cultivated for extended periods of time. We found evidence that STRO-1(+) cells isolated from the different locations are able to differentiate in vitro along the osteogenic and adipogenic lineages. Our results support the view that the annual process of antler regeneration might depend on the periodic activation of mesenchymal progenitor cells located in the pedicle periosteum. The findings of the present study indicate that not only limited tissue regeneration, but also extensive appendage regeneration in a postnatal mammal can occur as a stem cell-based process.	[Rolf, Hans J.; Schulz, Jutta; Seymour, Natascha; Schliephake, Henning; Napp, Joanna; Niebert, Sabine; Wiese, K. Guenter] Univ Gottingen, Dept Maxillofacial Surg, Univ Hosp, Gottingen, Germany; [Kierdorf, Uwe; Kierdorf, Horst] Univ Hildesheim, Dept Biol, Hildesheim, Germany; [Woelfel, Helmuth] Univ Gottingen, Fac Forest Sci & Forest Ecol, Wildlife Biol & Game Management, Gottingen, Germany	University of Gottingen; University of Hildesheim; University of Gottingen	Rolf, HJ (corresponding author), Univ Gottingen, Dept Maxillofacial Surg, Univ Hosp, Gottingen, Germany.	hrolf@uni-goettingen.de	Kierdorf, Uwe/F-2539-2012; Schliephake, Henning/I-8911-2019	Kierdorf, Uwe/0000-0003-0531-2460; Wiese, K. Gunter/0000-0001-6436-0468; Kierdorf, Horst/0000-0001-6411-9631; Napp, Joanna/0000-0002-9034-9980	German Research Society [RO 2520 1-1, 1-3]	German Research Society(German Research Foundation (DFG))	This research was supported by grants from the German Research Society (DFG/grant numbers: RO 2520 1-1, 1-3).	Akimenko MA, 2003, DEV DYNAM, V226, P190, DOI 10.1002/dvdy.10248; Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582-4934.2004.tb00320.x; Berg DK, 2007, BIOL REPROD, V77, P384, DOI 10.1095/biolreprod.106.058172; Brachvogel B, 2005, DEVELOPMENT, V132, P2657, DOI 10.1242/dev.01846; Cegielski M, 2006, B VET I PULAWY, V50, P247; CHRISTOV C, 2007, MOL BIOL CELL; Clark DE, 2006, ANAT REC PART A, V288A, P973, DOI 10.1002/ar.a.20364; DELLING G, 1972, BEITR PATHOL, V145, P100; Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182; Francis SM, 1998, J EXP ZOOL, V281, P36, DOI 10.1002/(SICI)1097-010X(19980501)281:1&lt;36::AID-JEZ6&gt;3.0.CO;2-D; Goss R.J., 1983, DEER ANTLERS REGENER; Goss R.J., 1984, SOFT HARD TISSUE REP, P554; GOSS RJ, 1995, ANAT REC, V241, P291, DOI 10.1002/ar.1092410302; GOSS RJ, 1980, CLIN ORTHOP RELAT R, P270; GOSS RJ, 1985, J EXP ZOOL, V235, P359, DOI 10.1002/jez.1402350307; Goss RJ., 1972, EPIDERMAL WOUND HEAL, P219; GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164; HARTWIG H, 1974, Zeitschrift fuer Jagdwissenschaft, V20, P1, DOI 10.1007/BF01901843; Jones EA, 2002, ARTHRITIS RHEUM-US, V46, P3349, DOI 10.1002/art.10696; Jones EA, 2006, CYTOM PART B-CLIN CY, V70B, P391, DOI 10.1002/cyto.b.20118; KIERDORF H, 2001, ROLE ANTLEROGENIC PE, P33; KIERDORF H, 1992, STATE DETERMINATION, P525; Kierdorf U, 2003, ANAT REC PART A, V273A, P741, DOI 10.1002/ar.a.10082; Kierdorf U, 2002, Z JAGDWISS, V48, P22, DOI 10.1007/BF02285354; KIERDORF U, 1994, ANN ANAT, V176, P251; KIERDORF U, 2004, BONE FORMATION ANTLE, P55; Kierdorf U, 2007, J MORPHOL, V268, P726, DOI 10.1002/jmor.10546; Li CY, 2007, J EXP ZOOL PART A, V307A, P95, DOI 10.1002/jez.a.352; Li CY, 2007, CELL TISSUE RES, V328, P65, DOI 10.1007/s00441-006-0333-y; Li CY, 2005, ANAT REC PART A, V282A, P163, DOI 10.1002/ar.a.20148; Matich J, 2003, CELL BIOL INT, V27, P625, DOI 10.1016/S1065-6995(03)00118-5; Morrison JI, 2006, J CELL BIOL, V172, P433, DOI 10.1083/jcb.200509011; MOUNT JG, 2006, ANTLERS MAY REGENERA, V161; NAPP J, 2006, ADV DEER BIOL DEER C; Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220; Price J, 2005, CURR TOP DEV BIOL, V67, P1, DOI 10.1016/S0070-2153(05)67001-9; Price JS, 2005, J ANAT, V207, P603, DOI 10.1111/j.1469-7580.2005.00478.x; ROLF HJ, 2006, ADV DEER BIOL DEER C; ROLF HJ, 2006, OSTEOLOGY, V15, P245; Romeis B., 1989, MIKROSKOPISCHE TECHN; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Sieber-Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129; Sieber-Blum Maya, 2004, Birth Defects Res C Embryo Today, V72, P162, DOI 10.1002/bdrc.20008; SIMMONS PJ, 1991, BLOOD, V78, P55; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Wislocki GB, 1942, AM J ANAT, V71, P371, DOI 10.1002/aja.1000710304; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170	47	57	66	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2064	10.1371/journal.pone.0002064	http://dx.doi.org/10.1371/journal.pone.0002064			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446198	Green Submitted, Green Published, gold			2022-12-25	WOS:000261572300033
J	Vaitaitis, GM; Wagner, DH				Vaitaitis, Gisela M.; Wagner, David H., Jr.			High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity	PLOS ONE			English	Article								Background: CD40-CD154 interactions have proven critical in autoimmunity, with the identification of CD4(lo)CD40(+) T cells (Th40 cells) as harboring an autoaggressive T cell population shedding new insights into those disease processes. Th40 cells are present at contained levels in non-autoimmune individuals but are significantly expanded in autoimmunity. Th40 cells are necessary and sufficient in transferring type 1 diabetes in mouse models. However, little is known about CD40 signaling in T cells and whether there are differences in that signaling and subsequent outcome depending on disease conditions. When CD40 is engaged, CD40 and TNF-receptor associated factors, TRAFs, become associated with lipid raft microdomains. Dysregulation of T cell homeostasis is emerging as a major contributor to autoimmune disease and thwarted apoptosis is key in breaking homeostasis. Methodology/Principal Findings: Cells were sorted into CD4(hi) and CD4(lo) (Th40 cells) then treated and assayed either as whole or fractionated cell lysates. Protein expression was assayed by western blot and Nf-kappa B DNA-binding activity by electrophoretic mobility shifts. We demonstrate here that autoimmune NOD Th40 cells have drastically exaggerated expression of CD40 on a per-cell-basis compared to non-autoimmune BALB/c. Immediately ex-vivo, untreated Th40 cells from NOD mice have high levels of CD40 and TRAF2 associated with the raft microdomain while Th40 cells from NOR and BALB/c mice do not. CD40 engagement of Th40 cells induces Nf-kappa B DNA-binding activity and anti-apoptotic Bcl-X-L expression in all three mouse strains. However, only in NOD Th40 cells is anti-apoptotic cFLIP(p43) induced which leads to preferential survival and proliferation. Importantly, CD40 engagement rescues NOD Th40 cells from Fas-induced death. Conclusions/Significance: CD40 may act as a switch between life and death promoting signals and NOD Th40 cells are poised for survival via this switch. This may explain how they expand in autoimmunity to thwart T cell homeostasis.	[Vaitaitis, Gisela M.; Wagner, David H., Jr.] Univ Colorado, Dept Med, Webb Waring Inst, Denver, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaitaitis, GM (corresponding author), Univ Colorado, Dept Med, Webb Waring Inst, Denver, CO 80202 USA.	David.Wagner@uchsc.edu		Vaitaitis, Gisela/0000-0001-6413-8322	National Institutes of Health [DK07501]; American Diabetes Association; Juvenile Diabetes Research Foundation; Kleberg Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK007501] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Kleberg Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from National Institutes of Health (grant # DK07501), the American Diabetes Association, the Juvenile Diabetes Research Foundation and the Kleberg Foundation.	Adorini L, 2003, ANN NY ACAD SCI, V987, P258, DOI 10.1111/j.1749-6632.2003.tb06057.x; Andrade RM, 2005, J IMMUNOL, V175, P6014, DOI 10.4049/jimmunol.175.9.6014; Balasa B, 1997, J IMMUNOL, V159, P4620; Benson RJ, 2006, EUR J IMMUNOL, V36, P2535, DOI 10.1002/eji.200535483; Bishop GA, 2003, CYTOKINE GROWTH F R, V14, P297, DOI 10.1016/S1359-6101(03)00024-8; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; Cooper CJ, 2004, J IMMUNOL, V173, P6532, DOI 10.4049/jimmunol.173.11.6532; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Harding SA, 2004, ATHEROSCLEROSIS, V176, P321, DOI 10.1016/j.atherosclerosis.2004.05.008; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HULEATT JW, 1995, J IMMUNOL, V154, P5684; Issazadeh S, 2000, J CLIN INVEST, V105, P1109, DOI 10.1172/JCI8607; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; KAWAKAMI K, 1995, IMMUNOL LETT, V46, P143, DOI 10.1016/0165-2478(95)00034-3; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kobata T, 2000, Rev Immunogenet, V2, P74; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Lafaille JJ, 1998, CYTOKINE GROWTH F R, V9, P139, DOI 10.1016/S1359-6101(98)00009-4; Lamhamedi-Cherradi SE, 1998, DIABETOLOGIA, V41, P178, DOI 10.1007/s001250050887; Lepault F, 2000, J IMMUNOL, V164, P240, DOI 10.4049/jimmunol.164.1.240; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Munroe ME, 2004, J BIOL CHEM, V279, P53222, DOI 10.1074/jbc.M410539200; Munroe ME, 2007, J IMMUNOL, V178, P671, DOI 10.4049/jimmunol.178.2.671; Nakamura H, 1999, LAB INVEST, V79, P261; Ott PA, 2005, CELL IMMUNOL, V235, P1, DOI 10.1016/j.cellimm.2005.05.003; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Quezada SA, 2003, ARTHRITIS RHEUM, V48, P2541, DOI 10.1002/art.11230; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Santamaria P, 2003, ANN NY ACAD SCI, V1005, P88, DOI 10.1196/annals.1288.010; Seetharaman R, 1999, J IMMUNOL, V163, P1577; SERREZE DV, 1994, J EXP MED, V180, P1553, DOI 10.1084/jem.180.4.1553; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Solanilla A, 2005, BLOOD, V105, P215, DOI 10.1182/blood-2003-07-2367; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Suda T, 1997, J ALLERGY CLIN IMMUN, V100, pS97, DOI 10.1016/S0091-6749(97)70013-7; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Toubi E, 2004, AUTOIMMUNITY, V37, P457, DOI 10.1080/08916930400002386; Vaitaitis GM, 2003, J IMMUNOL, V170, P3455, DOI 10.4049/jimmunol.170.7.3455; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Varo Nerea, 2005, Diab Vasc Dis Res, V2, P81, DOI 10.3132/dvdr.2005.014; Wagner DH, 2002, P NATL ACAD SCI USA, V99, P3782, DOI 10.1073/pnas.052247099; Wagner DH, 1999, INT J MOL MED, V4, P231; Waid DM, 2007, CLIN IMMUNOL, V124, P138, DOI 10.1016/j.clim.2007.05.003; Waid DM, 2004, EUR J IMMUNOL, V34, P1488, DOI 10.1002/eji.200324703; WAID DM, J LEUKOC BI IN PRESS; Wang X, 2004, FASEB J, V18, P1826, DOI 10.1096/fj.04-2047com; Wang XB, 2002, J IMMUNOL, V168, P2046, DOI 10.4049/jimmunol.168.4.2046; Xie P, 2006, J IMMUNOL, V176, P5388, DOI 10.4049/jimmunol.176.9.5388; Yan JC, 2004, CLIN CHIM ACTA, V339, P85, DOI 10.1016/j.cccn.2003.09.007; Yu SG, 2001, J AUTOIMMUN, V16, P37, DOI 10.1006/jaut.2000.0458; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	58	24	26	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2076	10.1371/journal.pone.0002076	http://dx.doi.org/10.1371/journal.pone.0002076			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446238	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300045
J	Yao, K; Gagnon, S; Akhyani, N; Williams, E; Fotheringham, J; Frohman, E; Stuve, O; Monson, N; Racke, MK; Jacobson, S				Yao, Karen; Gagnon, Susan; Akhyani, Nahid; Williams, Elizabeth; Fotheringham, Julie; Frohman, Elliot; Stuve, Olaf; Monson, Nancy; Racke, Michael K.; Jacobson, Steven			Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients	PLOS ONE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; JC VIRUS; HUMAN-HERPESVIRUS-6; INFECTION; VARIANT; HHV-6; ASSOCIATION; PREVALENCE; THERAPY; BRAIN	The alpha(4) integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaired immune surveillance due to natalizumab treatment may have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients treated with and without natalizumab were examined for evidence of HHV-6. In addition, we also superinfected a persistent JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA was detected in the CSF of a subset of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.	[Yao, Karen; Gagnon, Susan; Akhyani, Nahid; Williams, Elizabeth; Fotheringham, Julie; Jacobson, Steven] NIH, Viral Immunol Sect, Bethesda, MD 20892 USA; [Frohman, Elliot; Stuve, Olaf; Monson, Nancy; Racke, Michael K.] Univ Texas, SW Med Ctr, Ctr Immunol, Dept Neurol, Dallas, TX USA; [Yao, Karen] Johns Hopkins Univ, Dept Biol, Baltimore, MD USA	National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Yao, K (corresponding author), NIH, Viral Immunol Sect, Bldg 10, Bethesda, MD 20892 USA.	jacobsons@ninds.nih.gov	Calabrese, Massimiliano/I-6195-2012		National Institutes of Health, National Institute of Neurological Disorders and Stroke; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003040, Z01NS003040, Z01NS002817, ZIANS002817] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was funded by the National Institutes of Health, National Institute of Neurological Disorders and Stroke.	Ablashi DV, 1998, MULT SCLER, V4, P490, DOI 10.1177/135245859800400606; Ahlqvist J, 2005, J NEUROVIROL, V11, P384, DOI 10.1080/13550280591002379; Akhyani N, 2000, J INFECT DIS, V182, P1321, DOI 10.1086/315893; Alvarez-Lafuente R, 2006, BRAIN PATHOL, V16, P20, DOI 10.1111/j.1750-3639.2006.tb00558.x; Alvarez-Lafuente R, 2004, ARCH NEUROL-CHICAGO, V61, P1523, DOI 10.1001/archneur.61.10.1523; Alvarez-Lafuente R, 2002, ACTA NEUROL SCAND, V105, P95, DOI 10.1034/j.1600-0404.2002.1o050.x; Andre-Garnier E, 2004, J GEN VIROL, V85, P3333, DOI 10.1099/vir.0.80319-0; Bennett JL, 2006, NEUROL RES, V28, P291, DOI 10.1179/016164106X98189; Berger JR, 2005, NEW ENGL J MED, V353, P414, DOI 10.1056/NEJMe058122; Birnbaum T, 2005, CLIN INFECT DIS, V40, P887, DOI 10.1086/427943; BROWN P, 1975, AM J EPIDEMIOL, V102, P331, DOI 10.1093/oxfordjournals.aje.a112169; Cermelli C, 2003, J INFECT DIS, V187, P1377, DOI 10.1086/368166; Cermelli C, 2000, VIRAL IMMUNOL, V13, P255, DOI 10.1089/08828240050144590; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Dewhurst Stephen, 2004, Herpes, V11 Suppl 2, p105A; Dominguez G, 1999, J VIROL, V73, P8040, DOI 10.1128/JVI.73.10.8040-8052.1999; Donati D, 2003, NEUROLOGY, V61, P1405, DOI 10.1212/01.WNL.0000094357.10782.F9; Donati D, 2005, J VIROL, V79, P9439, DOI 10.1128/JVI.79.15.9439-9448.2005; Fotheringham J, 2007, J INFECT DIS, V195, P450, DOI 10.1086/510757; FRENKEL N, 1994, BONE MARROW TRANSPL, V14, P839; Gentile Giuseppe, 2000, Herpes, V7, P24; Gilden DH, 2005, LANCET NEUROL, V4, P195, DOI 10.1016/S1474-4422(05)01017-3; HOUFF SA, 1989, AIDS, V3, P843, DOI 10.1097/00002030-198912000-00010; Isaacson E, 2005, CLIN INFECT DIS, V40, P890, DOI 10.1086/427944; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; Khalili K, 2007, NEUROLOGY, V68, P985, DOI 10.1212/01.wnl.0000257832.38943.2b; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kroon FP, 1997, CLIN INFECT DIS, V25, P600, DOI 10.1086/513750; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Luppi M, 1999, J VIROL, V73, P754, DOI 10.1128/JVI.73.1.754-759.1999; Maeda Y, 2000, LEUKEMIA LYMPHOMA, V39, P229, DOI 10.3109/10428190009065823; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McFarland HF, 2006, ARCH NEUROL-CHICAGO, V63, P1366, DOI 10.1001/archneur.63.10.1366; Mock DJ, 1999, J NEUROVIROL, V5, P363, DOI 10.3109/13550289909029477; Ongradi J, 1999, J NEUROVIROL, V5, P529, DOI 10.3109/13550289909045382; Opsahl ML, 2005, BRAIN, V128, P516, DOI 10.1093/brain/awh390; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Ransohoff RM, 2005, NAT NEUROSCI, V8, P1275, DOI 10.1038/nn1005-1275; Rice GPA, 2005, NEUROLOGY, V64, P1336, DOI 10.1212/01.WNL.0000158329.30470.D0; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Ryschkewitsch C, 2004, J VIROL METHODS, V121, P217, DOI 10.1016/j.jviromet.2004.06.021; SECCHIERO P, 1995, J INFECT DIS, V171, P273, DOI 10.1093/infdis/171.2.273; Soldan SS, 2000, ANN NEUROL, V47, P306, DOI 10.1002/1531-8249(200003)47:3<306::AID-ANA5>3.0.CO;2-A; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Steinman L, 2005, NAT REV DRUG DISCOV, V4, P510, DOI 10.1038/nrd1752; Stuve O, 2006, ANN NEUROL, V59, P743, DOI 10.1002/ana.20858; Stuve O, 2006, ARCH NEUROL-CHICAGO, V63, P1383, DOI 10.1001/archneur.63.10.1383; Tishon A, 1996, NAT MED, V2, P1250, DOI 10.1038/nm1196-1250; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; Villoslada P, 2003, NEUROLOGY, V60, P1944, DOI 10.1212/01.WNL.0000069461.53733.F7; Winklhofer KF, 2000, VIROLOGY, V275, P323, DOI 10.1006/viro.2000.0503; YAMANISHI K, 1988, LANCET, V1, P1065; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693	55	45	47	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2028	10.1371/journal.pone.0002028	http://dx.doi.org/10.1371/journal.pone.0002028			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446218	Green Submitted, Green Published, gold			2022-12-25	WOS:000261572300002
J	Rodriguez, A; Ehlenberger, DB; Dickstein, DL; Hof, PR; Wearne, SL				Rodriguez, Alfredo; Ehlenberger, Douglas B.; Dickstein, Dara L.; Hof, Patrick R.; Wearne, Susan L.			Automated Three-Dimensional Detection and Shape Classification of Dendritic Spines from Fluorescence Microscopy Images	PLOS ONE			English	Article							CALCIUM DYNAMICS; NEURONS; PLASTICITY; STABILITY; MORPHOLOGY; DIFFUSION; NEOCORTEX; CORTEX; CA1	A fundamental challenge in understanding how dendritic spine morphology controls learning and memory has been quantifying three-dimensional (3D) spine shapes with sufficient precision to distinguish morphologic types, and sufficient throughput for robust statistical analysis. The necessity to analyze large volumetric data sets accurately, efficiently, and in true 3D has been a major bottleneck in deriving reliable relationships between altered neuronal function and changes in spine morphology. We introduce a novel system for automated detection, shape analysis and classification of dendritic spines from laser scanning microscopy (LSM) images that directly addresses these limitations. The system is more accurate, and at least an order of magnitude faster, than existing technologies. By operating fully in 3D the algorithm resolves spines that are undetectable with standard two-dimensional (2D) tools. Adaptive local thresholding, voxel clustering and Rayburst Sampling generate a profile of diameter estimates used to classify spines into morphologic types, while minimizing optical smear and quantization artifacts. The technique opens new horizons on the objective evaluation of spine changes with synaptic plasticity, normal development and aging, and with neurodegenerative disorders that impair cognitive function.	[Rodriguez, Alfredo; Ehlenberger, Douglas B.; Dickstein, Dara L.; Hof, Patrick R.; Wearne, Susan L.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; [Rodriguez, Alfredo; Ehlenberger, Douglas B.; Wearne, Susan L.] Mt Sinai Sch Med, Lab Biomath, New York, NY USA; [Rodriguez, Alfredo; Ehlenberger, Douglas B.; Dickstein, Dara L.; Hof, Patrick R.; Wearne, Susan L.] Mt Sinai Sch Med, Computat Neurobiol & Imaging Ctr, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Rodriguez, A (corresponding author), Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.	susan.wearne@mssm.edu	Dickstein, Dara/AAH-6603-2020; Dickstein, Dara/F-3036-2013		NIH [MH71818, DC05669, MH58911, AG05138]; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH058911, R01MH071818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005669] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by NIH grants MH71818 and DC05669 (SLW) and MH58911 and AG05138 (PRH).	Al-Kofahi KA, 2002, IEEE T INF TECHNOL B, V6, P171, DOI 10.1109/TITB.2002.1006304; Alvarez VA, 2007, ANNU REV NEUROSCI, V30, P79, DOI 10.1146/annurev.neuro.30.051606.094222; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bloodgood BL, 2005, SCIENCE, V310, P866, DOI 10.1126/science.1114816; Bloodgood BL, 2007, CURR OPIN NEUROBIOL, V17, P345, DOI 10.1016/j.conb.2007.04.003; BLOOM FE, 1997, NEUROINFORMATICS OVE, P83; Borgefors G, 1999, PATTERN RECOGN, V32, P1225, DOI 10.1016/S0031-3203(98)00082-X; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; Cheng J, 2007, J NEUROSCI METH, V165, P122, DOI 10.1016/j.jneumeth.2007.05.020; Dailey ME, 1996, J NEUROSCI, V16, P2983; Duan HL, 2003, CEREB CORTEX, V13, P950, DOI 10.1093/cercor/13.9.950; GLASER JR, 1990, COMPUT MED IMAG GRAP, V14, P307, DOI 10.1016/0895-6111(90)90105-K; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; HARRIS KM, 1992, J NEUROSCI, V12, P2685; He W, 2003, MICROSC MICROANAL, V9, P296, DOI 10.1017/S143192760303040X; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Holthoff K, 2002, NEURON, V33, P425, DOI 10.1016/S0896-6273(02)00576-7; Holtmaat AJGD, 2005, NEURON, V45, P279, DOI 10.1016/j.neuron.2005.01.003; Holtmaat A, 2006, NATURE, V441, P979, DOI 10.1038/nature04783; JACKINS CL, 1980, COMPUT VISION GRAPH, V14, P249, DOI 10.1016/0146-664X(80)90055-6; JONES EG, 1969, J CELL SCI, V5, P509; Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0; Koh IYY, 2002, NEURAL COMPUT, V14, P1283, DOI 10.1162/089976602753712945; Krichmar JL, 2002, BRAIN RES, V941, P11, DOI 10.1016/S0006-8993(02)02488-5; LEE TC, 1994, CVGIP-GRAPH MODEL IM, V56, P462, DOI 10.1006/cgip.1994.1042; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Majewska A, 2000, J NEUROSCI, V20, P8262, DOI 10.1523/JNEUROSCI.20-22-08262.2000; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Page TL, 2002, NEUROSCI LETT, V317, P37, DOI 10.1016/S0304-3940(01)02428-4; PETERS A, 1970, AM J ANAT, V127, P321, DOI 10.1002/aja.1001270402; RIDLER TW, 1978, IEEE T SYST MAN CYB, V8, P630, DOI 10.1109/tsmc.1978.4310039; Rodriguez A, 2006, NAT PROTOC, V1, P2152, DOI 10.1038/nprot.2006.313; Santamaria F, 2006, NEURON, V52, P635, DOI 10.1016/j.neuron.2006.10.025; Schikorski T, 1999, P NATL ACAD SCI USA, V96, P4107, DOI 10.1073/pnas.96.7.4107; Schmitt S, 2004, NEUROIMAGE, V23, P1283, DOI 10.1016/j.neuroimage.2004.06.047; SCORCIONI R, 2001, LECT NOTES COMP SCI, V2084, P30; STRATFORD K, 1989, COMP NEUR S, P296; Streekstra GJ, 2002, NETWORK-COMP NEURAL, V13, P381, DOI 10.1088/0954-898X/13/3/308; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Wearne SL, 2005, NEUROSCIENCE, V136, P661, DOI 10.1016/j.neuroscience.2005.05.053; Yuste R, 2000, NAT NEUROSCI, V3, P653, DOI 10.1038/76609; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang Y, 2007, NEUROIMAGE, V36, P346, DOI 10.1016/j.neuroimage.2007.02.044; Zhou Q, 2004, TRENDS NEUROSCI, V27, P378, DOI 10.1016/j.tins.2004.05.006; Zuo Y, 2005, NEURON, V46, P181, DOI 10.1016/j.neuron.2005.04.001	49	403	406	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1997	10.1371/journal.pone.0001997	http://dx.doi.org/10.1371/journal.pone.0001997			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431482	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700017
J	Jay, SM; Shepherd, BR; Bertram, JP; Pober, JS; Saltzman, WM				Jay, Steven M.; Shepherd, Benjamin R.; Bertram, James P.; Pober, Jordan S.; Saltzman, W. Mark			Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation	FASEB JOURNAL			English	Article						tissue engineering; VEGF; therapeutic revascularization	ISCHEMIC SKELETAL-MUSCLE; IN-VIVO; BIOLOGICAL-ACTIVITY; SUSTAINED DELIVERY; CONTROLLED-RELEASE; PROTEIN DELIVERY; ANGIOGENESIS; TISSUE; MICROSPHERES; REGENERATION	Transplantation of Bcl-2-transduced human umbilical vein endothelial cells (ECs) in protein gels into the gastrocnemius muscle improves local reperfusion in immunodeficient mouse hosts with induced hind limb ischemia. We tested the hypothesis that incorporation of local, sustained growth factor delivery could enhance and accelerate this effect. Tissue engineering scaffolds often use synthetic polymers to enable controlled release of proteins, but most synthetic delivery systems have major limitations, most notably hydrophobicity and inefficient protein loading. Here, we report the development of a novel alginate-based delivery system for vascular endothelial growth factor-A(165) (VEGF) that exhibits superior loading efficiency and physical properties to previous systems in vitro. In vivo, VEGF released from alginate microparticles within protein gels was biologically active and, when combined with EC transplantation, led to increased survival of transplanted cells at 28 days. The composite graft described also improved early (14 days) tissue perfusion and late (28 days) muscle myoglobin expression, a sign of recovery from ischemia, compared with EC transplantation and VEGF delivery separately. We conclude that our improved approach to sustained VEGF delivery in tissue engineering is useful in vivo and that the integration of high efficiency protein delivery enhances the therapeutic effect of protein gel-based EC transplantation.	[Jay, Steven M.; Shepherd, Benjamin R.; Bertram, James P.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA; [Jay, Steven M.; Shepherd, Benjamin R.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Dept Immunobiol, New Haven, CT 06511 USA; [Jay, Steven M.; Shepherd, Benjamin R.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Interdepartmental Program Vasc Biol & Therapeut, New Haven, CT 06511 USA	Yale University; Yale University; Yale University	Saltzman, WM (corresponding author), Yale Univ, Dept Biomed Engn, 55 Prospect St,MEC 415, New Haven, CT 06511 USA.	mark.saltzman@yale.edu	Jay, Steven/ABD-4344-2021	Jay, Steven/0000-0002-3827-5988	NHLBI NIH HHS [R01 HL085416, R01-HL-085416-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Choi SH, 2006, INT J PHARMACEUT, V311, P223, DOI 10.1016/j.ijpharm.2005.12.023; Cleland JL, 2001, J CONTROL RELEASE, V72, P13, DOI 10.1016/S0168-3659(01)00258-9; Elcin YM, 2001, ARTIF ORGANS, V25, P558, DOI 10.1046/j.1525-1594.2001.025007558.x; Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102; Faranesh AZ, 2004, MAGN RESON MED, V51, P1265, DOI 10.1002/mrm.20092; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fleming AB, 2001, J CONTROL RELEASE, V70, P29, DOI 10.1016/S0168-3659(00)00318-7; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Gu F, 2004, J CONTROL RELEASE, V96, P463, DOI 10.1016/j.jconrel.2004.02.021; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hill E, 2006, P NATL ACAD SCI USA, V103, P2494, DOI 10.1073/pnas.0506004103; Huang M, 2007, BIOMACROMOLECULES, V8, P1607, DOI 10.1021/bm061211k; Jain RK, 2005, NAT BIOTECHNOL, V23, P821, DOI 10.1038/nbt0705-821; Kim TK, 2002, J PHARM PHARMACOL, V54, P897, DOI 10.1211/002235702760089009; King TW, 2000, J BIOMED MATER RES, V51, P383, DOI 10.1002/1097-4636(20000905)51:3<383::AID-JBM12>3.0.CO;2-D; KLOCK G, 1994, APPL MICROBIOL BIOT, V40, P638; Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378-5173(01)00691-3; Lee H, 2002, TRANSPLANTATION, V73, P1589, DOI 10.1097/00007890-200205270-00011; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Mahoney MJ, 2006, TISSUE ENG, V12, P1915, DOI 10.1089/ten.2006.12.1915; Mahoney MJ, 2001, NAT BIOTECHNOL, V19, P934, DOI 10.1038/nbt1001-934; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Peters MC, 2002, J BIOMED MATER RES, V60, P668, DOI 10.1002/jbm.10134; Peters MC, 1998, J BIOMAT SCI-POLYM E, V9, P1267, DOI 10.1163/156856298X00389; Pieper JS, 2002, J BIOMED MATER RES, V62, P185, DOI 10.1002/jbm.10267; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Saltzman WM, 1999, PHARMACEUT RES, V16, P232, DOI 10.1023/A:1018824324275; Saltzman WM, 2002, NAT REV DRUG DISCOV, V1, P177, DOI 10.1038/nrd744; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x; Smith MK, 2006, TISSUE ENG, V12, P235, DOI 10.1089/ten.2006.12.235; Smith MK, 2004, TISSUE ENG, V10, P63, DOI 10.1089/107632704322791709; van Weel V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.c3; Wallace DG, 2003, ADV DRUG DELIVER REV, V55, P1631, DOI 10.1016/j.addr.2003.08.004; Wang X, 2007, BIOMATERIALS, V28, P4161, DOI 10.1016/j.biomaterials.2007.05.036; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Zheng CH, 2004, BIOCHEM BIOPH RES CO, V323, P1321, DOI 10.1016/j.bbrc.2004.09.007	43	50	52	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2949	2956		10.1096/fj.08-108803	http://dx.doi.org/10.1096/fj.08-108803			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18450813	Green Published			2022-12-25	WOS:000258089300035
J	Komatsu, D; Kato, M; Nakayama, J; Miyagawa, S; Kamata, T				Komatsu, D.; Kato, M.; Nakayama, J.; Miyagawa, S.; Kamata, T.			NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression	ONCOGENE			English	Article						Nox1; Ras; VEGF; ER K; Sp1	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE PHOSPHATASES; REACTIVE OXYGEN; FACTOR GENE; ACTIVATION; CELLS; SUPEROXIDE; CANCER; NOX1; ADENOCARCINOMA	Reactive oxygen species (ROS)-generating enzyme Nox1 is important in the induction of oncogenic Ras transformation phenotypes, but it is not defined whether Nox1 is involved in Ras-induced upregulation of vascular endothelial growth factor (VEGF), a potent stimulator of tumor angiogenesis. Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. Nox1siRNAs and DPI suppressed extracellular signal-regulated kinase (ERK)dependent phosphorylation of a transcription factor Sp1 and Sp1 binding to a VEGF promoter. Furthermore, tumors derived from Nox1siRNA-transfected KNRK cells markedly decreased neovascularization. The Nox1 activity was required for VEGF production in human colon cancer CaCO-2 cells, as in the case of KNRK cells. However, since overexpression of Nox1 in normal rat kidney cells failed to induce VEGF, the Nox1 activity alone was not sufficient to upregulate VEGF expression, which suggests that unlike the previously proposed model, Nox1 may act in concert with other effectors integrated into the Ras network. We propose that Nox1 mediates oncogenic Ras-induced upregulation of VEGF and angiogenesis by activating Sp1 through Ras-ERK-dependent phosphorylation of Sp1.	[Komatsu, D.; Kato, M.; Kamata, T.] Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Komatsu, D.; Miyagawa, S.] Shinshu Univ, Grad Sch Med, Dept Surg, Nagano 3908621, Japan; [Nakayama, J.] Shinshu Univ, Grad Sch Med, Inst Organ Transplantat Reconstruct Med & Tissue, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Carnesecchi S, 2006, EXP CELL RES, V312, P3413, DOI 10.1016/j.yexcr.2006.07.003; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Gioeli D, 1999, CANCER RES, V59, P279; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Mochizuki T, 2006, ONCOGENE, V25, P3699, DOI 10.1038/sj.onc.1209406; Omachi T, 2007, CANCER LETT, V246, P167, DOI 10.1016/j.canlet.2006.02.013; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Sambrook J., 2001, MOL CLONING; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Szanto I, 2005, J PATHOL, V207, P164, DOI 10.1002/path.1824; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	30	84	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4724	4732		10.1038/onc.2008.102	http://dx.doi.org/10.1038/onc.2008.102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18454179				2022-12-25	WOS:000258236300010
J	Droga-Mazovec, G; Bojic, L; Petelin, A; Ivanova, S; Romih, R; Repnik, U; Salvesen, GS; Stoka, V; Turk, V; Turk, B				Droga-Mazovec, Gabriela; Bojic, Lea; Petelin, Ana; Ivanova, Saska; Romih, Rok; Repnik, Urska; Salvesen, Guy S.; Stoka, Veronika; Turk, Vito; Turk, Boris			Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-MEMBRANE PERMEABILIZATION; ESCHERICHIA-COLI; OXIDATIVE STRESS; CYTOCHROME-C; FACTOR AIF; APOPTOSIS; PROTEASE; ACTIVATION; PROTEINS; SPECIFICITY	As a model for defining the role of lysosomal cathepsins in apoptosis, we characterized the action of the lysosomotropic agent LeuLeuOMe using distinct cellular models. LeuLeuOMe induces lysosomal membrane permeabilization, resulting in release of lysosomal cathepsins that cleave the proapoptotic Bcl-2 family member Bid and degrade the antiapoptotic member Bcl-2, Bcl-xL, or Mcl-1. The papain-like cysteine protease inhibitor E-64d largely prevented apoptosis, Bid cleavage, and Bcl-2/Bcl-xL/Mcl-1 degradation. The pancaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone failed to prevent Bid cleavage and degradation of anti-apoptotic Bcl-2 homologues but substantially decreased cell death, suggesting that cathepsin-mediated apoptosis in these cellular models mostly follows a caspase-dependent pathway. Moreover, in vitro experiments showed that one or more of the cysteine cathepsins B, L, S, K, and H could cleave Bcl-2, Bcl-xL, Mcl-1, Bak, and BimEL, whereas no Bax cleavage was observed. On the basis of inhibitor studies, we demonstrate that lysosomal disruption triggered by LeuLeuOMe occurs before mitochondrial damage. We propose that degradation of anti-apoptotic Bcl-2 family members by lysosomal cathepsins synergizes with cathepsin-mediated activation of Bid to trigger a mitochondrial pathway to apoptosis. Moreover, XIAP (X-chromosome-linked inhibitor of apoptosis) was also found to be a target of cysteine cathepsins, suggesting that cathepsins can mediate caspase-dependent apoptosis also downstream of mitochondria.	[Droga-Mazovec, Gabriela; Bojic, Lea; Petelin, Ana; Ivanova, Saska; Repnik, Urska; Stoka, Veronika; Turk, Vito; Turk, Boris] Jozef Stefan Inst, Dept Biochem Mol & Struct Biol, SI-1000 Ljubljana, Slovenia; [Romih, Rok] Univ Ljubljana, Fac Med, Inst Cell Biol, SI-1105 Ljubljana, Slovenia; [Salvesen, Guy S.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana; Sanford Burnham Prebys Medical Discovery Institute	Turk, B (corresponding author), Jozef Stefan Inst, Dept Biochem Mol & Struct Biol, SI-1000 Ljubljana, Slovenia.	boris.turk@ijs.si	Stoka, Veronika/AAM-2283-2021; Ivanova, Saska/AAJ-1283-2021	Turk, Boris/0000-0002-9007-5764; Ivanova, Saska/0000-0003-0080-6680				Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Barbosa CMV, 2006, EUR J PHARMACOL, V542, P37, DOI 10.1016/j.ejphar.2006.06.004; Barlic-Maganja D, 1998, BIOL CHEM, V379, P1449; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; Brunk UT, 2001, REDOX REP, V6, P91, DOI 10.1179/135100001101536094; CHARLEY M, 1986, J CLIN INVEST, V78, P1415, DOI 10.1172/JCI112730; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; D'Alessio KJ, 1999, PROTEIN EXPRES PURIF, V15, P213, DOI 10.1006/prep.1998.1013; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guncar G, 1998, STRUCTURE, V6, P51; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kirschke H, 1995, PROTEIN PROFILE, V2, P1587; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kobayashi Y, 2000, BIOCHEM BIOPH RES CO, V272, P687, DOI 10.1006/bbrc.2000.2836; Kopitar-Jerala N, 2001, BIOL CHEM, V382, P867, DOI 10.1515/BC.2001.106; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; Mijatovic T, 2006, NEOPLASIA, V8, P402, DOI 10.1593/neo.05850; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Murahashi H, 2003, J LEUKOCYTE BIOL, V73, P399, DOI 10.1189/jlb.0702335; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; THIELE DL, 1992, J IMMUNOL, V148, P3950; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; Turk B., 2005, MED CHEM REV, V2, P283, DOI [10.2174/1567203054637524, DOI 10.2174/1567203054637524]; Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	68	278	285	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19140	19150		10.1074/jbc.M802513200	http://dx.doi.org/10.1074/jbc.M802513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18469004	hybrid			2022-12-25	WOS:000257165600069
J	Timm, T; Balusamy, K; Li, XY; Biernat, J; Mandelkow, E; Mandelkow, EM				Timm, Thomas; Balusamy, Kiruthiga; Li, Xiaoyu; Biernat, Jacek; Mandelkow, Eckhard; Mandelkow, Eva-Maria			Glycogen synthase kinase (GSK) 3 beta directly phosphorylates serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ASSOCIATED DOMAINS; ALZHEIMER-LIKE STATE; PROTEIN-KINASE; NEURONAL POLARITY; TAU-PROTEIN; SAD KINASES; PAR-1; MARK/PAR-1; ESTABLISHMENT; DISEASE	MARK/Par-1, a kinase family with diverse functions particularly in inducing cell polarity, can phosphorylate microtubule-associated proteins in their repeat domain and cause their detachment from microtubules, and thereby microtubule destabilization. Because of its role in abnormal phosphorylation of the Tau protein in Alzheimer disease, we searched for regulatory kinases. MARK family kinases can be activated by phosphorylation of a conserved threonine (Thr-208 in MARK2), and inactivated by phosphorylation of a serine (Ser-212), both in the activation loop of the catalytic domain. Activation is achieved by the kinases MARKK/TAO1 or LKB1, although the inactivating kinase was unknown. We show here that GSK3 beta serves the role of the inhibitory kinase. Because GSK3 beta can also phosphorylate Tau at sites outside the repeat domain, the activation of GSK3 beta, and concomitant inactivation of MARK can shift the pattern of pathological phosphorylation of Tau protein in Alzheimer disease.	[Timm, Thomas; Balusamy, Kiruthiga; Li, Xiaoyu; Biernat, Jacek; Mandelkow, Eckhard; Mandelkow, Eva-Maria] Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society	Mandelkow, EM (corresponding author), Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.	mandelkow@mpasmb.desy.de						Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Benton R, 2002, DEV CELL, V3, P659, DOI 10.1016/S1534-5807(02)00320-9; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Chen YM, 2006, P NATL ACAD SCI USA, V103, P8534, DOI 10.1073/pnas.0509955103; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Drewes G, 2004, TRENDS BIOCHEM SCI, V29, P548, DOI 10.1016/j.tibs.2004.08.001; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Elbert M, 2005, MOL BIOL CELL, V16, P532, DOI 10.1091/mbc.E04-07-0549; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim L, 2006, CURR DRUG TARGETS, V7, P1411, DOI 10.2174/1389450110607011411; Kishi M, 2005, SCIENCE, V307, P929, DOI 10.1126/science.1107403; Kojima Y, 2007, J BIOL CHEM, V282, P23532, DOI 10.1074/jbc.M700590200; Kosuga S, 2005, J BIOL CHEM, V280, P42715, DOI 10.1074/jbc.M507941200; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Madhusudan Elzbieta A. Trafny, 1994, Protein Science, V3, P176; Mandelkow E, 2007, BRAIN PATHOL, V17, P83, DOI 10.1111/j.1750-3639.2007.00053.x; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marx A, 2006, J BIOL CHEM, V281, P27586, DOI 10.1074/jbc.M604865200; Matenia D, 2005, MOL BIOL CELL, V16, P4410, DOI 10.1091/mbc.E05-01-0081; Maurer MH, 2007, J PROTEOME RES, V6, P1198, DOI 10.1021/pr0605825; Muller J, 2003, EMBO J, V22, P4431, DOI 10.1093/emboj/cdg426; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Ossipova Olga, 2002, Gene Expression Patterns, V2, P145, DOI 10.1016/S0925-4773(02)00306-4; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Riechmann V, 2002, NAT CELL BIOL, V4, P337, DOI 10.1038/ncb782; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Spicer J, 2004, CURR BIOL, V14, pR383, DOI 10.1016/j.cub.2004.05.012; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Thies E, 2007, J NEUROSCI, V27, P2896, DOI 10.1523/JNEUROSCI.4674-06.2007; Timm T, 2006, NEURODEGENER DIS, V3, P207, DOI 10.1159/000095258; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Tochio N, 2006, PROTEIN SCI, V15, P2534, DOI 10.1110/ps.062391106	51	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18873	18882		10.1074/jbc.M706596200	http://dx.doi.org/10.1074/jbc.M706596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18424437	hybrid			2022-12-25	WOS:000257165600044
J	Toso, R; Zhu, H; Camire, RM				Toso, Raffaella; Zhu, Hua; Camire, Rodney M.			The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-XA; TICK ANTICOAGULANT PEPTIDE; COAGULATION-FACTOR-XA; RUSSELLS VIPER VENOM; SODIUM-BINDING-SITE; FACTOR VA BINDING; SERINE PROTEASES; ACTIVE-SITE; PLASMINOGEN-ACTIVATOR; SUBSTRATE-SPECIFICITY	Zymogens of the chymotrypsin-like serine protease family are converted to the protease state following insertion of a newly formed, highly conserved N terminus. This transition is accompanied by active site formation and ordering of several surface loops in the catalytic domain. Here we show that disruption of this transition in factor X through mutagenesis (FXa(I16L) and FXa(V17A)) not only alters active site function, but also significantly impairs Na+ and factor Va binding. Active site binding was improved in the presence of high NaCl or with saturating amounts of factor Va membranes, suggesting that allosteric linkage exists between these sites. In line with this, irreversible stabilization of FXa(I16L) with Glu-Gly-Arg-chloromethyl ketone fully rescued FVa binding. Furthermore, the K-m for prothrombin conversion with the factor Xa variants assembled into prothrombinase was unaltered, whereas the k(cat) was modestly reduced (3- to 4-fold). These findings show that intramolecular activation of factor X following the zymogen to protease transition not only drives catalytic site activation but also contributes to the formation of the Na+ and factor Va binding sites. This structural plasticity of the catalytic domain plays a key role in the regulation of exosite expression and prothrombinase assembly.	[Toso, Raffaella; Zhu, Hua; Camire, Rodney M.] Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Abramson Res Ctr 302E, Philadelphia, PA 19104 USA; [Camire, Rodney M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Abramson Res Ctr 302E, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, T32HL007439] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-74124-01, T32 HL-07439-26] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; Bock PE, 2007, J THROMB HAEMOST, V5, P81, DOI 10.1111/j.1538-7836.2007.02496.x; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; DAHLBACK B, 1978, BIOCHEMISTRY-US, V17, P4938, DOI 10.1021/bi00616a013; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; Gombos L, 2008, BIOCHEMISTRY-US, V47, P1675, DOI 10.1021/bi701454e; GOWDA DC, 1994, J BIOL CHEM, V269, P10644; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KAWABATA S, 1985, J BIOCHEM, V98, P1603, DOI 10.1093/oxfordjournals.jbchem.a135430; KEYT B, 1982, J BIOL CHEM, V257, P8687; Khan AR, 1998, PROTEIN SCI, V7, P815; Kirchhofer D, 2007, P NATL ACAD SCI USA, V104, P5306, DOI 10.1073/pnas.0700184104; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; Levigne S, 2007, J BIOL CHEM, V282, P31569, DOI 10.1074/jbc.M704837200; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lundblad R L, 1976, Methods Enzymol, V45, P156; Madoiwa S, 2001, BLOOD, V97, P3783, DOI 10.1182/blood.V97.12.3783; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Pasternak A, 1998, BIOCHEMISTRY-US, V37, P16201, DOI 10.1021/bi980951d; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PLAPP BV, 1971, J BIOL CHEM, V246, P939; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 2004, J BIOL CHEM, V279, P48262, DOI 10.1074/jbc.M409964200; ROBISON DJ, 1980, J BIOL CHEM, V255, P2014; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; SEGAL IH, 1975, ENZYME KINETICS BEHA; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; Toso R, 2006, J BIOL CHEM, V281, P8773, DOI 10.1074/jbc.M511419200; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; Venkateswarlu D, 2002, BIOPHYS J, V82, P1190, DOI 10.1016/S0006-3495(02)75476-3; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	64	35	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18627	18635		10.1074/jbc.M802205200	http://dx.doi.org/10.1074/jbc.M802205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460471	Green Published, hybrid			2022-12-25	WOS:000257165600019
J	Cole, AR; Soutar, MPM; Rembutsu, M; van Aalten, L; Hastie, CJ; Mclauchlan, H; Peggie, M; Balastik, M; Lu, KP; Sutherland, C				Cole, Adam R.; Soutar, Marc P. M.; Rembutsu, Makoto; van Aalten, Lidy; Hastie, C. James; Mclauchlan, Hilary; Peggie, Mark; Balastik, Martin; Lu, Kun Ping; Sutherland, Calum			Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE MEDIATOR PROTEIN-2; PROLYL ISOMERASE PIN1; GLYCOGEN-SYNTHASE KINASE-3; GROWTH-CONE COLLAPSE; ALZHEIMERS-DISEASE; TAU-PROTEIN; NEUROFIBRILLARY TANGLES; HIPPOCAMPAL-NEURONS; PHOSPHATASE 2A; OKADAIC ACID	Collapsin response mediator protein 2 (CRMP2) binds to microtubules and regulates axon outgrowth in neurons. This action is regulated by sequential phosphorylation by the kinases cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3) at sites that are hyperphosphorylated in Alzheimer disease. The increased phosphorylation in Alzheimer disease could be due to increases in Cdk5 and/or GSK3 activity or, alternatively, through decreased activity of a CRMP phosphatase. Here we establish that dephosphorylation of CRMP2 at the residues targeted by GSK3 (Ser-518/Thr-514/Thr-509) is carried out by a protein phosphatase 1 family member in vitro, in neuroblastoma cells, and primary cortical neurons. Inhibition of GSK3 activity using insulin-like growth factor-1 or the highly selective inhibitor CT99021 causes rapid dephosphorylation of CRMP2 at these sites. In contrast, pharmacological inhibition of Cdk5 using purvalanol results in only a gradual and incomplete dephosphorylation of CRMP2 at the site targeted by Cdk5 (Ser-522), suggesting a distinct phosphatase targets this residue. A direct comparison of dephosphorylation at the Cdk5 versus GSK3 sites in vitro shows that the Cdk5 site is comparatively resistant to phosphatase treatment. The presence of the peptidylprolyl isomerase enzyme, Pin1, does not affect dephosphorylation of Ser-522 in vitro, in cells, or in Pin1 transgenic mice. Instead, the relatively high resistance of this site to phosphatase treatment is at least in part due to the presence of basic residues located nearby. Similar sequences in Tau are also highly resistant to phosphatase treatment. We propose that relative resistance to phosphatases might be a common feature of Cdk5 substrates and could contribute to the hyperphosphorylation of CRMP2 and Tau observed in Alzheimer disease.	[Cole, Adam R.; Soutar, Marc P. M.; Rembutsu, Makoto; van Aalten, Lidy; Sutherland, Calum] Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; [Hastie, C. James; Mclauchlan, Hilary; Peggie, Mark] Univ Dundee, Coll Life Sci, Div Signal Transduct Therapy, Dundee DD1 4HN, Scotland; [Balastik, Martin; Lu, Kun Ping] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program, Boston, MA 02115 USA	University of Dundee; University of Dundee; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sutherland, C (corresponding author), Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	c.d.sutherland@dundee.ac.uk	Balastik, Martin/C-4410-2014; Soutar, Marc P M/G-3637-2011; Cole, Adam/B-9785-2011	Balastik, Martin/0000-0001-5833-9996; Soutar, Marc P M/0000-0003-0008-9423; Hastie, James/0000-0001-7164-4098; Sutherland, Calum/0000-0003-4398-7434	Biotechnology and Biological Sciences Research Council [C18727] Funding Source: Medline; Medical Research Council Funding Source: Medline; Alzheimers Research UK [ART-PG2007-4, ART-PG2005-1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; Cole AR, 2007, J NEUROCHEM, V103, P1132, DOI 10.1111/j.1471-4159.2007.04829.x; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamdane M, 2006, MOL CELL NEUROSCI, V32, P155, DOI 10.1016/j.mcn.2006.03.006; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Rembutsu M, 2008, BIOCHEMISTRY-US, V47, P2153, DOI 10.1021/bi702030w; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Swatton JE, 2004, EUR J NEUROSCI, V19, P2711, DOI 10.1111/j.0953-816X.2004.03365.x; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Tandon A, 2003, J NEUROCHEM, V86, P572, DOI 10.1046/j.1471-4159.2003.01865.x; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; YANG SD, 1981, FEBS LETT, V126, P57, DOI 10.1016/0014-5793(81)81032-0; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	43	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18227	18237		10.1074/jbc.M801645200	http://dx.doi.org/10.1074/jbc.M801645200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18460467	Green Published, hybrid			2022-12-25	WOS:000256949200051
J	Molina-Navarro, MM; Castells-Roca, L; Belli, G; Garcia-Martinez, J; Marin-Navarro, J; Moreno, J; Perez-Ortin, JE; Herrero, E				Molina-Navarro, Maria Micaela; Castells-Roca, Laia; Belli, Gemma; Garcia-Martinez, Jose; Marin-Navarro, Julia; Moreno, Joaquin; Perez-Ortin, Jose E.; Herrero, Enrique			Comprehensive transcriptional analysis of the oxidative response in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SACCHAROMYCES-CEREVISIAE; STRESS-RESPONSE; GENE-EXPRESSION; BINDING; TRANSLATION; PROTEOME; SYSTEM; DECAY; IRON	The oxidative stress response in Saccharomyces cerevisiae has been analyzed by parallel determination of mRNA levels and transcription rates for the entire genome. A mathematical algorithm has been adapted for a dynamic situation such as the response to stress, to calculate theoretical mRNA decay rates from the experimental data. Yeast genes have been grouped into 25 clusters according to mRNA level and transcription rate kinetics, and average mRNA decay rates have been calculated for each cluster. In most of the genes, changes in one or both experimentally determined parameters occur during the stress response. 24% of the genes are transcriptionally induced without an increase in mRNA levels. The lack of parallelism between the evolution of the mRNA amount and transcription rate predicts changes in mRNA stability during stress. Genes for ribosomal proteins and rRNA processing enzymes are abundant among those whose mRNAs are predicted to destabilize. The number of genes whose mRNAs are predicted to stabilize is lower, although some protein folding or proteasomal genes are among the latter. We have confirmed the mathematical predictions for several genes pertaining to different clusters by experimentally determining mRNA decay rates using the regulatable tetO promoter in transcriptional expression conditions not affected by the oxidative stress. This study indicates that the oxidative stress response in yeast cells is not only conditioned by gene transcription but also by the mRNA decay dynamics and that this complex response may be particularly relevant to explain the temporary down-regulation of protein synthesis occurring during stress.	[Molina-Navarro, Maria Micaela; Castells-Roca, Laia; Belli, Gemma; Herrero, Enrique] Univ Lleida, Dept Ciencies Med Basiques & IRBLLeida, Lleida 25008, Spain; [Marin-Navarro, Julia; Moreno, Joaquin] Univ Valencia, Secc Chips DNA, Serv Cent Ayuda Invest Expt, E-46100 Burjassot, Spain; [Garcia-Martinez, Jose] Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain	Universitat de Lleida; University of Valencia; University of Valencia	Herrero, E (corresponding author), Univ Lleida, Dept Ciencies Med Basiques & IRBLLeida, Montserrat Roig 2, Lleida 25008, Spain.	enric.herrero@cmb.udl.cat	belli, gemma/A-7424-2011; Herrero, Enrique/B-5592-2009; Garcia-Martinez, Jose/F-6790-2016; Bellí, Gemma/AAD-5325-2019; Castells-Roca, Laia/I-1227-2015; Garcia-Martinez, Jose/X-4995-2019; Pérez-Ortín, José E./K-8582-2014; , Marín-Navarro/F-7630-2016; Castells Roca, Laia/C-4444-2011	belli, gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; Garcia-Martinez, Jose/0000-0001-5866-5994; Bellí, Gemma/0000-0002-4161-3204; Castells-Roca, Laia/0000-0002-4604-9999; Garcia-Martinez, Jose/0000-0001-5866-5994; Pérez-Ortín, José E./0000-0002-1992-513X; , Marín-Navarro/0000-0001-7893-3423; , Micaela/0000-0002-2103-0351				Alberola TM, 2004, INT MICROBIOL, V7, P199; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; Bussemaker HJ, 2001, NAT GENET, V27, P167, DOI 10.1038/84792; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Garcia-Martinez J, 2004, MOL CELL, V15, P303, DOI 10.1016/j.molcel.2004.06.004; Gasch AP, 2003, TOP CURR GENET, V1, P11; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grigull J, 2004, MOL CELL BIOL, V24, P5534, DOI 10.1128/MCB.24.12.5534-5547.2004; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; Herrero E, 2008, BBA-GEN SUBJECTS, V1780, P1217, DOI 10.1016/j.bbagen.2007.12.004; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lee JW, 1996, J BIOL CHEM, V271, P24885, DOI 10.1074/jbc.271.40.24885; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Newbury SF, 2006, BIOCHEM SOC T, V34, P30, DOI 10.1042/BST0340030; OCONGARRIDO E, 2002, MOL MICROBIOL, V43, P993, DOI DOI 10.1046/J.1365-2958.2002.02795.X; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Perez-Ortin JE, 2007, TRENDS GENET, V23, P250, DOI 10.1016/j.tig.2007.03.006; Perez-Ortin Jose E., 2007, Briefings in Functional Genomics & Proteomics, V6, P282, DOI 10.1093/bfgp/elm029; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Rodriguez-Gabriel MA, 2003, EMBO J, V22, P6256, DOI 10.1093/emboj/cdg597; Rodriguez-Gabriel MA, 2006, MOL CELL BIOL, V26, P6347, DOI 10.1128/MCB.00286-06; Shenton D, 2006, J BIOL CHEM, V281, P29011, DOI 10.1074/jbc.M601545200; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Simon E, 2006, TRENDS BIOCHEM SCI, V31, P241, DOI 10.1016/j.tibs.2006.03.001; Sunnerhagen P, 2007, MOL GENET GENOMICS, V277, P341, DOI 10.1007/s00438-007-0221-5; Swaminathan S, 2006, MOL BIOL CELL, V17, P1472, DOI 10.1091/mbc.e05-07-0632; Tenenbaum SA, 2003, GENE, V317, P79, DOI 10.1016/S0378-1119(03)00661-9; Thorsen M, 2007, PHYSIOL GENOMICS, V30, P35, DOI 10.1152/physiolgenomics.00236.2006; Toledano MB, 2003, TOP CURR GENET, V1, P241; Toledano MB, 2007, FEBS LETT, V581, P3598, DOI 10.1016/j.febslet.2007.07.002; Vasudevan S, 2005, MOL CELL BIOL, V25, P9753, DOI 10.1128/MCB.25.22.9753-9763.2005; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wanke V, 1999, MOL MICROBIOL, V32, P753, DOI 10.1046/j.1365-2958.1999.01391.x; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906	43	60	60	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17908	17918		10.1074/jbc.M800295200	http://dx.doi.org/10.1074/jbc.M800295200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18424442	hybrid, Green Published			2022-12-25	WOS:000256949200019
J	Wagner, S; Pop, O; Haan, GJ; Baars, L; Koningstein, G; Klepsch, MM; Genevaux, P; Luirink, J; de Gier, JW				Wagner, Samuel; Pop, Ovidio; Haan, Gert-Jan; Baars, Louise; Koningstein, Gregory; Klepsch, Mirjam M.; Genevaux, Pierre; Luirink, Joen; de Gier, Jan-Willem			Biogenesis of MalF and the MalFGK(2) maltose transport complex in Escherichia coli requires YidC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; INNER MEMBRANE-PROTEINS; TRIGGER FACTOR; CONDUCTING CHANNEL; YIELDS MUTATIONS; SEC-TRANSLOCASE; RIBOSOME; INSERTION; SITE; BINDING	The polytopic inner membrane protein MalF is a constituent of the MalFGK(2) maltose transport complex in Escherichia coli. We have studied the biogenesis of MalF using a combination of in vivo and in vitro approaches. MalF is targeted via the SRP pathway to the Sec/YidC insertion site. Despite close proximity of nascent MalF to YidC during insertion, YidC is not required for the insertion of MalF into the membrane. However, YidC is required for the stability of MalF and the formation of the MalFGK2 maltose transport complex. Our data indicate that YidC supports the folding of MalF into a stable conformation before it is incorporated into the maltose transport complex.	[Pop, Ovidio; Haan, Gert-Jan; Koningstein, Gregory; Luirink, Joen] Vrije Univ Amsterdam, Dept Mol Microbiol, Inst Mol Cell Biol, NL-1081 HV Amsterdam, Netherlands; [Wagner, Samuel; Baars, Louise; Klepsch, Mirjam M.; de Gier, Jan-Willem] Stockholm Univ, Dept Biochem & Biophys, Ctr Biomembrane Res, SE-10691 Stockholm, Sweden; [Genevaux, Pierre] Univ Toulouse 3, CNRS, Inst Biol Cellulaire & Genet, Lab Microbiol & Genet Mol, F-31062 Toulouse 09, France	Vrije Universiteit Amsterdam; Stockholm University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Luirink, J (corresponding author), Vrije Univ Amsterdam, Dept Mol Microbiol, Inst Mol Cell Biol, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl; degier@dbb.su.se	Luirink, Joen/AAB-8658-2021; Genevaux, Pierre/A-4851-2015	GENEVAUX, Pierre/0000-0001-7539-3126; Luirink, J./0000-0001-8431-0804				Adams H, 2002, EUR J BIOCHEM, V269, P5564, DOI 10.1046/j.1432-1033.2002.03262.x; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; Clemons WM, 2004, CURR OPIN STRUC BIOL, V14, P390, DOI 10.1016/j.sbi.2004.07.006; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; Facey SJ, 2004, BBA-MOL CELL RES, V1694, P55, DOI 10.1016/j.bbamcr.2004.03.012; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Halic M, 2006, SCIENCE, V312, P745, DOI 10.1126/science.1124864; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; Hatzixanthis K, 2003, MOL MICROBIOL, V49, P1377, DOI 10.1046/j.1365-2958.2003.03642.x; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Ito K, 2005, ANNU REV MICROBIOL, V59, P211, DOI 10.1146/annurev.micro.59.030804.121316; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KIETER D, 2007, INT REV CYTOL, V259, P113; Kota J, 2005, J CELL BIOL, V168, P79, DOI 10.1083/jcb.200408106; Kota J, 2007, J CELL BIOL, V176, P617, DOI 10.1083/jcb.200612100; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lotz M, 2008, J MOL BIOL, V375, P901, DOI 10.1016/j.jmb.2007.10.089; Luirink J, 2005, ANNU REV MICROBIOL, V59, P329, DOI 10.1146/annurev.micro.59.030804.121246; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Rapoport TA, 2007, NATURE, V450, P663, DOI 10.1038/nature06384; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Sadlish H, 2005, NAT STRUCT MOL BIOL, V12, P870, DOI 10.1038/nsmb994; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; Shimohata N, 2007, J CELL BIOL, V176, P307, DOI 10.1083/jcb.200611121; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Tian HP, 2002, J BACTERIOL, V184, P111, DOI 10.1128/JB.184.1.111-118.2002; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Wagner S, 2007, MOL CELL PROTEOMICS, V6, P1527, DOI 10.1074/mcp.M600431-MCP200; Xie K, 2008, NAT REV MICROBIOL, V6, P234, DOI 10.1038/nrmicro3595	61	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17881	17890		10.1074/jbc.M801481200	http://dx.doi.org/10.1074/jbc.M801481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18456666	Green Published, hybrid			2022-12-25	WOS:000256949200016
J	Zhao, CG; Haase, W; Tampe, R; Abele, R				Zhao, Chenguang; Haase, Winfried; Tampe, Robert; Abele, Rupert			Peptide specificity and lipid activation of the lysosomal transport complex ABCB9 (TAPL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-PROCESSING TAP; ATP-DEPENDENT TRANSLOCATION; CROSS-PRESENTATION; BINDING; IDENTIFICATION; COMPARTMENT; HYDROLYSIS; PHAGOSOMES; MECHANISM; VARIANTS	The lysosomal ABC transporter associated with antigen processing-like (TAPL, ABCB9) acts as an ATP-dependent polypeptide transporter with broad length selectivity. To characterize in detail its substrate specificity, a procedure for functional reconstitution of human TAPL was developed. By intensive screening of detergents, ideal solubilization conditions were evolved with respect to efficiency, long term stability, and functionality of TAPL. TAPL was isolated in a two-step procedure with high purity and, subsequently, reconstituted into proteoliposomes. The peptide transport activity of reconstituted TAPL strongly depends on the lipid composition. With the help of combinatorial peptide libraries, the key positions of the peptides were localized to the N- and C-terminal residues with respect to peptide transport. At both ends, TAPL favors positively charged, aromatic, or hydrophobic residues and disfavors negatively charged residues as well as asparagine and methionine. Besides specific interactions of both terminal residues, electrostatic interactions are important, since peptides with positive net charge are more efficiently transported than negatively charged ones.	[Zhao, Chenguang; Tampe, Robert; Abele, Rupert] Goethe Univ Frankfurt, Inst Biochem, D-60438 Frankfurt, Germany; [Haase, Winfried] Max Planck Inst Biophys, D-60438 Frankfurt, Germany	Goethe University Frankfurt; Max Planck Society	Abele, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	abele@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015; Zhao, Chenguang/L-8577-2013	Tampé, Robert/0000-0002-0403-2160; 				Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; BACHMANN MF, 1995, EUR J IMMUNOL, V25, P1739, DOI 10.1002/eji.1830250637; Biemans-Oldehinkel E, 2006, FEBS LETT, V580, P1023, DOI 10.1016/j.febslet.2005.11.079; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Dani A, 2004, J CELL SCI, V117, P4219, DOI 10.1242/jcs.01288; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Demirel O, 2007, J BIOL CHEM, V282, P37836, DOI 10.1074/jbc.M708139200; DiRusso CC, 1998, MOL MICROBIOL, V27, P1, DOI 10.1046/j.1365-2958.1998.00645.x; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gromme M, 1997, EUR J IMMUNOL, V27, P898, DOI 10.1002/eji.1830270415; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; Herget M, 2007, J BIOL CHEM, V282, P3871, DOI 10.1074/jbc.M608480200; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Kobayashi A, 2003, BIOCHEM BIOPH RES CO, V309, P815, DOI 10.1016/j.bbrc.2003.08.081; Leveson-Gower DB, 2004, BIOCHEMISTRY-US, V43, P14257, DOI 10.1021/bi0491245; Lich JD, 2000, J EXP MED, V191, P1513, DOI 10.1084/jem.191.9.1513; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Monu N, 2007, CURR OPIN IMMUNOL, V19, P66, DOI 10.1016/j.coi.2006.11.017; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Ohara T, 2008, BIOL PHARM BULL, V31, P1, DOI 10.1248/bpb.31.1; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Rea PA, 2007, ANNU REV PLANT BIOL, V58, P347, DOI 10.1146/annurev.arplant.57.032905.105406; Ritz U, 2001, INT IMMUNOL, V13, P31, DOI 10.1093/intimm/13.1.31; RIVNAY B, 1982, J BIOL CHEM, V257, P2800; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Seddon AM, 2004, BBA-BIOMEMBRANES, V1666, P105, DOI 10.1016/j.bbamem.2004.04.011; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; Uinuk-ool TS, 2003, IMMUNOGENETICS, V55, P38, DOI 10.1007/s00251-003-0548-y; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Wang P, 1996, J IMMUNOL, V157, P213; Wolters JC, 2005, J BIOL CHEM, V280, P23631, DOI 10.1074/jbc.M503231200; Zhang F, 2000, J BIOL CHEM, V275, P23287, DOI 10.1074/jbc.M001819200; Zhao CG, 2006, N-S ARCH PHARMACOL, V372, P444, DOI 10.1007/s00210-005-0028-z; Zhou DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009; [No title captured]	49	25	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17083	17091		10.1074/jbc.M801794200	http://dx.doi.org/10.1074/jbc.M801794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434309	hybrid			2022-12-25	WOS:000256720600015
J	Brindley, AA; Pickersgill, RW; Partridge, JC; Dunstan, DJ; Hunt, DM; Warren, MJ				Brindley, Amanda A.; Pickersgill, Richard W.; Partridge, Julian C.; Dunstan, David J.; Hunt, David M.; Warren, Martin J.			Enzyme Sequence and Its Relationship to Hyperbaric Stability of Artificial and Natural Fish Lactate Dehydrogenases	PLOS ONE			English	Article								The cDNAs of lactate dehydrogenase b (LDH-b) from both deep-sea and shallow living fish species, Corphaenoides armatus and Gadus morhua respectively, have been isolated, sequenced and their encoded products overproduced as recombinant enzymes in E. coli. The proteins were characterised in terms of their kinetic and physical properties and their ability to withstand high pressures. Although the two proteins are very similar in terms of their primary structure, only 21 differences at the amino acid level exist between them, the enzyme from the deep-sea species has a significantly increased tolerance to pressure and a higher thermostability. It was possible to investigate whether the changes in the N-terminal or C-terminal regions played a greater role in barophilic adaptation by the construction of two chimeric enzymes by use of a common restriction site within the cDNAs. One of these hybrids was found to have even greater pressure stability than the recombinant enzyme from the deep-living fish species. It was possible to conclude that the major adaptive changes to pressure tolerance must be located in the N-terminal region of the protein. The types of changes that are found and their spatial location within the protein structure are discussed. An analysis of the kinetic parameters of the enzymes suggests that there is clearly a trade off between Km and kcat values, which likely reflects the necessity of the deep-sea enzyme to operate at low temperatures.	[Brindley, Amanda A.; Warren, Martin J.] Univ Kent, Dept Biosci, Canterbury, Kent, England; [Pickersgill, Richard W.] Univ London, Queen Mary, Sch Biol & Chem Sci, London, England; [Partridge, Julian C.] Univ Bristol, Sch Biol Sci, Bristol, Avon, England; [Dunstan, David J.] Univ London, Queen Mary, Dept Phys, London, England; [Hunt, David M.] UCL, Inst Ophthalmol, London, England	University of Kent; University of London; Queen Mary University London; University of Bristol; University of London; Queen Mary University London; University of London; University College London	Brindley, AA (corresponding author), Univ Kent, Dept Biosci, Canterbury, Kent, England.	a.a.brindley@kent.ac.uk	Dunstan, David J/F-9830-2012; Hunt, David M/K-6024-2012; Partridge, Julian C/F-2097-2014	Hunt, David M/0000-0002-9264-3948; Partridge, Julian C/0000-0003-3788-2900; Warren, Martin/0000-0002-6028-6456	Biotechnology and Biological Sciences Research Council (BBSRC)	Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The work was funded by a grant from the Biotechnology and Biological Sciences Research Council (BBSRC). No role was played by the sponsors in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	COHEN DM, 1990, FAO FISH SYNOP, V10, P1; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HENNESSEY JP, 1987, J EXP ZOOL, V241, P9, DOI 10.1002/jez.1402410103; HENNESSEY JP, 1985, J COMP PHYSIOL B, V155, P647, DOI 10.1007/BF00694577; HOCHACHKA PW, 2002, BIOCH APADTATION MEC; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Morita T, 2003, J BIOL CHEM, V278, P28060, DOI 10.1074/jbc.M302328200; Read JA, 2001, PROTEINS, V43, P175, DOI 10.1002/1097-0134(20010501)43:2<175::AID-PROT1029>3.0.CO;2-#; Scandurra R, 1998, BIOCHIMIE, V80, P933, DOI 10.1016/S0300-9084(00)88890-2; SCHMID G, 1979, EUR J BIOCHEM, V97, P407, DOI 10.1111/j.1432-1033.1979.tb13128.x; SIEBENALLER J, 1978, SCIENCE, V201, P255, DOI 10.1126/science.208149; SIEBENALLER JF, 1984, BIOCHIM BIOPHYS ACTA, V786, P161, DOI 10.1016/0167-4838(84)90085-2; SOMERO GN, 1992, ANNU REV PHYSIOL, V54, P557, DOI 10.1146/annurev.ph.54.030192.003013; SOMERO GN, 1979, NATURE, V282, P100, DOI 10.1038/282100a0; SOMERO GN, 1992, EXPERIENTIA, V48, P537, DOI 10.1007/BF01920236; SWEZEY RR, 1982, BIOCHEMISTRY-US, V21, P4496, DOI 10.1021/bi00261a047; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Yancey PH, 2004, CELL MOL BIOL, V50, P371; Yancey PH, 1999, J EXP BIOL, V202, P3597; Yancey PH, 2001, J EXP ZOOL, V289, P172, DOI 10.1002/1097-010X(20010215)289:3<172::AID-JEZ3>3.0.CO;2-J	22	30	30	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2042	10.1371/journal.pone.0002042	http://dx.doi.org/10.1371/journal.pone.0002042			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446214	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300014
J	Shelburne, CE; Shelburne, PS; Dhople, VM; Sweier, DG; Giannobile, WV; Kinney, JS; Coulter, WA; Mullally, BH; Lopatin, DE				Shelburne, Charles E.; Shelburne, P. Sandra; Dhople, Vishnu M.; Sweier, Domenica G.; Giannobile, William V.; Kinney, Janet S.; Coulter, Wilson A.; Mullally, Brian H.; Lopatin, Dennis E.			Serum Antibodies to Porphyromonas gingivalis Chaperone HtpG Predict Health in Periodontitis Susceptible Patients	PLOS ONE			English	Article								Background: Chaperones are ubiquitous conserved proteins critical in stabilization of new proteins, repair/removal of defective proteins and immunodominant antigens in innate and adaptive immunity. Periodontal disease is a chronic inflammatory infection associated with infection by Porphyromonas gingivalis that culminates in the destruction of the supporting structures of the teeth. We previously reported studies of serum antibodies reactive with the human chaperone Hsp90 in gingivitis, a reversible form of gingival disease confined to the oral soft tissues. In those studies, antibodies were at their highest levels in subjects with the best oral health. We hypothesized that antibodies to the HSP90 homologue of P. gingivalis (HtpG) might be associated with protection/resistance against destructive periodontitis. Methodology/Principal Findings: ELISA assays using cloned HtpG and peptide antigens confirmed gingivitis subjects colonized with P. gingivalis had higher serum levels of anti-HtpG and, concomitantly, lower levels of attachment loss. Additionally, serum antibody levels to P. gingivalis HtpG protein were higher in healthy subjects compared to patients with either chronic or aggressive periodontitis. We found a negative association between tooth attachment loss and anti-P. gingivalis HtpG (p = 0.043) but not anti-Fusobacterium nucleatum (an oral opportunistic commensal) HtpG levels. Furthermore, response to periodontal therapy was more successful in subjects having higher levels of anti-P. gingivalis HtpG before treatment (p = 0.018). There was no similar relationship to anti-F. nucleatum HtpG levels. Similar results were obtained when these experiments were repeated with a synthetic peptide of a region of P. gingivalis HtpG. Conclusions/Significance: Our results suggest: 1) anti-P. gingivalis HtpG antibodies are protective and therefore predict health periodontitis-susceptable patients; 2) may augment the host defence to periodontitis and 3) a unique peptide of P. gingivalis HtpG offers significant potential as an effective diagnostic target and vaccine candidate. These results are compatible with a novel immune control mechanism unrelated to direct binding of bacteria.	[Shelburne, Charles E.; Shelburne, P. Sandra; Dhople, Vishnu M.; Lopatin, Dennis E.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [Sweier, Domenica G.] Univ Michigan, Sch Dent, Dept Cariol, Restorat Sci & Endodont, Ann Arbor, MI USA; [Giannobile, William V.; Kinney, Janet S.] Univ Michigan, Sch Dent, Michigan Ctr Oral Hlth Res, Dept Periodont & Oral Med, Ann Arbor, MI USA; [Coulter, Wilson A.; Mullally, Brian H.] Queens Univ, Ctr Oral Res, Belfast, Antrim, North Ireland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Queens University Belfast	Shelburne, CE (corresponding author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.	ceshelbu@umich.edu	Dhople, Vishnu M/J-5377-2014	Giannobile, William/0000-0002-7102-9746	NIH/NIDCR [DE11117, U01-DE-14961]; NIH/NCRR [M01-RR000042]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011117, U01DE014961] Funding Source: NIH RePORTER	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Supported by NIH/NIDCR DE11117 (DEL) and patient sample collections were supported by NIH grants NIH/NIDCR U01-DE-14961 and NIH/NCRR M01-RR000042 (WVG). The sponsors of this work had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data and in the preparation, review, or approval of the manuscript.	BAGRAMIAN RA, 1993, J CLIN PERIODONTOL, V20, P269, DOI 10.1111/j.1600-051X.1993.tb00356.x; BAGRAMIAN RA, 1994, J CLIN PERIODONTOL, V21, P386, DOI 10.1111/j.1600-051X.1994.tb00734.x; Burnie JR, 2006, FEMS MICROBIOL REV, V30, P53, DOI 10.1111/j.1574-6976.2005.00001.x; Chatterjee A, 2007, AM J RESP CRIT CARE, V176, P667, DOI 10.1164/rccm.200702-291OC; Goulhen F, 2003, CRIT REV ORAL BIOL M, V14, P399, DOI 10.1177/154411130301400603; Hosokawa Y, 2006, CLIN EXP IMMUNOL, V146, P540, DOI 10.1111/j.1365-2249.2006.03233.x; Huszti Z, 2004, INFLAMM RES, V53, P551, DOI 10.1007/s00011-004-1296-7; Kinane DF, 1999, PERIODONTOL 2000, V20, P289, DOI 10.1111/j.1600-0757.1999.tb00164.x; Koets A, 2006, VACCINE, V24, P2550, DOI 10.1016/j.vaccine.2005.12.019; Kozarov E, 2006, MICROBES INFECT, V8, P687, DOI 10.1016/j.micinf.2005.09.004; Lee JY, 2006, J PERIODONTAL RES, V41, P10, DOI 10.1111/j.1600-0765.2005.00832.x; Lin SN, 2005, J MED MICROBIOL, V54, P225, DOI 10.1099/jmm.0.45871-0; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; Lopatin DE, 1999, J PERIODONTOL, V70, P1185, DOI 10.1902/jop.1999.70.10.1185; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MATTHEWS RC, 1991, IMMUNOLOGY, V74, P20; Mullally BH, 2000, J PERIODONTAL RES, V35, P232, DOI 10.1034/j.1600-0765.2000.035004232.x; Offenbacher Steven, 2005, J Int Acad Periodontol, V7, P157; Okada H, 1998, CRIT REV ORAL BIOL M, V9, P248, DOI 10.1177/10454411980090030101; Progulske-Fox A, 1999, J PERIODONTAL RES, V34, P393, DOI 10.1111/j.1600-0765.1999.tb02272.x; Prohaszka Z, 2004, MOL IMMUNOL, V41, P29, DOI 10.1016/j.molimm.2004.02.001; Rams TE, 2006, J PERIODONTAL RES, V41, P228, DOI 10.1111/j.1600-0765.2005.00860.x; Shamaei-Tousi A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001198; Shelburne CE, 2000, J MICROBIOL METH, V39, P97, DOI 10.1016/S0167-7012(99)00106-2; Shelburne CE, 2007, CELL MICROBIOL, V9, P1611, DOI 10.1111/j.1462-5822.2007.00897.x; Silness J, 1966, Acta Odontol Scand, V24, P747, DOI 10.3109/00016356609028739; Socransky S S, 1997, Ann Periodontol, V2, P3; Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x; Sudheesh PS, 2007, DIS AQUAT ORGAN, V74, P37, DOI 10.3354/dao074037; Sweier DG, 2004, J IMMUNOL METHODS, V285, P165, DOI 10.1016/j.jim.2003.11.009; Takenaka R, 2004, HELICOBACTER, V9, P194, DOI 10.1111/j.1083-4389.2004.00225.x; VANPOPERIN N, 1991, J CLIN MICROBIOL, V29, P2554, DOI 10.1128/JCM.29.11.2554-2558.1991; WOLFF LF, 1988, J PERIODONTAL RES, V23, P170, DOI 10.1111/j.1600-0765.1988.tb01353.x; Yamaguchi H, 2000, INFECT IMMUN, V68, P3448, DOI 10.1128/IAI.68.6.3448-3454.2000; Yamazaki K, 2004, CLIN EXP IMMUNOL, V135, P478, DOI 10.1111/j.1365-2249.2003.02375.x; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; Zugel U, 1999, CLIN MICROBIOL REV, V12, P19, DOI 10.1128/CMR.12.1.19	37	23	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1984	10.1371/journal.pone.0001984	http://dx.doi.org/10.1371/journal.pone.0001984			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431474	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700009
J	Roue, G; Pichereau, V; Lincet, H; Colomer, D; Sola, B				Roue, G.; Pichereau, V.; Lincet, H.; Colomer, D.; Sola, B.			Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators	ONCOGENE			English	Article						cyclin D1; heat shock protein; apoptotic factor; B-cell lymphoma; multiple myeloma	HEAT-SHOCK PROTEINS; BREAST-CANCER CELLS; NF-KAPPA-B; ECTOPIC EXPRESSION; D1 OVEREXPRESSION; MULTIPLE-MYELOMA; LINE; CARCINOMA; HSP70; P53	Cyclin D1 is a key regulator of cell proliferation. It also controls other aspects of the cell fate, such as cellular senescence, apoptosis and tumourigenesis. We used B-lymphoid cell lines producing cyclin D1 to investigate the role of this protein in B-cell lymphomas and leukaemias. Constitutive low levels of cyclin D1 had no effect per se on cell proliferation, but conferred resistance to various apoptotic stimuli in B cells. Activation of the proapoptotic protein, Bax, was reduced and mitochondrial permeabilization and phosphatidylserine exposure following cytokine withdrawal were delayed in cyclin D1-producing cells. Proteomic analysis showed that the presence of cyclin D1 led to intracellular accumulation of various molecular chaperones. The chaperone, heat shock protein ( Hsp) 70, bound to both Bax and the mitochondrial apoptosis inducing factor following cytokine withdrawal, and impeded inhibitors of kappa B (I kappa B)mediated inhibition of nuclear factor-kappa B anti-apoptotic signalling. Impairment of Hsp70 activity-using a pharmacological Hsp inhibitor or transfecting cells with an Hsp70-blocking antibody-restored the cellular response to mitochondrial apoptosis triggering. Thus, constitutive de-novo cyclin D1 production in B cells delays commitment to apoptosis by inducing Hsp70 chaperoning activity on pre- and post-mitochondrial pro-apoptotic factors.	[Roue, G.; Colomer, D.] Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Barcelona 08036, Spain; [Roue, G.; Sola, B.] Univ Caen, IFR 146, EA 3919, F-14032 Caen, France; [Pichereau, V.] Univ Caen, IFR 146, EA 956, USC INRA 2017,Lab Microbiol Environm, F-14032 Caen, France; [Lincet, H.] Ctr Lutte Canc Francois Baclesse, IFR 146, EA1773, GRECAN, Caen, France	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universite de Caen Normandie; INRAE; Universite de Caen Normandie; UNICANCER; Centre Francois Baclesse	Roue, G (corresponding author), Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Villarroel 170, Barcelona 08036, Spain.	groue@clinic.ub.es	PICHEREAU, Vianney/B-2168-2008; ROUÉ, GAËL/D-4759-2014; PICHEREAU, Vianney/Q-7236-2019; COLOMER, DOLORS/ABG-6894-2020	PICHEREAU, Vianney/0000-0003-1078-9407; ROUÉ, GAËL/0000-0003-0245-2257; PICHEREAU, Vianney/0000-0003-1078-9407; COLOMER, DOLORS/0000-0001-7486-8484; Sola, Brigitte/0000-0001-7278-9651	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer [7791, 3426]; Spanish Ministry of Education and Science [SAF06/8850]; Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Spanish Ministry of Education and Science(Spanish Government); Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	We thank A Barbaras and S Cabezas for expert technical assistance and JM Renoir (CNRS UMR 8612, Universite de Paris Sud, France) for the gift of anti-Hsp70/90 antibody. The work was financially supported by the Ligue contre le Cancer-Comite du Calvados, Cent pour sang la vie and the Association pour la Recherche contre le Cancer ( grant nos. 7791 and 3426) to BS, and by the Spanish Ministry of Education and Science (grant SAF06/8850) to DC. GR received a scholarship from the Ligue Nationale contre le Cancer-Comite du Calvados and has a postdoctoral position with the C-RED programme (Generalitat de Catalunya, Spain).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bertoni F, 2004, CURR OPIN HEMATOL, V11, P411, DOI 10.1097/01.moh.0000138682.13354.da; Bible KC, 2000, CLIN CANCER RES, V6, P661; Burstein E, 2003, CURR OPIN CELL BIOL, V15, P732, DOI 10.1016/j.ceb.2003.10.005; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Duquesne F, 2001, CELL DEATH DIFFER, V8, P51, DOI 10.1038/sj.cdd.4400768; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hochhauser D, 1996, J NATL CANCER I, V88, P1269, DOI 10.1093/jnci/88.18.1269; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kehn K, 2007, ONCOGENE, V26, P5060, DOI 10.1038/sj.onc.1210319; Kornmann M, 1999, CANCER RES, V59, P3505; Krieger S, 2005, EXP HEMATOL, V33, P652, DOI 10.1016/j.exphem.2005.03.011; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lamb J, 2003, CELL CYCLE, V2, P525, DOI 10.4161/cc.2.6.584; Le Moguen K, 2006, PROTEOMICS, V6, P5183, DOI 10.1002/pmic.200500925; Lee KH, 2005, EXP CELL RES, V307, P276, DOI 10.1016/j.yexcr.2005.03.014; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Macario AJL, 2007, FEBS LETT, V581, P3681, DOI 10.1016/j.febslet.2007.04.030; Martin JMC, 1999, CANCER RES, V59, P1134; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sauvageot N, 2002, EUR J BIOCHEM, V269, P5731, DOI 10.1046/j.1432-1033.2002.03288.x; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; Yokota S, 2000, CANCER RES, V60, P2942; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428	55	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4909	4920		10.1038/onc.2008.126	http://dx.doi.org/10.1038/onc.2008.126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438428				2022-12-25	WOS:000258596900005
J	Rahman-Roblick, R; Hellman, U; Becker, S; Bader, FG; Auer, G; Wiman, KG; Roblick, UJ				Rahman-Roblick, R.; Hellman, U.; Becker, S.; Bader, F. G.; Auer, G.; Wiman, K. G.; Roblick, U. J.			Proteomic identification of p53-dependent protein phosphorylation	ONCOGENE			English	Article						p53; proteomics; phosphorylation	CELL-DEATH; P53; DJ-1; ACTIVATION; APOPTOSIS; GENE; METASTASIS; REGULATOR; NM23	The p53 tumor suppressor regulates transcription of target genes. We have previously analysed the p53-dependent proteome and identified novel protein targets. Here we have examined p53-dependent phosphorylation using two-dimensional gel electrophoresis and staining with the fluorescent phosphoprotein dye Pro-Q Diamond. We report that p53 induces phosphorylation of a subset of proteins including Nm23, DJ-1, ANXA1 and PrxII. Our identification of p53-dependent phosphorylation of specific target proteins reveals new aspects of the p53-dependent cellular response and suggests that such posttranslational modi. cations may contribute to p53-mediated tumor suppression.	[Wiman, K. G.] Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Hellman, U.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden; [Becker, S.; Bader, F. G.; Auer, G.] Karolinska Inst, Karolinska Biom Ctr, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Bader, F. G.; Roblick, U. J.] Univ Schleswig Holstein, Dept Surg, D-23538 Lubeck, Germany	Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Uppsala University; Karolinska Institutet; University of Kiel; Schleswig Holstein University Hospital	Wiman, KG (corresponding author), Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Roblick, Uwe J/F-5906-2011	Wiman, Klas/0000-0002-7113-524X; Auer, Gert/0000-0003-3911-0285				Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bretaud S, 2007, J NEUROCHEM, V100, P1626, DOI 10.1111/j.1471-4159.2006.04291.x; Chen SL, 2003, MOL CARCINOGEN, V36, P204, DOI 10.1002/mc.10110; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Rahman-Roblick R, 2007, P NATL ACAD SCI USA, V104, P5401, DOI 10.1073/pnas.0700794104; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG LM, 1993, CANCER RES, V53, P717	18	27	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4854	4859		10.1038/onc.2008.124	http://dx.doi.org/10.1038/onc.2008.124			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438429				2022-12-25	WOS:000258445100010
J	Tur, V; van der Sloot, AM; Reis, CR; Szegezdi, E; Cool, RH; Samali, A; Serrano, L; Quax, WJ				Tur, Vicente; van der Sloot, Almer M.; Reis, Carlos R.; Szegezdi, Eva; Cool, Robbert H.; Samali, Afshin; Serrano, Luis; Quax, Wim J.			DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-SELECTIVE MUTANTS; FADD-DEPENDENT APOPTOSIS; NF-KAPPA-B; COMPUTATIONAL REDESIGN; MONOCLONAL-ANTIBODIES; BINDING; DEATH; DR5; SPECIFICITY; CASPASE-8	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) is a potential anticancer agent that selectively induces apoptosis in a variety of cancer cells by interacting with death receptors DR4 and DR5. TRAIL can also bind to decoy receptors ( DcR1, DcR2, and osteoprotegerin receptor) that cannot induce apoptosis. Different tumor types respond either to DR4 or to DR5 activation, and chemotherapeutic drugs can increase the expression of DR4 or DR5 in cancer cells. Thus, DR4 or DR5 receptor-specific TRAIL variants would permit new and tumor-selective therapies. Previous success in generating a DR5-selective TRAIL mutant using computer-assisted protein design prompted us to make a DR4-selective TRAIL variant. Technically, the design of DR4 receptor-selective TRAIL variants is considerably more challenging compared with DR5 receptor-selective variants, because of the lack of a crystal structure of the TRAIL-DR4 complex. A single amino acid substitution of Asp at residue position 218 of TRAIL to His or Tyr was predicted to have a favorable effect on DR4 binding specificity. Surface plasmon resonance-based receptor binding tests showed a lowered DR5 affinity in concert with increased DR4 specificity for the designed variants, D218H and D218Y. Binding to DcR1, DcR2, and osteoprotegerin was also decreased. Cell line assays confirmed that the variants could not induce apoptosis in DR5-responsive Jurkat and A2780 cells but were able to induce apoptosis in DR4-responsive EM-2 and ML-1 cells.	[Reis, Carlos R.; Cool, Robbert H.; Quax, Wim J.] Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; [Tur, Vicente; van der Sloot, Almer M.] Ctr Gen Regulat, CRG EMBL Syst Biol Unit, Barcelona 08003, Spain; [Szegezdi, Eva; Samali, Afshin] Natl Univ Ireland, Dept Biochem, Cell Stress & Apoptosis Res Grp, Galway, Ireland; [Szegezdi, Eva; Samali, Afshin] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Galway, Ireland; [Cool, Robbert H.] Triskel Therapeut BV, NL-9713 AV Groningen, Netherlands; [Serrano, Luis] Univ Pompeu Fabra, CRG, ICREA, EMBL CRG Syst Biol Res Unit, Barcelona 08003, Spain	University of Groningen; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); ICREA	Quax, WJ (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	w.j.quax@rug.nl	Quax, Wim/K-2802-2012; van der Sloot, Almer/M-7083-2015; Samali, Afshin/A-9571-2008; Serrano, Luis/B-3355-2013; Quax, Wim/O-2875-2019; Szegezdi, Eva/B-7142-2008	Quax, Wim/0000-0002-5162-9947; van der Sloot, Almer/0000-0003-0049-2044; Samali, Afshin/0000-0002-8610-8375; Serrano, Luis/0000-0002-5276-1392; Quax, Wim/0000-0002-5162-9947; Szegezdi, Eva/0000-0002-5708-3535; Cool, Robbert/0000-0002-9845-2202	ICREA Funding Source: Custom	ICREA(ICREA)		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bin L, 2007, J BIOL CHEM, V282, P28189, DOI 10.1074/jbc.M704210200; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Griffith TS, 1999, J IMMUNOL, V162, P2597; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kempkens O, 2006, EUR J CELL BIOL, V85, P753, DOI 10.1016/j.ejcb.2006.03.003; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Kiel C, 2004, J MOL BIOL, V340, P1039, DOI 10.1016/j.jmb.2004.05.050; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; MacFarlane M, 2005, CELL DEATH DIFFER, V12, P773, DOI 10.1038/sj.cdd.4401649; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schymkowitz JWH, 2005, P NATL ACAD SCI USA, V102, P10147, DOI 10.1073/pnas.0501980102; Shifman JM, 2002, J MOL BIOL, V323, P417, DOI 10.1016/S0022-2836(02)00881-1; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Szczepek M, 2007, NAT BIOTECHNOL, V25, P786, DOI 10.1038/nbt1317; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; van der Sloot AM, 2004, PROTEIN ENG DES SEL, V17, P673, DOI 10.1093/protein/gzh079; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x	38	53	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20560	20568		10.1074/jbc.M800457200	http://dx.doi.org/10.1074/jbc.M800457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18474604	Green Published, hybrid			2022-12-25	WOS:000257565300068
J	Ui, M; Tanaka, Y; Tsumuraya, T; Fujii, I; Inoue, M; Hirama, M; Tsumoto, K				Ui, Mihoko; Tanaka, Yoshikazu; Tsumuraya, Takeshi; Fujii, Ikuo; Inoue, Masayuki; Hirama, Masahiro; Tsumoto, Kouhei			How protein recognizes ladder-like polycyclic ethers - Interactions between ciguatoxin (CTX3C) fragments and its specific antibody 10C9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMBIERDISCUS-TOXICUS; PTYCHODISCUS-BREVIS; MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURE; SODIUM-CHANNELS; MARINE TOXINS; CIGUATERA; BINDING; COMPLEMENTARITY; BREVETOXINS	Ciguatoxins are a family of marine toxins composed of transfused polycyclic ethers. It has not yet been clarified at the atomic level on the pathogenic mechanism of these toxins or the interaction between a polycyclic ether compounds and a protein. Using the crystal structures of anti-ciguatoxin antibody 10C9 Fab in ligand-free form and in complexes with ABCD-ring (CTX3C-ABCD) and ABCDE-ring (CTX3C-ABCDE) fragments of the antigen CTX3C at resolutions of 2.6, 2.4, and 2.3 angstrom, respectively, we elucidated the mechanism of the interaction between the polycyclic ethers and the antibody. 10C9 Fab has an extraordinarily large and deep binding pocket at the center of the variable region, where CTX3C-ABCD or CTX3C-ABCDE binds longitudinally in the pocket via hydrogen bonds and van der Waals interactions. Upon antigen-antibody complexation, 10C9 Fab adjusts to the antigen fragments by means of rotational motion in the variable region. In addition, the antigen fragment lacking the E-ring induces a large motion in the constant region. Consequently, the thermostability of 10C9 Fab is enhanced by 10 degrees C upon complexation with CTX3C-ABCDE but not with CTX3C-ABCD. The crystal structures presented in this study also show that 10C9 Fab recoginition of CTX3C antigens requires molecular rearrangements over the entire antibody structure. These results further expand the fundamental understanding of the mechanism by which ladder-like polycyclic ethers are recognized and may be useful for the design of novel therapeutic agents by antibodies, marine toxins, or new diagnostic reagents for the detection and targeting of members of the polycyclic ether family.	[Ui, Mihoko; Tanaka, Yoshikazu; Tsumoto, Kouhei] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan; [Inoue, Masayuki] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 113003, Japan; [Tsumuraya, Takeshi; Fujii, Ikuo] Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5998570, Japan; Japan Sci & Technol Agcy, SORST, Sendai, Miyagi 9808578, Japan; [Inoue, Masayuki; Hirama, Masahiro] Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan	University of Tokyo; University of Tokyo; Osaka Metropolitan University; Japan Science & Technology Agency (JST); Tohoku University	Tsumoto, K (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan.	tsumoto@k.u-tokyo.ac.jp	Tsumuraya, Takeshi/W-1080-2019; Tanaka, Yoshikazu/B-7056-2009	Tsumuraya, Takeshi/0000-0001-8979-2160				AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; Braden BC, 1998, IMMUNOL REV, V163, P45, DOI 10.1111/j.1600-065X.1998.tb01187.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Demarest SJ, 2006, PROTEIN ENG DES SEL, V19, P325, DOI 10.1093/protein/gzl016; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; Garber E, 2007, BIOCHEM BIOPH RES CO, V355, P751, DOI 10.1016/j.bbrc.2007.02.042; Haruyama H, 2002, BIOL PHARM BULL, V25, P1537, DOI 10.1248/bpb.25.1537; Hirama M, 2005, CHEM REC, V5, P240, DOI 10.1002/tcr.20049; Hirama M, 2001, SCIENCE, V294, P1904, DOI 10.1126/science.1065757; Isbister GK, 2005, LANCET NEUROL, V4, P219, DOI 10.1016/S1474-4422(05)70041-7; JEFFREY PD, 1995, J MOL BIOL, V248, P344, DOI 10.1016/S0022-2836(95)80055-7; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levine David Z., 1995, Journal of the American Osteopathic Association, V95, P193; Lewis RJ, 2006, TOXICON, V48, P799, DOI 10.1016/j.toxicon.2006.07.019; Lewis RJ, 2001, TOXICON, V39, P97, DOI 10.1016/S0041-0101(00)00161-6; LIN YY, 1981, J AM CHEM SOC, V103, P6773, DOI 10.1021/ja00412a053; LOMBET A, 1987, FEBS LETT, V219, P355, DOI 10.1016/0014-5793(87)80252-1; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oguri H, 2003, J AM CHEM SOC, V125, P7608, DOI 10.1021/ja034990a; Oishi T, 2001, SYNLETT, P952; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLI MA, 1986, MOL PHARMACOL, V30, P129; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Romesberg FE, 1998, SCIENCE, V279, P1929, DOI 10.1126/science.279.5358.1929; SATAKE M, 1993, TETRAHEDRON LETT, V34, P1975, DOI 10.1016/S0040-4039(00)91978-6; SATAKE M, 1993, J AM CHEM SOC, V115, P361, DOI 10.1021/ja00054a061; SHIMIZU Y, 1986, J AM CHEM SOC, V108, P514, DOI 10.1021/ja00263a031; Tanaka F, 1996, J AM CHEM SOC, V118, P2332, DOI 10.1021/ja952220w; Vasudevan S, 2004, BLOOD CELL MOL DIS, V32, P176, DOI 10.1016/j.bcmd.2003.04.001; Wang SY, 2003, CELL SIGNAL, V15, P151, DOI 10.1016/S0898-6568(02)00085-2; Xu JA, 1999, SCIENCE, V286, P2345, DOI 10.1126/science.286.5448.2345; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011; Yasumoto T, 2001, CHEM REC, V1, P228, DOI 10.1002/tcr.1010; 1994, ACTA CRYSTALLOGR, V50, P760	38	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19440	19447		10.1074/jbc.M801282200	http://dx.doi.org/10.1074/jbc.M801282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18463096	hybrid			2022-12-25	WOS:000257387600030
J	Mowrer, KR; Wolfe, MS				Mowrer, Karen R.; Wolfe, Michael S.			Promotion of BACE1 mRNA alternative splicing reduces amyloid beta-peptide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CLEAVING ENZYME; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HUMAN BRAIN; SECRETASE ACTIVITY; SITE; INHIBITOR; MICE; PURIFICATION; MYELINATION	Production of the amyloid beta-peptide (A beta) via sequential proteolytic cleavage of the amyloid precursor protein by beta- and gamma-secretases is strongly implicated in the pathogenesis of Alzheimer disease. The beta-secretase that executes the first cleavage event is a transmembrane aspartyl protease known as beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). BACE1 pre-mRNA is alternatively spliced through the use of alternative splice sites in exons 3 and 4, although the significance of these splicing events is unclear. Here, we quantitatively measured relative levels of BACE1 transcripts and identified a novel splice variant of BACE1. We found a subtle but significant difference in BACE1 splicing between brain and pancreas, indicating the cellular environment can affect BACE1 alternative splicing. Furthermore, we have shown that BACE1 proteins translated from alternatively spliced transcripts have dramatically reduced beta-secretase activity and promotion of BACE1 alternative splicing reduces A beta production. These findings illustrate the importance of BACE1 alternative splicing in affecting the level of A beta produced in cells and suggest that targeting regulation of BACE1 alternative splicing is a potential therapeutic strategy for lowering beta-secretase activity.	[Wolfe, Michael S.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wolfe, MS (corresponding author), 77 Ave Louis Pasteur,HIM 754, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu						Aartsma-Rus A, 2007, RNA, V13, P1609, DOI 10.1261/rna.653607; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g; Ghosh AK, 2007, CURR ALZHEIMER RES, V4, P418, DOI 10.2174/156720507781788864; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Hills ID, 2007, CURR OPIN DRUG DISC, V10, P383; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Tanahashi H, 2007, NEUROSCI LETT, V428, P103, DOI 10.1016/j.neulet.2007.09.033; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zohar O, 2003, MOL BRAIN RES, V115, P63, DOI 10.1016/S0169-328X(03)00182-7	36	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18694	18701		10.1074/jbc.M801322200	http://dx.doi.org/10.1074/jbc.M801322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18468996	hybrid			2022-12-25	WOS:000257165600026
J	Zhang, MY; Wu, XF; Lee, AJ; Jin, W; Chang, M; Wright, A; Imaizumi, T; Sun, SC				Zhang, Minying; Wu, Xuefeng; Lee, Andrew J.; Jin, Wei; Chang, Mikyoung; Wright, Ato; Imaizumi, Tadaatsu; Sun, Shao-Cong			Regulation of I kappa B kinase-related kinases and antiviral responses by tumor suppressor CYLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYME CYLD; TANK-BINDING KINASE-1; VIRAL-INFECTION; INNATE IMMUNITY; IKK-EPSILON; MEDIATED ACTIVATION; CELLS; PATHWAYS; TBK1; LIPOPOLYSACCHARIDE	The I kappa B kinase (IKK)-related kinases, IKK epsilon and TBK1, participate in the induction of type I interferons (IFNs) during viral infections. Deregulated activation of IKK epsilon and TBK1 also contributes to the abnormal cell survival and transformation. However, how these kinases are negatively regulated remains unclear. We show here that the tumor suppressor CYLD has an essential role in preventing aberrant activation of IKK epsilon/TBK1. CYLD deficiency causes constitutive activation of IKK epsilon/TBK1, which is associated with hyper-induction of IFNs in virus-infected cells. We further show that CYLD targets a cytoplasmic RNA sensor, RIG-I, and inhibits the ubiquitination of this IKK epsilon/TBK1 stimulator. Consistent with the requirement of ubiquitination in RIG-I function, CYLD potently inhibits RIG-I-mediated activation of the IFN-beta promoter. These findings establish CYLD as a key negative regulator of IKK epsilon/TBK1 and suggest a role for CYLD in the control of RIG-I ubiquitination.	[Zhang, Minying; Wu, Xuefeng; Lee, Andrew J.; Jin, Wei; Chang, Mikyoung; Wright, Ato; Sun, Shao-Cong] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Lee, Andrew J.; Wright, Ato] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; [Imaizumi, Tadaatsu] Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 0368562, Japan	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Hirosaki University	Sun, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	ssun@mdanderson.org	Lee, Andrew/GVU-2817-2022; Wu, Xuefeng/F-5003-2011		NCI NIH HHS [CA94922] Funding Source: Medline; NIAID NIH HHS [AI057555, AI064639, R37 AI064639, R01 AI057555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064639, R37AI064639, R01AI057555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Agami R, 2007, CELL, V129, P1043, DOI 10.1016/j.cell.2007.05.048; Baccala R, 2007, NAT MED, V13, P543, DOI 10.1038/nm1590; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Crow Mary K, 2005, Curr Rheumatol Rep, V7, P463, DOI 10.1007/s11926-005-0053-4; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; HACKER H, 2006, SCI STKE, V357, pRE13, DOI DOI 10.1126/STKE.3572006RE13; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Imaizumi T, 2004, ENDOTHELIUM-J ENDOTH, V11, P169, DOI 10.1080/10623320490512156; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Matsui K, 2006, J IMMUNOL, V177, P5785, DOI 10.4049/jimmunol.177.9.5785; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nordmark G, 2006, NAT CLIN PRACT RHEUM, V2, P262, DOI 10.1038/ncprheum0173; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Perry AK, 2005, CELL RES, V15, P407, DOI 10.1038/sj.cr.7290309; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Zhao TJ, 2007, NAT IMMUNOL, V8, P592, DOI 10.1038/ni1465	45	100	108	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18621	18626		10.1074/jbc.M801451200	http://dx.doi.org/10.1074/jbc.M801451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18467330	hybrid, Green Published			2022-12-25	WOS:000257165600018
J	Zhang, ZWM; Simmerman, JA; Guibao, CD; Zheng, JJ				Zhang, Ziwei M.; Simmerman, Joseph A.; Guibao, Cristina D.; Zheng, Jie J.			GIT1 paxillin-binding domain is a four-helix bundle, and it binds to both paxillin LD2 and LD4 motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NMR STRUCTURE DETERMINATION; GTPASE-ACTIVATING PROTEIN; P21-ACTIVATED KINASE; TARGETING DOMAIN; CELL-ADHESION; FAMILY; PIX; PHOSPHORYLATION; LOCALIZATION	The G protein-coupled receptor kinase-interacting protein 1 (GIT1) is a multidomain protein that plays an important role in cell adhesion, motility, cytoskeletal remodeling, and membrane trafficking. GIT1 mediates the localization of the p21-activated kinase (PAK) and PAK-interactive exchange factor to focal adhesions, and its activation is regulated by the interaction between its C-terminal paxillin-binding domain (PBD) and the LD motifs of paxillin. In this study, we determined the solution structure of rat GIT1 PBD by NMR spectroscopy. The PBD folds into a four-helix bundle, which is structurally similar to the focal adhesion targeting and vinculin tail domains. Previous studies showed that GIT1 interacts with paxillin through the LD4 motif. Here, we demonstrated that in addition to the LD4 motif, the GIT1 PBD can also bind to the paxillin LD2 motif, and both LD2 and LD4 motifs competitively target the same site on the PBD surface. We also revealed that paxillin Ser(272) phosphorylation does not influence GIT1 PBD binding in vitro. These results are in agreement with the notion that phosphorylation of paxillin Ser(272) plays an essential role in regulating focal adhesion turnover.	[Zhang, Ziwei M.; Simmerman, Joseph A.; Guibao, Cristina D.; Zheng, Jie J.] St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA; [Zhang, Ziwei M.; Zheng, Jie J.] Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Zheng, JJ (corresponding author), St Jude Childrens Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	jie.zheng@stjude.org		Zheng, Jie/0000-0001-6524-6800	NCI NIH HHS [R25 CA023944] Funding Source: Medline; NIGMS NIH HHS [R01GM069916, R01 GM069916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA023944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bertolucci CM, 2005, PROTEIN SCI, V14, P644, DOI 10.1110/ps.041107205; Bertolucci CM, 2008, BIOCHEMISTRY-US, V47, P548, DOI 10.1021/bi702103n; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Cary Leslie A., 1999, Frontiers in Bioscience, V4, pD102, DOI 10.2741/Cary; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Goddard T.D., SPARKY 3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guntert P, 1998, Q REV BIOPHYS, V31, P145, DOI 10.1017/S0033583598003436; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Herrmann T, 2002, J BIOMOL NMR, V24, P171, DOI 10.1023/A:1021614115432; Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; Ilic D, 1998, J CELL BIOL, V143, P547; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Keller R., 2004, COMPUTER AIDED RESON, V1; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Loo TH, 2004, MOL CELL BIOL, V24, P3849, DOI 10.1128/MCB.24.9.3849-3859.2004; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Paris S, 2003, BIOCHEM J, V372, P391, DOI 10.1042/BJ20030047; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Prutzman KC, 2004, STRUCTURE, V12, P881, DOI 10.1016/S0969-2126(04)00097-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmalzigaug R, 2007, CELL SIGNAL, V19, P1733, DOI 10.1016/j.cellsig.2007.03.010; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	50	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18685	18693		10.1074/jbc.M801274200	http://dx.doi.org/10.1074/jbc.M801274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18448431	hybrid, Green Published			2022-12-25	WOS:000257165600025
J	Morley, S; Cecchini, M; Zhang, W; Virgulti, A; Noy, N; Atkinson, J; Manor, D				Morley, Samantha; Cecchini, Matt; Zhang, Wendy; Virgulti, Alessandro; Noy, Noa; Atkinson, Jeffrey; Manor, Danny			Mechanisms of ligand transfer by the hepatic tocopherol transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-DEFICIENCY; PHOSPHOLIPID TRANSFER PROTEIN; ACID-BINDING PROTEIN; ALPHA-TOCOPHEROL; RETINITIS-PIGMENTOSA; GAMMA-TOCOPHEROL; RAT-LIVER; ATAXIA; GENE; MUTATION	alpha-Tocopherol is a member of the vitamin E family that functions as the principal fat-soluble antioxidant in vertebrates. Body-wide distribution of tocopherol is regulated by the hepatic alpha-tocopherol transfer protein (alpha TTP), which stimulates secretion of the vitamin from hepatocytes to circulating lipoproteins. This biological activity of alpha TTP is thought to stem from its ability to facilitate the transfer of vitamin E between membranes, but the mechanism by which the protein exerts this activity remains poorly understood. Using a fluorescence energy transfer methodology, we found that the rate of tocopherol transfer from lipid vesicles to alpha TTP increases with increasing alpha TTP concentration. This concentration dependence indicates that ligand transfer by alpha TTP involves direct protein-membrane interaction. In support of this notion, equilibrium analyses employing filtration, dual polarization interferometry, and tryptophan fluorescence demonstrated the presence of a stable alpha TTP-bilayer complex. The physical association of alpha TTP with membranes is markedly sensitive to the presence of vitamin E in the bilayer. Some naturally occurring mutations in alpha TTP that cause the hereditary disorder ataxia with vitamin E deficiency diminish the effect of tocopherol on the protein-membrane association, suggesting a possible mechanism for the accompanying pathology.	[Noy, Noa; Manor, Danny] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; [Morley, Samantha] Cornell Univ, Ithaca, NY 14853 USA; [Cecchini, Matt; Zhang, Wendy; Virgulti, Alessandro; Atkinson, Jeffrey] Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada	Case Western Reserve University; Cornell University; Brock University	Manor, D (corresponding author), Case Western Reserve Univ, Sch Med, WG-48, Cleveland, OH 44106 USA.	dxm178@case.edu		Atkinson, Jeffrey/0000-0003-3710-4893	NIDDK NIH HHS [DK 067494, R01 DK067494, R01 DK067494-06, T32 DK 715827] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1983, PRINCIPLES FLUORESCE, P354; Arita M, 1997, P NATL ACAD SCI USA, V94, P12437, DOI 10.1073/pnas.94.23.12437; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; BEHRENS WA, 1986, J AM COLL NUTR, V5, P91; Cavalier L, 1998, AM J HUM GENET, V62, P301, DOI 10.1086/301699; Desrumaux C, 2001, J BIOL CHEM, V276, P5908, DOI 10.1074/jbc.M008420200; GARGOURI Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P255, DOI 10.1016/0005-2760(89)90012-X; GOTODA T, 1995, NEW ENGL J MED, V333, P1313, DOI 10.1056/NEJM199511163332003; Hentati A, 1996, ANN NEUROL, V39, P295, DOI 10.1002/ana.410390305; Horiguchi M, 2003, GENES CELLS, V8, P789, DOI 10.1046/j.1365-2443.2003.00676.x; Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Leonard SW, 2002, AM J CLIN NUTR, V75, P555, DOI 10.1093/ajcn/75.3.555; Lowe ME, 2002, J LIPID RES, V43, P2007, DOI 10.1194/jlr.R200012-JLR200; Meier R, 2003, J MOL BIOL, V331, P725, DOI 10.1016/S0022-2836(03)00724-1; Morley S, 2006, BIOCHEMISTRY-US, V45, P1075, DOI 10.1021/bi052271y; Morley S, 2004, BIOCHEMISTRY-US, V43, P4143, DOI 10.1021/bi0363073; MOWRI H, 1981, EUR J BIOCHEM, V117, P537; MURPHY DJ, 1981, J BIOL CHEM, V256, P464; Nava P, 2006, BIOORGAN MED CHEM, V14, P3721, DOI 10.1016/j.bmc.2006.01.053; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Panagabko C, 2003, BIOCHEMISTRY-US, V42, P6467, DOI 10.1021/bi034086v; Pang JJ, 2001, JPN J OPHTHALMOL, V45, P672, DOI 10.1016/S0021-5155(01)00425-7; Ponsin G, 2003, BIOCHEMISTRY-US, V42, P4444, DOI 10.1021/bi027006g; Qian JH, 2005, J LIPID RES, V46, P2072, DOI 10.1194/jlr.M500143-JLR200; Qian JH, 2006, BIOCHEMISTRY-US, V45, P8236, DOI 10.1021/bi060522c; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rao CS, 2005, BIOPHYS J, V89, P4017, DOI 10.1529/biophysj.105.070631; SATO Y, 1991, FEBS LETT, V288, P41, DOI 10.1016/0014-5793(91)80999-J; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200; Swanson JE, 1999, J LIPID RES, V40, P665; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; VERDON CP, 1988, ANAL BIOCHEM, V169, P109, DOI 10.1016/0003-2697(88)90261-8; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i; Yokota T, 1997, ANN NEUROL, V41, P826, DOI 10.1002/ana.410410621; Yokota T, 1996, NEW ENGL J MED, V335, P1770, DOI 10.1056/NEJM199612053352315; Yokota T, 2000, J NEUROL NEUROSUR PS, V68, P521, DOI 10.1136/jnnp.68.4.521; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	43	44	44	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17797	17804		10.1074/jbc.M800121200	http://dx.doi.org/10.1074/jbc.M800121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18458085	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000256949200007
J	Erceg, S; Lainez, S; Ronaghi, M; Stojkovic, P; Perez-Arago, MA; Moreno-Manzano, V; Moreno-Palanques, R; Planells-Cases, R; Stojkovic, M				Erceg, Slaven; Lainez, Sergio; Ronaghi, Mohammad; Stojkovic, Petra; Perez-Arago, Maria Amparo; Moreno-Manzano, Victoria; Moreno-Palanques, Ruben; Planells-Cases, Rosa; Stojkovic, Miodrag			Differentiation of Human Embryonic Stem Cells to Regional Specific Neural Precursors in Chemically Defined Medium Conditions	PLOS ONE			English	Article								Background: Human embryonic stem cells (hESC) provide a unique model to study early events in human development. The hESC-derived cells can potentially be used to replace or restore different tissues including neuronal that have been damaged by disease or injury. Methodology and Principal Findings: The cells of two different hESC lines were converted to neural rosettes using adherent and chemically defined conditions. The progenitor cells were exposed to retinoic acid (RA) or to human recombinant basic fibroblast growth factor (bFGF) in the late phase of the rosette formation. Exposing the progenitor cells to RA suppressed differentiation to rostral forebrain dopamine neural lineage and promoted that of spinal neural tissue including motor neurons. The functional characteristics of these differentiated neuronal precursors under both, rostral (bFGF) and caudalizing (RA) signals were confirmed by patch clamp analysis. Conclusions/Significance: These findings suggest that our differentiation protocol has the capacity to generate region-specific and electrophysiologically active neurons under in vitro conditions without embryoid body formation, co-culture with stromal cells and without presence of cells of mesodermal or endodermal lineages.	[Erceg, Slaven; Ronaghi, Mohammad; Stojkovic, Petra; Perez-Arago, Maria Amparo; Moreno-Manzano, Victoria; Moreno-Palanques, Ruben; Stojkovic, Miodrag] CIPF, Cellular Reprogramming Lab, Valencia, Spain; [Lainez, Sergio; Planells-Cases, Rosa] CIPF, Sensorial Biol Lab, Valencia, Spain	Prince Felipe Research Center; Prince Felipe Research Center	Erceg, S (corresponding author), CIPF, Cellular Reprogramming Lab, Valencia, Spain.	mstojkovic@cipf.es	Erceg, Slaven/ABC-4946-2021; Moreno, Victoria/B-4175-2014	Moreno, Victoria/0000-0002-6035-9491; Erceg, Slaven/0000-0003-3208-7705; Stojkovic, Miodrag/0000-0001-7526-6573	Regional Government Health Department; Instituto Carlos III belonging to the Spanish Ministry of Health and Consumer Affairs; Spanish Ministry of Education and Science [SAF2004-05684]	Regional Government Health Department; Instituto Carlos III belonging to the Spanish Ministry of Health and Consumer Affairs; Spanish Ministry of Education and Science(Spanish Government)	This work was supported by funds for research in the field of Regenerative Medicine from the Regional Government Health Department (Generalitat Valenciana), the Instituto Carlos III belonging to the Spanish Ministry of Health and Consumer Affairs, and through a grant from the Spanish Ministry of Education and Science SAF2004-05684. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Belluzzi O, 2003, J NEUROSCI, V23, P10411; Benzing C, 2006, NEUROREPORT, V17, P1675, DOI 10.1097/01.wnr.0000236861.01210.72; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Briscoe J, 2001, CURR OPIN NEUROBIOL, V11, P43, DOI 10.1016/S0959-4388(00)00172-0; Broccoli V, 1999, NATURE, V401, P164, DOI 10.1038/43670; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; Cheng LP, 2003, J NEUROSCI, V23, P9961; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; Dhara SK, 2008, DIFFERENTIATION, V76, P454, DOI 10.1111/j.1432-0436.2007.00256.x; Ding YQ, 2003, NAT NEUROSCI, V6, P933, DOI 10.1038/nn1104; Dottori M, 2008, STEM CELLS, V26, P1146, DOI 10.1634/stemcells.2007-1118; Du ZW, 2004, STEM CELLS DEV, V13, P372, DOI 10.1089/scd.2004.13.372; Freed WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001422; Gerrard L, 2005, STEM CELLS, V23, P1234, DOI 10.1634/stemcells.2005-0110; Itsykson P, 2005, MOL CELL NEUROSCI, V30, P24, DOI 10.1016/j.mcn.2005.05.004; Jelitai M, 2007, J NEUROSCI RES, V85, P1606, DOI 10.1002/jnr.21282; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Joannides AJ, 2007, STEM CELLS, V25, P731, DOI 10.1634/stemcells.2006-0562; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Ko JY, 2007, J NEUROCHEM, V103, P1417, DOI 10.1111/j.1471-4159.2007.04898.x; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Li XJ, 2008, STEM CELLS, V26, P886, DOI 10.1634/stemcells.2007-0620; Liu JP, 2001, NEURON, V32, P997, DOI 10.1016/S0896-6273(01)00544-X; Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Muhr J, 1999, NEURON, V23, P689, DOI 10.1016/S0896-6273(01)80028-3; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Nat R, 2007, GLIA, V55, P385, DOI 10.1002/glia.20463; Nordstrom U, 2006, PLOS BIOL, V4, P1438, DOI 10.1371/journal.pbio.0040252; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Pagani F, 2006, J NEUROSCI RES, V83, P1494, DOI 10.1002/jnr.20835; Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Roybon L, 2005, EXP NEUROL, V196, P373, DOI 10.1016/j.expneurol.2005.08.023; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Shin SJ, 2006, STEM CELLS, V24, P125, DOI 10.1634/stemcells.2004-0150; Simon HH, 2004, CELL TISSUE RES, V318, P53, DOI 10.1007/s00441-004-0973-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Tyzio R, 1999, J NEUROSCI, V19, P10372; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; Zhou YH, 2000, DEVELOPMENT, V127, P3829	62	101	107	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2122	10.1371/journal.pone.0002122	http://dx.doi.org/10.1371/journal.pone.0002122			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461168	Green Submitted, gold, Green Published			2022-12-25	WOS:000261642400043
J	Noor, AM; Moloney, G; Borle, M; Fegan, GW; Shewchuk, T; Snow, RW				Noor, Abdisalan M.; Moloney, Grainne; Borle, Mohamed; Fegan, Greg W.; Shewchuk, Tanya; Snow, Robert W.			The Use of Mosquito Nets and the Prevalence of Plasmodium falciparum Infection in Rural South Central Somalia	PLOS ONE			English	Article								Background: There have been resurgent efforts in Africa to estimate the public health impact of malaria control interventions such as insecticide treated nets (ITNs) following substantial investments in scaling-up coverage in the last five years. Little is known, however, on the effectiveness of ITN in areas of Africa that support low transmission. This hinders the accurate estimation of impact of ITN use on disease burden and its cost-effectiveness in low transmission settings. Methods and Principal Findings: Using a stratified two-stage cluster sample design, four cross-sectional studies were undertaken between March-June 2007 across three livelihood groups in an area of low intensity malaria transmission in South Central Somalia. Information on bed net use; age; and sex of all participants were recorded. A finger prick blood sample was taken from participants to examine for parasitaemia. Mantel-Haenzel methods were used to measure the effect of net use on parasitaemia adjusting for livelihood; age; and sex. A total of 10,587 individuals of all ages were seen of which 10,359 provided full information. Overall net use and parasite prevalence were 12.4% and 15.7% respectively. Age-specific protective effectiveness (PE) of bed net ranged from 39% among,5 years to 72% among 5-14 years old. Overall PE of bed nets was 54% (95% confidence interval 44%-63%) after adjusting for livelihood; sex; and age. Conclusions and Significance: Bed nets confer high protection against parasite infection in South Central Somalia. In such areas where baseline transmission is low, however, the absolute reductions in parasitaemia due to wide-scale net use will be relatively small raising questions on the cost-effectiveness of covering millions of people living in such settings in Africa with nets. Further understanding of the progress of disease upon infection against the cost of averting its consequent burden in low transmission areas of Africa is therefore required.	[Noor, Abdisalan M.; Fegan, Greg W.; Snow, Robert W.] Wellcome Trust Res Programme, Kenya Med Res Inst, Ctr Geog Med Res Coast, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; [Noor, Abdisalan M.; Snow, Robert W.] Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford, England; [Moloney, Grainne; Borle, Mohamed] Food Security Analysis Unit Somalia, Nairobi, Kenya; [Fegan, Greg W.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, London, England; [Shewchuk, Tanya] Somalia Support Ctr, United Nations Childrens Fund, Nairobi, Kenya	Kenya Medical Research Institute; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Noor, AM (corresponding author), Wellcome Trust Res Programme, Kenya Med Res Inst, Ctr Geog Med Res Coast, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya.	anoor@nairobi.kemri-wellcome.org	Snow, Robert William/AFR-1436-2022; Fegan, Greg W/O-8079-2018	Snow, Robert William/0000-0003-3725-6088; Fegan, Greg W/0000-0002-2663-2765	OFDA-USAID; UNICEF; SIDA; EC; GFATM [SOM-202-G01-M-00]; Wellcome Trust [081829, 079081]; Kenyan Medical Research Institute	OFDA-USAID(United States Agency for International Development (USAID)); UNICEF; SIDA; EC(European CommissionEuropean Commission Joint Research Centre); GFATM; Wellcome Trust(Wellcome TrustEuropean Commission); Kenyan Medical Research Institute	FFSAU funded training of assessment teams, data collection, paid enumerators and data entry clerks. FSAU nutrition surveillance project is funded primarily by OFDA-USAID and receives support from UNICEF, SIDA and EC for conducting nutrition assessments in Somalia. RDTs and anti-malarial treatment were provided by UNICEF through GFATM funding (SOM-202-G01-M-00). AMN is supported by the Wellcome Trust as a Research Training Fellow (#081829). RWS is supported by the Wellcome Trust as Principal Research Fellow (#079081). Both AMN and RWS acknowledge the support of the Kenyan Medical Research Institute. The funders did not have a role in study design, data collection and analysis, decision to publish, or preparation of manuscript.	Abdulla S, 2001, BMJ-BRIT MED J, V322, P270, DOI 10.1136/bmj.322.7281.270; [Anonymous], 2004, COCHRANE DB SYST REV; [Anonymous], 2004, BIODIVERSITE PALUDIS; Babiker HA, 1998, T ROY SOC TROP MED H, V92, P585, DOI 10.1016/S0035-9203(98)90774-X; Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; *FAO SWALIM, 2007, DAT; Fraser-Hurt N, 1999, T ROY SOC TROP MED H, V93, pS47, DOI 10.1016/S0035-9203(99)90327-9; *FSAU, 2005, AN SYST; *FSAU, 2006, PROJ BACKGR; *GFATM, 2002, ROUND 2 SOM PROJ PRO; *GFATM, 2006, ROUND 6 SOM PROJ PRO; Giha HA, 2000, T ROY SOC TROP MED H, V94, P645, DOI 10.1016/S0035-9203(00)90218-9; Guyatt HL, 2002, TROP MED INT HEALTH, V7, P298, DOI 10.1046/j.1365-3156.2002.00874.x; Habluetzel A, 1999, TROP MED INT HEALTH, V4, P557, DOI 10.1046/j.1365-3156.1999.00455.x; Hamad AA, 2000, PARASITOLOGY, V120, P447, DOI 10.1017/S0031182099005818; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; Henry MC, 2005, AM J TROP MED HYG, V73, P859, DOI 10.4269/ajtmh.2005.73.859; Howard SC, 2000, T ROY SOC TROP MED H, V94, P357, DOI 10.1016/S0035-9203(00)90103-2; Killeen GF, 2007, PLOS MED, V4, P1246, DOI 10.1371/journal.pmed.0040229; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; Roper C, 1998, PARASITOLOGY, V116, P501, DOI 10.1017/S0031182098002650; *SACB, 2000, STRAT FRAM SUPP HLTH, V1; SEXTON JD, 1990, AM J TROP MED HYG, V43, P11, DOI 10.4269/ajtmh.1990.43.11; SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P100, DOI 10.4269/ajtmh.2003.68.100; Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0; THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6; *UNICEF, 2006, SOM MULT IND CLUST S; WARSAME M, 1989, TROP MED PARASITOL, V40, P412; [No title captured]; [No title captured]; GLOBAL FUND MALARIA; [No title captured]	38	50	50	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2081	10.1371/journal.pone.0002081	http://dx.doi.org/10.1371/journal.pone.0002081			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461178	Green Submitted, gold, Green Published, Green Accepted			2022-12-25	WOS:000261642400005
J	Taylor, JG; Nolan, VG; Mendelsohn, L; Kato, GJ; Gladwin, MT; Steinberg, MH				Taylor, James G. V., I; Nolan, Vikki G.; Mendelsohn, Laurel; Kato, Gregory J.; Gladwin, Mark T.; Steinberg, Martin H.			Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain	PLOS ONE			English	Article								Background: Intravascular hemolysis in sickle cell anemia could contribute to complications associated with nitric oxide deficiency, advancing age, and increased mortality. We have previously reported that intense hemolysis is associated with increased risk of vascular complications in a small cohort of adults with sickle cell disease. These observations have not been validated in other populations. Methods: The distribution of serum lactic dehydrogenase (LDH) values was used as a surrogate measure of intravascular hemolysis in a contemporaneous patient group and an historical adult population from the Cooperative Study of Sickle Cell Disease (CSSCD), all with sickle cell anemia. Chronic hyper-hemolysis was defined by the top LDH quartile and was compared to the lowest LDH quartile. Results: Hyper-hemolysis subjects had higher systolic blood pressure, higher prevalence of leg ulcers (OR 3.27, 95% CI 1.925.53, P, 0.0001), priapism (OR 2.62, 95% CI 1.13-6.90, P = 0.03) and pulmonary hypertension (OR 4.32, 95% CI 2.12-8.60, P < 0.0001), while osteonecrosis (OR 0.32, 95% CI 0.19-0.54, P < 0.0001) and pain (OR 0.23, 95% CI 0.09-0.55, P = 0.0004) were less prevalent. Hyper-hemolysis was influenced by fetal hemoglobin and a thalassemia, and was a risk factor for early death in the CSSCD population (Hazard Ratio = 1.97, P = 0.02). Conclusions: Steady state LDH measurements can identify a chronic hyper-hemolysis phenotype which includes less frequent vasooclusive pain and earlier mortality. Clinicians should consider sickle cell specific therapies for these patients, as is done for those with more frequent acute pain. The findings also suggest that an important class of disease modifiers in sickle cell anemia affect the rate of hemolysis.	[Taylor, James G. V., I; Mendelsohn, Laurel; Kato, Gregory J.; Gladwin, Mark T.] NHLBI, Pulm & Vasc Med Branch, NIH, Bethesda, MD 20892 USA; [Nolan, Vikki G.; Steinberg, Martin H.] Boston Univ, Sch Med, Dept Med, Boston, MA USA; [Kato, Gregory J.; Gladwin, Mark T.] NIH, Clin Ctr, Crit Care Med Dept, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Taylor, JG (corresponding author), NHLBI, Pulm & Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	jamesta@mail.nih.gov	Taylor, James G./AAH-4782-2021; Kato, Gregory J/I-7615-2014	Taylor, James G./0000-0002-4421-1809; Kato, Gregory J/0000-0003-4465-3217; Steinberg, Martin/0000-0001-8800-8020	Intramural NIH research program [R01 HL68970, U54 HL70819, T32 HL007501]; NHLBI [R01 HL68970, U54 HL70819, T32 HL007501]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068970, T32HL007501, U54HL070819, ZIAHL006012] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL001174] Funding Source: NIH RePORTER	Intramural NIH research program; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER	This study was supported by the Intramural NIH research program and NHLBI grants R01 HL68970 (MHS); U54 HL70819 (MHS) and T32 HL007501 (VGN). The sponsor had no role in the design, data analysis, interpretation, or writing of the report. The manuscript was reviewed and cleared for publication by the Division of Intramural Research, National Institutes of Health prior to submission.	Alexander N, 2004, BRIT J HAEMATOL, V126, P606, DOI 10.1111/j.1365-2141.2004.05025.x; Ataga KI, 2006, BRIT J HAEMATOL, V134, P109, DOI 10.1111/j.1365-2141.2006.06110.x; Ballas SK, 1999, BRIT J HAEMATOL, V105, P491, DOI 10.1111/j.1365-2141.1999.01339.x; BALLAS SK, 1991, AM J HEMATOL, V36, P122, DOI 10.1002/ajh.2830360211; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHRISTAKIS J, 1990, LANCET, V335, P637, DOI 10.1016/0140-6736(90)90419-6; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; DOVER GJ, 1992, BLOOD, V80, P816; EMBURY SH, 1982, NEW ENGL J MED, V306, P270, DOI 10.1056/NEJM198202043060504; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; French JA, 1997, BLOOD, V89, P4591, DOI 10.1182/blood.V89.12.4591; Garner C, 2004, BLOOD, V104, P2184, DOI 10.1182/blood-2004-02-0527; Garner C, 1998, AM J HUM GENET, V62, P1468, DOI 10.1086/301859; GASTON M, 1987, CONTROL CLIN TRIALS, V8, pS131; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Hassan M, 2003, J NATL MED ASSOC, V95, P939; HIGGS DR, 1982, NEW ENGL J MED, V306, P1441, DOI 10.1056/NEJM198206173062402; Kato GJ, 2006, BLOOD, V107, P2279, DOI 10.1182/blood-2005-06-2373; Kato GJ, 2007, BLOOD REV, V21, P37, DOI 10.1016/j.blre.2006.07.001; Kato GJ, 2006, AM J HEMATOL, V81, P503, DOI 10.1002/ajh.20642; KOSHY M, 1989, BLOOD, V74, P1403; LANDE WM, 1988, BLOOD, V72, P2056; Lezcano NE, 2006, STROKE, V37, P1424, DOI 10.1161/01.STR.0000221173.97108.01; Machado RF, 2006, JAMA-J AM MED ASSOC, V296, P310, DOI 10.1001/jama.296.3.310; Menzel S, 2007, NAT GENET, V39, P1197, DOI 10.1038/ng2108; MILNER PF, 1993, CLIN ORTHOP RELAT R, P136; MILNER PF, 1991, NEW ENGL J MED, V325, P1476, DOI 10.1056/NEJM199111213252104; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001/jama.294.1.81; Nolan VG, 2006, BRIT J HAEMATOL, V133, P570, DOI 10.1111/j.1365-2141.2006.06074.x; Nolan VG, 2005, BLOOD, V106, P3264, DOI 10.1182/blood-2005-04-1594; O'Driscoll S, 2008, BRIT J HAEMATOL, V140, P206, DOI 10.1111/j.1365-2141.2007.06894.x; Ohene-Frempong K, 1998, BLOOD, V91, P288; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POILLON WN, 1993, P NATL ACAD SCI USA, V90, P5039, DOI 10.1073/pnas.90.11.5039; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Sebastiani P, 2007, BLOOD, V110, P2727, DOI 10.1182/blood-2007-04-084921; Steinberg MH, 2008, AM J HEMATOL, V83, P1, DOI 10.1002/ajh.21033; STEINBERG MH, 1984, BLOOD, V63, P1353; Taylor JG, 2008, AM J HEMATOL, V83, P6, DOI 10.1002/ajh.21035	44	134	136	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2095	10.1371/journal.pone.0002095	http://dx.doi.org/10.1371/journal.pone.0002095			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461136	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400017
J	Zavala, JA; Giri, AP; Jongsma, MA; Baldwin, IT				Zavala, Jorge A.; Giri, Ashok P.; Jongsma, Maarten A.; Baldwin, Ian T.			Digestive Duet: Midgut Digestive Proteinases of Manduca sexta Ingesting Nicotiana attenuata with Manipulated Trypsin Proteinase Inhibitor Expression	PLOS ONE			English	Article							ARMIGERA GUT PROTEINASES; HELICOVERPA-ARMIGERA; PROTEASE INHIBITORS; TRANSGENIC TOBACCO; PLANT DEFENSE; ADAPTATION; QUALITY; RESISTANCE; INSECTS; LEPIDOPTERA	Background: The defensive effect of endogenous trypsin proteinase inhibitors (NaTPIs) on the herbivore Manduca sexta was demonstrated by genetically altering NaTPI production in M. sexta's host plant, Nicotiana attenuata. To understand how this defense works, we studied the effects of NaTPI on M. sexta gut proteinase activity levels in different larval instars of caterpillars feeding freely on untransformed and transformed plants. Methodology/Principal Findings: Second and third instars larvae that fed on NaTPI-producing (WT) genotypes were lighter and had less gut proteinase activity compared to those that fed on genotypes with either little or no NaTPI activity. Unexpectedly, NaTPI activity in vitro assays not only inhibited the trypsin sensitive fraction of gut proteinase activity but also halved the NaTPI-insensitive fraction in third-instar larvae. Unable to degrade NaTPI, larvae apparently lacked the means to adapt to NaTPI in their diet. However, caterpillars recovered at least part of their gut proteinase activity when they were transferred from NaTPI-producing host plants to NaTPI-free host plants. In addition extracts of basal leaves inhibited more gut proteinase activity than did extracts of middle stem leaves with the same protein content. Conclusions/Significance: Although larvae can minimize the effects of high NaTPI levels by feeding on leaves with high protein and low NaTPI activity, the host plant's endogenous NaTPIs remain an effective defense against M. sexta, inhibiting gut proteinase and affecting larval performance.	[Zavala, Jorge A.; Baldwin, Ian T.] Max Planck Inst Chem Ecol, Dept Mol Ecol, Jena, Germany; [Giri, Ashok P.] Natl Chem Lab, Div Biochem Sci, Plant Mol Biol Unit, Pune, Maharashtra, India; [Jongsma, Maarten A.] Wageningen Univ, Res Ctr WageningenUR, Plant Res Int BV, Wageningen, Netherlands	Max Planck Society; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL); Plant Research International; Wageningen University & Research	Zavala, JA (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Jena, Germany.	Baldwin@ice.mpg.de	Baldwin, Ian T/K-1809-2013; Giri, Ashok/E-5196-2012; Jongsma, Maarten A/A-2118-2010	Jongsma, Maarten A/0000-0001-5799-2301; Zavala, Jorge/0000-0001-6265-0920; Baldwin, Ian/0000-0001-5371-2974	Max Planck Gesellschaft	Max Planck Gesellschaft(Max Planck Society)	Funded by the Max Planck Gesellschaft.	Ahn JE, 2007, INSECT MOL BIOL, V16, P295, DOI 10.1111/j.1365-2583.2007.00726.x; Awmack CS, 2002, ANNU REV ENTOMOL, V47, P817, DOI 10.1146/annurev.ento.47.091201.145300; Baldwin IT, 2001, PLANT PHYSIOL, V127, P1449, DOI 10.1104/pp.010762; BALDWIN IT, 1994, J CHEM ECOL, V20, P2345, DOI 10.1007/BF02033207; Baldwin IT, 1998, P NATL ACAD SCI USA, V95, P8113, DOI 10.1073/pnas.95.14.8113; BAUMHOVER AH, 1985, HDB INSECT REARING, V2, P387; Bayes A, 2005, P NATL ACAD SCI USA, V102, P16602, DOI 10.1073/pnas.0505489102; BERNAYS EA, 1984, J INSECT PHYSIOL, V30, P489, DOI 10.1016/0022-1910(84)90029-5; BIRK Y, 2003, WOUND INDUCED PROTEI; Bown DP, 2004, PHYSIOL ENTOMOL, V29, P278, DOI 10.1111/j.0307-6962.2004.00402.x; Brioschi D, 2007, INSECT BIOCHEM MOLEC, V37, P1283, DOI 10.1016/j.ibmb.2007.07.016; BROADWAY RM, 1988, J INSECT PHYSIOL, V34, P1111, DOI 10.1016/0022-1910(88)90213-2; BROADWAY RM, 1995, J INSECT PHYSIOL, V41, P107, DOI 10.1016/0022-1910(94)00101-L; BROADWAY RM, 1986, J INSECT PHYSIOL, V32, P827, DOI 10.1016/0022-1910(86)90097-1; Bubner B, 2006, PLANT CELL REP, V25, P668, DOI 10.1007/s00299-005-0111-4; Chen H, 2005, P NATL ACAD SCI USA, V102, P19237, DOI 10.1073/pnas.0509026102; Chougule NP, 2005, INSECT BIOCHEM MOLEC, V35, P355, DOI 10.1016/j.ibmb.2005.01.006; Christeller JT, 2005, FEBS J, V272, P5710, DOI 10.1111/j.1742-4658.2005.04975.x; Cloutier C, 2000, ARCH INSECT BIOCHEM, V44, P69, DOI 10.1002/1520-6327(200006)44:2&lt;69::AID-ARCH2&gt;3.0.CO;2-6; Damle MS, 2005, PHYTOCHEMISTRY, V66, P2659, DOI 10.1016/j.phytochem.2005.09.006; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Denno R.F., 1983, VARIABLE PLANTS HERB; Duffey SS, 1996, ARCH INSECT BIOCHEM, V32, P3, DOI 10.1002/(SICI)1520-6327(1996)32:1&lt;3::AID-ARCH2&gt;3.0.CO;2-1; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; Gatehouse LN, 1997, INSECT BIOCHEM MOLEC, V27, P929, DOI 10.1016/S0965-1748(97)00074-X; Giri AP, 1998, PLANT PHYSIOL, V116, P393, DOI 10.1104/pp.116.1.393; Giri AP, 2003, PHYTOCHEMISTRY, V63, P523, DOI 10.1016/S0031-9422(03)00181-X; Glawe GA, 2003, ECOLOGY, V84, P79, DOI 10.1890/0012-9658(2003)084[0079:ECABCW]2.0.CO;2; Gruden K, 1998, INSECT BIOCHEM MOLEC, V28, P549, DOI 10.1016/S0965-1748(98)00051-4; Gruden K, 2004, INSECT BIOCHEM MOLEC, V34, P365, DOI 10.1016/j.ibmb.2004.01.003; Harsulkar AM, 1999, PLANT PHYSIOL, V121, P497, DOI 10.1104/pp.121.2.497; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; Horn M, 2005, PLANT PHYSIOL, V139, P375, DOI 10.1104/pp.105.064006; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; JONGSMA MA, 1995, P NATL ACAD SCI USA, V92, P8041, DOI 10.1073/pnas.92.17.8041; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; KAROWE DN, 1989, J INSECT PHYSIOL, V35, P699, DOI 10.1016/0022-1910(89)90089-9; Kessler A, 2002, ECOLOGY, V83, P2346, DOI 10.1890/0012-9658(2002)083[2346:MQSOOI]2.0.CO;2; LAING W, 2002, PROTEIN PROTEIN INTE, P77; Larcher W, 2003, PHYSL PLANT ECOLOGY; Lopes AR, 2004, ARCH INSECT BIOCHEM, V55, P140, DOI 10.1002/arch.10134; Marchetti S, 1998, INSECT BIOCHEM MOLEC, V28, P449, DOI 10.1016/S0965-1748(98)00010-1; MATTSON WJ, 1980, ANNU REV ECOL SYST, V11, P119, DOI 10.1146/annurev.es.11.110180.001003; McManus MT, 1999, TRANSGENIC RES, V8, P383, DOI 10.1023/A:1008957610872; PETERSON AM, 1995, INSECT BIOCHEM MOLEC, V25, P765, DOI 10.1016/0965-1748(94)00092-V; PETERSON AM, 1994, INSECT BIOCHEM MOLEC, V24, P463, DOI 10.1016/0965-1748(94)90041-8; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; RYAN CA, 1972, SCIENCE, V175, P776; Schoonhoven L. M., 2005, Insect-plant biology; SCRIBER JM, 1981, ANNU REV ENTOMOL, V26, P183, DOI 10.1146/annurev.en.26.010181.001151; Simpson S.J., 1990, P111; Slansky F. Jr, 1985, P87; Strauss Sharon Y., 2002, P77; Tatar M, 2000, TRENDS ECOL EVOL, V15, P207, DOI 10.1016/S0169-5347(00)01834-6; Van Dam NM, 2001, J CHEM ECOL, V27, P547, DOI 10.1023/A:1010341022761; Volpicella M, 2003, EUR J BIOCHEM, V270, P10, DOI 10.1046/j.1432-1033.2003.03368.x; Winterer J., 2002, AgBiotechNet, V4, P1; Winterer J, 2001, MOL ECOL, V10, P1069, DOI 10.1046/j.1365-294X.2001.01239.x; Woods HA, 2004, FUNCT ECOL, V18, P103, DOI 10.1111/j.1365-2435.2004.00823.x; Wu YR, 1997, MOL BREEDING, V3, P371, DOI 10.1023/A:1009681323131; Zalucki MP, 2002, ANNU REV ENTOMOL, V47, P361, DOI 10.1146/annurev.ento.47.091201.145220; Zavala JA, 2004, PLANT PHYSIOL, V134, P1181, DOI 10.1104/pp.103.035634; Zavala JA, 2004, P NATL ACAD SCI USA, V101, P1607, DOI 10.1073/pnas.0305096101; Zavala JA, 2006, PLANT CELL ENVIRON, V29, P1751, DOI 10.1111/j.1365-3040.2006.01551.x; Zavala Jorge A., 2004, BMC Ecology, V4, P11, DOI 10.1186/1472-6785-4-11	66	26	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2008	10.1371/journal.pone.0002008	http://dx.doi.org/10.1371/journal.pone.0002008			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431489	Green Submitted, gold, Green Published			2022-12-25	WOS:000261558700024
J	Aoto, T; Saitoh, N; Sakamoto, Y; Watanabe, S; Nakao, M				Aoto, Takahiro; Saitoh, Noriko; Sakamoto, Yasuo; Watanabe, Sugiko; Nakao, Mitsuyoshi			Polycomb group protein-associated chromatin is reproduced in post-mitotic G(1) phase and is required for S phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; ACTIVE GENES; HETEROCHROMATIN; METHYLATION; COMPLEX; REPLICATION; NUCLEAR; TARGET; FORM	Polycomb group (PcG) proteins form two distinct complexes, PRC1 and PRC2, to regulate developmental target genes by maintaining the epigenetic state in cells. PRC2 methylates histone H3 at lysine 27 (H3K27), and PRC1 then recognizes methyl-H3K27 to form repressive chromatin. However, it remains unknown how PcG proteins maintain stable and plastic chromatin during cell division. Here we report that PcG-associated chromatin is reproduced in the G(1) phase in post-mitotic cells and is required for subsequent S phase progression. In dividing cells, H3K27 trimethylation ( H3K27Me(3)) marked mitotic chromosome arms where PRC2 (Suz12 and Ezh2) co-existed, whereas PRC1 (Bmi1 and Pc2) appeared in distinct foci in the pericentromeric regions. As each PRC complex was increasingly assembled from mitosis to G(1) phase, PRC1 formed H3K27Me(3)-based chromatin intensively during middle and late G(1) phase; this chromatin was highly resistant to in situ nuclease treatment. Thus, the transition from mitosis to G(1) phase is crucial for PcG-mediated chromatin inheritance. Knockdown of Suz12 markedly reduced the amount of H3K27Me(3) on mitotic chromosomes, and as a consequence, PRC1 foci were not fully transmitted to post-mitotic daughter cells. S phase progression was markedly delayed in these Suz12-knockdown cells. The fact that PcG-associated chromatin is reproduced during post-mitotic G(1) phase suggests the possibility that PcG proteins enable their target chromatin to be remodeled in response to stimuli in the G(1) phase.	[Aoto, Takahiro; Saitoh, Noriko; Sakamoto, Yasuo; Watanabe, Sugiko; Nakao, Mitsuyoshi] Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan	Kumamoto University	Saitoh, N (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, 2-2-1 Honjo, Kumamoto 8600811, Japan.	norikos@kumamoto-u.ac.jp; mnakao@gpo.kumamoto-u.ac.jp	Watanabe, Sugiko/Q-6201-2019	Watanabe, Sugiko/0000-0002-2120-9546				Aoto T, 2006, DEV BIOL, V298, P354, DOI 10.1016/j.ydbio.2006.04.450; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costa S, 2007, TRENDS CELL BIOL, V17, P101, DOI 10.1016/j.tcb.2006.12.005; Craig JM, 2005, BIOESSAYS, V27, P17, DOI 10.1002/bies.20145; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Easwaran HP, 2004, EMBO REP, V5, P1181, DOI 10.1038/sj.embor.7400295; Fitzgerald DP, 2001, MOL CELL BIOL, V21, P6585, DOI 10.1128/MCB.21.19.6585-6597.2001; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Goodrich J, 2002, ANNU REV CELL DEV BI, V18, P707, DOI 10.1146/annurev.cellbio.18.040202.114836; Gu JM, 2004, MOL BIOL CELL, V15, P3320, DOI 10.1091/mbc.E04-03-0227; Hagstrom K, 1997, CURR OPIN GENET DEV, V7, P814, DOI 10.1016/S0959-437X(97)80045-7; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; HOEHN H, 1972, EXP CELL RES, V75, P275, DOI 10.1016/0014-4827(72)90548-4; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Ichimura T, 2005, J BIOL CHEM, V280, P13928, DOI 10.1074/jbc.M413654200; Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kreitz S, 2000, EXP CELL RES, V261, P284, DOI 10.1006/excr.2000.5064; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Martinez AM, 2006, CELL CYCLE, V5, P1189, DOI 10.4161/cc.5.11.2781; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Remboutsika E, 1999, J CELL SCI, V112, P1671; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakamoto Y, 2007, J BIOL CHEM, V282, P16391, DOI 10.1074/jbc.M700011200; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Voncken JW, 1999, J CELL SCI, V112, P4627; VONDERHAAR BK, 1974, J CELL BIOL, V63, P707, DOI 10.1083/jcb.63.2.707; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Xie SQ, 2006, MOL BIOL CELL, V17, P1723, DOI 10.1091/mbc.E05-08-0726; Yamamoto K, 2004, J BIOL CHEM, V279, P401, DOI 10.1074/jbc.M307344200; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	49	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18905	18915		10.1074/jbc.M709322200	http://dx.doi.org/10.1074/jbc.M709322200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18453536	hybrid			2022-12-25	WOS:000257165600047
J	Cao, JS; Shan, DD; Revett, T; Li, DM; Wu, LY; Liu, W; Tobin, JF; Gimeno, RE				Cao, Jingsong; Shan, Dandan; Revett, Tracy; Li, Dongmei; Wu, Leeying; Liu, Wei; Tobin, James F.; Gimeno, Ruth E.			Molecular identification of a novel mammalian brain isoform of acyl-CoA : lysophospholipid acyltransferase with prominent ethanolamine lysophospholipid acylating activity, LPEAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; COENZYME-A; CLONING; ENZYME; METABOLISM; GLYCEROLIPIDS; PHOSPHOLIPIDS; CATALYZES; CELLS	Acyl-CoA-dependent lysophospholipid acyltransferases play an important role in attaining the appropriate molecular species of phospholipids. A number of genes encoding these activities were recently identified. It has become clear that multiple genes can encode one enzymatic activity and that a given gene may encode multiple activities. Here we report the identification of a gene encoding a mammalian acyl-CoA-dependent lysophospholipid acyltransferase with prominent activity toward ethanolamine-containing lysophospholipids, which we termed acyl-CoA: lysophosphatidylethanolamine acyltransferase 2, LPEAT2 (previously annotated as AYTL3 or AGPAT7). LPEAT2 is predominantly expressed in brain, coinciding with an enrichment of phosphatidylethanolamine in this tissue. Ectopic expression of LPEAT2 in mammalian HEK293T cells led to a dramatic increase (up to 9-fold) in LPEAT activity when compared with cells transfected with empty vector or an unrelated acyltransferase. LPEAT2 also exhibited significant acyl-CoA-dependent acyltransferase activity toward 1-O-alkenyl-lysophosphatidylethanolamine, lysophosphatidylglycerol, 1-O-alkyl-lysophosphatidylcholine, lysophosphatidylserine, and lysophosphatidylcholine but lacked appreciable acylating activity toward glycerol 3-phosphate, lysophosphatidic acid, lysophosphatidylinositol, and diacylglycerol, demonstrating multiple but selective functions of LPEAT2 as an enzyme involved in phospholipid remodeling. LPEAT2 recognizes a broad range of medium and long chain fatty acyl-CoA, and its activity was not affected by Ca2+. When overexpressed in mammalian cells, LPEAT2 is localized to the endoplasmic reticulum. siRNA-mediated knockdown of LPEAT2 in HEK293T cells significantly decreased LPEAT and 1-alkenyl-LPEAT activities but did not affect other lysophospholipid acylating activities. These findings identify LPEAT2 as an important enzyme in the biosynthesis of ethanolamine-containing phospholipids, especially in brain.	[Cao, Jingsong; Shan, Dandan; Revett, Tracy; Li, Dongmei; Tobin, James F.; Gimeno, Ruth E.] Wyeth Res, Dept Cardiovasc & Metab Dis, Cambridge, MA 02140 USA; [Wu, Leeying; Liu, Wei] Wyeth Res, Dept Bioinformat, Cambridge, MA 02140 USA	Pfizer; Pfizer	Cao, JS (corresponding author), Wyeth Res, Dept Cardiovasc & Metab Dis, Cambridge, MA 02140 USA.	jcao@wyeth.com; rgimeno@wyeth.com						Beigneux AP, 2006, J LIPID RES, V47, P734, DOI 10.1194/jlr.M500556-JLR200; Cao JS, 2007, J LIPID RES, V48, P583, DOI 10.1194/jlr.M600331-JLR200; Cao JS, 2006, P NATL ACAD SCI USA, V103, P19695, DOI 10.1073/pnas.0609140103; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; Cheng JB, 2004, J BIOL CHEM, V279, P37798, DOI 10.1074/jbc.M406226200; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Guan ZZ, 2001, ANAL BIOCHEM, V297, P137, DOI 10.1006/abio.2001.5303; Guan ZZ, 1999, J NEUROPATH EXP NEUR, V58, P740, DOI 10.1097/00005072-199907000-00008; Hishikawa D, 2008, P NATL ACAD SCI USA, V105, P2830, DOI 10.1073/pnas.0712245105; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1963, J BIOL CHEM, V238, P898; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; MERKL I, 1963, J BIOL CHEM, V238, P905; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; NITSCH R, 1991, ANN NY ACAD SCI, V640, P110; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; Shindou H, 2007, J BIOL CHEM, V282, P6532, DOI 10.1074/jbc.M609641200; SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x; Soupene E, 2008, P NATL ACAD SCI USA, V105, P88, DOI 10.1073/pnas.0709737104; Turkish AR, 2005, J BIOL CHEM, V280, P14755, DOI 10.1074/jbc.M500025200; Vance DE, 2007, J BIOL CHEM, V282, P33237, DOI 10.1074/jbc.R700028200; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; Yang YZ, 2004, J BIOL CHEM, V279, P55866, DOI 10.1074/jbc.M406710200; Ye GM, 2005, DNA SEQUENCE, V16, P386, DOI 10.1080/10425170500213712; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Zhao Y, 2008, J BIOL CHEM, V283, P8258, DOI 10.1074/jbc.M710422200	32	60	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19049	19057		10.1074/jbc.M800364200	http://dx.doi.org/10.1074/jbc.M800364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458083	hybrid			2022-12-25	WOS:000257165600060
J	Kumaran, D; Rawat, R; Ludivico, ML; Ahmed, SA; Swaminathan, S				Kumaran, Desigan; Rawat, Richa; Ludivico, Matthew L.; Ahmed, S. Ashraf; Swaminathan, Subramanyam			Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; ELECTRON-DENSITY MAPS; ACTIVE-SITE RESIDUES; LIGHT-CHAIN; MOLECULAR-GRAPHICS; CRYSTAL-STRUCTURE; PROTEASE ACTIVITY; TETANUS TOXIN; CLEAVAGE; SYNAPTOBREVIN	The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins cleave specific soluble N-ethylmaleimidesensitive factor attachment protein receptor complex proteins and block the release of neurotransmitters that cause flaccid paralysis and are considered potential bioweapons. Botulinum neurotoxin type A is the most potent among the clostridial neurotoxins, and to date there is no post-exposure therapeutic intervention available. To develop inhibitors leading to drug design, it is imperative that critical interactions between the enzyme and the substrate near the active site are known. Although enzyme-substrate interactions at exosites away from the active site are mapped in detail for botulinum neurotoxin type A, information about the active site interactions is lacking. Here, we present the crystal structures of botulinum neurotoxin type A catalytic domain in complex with four inhibitory substrate analog tetrapeptides, viz. RRGC, RRGL, RRGI, andRRGM at resolutions of 1.6-1.8 A. These structures show for the first time the interactions between the substrate and enzyme at the active site and delineate residues important for substrate stabilization and catalytic activity. We show that OH of Tyr(366) and NH2 of Arg(363) are hydrogen-bonded to carbonyl oxygens of P1 and P1' of the substrate analog and position it for catalytic activity. Most importantly, the nucleophilic water is replaced by the amino group of the N-terminal residue of the tetrapeptide. Furthermore, the S1' site is formed by Phe(194), Thr(215), Thr(220), Asp(370), and Arg(363). The K-i of the best inhibitory tetrapeptide is 157 nM.	[Kumaran, Desigan; Rawat, Richa; Swaminathan, Subramanyam] Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; [Ludivico, Matthew L.; Ahmed, S. Ashraf] USA, Med Res Inst Infect Dis, Dept Mol Biol, Integrated Toxicol Div, Ft Detrick, MD 21702 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Swaminathan, S (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.	swami@bnl.gov						Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2005, BIOCHEMISTRY-US, V44, P8291, DOI 10.1021/bi050253a; Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; AHMED SA, 2008, PROTEIN J IN PRESS; Binz T, 2002, BIOCHEMISTRY-US, V41, P1717, DOI 10.1021/bi0157969; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burnett JC, 2007, J BIOL CHEM, V282, P5004, DOI 10.1074/jbc.M608166200; Cornille F, 1997, J BIOL CHEM, V272, P3459, DOI 10.1074/jbc.272.6.3459; DASGUPTA BR, 1983, TOXICON, V21, P566, DOI 10.1016/0041-0101(83)90136-8; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Eswaramoorthy S, 2004, BIOCHEMISTRY-US, V43, P2209, DOI 10.1021/bi035844k; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; Fu ZJ, 2006, BIOCHEMISTRY-US, V45, P8903, DOI 10.1021/bi060786z; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Li L, 2000, BIOCHEMISTRY-US, V39, P2399, DOI 10.1021/bi992321x; LUDIVICO ML, 2006, 43 ANN M IBRCC INT B, P43; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MENESTRINA G, 1994, MOL ASPECTS MED, V15, P79, DOI 10.1016/0098-2997(94)90043-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Montecucco C, 1996, ARCH TOX S, V18, P342; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; OGUMA K, 1995, MICROBIOL IMMUNOL, V39, P161, DOI 10.1111/j.1348-0421.1995.tb02184.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellizzari R, 1996, J BIOL CHEM, V271, P20353, DOI 10.1074/jbc.271.34.20353; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rigoni M, 2001, BIOCHEM BIOPH RES CO, V288, P1231, DOI 10.1006/bbrc.2001.5911; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SATHYAMOORTHY V, 1985, BIOCHEM BIOPH RES CO, V127, P768, DOI 10.1016/S0006-291X(85)80009-7; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schiavo Giampietro, 1994, Seminars in Cell Biology, V5, P221, DOI 10.1006/scel.1994.1028; Schmidt JJ, 2002, FEBS LETT, V532, P423, DOI 10.1016/S0014-5793(02)03738-9; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Silvaggi NR, 2007, CHEM BIOL, V14, P533, DOI 10.1016/j.chembiol.2007.03.014; Simpson LL, 2000, BIOCHIMIE, V82, P943, DOI 10.1016/S0300-9084(00)01169-X; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P95; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Swaminathan S, 2004, MOVEMENT DISORD, V19, pS17, DOI 10.1002/mds.20005; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8	50	51	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18883	18891		10.1074/jbc.M801240200	http://dx.doi.org/10.1074/jbc.M801240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18434312	hybrid			2022-12-25	WOS:000257165600045
J	Roy, B; Halvey, EJ; Garthwaite, J				Roy, Brijesh; Halvey, Edward J.; Garthwaite, John			An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YC-1 BINDING-SITE; CARBON-MONOXIDE; FUNCTIONAL-CHARACTERIZATION; COUPLED RECEPTORS; CEREBELLAR CELLS; RESONANCE RAMAN; GTP ANALOGS; NO; INHIBITION; ATP	Nitric oxide (NO) exerts physiological effects by activating specialized receptors that are coupled to guanylyl cyclase activity, resulting in cGMP synthesis from GTP. Despite its widespread importance as a signal transduction pathway, the way it operates is still understood only in descriptive terms. The present work aimed to elucidate a formal mechanism for NO receptor activation and its modulation by GTP, ATP, and allosteric agents, such as YC-1 and BAY 41-2272. The model comprised a module in which NO, the nucleotides, and allosteric agents bind and the protein undergoes a conformational change, dovetailing with a catalytic module where GTP is converted to cGMP and pyrophosphate. Experiments on NO-activated guanylyl cyclase purified from bovine lung allowed values for all of the binding and isomerization constants to be derived. The catalytic module was a modified version of one describing the kinetics of adenylyl cyclase. The resulting enzyme-linked receptor mechanism faithfully reproduces all of the main functional properties of NO-activated guanylyl cyclase reported to date and provides a thermodynamically sound interpretation of those properties. With appropriate modification, it also replicates activation by carbon monoxide and the remarkable enhancement of that activity brought about by the allosteric agents. In addition, the mechanism enhances understanding of the behavior of the receptor in a cellular setting.	[Roy, Brijesh; Halvey, Edward J.; Garthwaite, John] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Garthwaite, J (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	john.garthwaite@ucl.ac.uk			Medical Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Attwell D, 2005, NAT REV NEUROSCI, V6, P841, DOI 10.1038/nrn1784; Becker E M, 2001, BMC Pharmacol, V1, P13, DOI 10.1186/1471-2210-1-13; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Bellamy TC, 2002, MOL CELL BIOCHEM, V230, P165, DOI 10.1023/A:1014204426331; BRANDWEIN HJ, 1982, J BIOL CHEM, V257, P1309; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Cary SPL, 2005, P NATL ACAD SCI USA, V102, P13064, DOI 10.1073/pnas.0506289102; CHA S, 1968, J BIOL CHEM, V243, P820; Chang FJ, 2005, J BIOL CHEM, V280, P11513, DOI 10.1074/jbc.M412203200; CHRISMAN TD, 1975, J BIOL CHEM, V250, P374; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Colquhoun D, 2004, BIOPHYS J, V86, P3510, DOI 10.1529/biophysj.103.038679; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V4th; Costa T, 2005, TRENDS PHARMACOL SCI, V26, P618, DOI 10.1016/j.tips.2005.10.009; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; Friebe A, 1998, MOL PHARMACOL, V54, P962, DOI 10.1124/mol.54.6.962; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; Friebe A, 1996, NATURE, V382, P120, DOI 10.1038/382120a0; Garthwaite J, 2005, FRONT BIOSCI-LANDMRK, V10, P1868; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Griffiths C, 2003, MOL PHARMACOL, V64, P1349, DOI 10.1124/mol.64.6.1349; HATAKEYAMA K, 1992, J BIOL CHEM, V267, P20734; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; Kazerounian S, 2002, BIOCHEMISTRY-US, V41, P3396, DOI 10.1021/bi0110894; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Koesling D, 2004, NEUROCHEM INT, V45, P813, DOI 10.1016/j.neuint.2004.03.011; Lamothe M, 2004, BIOCHEMISTRY-US, V43, P3039, DOI 10.1021/bi0360051; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Ma XL, 2007, EMBO J, V26, P578, DOI 10.1038/sj.emboj.7601521; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Martin E, 2006, J BIOL CHEM, V281, P27836, DOI 10.1074/jbc.M601078200; Mergia E, 2006, J CLIN INVEST, V116, P1731, DOI 10.1172/JCI27657; Mo E, 2004, J BIOL CHEM, V279, P26149, DOI 10.1074/jbc.M400916200; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mullershausen F, 2004, CIRCULATION, V109, P1711, DOI 10.1161/01.CIR.0000126286.47618.BD; Neubig RR, 2003, PHARMACOL REV, V55, P597, DOI 10.1124/pr.55.4.4; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Pal B, 2005, J INORG BIOCHEM, V99, P267, DOI 10.1016/j.jinorgbio.2004.09.027; Roy B, 2006, P NATL ACAD SCI USA, V103, P12185, DOI 10.1073/pnas.0602544103; Ruiz-Stewart I, 2004, P NATL ACAD SCI USA, V101, P37, DOI 10.1073/pnas.0305080101; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Russwurm M, 2005, METHOD ENZYMOL, V396, P492, DOI 10.1016/S0076-6879(05)96041-2; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Schmidt K, 2001, MOL PHARMACOL, V59, P220, DOI 10.1124/mol.59.2.220; Schmidt P, 2003, EUR J PHARMACOL, V468, P167, DOI 10.1016/S0014-2999(03)01674-1; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; Stasch JP, 2002, BRIT J PHARMACOL, V135, P333, DOI 10.1038/sj.bjp.0704484; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1995, BIOCHEMISTRY-US, V34, P16397, DOI 10.1021/bi00050a021; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Suzuki T, 2001, FEBS LETT, V507, P49, DOI 10.1016/S0014-5793(01)02943-X; Teng CM, 1997, EUR J PHARMACOL, V320, P161, DOI 10.1016/S0014-2999(96)00911-9; Tsoukias NM, 2004, AM J PHYSIOL-HEART C, V286, pH1043, DOI 10.1152/ajpheart.00525.2003; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wykes V, 2004, BRIT J PHARMACOL, V141, P1087, DOI 10.1038/sj.bjp.0705745; Yazawa S, 2006, J BIOL CHEM, V281, P21763, DOI 10.1074/jbc.M508983200; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	77	44	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18841	18851		10.1074/jbc.M801712200	http://dx.doi.org/10.1074/jbc.M801712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18463095	hybrid			2022-12-25	WOS:000257165600041
J	Abboud-Jarrous, G; Atzmon, R; Peretz, T; Palermo, C; Gadea, BB; Joyce, JA; Vlodavsky, I				Abboud-Jarrous, Ghada; Atzmon, Ruth; Peretz, Tamar; Palermo, Carmela; Gadea, Bedrick B.; Joyce, Johanna A.; Vlodavsky, Israel			Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASES; MULTISTAGE TUMORIGENESIS; HEPARANASE EXPRESSION; MAMMALIAN HEPARANASE; SECRETORY VESICLES; PROCATHEPSIN-L; BREAST-CANCER; CELL-LINES; METASTASIS; PROTEIN	Heparanase is an endo-beta-D-glucuronidase that degrades heparan sulfate in the extracellular matrix and on the cell surface. Human proheparanase is produced as a latent protein of 543 amino acids whose activation involves excision of an internal linker segment (Ser(110)-Gln(157)), yielding the active heterodimer composed of 8-and 50-kDa subunits. Applying cathepsin L knock-out tissues and cultured fibroblasts, as well as cathepsin L gene silencing and overexpression strategies, we demonstrate, for the first time, that removal of the linker peptide and conversion of proheparanase into its active 8 + 50-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites (Y156Q and Y146Q) was critical for activation of proheparanase. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry demonstrates that the entire linker segment is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Mass spectrometry demonstrated further that an active 8-kDa subunit can be generated by several alternative adjacent endocleavages, yielding the precise 8-kDa subunit and/ or slightly elongated forms. Altogether, the mode of action presented here demonstrates that processing and activation of proheparanase can be brought about solely by cathepsin L. The critical involvement of cathepsin L in proheparanase processing and activation offers new strategies for inhibiting the prometastatic, proangiogenic, and proinflammatory activities of heparanase.	[Abboud-Jarrous, Ghada; Atzmon, Ruth; Peretz, Tamar] Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; [Palermo, Carmela; Gadea, Bedrick B.; Joyce, Johanna A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Vlodavsky, Israel] Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Memorial Sloan Kettering Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel.	vlodavsk@cc.huji.ac.il			NATIONAL CANCER INSTITUTE [R01CA125162, R01CA106456] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 106456, R01 CA 125162-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Ahn K, 2002, TRAFFIC, V3, P147, DOI 10.1034/j.1600-0854.2002.030207.x; Britton C, 2004, J CELL SCI, V117, P5133, DOI 10.1242/jcs.01387; Cohen I, 2007, CLIN CANCER RES, V13, P4069, DOI 10.1158/1078-0432.CCR-06-2546; Collette J, 2004, INT REV CYTOL, V241, P1, DOI 10.1016/S0074-7696(04)41001-8; Edovitsky E, 2006, BLOOD, V107, P3609, DOI 10.1182/blood-2005-08-3301; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Frohlich E, 2004, ARCH DERMATOL RES, V295, P411, DOI 10.1007/s00403-003-0449-9; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gohji K, 2001, J UROLOGY, V166, P1286, DOI 10.1016/S0022-5347(05)65754-0; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Hook VYH, 2006, CELL MOL NEUROBIOL, V26, P449, DOI 10.1007/s10571-006-9047-7; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Judice WAS, 2004, EUR J BIOCHEM, V271, P1046, DOI 10.1111/j.1432-1033.2004.04008.x; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Koliopanos A, 2001, CANCER RES, V61, P4655; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; Lecaille F, 2001, EUR J BIOCHEM, V268, P2733, DOI 10.1046/j.1432-1327.2001.02172.x; Loser R, 2005, J MED CHEM, V48, P7688, DOI 10.1021/jm050686b; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Nardella C, 2004, BIOCHEMISTRY-US, V43, P1862, DOI 10.1021/bi030203a; Nomura T, 1997, BIOCHEM BIOPH RES CO, V230, P143, DOI 10.1006/bbrc.1996.5905; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Simizu S, 2004, J BIOL CHEM, V279, P2697, DOI 10.1074/jbc.M300541200; Simizu S, 2007, CANCER RES, V67, P7841, DOI 10.1158/0008-5472.CAN-07-1053; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Xing RY, 1998, BIOCHEM J, V332, P499, DOI 10.1042/bj3320499; Yasothornsrikul S, 1999, BIOCHEMISTRY-US, V38, P7421, DOI 10.1021/bi990239w; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100; Zajc I, 2002, CANCER LETT, V187, P185, DOI 10.1016/S0304-3835(02)00452-4; Zetser A, 2003, CANCER RES, V63, P7733; Zheng X, 2004, CANCER RES, V64, P1773, DOI 10.1158/0008-5472.CAN-03-0820	43	132	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18167	18176		10.1074/jbc.M801327200	http://dx.doi.org/10.1074/jbc.M801327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450756	Green Published, hybrid			2022-12-25	WOS:000256949200045
J	Hu, NJ; Yusof, AM; Winter, A; Osman, A; Reeve, AK; Hofmann, A				Hu, Nien-Jen; Yusof, Adlina Mohd; Winter, Anja; Osman, Asiah; Reeve, Amy K.; Hofmann, Andreas			The crystal structure of calcium-bound annexin Gh1 from Gossypium hirsutum and its implications for membrane binding mechanisms of plant annexins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; PROTEIN; PROGRAM; IDENTIFICATION; LOCALIZATION; REFINEMENT; EXPRESSION; SEQUENCE; STRESS; FAMILY	Plant annexins show distinct differences in comparison with their animal orthologues. In particular, the endonexin sequence, which is responsible for coordination of calcium ions in type II binding sites, is only partially conserved in plant annexins. The crystal structure of calcium-bound cotton annexin Gh1 was solved at 2.5 angstrom resolution and shows three metal ions coordinated in the first and fourth repeat in types II and III binding sites. Although the protein has no detectable affinity for calcium in solution, in the presence of phospholipid vesicles, we determined a stoichiometry of four calcium ions per protein molecule using isothermal titration calorimetry. Further analysis of the crystal structure showed that binding of a fourth calcium ion is structurally possible in the DE loop of the first repeat. Data from this study are in agreement with the canonical membrane binding of annexins, which is facilitated by the convex surface associating with the phospholipid bilayer by a calcium bridging mechanism. In annexin Gh1, this membrane-binding state is characterized by four calcium bridges in the I/IV module of the protein and by direct interactions of several surface-exposed basic and hydrophobic residues with the phospholipid membrane. Analysis of the protein fold stability revealed that the presence of calcium lowers the thermal stability of plant annexins. Furthermore, an additional unfolding step was detected at lower temperatures, which can be explained by the anchoring of the N-terminal domain to the C-terminal core by two conserved hydrogen bonds.	[Hu, Nien-Jen; Yusof, Adlina Mohd; Winter, Anja; Reeve, Amy K.; Hofmann, Andreas] Univ Edinburgh, Sch Biol Sci, Inst Struct & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; [Hu, Nien-Jen] Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Div Mol Biosci, London SW7 2AZ, England; [Yusof, Adlina Mohd] Ohio State Univ, Dept Mol Genet Immunol & Med Genet, Columbus, OH 43210 USA; [Winter, Anja; Osman, Asiah; Hofmann, Andreas] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Struct Chem Program, Brisbane, Qld 4111, Australia; [Reeve, Amy K.] Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Edinburgh; Imperial College London; University System of Ohio; Ohio State University; Griffith University; Newcastle University - UK	Hofmann, A (corresponding author), Griffith Univ, Eskitis Inst Cell & Mol Therapies, Struct Chem Program, N75 Don Young Rd, Nathan, Qld 4111, Australia.	a.hofmann@griffith.edu.au	Hofmann, Andreas/M-9870-2019; Winter, Anja/B-9517-2008; Asiah, Osman/B-9607-2008; Hofmann, Andreas/B-9515-2008; Osman, Asiah/AAK-5173-2021	Hofmann, Andreas/0000-0003-4408-5467; Winter, Anja/0000-0002-8602-8009; Hofmann, Andreas/0000-0003-4408-5467; Hu, Nien-Jen/0000-0002-0917-0677; Reeve, Amy/0000-0002-4474-2204	MRC [G0500367] Funding Source: UKRI; Medical Research Council [G0500367] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDRAWIS A, 1993, PLANT J, V3, P763, DOI 10.1111/j.1365-313X.1993.00763.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battey NH, 1996, PLANT PHYSIOL, V112, P1391, DOI 10.1104/pp.112.3.1391; BLACKBOURN HD, 1991, PLANTA, V184, P67, DOI 10.1007/BF00208238; BLACKBOURN HD, 1993, PHYSIOL PLANTARUM, V89, P27, DOI 10.1111/j.1399-3054.1993.tb01782.x; BLACKBOURN HD, 1992, PLANT PHYSIOL, V99, P864, DOI 10.1104/pp.99.3.864; BOUSTEAD CM, 1989, FEBS LETT, V244, P456, DOI 10.1016/0014-5793(89)80582-4; Bouzenzana J, 2006, MOL MICROBIOL, V62, P552, DOI 10.1111/j.1365-2958.2006.05389.x; Breton G, 2000, PLANT CELL PHYSIOL, V41, P177, DOI 10.1093/pcp/41.2.177; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carroll AD, 1998, PLANT CELL, V10, P1267, DOI 10.1105/tpc.10.8.1267; Clark GB, 2001, PLANT PHYSIOL, V126, P1072, DOI 10.1104/pp.126.3.1072; CLARK GB, 1995, PLANT PHYSIOL, V109, P1133, DOI 10.1104/pp.109.4.1133; Clark Greg, 2005, Gravit Space Biol Bull, V18, P113; Dabitz N, 2005, BIOCHEMISTRY-US, V44, P16292, DOI 10.1021/bi0516226; DeLano WL, 2002, PYMOL USERS MANUAL; Delmer DP, 1997, CELL MOL LIFE SCI, V53, P546, DOI 10.1007/s000180050070; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; Gidrol X, 1996, P NATL ACAD SCI USA, V93, P11268, DOI 10.1073/pnas.93.20.11268; Hofmann A, 2000, J BIOL CHEM, V275, P8072, DOI 10.1074/jbc.275.11.8072; Hofmann A, 2002, BIOINFORMATICS, V18, P209, DOI 10.1093/bioinformatics/18.1.209; Hofmann A, 2003, MOL B INT U, P38; Hofmann A, 2002, PROTEIN SCI, V11, P2033, DOI 10.1110/ps.4770102; Hofmann A, 2003, EUR J BIOCHEM, V270, P2557, DOI 10.1046/j.1432-1033.2003.03612.x; Hofmann A, 2000, BIOCHEMISTRY-US, V39, P7712, DOI 10.1021/bi992359+; Hofmann A., 2004, ANNEXINS, V1, P51; Hoshino D, 2004, PLANTA, V219, P867, DOI 10.1007/s00425-004-1285-7; HOSHINO T, 1995, BIOCHEM MOL BIOL INT, V35, P749; HU NJ, 2005, APPL SPECTROSC, V59, pA68; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; Jacob-Wilk D, 2006, P NATL ACAD SCI USA, V103, P12191, DOI 10.1073/pnas.0605098103; JATZKE C, 1999, THESIS W WILHELMS U; Kovacs I, 1998, PLANT J, V15, P185, DOI 10.1046/j.1365-313X.1998.00194.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurek I, 2002, P NATL ACAD SCI USA, V99, P11109, DOI 10.1073/pnas.162077099; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1992, JOINT CCP4 ESF EAMCB, V26, P26; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ouellet F, 1997, PLANT PHYSIOL, V114, P1302; PAGANO RE, 1978, ANNU REV BIOPHYS BIO, V7, P435, DOI 10.1146/annurev.bb.07.060178.002251; Patel DR, 2005, BIOCHEMISTRY-US, V44, P2833, DOI 10.1021/bi047642+; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; Pathuri P, 2007, J MOL BIOL, V368, P493, DOI 10.1016/j.jmb.2007.02.016; Perron B, 1997, J BIOL CHEM, V272, P11321; Proust J, 1999, PLANT MOL BIOL, V39, P361, DOI 10.1023/A:1006199814795; Seals DF, 1997, PLANT PHYSIOL, V115, P753, DOI 10.1104/pp.115.2.753; SHIN H, 1995, PLANT PHYSIOL, V108, P68; Shin HS, 1999, PLANT PHYSIOL, V119, P925, DOI 10.1104/pp.119.3.925; Thonat C, 1997, PLANT PHYSIOL, V114, P981, DOI 10.1104/pp.114.3.981; Tran JT, 2002, ACTA CRYSTALLOGR D, V58, P1854, DOI 10.1107/S0907444902013288; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	56	25	28	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18314	18322		10.1074/jbc.M801051200	http://dx.doi.org/10.1074/jbc.M801051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441010	hybrid, Green Submitted			2022-12-25	WOS:000256949200059
J	Popuri, V; Bachrati, CZ; Muzzolini, L; Mosedale, G; Costantini, S; Giacomini, E; Hickson, ID; Vindigni, A				Popuri, Venkateswarlu; Bachrati, Csanad Z.; Muzzolini, Laura; Mosedale, Georgina; Costantini, Silvia; Giacomini, Elisa; Hickson, Ian D.; Vindigni, Alessandro			The human RecQ helicases, BLM and RECQ1, display distinct DNA substrate specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME HELICASE; STRAND-ANNEALING ACTIVITIES; ROTHMUND-THOMSON-SYNDROME; WERNER-SYNDROME HELICASE; MODEL REPLICATION FORK; SYNDROME GENE-PRODUCT; R-LOOP FORMATION; SYNDROME PROTEIN; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS	RecQ helicases maintain chromosome stability by resolving a number of highly specific DNA structures that would otherwise impede the correct transmission of genetic information. Previous studies have shown that two human RecQ helicases, BLM and WRN, have very similar substrate specificities and preferentially unwind noncanonical DNA structures, such as synthetic Holliday junctions and G-quadruplex DNA. Here, we extend this analysis of BLM to include new substrates and have compared the substrate specificity of BLM with that of another human RecQ helicase, RECQ1. Our findings show that RECQ1 has a distinct substrate specificity compared with BLM. In particular, RECQ1 cannot unwind G-quadruplexes or RNA- DNA hybrid structures, even in the presence of the single-stranded binding protein, human replication protein A, that stimulates its DNA helicase activity. Moreover, RECQ1 cannot substitute for BLM in the regression of a model replication fork and is very inefficient in displacing plasmid D-loops lacking a 3'-tail. Conversely, RECQ1, but not BLM, is able to resolve immobile Holliday junction structures lacking an homologous core, even in the absence of human replication protein A. Mutagenesis studies show that the N-terminal region ( residues 1-56) of RECQ1 is necessary both for protein oligomerization and for this Holliday junction disruption activity. These results suggest that the N-terminal domain or the higher order oligomer formation promoted by the N terminus is essential for the ability of RECQ1 to disrupt Holliday junctions. Collectively, our findings highlight several differences between the substrate specificities of RECQ1 and BLM ( and by inference WRN) and suggest that these enzymes play nonoverlapping functions in cells.	[Popuri, Venkateswarlu; Muzzolini, Laura; Costantini, Silvia; Giacomini, Elisa; Vindigni, Alessandro] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Bachrati, Csanad Z.; Mosedale, Georgina; Hickson, Ian D.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Oxford	Vindigni, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	vindigni@icgeb.org	Bachrati, Csanad/ABF-2020-2021; Hickson, Ian/AAJ-7548-2020	Bachrati, Csanad/0000-0003-1703-5894; Hickson, Ian/0000-0002-0583-566X	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Cancer Research UK Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Cancer Research UK(Cancer Research UK)		Bachrati CZ, 2006, METHOD ENZYMOL, V409, P86, DOI 10.1016/S0076-6879(05)09005-1; Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bayne EH, 2005, TRENDS GENET, V21, P370, DOI 10.1016/j.tig.2005.05.007; BENSON FE, 1994, J BIOL CHEM, V269, P5195; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Broccoli S, 2004, MOL MICROBIOL, V52, P1769, DOI 10.1111/j.1365-2958.2004.04092.x; Buttner K, 2007, NAT STRUCT MOL BIOL, V14, P647, DOI 10.1038/nsmb1246; Camps M, 2005, FRONT BIOSCI-LANDMRK, V10, P689, DOI 10.2741/1564; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Cobb JA, 2006, NUCLEIC ACIDS RES, V34, P4106, DOI 10.1093/nar/gkl557; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; Futami K, 2008, CANCER SCI, V99, P71, DOI 10.1111/j.1349-7006.2007.00647.x; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hartung F, 2006, J PLANT PHYSIOL, V163, P287, DOI 10.1016/j.jplph.2005.10.013; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Li DH, 2006, J CLIN ONCOL, V24, P1720, DOI 10.1200/JCO.2005.04.4206; Li DH, 2006, CANCER RES, V66, P3323, DOI 10.1158/0008-5472.CAN-05-3032; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200; Machwe A, 2006, BIOCHEMISTRY-US, V45, P13939, DOI 10.1021/bi0615487; Macris MA, 2006, DNA REPAIR, V5, P172, DOI 10.1016/j.dnarep.2005.09.005; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Muzzolini L, 2007, PLOS BIOL, V5, P157, DOI 10.1371/journal.pbio.0050020; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; REABAN ME, 1994, J BIOL CHEM, V269, P21850; SEN D, 1992, METHOD ENZYMOL, V211, P191; Sharma S, 2005, J BIOL CHEM, V280, P28072, DOI 10.1074/jbc.M500264200; Sharma S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001297; Sharma S, 2007, MOL CELL BIOL, V27, P1784, DOI 10.1128/MCB.01620-06; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shin JH, 2006, J BIOL CHEM, V281, P26914, DOI 10.1074/jbc.M605518200; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wu L, 2006, ANNU REV GENET, V40, P279, DOI 10.1146/annurev.genet.40.110405.090636; Wu X, 2001, NUCLEIC ACIDS RES, V29, P1765, DOI 10.1093/nar/29.8.1765; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	62	117	117	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17766	17776		10.1074/jbc.M709749200	http://dx.doi.org/10.1074/jbc.M709749200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18448429	hybrid			2022-12-25	WOS:000256949200004
J	Reynolds, CH; Garwood, CJ; Wray, S; Price, C; Kellie, S; Perera, T; Zvelebil, M; Yang, A; Sheppard, PW; Varndell, IM; Hanger, DP; Anderton, BH				Reynolds, C. Hugh; Garwood, Claire J.; Wray, Selina; Price, Caroline; Kellie, Stuart; Perera, Timothy; Zvelebil, Marketa; Yang, Alice; Sheppard, Paul W.; Varndell, Ian M.; Hanger, Diane P.; Anderton, Brian H.			Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase C gamma 1, Grb2, and Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE BRAIN; HELICAL FILAMENT-TAU; NANOELECTROSPRAY MASS-SPECTROMETRY; ACTIVATED PROTEIN-KINASES; N-TERMINAL KINASE; SH3 DOMAIN; IN-VITRO; TYROSINE PHOSPHORYLATION; INDUCED NEUROTOXICITY	The microtubule-associated protein tau can associate with various other proteins in addition to tubulin, including the SH3 domains of Src family tyrosine kinases. Tau is well known to aggregate to form hyperphosphorylated filamentous deposits in several neurodegenerative diseases (tauopathies) including Alzheimer disease. We now report that tau can bind to SH3 domains derived from the p85 alpha subunit of phosphatidylinositol 3-kinase, phospholipase C gamma 1, and the N-terminal (but not the C-terminal) SH3 of Grb2 as well as to the kinases Fyn, cSrc, and Fgr. However, the short inserts found in neuron-specific isoforms of Src prevented the binding of tau. The experimentally determined binding of tau peptides is well accounted for when modeled into the peptide binding cleft in the SH3 domain of Fyn. After phosphorylation in vitro or in transfected cells, tau showed reduced binding to SH3 domains; no binding was detected with hyperphosphorylated tau isolated from Alzheimer brain, but SH3 binding was restored by phosphatase treatment. Tau mutants with serines and threonines replaced by glutamate, to mimic phosphorylation, showed reduced SH3 binding. These results strongly suggest that tau has a potential role in cell signaling in addition to its accepted role in cytoskeletal assembly, with regulation by phosphorylation that may be disrupted in the tauopathies including Alzheimer disease.	[Reynolds, C. Hugh; Garwood, Claire J.; Wray, Selina; Hanger, Diane P.; Anderton, Brian H.] Kings Coll London, MRC Ctr Neurodegenerat Res, Dept Neurosci, Inst Psychiat, London SE5 8AF, England; [Price, Caroline; Kellie, Stuart; Perera, Timothy] Yamanouchi Res Inst, Oxford OX4 4XS, England; [Kellie, Stuart] Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia; [Zvelebil, Marketa; Yang, Alice] UCL, Ludwig Inst Canc Res, London WC1E 6BT, England; [Zvelebil, Marketa] Inst Canc Res, London SW3 6JB, England; [Sheppard, Paul W.; Varndell, Ian M.] Biomol Int, Exeter EX2 8NL, Devon, England	University of London; King's College London; University of Queensland; Ludwig Institute for Cancer Research; University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Reynolds, CH (corresponding author), Kings Coll London, MRC Ctr Neurodegenerat Res, Dept Neurosci, Inst Psychiat, Box O37,De Crespigny Pk, Denmark Hill, London SE5 8AF, England.	h.reynolds@iop.kcl.ac.uk	Kellie, Stuart/A-6036-2010; Wray, Selina/C-3682-2009; Hanger, Diane/C-5697-2009	Wray, Selina/0000-0003-3062-7050; Hanger, Diane/0000-0002-3044-9816; Garwood, Claire/0000-0001-8611-177X; Kellie, Stuart/0000-0002-8163-1474; Zvelebil, Marketa/0000-0001-8018-5591	Medical Research Council [G0300408] Funding Source: Medline; MRC [G0300408] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Bhaskar K, 2005, J BIOL CHEM, V280, P35119, DOI 10.1074/jbc.M505895200; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRANDT R, 2008, NEUROBIOL A IN PRESS; Brandt Roland, 2004, Current Alzheimer Research, V1, P255, DOI 10.2174/1567205043332054; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Chohan MO, 2006, J ALZHEIMERS DIS, V10, P81; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Collins MO, 2005, J BIOL CHEM, V280, P5972, DOI 10.1074/jbc.M411220200; DAVIS DR, 1995, BIOCHEM J, V309, P941, DOI 10.1042/bj3090941; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Eidenmuller J, 2000, BIOCHEMISTRY-US, V39, P13166, DOI 10.1021/bi001290z; Eidenmuller J, 2001, BIOCHEM J, V357, P759, DOI 10.1042/0264-6021:3570759; Ekinci FJ, 2000, CELL MOL NEUROBIOL, V20, P497, DOI 10.1023/A:1007075115574; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FINAN P, 1994, J BIOL CHEM, V269, P13752; Finan P, 1996, J MOL BIOL, V261, P173, DOI 10.1006/jmbi.1996.0450; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; GARVER TD, 1994, J NEUROCHEM, V63, P2279; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hanger DP, 2002, FEBS LETT, V531, P538, DOI 10.1016/S0014-5793(02)03611-6; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; KOSIK KS, 1993, BRAIN PATHOL, V3, P39, DOI 10.1111/j.1750-3639.1993.tb00724.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee G, 1998, J CELL SCI, V111, P3167; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; Li T, 2007, NEUROSCI LETT, V414, P203, DOI 10.1016/j.neulet.2006.11.073; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Lin YT, 2007, J NEUROCHEM, V103, P802, DOI 10.1111/j.1471-4159.2007.04792.x; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lu PJ, 1999, NATURE, V399, P784; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Mayer BJ, 2001, J CELL SCI, V114, P1253; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MULOT SFC, 1994, FEBS LETT, V349, P359, DOI 10.1016/0014-5793(94)00702-0; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; Smith MJ, 2000, FEBS LETT, V484, P265, DOI 10.1016/S0014-5793(00)02169-4; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Vega IE, 2005, MOL BRAIN RES, V138, P135, DOI 10.1016/j.molbrainres.2005.04.015; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Williamson R, 2008, FASEB J, V22, P1552, DOI 10.1096/fj.07-9766com; Yanagawa H, 1998, BIOCHEMISTRY-US, V37, P1979, DOI 10.1021/bi9724265; YANG SD, 1994, J NEUROCHEM, V63, P1416; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	84	174	186	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18177	18186		10.1074/jbc.M709715200	http://dx.doi.org/10.1074/jbc.M709715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18467332	hybrid			2022-12-25	WOS:000256949200046
J	Chernov, AV; Shiryaev, SA; Aleshin, AE; Ratnikov, BI; Smith, JW; Liddington, RC; Strongin, AY				Chernov, Andrei V.; Shiryaev, Sergey A.; Aleshin, Alexander E.; Ratnikov, Boris I.; Smith, Jeffrey W.; Liddington, Robert C.; Strongin, Alex Y.			The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; DENGUE-VIRUS; NONSTRUCTURAL PROTEIN-3; CRYSTAL-STRUCTURE; SERINE-PROTEASE; NUCLEOSIDE TRIPHOSPHATASE; NUCLEAR-LOCALIZATION; AMINO-ACIDS; DOMAIN; CLEAVAGE	Similar to many flavivirus types including Dengue and yellow fever viruses, the nonstructural NS3 multifunctional protein of West Nile virus (WNV) with an N-terminal serine proteinase domain and an RNA triphosphatase, an NTPase domain, and an RNA helicase in the C-terminal domain is implicated in both polyprotein processing and RNA replication and is therefore a promising drug target. To exhibit its proteolytic activity, NS3 proteinase requires the presence of the cofactor encoded by the upstream NS2B sequence. During our detailed investigation of the biology of the WNV helicase, we characterized the ATPase and RNA/DNA unwinding activities of the full-length NS2B-NS3 proteinase-helicase protein as well as the individual NS3 helicase domain lacking both the NS2B cofactor and the NS3 proteinase sequence and the individual NS3 proteinase-helicase lacking only the NS2B cofactor. We determined that both the NS3 helicase and NS3 proteinase-helicase constructs are capable of unwinding both the DNA and the RNA templates. In contrast, the full-length NS2B-NS3 proteinase-helicase unwinds only the RNA templates, whereas its DNA unwinding activity is severely repressed. Our data suggest that the productive, catalytically competent fold of the NS2B-NS3 proteinase moiety represents an essential component of the RNA-DNA substrate selectivity mechanism in WNV and, possibly, in other flaviviruses. Based on our data, we hypothesize that the mechanism we have identified plays a role yet to be determined in WNV replication occurring both within the virus-induced membrane-bound replication complexes in the host cytoplasm and in the nuclei of infected cells.	[Chernov, Andrei V.; Shiryaev, Sergey A.; Aleshin, Alexander E.; Ratnikov, Boris I.; Smith, Jeffrey W.; Liddington, Robert C.; Strongin, Alex Y.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Chernov, Andrei/I-1623-2019	Strongin, Alex/0000-0003-3765-3016; Chernov, Andrei/0000-0002-3294-5418	NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055789] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NCRR NIH HHS [RR020843, U54 RR020843] Funding Source: Medline; NIAID NIH HHS [AI055789] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aleshin AE, 2007, PROTEIN SCI, V16, P795, DOI 10.1110/ps.072753207; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004; Bera AK, 2007, J BIOL CHEM, V282, P12883, DOI 10.1074/jbc.M611318200; Beran RKF, 2007, J BIOL CHEM, V282, P34913, DOI 10.1074/jbc.M707165200; Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001; Brooks AJ, 2002, J BIOL CHEM, V277, P36399, DOI 10.1074/jbc.M204977200; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; Dahl G, 2007, FEBS J, V274, P5979, DOI 10.1111/j.1742-4658.2007.06120.x; Erbel P, 2006, NAT STRUCT MOL BIOL, V13, P372, DOI 10.1038/nsmb1073; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Frick DN, 2003, DRUG NEWS PERSPECT, V16, P355, DOI 10.1358/dnp.2003.16.6.829307; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gu BH, 2005, PROTEIN PEPTIDE LETT, V12, P315, DOI 10.2174/0929866053765716; Hayes EB, 2005, EMERG INFECT DIS, V11, P1167, DOI 10.3201/eid1108.050289a; Johnston PA, 2007, ASSAY DRUG DEV TECHN, V5, P737, DOI 10.1089/adt.2007.101; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Keller Thomas H, 2006, Novartis Found Symp, V277, P102, DOI 10.1002/0470058005.ch8; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; Kummerer BM, 2002, J VIROL, V76, P4773, DOI 10.1128/JVI.76.10.4773-4784.2002; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Lindenbach BD, 2007, FIELDS VIROLOGY, P1101; Liu WJ, 2002, J VIROL, V76, P10766, DOI 10.1128/JVI.76.21.10766-10775.2002; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Luo D, 2008, J VIROL, V82, P173, DOI 10.1128/JVI.01788-07; Maga G, 2005, BIOCHEMISTRY-US, V44, P9637, DOI 10.1021/bi047437u; Mastrangelo E, 2007, J MOL BIOL, V372, P444, DOI 10.1016/j.jmb.2007.06.055; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; Padmanabhan R, 2006, Novartis Found Symp, V277, P74, DOI 10.1002/0470058005.ch6; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Ray Debashish, 2006, Recent Pat Antiinfect Drug Discov, V1, P45, DOI 10.2174/157489106775244055; Sampath A, 2006, J VIROL, V80, P6686, DOI 10.1128/JVI.02215-05; Sejvar JJ, 2004, NEUROLOGY, V63, P206, DOI 10.1212/01.WNL.0000130361.62281.69; Shiryaev SA, 2006, BIOCHEM J, V393, P503, DOI 10.1042/BJ20051374; Shiryaev SA, 2007, J VIROL, V81, P4501, DOI 10.1128/JVI.02719-06; Shiryaev SA, 2007, PROTEIN EXPRES PURIF, V52, P334, DOI 10.1016/j.pep.2006.11.009; Shiryaev SA, 2007, BIOCHEM J, V401, P743, DOI 10.1042/BJ20061136; Solomon T, 2003, LANCET INFECT DIS, V3, P189, DOI 10.1016/S1473-3099(03)00574-7; Uchil PD, 2006, J VIROL, V80, P5451, DOI 10.1128/JVI.01982-05; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Xu Ting, 2006, Novartis Found Symp, V277, P87, DOI 10.1002/0470058005.ch7; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963; Zhang C, 2005, J VIROL, V79, P8687, DOI 10.1128/JVI.79.14.8687-8697.2005	48	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17270	17278		10.1074/jbc.M801719200	http://dx.doi.org/10.1074/jbc.M801719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442976	hybrid, Green Published			2022-12-25	WOS:000256720600036
J	Shen, CY; Chen, YF; Liu, HQ; Zhang, KJ; Zhang, T; Lin, A; Jing, NH				Shen, Chengyong; Chen, Yongfeng; Liu, Huaqing; Zhang, Kejing; Zhang, Ting; Lin, Anning; Jing, Naihe			Hydrogen peroxide promotes A beta production through JNK-dependent activation of gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; NEUROBLASTOMA-CELLS; H2O2 ACCUMULATION; TRANSGENIC MICE; KINASE; PRESENILIN; CLEAVAGE	Accumulation of senile plaques composed of amyloid beta-peptide (A beta) is a pathological hallmark of Alzheimer disease ( AD), and A beta is generated through the sequential cleavage of amyloid precursor protein (APP) by beta- and gamma-secretase. Although oxidative stress has been implicated in the AD pathogenesis by inducing A beta production, the underlying mechanism remains elusive. Here we show that the pro-oxidant H2O2 promotes A beta production through c-Jun N-terminal kinase (JNK)-dependent activation of gamma-secretase. Treatment with H2O2 induced significant increase in the levels of intracellular and secreted A beta in human neuroblastoma SH-SY5Y cells. Although gamma-secretase-mediated cleavage of APP or C99 was enhanced upon H2O2 treatment, expression of APP or its alpha/beta-secretase-mediated cleavage was not affected. Silencing of the stress-activated JNK by small interfering RNA or the specific JNK inhibitor SP600125 reduced H2O2-induced gamma-secretase-mediated cleavage of APP. JNK activity was augmented in human brain tissues from AD patients and active JNK located surrounding the senile plaques in the brain of AD model mouse. Our data suggest that oxidative stress-activated JNK may contribute to senile plaque expansion through the promotion of gamma-secretase-mediated APP cleavage and A beta production.	[Shen, Chengyong; Chen, Yongfeng; Liu, Huaqing; Zhang, Kejing; Zhang, Ting; Jing, Naihe] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Stem Cell Biol,Lab Mol Cell Biol, Shanghai 200031, Peoples R China; [Lin, Anning] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chicago	Jing, NH (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Stem Cell Biol,Lab Mol Cell Biol, Shanghai 200031, Peoples R China.	njing@sibs.ac.cn		Zhang, Ting/0000-0001-6330-8473	NCI NIH HHS [CA100460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Benzing WC, 1999, NEUROBIOL AGING, V20, P581, DOI 10.1016/S0197-4580(99)00065-2; Cheng LP, 2004, FEBS LETT, V565, P195, DOI 10.1016/j.febslet.2004.03.097; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; Funato H, 1998, AM J PATHOL, V152, P1633; Hartzell HC, 2007, SCIENCE, V317, P1331, DOI 10.1126/science.1148142; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jin SM, 2007, CELL DEATH DIFFER, V14, P189, DOI 10.1038/sj.cdd.4402003; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Marjaux E, 2004, NEURON, V42, P189, DOI 10.1016/S0896-6273(04)00218-1; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McLendon C, 2000, FASEB J, V14, P2383; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Ni YX, 2006, NAT MED, V12, P1390, DOI 10.1038/nm1485; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Ono K, 2006, BBA-MOL BASIS DIS, V1762, P575, DOI 10.1016/j.bbadis.2006.03.002; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Ruffels J, 2004, EUR J PHARMACOL, V483, P163, DOI 10.1016/j.ejphar.2003.10.032; Saido TC, 2006, NEUROSCI RES, V54, P235, DOI 10.1016/j.neures.2005.12.015; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Schallreuter KU, 2001, J INVEST DERMATOL, V116, P167, DOI 10.1046/j.1523-1747.2001.00220.x; Selkoe DJ, 2007, CELL, V131, P215, DOI 10.1016/j.cell.2007.10.012; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Swatton JE, 2004, EUR J NEUROSCI, V19, P2711, DOI 10.1111/j.0953-816X.2004.03365.x; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tamagno E, 2008, J NEUROCHEM, V104, P683, DOI 10.1111/j.1471-4159.2007.05072.x; Tang K, 2003, EUR J NEUROSCI, V18, P102, DOI 10.1046/j.1460-9568.2003.02731.x; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xie ZC, 2007, J NEUROSCI, V27, P1247, DOI 10.1523/JNEUROSCI.5320-06.2007; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088; Zhou Y, 2008, FASEB J, V22, P47, DOI 10.1096/fj.07-8175com; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2004, LANCET NEUROL, V3, P219, DOI 10.1016/S1474-4422(04)00707-0	51	141	147	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17721	17730		10.1074/jbc.M800013200	http://dx.doi.org/10.1074/jbc.M800013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18436531	Green Published, hybrid			2022-12-25	WOS:000256720600078
J	May, JS; Smith, CM; Gill, MB; Stevenson, PG				May, Janet S.; Smith, Christopher M.; Gill, Michael B.; Stevenson, Philip G.			An Essential Role for the Proximal but Not the Distal Cytoplasmic Tail of Glycoprotein M in Murid Herpesvirus 4 Infection	PLOS ONE			English	Article								Murid herpesvirus-4 (MuHV-4) provides a tractable model with which to define common, conserved features of gammaherpesvirus biology. The multi-membrane spanning glycoprotein M (gM) is one of only 4 glycoproteins that are essential for MuHV-4 lytic replication. gM binds to gN and is thought to function mainly secondary envelopment and virion egress, for which several predicted trafficking motifs in its C-terminal cytoplasmic tail could be important. We tested the contribution of the gM cytoplasmic tail to MuHV-4 lytic replication by making recombinant viruses with varying C-terminal deletions. Removing an acidic cluster and a distal YXX Phi motif altered the capsid distribution somewhat in infected cells but had little effect on virus replication, either in vitro or in vivo. In contrast, removing a proximal YXX Phi motif as well completely prevented productive replication. gM was still expressed, but unlike its longer forms showed only limited colocalization with co-transfected gN, and in the context of whole virus appeared to support gN expression less well. We conclude that some elements of the gM cytoplasmic tail are dispensible for MuHV-4 replication, but the tail as a whole is not.	[May, Janet S.; Smith, Christopher M.; Gill, Michael B.; Stevenson, Philip G.] Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England	University of Cambridge	May, JS (corresponding author), Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England.	pgs27@cam.ac.uk	Stevenson, Philip g/F-9688-2014; Stevenson, Philip/F-6651-2011	Stevenson, Philip g/0000-0002-3520-5060; 	C.J. Martin fellowship; Wellcome Trust Senior Clinical Fellow [GR076956MA]; Medical Research Council [G0400427, G9800903]; CR-UK [C19612/A6189]; Medical Research Council [G9800943] Funding Source: researchfish; MRC [G0400427, G9800943] Funding Source: UKRI	C.J. Martin fellowship(National Health and Medical Research Council (NHMRC) of Australia); Wellcome Trust Senior Clinical Fellow(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CR-UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	CMS was supported by a C.J. Martin fellowship. PGS is a Wellcome Trust Senior Clinical Fellow (GR076956MA). This work was also supported by Medical Research Council grants G0400427 and G9800903, and CR-UK grant C19612/A6189.	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Bortz E, 2003, J VIROL, V77, P13425, DOI 10.1128/JVI.77.24.13425-13432.2003; Brack AR, 1999, J VIROL, V73, P5364, DOI 10.1128/JVI.73.7.5364-5372.1999; Browne H, 2004, J VIROL, V78, P1039, DOI 10.1128/JVI.78.2.1039-1041.2004; Coleman HM, 2003, J VIROL, V77, P2410, DOI 10.1128/JVI.77.4.2410-2417.2003; Crump CM, 2004, J GEN VIROL, V85, P3517, DOI 10.1099/vir.0.80361-0; De Lima BD, 2004, J VIROL, V78, P5103, DOI 10.1128/JVI.78.10.5103-5112.2004; Dijkstra JM, 1996, J VIROL, V70, P5684, DOI 10.1128/JVI.70.8.5684-5688.1996; Doherty PC, 2001, PHILOS T R SOC B, V356, P581, DOI 10.1098/rstb.2000.0786; EFSTATHIOU S, 1990, J GEN VIROL, V71, P1355, DOI 10.1099/0022-1317-71-6-1355; Gillet L, 2007, J VIROL, V81, P280, DOI 10.1128/JVI.01616-06; Gillet L, 2006, J GEN VIROL, V87, P3515, DOI 10.1099/vir.0.82313-0; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Hobom U, 2000, J VIROL, V74, P7720, DOI 10.1128/JVI.74.17.7720-7729.2000; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Jons A, 1998, J VIROL, V72, P550; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Koyano S, 2003, J GEN VIROL, V84, P1485, DOI 10.1099/vir.0.18941-0; KOZUCH O, 1993, ACTA VIROL, V37, P101; Krzyzaniak M, 2007, J VIROL, V81, P10316, DOI 10.1128/JVI.00375-07; Lake CM, 2000, J VIROL, V74, P11162, DOI 10.1128/JVI.74.23.11162-11172.2000; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Mach M, 2005, J VIROL, V79, P2160, DOI 10.1128/JVI.79.4.2160-2170.2005; Mach M, 2000, J VIROL, V74, P11881, DOI 10.1128/JVI.74.24.11881-11892.2000; May JS, 2005, TRAFFIC, V6, P780, DOI 10.1111/j.1600-0854.2005.00316.x; May JS, 2005, J VIROL, V79, P5059, DOI 10.1128/JVI.79.8.5059-5068.2005; May JS, 2005, J GEN VIROL, V86, P919, DOI 10.1099/vir.0.80661-0; May JS, 2005, J VIROL, V79, P3459, DOI 10.1128/JVI.79.6.3459-3467.2005; Mettenleiter TC, 2002, J VIROL, V76, P1537, DOI 10.1128/JVI.76.4.1537-1547.2002; Moorman NJ, 2004, J VIROL, V78, P10282, DOI 10.1128/JVI.78.19.10282-10290.2004; Moorman NJ, 2003, VIROLOGY, V307, P179, DOI 10.1016/S0042-6822(02)00023-5; NASH AA, 1994, CURR OPIN IMMUNOL, V6, P560, DOI 10.1016/0952-7915(94)90141-4; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Rosa GT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000560; SCALZO AA, 1995, J GEN VIROL, V76, P2895, DOI 10.1099/0022-1317-76-11-2895; Smith CM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001048; Song MJ, 2005, P NATL ACAD SCI USA, V102, P3805, DOI 10.1073/pnas.0404521102; Stevenson PG, 2005, VIRAL IMMUNOL, V18, P445, DOI 10.1089/vim.2005.18.445; Stevenson PG, 2004, CURR OPIN IMMUNOL, V16, P456, DOI 10.1016/j.coi.2004.05.002; Stevenson PG, 2002, MICROBES INFECT, V4, P1177, DOI 10.1016/S1286-4579(02)01643-X; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P3275, DOI 10.1099/0022-1317-73-12-3275; Tischer BK, 2002, J GEN VIROL, V83, P997, DOI 10.1099/0022-1317-83-5-997; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Virgin HW, 1999, CURR OPIN IMMUNOL, V11, P371, DOI 10.1016/S0952-7915(99)80063-6; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Ziegler C, 2005, J GEN VIROL, V86, P11, DOI 10.1099/vir.0.80393-0	49	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2131	10.1371/journal.pone.0002131	http://dx.doi.org/10.1371/journal.pone.0002131			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461133	Green Submitted, Green Published, gold			2022-12-25	WOS:000261642400052
J	Todryk, SM; Bejon, P; Mwangi, T; Plebanski, M; Urban, B; Marsh, K; Hill, AVS; Flanagan, KL				Todryk, Stephen M.; Bejon, Philip; Mwangi, Tabitha; Plebanski, Magdalena; Urban, Britta; Marsh, Kevin; Hill, Adrian V. S.; Flanagan, Katie L.			Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4(+) CD25(high) T Cells with Susceptibility in Kenyans	PLOS ONE			English	Article								Background: Immunity to malaria develops naturally in endemic regions, but the protective immune mechanisms are poorly understood. Many vaccination strategies aim to induce T cells against diverse pre-erythrocytic antigens, but correlates of protection in the field have been limited. The objective of this study was to investigate cell-mediated immune correlates of protection in natural malaria. Memory T cells reactive against thrombospondin-related adhesive protein (TRAP) and circumsporozoite (CS) protein, major vaccine candidate antigens, were measured, as were frequencies of CD4(+) CD25(high) T cells, which may suppress immunity, and CD56(+) NK cells and gamma delta T cells, which may be effectors or may modulate immunity. Methodology and Principal Findings: 112 healthy volunteers living in rural Kenya were entered in the study. Memory T cells reactive against TRAP and CS were measured using a cultured IFN gamma ELISPOT approach, whilst CD4(+) CD25(high) T cells, CD56(+) NK cells, and gamma delta T cells were measured by flow cytometry. We found that T cell responses against TRAP were established early in life (< 5 years) in contrast to CS, and cultured ELISPOT memory T cell responses did not correlate with ex-vivo IFN gamma ELISPOT effector responses. Data was examined for associations with risk of clinical malaria for a period of 300 days. Multivariate logistic analysis incorporating age and CS response showed that cultured memory T cell responses against TRAP were associated with a significantly reduced incidence of malaria (p = 0.028). This was not seen for CS responses. Higher numbers of CD4(+) CD25(high) T cells, potentially regulatory T cells, were associated with a significantly increased risk of clinical malaria (p = 0.039). Conclusions: These data demonstrate a role for central memory T cells in natural malarial immunity and support current vaccination strategies aimed at inducing durable protective T cell responses against the TRAP antigen. They also suggest that CD4(+) CD25(high) T cells may negatively affect naturally acquired malarial immunity.	[Todryk, Stephen M.; Bejon, Philip; Urban, Britta; Hill, Adrian V. S.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England; [Todryk, Stephen M.; Bejon, Philip; Mwangi, Tabitha; Urban, Britta; Marsh, Kevin; Flanagan, Katie L.] Kenya Med Res Inst KEMRI, Ctr Geograph Med Res Coast, Wellcome Trust Collaborat Res Programme, Kilifi, Kenya; [Hill, Adrian V. S.] Wellcome Trust Ctr Human Genet, Oxford, England; [Plebanski, Magdalena] Monash Univ, Dept Immunol, Clayton, Vic, Australia; [Flanagan, Katie L.] Med Res Council MRC Lab, Fajara, Gambia; [Todryk, Stephen M.] Northumbria Univ, Sch Appl Sci, Newcastle Upon Tyne, Tyne & Wear, England	University of Oxford; Kenya Medical Research Institute; University of Oxford; Wellcome Centre for Human Genetics; Monash University; University of London; London School of Hygiene & Tropical Medicine; Northumbria University	Todryk, SM (corresponding author), Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England.	stephen.todryk@unn.ac.uk	Todryk, Stephen/AAA-3950-2019; Plebanski, Magdalena/AAU-3144-2021; Urban, Britta/W-6087-2018	Todryk, Stephen/0000-0003-4566-0793; Urban, Britta/0000-0002-4197-8393; , Magdalena/0000-0001-6889-3667; Flanagan, Katie/0000-0002-1575-1953	Wellcome Trust [fellowship]; Medical Research council	Wellcome Trust(Wellcome Trust); Medical Research council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge funding support from the Wellcome Trust and the Medical Research council. KF was supported by a Wellcome Trust fellowship in Clinical Tropical Medicine. AVSH is a Wellcome Trust Principal Research Fellow. Funders had no role in any aspect of this project.	Bejon P, 2006, CLIN INFECT DIS, V42, P1102, DOI 10.1086/501459; Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029; Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453; FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218; Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06&lt;1943::AID-IMMU1943&gt;3.0.CO;2-1; Flanagan KL, 2003, AM J TROP MED HYG, V68, P421, DOI 10.4269/ajtmh.2003.68.421; Flanagan KL, 2001, J IMMUNOL, V167, P4729, DOI 10.4049/jimmunol.167.8.4729; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746; Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689; Mbogo CM, 2003, AM J TROP MED HYG, V68, P734; Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006; Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009; RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y; Roetynck S, 2006, IMMUNOL REV, V214, P251, DOI 10.1111/j.1600-065X.2006.00446.x; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Taniguchi T, 2007, IMMUNOLOGY, V122, P514, DOI 10.1111/j.1365-2567.2007.02661.x; Vuola JM, 2005, J IMMUNOL, V174, P449, DOI 10.4049/jimmunol.174.1.449; Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006; Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006; Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102; Weedall GD, 2007, INT J PARASITOL, V37, P77, DOI 10.1016/j.ijpara.2006.09.001; White KL, 1996, J IMMUNOL, V156, P3374	28	77	77	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2027	10.1371/journal.pone.0002027	http://dx.doi.org/10.1371/journal.pone.0002027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446217	Green Published, gold, Green Accepted			2022-12-25	WOS:000261572300001
J	McDonnell, MA; Abedin, MJ; Melendez, M; Platikanova, TN; Ecklund, JR; Ahmed, K; Kelekar, A				McDonnell, Maureen A.; Abedin, Md. Joynal; Melendez, Manuel; Platikanova, Teodora N.; Ecklund, Johanna R.; Ahmed, Khalil; Kelekar, Ameeta			Phosphorylation of murine caspase-9 by the protein kinase casein kinase 2 regulates its cleavage by caspase-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; CYTOCHROME-C; IN-VIVO; INDEPENDENT ACTIVATION; MEDIATED APOPTOSIS; PHOSPHATASE 2A; EMERGING ROLE; CANCER-CELLS; CK2; MODULATION	Previous studies from our laboratory had indicated that cytochrome c-independent processing and activation of caspase-9 by caspase-8 contributed to early amplification of the caspase cascade in tumor necrosis factor (TNF)-alpha-treated murine cells. Here we show that murine caspase-9 is phosphorylated by casein kinase 2 (CK2) on a serine near the site of caspase-8 cleavage. CK2 has been shown to regulate cleavage of the pro-apoptotic Bid protein by phosphorylating serine residues near its caspase-8 cleavage site. Similarly, CK2 modification of Ser(348) on caspase-9 appears to render the protease refractory to cleavage by active caspase-8. This phosphorylation did not affect the ability of caspase-9 to autoprocess. Substitution of Ser(348) abolished phosphorylation but not cleavage, and a phospho-site mutant promoted apoptosis in TNF-alpha-treated caspase-9 knock-out mouse embryo fibroblasts. Furthermore, inhibition of CK2 activity and RNA interference-mediated knockdown of the kinase accelerated caspase-9 activation, whereas phosphatase inhibition delayed both caspase-9 activation and death in response to TNF receptor occupation. Taken together, these studies show that TNF receptor cross-linking promotes dephosphorylation of caspase-9, rendering it susceptible to processing by activated caspase-8 protein. Thus, our data suggest that modification of procaspase-9 to protect it from inappropriate cleavage and activation is yet another mechanism by which the oncogenic kinase CK2 promotes survival.	[McDonnell, Maureen A.; Ecklund, Johanna R.; Ahmed, Khalil; Kelekar, Ameeta] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Abedin, Md. Joynal] Univ Minnesota, Dept Renal Med, Minneapolis, MN 55455 USA; [Melendez, Manuel] Univ Minnesota, Coll Liberal Arts, Minneapolis, MN 55455 USA; [Platikanova, Teodora N.] Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA; [Ahmed, Khalil; Kelekar, Ameeta] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA; [Ahmed, Khalil] Minneapolis Vet Affairs Med Ctr, Res Serv, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Kelekar, A (corresponding author), 312 Church St SE,7-122 NHH, Minneapolis, MN 55455 USA.	ameeta@umn.edu			NATIONAL CANCER INSTITUTE [R01CA015062, R37CA015062] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA015062, CA 15062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Canton DA, 2006, CELL SIGNAL, V18, P267, DOI 10.1016/j.cellsig.2005.07.008; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Gyrd-Hansen M, 2006, MOL CELL BIOL, V26, P7880, DOI 10.1128/MCB.00716-06; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200; McDonnell MA, 2003, CELL DEATH DIFFER, V10, P1005, DOI 10.1038/sj.cdd.4401271; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Meyer K, 2005, VIROLOGY, V336, P198, DOI 10.1016/j.virol.2005.03.016; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Olsen BB, 2003, FEBS LETT, V546, P218, DOI 10.1016/S0014-5793(03)00575-1; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Raina D, 2005, J BIOL CHEM, V280, P11147, DOI 10.1074/jbc.M413787200; Ruzzene M, 1999, FEBS LETT, V461, P32, DOI 10.1016/S0014-5793(99)01409-X; Sarno S, 2000, BIOCHEMISTRY-US, V39, P12324, DOI 10.1021/bi0011431; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Seldin DC, 2005, MOL CELL BIOCHEM, V274, P63, DOI 10.1007/s11010-005-3078-0; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Wang GX, 2005, MOL CELL BIOCHEM, V274, P201, DOI 10.1007/s11010-005-2952-0; Yin XY, 2000, J BIOL CHEM, V275, P6850, DOI 10.1074/jbc.275.10.6850; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20149	20158		10.1074/jbc.M802846200	http://dx.doi.org/10.1074/jbc.M802846200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18467326	hybrid, Green Published			2022-12-25	WOS:000257565300031
J	Johnson, SAS; Dubeau, L; Johnson, DL				Johnson, Sandra A. S.; Dubeau, Louis; Johnson, Deborah L.			Enhanced RNA polymerase III-dependent transcription is required for oncogenic transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; C-MYC; RETINOBLASTOMA PROTEIN; CELL-PROLIFERATION; EXPRESSION; GROWTH; TFIIIB; GENE; ACTIVATION; REPRESSION	RNA polymerase (pol) III transcription, responsible for the synthesis of various stable RNAs, including 5 S rRNAs and tRNAs, is regulated by oncogenic proteins and tumor suppressors. Although it is well established that RNA pol III-dependent transcription is deregulated in transformed cells and malignant tumors, it has not been determined whether this represents a cause or consequence of these processes. We show that Rat1a fibroblasts undergoing oncogenic transformation by the TATA-binding protein or c-Myc display enhanced RNA pol III transcription. Decreased expression of the RNA pol III-specific transcription factor Brf1 prevented this increase in RNA pol III transcription. Although the overall proliferation rates of these cells remained unchanged, the ability of cells to grow in an anchorage-independent manner and form tumors in mice was markedly reduced. Although overexpression of Brf1 modestly stimulated RNA pol III transcription, expression of a phosphomimic, Brf1-T145D, more significantly induced transcription. However, these increases in transcription were not sufficient to promote cellular transformation. Together, these results demonstrate that enhanced RNA pol III transcription is essential for anchorage-independent growth and tumorigenesis and that these events can be uncoupled from effects on anchorage-dependent proliferation.	[Johnson, Sandra A. S.; Johnson, Deborah L.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; [Dubeau, Louis] Univ So Calif, Keck Sch Med, Pathol & Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Johnson, DL (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, HMR 600 MC 9097,2011 Zonal Ave, Los Angeles, CA 90089 USA.	johnsond@usc.edu			NATIONAL CANCER INSTITUTE [T32CA009659, R01CA074138, R01CA108614] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA108614, CA74138, CA108614, R01 CA074138, 2 T32 CA009659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Fairley JA, 2003, EMBO J, V22, P5841, DOI 10.1093/emboj/cdg544; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goodfellow SJ, 2007, CELL CYCLE, V6, P2323, DOI 10.4161/cc.6.19.4767; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Johnson SS, 2007, MOL CELL, V26, P367, DOI 10.1016/j.molcel.2007.03.021; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; LIEBHABER SA, 1978, CELL, V13, P121, DOI 10.1016/0092-8674(78)90143-5; Majello B, 1998, AIDS, V12, P1957, DOI 10.1097/00002030-199815000-00006; Marshall L, 2008, CELL, V133, P78, DOI 10.1016/j.cell.2008.02.035; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Rzymowska J, 1997, TUMORI, V83, P938, DOI 10.1177/030089169708300613; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Wang C, 2003, MOL BIOL CELL, V14, P2425, DOI 10.1091/mbc.E02-12-0818; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; WOIWODE A, 2008, MOL CELL BI IN PRESS; ZETTERBE.A, 1965, EXP CELL RES, V40, P1, DOI 10.1016/0014-4827(65)90284-3; Zhong SP, 2007, MOL CELL BIOL, V27, P54, DOI 10.1128/MCB.01365-06; Zhong SP, 2004, MOL CELL BIOL, V24, P5119, DOI 10.1128/MCB.24.12.5119-5129.2004	40	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19184	19191		10.1074/jbc.M802872200	http://dx.doi.org/10.1074/jbc.M802872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18456653	hybrid, Green Published			2022-12-25	WOS:000257387600003
J	Bakrac, B; Gutierrez-Aguirre, I; Podlesek, Z; Sonnen, AFP; Gilbert, RJC; Macek, P; Lakey, JH; Anderluh, G				Bakrac, Biserka; Gutierrez-Aguirre, Ion; Podlesek, Zdravko; Sonnen, Andreas F. -P.; Gilbert, Robert J. C.; Macek, Peter; Lakey, Jeremy H.; Anderluh, Gregor			Molecular determinants of sphingomyelin specificity of a eukaryotic pore-forming toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYSIN EQUINATOXIN-II; ANEMONE ACTINIA-EQUINA; MEMBRANE-PROTEIN INTERACTIONS; SEA-ANEMONE; STICHOLYSIN-II; CRYSTAL-STRUCTURE; MODEL MEMBRANES; LIPID-MEMBRANES; NEUTRAL SPHINGOMYELINASE; STRUCTURAL BASIS	Sphingomyelin (SM) is abundant in the outer leaflet of the cell plasma membrane, with the ability to concentrate in so-called lipid rafts. These specialized cholesterol-rich microdomains not only are associated with many physiological processes but also are exploited as cell entry points by pathogens and protein toxins. SM binding is thus a widespread and important biochemical function, and here we reveal the molecular basis of SM recognition by the membrane-binding eukaryotic cytolysin equinatoxin II (EqtII). The presence of SM in membranes drastically improves the binding and permeabilizing activity of EqtII. Direct binding assays showed that EqtII specifically binds SM, but not other lipids and, curiously, not even phosphatidylcholine, which presents the same phosphorylcholine headgroup. Analysis of the EqtII interfacial binding site predicts that electrostatic interactions do not play an important role in the membrane interaction and that the two most important residues for sphingomyelin recognition are Trp(112) and Tyr(113) exposed on a large loop. Experiments using site-directed mutagenesis, surface plasmon resonance, lipid monolayer, and liposome permeabilization assays clearly showed that the discrimination between sphingomyelin and phosphatidylcholine occurs in the region directly below the phosphorylcholine headgroup. Because the characteristic features of SM chemistry lie in this sub-interfacial region, the recognition mechanism may be generic for all SM-specific proteins.	[Bakrac, Biserka; Gutierrez-Aguirre, Ion; Podlesek, Zdravko; Macek, Peter; Anderluh, Gregor] Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; [Sonnen, Andreas F. -P.; Gilbert, Robert J. C.] Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; [Lakey, Jeremy H.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Ljubljana; University of Oxford; Wellcome Centre for Human Genetics; Newcastle University - UK	Anderluh, G (corresponding author), Univ Ljubljana, Biotech Fac, Dept Biol, Vecna Pot 111, Ljubljana 1000, Slovenia.	gregor.anderluh@bf.uni-lj.si	Maček, Peter/U-4662-2017; Maček, Peter/Y-9877-2019; Anderluh, Gregor/C-6905-2014	Maček, Peter/0000-0001-6470-7759; Maček, Peter/0000-0001-6470-7759; Anderluh, Gregor/0000-0002-9916-8465; Gutierrez Aguirre, Ion/0000-0002-8348-8616; Lakey, Jeremy/0000-0003-4646-9085	Wellcome Trust [56232, 40422, 55979] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ago H, 2006, J BIOL CHEM, V281, P16157, DOI 10.1074/jbc.M601089200; Alegre-Cebollada J, 2006, FEBS J, V273, P863, DOI 10.1111/j.1742-4658.2006.05122.x; Alegre-Cebollada J, 2004, FEBS LETT, V575, P14, DOI 10.1016/j.febslet.2004.08.031; Anderluh G, 2005, ANAL BIOCHEM, V344, P43, DOI 10.1016/j.ab.2005.06.013; Anderluh G, 2005, J MOL BIOL, V347, P27, DOI 10.1016/j.jmb.2004.12.058; Anderluh G, 2003, CEL MOL MEC TOX ACT, V5, P132; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Anderluh G, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P141; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; BATISTA U, 1990, CELL BIOL INT REP, V14, P1013, DOI 10.1016/0309-1651(90)90113-D; Bavdek A, 2007, BIOCHEMISTRY-US, V46, P4425, DOI 10.1021/bi602497g; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; BERNHEIMER AW, 1976, P NATL ACAD SCI USA, V73, P467, DOI 10.1073/pnas.73.2.467; Birck C, 2004, J MOL BIOL, V344, P1409, DOI 10.1016/j.jmb.2004.10.007; Blatner NR, 2007, EMBO J, V26, P3709, DOI 10.1038/sj.emboj.7601800; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonev BB, 2003, BIOPHYS J, V84, P2382, DOI 10.1016/S0006-3495(03)75044-9; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Carrizo ME, 2005, J BIOL CHEM, V280, P10614, DOI 10.1074/jbc.M411989200; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; de los Rios V, 1999, FEBS LETT, V455, P27, DOI 10.1016/S0014-5793(99)00846-7; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Gutierrez-Aguirre I, 2004, BIOCHEM J, V384, P421, DOI 10.1042/BJ20040601; Gutierrez-Aguirre I, 2006, BIOCHEM J, V398, P381, DOI 10.1042/BJ20060206; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Hong HD, 2007, J AM CHEM SOC, V129, P8320, DOI 10.1021/ja068849o; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Jiang XY, 2003, BIOCHEM BIOPH RES CO, V312, P562, DOI 10.1016/j.bbrc.2003.10.159; Jiang XY, 2002, TOXICON, V40, P1563, DOI 10.1016/S0041-0101(02)00173-3; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; Kiyokawa E, 2005, J BIOL CHEM, V280, P24072, DOI 10.1074/jbc.M502244200; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; Kristan K, 2007, FEBS J, V274, P539, DOI 10.1111/j.1742-4658.2006.05608.x; Lafont F, 2004, CURR OPIN MICROBIOL, V7, P4, DOI 10.1016/j.mib.2003.12.007; Lee SA, 2006, J BIOL CHEM, V281, P37091, DOI 10.1074/jbc.M608610200; Lomize AL, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-44; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MACEK P, 1981, TOXICON, V19, P233, DOI 10.1016/0041-0101(81)90026-X; MACEK P, 1992, FEMS MICROBIOL IMMUN, V105, P121, DOI 10.1016/0378-1097(92)90082-Y; MACEK P, 1983, STRUCTURAL FUNCTIONA; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Mancheno JA, 2006, BIOPHYS CHEM, V119, P219, DOI 10.1016/j.bpc.2005.09.021; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Martin-Benito J, 2000, BIOPHYS J, V78, P3186, DOI 10.1016/S0006-3495(00)76855-X; Meier C, 2006, STRUCTURE, V14, P1157, DOI 10.1016/j.str.2006.05.012; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Openshaw AEA, 2005, J BIOL CHEM, V280, P35011, DOI 10.1074/jbc.M506800200; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; Schlattner U, 2000, J BIOENERG BIOMEMBR, V32, P123, DOI 10.1023/A:1005576831968; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Tomita T, 2004, J BIOL CHEM, V279, P26975, DOI 10.1074/jbc.M402676200; TURK T, 1989, TOXICON, V27, P375, DOI 10.1016/0041-0101(89)90184-0; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; van Meer G, 2005, EMBO J, V24, P3159, DOI 10.1038/sj.emboj.7600798; Veatch SL, 2003, BIOPHYS J, V85, P3074, DOI 10.1016/S0006-3495(03)74726-2; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; ZECCHINI M, 1994, THESIS U PADOVA	73	136	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18665	18677		10.1074/jbc.M708747200	http://dx.doi.org/10.1074/jbc.M708747200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18442982	hybrid, Green Published			2022-12-25	WOS:000257165600023
J	Pan, D; Zhang, CM; Kirillov, S; Hou, YM; Cooperman, BS				Pan, Dongli; Zhang, Chun-Mei; Kirillov, Stanislav; Hou, Ya-Ming; Cooperman, Barry S.			Perturbation of the tRNA tertiary core differentially affects specific steps of the elongation cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; MOLECULAR-DYNAMICS SIMULATIONS; AMINOACYL-TRANSFER-RNA; CRYSTAL-STRUCTURE; CODING SPECIFICITY; TERNARY COMPLEX; CRYO-EM; T-LOOP; EF-TU; RIBOSOME	The tRNA tertiary core region is important for both tRNA stability and activity in the translation elongation cycle. Here we report the effects of mutating each of two highly conserved base pairs in the tertiary core of Phe-tRNA(Phe), 18-55 and 19-56, on rate and equilibrium constants for specific steps of this cycle, beginning with formation of aminoacyl-tRNA.EF-Tu.GTP ternary complexs and culminating with translocation of A-site-bound peptidyl-tRNA into the P-site. We find that codon-dependent binding of aminoacyl-tRNA to the A/T-site and proofreading of near-cognate tRNA are sensitive to perturbation of either base pair; formation of the ternary complex and accommodation from the A/T to the A-site are sensitive to 18-55 perturbation only, and translocation of peptidyl-tRNA from the A- to P-site is insensitive to perturbation of either. These results underline the importance of the core region in promoting the efficiency and accuracy of translation, and they likely reflect different requirements for structural integrity of the core during specific steps of the elongation cycle.	[Pan, Dongli; Kirillov, Stanislav; Cooperman, Barry S.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Zhang, Chun-Mei; Hou, Ya-Ming] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu	Pan, Dongli/ABQ-7026-2022	Pan, Dongli/0000-0002-0421-6242; Hou, Ya-Ming/0000-0001-6546-2597	NIGMS NIH HHS [GM 071014, GM 56662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056662, R01GM071014] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; Betteridge T, 2007, RNA, V13, P1594, DOI 10.1261/rna.475407; Bieling P, 2006, NAT STRUCT MOL BIOL, V13, P423, DOI 10.1038/nsmb1091; Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; Daviter T, 2006, BIOCHIMIE, V88, P1001, DOI 10.1016/j.biochi.2006.04.013; de Smit MH, 2002, NUCLEIC ACIDS RES, V30, P4232, DOI 10.1093/nar/gkf539; Doyon FR, 2004, J MOL BIOL, V343, P55, DOI 10.1016/j.jmb.2004.08.025; Frank J, 2005, FEBS LETT, V579, P959, DOI 10.1016/j.febslet.2004.10.105; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; Herr AJ, 1999, EMBO J, V18, P2886, DOI 10.1093/emboj/18.10.2886; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; Korostelev A, 2006, CELL, V126, P1065, DOI 10.1016/j.cell.2006.08.032; Kothe U, 2006, BIOCHEMISTRY-US, V45, P12767, DOI 10.1021/bi061192z; Li W, 2007, P NATL ACAD SCI USA, V104, P16540, DOI 10.1073/pnas.0708094104; Li W, 2006, RNA, V12, P1240, DOI 10.1261/rna.2294806; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Pan DL, 2006, NAT STRUCT MOL BIOL, V13, P354, DOI 10.1038/nsmb1074; Pan DL, 2007, MOL CELL, V25, P519, DOI 10.1016/j.molcel.2007.01.014; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; PETERSON ET, 1993, EMBO J, V12, P2959, DOI 10.1002/j.1460-2075.1993.tb05958.x; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Sanbonmatsu KY, 2006, BIOCHIMIE, V88, P1075, DOI 10.1016/j.biochi.2006.07.002; Sanbonmatsu KY, 2005, P NATL ACAD SCI USA, V102, P15854, DOI 10.1073/pnas.0503456102; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Semenkov YP, 2000, NAT STRUCT BIOL, V7, P1027; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; SMITH D, 1989, J MOL BIOL, V206, P503, DOI 10.1016/0022-2836(89)90497-X; SMITH D, 1989, J MOL BIOL, V206, P489, DOI 10.1016/0022-2836(89)90496-8; Trylska J, 2005, BIOPHYS J, V89, P1455, DOI 10.1529/biophysj.104.058495; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; WINTERMEYER W, 1979, EUR J BIOCHEM, V98, P465; Zagryadskaya EI, 2004, J MOL BIOL, V340, P435, DOI 10.1016/j.jmb.2004.05.002	37	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18431	18440		10.1074/jbc.M801560200	http://dx.doi.org/10.1074/jbc.M801560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18448426	Green Published, hybrid			2022-12-25	WOS:000256949200071
J	Vajpai, N; Strauss, A; Fendrich, G; Cowan-Jacob, SW; Manley, PW; Grzesiek, S; Jahnke, W				Vajpai, Navratna; Strauss, Andre; Fendrich, Gabriele; Cowan-Jacob, Sandra W.; Manley, Paul W.; Grzesiek, Stephan; Jahnke, Wolfgang			Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; RECEPTOR TYROSINE KINASES; CHRONIC MYELOID-LEUKEMIA; INFECTED INSECT CELLS; BCR-ABL; STRUCTURAL BASIS; SELECTIVE INHIBITOR; STI-571 INHIBITION; CRYSTAL-STRUCTURES; C-ABL	Current structural understanding of kinases is largely based on x-ray crystallographic studies, whereas very little data exist on the conformations and dynamics that kinases adopt in the solution state. ABL kinase is an important drug target in the treatment of chronic myelogenous leukemia. Here, we present the first characterization of ABL kinase in complex with three clinical inhibitors (imatinib, nilotinib, and dasatinib) by modern solution NMR techniques. Structural and dynamical results were derived from complete backbone resonance assignments, experimental residual dipolar couplings, and N-15 relaxation data. Residual dipolar coupling data on the imatinib and nilotinib complexes show that the activation loop adopts the inactive conformation, whereas the dasatinib complex preserves the active conformation, which does not support contrary predictions based upon molecular modeling. Nanosecond as well as microsecond dynamics can be detected for certain residues in the activation loop in the inactive and active conformation complexes.	[Vajpai, Navratna; Grzesiek, Stephan] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Strauss, Andre; Fendrich, Gabriele; Cowan-Jacob, Sandra W.; Manley, Paul W.; Jahnke, Wolfgang] Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	University of Basel; Novartis	Grzesiek, S (corresponding author), Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.	stephan.grzesiek@unibas.ch; wolfgang.jahnke@novartis.com	manley, paul william/GVT-9482-2022	Grzesiek, Stephan/0000-0003-1998-4225				Cowan-Jacob SW, 2007, ACTA CRYSTALLOGR D, V63, P80, DOI 10.1107/S0907444906047287; Cowan-Jacob SW, 2004, MINI-REV MED CHEM, V4, P285, DOI 10.2174/1389557043487321; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sass J, 1999, J AM CHEM SOC, V121, P2047, DOI 10.1021/ja983887w; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Seeliger MA, 2007, STRUCTURE, V15, P299, DOI 10.1016/j.str.2007.01.015; Strauss A, 2005, J BIOMOL NMR, V31, P343, DOI 10.1007/s10858-005-2451-3; Strauss A, 2003, J BIOMOL NMR, V26, P367, DOI 10.1023/A:1024013111478; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tokarski JS, 2006, CANCER RES, V66, P5790, DOI 10.1158/0008-5472.CAN-05-4187; VAJPAI N, 2008, BIOMOL NMR ASSIGN; Verkhivker GA, 2007, BIOPOLYMERS, V85, P333, DOI 10.1002/bip.20656; Vogtherr M, 2006, ANGEW CHEM INT EDIT, V45, P993, DOI 10.1002/anie.200502770; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weisberg E, 2006, BRIT J CANCER, V94, P1765, DOI 10.1038/sj.bjc.6603170; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Wiesner S, 2006, EMBO J, V25, P4686, DOI 10.1038/sj.emboj.7601315; Wisniewski D, 2002, CANCER RES, V62, P4244; Wissing J, 2004, MOL CELL PROTEOMICS, V3, P1181, DOI 10.1074/mcp.M400124-MCP200; Young MA, 2006, CANCER RES, V66, P1007, DOI 10.1158/0008-5472.CAN-05-2788	43	160	161	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18292	18302		10.1074/jbc.M801337200	http://dx.doi.org/10.1074/jbc.M801337200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434310	hybrid			2022-12-25	WOS:000256949200057
J	Bashiri, G; Squire, CJ; Moreland, NJ; Baker, EN				Bashiri, Ghader; Squire, Christopher J.; Moreland, Nicole J.; Baker, Edward N.			Crystal structures of F-420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS; BACTERIAL LUCIFERASE; ALCOHOL-DEHYDROGENASE; IN-VITRO; PURIFICATION; REFINEMENT; METABOLISM; RESISTANCE; SMEGMATIS; REDUCTASE	The modified flavin coenzyme F-420 is found in a restricted number of microorganisms. It is widely distributed in mycobacteria, however, where it is important in energy metabolism, and in Mycobacterium tuberculosis (Mtb) is implicated in redox processes related to non-replicating persistence. In Mtb, the F-420-dependent glucose-6-phosphate dehydrogenase FGD1 provides reduced F-420 for the in vivo activation of the nitroimidazopyran prodrug PA-824, currently being developed for anti-tuberculosis therapy against both replicating and persistent bacteria. The structure of M. tuberculosis FGD1 has been determined by x-ray crystallography both in its apo state and in complex with F-420 and citrate at resolutions of 1.90 and 1.95 angstrom, respectively. The structure reveals a highly specific F420 binding mode, which is shared with several other F-420-dependent enzymes. Citrate occupies the substrate binding pocket adjacent to F-420 and is shown to be a competitive inhibitor (IC50 43 mu M). Modeling of the binding of the glucose 6-phosphate (G6P) substrate identifies a positively charged phosphate binding pocket and shows that G6P, like citrate, packs against the isoalloxazine moiety of F-420 and helps promote a butterfly bend conformation that facilitates F-420 reduction and catalysis.	[Baker, Edward N.] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1, New Zealand	University of Auckland; University of Auckland	Baker, EN (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland 1, New Zealand.	ted.baker@auckland.ac.nz	; Bashiri, Ghader/R-4957-2017	Moreland, Nicole/0000-0001-6548-637X; Baker, Edward/0000-0003-2456-7661; Bashiri, Ghader/0000-0002-5092-3749; Squire, Christopher/0000-0001-9212-0461				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Aufhammer SW, 2005, PROTEIN SCI, V14, P1840, DOI 10.1110/ps.041289805; Aufhammer SW, 2004, STRUCTURE, V12, P361, DOI 10.1016/j.str.2004.02.010; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bair TB, 2001, ARCH MICROBIOL, V176, P37, DOI 10.1007/s002030100290; Bashiri G, 2007, PROTEIN EXPRES PURIF, V54, P38, DOI 10.1016/j.pep.2007.01.014; Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065; CHEESEMAN P, 1972, J BACTERIOL, V112, P527, DOI 10.1128/JB.112.1.527-531.1972; DANIELS L, 1985, SYST APPL MICROBIOL, V6, P12, DOI 10.1016/S0723-2020(85)80004-7; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Duncan K, 2004, CURR OPIN MICROBIOL, V7, P460, DOI 10.1016/j.mib.2004.08.011; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; EIRICH LD, 1978, BIOCHEMISTRY-US, V17, P4583, DOI 10.1021/bi00615a002; EIRICH LD, 1979, J BACTERIOL, V140, P20, DOI 10.1128/JB.140.1.20-27.1979; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; Fisher AJ, 1996, J BIOL CHEM, V271, P21956, DOI 10.1074/jbc.271.36.21956; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Isabelle D, 2002, APPL ENVIRON MICROB, V68, P5750, DOI 10.1128/AEM.68.11.5750-5755.2002; JACOBSON FS, 1982, J BIOL CHEM, V257, P3385; Jensen JH, 2005, PROTEINS, V61, P704, DOI DOI 10.1002/prot.20660; Klein AR, 1996, EUR J BIOCHEM, V239, P93, DOI 10.1111/j.1432-1033.1996.0093u.x; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1128/AAC.49.6.2294-2301.2005; Lyubimov AY, 2007, PROTEIN SCI, V16, P2647, DOI 10.1110/ps.073168207; Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Purwantini E, 1996, J BACTERIOL, V178, P2861, DOI 10.1128/jb.178.10.2861-2866.1996; Purwantini E, 1998, J BACTERIOL, V180, P2212, DOI 10.1128/JB.180.8.2212-2219.1998; Purwantini E, 1997, FEMS MICROBIOL LETT, V146, P129, DOI 10.1016/S0378-1097(96)00465-X; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Shi LB, 2005, P NATL ACAD SCI USA, V102, P15629, DOI 10.1073/pnas.0507850102; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; WALSH C, 1986, ACCOUNTS CHEM RES, V19, P216, DOI 10.1021/ar00127a004; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	46	65	71	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17531	17541		10.1074/jbc.M801854200	http://dx.doi.org/10.1074/jbc.M801854200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434308	hybrid			2022-12-25	WOS:000256720600060
J	Walshe, CA; Beers, SA; French, RR; Chan, CHT; Johnson, PW; Packham, GK; Glennie, MJ; Cragg, MS				Walshe, Claire A.; Beers, Stephen A.; French, Ruth R.; Chan, Claude H. T.; Johnson, Peter W.; Packham, Graham K.; Glennie, Martin J.; Cragg, Mark S.			Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASE; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; THERAPEUTIC ACTIVITY; IN-VIVO; APOPTOSIS; RITUXIMAB; LYMPHOMA; SURFACE; ACTIVATION	The anti-CD20 monoclonal antibody (mAb) rituximab is now routinely used for the treatment of non-Hodgkins lymphoma and is being examined in a wide range of other B-cell disorders, such as rheumatoid arthritis. Despite intensive study, the mechanism of action still remains uncertain. In the current study, anti-CD20 mAb-induced calcium signaling was investigated. Previously, we grouped anti-CD20 mAbs into Type I (rituximab-like) and Type II (B1-like) based upon various characteristics such as their ability to induce complement activation and redistribute CD20 into detergent-insoluble membrane domains. Here we show that only Type I mAbs are capable of inducing a calcium flux in B cells and that this is tightly correlated with the expression of the B-cell antigen receptor (BCR). Inhibitor analysis revealed that the signaling cascade employed by CD20 was strikingly similar to that utilized by the BCR, with inhibitors of Syk, Src, and PI3K, but not EGTA, p38, or ERK1/2, completely ablating calcium flux. Furthermore, binding of Type I but not Type II mAbs caused direct association of CD20 with the BCR as measured by FRET and resulted in the phosphorylation of BCR-specific adaptor proteins BLNK and SLP-76. Crucially, variant Ramos cells lacking BCR expression but with unchanged CD20 expression were completely unable to induce calcium flux following ligation of CD20. Collectively, these data indicate that CD20 induces cytosolic calcium flux through its ability to associate with and "hijack" the signaling potential of the BCR.	[Walshe, Claire A.; Beers, Stephen A.; French, Ruth R.; Chan, Claude H. T.; Johnson, Peter W.; Packham, Graham K.; Glennie, Martin J.; Cragg, Mark S.] Univ Southampton, Gen Hosp, Sch Med, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Southampton	Cragg, MS (corresponding author), Southampton Gen Hosp, Sch Med, Canc Sci Div, Tenovus Lab, Tremona Rd, Southampton SO16 6YD, Hants, England.	msc@soton.ac.uk	Johnson, Peter/L-2403-2018; Johnson, Peter/O-3529-2019; Cragg, Mark S/E-5965-2010	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Cragg, Mark S/0000-0003-2077-089X; Beers, Stephen/0000-0002-3765-3342; chan, claude/0000-0003-0530-9480; Packham, Graham/0000-0002-9232-5691	Worldwide Cancer Research [04-0427] Funding Source: Medline	Worldwide Cancer Research		BOURGET I, 1993, EUR J IMMUNOL, V23, P768, DOI 10.1002/eji.1830230330; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chan HTC, 2003, CANCER RES, V63, P5480; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cragg Mark S., 2005, V8, P140; Cragg MS, 1999, CURR OPIN IMMUNOL, V11, P541, DOI 10.1016/S0952-7915(99)00010-2; Cragg MS, 2004, BLOOD, V104, P2540, DOI 10.1182/blood-2004-05-1733; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Cragg MS, 1999, BRIT J CANCER, V79, P850, DOI 10.1038/sj.bjc.6690136; CRAGG MS, 2002, LEUKOCYTE TYPING, V7, P95; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Di Gaetano N, 2003, J IMMUNOL, V171, P1581, DOI 10.4049/jimmunol.171.3.1581; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; Glennie MJ, 2007, MOL IMMUNOL, V44, P3823, DOI 10.1016/j.molimm.2007.06.151; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; Gopal AK, 1999, J LAB CLIN MED, V134, P445, DOI 10.1016/S0022-2143(99)90164-6; Hofmeister JK, 2000, BLOOD CELL MOL DIS, V26, P133, DOI 10.1006/bcmd.2000.0287; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Maloney David G, 2003, Curr Hematol Rep, V2, P13; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; Mathas S, 2000, CANCER RES, V60, P7170; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Tutt AL, 1998, J IMMUNOL, V161, P3176; Unruh TL, 2005, IMMUNOLOGY, V116, P223, DOI 10.1111/j.1365-2567.2005.02213.x; VUIST WMJ, 1994, BLOOD, V83, P899	39	110	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					16971	16984		10.1074/jbc.M708459200	http://dx.doi.org/10.1074/jbc.M708459200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426802	hybrid			2022-12-25	WOS:000256720600003
J	Yamaguchi, Y; Larkin, D; Lara-Lemus, R; Ramos-Castaneda, J; Liu, M; Arvan, P				Yamaguchi, Yukihiro; Larkin, Dennis; Lara-Lemus, Roberto; Ramos-Castaneda, Jose; Liu, Ming; Arvan, Peter			Endoplasmic reticulum (ER) chaperone regulation and survival of cells compensating for deficiency in the ER stress response kinase, PERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; OXIDE-INDUCED APOPTOSIS; MESSENGER-RNA; TRANSCRIPTION FACTOR; QUALITY-CONTROL; TRANSLATIONAL CONTROL; GLUCOSE-HOMEOSTASIS; STORAGE DISEASES; ATF6; DEGRADATION	The activity of PERK, an endoplasmic reticulum (ER) transmembrane protein kinase, assists in an ER stress response designed to inhibit general protein synthesis while allowing up-regulated synthesis of selective proteins such as the ATF4 transcription factor. PERK null mice exhibit phenotypes that especially affect secretory cell types. Although embryonic fibroblasts from these mice are difficult to transfect with high efficiency, we have generated 293 cells stably expressing the PERK-K618A dominant negative mutant. 293/PERK-K618A cells, in response to ER stress: (a) do not properly inhibit general protein synthesis, (b) exhibit defective/delayed induction of ATF4 and BiP, and (c) exhibit exuberant splice activation of XBP1 and robust cleavage activation of ATF6, with abnormal regulation of calreticulin levels. The data suggest compensatory mechanisms allowing for cell survival in the absence of functional PERK. Interestingly, although induction of CHOP (a transcription factor implicated in apoptosis) is notably delayed after onset of ER stress, 293/ PERK-K618A cells eventually produce CHOP at normal or even supranormal levels and exhibit increased apoptosis either in response to general ER stress or, more importantly, to specific misfolded secretory proteins.	[Arvan, Peter] Univ Michigan, Sch Med, Div Metab Endocrinol & Diabet, Med Ctr, Ann Arbor, MI 48109 USA; [Ramos-Castaneda, Jose] Ctr Invest Enfermedades Infecciosas, Cuernavaca 62580, Morelos, Mexico	University of Michigan System; University of Michigan	Arvan, P (corresponding author), Univ Michigan, Sch Med, Div Metab Endocrinol & Diabet, Med Ctr, 5560 MSRB2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Lara-Lemus, Roberto/J-4531-2013; Ramos-Castañeda, jose/V-6678-2019	Lara-Lemus, Roberto/0000-0001-5419-4283; 	NIDDK NIH HHS [R01 DK048280-15, R01 DK048280, DK48280, R01 DK40344, R01 DK040344-21, R01 DK040344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280, R01DK040344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baryshev M, 2004, J MOL ENDOCRINOL, V32, P903, DOI 10.1677/jme.0.0320903; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen Y, 2005, HUM MOL GENET, V14, P2559, DOI 10.1093/hmg/ddi259; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lee D, 2007, J MOL BIOL, V372, P331, DOI 10.1016/j.jmb.2007.06.071; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li YL, 2003, ENDOCRINOLOGY, V144, P3505, DOI 10.1210/en.2003-0236; Liu M, 2005, J BIOL CHEM, V280, P13209, DOI 10.1074/jbc.C400475200; Liu M, 2007, P NATL ACAD SCI USA, V104, P15841, DOI 10.1073/pnas.0702697104; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Menon S, 2007, J BIOL CHEM, V282, P6183, DOI 10.1074/jbc.M608863200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Murphy TC, 2001, BIOTECHNOL BIOENG, V75, P621, DOI 10.1002/bit.1190; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Ramos-Castaneda J, 2005, J BIOL CHEM, V280, P9467, DOI 10.1074/jbc.M413243200; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	53	42	42	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17020	17029		10.1074/jbc.M802466200	http://dx.doi.org/10.1074/jbc.M802466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426796	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000256720600008
J	Lee, JK; Prussi, A; Paal, T; White, LK; Snyder, JP; Plemper, RK				Lee, Jin K.; Prussi, Andrew; Paal, Tanja; White, Laura K.; Snyder, James P.; Plemper, Richard K.			Functional interaction between paramyxovirus fusion and attachment proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASLES-VIRUS HEMAGGLUTININ; CANINE-DISTEMPER VIRUS; NEWCASTLE-DISEASE VIRUS; RESPIRATORY SYNCYTIAL VIRUS; CELL-FUSION; F-PROTEIN; MEMBRANE-FUSION; SENDAI-VIRUS; ENVELOPE PROTEIN; NIPAH VIRUS	Paramyxovirinae envelope glycoproteins constitute a premier model to dissect how specific and dynamic interactions in multisubunit membrane protein complexes can control deep-seated conformational rearrangements. However, individual residues that determine reciprocal specificity of the viral attachment and fusion (F) proteins have not been identified. We have developed an assay based on a pair of canine distemper virus (CDV) F proteins (strains Onderstepoort (ODP) and Lederle) that share similar to 95% identity but differ in their ability to form functional complexes with the measles virus (MV) attachment protein (H). Characterization of CDV F chimeras and mutagenesis reveals four residues in CDV F-ODP (positions 164, 219, 233, and 317) required for productive interaction with MV H. Mutating these residues to the Lederle type disrupts triggering of F-ODP by MV H without affecting functionality when co-expressed with CDV H. Co-immunoprecipitation shows a stronger physical interaction of F-ODP than F-Lederle with MVH. Mutagenesis of MVF highlights the MV residues homologous to CDV F residues 233 and 317 as determinants for physical glycoprotein interaction and fusion activity under homotypic conditions. In assay reversal, the introduction of sections of the CDV H stalk into MV H shows a five-residue fragment (residues 110-114) to mediate specificity for CDV F-Lederle. All of the MV H stalk chimeras are surface-expressed, show hemadsorption activity, and trigger MV F. Combining the five-residue H chimera with the CDV F-ODP quadruple mutant partially restores activity, indicating that the residues identified in either glycoprotein contribute interdependently to the formation of functional complexes. Their localization in structural models of F and H suggests that placement in particular of F residue 233 in close proximity to the 110-114 region of H is structurally conceivable.	[Lee, Jin K.; Paal, Tanja; White, Laura K.; Plemper, Richard K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Prussi, Andrew; Snyder, James P.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA	Emory University; Emory University	Plemper, RK (corresponding author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr,Ste 520, Atlanta, GA 30322 USA.	rplempe@emory.edu		Prussia, Andrew/0000-0002-7038-9520; White, Laura/0000-0003-2909-6627	NIAID NIH HHS [AI071002, AI056179, R01 AI071002, R21 AI056179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056179, R01AI071002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG MA, 1982, J GEN VIROL, V59, P187, DOI 10.1099/0022-1317-59-1-187; Bonaparte MI, 2005, P NATL ACAD SCI USA, V102, P10652, DOI 10.1073/pnas.0504887102; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Cathomen T, 1998, J VIROL, V72, P1224, DOI 10.1128/JVI.72.2.1224-1234.1998; Chen L, 2001, STRUCTURE, V9, P255, DOI 10.1016/S0969-2126(01)00581-0; Cheng HL, 2005, COUNS PSYCHOL, V33, P72, DOI 10.1177/0011000004270343; Colf LA, 2007, NAT STRUCT MOL BIOL, V14, P1227, DOI 10.1038/nsmb1342; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Corey EA, 2007, J VIROL, V81, P9900, DOI 10.1128/JVI.00909-07; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; Deng R, 1997, ARCH VIROL, P115; DENG RT, 1995, VIROLOGY, V209, P457, DOI 10.1006/viro.1995.1278; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dutch RE, 2000, BIOSCIENCE REP, V20, P597; Dutch RE, 2001, VIROLOGY, V281, P138, DOI 10.1006/viro.2000.0817; Gravel KA, 2003, J VIROL, V77, P11040, DOI 10.1128/JVI.77.20.11040-11049.2003; Griffin DE., 2007, FIELDS VIROLOGY, P1551; Hashiguchi T, 2007, P NATL ACAD SCI USA, V104, P19535, DOI 10.1073/pnas.0707830104; HU XL, 1992, J VIROL, V66, P1528, DOI 10.1128/JVI.66.3.1528-1534.1992; KIELIAN M, 1990, MOL BIOL MED, V7, P17; Lamb RA, 2006, VIROLOGY, V344, P30, DOI 10.1016/j.virol.2005.09.007; Lamb RA, 2007, CURR OPIN STRUC BIOL, V17, P427, DOI 10.1016/j.sbi.2007.08.016; Lawrence MC, 2004, J MOL BIOL, V335, P1343, DOI 10.1016/j.jmb.2003.11.032; Lee JK, 2007, J VIROL, V81, P8821, DOI 10.1128/JVI.00754-07; Ludwig K, 2008, J VIROL, V82, P3775, DOI 10.1128/JVI.02154-07; Lyles D. S., 2007, FIELDS VIROLOGY, V1, P1364; Manchester M, 2000, J VIROL, V74, P3967, DOI 10.1128/JVI.74.9.3967-3974.2000; Melanson VR, 2006, J VIROL, V80, P623, DOI 10.1128/JVI.80.2.623-633.2006; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Negrete OA, 2005, NATURE, V436, P401, DOI 10.1038/nature03838; Negrete Oscar A, 2006, PLoS Pathog, V2, pe7; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; Oldstone MBA, 2002, VIROLOGY, V299, P162, DOI 10.1006/viro.2002.1507; Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001; Plemper RK, 2000, J VIROL, V74, P6485, DOI 10.1128/JVI.74.14.6485-6493.2000; Plemper RK, 2005, ANTIMICROB AGENTS CH, V49, P3755, DOI 10.1128/AAC.49.9.3755-3761.2005; Plemper RK, 2003, J VIROL, V77, P4181, DOI 10.1128/JVI.77.7.4181-4190.2003; Plemper RK, 2002, J VIROL, V76, P5051, DOI 10.1128/JVI.76.10.5051-5061.2002; Plemper RK, 2001, J BIOL CHEM, V276, P44239, DOI 10.1074/jbc.M105967200; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; *SCHROD, 2005, MACROMODEL VERS 9 1; *SCHROD, 2005, PRIM; Seki F, 2003, J VIROL, V77, P9943, DOI 10.1128/JVI.77.18.9943-9950.2003; Smith BJ, 2002, PROTEIN ENG, V15, P365, DOI 10.1093/protein/15.5.365; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; STERN LBL, 1995, J VIROL, V69, P1661, DOI 10.1128/JVI.69.3.1661-1668.1995; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Tanabayashi K, 1996, J VIROL, V70, P6112, DOI 10.1128/JVI.70.9.6112-6118.1996; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Tatsuo H, 2001, J VIROL, V75, P5842, DOI 10.1128/JVI.75.13.5842-5850.2001; THOMPSON SD, 1988, J VIROL, V62, P4653, DOI 10.1128/JVI.62.12.4653-4660.1988; Tomasi M, 2003, FEBS LETT, V536, P56, DOI 10.1016/S0014-5793(03)00010-3; Tsurudome M, 1998, J GEN VIROL, V79, P279, DOI 10.1099/0022-1317-79-2-279; TSURUDOME M, 1995, VIROLOGY, V213, P190, DOI 10.1006/viro.1995.1559; von Messling V, 2001, J VIROL, V75, P6418, DOI 10.1128/JVI.75.14.6418-6427.2001; von Messling V, 2002, J VIROL, V76, P4172, DOI 10.1128/JVI.76.9.4172-4180.2002; Vongpunsawad S, 2004, J VIROL, V78, P302, DOI 10.1128/JVI.78.1.302-313.2004; Wang ZY, 2004, VIRUS RES, V99, P177, DOI 10.1016/j.virusres.2003.11.010; WILD TF, 1994, J VIROL, V68, P7546, DOI 10.1128/JVI.68.11.7546-7548.1994; Yao QZ, 1997, J VIROL, V71, P650, DOI 10.1128/JVI.71.1.650-656.1997; Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322; Yin HS, 2005, P NATL ACAD SCI USA, V102, P9288, DOI 10.1073/pnas.0503989102; Yuan P, 2005, STRUCTURE, V13, P803, DOI 10.1016/j.str.2005.02.019	64	87	90	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16561	16572		10.1074/jbc.M801018200	http://dx.doi.org/10.1074/jbc.M801018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18426797	hybrid, Green Published			2022-12-25	WOS:000256497100033
J	Targett-Adams, P; Hope, G; Boulant, S; McLauchlan, J				Targett-Adams, Paul; Hope, Graham; Boulant, Steeve; McLauchlan, John			Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED INTRAMEMBRANE PROTEOLYSIS; GAMMA-SECRETASE; LIPID DROPLETS; HLA-E; ENDOPLASMIC-RETICULUM; ASPARTIC PROTEASE; INFECTIOUS VIRUS; IN-VITRO; CLEAVAGE; REPLICATION	Complete maturation of hepatitis C virus (HCV) core protein requires coordinate cleavage by signal peptidase and an intramembrane protease, signal peptide peptidase. We show that reducing the intracellular levels of signal peptide peptidase lowers the titer of infectious virus released from cells, indicating that it plays an important role in virus production. Proteolysis by the enzyme at a signal peptide between core and the E1 glycoprotein is needed to permit targeting of core to lipid droplets. From mutagenesis studies, introducing mutations into the core-E1 signal peptide delayed the appearance of signal peptide peptidase-processed core until between 48 and 72 h after the beginning of the infectious cycle. Accumulation of mature core at these times coincided with its localization to lipid droplets and a rise in titer of infectious HCV. Therefore, processing of core by signal peptide peptidase is a critical event in the virus life cycle. To study the stage in virus production that may be blocked by interfering with intramembrane cleavage of core, we examined the distribution of viral RNA in cells harboring the core-E1 signal peptide mutant. Results revealed that colocalization of core with HCV RNA required processing of the protein by signal peptide peptidase. Our findings provide new insights into the sequence requirements for proteolysis by signal peptide peptidase. Moreover, they offer compelling evidence for a function for an intramembrane protease to facilitate the association of core with viral genomes, thereby creating putative sites for assembly of nascent virus particles.	[Targett-Adams, Paul; Hope, Graham; Boulant, Steeve; McLauchlan, John] Univ Glasgow, Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow	McLauchlan, J (corresponding author), Univ Glasgow, Inst Virol, MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	j.mclauchlan@vir.gla.ac.uk	Boulant, Steeve/W-3754-2019	Boulant, Steeve/0000-0001-8614-4993; Targett-Adams, Paul/0000-0003-4967-1668	MRC [MC_U130184143] Funding Source: UKRI; Medical Research Council [MC_U130184143, MC_UU_12014/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ait-Goughoulte M, 2006, J GEN VIROL, V87, P855, DOI 10.1099/vir.0.81664-0; Bland FA, 2003, J BIOL CHEM, V278, P33747, DOI 10.1074/jbc.M305593200; Boulant S, 2007, J GEN VIROL, V88, P2204, DOI 10.1099/vir.0.82898-0; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Clayton RF, 2002, J VIROL, V76, P7672, DOI 10.1128/JVI.76.15.7672-7682.2002; Crawshaw SG, 2004, BIOCHEM J, V384, P9, DOI 10.1042/BJ20041216; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Glasgow GM, 1998, J GEN VIROL, V79, P2405, DOI 10.1099/0022-1317-79-10-2405; Hegde RS, 2006, TRENDS BIOCHEM SCI, V31, P563, DOI 10.1016/j.tibs.2006.08.004; Heimann M, 2006, J VIROL, V80, P1915, DOI 10.1128/JVI.80.4.1915-1921.2006; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hope RG, 2006, J GEN VIROL, V87, P623, DOI 10.1099/vir.0.81371-0; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2003, ANAL BIOCHEM, V319, P327, DOI 10.1016/S0003-2697(03)00298-7; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Loureiro J, 2006, NATURE, V441, P894, DOI 10.1038/nature04830; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; Murray CL, 2007, J VIROL, V81, P10220, DOI 10.1128/JVI.00793-07; Ohba K, 1996, FEBS LETT, V378, P232, DOI 10.1016/0014-5793(95)01441-1; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Randall G, 2007, P NATL ACAD SCI USA, V104, P12884, DOI 10.1073/pnas.0704894104; Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Targett-Adams P, 2008, J VIROL, V82, P2182, DOI 10.1128/JVI.01565-07; Targett-Adams P, 2006, J BIOL CHEM, V281, P29221, DOI 10.1074/jbc.M605373200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	44	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16850	16859		10.1074/jbc.M802273200	http://dx.doi.org/10.1074/jbc.M802273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424431	hybrid			2022-12-25	WOS:000256497100062
J	Cannon, NA; Donlin, MJ; Fan, XF; Aurora, R; Tavis, JE				Cannon, Nathan A.; Donlin, Maureen J.; Fan, Xiaofeng; Aurora, Rajeev; Tavis, John E.		Virahep-C Study Grp	Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy	PLOS ONE			English	Article								Background: Pegylated interferon plus ribavirin therapy for hepatitis C virus (HCV) fails in approximately half of genotype 1 patients. Treatment failure occurs either by nonresponse (minimal declines in viral titer) or relapse (robust initial responses followed by rebounds of viral titers during or after therapy). HCV is highly variable genetically. To determine if viral genetic differences contribute to the difference between response and relapse, we examined the inter-patient genetic diversity and mutation pattern in the full open reading frame HCV genotype 1a consensus sequences. Methodology/Principal Findings: Pre- and post-therapy sequences were analyzed for 10 nonresponders and 10 relapsers from the Virahep-C clinical study. Pre- therapy interpatient diversity among the relapsers was higher than in the nonresponders in the viral NS2 and NS3 genes, and post-therapy diversity was higher in the relapsers for most of HCV's ten genes. Pre- therapy diversity among the relapsers was intermediate between that of the non-responders and responders to therapy. The average mutation rate was just 0.9% at the amino acid level and similar numbers of mutations occurred in the nonresponder and relapser sequences, but the mutations in NS2 of relapsers were less conservative than in nonresponders. Finally, the number and distribution of regions under positive selection was similar between the two groups, although the nonresponders had more foci of positive selection in E2. Conclusions/Significance: The HCV sequences were unexpectedly stable during failed antiviral therapy, both nonresponder and relapser sequences were under selective pressure during therapy, and variation in NS2 may have contributed to the difference in response between the nonresponder and relapser groups. These data support a role for viral genetic variability in determining the outcome of anti-HCV therapy, with those sequences that are more distant from an optimal sequence being less able to resist the pressures of interferon-based therapy.	[Cannon, Nathan A.; Donlin, Maureen J.; Aurora, Rajeev; Tavis, John E.] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA; [Fan, Xiaofeng] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA; [Tavis, John E.] St Louis Univ, Sch Med, St Louis Univ Liver Ctr, St Louis, MO USA	Saint Louis University; Saint Louis University; Saint Louis University	Cannon, NA (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA.	tavisje@slu.edu	Donlin, Maureen J./M-4709-2019	Aurora, Rajeev/0000-0002-6609-6055; Donlin, Maureen/0000-0001-7312-079X	United States of America National Institutes of Health [DK60345]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK060345] Funding Source: NIH RePORTER	United States of America National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by grant number DK60345 from the United States of America National Institutes of Health. The funding agency had no role in designing or performing the study.	Abbate I, 2004, J HEPATOL, V40, P831, DOI 10.1016/j.jhep.2004.01.019; Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436; Arataki K, 2006, INTERVIROLOGY, V49, P352, DOI 10.1159/000095155; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P93; Branch AD, 2005, SEMIN LIVER DIS, V25, P105, DOI 10.1055/s-2005-864786; Brown RJP, 2005, J GEN VIROL, V86, P1931, DOI 10.1099/vir.0.80957-0; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Chambers TJ, 2005, J VIROL, V79, P3071, DOI 10.1128/JVI.79.5.3071-3083.2005; Chayama K, 2000, HEPATOLOGY, V32, P1138, DOI 10.1053/jhep.2000.19364; Chen S, 2002, WORLD J GASTROENTERO, V8, P686, DOI 10.3748/wjg.v8.i4.686; Conjeevaram HS, 2006, GASTROENTEROLOGY, V131, P470, DOI 10.1053/j.gastro.2006.06.008; DAL PF, 2007, J INFECT DIS, V196, P998; Donlin MJ, 2007, J VIROL, V81, P8211, DOI 10.1128/JVI.00487-07; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fan XF, 2006, BIOCHEM BIOPH RES CO, V346, P1163, DOI 10.1016/j.bbrc.2006.06.039; Fares MA, 2004, BIOINFORMATICS, V20, P2867, DOI 10.1093/bioinformatics/bth303; Forns X, 1999, TRENDS MICROBIOL, V7, P402, DOI 10.1016/S0966-842X(99)01590-5; Francois C, 2000, J VIROL, V74, P5587, DOI 10.1128/JVI.74.12.5587-5596.2000; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gaudieri S, 2006, J VIROL, V80, P11094, DOI 10.1128/JVI.00912-06; Gaudy C, 2005, J CLIN MICROBIOL, V43, P750, DOI 10.1128/JCM.43.2.750-754.2005; Gerotto M, 2000, GASTROENTEROLOGY, V119, P1649, DOI 10.1053/gast.2000.20230; Gupta R, 2006, J CLIN MICROBIOL, V44, P709, DOI 10.1128/JCM.44.3.709-715.2006; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hamano K, 2005, J GASTROEN HEPATOL, V20, P1401, DOI 10.1111/j.1440-1746.2005.04024.x; Hung CH, 2003, J VIRAL HEPATITIS, V10, P87, DOI 10.1046/j.1365-2893.2003.00414.x; Jones CT, 2007, J VIROL, V81, P8374, DOI 10.1128/JVI.00690-07; Kaukinen P, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-66; Kim WR, 2002, HEPATOLOGY, V36, P227, DOI 10.1053/jhep.2002.34734; Kohashi T, 2006, J VIRAL HEPATITIS, V13, P582, DOI 10.1111/j.1365-2893.2006.00739.x; Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lorenz IC, 2006, NATURE, V442, P831, DOI 10.1038/nature04975; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Morishima C, 2006, J INFECT DIS, V193, P931, DOI 10.1086/500952; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Odeberg J, 1998, J MED VIROL, V56, P33, DOI 10.1002/(SICI)1096-9071(199809)56:1<33::AID-JMV6>3.0.CO;2-O; Pawlotsky JM, 1999, J VIROL, V73, P6490, DOI 10.1128/JVI.73.8.6490-6499.1999; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Poon AFY, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030045; Puig-Basagoiti F, 2001, J MED VIROL, V65, P35, DOI 10.1002/jmv.1098; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Sarrazin C, 2001, VIROLOGY, V289, P150, DOI 10.1006/viro.2001.1092; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580; VANDOORN LJ, 1995, J VIROL, V69, P773, DOI 10.1128/JVI.69.2.773-778.1995; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Veillon P, 2007, WORLD J GASTROENTERO, V13, P1195, DOI 10.3748/wjg.v13.i8.1195; VON WM, 2003, J VIRAL HEPATITUS, V10, P413; Vuillermoz I, 2004, J MED VIROL, V74, P41, DOI 10.1002/jmv.20144; Walewski JL, 2002, RNA, V8, P557, DOI 10.1017/S1355838202029023; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Yang SS, 2003, LIVER INT, V23, P426, DOI 10.1111/j.1478-3231.2003.00875.x; Yao E, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-88; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; 2004, J CLIN PHARM, V44, P20	66	41	43	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2123	10.1371/journal.pone.0002123	http://dx.doi.org/10.1371/journal.pone.0002123			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18463735	gold, Green Submitted, Green Published			2022-12-25	WOS:000261642400044
J	Nakav, S; Chaimovitz, C; Sufaro, Y; Lewis, EC; Shaked, G; Czeiger, D; Zlotnik, M; Douvdevani, A				Nakav, Sigal; Chaimovitz, Cidio; Sufaro, Yuval; Lewis, Eli C.; Shaked, Gad; Czeiger, David; Zlotnik, Moshe; Douvdevani, Amos			Anti-Inflammatory Preconditioning by Agonists of Adenosine A1 Receptor	PLOS ONE			English	Article							PERITONEAL MESOTHELIAL CELLS; ADENOSINE RECEPTORS; DOWN-REGULATION; UP-REGULATION; EXPRESSION; INVOLVEMENT; INHIBITION; CYTOKINES; MURINE; MICE	Background: Adenosine levels rise during inflammation and modulate inflammatory responses by engaging with four different G protein-coupled receptors. It is suggested that adenosine exhibits pro-inflammatory effects through its A(1) receptor (A(1)R), and anti-inflammatory effects through A(2A) receptor (A(2A)R). Therefore, understanding of the mechanisms that govern adenosine receptor regulation may advance treatment of various inflammatory disorders. We previously reported that peak A(1)R expression during leukocyte recruitment, is followed by a peak in A(2A)R during inflammation resolution. Principal Findings: Here, we examined whether A(1)R activation sequentially induces A(2A)R expression and by this reverses inflammation. The effect of adenosine on A(1)R mediated A(2A)R expression was examined in peritoneal macrophages (PM Phi) and primary peritoneal mesothelial cells (PMC) in vitro. Induction of A(2A)R was inhibited by pertussis toxin (PTX) and partly dependent on A(2A)R stimulation. Administration of A(1)R agonists to healthy mice reduced A(1)R expression and induced A(2A)R production in PMC. Mice that were preconditioned with A(1)R agonists 24 hours before E. coli inoculation exhibited decreased TNF alpha and IL-6 sera levels and reduced leukocytes recruitment. Preconditioning was blocked by pretreatment with A(1)R antagonist, as well as, or by late treatment with A(2A)R antagonist, and was absent in A(2A)R(-/-) mice. Conclusions: Our data suggest that preconditioning by an A(1)R-agonist promotes the resolution of inflammation by inducing the production of A(2A)R. Future implications may include early treatment during inflammatory disorders or pretreatment before anticipated high risk inflammatory events, such as invasive surgery and organ transplantation.	[Nakav, Sigal; Sufaro, Yuval; Lewis, Eli C.; Douvdevani, Amos] Soroka Med Univ Ctr, Dept Clin Biochem, Beer Sheva, Israel; [Chaimovitz, Cidio; Zlotnik, Moshe; Douvdevani, Amos] Ben Gurion Univ Negev, Soroka Med Univ Ctr, Dept Nephrol, Beer Sheva, Israel; [Shaked, Gad; Czeiger, David] Ben Gurion Univ Negev, Soroka Med Univ Ctr, Dept Gen Surg, Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center	Nakav, S (corresponding author), Soroka Med Univ Ctr, Dept Clin Biochem, Beer Sheva, Israel.	amosd@bgu.ac.il	LEWIS, ELI C/F-1552-2012	LEWIS, ELI C/0000-0002-4189-2207; Douvdevani, Amos/0000-0002-0197-6481	Israeli Science Foundation [558/06]; Dr. Montague Robin Fleisher Kidney Transplant Unit Fund	Israeli Science Foundation(Israel Science Foundation); Dr. Montague Robin Fleisher Kidney Transplant Unit Fund	This work was supported by a grant of the Israeli Science Foundation (Grant #558/06) and by the Dr. Montague Robin Fleisher Kidney Transplant Unit Fund.	Andresen BT, 1999, J PHARMACOL EXP THER, V291, P76; Arslan G, 1997, NEUROPHARMACOLOGY, V36, P1319, DOI 10.1016/S0028-3908(97)00090-7; Basok A, 2001, J AM SOC NEPHROL, V12, P695, DOI 10.1681/ASN.V124695; ChungWelch N, 1997, MICROVASC RES, V54, P108, DOI 10.1006/mvre.1997.2038; COOPER JA, 1995, BRIT J CLIN PHARMACO, V40, P43, DOI 10.1111/j.1365-2125.1995.tb04533.x; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; DOUVDEVANI A, 1994, KIDNEY INT, V46, P993, DOI 10.1038/ki.1994.359; Einbinder T, 2003, KIDNEY INT, V63, P2103, DOI 10.1046/j.1523-1755.2003.00014.x; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hausmann MJ, 2000, KIDNEY INT, V57, P476, DOI 10.1046/j.1523-1755.2000.00867.x; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Man L, 2003, KIDNEY INT, V64, P2064, DOI 10.1046/j.1523-1755.2003.00338.x; Mazar J, 2005, ANESTHESIOLOGY, V102, P1174, DOI 10.1097/00000542-200506000-00017; McColl SR, 2005, FASEB J, V19, P187, DOI 10.1096/fj.05-4804fje; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; Navarro A, 1999, BRAIN RES, V816, P47, DOI 10.1016/S0006-8993(98)01062-2; OLAH ME, 1995, ARCH INT PHARMACOD T, V329, P135; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ren HZ, 1999, MOL PHARMACOL, V55, P309, DOI 10.1124/mol.55.2.309; Rogachev B, 2006, KIDNEY INT, V70, P675, DOI 10.1038/sj.ki.5001609; ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/jem.167.3.1186; SALMON JE, 1993, J IMMUNOL, V151, P2775; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Sullivan GW, 2001, BRIT J PHARMACOL, V132, P1017, DOI 10.1038/sj.bjp.0703893; Sullivan GW, 2004, J INFECT DIS, V189, P1897, DOI 10.1086/386311; TOPLEY N, 1995, PERITON DIALYSIS INT, V15, pS35; Trincavelli ML, 2002, BIOCHEM PHARMACOL, V64, P625, DOI 10.1016/S0006-2952(02)01222-4	34	50	53	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2107	10.1371/journal.pone.0002107	http://dx.doi.org/10.1371/journal.pone.0002107			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461129	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400029
J	Schutzer, SE; Schlater, LRK; Ronning, CM; DeShazer, D; Luft, BJ; Dunn, JJ; Ravel, J; Fraser-Liggett, CM; Nierman, WC				Schutzer, Steven E.; Schlater, Linda R. K.; Ronning, Catherine M.; DeShazer, David; Luft, Benjamin J.; Dunn, John J.; Ravel, Jacques; Fraser-Liggett, Claire M.; Nierman, William C.			Characterization of Clinically-Attenuated Burkholderia mallei by Whole Genome Sequencing: Candidate Strain for Exclusion from Select Agent Lists	PLOS ONE			English	Article							GLANDERS; MODEL	Background: Burkholderia mallei is an understudied biothreat agent responsible for glanders which can be lethal in humans and animals. Research with this pathogen has been hampered in part by constraints of Select Agent regulations for safety reasons. Whole genomic sequencing (WGS) is an apt approach to characterize newly discovered or poorly understood microbial pathogens. Methodology/Principal Findings: We performed WGS on a strain of B. mallei, SAVP1, previously pathogenic, that was experimentally infected in 6 equids ( 4 ponies, 1 mule, 1 donkey), natural hosts, for purposes of producing antibodies. Multiple high inocula were used in some cases. Unexpectedly SAVP1 appeared to be avirulent in the ponies and mule, and attenuated in the donkey, but induced antibodies. We determined the genome sequence of SAVP1 and compared it to a strain that was virulent in horses and a human. In comparison, this phenotypic avirulent SAVP1 strain was missing multiple genes including all the animal type III secretory system (T3SS) complex of genes demonstrated to be essential for virulence in mice and hamster models. The loss of these genes in the SAVP1 strain appears to be the consequence of a multiple gene deletion across insertion sequence ( IS) elements in the B. mallei genome. Therefore, the strain by itself is unlikely to revert naturally to its virulent phenotype. There were other genes present in one strain and not the other and vice-versa. Conclusion/Significance: The discovery that this strain of B. mallei was both avirulent in the natural host ponies, and did not possess T3SS associated genes may be fortuitous to advance biodefense research. The deleted virulence-essential T3SS is not likely to be re-acquired naturally. These findings may provide a basis for exclusion of SAVP1 from the Select Agent regulation or at least discussion of what else would be required for exclusion. This exclusion could accelerate research by investigators not possessing BSL-3 facilities and facilitate the production of reagents such as antibodies without the restraints of Select Agent regulation.	[Schutzer, Steven E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; [Schlater, Linda R. K.] USDA, Ames, IA USA; [Ronning, Catherine M.; Nierman, William C.] J Craig Venter Inst, Rockville, MD USA; [DeShazer, David] US Army Med Res Inst Infect Dis, Fort Detrick, MD USA; [Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY USA; [Dunn, John J.] Brookhaven Natl Lab, Biol Dept, Upton, NY USA; [Ravel, Jacques; Fraser-Liggett, Claire M.] Univ Maryland, Sch Med, Dept Med, Inst Genome Sci, Baltimore, MD USA; [Ravel, Jacques; Fraser-Liggett, Claire M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Inst Genome Sc, Baltimore, MD USA; [Nierman, William C.] George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Agriculture (USDA); J. Craig Venter Institute; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; George Washington University	Schutzer, SE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, 185 S Orange Ave, Newark, NJ 07103 USA.	schutzer@umdnj.edu	Ravel, Jacques/D-2530-2009	Fraser, Claire/0000-0003-1462-2428; Luft, Benjamin/0000-0001-9008-7004; Ravel, Jacques/0000-0002-0851-2233	National Institutes of Health [N01-AI30071, U01 AI056480, AI063757]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI063757, U01AI056480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work was funded in part by several grants from the National Institutes of Health (N01-AI30071, U01 AI056480, AI063757). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*CDC, 2000, GLAND BURKH MALL; *CDCP, 2006, SEL AG PROGR NOT EXC; *CDCP, 2005, SEL AG PROGR; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P532; DeShazer D, 2001, MICROB PATHOGENESIS, V30, P253, DOI 10.1006/mpat.2000.0430; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; Fraser CM., 1991, MERCK VET MANUAL HDB, V7th; Fritz DL, 1999, VET PATHOL, V36, P276, DOI 10.1354/vp.36-4-276; Fritz DL, 2000, VET PATHOL, V37, P626, DOI 10.1354/vp.37-6-626; Geissler Erhard, 1999, BIOL TOXIN WEAPONS R; Haas BJ, 2003, NUCLEIC ACIDS RES, V31, P5654, DOI 10.1093/nar/gkg770; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Koenig RL, 2006, 4 HORSEMAN ONE MANS; KORTPETER M, 2001, USAMRIIDS MED MANAGE; Lopez J, 2003, MICROBES INFECT, V5, P1125, DOI 10.1016/j.micinf.2003.07.004; Mandell GL, 1995, MANDELL DOUGLAS BENN; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Schell MA, 2007, MOL MICROBIOL, V64, P1466, DOI 10.1111/j.1365-2958.2007.05734.x; SHEA D, 2004, SMALL SCALE TERRORIS; Srinivasan A, 2001, NEW ENGL J MED, V345, P256, DOI 10.1056/NEJM200107263450404; Ulrich RL, 2004, INFECT IMMUN, V72, P6589, DOI 10.1128/IAI.72.11.6589-6596.2004; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; Wheelis M, 1998, NATURE, V395, P213, DOI 10.1038/26089; Whitlock GC, 2007, FEMS MICROBIOL LETT, V277, P115, DOI 10.1111/j.1574-6968.2007.00949.x; WILKINSON L, 1981, MED HIST, V25, P363, DOI 10.1017/S0025727300034876; YABUUCHI E, 1992, MICROBIOL IMMUNOL, V36, P1251, DOI 10.1111/j.1348-0421.1992.tb02129.x; 2005, FED REG, V70, P13242	29	10	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2058	10.1371/journal.pone.0002058	http://dx.doi.org/10.1371/journal.pone.0002058			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446194	Green Submitted, gold, Green Published			2022-12-25	WOS:000261572300027
J	Wilson, AB; Teugels, GG; Meyer, A				Wilson, Anthony B.; Teugels, Guy G.; Meyer, Axel			Marine Incursion: The Freshwater Herring of Lake Tanganyika Are the Product of a Marine Invasion into West Africa	PLOS ONE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MITOCHONDRIAL-DNA SEQUENCE; CICHLID FISHES; SPECIES FLOCK; EXPLOSIVE SPECIATION; LEVEL FLUCTUATIONS; ANCIENT LAKES; EVOLUTION; PHYLOGENY; DIVERGENCE	The spectacular marine-like diversity of the endemic fauna of Lake Tanganyika, the oldest of the African Great Lakes, led early researchers to suggest that the lake must have once been connected to the ocean. Recent geophysical reconstructions clearly indicate that Lake Tanganyika formed by rifting in the African subcontinent and was never directly linked to the sea. Although the Lake has a high proportion of specialized endemics, the absence of close relatives outside Tanganyika has complicated phylogeographic reconstructions of the timing of lake colonization and intralacustrine diversification. The freshwater herring of Lake Tanganyika are members of a large group of pellonuline herring found in western and southern Africa, offering one of the best opportunities to trace the evolutionary history of members of Tanganyika's biota. Molecular phylogenetic reconstructions indicate that herring colonized West Africa 25-50MYA, at the end of a major marine incursion in the region. Pellonuline herring subsequently experienced an evolutionary radiation in West Africa, spreading across the continent and reaching East Africa's Lake Tanganyika during its early formation. While Lake Tanganyika has never been directly connected with the sea, the endemic freshwater herring of the lake are the descendents of an ancient marine incursion, a scenario which may also explain the origin of other Tanganyikan endemics.	[Wilson, Anthony B.; Meyer, Axel] Univ Konstanz, Dept Biol, Constance, Germany; [Wilson, Anthony B.] Univ Zurich, Zool Museum, Zurich, Switzerland; [Teugels, Guy G.] Royal Museum Cent Africa, Ichthyol Lab, Tervuren, Belgium	University of Konstanz; University of Zurich; Royal Museum for Central Africa	Wilson, AB (corresponding author), Univ Konstanz, Dept Biol, Constance, Germany.	tony.wilson@zm.uzh.ch	Wilson, Anthony B/D-2907-2011; Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193; Wilson, Anthony/0000-0002-2848-8816	National Research Council; Swiss National Science Foundation; Deutsche Forschungsgemeinschaft	National Research Council; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was funded by research grants from the National Research Council and Swiss National Science Foundation to ABW and a grant from the Deutsche Forschungsgemeinschaft to AM. The funding agencies played no role in the analysis or interpretation of the data presented here.	Albrecht C, 2006, ORG DIVERS EVOL, V6, P294, DOI 10.1016/j.ode.2005.12.003; Arambourg C, 1943, B SOC GEOLOGIQUE FRA, VXIII, P281, DOI [10.2113/gssgfbull.S5-XIII.4-6.281, DOI 10.2113/GSSGFBULL.S5-XIII.4-6.281]; Barker FK, 2002, SYST BIOL, V51, P625, DOI 10.1080/10635150290102302; Beadle LC., 1974, INLAND WATERS AFRICA; Brandstatter A, 2005, MOL PHYLOGENET EVOL, V34, P382, DOI 10.1016/j.ympev.2004.10.019; BRANISA L., 1964, BULL MUS NAT HIST NATUR, V36, P279; Briggs JC, 2005, J BIOGEOGR, V32, P287, DOI 10.1111/j.1365-2699.2004.01170.x; Broughton RE, 2001, GENOME RES, V11, P1958, DOI 10.1101/gr.156801; CAVENDER TM, 1991, CYPRINID FISHES SYST, P34; CHANG YS, 1994, J MOL EVOL, V38, P138, DOI 10.1007/BF00166161; Cohen AS, 1997, BASIN RES, V9, P107, DOI 10.1046/j.1365-2117.1997.00038.x; Coulter G. W., 1991, LAKE TANGANYIKA ITS; Di Dario F, 2002, COPEIA, P496; Duftner N, 2005, J MOL EVOL, V60, P277, DOI 10.1007/s00239-004-0017-8; Durand JD, 2005, MOL PHYLOGENET EVOL, V36, P277, DOI 10.1016/j.ympev.2005.01.019; Giresse P, 2005, J AFR EARTH SCI, V43, P301, DOI 10.1016/j.jafrearsci.2005.07.009; Gorthner A., 1994, ARCH HYDROBIOL, V44, P97; Gourene Germain, 1994, Journal of African Zoology, V108, P77; GRANDE L, 1985, American Museum Novitates, P1; GRANDE L, 1985, B AM MUS NAT HIST, V181, P235; Guiraud R, 2005, J AFR EARTH SCI, V43, P83, DOI 10.1016/j.jafrearsci.2005.07.017; Guiraud R, 2001, PALAEOTECTONIC ATLAS; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hauser L, 1998, J FISH BIOL, V53, P413, DOI 10.1006/jfbi.1998.0826; Hrbek T, 1999, EVOLUTION, V53, P1200, DOI 10.1111/j.1558-5646.1999.tb04533.x; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Inoue JG, 2000, FISHERIES SCI, V66, P924, DOI 10.1046/j.1444-2906.2000.00148.x; Inoue JG, 2001, FISHERIES SCI, V67, P828, DOI 10.1046/j.1444-2906.2001.00329.x; Joyce DA, 2005, NATURE, V435, P90, DOI 10.1038/nature03489; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Koblmuller S, 2005, J MOL EVOL, V60, P297, DOI 10.1007/s00239-004-0033-8; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; Kocher TD, 2004, NAT REV GENET, V5, P288, DOI 10.1038/nrg1316; Kontula T, 2003, MOL PHYLOGENET EVOL, V27, P143, DOI 10.1016/S1055-7903(02)00376-7; Lavoue S, 2005, MOL PHYLOGENET EVOL, V37, P165, DOI 10.1016/j.ympev.2005.03.024; Lavoue S, 2007, MOL PHYLOGENET EVOL, V43, P1096, DOI 10.1016/j.ympev.2006.09.018; Li CH, 2007, MOL PHYLOGENET EVOL, V44, P386, DOI 10.1016/j.ympev.2006.10.030; Marijnissen SAE, 2006, MOL PHYLOGENET EVOL, V40, P628, DOI 10.1016/j.ympev.2006.03.025; Martens K, 1994, SPECIATION ANCIENT L; Michel E, 2000, ADV ECOL RES, V31, P275, DOI 10.1016/S0065-2504(00)31016-9; MILLER RR, 1982, J PALEONTOL, V56, P423; Moore J. E. S., 1897, NATURE, V56, P198, DOI DOI 10.1038/056198C0; Moore JES, 1903, TANGANYIKA PROBLEM; NISHIDA M, 1991, EXPERIENTIA, V47, P974, DOI 10.1007/BF01929896; PAABO S, 1991, J MOL EVOL, V33, P426, DOI 10.1007/BF02103134; Palumbi S., 2002, SIMPLE FOOLS GUIDE P; Phiri H, 1999, FISH RES, V41, P63, DOI 10.1016/S0165-7836(99)00008-9; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rutschmann F., 2005, BAYESIAN MOL DATING; Saitoh K, 2003, J MOL EVOL, V56, P464, DOI 10.1007/s00239-002-2417-y; Salzburger W, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-17; Salzburger W, 2002, SYST BIOL, V51, P113, DOI 10.1080/106351502753475907; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; SNOEKS J, 1994, ARCH HYDROBIOLOGIE S, P355; Stiassny MLJ, 1999, SCI AM, V280, P64, DOI 10.1038/scientificamerican0299-64; Stiassny MLJ, 2002, COPEIA, P67, DOI 10.1643/0045-8511(2002)002[0067:ROSBCP]2.0.CO;2; Streelman JT, 2003, TRENDS ECOL EVOL, V18, P126; Sturmbauer C, 2001, MOL BIOL EVOL, V18, P144, DOI 10.1093/oxfordjournals.molbev.a003788; Sturmbauer C, 1998, J FISH BIOL, V53, P18; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thorne JL, 2002, SYST BIOL, V51, P689, DOI 10.1080/10635150290102456; Tiercelin J.J., 1991, LAKE TANGANYIKA ITS, P7; Turner GF, 2001, MOL ECOL, V10, P793, DOI 10.1046/j.1365-294x.2001.01200.x; TZENG CS, 1992, NUCLEIC ACIDS RES, V20, P4853, DOI 10.1093/nar/20.18.4853; Van Damme D, 2003, HYDROBIOLOGIA, V498, P1, DOI 10.1023/A:1026298512117; Verheyen E, 1996, PHILOS T ROY SOC B, V351, P797, DOI 10.1098/rstb.1996.0074; von Rintelen T, 2004, P ROY SOC B-BIOL SCI, V271, P2541, DOI 10.1098/rspb.2004.2842; Waddell PJ, 2000, MOL BIOL EVOL, V17, P1988, DOI 10.1093/oxfordjournals.molbev.a026300; Wang HY, 2002, MOL BIOL EVOL, V19, P138, DOI 10.1093/oxfordjournals.molbev.a004066; Waters JM, 2000, SYST BIOL, V49, P777, DOI 10.1080/106351500750049824; WHITEHEAD PJ, 1988, FAO FISHERIES SYNOPS, V125, P1; Whitehead PJP, 1985, AM MUSEUM NOVIT, V2835, P1, DOI [10.2307/772463, DOI 10.2307/772463]; WHITEHEAD PJP, 1985, FAO FISHERIES SYNOPS, V7, P1; Wilson AB, 2004, P ROY SOC B-BIOL SCI, V271, P529, DOI 10.1098/rspb.2003.2624; Wilson AB, 2001, J HERED, V92, P159, DOI 10.1093/jhered/92.2.159; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; Xia XH, 2003, MOL PHYLOGENET EVOL, V26, P1, DOI 10.1016/S1055-7903(02)00326-3; Yabumoto Y, 1988, B KITAKYUSHU MUS NAT, V8, P55; Yang Z., 2000, PHYLOGENETIC ANAL MA; ZWICKL D.J., 2006, THESIS U TEXAS AUSTI	81	37	37	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1979	10.1371/journal.pone.0001979	http://dx.doi.org/10.1371/journal.pone.0001979			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431469	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700004
J	Yalcin, S; Zhang, X; Luciano, JP; Mungamuri, SK; Marinkovic, D; Vercherat, C; Sarkar, A; Grisotto, M; Taneja, R; Ghaffari, S				Yalcin, Safak; Zhang, Xin; Luciano, Julia P.; Mungamuri, Sathish Kumar; Marinkovic, Dragan; Vercherat, Cecile; Sarkar, Abby; Grisotto, Marcos; Taneja, Reshma; Ghaffari, Saghi			Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ATM-DEFICIENT MICE; DNA-DAMAGE; SIGNALING PATHWAY; TUMOR SUPPRESSION; LIFE-SPAN; REDOX REGULATION; ACTIVATION; EXPRESSION; PROTEIN	Unchecked accumulation of reactive oxygen species (ROS) compromises maintenance of hematopoietic stem cells. Regulation of ROS by the tumor suppressor protein ataxia telangiectasia mutated (ATM) is critical for preserving the hematopoietic stem cell pool. In this study we demonstrate that the Foxo3 member of the Forkhead Box O (FoxO) family of transcription factors is essential for normal ATM expression. In addition, we show that loss of Foxo3 leads to defects in hematopoietic stem cells, and these defects result from an overaccumulation of ROS. Foxo3 suppression of ROS in hematopoietic stem cells is mediated partly by regulation of ATM expression. We identify ROS-independent modulations of ATM and p16(INK4a) and ROS-mediated activation of p53/p21(CIP1/WAF1/Sdi1) tumor suppressor pathways as major contributors to Foxo3-null hematopoietic stem cells defects. Our studies demonstrate that Foxo3 represses ROS in part via regulation of ATM and that this repression is required for maintenance of the hematopoietic stem cell pool.	[Yalcin, Safak; Zhang, Xin; Luciano, Julia P.; Mungamuri, Sathish Kumar; Marinkovic, Dragan; Sarkar, Abby; Grisotto, Marcos; Ghaffari, Saghi] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; [Taneja, Reshma; Ghaffari, Saghi] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA; [Vercherat, Cecile; Taneja, Reshma; Ghaffari, Saghi] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Ghaffari, Saghi] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Ghaffari, S (corresponding author), Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.	Saghi.Ghaffari@mssm.edu	Marinkovic, Dragan/C-7244-2009; Grisotto, Marcos/I-4461-2012; Taneja, Reshma/F-9658-2014	Marinkovic, Dragan/0000-0002-6730-4370; Grisotto, Marcos/0000-0003-2077-7979; Taneja, Reshma/0000-0002-2151-2094; Zhang, Xin/0000-0001-5113-1420; Reshma, Taneja/0000-0001-6214-6177; Sarkar, Abby/0000-0001-6101-1721; Mungamuri, Sathish Kumar/0000-0002-0012-5298	American Cancer Society Research Scholarship [RSG LIB-110480]; Career Enhancement Award [K18 HL76510-01]; Black Family exploratory research award; Mount Sinai School of Medicine research funds	American Cancer Society Research Scholarship(American Cancer Society); Career Enhancement Award; Black Family exploratory research award; Mount Sinai School of Medicine research funds	This work was supported by American Cancer Society Research Scholarship RSG LIB-110480, Career Enhancement Award K18 HL76510-01, a Black Family exploratory research award, and Mount Sinai School of Medicine research funds ( to S. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kalberer CP, 2000, P NATL ACAD SCI USA, V97, P5411, DOI 10.1073/pnas.100082597; Kamsler A, 2001, CANCER RES, V61, P1849; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lavin Martin F, 2004, Methods Mol Biol, V281, P163; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; LEMIEUX ME, 1995, BLOOD, V86, P1339, DOI 10.1182/blood.V86.4.1339.bloodjournal8641339; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Marinkovic D, 2007, J CLIN INVEST, V117, P2133, DOI 10.1172/JCI31807; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Morales M, 2005, GENE DEV, V19, P3043, DOI 10.1101/gad.1373705; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Passegue E, 2005, J EXP MED, V202, P1599, DOI 10.1084/jem.20050967; Peter Y, 2001, EMBO J, V20, P1538, DOI 10.1093/emboj/20.7.1538; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; SUDA T, 1983, J CELL PHYSIOL, V117, P308, DOI 10.1002/jcp.1041170305; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; You H, 2005, CELL CYCLE, V4, P37, DOI 10.4161/cc.4.1.1401; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516	51	189	195	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2008	283	37					25692	25705		10.1074/jbc.M800517200	http://dx.doi.org/10.1074/jbc.M800517200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	345QZ	18424439	hybrid, Green Published			2022-12-25	WOS:000259012700064
J	Navab, R; Pedraza, C; Fallavollita, L; Wang, N; Chevet, E; Auguste, P; Jenna, S; You, Z; Bikfalvi, A; Hu, J; O'Connor, R; Erickson, A; Mort, JS; Brodt, P				Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; Auguste, P.; Jenna, S.; You, Z.; Bikfalvi, A.; Hu, J.; O'Connor, R.; Erickson, A.; Mort, J. S.; Brodt, P.			Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels	ONCOGENE			English	Article						IGF; cathepsin L; apoptosis; invasion; metastasis	GROWTH-FACTOR RECEPTOR; CYSTEINE PROTEINASE; ENDOSOMAL PROTEOLYSIS; MELANOMA-CELLS; PROCATHEPSIN-L; ANTISENSE RNA; INSULIN; CANCER; CARCINOMA; METASTASIS	The lysosomal cysteine proteinase cathepsin L is involved in proteolytic processing of internalized proteins. In transformed cells, where it is frequently overexpressed, its intracellular localization and functions can be altered. Previously, we reported that treatment of highly metastatic, murine carcinoma H-59 cells with small molecule cysteine proteinase inhibitors altered the responsiveness of the type I insulin-like growth factor (IGF-I) receptor and consequently reduced cell invasion and metastasis. To assess more specifically the role of cathepsin L in IGF-I-induced signaling and tumorigenicity, we generated H-59 subclones with reduced cathepsin L expression levels. These clonal lines showed an altered responsiveness to IGF-I in vitro, as evidenced by (i) loss of IGF-I-induced receptor phosphorylation and Shc recruitment, (ii) reduced IGF-I (but not IGF-II)-induced cellular proliferation and migration, (iii) decreased anchorage-independent growth and (iv) reduced plasma membrane levels of IGF-IR. These changes resulted in increased apoptosis in vivo and an impaired ability of the cells to form liver metastases. The results demonstrate that cathepsin L expression levels regulate cell responsiveness to IGF-I and thereby identify a novel function for cathepsin L in the control of the tumorigenic/metastatic phenotype.	[Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; You, Z.; Mort, J. S.; Brodt, P.] McGill Univ, Dept Surg, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Brodt, P.] McGill Univ, Dept Med, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.; Jenna, S.; Brodt, P.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.] Univ Bordeaux 2, INSERM, Team Avenir, U889, F-33076 Bordeaux, France; [Bikfalvi, A.] Univ Bordeaux 1, INSERM, E0113, Bordeaux, France; [Auguste, P.] Univ Bordeaux 1, INSERM, U889, Bordeaux, France; [Hu, J.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [O'Connor, R.] Univ Coll Cork, Dept Biochem, Cork, Ireland; [Erickson, A.] Univ N Carolina Chapel Hill, Dept Biochem & Biophys, N Carolina, NC USA; [Mort, J. S.] McGill Univ, Shriners Hosp, Montreal, PQ, Canada	McGill University; McGill University; McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University College Cork; University of North Carolina; University of North Carolina Chapel Hill; McGill University	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Room H6-25,687 Pine Ave W, Montreal, PQ H3A IA1, Canada.	pnina.brodt@muhc.mcgill.ca	chevet, eric/E-4992-2016; O'Connor, Rosemary/B-7902-2014; Navab, Roya/AGD-7380-2022	chevet, eric/0000-0001-5855-4522; O'Connor, Rosemary/0000-0002-0687-3422; Auguste, Patrick/0000-0003-1485-0295; Hu, Jim/0000-0001-9134-7103	Canadian Institute for Health Research [MT-10505]; National Cancer Institute of Canada; National Science Foundation [MCB-96141139]	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); National Science Foundation(National Science Foundation (NSF))	This work was supported initially by Grant MT-10505 from the Canadian Institute for Health Research and subsequently by a Terry Fox Frontiers Initiative Grant from the National Cancer Institute of Canada (to PB) and by Grant MCB-96141139 from the National Science Foundation (to AE). We thank Dr Edmund Ziomek (Biotechnology Research Institute, Montreal, QC, Canada) for gifts of CathC and CathS cDNA, and Drs Amir Samani and Donglei Zhang (formerly of the Division of Surgical Research, McGill University) for their help with the study.	Ahn K, 2002, TRAFFIC, V3, P147, DOI 10.1034/j.1600-0854.2002.030207.x; Authier F, 2005, FEBS LETT, V579, P4309, DOI 10.1016/j.febslet.2005.06.066; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benavides F, 2002, AM J PATHOL, V161, P693, DOI 10.1016/S0002-9440(10)64225-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buckley DA, 2002, J CLIN PATHOL-MOL PA, V55, P46, DOI 10.1136/mp.55.1.46; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Clague MJ, 2001, J CELL SCI, V114, P3075; Collette J, 2004, INT REV CYTOL, V241, P1, DOI 10.1016/S0074-7696(04)41001-8; Denley A, 2003, HORM METAB RES, V35, P778; Desbuquois B, 2003, ENDOCRINOLOGY, V144, P5308, DOI 10.1210/en.2002-0154; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gordon PV, 2005, AM J PHYSIOL-GASTR L, V289, pG79, DOI 10.1152/ajpgi.00384.2004; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Guan J, 1996, ENDOCRINOLOGY, V137, P893, DOI 10.1210/en.137.3.893; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Ishidoh K, 1998, BIOL CHEM, V379, P131; Iwata Y, 1997, ARTHRITIS RHEUM, V40, P499, DOI 10.1002/art.1780400316; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nam T, 2002, ENDOCRINOLOGY, V143, P30, DOI 10.1210/en.143.1.30; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; SAMANI AA, 2001, SURG ONCOL CLIN N AM, V10, pR8; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Wang N, 2006, CANCER RES, V66, P3062, DOI 10.1158/0008-5472.CAN-05-2638; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; [杨啊晶 YANG Ajing], 2007, [中国新药杂志, Chinese Journal New Drugs], V16, P7; Yang M, 2007, NAT CELL BIOL, V9, P970, DOI 10.1038/ncb1623; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	60	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4973	4985		10.1038/onc.2008.144	http://dx.doi.org/10.1038/onc.2008.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469859				2022-12-25	WOS:000258914800001
J	Deng, HB; Yu, F; Chen, JQ; Zhao, YM; Xiang, JL; Lin, AN				Deng, Hongbin; Yu, Fei; Chen, Jianqun; Zhao, Yingming; Xiang, Jialing; Lin, Anning			Phosphorylation of bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; PROTEIN-KINASE KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-METABOLISM; TERMINAL KINASE; BCL-2; IDENTIFICATION; INHIBITION; SURVIVAL	The mitogen-activated protein kinase JNK1 suppresses interleukin-3 withdrawal-induced cell death through phosphorylation of the BH3-only pro-apoptotic Bcl-2 family protein Bad at Thr-201. It is unknown whether JNK1 regulates glycolysis, an important metabolic process that is involved in cell survival, and if so, whether the regulation depends on Thr-201 phosphorylation of Bad. Here we report that phosphorylation of Bad by JNK1 is required for glycolysis through activation of phosphofructokinase-1 (PFK-1), one of the key enzymes that catalyze glycolysis. Genetic disruption of Jnk1 alleles or silencing of Jnk1 by small interfering RNA abrogates glycolysis induced by growth/survival factors such as serum or interleukin-3. Proteomic analysis identifies PFK-1 as a novel Bad-associated protein. Although the interaction between PFK-1 and Bad is independent of JNK1, Thr-201 phosphorylation of Bad by JNK1 is required for PFK-1 activation. Thus, our results provide a novel molecular mechanism by which JNK1 promotes glycolysis for cell survival.	[Deng, Hongbin; Lin, Anning] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Yu, Fei; Chen, Jianqun; Lin, Anning] Nanjing Univ, Sch Life Sci, Inst Signal Transduct, Nanjing 210093, Peoples R China; [Zhao, Yingming] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Xiang, Jialing] IIT, Dept Biol Chem & Phys sci, Chicago, IL 60616 USA	University of Chicago; Nanjing University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Illinois Institute of Technology	Lin, AN (corresponding author), Univ Chicago, Ben May Dept Canc Res, Ctr Integrat Sci Bldg,Rm W340,929 E 57th St, Chicago, IL 60637 USA.	alin@huggins.bsd.uchicago.edu	Deng, Hongbin/AAN-3603-2020	Deng, Hongbin/0000-0002-4398-8819	NATIONAL CANCER INSTITUTE [R01CA100460, K01CA090516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071409] Funding Source: NIH RePORTER; NCI NIH HHS [CA 090516, CA 100460] Funding Source: Medline; NIGMS NIH HHS [GM 071409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hammaker DR, 2004, J IMMUNOL, V172, P1612, DOI 10.4049/jimmunol.172.3.1612; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito M, 1999, MOL CELL BIOL, V19, P7539; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; LAYZER RB, 1969, J BIOL CHEM, V244, P3823; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin AN, 2006, DEV CELL, V10, P277, DOI 10.1016/j.devcel.2006.02.006; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2007, ONCOGENE, V26, P3267, DOI 10.1038/sj.onc.1210417; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; RATT MC, 1992, NATURE, V356, P397; Rempel A, 1996, CANCER RES, V56, P2468; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SAPICO V, 1970, J BIOL CHEM, V245, P3252; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Uehara T, 2005, J HEPATOL, V42, P850, DOI 10.1016/j.jhep.2005.01.030; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	58	47	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					20754	20760		10.1074/jbc.M800024200	http://dx.doi.org/10.1074/jbc.M800024200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18469002	Green Published, hybrid			2022-12-25	WOS:000257746100016
J	Mannaioni, G; Orr, AG; Hamill, CE; Yuan, HJ; Pedone, KH; Mccoy, KL; Palmini, RB; Junge, CE; Lee, CJ; Yepes, M; Hepler, JR; Traynelis, SF				Mannaioni, Guido; Orr, Anna G.; Hamill, Cecily E.; Yuan, Hongjie; Pedone, Katherine H.; Mccoy, Kelly L.; Palmini, Rolando Berlinguer; Junge, Candice E.; Lee, C. Justin; Yepes, Manuel; Hepler, John R.; Traynelis, Stephen F.			Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; THROMBIN RECEPTOR; LYSOPHOSPHATIDIC ACID; MICE LACKING; LATE-PHASE; SYSTEM; EXPRESSION; GLUTAMATE; CURRENTS; LOCALIZATION	Protease-activated receptor-1 (PAR1) is activated by a number of serine proteases, including plasmin. Both PAR1 and plasminogen, the precursor of plasmin, are expressed in the central nervous system. In this study we examined the effects of plasmin in astrocyte and neuronal cultures as well as in hippocampal slices. We find that plasmin evokes an increase in both phosphoinositide hydrolysis (EC50 64 nM) and Fura-2/AM fluorescence (195 +/- 6.7% above base line, EC50 65 nM) in cortical cultured murine astrocytes. Plasmin also activates extracellular signal-regulated kinase (ERK1/2) within cultured astrocytes. The plasmin-induced rise in intracellular Ca2+ concentration ([Ca2+](i)) and the increase in phospho-ERK1/2 levels were diminished in PAR1(-/-) astrocytes and were blocked by 1 mu M BMS-200261, a selective PAR1 antagonist. However, plasmin had no detectable effect on ERK1/2 or [Ca2+](i) signaling in primary cultured hippocampal neurons or in CA1 pyramidal cells in hippocampal slices. Plasmin (100-200 nM) application potentiated the N-methyl-D-aspartate (NMDA) receptor-dependent component of miniature excitatory postsynaptic currents recorded from CA1 pyramidal neurons but had no effect on alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate- or gamma-aminobutyric acid receptor-mediated synaptic currents. Plasmin also increased NMDA-induced whole cell receptor currents recorded from CA1 pyramidal cells (2.5 +/- 0.3-fold potentiation over control). This effect was blocked by BMS-200261 (1 mu M; 1.02 +/- 0.09-fold potentiation over control). These data suggest that plasmin may serve as an endogenous PAR1 activator that can increase [Ca2+](i) in astrocytes and potentiate NMDA receptor synaptic currents in CA1 pyramidal neurons.	[Orr, Anna G.; Hamill, Cecily E.; Yuan, Hongjie; Pedone, Katherine H.; Mccoy, Kelly L.; Hepler, John R.; Traynelis, Stephen F.] Emory Univ, Dept Pharmacol, Rollins Res Ctr 5062, Atlanta, GA 30322 USA; [Mannaioni, Guido; Palmini, Rolando Berlinguer] Univ Florence, Dipartimento Farmacol, I-50139 Florence, Italy; [Junge, Candice E.] Agensys Inc, Santa Monica, CA 90404 USA; [Lee, C. Justin] Korea Inst Sci & Technol, Seoul 136791, South Korea; [Yepes, Manuel] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University; University of Florence; Korea Institute of Science & Technology (KIST); Emory University	Traynelis, SF (corresponding author), Emory Univ, Dept Pharmacol, Rollins Res Ctr 5062, 1510 Clifton Rd, Atlanta, GA 30322 USA.	strayne@emory.edu	Lee, C. Justin/AAC-1663-2019; Berlinguer Palmini, Rolando/G-7745-2011; Palmini, Rolando Berlinguer/K-8764-2013; Yepes, Manuel/C-3576-2011	Palmini, Rolando Berlinguer/0000-0002-1786-496X; Yuan, Hongjie/0000-0002-8127-7145; Lee, C Justin/0000-0002-3555-0980; Orr, Anna/0000-0002-4036-4277; mannaioni, guido/0000-0002-8273-7377	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043875, R01NS049478, F31NS054515, R01NS039419] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NINDS NIH HHS [NS 039419, NS 049478, NS 43875, NS 530062, NS 054515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almonte AG, 2007, NEUROBIOL LEARN MEM, V88, P295, DOI 10.1016/j.nlm.2007.04.004; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Basham ME, 2001, J NEUROCHEM, V77, P318, DOI 10.1046/j.1471-4159.2001.t01-1-00239.x; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Carmignoto G, 2000, PROG NEUROBIOL, V62, P561, DOI 10.1016/S0301-0082(00)00029-0; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DASCAL N, 1987, PFLUG ARCH EUR J PHY, V409, P512, DOI 10.1007/BF00583809; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Holtsberg FW, 1997, J NEUROCHEM, V69, P68; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Ito M, 2006, MOL PHARMACOL, V70, P1720, DOI 10.1124/mol.106.022467; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lisman J, 2003, PHILOS T ROY SOC B, V358, P829, DOI 10.1098/rstb.2002.1242; Loew D, 2000, BIOCHEMISTRY-US, V39, P10812, DOI 10.1021/bi0003341; Mannaioni G, 2001, J NEUROSCI, V21, P5925, DOI 10.1523/JNEUROSCI.21-16-05925.2001; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Matys T, 2005, NEUROSCIENCE, V135, P715, DOI 10.1016/j.neuroscience.2005.06.076; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; Mizutani A, 1996, BRAIN RES, V739, P276, DOI 10.1016/S0006-8993(96)00834-7; Mizutani A, 1997, BRAIN RES, V761, P93, DOI 10.1016/S0006-8993(97)00338-7; Muller CM, 1998, NAT NEUROSCI, V1, P47, DOI 10.1038/248; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nagai T, 2006, J NEUROSCI, V26, P12374, DOI 10.1523/JNEUROSCI.3139-06.2006; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Nicoll RA, 2003, PHILOS T R SOC B, V358, P721, DOI 10.1098/rstb.2002.1228; ORON Y, 1985, NATURE, V313, P141, DOI 10.1038/313141a0; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P18201, DOI 10.1073/pnas.0509232102; Pawlak R, 2002, NEUROSCIENCE, V113, P995, DOI 10.1016/S0306-4522(02)00166-5; Quinton TM, 2004, J BIOL CHEM, V279, P18434, DOI 10.1074/jbc.M401431200; RALL WILFRID, 1962, BIOPHYS JOUR, V2, P145; Rickard A, 2005, AM J PHYSIOL-RENAL, V288, pF714, DOI 10.1152/ajprenal.00288.2004; Salles FJ, 2002, J NEUROSCI, V22, P2125, DOI 10.1523/JNEUROSCI.22-06-02125.2002; Smith MA, 2003, J PHYSIOL-LONDON, V548, P245, DOI 10.1113/jphysiol.2002.036376; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Stricker C, 1996, J PHYSIOL-LONDON, V490, P419, DOI 10.1113/jphysiol.1996.sp021155; Traynelis SF, 2007, CURR OPIN HEMATOL, V14, P230, DOI 10.1097/MOH.0b013e3280dce568; Walker DL, 2002, PHARMACOL BIOCHEM BE, V71, P379, DOI 10.1016/S0091-3057(01)00698-0; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Yang YX, 1997, BRAIN RES, V761, P11, DOI 10.1016/S0006-8993(97)00311-9; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493	53	62	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20600	20611		10.1074/jbc.M803015200	http://dx.doi.org/10.1074/jbc.M803015200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18474593	Green Published, hybrid			2022-12-25	WOS:000257565300072
J	Kakusho, N; Taniyama, C; Masai, H				Kakusho, Naoko; Taniyama, Chika; Masai, Hisao			Identification of stimulators and inhibitors of Cdc7 kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC7-RELATED KINASE; CELL-CYCLE REGULATION; PROTEIN-KINASE; S-PHASE; REGULATORY SUBUNIT; DNA-REPLICATION; PHOSPHORYLATION; POLYAMINES; BINDING; COMPLEX	Cdc7 is a serine-threonine kinase that regulates initiation and progression of DNA replication. The activity of purified Cdc7 kinase is significantly stimulated by polyamines such as spermine or spermidine. Positively charged polymers of lysine or arginine also stimulate its kinase activity, whereas the negatively charged substances such as polyglutamate or nucleic acids significantly inhibit the kinase activity. Spermine affects both the K-m and V-max of Cdc7 kinase for a minichromosome maintenance (MCM) substrate. We also found that histones, lysine- and arginine-rich basic proteins, can stimulate Cdc7 kinase activity, and a MCM complex in association with histone is a more efficient substrate of Cdc7 than the free MCM complex. These results identify potential cellular inhibitors and stimulators of Cdc7 kinase and suggest that Cdc7 may be another target of cellular polyamines and that histones may stimulate Cdc7-mediated phosphorylation of chromatin-bound substrates. Ectopic expression of an antizyme, known to reduce the cellular polyamine levels, resulted in reduction of Cdc7-mediated phosphorylation of MCM4 protein, suggesting physiological roles of polyamines in regulation of Cdc7 kinase activity in the cells.	[Kakusho, Naoko; Taniyama, Chika; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), 3-18-22 Honkomagome,Bunkyo Ku, Tokyo 1138613, Japan.	masai-hs@igakuken.or.jp						Bailis JM, 2003, NAT CELL BIOL, V5, P1111, DOI 10.1038/ncb1069; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; Gerard A, 2006, EMBO REP, V7, P817, DOI 10.1038/sj.embor.7400750; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; Mangold U, 2005, IUBMB LIFE, V57, P671, DOI 10.1080/15216540500307031; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; Ogino K, 2006, P NATL ACAD SCI USA, V103, P8131, DOI 10.1073/pnas.0602498103; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sheu YJ, 2006, MOL CELL, V24, P101, DOI 10.1016/j.molcel.2006.07.033; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; You ZY, 1999, MOL CELL BIOL, V19, P8003	38	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19211	19218		10.1074/jbc.M803113200	http://dx.doi.org/10.1074/jbc.M803113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18442972	hybrid			2022-12-25	WOS:000257387600006
J	Momcilovic, M; Iram, SH; Liu, Y; Carlson, M				Momcilovic, Milica; Iram, Surtaj H.; Liu, Yang; Carlson, Marian			Roles of the glycogen-binding domain and Snf4 in glucose inhibition of SNF1 protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSON-WHITE-SYNDROME; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; UPSTREAM KINASE; HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-HYPERTROPHY; GAMMA(2) SUBUNIT; CATALYTIC DOMAIN; STRUCTURAL BASIS; ACTIVATES SNF1	The SNF1/AMP-activated protein kinase (AMPK) family is required for adaptation to metabolic stress and energy homeostasis. The gamma subunit of AMPK binds AMP and ATP, and mutations that affect binding cause human disease. We have here addressed the role of the Snf4 (gamma) subunit in regulating SNF1 protein kinase in response to glucose availability in Saccharomyces cerevisiae. Previous studies of mutant cells lacking Snf4 suggested that Snf4 counteracts autoinhibition by the C-terminal sequence of the Snf1 catalytic subunit but is dispensable for glucose regulation, and AMP does not activate SNF1 in vitro. We first introduced substitutions at sites that, in AMPK, contribute to nucleotide binding and regulation. Mutations at several sites relieved glucose inhibition of SNF1, as judged by catalytic activity, phosphorylation of the activation-loop Thr-210, and growth assays, although analogs of the severe human mutations R531G/Q had little effect. We further showed that alterations of Snf4 residues that interact with the glycogen-binding domain (GBD) of the beta subunit strongly relieved glucose inhibition. Finally, substitutions in the GBD of the Gal83 beta subunit that are predicted to disrupt interactions with Snf4 and also complete deletion of the GBD similarly relieved glucose inhibition of SNF1. Analysis of mutant cells lacking glycogen synthase showed that regulation of SNF1 is normal in the absence of glycogen. These findings reveal novel roles for Snf4 and theGBDin regulation of SNF1.	[Momcilovic, Milica] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Iram, Surtaj H.; Liu, Yang; Carlson, Marian] Columbia Univ, Dept Genet & Dev & Microbiol, New York, NY 10032 USA	Columbia University; Columbia University	Carlson, M (corresponding author), 701 W 168th St,HSC922, New York, NY 10032 USA.	mbc1@columbia.edu	Iram, Surtaj Hussain/T-5510-2019	Iram, Surtaj/0000-0002-0672-0936	NIGMS NIH HHS [GM34095, R01 GM034095] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034095, R37GM034095] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, PROTEIN SCI, V13, P155, DOI 10.1110/ps.03340004; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Amodeo GA, 2007, NATURE, V449, P492, DOI 10.1038/nature06127; Arad M, 2003, CIRCULATION, V107, P2850, DOI 10.1161/01.CIR.0000075270.13497.2B; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Burwinkel B, 2005, AM J HUM GENET, V76, P1034, DOI 10.1086/430840; CARLSON M, 1981, GENETICS, V98, P25; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dubacq C, 2004, MOL CELL BIOL, V24, P2560, DOI 10.1128/MCB.24.6.2560-2572.2004; Elbing K, 2006, J BIOL CHEM, V281, P26170, DOI 10.1074/jbc.M603811200; ESTRUCH F, 1992, GENETICS, V132, P639; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hedbacker K, 2008, FRONT BIOSCI-LANDMRK, V13, P2408, DOI 10.2741/2854; Hedbacker K, 2006, EUKARYOT CELL, V5, P1950, DOI 10.1128/EC.00256-06; Hong SP, 2007, J BIOL CHEM, V282, P16838, DOI 10.1074/jbc.M700146200; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hyman LE, 2002, J BIOL CHEM, V277, P15586, DOI 10.1074/jbc.M200800200; Jackson T, 2000, BBA-GENE STRUCT EXPR, V1491, P161, DOI 10.1016/S0167-4781(00)00052-X; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Jin XS, 2007, STRUCTURE, V15, P1285, DOI 10.1016/j.str.2007.07.017; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kuchin S, 2002, MOL CELL BIOL, V22, P3994, DOI 10.1128/MCB.22.12.3994-4000.2002; Leech A, 2003, EUKARYOT CELL, V2, P265, DOI 10.1128/EC.2.2.265-273.2003; MATSUMOTO K, 1981, MOL CELL BIOL, V1, P83, DOI 10.1128/MCB.1.2.83; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, GENETICS, V115, P247; Orlova M, 2006, EUKARYOT CELL, V5, P1831, DOI 10.1128/EC.00110-06; Platara M, 2006, J BIOL CHEM, V281, P36632, DOI 10.1074/jbc.M606483200; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Polekhina G, 2005, STRUCTURE, V13, P1453, DOI 10.1016/j.str.2005.07.008; Portillo F, 2005, FEBS LETT, V579, P512, DOI 10.1016/j.febslet.2004.12.019; Ramsey KL, 2004, MOL CELL BIOL, V24, P6362, DOI 10.1128/MCB.24.14.6362-6378.2004; Ribar B, 2006, MOL CELL BIOL, V26, P3999, DOI 10.1128/MCB.00293-06; Rubenstein EM, 2008, J BIOL CHEM, V283, P222, DOI 10.1074/jbc.M707957200; Rudolph MJ, 2007, STRUCTURE, V15, P65, DOI 10.1016/j.str.2006.11.014; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Scott JW, 2007, EMBO J, V26, P806, DOI 10.1038/sj.emboj.7601542; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shirra MK, 1999, GENETICS, V152, P73; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Vincent O, 1999, EMBO J, V18, P6672, DOI 10.1093/emboj/18.23.6672; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wiatrowski HA, 2004, MOL CELL BIOL, V24, P352, DOI 10.1128/MCB.24.1.352-361.2004; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOODS A, 1994, J BIOL CHEM, V269, P19509; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiao B, 2007, NATURE, V449, P496, DOI 10.1038/nature06161; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200; Zou LQ, 2005, CIRC RES, V97, P323, DOI 10.1161/01.RES.0000179035.20319.c2	82	38	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19521	19529		10.1074/jbc.M803624200	http://dx.doi.org/10.1074/jbc.M803624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474591	Green Published, hybrid			2022-12-25	WOS:000257387600038
J	Scott, FL; Fuchs, GJ; Boyd, SE; Denault, JB; Hawkins, CJ; Dequiedt, F; Salvesen, GS				Scott, Fiona L.; Fuchs, Greg J.; Boyd, Sarah E.; Denault, Jean-Bernard; Hawkins, Christine J.; Dequiedt, Franck; Salvesen, Guy S.			Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE-7; APOPTOSIS; ACTIVATION; SPECIFICITY; RECEPTOR; HDAC7; PHOSPHORYLATION; DIFFERENTIATION; ACETYLATION; INHIBITOR	Caspase-8 is the initiator caspase of the extrinsic apoptosis pathway and also has a role in non-apoptotic physiologies. Identifying endogenous substrates for caspase-8 by using integrated bioinformatics and biological approaches is required to delineate the diverse roles of this caspase. We describe a number of novel putative caspase-8 substrates using the Prediction of Protease Specificity (PoPS) program, one of which is histone deacetylase 7 (HDAC7). HDAC7 is cleaved faster than any other caspase-8 substrate described to date. It is also cleaved in primary CD4(+)CD8(+) thymocytes undergoing extrinsic apoptosis. By using naturally occurring caspase inhibitors that have evolved exquisite specificity at concentrations found within the cell, we could unequivocally assign the cleavage activity to caspase-8. Importantly, cleavage of HDAC7 alters its subcellular localization and abrogates its Nur77 repressor function. Thus we demonstrate a direct role for initiator caspase-mediated proteolysis in promoting gene transcription.	[Scott, Fiona L.; Fuchs, Greg J.; Denault, Jean-Bernard; Salvesen, Guy S.] Burnham Inst Med Res, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; [Boyd, Sarah E.] Monash Univ, Fac Informat Technol, Melbourne, Vic 3800, Australia; [Hawkins, Christine J.] La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; [Hawkins, Christine J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Childrens Canc Ctr, Parkville, Vic 3050, Australia; [Dequiedt, Franck] Fac Agron, Cellular & Mol Biol Unit, B-5030 Gembloux, Belgium	Sanford Burnham Prebys Medical Discovery Institute; Monash University; La Trobe University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Scott, FL (corresponding author), Burnham Inst Med Res, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fscott@burnham.org	Denault, Jean-Bernard/AAC-5945-2019; Boyd, Sarah E/I-9047-2012; Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071; Boyd, Sarah/0000-0002-7264-8602; Dequiedt, Franck/0000-0003-1234-7477	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NCRR NIH HHS [RR20843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Black S, 2004, CELL DEATH DIFFER, V11, P90, DOI 10.1038/sj.cdd.4401307; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; He YW, 2002, J LEUKOCYTE BIOL, V72, P440; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; McStay GP, 2008, CELL DEATH DIFFER, V15, P322, DOI 10.1038/sj.cdd.4402260; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Ryan CA, 2002, BIOCHEM J, V366, P595, DOI 10.1042/BJ20020863; Salmena L, 2005, J EXP MED, V202, P727, DOI 10.1084/jem.20050683; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Siggs OM, 2006, CURR OPIN IMMUNOL, V18, P175, DOI 10.1016/j.coi.2006.01.001; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wittmann JG, 2004, FEBS LETT, V568, P23, DOI 10.1016/j.febslet.2004.05.004; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	43	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19499	19510		10.1074/jbc.M800331200	http://dx.doi.org/10.1074/jbc.M800331200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18458084	Green Published, hybrid			2022-12-25	WOS:000257387600036
J	Shetty, S; Shetty, P; Idell, S; Velusamy, T; Bhandary, YP; Shetty, RS				Shetty, Sreerama; Shetty, Praveenkumar; Idell, Steven; Velusamy, Thirunavukkarasu; Bhandary, Yashodhar P.; Shetty, Rashmi S.			Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR EXPRESSION; RNA-BINDING-PROTEIN; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; MESSENGER-RNA; DNA-DAMAGE; PAI-1 GENE; INDUCTION; CANCER; CELLS	H1299 lung carcinoma cells lacking p53 (p53(-/-)) express minimal amounts of plasminogen activator inhibitor-1 (PAI-1) protein as well as mRNA. p53(-/-) cells express highly unstable PAI-1 mRNA. Transfection of p53 in p53(-/-) cells enhanced PAI-1 expression and stabilized PAI-1 mRNA. On the contrary, inhibition of p53 expression by RNA silencing in non-malignant human lung epithelial (Beas2B) cells decreased basal as well as urokinase-type plasminogen activator-induced PAI-1 expression because of accelerated degradation of PAI-1 mRNA. Purified p53 protein specifically binds to the PAI-1 mRNA 3'-untranslated region (UTR), and endogenous PAI-1 mRNA forms an immune complex with p53. Treatment of purified p53 protein with anti-p53 antibody abolished p53 binding to the 3'-UTR of PAI-1 mRNA. The p53 binding region maps to a 70-nucleotide PAI-1 mRNA 3'-UTR sequence, and insertion of the p53-binding sequence into beta-globin mRNA destabilized the chimeric transcript. Deletion experiments indicate that the carboxyl-terminal region (amino acid residues 296-393) of p53 protein interacts with PAI-1 mRNA. These observations demonstrate a novel role for p53 as an mRNA-binding protein that regulates increased PAI-1 expression and stabilization of PAI-1 mRNA in human lung epithelial and carcinoma cells.	[Shetty, Sreerama] Univ Texas Hlth Ctr Tyler, Texas Lung Injury Inst, Dept Specialty Care Serv, Tyler, TX 75708 USA	University of Texas System; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Shetty, S (corresponding author), Univ Texas Hlth Ctr Tyler, Texas Lung Injury Inst, Dept Specialty Care Serv, 11937,US Highway 271,Lab C-6, Tyler, TX 75708 USA.	sreerama.shetty@uthct.edu	Velusamy, Thiruanvukkarasu/D-5144-2011; Bhandary, Yashodhar P/J-9078-2017; Shetty, Praveenkumar Shetty Praveenkumar/AAO-1349-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071147, R01HL062453] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL071147, P01HL-62453] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barua RS, 2002, CIRCULATION, V106, P905, DOI 10.1161/01.CIR.0000029091.61707.6B; Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Ghosh S, 2002, AM J RESP CRIT CARE, V166, P890, DOI 10.1164/rccm.2109094; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Inoue M, 2005, ONCOL REP, V14, P1445; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lane D, 2004, NEW ENGL J MED, V350, P2711, DOI 10.1056/NEJMcibr041288; Lau HKF, 2002, BRIT J HAEMATOL, V117, P151, DOI 10.1046/j.1365-2141.2002.03402.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mishra A, 2000, AM J RESP CELL MOL, V22, P543, DOI 10.1165/ajrcmb.22.5.3851; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Nyunoya T, 2006, AM J RESP CELL MOL, V35, P681, DOI 10.1165/rcmb.2006-0169OC; OLMAN MA, 1995, J CLIN INVEST, V96, P1621, DOI 10.1172/JCI118201; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parra M, 2001, J BIOL CHEM, V276, P36303, DOI 10.1074/jbc.M103735200; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Shetty S, 2005, J BIOL CHEM, V280, P28133, DOI 10.1074/jbc.M413190200; Shetty S, 2004, AM J RESP CELL MOL, V31, P100, DOI 10.1165/rcmb.2003-0104OC; Shetty S, 2003, J BIOL CHEM, V278, P18124, DOI 10.1074/jbc.M207445200; Shetty S, 1999, MOL CELL BIOCHEM, V199, P189, DOI 10.1023/A:1006914800447; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; Shetty S, 2000, J BIOL CHEM, V275, P13771, DOI 10.1074/jbc.275.18.13771; SHETTY S, 2006, ENCY RESP MED, P205; Shetty S, 2007, MOL CELL BIOL, V27, P5607, DOI 10.1128/MCB.00080-07; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Sisson TH, 1999, HUM GENE THER, V10, P2315, DOI 10.1089/10430349950016960; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Swaisgood CM, 2000, AM J PATHOL, V157, P177, DOI 10.1016/S0002-9440(10)64529-4; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tressler RJ, 1999, APMIS, V107, P168, DOI 10.1111/j.1699-0463.1999.tb01540.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; YANAMANDRA N, 2005, CLIN EXP METASTAS, V18, P611	46	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19570	19580		10.1074/jbc.M710268200	http://dx.doi.org/10.1074/jbc.M710268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18469003	Green Published, hybrid			2022-12-25	WOS:000257387600043
J	Polyak, MJ; Li, HD; Shariat, N; Deans, JP				Polyak, Maria J.; Li, Haidong; Shariat, Neda; Deans, Julie P.			CD20 homo-oligomers physically associate with the B cell antigen receptor - Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IG-ALPHA/IG-BETA; MU-HEAVY CHAIN; LIPID RAFTS; MEMBRANE RAFTS; LYMPHOCYTES-B; ACTIVATION; COMPLEX; SURFACE; PHOSPHORYLATION; IDENTIFICATION	B cell antigen receptor (BCR) signaling initiates sustained cellular calcium influx necessary for the development, differentiation, and activation of B lymphocytes. CD20 is a B cell-restricted tetraspanning protein organized in the plasma membrane as multimeric molecular complexes involved in BCR-activated calcium entry. Using coprecipitation of native CD20 with tagged or truncated forms of the molecule, we provide here direct evidence of CD20 homo-oligomerization into tetramers. Additionally, the function of CD20 was explored by examining its association with surface-labeled and intracellular proteins before and after BCR signaling. Two major surface-labeled proteins that coprecipitated with CD20 were identified as the heavy and light chains of cell surface IgM, the antigen-binding components of the BCR. After activation, BCR-CD20 complexes dissociated, and phosphoproteins and calmodulin-binding proteins were transiently recruited to CD20. These data provide new evidence of the involvement of CD20 in signaling downstream of the BCR and, together with the previously described involvement of CD20 in calcium influx, the first evidence of physical coupling of the BCR to a calcium entry pathway.	[Deans, Julie P.] Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Fac Med, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Deans, JP (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Fac Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jdeans@ucalgary.ca						BERGMAN Y, 1978, EUR J IMMUNOL, V8, P876, DOI 10.1002/eji.1830081210; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Carter RH, 1997, J IMMUNOL, V158, P3062; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Engelke M, 2007, IMMUNOL REV, V218, P235, DOI 10.1111/j.1600-065X.2007.00539.x; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Gwack Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007; HUH YO, 1994, AM J CLIN PATHOL, V101, P283, DOI 10.1093/ajcp/101.3.283; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; Kim JH, 2005, J IMMUNOL, V175, P147, DOI 10.4049/jimmunol.175.1.147; Kim JH, 2007, INT IMMUNOL, V19, P1403, DOI 10.1093/intimm/dxm110; Kremyanskaya M, 2005, J IMMUNOL, V174, P1501, DOI 10.4049/jimmunol.174.3.1501; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Li HD, 2004, J BIOL CHEM, V279, P19893, DOI 10.1074/jbc.M400525200; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Liang YH, 2001, GENOMICS, V72, P119, DOI 10.1006/geno.2000.6472; LINTHICUM DS, 1975, J ULTRA MOL STRUCT R, V51, P55, DOI 10.1016/S0022-5320(75)80008-6; Luik RM, 2007, TRENDS MOL MED, V13, P103, DOI 10.1016/j.molmed.2007.01.004; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; MELCHERS F, 1972, BIOCHEMISTRY-US, V11, P2204, DOI 10.1021/bi00761a031; Mignen O, 2008, J PHYSIOL-LONDON, V586, P419, DOI 10.1113/jphysiol.2007.147249; Mutch CM, 2007, INT IMMUNOL, V19, P19, DOI 10.1093/intimm/dxl118; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; PETRIS SD, 1978, NATURE, V272, P66, DOI 10.1038/272066a0; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Scharenberg AM, 2007, NAT REV IMMUNOL, V7, P778, DOI 10.1038/nri2172; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; Uchida J, 2004, INT IMMUNOL, V16, P119, DOI 10.1093/intimm/dxh009; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; Vilen BJ, 1999, IMMUNITY, V10, P239, DOI 10.1016/S1074-7613(00)80024-2; Vilen BJ, 2002, J IMMUNOL, V168, P4344, DOI 10.4049/jimmunol.168.9.4344	42	84	93	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18545	18552		10.1074/jbc.M800784200	http://dx.doi.org/10.1074/jbc.M800784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474602	hybrid			2022-12-25	WOS:000257165600010
J	Verdone, G; Doliana, R; Corazza, A; Colebrooke, SA; Spessotto, P; Bot, S; Bucciotti, F; Capuano, A; Silvestri, A; Viglino, P; Campbell, ID; Colombatti, A; Esposito, G				Verdone, Giuliana; Doliana, Roberto; Corazza, Alessandra; Colebrooke, Simon A.; Spessotto, Paola; Bot, Simonetta; Bucciotti, Francesco; Capuano, Alessandra; Silvestri, Alessandra; Viglino, Paolo; Campbell, Iain D.; Colombatti, Alfonso; Esposito, Gennaro			The solution structure of EMILIN1 globular C1q domain reveals a disordered insertion necessary for interaction with the alpha 4 beta 1 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE EXPERIMENTS; CRYSTAL-STRUCTURE; CELL-ADHESION; CHEMICAL-SHIFT; NMR ASSIGNMENTS; BINDING; SEQUENCE; COMPONENT; MACROMOLECULES; IDENTIFICATION	The extracellular matrix protein EMILIN1 (elastin microfibril interface located protein 1) is implicated in maintaining blood pressure homeostasis via the N-terminal elastin microfibril interface domain and in trophoblast invasion of the uterine wall via the globular C1q (gC1q) domain. Here, we describe the first NMR-based homology model structure of the human 52-kDa homotrimer of the EMILIN1 gC1q domain. In contrast to all of the gC1q (crystal) structures solved to date, the 10-stranded beta-sandwich fold of the gC1q domain is reduced to nine beta strands with a consequent increase in the size of the central cavity lumen. An unstructured loop, resulting from an insertion unique to EMILIN1 and EMILIN2 family members and located at the trimer apex upstream of the missing strand, specifically engages the alpha 4 beta 1 integrin. Using both Jurkat T and EA.hy926 endothelial cells as well as site-directed mutagenesis, we demonstrate that the ability of alpha 4 beta 1 integrins to recognize the trimeric EMILIN1 gC1q domain mainly depends on a single glutamic acid residue (Glu(933)). Static and flow adhesion of T cells and haptotactic migration of endothelial cells on gC1q is fully dependent on this residue. Thus, EMILIN1 gC1q-alpha 4 beta 1 represents a unique ligand/receptor system, with a requirement for a 3-fold arrangement of the interaction site.	[Doliana, Roberto; Spessotto, Paola; Bot, Simonetta; Bucciotti, Francesco; Capuano, Alessandra; Silvestri, Alessandra; Colombatti, Alfonso] Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; [Verdone, Giuliana; Corazza, Alessandra; Viglino, Paolo; Colombatti, Alfonso; Esposito, Gennaro] Univ Udine, Dipartimento Sci & Tecnol Biomed, Ctr Eccellenza MATI, I-33100 Udine, Italy; [Colebrooke, Simon A.; Campbell, Iain D.] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; [Colebrooke, Simon A.; Campbell, Iain D.] Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; [Corazza, Alessandra; Viglino, Paolo; Esposito, Gennaro] Consorzio INBB, I-00136 Rome, Italy	IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Oxford; University of Oxford	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, Via Franco Gallini 2, I-33081 Aviano, Italy.	acolombatti@cro.it	Bucciotti, Francesco/AAZ-1255-2020; Corazza, Alessandra/AGB-1457-2022; Spessotto, Paola/K-5005-2012; Doliana, Roberto/AAA-1479-2019; Capuano, Alessandra/AAC-2129-2020	Bucciotti, Francesco/0000-0002-4253-855X; Corazza, Alessandra/0000-0003-2272-1928; Spessotto, Paola/0000-0002-3033-404X; Doliana, Roberto/0000-0002-8324-7564; Capuano, Alessandra/0000-0002-5443-0570; Silvestri, Alessandra/0000-0003-4891-1826; colombatti, alfonso/0000-0002-3676-2379	Telethon [E.1256] Funding Source: Medline; Wellcome Trust Funding Source: Medline; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Chou JJ, 2000, J BIOMOL NMR, V18, P217, DOI 10.1023/A:1026563923774; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Doliana R, 1999, J BIOL CHEM, V274, P16773, DOI 10.1074/jbc.274.24.16773; Doliana R, 2001, J BIOL CHEM, V276, P12003, DOI 10.1074/jbc.M011591200; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Giacomello E, 1999, BIOTECHNIQUES, V26, P758, DOI 10.2144/99264pf01; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hauzenberger D, 1995, CRIT REV IMMUNOL, V15, P285, DOI 10.1615/CritRevImmunol.v15.i3-4.60; Kilger G, 1997, INT IMMUNOL, V9, P219, DOI 10.1093/intimm/9.2.219; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kvansakul M, 2003, MATRIX BIOL, V22, P145, DOI 10.1016/S0945-053X(02)00119-1; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Machin M, 2006, ANN BIOMED ENG, V34, P833, DOI 10.1007/s10439-006-9086-8; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Radivojac P, 2007, BIOPHYS J, V92, P1439, DOI 10.1529/biophysj.106.094045; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Spessotto P, 2003, MATRIX BIOL, V22, P351, DOI 10.1016/S0945-053X(03)00050-7; Spessotto P, 2003, J BIOL CHEM, V278, P6160, DOI 10.1074/jbc.M208322200; Spessotto P, 2000, METH MOL B, V139, P321; Spessotto P, 2006, J CELL SCI, V119, P4574, DOI 10.1242/jcs.03232; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Verdone G, 2004, J BIOMOL NMR, V29, P91, DOI 10.1023/B:JNMR.0000019460.94913.6a; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035	45	26	27	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18947	18956		10.1074/jbc.M801085200	http://dx.doi.org/10.1074/jbc.M801085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18463100	hybrid			2022-12-25	WOS:000257165600051
J	Dostalek, M; Hardy, KD; Milne, GL; Morrow, JD; Chen, C; Gonzalez, FJ; Gu, J; Ding, X; Johnson, DA; Johnson, JA; Martin, MV; Guengerich, FP				Dostalek, Miroslav; Hardy, Klarissa D.; Milne, Ginger L.; Morrow, Jason D.; Chen, Chi; Gonzalez, Frank J.; Gu, Jun; Ding, Xinxin; Johnson, Delinda A.; Johnson, Jeffrey A.; Martin, Martha V.; Guengerich, F. Peter			Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC DELETION; NADPH-CYTOCHROME-P450 REDUCTASE GENE; NICOTINAMIDE N-METHYLTRANSFERASE; ANTIOXIDANT RESPONSE ELEMENT; HYDROGEN-PEROXIDE FORMATION; MIXED-FUNCTION OXIDATION; GLUTATHIONE-PEROXIDASE; MOUSE-LIVER; IN-VIVO; MICROSOMAL CYTOCHROME-P-450	Reactive oxygen species (ROS) and oxidative stress have been considered in a variety of disease models, and cytochrome P450 (P450) enzymes have been suggested to be a source of ROS. Induction of P450s by phenobarbital (PB), beta-naphthoflavone (beta NF), or clofibrate in a mouse model increased ROS parameters in the isolated liver microsomes, but isoniazid treatment did not. However, when F-2-isoprostanes (F-2-IsoPs) were measured in tissues and urine, PB showed the strongest effect and beta NF had a measurable but weaker effect. The same trend was seen when an Nfr2-based transgene reporter sensitive to ROS was analyzed in the mice. This pattern had been seen earlier with F-2-IsoPs both in vitro and in vivo with rats (Dostalek, M., Brooks, J. D., Hardy, K. D., Milne, G. L., Moore, M. M., Sharma, S., Morrow, J. D., and Guengerich, F. P. (2007) Mol. Pharmacol. 72, 1419 1424). One possibility for the general in vitro-in vivo discrepancy in oxidative stress found in both mice and rats is that PB treatment might attenuate protective systems. One potential candidate suggested by an mRNA microarray was nicotinamide N-methyltransferase. PB was found to elevate nicotinamide N-methyltransferase activity 3- to 4-fold in mice and rats and to attenuate levels of NAD(+), NADP(+), NADH, and NADPH in both species (20-40%), due to the enhanced excretion of (N-methyl)nicotinamide. PB also down-regulated glutathione peroxidase and glutathione reductase, which together constitute a key enzymatic system that uses NADPH in protecting against oxidative stress. These multiple effects on the protective systems are proposed to be more important than P450 induction in oxidative stress and emphasize the importance of studying in vivo models.	[Dostalek, Miroslav; Martin, Martha V.; Guengerich, F. Peter] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; [Dostalek, Miroslav; Hardy, Klarissa D.; Milne, Ginger L.; Morrow, Jason D.; Martin, Martha V.; Guengerich, F. Peter] Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; [Hardy, Klarissa D.; Milne, Ginger L.; Morrow, Jason D.] Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Nashville, TN 37232 USA; [Chen, Chi; Gonzalez, Frank J.] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; [Gu, Jun; Ding, Xinxin] SUNY Albany, New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; [Gu, Jun; Ding, Xinxin] SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; [Johnson, Delinda A.; Johnson, Jeffrey A.] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University of Wisconsin System; University of Wisconsin Madison	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,2200 Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu	Milne, Ginger/D-7648-2014; Chen, Chi/AAF-5343-2020	Milne, Ginger/0000-0003-3890-151X; Chen, Chi/0000-0001-9703-604X; Jackson, Klarissa/0000-0002-9388-9800	NCI NIH HHS [R37 CA090426] Funding Source: Medline; NIDDK NIH HHS [R01 DK48831] Funding Source: Medline; NIEHS NIH HHS [R01 ES07462, R01 ES10042, R01 ES007462, P01 ES13125, R01 ES08089, R01 ES007462-13, P30 ES000267] Funding Source: Medline; NIGMS NIH HHS [P50 GM16431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA090426, Z01BC005562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES007462, R01ES008089, R01ES010042, P01ES013125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burk RF, 2008, FREE RADICAL BIO MED, V44, P1617, DOI 10.1016/j.freeradbiomed.2008.01.016; BURK RF, 1997, BIOTRANSFORMATION, V3, P229; CARLBERG I, 1981, BIOCHIM BIOPHYS ACTA, V677, P140, DOI 10.1016/0304-4165(81)90155-0; Caro AA, 2004, ANNU REV PHARMACOL, V44, P27, DOI 10.1146/annurev.pharmtox.44.101802.121704; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen ZH, 2005, J BIOL CHEM, V280, P41921, DOI 10.1074/jbc.M508556200; COHEN G, 1970, ANAL BIOCHEM, V34, P30, DOI 10.1016/0003-2697(70)90083-7; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; CONWAY JG, 1983, J BIOL CHEM, V258, P3825; Crapo J D, 1978, Methods Enzymol, V53, P382; Dalton TP, 2002, CHEM-BIOL INTERACT, V141, P77, DOI 10.1016/S0009-2797(02)00067-4; DEMONTELLANO PRO, 1981, BIOCHEM J, V195, P761, DOI 10.1042/bj1950761; Dong H, 2002, BIOCHEM BIOPH RES CO, V298, P675, DOI 10.1016/S0006-291X(02)02528-7; Dostalek M, 2007, MOL PHARMACOL, V72, P1419, DOI 10.1124/mol.107.040238; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Ernster L., 1967, METHODS ENZYMOL, V10, P574, DOI [10.1016/0076-6879(67)10099-2, DOI 10.1016/0076-6879(67)10099-2]; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; Gong PF, 2006, HEPATOLOGY, V43, P144, DOI 10.1002/hep.21004; Gonzalez FJ, 2005, MUTAT RES-FUND MOL M, V569, P101, DOI 10.1016/j.mrfmmm.2004.04.021; GRIFFITH.MM, 1972, J BIOL CHEM, V247, P1473; Gu J, 2005, MOL PHARMACOL, V67, P623, DOI 10.1124/mol.104.007898; Gu J, 2003, J BIOL CHEM, V278, P25895, DOI 10.1074/jbc.M303125200; Gu J, 2007, J PHARMACOL EXP THER, V321, P9, DOI 10.1124/jpet.106.118240; Guengerich F. P., 2007, PRINCIPLES METHODS T, P1981; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P1698, DOI 10.1021/bi00536a035; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; Henderson CJ, 2003, J BIOL CHEM, V278, P13480, DOI 10.1074/jbc.M212087200; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; Imaoka S, 2004, CANCER LETT, V203, P117, DOI 10.1016/j.canlet.2003.09.009; Isayama F, 2003, FREE RADICAL BIO MED, V35, P1568, DOI 10.1016/j.freeradbiomed.2003.09.007; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P711, DOI 10.1016/j.freeradbiomed.2004.10.024; KAMINSKY LS, 1984, EUR J BIOCHEM, V141, P141, DOI 10.1111/j.1432-1033.1984.tb08168.x; KAUFFMAN FC, 1987, BIOCHEM PHARMACOL, V36, P1083, DOI 10.1016/0006-2952(87)90418-7; KAUFFMAN FC, 1977, BIOCHEM J, V166, P583, DOI 10.1042/bj1660583; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Liebler DC, 2006, CHEM RES TOXICOL, V19, P610, DOI 10.1021/tx0600292; Liu LP, 2001, MOL CELL BIOCHEM, V223, P89, DOI 10.1023/A:1017904912654; Morgan WA, 1997, ARCH TOXICOL, V71, P582, DOI 10.1007/s002040050430; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Musfeld C, 2001, J PHARMACEUT BIOMED, V24, P391, DOI 10.1016/S0731-7085(00)00425-8; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nieto N, 2002, J BIOL CHEM, V277, P9853, DOI 10.1074/jbc.M110506200; NORDBLOM GD, 1977, ARCH BIOCHEM BIOPHYS, V180, P343, DOI 10.1016/0003-9861(77)90047-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PALMER G, 1992, J BIOL CHEM, V267, P665; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; PERSSON JO, 1990, XENOBIOTICA, V20, P887, DOI 10.3109/00498259009046904; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; Pollak N, 2007, J BIOL CHEM, V282, P33562, DOI 10.1074/jbc.M704442200; Robertson Graham, 2001, American Journal of Physiology, V281, pG1135; SANO A, 1992, CHEM PHARM BULL, V40, P153; SEIFERT R, 1984, BIOCHIM BIOPHYS ACTA, V801, P259, DOI 10.1016/0304-4165(84)90075-8; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Thomas RS, 2001, MOL PHARMACOL, V60, P1189, DOI 10.1124/mol.60.6.1189; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Tomida M, 2008, J CANCER RES CLIN, V134, P551, DOI 10.1007/s00432-007-0318-6; Tong V, 2003, FREE RADICAL BIO MED, V34, P1435, DOI 10.1016/S0891-5849(03)00151-5; TORRELLAS A, 1981, PHYSIOL BEHAV, V26, P129, DOI 10.1016/0031-9384(81)90088-3; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Weng Y, 2005, J BIOL CHEM, V280, P31686, DOI 10.1074/jbc.M504447200; West JD, 2006, CHEM RES TOXICOL, V19, P173, DOI 10.1021/tx050321u; WHEELER CR, 1990, ANAL BIOCHEM, V184, P193, DOI 10.1016/0003-2697(90)90668-Y; WHITE A, 1964, PRINCIPLES BIOCH, P954; Yan L, 1999, PHARMACOGENETICS, V9, P307, DOI 10.1097/00008571-199906000-00005; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	76	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17147	17157		10.1074/jbc.M802447200	http://dx.doi.org/10.1074/jbc.M802447200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442974	hybrid, Green Published			2022-12-25	WOS:000256720600023
J	Hossain, MA; Rosengren, KJ; Haugaard-Jonsson, LM; Zhang, S; Layfield, S; Ferraro, T; Daly, NL; Tregear, GW; Wade, JD; Bathgate, RAD				Hossain, Mohammed Akhter; Rosengren, K. Johan; Haugaard-Joensson, Linda M.; Zhang, Soude; Layfield, Sharon; Ferraro, Tania; Daly, Norelle L.; Tregear, Geoffrey W.; Wade, John D.; Bathgate, Ross A. D.			The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CHIMERIC PEPTIDE; SPLICE VARIANTS; H3 RELAXIN; B-CHAIN; LGR7; LIGAND; IDENTIFICATION; AFFINITY; GPCR142	The relaxin peptides are a family of hormones that share a structural fold characterized by two chains, A and B, that are cross-braced by three disulfide bonds. Relaxins signal through two different classes of G-protein-coupled receptors (GPCRs), leucine-rich repeat-containing GPCRs LGR7 and LGR8 together with GPCR135 and GPCR142, now referred to as the relaxin family peptide (RXFP) receptors 1-4, respectively. Although key binding residues have been identified in the B-chain of the relaxin peptides, the role of the A-chain in their activity is currently unknown. A recent study showed that INSL3 can be truncated at the N terminus of its A-chain by up to 9 residues without affecting the binding affinity to its receptor RXFP2 while becoming a high affinity antagonist. This suggests that the N terminus of the INSL3 A-chain contains residues essential for RXFP2 activation. In this study, we have synthesized A-chain truncated human relaxin-2 and -3 (H2 and H3) relaxin peptides, characterized their structure by both CD and NMR spectroscopy, and tested their binding and cAMP activities on RXFP1, RXFP2, and RXFP3. In stark contrast to INSL3, A-chain-truncated H2 relaxin peptides lost RXFP1 and RXFP2 binding affinity and concurrently cAMP-stimulatory activity. H3 relaxin A-chain-truncated peptides displayed similar properties on RXFP1, highlighting a similar binding mechanism for H2 and H3 relaxin. In contrast, A-chain-truncated H3 relaxin peptides showed identical activity on RXFP3, highlighting that the B-chain is the sole determinant of the H3 relaxin-RXFP3 interaction. Our results provide new insights into the action of relaxins and demonstrate that the role of the A-chain for relaxin activity is both peptide- and receptor-dependent.	[Hossain, Mohammed Akhter; Zhang, Soude; Layfield, Sharon; Ferraro, Tania; Tregear, Geoffrey W.; Wade, John D.; Bathgate, Ross A. D.] Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; [Tregear, Geoffrey W.; Bathgate, Ross A. D.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; [Wade, John D.] Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia; [Rosengren, K. Johan; Haugaard-Joensson, Linda M.] Univ Kalmar, Sch Pure & Appl Nat Sci, SE-39182 Kalmar, Sweden; [Daly, Norelle L.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; University of Melbourne; Linnaeus University; University of Kalmar; University of Queensland	Bathgate, RAD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.	bathgate@florey.edu.au	Haugaard-Kedstrom, Linda/F-3705-2011; Haugaard-Kedstrom, Linda/O-7121-2014; Daly, Norelle L/D-4302-2013; Bathgate, Ross/ABE-6471-2020; Rosengren, K. Johan/P-4450-2016	Haugaard-Kedstrom, Linda/0000-0003-0113-6535; Haugaard-Kedstrom, Linda/0000-0003-0113-6535; Daly, Norelle L/0000-0002-4697-6602; Bathgate, Ross/0000-0001-6301-861X; Rosengren, K. Johan/0000-0002-5007-8434; Wade, John/0000-0002-1352-6568; Hossain, Mohammed/0000-0002-9961-0006				Bathgate R. A. D., 2006, PHYSL REPROD, P679; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bathgate RAD, 2006, BIOCHEMISTRY-US, V45, P1043, DOI 10.1021/bi052233e; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; BULLESBACH EE, 1987, J BIOL CHEM, V262, P12496; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; BULLESBACH EE, 1986, BIOCHEMISTRY-US, V25, P5998; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Cierpicki T, 2002, J MAGN RESON, V157, P178, DOI 10.1006/jmre.2002.2597; Del Borgo MP, 2006, J BIOL CHEM, V281, P13068, DOI 10.1074/jbc.M600472200; Del Borgo MP, 2005, J PEPT SCI, V11, P564, DOI 10.1002/psc.652; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Halls ML, 2005, ANN NY ACAD SCI, V1041, P17, DOI 10.1196/annals.1282.004; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; JOHNSON WC, 1990, PROTEIN-STRUCT FUNCT, V7, P214; Kuei C, 2007, J BIOL CHEM, V282, P25425, DOI 10.1074/jbc.M701416200; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lin F, 2004, J PEPT SCI, V10, P257, DOI 10.1002/psc.521; Liu CL, 2005, J BIOL CHEM, V280, P292, DOI 10.1074/jbc.M409916200; Liu CL, 2005, MOL PHARMACOL, V67, P231, DOI 10.1124/mol.104.006700; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; Muda M, 2005, MOL HUM REPROD, V11, P591, DOI 10.1093/molehr/gah205; Rosengren KJ, 2006, J BIOL CHEM, V281, P28287, DOI 10.1074/jbc.M603829200; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SCHWABE C, 1977, SCIENCE, V197, P914, DOI 10.1126/science.887933; Scott DJ, 2007, MOL ENDOCRINOL, V21, P1699, DOI 10.1210/me.2007-0097; Scott DJ, 2006, J BIOL CHEM, V281, P34942, DOI 10.1074/jbc.M602728200; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Van Der Westhuizen ET, 2005, ANN NY ACAD SCI, V1041, P332, DOI 10.1196/annals.1282.053; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	38	75	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17287	17297		10.1074/jbc.M801911200	http://dx.doi.org/10.1074/jbc.M801911200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434306	hybrid			2022-12-25	WOS:000256720600038
J	Mikkelsen, JH; Gyrup, C; Kristensen, P; Overgaard, MT; Poulsen, CB; Laursen, LS; Oxvig, C				Mikkelsen, Jakob H.; Gyrup, Claus; Kristensen, Peter; Overgaard, Michael T.; Poulsen, Christine B.; Laursen, Lisbeth S.; Oxvig, Claus			Inhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; FACTOR-I RECEPTOR; GROWTH-FACTORS; PAPP-A; PHYSIOLOGICAL INHIBITOR; FACTOR VIIA; INSULIN; IGF; CANCER; EXPRESSION	The metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) cleaves both insulin-like growth factor (IGF)-binding protein 4 (IGFBP-4) and -5 at a single site in their central domain causing the release of bioactive IGF. Inhibition of IGF signaling is relevant in human disease, and several drugs in development target the IGF receptor. However, inhibition of PAPP-A activity may be a valuable alternative. We have generated monoclonal phage-derived single chain fragment variable (scFv) antibodies which selectively inhibit the cleavage of IGFBP-4 by PAPP-A, relevant under conditions where cleavage of IGFBP-4 represents the final step in the delivery of IGF to the IGF receptor. None of the antibodies inhibited the homologous proteinase PAPP-A2, which allowed mapping of antibody binding by means of chimeras between PAPP-A and PAPP-A2 to the C-terminal Lin12-Notch repeat module, separated from the proteolytic domain by almost 1000 amino acids. Hence, the antibodies define a substrate binding exosite that can be targeted for the selective inhibition of PAPP-A proteolytic activity against IGFBP-4. In addition, we show that the Lin12-Notch repeat module reversibly binds a calcium ion and that bound calcium is required for antibody binding, providing a strategy for the further development of selective inhibitory compounds. To our knowledge these data represent the first example of differential inhibition of cleavage of natural proteinase substrates by exosite targeting. Generally, exosite inhibitors are less likely to affect the activity of related proteolytic enzymes with similar active site environments. In the case of PAPP-A, selective inhibition of IGFBP-4 cleavage by interference with exosite binding is a further advantage, as the activity against other known or unknown PAPP-A substrates, whose cleavage may not depend on binding to the same exosite, is not targeted.	[Mikkelsen, Jakob H.; Gyrup, Claus; Kristensen, Peter; Overgaard, Michael T.; Poulsen, Christine B.; Laursen, Lisbeth S.; Oxvig, Claus] Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark	Aarhus University	Oxvig, C (corresponding author), Univ Aarhus, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	co@mb.au.dk	Overgaard, Michael Toft/E-1354-2011; Kristensen, Peter/T-6684-2018	Overgaard, Michael Toft/0000-0002-1423-2481; Kristensen, Peter/0000-0001-7205-6853; Oxvig, Claus/0000-0002-4715-9719; Mikkelsen, Jakob Hauge/0000-0002-2914-3297; Laursen, Lisbeth Schmidt/0000-0002-8676-5869				Amour A, 2007, BIOCHEM SOC T, V35, P555, DOI 10.1042/BST0350555; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Bayes-Genis A, 2001, ARTERIOSCL THROM VAS, V21, P335, DOI 10.1161/01.ATV.21.3.335; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Boldt HB, 2004, J BIOL CHEM, V279, P38525, DOI 10.1074/jbc.M405222200; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Boldt HB, 2006, PROTEIN EXPRES PURIF, V48, P261, DOI 10.1016/j.pep.2006.01.024; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Durai R, 2007, INT J ONCOL, V30, P883; Forbes BE, 2002, EUR J BIOCHEM, V269, P961, DOI 10.1046/j.0014-2956.2001.02735.x; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gyrup C, 2007, CLIN CHEM, V53, P947, DOI 10.1373/clinchem.2006.080614; Gyrup C, 2007, BIOCHEMISTRY-US, V46, P1972, DOI 10.1021/bi062229i; Harrington SC, 2007, CIRC RES, V100, P1696, DOI 10.1161/CIRCRESAHA.106.146183; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kornacker MG, 2005, BIOCHEMISTRY-US, V44, P11567, DOI 10.1021/bi050932l; Kristensen P, 1998, FOLD DES, V3, P321, DOI 10.1016/S1359-0278(98)00044-3; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Laursen LS, 2007, MOL ENDOCRINOL, V21, P1246, DOI 10.1210/me.2006-0522; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Ning Y, 2008, MOL ENDOCRINOL, V22, P1213, DOI 10.1210/me.2007-0536; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 2004, FEBS LETT, V560, P147, DOI 10.1016/S0014-5793(04)00095-X; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, V1, P754; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Qin XZ, 2006, ENDOCRINOLOGY, V147, P5653, DOI 10.1210/en.2006-1055; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Soe R, 2002, EUR J BIOCHEM, V269, P2247, DOI 10.1046/j.1432-1033.2002.02883.x; STOCKER W, 1995, PROTEIN SCI, V4, P823; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Tallant C, 2006, J BIOL CHEM, V281, P17920, DOI 10.1074/jbc.M600907200; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Weyer K, 2007, J BIOL CHEM, V282, P10988, DOI 10.1074/jbc.M607903200; Wong MS, 1999, BBA-PROTEIN STRUCT M, V1432, P293, DOI 10.1016/S0167-4838(99)00106-5; Xu XP, 2007, BIOCHEM J, V406, P147, DOI 10.1042/BJ20070591	58	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16772	16780		10.1074/jbc.M802429200	http://dx.doi.org/10.1074/jbc.M802429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18434323	hybrid, Green Published			2022-12-25	WOS:000256497100054
J	Parajes, S; Quinteiro, C; Dominguez, F; Loidi, L				Parajes, Silvia; Quinteiro, Celsa; Dominguez, Fernando; Loidi, Lourdes			High Frequency of Copy Number Variations and Sequence Variants at CYP21A2 Locus: Implication for the Genetic Diagnosis of 21-Hydroxylase Deficiency	PLOS ONE			English	Article							CONGENITAL ADRENAL-HYPERPLASIA; MUTATION ANALYSIS; CLASSICAL FORMS; RCCX MODULE; HAPLOTYPES; PHENOTYPE; DISEASE; IDENTIFICATION; POPULATION; SWEDEN	Background:The systematic study of the human genome indicates that the inter-individual variability is greater than expected and it is not only related to sequence polymorphisms but also to gene copy number variants (CNVs). Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency (21OHD) is the most common autosomal recessive disorder with a carrier frequency of 1:25 to 1:10. The gene that encodes 21-hydroxylase enzyme, CYP21A2, is considered to be one of the most polymorphic human genes. Copy number variations, such as deletions, which are severe mutations common in 21OHD patients, or gene duplications, which have been reported as rare events, have also been described. The correct characterization of 21OHD alleles is important for disease carrier detection and genetic counselling Methodology and Findings:CYP21A2 genotyping by sequencing has been performed in a random sample of the Spanish population, where 144 individuals recruited from university students and employees of the hospital were studied. The frequency of CYP21A2 mutated alleles in our sample was 15.3% (77.3% were mild mutations, 9% were severe mutations and 13.6% were novel variants). Gene dosage assessment was also performed when CYP21A2 gene duplication was suspected. This analysis showed that 7% of individuals bore a chromosome with a duplicated CYP21A2 gene, where one of the copies was mutated. Conclusions:As far as we know, the present study has shown the highest frequency of 21OHD carriers reported by a genotyping analysis. In addition, a high frequency of alleles with CYP21A2 duplications, which could be misinterpreted as 21OHD alleles, was found. Moreover, a high frequency of novel genetic variations with an unknown effect on 21-hydroxylase activity was also found. The high frequency of gene duplications, as well as novel variations, should be considered since they have an important involvement in carrier testing and genetic counseling.	[Parajes, Silvia; Quinteiro, Celsa; Dominguez, Fernando; Loidi, Lourdes] Hosp Clin Univ, Fdn Publ Galega Med Xenom, Unidad Med Mol, Santiago De Compostela, A Coruna, Spain; [Dominguez, Fernando] Univ Santiago Compostela, Dept Fisiol, La Coruna, Spain	Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela	Parajes, S (corresponding author), Hosp Clin Univ, Fdn Publ Galega Med Xenom, Unidad Med Mol, Santiago De Compostela, A Coruna, Spain.	lloidi@usc.es	Parajes, Silvia/J-1582-2012	dominguez, fernando/0000-0002-5003-4335				Balsamo A, 2000, CLIN ENDOCRINOL, V53, P117, DOI 10.1046/j.1365-2265.2000.01048.x; Baradaran-Heravi A, 2007, CLIN ENDOCRINOL, V67, P335, DOI 10.1111/j.1365-2265.2007.02886.x; Barbaro M, 2006, J MOL MED, V84, P521, DOI 10.1007/s00109-006-0043-7; Baumgartner-Parzer SM, 2007, J CLIN ENDOCR METAB, V92, P1164, DOI 10.1210/jc.2006-2189; Baumgartner-Parzer SM, 2005, J CLIN ENDOCR METAB, V90, P775, DOI 10.1210/jc.2004-1728; Blanchong CA, 2000, J EXP MED, V191, P2183, DOI 10.1084/jem.191.12.2183; Brosnan PG, 1999, ARCH PEDIAT ADOL MED, V153, P1272, DOI 10.1001/archpedi.153.12.1272; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Deneux C, 2001, J CLIN ENDOCR METAB, V86, P207, DOI 10.1210/jc.86.1.207; Fitness J, 1999, J CLIN ENDOCR METAB, V84, P960, DOI 10.1210/jc.84.3.960; Friaes A, 2006, MOL GENET METAB, V88, P58, DOI 10.1016/j.ymgme.2005.11.015; Grischuk Y, 2006, J CLIN ENDOCR METAB, V91, P4976, DOI 10.1210/jc.2006-0777; HAGLUNDSTENGLER B, 1991, P NATL ACAD SCI USA, V88, P8352, DOI 10.1073/pnas.88.19.8352; Koppens PFJ, 2002, HUM GENET, V111, P405, DOI 10.1007/s00439-002-0810-7; Krone N, 1999, Hum Mutat, V14, P90, DOI 10.1002/(SICI)1098-1004(1999)14:1<90::AID-HUMU20>3.0.CO;2-H; Krone N, 2000, J CLIN ENDOCR METAB, V85, P1059, DOI 10.1210/jc.85.3.1059; Krone N, 2006, EXP CLIN ENDOCR DIAB, V114, P111, DOI 10.1055/s-2005-872841; Krone N, 2007, CLIN ENDOCRINOL, V66, P162, DOI 10.1111/j.1365-2265.2006.02740.x; Lee HH, 2004, GENOMICS, V83, P944, DOI 10.1016/j.ygeno.2003.11.006; LISTE MTR, 2004, CRIBADO NEONATAL HIP; Loidi L, 2006, CLIN ENDOCRINOL, V64, P330, DOI 10.1111/j.1365-2265.2006.02465.x; New MI, 2006, J CLIN ENDOCR METAB, V91, P4205, DOI 10.1210/jc.2006-1645; Parajes S, 2007, CLIN CHEM, V53, P1577, DOI 10.1373/clinchem.2007.087361; Robins T, 2007, J MOL MED, V85, P243, DOI 10.1007/s00109-006-0121-x; Rumsby G, 1998, CLIN ENDOCRINOL, V48, P707, DOI 10.1046/j.1365-2265.1998.00402.x; SINNOTT PJ, 1991, HUM GENET, V87, P361; Speiser PW, 2003, NEW ENGL J MED, V349, P776, DOI 10.1056/NEJMra021561; Steigert M, 2002, J CLIN ENDOCR METAB, V87, P4106, DOI 10.1210/jc.2002-012093; Stikkelbroeck NMML, 2003, J CLIN ENDOCR METAB, V88, P3852, DOI 10.1210/jc.2002-021681; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; Thilen A, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.4.e11; van der Kamp HJ, 2004, EUR J ENDOCRINOL, V151, pU71, DOI 10.1530/eje.0.151U071; WEDELL A, 1994, HUM GENET, V94, P50, DOI 10.1007/BF02272841; WEDELL A, 1994, J CLIN ENDOCR METAB, V78, P1145, DOI 10.1210/jc.78.5.1145; White PC, 2000, ENDOCR REV, V21, P245, DOI 10.1210/er.21.3.245; Yang ZY, 1999, J BIOL CHEM, V274, P12147, DOI 10.1074/jbc.274.17.12147; ZERAH M, 1990, J CLIN ENDOCR METAB, V70, P1662, DOI 10.1210/jcem-70-6-1662	37	55	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2138	10.1371/journal.pone.0002138	http://dx.doi.org/10.1371/journal.pone.0002138			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478071	Green Published, gold, Green Submitted			2022-12-25	WOS:000262172800003
J	Southern, P; Horbul, J; Maher, D; Davis, DA				Southern, Peter; Horbul, Julie; Maher, Diane; Davis, Dana A.			C. albicans Colonization of Human Mucosal Surfaces	PLOS ONE			English	Article								Background: Candida albicans is a low level commensal organism in normal human populations with the continuous potential to expand and cause a spectrum of clinical conditions. Methodology/Principal Findings: Using ex vivo human organ cultures and populations of primary human cells, we have developed several related experimental systems to examine early-stage interactions between C. albicans and mucosal surfaces. Experiments have been conducted both with exogenously added C. albicans and with overtly normal human mucosal surfaces supporting pre-existing infections with natural isolates of Candida. Under different culture conditions, we have demonstrated the formation of C. albicans colonies on human target cells and filament formation, equivalent to tissue invasion. Conclusions/Significance: These organ culture systems provide a valuable new resource to examine the molecular and cellular basis for Candida colonization of human mucosal surfaces.	[Southern, Peter; Horbul, Julie; Maher, Diane; Davis, Dana A.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Southern, P (corresponding author), Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.	south003@umn.edu			NIH [DE 15090]; Burroughs Wellcome Fund [Investigators in Pathogenesis of Infectious Disease Award]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE015090] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	NIH: DE 15090 (PS) Investigators in Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund (DAD).	Andrei G, 2006, ANTIVIR RES, V71, P96, DOI 10.1016/j.antiviral.2006.05.023; Ayehunie S, 2006, TOXICOL IN VITRO, V20, P689, DOI 10.1016/j.tiv.2005.10.002; Baczynska A, 2007, HUM REPROD, V22, P968, DOI 10.1093/humrep/del455; Barousse MM, 2005, INFECT IMMUN, V73, P7765, DOI 10.1128/IAI.73.11.7765-7767.2005; Cannon RD, 1999, CRIT REV ORAL BIOL M, V10, P359, DOI 10.1177/10454411990100030701; Cassone A, 2007, INFECT IMMUN, V75, P4675, DOI 10.1128/IAI.00083-07; Chapman RL, 2007, SEMIN PERINATOL, V31, P39, DOI 10.1053/j.semperi.2007.01.006; Davis D, 2000, INFECT IMMUN, V68, P5953, DOI 10.1128/IAI.68.10.5953-5959.2000; de Repentigny L, 2004, CLIN MICROBIOL REV, V17, P729, DOI 10.1128/CMR.17.4.729-759.2004; Dieterich C, 2002, MICROBIOL-SGM, V148, P497, DOI 10.1099/00221287-148-2-497; Dongari-Bagtzoglou A, 2006, MICROB PATHOGENESIS, V40, P271, DOI 10.1016/j.micpath.2006.02.004; Dongari-Bagtzoglou A, 2006, NAT PROTOC, V1, P2012, DOI 10.1038/nprot.2006.323; Ellepola ANB, 2000, CRIT REV ORAL BIOL M, V11, P172, DOI 10.1177/10454411000110020301; Feng Z, 2005, J DENT RES, V84, P445, DOI 10.1177/154405910508400509; Fidel PL, 2007, AM J REPROD IMMUNOL, V57, P2, DOI 10.1111/j.1600-0897.2006.00450.x; Fidel Paul L Jr, 2005, Curr Opin Infect Dis, V18, P107; Fidel PL, 2004, TRENDS MICROBIOL, V12, P220, DOI 10.1016/j.tim.2004.03.006; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Gipson IK, 2001, J CLIN ENDOCR METAB, V86, P594, DOI 10.1210/jc.86.2.594; Guenthner PC, 2005, INFECT IMMUN, V73, P4155, DOI 10.1128/IAI.73.7.4155-4160.2005; HOROWITZ BJ, 1987, OBSTET GYNECOL, V69, P883; Jayatilake JAMS, 2005, J ORAL PATHOL MED, V34, P240, DOI 10.1111/j.1600-0714.2005.00307.x; Johnson AS, 2005, J VIROL, V79, P13769, DOI 10.1128/JVI.79.21.13769-13777.2005; JOKINEN K, 1976, J LARYNGOL OTOL, V90, P945, DOI 10.1017/S0022215100082955; Kaufman D A, 2007, Minerva Ginecol, V59, P311; Krunkosky TM, 2007, MICROB PATHOGENESIS, V42, P98, DOI 10.1016/j.micpath.2006.11.003; Kumamoto CA, 2005, ANNU REV MICROBIOL, V59, P113, DOI 10.1146/annurev.micro.59.030804.121034; Lackner A, 2005, AM J RHINOL, V19, P125, DOI 10.1177/194589240501900203; MAGEE BB, 1987, J BACTERIOL, V169, P1639, DOI 10.1128/jb.169.4.1639-1643.1987; Maher D, 2005, P NATL ACAD SCI USA, V102, P11504, DOI 10.1073/pnas.0500848102; Maher D, 2004, J INFECT DIS, V190, P1989, DOI 10.1086/425423; Maher DM, 2005, J HISTOCHEM CYTOCHEM, V53, P631, DOI 10.1369/jhc.4A6534.2005; Malic S, 2007, ORAL MICROBIOL IMMUN, V22, P188, DOI 10.1111/j.1399-302X.2007.00344.x; Mendling W, 2000, MYCOSES, V43, P387, DOI 10.1111/j.1439-0507.2000.00604.x; Mostefaoui Y, 2004, CYTOKINE, V25, P162, DOI 10.1016/j.cyto.2003.11.015; Mylonakis E, 2007, PLOS PATHOG, V3, P859, DOI 10.1371/journal.ppat.0030101; Netea MG, 2008, NAT REV MICROBIOL, V6, P67, DOI 10.1038/nrmicro1815; NORVELL MK, 1984, J REPROD MED, V29, P269; Perry M, 1998, IMMUNOL TODAY, V19, P414, DOI 10.1016/S0167-5699(98)01307-3; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Rebbapragada A, 2007, AIDS, V21, P589, DOI 10.1097/QAD.0b013e328012b896; Reed BD, 2003, J WOMENS HEALTH, V12, P979, DOI 10.1089/154099903322643901; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; Rupp S, 2007, FUTURE MICROBIOL, V2, P141, DOI 10.2217/17460913.2.2.141; Sandovsky-Losica H, 2006, MED MYCOL, V44, P329, DOI 10.1080/13693780500434701; Schaller M, 1998, MOL MICROBIOL, V29, P605, DOI 10.1046/j.1365-2958.1998.00957.x; Schaller M, 2003, INFECT IMMUN, V71, P3227, DOI 10.1128/IAI.71.6.3227-3234.2003; Selmecki A, 2006, SCIENCE, V313, P367, DOI 10.1126/science.1128242; Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9; SOUTHGATE J, 1987, LAB INVEST, V56, P211; Steele C, 2000, J INFECT DIS, V182, P1479, DOI 10.1086/315872; Urban CF, 2006, CELL MICROBIOL, V8, P1687, DOI 10.1111/j.1462-5822.2006.00792.x; Wang BN, 2006, P NATL ACAD SCI USA, V103, P2380, DOI 10.1073/pnas.0506668103	54	37	37	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2067	10.1371/journal.pone.0002067	http://dx.doi.org/10.1371/journal.pone.0002067			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446191	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300036
J	Egelhofer, TA; Villen, J; McCusker, D; Gygi, SP; Kellogg, DR				Egelhofer, Thea A.; Villen, Judit; McCusker, Derek; Gygi, Steven P.; Kellogg, Douglas R.			The Septins Function in G1 Pathways that Influence the Pattern of Cell Growth in Budding Yeast	PLOS ONE			English	Article								The septins are a conserved family of proteins that have been proposed to carry out diverse functions. In budding yeast, the septins become localized to the site of bud emergence in G1 but have not been thought to carry out important functions at this stage of the cell cycle. We show here that the septins function in redundant mechanisms that are required for formation of the bud neck and for the normal pattern of cell growth early in the cell cycle. The Shs1 septin shows strong genetic interactions with G1 cyclins and is directly phosphorylated by G1 cyclin-dependent kinases, consistent with a role in early cell cycle events. However, Shs1 phosphorylation site mutants do not show genetic interactions with the G1 cyclins or obvious defects early in the cell cycle. Rather, they cause an increased cell size and aberrant cell morphology that are dependent upon inhibitory phosphorylation of Cdk1 at the G2/M transition. Shs1 phosphorylation mutants also show defects in interaction with the Gin4 kinase, which associates with the septins during G2/M and plays a role in regulating inhibitory phosphorylation of Cdk1. Phosphorylation of Shs1 by G1 cyclin-dependent kinases plays a role in events that influence Cdk1 inhibitory phosphorylation.	[Egelhofer, Thea A.; McCusker, Derek; Kellogg, Douglas R.] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; [Villen, Judit; Gygi, Steven P.] Harvard Med Sch, Taplin Biol Mass Spectrometry Facil, Dept Cell Biol, Boston, MA USA	University of California System; University of California Santa Cruz; Harvard University; Harvard Medical School	Kellogg, DR (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	kellogg@biology.ucsc.edu		Villen, Judit/0000-0002-1005-1739; McCusker, Derek/0000-0003-1455-1711	Spanish Ministry of Education and Science [postdoctoral fellowship]; NIH [GM53959]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053959] Funding Source: NIH RePORTER	Spanish Ministry of Education and Science(Spanish Government); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	J. Villen was supported by a postdoctoral fellowship from the Spanish Ministry of Education and Science. This work was supported by NIH Grant GM53959.	ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Barral Y, 2000, MOL CELL, V5, P841, DOI 10.1016/S1097-2765(00)80324-X; Beites CL, 2005, BIOCHEM J, V385, P347, DOI 10.1042/BJ20041090; Beites CL, 2001, METHOD ENZYMOL, V329, P499; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Caviston JP, 2003, MOL BIOL CELL, V14, P4051, DOI 10.1091/mbc.E03-04-0247; Cid VJ, 2001, MICROBIOL-SGM, V147, P1437, DOI 10.1099/00221287-147-6-1437; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dephoure N, 2005, P NATL ACAD SCI USA, V102, P17940, DOI 10.1073/pnas.0509080102; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Finger FP, 2005, BIOESSAYS, V27, P5, DOI 10.1002/bies.20167; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Gladfelter AS, 2005, J CELL SCI, V118, P1617, DOI 10.1242/jcs.02286; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Harvey SL, 2005, CELL, V122, P407, DOI 10.1016/j.cell.2005.05.029; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Jeffery DA, 2001, J MOL BIOL, V306, P997, DOI 10.1006/jmbi.2000.4417; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; McCusker D, 2007, NAT CELL BIOL, V9, P506, DOI 10.1038/ncb1568; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Mimura S, 2004, NATURE, V431, P1118, DOI 10.1038/nature03024; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; Moffat J, 2004, NAT CELL BIOL, V6, P59, DOI 10.1038/ncb1078; Morgan D. O., 2006, CELL CYCLE PRINCIPLE; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Mosch HU, 1997, GENETICS, V145, P671; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pruyne D, 2004, MOL BIOL CELL, V15, P4971, DOI 10.1091/mbc.E04-04-0296; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Sheu YJ, 2000, MOL CELL BIOL, V20, P5235, DOI 10.1128/MCB.20.14.5235-5247.2000; Sinha I, 2007, DEV CELL, V13, P421, DOI 10.1016/j.devcel.2007.06.011; Smolka MB, 2006, J CELL BIOL, V175, P743, DOI 10.1083/jcb.200605081; Spiliotis ET, 2008, J CELL BIOL, V180, P295, DOI 10.1083/jcb.200710039; Spiliotis ET, 2006, J CELL SCI, V119, P4, DOI 10.1242/jcs.02746; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Vallen EA, 2000, MOL BIOL CELL, V11, P593, DOI 10.1091/mbc.11.2.593; Vega IE, 2003, NEUROREPORT, V14, P31, DOI 10.1097/00001756-200301200-00006; Versele M, 2005, TRENDS CELL BIOL, V15, P414, DOI 10.1016/j.tcb.2005.06.007; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	71	39	39	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2022	10.1371/journal.pone.0002022	http://dx.doi.org/10.1371/journal.pone.0002022			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431499	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700034
J	Fu, XA; Wan, S; Lyu, YL; Liu, LF; Qi, HY				Fu, Xuan; Wan, Shan; Lyu, Yi Lisa; Liu, Leroy F.; Qi, Haiyan			Etoposide Induces ATM-Dependent Mitochondrial Biogenesis through AMPK Activation	PLOS ONE			English	Article							ATAXIA-TELANGIECTASIA CELLS; NUCLEAR RESPIRATORY FACTORS; N-ACETYL CYSTEINE; PROTEIN-KINASE; DNA-DAMAGE; DEFICIENT MICE; OXIDATIVE STRESS; SKELETAL-MUSCLE; LKB1-INDEPENDENT MANNER; TRANSCRIPTION FACTOR	Background: DNA damage such as double-stranded DNA breaks (DSBs) has been reported to stimulate mitochondrial biogenesis. However, the underlying mechanism is poorly understood. The major player in response to DSBs is ATM (ataxia telangiectasia mutated). Upon sensing DSBs, ATM is activated through autophosphorylation and phosphorylates a number of substrates for DNA repair, cell cycle regulation and apoptosis. ATM has been reported to phosphorylate the a subunit of AMP-activated protein kinase (AMPK), which senses AMP/ATP ratio in cells, and can be activated by upstream kinases. Here we provide evidence for a novel role of ATM in mitochondrial biogenesis through AMPK activation in response to etoposide-induced DNA damage. Methodology/Principal Findings: Three pairs of human ATM+ and ATM- cells were employed. Cells treated with etoposide exhibited an ATM- dependent increase in mitochondrial mass as measured by 10-N-Nonyl-Acridine Orange and MitoTracker Green FM staining, as well as an increase in mitochondrial DNA content. In addition, the expression of several known mitochondrial biogenesis regulators such as the major mitochondrial transcription factor NRF-1, PGC-1 alpha and TFAM was also elevated in response to etoposide treatment as monitored by RT-PCR. Three pieces of evidence suggest that etoposide-induced mitochondrial biogenesis is due to ATM- dependent activation of AMPK. First, etoposide induced ATM- dependent phosphorylation of AMPK a subunit at Thr172, indicative of AMPK activation. Second, inhibition of AMPK blocked etoposide-induced mitochondrial biogenesis. Third, activation of AMPK by AICAR (an AMP analogue) stimulated mitochondrial biogenesis in an ATM- dependent manner, suggesting that ATM may be an upstream kinase of AMPK in the mitochondrial biogenesis pathway. Conclusions/Significance: These results suggest that activation of ATM by etoposide can lead to mitochondrial biogenesis through AMPK activation. We propose that ATM-dependent mitochondrial biogenesis may play a role in DNA damage response and ROS regulation, and that defect in ATM-dependent mitochondrial biogenesis could contribute to the manifestations of A-T disease.	[Fu, Xuan; Wan, Shan; Lyu, Yi Lisa; Liu, Leroy F.; Qi, Haiyan] UMDNJ Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), UMDNJ Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ USA.	lliu@umdnj.edu; qiha@umdnj.edu		Liu, Leroy/0000-0001-9396-763X	NIH [CA102463, CA39662]; NATIONAL CANCER INSTITUTE [R01CA039662, R01CA102463] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants CA102463 and CA39662. Funders played no role in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; AMBROSE M, 2007, HUM MOL GENET; AMMANN AJ, 1971, J PEDIATR-US, V78, P821, DOI 10.1016/S0022-3476(71)80353-0; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BAR RS, 1978, NEW ENGL J MED, V298, P1164, DOI 10.1056/NEJM197805252982103; BARBE J, 1983, BIOCHEM BIOPH RES CO, V117, P556, DOI 10.1016/0006-291X(83)91236-6; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; BODER E, 1985, ATAXIA TELANGIECTASI, P1; Browne SE, 2004, FREE RADICAL BIO MED, V36, P938, DOI 10.1016/j.freeradbiomed.2004.01.003; Chang DTW, 2006, PROG NEUROBIOL, V80, P241, DOI 10.1016/j.pneurobio.2006.09.003; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Chen SJ, 2004, BIOCHEM BIOPH RES CO, V317, P1037, DOI 10.1016/j.bbrc.2004.03.149; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015; Eaton JS, 2007, J CLIN INVEST, V117, P2723, DOI 10.1172/JCI31604; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; GUERRERO R, 1984, J GEN MICROBIOL, V130, P2247; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2007, J IMMUNOL, V178, P103, DOI 10.4049/jimmunol.178.1.103; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Kanki T, 2004, MOL CELL BIOL, V24, P9823, DOI 10.1128/MCB.24.22.9823-9834.2004; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; Lee CF, 2005, ANN NY ACAD SCI, V1042, P246, DOI 10.1196/annals.1338.027; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Marecki JC, 2002, ARCH BIOCHEM BIOPHYS, V402, P227, DOI 10.1016/S0003-9861(02)00078-4; Mathur A, 2000, CARDIOVASC RES, V46, P126, DOI 10.1016/S0008-6363(00)00002-X; McFarlin D E, 1971, Res Publ Assoc Res Nerv Ment Dis, V49, P275; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; MEREDITH MJ, 1987, CANCER RES, V47, P4576; Miyoshi N, 2007, INT J CANCER, V120, P484, DOI 10.1002/ijc.22350; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MORRELL D, 1990, CANCER GENET CYTOGEN, V50, P119, DOI 10.1016/0165-4608(90)90245-6; MORRELL D, 1986, J NATL CANCER I, V77, P89; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; QI H, 2006, CANCER, V66; Quick KL, 2001, ANN NEUROL, V49, P627, DOI 10.1002/ana.1005; Reichenbach J, 1999, CLIN EXP IMMUNOL, V117, P535; Reichenbach J, 2002, ANTIOXID REDOX SIGN, V4, P465, DOI 10.1089/15230860260196254; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; Reliene R, 2004, CANCER RES, V64, P5148, DOI 10.1158/0008-5472.CAN-04-0442; Reliene R, 2006, DNA REPAIR, V5, P852, DOI 10.1016/j.dnarep.2006.05.003; Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512; Sadun AA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1342, DOI 10.1001/archopht.121.9.1342-b; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Schubert R, 2004, HUM MOL GENET, V13, P1793, DOI 10.1093/hmg/ddh189; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Sun Y, 2007, MOL CELL BIOCHEM, V306, P239, DOI 10.1007/s11010-007-9575-6; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; Tanaka T, 2007, CELL CYCLE, V6, P371, DOI 10.4161/cc.6.3.3835; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; Tavani F, 2003, NEURORADIOLOGY, V45, P315, DOI 10.1007/s00234-003-0945-9; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu J, 2007, J BIOENERG BIOMEMBR, V39, P195, DOI 10.1007/s10863-007-9077-y; Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004; Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2; Zhang AL, 2006, J BIOL CHEM, V281, P35997, DOI 10.1074/jbc.M604149200; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhang Y, 2007, AUTOPHAGY, V3, P337, DOI 10.4161/auto.4127; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	90	139	146	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2009	10.1371/journal.pone.0002009	http://dx.doi.org/10.1371/journal.pone.0002009			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431490	gold, Green Submitted, Green Published			2022-12-25	WOS:000261558700025
J	Mok, BW; Ribacke, U; Rasti, N; Kironde, F; Chen, QJ; Nilsson, P; Wahlgren, M				Mok, Bobo W.; Ribacke, Ulf; Rasti, Niloofar; Kironde, Fred; Chen, Qijun; Nilsson, Peter; Wahlgren, Mats			Default Pathway of var2csa Switching and Translational Repression in Plasmodium falciparum	PLOS ONE			English	Article								Antigenic variation is a subtle process of fundamental importance to the survival of a microbial pathogen. In Plasmodium falciparum malaria, PfEMP1 is the major variable antigen and adhesin expressed at the surface of the infected erythrocyte, which is encoded for by members of a family of 60 var-genes. Peri-nuclear repositioning and epigenetic mechanisms control their mono-allelic expression. The switching of PfEMP1 depends in part on variable transition rates and short-lived immune responses to shared minor epitopes. Here we show var-genes to switch to a common gene that is highly transcribed, but sparsely translated into PfEMP1 and not expressed at the erythrocyte surface. Highly clonal and adhesive P. falciparum, which expressed distinct var-genes and the corresponding PfEMP1s at onset, were propagated without enrichment or panning. The parasites successively and spontaneously switched to transcribe a shared var-gene (var2csa) matched by the loss of PfEMP1 surface expression and host cell-binding. The var2csa gene repositioned in the peri-nuclear area upon activation, away from the telomeric clusters and heterochromatin to transcribe spliced, full-length RNA. Despite abundant transcripts, the level of intracellular PfEMP1 was low suggesting post-transcriptional mechanisms to partake in protein expression. In vivo, off-switching and translational repression may constitute one pathway, among others, coordinating PfEMP1 expression.	[Mok, Bobo W.; Ribacke, Ulf; Rasti, Niloofar; Chen, Qijun; Wahlgren, Mats] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden; [Mok, Bobo W.; Ribacke, Ulf; Rasti, Niloofar; Chen, Qijun; Wahlgren, Mats] Swedish Inst Infect Dis Control SMI, Stockholm, Sweden; [Kironde, Fred] Makerere Univ, Fac Med, Dept Biochem, Kampala, Uganda; [Nilsson, Peter] Royal Inst Technol, Sch Biotechnol, Dept Gene Technol, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Makerere University; Royal Institute of Technology	Mok, BW (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden.	mats.wahlgren@ki.se	Nilsson, Peter/E-4547-2010	Nilsson, Peter/0000-0002-4657-8532; Mok, Bobo/0000-0003-3187-2736; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Kironde, Fred/0000-0003-4981-6417	Swedish Institute for Infectious Disease Control; European Union (BioMalPar); Swedish Research Council; Swedish International Development Cooperation Agency (Sida/ SAREC)	Swedish Institute for Infectious Disease Control; European Union (BioMalPar)(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish International Development Cooperation Agency (Sida/ SAREC)	The work was funded by grants from the Swedish Institute for Infectious Disease Control (SMI), the European Union (BioMalPar), the Swedish Research Council and the Swedish International Development Cooperation Agency (Sida/ SAREC).	Avril M, 2006, MICROBES INFECT, V8, P2863, DOI 10.1016/j.micinf.2006.09.005; BARNWELL JW, 1983, CIBA F SYMP, V94, P117; BIGGS BA, 1989, P NATL ACAD SCI USA, V86, P2428, DOI 10.1073/pnas.86.7.2428; Calderwood MS, 2003, J BIOL CHEM, V278, P34125, DOI 10.1074/jbc.M213065200; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Chookajorn T, 2007, P NATL ACAD SCI USA, V104, P899, DOI 10.1073/pnas.0609084103; Coulson RMR, 2004, GENOME RES, V14, P1548, DOI 10.1101/gr.2218604; DAVID PH, 1983, P NATL ACAD SCI-BIOL, V80, P5075, DOI 10.1073/pnas.80.16.5075; Duffy MF, 2002, MOL MICROBIOL, V43, P1285, DOI 10.1046/j.1365-2958.2002.02822.x; Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x; Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Dzikowski R, 2006, PLOS PATHOG, V2, P184, DOI 10.1371/journal.ppat.0020022; Frank M, 2006, J BIOL CHEM, V281, P9942, DOI 10.1074/jbc.M513067200; Frank M, 2007, MOL MICROBIOL, V64, P1486, DOI 10.1111/j.1365-2958.2007.05736.x; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Gamain B, 2005, J INFECT DIS, V191, P1010, DOI 10.1086/428137; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gatton ML, 2003, TRENDS PARASITOL, V19, P202, DOI 10.1016/S1471-4922(03)00067-9; Haase RN, 2006, INFECT IMMUN, V74, P3035, DOI 10.1128/IAI.74.5.3035-3038.2006; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101; Kaestli M, 2006, J INFECT DIS, V193, P1567, DOI 10.1086/503776; Kaestli M, 2004, J INFECT DIS, V189, P1942, DOI 10.1086/383250; Kyes SA, 2003, MOL MICROBIOL, V48, P1339, DOI 10.1046/j.1365-2958.2003.03505.x; Kyes S, 2007, MOL MICROBIOL, V63, P1237, DOI 10.1111/j.1365-2958.2007.05587.x; Lavstsen T, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-21; Maier AG, 2007, BLOOD, V109, P1289, DOI 10.1182/blood-2006-08-043364; Mair GR, 2006, SCIENCE, V313, P667, DOI 10.1126/science.1125129; Mok BW, 2007, MOL BIOCHEM PARASIT, V151, P184, DOI 10.1016/j.molbiopara.2006.11.006; Nielsen MA, 2005, J INFECT DIS, V192, P520, DOI 10.1086/431678; Noviyanti R, 2001, MOL BIOCHEM PARASIT, V114, P227, DOI 10.1016/S0166-6851(01)00266-3; Qazi KR, 2005, VACCINE, V23, P1114, DOI 10.1016/j.vaccine.2004.08.033; Ralph SA, 2005, P NATL ACAD SCI USA, V102, P5414, DOI 10.1073/pnas.0408883102; Rasti N, 2006, P NATL ACAD SCI USA, V103, P13795, DOI 10.1073/pnas.0601519103; Ribacke U, 2007, MOL BIOCHEM PARASIT, V155, P33, DOI 10.1016/j.molbiopara.2007.05.005; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; Rottmann M, 2006, INFECT IMMUN, V74, P3904, DOI 10.1128/IAI.02073-05; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Trimnell AR, 2006, MOL BIOCHEM PARASIT, V148, P169, DOI 10.1016/j.molbiopara.2006.03.012; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; Voss TS, 2006, NATURE, V439, P1004, DOI 10.1038/nature04407; Voss TS, 2003, MOL MICROBIOL, V48, P1593, DOI 10.1046/j.1365-2958.2003.03528.x; Winter G, 2003, MOL BIOCHEM PARASIT, V127, P179, DOI 10.1016/S0166-6851(03)00004-5; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	47	44	45	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1982	10.1371/journal.pone.0001982	http://dx.doi.org/10.1371/journal.pone.0001982			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431472	Green Submitted, gold, Green Published			2022-12-25	WOS:000261558700007
J	Slaughter, BD; Huff, JM; Wiegraebe, W; Schwartz, JW; Li, R				Slaughter, Brian D.; Huff, Joseph M.; Wiegraebe, Winfried; Schwartz, Joel W.; Li, Rong			SAM Domain-Based Protein Oligomerization Observed by Live-Cell Fluorescence Fluctuation Spectroscopy	PLOS ONE			English	Article								Sterile-alpha-motif (SAM) domains are common protein interaction motifs observed in organisms as diverse as yeast and human. They play a role in protein homo- and hetero-interactions in processes ranging from signal transduction to RNA binding. In addition, mutations in SAM domain and SAM-mediated oligomers have been linked to several diseases. To date, the observation of heterogeneous SAM-mediated oligomers in vivo has been elusive, which represents a common challenge in dissecting cellular biochemistry in live-cell systems. In this study, we report the oligomerization and binding stoichiometry of high-order, multi-component complexes of (SAM) domain proteins Ste11 and Ste50 in live yeast cells using fluorescence fluctuation methods. Fluorescence cross-correlation spectroscopy (FCCS) and 1-dimensional photon counting histogram (1dPCH) confirm the SAM-mediated interaction and oligomerization of Ste11 and Ste50. Two-dimensional PCH (2dPCH), with endogenously expressed proteins tagged with GFP or mCherry, uniquely indicates that Ste11 and Ste50 form a heterogeneous complex in the yeast cytosol comprised of a dimer of Ste11 and a monomer of Ste50. In addition, Ste50 also exists as a high order oligomer that does not interact with Ste11, and the size of this oligomer decreases in response to signals that activate the MAP kinase cascade. Surprisingly, a SAM domain mutant of Ste50 disrupted not only the Ste50 oligomers but also Ste11 dimerization. These results establish an in vivo model of Ste50 and Ste11 homo- and heterooligomerization and highlight the usefulness of 2dPCH for quantitative dissection of complex molecular interactions in genetic model organisms such as yeast.	[Slaughter, Brian D.; Huff, Joseph M.; Wiegraebe, Winfried; Schwartz, Joel W.; Li, Rong] Stowers Inst Med Res, Kansas City, MO USA	Stowers Institute for Medical Research	Slaughter, BD (corresponding author), Stowers Inst Med Res, Kansas City, MO USA.	rli@stowers-institute.org			NIH [GM057063, F32 GM077923-01A1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM077923, R01GM057063] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported by NIH grant GM057063 to RL and NIH fellowship F32 GM077923-01A1 to BS.	Bacia K, 2006, NAT METHODS, V3, P83, DOI 10.1038/NMETH822; Bacia K, 2003, METHODS, V29, P74, DOI 10.1016/S1046-2023(02)00291-8; Bhattacharjya S, 2005, PROTEIN SCI, V14, P828, DOI 10.1110/ps.041122105; Bhattacharjya S, 2004, J MOL BIOL, V344, P1071, DOI 10.1016/j.jmb.2004.09.018; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Chen Y, 2005, BIOPHYS J, V88, P2177, DOI 10.1529/biophysj.104.048413; Chen Y, 2003, P NATL ACAD SCI USA, V100, P15492, DOI 10.1073/pnas.2533045100; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Cicero DO, 2006, CELL BIOCHEM BIOPHYS, V44, P475, DOI 10.1385/CBB:44:3:475; DIGMAN MA, 2007, BIOPHYS J; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; Grimshaw SJ, 2004, J BIOL CHEM, V279, P2192, DOI 10.1074/jbc.M305605200; Haustein E, 2003, METHODS, V29, P153, DOI 10.1016/S1046-2023(02)00306-7; Hillesheim LN, 2006, BIOPHYS J, V91, P4273, DOI 10.1529/biophysj.106.085845; HINK MA, 2007, BIOPHYS J; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kantaputra PN, 2003, J DENT RES, V82, P433, DOI 10.1177/154405910308200606; Kask P, 1999, P NATL ACAD SCI USA, V96, P13756, DOI 10.1073/pnas.96.24.13756; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kwan JJ, 2006, J MOL BIOL, V356, P142, DOI 10.1016/j.jmb.2005.11.012; Kwan JJ, 2004, J MOL BIOL, V342, P681, DOI 10.1016/j.jmb.2004.06.064; Lamson RE, 2002, MOL CELL BIOL, V22, P2939, DOI 10.1128/MCB.22.9.2939-2951.2002; Maeder CI, 2007, NAT CELL BIOL, V9, P1319, DOI 10.1038/ncb1652; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Ramezani-Rad M, 2003, CURR GENET, V43, P161, DOI 10.1007/s00294-003-0383-6; Rigler R, 1998, J BIOTECHNOL, V63, P97, DOI 10.1016/S0168-1656(98)00079-0; Saffarian S, 2007, BIOPHYS J, V93, P1021, DOI 10.1529/biophysj.107.105494; Sahin MT, 2004, CLIN EXP DERMATOL, V29, P486, DOI 10.1111/j.1365-2230.2004.01584.x; Schwille P, 1997, BIOPHYS J, V72, P1878, DOI 10.1016/S0006-3495(97)78833-7; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Sheff MA, 2004, YEAST, V21, P661, DOI 10.1002/yea.1130; Slaughter BD, 2007, P NATL ACAD SCI USA, V104, P20320, DOI 10.1073/pnas.0710336105; Tatebayashi K, 2006, EMBO J, V25, P3033, DOI 10.1038/sj.emboj.7601192; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thompson NL, 2002, CURR OPIN STRUC BIOL, V12, P634, DOI 10.1016/S0959-440X(02)00368-8; Tognon CE, 2004, MOL CELL BIOL, V24, P4636, DOI 10.1128/MCB.24.11.4636-4650.2004; Truckses DM, 2006, MOL CELL BIOL, V26, P912, DOI 10.1128/MCB.26.3.912-928.2006; Wu CL, 2006, GENE DEV, V20, P734, DOI 10.1101/gad.1375706	45	27	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1931	10.1371/journal.pone.0001931	http://dx.doi.org/10.1371/journal.pone.0001931			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431466	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700001
J	Livesey, MR; Cooper, MA; Deeb, TZ; Carland, JE; Kozuska, J; Hales, TG; Lambert, JJ; Peters, JA				Livesey, Matthew R.; Cooper, Michelle A.; Deeb, Tarek Z.; Carland, Jane E.; Kozuska, Janna; Hales, Tim. G.; Lambert, Jeremy J.; Peters, John A.			Structural determinants of Ca2+ permeability and conduction in the human 5-hydroxytryptamine type 3A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL CONDUCTANCE; GATED ION-CHANNEL; RECOMBINANT 5-HT3 RECEPTOR; CYS-LOOP FAMILY; NICOTINIC ACETYLCHOLINE; HEK-293 CELLS; SUBUNIT; SELECTIVITY; EXPRESSION; PERMEATION	Cation-selective cysteine (Cys)-loop transmitter-gated ion channels provide an important pathway for Ca2+ entry into neurones. We examined the influence on Ca2+ permeation of amino acids located at intra-and extracellular ends of the conduction pathway of the human 5-hydroxytryptamine type 3A (5-HT3A) receptor. Mutation of cytoplasmic arginine residues 432, 436, and 440 to glutamine, aspartate, and alanine (the aligned residues of the human 5-HT3B subunit (yielding 5-HT3A(QDA)) increased P-Ca/P-Cs from 1.4 to 3.7. The effect was attributable to the removal of an electrostatic influence of the Arg-436 residue. Despite its relatively high permeability to Ca2+, the single channel conductance of the 5-HT3A(QDA) receptor was depressed in a concentration-dependent and voltage-independent manner by extracellular Ca2+. A conserved aspartate, located toward the extracellular end of the conduction pathway and known to influence ionic selectivity, contributed to the inhibitory effect of Ca2+ on macroscopic currents mediated by5-HT3A receptors. We introduced a D293A mutation into the 5HT(3A)(QDA) receptor(yielding the 5-HT3A(QDA D293A) construct) to determine whether the aspartate is required for the suppression of single channel conductance by Ca2+. The D293A mutation decreased the P-Ca/P-Cs ratio to 0.25 and reduced inwardly directed single channel conductance from 41 to 30 pS but did not prevent suppression of single channel conductance by Ca2+. The D293A mutation also reduced P-Ca/P-Cs when engineered into the wild-type 5-HT3A receptor. The data helped to identify key residues in the cytoplasmic domain (Arg-436) and extracellular vestibule (Asp-293) that markedly influence P-Ca/P-Cs and additionally directly demonstrated a depression of single channel conductance by Ca2+.	[Livesey, Matthew R.; Cooper, Michelle A.; Carland, Jane E.; Kozuska, Janna; Lambert, Jeremy J.; Peters, John A.] Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; [Deeb, Tarek Z.; Hales, Tim. G.] George Washington Univ, Dept Physiol & Pharmacol, Washington, DC 20037 USA; [Hales, Tim. G.] George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA	University of Dundee; George Washington University; George Washington University	Peters, JA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	j.a.peters@dundee.ac.uk		Livesey, Matthew/0000-0002-3441-7977; Carland, Jane/0000-0002-1456-876X	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; Barrera NP, 2005, P NATL ACAD SCI USA, V102, P12595, DOI 10.1073/pnas.0503253102; BELLELI D, 1995, MOL PHARM, V48, P1054; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; Bruss M, 2000, N-S ARCH PHARMACOL, V362, P392, DOI 10.1007/s002100000342; BUTLER JN, 1968, BIOPHYS J, V8, P1426, DOI 10.1016/S0006-3495(68)86564-6; Chameau P, 2006, CELL TISSUE RES, V326, P573, DOI 10.1007/s00441-006-0255-8; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Deeb TZ, 2007, J BIOL CHEM, V282, P6172, DOI 10.1074/jbc.M607698200; DEKKER ER, 1990, J NEUROSCI, V10, P3413; Dubin AE, 1999, J BIOL CHEM, V274, P30799, DOI 10.1074/jbc.274.43.30799; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; Ferezou I, 2002, J NEUROSCI, V22, P7389; Fink KB, 2007, PHARMACOL REV, V59, P360, DOI 10.1124/pr.107.07103; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Hales TG, 2006, J BIOL CHEM, V281, P8062, DOI 10.1074/jbc.M513222200; Hilf RJC, 2008, NATURE, V452, P375, DOI 10.1038/nature06717; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hu XQ, 2008, J BIOL CHEM, V283, P6826, DOI 10.1074/jbc.M707571200; Hu XQ, 2005, J PHYSIOL-LONDON, V568, P381, DOI 10.1113/jphysiol.2005.092866; Hubbard PC, 2000, EUR J PHARMACOL, V394, P189, DOI 10.1016/S0014-2999(00)00143-6; Ivanov I, 2007, J AM CHEM SOC, V129, P8217, DOI 10.1021/ja070778l; Jansen M, 2008, J GEN PHYSIOL, V131, P137, DOI 10.1085/jgp.200709896; Jensen ML, 2005, J NEUROCHEM, V92, P217, DOI 10.1111/j.1471-4159.2004.02883.x; Karnovsky AM, 2003, GENE, V319, P137, DOI 10.1016/S0378-1119(03)00803-5; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Krzywkowski K, 2008, P NATL ACAD SCI USA, V105, P722, DOI 10.1073/pnas.0708454105; Krzywkowski K, 2007, PHARMACOGENET GENOM, V17, P255, DOI 10.1097/FPC.0b013e3280117269; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Mochizuki S, 1999, AMINO ACIDS, V17, P243, DOI 10.1007/BF01366923; Niemeyer MI, 2001, EUR J PHARMACOL, V428, P153, DOI 10.1016/S0014-2999(01)01251-1; Niesler B, 2003, GENE, V310, P101, DOI 10.1016/S0378-1119(03)00503-1; Niesler B, 2007, MOL PHARMACOL, V72, P8, DOI 10.1124/mol.106.032144; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Peters JA, 2005, TRENDS PHARMACOL SCI, V26, P587, DOI 10.1016/j.tips.2005.09.011; Reeves DC, 2005, J NEUROSCI, V25, P9358, DOI 10.1523/JNEUROSCI.1045-05.2005; Roerig B, 1997, J NEUROSCI, V17, P8353; Sine SM, 2006, NATURE, V440, P448, DOI 10.1038/nature04708; Solt K, 2005, J PHARMACOL EXP THER, V315, P771, DOI 10.1124/jpet.105.090621; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; Tapia L, 2007, MOL PHARMACOL, V71, P769, DOI 10.1124/mol.106.030445; Thompson AJ, 2006, CURR PHARM DESIGN, V12, P3615, DOI 10.2174/138161206778522029; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang HL, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040041; WANG JJ, 1994, J CHEM SOC FARADAY T, V90, P3281, DOI 10.1039/ft9949003281; Zhou FM, 1999, J NEUROPHYSIOL, V82, P2989, DOI 10.1152/jn.1999.82.6.2989	51	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19301	19313		10.1074/jbc.M802406200	http://dx.doi.org/10.1074/jbc.M802406200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474595	Green Published, hybrid			2022-12-25	WOS:000257387600016
J	Horman, S; Morel, N; Vertommen, D; Hussain, N; Neumann, D; Beauloye, C; El Najjar, N; Forcet, C; Viollet, B; Walsh, MP; Hue, L; Rider, MH				Horman, Sandrine; Morel, Nicole; Vertommen, Didier; Hussain, Nusrat; Neumann, Dietbert; Beauloye, Christophe; El Najjar, Nicole; Forcet, Christelle; Viollet, Benoit; Walsh, Michael P.; Hue, Louis; Rider, Mark H.			AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CELL; CALMODULIN; CONTRACTION; ISCHEMIA; HEART; IDENTIFICATION; COMPONENTS; CALCIUM; SITES	Smooth muscle contraction is initiated by a rise in intracellular calcium, leading to activation of smooth muscle myosin light chain kinase (MLCK) via calcium/calmodulin (CaM). Activated MLCK then phosphorylates the regulatory myosin light chains, triggering cross-bridge cycling and contraction. Here, we show that MLCK is a substrate of AMP-activated protein kinase (AMPK). The phosphorylation site in chicken MLCK was identified by mass spectrometry to be located in the CaM-binding domain at Ser(815). Phosphorylation by AMPK desensitized MLCK by increasing the concentration of CaM required for half-maximal activation. In primary cultures of rat aortic smooth muscle cells, vasoconstrictors activated AMPK in a calcium-dependent manner via CaM-dependent protein kinase kinase-beta, a known upstream kinase of AMPK. Indeed, vasoconstrictor-induced AMPK activation was abrogated by the STO-609 CaM-dependent protein kinase kinase-beta inhibitor. Myosin light chain phosphorylation was increased under these conditions, suggesting that contraction would be potentiated by ablation of AMPK. Indeed, in aortic rings from mice in which alpha 1, the major catalytic subunit isoform in arterial smooth muscle, had been deleted, KCl- or phenylephrine-induced contraction was increased. The findings suggest that AMPK attenuates contraction by phosphorylating and inactivating MLCK. This might contribute to reduced ATP turnover in the tonic phase of smooth muscle contraction.	[Horman, Sandrine; Vertommen, Didier; Hussain, Nusrat; El Najjar, Nicole; Hue, Louis; Rider, Mark H.] Catholic Univ Louvain, Hormone & Metab Res Unit, de Duve Inst, B-1200 Brussels, Belgium; [Morel, Nicole] Catholic Univ Louvain, Lab Cellular Phys, B-1200 Brussels, Belgium; [Horman, Sandrine; Beauloye, Christophe] Catholic Univ Louvain, Div Cardiol, B-1200 Brussels, Belgium; [Neumann, Dietbert] Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; [Forcet, Christelle] Fac Med Rockefeller, Lab Genet Mol Signalisat & Canc, F-69373 Lyon 08, France; [Viollet, Benoit] Univ Paris 05, CNRS UMR 8104, INSERM U567, Dept Endocrinol Metab & Canc,Inst Cochin, F-75014 Paris, France; [Walsh, Michael P.] Univ Calgary, Fac Med, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; [Walsh, Michael P.] Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Swiss Federal Institutes of Technology Domain; ETH Zurich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Calgary; University of Calgary	Rider, MH (corresponding author), Catholic Univ Louvain, Hormone & Metab Res Unit, de Duve Inst, Ave Hippocrate 75, B-1200 Brussels, Belgium.	mark.rider@uclouvain.be	Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Neumann, Dietbert/0000-0002-4316-684X; Vertommen, Didier/0000-0001-7648-8282	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CONTI MA, 1981, J BIOL CHEM, V256, P3178; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; GODFRAIND T, 1969, BRIT J PHARMACOL, V36, P549, DOI 10.1111/j.1476-5381.1969.tb08010.x; Goirand F, 2007, J PHYSIOL-LONDON, V581, P1163, DOI 10.1113/jphysiol.2007.132589; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Ishikawa Y, 2003, FEBS LETT, V550, P57, DOI 10.1016/S0014-5793(03)00817-2; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim I, 2000, J PHYSIOL-LONDON, V526, P367, DOI 10.1111/j.1469-7793.2000.00367.x; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Mayer A, 2008, EUR J IMMUNOL, V38, P948, DOI 10.1002/eji.200738045; MOREL N, 1994, J CARDIOVASC PHARM, V24, P524, DOI 10.1097/00005344-199410000-00002; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; Nemenoff Raphael A., 1998, Frontiers in Bioscience, V3, pD194; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAYNE ME, 1986, J BIOL CHEM, V261, P6346; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Rubin LJ, 2005, J APPL PHYSIOL, V98, P296, DOI 10.1152/japplphysiol.00075.2004; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Woodrum DA, 2001, MOL CELL ENDOCRINOL, V177, P135, DOI 10.1016/S0303-7207(01)00407-5	41	94	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18505	18512		10.1074/jbc.M802053200	http://dx.doi.org/10.1074/jbc.M802053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18426792	hybrid			2022-12-25	WOS:000257165600005
J	Yamashita, T; Ohneda, K; Nagano, M; Miyoshi, C; Kaneko, N; Miwa, Y; Yamamoto, M; Ohneda, O; Fujii-Kuriyama, Y				Yamashita, Toshiharu; Ohneda, Kinuko; Nagano, Masumi; Miyoshi, Chika; Kaneko, Naomi; Miwa, Yoshihiro; Yamamoto, Masayuki; Ohneda, Osamu; Fujii-Kuriyama, Yoshiaki			Hypoxia-inducible transcription factor-2 alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR; HIF-2-ALPHA; HIF-1-ALPHA; EXPRESSION; ANGIOGENESIS; HOMEOSTASIS; GENE; ERYTHROPOIETIN	The hypoxia-inducible transcription factors (HIF)-1 alpha and -2 alpha mediate responses to hypoxia, such as tumor neovascularization. To determine the function of HIF-2 alpha in vascular endothelial cells (ECs), we examined vascular formation in HIF-2 alpha knockdown (kd/kd) mice transplanted with tumors. We observed that both the tumor size and the number of large vessels growing within transplanted melanomas were significantly reduced in kd/kd recipients compared with wild-type (WT) mice. In contrast, we observed a similar extent of vascular formation within fibrosarcomas transplanted from either kd/kd or WT mice into WT recipients. Thus, HIF-2 alpha expression in host animal ECs, but not in the tumor cells, is crucial for tumor neovascularization. HIF-2 alpha may function through ephrin A1 as the expression of ephrin A1 and related genes was markedly reduced in kd/kd ECs, and HIF-2 alpha specifically bound a hypoxia-response element sequence in the ephrin A1 promoter. Treatment of WTECs with an ephrin A1 inhibitor ( ephrin A1-Fc) also impaired neovascularization. We conclude that in ECs, HIF-2 alpha plays an essential role in vascular remodeling during tumor vascularization through activation of at least ephrin A1.	[Yamashita, Toshiharu; Nagano, Masumi; Ohneda, Osamu] Univ Tsukuba, Dept Regenerat Med, Tsukuba, Ibaraki 3058575, Japan; [Yamashita, Toshiharu; Nagano, Masumi; Miyoshi, Chika; Kaneko, Naomi; Yamamoto, Masayuki; Ohneda, Osamu] Univ Tsukuba, Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058575, Japan; [Miyoshi, Chika; Kaneko, Naomi; Yamamoto, Masayuki; Fujii-Kuriyama, Yoshiaki] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; [Miyoshi, Chika; Kaneko, Naomi; Yamamoto, Masayuki] Univ Tsukuba, Japan Sci & Technol Exploratory Res Adv Technol E, Tsukuba, Ibaraki 3058575, Japan; [Miwa, Yoshihiro] Univ Tsukuba, Dept Mol Pharmacol, Tsukuba, Ibaraki 3058575, Japan; [Fujii-Kuriyama, Yoshiaki] Univ Tsukuba, Japan Sci & Technol Solut Oriented Res Sci & Tech, Tsukuba, Ibaraki 3058575, Japan; [Ohneda, Kinuko] Takasaki Univ Hlth & Welf, Fac Pharm, Mol Pathophysiol Lab, Takasaki, Gunma 3700033, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Ohneda, O (corresponding author), Univ Tsukuba, Dept Regenerat Med, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	oohneda@md.tsukuba.ac.jp; ykfujii@tara.tsukuba.ac.jp	Ohneda, Kinuko/AAC-8822-2019; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Miyoshi, Chika/0000-0002-7109-1777				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Cheng N, 2002, MOL CANCER RES, V1, P2; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Daniel TO, 1996, KIDNEY INT, V50, pS73; FADELE AO, 2004, MOL INT, V2, P229; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Ohneda O, 1998, BLOOD, V92, P908; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Sowter HM, 2003, CANCER RES, V63, P6130; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	41	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18926	18936		10.1074/jbc.M709133200	http://dx.doi.org/10.1074/jbc.M709133200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18434321	hybrid			2022-12-25	WOS:000257165600049
J	Mueller, S; Kleinau, G; Jaeschke, H; Paschke, R; Krause, G				Mueller, Sandra; Kleinau, Gunnar; Jaeschke, Holger; Paschke, Ralf; Krause, Gerd			Extended hormone binding site of the human thyroid stimulating hormone receptor - Distinctive acidic residues in the hinge region are involved in bovine thyroid stimulating hormone binding and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTOR; LEUCINE-RICH REPEATS; VIRUS TYPE-1 ENTRY; HUMAN TSH RECEPTOR; CRYSTAL-STRUCTURE; GONADOTROPIN RECEPTORS; SUPERACTIVE ANALOGS; EXTRACELLULAR DOMAIN; DIRECTED MUTAGENESIS	The human thyroid stimulating hormone receptor (hTSHR) belongs to the glycoprotein hormone receptors that bind the hormones at their large extracellular domain. The extracellular hinge region of the TSHR connects the N-terminal leucine-rich repeat domain with the membrane-spanning serpentine domain. From previous studies we reasoned that apart from hormone binding at the leucine-rich repeat domain, additional multiple hormone contacts might exist at the hinge region of the TSHR by complementary charge-charge recognition. Here we investigated highly conserved charged residues in the hinge region of the TSHR by site-directed mutagenesis to identify amino acids interacting with bovine TSH (bTSH). Indeed, the residues Glu-297, Glu-303, and Asp-382 in the TSHR hinge region are essential for bTSH binding and partially for signal transduction. Side chain substitutions showed that the negative charge of Glu-297 and Asp-382 is necessary for recognition of bTSH by the hTSHR. Multiple combinations of alanine mutants of the identified positions revealed an increased negative effect on hormone binding. An assembled model suggests that the deciphered acidic residues form negatively charged patches at the hinge region resulting in an extended binding mode for bTSH on the hTSHR. Our data indicate that certain positively charged residues of bTSH might be involved in interaction with the identified negatively charged amino acids of the hTSHR hinge region. We demonstrate that the hinge region represents an extracellular intermediate connector for both hormone binding and signal transduction of the hTSHR.	[Kleinau, Gunnar; Krause, Gerd] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Mueller, Sandra; Paschke, Ralf] Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Leipzig University	Krause, G (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Kleinau, Gunnar/GPX-6330-2022; Horstmann, Britta/C-2154-2008					Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Bonomi M, 2006, MOL ENDOCRINOL, V20, P3351, DOI 10.1210/me.2005-0521; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Case D. A., 2002, AMBER 7; Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; DALLAS JS, 1994, ENDOCRINOLOGY, V134, P1437, DOI 10.1210/en.134.3.1437; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Gromoll J, 2002, EUR J ENDOCRINOL, V147, P597, DOI 10.1530/eje.0.1470597; Grossmann M, 1998, NAT BIOTECHNOL, V16, P871, DOI 10.1038/nbt0998-871; Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373; Jeffreys J, 2002, THYROID, V12, P1051, DOI 10.1089/105072502321085144; Johnstone AP, 2003, CLIN ENDOCRINOL, V59, P437, DOI 10.1046/j.1365-2265.2003.01864.x; Kleinau G, 2004, J BIOL CHEM, V279, P51590, DOI 10.1074/jbc.M404748200; Kleinau G, 2007, MOL ENDOCRINOL, V21, P574, DOI 10.1210/me.2006-0309; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; KOSUGI S, 1991, J BIOL CHEM, V266, P19413; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leitolf H, 2000, J BIOL CHEM, V275, P27457; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; Muller T, 2003, J CLIN ENDOCR METAB, V88, P2242, DOI 10.1210/jc.2002-021946; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Sanders J, 2007, THYROID, V17, P395, DOI 10.1089/thy.2007.0034; Shepherd PS, 1999, MOL CELL ENDOCRINOL, V149, P197, DOI 10.1016/S0303-7207(98)00207-X; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Standfuss J, 2007, J MOL BIOL, V372, P1179, DOI 10.1016/j.jmb.2007.03.007; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Szkudlinski MW, 2004, CANC TREAT, V122, P345; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18048	18055		10.1074/jbc.M800449200	http://dx.doi.org/10.1074/jbc.M800449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441013	hybrid			2022-12-25	WOS:000256949200034
J	Kniazeff, J; Shi, L; Loland, CJ; Javitch, JA; Weinstein, H; Gether, U				Kniazeff, Julie; Shi, Lei; Loland, Claus J.; Javitch, Jonathan A.; Weinstein, Harel; Gether, Ulrik			An intracellular interaction network regulates conformational transitions in the dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL-MODE ANALYSIS; CATION-PI INTERACTIONS; NEUROTRANSMITTER TRANSPORTERS; MOLECULAR-DYNAMICS; SEROTONIN TRANSPORTER; BACTERIAL HOMOLOG; ESCHERICHIA-COLI; BINDING-SITE; MUTATION; MECHANISM	Neurotransmitter: sodium symporters (NSS)(1) mediate sodium-dependent reuptake of neurotransmitters from the synaptic cleft and are targets for many psychoactive drugs. The crystal structure of the prokaryotic NSS protein, LeuT, was recently solved at high resolution; however, the mechanistic details of regulation of the permeation pathway in this class of proteins remain unknown. Here we combine computational modeling and experimental probing in the dopamine transporter (DAT) to demonstrate the functional importance of a conserved intracellular interaction network. Our data suggest that a salt bridge between Arg-60 in the N terminus close to the cytoplasmic end of transmembrane segment (TM) 1 and Asp-436 at the cytoplasmic end of TM8 is stabilized by a cation-pi interaction between Arg-60 and Tyr-335 at the cytoplasmic end of TM6. Computational probing illustrates how the interactions may determine the flexibility of the permeation pathway, and mutagenesis within the network and results from assays of transport, as well as the state-dependent accessibility of a substituted cysteine in TM3, support the role of this network in regulating access between the substrate binding site and the intracellular milieu. The mechanism that emerges from these findings may be unique to the NSS family, where the local disruption of ionic interactions modulates the transition of the transporter between the outward-and inward-facing conformations.	[Kniazeff, Julie; Loland, Claus J.; Gether, Ulrik] Univ Copenhagen, Panum Inst, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; [Kniazeff, Julie; Loland, Claus J.; Gether, Ulrik] Univ Copenhagen, Panum Inst, Dept Neurosci & Pharmacol, Ctr Pharmacogenom, DK-2200 Copenhagen, Denmark; [Shi, Lei; Weinstein, Harel] Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; [Shi, Lei; Weinstein, Harel] Cornell Univ, Weill Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY 10021 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	University of Copenhagen; University of Copenhagen; Cornell University; Cornell University; Columbia University; Columbia University; Columbia University	Weinstein, H (corresponding author), Rm E-509,1300 York Ave, New York, NY 10065 USA.	haw2002@med.cornell.edu	Loland, Claus/E-5975-2014; Shi, Lei/AAV-1321-2020; WEINSTEIN, HAREL/O-8245-2019	Loland, Claus/0000-0002-1773-1446; Shi, Lei/0000-0002-4137-096X; WEINSTEIN, HAREL/0000-0003-3473-9818; Javitch, Jonathan/0000-0001-7395-2967; Kniazeff, Julie/0000-0002-0426-0999; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, K05DA022413, R01DA017293] Funding Source: NIH RePORTER; NIDA NIH HHS [K05 DA022413, R01 DA017293, P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; Binet V, 2007, J BIOL CHEM, V282, P12154, DOI 10.1074/jbc.M611071200; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; CUI C, 2006, NORMAL MODE ANAL THE; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gether U, 2006, TRENDS PHARMACOL SCI, V27, P375, DOI 10.1016/j.tips.2006.05.003; Goldberg NR, 2003, EUR J PHARMACOL, V479, P3, DOI 10.1016/j.ejphar.2003.08.052; HAYWARD S, 1995, PROTEINS, V23, P177, DOI 10.1002/prot.340230207; Henry LK, 2006, NEURON, V49, P791, DOI 10.1016/j.neuron.2006.03.002; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Ma JP, 2005, STRUCTURE, V13, P373, DOI 10.1016/j.str.2005.02.002; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Quick M, 2006, J BIOL CHEM, V281, P26444, DOI 10.1074/jbc.M602438200; Rudnick G, 2006, HANDB EXP PHARM, V175, P59; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Singh SK, 2007, NATURE, V448, P952, DOI 10.1038/nature06038; Slutsky MM, 2004, PROTEIN SCI, V13, P2244, DOI 10.1110/ps.04702104; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Sotomayor M, 2004, BIOPHYS J, V87, P3050, DOI 10.1529/biophysj.104.046045; Suhre K, 2004, NUCLEIC ACIDS RES, V32, pW610, DOI 10.1093/nar/gkh368; Tama F, 2003, PROTEIN PEPTIDE LETT, V10, P119, DOI 10.2174/0929866033479077; Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905; Torres GE, 2007, CURR OPIN NEUROBIOL, V17, P304, DOI 10.1016/j.conb.2007.05.002; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; ZHOU W, 1994, MOL PHARMACOL, V45, P165; Zhou Z, 2007, SCIENCE, V317, P1390, DOI 10.1126/science.1147614; Zomot E, 2007, NATURE, V449, P726, DOI 10.1038/nature06133	40	108	110	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17691	17701		10.1074/jbc.M800475200	http://dx.doi.org/10.1074/jbc.M800475200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426798	hybrid, Green Published			2022-12-25	WOS:000256720600075
J	Kovanen, PE; Bernard, J; Al-Shami, A; Liu, CY; Bollenbacher-Reilley, J; Young, L; Pise-Masison, C; Spolski, R; Leonard, WJ				Kovanen, Panu E.; Bernard, Jerome; Al-Shami, Amin; Liu, Chengyu; Bollenbacher-Reilley, Julie; Young, Lynn; Pise-Masison, Cynthia; Spolski, Rosanne; Leonard, Warren J.			T-cell development and function are modulated by dual specificity phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALSE DISCOVERY RATE; IMMUNE-RESPONSE; HOMEOSTATIC PROLIFERATION; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; TARGET GENES; MAP KINASES; IN-VIVO; INTERLEUKIN-2; CYTOKINES	Interleukin-2 (IL-2) is a pleiotropic cytokine that regulates lymphocyte proliferation and peripheral tolerance. IL-2 activates mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase, and signal transducer and activator of transcription (STAT) pathways and modulates expression of target genes. Systematic analysis of IL-2 target genes has revealed regulation of potential feedback inhibitors of IL-2 signaling, including several suppressor of cytokine signaling (SOCS) family members as well as MAPK pathway-regulating dual specificity phosphatases (DUSPs). Here we have evaluated the in vivo actions of DUSP5, an extracellular signal-regulated kinase 1/2 (ERK1/2)-specific phosphatase, by generating transgenic mice overexpressing DUSP5 within the lymphoid compartment. We show that transgenic DUSP5 expression results in a block in thymocyte development at the double positive stage. We also demonstrate that DUSP5-expressing mature T cells exhibit decreased IL-2-dependent proliferation and defective IL-2-mediated induction of genes. Finally, DUSP5 transgenic mice develop autoimmune symptoms, suggesting a role for the MAPK pathway in the regulation of tolerance. Thus, proper regulation of DUSP5 activity is critical for normal immune system development, IL-2 actions, and tolerance.	[Kovanen, Panu E.; Bernard, Jerome; Al-Shami, Amin; Bollenbacher-Reilley, Julie; Spolski, Rosanne; Leonard, Warren J.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; [Liu, Chengyu] NHLBI, Transgen Mouse Core Facil, NIH, Bethesda, MD 20892 USA; [Young, Lynn] NIH, Bioinformat & Mol Anal Sect, Computat Biosci & Engn Lab, CIT, Bethesda, MD 20892 USA; [Pise-Masison, Cynthia] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7B05, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Al-Shami, Amin/D-3889-2009; Leonard, Warren/AAA-1397-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005401, Z01HL005401, Z01HL005907, ZICHL005907] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blais ME, 2006, IMMUNOL REV, V209, P103, DOI 10.1111/j.0105-2896.2006.00341.x; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Cornish AL, 2003, J BIOL CHEM, V278, P22755, DOI 10.1074/jbc.M303021200; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dorfman K, 1996, ONCOGENE, V13, P925; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Grossman Z, 2004, NAT REV IMMUNOL, V4, P387, DOI 10.1038/nri1355; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Held W, 1996, J EXP MED, V184, P2037, DOI 10.1084/jem.184.5.2037; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Khaled AR, 2002, NAT REV IMMUNOL, V2, P817, DOI 10.1038/nri931; Kim HP, 2006, CYTOKINE GROWTH F R, V17, P349, DOI 10.1016/j.cytogfr.2006.07.003; Kovanen PE, 2005, INT IMMUNOL, V17, P1009, DOI 10.1093/intimm/dxh283; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Lee SK, 2005, IMMUNOL REV, V208, P169, DOI 10.1111/j.0105-2896.2005.00339.x; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIN JX, 2003, CYTOKINE HDB, P167; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Malek TR, 2003, J LEUKOCYTE BIOL, V74, P961, DOI 10.1189/jlb.0603272; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; McNeil LK, 2005, P NATL ACAD SCI USA, V102, P13574, DOI 10.1073/pnas.0505110102; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rui LX, 2006, J IMMUNOL, V177, P5337, DOI 10.4049/jimmunol.177.8.5337; Sanchez-Gongora E, 2000, J BIOL CHEM, V275, P31379, DOI 10.1074/jbc.M000382200; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066; Theodosiou A, 2002, GENOME BIOL, V3; WASSARMAN PM, 1993, METHOD ENZYMOL, P747; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764	57	41	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17362	17369		10.1074/jbc.M709887200	http://dx.doi.org/10.1074/jbc.M709887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430737	Green Published, hybrid			2022-12-25	WOS:000256720600045
J	Oglesby, AG; Farrow, JM; Lee, JH; Tomaras, AP; Greenberg, EP; Pesci, EC; Vasil, ML				Oglesby, Amanda G.; Farrow, John M., III; Lee, Joon-Hee; Tomaras, Andrew P.; Greenberg, E. P.; Pesci, Everett C.; Vasil, Michael L.			The influence of iron on Pseudomonas aeruginosa physiology - A regulatory link between iron and quorum sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE FACTOR EXPRESSION; QUINOLONE SIGNAL SYNTHESIS; SMALL RNA; TRANSCRIPTIONAL REGULATION; SIGMA-FACTOR; IDENTIFICATION; VECTORS; ANTHRANILATE; SIDEROPHORE; EXOTOXIN	In iron-replete environments, the Pseudomonas aeruginosa Fur (ferric uptake regulator) protein represses expression of two small regulatory RNAs encoded by prrF1 and prrF2. Here we describe the effects of iron and PrrF regulation on P. aeruginosa physiology. We show that PrrF represses genes encoding enzymes for the degradation of anthranilate (i.e. antABC), a precursor of the Pseudomonas quinolone signal (PQS). Under iron-limiting conditions, PQS production was greatly decreased in a Delta prrF1,2 mutant as compared with wild type. The addition of anthranilate to the growth medium restored PQS production to the Delta prrF1,2 mutant, indicating that its defect in PQS production is a consequence of anthranilate degradation. PA2511 was shown to encode an anthranilate-dependent activator of the ant genes and was subsequently renamed antR. AntR was not required for regulation of antA by PrrF but was required for optimal iron activation of antA. Furthermore, iron was capable of activating both antA and antR in a Delta prrF1,2 mutant, indicating the presence of two distinct yet overlapping pathways for iron activation of antA (AntR-dependent and PrrF-dependent). Additionally, several quorum-sensing regulators, including PqsR, influenced antA expression, demonstrating that regulation of anthranilate metabolism is intimately woven into the quorum-sensing network of P. aeruginosa. Overall, our data illustrate the extensive control that both iron regulation and quorum sensing exercise in basic cellular physiology, underlining how intermediary metabolism can affect the regulation of virulence factors in P. aeruginosa.	[Oglesby, Amanda G.; Tomaras, Andrew P.; Vasil, Michael L.] Univ Colorado Denver, Aurora, CO 80231 USA; [Farrow, John M., III; Pesci, Everett C.] E Carolina Univ, Greenville, NC 27858 USA; [Lee, Joon-Hee] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; [Greenberg, E. P.] Univ Washington, Sch Med, Seattle, WA 98195 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; East Carolina University; Pusan National University; University of Washington; University of Washington Seattle	Oglesby, AG (corresponding author), UCHSC, 12800 E 19th Ave,Mail Stop 8333, Aurora, CO 80045 USA.	amanda.oglesby@uchsc.edu		Pesci, Everett/0000-0002-7490-7591; Greenberg, Everett/0000-0001-9474-8041; Farrow, John/0000-0003-1619-2388; Oglesby, Mandy/0000-0003-4440-3840	NIAID NIH HHS [R37-NIH AI15940, R01-AI46682] Funding Source: Medline; NIGMS NIH HHS [5R01-GM058026-09] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015940, R01AI046682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiba H, 2007, CURR OPIN MICROBIOL, V10, P134, DOI 10.1016/j.mib.2007.03.010; Beare PA, 2003, MOL MICROBIOL, V47, P195, DOI 10.1046/j.1365-2958.2003.03288.x; Becher A, 2000, BIOTECHNIQUES, V29, P948, DOI 10.2144/00295bm04; BRINT JM, 1995, J BACTERIOL, V177, P7155, DOI 10.1128/jb.177.24.7155-7163.1995; Calfee MW, 2001, P NATL ACAD SCI USA, V98, P11633, DOI 10.1073/pnas.201328498; Chugani SA, 2001, P NATL ACAD SCI USA, V98, P2752, DOI 10.1073/pnas.051624298; Collier DN, 2002, FEMS MICROBIOL LETT, V215, P41, DOI 10.1111/j.1574-6968.2002.tb11367.x; Erickson DL, 2002, INFECT IMMUN, V70, P1783, DOI 10.1128/IAI.70.4.1783-1790.2002; ESSAR DW, 1990, J BACTERIOL, V172, P884, DOI 10.1128/jb.172.2.884-900.1990; FARINHA MA, 1990, J BACTERIOL, V172, P3496, DOI 10.1128/jb.172.6.3496-3499.1990; Farrow JM, 2007, J BACTERIOL, V189, P3425, DOI 10.1128/JB.00209-07; Gallagher LA, 2002, J BACTERIOL, V184, P6472, DOI 10.1128/JB.184.23.6472-6480.2002; Gottesman S, 2006, COLD SPRING HARB SYM, V71, P1, DOI 10.1101/sqb.2006.71.016; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; Guina T, 2003, P NATL ACAD SCI USA, V100, P2771, DOI 10.1073/pnas.0435846100; Hoang TT, 2000, PLASMID, V43, P59, DOI 10.1006/plas.1999.1441; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hunt TA, 2002, MICROBIOL-SGM, V148, P3183, DOI 10.1099/00221287-148-10-3183; Lamont IL, 2002, P NATL ACAD SCI USA, V99, P7072, DOI 10.1073/pnas.092016999; LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x; Lee JH, 2006, MOL MICROBIOL, V59, P602, DOI 10.1111/j.1365-2958.2005.04960.x; Leoni L, 2000, J BACTERIOL, V182, P1481, DOI 10.1128/JB.182.6.1481-1491.2000; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Masse E, 2005, J BACTERIOL, V187, P6962, DOI 10.1128/JB.187.20.6962-6971.2005; McGrath S, 2004, FEMS MICROBIOL LETT, V230, P27, DOI 10.1016/S0378-1097(03)00849-8; Medina G, 2003, MICROBIOL-SGM, V149, P3073, DOI 10.1099/mic.0.26282-0; Meyer JM, 1996, INFECT IMMUN, V64, P518, DOI 10.1128/IAI.64.2.518-523.1996; Newman JR, 1999, GENE, V227, P197, DOI 10.1016/S0378-1119(98)00601-5; OCHSNER UA, 1995, P NATL ACAD SCI USA, V92, P6424, DOI 10.1073/pnas.92.14.6424; Ochsner UA, 2002, MOL MICROBIOL, V45, P1277, DOI 10.1046/j.1365-2958.2002.03084.x; Palmer KL, 2005, J BACTERIOL, V187, P5267, DOI 10.1128/JB.187.15.5267-5277.2005; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pesci EC, 1999, P NATL ACAD SCI USA, V96, P11229, DOI 10.1073/pnas.96.20.11229; PRINCE RW, 1993, J BACTERIOL, V175, P2589, DOI 10.1128/JB.175.9.2589-2598.1993; Rumbaugh KP, 1999, INFECT IMMUN, V67, P5854, DOI 10.1128/IAI.67.11.5854-5862.1999; Schuster M, 2003, J BACTERIOL, V185, P2066, DOI 10.1128/JB.185.7.2066-2079.2003; Somerville G, 1999, J BACTERIOL, V181, P1072, DOI 10.1128/JB.181.4.1072-1078.1999; Urata M, 2004, J BACTERIOL, V186, P6815, DOI 10.1128/JB.186.20.6815-6823.2004; Vasil ML, 2007, BIOMETALS, V20, P587, DOI 10.1007/s10534-006-9067-2; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; Wade DS, 2005, J BACTERIOL, V187, P4372, DOI 10.1128/JB.187.13.4372-4380.2005; Wilderman PJ, 2004, P NATL ACAD SCI USA, V101, P9792, DOI 10.1073/pnas.0403423101; Wu H, 2001, MICROBIOL-SGM, V147, P1105, DOI 10.1099/00221287-147-5-1105; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	149	152	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15558	15567		10.1074/jbc.M707840200	http://dx.doi.org/10.1074/jbc.M707840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18424436	Green Published, hybrid			2022-12-25	WOS:000256332500009
J	Suh, JM; Stenesen, D; Peters, JM; Inoue, A; Cade, A; Graff, JM				Suh, Jae Myoung; Stenesen, Drew; Peters, John M.; Inoue, Akiko; Cade, Angela; Graff, Jonathan M.			An RGS-Containing Sorting Nexin Controls Drosophila Lifespan	PLOS ONE			English	Article								The pursuit of eternal youth has existed for centuries and recent data indicate that fat-storing tissues control lifespan. In a D. melanogaster fat body insertional mutagenic enhancer trap screen designed to isolate genes that control longevity, we identified a regulator of G protein signaling (RGS) domain containing sorting nexin, termed snazarus (sorting nexin lazarus, snz). Flies with insertions into the 5' UTR of snz live up to twice as long as controls. Transgenic expression of UAS-Snz from the snz Gal4 enhancer trap insertion, active in fat metabolic tissues, rescued lifespan extension. Further, the lifespan extension of snz mutants was independent of endosymbiont, e. g., Wolbachia, effects. Notably, old snz mutant flies remain active and fertile indicating that snz mutants have prolonged youthfulness, a goal of aging research. Since mammals have snz-related genes, it is possible that the functions of the snz family may be conserved to humans.	[Suh, Jae Myoung; Stenesen, Drew; Peters, John M.; Inoue, Akiko; Cade, Angela; Graff, Jonathan M.] Univ Texas SW Med Ctr, Dept Dev Biol, Dallas, TX 75390 USA; [Graff, Jonathan M.] Univ Texas SW Med Ctr, Dept Mol Biol, Dallas, TX USA; [Graff, Jonathan M.] Univ Texas SW Med Ctr, Dept Internal Med, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas SW Med Ctr, Dept Dev Biol, Dallas, TX 75390 USA.	Jon.Graff@utsouthwestern.edu	Suh, Jae Myoung/B-3268-2015	Suh, Jae Myoung/0000-0001-8097-4662	NIH NIDDK	NIH NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by awards to JMG from the NIH and the NIDDK.	Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beinert N, 2004, CHROMOSOMA, V113, P271, DOI 10.1007/s00412-004-0313-5; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dali-Youcef N, 2007, ANN MED, V39, P335, DOI 10.1080/07853890701408194; DAVID J, 1975, EXP GERONTOL, V10, P17, DOI 10.1016/0531-5565(75)90011-X; ECONOMOS AC, 1979, MECH AGEING DEV, V10, P233, DOI 10.1016/0047-6374(79)90037-X; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fry AJ, 2004, HEREDITY, V93, P379, DOI 10.1038/sj.hdy.6800514; Gargano JW, 2005, EXP GERONTOL, V40, P386, DOI 10.1016/j.exger.2005.02.005; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Gutierrez E, 2007, NATURE, V445, P275, DOI 10.1038/nature05382; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Helfand SL, 2003, ANNU REV GENET, V37, P329, DOI 10.1146/annurev.genet.37.040103.095211; Holliday R, 2006, ANN NY ACAD SCI, V1067, P1, DOI 10.1196/annals.1354.002; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792; Mollereau B, 2000, MECH DEVELOP, V93, P151, DOI 10.1016/S0925-4773(00)00287-2; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; Parks AL, 2004, NAT GENET, V36, P288, DOI 10.1038/ng1312; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Picard F, 2005, INT J OBESITY, V29, pS36, DOI 10.1038/sj.ijo.0802912; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; ROSE MR, 1992, EXP GERONTOL, V27, P241, DOI 10.1016/0531-5565(92)90048-5; ROSEMAN RR, 1995, GENETICS, V141, P1061; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Suh JM, 2007, CELL METAB, V6, P195, DOI 10.1016/j.cmet.2007.08.001; Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012; Summers SA, 2000, INT J OBESITY, V24, pS67, DOI 10.1038/sj.ijo.0801509; TAKASUISHIKAWA E, 1992, MOL GEN GENET, V232, P17, DOI 10.1007/BF00299132; Toivonen JM, 2007, PLOS GENET, V3, P973, DOI 10.1371/journal.pgen.0030095; Tong JJY, 2007, NAT GENET, V39, P476, DOI 10.1038/ng2004; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Willars GB, 2006, SEMIN CELL DEV BIOL, V17, P363, DOI 10.1016/j.semcdb.2006.03.005; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xie GX, 2007, J MOL BIOL, V366, P349, DOI 10.1016/j.jmb.2006.11.045; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	64	17	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2152	10.1371/journal.pone.0002152	http://dx.doi.org/10.1371/journal.pone.0002152			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478054	Green Published, gold, Green Submitted			2022-12-25	WOS:000262172800017
J	Bakkum, DJ; Chao, ZC; Potter, SM				Bakkum, Douglas J.; Chao, Zenas C.; Potter, Steve M.			Long-Term Activity-Dependent Plasticity of Action Potential Propagation Delay and Amplitude in Cortical Networks	PLOS ONE			English	Article								Background: The precise temporal control of neuronal action potentials is essential for regulating many brain functions. From the viewpoint of a neuron, the specific timings of afferent input from the action potentials of its synaptic partners determines whether or not and when that neuron will fire its own action potential. Tuning such input would provide a powerful mechanism to adjust neuron function and in turn, that of the brain. However, axonal plasticity of action potential timing is counter to conventional notions of stable propagation and to the dominant theories of activity-dependent plasticity focusing on synaptic efficacies. Methodology/Principal Findings: Here we show the occurrence of activity-dependent plasticity of action potential propagation delays ( up to 4 ms or 40% after minutes and 13 ms or 74% after hours) and amplitudes ( up to 87%). We used a multi-electrode array to induce, detect, and track changes in propagation in multiple neurons while they adapted to different patterned stimuli in controlled neocortical networks in vitro. The changes did not occur when the same stimulation was repeated while blocking ionotropic gabaergic and glutamatergic receptors. Even though induction of changes in action potential timing and amplitude depended on synaptic transmission, the expression of these changes persisted in the presence of the synaptic receptor blockers. Conclusions/Significance: We conclude that, along with changes in synaptic efficacy, propagation plasticity provides a cellular mechanism to tune neuronal network function in vitro and potentially learning and memory in the brain.	[Bakkum, Douglas J.; Chao, Zenas C.; Potter, Steve M.] Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Bakkum, DJ (corresponding author), Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30332 USA.	steve.potter@bme.gatech.edu			National Institutes of Health (NIH)-National Institute of Neurological Disorders and Stroke [NS38628]; NIH-National Institute of Biomedical Imaging and Bioengineering [EB00786]; ArtsWA; Whitaker Foundation; National Science Foundation Center for Behavioral Neuroscience; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038628] Funding Source: NIH RePORTER	National Institutes of Health (NIH)-National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH-National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); ArtsWA; Whitaker Foundation; National Science Foundation Center for Behavioral Neuroscience; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by National Institutes of Health (NIH)-National Institute of Neurological Disorders and Stroke Grants NS38628, NIH-National Institute of Biomedical Imaging and Bioengineering Grant EB00786, ArtsWA, the Whitaker Foundation, and the National Science Foundation Center for Behavioral Neuroscience.	Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; Alle H, 2006, SCIENCE, V311, P1290, DOI 10.1126/science.1119055; Anderson JC, 2002, J NEUROCYTOL, V31, P211, DOI 10.1023/A:1024113707630; Bakkum DJ, 2004, EMBODIED ARTIFICIAL; Bakkum Douglas J, 2007, Front Neurorobot, V1, P5, DOI 10.3389/neuro.12.005.2007; Baruchi I, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.050901; BEDLACK RS, 1994, NEURON, V13, P1187, DOI 10.1016/0896-6273(94)90056-6; Beggs JM, 2003, J NEUROSCI, V23, P11167; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Carp JS, 2001, EXP BRAIN RES, V136, P269, DOI 10.1007/s002210000608; CHAO ZC, 2008, PLOS COMP B IN PRESS; Chao ZC, 2007, J NEURAL ENG, V4, P294, DOI 10.1088/1741-2560/4/3/015; Clark B, 2006, CURR BIOL, V16, pR585, DOI 10.1016/j.cub.2006.07.007; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; Daoudal G, 2003, LEARN MEMORY, V10, P456, DOI 10.1101/lm.64103; Darbon P, 2002, EUR J NEUROSCI, V15, P671, DOI 10.1046/j.1460-9568.2002.01904.x; Debanne D, 2004, NAT REV NEUROSCI, V5, P304, DOI 10.1038/nrn1397; Eurich CW, 1999, PHYS REV LETT, V82, P1594, DOI 10.1103/PhysRevLett.82.1594; Faisal AA, 2007, PLOS COMPUT BIOL, V3, P783, DOI 10.1371/journal.pcbi.0030079; Fields RD, 2005, NEUROSCIENTIST, V11, P528, DOI 10.1177/1073858405282304; Foss J, 2000, J NEUROPHYSIOL, V84, P975, DOI 10.1152/jn.2000.84.2.975; Ganguly K, 2000, NAT NEUROSCI, V3, P1018, DOI 10.1038/79838; GOLDSTEIN SS, 1974, BIOPHYS J, V14, P731, DOI 10.1016/S0006-3495(74)85947-3; HALTER JA, 1995, J NEUROPHYSIOL, V73, P867, DOI 10.1152/jn.1995.73.2.867; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Izhikevich EM, 2006, NEURAL COMPUT, V18, P245, DOI 10.1162/089976606775093882; Jimbo Y, 1999, BIOPHYS J, V76, P670, DOI 10.1016/S0006-3495(99)77234-6; Kawaguchi H, 1998, EXP BRAIN RES, V122, P378, DOI 10.1007/s002210050526; Latham PE, 2000, J NEUROPHYSIOL, V83, P828, DOI 10.1152/jn.2000.83.2.828; LIPSKI J, 1981, J NEUROSCI METH, V4, P1, DOI 10.1016/0165-0270(81)90015-7; Ma JF, 2007, NEURAL COMPUT, V19, P2124, DOI 10.1162/neco.2007.19.8.2124; MANOR Y, 1991, BIOPHYS J, V60, P1424, DOI 10.1016/S0006-3495(91)82179-8; Marom S, 2002, Q REV BIOPHYS, V35, P63, DOI 10.1017/S0033583501003742; McIntyre CC, 2000, ANN BIOMED ENG, V28, P219, DOI 10.1114/1.262; Milton JG, 2000, J PHYSIOL-PARIS, V94, P489, DOI 10.1016/S0928-4257(00)01102-5; Nakanishi K, 1998, BRAIN RES, V795, P137, DOI 10.1016/S0006-8993(98)00283-2; Patolsky F, 2006, SCIENCE, V313, P1100, DOI 10.1126/science.1128640; Potter SM, 2001, J NEUROSCI METH, V110, P17, DOI 10.1016/S0165-0270(01)00412-5; POTTER SM, 2006, ADV NETWORK ELECTROP; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Shahaf G, 2001, J NEUROSCI, V21, P8782, DOI 10.1523/JNEUROSCI.21-22-08782.2001; Shu YS, 2006, NATURE, V441, P761, DOI 10.1038/nature04720; SIK A, 1995, J NEUROSCI, V15, P6651; SUGIHARA I, 1993, J PHYSIOL-LONDON, V470, P243, DOI 10.1113/jphysiol.1993.sp019857; Suzuki I, 2007, BIOCHEM BIOPH RES CO, V356, P470, DOI 10.1016/j.bbrc.2007.03.006; SWADLOW HA, 1985, J NEUROPHYSIOL, V54, P1346, DOI 10.1152/jn.1985.54.5.1346; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Wagenaar D. A., 2005, IEEE EMBS C NEUR ENG; Wagenaar DA, 2004, J NEUROSCI METH, V138, P27, DOI 10.1016/j.jneumeth.2004.03.005; Wagenaar DA, 2002, J NEUROSCI METH, V120, P113, DOI 10.1016/S0165-0270(02)00149-8; Wagenaar DA, 2004, J NEURAL ENG, V1, DOI 10.1088/1741-2560/1/1/006; WAXMAN SG, 1972, NATURE-NEW BIOL, V238, P217, DOI 10.1038/newbio238217a0; Waxman SG, 1997, CURR BIOL, V7, pR406, DOI 10.1016/S0960-9822(06)00203-X; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Xu J, 2005, J NEUROSCI, V25, P1750, DOI 10.1523/JNEUROSCI.4217-04.2005; Zhang W, 2003, NAT REV NEUROSCI, V4, P885, DOI 10.1038/nrn1248	57	77	77	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2088	10.1371/journal.pone.0002088	http://dx.doi.org/10.1371/journal.pone.0002088			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461127	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400011
J	Rudick, CN; Bryce, PJ; Guichelaar, LA; Berry, RE; Klumpp, DJ				Rudick, Charles N.; Bryce, Paul J.; Guichelaar, Laura A.; Berry, Ruth E.; Klumpp, David J.			Mast Cell-Derived Histamine Mediates Cystitis Pain	PLOS ONE			English	Article								Background: Mast cells trigger inflammation that is associated with local pain, but the mechanisms mediating pain are unclear. Interstitial cystitis (IC) is a bladder disease that causes debilitating pelvic pain of unknown origin and without consistent inflammation, but IC symptoms correlate with elevated bladder lamina propria mast cell counts. We hypothesized that mast cells mediate pelvic pain directly and examined pain behavior using a murine model that recapitulates key aspects of IC. Methods and Findings: Infection of mice with pseudorabies virus (PRV) induces a neurogenic cystitis associated with lamina propria mast cell accumulation dependent upon tumor necrosis factor alpha (TNF), TNF-mediated bladder barrier dysfunction, and pelvic pain behavior, but the molecular basis for pelvic pain is unknown. In this study, both PRV-induced pelvic pain and bladder pathophysiology were abrogated in mast cell-deficient mice but were restored by reconstitution with wild type bone marrow. Pelvic pain developed normally in TNF-and TNF receptor-deficient mice, while bladder pathophysiology was abrogated. Conversely, genetic or pharmacologic disruption of histamine receptor H1R or H2R attenuated pelvic pain without altering pathophysiology. Conclusions: These data demonstrate that mast cells promote cystitis pain and bladder pathophysiology through the separable actions of histamine and TNF, respectively. Therefore, pain is independent of pathology and inflammation, and histamine receptors represent direct therapeutic targets for pain in IC and other chronic pain conditions.	[Rudick, Charles N.; Guichelaar, Laura A.; Berry, Ruth E.; Klumpp, David J.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Klumpp, David J.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL USA; [Bryce, Paul J.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Rudick, CN (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.	d-klumpp@northwestern.edu			NIDDK [R01DK066112, T32DK062716-05]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK062716, R01DK066112] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIDDK R01DK066112 (D.J.K.) and T32DK062716-05 (C.N.R.).	Barbara G, 2004, GASTROENTEROLOGY, V126, P693, DOI 10.1053/j.gastro.2003.11.055; Barbara G, 2007, GASTROENTEROLOGY, V132, P26, DOI 10.1053/j.gastro.2006.11.039; Berkley KJ, 2005, SCIENCE, V308, P1587, DOI 10.1126/science.1111445; BOUCHER W, 1995, BRIT J UROL, V76, P94, DOI 10.1111/j.1464-410X.1995.tb07840.x; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen MC, 2006, J UROLOGY, V175, P754, DOI 10.1016/S0022-5347(05)00171-0; Chen MC, 2007, AM J PHYSIOL-RENAL, V292, pF1372, DOI 10.1152/ajprenal.00472.2006; Chen MC, 2006, AM J PHYSIOL-RENAL, V291, pF741, DOI 10.1152/ajprenal.00081.2006; Dasgupta P, 2001, BJU INT, V88, P183, DOI 10.1046/j.1464-410x.2001.02258.x; Doggweiler R, 1998, J UROLOGY, V160, P1551, DOI 10.1016/S0022-5347(01)62611-9; Dozmorov I, 2003, PHYSIOL GENOMICS, V12, P239, DOI 10.1152/physiolgenomics.00141.2002; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; Elbadawi A, 1997, UROLOGY, V49, P14, DOI 10.1016/S0090-4295(99)80329-X; ELMANSOURY M, 1994, J UROLOGY, V152, P350, DOI 10.1016/S0022-5347(17)32737-4; Fang X, 2006, J NEUROSCI, V26, P7281, DOI 10.1523/JNEUROSCI.1072-06.2006; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Guerios SD, 2006, NEUROSCI LETT, V392, P193, DOI 10.1016/j.neulet.2005.09.026; HANNO P, 2007, CAMPBELLWALSH UROLOG, P631; Hwang SJ, 2005, BRAIN RES, V1062, P86, DOI 10.1016/j.brainres.2005.09.026; Jasmin L, 1998, J NEUROSCI, V18, P10016; Jasmin L, 2000, J UROLOGY, V164, P852, DOI 10.1016/S0022-5347(05)67326-0; Jones CA, 1997, UROLOGY, V49, P2, DOI 10.1016/S0090-4295(99)80327-6; Laird JMA, 2001, PAIN, V92, P335, DOI 10.1016/S0304-3959(01)00275-5; Laird JMA, 2002, J NEUROSCI, V22, P8352; Leiby BE, 2007, J UROLOGY, V177, P142, DOI 10.1016/j.juro.2006.08.096; Mobarakeh JI, 2006, NEUROPHARMACOLOGY, V51, P612, DOI 10.1016/j.neuropharm.2006.05.003; Mobarakeh JI, 2000, EUR J PHARMACOL, V391, P81, DOI 10.1016/S0014-2999(00)00060-1; Mukerji Gaurav, 2006, BMC Urol, V6, P6, DOI 10.1186/1471-2490-6-6; Mukerji G, 2006, J UROLOGY, V176, P797, DOI 10.1016/j.juro.2006.03.074; Novi JM, 2005, J UROLOGY, V174, P937, DOI 10.1097/01.ju.0000169258.31345.5d; PARSONS CL, 1994, NEUROUROL URODYNAM, V13, P515, DOI 10.1002/nau.1930130503; Rudick CN, 2007, AM J PHYSIOL-REG I, V293, pR1191, DOI 10.1152/ajpregu.00411.2007; Ruscheweyh R, 2007, J COMP NEUROL, V502, P325, DOI 10.1002/cne.21311; Saban R, 2002, AM J PHYSIOL-RENAL, V283, pF616, DOI 10.1152/ajprenal.00096.2002; Sant GR, 2003, J UROLOGY, V170, P810, DOI 10.1097/01.ju.0000083020.06212.3d; SIMONE DA, 1991, SOMATOSENS MOT RES, V8, P271, DOI 10.3109/08990229109144750; Sturge WA, 1883, BRAIN, V5, P492, DOI [10.1093/brain/5.4.492, DOI 10.1093/BRAIN/5.4.492]; Thilagarajah R, 2001, BJU INT, V87, P207, DOI 10.1046/j.1464-410x.2001.02031.x; Tomaszewski JE, 2001, UROLOGY, V57, P67, DOI 10.1016/S0090-4295(01)01166-9; Tsai M, 2005, CHEM IMMUNOL ALLERGY, V87, P179, DOI 10.1159/000087644; Ustinova EE, 2007, AM J PHYSIOL-RENAL, V292, pF123, DOI 10.1152/ajprenal.00162.2006; Wesselmann U, 2001, WORLD J UROL, V19, P180, DOI 10.1007/s003450100201; Winnard KP, 2006, AM J PHYSIOL-REG I, V291, pR1592, DOI 10.1152/ajpregu.00455.2006; Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232; Yu S, 2007, AM J PHYSIOL-GASTR L, V293, pG850, DOI 10.1152/ajpgi.00277.2007	45	76	81	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2096	10.1371/journal.pone.0002096	http://dx.doi.org/10.1371/journal.pone.0002096			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461160	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400018
J	Stevens, W; Kamali, A; Karita, E; Anzala, O; Sanders, EJ; Jaoko, W; Kaleebu, P; Mulenga, J; Dally, L; Fast, P; Gilmour, J; Farah, B; Birungi, J; Hughes, P; Manigart, O; Stevens, G; Yates, S; Thomson, H; von Lieven, A; Krebs, M; Price, MA; Stoll-Johnson, L; Ketter, N				Stevens, Wendy; Kamali, Anatoli; Karita, Etienne; Anzala, Omu; Sanders, Eduard J.; Jaoko, Walter; Kaleebu, Pontiano; Mulenga, Joseph; Dally, Len; Fast, Pat; Gilmour, Jill; Farah, Bashir; Birungi, Josephine; Hughes, Peter; Manigart, Olivier; Stevens, Gwynn; Yates, Sarah; Thomson, Helen; von Lieven, Andrea; Krebs, Marietta; Price, Matt A.; Stoll-Johnson, Lisa; Ketter, Nzeera			Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials	PLOS ONE			English	Article							IMMUNOHEMATOLOGICAL REFERENCE RANGES; HEPATITIS-C-VIRUS; COUNT; NEUTROPENIA; CHILDREN; UGANDA; SEX	Background: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. Methods: Asymptomatic persons, aged 18-60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). Results and Conclusions: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons.	[Stevens, Wendy] Univ Witwatersrand, Contract Lab Serv CLS, Johannesburg, South Africa; [Kamali, Anatoli; Kaleebu, Pontiano; Hughes, Peter] Uganda Virus Res Inst UVRI, Unit on AIDS, Med Res Council MRC, Entebbe, Uganda; [Karita, Etienne] Projet San Francisco PSF, Kigali, Rwanda; [Anzala, Omu; Jaoko, Walter; Farah, Bashir] Kenyatta Natl Hosp & Kangemi, Kenya AIDS Vaccine Initiative KAVI, Nairobi, Kenya; [Sanders, Eduard J.] Kenya Med Res Inst KEMRI, Ctr Geograph Med Res Coast CGMRC, Kilifi, Kenya; [Mulenga, Joseph; Manigart, Olivier] Zambia Emory HIV Res Project ZEHRP, Lusaka, Zambia; [Dally, Len] The EMMES Corp, Washington, DC USA; [Fast, Pat; Gilmour, Jill; Stevens, Gwynn; Yates, Sarah; Thomson, Helen; von Lieven, Andrea; Krebs, Marietta; Price, Matt A.] Int AIDS Vaccine Initiative IAVI, New York, NY USA; [Birungi, Josephine] Uganda Virus Res Inst UVRI, IAVI, HIV Vaccine Program, Entebbe, Uganda; [Stoll-Johnson, Lisa] Novartis, Boston, MA USA; [Ketter, Nzeera] Johnson & Johnson, New Brunswick, NJ USA	University of Witwatersrand; Kenyatta National Hospital; Kenya Medical Research Institute; Emmes Corporation; International AIDS Vaccine Initiative; International AIDS Vaccine Initiative; Novartis; Johnson & Johnson; Johnson & Johnson USA	Stevens, W (corresponding author), Univ Witwatersrand, Contract Lab Serv CLS, Johannesburg, South Africa.	mprice@iavi.org	Jaoko, Walter/AAN-5048-2020; Price, Matt/AAK-6881-2021	Price, Matt/0000-0002-2918-1373; Jaoko, Walter/0000-0002-7134-6581	United States Agency for International Development (USAID)	United States Agency for International Development (USAID)(United States Agency for International Development (USAID))	Funding was from the United States Agency for International Development (USAID). The study sponsor, IAVI, designed the study, data collection analysis and interpretation was done in concert with the site investigators.	Aboul-Hassan Samir, 1997, Journal of the Egyptian Society of Parasitology, V27, P47; AZIKIWE AN, 1984, E AFR MED J, V61, P482; Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664; Bedu-Addo G, 2002, LANCET, V360, P449, DOI 10.1016/S0140-6736(02)09680-0; BEIGHTON P, 1974, ANN RHEUM DIS, V33, P442, DOI 10.1136/ard.33.5.442; Biggar RJ, 2006, EMERG INFECT DIS, V12, P1440, DOI 10.3201/eid1209.041068; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Booth M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-13; BRICKMAN AS, 1993, AM J HYPERTENS, V6, P46, DOI 10.1093/ajh/6.1.46; Excler JL, 2000, J HUMAN VIROL, V3, P193; EZEILO GC, 1972, LANCET, V2, P1003; FAST PE, 2007, AIDS VACCINE DEV CHA, P87; GILL GV, 1979, T ROY SOC TROP MED H, V73, P111, DOI 10.1016/0035-9203(79)90142-1; Gilmour JW, 2007, CURR OPIN HIV AIDS, V2, P201, DOI 10.1097/COH.0b013e3280eec77a; GLENNCROSS D, 2005, RESULTS WHO NHLS QAS; Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6; Kasili E G, 1969, East Afr Med J, V46, P676; KOH ET, 1980, AM J CLIN NUTR, V33, P1828, DOI 10.1093/ajcn/33.8.1828; Lugada ES, 2004, SCAND J IMMUNOL, V59, P203, DOI 10.1111/j.0300-9475.2004.01376.x; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; Menard D, 2003, CLIN DIAGN LAB IMMUN, V10, P443, DOI 10.1128/CDLI.10.3.443-445.2003; National Committee on Clinical Laboratory Standards (NCCLS), 2000, C28A2 NCCLS, V20; Scott LE, 2003, CYTOM PART B-CLIN CY, V54B, P46, DOI 10.1002/cyto.b.10016; SEEDAT YK, 1981, S AFR MED J, V60, P7; SHAPER AG, 1971, LANCET, V2, P1021; Stiles T, 2003, GOOD CLIN LAB PRACTI; Tess BH, 2000, AM J TROP MED HYG, V62, P138, DOI 10.4269/ajtmh.2000.62.138; Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410, DOI 10.1128/CDLI.6.3.410-414.1999; TUGUME SB, 1995, CLIN DIAGN LAB IMMUN, V2, P233, DOI 10.1128/CDLI.2.2.233-235.1995; UNAIDS, 2006, REP GLOB AIDS EP; Van Rooyen J. M., 2002, Ethnicity and Disease, V12, P69	31	21	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2043	10.1371/journal.pone.0002043	http://dx.doi.org/10.1371/journal.pone.0002043			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446196	Green Accepted, gold, Green Submitted, Green Published			2022-12-25	WOS:000261572300015
J	Cheng, C; Li, LM				Cheng, Chao; Li, Lei M.			Inferring MicroRNA Activities by Combining Gene Expression with MicroRNA Target Prediction	PLOS ONE			English	Article							POSTTRANSCRIPTIONAL REGULATION; SYSTEMATIC IDENTIFICATION; TRANSCRIPTION FACTORS; LET-7; INVOLVEMENT; PROFILES; GENOMICS; DATABASE; MIRNAS; TOOLS	Background: MicroRNAs (miRNAs) play crucial roles in a variety of biological processes via regulating expression of their target genes at the mRNA level. A number of computational approaches regarding miRNAs have been proposed, but most of them focus on miRNA gene finding or target predictions. Little computational work has been done to investigate the effective regulation of miRNAs. Methodology/Principal Findings: We propose a method to infer the effective regulatory activities of miRNAs by integrating microarray expression data with miRNA target predictions. The method is based on the idea that regulatory activity changes of miRNAs could be reflected by the expression changes of their target transcripts measured by microarray. To validate this method, we apply it to the microarray data sets that measure gene expression changes in cell lines after transfection or inhibition of several specific miRNAs. The results indicate that our method can detect activity enhancement of the transfected miRNAs as well as activity reduction of the inhibited miRNAs with high sensitivity and specificity. Furthermore, we show that our inference is robust with respect to false positives of target prediction. Conclusions/Significance: A huge amount of gene expression data sets are available in the literature, but miRNA regulation underlying these data sets is largely unknown. The method is easy to be implemented and can be used to investigate the miRNA effective regulation underlying the expression change profiles obtained from microarray experiments.	[Cheng, Chao; Li, Lei M.] Univ So Calif, Dept Biol Sci, Mol & Computat Biol Program, Los Angeles, CA 90089 USA; [Li, Lei M.] Univ So Calif, Dept Math, Los Angeles, CA USA	University of Southern California; University of Southern California	Li, LM (corresponding author), Univ So Calif, Dept Biol Sci, Mol & Computat Biol Program, Los Angeles, CA 90089 USA.	lilei@usc.edu	Li, Lei M/C-7196-2009	Li, Lei M/0000-0002-6571-1079	NIH [R01 GM75308-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075308] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The work is supported by the NIH grant R01 GM75308-01.	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen PY, 2005, BIOL CHEM, V386, P1205, DOI 10.1515/BC.2005.139; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cheng C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-116; Cheng C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-452; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Demeter J, 2007, NUCLEIC ACIDS RES, V35, pD766, DOI 10.1093/nar/gkl1019; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Dugas DV, 2004, CURR OPIN PLANT BIOL, V7, P512, DOI 10.1016/j.pbi.2004.07.011; Enright AJ, 2004, GENOME BIOL, V5; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001; Hsu PWC, 2006, NUCLEIC ACIDS RES, V34, pD135, DOI 10.1093/nar/gkj135; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Karp X, 2005, SCIENCE, V310, P1288, DOI 10.1126/science.1121566; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Sontheimer EJ, 2005, CELL, V122, P9, DOI 10.1016/j.cell.2005.06.030; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; VOLINIA S, 2006, P NATL; Wang XW, 2006, NUCLEIC ACIDS RES, V34, P1646, DOI 10.1093/nar/gkl068; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yu ZB, 2007, NUCLEIC ACIDS RES, V35, P152, DOI 10.1093/nar/gkl1032	49	83	89	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1989	10.1371/journal.pone.0001989	http://dx.doi.org/10.1371/journal.pone.0001989			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431476	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700011
J	Elcheva, I; Tarapore, RS; Bhatia, N; Spiegelman, VS				Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.			Overexpression of mRNA-binding protein CRD-BP in malignant melanomas	ONCOGENE			English	Article						CRD-BP; beta-TrCP; mRNA stability; melanoma; Wnt/beta-catenin signaling; NF-kappa B	NF-KAPPA-B; UBIQUITIN LIGASE RECEPTOR; C-MYC; BETA-CATENIN; CODING REGION; CELLS; ACTIVATION; EXPRESSION; CANCER; HOMOLOG	Wnt/beta-catenin signaling pathway plays an important role in embryogenesis, stem cell maintenance, tumorigenesis and aging. Here, we show that RNA-binding protein, coding region determinant-binding protein (CRD-BP) (a transcriptional target of Wnt signaling pathway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activated Wnt/beta-catenin signaling pathway. Upregulation of CRD-BP is associated with an elevated level of beta-TrCP1 ubiquitin ligase receptor and activation of nuclear transcriptional factors-kappa B (NF-kappa B) signaling. Knockdown of CRD-BP inhibits NF-kappa B activity, induces apoptosis, and suppresses proliferation and tumorigenic properties of melanoma cells.	[Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.] Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Tarapore, R. S.; Spiegelman, V. S.] Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Spiegelman, V. S.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Spiegelman, VS (corresponding author), Univ Wisconsin, Dept Dermatol, Sch Med, 445 Henry Mall,Room 301, Madison, WI 53706 USA.	spiegelman@dermatology.wisc.edu	Tarapore, Rohinton/J-8300-2012	Spiegelman, Vladimir S/0000-0003-4847-155X	NCI [CA121851]; NATIONAL CANCER INSTITUTE [R01CA121851] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs N Maddodi, S Devi, J Ross, P Robbins, K Kinzler and B Vogelstein for their generous gifts of reagents, S Reagan-Shaw for statistical analysis, Drs V Setaluri and S Fuchs for critical reading of the paper, and Dr K Spiegelman and Ms I Larsen for help with the paper preparation. This study was supported by NCI Grant CA121851 ( to VSS).	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Smalley KSM, 2004, J INVEST DERMATOL, V123, pXVI, DOI 10.1111/j.0022-202X.2004.23430.x; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yang JM, 2001, CANCER RES, V61, P4901	32	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5069	5074		10.1038/onc.2008.141	http://dx.doi.org/10.1038/onc.2008.141			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454174				2022-12-25	WOS:000258914800009
J	Leung, N; Turbide, C; Balachandra, B; Marcus, V; Beauchemin, N				Leung, N.; Turbide, C.; Balachandra, B.; Marcus, V.; Beauchemin, N.			Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam(1-/-) mice	ONCOGENE			English	Article						CEACAM1; Wnt signaling; intestinal cancer; tumor suppressor; mouse model	FAMILIAL ADENOMATOUS POLYPOSIS; CELL-ADHESION MOLECULE; ABERRANT CRYPT FOCI; COLORECTAL-CANCER; BETA-CATENIN; BILIARY GLYCOPROTEIN; C-CAM; K-RAS; CEACAM1; APC	The carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is downregulated in colonic and intestinal hyperplastic lesions as well as in other cancers, where it functions as a tumor suppressor. To investigate the functions of CEACAM1 in the normal intestine and in intestinal tumors, we generated a compound knockout mouse model and examined both Ceacam1(-/-) and Apc(1638N/+): Ceacam1(-/-) mice. Ceacam1(-/-) intestinal cells exhibited a significant decrease in apoptosis, with no change in proliferation or migration, however. Compound Apc(1638N/+): Ceacam1(-/-) mice demonstrated an increase in intestinal tumor multiplicity and tumor progression. Increases in intussusceptions and desmoid lesions were also observed. We have shown that CEACAM1-L associates with beta-catenin by co-immunoprecipitation and colocalization in CEACAM1-L-transfected CT26 and CT51 mouse colon carcinoma cells. Ceacam1(-/-) enterocytes displayed decreased glycogen synthase kinase 3-beta activity with corresponding nuclear localization of beta-catenin. Increased T-cell factor/Lef transcriptional activity was observed in CEACAM1-null CT51 colonic cells and in Caco2 colon cancer cells in which CEACAM1 was downregulated. A significant increased expression in c-Myc and cyclin D1 targets of the Wnt signaling pathway was also revealed in the Ceacam1(-/-) intestine. CEACAM1 therefore actively participates in Wnt signaling in intestinal cells and its downregulation in intestinal tissue contributes to malignancy by augmenting tumor multiplicity and progression.	[Beauchemin, N.] McGill Univ, McGill Canc Ctr, Lab 711, Montreal, PQ H3G 1Y6, Canada; [Leung, N.; Beauchemin, N.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Balachandra, B.] Univ Alberta, Dept Pathol, Royal Alexandra Hosp, Edmonton, AB T6G 2E1, Canada; [Marcus, V.] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; Royal Alexandra Hospital; University of Alberta; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Lab 711, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca						Abou-Rjaily GA, 2004, J CLIN INVEST, V114, P944, DOI 10.1172/JCI200421786; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Azar T, 1997, ANN SURG, V226, P134, DOI 10.1097/00000658-199708000-00003; Beauchemin N, 1999, EXP CELL RES, V252, P243; Buckhaults P, 2001, CANCER RES, V61, P6996; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hokari M, 2007, LIFE SCI, V81, P336, DOI 10.1016/j.lfs.2007.06.002; Horst AK, 2004, HANDB EXP PHARM, V165, P283, DOI 10.1007/978-3-540-68170-0_10; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; HSIEH JT, 1995, CANCER RES, V55, P190; JIN L, 2008, EXP BIOL ME IN PRESS, V233; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kunath T, 1995, ONCOGENE, V11, P2375; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Poy MN, 2002, J BIOL CHEM, V277, P1076, DOI 10.1074/jbc.M108415200; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Yang WC, 2005, CANCER RES, V65, P9363, DOI 10.1158/0008-5472.CAN-05-2113	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4943	4953		10.1038/onc.2008.136	http://dx.doi.org/10.1038/onc.2008.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454175				2022-12-25	WOS:000258596900008
J	Paulson, QX; Pusapati, RV; Hong, S; Weaks, RL; Conti, CJ; Johnson, DG				Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.			Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis	ONCOGENE			English	Article						Rb; ATM; oncogenic stress; DNA-damage response	ONCOGENE-INDUCED SENESCENCE; ATAXIA-TELANGIECTASIA; HUMAN TUMORIGENESIS; SIGNALING PATHWAY; BLADDER-CANCER; LUNG-CANCER; PROLIFERATION; OVEREXPRESSION; RETINOBLASTOMA; GENE	Many early stage human tumors display markers of a DNA-damage response (DDR), including ataxia telangiectasia mutated (ATM) kinase activation. This suggests that DNA damage accumulates during the process of carcinogenesis and that the ATM-dependent response to this damage may function to suppress cancer progression. The E2F3a transcription factor plays an important role in regulating cell proliferation and is amplified in a subset of human cancers. Similar to human premalignant lesions, we find activated ATM and other markers of the DDR in the hyperplastic epidermis of transgenic mice expressing E2F3a through a keratin 5 (K5) promoter. Primary keratinocytes from K5 E2F3a transgenic mice contain increased levels of DNA breaks compared to wild-type cells. E2F3a overexpression also induced DNA damage in primary human fibroblasts that was inhibited by blocking DNA replication. The absence of ATM impaired apoptosis induced by E2F3a and treating K5 E2F3a transgenic mice with caffeine, an inhibitor of ATM and Rad3-related (ATR), promoted skin tumor development. These findings demonstrate that the deregulated expression of E2F3a causes DNA damage under physiological conditions and indicate that the ATM-dependent response to this damage is important for the induction of apoptosis and tumor suppression.	[Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.] Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	National Institutes of Health [CA098601, CA79648, U01CA105345, ES07784, CA16672]; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA098601, U01CA105345, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Mark McArthur for pathological analysis of skin lesions, Jen Smith and Pam Blau for technical assistance, Lezlee Coghlan, Dale Weiss and coworkers for animal care, Chris Brown and Joi Holcomb for graphics and Shawnda Sanders for preparation of the manuscript. This work was supported by National Institutes of Health Grants CA098601 and CA79648( to DGJ), U01CA105345, ES07784, and CA16672. RLW is supported by an American Legion Auxiliary Fellowship.	Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Humbert PO, 2000, GENE DEV, V14, P690; Hunt CR, 2007, CANCER RES, V67, P3010, DOI 10.1158/0008-5472.CAN-06-4328; Karaa A, 2007, INT J DERMATOL, V46, P671, DOI 10.1111/j.1365-4632.2007.03260.x; Kinzler KW, 1997, NATURE, V386, P763; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mandel HG, 2002, FOOD CHEM TOXICOL, V40, P1231, DOI 10.1016/S0278-6915(02)00093-5; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Veltman JA, 2003, CANCER RES, V63, P2872; Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	36	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4954	4961		10.1038/onc.2008.138	http://dx.doi.org/10.1038/onc.2008.138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469863	Bronze			2022-12-25	WOS:000258596900009
J	Grether-Beck, S; Salahshour-Fard, M; Timmer, A; Brenden, H; Felsner, I; Walli, R; Fullekrug, J; Krutmann, J				Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Fuellekrug, J.; Krutmann, J.			Ceramide and raft signaling are linked with each other in UVA radiation-induced gene expression	ONCOGENE			English	Article						signaling; UVA; rafts; ceramide	LEMLI-OPITZ-SYNDROME; CONGENITAL PHOTOSENSITIVITY SYNDROME; LIPID RAFTS; ACID SPHINGOMYELINASE; BIOLOGICAL-SYSTEMS; PLASMA-MEMBRANE; INSULIN-RECEPTOR; CELL-MEMBRANES; DNA-SEQUENCE; CHOLESTEROL	Solar ultraviolet A (UVA) (320-400 nm) radiation-induced gene expression in keratinocytes is initiated at the level of the cell membrane via generation of singlet oxygen and subsequent formation of ceramide from sphingomyelin. We now report that the UVA response also involves raft signaling and that ceramide and raft signaling are linked with each other. Upon UVA irradiation, the lipid composition of rafts decreased 40% in sphingomyelin and 60% in cholesterol (Chol). Also, decrease of Chol increased the susceptibility towards UVA-induced gene expression, whereas increase of Chol completely abolished their capacity to generate signaling ceramides and to mount the subsequent UVA response. This inhibition was not associated with UVA-induced Chol oxidation and was also seen after treatment of cells with plant sterols. The UVA responsiveness depended on the ratio of Chol versus ceramide in rafts. A ratio smaller than 1 permitted initiation and transduction of the signaling response, whereas a ratio greater than 1, for example, upon sterol pretreatment, abolished this response, indicating that UVA radiation-induced ceramide signaling is controlled by the lipid composition of rafts.	[Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Krutmann, J.] Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; [Fuellekrug, J.] Heidelberg Univ, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Grether-Beck, S (corresponding author), Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	grether-beck@uni-duesseldorf.de	Füllekrug, Joachim/A-6581-2008					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anstey AV, 1999, J AM ACAD DERMATOL, V41, P121, DOI 10.1016/S0190-9622(99)70420-2; Anstey AV, 1999, BRIT J DERMATOL, V141, P406; Azurdia RM, 2001, BRIT J DERMATOL, V144, P143, DOI 10.1046/j.1365-2133.2001.03964.x; BACHOWSKI GJ, 1988, LIPIDS, V23, P580, DOI 10.1007/BF02535601; BATTA AK, 1995, J LIPID RES, V36, P705; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Charman CR, 1998, BRIT J DERMATOL, V138, P885; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Girotti AW, 1998, J LIPID RES, V39, P1529; GIROTTI AW, 1992, J PHOTOCH PHOTOBIO B, V13, P105, DOI 10.1016/1011-1344(92)85050-5; Girotti AW, 2000, METHOD ENZYMOL, V319, P85; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Grether-Beck S, 2005, J INVEST DERMATOL, V125, P545, DOI 10.1111/j.0022-202X.2005.23782.x; Grether-Beck S, 2003, J BIOL CHEM, V278, P47498, DOI 10.1074/jbc.M309511200; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Gulbins E, 2006, AM J PHYSIOL-REG I, V290, pR11, DOI 10.1152/ajpregu.00416.2005; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Johnston I, 2006, LANGMUIR, V22, P11284, DOI 10.1021/la061636s; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Korytowski W, 1999, PHOTOCHEM PHOTOBIOL, V70, P484; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Reiterer G, 2005, J NUTR, V135, P2114, DOI 10.1093/jn/135.9.2114; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Schmuth M, 2004, J INVEST DERMATOL, V123, P41, DOI 10.1111/j.0022-202X.2004.22707.x; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarz T, 2005, EXP DERMATOL, V14, P788, DOI 10.1111/j.1600-0625.2005.0355g.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Tyrrell RM, 2006, PROG BIOPHYS MOL BIO, V92, P86, DOI 10.1016/j.pbiomolbio.2006.02.002; Tyrrell RM, 2004, ANTIOXID REDOX SIGN, V6, P835, DOI 10.1089/1523086041798033; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; Wolf C, 1996, J LIPID RES, V37, P1325; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	64	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4768	4778		10.1038/onc.2008.116	http://dx.doi.org/10.1038/onc.2008.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438433				2022-12-25	WOS:000258445100002
J	Braem, C; Recolin, B; Rancourt, RC; Angiolini, C; Barthes, P; Branchu, P; Court, F; Cathala, G; Ferguson-Smith, AC; Forne, T				Braem, Caroline; Recolin, Benedicte; Rancourt, Rebecca C.; Angiolini, Christopher; Barthes, Pauline; Branchu, Priscillia; Court, Franck; Cathala, Guy; Ferguson-Smith, Anne C.; Forne, Thierry			Genomic matrix attachment region and chromosome conformation capture quantitative real time PCR assays identify novel putative regulatory elements at the imprinted Dlk1/Gtl2 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENES; CHROMATIN; DOMAIN; GTL2; IGF2; H19; IDENTIFICATION; TRANSCRIPTS; ANTISENSE; MICE	We previously showed that genomic imprinting regulates matrix attachment region activities at the mouse Igf2 (insulin-like growth factor 2) locus and that these activities are functionally linked to neighboring differentially methylated regions (DMRs). Here, we investigate the similarly structured Dlk1/Gtl2 imprinted domain and show that in the mouse liver, the G/C-rich intergenic germ line-derived DMR, a sequence involved in domain-wide imprinting, is highly retained within the nuclear matrix fraction exclusively on the methylated paternal copy, reflecting its differential function on that chromosome. Therefore, not only "classical" A/T-rich matrix attachment region (MAR) sequences but also other important regulatory DNA elements (such as DMRs) can be recovered from genomic MAR assays following a high salt treatment. Interestingly, the recovery of one A/T-rich sequence (MAR4) from the "nuclear matrix" fraction is strongly correlated with gene expression. We show that this element possesses an intrinsic activity that favors transcription, and using chromosome conformation capture quantitative real time PCR assays, we demonstrate that the MAR4 interacts with the intergenic germ line-derived DMR specifically on the paternal allele but not with the Dlk1/Gtl2 promoters. Altogether, our findings shed a new light on gene regulation at this locus.	[Braem, Caroline; Recolin, Benedicte; Barthes, Pauline; Branchu, Priscillia; Court, Franck; Cathala, Guy; Forne, Thierry] Univ Montpellier 2, CNRS, UMR 5535, Inst Genet Mol,IGMM,IFR 122, F-34293 Montpellier 5, France; [Rancourt, Rebecca C.; Angiolini, Christopher; Ferguson-Smith, Anne C.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Cambridge	Forne, T (corresponding author), Univ Montpellier 2, CNRS, UMR 5535, Inst Genet Mol,IGMM,IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	forne@igmm.cnrs.fr	Ferguson-Smith, Anne C/G-7534-2011; Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; Rancourt, Rebecca/0000-0003-2696-7220; court, franck/0000-0003-0327-9708; Branchu, Priscilla/0000-0002-8127-1181; Ferguson-Smith, Anne/0000-0002-7608-5894	MRC [G0701196] Funding Source: UKRI; Cancer Research UK Funding Source: Medline; Medical Research Council [G0701196] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; da Rocha ST, 2007, DEV BIOL, V306, P810, DOI 10.1016/j.ydbio.2007.02.043; Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060; Freking BA, 2002, GENOME RES, V12, P1496, DOI 10.1101/gr.571002; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Kanduri C, 2006, EMBO J, V25, P2096, DOI 10.1038/sj.emboj.7601090; Kono T, 2004, NATURE, V428, P860, DOI 10.1038/nature02402; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Lin SP, 2007, DEVELOPMENT, V134, P417, DOI 10.1242/dev.02726; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Lutfalla G, 2006, METHOD ENZYMOL, V410, P386, DOI 10.1016/S0076-6879(06)10019-1; Mancini-DiNardo D, 2006, GENE DEV, V20, P1268, DOI 10.1101/gad.1416906; Milligan L, 2002, EMBO REP, V3, P774, DOI 10.1093/embo-reports/kvf142; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Paulsen M, 2001, GENOME RES, V11, P2085, DOI 10.1101/gr.206901; Purbowasito N, 2004, DNA RES, V11, P391, DOI 10.1093/dnares/11.6.391; RAGHUNANDAN R, 2008, STEM CELLS IN PRESS, V17; Schmidt JV, 2000, GENE DEV, V14, P1997; Schuster-Gossler K, 1998, DEV DYNAM, V212, P214, DOI 10.1002/(SICI)1097-0177(199806)212:2<214::AID-AJA6>3.0.CO;2-K; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smit M, 2003, GENETICS, V163, P453; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Takeda H, 2006, P NATL ACAD SCI USA, V103, P8119, DOI 10.1073/pnas.0602844103; Tierling S, 2006, GENOMICS, V87, P225, DOI 10.1016/j.ygeno.2005.09.018; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Weber M, 2005, PROG MOLEC, V38, P207; Weber M, 2003, MOL CELL BIOL, V23, P8953, DOI 10.1128/MCB.23.24.8953-8959.2003; Weber ML, 2003, ANAL BIOCHEM, V320, P252, DOI 10.1016/S0003-2697(03)00396-8	33	26	26	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18612	18620		10.1074/jbc.M801883200	http://dx.doi.org/10.1074/jbc.M801883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458080	Green Published, hybrid			2022-12-25	WOS:000257165600017
J	Popolo, L; Ragni, E; Carotti, C; Palomares, O; Aardema, R; Back, JW; Dekker, HL; de Koning, LJ; de Jong, L; de Koster, CG				Popolo, Laura; Ragni, Enrico; Carotti, Cristina; Palomares, Oscar; Aardema, Ronald; Back, Jaap Willem; Dekker, Henk L.; de Koning, Leo J.; de Jong, Luitzen; de Koster, Chris G.			Disulfide bond structure and domain organization of yeast beta(1,3)-glucanosyltransferases involved in cell wall biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING MODULES; SECONDARY STRUCTURE PREDICTION; ANCHORED PROTEIN GP115; AMINO-ACID-SEQUENCE; SERINE-RICH REGION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; OLIVE POLLEN; ASPERGILLUS-FUMIGATUS; ALLERGENIC ACTIVITY	The Gel/Gas/Phr family of fungal beta(1,3)-glucanosyltransferases plays an important role in cell wall biogenesis by processing the main component beta(1,3)-glucan. Two subfamilies are distinguished depending on the presence or absence of a C-terminal cysteine-rich domain, denoted "Cys-box." The N-terminal domain (NtD) contains the catalytic residues for transglycosidase activity and is separated from the Cys-box by a linker region. To obtain a better understanding of the structure and function of the Cys-box-containing subfamily, we identified the disulfide bonds in Gas2p from Saccharomyces cerevisiae by an improved mass spectrometric methodology. We mapped two separate intra-domain clusters of three and four disulfide bridges. One of the bonds in the first cluster connects a central Cys residue of the NtD with a single conserved Cys residue in the linker. Site-directed mutagenesis of the Cys residue in the linker resulted in an endoplasmic reticulum precursor that was not matured and underwent a gradual degradation. The relevant disulfide bond has a crucial role in folding as it may stabilize the NtD and facilitate its interaction with the C-terminal portion of a Gas protein. The four disulfide bonds in the Cys-box are arranged in a manner consistent with a partial structural resemblance with the plant X8 domain, an independent carbohydrate-binding module that possesses only three disulfide bonds. Deletion of the Cys-box in Gas2 or Gas1 proteins led to the formation of an NtD devoid of any enzymatic activity. The results suggest that the Cys-box is required for proper folding of the NtD and/or substrate binding.	[Popolo, Laura; Ragni, Enrico; Carotti, Cristina] Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; [Palomares, Oscar] Univ Complutense, Fac Ciencias Quim, Dept Bioquim & Biol Mol, Madrid 28040, Spain; [Aardema, Ronald; Back, Jaap Willem; Dekker, Henk L.; de Koning, Leo J.; de Jong, Luitzen; de Koster, Chris G.] Univ Amsterdam, Swammerdam Inst Life Sci, Biomol Mass Spectrometry Grp, NL-1018 WV Amsterdam, Netherlands	University of Milan; Complutense University of Madrid; University of Amsterdam	Popolo, L (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy.	Laura.Popolo@unimi.it	B, Jw/N-7879-2019; de Jong, Luitzen/E-7882-2011; Back, JW/B-3641-2009; Palomares, Oscar/ABG-5229-2020; Ragni, Enrico/J-4292-2015; de Koning, Leo/HHC-2065-2022; Aardema, Ronald/C-2973-2008; Popolo, Laura/B-1173-2017	B, Jw/0000-0002-1310-4373; Back, JW/0000-0002-1310-4373; Ragni, Enrico/0000-0003-0272-7417; Palomares, Oscar/0000-0003-4516-0369; Popolo, Laura/0000-0002-5590-0167; de Koster, Chris/0000-0003-2872-2796				Barral P, 2005, BIOCHEM J, V390, P77, DOI 10.1042/BJ20050456; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Carotti C, 2004, EUR J BIOCHEM, V271, P3635, DOI 10.1111/j.1432-1033.2004.04297.x; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; De Bernardis F, 1998, INFECT IMMUN, V66, P3317, DOI 10.1128/IAI.66.7.3317-3325.1998; de Koning LJ, 2006, FEBS J, V273, P281, DOI 10.1111/j.1742-4658.2005.05053.x; de Medina-Redondo M, 2008, MOL MICROBIOL, V68, P1283, DOI 10.1111/j.1365-2958.2008.06233.x; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fonzi WA, 1999, J BACTERIOL, V181, P7070, DOI 10.1128/JB.181.22.7070-7079.1999; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gallegos-Perez JL, 2005, ANAL BIOCHEM, V346, P311, DOI 10.1016/j.ab.2005.08.003; GATTI E, 1994, J BIOL CHEM, V269, P19695; Hartland RP, 1996, J BIOL CHEM, V271, P26843, DOI 10.1074/jbc.271.43.26843; Hirayama H, 2008, J BIOCHEM, V143, P555, DOI 10.1093/jb/mvm249; Hong TY, 2002, MICROBIOL-SGM, V148, P1151, DOI 10.1099/00221287-148-4-1151; Huecas S, 2001, J BIOL CHEM, V276, P27959, DOI 10.1074/jbc.M103041200; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Johansson P, 2004, PLANT CELL, V16, P874, DOI 10.1105/tpc.020065; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Klis FM, 2006, YEAST, V23, P185, DOI 10.1002/yea.1349; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lesage G, 2004, GENETICS, V167, P35, DOI 10.1534/genetics.167.1.35; Lesage G, 2006, MICROBIOL MOL BIOL R, V70, P317, DOI 10.1128/MMBR.00038-05; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mouyna I, 2005, MOL MICROBIOL, V56, P1675, DOI 10.1111/j.1365-2958.2005.04654.x; Mouyna I, 2000, BIOCHEM J, V347, P741, DOI 10.1042/0264-6021:3470741; NAKAGAWA S, 1994, J AM CHEM SOC, V116, P5513, DOI 10.1021/ja00091a083; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; Palomares O, 2003, BIOCHEM J, V369, P593, DOI 10.1042/BJ20020423; Palomares O, 2005, CLIN EXP ALLERGY, V35, P345, DOI 10.1111/j.1365-2222.2004.02186.x; Papaleo E, 2006, J MOL MODEL, V12, P237, DOI 10.1007/s00894-005-0025-7; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; Popolo L, 1997, J BACTERIOL, V179, P463, DOI 10.1128/jb.179.2.463-469.1997; Ragni E, 2007, YEAST, V24, P297, DOI 10.1002/yea.1473; Ragni E, 2007, EUKARYOT CELL, V6, P302, DOI 10.1128/EC.00321-06; Rees D. A., 1982, POLYSACCHARIDES, P196; REES DA, 1971, J CHEM SOC B, P469, DOI 10.1039/j29710000469; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Sunna A, 2001, BIOCHEM J, V356, P791, DOI 10.1042/0264-6021:3560791; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; Trevino MA, 2008, PROTEIN SCI, V17, P371, DOI 10.1110/ps.073230008; VAI M, 1991, J BIOL CHEM, V266, P12242; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; Valdivieso MH, 2000, J BACTERIOL, V182, P4752, DOI 10.1128/JB.182.17.4752-4757.2000; Wu J, 1997, PROTEIN SCI, V6, P391; Wu Jiang, 2002, Methods Mol Biol, V194, P1; Yin QY, 2007, FEMS YEAST RES, V7, P887, DOI 10.1111/j.1567-1364.2007.00272.x; Yin QY, 2005, J BIOL CHEM, V280, P20894, DOI 10.1074/jbc.M500334200; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	55	29	35	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18553	18565		10.1074/jbc.M801562200	http://dx.doi.org/10.1074/jbc.M801562200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18468997	hybrid, Green Published			2022-12-25	WOS:000257165600011
J	Strohecker, AM; Yehiely, F; Chen, F; Cryns, VL				Strohecker, Anne M.; Yehiely, Fruma; Chen, Feng; Cryns, Vincent L.			Caspase cleavage of HER-2 releases a bad-like cell death effector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; POSTTRANSLATIONAL N-MYRISTOYLATION; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; BREAST-CANCER CELLS; INDUCED APOPTOSIS; BH3-ONLY PROTEINS; BH3 DOMAIN; PROMOTES APOPTOSIS; CD95 FAS/APO-1	Human epidermal growth factor receptor-2 (HER-2/ErbB2/neu), a receptor tyrosine kinase that is amplified/overexpressed in poor prognosis breast carcinomas, confers resistance to apoptosis by activating cell survival pathways. Here we demonstrate that the cytoplasmic tail of HER-2 is cleaved by caspases at Asp(1016)/Asp(1019) to release a similar to 47-kDa product, which is subsequently proteolyzed by caspases at Asp(1125) into an unstable 22-kDa fragment that is degraded by the proteasome and a predicted 25-kDa product. Both the 47- and 25-kDa products translocate to mitochondria, release cytochrome c by a Bcl-x(L)-suppressible mechanism, and induce caspase-dependent apoptosis. The 47- and 25-kDa HER-2 cleavage products share a functional BH3-like domain, which is required for cytochrome c release in cells and isolated mitochondria and for apoptosis induction. Caspase-cleaved HER-2 binds Bcl-x(L) and acts synergistically with truncated Bid to induce apoptosis, mimicking the actions of the BH3-only protein Bad. Moreover, the HER-2 cleavage products cooperate with Noxa to induce apoptosis in cells expressing both Bcl-x(L) and Mcl-1, confirming their Bad-like function. Collectively, our results indicate that caspases activate a previously unrecognized proapoptotic function of HER-2 by releasing a Bad-like cell death effector.	[Cryns, Vincent L.] Northwestern Univ, Feinberg Sch Med, Dept Med, Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Cell Death Regulat Lab, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Cell Death Regulat Lab, Lurie 4-113,303 E Super St, Chicago, IL 60611 USA.	v-cryns@northwestern.edu		Cryns, Vincent/0000-0003-0355-2268	NATIONAL CANCER INSTITUTE [R01CA097198] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 097198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen F, 2004, J BIOL CHEM, V279, P27542, DOI 10.1074/jbc.M400971200; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cuello M, 2001, CANCER RES, V61, P4892; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Sakurai N, 2006, J BIOL CHEM, V281, P14288, DOI 10.1074/jbc.M510338200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wong L, 1999, J BIOL CHEM, V274, P8900, DOI 10.1074/jbc.274.13.8900; Yang XH, 2001, CANCER RES, V61, P348; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	60	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18269	18282		10.1074/jbc.M802156200	http://dx.doi.org/10.1074/jbc.M802156200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18420586	Green Published, hybrid			2022-12-25	WOS:000256949200055
J	Woodley, DT; Hou, YP; Martin, S; Li, W; Chen, M				Woodley, David T.; Hou, Yingping; Martin, Sabrina; Li, Wei; Chen, Mei			Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VII COLLAGEN GENE; EPIDERMAL GROWTH-FACTOR; ANCHORING FIBRILS; ANTIPARALLEL DIMER; PROCOLLAGEN-VII; NC1 DOMAIN; COL7A1; FORMS; SKIN; SUBSTITUTIONS	Type VII collagen (C7) is a major component of anchoring fibrils, structures that mediate epidermal-dermal adherence. Mutations in gene COL7A1 encoding for C7 cause dystrophic epidermolysis bullosa (DEB), a genetic mechano-bullous disease. The biological consequences of specific COL7A1 mutations and the molecular mechanisms leading to DEB clinical phenotypes are unknown. In an attempt to establish genotype-phenotype relationships, we generated four individual substitution mutations that have been associated with recessive DEB, G2049E, R2063W, G2569R, and G2575R, and purified the recombinant mutant proteins. All mutant proteins were synthesized and secreted as a 290-kDa mutant C7 alpha chain at levels similar to wild type C7. The G2569R and G2575R glycine substitution mutations resulted in mutant C7 with increased sensitivity to protease degradation and decreased ability to form trimers. Limited proteolytic digestion of mutant G2049E and R2063W proteins yielded aberrant fragments and a triple helix with reduced stability. These two mutations next to the 39-amino acid helical interruption hinge region caused local destabilization of the triple-helix that exposed an additional highly sensitive proteolytic site within the region of the mutation. Our functional studies demonstrated that C7 is a potent pro-motility matrix for skin human keratinocyte migration and that this activity resides within the triple helical domain. Furthermore, G2049E and R2063W mutations reduced the ability of C7 to support fibroblast adhesion and keratinocyte migration. We conclude that known recessive DEB C7 mutations perturb critical functions of the C7 molecule and likely contribute to the clinical phenotypes of DEB patients.	[Woodley, David T.; Hou, Yingping; Martin, Sabrina; Li, Wei; Chen, Mei] Univ So Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90033 USA	University of Southern California	Woodley, DT (corresponding author), Univ So Calif, Keck Sch Med, Dept Dermatol, Rm 6322,1441 Eastlake Ave, Los Angeles, CA 90033 USA.	dwoodley@usc.edu; chenm@usc.edu			NIAMS NIH HHS [R01 AR 47981, R01 AR 33625] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625, R01AR047981] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; Brittingham R, 2005, J BIOL CHEM, V280, P191, DOI 10.1074/jbc.M406210200; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; Chen M, 1999, EXP CELL RES, V249, P231, DOI 10.1006/excr.1999.4473; Chen M, 2002, J BIOL CHEM, V277, P2118, DOI 10.1074/jbc.M108779200; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chen M, 1997, J INVEST DERMATOL, V108, P125, DOI 10.1111/1523-1747.ep12332300; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Gardella R, 2002, J INVEST DERMATOL, V119, P1456, DOI 10.1046/j.1523-1747.2002.19606.x; Goto M, 2006, J INVEST DERMATOL, V126, P2614, DOI 10.1038/sj.jid.5700435; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; Hovnanian A, 1997, AM J HUM GENET, V61, P599, DOI 10.1086/515495; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; Jarvikallio A, 1997, HUM MUTAT, V10, P338; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAPIERE JC, 1994, J INVEST DERMATOL, V103, P637, DOI 10.1111/1523-1747.ep12398270; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P2, DOI 10.1111/1523-1747.ep12462409; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PUKKINEN L, 1999, MATRIX BIOL, V18, P29; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P373; UITTO J, 1993, SEMIN DERMATOL, V12, P191; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1995, P ASSOC AM PHYSICIAN, V107, P245; UITTO J, 1994, ARCH DERMATOL RES, V287, P16, DOI 10.1007/BF00370713; UITTO J, 1992, J INVEST DERMATOL, V38, P391; Varki R, 2007, J MED GENET, V44, P181, DOI 10.1136/jmg.2006.045302; Woodley DT, 2007, MOL THER, V15, P628, DOI 10.1038/sj.mt.6300041; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118	40	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17838	17845		10.1074/jbc.M709452200	http://dx.doi.org/10.1074/jbc.M709452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450758	Green Published, hybrid			2022-12-25	WOS:000256949200011
J	Harris, EN; Weigel, JA; Weigel, PH				Harris, Edward N.; Weigel, Janet A.; Weigel, Paul H.			The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPATIC SINUSOIDAL ENDOTHELIUM; MOLECULAR-WEIGHT HEPARINS; CHONDROITIN SULFATE; SCAVENGER RECEPTOR; TISSUE FACTOR; MEDIATED ENDOCYTOSIS; BINDING-PROTEINS; FACTOR-XA; CLASS-B	The hyaluronic acid receptor for endocytosis (HARE; also designated Stabilin-2) mediates systemic clearance of hyaluronan and chondroitin sulfates from the vascular and lymphatic circulations. The internalized glycosaminoglycans are degraded in lysosomes, thus completing their normal turnover process. Sinusoidal endothelial cells of human liver, lymph node, and spleen express two HARE isoforms of 315 and 190 kDa. Here we report that the 190- and 315-kDa HARE isoforms, expressed stably either in Flp-In 293 cell lines or as soluble ectodomains, specifically bind heparin (Hep). The K-d for Hep binding to purified 190- and 315-kDa HARE ectodomains was 17.2 +/- 4.9 and 23.4 +/- 5.3 nM, respectively. Cells expressing HARE readily and specifically internalized I-125-streptavidin-biotin-Hep complexes, which was inhibited > 70% by hyperosmolar conditions, confirming that uptake is mediated by the clathrin-coated pit pathway. Internalization of Hep occurred for many hours with an estimated HARE recycling time of similar to 12 min. Internalized fluorescent streptavidin-biotin-Hep was present in a typical endocytic vesicular pattern and was delivered to lysosomes. We conclude that HARE in the sinusoidal endothelial cells of lymph nodes and liver likely mediates the efficient systemic clearance of Hep and many different Hep-binding protein complexes from the lymphatic and vascular circulations.	[Harris, Edward N.; Weigel, Janet A.; Weigel, Paul H.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; [Harris, Edward N.; Weigel, Janet A.; Weigel, Paul H.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu	Harris, Edward N/A-1596-2011		NIGMS NIH HHS [GM69961, R01 GM069961] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069961] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Bame KJ, 1998, BIOCHEM J, V336, P191, DOI 10.1042/bj3360191; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; BARZU T, 1986, BIOCHEM J, V238, P847, DOI 10.1042/bj2380847; BARZU T, 1987, THROMB RES, V47, P601, DOI 10.1016/0049-3848(87)90365-3; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugatti A, 2007, ANTIMICROB AGENTS CH, V51, P2337, DOI 10.1128/AAC.01362-06; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; Delputte PL, 2002, J VIROL, V76, P4312, DOI 10.1128/JVI.76.9.4312-4320.2002; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dinwoodey DL, 2006, CLIN GERIATR MED, V22, P1, DOI 10.1016/j.cger.2005.09.007; Drzeniek Z, 1999, BLOOD, V93, P2884; ENJYOJI K, 1995, BIOCHEMISTRY-US, V34, P5725, DOI 10.1021/bi00017a004; Falkowski M, 2003, HISTOCHEM CELL BIOL, V120, P361, DOI 10.1007/s00418-003-0585-5; Gustafson S, 1997, GLYCOCONJUGATE J, V14, P561, DOI 10.1023/A:1018528308132; Hansen B, 2005, EXP CELL RES, V303, P160, DOI 10.1016/j.yexcr.2004.09.017; Harris EN, 2007, J BIOL CHEM, V282, P2785, DOI 10.1074/jbc.M607787200; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIEBERT L, 1981, THROMB RES, V21, P383, DOI 10.1016/0049-3848(81)90139-0; Hirsh J, 2004, CHEST, V126, p188S, DOI 10.1378/chest.126.3_suppl.188S; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Howard MJ, 2002, J BIOL CHEM, V277, P32320, DOI 10.1074/jbc.M203631200; Jacobs LG, 2003, J AM GERIATR SOC, V51, P1472, DOI 10.1046/j.1532-5415.2003.51469.x; Jung MY, 2007, J LEUKOCYTE BIOL, V82, P1156, DOI 10.1189/jlb.0107052; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; Kyosseva SV, 2008, J BIOL CHEM, V283, P15047, DOI 10.1074/jbc.M709921200; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LINDAHL U, 1990, BIOCHEM SOC T, V18, P803, DOI 10.1042/bst0180803; MAHADOO J, 1978, THROMB RES, V12, P79, DOI 10.1016/0049-3848(78)90087-7; Mahtouk K, 2005, ONCOGENE, V24, P3512, DOI 10.1038/sj.onc.1208536; Malerod L, 2002, CELL TISSUE RES, V307, P173, DOI 10.1007/s00441-001-0476-9; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; McGary CT, 2003, METHOD ENZYMOL, V363, P354; Mentz S, 1999, J NEUROCHEM, V72, P980, DOI 10.1046/j.1471-4159.1999.0720980.x; Mousa Shaker A, 2005, Future Oncol, V1, P395, DOI 10.1517/14796694.1.3.395; Nakamura T, 2000, BIOL PHARM BULL, V23, P743; Norrby K, 2006, APMIS, V114, P79, DOI 10.1111/j.1600-0463.2006.apm_235.x; Oie CI, 2008, AM J PHYSIOL-GASTR L, V294, pG520, DOI 10.1152/ajpgi.00489.2007; OKA JA, 1989, J BIOL CHEM, V264, P12016; OKA JA, 1988, J CELL BIOCHEM, V36, P169, DOI 10.1002/jcb.240360208; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; PRAANINGVANDALEN DP, 1981, GASTROENTEROLOGY, V81, P1036; Price GC, 2004, ANAESTHESIA, V59, P483, DOI 10.1111/j.1365-2044.2004.03679.x; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; Savage JM, 2001, J CELL PHYSIOL, V187, P283, DOI 10.1002/jcp.1076; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Ulbrich SE, 2004, MOL CELL ENDOCRINOL, V214, P9, DOI 10.1016/j.mce.2003.12.002; Urano K, 1997, BIOL PHARM BULL, V20, P680; Weigel JA, 2003, J BIOL CHEM, V278, P42802, DOI 10.1074/jbc.M307201200; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1980, J BIOL CHEM, V255, P6111; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009; YU Q, 1995, BIOTECHNIQUES, V19, P122; Yuasa Hiroaki, 2003, Drug Metab Pharmacokinet, V18, P273, DOI 10.2133/dmpk.18.273; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	72	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17341	17350		10.1074/jbc.M710360200	http://dx.doi.org/10.1074/jbc.M710360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434317	Green Published, hybrid			2022-12-25	WOS:000256720600043
J	Lomonaco, SL; Kahana, S; Blass, M; Brody, Y; Okhrimenko, H; Xiang, C; Finniss, S; Blumberg, PM; Lee, HK; Brodie, C				Lomonaco, Stephanie L.; Kahana, Sarit; Blass, Michal; Brody, Yehuda; Okhrimenko, Hana; Xiang, Cunli; Finniss, Susan; Blumberg, Peter M.; Lee, Hae-Kyung; Brodie, Chaya			Phosphorylation of protein kinase C delta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1 - Role in the apoptotic effect of etoposide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; PKC-DELTA; PHYSIOLOGICAL FUNCTIONS; MAPK PHOSPHATASE-1; SIGNALING PATHWAYS; GLIOMA-CELLS; P38 MAPK; SURVIVAL; INVOLVEMENT; OVEREXPRESSION	The mechanism underlying the important role of protein kinase C delta (PKC delta) in the apoptotic effect of etoposide in glioma cells is incompletely understood. Here, we examined the role of PKC delta in the activation of Erk1/2 by etoposide. We found that etoposide induced persistent activation of Erk1/2 and nuclear translocation of phospho-Erk1/2. MEK1 inhibitors decreased the apoptotic effect of etoposide, whereas inhibitors of p38 and JNK did not. The activation of Erk1/2 by etoposide was downstream of PKC delta since the phosphorylation of Erk1/2 was inhibited by a PKC delta-KD mutant and PKC delta small interfering RNA. We recently reported that phosphorylation of PKC delta on tyrosines 64 and 187 was essential for the apoptotic effect of etoposide. Using PKC delta tyrosine mutants, we found that the phosphorylation of PKC delta on these tyrosine residues, but not on tyrosine 155, was also essential for the activation of Erk1/2 by etoposide. In contrast, nuclear translocation of PKC delta was independent of its tyrosine phosphorylation and not necessary for the phosphorylation of Erk1/2. Etoposide induced down-regulation of kinase phosphatase-1 (MKP-1), which correlated with persistent phosphorylation of Erk1/2 and was dependent on the tyrosine phosphorylation of PKC delta. Moreover, silencing of MKP-1 increased the phosphorylation of Erk1/2 and the apoptotic effect of etoposide. Etoposide induced polyubiquitylation and degradation of MKP-1 that was dependent on PKC delta and on its tyrosine phosphorylation. These results indicate that distinct phosphorylation of PKC delta on tyrosines 64 and 187 specifically activates the Erk1/2 pathway by the down-regulation of MKP-1, resulting in the persistent phosphorylation of Erk1/2 and cell apoptosis.	[Lomonaco, Stephanie L.; Xiang, Cunli; Finniss, Susan; Lee, Hae-Kyung; Brodie, Chaya] Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, William & Karen Davidson Lab Cell Signaling & Tum, Detroit, MI 48202 USA; [Kahana, Sarit; Blass, Michal; Brody, Yehuda; Okhrimenko, Hana; Brodie, Chaya] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel; [Blumberg, Peter M.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA	Henry Ford Health System; Henry Ford Hospital; Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brodie, C (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, William & Karen Davidson Lab Cell Signaling & Tum, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nscha@neuro.hfh.edu			NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270, R01CA109196] Funding Source: NIH RePORTER; NCI NIH HHS [CA109196] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Choi BH, 2006, J CELL SCI, V119, P1329, DOI 10.1242/jcs.02837; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gomel R, 2007, MOL CANCER RES, V5, P627, DOI 10.1158/1541-7786.MCR-06-0255; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Jun CD, 1999, J IMMUNOL, V162, P3395; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Lin YW, 2003, J BIOL CHEM, V278, P21534, DOI 10.1074/jbc.M301854200; Lu W, 2007, CELL SIGNAL, V19, P2165, DOI 10.1016/j.cellsig.2007.06.015; Lu W, 2007, BIOCHEM BIOPH RES CO, V352, P431, DOI 10.1016/j.bbrc.2006.11.028; Okhrimenko H, 2005, J BIOL CHEM, V280, P23643, DOI 10.1074/jbc.M501374200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; SHAUL YD, 2006, BIOCHIM BIOPHYS ACTA, V1773, P1213; Short MD, 2006, MOL BIOL CELL, V17, P1995, DOI 10.1091/mbc.E05-09-0869; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Vauzour D, 2007, J NEUROCHEM, V103, P1355, DOI 10.1111/j.1471-4159.2007.04841.x; Venugopal SK, 2007, J BIOL CHEM, V282, P31900, DOI 10.1074/jbc.M703729200; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zheng YL, 2007, MOL BIOL CELL, V18, P404, DOI 10.1091/mbc.E06-09-0851; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	48	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17731	17739		10.1074/jbc.M801727200	http://dx.doi.org/10.1074/jbc.M801727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434324	Green Published, hybrid			2022-12-25	WOS:000256720600079
J	Zhang, AS; Yang, F; Meyer, K; Hernandez, C; Chapman-Arvedson, T; Bjorkman, PJ; Enns, CA				Zhang, An-Sheng; Yang, Fan; Meyer, Kathrin; Hernandez, Catalina; Chapman-Arvedson, Tara; Bjorkman, Pamela J.; Enns, Caroline A.			Neogenin-mediated hemojuvelin shedding occurs after hemojuvelin traffics to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-METABOLISM; CELL-SURFACE; EXPRESSION PATTERN; PROTEIN; MOUSE; HEPCIDIN; RECEPTOR; GENE; MOLECULE; ACTIVATION	HFE2 (hemochromatosis type 2 gene) is highly expressed in skeletal muscle and liver hepatocytes. Its encoded protein, hemojuvelin (HJV), is a co-receptor for the bone morphogenetic proteins 2 and 4 (BMP2 and BMP4) and enhances the BMP-induced hepcidin expression. Hepcidin is a central iron regulatory hormone predominantly secreted from hepatocytes. HJV also binds neogenin, a membrane protein widely expressed in many tissues. Neogenin is required for the processing and release of HJV from cells. The role that neogenin plays in HJV trafficking was investigated, using HepG2 cells, a human hepatoma cell line. Knockdown of endogenous neogenin markedly suppresses HJV release but has no evident effect on HJV trafficking to the plasma membrane. The addition of a soluble neogenin ectodomain to cells markedly inhibits HJV release, indicating that the HJV shedding is not processed before trafficking to the cell surface. At the plasma membrane it undergoes endocytosis in a dynamin-independent but cholesterol-dependent manner. The additional findings that HJV release is coupled to lysosomal degradation of neogenin and that cholesterol depletion by filipin blocks both HJV endocytosis and HJV release suggest that neogenin-mediated HJV release occurs after the HJV-neogenin complex is internalized from the cell surface.	[Zhang, An-Sheng; Meyer, Kathrin; Hernandez, Catalina; Enns, Caroline A.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; [Yang, Fan; Bjorkman, Pamela J.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Bjorkman, Pamela J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Chapman-Arvedson, Tara] Amgen Inc, Thousand Oaks, CA 91320 USA	Oregon Health & Science University; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Amgen	Zhang, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhanga@ohsu.edu	Zhu, Ren-Yuan/V-8966-2019; Yang, Fan/GYU-4249-2022	Zhu, Ren-Yuan/0000-0003-3091-7461; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054488, R37DK054488, R01DK080765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54488, DK080765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2007, J CLIN INVEST, V117, P1933, DOI 10.1172/JCI31342; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; Chadda R, 2007, TRAFFIC, V8, P702, DOI 10.1111/j.1600-0854.2007.00565.x; Cole SJ, 2007, INT J BIOCHEM CELL B, V39, P1569, DOI 10.1016/j.biocel.2006.11.009; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Huang FW, 2005, J CLIN INVEST, V115, P2187, DOI 10.1172/JCI25049; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Kuninger D, 2006, J CELL SCI, V119, P3273, DOI 10.1242/jcs.03074; Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845; Lin L, 2008, BLOOD CELL MOL DIS, V40, P122, DOI 10.1016/j.bcmd.2007.06.023; Lin L, 2007, BLOOD, V110, P2182, DOI 10.1182/blood-2007-04-087593; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Mawdsley DJ, 2004, DEV BIOL, V269, P302, DOI 10.1016/j.ydbio.2004.02.001; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Silvestri L, 2007, BLOOD, V109, P4503, DOI 10.1182/blood-2006-08-041004; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; VanSlyke JK, 2005, MOL BIOL CELL, V16, P5247, DOI 10.1091/mbc.E05-05-0415; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Wilson MD, 2001, NUCLEIC ACIDS RES, V29, P1352, DOI 10.1093/nar/29.6.1352; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Yang F, 2008, BIOCHEMISTRY-US, V47, P4237, DOI 10.1021/bi800036h; Zhang AS, 2007, J BIOL CHEM, V282, P12547, DOI 10.1074/jbc.M608788200; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2005, J BIOL CHEM, V280, P33885, DOI 10.1074/jbc.M506207200	51	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17494	17502		10.1074/jbc.M710527200	http://dx.doi.org/10.1074/jbc.M710527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445598	Green Published, hybrid			2022-12-25	WOS:000256720600057
J	Kolodziejczyk, A; Sun, XJ; Meinertzhagen, IA; Nassel, DR				Kolodziejczyk, Agata; Sun, Xuejun; Meinertzhagen, Ian A.; Nassel, Dick R.			Glutamate, GABA and Acetylcholine Signaling Components in the Lamina of the Drosophila Visual System	PLOS ONE			English	Article							CHLORIDE CHANNEL SUBUNITS; CHOLINE-ACETYLTRANSFERASE; NERVOUS-SYSTEM; OPTIC LOBE; IMMUNOCYTOCHEMICAL LOCALIZATION; SYNAPTIC POPULATIONS; ACID DECARBOXYLASE; MUSCA-DOMESTICA; LIGAND-BINDING; WILD-TYPE	Synaptic connections of neurons in the Drosophila lamina, the most peripheral synaptic region of the visual system, have been comprehensively described. Although the lamina has been used extensively as a model for the development and plasticity of synaptic connections, the neurotransmitters in these circuits are still poorly known. Thus, to unravel possible neurotransmitter circuits in the lamina of Drosophila we combined Gal4 driven green fluorescent protein in specific lamina neurons with antisera to gamma-aminobutyric acid (GABA), glutamic acid decarboxylase, a GABA(B) type of receptor, L-glutamate, a vesicular glutamate transporter (vGluT), ionotropic and metabotropic glutamate receptors, choline acetyltransferase and a vesicular acetylcholine transporter. We suggest that acetylcholine may be used as a neurotransmitter in both L4 monopolar neurons and a previously unreported type of wide-field tangential neuron (Cha-Tan). GABA is the likely transmitter of centrifugal neurons C2 and C3 and GABA(B) receptor immunoreactivity is seen on these neurons as well as the Cha-Tan neurons. Based on an rdl-Gal4 line, the ionotropic GABA(A) receptor subunit RDL may be expressed by L4 neurons and a type of tangential neuron (rdl-Tan). Strong vGluT immunoreactivity was detected in alpha-processes of amacrine neurons and possibly in the large monopolar neurons L1 and L2. These neurons also express glutamate-like immunoreactivity. However, antisera to ionotropic and metabotropic glutamate receptors did not produce distinct immunosignals in the lamina. In summary, this paper describes novel features of two distinct types of tangential neurons in the Drosophila lamina and assigns putative neurotransmitters and some receptors to a few identified neuron types.	[Kolodziejczyk, Agata; Nassel, Dick R.] Stockholm Univ, Dept Zool, S-10691 Stockholm, Sweden; [Sun, Xuejun; Meinertzhagen, Ian A.] Dalhousie Univ, Life Sci Ctr, Halifax, NS, Canada	Stockholm University; Dalhousie University	Kolodziejczyk, A (corresponding author), Stockholm Univ, Dept Zool, S-10691 Stockholm, Sweden.	dnassel@zoologi.su.se	Kolodziejczyk, Agata Maria/AAI-9174-2020	Kolodziejczyk, Agata Maria/0000-0002-7030-3555; Meinertzhagen, Ian/0000-0002-6578-4526	Swedish Research Council [VR 621-2004-3715]; NIH [EY-03592]; NATIONAL EYE INSTITUTE [R01EY003592] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the Swedish Research Council (VR 621-2004-3715 to DRN) and by NIH grant EY-03592 (to IAM).	BARBER RP, 1989, J COMP NEUROL, V280, P533, DOI 10.1002/cne.902800404; Barth M, 1997, J NEUROSCI, V17, P1493; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; BICKER G, 1988, J NEUROSCI, V8, P2108; Bogdanik L, 2004, J NEUROSCI, V24, P9105, DOI 10.1523/JNEUROSCI.2724-04.2004; BOSCHEK CB, 1971, Z ZELLFORSCH MIK ANA, V118, P369; BRAITENBERG V, 1967, EXP BRAIN RES, V3, P271; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUCHNER E, 1986, CELL TISSUE RES, V246, P57; BUCHNER E, 1988, CELL TISSUE RES, V253, P357, DOI 10.1007/BF00222292; Chen KY, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-1; Clandinin TR, 2002, NEURON, V35, P827, DOI 10.1016/S0896-6273(02)00876-0; COOMBE PE, 1989, J COMP PHYSIOL A, V166, P23, DOI 10.1007/BF00190206; Daniels RW, 2008, J COMP NEUROL, V508, P131, DOI 10.1002/cne.21670; Daniels RW, 2004, J NEUROSCI, V24, P10466, DOI 10.1523/JNEUROSCI.3001-04.2004; DATUM KH, 1986, J COMP PHYSIOL A, V159, P241, DOI 10.1007/BF00612306; DATUM KH, 1989, CELL TISSUE RES, V256, P153; Douglass JK, 2005, VISUAL NEUROSCI, V22, P345, DOI 10.1017/S095252380522309X; Douglass JK, 2003, MICROSC RES TECHNIQ, V62, P132, DOI 10.1002/jemt.10367; Douglass JK, 2007, J COMP PHYSIOL A, V193, P233, DOI 10.1007/s00359-006-0185-7; Enell L, 2007, J COMP NEUROL, V505, P18, DOI 10.1002/cne.21472; Eroglu C, 2003, P NATL ACAD SCI USA, V100, P10219, DOI 10.1073/pnas.1737042100; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; Featherstone DE, 2000, NEURON, V27, P71, DOI 10.1016/S0896-6273(00)00010-6; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Gorska-Andrzejak J, 2005, PHOTOCH PHOTOBIO SCI, V4, P721, DOI 10.1039/b417023g; Hamasaka Y, 2005, J NEUROBIOL, V65, P225, DOI 10.1002/neu.20184; Hamasaka Y, 2007, J COMP NEUROL, V505, P32, DOI 10.1002/cne.21471; Hardie R.C., 1989, P235; HARDIE RC, 1987, J COMP PHYSIOL A, V161, P201, DOI 10.1007/BF00615241; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; HARRISON JB, 1995, J NEUROENDOCRINOL, V7, P347, DOI 10.1111/j.1365-2826.1995.tb00768.x; HAUSER H, 1975, THESIS E KARLS U TUB; HEPLER JR, 1988, J HISTOCHEM CYTOCHEM, V36, P13, DOI 10.1177/36.1.2891743; Hiesinger PR, 2006, CURR BIOL, V16, P1835, DOI 10.1016/j.cub.2006.07.047; Hiesinger PR, 2001, J COMP NEUROL, V429, P277, DOI 10.1002/1096-9861(20000108)429:2<277::AID-CNE8>3.0.CO;2-8; Homberg U, 2002, MICROSC RES TECHNIQ, V56, P189, DOI 10.1002/jemt.10024; Hosie AM, 1997, TRENDS NEUROSCI, V20, P578, DOI 10.1016/S0166-2236(97)01127-2; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; JACKSON FR, 1990, J NEUROCHEM, V54, P1068, DOI 10.1111/j.1471-4159.1990.tb02359.x; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; JANSONIUS NM, 1993, J COMP PHYSIOL A, V173, P187, DOI 10.1007/BF00192977; JARVILEHTO M, 1973, Z ZELLFORSCH MIK ANA, V136, P291, DOI 10.1007/BF00307446; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; JONAS PE, 1994, J NEUROBIOL, V25, P1494, DOI 10.1002/neu.480251203; Juusola M, 1996, TRENDS NEUROSCI, V19, P292, DOI 10.1016/S0166-2236(96)10028-X; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kitamoto T, 2000, J NEUROBIOL, V42, P161, DOI 10.1002/(SICI)1097-4695(20000205)42:2<161::AID-NEU1>3.0.CO;2-P; Kitamoto T, 1998, J BIOL CHEM, V273, P2706, DOI 10.1074/jbc.273.5.2706; Klemm N, 1976, Prog Neurobiol, V7, P99, DOI 10.1016/0301-0082(76)90014-9; LAUGHLIN SB, 1989, J EXP BIOL, V144, P113; Lee RC, 2003, NAT NEUROSCI, V6, P557, DOI 10.1038/nn1063; MADL JE, 1986, J HISTOCHEM CYTOCHEM, V34, P317, DOI 10.1177/34.3.2419390; Mahr A, 2006, GENE EXPR PATTERNS, V6, P299, DOI 10.1016/j.modgep.2005.07.006; Meinertzhagen I. A., 1996, Society for Neuroscience Abstracts, V22, P655; Meinertzhagen I A, 2001, Prog Brain Res, V131, P53; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; MEINERTZHAGEN IA, 1993, PROG RETIN RES, V12, P13, DOI 10.1016/0278-4327(93)90003-C; Meinertzhagen IA, 1999, MICROSC RES TECHNIQ, V45, P96, DOI 10.1002/(SICI)1097-0029(19990415)45:2<96::AID-JEMT4>3.0.CO;2-L; Meinertzhagen IA, 2000, EUR J NEUROSCI, V12, P1342, DOI 10.1046/j.1460-9568.2000.00033.x; Meinertzhagen Ian A., 1993, P1363; MELAMED J, 1967, J ULTRA MOL STRUCT R, V21, P313, DOI 10.1016/S0022-5320(67)80098-4; MEYER EP, 1986, HISTOCHEMISTRY, V84, P207, DOI 10.1007/BF00495784; Mezler M, 2001, EUR J NEUROSCI, V13, P477, DOI 10.1046/j.1460-9568.2001.01410.x; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Nassel DR, 2006, CELL TISSUE RES, V326, P1, DOI 10.1007/s00441-006-0210-8; NASSEL DR, 1991, PROG NEUROBIOL, V37, P179, DOI 10.1016/0301-0082(91)90027-X; NASSEL DR, 1988, CELL TISSUE RES, V253, P639; Nassel DR, 2002, PROG NEUROBIOL, V68, P1, DOI 10.1016/S0301-0082(02)00057-6; Ng M, 2002, NEURON, V36, P463, DOI 10.1016/S0896-6273(02)00975-3; NICOL D, 1982, J COMP NEUROL, V207, P29, DOI 10.1002/cne.902070104; Okabe S, 1999, J NEUROSCI, V19, P7781; Panneels V, 2003, PROTEIN EXPRES PURIF, V30, P275, DOI 10.1016/S1046-5928(03)00100-1; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; Prokop A, 2006, SEMIN CELL DEV BIOL, V17, P20, DOI 10.1016/j.semcdb.2005.11.010; PYZA E, 1995, J NEUROSCI, V15, P407; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Rister J, 2007, NEURON, V56, P155, DOI 10.1016/j.neuron.2007.09.014; Salvaterra Paul M., 2001, Gene Expression Patterns, V1, P73, DOI 10.1016/S1567-133X(01)00011-4; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SARTHY PV, 1991, J NEUROCHEM, V57, P1757, DOI 10.1111/j.1471-4159.1991.tb06378.x; Sattelle DB, 2005, BIOESSAYS, V27, P366, DOI 10.1002/bies.20207; SATTELLE DB, 1991, NEUROCHEM RES, V16, P363, DOI 10.1007/BF00966100; SCHUSTER R, 1993, J COMP NEUROL, V335, P149, DOI 10.1002/cne.903350202; SHAW SR, 1986, P NATL ACAD SCI USA, V83, P7961, DOI 10.1073/pnas.83.20.7961; SHAW SR, 1981, NEURONES IMPULSES, P61; Sinakevitch I, 2004, J COMP NEUROL, V468, P6, DOI 10.1002/cne.10929; Sinakevitch I, 2003, J COMP NEUROL, V467, P150, DOI 10.1002/cne.10925; STRAUSFELD NJ, 1977, SCIENCE, V195, P894, DOI 10.1126/science.841315; STRAUSFELD NJ, 1971, Z ZELLFORSCH MIK ANA, V121, P377, DOI 10.1007/BF00337640; STRAUSFELD NJ, 1980, HDB SENSORY PHYSL, P1; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; Stuart AE, 2007, PROG NEUROBIOL, V82, P202, DOI 10.1016/j.pneurobio.2007.03.006; Takagawa K, 1996, NEUROSCI RES, V24, P237, DOI 10.1016/0168-0102(95)00999-X; TRUJILLO.O, 1965, J ULTRA MOL STRUCT R, V13, P1, DOI 10.1016/S0022-5320(65)80086-7; ULTSCH A, 1993, FEBS LETT, V324, P171, DOI 10.1016/0014-5793(93)81387-F; UUSITALO RO, 1995, J NEUROPHYSIOL, V73, P1782, DOI 10.1152/jn.1995.73.5.1782; Warrant E, 2006, INVERTEBRATE VISION, pXIX; Wilson RI, 2005, J NEUROSCI, V25, P9069, DOI 10.1523/JNEUROSCI.2070-05.2005; Witte I, 2002, J NEUROCHEM, V83, P504, DOI 10.1046/j.1471-4159.2002.01076.x; Yasuyama K, 1996, J NEUROBIOL, V30, P205, DOI 10.1002/(SICI)1097-4695(199606)30:2<205::AID-NEU3>3.0.CO;2-9; Yasuyama K, 1999, MICROSC RES TECHNIQ, V45, P65, DOI 10.1002/(SICI)1097-0029(19990415)45:2<65::AID-JEMT2>3.0.CO;2-0; YASUYAMA K, 1995, J COMP NEUROL, V361, P25, DOI 10.1002/cne.903610103; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200	104	82	84	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2110	10.1371/journal.pone.0002110	http://dx.doi.org/10.1371/journal.pone.0002110			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18464935	Green Submitted, Green Published, gold			2022-12-25	WOS:000261642400032
J	Matynia, A; Anagnostaras, SG; Wiltgen, BJ; Lacuesta, M; Fanselow, MS; Silva, AJ				Matynia, Anna; Anagnostaras, Stephan G.; Wiltgen, Brian J.; Lacuesta, Maress; Fanselow, Michael S.; Silva, Alcino J.			A High Through-Put Reverse Genetic Screen Identifies Two Genes Involved in Remote Memory in Mice	PLOS ONE			English	Article								Previous studies have revealed that the initial stages of memory formation require several genes involved in synaptic, transcriptional and translational mechanisms. In contrast, very little is known about the molecular and cellular mechanisms underlying later stages of memory, including remote memory (i.e. 7-day memory). To identify genes required for remote memory, we screened randomly selected mouse strains harboring known mutations. In our primary reverse genetic screen, we identified 4 putative remote memory mutant strains out of a total of 54 lines analyzed. Additionally, we found 11 other mutant strains with other abnormal profiles. Secondary screens confirmed that mutations of integrin beta 2 (Itg beta 2) and steryl-O-acyl transferase 1 (Soat1) specifically disrupted remote memory. This study identifies some of the first genes required for remote memory, and suggests that screens of targeted mutants may be an efficient strategy to identify molecular requirements for this process.	[Matynia, Anna; Anagnostaras, Stephan G.; Lacuesta, Maress; Silva, Alcino J.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; [Matynia, Anna; Anagnostaras, Stephan G.; Lacuesta, Maress; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; [Wiltgen, Brian J.; Fanselow, Michael S.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Matynia, A (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA.	alcinojsilva@gmail.com	Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Anagnostaras, Stephan/0000-0002-6906-1181; Silva, Alcino/0000-0001-5525-0494	 [RO1 MH61094];  [P50 MH077972]; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH077972, R01MH061094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013622] Funding Source: NIH RePORTER	; ; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a grant to AJS and MSF (RO1 MH61094) and P50 MH077972 to AJS.	Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; Apicelli AJ, 2003, GLIA, V42, P225, DOI 10.1002/glia.10214; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; Berman DE, 2001, SCIENCE, V291, P2417, DOI 10.1126/science.1058165; Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Cook MN, 2007, MAMM GENOME, V18, P559, DOI 10.1007/s00335-007-9035-3; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Fanselow MS, 2000, BEHAV BRAIN RES, V110, P73, DOI 10.1016/S0166-4328(99)00186-2; Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Gale GD, 2004, J NEUROSCI, V24, P3810, DOI 10.1523/JNEUROSCI.4100-03.2004; Geinisman Y, 2001, J NEUROSCI, V21, P5568, DOI 10.1523/JNEUROSCI.21-15-05568.2001; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Hayashi ML, 2004, NEURON, V42, P773, DOI 10.1016/j.neuron.2004.05.003; Herrick TM, 2002, DEVELOPMENT, V129, P787; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Jiang MS, 2001, P NATL ACAD SCI USA, V98, P3577, DOI 10.1073/pnas.051632598; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104; MAKRYDIMAS G, 1995, PRENATAL DIAG, V15, P325, DOI 10.1002/pd.1970150405; Matynia A, 2002, ANNU REV GENET, V36, P687, DOI 10.1146/annurev.genet.36.062802.091007; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; PAYLOR R, 1994, BEHAV NEUROSCI, V108, P810, DOI 10.1037/0735-7044.108.4.810; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Reijmers LG, 2006, LEARN MEMORY, V13, P143, DOI 10.1101/lm.98606; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; Sayah DM, 2000, MOL PSYCHIATR, V5, P369, DOI 10.1038/sj.mp.4000742; Schmitz G, 2001, NEUROCHEM RES, V26, P1045, DOI 10.1023/A:1012357106398; Shema R, 2007, SCIENCE, V317, P951, DOI 10.1126/science.1144334; Silva AJ, 1996, CURR BIOL, V6, P1509, DOI 10.1016/S0960-9822(96)00756-7; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; TAYLOR GM, 1988, CLIN EXP IMMUNOL, V71, P324; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wehner J. M., 1996, MENTAL RETARDATION D, V2, P243, DOI DOI 10.1002/(SICI)1098-2779(1996)2:4<243::AID-; Wiltgen BJ, 2007, LEARN MEMORY, V14, P313, DOI 10.1101/lm.430907; Wolfer DP, 2002, TRENDS NEUROSCI, V25, P336, DOI 10.1016/S0166-2236(02)02192-6; Wollmer MA, 2003, MOL PSYCHIATR, V8, P635, DOI 10.1038/sj.mp.4001296; YAMAMOTO T, 1994, BEHAV BRAIN RES, V65, P123, DOI 10.1016/0166-4328(94)90097-3; YAMAMOTO T, 1995, NEUROSCI RES, V22, P31, DOI 10.1016/0168-0102(95)00875-T	56	22	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2121	10.1371/journal.pone.0002121	http://dx.doi.org/10.1371/journal.pone.0002121			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18464936	Green Published, gold			2022-12-25	WOS:000261642400042
J	Rudrappa, T; Splaine, RE; Biedrzycki, ML; Bais, HP				Rudrappa, Thimmaraju; Splaine, Robert E.; Biedrzycki, Meredith L.; Bais, Harsh P.			Cyanogenic Pseudomonads Influence Multitrophic Interactions in the Rhizosphere	PLOS ONE			English	Article							BIOFILM FORMATION; CYANIDE PRODUCTION; BACILLUS-SUBTILIS; CAENORHABDITIS-ELEGANS; MASTER REGULATOR; AERUGINOSA; GROWTH; AUXIN; RHIZOBACTERIA; BIOCONTROL	In the rhizosphere, plant roots cope with both pathogenic and beneficial bacterial interactions. The exometabolite production in certain bacterial species may regulate root growth and other root-microbe interactions in the rhizosphere. Here, we elucidated the role of cyanide production in pseudomonad virulence affecting plant root growth and other rhizospheric processes. Exposure of Arabidopsis thaliana Col-0 seedlings to both direct (with KCN) and indirect forms of cyanide from different pseudomonad strains caused significant inhibition of primary root growth. Further, we report that this growth inhibition was caused by the suppression of an auxin responsive gene, specifically at the root tip region by pseudomonad cyanogenesis. Additionally, pseudomonad cyanogenesis also affected other beneficial rhizospheric processes such as Bacillus subtilis colonization by biofilm formation on A. thaliana Col-0 roots. The effect of cyanogenesis on B. subtilis biofilm formation was further established by the down regulation of important B. subtilis biofilm operons epsA and yqxM. Our results show, the functional significance of pseudomonad cyanogenesis in regulating multitrophic rhizospheric interactions.	[Rudrappa, Thimmaraju; Splaine, Robert E.; Biedrzycki, Meredith L.; Bais, Harsh P.] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19717 USA; [Rudrappa, Thimmaraju; Splaine, Robert E.; Biedrzycki, Meredith L.; Bais, Harsh P.] Delaware Biotechnol Inst, Newark, DE USA	University of Delaware	Rudrappa, T (corresponding author), Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19717 USA.	hbais@udel.edu	Rechsteiner, Cynthia/C-5894-2011		University of Delaware; EPSCoR	University of Delaware; EPSCoR(National Science Foundation (NSF)NSF - Office of the Director (OD))	HPB acknowledges the University of Delaware and EPSCoR for faculty start-up grant. RES acknowledges the Science and Engineering program at University of Delaware for the undergraduate research funding support.	Albury MS, 1996, J BIOL CHEM, V271, P17062, DOI 10.1074/jbc.271.29.17062; ALSTROM S, 1989, BIOL FERT SOILS, V7, P232, DOI 10.1007/BF00709654; [Anonymous], [No title captured]; Antoun H, 1998, PLANT SOIL, V204, P57, DOI 10.1023/A:1004326910584; ASKELAND RA, 1983, APPL ENVIRON MICROB, V45, P1802, DOI 10.1128/AEM.45.6.1802-1807.1983; AUDUS LJ, 1960, ENCY PLANT PHYSL 2, V12, P360; Bais HP, 2004, PLANT PHYSIOL, V134, P307, DOI 10.1104/pp.103.028712; Ballhorn DJ, 2005, J CHEM ECOL, V31, P1445, DOI 10.1007/s10886-005-5791-2; Bano N, 2003, CURR MICROBIOL, V46, P324, DOI 10.1007/s00284-002-3857-8; BEGONIA MFT, 1994, FEMS MICROBIOL ECOL, V15, P227, DOI 10.1111/j.1574-6941.1994.tb00246.x; Blumer C, 2000, ARCH MICROBIOL, V173, P170, DOI 10.1007/s002039900127; BONNER J, 1952, ANNU REV PLANT PHYS, V3, P59, DOI 10.1146/annurev.pp.03.060152.000423; Branda SS, 2006, MOL MICROBIOL, V59, P1229, DOI 10.1111/j.1365-2958.2005.05020.x; Branda SS, 2004, J BACTERIOL, V186, P3970, DOI 10.1128/JB.186.12.3970-3979.2004; Branda SS, 2001, P NATL ACAD SCI USA, V98, P11621, DOI 10.1073/pnas.191384198; Brinker A.M., 1989, PHYTOCHEMISTRY B, V21, P24; Britigan BE, 1999, INFECT IMMUN, V67, P1207, DOI 10.1128/IAI.67.3.1207-1212.1999; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; BUDZIKIEWICZ H, 1993, FEMS MICROBIOL LETT, V104, P209, DOI 10.1111/j.1574-6968.1993.tb05868.x; CALDOGNO FR, 1978, CELLULAR MOL LIFE SC, V34, P1948; Casimiro I, 2001, PLANT CELL, V13, P843, DOI 10.1105/tpc.13.4.843; Castric P.A., 1981, CYANIDE BIOL, P233; CASTRIC PA, 1977, J BACTERIOL, V130, P826, DOI 10.1128/JB.130.2.826-831.1977; Chu F, 2006, MOL MICROBIOL, V59, P1216, DOI 10.1111/j.1365-2958.2005.05019.x; De Vleesschauwer D, 2006, MOL PLANT MICROBE IN, V19, P1406, DOI 10.1094/MPMI-19-1406; Fu XD, 2003, NATURE, V421, P740, DOI 10.1038/nature01387; Fukaki H, 2007, INT REV CYTOL, V256, P111, DOI 10.1016/S0074-7696(07)56004-3; Gallagher LA, 2001, J BACTERIOL, V183, P6207, DOI 10.1128/JB.183.21.6207-6214.2001; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; GROSSMANN K, 1995, PLANT GROWTH REGUL, V16, P183, DOI 10.1007/BF00029539; Grossmann K, 2003, J PLANT GROWTH REGUL, V22, P109, DOI 10.1007/s00344-003-0020-0; Hamon MA, 2004, MOL MICROBIOL, V52, P847, DOI 10.1111/j.1365-2958.2004.04023.x; Hayden KJ, 2002, EVOL ECOL RES, V4, P155; Jander G, 2000, J BACTERIOL, V182, P3843, DOI 10.1128/JB.182.13.3843-3845.2000; Jandhyala D, 2003, APPL ENVIRON MICROB, V69, P4794, DOI 10.1128/AEM.69.8.4794-4805.2003; Kearns DB, 2005, MOL MICROBIOL, V55, P739, DOI 10.1111/j.1365-2958.2004.04440.x; KNOWLES CJ, 1986, ADV MICROB PHYSIOL, V27, P73, DOI 10.1016/S0065-2911(08)60304-5; Kremer RJ, 2001, CURR MICROBIOL, V43, P182, DOI 10.1007/s002840010284; Kremer RJ, 1996, WEED TECHNOL, V10, P601, DOI 10.1017/S0890037X00040525; Laville J, 1998, J BACTERIOL, V180, P3187, DOI 10.1128/JB.180.12.3187-3196.1998; LEONOVA LA, 1985, J PLANT GROWTH REGUL, V4, P169, DOI 10.1007/BF02266954; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Olvera C, 1999, FEMS MICROBIOL LETT, V179, P85, DOI 10.1111/j.1574-6968.1999.tb08712.x; Pessi G, 2000, J BACTERIOL, V182, P6940, DOI 10.1128/JB.182.24.6940-6949.2000; Raghavendra AS, 2003, TRENDS PLANT SCI, V8, P546, DOI 10.1016/j.tplants.2003.09.015; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rennert T, 2002, J ENVIRON QUAL, V31, P745, DOI 10.2134/jeq2002.0745; RODGERS PB, 1978, J GEN MICROBIOL, V108, P261, DOI 10.1099/00221287-108-2-261; RUDRAPPA T, 2007, PLANT SIGNAL BEHAV, V2, pE1; RUDRAPPA T, 2007, PLANT SIGNAL BEHAV, V2, P5; Rudrappa T, 2007, PLANTA, V226, P283, DOI 10.1007/s00425-007-0480-8; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SIEDOW JN, 2000, BIOCHIM BIOPHYS ACTA, V15, P432; Silo-Suh L, 2002, P NATL ACAD SCI USA, V99, P15699, DOI 10.1073/pnas.242343999; Tattersall DB, 2001, SCIENCE, V293, P1826, DOI 10.1126/science.1062249; Taylor LP, 2005, CURR OPIN PLANT BIOL, V8, P317, DOI 10.1016/j.pbi.2005.03.005; Terada LS, 1999, INFECT IMMUN, V67, P2371, DOI 10.1128/IAI.67.5.2371-2376.1999; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Umbach AL, 2006, BBA-BIOENERGETICS, V1757, P135, DOI 10.1016/j.bbabio.2005.12.005; VINING LC, 1990, ANNU REV MICROBIOL, V44, P395, DOI 10.1146/annurev.mi.44.100190.002143; VOISARD C, 1994, MOLECULAR ECOLOGY OF RHIZOSPHERE MICROORGANISMS, P67, DOI 10.1002/9783527615810.ch6; Walker TS, 2004, PLANT PHYSIOL, V134, P320, DOI 10.1104/pp.103.027888; Wood WB, 1988, NEMATODE CAENORHABDI; Zeller SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000846; Zlosnik JEA, 2004, LETT APPL MICROBIOL, V38, P360, DOI 10.1111/j.1472-765X.2004.01489.x	67	29	30	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2073	10.1371/journal.pone.0002073	http://dx.doi.org/10.1371/journal.pone.0002073			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446201	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300042
J	Van Raam, BJ; Sluiter, W; de Wit, E; Roos, D; Verhoeven, AJ; Kuijpers, TW				Van Raam, Bram J.; Sluiter, Wim; de Wit, Elly; Roos, Dirk; Verhoeven, Arthur J.; Kuijpers, Taco W.			Mitochondrial Membrane Potential in Human Neutrophils Is Maintained by Complex III Activity in the Absence of Supercomplex Organisation	PLOS ONE			English	Article								Background: Neutrophils depend mainly on glycolysis for their energy provision. Their mitochondria maintain a membrane potential (Delta psi(m)), which is usually generated by the respiratory chain complexes. We investigated the source of Dym in neutrophils, as compared to peripheral blood mononuclear leukocytes and HL-60 cells, and whether neutrophils can still utilise this Dym for the generation of ATP. Methods and Principal Findings: Individual activity of the oxidative phosphorylation complexes was significantly reduced in neutrophils, except for complex II and V, but Dym was still decreased by inhibition of complex III, confirming the role of the respiratory chain in maintaining Dym. Complex V did not maintain Dym by consumption of ATP, as has previously been suggested for eosinophils. We show that complex III in neutrophil mitochondria can receive electrons from glycolysis via the glycerol-3-phosphate shuttle. Furthermore, respiratory supercomplexes, which contribute to efficient coupling of the respiratory chain to ATP synthesis, were lacking in neutrophil mitochondria. When HL-60 cells were differentiated to neutrophil-like cells, they lost mitochondrial supercomplex organisation while gaining increased aerobic glycolysis, just like neutrophils. Conclusions: We show that neutrophils can maintain Dym via the glycerol-3-phosphate shuttle, whereby their mitochondria play an important role in the regulation of aerobic glycolysis, rather than producing energy themselves. This peculiar mitochondrial phenotype is acquired during differentiation from myeloid precursors.	[Van Raam, Bram J.; Roos, Dirk; Verhoeven, Arthur J.; Kuijpers, Taco W.] Sanquin Res & Landsteiner Lab, Dept Blood Cell Res, Amsterdam, Netherlands; [Van Raam, Bram J.; Kuijpers, Taco W.] Univ Amsterdam, Dept Paediat Immunol, Academ Med Ctr, Emma Childrens Hosp, Amsterdam, Netherlands; [Sluiter, Wim; de Wit, Elly] Erasmus MC, Mitochondrial Res Unit, Dept Biochem, Rotterdam, Netherlands	University of Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC	Van Raam, BJ (corresponding author), Sanquin Res & Landsteiner Lab, Dept Blood Cell Res, Amsterdam, Netherlands.	a.verhoeven@sanquin.nl	van Raam, Bram/C-4121-2011	van Raam, Bram/0000-0002-6500-2731	Nederlandse Organisatie voor Wetenschappelijk Onderzoek [917.46.319]	Nederlandse Organisatie voor Wetenschappelijk Onderzoek(Netherlands Organization for Scientific Research (NWO)European Commission)	This work was supported by a grant from the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO-Vidi scheme 917.46.319). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; BERKICH DA, 1991, J BIOL CHEM, V266, P123; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Boekema EJ, 2007, J BIOL CHEM, V282, P1, DOI 10.1074/jbc.R600031200; BORREGAARD N, 1982, J CLIN INVEST, V70, P550, DOI 10.1172/JCI110647; Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729; D'Aurelio M, 2006, HUM MOL GENET, V15, P2157, DOI 10.1093/hmg/ddl141; de Wit LEA, 2007, J IMMUNOL METHODS, V326, P76, DOI 10.1016/j.jim.2007.07.009; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964; Gao YQ, 2005, CELL, V123, P195, DOI 10.1016/j.cell.2005.10.001; Genova Maria Luisa, 2003, Ital J Biochem, V52, P58; Kuijpers TW, 2004, BLOOD, V103, P3915, DOI 10.1182/blood-2003-11-3940; Lefebvre-Legendre L, 2003, MOL MICROBIOL, V47, P1329, DOI 10.1046/j.1365-2958.2003.03371.x; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Maianski NA, 2004, CELL DEATH DIFFER, V11, P143, DOI 10.1038/sj.cdd.4401320; Matmati M, 2007, J LEUKOCYTE BIOL, V81, P440, DOI 10.1189/jlb.0406276; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Nicholls DG, 2006, J BIOL CHEM, V281, P14864, DOI 10.1074/jbc.M510916200; Peachman KK, 2001, P NATL ACAD SCI USA, V98, P1717, DOI 10.1073/pnas.98.4.1717; Peyssonnaux C, 2004, CELL CYCLE, V3, P168; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; Roos D, 1986, Methods Enzymol, V132, P225; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schagger H, 2001, J BIOL CHEM, V276, P37861; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006	38	102	107	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2013	10.1371/journal.pone.0002013	http://dx.doi.org/10.1371/journal.pone.0002013			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431494	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700029
J	Weldingh, K; Andersen, P				Weldingh, Karin; Andersen, Peter			ESAT-6/CFP10 Skin Test Predicts Disease in M-tuberculosis-Infected Guinea Pigs	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; SUBUNIT VACCINE; ANTIGENS; DIAGNOSIS; PROTEIN; FUSION; CATTLE; GAMMA	Background: Targeted preventive chemotherapy of individuals with progressive subclinical (incipient) disease before it becomes contagious would break the chain of tuberculosis transmission in high endemic regions. We have studied the ability of a skin test response to ESAT-6 and CFP10 (E6/C10) to predict later development of tuberculosis disease in the guinea pig model. Methods and Findings: Guinea pigs, either vaccinated with BCG or unvaccinated, were infected with a low dose of Mycobacterium tuberculosis by the aerosol route and the development of delayed type hypersensitivity responses to E6/C10 and to purified protein derivative (PPD) were followed until the onset of clinical disease. We demonstrated a negative correlation between the size of the skin test response and the time to the onset of clinical disease; a large E6/C10 skin test response correlated to a shorter survival time post skin testing, while a small E6/C10 skin test reaction correlated with a longer survival time (r = 20.6 and P < 0.0001). No correlation was found using PPD. Conclusions: Our data suggest that it may be possible to develop a prognostic skin test based on E6/C10 that will allow the identification of individuals with incipient disease, who have the highest risk of developing active tuberculosis in the near future.	[Weldingh, Karin; Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark	Statens Serum Institut	Weldingh, K (corresponding author), Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark.	kwe@ssi.dk		Andersen, Peter/0000-0002-5869-2551				ANDERSEN P, 1995, J IMMUNOL, V154, P3359; Andersen P, 2007, TRENDS MOL MED, V13, P175, DOI 10.1016/j.molmed.2007.03.004; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; AREND SM, 2007, TUBERCULOSIS ED 1221; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Buddle BM, 1999, CLIN DIAGN LAB IMMUN, V6, P1; Dietrich J, 2005, J IMMUNOL, V174, P6332, DOI 10.4049/jimmunol.174.10.6332; Doherty TM, 2005, CLIN MICROBIOL REV, V18, P687, DOI 10.1128/CMR.18.4.687-702.2005; Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002; Harboe M, 1998, INFECT IMMUN, V66, P717, DOI 10.1128/IAI.66.2.717-723.1998; Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49; Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004; Orme IM, 2001, TRENDS MICROBIOL, V9, P115, DOI 10.1016/S0966-842X(00)01949-1; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Shi L, 2004, INFECT IMMUN, V72, P2420, DOI 10.1128/IAI.72.4.2420-2424.2004; Styblo K, 1980, Adv Tuberc Res, V20, P1; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000; Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002; Whalen CC, 2005, JAMA-J AM MED ASSOC, V293, P2785, DOI 10.1001/jama.293.22.2785; *WHO, 2006, GLOB TUB CONTR SURV; WHO/UNAIDS, 1999, WEEKLY EPIDEMIOLOGIC, V74, P385; Williams A, 2005, TUBERCULOSIS, V85, P29, DOI 10.1016/j.tube.2004.09.009	25	26	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1978	10.1371/journal.pone.0001978	http://dx.doi.org/10.1371/journal.pone.0001978			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431468	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700003
J	Yang, ZJ; Price, CD; Bosco, G; Tucci, M; El-Badri, NS; Mangar, D; Camporesi, EM				Yang, Zhong-Jin; Price, Chrystal D.; Bosco, Gerardo; Tucci, Micheal; El-Badri, Nagwa S.; Mangar, Devanand; Camporesi, Enrico M.			The Effect of Isovolemic Hemodilution with Oxycyte (R), a Perfluorocarbon Emulsion, on Cerebral Blood Flow in Rats	PLOS ONE			English	Article								Background: Cerebral blood flow (CBF) is auto-regulated to meet the brain's metabolic requirements. Oxycyte (R) is a perfluorocarbon emulsion that acts as a highly effective oxygen carrier compared to blood. The aim of this study is to determine the effects of Oxycyte (R) on regional CBF (rCBF), by evaluating the effects of stepwise isovolemic hemodilution with Oxycyte (R) on CBF. Methodology: Male rats were intubated and ventilated with 100% O-2 under isoflurane anesthesia. The regional (striatum) CBF (rCBF) was measured with a laser doppler flowmeter (LDF). Stepwise isovolemic hemodilution was performed by withdrawing 4ml of blood and substituting the same volume of 5% albumin or 2 ml Oxycyte (R) plus 2 ml albumin at 20-minute intervals until the hematocrit (Hct) values reached 5%. Principal Findings: In the albumin-treated group, rCBF progressively increased to approximately twice its baseline level (208 +/- 30%) when Hct levels were less than 10%. In the Oxycyte (R)-treated group on the other hand, rCBF increased by significantly smaller increments, and this group's mean rCBF was only slightly higher than baseline (118 +/- 18%) when Hct levels were less than 10%. Similarly, in the albumin-treated group, rCBF started to increase when hemodilution with albumin caused the CaO2 to decrease below 17.5 ml/dl. Thereafter, the increase in rCBF was accompanied by a nearly proportional decrease in the CaO2 level. In the Oxycyte (R)-treated group, the increase in rCBF was significantly smaller than in the albumin-treated group when the CaO2 level dropped below 10 ml/dl (142 +/- 20% vs. 186 +/- 26%), and rCBF returned to almost baseline levels (106 +/- 15) when the CaO2 level was below 7 ml/dl. Conclusions/Significance: Hemodilution with Oxycyte (R) was accompanied with higher CaO2 and PO2 than control group treated with albumin alone. This effect may be partially responsible for maintaining relatively constant CBF and not allowing the elevated blood flow that was observed with albumin.	[Price, Chrystal D.; El-Badri, Nagwa S.; Mangar, Devanand; Camporesi, Enrico M.] Univ S Florida, Dept Anesthesiol, Tampa, FL USA; [Yang, Zhong-Jin; Tucci, Micheal] SUNY Upstate Med Univ, Dept Anesthesiol, Syracuse, NY USA; [Bosco, Gerardo] Univ G dAnnunzio, Dept Physiol, Chieti, Italy	State University System of Florida; University of South Florida; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; G d'Annunzio University of Chieti-Pescara	Camporesi, EM (corresponding author), Univ S Florida, Dept Anesthesiol, Tampa, FL USA.	ecampore@health.usf.edu		BOSCO, GERARDO/0000-0001-6595-7944	Synthetic Blood International Inc. Costa Mesa, CA	Synthetic Blood International Inc. Costa Mesa, CA	The authors thank Synthetic Blood International Inc (Synthetic Blood International Inc. Costa Mesa, CA) for providing Oxycyte and an education grant that partially supported this work.	Briceno JC, 1997, ASAIO J, V43, P13; Briceno JC, 1999, ASAIO J, V45, P322, DOI 10.1097/00002480-199907000-00013; Cabrales P, 2004, AM J PHYSIOL-HEART C, V287, pH320, DOI 10.1152/ajpheart.01166.2003; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; ECKSTEIN EC, 1989, T AM SOC ART INT ORG, V35, P188; FAITHFULL NS, 1992, BIOMAT ARTIF CELL IM, V20, P797, DOI 10.3109/10731199209119721; Faithfull NS, 2003, ADV EXP MED BIOL, V530, P271; Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007; Hill SE, 2005, ANN THORAC SURG, V80, P1401, DOI 10.1016/j.athoracsur.2005.03.107; HIRAGA S, 1987, CANCER RES, V47, P3296; HOLMAN WL, 1995, J THORAC CARDIOV SUR, V110, P774, DOI 10.1016/S0022-5223(95)70111-7; Jouan-Hureaux V, 2006, TRANSFUSION, V46, P1892, DOI 10.1111/j.1537-2995.2006.01000.x; KEIPERT PE, 1994, ADV EXP MED BIOL, V345, P197; KLINE RA, 1991, AM J SURG, V162, P103, DOI 10.1016/0002-9610(91)90168-D; LEE PA, 1988, AM J PHYSIOL, V254, pH719, DOI 10.1152/ajpheart.1988.254.4.H719; LEE PA, 1986, EXP MED BIOL, V200, P59; Lowe KC, 2001, J FLUORINE CHEM, V109, P59, DOI 10.1016/S0022-1139(01)00374-8; Lowe KC, 1999, BLOOD REV, V13, P171, DOI 10.1054/blre.1999.0113; Nolte D, 2000, ANESTHESIOLOGY, V93, P1261, DOI 10.1097/00000542-200011000-00020; Paxinos G, 1988, RAT BRAIN STEREOTAXI; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; TODD MM, 1994, AM J PHYSIOL-HEART C, V267, pH2025, DOI 10.1152/ajpheart.1994.267.5.H2025; Todd MM, 1997, J CEREBR BLOOD F MET, V17, P1319, DOI 10.1097/00004647-199712000-00007; Tomiyama Y, 1999, AM J PHYSIOL-HEART C, V276, pH1190, DOI 10.1152/ajpheart.1999.276.4.H1190; Tomiyama Y, 2000, AM J PHYSIOL-HEART C, V279, pH1949, DOI 10.1152/ajpheart.2000.279.4.H1949; Tonnesen J, 2005, EXP PHYSIOL, V90, P349, DOI 10.1113/expphysiol.2004.029512; Vocelka C, 1995, J Extra Corpor Technol, V27, P6; WASCHKE KF, 1994, ANESTH ANALG, V79, P874; Woitzik J, 2005, NEUROL RES, V27, P509, DOI 10.1179/016164105X15677; Woitzik J, 2007, J NEUROSURG, V106, P872, DOI 10.3171/jns.2007.106.5.872	30	9	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2010	10.1371/journal.pone.0002010	http://dx.doi.org/10.1371/journal.pone.0002010			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431491	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700026
J	Bae, JB; Mukhopadhyay, SS; Liu, L; Zhang, N; Tan, J; Akhter, S; Liu, X; Shen, X; Li, L; Legerski, RJ				Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Liu, X.; Shen, X.; Li, L.; Legerski, R. J.			Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links	ONCOGENE			English	Article						Snm1B/Apollo; interstrand cross-links; cell cycle checkpoint; ATM	DOUBLE-STRAND BREAKS; FANCONI-ANEMIA PROTEINS; NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MITOMYCIN-C; ATAXIA-TELANGIECTASIA; V(D)J RECOMBINATION; SIGNALING PATHWAYS; DAMAGE CHECKPOINT	The removal of DNA interstrand cross-links (ICLs) has proven to be notoriously complicated due to the involvement of multiple pathways of DNA repair, which include the Fanconi anemia/BRCA pathway, homologous recombination and components of the nucleotide excision and mismatch repair pathways. Members of the SNM1 gene family have also been shown to have a role in mediating cellular resistance to ICLs, although their precise function has remained elusive. Here, we show that knockdown of Snm1B/Apollo in human cells results in hypersensitivity to mitomycin C (MMC), but not to IR. We also show that Snm1B-deficient cells exhibit a defective S phase checkpoint in response to MMC, but not to IR, and this finding may account for the specific sensitivity to the cross-linking drug. Interestingly, although previous studies have largely implicated ATR as the major kinase activated in response to ICLs, we show that it is activation of the ATM-mediated checkpoint that is defective in Snm1B-deficient cells. The requirement for Snm1B in ATM checkpoint activation specifically after ICL damage is correlated with its role in promoting double-strand break formation, and thus replication fork collapse. Consistent with this result Snm1B was found to interact directly with Mus81-Eme1, an endonuclease previously implicated in fork collapse. In addition, we also show that Snm1B interacts with the Mre11-Rad50-Nbs1 (MRN) complex and with FancD2 further substantiating its role as a checkpoint/DNA repair protein.	[Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Legerski, R. J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Liu, X.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Shen, X.; Li, L.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org		mukhopadhyay, sudit/0000-0001-5888-0598	NCI [CA052461, CA097175]; Cancer Center Support (Core) [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA097175, R01CA052461] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support (Core); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tanya Paull and Steve Patrick for the gift of MRN protein, and Jeffrey Parvin for the gift of FancD2 protein. This work was supported by NCI Grants CA052461 and CA097175. DNA sequencing resources were supported by the Cancer Center Support (Core) Grant CA16672.	Ahkter S, 2005, MOL CELL BIOL, V25, P10071, DOI 10.1128/MCB.25.22.10071-10078.2005; Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Akkari YMN, 2001, MOL GENET METAB, V74, P403, DOI 10.1006/mgme.2001.3259; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barber LJ, 2005, MOL CELL BIOL, V25, P2297, DOI 10.1128/MCB.25.6.2297-2309.2005; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chaturvedi P, 2002, CANCER RES, V62, P1797; Demuth I, 2004, ONCOGENE, V23, P8611, DOI 10.1038/sj.onc.1207895; Dominski Z, 2007, CRIT REV BIOCHEM MOL, V42, P67, DOI 10.1080/10409230701279118; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Freibaum BD, 2006, J BIOL CHEM, V281, P15033, DOI 10.1074/jbc.C600038200; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HAASE E, 1989, MOL GEN GENET, V218, P64, DOI 10.1007/BF00330566; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; HENRIQUES JAP, 1980, GENETICS, V95, P273; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Ishiai M, 2004, MOL CELL BIOL, V24, P10733, DOI 10.1128/MCB.24.24.10733-10741.2004; Lambert S, 2005, BIOCHIMIE, V87, P591, DOI 10.1016/j.biochi.2004.10.020; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Li XR, 2005, DNA REPAIR, V4, P163, DOI 10.1016/j.dnarep.2004.08.012; Li XR, 2003, DNA REPAIR, V2, P121, DOI 10.1016/S1568-7864(02)00192-1; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; Mladenov E, 2007, J CELL PHYSIOL, V211, P468, DOI 10.1002/jcp.20957; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pichierri P, 2004, CELL CYCLE, V3, P698; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pichierri P, 2002, HUM MOL GENET, V11, P2531, DOI 10.1093/hmg/11.21.2531; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; RUHLAND A, 1981, MUTAT RES, V91, P457, DOI 10.1016/0165-7992(81)90052-X; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SEYSCHAB H, 1995, BLOOD, V85, P2233, DOI 10.1182/blood.V85.8.2233.bloodjournal8582233; Shen X, 2006, J BIOL CHEM, V281, P13869, DOI 10.1074/jbc.C600071200; Sobeck A, 2006, MOL CELL BIOL, V26, P425, DOI 10.1128/MCB.26.2.425-437.2006; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zheng HY, 2006, DNA REPAIR, V5, P566, DOI 10.1016/j.dnarep.2006.01.010; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	68	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5045	5056		10.1038/onc.2008.139	http://dx.doi.org/10.1038/onc.2008.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469862	Green Accepted			2022-12-25	WOS:000258914800007
J	Bitomsky, N; Wethkamp, N; Marikkannu, R; Klempnauer, KH				Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H			siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression	ONCOGENE			English	Article						Pdcd4; p21(Waf1/Cip1); siRNA; p53; DNA damage response	SUPPRESSOR PROTEIN PDCD4; TERMINAL MA-3 DOMAIN; NF-KAPPA-B; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; ANTISENSE OLIGODEOXYNUCLEOTIDE; GENE-EXPRESSION; P21 WAF1/CIP1; BREAST; P53	The transformation suppressor gene, programmed cell death gene 4 (Pdcd4), inhibits tumor-promoter-mediated transformation of mouse keratinocytes and has been implicated as a tumor suppressor gene in the development of human cancer. The Pdcd4 protein interacts with translation initiation factors eIF4A and eIF4G and binds to RNA, suggesting that it might be involved in regulating protein translation or other aspects of RNA metabolism. To study the function of Pdcd4 in more detail, we have downregulated Pdcd4 expression in HeLa cells by stable expression of shRNA. We have found that diminished Pdcd4 expression leads to increased expression of p21(Waf1/Cip1) and several other p53-regulated genes. Reporter gene studies demonstrate that Pdcd4 interferes with the activation of p53-responsive promoters genes by p53. Pdcd4 knockdown cells show decreased apoptosis and increased survival after UV irradiation. Taken together, our observations suggest a modelin which low Pdcd4 expression after DNA damage favors the survival of cells, which would be eliminated by apoptosis under normal levels of Pdcd4 expression. Our results provide the first evidence that Pdcd4 is important role in the DNA-damage response and suggest that low levels of Pdcd4 expression observed in certain tumor cells contribute to tumorigenesis by affecting the fate of DNA-damaged cells.	[Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Biankin AV, 2001, CANCER RES, V61, P8830; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Fan YP, 2003, MOL CANCER THER, V2, P773; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gao F, 2007, ONCOL REP, V17, P123; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Goke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; JUNG JM, 1995, ONCOGENE, V11, P2021; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Wen YH, 2007, ONCOL REP, V18, P1387; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	62	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4820	4829		10.1038/onc.2008.115	http://dx.doi.org/10.1038/onc.2008.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427550				2022-12-25	WOS:000258445100007
J	Iwasaki, K; Hayashi, K; Fujioka, T; Sobue, K				Iwasaki, Kazuhiro; Hayashi, Ken'ichiro; Fujioka, Tomoaki; Sobue, Kenji			Rho/Rho-associated kinase signal regulates myogenic differentiation via myocardin-related transcription factor-A/Smad-dependent transcription of the Id3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; MYOBLAST DIFFERENTIATION; CELL-DIFFERENTIATION; C2C12 MYOBLASTS; ACTIN DYNAMICS; RHOA GTPASE; MUSCLE; PROTEIN; MYOD; EXPRESSION	RhoA is known to be involved in myogenic differentiation, but whether it acts as a positive or negative regulator is controversial. To resolve this issue, we investigated the differentiation stage-specific roles of RhoA and its effector, Rho-associated kinase, using C2C12 myoblasts. We found that proliferating myoblasts show high levels of RhoA and serum-response factor activities and strong expression of the downstream target of RhoA, myocardin-related transcription factor-A (MRTF-A or MAL); these activities and expression are markedly lower in differentiating myocytes. We further demonstrated that, in proliferating myoblasts, an increase in MRTF-A, which forms a complex with Smad1/4, strikingly activates the expression level of the Id3 gene; the Id3 gene product is a potent inhibitor of myogenic differentiation. Finally, we found that during differentiation, one of the forkhead transcription factors translocates into the nucleus and suppresses Id3 expression by preventing the association of the MRTF-A-Smad complex with the Id3 promoter, which leads to the enhancement of myogenic differentiation. We conclude that RhoA/Rho-associated kinase signaling plays positive and negative roles in myogenic differentiation, mediated by MRTF-A/Smad-dependent transcription of the Id3 gene in a differentiation stage-specific manner.	[Iwasaki, Kazuhiro; Hayashi, Ken'ichiro; Sobue, Kenji] Osaka Univ, Grad Sch Med, Dept Neurosci D13, Suita, Osaka 5650871, Japan; [Iwasaki, Kazuhiro; Fujioka, Tomoaki] Osaka Univ, Grad Sch Med, Res Ctr Child Mental Dev, Suita, Osaka 5650871, Japan; [Sobue, Kenji] Iwate Med Univ, Dept Urol, Morioka, Iwate 0208505, Japan	Osaka University; Osaka University; Iwate Medical University	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp						Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bois PRJ, 2005, MOL CELL BIOL, V25, P7645, DOI 10.1128/MCB.25.17.7645-7656.2005; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Charrasse S, 2006, MOL BIOL CELL, V17, P749, DOI 10.1091/mbc.E05-04-0284; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fan WQ, 2007, J BIOL CHEM, V282, P7329, DOI 10.1074/jbc.M610447200; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayashi K, 2006, MOL CELL BIOL, V26, P9456, DOI 10.1128/MCB.00759-06; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kollias HD, 2006, MOL CELL BIOL, V26, P6248, DOI 10.1128/MCB.00384-06; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; L'honore A, 2003, MOL BIOL CELL, V14, P2151, DOI 10.1091/mbc.e02-07-0451; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Long XC, 2007, P NATL ACAD SCI USA, V104, P16570, DOI 10.1073/pnas.0708253104; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Melnikova IN, 1999, EXP CELL RES, V247, P94, DOI 10.1006/excr.1998.4330; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Muscat George E. O., 1992, Gene Expression, V2, P241; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Park J, 2003, MOL CELLS, V16, P216; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Qiu P, 2005, CIRC RES, V97, P983, DOI 10.1161/01.RES.0000190604.90049.71; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Travaglione S, 2005, CELL DEATH DIFFER, V12, P78, DOI 10.1038/sj.cdd.4401522; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; von Bubnoff A, 2005, DEV BIOL, V281, P210, DOI 10.1016/j.ydbio.2005.02.014; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Wu JM, 2005, BBA-GENE STRUCT EXPR, V1731, P13, DOI 10.1016/j.bbaexp.2005.08.008; Xu L, 2006, BBA-GENE STRUCT EXPR, V1759, P503, DOI 10.1016/j.bbaexp.2006.11.001; Yoshiko Y, 2002, AM J PHYSIOL-CELL PH, V283, pC1278, DOI 10.1152/ajpcell.00168.2002	59	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					21230	21241		10.1074/jbc.M710525200	http://dx.doi.org/10.1074/jbc.M710525200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18477564	hybrid, Green Published			2022-12-25	WOS:000257746100065
J	Enesa, K; Ito, K; Luong, LA; Thorbjornsen, I; Phua, C; To, Y; Dean, J; Haskard, DO; Boyle, J; Adcock, I; Evans, PC				Enesa, Karine; Ito, Kazuhiro; Luong, Le A.; Thorbjornsen, Ingvild; Phua, Chee; To, Yasuo; Dean, Jonathan; Haskard, Dorian O.; Boyle, Joseph; Adcock, Ian; Evans, Paul C.			Hydrogen peroxide prolongs nuclear localization of NF-kappa B in activated cells by suppressing negative regulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-SUPEROXIDE DISMUTASE; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; IL-8 GENE-EXPRESSION; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; DEUBIQUITINATING ENZYME; DISEASE DEVELOPMENT; INDUCED ARTHRITIS	NF-kappa B transcription factors induce pro-inflammatory molecules (e. g. IL-8) in response to cytokines (e. g. TNF alpha, IL-1 beta) or other stimuli. In the basal state, they are sequestered in the cytoplasm by inhibitory I kappa B proteins. Pro-inflammatory signaling triggers polyubiquitination of intermediaries (e. g. RIP1), which activate I kappa B kinases that trigger Ser phosphorylation and degradation of I kappa B alpha, thereby promoting nuclear translocation of NF-kappa B. A negative feedback loop exists whereby NF-kappa B drives resynthesis of I kappa B alpha, which promotes export of NF-kappa B from the nucleus to the cytoplasm. This process relies on Cezanne, a deubiquitinating cysteine protease that stabilizes resynthesized I kappa B alpha by removing polyubiquitin from modified intermediaries. H2O2 is generated during inflammation. Here we examined the effects of H2O2 on NF-kappa B dynamics and pro-inflammatory activation in cultured cells co-stimulated with TNF alpha or IL-1 beta. Quantitative reverse transcription-PCR and enzyme-linked immunosorbent assay revealed that H2O2 enhanced the induction of IL-8 by TNF alpha or IL-1 beta. We demonstrated by using assays of NF-kappa B nuclear localization and by imaging of live cells expressing a fluorescent form of NF-kappa B that H2O2 prolonged NF-kappa B nuclear localization in cells co-stimulated with TNF alpha or IL-1 beta by suppressing its export from the nucleus. We provide evidence that H2O2 suppresses NF-kappa B export by prolonging polyubiquitination of signaling intermediaries, which promotes Ser phosphorylation and destabilization of newly synthesized I kappa B alpha proteins. Finally, we observed that the catalytic activity of Cezanne and its ability to suppress RIP1 polyubiquitination and NF-kappa B transcriptional activity were inhibited by H2O2. We conclude that H2O2 prolongs NF-kappa B activation in co-stimulated cells by suppressing the negative regulatory functions of Cezanne and I kappa B alpha.	[Enesa, Karine; Luong, Le A.; Thorbjornsen, Ingvild; Phua, Chee; Haskard, Dorian O.; Boyle, Joseph; Evans, Paul C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Sci Unit, London W12 0NN, England; [Dean, Jonathan] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, London W12 0NN, England	Imperial College London; Imperial College London; University of Oxford	Evans, PC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Sci Unit, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	paul.evans@imperial.ac.uk	Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019	Adcock, Ian/0000-0003-2101-8843; Dean, Jonathan/0000-0002-0703-2756	Medical Research Council [G0400503B] Funding Source: researchfish; British Heart Foundation Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); British Heart Foundation(British Heart Foundation)		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dai L, 2003, GENE THER, V10, P550, DOI 10.1038/sj.gt.3301916; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Gelderman KA, 2007, ANTIOXID REDOX SIGN, V9, P1541, DOI 10.1089/ars.2007.1569; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; KAKIMOTO K, 1993, CLIN EXP IMMUNOL, V94, P241; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Nelson G, 2002, J CELL SCI, V115, P1137; Orozco LD, 2007, CIRC RES, V100, P1703, DOI 10.1161/CIRCRESAHA.107.151720; PATRIDGE J, 2007, FASEB J, V21, P3553; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tsaprouni LG, 2007, CLIN EXP IMMUNOL, V150, P151, DOI 10.1111/j.1365-2249.2007.03484.x; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	50	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18582	18590		10.1074/jbc.M801312200	http://dx.doi.org/10.1074/jbc.M801312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474597	hybrid			2022-12-25	WOS:000257165600014
J	Igarashi, J; Murase, M; Iizuka, A; Pichierri, F; Martinkova, M; Shimizu, T				Igarashi, Jotaro; Murase, Motohiko; Iizuka, Aya; Pichierri, Fabio; Martinkova, Marketa; Shimizu, Toru			Elucidation of the heme binding site of heme-regulated eukaryotic initiation factor 2 alpha kinase and the role of the regulatory motif in heme sensing by spectroscopic and catalytic studies of mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRANSLATIONAL CONTROL; EIF2-ALPHA KINASE; RAT HEPATOCYTES; RESONANCE; DEGRADATION; INDUCTION; MYOGLOBIN; SENSOR; EIF2	Heme-regulated eukaryotic initiation factor 2 alpha (eIF2 alpha) kinase (HRI) functions in response to the heme iron concentration. At the appropriate heme iron concentrations under normal conditions, HRI function is suppressed by binding of the heme iron. Conversely, upon heme iron shortage, HRI auto-phosphorylates and subsequently phosphorylates the substrate, eIF2 alpha, leading to the termination of protein synthesis. The molecular mechanism of heme sensing by HRI, including identification of the specific binding site, remains to be established. In the present study we demonstrate that His-119/His-120 and Cys-409 are the axial ligands for the Fe(III)-protoporphyrin IX complex (hemin) in HRI, based on spectral data on site-directed mutant proteins. Cys-409 is part of the heme-regulatory CysPro motif in the kinase domain. A P410A full-length mutant protein displayed loss of heme iron affinity. Surprisingly, inhibitory effects of the heme iron on catalysis and changes in the heme dissociation rate constants in full-length His-119/His-120 and Cys-409 mutant proteins were marginally different to wild type. In contrast, heme-induced inhibition of Cys-409 mutants of the isolated kinase domain and N-terminal-truncated proteins was substantially weaker than that of the full-length enzyme. A pulldown assay disclosed heme-dependent interactions between the N-terminal and kinase domains. Accordingly, we propose that heme regulation is induced by interactions between heme and the catalytic domain in conjunction with global tertiary structural changes at the N-terminal domain that accompany heme coordination and not merely by coordination of the heme iron with amino acids on the protein surface.	[Igarashi, Jotaro; Murase, Motohiko; Iizuka, Aya; Martinkova, Marketa; Shimizu, Toru] Tohoku Univ Katahira, Inst Multidisciplinary Res Adv Mat, Grad Sch Engn, Sendai, Miyagi 9808577, Japan; [Pichierri, Fabio] Tohoku Univ Katahira, Dept Appl Chem, Grad Sch Engn, Sendai, Miyagi 9808577, Japan	Tohoku University; Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Igarashi, Jotaro/B-4550-2008; Igarashi, Jotaro/ABC-9207-2021; Pichierri, Fabio/GQR-2816-2022; Martinkova, Marketa/E-3748-2012	Igarashi, Jotaro/0000-0002-6165-3350; Igarashi, Jotaro/0000-0002-6165-3350; Martinkova, Marketa/0000-0002-0865-8785				Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Connor JH, 2005, J BIOL CHEM, V280, P13512, DOI 10.1074/jbc.M501156200; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Han XM, 2005, J PHARMACOL EXP THER, V314, P128, DOI 10.1124/jpet.105.084699; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hinnebusch AG, 2005, NAT STRUCT MOL BIOL, V12, P835, DOI 10.1038/nsmb1005-835; HSU MC, 1971, J AM CHEM SOC, V93, P3515; Hu RG, 2008, P NATL ACAD SCI USA, V105, P76, DOI 10.1073/pnas.0710568105; Igarashi J, 2004, J BIOL CHEM, V279, P15752, DOI 10.1074/jbc.M310273200; Igarashi J, 2003, BBA-PROTEINS PROTEOM, V1650, P99, DOI 10.1016/S1570-9639(03)00205-X; Igarashi J, 2008, ACTA CHIM SLOV, V55, P67; Inuzuka T, 2004, J BIOL CHEM, V279, P6778, DOI 10.1074/jbc.C300464200; Ishikawa H, 2005, MOL CELL, V19, P171, DOI 10.1016/j.molcel.2005.05.027; Kiefl C, 2002, J AM CHEM SOC, V124, P3385, DOI 10.1021/ja011961w; KOENIG DF, 1965, ACTA CRYSTALLOGR, V18, P663, DOI 10.1107/S0365110X65001536; Liao M, 2007, J PHARMACOL EXP THER, V323, P979, DOI 10.1124/jpet.107.124602; MATHEWS MB, 2007, TRANSLATIONAL CONTRO; MATINKOVA M, 2007, FEBS LETT, V581, P4109; Miksanova M, 2006, BIOCHEMISTRY-US, V45, P9894, DOI 10.1021/bi060556k; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; Sasakura Y, 2006, ACCOUNTS CHEM RES, V39, P37, DOI 10.1021/ar0501525; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yang JH, 2005, J BIOL CHEM, V280, P7671, DOI 10.1074/jbc.M411664200; Zhan K, 2002, MOL CELL BIOL, V22, P7134, DOI 10.1128/MCB.22.20.7134-7146.2002; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x	31	81	82	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18782	18791		10.1074/jbc.M801400200	http://dx.doi.org/10.1074/jbc.M801400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18450746	hybrid			2022-12-25	WOS:000257165600035
J	Delva, E; Jennings, JM; Calkins, CC; Kottke, MD; Faundez, V; Kowalczyk, AP				Delva, Emmanuella; Jennings, Jean Marie; Calkins, Catharine C.; Kottke, Margaret D.; Faundez, Victor; Kowalczyk, Andrew P.			Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; PLASMA-MEMBRANE; LIPID RAFTS; INHIBITION; CAVEOLAE; INTERNALIZATION; ADHESION; CADHERIN; ANTIGEN; DSG3	Pemphigus vulgaris (PV) is a life-threatening autoimmune disease characterized by oral mucosal erosions and epidermal blistering. The autoantibodies generated target the desmosomal cadherin desmoglein-3 (Dsg3). Previous studies demonstrate that upon PV IgG binding, Dsg3 is internalized and enters an endo-lysosomal pathway where it is degraded. To define the endocytic machinery involved in PV IgG-induced Dsg3 internalization, human keratinocytes were incubated with PV IgG, and various tools were used to perturb distinct endocytic pathways. The PV IgG.Dsg3 complex failed to colocalize with clathrin, and inhibitors of clathrin- and dynamin-dependent pathways had little or no effect on Dsg3 internalization. In contrast, cholesterol binding agents such as filipin and nystatin and the tyrosine kinase inhibitor genistein dramatically inhibited Dsg3 internalization. Furthermore, the Dsg3 cytoplasmic tail specified sensitivity to these inhibitors. Moreover, inhibition of Dsg3 endocytosis with genistein prevented disruption of desmosomes and loss of adhesion in the presence of PV IgG. Altogether, these results suggest that PV IgG-induced Dsg3 internalization is mediated through a clathrin- and dynamin-independent pathway and that Dsg3 endocytosis is tightly coupled to the pathogenic activity of PV IgG.	[Delva, Emmanuella] Emory Clin, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30332 USA; [Calkins, Catharine C.; Kottke, Margaret D.; Kowalczyk, Andrew P.] Emory Clin, Dept Dermatol, Atlanta, GA 30332 USA; [Delva, Emmanuella; Jennings, Jean Marie; Calkins, Catharine C.; Faundez, Victor; Kowalczyk, Andrew P.] Emory Clin, Dept Cell Biol, Atlanta, GA 30332 USA	Emory University; Emory University; Emory University	Kowalczyk, AP (corresponding author), Emory Clin, Dept Cell Biol, 615 Michael St,Rm 465, Atlanta, GA 30332 USA.	akowalc@emory.edu		Faundez, Victor/0000-0002-2114-5271	NATIONAL CANCER INSTITUTE [F31CA110278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007587, R01AR050501, R21AR050779, R01AR048266] Funding Source: NIH RePORTER; NCI NIH HHS [F31 CA 110278-02] Funding Source: Medline; NIAMS NIH HHS [R01 AR 048266, R21 AR 50779, T32 AR 007587, R01 AR 050501] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; AMAGAI M, 1995, J INVEST DERMATOL, V105, P243, DOI 10.1111/1523-1747.ep12317587; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Anhalt GJ, 2004, J AM ACAD DERMATOL, V51, pS20, DOI 10.1016/j.jaad.2004.01.011; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; Berkowitz P, 2008, J INVEST DERMATOL, V128, P738, DOI 10.1038/sj.jid.5701080; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Freedman SD, 1999, AM J PHYSIOL-CELL PH, V276, pC306, DOI 10.1152/ajpcell.1999.276.2.C306; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; IWATSUKI K, 1989, J AM ACAD DERMATOL, V20, P578, DOI 10.1016/S0190-9622(89)70066-9; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kottke MD, 2006, J CELL SCI, V119, P797, DOI 10.1242/jcs.02888; KOWALCZYK AP, 1995, J INVEST DERMATOL, V105, P147, DOI 10.1111/1523-1747.ep12316680; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Lanza A, 2006, J CUTAN PATHOL, V33, P401, DOI 10.1111/j.0303-6987.2006.00523.x; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Liu J, 2004, KIDNEY INT, V66, P227, DOI 10.1111/j.1523-1755.2004.00723.x; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Nava P, 2007, MOL BIOL CELL, V18, P4565, DOI 10.1091/mbc.E07-05-0426; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sanchez-Carpintero I, 2004, BRIT J DERMATOL, V151, P565, DOI 10.1111/j.1365-2133.2004.06147.x; Setzer SV, 2004, J INVEST DERMATOL, V123, P426, DOI 10.1111/j.0022-202X.2004.23319.x; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sharma P, 2007, J DERMATOL SCI, V48, P1, DOI 10.1016/j.jdermsci.2007.05.005; Shu E, 2007, ARCH DERMATOL RES, V299, P165, DOI 10.1007/s00403-007-0754-9; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Skretting G, 1999, J CELL SCI, V112, P3899; Stanley JR, 2001, J INVEST DERMATOL, V116, P489, DOI 10.1046/j.1523-1747.2001.01307.x; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Waschke J, 2006, J CELL BIOL, V175, P721, DOI 10.1083/jcb.200605125; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Yamamoto Y, 2007, J BIOL CHEM, V282, P17866, DOI 10.1074/jbc.M607963200; Yao Q, 2005, J MOL BIOL, V348, P491, DOI 10.1016/j.jmb.2005.02.003; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	67	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18303	18313		10.1074/jbc.M710046200	http://dx.doi.org/10.1074/jbc.M710046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434319	hybrid, Green Published			2022-12-25	WOS:000256949200058
J	Molina, ML; Barrera, FN; Encinar, JA; Renart, ML; Fernandez, AM; Poveda, JA; Santoro, J; Bruix, M; Gavilanes, F; Fernandez-Ballester, G; Neira, JL; Gonzalez-Ros, JM				Molina, M. Luisa; Barrera, Francisco N.; Encinar, Jose A.; Renart, M. Lourdes; Fernandez, Asia M.; Poveda, Jose A.; Santoro, Jorge; Bruix, Marta; Gavilanes, Francisco; Fernandez-Ballester, Gregorio; Neira, Jose L.; Gonzalez-Ros, Jose M.			N-type inactivation of the potassium channel KcsA by the Shaker B "Ball" peptide - Mapping the inactivating peptide-binding epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER DIFFERENCE NMR; GATED K+ CHANNEL; LIGAND-BINDING; OPEN PORE; PROTEIN; STABILITY; RECEPTOR; SPECTROSCOPY; MODEL; SUBSTITUTION	The effects of the inactivating peptide from the eukaryotic Shaker B K+ channel (the ShB peptide) on the prokaryotic KcsA channel have been studied using patch clamp methods. The data show that the peptide induces rapid, N-type inactivation in KcsA through a process that includes functional uncoupling of channel gating. We have also employed saturation transfer difference (STD) NMR methods to map the molecular interactions between the inactivating peptide and its channel target. The results indicate that binding of the ShB peptide to KcsA involves the ortho and meta protons of Tyr(8), which exhibit the strongest STD effects; the C4H in the imidazole ring of His(16); the methyl protons of Val(4), Leu(7), and Leu(10) and the side chain amine protons of one, if not both, the Lys(18) and Lys(19) residues. When a noninactivating ShB-L7E mutant is used in the studies, binding to KcsA is still observed but involves different amino acids. Thus, the strongest STD effects are now seen on the methyl protons of Val(4) and Leu(10), whereas His(16) seems similarly affected as before. Conversely, STD effects on Tyr(8) are strongly diminished, and those on Lys(18) and/or Lys(19) are abolished. Additionally, Fourier transform infrared spectroscopy of KcsA in presence of C-13-labeled peptide derivatives suggests that the ShB peptide, but not the ShB-L7E mutant, adopts a beta-hairpin structure when bound to the KcsA channel. Indeed, docking such a beta-hairpin structure into an open pore model for K+ channels to simulate the inactivating peptide/ channel complex predicts interactions well in agreement with the experimental observations.	[Molina, M. Luisa; Barrera, Francisco N.; Encinar, Jose A.; Renart, M. Lourdes; Fernandez, Asia M.; Poveda, Jose A.; Fernandez-Ballester, Gregorio; Neira, Jose L.; Gonzalez-Ros, Jose M.] Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; [Santoro, Jorge; Bruix, Marta] CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; [Gavilanes, Francisco] Univ Complutense, Fac Ciencias Quim, Dept Bioquim, E-28040 Madrid, Spain; [Neira, Jose L.] Biocomputat & Complex Syst Phys Inst, Zaragoza 50009, Spain	Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Complutense University of Madrid	Gonzalez-Ros, JM (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Edificio Torregaitan, Alicante 03202, Spain.	gonzalez.ros@umh.es	Neira, Jose/ABF-4210-2021; Bruix, Marta/H-4161-2011; Gallego, María Luisa Molina/K-4810-2017; Encinar, José A/F-2946-2013; Carvajal, Asia Fernandez/G-8877-2015; Gavilanes, Francisco/K-9903-2014; Encinar, José Antonio/AAE-9141-2020; Poveda Larrosa, Jose Antonio/H-5925-2015	Bruix, Marta/0000-0002-0096-3558; Gallego, María Luisa Molina/0000-0001-9190-6948; Encinar, José A/0000-0002-7219-3863; Gavilanes, Francisco/0000-0003-1047-2362; Encinar, José Antonio/0000-0002-7219-3863; Barrera, Francisco N./0000-0002-5200-7891; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Poveda Larrosa, Jose Antonio/0000-0003-0722-3752; Fernandez-Carvajal, Asia/0000-0003-2741-1427; Neira, Jose Luis/0000-0002-4933-0428; Renart, Maria Lourdes/0000-0002-6717-4756				Abbott GW, 1998, BIOCHEMISTRY-US, V37, P1640, DOI 10.1021/bi972350c; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Carlomagno T, 2005, ANNU REV BIOPH BIOM, V34, P245, DOI 10.1146/annurev.biophys.34.040204.144419; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cordero-Morales JF, 2007, NAT STRUCT MOL BIOL, V14, P1062, DOI 10.1038/nsmb1309; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; Encinar JA, 2005, FEBS LETT, V579, P5199, DOI 10.1016/j.febslet.2005.08.038; Encinar JA, 2003, BIOCHEMISTRY-US, V42, P8879, DOI 10.1021/bi0343121; Encinar JA, 1998, BIOCHEM J, V331, P497, DOI 10.1042/bj3310497; Encinar JA, 2002, BIOCHEMISTRY-US, V41, P12263, DOI 10.1021/bi020188u; Encinar JA, 1996, BIOPHYS J, V71, P1313, DOI 10.1016/S0006-3495(96)79331-1; EVANS PA, 1991, PROTEINS, V9, P248, DOI 10.1002/prot.340090404; FERNANDEZBALLESTER G, 1995, BIOPHYS J, V68, P858, DOI 10.1016/S0006-3495(95)80262-6; FERNANDEZBALLESTER G, 1992, BIOCHEM J, V288, P421, DOI 10.1042/bj2880421; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hong SY, 1999, BIOCHEM PHARMACOL, V58, P1775, DOI 10.1016/S0006-2952(99)00259-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Klein J, 1999, J AM CHEM SOC, V121, P5336, DOI 10.1021/ja990706x; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; KUKULJAN M, 1995, AM J PHYSIOL-CELL PH, V268, pC535, DOI 10.1152/ajpcell.1995.268.3.C535; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meuser D, 1999, FEBS LETT, V462, P447, DOI 10.1016/S0014-5793(99)01579-3; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Molina ML, 2006, J BIOL CHEM, V281, P18837, DOI 10.1074/jbc.M600342200; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Post CB, 2003, CURR OPIN STRUC BIOL, V13, P581, DOI 10.1016/j.sbi.2003.09.012; Prost E, 2002, J MAGN RESON, V159, P76, DOI 10.1016/S1090-7807(02)00003-4; Riquelme G, 1999, PFLUG ARCH EUR J PHY, V438, P879, DOI 10.1007/s004240051119; RIQUELME G, 1990, BIOCHEMISTRY-US, V29, P11215, DOI 10.1021/bi00503a009; Schott MK, 1998, EUR BIOPHYS J BIOPHY, V27, P99, DOI 10.1007/s002490050115; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; Tovchigrechko A, 2006, NUCLEIC ACIDS RES, V34, pW310, DOI 10.1093/nar/gkl206; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yan JL, 2003, J MAGN RESON, V163, P270, DOI 10.1016/S1090-7807(03)00106-X; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	57	10	10	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18076	18085		10.1074/jbc.M710132200	http://dx.doi.org/10.1074/jbc.M710132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18430729	hybrid			2022-12-25	WOS:000256949200037
J	Apostolidou, M; Jayasinghe, SA; Langen, R				Apostolidou, Melania; Jayasinghe, Sajith A.; Langen, Ralf			Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLIZATION IN-VITRO; DIABETES-MELLITUS; TRANSGENIC MICE; INTRACELLULAR AMYLOIDOGENESIS; HUMAN CALCITONIN; FIBRIL FORMATION; COS-1 CELLS; T4 LYSOZYME; PROTEIN; AGGREGATION	Human islet amyloid polypeptide (hIAPP) misfolding is thought to play an important role in the pathogenesis of type II diabetes mellitus. It has recently been shown that membranes can catalyze the misfolding of hIAPP via an alpha-helical intermediate of unknown structure. To better understand the mechanism of membrane-mediated misfolding, we used site-directed spin labeling and EPR spectroscopy to generate a three-dimensional structural model of this membrane-bound form. We find that hIAPP forms a single alpha-helix encompassing residues 9-22. The helix is flanked by N- and C-terminal regions that do not take up a clearly detectable secondary structure and are less ordered. Residues 21 and 22 are located in a transitional region between the alpha-helical structure and C terminus and exhibit significant mobility. The alpha-helical structure presented here has important implications for membrane-mediated aggregation. Anchoring hIAPP to the membrane not only increases the local concentration but also reduces the encounter between peptides to essentially a two-dimensional process. It is significant to note that the alpha-helical membrane-bound form leaves much of an important amyloidogenic region of hIAPP (residues 20-29) exposed for misfolding. Misfolding of this and other regions is likely further aided by the low dielectric environment near the membrane that is known to promote secondary structure formation. Based upon these considerations, a structural model for membrane-mediated aggregation is discussed.	[Apostolidou, Melania; Langen, Ralf] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Jayasinghe, Sajith A.] Calif State Univ, Dept Chem & Biochem, San Marcos, CA 92096 USA	University of Southern California; California State University System; California State University San Marcos	Langen, R (corresponding author), Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Biochem & Mol Biol, 1501 San Pablo St, Los Angeles, CA 90033 USA.	langen@usc.edu			NIA NIH HHS [AG027936] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG027936] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Bokvist M, 2004, J MOL BIOL, V335, P1039, DOI 10.1016/j.jmb.2003.11.046; BREEZE AL, 1991, BIOCHEMISTRY-US, V30, P575, DOI 10.1021/bi00216a036; Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEKONING EJP, 1994, P NATL ACAD SCI USA, V91, P8467, DOI 10.1073/pnas.91.18.8467; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hiddinga HJ, 1999, AM J PATHOL, V154, P1077, DOI 10.1016/S0002-9440(10)65360-6; Hoppener JWM, 1999, DIABETOLOGIA, V42, P427, DOI 10.1007/s001250051175; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Jayasinghe SA, 2005, BIOCHEMISTRY-US, V44, P12113, DOI 10.1021/bi050840w; Jayasinghe SA, 2004, J BIOL CHEM, V279, P48420, DOI 10.1074/jbc.M406853200; Jayasinghe SA, 2007, BBA-BIOMEMBRANES, V1768, P2002, DOI 10.1016/j.bbamem.2007.01.022; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Knight JD, 2004, J MOL BIOL, V341, P1175, DOI 10.1016/j.jmb.2004.06.086; Knight JD, 2006, BIOCHEMISTRY-US, V45, P9496, DOI 10.1021/bi060579z; Kurganov B, 2004, PEPTIDES, V25, P217, DOI 10.1016/j.peptides.2004.01.001; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Lashuel HA, 2006, Q REV BIOPHYS, P1, DOI DOI 10.1017/S00033583506004422; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Luca S, 2007, BIOCHEMISTRY-US, V46, P13505, DOI 10.1021/bi701427q; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Moriarty DF, 1999, BIOCHEMISTRY-US, V38, P1811, DOI 10.1021/bi981658g; Motta A, 1998, PROTEINS, V32, P314, DOI 10.1002/(SICI)1097-0134(19980815)32:3<314::AID-PROT7>3.3.CO;2-J; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; OBRIEN T, 1995, AM J PATHOL, V147, P609; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Ritzel RA, 2003, DIABETES, V52, P1701, DOI 10.2337/diabetes.52.7.1701; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Soeller WC, 1998, DIABETES, V47, P743, DOI 10.2337/diabetes.47.5.743; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Williamson JA, 2007, PROTEIN SCI, V16, P110, DOI 10.1110/ps.062486907; Wimley WC, 1998, J MOL BIOL, V277, P1091, DOI 10.1006/jmbi.1998.1640	50	153	154	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17205	17210		10.1074/jbc.M801383200	http://dx.doi.org/10.1074/jbc.M801383200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442979	Green Published, hybrid			2022-12-25	WOS:000256720600029
J	Czabany, T; Wagner, A; Zweytick, D; Lohner, K; Leitner, E; Ingolic, E; Daum, G				Czabany, Tibor; Wagner, Andrea; Zweytick, Dagmar; Lohner, Karl; Leitner, Erich; Ingolic, Elisabeth; Daum, Guenther			Structural and biochemical properties of lipid particles from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; STERYL ESTER HYDROLASE; ESTERIFICATION; ACID; ACYLTRANSFERASE; TRIACYLGLYCEROL; GENES; CORE; IDENTIFICATION; EXPRESSION	The two most prominent neutral lipids of the yeast Saccharomyces cerevisiae, triacylglycerols (TAG) and steryl esters (SE), are synthesized by the two TAG synthases Dga1p and Lro1p and the two SE synthases Are1p and Are2p. In this study, we made use of a set of triple mutants with only one of these acyltransferases active to elucidate the contribution of each single enzyme to lipid particle (LP)/droplet formation. Depending on the remaining acyltransferases, LP from triple mutants contained only TAG or SE, respectively, with specific patterns of fatty acids and sterols. Biophysical investigations, however, revealed that individual neutral lipids strongly affected the internal structure of LP. SE form several ordered shells below the surface phospholipid monolayer of LP, whereas TAG are more or less randomly packed in the center of the LP. We propose that this structural arrangement of neutral lipids in LP may be important for their physiological role especially with respect to mobilization of TAG and SE reserves.	[Czabany, Tibor; Wagner, Andrea; Daum, Guenther] Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; [Zweytick, Dagmar; Lohner, Karl] Austrian Acad Sci, Inst Biophys & Nanosyst Res, A-8042 Graz, Austria; [Leitner, Erich] Graz Univ Technol, Inst Food Chem & Technol, A-8010 Graz, Austria; [Ingolic, Elisabeth] Graz Univ Technol, Res Inst Electron Microscopy & Finestruct Res, A-8010 Graz, Austria	Graz University of Technology; Austrian Academy of Sciences; Graz University of Technology; Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at	Leitner, Erich/AAG-8826-2021	Czabany, Tibor/0000-0003-1754-6723; Leitner, Erich/0000-0003-2520-2111; Zweytick, Dagmar/0000-0002-4766-7713	Austrian Science Fund (FWF) [W 901] Funding Source: researchfish; Austrian Science Fund FWF [W 901] Funding Source: Medline	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF))		ArthingtonSkaggs BA, 1996, FEBS LETT, V392, P161, DOI 10.1016/0014-5793(96)00807-1; Athenstaedt K, 2005, J BIOL CHEM, V280, P37301, DOI 10.1074/jbc.M507261200; Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; ATKINSON D, 1977, P NATL ACAD SCI USA, V74, P1042, DOI 10.1073/pnas.74.3.1042; Czabany T, 2007, BBA-MOL CELL BIOL L, V1771, P299, DOI 10.1016/j.bbalip.2006.07.001; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAID A, 1983, METHOD ENZYMOL, V96, P192; Jandrositz A, 2005, BBA-MOL CELL BIOL L, V1735, P50, DOI 10.1016/j.bbalip.2005.04.005; Jensen-Pergakes K, 2001, J BACTERIOL, V183, P4950, DOI 10.1128/JB.183.17.4950-4957.2001; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Koffel R, 2006, EUKARYOT CELL, V5, P1018, DOI 10.1128/EC.00002-06; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; KROON PA, 1981, J BIOL CHEM, V256, P5332; Kurat CF, 2006, J BIOL CHEM, V281, P491, DOI 10.1074/jbc.M508414200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGGNER P, 1977, H-S Z PHYSIOL CHEM, V358, P771, DOI 10.1515/bchm2.1977.358.2.771; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lockshon D, 2007, GENETICS, V175, P77, DOI 10.1534/genetics.106.064428; Low CP, 2005, FEMS YEAST RES, V5, P1199, DOI 10.1016/j.femsyr.2005.07.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISETT JD, 1984, BIOCHEMISTRY-US, V23, P5343, DOI 10.1021/bi00317a037; MORRISON WR, 1964, J LIPID RES, V5, P600; Mullner H, 2005, J BIOL CHEM, V280, P13321, DOI 10.1074/jbc.M409914200; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oelkers PM, 2004, TOP CURR GENET, V6, P289; Pregetter M, 1999, J BIOL CHEM, V274, P1334, DOI 10.1074/jbc.274.3.1334; Quail M A, 1996, Methods Mol Biol, V53, P123; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Sorger D, 2004, J BIOL CHEM, V279, P31190, DOI 10.1074/jbc.M403251200; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Valachovic M, 2002, FEMS MICROBIOL LETT, V206, P121, DOI 10.1016/S0378-1097(01)00529-8; Valachovic M, 2001, FEMS MICROBIOL LETT, V197, P41, DOI 10.1111/j.1574-6968.2001.tb10580.x; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x	48	113	115	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17065	17074		10.1074/jbc.M800401200	http://dx.doi.org/10.1074/jbc.M800401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430725	hybrid			2022-12-25	WOS:000256720600013
J	Towpik, J; Graczyk, D; Gajda, A; Lefebvre, O; Boguta, M				Towpik, Joanna; Graczyk, Damian; Gajda, Anna; Lefebvre, Olivier; Boguta, Magdalena			Derepression of RNA polymerase III transcription by phosphorylation and nuclear export of its negative regulator, Maf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SACCHAROMYCES-CEREVISIAE; REPRESSION; DEPHOSPHORYLATION; LOCALIZATION; TRANSPORT; REQUIRES; STRESS; GENES; YEAST	Maf1 is the global repressor of RNA polymerase III (Pol III) in yeast Saccharomyces cerevisiae. Transcription regulation by Maf1 is important under stress conditions and during the switch between fermentation and respiration. Under repressive conditions on nonfermentable carbon sources, Maf1 is dephosphorylated and located predominantly in the nucleus. When cells were shifted to glucose medium, Maf1 became phosphorylated and concomitantly relocated to the cytoplasm. This relocation was dependent on Msn5, a carrier responsible for export of several other phosphoproteins out of the nucleus. Using coimmunoprecipitation, Maf1 was found to interact with Msn5. When msn5-Delta cells were transferred to glucose, Maf1 remained in the nucleus. Remarkably, despite constitutive presence in the nucleus, Maf1 was dephosphorylated and phosphorylated normally in the msn5-Delta mutant, and Pol III was under proper regulation. That phosphorylation of Maf1 and Pol III derepression are tightly linked was shown by studying tRNA transcription in Maf1 mutants with an altered pattern of phosphorylation. In summary, we conclude that phosphorylation of Maf1 inside the nucleus acts both directly by decreasing of Maf1-mediated repression of Pol III and indirectly by stimulation of Msn5 binding and export of nuclear Maf1 to the cytoplasm.	[Towpik, Joanna; Graczyk, Damian; Gajda, Anna; Boguta, Magdalena] Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; [Gajda, Anna; Lefebvre, Olivier] CEA, iBiTecs, F-91191 Gif Sur Yvette, France	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boguta, M (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	magda@ibb.waw.pl	Graczyk, Damian/J-6494-2016; LEFEBVRE, Olivier/C-3847-2014	LEFEBVRE, Olivier/0000-0002-3903-9450; Graczyk, Damian/0000-0002-6006-647X; Boguta, Magdalena/0000-0002-1545-0691				Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Budovskaya YV, 2005, P NATL ACAD SCI USA, V102, P13933, DOI 10.1073/pnas.0501046102; Ciesla M, 2007, MOL CELL BIOL, V27, P7693, DOI 10.1128/MCB.01051-07; Desai N, 2005, J BIOL CHEM, V280, P6455, DOI 10.1074/jbc.M412375200; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Geiduschek EP, 2006, CURR BIOL, V16, pR849, DOI 10.1016/j.cub.2006.08.071; Griffioen G, 2002, CURR GENET, V41, P199, DOI 10.1007/s00294-002-0308-9; Hopper AK, 1999, CURR BIOL, V9, pR803, DOI 10.1016/S0960-9822(99)80494-1; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kaplun L, 2003, J BIOL CHEM, V278, P48727, DOI 10.1074/jbc.M308671200; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; Moir RD, 2006, P NATL ACAD SCI USA, V103, P15044, DOI 10.1073/pnas.0607129103; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Oficjalska-Pham D, 2006, MOL CELL, V22, P623, DOI 10.1016/j.molcel.2006.04.008; Pluta K, 2001, MOL CELL BIOL, V21, P5031, DOI 10.1128/MCB.21.15.5031-5040.2001; Quan XX, 2006, MOL MICROBIOL, V62, P592, DOI 10.1111/j.1365-2958.2006.05395.x; Reina JH, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000134; Roberts DN, 2006, MOL CELL, V22, P633, DOI 10.1016/j.molcel.2006.04.009; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Tsang CK, 2007, CELL CYCLE, V6, P25, DOI 10.4161/cc.6.1.3675; Ueta R, 2007, MOL BIOL CELL, V18, P2980, DOI 10.1091/mbc.E06-11-1054; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; Willis IM, 2007, TRENDS BIOCHEM SCI, V32, P51, DOI 10.1016/j.tibs.2006.12.001	26	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17168	17174		10.1074/jbc.M709157200	http://dx.doi.org/10.1074/jbc.M709157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445601	hybrid			2022-12-25	WOS:000256720600025
J	Miyauchi, Y; Kato, M; Tokunaga, F; Iwai, K				Miyauchi, Yasuhiro; Kato, Michiko; Tokunaga, Fuminori; Iwai, Kazuhiro			The COP9/signalosome increases the efficiency of von hippel-lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; COP9 SIGNALOSOME; HIF-ALPHA; C-ELEGANS; COMPLEX; NEDD8; CUL1; NEDDYLATION; UBIQUITYLATION; DENEDDYLATION	Oxygen-dependent ubiquitination of the alpha-subunit of hypoxia-inducible factor (HIF-alpha) by the (von Hippel-Lindau protein)-Elongin B/C-Cullin2-Rbx1 (VBC-Cul2) ubiquitin ligase, a member of the cullin-RING ubiquitin ligases (CRLs), plays a central role in controlling oxygen metabolism. Nedd8 conjugation of cullins enhances the ligase activity of CRLs, and the COP9/ signalosome (CSN) enhances the degradation of several CRL substrates, although it removes Nedd8 from cullins. Here we demonstrate that CSN increased the efficiency of the VBC-Cul2 complex for recognizing and ubiquitinating substrates by facilitating the dissociation of ubiquitinated substrates from the pVHL subunit of the complex. Moreover CSN enhanced HIF-1 alpha degradation by promoting the dissociation of HIF-1 alpha from pVHL in cells. The length of the polyubiquitin chain conjugated to the substrate appeared to be involved in CSN-mediated dissociation of the substrate from pVHL. In contrast to other mechanisms underlying CSN-mediated activation of CRLs, the dissociation of ubiquitinated substrates from pVHL did not require the deneddylation activity of CSN, implying that CSN enhances degradation of CRL substrates by multiple mechanisms.	[Iwai, Kazuhiro] Osaka Univ, Grad Sch Med, Dept Biophys & Biochem, Osaka 5650871, Japan; [Iwai, Kazuhiro] Osaka Univ, Grad Sch Frontier Biosci, Cell Biol & Metab Grp, Osaka 5650871, Japan; [Miyauchi, Yasuhiro; Kato, Michiko; Tokunaga, Fuminori; Iwai, Kazuhiro] Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan; [Kato, Michiko; Tokunaga, Fuminori; Iwai, Kazuhiro] Japan Sci Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; Osaka Metropolitan University; Japan Science & Technology Agency (JST)	Iwai, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Biophys & Biochem, 2-2 Yamadaoka, Osaka 5650871, Japan.	kiwai@cellbio.med.osaka-u.ac.jp	IWAI, KAZUHIRO/GSN-7385-2022	Tokunaga, Fuminori/0000-0003-3626-9119; Iwai, Kazuhiro/0000-0001-5620-5951				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chew EH, 2007, J BIOL CHEM, V282, P17032, DOI 10.1074/jbc.M701153200; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; George DJ, 2003, NEW ENGL J MED, V349, P419, DOI 10.1056/NEJMp030061; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; He Q, 2005, GENE DEV, V19, P1518, DOI 10.1101/gad.1322205; Hetfeld BKJ, 2005, CURR BIOL, V15, P1217, DOI 10.1016/j.cub.2005.05.059; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Megumi Y, 2005, GENES CELLS, V10, P679, DOI 10.1111/j.1365-2443.2005.00869.x; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Sakamoto H, 2007, INT J UROL, V14, P167, DOI 10.1111/j.1442-2042.2006.01645.x; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Tomoda K, 2005, BLOOD, V105, P775, DOI 10.1182/blood-2004-04-1242; Wee S, 2005, NAT CELL BIOL, V7, P387, DOI 10.1038/ncb1241; Wu JT, 2005, NAT CELL BIOL, V7, P1014, DOI 10.1038/ncb1301; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16622	16631		10.1074/jbc.M710599200	http://dx.doi.org/10.1074/jbc.M710599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424433	hybrid			2022-12-25	WOS:000256497100039
J	Shimojo, M; Sahara, N; Mizoroki, T; Funamoto, S; Morishima-Kawashima, M; Kudo, T; Takeda, M; Ihara, Y; Ichinose, H; Takashima, A				Shimojo, Masafumi; Sahara, Naruhiko; Mizoroki, Tatsuya; Funamoto, Satoru; Morishima-Kawashima, Maho; Kudo, Takashi; Takeda, Masatoshi; Ihara, Yasuo; Ichinose, Hiroshi; Takashima, Akihiko			Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains - Familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETASE ACTIVITY; INTRAMEMBRANE CLEAVAGE; TRANSMEMBRANE DOMAIN; PRESENILIN MUTATIONS; TALKING POINT; ZETA-CLEAVAGE; A-BETA-40; COMPLEX; MICE; DEPOSITION	Presenilin (PS)/gamma-secretase-mediated intramembranous proteolysis of amyloid precursor protein produces amyloid beta(A beta) peptides in which A beta species of different lengths are generated through multiple cleavages at the gamma-, zeta-, and epsilon-sites. An increased A beta 42/A beta 40 ratio is a common characteristic of most cases of familial Alzheimer disease (FAD)-linked PS mutations. However, the molecular mechanisms underlying amyloid precursor protein proteolysis leading to increased A beta 42/A beta 40 ratios still remain unclear. Here, we report our findings on the enzymatic analysis of gamma-secretase derived from I213T mutant PS1-expressing PS1/PS2-deficient (PS-/-) cells and from the brains of I213T mutant PS1 knock-in mice. Kinetics analyses revealed that the FAD mutation reduced de novo A beta generation, suggesting that mutation impairs the total catalytic rate of gamma-secretase. Analysis of each A beta species revealed that the FAD mutation specifically reduced A beta 40 levels more drastically than A beta 42 levels, leading to an increased A beta 42/A beta 40 ratio. By contrast, the FAD mutation increased the generation of longer A beta species such as A beta 43, A beta 45, and >A beta 46. These results were confirmed by analyses of gamma-secretase derived from I213T knock-in mouse brains, in which the reduction of de novo A beta generation was mutant allele dose-dependent. Our findings clearly indicate that the mechanism underlying the increased A beta 42/A beta 40 ratio observed in cases of FAD mutations is related to the differential inhibition of gamma-site cleavage reactions, in which the reaction producing A beta 40 is subject to more inhibition than that producing A beta 42. Our results also provide novel insight into how enhancing the generation of longer A beta s may contribute to Alzheimer disease onset.	[Shimojo, Masafumi; Sahara, Naruhiko; Mizoroki, Tatsuya; Takashima, Akihiko] RIKEN, Lab Alzheimers Dis, Brain Sci Inst, Wako, Saitama 3510198, Japan; [Shimojo, Masafumi; Ichinose, Hiroshi] Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan; [Funamoto, Satoru; Ihara, Yasuo] Doshisha Univ, Fac Life & Med Sci, Kyoto 6190225, Japan; [Morishima-Kawashima, Maho] Hokkaido Univ, Dept Mol Neuropathol, Sapporo, Hokkaido 0600812, Japan; [Kudo, Takashi; Takeda, Masatoshi] Osaka Univ, Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan	RIKEN; Tokyo Institute of Technology; Doshisha University; Hokkaido University; Osaka University	Takashima, A (corresponding author), 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.jp	Ichinose, Hiroshi/D-8986-2015	Ichinose, Hiroshi/0000-0001-6008-6860				Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Funamoto S, 2004, BIOCHEMISTRY-US, V43, P13532, DOI 10.1021/bi049399k; Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kakuda N, 2006, J BIOL CHEM, V281, P14776, DOI 10.1074/jbc.M513453200; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Karlstrom H, 2008, J NEUROCHEM, V104, P573, DOI 10.1111/j.1471-4159.2007.05038.x; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kumar-Singh S, 2006, HUM MUTAT, V27, P686, DOI 10.1002/humu.20336; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Plant LD, 2003, J NEUROSCI, V23, P5531; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Selkoe DJ, 2007, CELL, V131, P215, DOI 10.1016/j.cell.2007.10.012; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shimojo M, 2007, NEUROSCI RES, V57, P446, DOI 10.1016/j.neures.2006.12.005; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanemura K, 2006, J BIOL CHEM, V281, P5037, DOI 10.1074/jbc.M509145200; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 2007, EMBO REP, V8, P136, DOI 10.1038/sj.embor.7400896; Yagishita S, 2006, BIOCHEMISTRY-US, V45, P3952, DOI 10.1021/bi0521846; Yagishita S, 2008, J BIOL CHEM, V283, P733, DOI 10.1074/jbc.M707103200; Yin YI, 2007, J BIOL CHEM, V282, P23639, DOI 10.1074/jbc.M704601200; Yoshiike Y, 2003, J BIOL CHEM, V278, P23648, DOI 10.1074/jbc.M212785200; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200	42	27	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16488	16496		10.1074/jbc.M801279200	http://dx.doi.org/10.1074/jbc.M801279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18430735	hybrid			2022-12-25	WOS:000256497100025
J	Huguenin, M; Muller, EJ; Trachsel-Rosmann, S; Oneda, B; Ambort, D; Sterchi, EE; Lottaz, D				Huguenin, Maya; Mueller, Eliane J.; Trachsel-Roesmann, Sandra; Oneda, Beatrice; Ambort, Daniel; Sterchi, Erwin E.; Lottaz, Daniel			The Metalloprotease Meprin beta Processes E-Cadherin and Weakens Intercellular Adhesion	PLOS ONE			English	Article								Background: Meprin (EC 3.4.24.18), an astacin-like metalloprotease, is expressed in the epithelium of the intestine and kidney tubules and has been related to cancer, but the mechanistic links are unknown. Methodology/Principal Findings: We used MDCK and Caco-2 cells stably transfected with meprin alpha and or meprin beta to establish models of renal and intestinal epithelial cells expressing this protease at physiological levels. In both models E-cadherin was cleaved, producing a cell-associated 97-kDa E-cadherin fragment, which was enhanced upon activation of the meprin zymogen and reduced in the presence of a meprin inhibitor. The cleavage site was localized in the extracellular domain adjacent to the plasma membrane. In vitro assays with purified components showed that the 97-kDa fragment was specifically generated by meprin beta, but not by ADAM-10 or MMP-7. Concomitantly with E-cadherin cleavage and degradation of the E-cadherin cytoplasmic tail, the plaque proteins beta-catenin and plakoglobin were processed by an intracellular protease, whereas alpha-catenin, which does not bind directly to E-cadherin, remained intact. Using confocal microscopy, we observed a partial colocalization of meprin beta and E-cadherin at lateral membranes of incompletely polarized cells at preconfluent or early confluent stages. Meprin beta-expressing cells displayed a reduced strength of cell-cell contacts and a significantly lower tendency to form multicellular aggregates. Conclusions/Significance: By identifying E-cadherin as a substrate for meprin beta in a cellular context, this study reveals a novel biological role of this protease in epithelial cells. Our results suggest a crucial role for meprin beta in the control of adhesiveness via cleavage of E-cadherin with potential implications in a wide range of biological processes including epithelial barrier function and cancer progression.	[Huguenin, Maya; Trachsel-Roesmann, Sandra; Oneda, Beatrice; Ambort, Daniel; Sterchi, Erwin E.; Lottaz, Daniel] Univ Bern, Inst Biochem & Mol Biol, Bern, Switzerland; [Mueller, Eliane J.] Univ Bern, Inst Animal Pathol, Bern, Switzerland	University of Bern; University of Bern	Huguenin, M (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Bern, Switzerland.	daniel.lottaz@insel.ch			Bernese Cancer League BKL; Swiss National Science Foundation SNF [3100A0-100772]	Bernese Cancer League BKL; Swiss National Science Foundation SNF(Swiss National Science Foundation (SNSF))	This study was supported by the Bernese Cancer League BKL (to D. L.) and the Swiss National Science Foundation SNF (grant #3100A0-100772 to E. S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker C, 2003, BIOL CHEM, V384, P825, DOI 10.1515/BC.2003.092; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bond JS, 2005, FEBS LETT, V579, P3317, DOI 10.1016/j.febslet.2005.03.045; BOND JS, 1986, BIOMED BIOCHIM ACTA, V45, P1515; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Crisman JM, 2004, J IMMUNOL, V172, P4510, DOI 10.4049/jimmunol.172.7.4510; Davies G, 2001, CLIN CANCER RES, V7, P3289; Dietrich JM, 1996, J BIOL CHEM, V271, P2271, DOI 10.1074/jbc.271.4.2271; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; GRAFF JR, 1995, CANCER RES, V55, P5195; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Herzog C, 2005, CYTOKINE, V31, P394, DOI 10.1016/j.cyto.2005.06.012; Hung CF, 2006, EXP DERMATOL, V15, P315, DOI 10.1111/j.0906-6705.2006.00411.x; Ishmael FT, 2005, J BIOL CHEM, V280, P13895, DOI 10.1074/jbc.M414218200; Keller SH, 2003, BIOCHEM BIOPH RES CO, V307, P215, DOI 10.1016/S0006-291X(03)01143-4; Kohler D, 2000, FEBS LETT, V465, P2, DOI 10.1016/S0014-5793(99)01712-3; Kruse MN, 2004, BIOCHEM J, V378, P383, DOI 10.1042/BJ20031163; Lottaz D, 1999, CANCER RES, V59, P1127; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Matters GL, 2005, CLIN EXP METASTAS, V22, P331, DOI 10.1007/s10585-005-0660-5; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Noe V, 2001, J CELL SCI, V114, P111; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Pischitzis A, 1999, EUR J BIOCHEM, V261, P421, DOI 10.1046/j.1432-1327.1999.00268.x; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; Richmond PJM, 1997, CANCER RES, V57, P3189; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rosmann S, 2002, J BIOL CHEM, V277, P40650, DOI 10.1074/jbc.M206203200; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; TRACHTMAN H, 1995, BIOCHEM BIOPH RES CO, V208, P498, DOI 10.1006/bbrc.1995.1366; UMBAS R, 1992, CANCER RES, V52, P5104; Weis WI, 2006, J BIOL CHEM, V281, P35593, DOI 10.1074/jbc.R600027200; Wild-Bode C, 2006, J BIOL CHEM, V281, P23824, DOI 10.1074/jbc.M601542200; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200; Zlobec I, 2007, J PATHOL, V212, P260, DOI 10.1002/path.2164	56	59	60	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2153	10.1371/journal.pone.0002153	http://dx.doi.org/10.1371/journal.pone.0002153			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478055	Green Published, Green Accepted, gold			2022-12-25	WOS:000262172800018
J	Bate, R; Coticelli, P; Tren, R; Attaran, A				Bate, Roger; Coticelli, Philip; Tren, Richard; Attaran, Amir			Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa - A Six Country Study	PLOS ONE			English	Article								A range of antimalarial drugs were procured from private pharmacies in urban and peri-urban areas in the major cities of six African countries, situated in the part of that continent and the world that is most highly endemic for malaria. Semiquantitative thin-layer chromatography (TLC) and dissolution testing were used to measure active pharmaceutical ingredient content against internationally acceptable standards. 35% of all samples tested failed either or both tests, and were substandard. Further, 33% of treatments collected were artemisinin monotherapies, most of which (78%) were manufactured in disobservance of an appeal by the World Health Organisation (WHO) to withdraw these clinically inappropriate medicines from the market. The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies in the private sector risks patient safety and, through drug resistance, places the future of malaria treatment at risk globally.	[Bate, Roger; Coticelli, Philip; Tren, Richard] Africa Fighting Malaria, Washington, DC USA; [Bate, Roger] American Enterprise Inst, Washington, DC USA; [Attaran, Amir] Univ Ottawa, Inst Populat Hlth & Fac Law & Med, Ottawa, ON, Canada	University of Ottawa	Bate, R (corresponding author), Africa Fighting Malaria, Washington, DC USA.	pcoticelli@fightingmalaria.org			Africa Fighting Malaria; Ohrstrom Foundation	Africa Fighting Malaria; Ohrstrom Foundation	Funding for this study was provided in full by Africa Fighting Malaria, drawing on a general budgetary support grant made by the Ohrstrom Foundation. The authors' work was entirely independent of the Ohrstrom Foundation.	Amin AA, 2005, J CLIN PHARM THER, V30, P559, DOI 10.1111/j.1365-2710.2005.00685.x; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Basco LK, 2004, AM J TROP MED HYG, V70, P245, DOI 10.4269/ajtmh.2004.70.245; Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x; Gomes M, 1998, Bull World Health Organ, V76 Suppl 1, P9; Goodman C, 2007, AM J TROP MED HYG, V77, P203, DOI 10.4269/ajtmh.2007.77.203; Green MD, 2006, J POSTGRAD MED, V52, P288; Hall KA, 2006, AM J TROP MED HYG, V75, P804, DOI 10.4269/ajtmh.2006.75.804; Lon CT, 2006, T ROY SOC TROP MED H, V100, P1019, DOI 10.1016/j.trstmh.2006.01.003; Minzi OMS, 2003, J CLIN PHARM THER, V28, P117, DOI 10.1046/j.1365-2710.2003.00470.x; Newton PN, 2006, PLOS MED, V3, P752, DOI 10.1371/journal.pmed.0030197; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Vijaykadga Saowanit, 2006, Southeast Asian J Trop Med Public Health, V37 Suppl 3, P5	14	101	103	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2132	10.1371/journal.pone.0002132	http://dx.doi.org/10.1371/journal.pone.0002132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461128	Green Published, gold			2022-12-25	WOS:000261642400053
J	Suzawa, M; Ingraham, HA				Suzawa, Miyuki; Ingraham, Holly A.			The Herbicide Atrazine Activates Endocrine Gene Networks via Non-Steroidal NR5A Nuclear Receptors in Fish and Mammalian Cells	PLOS ONE			English	Article								Atrazine (ATR) remains a widely used broadleaf herbicide in the United States despite the fact that this s-chlorotriazine has been linked to reproductive abnormalities in fish and amphibians. Here, using zebrafish we report that environmentally relevant ATR concentrations elevated zcyp19a1 expression encoding aromatase (2.2 mu g/L), and increased the ratio of female to male fish (22 mu g/L). ATR selectively increased zcyp19a1, a known gene target of the nuclear receptor SF-1 (NR5A1), whereas zcyp19a2, which is estrogen responsive, remained unchanged. Remarkably, in mammalian cells ATR functions in a cell-specific manner to upregulate SF-1 targets and other genes critical for steroid synthesis and reproduction, including Cyp19A1, StAR, Cyp11A1, hCG, FSTL3, LH(ss), INH alpha, alpha GSU, and 11(ss)-HSD2. Our data appear to eliminate the possibility that ATR directly affects SF-1 DNA- or ligand-binding. Instead, we suggest that the stimulatory effects of ATR on the NR5A receptor subfamily (SF-1, LRH-1, and zff1d) are likely mediated by receptor phosphorylation, amplification of cAMP and PI3K signaling, and possibly an increase in the cAMP-responsive cellular kinase SGK-1, which is known to be upregulated in infertile women. Taken together, we propose that this pervasive and persistent environmental chemical alters hormone networks via convergence of NR5A activity and cAMP signaling, to potentially disrupt normal endocrine development and function in lower and higher vertebrates.	[Suzawa, Miyuki; Ingraham, Holly A.] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; [Suzawa, Miyuki; Ingraham, Holly A.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Suzawa, M (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	holly.ingraham@ucsf.edu			Susan B. Komen [postdoctoral fellowship]; NIH-RO1	Susan B. Komen(Susan G. Komen Breast Cancer Foundation); NIH-RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a Susan B. Komen postdoctoral fellowship to M.S. and NIH-RO1 support to H.A.I.	Biron-Shental T, 2008, PLACENTA, V29, P51, DOI 10.1016/j.placenta.2007.09.001; Carr JA, 2003, ENVIRON TOXICOL CHEM, V22, P396, DOI [10.1897/1551-5028(2003)022&lt;0396:ROLXLT&gt;2.0.CO;2, 10.1002/etc.5620220222]; Chen WY, 2005, MOL CELL BIOL, V25, P10442, DOI 10.1128/MCB.25.23.10442-10453.2005; Crain DA, 1997, ENVIRON HEALTH PERSP, V105, P528, DOI 10.2307/3433582; Crews D, 2006, ENDOCRINOLOGY, V147, pS4, DOI 10.1210/en.2005-1122; de-Souza Bruno Ferraz, 2006, Pediatr Endocrinol Rev, V3, P359; Eldridge JC, 1999, REPROD TOXICOL, V13, P491, DOI 10.1016/S0890-6238(99)00056-8; Fan WQ, 2007, ENVIRON HEALTH PERSP, V115, P720, DOI 10.1289/ehp.9758; Fan W, 2007, BIOCHEM BIOPH RES CO, V355, P1012, DOI 10.1016/j.bbrc.2007.02.062; Fenske M, 2004, AQUAT TOXICOL, V67, P105, DOI 10.1016/j.aquatox.2003.10.008; FEROZEZAIDI F, 2007, ROLE REGULATION SERU; Filipov NM, 2005, TOXICOL SCI, V86, P324, DOI 10.1093/toxsci/kfi188; Forson D, 2006, ENVIRON TOXICOL CHEM, V25, P168, DOI 10.1897/05-260R.1; Forson DD, 2006, ECOL APPL, V16, P2325, DOI 10.1890/1051-0761(2006)016[2325:AIRSIT]2.0.CO;2; Friedmann AS, 2002, REPROD TOXICOL, V16, P275, DOI 10.1016/S0890-6238(02)00019-9; Gaido KW, 2000, MOL PHARMACOL, V58, P852, DOI 10.1124/mol.58.4.852; Greenlee AR, 2004, ENVIRON HEALTH PERSP, V112, P703, DOI 10.1289/ehp.6774; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hayes T, 2002, NATURE, V419, P895, DOI 10.1038/419895a; Hayes T, 2003, ENVIRON HEALTH PERSP, V111, P568, DOI 10.1289/ehp.5932; Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499; He YW, 2002, J LEUKOCYTE BIOL, V72, P440; Hinfray N, 2006, ENVIRON TOXICOL, V21, P332, DOI 10.1002/tox.20203; Kazeto Y, 2004, AQUAT TOXICOL, V69, P25, DOI 10.1016/j.aquatox.2004.04.008; Kazeto YK, 2001, BIOCHEM BIOPH RES CO, V288, P503, DOI 10.1006/bbrc.2001.5796; Keller JM, 2004, MAR ENVIRON RES, V58, P347, DOI 10.1016/j.marenvres.2004.03.080; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Kiesecker JM, 2002, P NATL ACAD SCI USA, V99, P9900, DOI 10.1073/pnas.152098899; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lan HC, 2007, MOL CELL BIOL, V27, P2027, DOI 10.1128/MCB.02253-06; Lee CT, 2006, EUR J NEUROSCI, V23, P1311, DOI 10.1111/j.1460-9568.2006.04650.x; Mehats Celine, 2007, BMC Pregnancy Childbirth, V7 Suppl 1, pS12, DOI 10.1186/1471-2393-7-S1-S12; MESSNER B, 1979, BIOCHEM PHARMACOL, V28, P207, DOI 10.1016/0006-2952(79)90505-7; Moore A, 1998, PESTIC BIOCHEM PHYS, V62, P41, DOI 10.1006/pest.1998.2366; Oger S, 2005, J IMMUNOL, V174, P8082, DOI 10.4049/jimmunol.174.12.8082; Okamoto A, 2006, PLACENTA, V27, P317, DOI 10.1016/j.placenta.2004.12.007; Orn S, 2003, AQUAT TOXICOL, V65, P397, DOI 10.1016/S0166-445X(03)00177-2; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Poulin H, 2006, BIOCHEM BIOPH RES CO, V346, P306, DOI 10.1016/j.bbrc.2006.05.134; Rayner JL, 2004, TOXICOL APPL PHARM, V195, P23, DOI 10.1016/j.taap.2003.11.005; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Roberge M, 2004, TOXICOL LETT, V154, P61, DOI 10.1016/j.toxlet.2004.07.005; Rooney AA, 2003, TOXICOL SCI, V76, P366, DOI 10.1093/toxsci/kfg250; Rowe AM, 2008, BASIC CLIN PHARMACOL, V102, P139, DOI 10.1111/j.1742-7843.2007.00175.x; Safe SH, 2002, ENVIRON HEALTH PERSP, V110, P925, DOI 10.1289/ehp.02110s6925; Safe SH, 2001, REPROD FERT DEVELOP, V13, P307, DOI 10.1071/RD00108; Sanderson JT, 2002, TOXICOL APPL PHARM, V182, P44, DOI 10.1006/taap.2002.9420; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Singleton DW, 2004, MOL CELL ENDOCRINOL, V221, P47, DOI 10.1016/j.mce.2004.04.010; Spalding RF, 2003, J ENVIRON QUAL, V32, P84, DOI 10.2134/jeq2003.0084; Spano L, 2004, AQUAT TOXICOL, V66, P369, DOI 10.1016/j.aquatox.2003.10.009; Stoker TE, 2002, TOXICOL SCI, V67, P198, DOI 10.1093/toxsci/67.2.198; Storrs SI, 2004, ENVIRON HEALTH PERSP, V112, P1054, DOI 10.1289/ehp.6821; Tavera-Mendoza L, 2002, ENVIRON TOXICOL CHEM, V21, P1264, DOI [10.1897/1551-5028(2002)021<1264:ROTATX>2.0.CO;2, 10.1897/1551-5028(2002)021&lt;1264:ROTATX&gt;2.0.CO;2]; Tavera-Mendoza L, 2002, ENVIRON TOXICOL CHEM, V21, P527, DOI 10.1897/1551-5028(2002)021&lt;0527:ROTATX&gt;2.0.CO;2; Tong SK, 2003, J STEROID BIOCHEM, V86, P381, DOI 10.1016/S0960-0760(03)00347-9; Trentacoste SV, 2001, J ANDROL, V22, P142; Uchida D, 2004, COMP BIOCHEM PHYS A, V137, P11, DOI 10.1016/S1095-6433(03)00178-8; von Hofsten J, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-63; Weck J, 2006, MOL ENDOCRINOL, V20, P1090, DOI 10.1210/me.2005-0199; Xia Y, 2004, MOL ENDOCRINOL, V18, P979, DOI 10.1210/me.2003-0364; Xue Q, 2007, J CLIN ENDOCR METAB, V92, P3261, DOI 10.1210/jc.2007-0494; Zeitoun KM, 1999, FERTIL STERIL, V72, P961, DOI 10.1016/S0015-0282(99)00393-3	70	124	131	6	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2117	10.1371/journal.pone.0002117	http://dx.doi.org/10.1371/journal.pone.0002117			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461179	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400039
J	Schlaepfer, E; Speck, RF				Schlaepfer, Erika; Speck, Roberto F.			Anti-HIV Activity Mediated by Natural Killer and CD8+Cells after Toll-Like Receptor 7/8 Triggering	PLOS ONE			English	Article								We previously found that triggering TLR7/8 either by single stranded HIV RNA or synthetic compounds induced changes in the lymphoid microenvironment unfavorable to HIV. In this study, we used selective TLR7 and 8 agonists to dissect their contribution to the anti-HIV effects. While triggering TLR7 inhibited efficiently HIV replication in lymphoid suspension cells from tonsillar origin, its effect was inconsistent in peripheral blood mononuclear cells (PBMC). In contrast, triggering TLR8 showed a very prominent and overall very consistent effect in PBMC and tonsillar lymphoid suspension cells. Depletion of dendritic cells (DC), Natural killer cells (NK) and CD8+ T-cells from PBMC resulted in the reversal of TLR8 induced anti-HIV effects. Especially noteworthy, depletion of either NK or CD8+ T-cells alone was only partially effective. We interpret these findings that DC are the initiator of complex changes in the microenvironment that culminates in the anti-HIV active NK and CD8+ effector cells. The near lack of NK and the low number of CD8+ T-cells in tonsillar lymphoid suspension cells may explain the lower TLR8 agonist's anti-HIV effects in that tissue. However, additional cell-type specific differences must exist since the TLR7 agonists had a very strong inhibitory effect in tonsillar lymphoid suspension cells. Separation of effector from the CD4+ target cells did not abolish the anti-HIV effects pointing to the critical role of soluble factors. Triggering TLR7 or 8 were accompanied by major changes in the cytokine milieu; however, it appeared that not a single soluble factor could be assigned for the potent effects. These results delineate the complex effects of triggering TLR7/8 for an efficient antiviral defense. While the ultimate mechanism(s) remains unknown, the potent effects described may have therapeutic value for treating chronic viral diseases. Notably, HIV replication is blocked by TLR triggering before HIV integrates into the host chromosome which would prevent the establishment or maintenance of the latent reservoir.	[Schlaepfer, Erika; Speck, Roberto F.] Univ Zurich Hosp, Dept Internal Med, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Schlaepfer, E (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland.	roberto.speck@usz.ch	Speck, Roberto F/O-2433-2016	Speck, Roberto/0000-0002-8453-1137	Stiftung fur wissenschaftliche Forschung an der Universitat Zurich	Stiftung fur wissenschaftliche Forschung an der Universitat Zurich	This study was supported by the "Stiftung fur wissenschaftliche Forschung an der Universitat Zurich".	Ahonen CL, 1999, CELL IMMUNOL, V197, P62, DOI 10.1006/cimm.1999.1555; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Alter G, 2007, J IMMUNOL, V178, P7658, DOI 10.4049/jimmunol.178.12.7658; Barton GM, 2007, SEMIN IMMUNOL, V19, P33, DOI 10.1016/j.smim.2007.01.003; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Chan SY, 2000, J VIROL, V74, P4933, DOI 10.1128/JVI.74.10.4933-4937.2000; Cox K, 2005, J LEUKOCYTE BIOL, V78, P1142, DOI 10.1189/jlb.1103-532; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gorski KS, 2006, INT IMMUNOL, V18, P1115, DOI 10.1093/intimm/dxl046; Hardy AW, 2007, P NATL ACAD SCI USA, V104, P17453, DOI 10.1073/pnas.0707244104; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hengel H, 2003, INT IMMUNOPHARMACOL, V3, P1159, DOI 10.1016/S1567-5769(03)00028-6; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kantakamalakul W, 2003, J IMMUNOL METHODS, V272, P189, DOI 10.1016/S0022-1759(02)00505-7; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Klimkait T, 1998, ARCH VIROL, V143, P2109, DOI 10.1007/s007050050447; Levy JA, 2003, TRENDS IMMUNOL, V24, P628, DOI 10.1016/j.it.2003.10.005; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Piccioli D, 2007, BLOOD, V109, P5371, DOI 10.1182/blood-2006-08-038422; Schlaepfer E, 2006, J IMMUNOL, V176, P2888, DOI 10.4049/jimmunol.176.5.2888; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433	36	28	30	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1999	10.1371/journal.pone.0001999	http://dx.doi.org/10.1371/journal.pone.0001999			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431484	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700019
J	Guinez, C; Mir, AM; Dehennaut, V; Cacan, R; Harduin-Lepers, A; Michalski, JC; Lefebvre, T				Guinez, Celine; Mir, Anne-Marie; Dehennaut, Vanessa; Cacan, Rene; Harduin-Lepers, Anne; Michalski, Jean-Claude; Lefebvre, Tony			Protein ubiquitination is modulated by O-GlcNAc glycosylation	FASEB JOURNAL			English	Article						OGT RNA interference; heat shock; proteasomal degradation	NUCLEOCYTOPLASMIC PROTEINS; PHOSPHORYLATION; DEGRADATION; TURNOVER; NUCLEAR; GLUCOSE; STRESS; SENSOR	During the past two decades, O-GlcNAc modification of cytosolic and nuclear proteins has been intensively studied. Nevertheless, the function of this post-translational modification remains unclear. It has been recently speculated that O-GlcNAc could act as a protective signal against proteasomal degradation, both by modifying target substrates and/or by inhibiting the proteasome itself. In this work, we have investigated the putative relation between O-GlcNAc and the ubiquitin pathway. First, we showed that the level of both modifications increased rapidly after thermal stress but, unlike ubiquitinated proteins, O-GlcNAc-modified proteins failed to be stabilized by inhibiting proteasome function. Increasing O-GlcNAc levels, using glucosamine or PUGNAc, enhanced ubiquitination. Inversely, when O-GlcNAc levels were reduced, using forskolin or glucose deprivation, ubiquitination decreased. Targeted-RNA interference of O-GlcNAc transferase also reduced ubiquitination and moreover halved cell thermotolerance. Finally, we demonstrated that the ubiquitin-activating enzyme E1 was O-GlcNAc modified and that its glycosylation and its interaction with Hsp70 varied according to the conditions of cell culture. Altogether, these results show that O-GlcNAc and ubiquitin are not strictly antagonistic post-translational modifications, but rather that the former might regulate the latter, and also suggest that E1 could be one of the common links between the two pathways.	[Guinez, Celine; Mir, Anne-Marie; Dehennaut, Vanessa; Cacan, Rene; Harduin-Lepers, Anne; Michalski, Jean-Claude; Lefebvre, Tony] USTL, Lab Glycobiol Struct & Fonctionnelle, CNRS, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Lefebvre, T (corresponding author), USTL, Lab Glycobiol Struct & Fonctionnelle, CNRS, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France.	tony.lefebvre@univ-lille1.fr	dehennaut, vanessa/I-7435-2018; Anne, Harduin-Lepers/O-7503-2017; Lefebvre, Tony/AAZ-1724-2021; Lefebvre, Tony/AAW-9169-2021	dehennaut, vanessa/0000-0001-6421-0793; Anne, Harduin-Lepers/0000-0002-1233-3799; Lefebvre, Tony/0000-0001-9883-2240; 				Cacan R, 1998, BIOCHIMIE, V80, P59, DOI 10.1016/S0300-9084(98)80057-6; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Guinez C, 2006, GLYCOBIOLOGY, V16, P22, DOI 10.1093/glycob/cwj041; Guinez C, 2004, BIOCHEM BIOPH RES CO, V319, P21, DOI 10.1016/j.bbrc.2004.04.144; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Love, 2005, SCI STKE, V2005, DOI DOI 10.1126/STKE.3122005RE13; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MAYER J, 2005, ESSAYS BIOCH UBIQUIT; Minegishi N, 2005, GENES CELLS, V10, P693, DOI 10.1111/j.1365-2443.2005.00864.x; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Sohn KC, 2004, BIOCHEM BIOPH RES CO, V322, P1045, DOI 10.1016/j.bbrc.2004.08.023; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; Windheim M, 2008, BIOCHEM J, V409, P723, DOI 10.1042/BJ20071338; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	27	82	85	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2901	2911		10.1096/fj.07-102509	http://dx.doi.org/10.1096/fj.07-102509			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434435				2022-12-25	WOS:000258089300030
J	Castro, A; Lemos, C; Falcao, A; Glass, NL; Videira, A				Castro, Ana; Lemos, Catarina; Falcao, Artur; Glass, N. Louise; Videira, Arnaldo			Increased resistance of complex I mutants to phytosphingosine-induced programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; OXIDATIVE STRESS; ROS RELEASE; APOPTOSIS; MITOCHONDRIA; SUBUNIT; GENE; DISRUPTION; MECHANISM	We have studied the effects of phytosphingosine (PHS) on cells of the filamentous fungus Neurospora crassa. Highly reduced viability, impairment of asexual spore germination, DNA condensation and fragmentation, and production of reactive oxygen species were observed in conidia treated with the drug, suggesting that PHS induces an apoptosis-like death in this fungus. Interestingly, we found that complex I mutants are more resistant to PHS treatment than the wild type strain. This effect appears to be specific because it was not observed in mutants defective in other components of the mitochondrial respiratory chain, pointing to a particular involvement of complex I in cell death. The response of the mutant strains to PHS correlated with their response to hydrogen peroxide. The fact that complex I mutants generate fewer reactive oxygen species than the wild type strain when exposed to PHS likely explains the PHS-resistant phenotype. As compared with the wild type strain, we also found that a strain containing a deletion in the gene encoding an AIF (apoptosis-inducing factor)-like protein is more resistant to PHS and H2O2. In contrast, a strain containing a deletion in a gene encoding an AMID (AIF-homologous mitochondrion-associated inducer of death)-like polypeptide is more sensitive to both drugs. These results indicate that N. crassa has the potential to be a model organism to investigate the molecular basis of programmed cell death in eukaryotic species.	[Castro, Ana; Lemos, Catarina; Falcao, Artur; Videira, Arnaldo] Univ Porto, IBMC, P-4150180 Oporto, Portugal; [Castro, Ana; Lemos, Catarina; Falcao, Artur] Univ Fernando Pessoa, Fac Ciencias Saude, P-4200150 Oporto, Portugal; [Glass, N. Louise] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Videira, Arnaldo] Univ Porto, ICBAS, P-4099003 Oporto, Portugal	Universidade do Porto; Universidade Fernando Pessoa; University of California System; University of California Berkeley; Universidade do Porto	Videira, A (corresponding author), Univ Porto, IBMC, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	avideira@ibmc.up.pt	Videira, Arnaldo/H-8150-2013; castro, ana/A-9232-2014; Glass, N. Louise/ABA-7303-2021; Lima, Marta T/C-7042-2009	castro, ana/0000-0003-4035-3444; Lemos, Catarina/0000-0003-3468-4191; Videira, Arnaldo/0000-0001-7267-4459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060468] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM60468] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Amin S, 2004, MICROBIOL-SGM, V150, P1937, DOI 10.1099/mic.0.26830-0; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Benit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316; Chen CB, 2005, P NATL ACAD SCI USA, V102, P3459, DOI 10.1073/pnas.0407960102; Cheng JJ, 2003, MOL CELL BIOL, V23, P163, DOI 10.1128/MCB.23.1.163-177.2003; Chernyak BV, 2006, BBA-BIOENERGETICS, V1757, P525, DOI 10.1016/j.bbabio.2006.02.019; Colot HV, 2006, P NATL ACAD SCI USA, V103, P10352, DOI 10.1073/pnas.0601456103; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Davis R.H., 2000, NEUROSPORA CONTRIBUT; Davis RH, 2002, NAT REV GENET, V3, P397, DOI 10.1038/nrg797; Dementhon K, 2006, EUKARYOT CELL, V5, P2161, DOI 10.1128/EC.00253-06; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; DUARTE M, 1995, GENETICS, V139, P1211; Duarte M, 2003, BIOCHEM J, V371, P1005, DOI 10.1042/BJ20021374; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Eisler H, 2004, EXP CELL RES, V300, P345, DOI 10.1016/j.yexcr.2004.07.025; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; FECKE W, 1994, EUR J BIOCHEM, V220, P551, DOI 10.1111/j.1432-1033.1994.tb18655.x; Fedorova ND, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-177; Ferreirinha F, 1999, BIOCHEM J, V342, P551, DOI 10.1042/0264-6021:3420551; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hamann A, 2007, MOL MICROBIOL, V65, P948, DOI 10.1111/j.1365-2958.2007.05839.x; Hattori N, 1998, GENOMICS, V49, P52, DOI 10.1006/geno.1997.5192; Huang G, 2007, CELL DEATH DIFFER, V14, P327, DOI 10.1038/sj.cdd.4402004; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; Ladha JS, 2005, CELL DEATH DIFFER, V12, P1417, DOI 10.1038/sj.cdd.4401668; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li W, 2006, MOL BIOL CELL, V17, P1802, DOI 10.1091/mbc.E05-04-0333; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; LU B.C.K., 2006, MYCOTA GROWTH DIFFER, P167; Ludovico P, 2005, IUBMB LIFE, V57, P129, DOI 10.1080/15216540500090553; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Marella M, 2007, J BIOL CHEM, V282, P24146, DOI 10.1074/jbc.M701819200; Marques I, 2005, BBA-BIOENERGETICS, V1707, P211, DOI 10.1016/j.bbabio.2004.12.003; McCluskey K, 2003, ADV APPL MICROBIOL, V52, P245, DOI 10.1016/S0065-2164(03)01010-4; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Perkins D., 2001, NEUROSPORA COMPENDIU; Phillips AJ, 2003, P NATL ACAD SCI USA, V100, P14327, DOI 10.1073/pnas.2332326100; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Reeves MB, 2007, SCIENCE, V316, P1345, DOI 10.1126/science.1142984; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Robson GD, 2006, MED MYCOL, V44, pS109, DOI 10.1080/13693780600835765; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Semighini CP, 2006, MOL MICROBIOL, V59, P753, DOI 10.1111/j.1365-2958.2005.04976.x; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; Span LFR, 2002, CYTOMETRY, V47, P24, DOI 10.1002/cyto.10028; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Taha TA, 2006, BBA-BIOMEMBRANES, V1758, P2027, DOI 10.1016/j.bbamem.2006.10.018; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; Vogel H.J., 1956, MICROB GENET B, V13, P42; Wang XD, 2001, GENE DEV, V15, P2922; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	64	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19314	19321		10.1074/jbc.M802112200	http://dx.doi.org/10.1074/jbc.M802112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474589	hybrid, Green Published			2022-12-25	WOS:000257387600017
J	Fischle, W; Franz, H; Jacobs, SA; Allis, CD; Khorasanizadeh, S				Fischle, Wolfgang; Franz, Henriette; Jacobs, Steven A.; Allis, C. David; Khorasanizadeh, Sepideh			Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; EXPRESSION; DOMAINS; BINDING; PHOSPHORYLATION; EVOLUTION; DYNAMICS; SITES; MARKS; H1	Previous studies have shown two homologous chromodomain modules in the HP1 and Polycomb proteins exhibit discriminatory binding to related methyllysine residues (embedded in ARKS motifs) of the histone H3 tail. Methylated ARK(S/T) motifs have recently been identified in other chromatin factors (e. g. linker histone H1.4 and lysine methyltransferase G9a). These are thought to function as peripheral docking sites for the HP1 chromodomain. In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2. These have putative functions ranging from establishment of histone H4 acetylation during spermiogenesis to regulation of transcription co-repressor complexes. To delineate the biochemical functions of the CDY family chromodomains, we analyzed their specificity of methyllysine recognition. We detected substantial differences among these factors. The CDY chromodomain exhibits discriminatory binding to lysine-methylated ARK(S/T) motifs, whereas the CDYL2 chromodomain binds with comparable strength to multiple ARK(S/T) motifs. Interestingly, subtle amino acid changes in the CDYL chromodomain prohibit such binding interactions in vitro and in vivo. However, point mutations can rescue binding. In support of the in vitro binding properties of the chromodomains, the full-length CDY family proteins exhibit substantial variability in chromatin localization. Our studies underscore the significance of subtle sequence differences in a conserved signaling module for diverse epigenetic regulatory pathways.	[Fischle, Wolfgang; Jacobs, Steven A.; Allis, C. David; Khorasanizadeh, Sepideh] Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Fischle, Wolfgang; Allis, C. David] Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; [Fischle, Wolfgang; Franz, Henriette] Max Planck Inst Biophys Chem, Lab Chromatin Biochem, D-37077 Gottingen, Germany	University of Virginia; Rockefeller University; Max Planck Society	Khorasanizadeh, S (corresponding author), Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	khorasan@virginia.edu		Franz, Henriette/0000-0001-9358-7442	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R01GM063959, R01GM064786, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM064786, GM63959, GM53512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Caron C, 2003, EMBO REP, V4, P877, DOI 10.1038/sj.embor.embor917; Chin HG, 2006, BIOCHEMISTRY-US, V45, P3272, DOI 10.1021/bi051997r; Delaval K, 2007, EMBO J, V26, P720, DOI 10.1038/sj.emboj.7601513; Dormann HL, 2006, CELL CYCLE, V5, P2842, DOI 10.4161/cc.5.24.3540; Dorus S, 2003, HUM MOL GENET, V12, P1643, DOI 10.1093/hmg/ddg185; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Flanagan JF, 2007, J MOL BIOL, V369, P334, DOI 10.1016/j.jmb.2007.03.024; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Garcia BA, 2004, J PROTEOME RES, V3, P1219, DOI 10.1021/pr0498887; Govin J, 2005, TRENDS BIOCHEM SCI, V30, P357, DOI 10.1016/j.tibs.2005.05.001; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Hake SB, 2006, P NATL ACAD SCI USA, V103, P6428, DOI 10.1073/pnas.0600803103; Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518; Henkels CH, 2007, MOL CELL, V27, P521, DOI 10.1016/j.molcel.2007.08.002; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hughes JF, 2005, NATURE, V437, P101, DOI 10.1038/nature04101; Hughes RM, 2007, P NATL ACAD SCI USA, V104, P11184, DOI 10.1073/pnas.0610850104; Jacobs SA, 2004, METHOD ENZYMOL, V376, P131; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Khalil AM, 2004, P NATL ACAD SCI USA, V101, P16583, DOI 10.1073/pnas.0406325101; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368; Kleiman SE, 2003, HUM GENET, V113, P486, DOI 10.1007/s00439-003-0990-9; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Mito Y, 2007, SCIENCE, V315, P1408, DOI 10.1126/science.1134004; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715; Ooi SL, 2007, CURR OPIN CELL BIOL, V19, P257, DOI 10.1016/j.ceb.2007.04.015; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722	47	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19626	19636		10.1074/jbc.M802655200	http://dx.doi.org/10.1074/jbc.M802655200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18450745	Green Published, hybrid			2022-12-25	WOS:000257387600048
J	Kroschewski, H; Lim, SP; Butcher, RE; Yap, TL; Lescar, J; Wright, PJ; Vasudevan, SG; Davidson, AD				Kroschewski, Helga; Lim, Siew Pheng; Butcher, Rebecca E.; Yap, Thai Leong; Lescar, Julien; Wright, Peter J.; Vasudevan, Subhash G.; Davidson, Andrew D.			Mutagenesis of the dengue virus type 2 NS5 methyltransferase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; AMINO-ACID-RESIDUES; MESSENGER-RNA; CRYSTAL-STRUCTURE; CAP METHYLATION; LAMBDA-2 PROTEIN; SEQUENCE MOTIFS; CAPPING ENZYME; GUANINE N-7; IDENTIFICATION	The Flavivirus NS5 protein possesses both (guanine-N7)-methyltransferase and nucleoside-2'-O methyltransferase activities required for sequential methylation of the cap structure present at the 5' end of the Flavivirus RNA genome. Seventeen mutations were introduced into the dengue virus type 2 NS5 methyltransferase domain, targeting amino acids either predicted to be directly involved in S-adenosyl-L-methionine binding or important for NS5 conformation and/or charged interactions. The effects of the mutations on (i) (guanine-N7)methyltransferase and nucleoside-2'-O methyltransferase activities using biochemical assays based on a bacterially expressed NS5 methyltransferase domain and (ii) viral replication using a dengue virus type 2 infectious cDNA clone were examined. Clustered mutations targeting the S-adenosyl-L-methionine binding pocket or an active site residue abolished both methyltransferase activities and viral replication, demonstrating that both methyltransferase activities utilize a single S-adenosyl-L-methionine binding pocket. Substitutions to single amino acids binding S-adenosyl-L-methionine decreased both methyltransferase activities by varying amounts. However, viruses that replicated at wild type levels could be recovered with mutations that reduced both activities by > 75%, suggesting that only a threshold level of methyltransferase activity was required for virus replication in vivo. Mutation of residues outside of regions directly involved in S-adenosyl-L-methionine binding or catalysis also affected methyltransferase activity and virus replication. The recovery of viruses containing compensatory second site mutations in the NS5 and NS3 proteins identified regions of the methyltransferase domain important for overall stability of the protein or likely to play a role in virus replication distinct from that of cap methylation.	[Kroschewski, Helga; Davidson, Andrew D.] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Lim, Siew Pheng; Yap, Thai Leong; Vasudevan, Subhash G.] Novartis Inst Trop Dis, Singapore 138670, Singapore; [Butcher, Rebecca E.; Wright, Peter J.] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; [Yap, Thai Leong; Lescar, Julien] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; [Vasudevan, Subhash G.] Duke NUS Grad Med Sch, Singapore, Singapore	University of Bristol; Novartis; Monash University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Davidson, AD (corresponding author), Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England.	andrew.davidson@bristol.ac.uk	Pheng, Lim Siew/AAG-4368-2021; Lim, Siew Pheng/P-8528-2016	Pheng, Lim Siew/0000-0002-7377-5662; Vasudevan, Subhash/0000-0002-5083-3831				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Assenberg R, 2007, J GEN VIROL, V88, P2228, DOI 10.1099/vir.0.82757-0; Benarroch D, 2004, J BIOL CHEM, V279, P35638, DOI 10.1074/jbc.M400460200; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Delano W.L., 2002, DELANO SCI; Dong HP, 2008, J VIROL, V82, P4295, DOI 10.1128/JVI.02202-07; Dong HP, 2007, J VIROL, V81, P4412, DOI 10.1128/JVI.02455-06; Egloff MP, 2007, J MOL BIOL, V372, P723, DOI 10.1016/j.jmb.2007.07.005; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; Hanley KA, 2002, J VIROL, V76, P525, DOI 10.1128/JVI.76.2.525-531.2002; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; HERCYK N, 1988, VIROLOGY, V163, P222, DOI 10.1016/0042-6822(88)90253-X; Johansson M, 2001, J GEN VIROL, V82, P735, DOI 10.1099/0022-1317-82-4-735; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Khromykh AA, 1999, J VIROL, V73, P9247, DOI 10.1128/JVI.73.11.9247-9255.1999; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Li JR, 2007, J VIROL, V81, P4104, DOI 10.1128/JVI.02681-06; Li JR, 2006, P NATL ACAD SCI USA, V103, P8493, DOI 10.1073/pnas.0509821103; Li JR, 2005, J VIROL, V79, P13373, DOI 10.1128/JVI.79.21.13373-13384.2005; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Liu WJ, 2002, J VIROL, V76, P10766, DOI 10.1128/JVI.76.21.10766-10775.2002; Luo D, 2008, J VIROL, V82, P173, DOI 10.1128/JVI.01788-07; Luongo CL, 1998, J BIOL CHEM, V273, P23773, DOI 10.1074/jbc.273.37.23773; Luzhkov VB, 2007, BIOORGAN MED CHEM, V15, P7795, DOI 10.1016/j.bmc.2007.08.049; Malet H, 2007, J BIOL CHEM, V282, P10678, DOI 10.1074/jbc.M607273200; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; Mao XD, 1996, MOL CELL BIOL, V16, P475; Mastrangelo E, 2007, PROTEIN SCI, V16, P1133, DOI 10.1110/ps.072758107; Ogino T, 2005, J BIOL CHEM, V280, P4429, DOI 10.1074/jbc.M411167200; Pryor MJ, 2001, AM J TROP MED HYG, V65, P427, DOI 10.4269/ajtmh.2001.65.427; Ramadevi N, 1998, P NATL ACAD SCI USA, V95, P13537, DOI 10.1073/pnas.95.23.13537; Ray D, 2006, J VIROL, V80, P8362, DOI 10.1128/JVI.00814-06; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Selisko B, 2006, VIROLOGY, V351, P145, DOI 10.1016/j.virol.2006.03.026; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Sutton G, 2007, NAT STRUCT MOL BIOL, V14, P449, DOI 10.1038/nsmb1225; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Wu SG, 2005, BIODRUGS, V19, P383, DOI 10.2165/00063030-200519060-00005; Yap TL, 2007, J VIROL, V81, P4753, DOI 10.1128/JVI.02283-06; Zhou YS, 2007, J VIROL, V81, P3891, DOI 10.1128/JVI.02704-06	54	62	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19410	19421		10.1074/jbc.M800613200	http://dx.doi.org/10.1074/jbc.M800613200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18469001	hybrid			2022-12-25	WOS:000257387600027
J	Li, ZB; Kollias, HD; Wagner, KR				Li, Zhao Bo; Kollias, Helen D.; Wagner, Kathryn R.			Myostatin directly regulates skeletal muscle fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SUPERFAMILY MEMBER; TRANSFORMING GROWTH-FACTOR-BETA-1; MUSCULAR-DYSTROPHY; TGF-BETA; CONNECTIVE-TISSUE; SIGNALING PATHWAY; MDX MICE; GROWTH; EXPRESSION; GENE	Skeletal muscle fibrosis is a major pathological hallmark of chronic myopathies in which myofibers are replaced by progressive deposition of collagen and other extracellular matrix proteins produced by muscle fibroblasts. Recent studies have shown that in the absence of the endogenous muscle growth regulator myostatin, regeneration of muscle is enhanced, and muscle fibrosis is correspondingly reduced. We now demonstrate that myostatin not only regulates the growth of myocytes but also directly regulates muscle fibroblasts. Our results show that myostatin stimulates the proliferation of muscle fibroblasts and the production of extracellular matrix proteins both in vitro and in vivo. Further, muscle fibroblasts express myostatin and its putative receptor activin receptor IIB. Proliferation of muscle fibroblasts, induced by myostatin, involves the activation of Smad, p38 MAPK and Akt pathways. These results expand our understanding of the function of myostatin in muscle tissue and provide a potential target for anti-fibrotic therapies.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Wagner, KR (corresponding author), Meyer 5-119,600 N Wolfe St, Baltimore, MD 21287 USA.	kwagner@jhmi.edu			NIAMS NIH HHS [U54AR052646] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen DL, 2008, AM J PHYSIOL-ENDOC M, V294, pE918, DOI 10.1152/ajpendo.00798.2007; Amthor H, 2004, DEV BIOL, V270, P19, DOI 10.1016/j.ydbio.2004.01.046; Andreetta F, 2006, J NEUROIMMUNOL, V175, P77, DOI 10.1016/j.jneuroim.2006.03.005; Berk BC, 2007, J CLIN INVEST, V117, P568, DOI 10.1172/JCI31044; BERNASCONI P, 1995, J CLIN INVEST, V96, P1137, DOI 10.1172/JCI118101; BISCHOFF R, 1994, MYOGENESIS, V2, P97; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Gagliardini E, 2007, EXPERT OPIN BIOL TH, V7, P293, DOI 10.1517/14712598.7.3.293; Gressner AM, 2006, J CELL MOL MED, V10, P76, DOI 10.1111/j.1582-4934.2006.tb00292.x; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; Horowitz JC, 2007, CELL SIGNAL, V19, P761, DOI 10.1016/j.cellsig.2006.10.001; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kaariainen M, 2000, SCAND J MED SCI SPOR, V10, P332, DOI 10.1034/j.1600-0838.2000.010006332.x; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McCroskery S, 2005, J CELL SCI, V118, P3531, DOI 10.1242/jcs.02482; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Mendias CL, 2008, P NATL ACAD SCI USA, V105, P388, DOI 10.1073/pnas.0707069105; Morissette MR, 2006, CIRC RES, V99, P15, DOI 10.1161/01.RES.0000231290.45676.d4; Mutsaers SE, 2006, CURR OPIN PULM MED, V12, P251, DOI 10.1097/01.mcp.0000230627.88386.b9; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Qiao CP, 2008, HUM GENE THER, V19, P241, DOI 10.1089/hum.2007.159; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Sharma M, 1999, J CELL PHYSIOL, V180, P1; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Wagner KR, 2005, CURR OPIN RHEUMATOL, V17, P720, DOI 10.1097/01.bor.0000184163.61558.ca; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Wagner KR, 2005, P NATL ACAD SCI USA, V102, P2519, DOI 10.1073/pnas.0408729102; Yang W, 2007, J BIOL CHEM, V282, P3799, DOI 10.1074/jbc.M610185200; Zhu J, 2007, J BIOL CHEM, V282, P25852, DOI 10.1074/jbc.M704146200; Zhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007	43	195	207	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19371	19378		10.1074/jbc.M802585200	http://dx.doi.org/10.1074/jbc.M802585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18453534	Green Published, hybrid			2022-12-25	WOS:000257387600023
J	Singhal, SS; Yadav, S; Drake, K; Singhal, J; Awasthi, S				Singhal, Sharad S.; Yadav, Sushma; Drake, Kenneth; Singhal, Jyotsana; Awasthi, Sanjay			Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER DOXORUBICIN RESISTANCE; HEAT-SHOCK; ERYTHROCYTE GLUTATHIONE; LUNG-CANCER; DEPENDENT TRANSPORT; G-PROTEIN; RLIP76; CELLS; BINDING; STRESS	Hsf-1 (heat shock factor-1) is a transcription factor that is known to regulate cellular heat shock response through its binding with the multispecific transporter protein, Ralbp1. Results of present studies demonstrate that Hsf-1 causes specific and saturable inhibition of the transport activity of Ralbp1 and that the combination of Hsf-1 and POB1 causes nearly complete inhibition through specific bindings with Ralbp1. Augmentation of cellular levels of Hsf-1 and POB1 caused dramatic apoptosis in non-small cell lung cancer cell line H358 through Ralbp1 inhibition. These findings indicate a novel model for mutual regulation of Hsf-1 and Ralbp1 through Ralbp1-mediated sequestration of Hsf-1 in the cellular cytoskeleton and Hsf1-mediated inhibition of the transport activity of membrane-bound Ralbp1.	[Singhal, Sharad S.; Yadav, Sushma; Drake, Kenneth; Singhal, Jyotsana; Awasthi, Sanjay] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Awasthi, S (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd,EAD Rm 552, Ft Worth, TX 76107 USA.	sawasthi@hsc.unt.edu	Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NCI NIH HHS [CA 104661, CA77495] Funding Source: Medline; PHS HHS [ISIORR018999-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077495, R01CA104661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 1999, TOXICOL APPL PHARM, V155, P215, DOI 10.1006/taap.1998.8617; AWASTHI S, 1994, J CLIN INVEST, V93, P958, DOI 10.1172/JCI117102; Awasthi S, 1998, BIOCHEMISTRY-US, V37, P5239, DOI 10.1021/bi972131r; Awasthi S, 2005, CANCER RES, V65, P6022, DOI 10.1158/0008-5472.CAN-05-0968; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Awasthi S, 2003, INT J ONCOL, V22, P721; Awasthi S, 2003, INT J ONCOL, V22, P713; AWASTHI YC, 1981, BLOOD, V58, P733; Awasthi YC, 2007, CURR DRUG METAB, V8, P315, DOI 10.2174/138920007780655414; BROADWAY NM, 1995, BIOCHEM J, V310, P989, DOI 10.1042/bj3100989; Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200; Hammill AK, 1999, EXP CELL RES, V251, P16, DOI 10.1006/excr.1999.4581; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Inouye S, 2003, MOL CELL BIOL, V23, P5882, DOI 10.1128/MCB.23.16.5882-5895.2003; Jia ZZ, 2007, J BIOL CHEM, V282, P20573, DOI 10.1074/jbc.M700568200; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kabakov AE, 2006, RADIAT RES, V165, P410, DOI 10.1667/RR3514.1; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; Leich F, 2007, J BIOL CHEM, V282, P27640, DOI 10.1074/jbc.M702240200; Li J, 2006, BIOCHEMISTRY-US, V45, P12253, DOI 10.1021/bi060780+; MIVECHI NF, 1992, CANCER RES, V52, P6815; MIVECHI NF, 1995, J CELL BIOCHEM, V59, P266, DOI 10.1002/jcb.240590215; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Oosterhoff JK, 2003, ONCOGENE, V22, P2920, DOI 10.1038/sj.onc.1206397; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; Sharma R, 2004, INT J CANCER, V112, P934, DOI 10.1002/ijc.20516; Sharma R, 2008, BIOCHEMISTRY-US, V47, P143, DOI 10.1021/bi701559f; SINGHAL J, 2008, INT J RAD O IN PRESS; Singhal S.S., 2006, TOXICOLOGY GLUTATHIO, P231; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Singhal SS, 2006, BIOCHEM BIOPH RES CO, V348, P722, DOI 10.1016/j.bbrc.2006.07.118; Singhal SS, 2006, CANCER RES, V66, P2354, DOI 10.1158/0008-5472.CAN-05-3534; Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005; Stuckler D, 2005, CANCER RES, V65, P991; Tanaka KI, 2007, J BIOL CHEM, V282, P23240, DOI 10.1074/jbc.M704081200; Taylor DM, 2007, CELL STRESS CHAPERON, V12, P151, DOI 10.1379/CSC-254R.1; Yadav S, 2005, BIOCHEM BIOPH RES CO, V328, P1003, DOI 10.1016/j.bbrc.2005.01.055; Yadav S, 2004, BIOCHEMISTRY-US, V43, P16243, DOI 10.1021/bi0482811; Yadav S, 2007, CANCER METAST REV, V26, P59, DOI 10.1007/s10555-007-9043-5; Yang YS, 2003, J BIOL CHEM, V278, P41380, DOI 10.1074/jbc.M305766200	44	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19714	19729		10.1074/jbc.M708703200	http://dx.doi.org/10.1074/jbc.M708703200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474607	Green Published, hybrid			2022-12-25	WOS:000257387600056
J	Kumar, R; Cheney, KM; Mckirdy, R; Neilsen, PM; Schulz, REB; Lee, J; Cohen, J; Booker, GW; Callen, DF				Kumar, Raman; Cheney, Kelly M.; Mckirdy, Ross; Neilsen, Paul M.; Schulz, Rene E. B.; Lee, Jaclyn; Cohen, Juliane; Booker, Grant W.; Callen, David F.			CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; E-PROTEIN FUNCTION; NUCLEAR-MATRIX; BREAST-CANCER; ETO PROTEIN; MYND DOMAIN; PROTOONCOGENE; INTERACTS; TARGET; MTG8	Transcriptional repression plays a critical role in development and homeostasis. The ETO family represents a group of highly conserved and ubiquitously expressed transcriptional regulatory proteins that are components of a diverse range of multiprotein repressor complexes. ETO proteins function as transcriptional repressors by interacting with a number of transcription factors that bind to their cognate consensus DNA binding sequences within the promoters of target genes. We previously reported that the classical C2H2 zinc finger DNA-binding protein, ZNF652, specifically and functionally interacts with the ETO protein CBFA2T3 and has a role in the suppression of breast oncogenesis. Here we report the identification and validation of the ZNF652 consensus DNA binding sequence. Our results show that the E-box gene HEB is a direct target of CBFA2T3-ZNF652-mediated transcriptional repression. The CBFA2T3-ZNF652 complex regulates HEB expression by binding to a single ZNF652 response element located within the promoter sequence of HEB. This study also shows that the NHR3 and NHR4 domains of CBFA2T3 interact with a conserved proline-rich region located within the C terminus of ZNF652. Our results, together with previous reports, indicate that HEB has a complex relationship with CBFA2T3; CBFA2T3 interacts with ZNF652 to repress HEB expression, and in addition CBFA2T3 interacts with the HEB protein to inhibit its activator function. These findings suggest that CBFA2T3-ZNF652-mediated HEB regulation may play an important role in hematopoiesis and myogenesis.	[Kumar, Raman; Cheney, Kelly M.; Mckirdy, Ross; Neilsen, Paul M.; Schulz, Rene E. B.; Lee, Jaclyn; Cohen, Juliane; Callen, David F.] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Inst Med & Vet Sci, Breast Canc Genet Grp,Discipline Med,Hanson Inst, Adelaide, SA 5000, Australia; [Booker, Grant W.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide	Kumar, R (corresponding author), Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Inst Med & Vet Sci, Breast Canc Genet Grp,Discipline Med,Hanson Inst, Frome Rd, Adelaide, SA 5000, Australia.	raman.sharma@imvs.sa.gov.au	Callen, David F/G-1975-2012; Kumar, Raman/AHE-0538-2022	Kumar, Raman/0000-0001-7976-8386; Callen, David/0000-0002-6189-9991; Neilsen, Paul/0000-0001-7937-3675; Kumar, Raman Krishna/0000-0003-4343-0951				Amann JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Jardin F, 2007, PATHOL BIOL, V55, P73, DOI 10.1016/j.patbio.2006.04.001; Jepsen K, 2002, J CELL SCI, V115, P689; Kazanjian A, 2006, CRIT REV ONCOL HEMAT, V59, P85, DOI 10.1016/j.critrevonc.2006.02.002; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kochetkova M, 2002, CANCER RES, V62, P4599; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSMAN A, 2003, SOC NEUR 8 ANN M KEY; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Liu YZ, 2007, CANCER CELL, V11, P483, DOI 10.1016/j.ccr.2007.04.010; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Plevin MJ, 2006, P NATL ACAD SCI USA, V103, P10242, DOI 10.1073/pnas.0603463103; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; Rossetti S, 2004, GENOMICS, V84, P1, DOI 10.1016/j.ygeno.2004.02.011; Rothenberg EV, 2005, ANNU REV IMMUNOL, V23, P601, DOI 10.1146/annurev.immunol.23.021704.115737; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Spadaccini R, 2006, J MOL BIOL, V358, P498, DOI 10.1016/j.jmb.2006.01.087; Utku Y, 2006, MOL BIOSYST, V2, P312, DOI 10.1039/b603229j; Wei YF, 2007, NAT STRUCT MOL BIOL, V14, P653, DOI 10.1038/nsmb1258; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	51	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19026	19038		10.1074/jbc.M709136200	http://dx.doi.org/10.1074/jbc.M709136200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18456661	hybrid			2022-12-25	WOS:000257165600058
J	Funami, K; Sasai, M; Oshiumi, H; Seya, T; Matsumoto, M				Funami, Kenji; Sasai, Miwa; Oshiumi, Hiroyuki; Seya, Tsukasa; Matsumoto, Misako			Homo-oligomerization is essential for toll/interleukin-1 receptor domain-containing adaptor molecule-1-mediated NF-kappa B and interferon regulatory factor-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; SIGNAL-TRANSDUCTION; RIG-I; ANTIVIRAL RESPONSES; TRIF; PATHWAY; PROTEIN; BETA; INDUCTION	Toll-IL-1 receptor (TIR) domain-containing adaptor molecule-1 (TICAM-1, also named TIR domain-containing adaptor-inducing interferon (IFN)-beta or TRIF)) is a signaling adaptor of Toll-like receptor (TLR) 3/4 that activates the transcription factors, interferon regulatory factor-3 (IRF-3) and NF-kappa B leading to inducing IFN-beta production. The mechanisms by which TICAM-1 is activated by TLR3/4 to serve as a signaling platform are unknown. In this study, we show that homo-oligomerization of TICAM-1 is critical for TICAM-1-mediated activation of NF-kappa B and IRF-3. Both TIR and C-terminal domain of TICAM-1 mediated TICAM-1 oligomerization. Pro(434) located in the TIR domain and the C-terminal region, with the exception of the RIP homotypic-interacting motif, were determinants of TICAM-1 oligomerization. Mutation of TIR domain (P434H) or deletion of C-terminal domain greatly reduced TICAM-1-mediated NF-kappa B and IFN-beta promoter activation. TICAM-1 oligomerization at either the TIR domain or the C-terminal region resulted in recruitment of tumor necrosis factor receptor-associated factor 3, a downstream signaling molecule essential for TICAM-1-mediated IRF- 3 activation, but not recruitment of the IRF- 3 kinase complex, NF-kappa B-activating kinase-associated protein 1 and TANK-binding kinase 1. In addition, RIP homotypic-interacting motif mutant, which possesses two oligomerization motifs but not the RIP1 binding motif, also failed to recruit NF-kappa B-activating kinase-associated protein 1 and TANK-binding kinase 1. Thus, full activation and formation of TICAM-1 signalosomes requires oligomerization induced at two different sites and RIP1 binding.	[Funami, Kenji; Sasai, Miwa; Oshiumi, Hiroyuki; Seya, Tsukasa; Matsumoto, Misako] Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Matsumoto, M (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	matumoto@pop.med.hokudai.ac.jp	Oshiumi, Hiroyuki/G-1645-2012; 美佐子, 松本/A-4497-2012; Funami, Kenji/A-4284-2012; Seya, Tsukasa/A-4336-2012	Oshiumi, Hiroyuki/0000-0003-1567-8722; Sasai, Miwa/0000-0001-6440-3958				Akazawa T, 2007, P NATL ACAD SCI USA, V104, P252, DOI 10.1073/pnas.0605978104; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; Davis CN, 2006, P NATL ACAD SCI USA, V103, P2953, DOI 10.1073/pnas.0510802103; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Funami K, 2007, J IMMUNOL, V179, P6867, DOI 10.4049/jimmunol.179.10.6867; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Loiarro M, 2007, J LEUKOCYTE BIOL, V82, P801, DOI 10.1189/jlb.1206746; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Rowe DC, 2006, P NATL ACAD SCI USA, V103, P6299, DOI 10.1073/pnas.0510041103; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Sasai M, 2005, J IMMUNOL, V174, P27, DOI 10.4049/jimmunol.174.1.27; Sasai M, 2006, J IMMUNOL, V177, P8676, DOI 10.4049/jimmunol.177.12.8676; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Tsujita T, 2004, J BIOL CHEM, V279, P48588, DOI 10.1074/jbc.M407634200; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	41	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18283	18291		10.1074/jbc.M801013200	http://dx.doi.org/10.1074/jbc.M801013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450748	Green Published, hybrid			2022-12-25	WOS:000256949200056
J	Ching, W; Hang, HC; Nusse, R				Ching, Wendy; Hang, Howard C.; Nusse, Roel			Lipid-independent secretion of a Drosophila Wnt protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-RANGE ACTION; TRANSMEMBRANE PROTEIN; MORPHOGEN GRADIENT; SIGNALING PROTEINS; RETROMER COMPLEX; WINGLESS; PORCUPINE; PALMITOYLATION; GLYCOSYLATION; WNTLESS	Wnt proteins comprise a large class of secreted signaling molecules with key roles during embryonic development and throughout adult life. Recently, much effort has been focused on understanding the factors that regulate Wnt signal production. For example, Porcupine and Wntless/Evi/Sprinter have been identified as being required in Wnt-producing cells for the processing and secretion of many Wnt proteins. Interestingly, in this study we find that WntD, a recently characterized Drosophila Wnt family member, does not require Porcupine or Wntless/Evi/Sprinter for its secretion or signaling activity. Because Porcupine is involved in post-translational lipid modification of Wnt proteins, we used a novel labeling method and mass spectrometry to ask whether WntD undergoes lipid modification and found that it does not. Although lipid modification is also hypothesized to be required for Wnt secretion, we find that WntD is secreted very efficiently. WntD secretion does, however, maintain a requirement for the secretory pathway component Rab1. Our results show that not all Wnt family members require lipid modification, Porcupine, or Wntless/Evi/Sprinter for secretion and suggest that different modes of secretion may exist for different Wnt proteins.	[Ching, Wendy; Nusse, Roel] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; [Ching, Wendy; Nusse, Roel] Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA; [Hang, Howard C.] Rockefeller Univ, Lab Chem Biol & Microbial Pathogenesis, New York, NY 10065 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Rockefeller University	Nusse, R (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.	rnusse@stanford.edu			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Belenkaya TY, 2008, DEV CELL, V14, P120, DOI 10.1016/j.devcel.2007.12.003; Fradkin LG, 2004, DEV BIOL, V272, P362, DOI 10.1016/j.ydbio.2004.04.034; Franch-Marro X, 2008, NAT CELL BIOL, V10, P170, DOI 10.1038/ncb1678; Galli LM, 2007, DEVELOPMENT, V134, P3339, DOI 10.1242/dev.02881; Ganguly A, 2005, DEVELOPMENT, V132, P3419, DOI 10.1242/dev.01903; Goodman RM, 2006, DEVELOPMENT, V133, P4901, DOI 10.1242/dev.02674; Gordon MD, 2005, NATURE, V437, P746, DOI 10.1038/nature04073; Hang HC, 2007, J AM CHEM SOC, V129, P2744, DOI 10.1021/ja0685001; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Komekado H, 2007, GENES CELLS, V12, P521, DOI 10.1111/j.1365-2443.2007.01068.x; Kurayoshi M, 2007, BIOCHEM J, V402, P515, DOI 10.1042/BJ20061476; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Miura GI, 2006, CELL CYCLE, V5, P1184, DOI 10.4161/cc.5.11.2804; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pan CL, 2008, DEV CELL, V14, P132, DOI 10.1016/j.devcel.2007.12.001; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Port F, 2008, NAT CELL BIOL, V10, P178, DOI 10.1038/ncb1687; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200; Zhang J, 2007, GENETICS, V176, P1307, DOI 10.1534/genetics.106.066761	35	87	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17092	17098		10.1074/jbc.M802059200	http://dx.doi.org/10.1074/jbc.M802059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430724	hybrid, Green Published			2022-12-25	WOS:000256720600016
J	Hong, SJ; Lardaro, T; Oh, MS; Huh, Y; Ding, YM; Kang, UJ; Kirfel, J; Buettner, R; Kim, KS				Hong, Seok Jong; Lardaro, Thomas; Oh, Myung Sook; Huh, Youngbuhm; Ding, Yunmin; Kang, Un Jung; Kirfel, Jutta; Buettner, Reinhard; Kim, Kwang-Soo			Regulation of the noradrenaline neurotransmitter phenotype by the transcription factor AP-2 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; SYMPATHETIC-NERVOUS-SYSTEM; NEURAL CREST; FACTOR AP-2; TYROSINE-HYDROXYLASE; MOUSE EMBRYOGENESIS; GENE-EXPRESSION; RETINOIC ACID; CELL LINEAGE; PHOX2 GENES	AP-2 family transcription factors are essential for development and morphogenesis of diverse tissues and organs, but their precise roles in specification of neural crest stem cell (NCSC)derived cell types have not been determined. Among three members known to be expressed in the NCSC (i.e. AP-2 alpha, AP-2 beta, and AP-2 gamma), we found that only AP-2 beta is predominantly expressed in the sympathetic ganglia of developing mouse embryos, supporting its role in sympathetic development. Indeed, AP-2 beta null mice expressed significantly reduced levels of both noradrenaline (NA) and NA-synthesizing dopamine beta-hydroxylase in the peripheral nervous system. Strikingly, we also found that NA neuron development was significantly compromised in the locus coeruleus as well. Pharmacological treatment with an NA intermediate during pregnancy significantly rescues the neonatal lethality of AP-2 beta(-/-) mice, indicating that NA deficiency is one of the main causes for lethality found in AP-2 beta(-/-) mice. We also showed that forced expression of AP-2 alpha, but not other AP-2 factors, in NCSC favors their differentiation into NA neurons. In summary, we propose that AP-2 alpha plays critical and distinctive roles in the NA phenotype specification in both the peripheral and central nervous system during development.	[Kim, Kwang-Soo] Harvard Univ, McLean Hosp, Sch Med, Neurobiol Lab,MRC215, Belmont, MA 02478 USA; [Ding, Yunmin; Kang, Un Jung] Univ Chicago, Dept Neurol & Neurobiol, Chicago, IL 60637 USA; [Kirfel, Jutta; Buettner, Reinhard] Univ Hosp, Inst Pathol, D-53127 Bonn, Germany	Harvard University; McLean Hospital; University of Chicago; University of Bonn	Kim, KS (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Neurobiol Lab,MRC215, 115 Mill St, Belmont, MA 02478 USA.	kskim@mclean.harvard.edu	Oh, Myung Sook/AAH-9948-2020; Kang, Un/AAV-2858-2020	Kang, Un/0000-0002-5970-6839	NIDCD NIH HHS [R01 DC006501, DC006501] Funding Source: Medline; NIMH NIH HHS [R01 MH048866, MH48866] Funding Source: Medline; NINDS NIH HHS [R01 NS053919-01A2, R01 NS084869, R01 NS053919] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048866, R29MH048866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006501] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; Andersson E, 2006, CELL, V124, P393, DOI [10.1016/j.cell.2005.10.037, 10.1016/J.CELL.2005.10.037]; Andersson E, 2006, DEVELOPMENT, V133, P507, DOI 10.1242/dev.02224; Brewer S, 2004, DEV BIOL, V267, P135, DOI 10.1016/j.ydbio.2003.10.039; Bronner-Fraser M, 2002, J PHYSIOLOGY-PARIS, V96, P3, DOI 10.1016/S0928-4257(01)00074-2; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Coppola E, 2005, EMBO J, V24, P4392, DOI 10.1038/sj.emboj.7600897; Ebert SN, 1998, J NEUROCHEM, V70, P2286; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; GRECO D, 1995, J NEUROCHEM, V65, P510; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Holzschuh J, 2003, DEVELOPMENT, V130, P5741, DOI 10.1242/dev.00816; Hong SJ, 2006, J NEUROCHEM, V98, P773, DOI 10.1111/j.1471-4159.2006.03924.x; Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034; Huber K, 2006, DEV BIOL, V298, P335, DOI 10.1016/j.ydbio.2006.07.010; Ichikawa H, 2005, BRAIN RES, V1036, P192, DOI 10.1016/j.brainres.2004.10.028; Kele J, 2006, DEVELOPMENT, V133, P495, DOI 10.1242/dev.02223; Kim HS, 2001, J NEUROCHEM, V76, P280, DOI 10.1046/j.1471-4159.2001.00044.x; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; Lucas ME, 2006, DEVELOPMENT, V133, P4015, DOI 10.1242/dev.02574; Marquardt T, 2001, CELL, V106, P651, DOI 10.1016/S0092-8674(01)00499-8; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Morikawa Y, 2007, DEV BIOL, V307, P114, DOI 10.1016/j.ydbio.2007.04.027; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Sauka-Spengler T, 2006, CURR OPIN GENET DEV, V16, P360, DOI 10.1016/j.gde.2006.06.006; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Thomas SA, 1998, J NEUROCHEM, V70, P2468; Wang HV, 2004, DEV DYNAM, V231, P128, DOI 10.1002/dvdy.20119; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	43	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16860	16867		10.1074/jbc.M709106200	http://dx.doi.org/10.1074/jbc.M709106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424435	Green Published, hybrid			2022-12-25	WOS:000256497100063
J	Stotz, SC; Vriens, J; Martyn, D; Clardy, J; Clapham, DE				Stotz, Stephanie C.; Vriens, Joris; Martyn, Derek; Clardy, Jon; Clapham, David E.			Citral Sensing by TRANSient Receptor Potential Channels in Dorsal Root Ganglion Neurons	PLOS ONE			English	Article							CAPSAICIN-RECEPTOR; ION-CHANNEL; TRP CHANNEL; 2-AMINOETHOXYDIPHENYL BORATE; TOPICAL CAPSAICIN; ACTIVATION; HEAT; PAIN; REVEALS; CONSTITUENTS	Transient receptor potential (TRP) ion channels mediate key aspects of taste, smell, pain, temperature sensation, and pheromone detection. To deepen our understanding of TRP channel physiology, we require more diverse pharmacological tools. Citral, a bioactive component of lemongrass, is commonly used as a taste enhancer, as an odorant in perfumes, and as an insect repellent. Here we report that citral activates TRP channels found in sensory neurons (TRPV1 and TRPV3, TRPM8, and TRPA1), and produces long-lasting inhibition of TRPV1 -3 and TRPM8, while transiently blocking TRPV4 and TRPA1. Sustained citral inhibition is independent of internal calcium concentration, but is state-dependent, developing only after TRP channel opening. Citral's actions as a partial agonist are not due to cysteine modification of the channels nor are they a consequence of citral's stereoisoforms. The isolated aldehyde and alcohol cis and trans enantiomers (neral, nerol, geranial, and geraniol) each reproduce citral's actions. In juvenile rat dorsal root ganglion neurons, prolonged citral inhibition of native TRPV1 channels enabled the separation of TRPV2 and TRPV3 currents. We find that TRPV2 and TRPV3 channels are present in a high proportion of these neurons (94% respond to 2-aminoethyldiphenyl borate), consistent with our immunolabeling experiments and previous in situ hybridization studies. The TRPV1 activation requires residues in transmembrane segments two through four of the voltage-sensor domain, a region previously implicated in capsaicin activation of TRPV1 and analogous menthol activation of TRPM8. Citral's broad spectrum and prolonged sensory inhibition may prove more useful than capsaicin for allodynia, itch, or other types of pain involving superficial sensory nerves and skin.	[Stotz, Stephanie C.; Vriens, Joris; Clapham, David E.] Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA; [Stotz, Stephanie C.; Vriens, Joris; Clapham, David E.] Harvard Med Sch, Dept Neurobiol, Boston, MA USA; [Martyn, Derek; Clardy, Jon] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Stotz, SC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Vriens, Joris/G-9966-2018; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Vriens, Joris/0000-0002-2502-0409; 	Howard Hughes Medical Institute	Howard Hughes Medical Institute(Howard Hughes Medical Institute)	Howard Hughes Medical Institute provided funding only. Fonds voor Wetenschappelijk Onderzoek, Flanders provided salary support for Joris Vriens.	Araneda RC, 2004, J PHYSIOL-LONDON, V555, P743, DOI 10.1113/jphysiol.2003.058040; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; Binzen U, 2006, NEUROSCIENCE, V142, P527, DOI 10.1016/j.neuroscience.2006.06.020; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Colton C. K., 2007, V179, P173; DEAL CL, 1991, CLIN THER, V13, P383; Dudai N, 2005, PLANTA MED, V71, P484, DOI 10.1055/s-2005-864146; EPSTEIN JB, 1994, ORAL SURG ORAL MED O, V77, P135, DOI 10.1016/0030-4220(94)90275-5; FRANCKOWIAK G, 1985, EUR J PHARMACOL, V114, P223, DOI 10.1016/0014-2999(85)90631-4; Frosch PJ, 2005, CONTACT DERMATITIS, V52, P216, DOI 10.1111/j.0105-1873.2005.00563.x; Greffrath W, 2003, NEUROREPORT, V14, P2251, DOI 10.1097/00001756-200312020-00023; Heydorn S, 2003, CONTACT DERMATITIS, V49, P32, DOI 10.1111/j.0105-1873.2003.00144.x; Hille B., 1992, IONIC CHANNELS EXCIT; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959-4388(03)00101-6; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Karashima Y, 2007, J NEUROSCI, V27, P9874, DOI 10.1523/JNEUROSCI.2221-07.2007; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kim D, 2007, J NEUROSCI, V27, P6500, DOI 10.1523/JNEUROSCI.0623-07.2007; Liapi A, 2005, EUR J NEUROSCI, V22, P825, DOI 10.1111/j.1460-9568.2005.04270.x; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; More JD, 2002, ORG LETT, V4, P3001, DOI 10.1021/ol026427n; Oka Y, 2006, NEURON, V52, P857, DOI 10.1016/j.neuron.2006.10.019; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Picquet M, 2000, EUR J ORG CHEM, V2000, P2361, DOI 10.1002/1099-0690(200007)2000:13<2361::AID-EJOC2361>3.0.CO;2-S; Price DN, 2006, J INSECT PHYSIOL, V52, P309, DOI 10.1016/j.jinsphys.2005.11.010; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Rau KK, 2007, J NEUROPHYSIOL, V97, P2651, DOI 10.1152/jn.00840.2006; Roberts LA, 2002, BRIT J PHARMACOL, V137, P421, DOI 10.1038/sj.bjp.0704904; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Sadraei H, 2003, FITOTERAPIA, V74, P445, DOI 10.1016/S0367-326X(03)00109-6; Salvatore A, 2004, J CHEM ECOL, V30, P323, DOI 10.1023/B:JOEC.0000017980.66124.d1; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WATSON CPN, 1988, PAIN, V35, P289, DOI 10.1016/0304-3959(88)90139-X; WATSON CPN, 1992, PAIN, V51, P375, DOI 10.1016/0304-3959(92)90223-X; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Xu HX, 2005, J NEUROSCI, V25, P8924, DOI 10.1523/JNEUROSCI.2574-05.2005; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zgani I, 2004, J MED CHEM, V47, P4600, DOI 10.1021/jm049861z; Zou ZH, 2006, SCIENCE, V311, P1477, DOI 10.1126/science.1124755	55	94	101	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2082	10.1371/journal.pone.0002082	http://dx.doi.org/10.1371/journal.pone.0002082			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461159	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400006
J	Delmas, O; Holmes, EC; Talbi, C; Larrous, F; Dacheux, L; Bouchier, C; Bourhy, H				Delmas, Olivier; Holmes, Edward C.; Talbi, Chiraz; Larrous, Florence; Dacheux, Laurent; Bouchier, Christiane; Bourhy, Herve			Genomic Diversity and Evolution of the Lyssaviruses	PLOS ONE			English	Article								Lyssaviruses are RNA viruses with single-strand, negative-sense genomes responsible for rabies-like diseases in mammals. To date, genomic and evolutionary studies have most often utilized partial genome sequences, particularly of the nucleoprotein and glycoprotein genes, with little consideration of genome-scale evolution. Herein, we report the first genomic and evolutionary analysis using complete genome sequences of all recognised lyssavirus genotypes, including 14 new complete genomes of field isolates from 6 genotypes and one genotype that is completely sequenced for the first time. In doing so we significantly increase the extent of genome sequence data available for these important viruses. Our analysis of these genome sequence data reveals that all lyssaviruses have the same genomic organization. A phylogenetic analysis reveals strong geographical structuring, with the greatest genetic diversity in Africa, and an independent origin for the two known genotypes that infect European bats. We also suggest that multiple genotypes may exist within the diversity of viruses currently classified as 'Lagos Bat'. In sum, we show that rigorous phylogenetic techniques based on full length genome sequence provide the best discriminatory power for genotype classification within the lyssaviruses.	[Delmas, Olivier; Talbi, Chiraz; Larrous, Florence; Dacheux, Laurent; Bourhy, Herve] WHO, Collaborating Ctr Reference & Res Rabies, UPRE Lyssavirus Dynam & Host Adaptat, Inst Pasteur, Paris, France; [Holmes, Edward C.] Penn State Univ, Dept Biol, Ctr Infect Dis Dynam, Mueller Lab, University Pk, PA USA; [Bouchier, Christiane] Pasteur Genopole Ile France, Plate forme Genom, Inst Pasteur, Paris, France; [Holmes, Edward C.] NIH, Fogarty Int Ctr, Bethesda, MD USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; World Health Organization; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Delmas, O (corresponding author), WHO, Collaborating Ctr Reference & Res Rabies, UPRE Lyssavirus Dynam & Host Adaptat, Inst Pasteur, Paris, France.	hbourhy@pasteur.fr	Larrous, Florence/AAH-9400-2019; Dacheux, Laurent/AAJ-5372-2020; Holmes, Edward/GVR-9499-2022; Holmes, Edward/Y-2789-2019; Bourhy, Hervé/F-5272-2010	Larrous, Florence/0000-0003-0881-4263; Holmes, Edward/0000-0001-9596-3552; Dacheux, Laurent/0000-0002-4401-3706	European commission through the VIZIER Integrated project [LSHG-CT-2004-511966]; Genomic Platform Ile de France Analyse de la Diversite Genetique des Rhabdoviridae; NIH [GM080533-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080533] Funding Source: NIH RePORTER	European commission through the VIZIER Integrated project; Genomic Platform Ile de France Analyse de la Diversite Genetique des Rhabdoviridae; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	O. Delmas was supported by the European commission through the VIZIER Integrated project (LSHG-CT-2004-511966). This work was also funded by the VIZIER program, and by the grant of Genomic Platform Ile de France Analyse de la Diversite Genetique des Rhabdoviridae 2005 to 2006, and in part by NIH grant number GM080533-01.	Arai YT, 2003, EMERG INFECT DIS, V9, P333, DOI 10.3201/eid0903.020252; Auewarakul P, 2005, VIRUS RES, V109, P33, DOI 10.1016/j.virusres.2004.10.004; Badrane H, 2001, J VIROL, V75, P8096, DOI 10.1128/JVI.75.17.8096-8104.2001; Botvinkin AD, 2003, EMERG INFECT DIS, V9, P1623, DOI 10.3201/eid0912.030374; Bourhy H, 2005, J GEN VIROL, V86, P2849, DOI 10.1099/vir.0.81128-0; BOURHY H, 1989, J GEN VIROL, V70, P2063, DOI 10.1099/0022-1317-70-8-2063; BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; Bourhy H, 1999, J GEN VIROL, V80, P2545, DOI 10.1099/0022-1317-80-10-2545; Davis PL, 2007, ARCH VIROL, V152, P1251, DOI 10.1007/s00705-007-0962-9; Davis PL, 2006, INFECT GENET EVOL, V6, P464, DOI 10.1016/j.meegid.2006.02.007; Davis PL, 2005, J VIROL, V79, P10487, DOI 10.1128/JVI.79.16.10487-10497.2005; Emonet S, 2006, BIOCHEM BIOPH RES CO, V344, P1080, DOI 10.1016/j.bbrc.2006.04.015; Emonet SF, 2007, NAT PROTOC, V2, P340, DOI 10.1038/nprot.2006.453; Faber M, 2004, P NATL ACAD SCI USA, V101, P16328, DOI 10.1073/pnas.0407289101; Finke S, 1999, J VIROL, V73, P3818, DOI 10.1128/JVI.73.5.3818-3825.1999; Gifford R, 2006, AIDS, V20, P1521, DOI 10.1097/01.aids.0000237368.64488.ae; Gould AR, 2002, VIRUS RES, V89, P1, DOI 10.1016/S0168-1702(02)00056-4; Gould AR, 1998, VIRUS RES, V54, P165, DOI 10.1016/S0168-1702(98)00025-2; Holmes EC, 2002, VIROLOGY, V292, P247, DOI 10.1006/viro.2001.1271; KISSI B, 1995, VIROLOGY, V209, P526, DOI 10.1006/viro.1995.1285; Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360; Kuzmin IV, 2005, VIRUS RES, V111, P28, DOI 10.1016/j.virusres.2005.03.008; Kuzmin IV, 2003, VIRUS RES, V97, P65, DOI 10.1016/S0168-1702(03)00217-X; KUZMIN IV, 2008, J CLIN MICROBIOL; LeMercier P, 1997, J GEN VIROL, V78, P1571, DOI 10.1099/0022-1317-78-7-1571; Marston DA, 2007, J GEN VIROL, V88, P1302, DOI 10.1099/vir.0.82692-0; Nadin-Davis SA, 2002, VIROLOGY, V298, P286, DOI 10.1006/viro.2002.1492; Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; SHOPE RE, 1982, YALE J BIOL MED, V55, P271; Steele J.H., 1991, P1; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TORDO N, 1988, VIROLOGY, V165, P565, DOI 10.1016/0042-6822(88)90600-9; TORDO N, 1986, P NATL ACAD SCI USA, V83, P3914, DOI 10.1073/pnas.83.11.3914; Warrell MJ, 2004, LANCET, V363, P959, DOI 10.1016/S0140-6736(04)15792-9; Warrilow D, 2002, VIROLOGY, V297, P109, DOI 10.1006/viro.2002.1417; Wu XF, 2007, VIRUS RES, V129, P91, DOI 10.1016/j.virusres.2007.06.022	38	117	139	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2057	10.1371/journal.pone.0002057	http://dx.doi.org/10.1371/journal.pone.0002057			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446239	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300026
J	Schulte, R; Talamas, J; Doucet, C; Hetzer, MW				Schulte, Roberta; Talamas, Jessica; Doucet, Christine; Hetzer, Martin W.			Single Bead Affinity Detection (SINBAD) for the Analysis of Protein-Protein Interactions	PLOS ONE			English	Article								We present a miniaturized pull-down method for the detection of protein-protein interactions using standard affinity chromatography reagents. Binding events between different proteins, which are color-coded with quantum dots (QDs), are visualized on single affinity chromatography beads by fluorescence microscopy. The use of QDs for single molecule detection allows the simultaneous analysis of multiple protein-protein binding events and reduces the amount of time and material needed to perform a pull-down experiment.	[Schulte, Roberta; Talamas, Jessica; Doucet, Christine; Hetzer, Martin W.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Schulte, R (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hetzer@salk.edu		Doucet, Christine/0000-0002-1611-8279	Salk Institute [Innovation Grant]; NIH [R01 GM073994]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073994] Funding Source: NIH RePORTER	Salk Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Innovation Grant, Salk Institute. This work was supported by the Pew Scholar program and NIH R01 GM073994.	Anderson DJ, 2007, NAT CELL BIOL, V9, P1160, DOI 10.1038/ncb1636; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Burbulis I, 2007, NAT METHODS, V4, P1011, DOI 10.1038/nmeth1127; D'Angelo MA, 2006, SCIENCE, V312, P440, DOI 10.1126/science.1124196; Franz C, 2007, EMBO REP, V8, P165, DOI 10.1038/sj.embor.7400889; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HETZER M, 2005, ANN REV CELL DEV BIO; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Oh BK, 2006, SMALL, V2, P103, DOI 10.1002/smll.200500260; Patel SS, 2008, MOL CELL PROTEOMICS, V7, P121, DOI 10.1074/mcp.M700407-MCP200; Patolsky F, 2006, ANAL CHEM, V78, P4260, DOI 10.1021/ac069419j; Stansel RM, 2001, EMBO J, V20, P5532; Walther TC, 2003, CELL, V113, P195, DOI 10.1016/S0092-8674(03)00235-6; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Zhang CY, 2006, ANALYST, V131, P484, DOI 10.1039/b514309h	20	7	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2061	10.1371/journal.pone.0002061	http://dx.doi.org/10.1371/journal.pone.0002061			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446240	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300030
J	Wellens, A; Garofalo, C; Nguyen, H; Van Gerven, N; Slattegard, R; Hernalsteens, JP; Wyns, L; Oscarson, S; De Greve, H; Hultgren, S; Bouckaert, J				Wellens, Adinda; Garofalo, Corinne; Nguyen, Hien; Van Gerven, Nani; Slattegard, Rikard; Hernalsteens, Jean-Pierre; Wyns, Lode; Oscarson, Stefan; De Greve, Henri; Hultgren, Scott; Bouckaert, Julie			Intervening with Urinary Tract Infections Using Anti-Adhesives Based on the Crystal Structure of the FimH-Oligomannose-3 Complex	PLOS ONE			English	Article								Background: Escherichia coli strains adhere to the normally sterile human uroepithelium using type 1 pili, that are long, hairy surface organelles exposing a mannose-binding FimH adhesin at the tip. A small percentage of adhered bacteria can successfully invade bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia and alpha 3 beta 1 integrins found throughout the uroepithelium. Invaded bacteria replicate and mature into dense, biofilm-like inclusions in preparation of fluxing and of infection of neighbouring cells, being the major cause of the troublesome recurrent urinary tract infections. Methodology/Principal Findings: We demonstrate that alpha-D-mannose based inhibitors of FimH not only block bacterial adhesion on uroepithelial cells but also antagonize invasion and biofilm formation. Heptyl a-D-mannose prevents binding of type 1-piliated E. coli to the human bladder cell line 5637 and reduces both adhesion and invasion of the UTI89 cystitis isolate instilled in mouse bladder via catheterization. Heptyl a-D-mannose also specifically inhibited biofilm formation at micromolar concentrations. The structural basis of the great inhibitory potential of alkyl and aryl alpha-D-mannosides was elucidated in the crystal structure of the FimH receptor-binding domain in complex with oligomannose-3. FimH interacts with Man alpha 1,3Man beta 1,4GlcNAc beta 1,4GlcNAc in an extended binding site. The interactions along the alpha 1,3 glycosidic bond and the first beta 1,4 linkage to the chitobiose unit are conserved with those of FimH with butyl a-D-mannose. The strong stacking of the central mannose with the aromatic ring of Tyr48 is congruent with the high affinity found for synthetic inhibitors in which this mannose is substituted for by an aromatic group. Conclusions/Significance: The potential of ligand-based design of antagonists of urinary tract infections is ruled by the structural mimicry of natural epitopes and extends into blocking of bacterial invasion, intracellular growth and capacity to fluxing and of recurrence of the infection.	[Wellens, Adinda; Nguyen, Hien; Wyns, Lode; De Greve, Henri; Bouckaert, Julie] Free Univ Brussels, Dept Mol & Cellular Interact, Brussels, Belgium; [Wellens, Adinda; Nguyen, Hien; Wyns, Lode; De Greve, Henri; Bouckaert, Julie] Free Univ Brussels, Brussels, Belgium; [Garofalo, Corinne; Hultgren, Scott] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO USA; [Van Gerven, Nani; Hernalsteens, Jean-Pierre] Free Univ Brussels, Viral Genet, Brussels, Belgium; [Slattegard, Rikard] Stockholm Univ, Arrhenius Lab, Dept Organ Chem, Stockholm, Sweden; [Oscarson, Stefan] Univ Coll Dublin, Ctr Synthesis & Chem Biol, Dublin, Ireland	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Washington University (WUSTL); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Stockholm University; University College Dublin	Wellens, A (corresponding author), Free Univ Brussels, Dept Mol & Cellular Interact, Brussels, Belgium.	bouckaej@vub.ac.be		Oscarson, Stefan/0000-0002-8273-4918; Bouckaert, Julie/0000-0001-8112-1442; Van Gerven, Nani/0000-0002-4269-3904; Hernalsteens, Jean-Pierre/0000-0003-2146-0586	FWO-Flanders (FWO) [postdoctoral fellowship]; Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen); EMBL;  [DK51406];  [Scor P50 DK64540];  [AI48689]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406, P50DK064540] Funding Source: NIH RePORTER	FWO-Flanders (FWO)(FWO); Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); EMBL; ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	JB received a postdoctoral fellowship from the FWO-Flanders (FWO). NVG is a recipient of a Ph.D grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen). The use of beamline X12 at the DESY synchrotron in Hamburg, Germany for project PX-06-92 was funded by the EMBL. Supported by grants DK51406, Scor P50 DK64540 and AI48689.	ANDERSON BN, J BACTERIOL, V189, P1794; Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550; Apodaca G, 2004, TRAFFIC, V5, P117, DOI 10.1046/j.1600-0854.2003.00156.x; Aprikian P, 2007, J BIOL CHEM, V282, P23437, DOI 10.1074/jbc.M702037200; ARONSON M, 1979, ISRAEL J MED SCI, V15, P88; Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x; Bishop BL, 2007, NAT MED, V13, P625, DOI 10.1038/nm1572; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; Bouckaert J, 2006, MOL MICROBIOL, V61, P1556, DOI 10.1111/j.1365-2958.2006.05352.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1992, IRIS 4D SERIES; Cavallone D, 2004, J BIOL CHEM, V279, P216, DOI 10.1074/jbc.M308821200; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; De Greve H, 2007, CURR OPIN STRUC BIOL, V17, P506, DOI 10.1016/j.sbi.2007.06.011; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Duncan MJ, 2005, J BIOL CHEM, V280, P37707, DOI 10.1074/jbc.M501249200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eto DS, 2007, PLOS PATHOG, V3, P949, DOI 10.1371/journal.ppat.0030100; Eto DS, 2007, NAT MED, V13, P531, DOI 10.1038/nm0507-531; Eto DS, 2006, CELL MICROBIOL, V8, P704, DOI 10.1111/j.1462-5822.2006.00691.x; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; Foulquier F, 2004, EUR J BIOCHEM, V271, P398, DOI 10.1046/j.1432-1033.2003.03938.x; Foxman B, 2003, DM-DIS MON, V49, P53, DOI 10.1067/mda.2003.7; Garofalo CK, 2007, INFECT IMMUN, V75, P52, DOI 10.1128/IAI.01123-06; Geerlings SE, 2002, INT J ANTIMICROB AG, V19, P539, DOI 10.1016/S0924-8579(02)00090-0; Geerlings SE, 2002, DIABETES CARE, V25, P1405, DOI 10.2337/diacare.25.8.1405; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; IMBERTY A, 1993, ADV BIOPH C, V0003; Justice SS, 2006, P NATL ACAD SCI USA, V103, P19884, DOI 10.1073/pnas.0606329104; Justice SS, 2006, INFECT IMMUN, V74, P4793, DOI 10.1128/IAI.00355-06; Justice SS, 2004, P NATL ACAD SCI USA, V101, P1333, DOI 10.1073/pnas.0308125100; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Langermann S, 2000, J INFECT DIS, V181, P774, DOI 10.1086/315258; Liang FX, 2001, BIOCHEM J, V355, P13, DOI 10.1042/0264-6021:3550013; Litynska A, 2002, ACTA BIOCHIM POL, V49, P491; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Min GW, 2002, J MOL BIOL, V317, P697, DOI 10.1006/jmbi.2002.5442; MINION FC, 1989, J BACTERIOL, V165, P1033; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mysorekar IU, 2006, P NATL ACAD SCI USA, V103, P14170, DOI 10.1073/pnas.0602136103; NEESER JR, 1986, INFECT IMMUN, V52, P428, DOI 10.1128/IAI.52.2.428-436.1986; Nilsson LM, 2006, J BIOL CHEM, V281, P16656, DOI 10.1074/jbc.M511496200; Nilsson LM, 2006, APPL ENVIRON MICROB, V72, P3005, DOI 10.1128/AEM.72.4.3005-3010.2006; NORDEN NE, 1973, J BIOL CHEM, V248, P6210; Orndorff PE, 2004, INFECT IMMUN, V72, P1929, DOI 10.1128/IAI.72.4.1929-1938.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak J, 2001, J BIOL CHEM, V276, P9924, DOI 10.1074/jbc.M008610200; Rijavec M, 2006, CURR MICROBIOL, V53, P158, DOI 10.1007/s00284-005-0501-4; ROSENSTEIN IJ, 1988, LANCET, V2, P1327; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Schilling JD, 2002, INT J ANTIMICROB AG, V19, P457, DOI 10.1016/S0924-8579(02)00098-5; Serafini-Cessi F, 2005, GLYCOCONJUGATE J, V22, P383, DOI 10.1007/s10719-005-2142-z; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Svanborg C, 2006, CURR OPIN MICROBIOL, V9, P33, DOI 10.1016/j.mib.2005.12.012; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Touaibia M, 2007, CHEMMEDCHEM, V2, P1190, DOI 10.1002/cmdc.200700063; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Valle J, 2006, P NATL ACAD SCI USA, V103, P12558, DOI 10.1073/pnas.0605399103; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Wright KJ, 2007, CELL MICROBIOL, V9, P2230, DOI 10.1111/j.1462-5822.2007.00952.x; Xie B, 2006, J BIOL CHEM, V281, P14644, DOI 10.1074/jbc.M600877200; Zhou G, 2001, J CELL SCI, V114, P4095	72	194	211	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2040	10.1371/journal.pone.0002040	http://dx.doi.org/10.1371/journal.pone.0002040			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446213	Green Published, gold			2022-12-25	WOS:000261572300012
J	Zhang, JX; Diehl, GE; Littman, DR				Zhang, Jing-xin; Diehl, Gretchen E.; Littman, Dan R.			Relief of Preintegration Inhibition and Characterization of Additional Blocks for HIV Replication in Primary Mouse T Cells	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CENTRAL-NERVOUS-SYSTEM; QUANTITATIVE ASSAY; VIRAL-DNA; HUMAN CD4; INFECTION; EXPRESSION; LYMPHOCYTES; ENTRY; CCR5	Development of a small animal model to study HIV replication and pathogenesis has been hampered by the failure of the virus to replicate in non- primate cells. Most studies aimed at achieving replication in murine cells have been limited to fibroblast cell lines, but generating an appropriate model requires overcoming blocks to viral replication in primary T cells. We have studied HIV- 1 replication in CD4(+) T cells from human CD4/CCR5/Cyclin T1 transgenic mice. Expression of hCD4 and hCCR5 in mouse CD4(+) T cells enabled efficient entry of R5 strain HIV- 1. In mouse T cells, HIV- 1 underwent reverse transcription and nuclear import as efficiently as in human T cells. In contrast, chromosomal integration of HIV- 1 proviral DNA was inefficient in activated mouse T cells. This process was greatly enhanced by providing a secondary T cell receptor ( TCR) signal after HIV- 1 infection, especially between 12 to 24 h post infection. This effect was specific for primary mouse T cells. The pathways involved in HIV replication appear to be PKC theta-, CARMA1-, and WASp-independent. Treatment with Cyclosporin A (CsA) further relieved the pre-integration block. However, transcription of HIV-1 RNA was still reduced in mouse CD4+ T cells despite expression of the hCyclin T1 transgene. Additional post-transcriptional defects were observed at the levels of Gag expression, Gag processing, Gag release and virus infectivity. Together, these post-integration defects resulted in a dramatically reduced yield of infectious virus (300-500 fold) after a single cycle of HIV-1 replication. This study implies the existence of host factors, in addition to those already identified, that are critical for HIV-1 replication in mouse cells. This study also highlights the differences between primary T cells and cell lines regarding pre-integration steps in the HIV-1 replication cycle.	[Zhang, Jing-xin; Diehl, Gretchen E.; Littman, Dan R.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10003 USA; [Littman, Dan R.] NYU, Sch Med, Dept Microbiol & Pathol, New York, NY USA; [Littman, Dan R.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA	New York University; New York University; Howard Hughes Medical Institute; New York University	Zhang, JX (corresponding author), NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10003 USA.	littman@saturn.med.nyu.edu		Diehl, Gretchen/0000-0002-1841-2842	National Institutes of Health [AI033856, AI033303]; American Cancer Society; Biogen Idec; Genetech; Ronald Levy Postdoctoral Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033303, R37AI033303, R01AI033856] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Biogen Idec(Biogen); Genetech; Ronald Levy Postdoctoral Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the National Institutes of Health to DRL (AI033856; AI033303). GED is supported by the American Cancer Society-Biogen Idec/Genetech/Ronald Levy Postdoctoral Fellowship. The sponsors had no role in design or conduct of the study.	Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baenziger S, 2006, P NATL ACAD SCI USA, V103, P15951, DOI 10.1073/pnas.0604493103; Baumann JG, 2004, J VIROL, V78, P12537, DOI 10.1128/JVI.78.22.12537-12547.2004; Berthoux L, 2004, J VIROL, V78, P11739, DOI 10.1128/JVI.78.21.11739-11750.2004; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; Chen BK, 2001, P NATL ACAD SCI USA, V98, P15239, DOI 10.1073/pnas.261563198; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; Coskun AK, 2006, J VIROL, V80, P3406, DOI 10.1128/JVI.80.7.3406-3415.2006; Cuenda A, 2000, METH MOL B, V99, P161; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 2001, MOL CELL BIOL, V21, P1164, DOI 10.1128/MCB.21.4.1164-1172.2001; De SK, 1997, J CLIN INVEST, V99, P1484, DOI 10.1172/JCI119310; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Garza HH, 1996, J IMMUNOL, V156, P3631; Goffinet C, 2007, P NATL ACAD SCI USA, V104, P1015, DOI 10.1073/pnas.0607414104; Greger JG, 2005, J VIROL, V79, P4610, DOI 10.1128/JVI.79.8.4610-4618.2005; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hatziioannou T, 2005, J VIROL, V79, P15586, DOI 10.1128/JVI.79.24.15586-15589.2005; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Holm GH, 2004, J VIROL, V78, P4541, DOI 10.1128/JVI.78.9.4541-4551.2004; Huang YP, 2007, J CELL SCI, V120, P723, DOI 10.1242/jcs.000786; Hubner W, 2006, VIROLOGY, V352, P27, DOI 10.1016/j.virol.2006.04.024; Jamieson BD, 1997, J VIROL, V71, P8245, DOI 10.1128/JVI.71.11.8245-8253.1997; Julias JG, 2001, J VIROL, V75, P6537, DOI 10.1128/JVI.75.14.6537-6546.2001; Keppler OT, 2002, J EXP MED, V195, P719, DOI 10.1084/jem.20011549; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; Mariani R, 2000, J VIROL, V74, P3859, DOI 10.1128/JVI.74.8.3859-3870.2000; Mariani R, 2001, J VIROL, V75, P3141, DOI 10.1128/JVI.75.7.3141-3151.2001; McCune JM, 1997, SCIENCE, V278, P2141, DOI 10.1126/science.278.5346.2141; Morner A, 1999, J VIROL, V73, P2343; Noser JA, 2006, J VIROL, V80, P7769, DOI 10.1128/JVI.02427-05; O'Doherty U, 2002, J VIROL, V76, P10942, DOI 10.1128/JVI.76.21.10942-10950.2002; Oswald-Richter K, 2004, EUR J IMMUNOL, V34, P1705, DOI 10.1002/eji.200424892; Reed M, 2002, J VIROL, V76, P436, DOI 10.1128/JVI.76.1.436-443.2002; Sastry L, 2004, HUM GENE THER, V15, P221, DOI 10.1089/104303404772680029; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; Sokolskaja E, 2006, J VIROL, V80, P2855, DOI 10.1128/JVI.80.6.2855-2862.2006; Sokolskaja E, 2006, CURR OPIN MICROBIOL, V9, P404, DOI 10.1016/j.mib.2006.06.011; Sun JL, 2006, J VIROL, V80, P1850, DOI 10.1128/JVI.80.4.1850-1862.2006; Sundrud MS, 2005, BLOOD, V106, P3440, DOI 10.1182/blood-2005-03-0857; Swanson CM, 2004, EMBO J, V23, P2632, DOI 10.1038/sj.emboj.7600270; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004; Tsurutani N, 2007, J VIROL, V81, P677, DOI 10.1128/JVI.00870-06; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zheng YH, 2003, NAT CELL BIOL, V5, P611, DOI 10.1038/ncb1000; Zhou Y, 2005, J VIROL, V79, P2199, DOI 10.1128/JVI.79.4.2199-2210.2005	60	29	30	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2035	10.1371/journal.pone.0002035	http://dx.doi.org/10.1371/journal.pone.0002035			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446227	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300008
J	Kerkhoven, RM; Sie, D; Nieuwland, M; Heimerikx, M; De Ronde, J; Brugman, W; Velds, A				Kerkhoven, Ron M.; Sie, Daoud; Nieuwland, Marja; Heimerikx, Mike; De Ronde, Jorma; Brugman, Wim; Velds, Arno			The T7-Primer Is a Source of Experimental Bias and Introduces Variability between Microarray Platforms	PLOS ONE			English	Article								Eberwine(-like) amplification of mRNA adds distinct 6-10 bp nucleotide stretches to the 59 end of amplified RNA transcripts. Analysis of over six thousand microarrays reveals that probes containing motifs complementary to these stretches are associated with aberrantly high signals up to a hundred fold the signal observed in unaffected probes. This is not observed when total RNA is used as target source. Different T7 primer sequences are used in different laboratories and platforms and consequently different T7 primer bias is observed in different datasets. This will hamper efforts to compare data sets across platforms.	[Kerkhoven, Ron M.; Sie, Daoud; Nieuwland, Marja; Heimerikx, Mike; De Ronde, Jorma; Brugman, Wim; Velds, Arno] Netherlands Canc Inst, Cent Microarray Facil, Amsterdam, Netherlands	Netherlands Cancer Institute	Kerkhoven, RM (corresponding author), Netherlands Canc Inst, Cent Microarray Facil, Amsterdam, Netherlands.	r.kerkhoven@nki.nl		Velds, Arno/0000-0003-4333-8872; Sie, Daoud/0000-0001-6762-2582				Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; He ZL, 2005, APPL ENVIRON MICROB, V71, P3753, DOI 10.1128/AEM.71.7.3753-3760.2005; Kuo WP, 2006, NAT BIOTECHNOL, V24, P832, DOI 10.1038/nbt1217; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Nacheva GA, 2003, EUR J BIOCHEM, V270, P1458, DOI 10.1046/j.1432-1033.2003.03510.x; Petalidis L, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng142; Petersen D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-63; *R DEV COR TEAM, 2007, LANG ENV STAT COMP R; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546	12	19	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1980	10.1371/journal.pone.0001980	http://dx.doi.org/10.1371/journal.pone.0001980			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431470	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700005
J	Adachi, Y; Shibai, Y; Mitsushita, J; Shang, WH; Hirose, K; Kamata, T				Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Hirose, K.; Kamata, T.			Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6	ONCOGENE			English	Article						Ras; Nox1; ROS; GATA-6; gene expression	COLON EPITHELIAL-CELLS; NADPH OXIDASE; TRANSCRIPTION FACTORS; NAD(P)H OXIDASE; REACTIVE OXYGEN; MUSCLE-CELLS; BINDING; SUPEROXIDE; PROTEIN; NOX1	Ras oncogene upregulates the expression of nicotinamide adenine dinucleotide phosphate oxidase (Nox) 1 via the Raf/MEK/ERK pathway, leading to the elevated production of reactive oxygen species that is essential for maintenance of Ras-transformation phenotypes. However, the precise transcriptional control mechanism underlying Ras-induced Nox1 expression remains to be elucidated. Here we demonstrated that via the MEK/ERK pathway, Ras signaling enhances the activity of the functional Nox1 promoter (nt -321 to -1) in colon cancer CaCo-2 cells and thereby induces the formation of the specific protein DNA complexes in the two GATA-binding site-containing regions (nt -161 to -136 and -125 to -100). Supershift assays with GATA antibodies, protein analyses and chromatin immunoprecipitation revealed that GATA-6 is a component of the specific protein - DNA complexes at the Nox1 promoter. GATA-6 was able to trans-activate the Nox1 promoter but not a promoter in which the GATA-binding sites are mutated. Moreover, GATA-6 was phosphorylated at serine residues by MEK-activated ERK, which increased GATA-6 DNA binding, correlating with suppression of the Nox1 promoter activity by an MEK inhibitor PD98059. Finally, the site-directed mutation of the consensus ERK phosphorylation site (PYS(120)P to PYA(120)P) of GATA-6 abolished its trans-activation activity, suppressing of the growth of CaCo-2 cells. On the basis of these results, we propose that oncogenic Ras signaling upregulates the transcription of Nox1 through MEK-ERK-dependent phosphorylation of GATA-6.	[Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Kamata, T.] Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Hirose, K.] Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr J Downward, Dr E Nishida and Dr M Maeda for plasmid DNAs. This study was supported by Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (TK).	ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brewer AC, 2006, FREE RADICAL BIO MED, V40, P260, DOI 10.1016/j.freeradbiomed.2005.08.022; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Debruyne PR, 2003, ONCOGENE, V22, P7199, DOI 10.1038/sj.onc.1206628; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Yu YL, 2005, J BIOL CHEM, V280, P29533, DOI 10.1074/jbc.M506514200	35	92	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4921	4932		10.1038/onc.2008.133	http://dx.doi.org/10.1038/onc.2008.133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454176				2022-12-25	WOS:000258596900006
J	Zhang, Y; Wang, Z; Li, X; Magnuson, NS				Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S.			Pim kinase-dependent inhibition of c-Myc degradation	ONCOGENE			English	Article						c-Myc; phosphorylation; Pim-1/Pim-2; stabilization	TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; LYMPHOID TUMORS; N-MYC; PROTOONCOGENE; PHOSPHORYLATION; LYMPHOMAGENESIS; CANCER; IDENTIFICATION; GROWTH	Pim kinases are found to be highly expressed in leukemia, lymphoma, prostate and pancreatic cancer. Bitransgenic mice overexpressing either Pim-1 or Pim-2 and c-Myc succumb to pre-B-cell lymphoma at a strikingly accelerated speed. Despite that Pim-1/Pim-2 has long been recognized as a strong synergistic partner with c-Myc in tumorigenesis, the mechanism underlying the synergism is still not well understood. Overexpression of Pim-1/Pim-2 kinase dramatically stabilizes c-Myc in vivo, and the stabilization is partially mediated by phosphorylation of c-Myc by Pim kinase on a novel site, Ser329. We provide evidence that Pim-2 is more efficient in directly phosphorylating c-Myc Ser329 to stabilize c-Myc. In contrast, we find that Pim-1 is more effective in mediating a decrease in c-Myc Thr58 phosphorylation and an increase in c-Myc Ser62 phosphorylation than in phosphorylating Ser329. In either case, through stabilizing c-Myc, Pim-1/Pim-2 kinases enhance the transcriptional activity of c-Myc. Also knocking down either Pim-1 or Pim-2 dramatically decreases the endogenous levels of c-Myc and thus, its transcriptional activity. Finally, coexpression of the Pim kinases and c-Myc enhances the transforming activity of c-Myc as does the phosphomimic mutant of c-Myc on Ser329. We conclude that these findings appear to explain at least in part the mechanism underlying the synergism between the Pim kinases and c-Myc in tumorigenesis.	[Zhang, Y.; Wang, Z.; Magnuson, N. S.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA; [Li, X.] Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83843 USA	Washington State University; Idaho; University of Idaho	Magnuson, NS (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA.	magnuson@wsu.edu	Zhang, Yandong/AAE-2231-2019	Zhang, Yandong/0000-0002-1900-7224	NATIONAL CANCER INSTITUTE [R01CA104470] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA104470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1991, CANCER RES, V51, P958; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; CUYPERS HT, 1984, CELL, V37, P141; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; DEBOTH NJ, 1989, LEUKEMIA RES, V13, P53, DOI 10.1016/0145-2126(89)90031-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Malempati S, 2006, LEUKEMIA, V20, P1572, DOI 10.1038/sj.leu.2404317; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; MOROY T, 1991, ONCOGENE, V6, P1941; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Peng C, 2007, J BIOCHEM, V141, P353, DOI 10.1093/jb/mvm040; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	33	165	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4809	4819		10.1038/onc.2008.123	http://dx.doi.org/10.1038/onc.2008.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438430				2022-12-25	WOS:000258445100006
J	Ishida, H; Borman, MA; Ostrander, J; Vogel, HJ; MacDonald, JA				Ishida, Hiroaki; Borman, Meredith A.; Ostrander, Janina; Vogel, Hans J.; MacDonald, Justin A.			Solution structure of the calponin homology (CH) domain from the smoothelin-like 1 protein - A unique apocalmodulin-binding mode and the possible role of the C-terminal type-2 CH-domain in smooth muscle relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING; IQ MOTIF; CALMODULIN-BINDING; MYOSIN-V; F-ACTIN; DIPOLAR COUPLINGS; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; NMR; CONTRACTILITY	The SMTNL1 protein contains a single type-2 calponin homology (CH) domain at its C terminus that shares sequence identity with the smoothelin family of smooth muscle-specific proteins. In contrast to the smoothelins, SMTNL1 does not associate with F-actin in vitro, and its specific role in smooth muscle remains unclear. In addition, the biological function of the C-terminal CH-domains found in the smoothelin proteins is also poorly understood. In this work, we have therefore determined the solution structure of the CH-domain of mouse SMTNL1 (SMTNL1-CH; residues 346-459). The secondary structure and the overall fold for the C-terminal type-2 CH-domain is very similar to that of other CH-domains. However, two clusters of basic residues form a unique surface structure that is characteristic of SMTNL1-CH. Moreover, the protein has an extended C-terminal alpha-helix, which contains a calmodulin (CaM)-binding IQ-motif, that is also a distinct feature of the smoothelins. We have characterized the binding of apo-CaM to SMTNL1-CH through its IQ-motif by isothermal titration calorimetry and NMR chemical shift perturbation studies. In addition, we have used the HADDOCK protein-protein docking approach to construct a model for the complex of apo-CaM and SMTNL1-CH. The model revealed a close interaction of SMTNL1-CH with the two Ca2+ binding loop regions of the C-terminal domain of apo-CaM; this mode of apo-CaM binding is distinct from previously reported interactions of apo-CaM with IQ-motifs. Finally, we comment on the putative role of the CH-domain in the biological function of SMTNL1.	[Ishida, Hiroaki; Vogel, Hans J.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 4N1, Canada; [Borman, Meredith A.; Ostrander, Janina; MacDonald, Justin A.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	MacDonald, JA (corresponding author), Univ Calgary, Fac Med, Libin Cardiovasc Inst Alberta, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jmacdo@ucalgary.ca		MacDonald, Justin/0000-0002-9238-8473				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Borman MA, 2004, FEBS LETT, V573, P207, DOI 10.1016/j.febslet.2004.08.002; Borrego-Diaz E, 2006, J STRUCT BIOL, V155, P230, DOI 10.1016/j.jsb.2006.01.013; Bramham J, 2002, STRUCTURE, V10, P249, DOI 10.1016/S0969-2126(02)00703-7; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Chou JJ, 2000, J BIOMOL NMR, V18, P217, DOI 10.1023/A:1026563923774; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cui YF, 2003, ANAL BIOCHEM, V315, P175, DOI 10.1016/S0003-2697(03)00007-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dickerson JB, 2006, BRAIN RES, V1092, P16, DOI 10.1016/j.brainres.2006.03.048; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gifford JL, 2007, BIOCHEM J, V405, P199, DOI 10.1042/BJ20070255; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Houdusse A, 2006, P NATL ACAD SCI USA, V103, P19326, DOI 10.1073/pnas.0609436103; ITAKURA M, 1992, J BIOCHEM, V112, P183, DOI 10.1093/oxfordjournals.jbchem.a123875; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; Jee JunGoo, 2003, Journal of Structural and Functional Genomics, V4, P179, DOI 10.1023/A:1026122726574; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Korenbaum E, 2002, J CELL SCI, V115, P3543, DOI 10.1242/jcs.00003; Li QW, 2004, BIOCHEM BIOPH RES CO, V317, P787, DOI 10.1016/j.bbrc.2004.03.119; Martin SR, 2004, FEBS LETT, V567, P166, DOI 10.1016/j.febslet.2004.04.053; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Nakamura F, 2005, J BIOL CHEM, V280, P32426, DOI 10.1074/jbc.M502203200; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Putkey JA, 2003, J BIOL CHEM, V278, P49667, DOI 10.1074/jbc.C300372200; Putkey JA, 2008, J BIOL CHEM, V283, P1401, DOI 10.1074/jbc.M703831200; Quensel C, 2002, J CELL BIOCHEM, V85, P403, DOI 10.1002/jcb.10143; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SOBEL JS, 1988, DEV BIOL, V126, P47, DOI 10.1016/0012-1606(88)90237-0; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Sun HB, 2006, J BIOMOL NMR, V36, P295, DOI 10.1007/s10858-006-9062-5; Suzuki T, 2002, J BIOL CHEM, V277, P14933, DOI 10.1074/jbc.M111842200; Szymanski PT, 2004, J MUSCLE RES CELL M, V25, P7, DOI 10.1023/B:JURE.0000021349.47697.bf; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; Terrak M, 2005, P NATL ACAD SCI USA, V102, P12718, DOI 10.1073/pnas.0503899102; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; van Eys GJ, 2007, TRENDS CARDIOVAS MED, V17, P26, DOI 10.1016/j.tcm.2006.11.001; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	56	23	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20569	20578		10.1074/jbc.M800627200	http://dx.doi.org/10.1074/jbc.M800627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18477568	hybrid			2022-12-25	WOS:000257565300069
J	Bjorkblom, B; Vainio, JC; Hongisto, V; Herdegen, T; Courtney, MJ; Coffey, ET				Bjorkblom, Benny; Vainio, Jenni C.; Hongisto, Vesa; Herdegen, Thomas; Courtney, Michael J.; Coffey, Eleanor T.			All JNKs can kill, but nuclear localization is critical for neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASES; C-JUN PHOSPHORYLATION; CEREBELLAR GRANULE NEURONS; TRANSCRIPTION FACTOR; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; BRAIN-DEVELOPMENT; STRESS; PATHWAY	JNKs are implicated in a range of brain pathologies and receive considerable attention as potential therapeutic targets. However, JNKs also regulate physiological and homeostatic processes. Anattractive hypothesis from the drug development perspective is that distinct JNK isoforms mediate "physiological" and "pathological" responses. However, this lacks experimental evaluation. Here we investigate the isoforms, subcellular pools, and c-Jun/ATF2 targets of JNK in death of central nervous system neurons following withdrawal of trophic support. We use gene knockouts, gene silencing, subcellularly targeted dominant negative constructs, and pharmacological inhibitors. Combined small interfering RNA knockdown of all JNKs 1, 2, and 3, provides substantial neuroprotection. In contrast, knockdown or knock-out of individual JNKs or two JNKs together does not protect. This explains why the evidence for JNK in neuronal death has to date been largely pharmacological. Complete knockdown of c-Jun and ATF2 using small interfering RNA also fails to protect, casting doubt on c-Jun as a critical effector of JNK in neuronal death. Nonetheless, the death requires nuclear but not cytosolic JNK activity as nuclear dominant negative inhibitors of JNK protect, whereas cytosolic inhibitors only block physiological JNK function. Thus any one of the three JNKs is capable of mediating apoptosis and inhibition of nuclear JNK is protective.	[Coffey, Eleanor T.] Univ Turku, Turku Ctr Biotechnol, Abo Akad, FIN-20521 Turku, Finland; [Bjorkblom, Benny; Vainio, Jenni C.; Hongisto, Vesa; Courtney, Michael J.; Coffey, Eleanor T.] Abo Akad Univ, FIN-20521 Turku, Finland; [Herdegen, Thomas] Inst Pharmacol, D-24105 Kiel, Germany; [Courtney, Michael J.] Univ Kuopio, Dept Neurobiol, AI Virtanen Inst, FIN-70211 Kuopio, Finland	Abo Akademi University; University of Turku; Abo Akademi University; University of Eastern Finland	Coffey, ET (corresponding author), Univ Turku, Turku Ctr Biotechnol, Abo Akad, Tykistokatu 6, FIN-20521 Turku, Finland.	ecoffey@btk.fi	Courtney, Michael J/D-6648-2016; herdegen, thomas/E-5135-2010	Courtney, Michael J/0000-0001-8693-3933; Coffey, Eleanor/0000-0002-9717-5610				Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Besirli CG, 2005, J CELL BIOL, V170, P401, DOI 10.1083/jcb.200501138; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Brazil M, 2003, NAT REV DRUG DISCOV, V2, P5, DOI 10.1038/nrd993; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; Eilers A, 1998, J NEUROSCI, V18, P1713; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Hu YH, 1997, J BIOL CHEM, V272, P9113; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Keramaris E, 2005, J BIOL CHEM, V280, P1132, DOI 10.1074/jbc.M410127200; Kimberly WT, 2005, J NEUROSCI, V25, P5533, DOI 10.1523/JNEUROSCI.4883-04.2005; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Nielsen C, 2007, CANCER RES, V67, P178, DOI 10.1158/0008-5472.CAN-06-2801; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Resnick L, 2004, DRUG DISCOV TODAY, V9, P932, DOI 10.1016/S1359-6446(04)03251-9; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Tararuk T, 2006, J CELL BIOL, V173, P265, DOI 10.1083/jcb.200511055; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Virdee K, 1997, J NEUROCHEM, V69, P550; Waetzig V, 2006, PROG NEUROBIOL, V80, P84, DOI 10.1016/j.pneurobio.2006.08.002; Watson A, 1998, J NEUROSCI, V18, P751; Westerlund N, 2008, EXPERT OPIN THER TAR, V12, P31, DOI 10.1517/14728222.12.1.31; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	45	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19704	19713		10.1074/jbc.M707744200	http://dx.doi.org/10.1074/jbc.M707744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474608	hybrid, Green Published			2022-12-25	WOS:000257387600055
J	Izquierdo, JM				Izquierdo, Jose M.			Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BINDING-PROTEIN; IMMUNE-SYSTEM; ELAV PROTEIN; TIA-1; DIFFERENTIATION; EXPRESSION; PTB; STABILIZATION; REPRESSION	Exclusion of exon 6 by alternative RNA splicing of the primary transcript of the apoptosis receptor Fas produces a soluble isoform that prevents programmed cell death. I report that antiapoptotic regulator Hu antigen R (HuR, ELAVL1), a member of the embryonic lethal, abnormal vision, Drosophila-like (ELAVL) family, promotes Fas exon 6 skipping by binding to an exonic splicing silencer. HuR inhibits the association of U2 small nuclear ribonucleoprotein (snRNP) auxiliary factor 65 kDa (U2AF65) with the upstream 3' splice site, without decreasing recognition of the downstream 5' splice site by U1 snRNP but by antagonizing the role of TIA-1 (T-cell intracellular antigen 1)/TIAR (TIA-1 related protein) on exon definition. Remarkably, U1 snRNP-mediated recognition of the 5' splice site is partially required for efficient U2AF65 inhibition. Further, the silencing capacity of HuR as splicing regulator resides in the RRM1 and hinge-RRM3 domains. Taken together, these results support a functional link between HuR as repressor of alternative Fas splicing and the molecular mechanisms modulating programmed cell death.	Univ Autonoma Madrid, Dept Mol Biol, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Izquierdo, JM (corresponding author), Univ Autonoma Madrid, Dept Mol Biol, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.	jmizquierdo@cbm.uam.es		Izquierdo, Jose M/0000-0002-7942-4046				Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299; Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bidere N, 2006, ANNU REV IMMUNOL, V24, P321, DOI 10.1146/annurev.immunol.24.021605.090513; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Corsini L, 2007, NAT STRUCT MOL BIOL, V14, P620, DOI 10.1038/nsmb1260; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fialcowitz-White EJ, 2007, J BIOL CHEM, V282, P20948, DOI 10.1074/jbc.M701751200; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gao FB, 1996, J CELL SCI, V109, P579; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Inoue M, 2000, NUCLEIC ACIDS RES, V28, P1743, DOI 10.1093/nar/28.8.1743; Isquierdo JM, 2006, BIOCHEM BIOPH RES CO, V348, P703, DOI 10.1016/j.bbrc.2006.7.114; Izquierdo JM, 2005, MOL CELL, V19, P475, DOI 10.1016/j.molcel.2005.06.015; Izquierdo JM, 2007, J BIOL CHEM, V282, P19410, DOI 10.1074/jbc.M700688200; Izquierdo JM, 2007, J BIOL CHEM, V282, P1539, DOI 10.1074/jbc.C600198200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Lopez de Silanes I., 2005, RNA BIOL, V2, P11, DOI DOI 10.4161/RNA.2.1.1552; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; McAlinden A, 2007, J BIOL CHEM, V282, P24444, DOI 10.1074/jbc.M702717200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Spellman R, 2006, TRENDS BIOCHEM SCI, V31, P73, DOI 10.1016/j.tibs.2005.12.003; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Zhu H, 2003, MOL CELL BIOL, V23, P5959, DOI 10.1128/MCB.23.17.5959-5971.2003; Zhu H, 2008, MOL CELL BIOL, V28, P1240, DOI 10.1128/MCB.01509-07; Zhu H, 2006, MOL BIOL CELL, V17, P5105, DOI 10.1091/mbc.E06-02-0099; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; Zuccato E, 2004, J BIOL CHEM, V279, P16980, DOI 10.1074/jbc.M313439200	45	108	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19077	19084		10.1074/jbc.M800017200	http://dx.doi.org/10.1074/jbc.M800017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18463097	hybrid			2022-12-25	WOS:000257165600063
J	Mans, BJ; Ribeiro, JMC; Andersen, JF				Mans, Ben J.; Ribeiro, Jose M. C.; Andersen, John F.			Structure, function, and evolution of biogenic amine-binding proteins in soft ticks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-BINDING; PLATELET-AGGREGATION; SALIVARY PROTEINS; INHIBITOR; LIPOCALIN; CLONING; FAMILY; IDENTIFICATION; EXPRESSION; SEROTONIN	Two highly abundant lipocalins, monomine and monotonin, have been isolated from the salivary gland of the soft tick Argas monolakensis and shown to bind histamine and 5-hydroxytryptamine (5-HT), respectively. The crystal structures of monomine and a paralog of monotonin were determined in the presence of ligands to compare the determinants of ligand binding. Both the structures and binding measurements indicate that the proteins have a single binding site rather than the two sites previously described for the female-specific histaminebinding protein (FS-HBP), the histamine-binding lipocalin of the tick Rhipicephalus appendiculatus. The binding sites of monomine and monotonin are similar to the lower, low affinity site of FS-HBP. The interaction of the protein with the aliphatic amine group of the ligand is very similar for the all of the proteins, whereas specificity is determined by interactions with the aromatic portion of the ligand. Interestingly, protein interaction with the imidazole ring of histamine differs significantly between the low affinity binding site of FS-HBP and monomine, suggesting that histamine binding has evolved independently in the two lineages. From the conserved features of these proteins, a tick lipocalin biogenic amine-binding motif could be derived that was used to predict biogenic amine-binding function in other tick lipocalins. Heterologous expression of genes from salivary gland libraries led to the discovery of biogenic amine-binding proteins in soft (Ornithodoros) and hard (Ixodes) tick genera. The data generated were used to reconstruct the most probable evolutionary pathway for the evolution of biogenic amine-binding in tick lipocalins.	[Mans, Ben J.; Ribeiro, Jose M. C.; Andersen, John F.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Andersen, JF (corresponding author), 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.	jandersen@mail.nih.gov	Mans, Ben J./M-2427-2017	Mans, Ben J./0000-0002-0177-0029; Ribeiro, Jose/0000-0002-9107-0818	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, ZIAAI000810] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersen JF, 2003, J BIOL CHEM, V278, P4611, DOI 10.1074/jbc.M211438200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calvo E, 2006, J BIOL CHEM, V281, P1935, DOI 10.1074/jbc.M510359200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Francischetti IMB, 2008, INSECT BIOCHEM MOLEC, V38, P1, DOI 10.1016/j.ibmb.2007.09.009; GADDUM JH, 1949, J PHYSIOL-LONDON, V108, P240; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jutel M, 2005, INT ARCH ALLERGY IMM, V137, P82, DOI 10.1159/000085108; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Limbird, 1996, GOODMAN GILMANS PHAR; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mans BJ, 2008, INSECT BIOCHEM MOLEC, V38, P42, DOI 10.1016/j.ibmb.2007.09.003; Mans Ben J, 2005, Curr Opin Investig Drugs, V6, P1131; Mans BJ, 2002, MOL BIOL EVOL, V19, P1695, DOI 10.1093/oxfordjournals.molbev.a003992; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; Mans BJ, 2003, MOL BIOL EVOL, V20, P1158, DOI 10.1093/molbev/msg126; Mans BJ, 2001, ELECTROPHORESIS, V22, P1739, DOI 10.1002/1522-2683(200105)22:9&lt;1739::AID-ELPS1739&gt;3.0.CO;2-7; McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Nunn MA, 2005, J IMMUNOL, V174, P2084, DOI 10.4049/jimmunol.174.4.2084; Oleaga A, 2007, INSECT BIOCHEM MOLEC, V37, P1149, DOI 10.1016/j.ibmb.2007.07.003; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; RIBEIRO JMC, 1994, J EXP MED, V180, P2251, DOI 10.1084/jem.180.6.2251; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; Roversi P, 2007, J MOL BIOL, V369, P784, DOI 10.1016/j.jmb.2007.03.064; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Valenzuela JG, 2002, INSECT MOL BIOL, V11, P149, DOI 10.1046/j.1365-2583.2002.00319.x; VANNUETEN JM, 1985, PHARMACOL RES COMMUN, V17, P585, DOI 10.1016/0031-6989(85)90067-0; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WEBSTER ME, 1970, METHOD ENZYMOL, V19, P681; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	43	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18721	18733		10.1074/jbc.M800188200	http://dx.doi.org/10.1074/jbc.M800188200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18445596	Green Published, hybrid			2022-12-25	WOS:000257165600029
J	Sun, W; Parry, S; Panico, M; Morris, HR; Kjellberg, M; Engstrom, A; Dell, A; Schedin-Weiss, S				Sun, Wei; Parry, Simon; Panico, Maria; Morris, Howard R.; Kjellberg, Margareta; Engstrom, Ake; Dell, Anne; Schedin-Weiss, Sophia			N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING; HUMAN-PLASMA; THROMBOMODULIN; COAGULATION; COMPLEX; ANTITHROMBIN; MECHANISM; SERPINS; GLYCOSYLATION; PURIFICATION	Protein C inhibitor (PCI) is a serine protease inhibitor, displaying broad protease specificity, found in blood and other tissues. In blood, it is capable of inhibiting both procoagulant and anticoagulant proteases. Mechanisms that provide specificity to PCI remain largely unrevealed. In this study we have for the first time provided a full explanation for the marked size heterogeneity of blood-derived PCI and identified functional differences between naturally occurring PCI variants. The heterogeneity was caused by differences in N-glycan structures, N-glycosylation occupancy, and the presence of a Delta 6-N-cleaved form. Bi-, tri-, and tetra-antennary complex N-glycans were identified. Fucose residues were identified both on the core GlcNAc and as parts of sialyl-Le(a/x) epitopes. Moreover, a glycan with a composition that implied a di-sialyl antenna was observed. PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243. The overall removal of N-glycans affected the maximal heparin- and thrombomodulin-enhanced rates of thrombin inhibition differently in different solution conditions. In contrast, the Delta 6-N-region increased both the heparin- and the thrombomodulin-enhanced rates of thrombin inhibition at all conditions examined. These results thus demonstrate that the N-linked glycans and the N-terminal region of blood-derived PCI in different ways affect the cofactor-enhanced rates of thrombin inhibition and provide information on the mechanisms by which this may be achieved. The findings are medically important, in view of the documented association of PCI with atherosclerotic plaques and the promising effect of PCI on reducing hypercoagulability states.	[Sun, Wei; Engstrom, Ake; Schedin-Weiss, Sophia] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; [Parry, Simon; Panico, Maria; Morris, Howard R.; Dell, Anne] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; [Morris, Howard R.] M SCAN Ltd, Wokingham RG4 12TZ, Berks, England; [Kjellberg, Margareta] Lund Univ, Univ Hosp, Dept Clin Chem, SE-20502 Malmo, Sweden	Uppsala University; Imperial College London; Lund University; Skane University Hospital	Schedin-Weiss, S (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Box 582, SE-75123 Uppsala, Sweden.	Sophia.Schedin_Weiss@imbim.uu.se		Schedin Weiss, Sophia/0000-0003-2143-7052	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ben-Dor S, 2004, GLYCOBIOLOGY, V14, P95, DOI 10.1093/glycob/cwh004; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Di Cera E, 2007, PHYS CHEM CHEM PHYS, V9, P1292, DOI 10.1039/b616819a; ECKE S, 1992, ANN NY ACAD SCI, V667, P84, DOI 10.1111/j.1749-6632.1992.tb51601.x; Elisen MGLM, 1996, THROMB HAEMOSTASIS, V75, P760; Fortenberry YM, 2007, J THROMB HAEMOST, V5, P1486, DOI 10.1111/j.1538-7836.2007.02574.x; Fujita M, 2000, THROMB HAEMOSTASIS, V84, P54; Fujita M, 2002, THROMB RES, V105, P95, DOI 10.1016/S0049-3848(01)00398-X; Geiger M, 1996, IMMUNOPHARMACOLOGY, V32, P53, DOI 10.1016/0162-3109(96)00013-6; Geiger M, 2007, THROMB HAEMOSTASIS, V97, P343, DOI 10.1160/TH06-09-0488; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Hayashi T, 2007, J THROMB HAEMOST, V5, P1477, DOI 10.1111/j.1538-7836.2007.02594.x; Izutani W, 2001, THROMB RES, V104, P65, DOI 10.1016/S0049-3848(01)00342-5; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KAZAMA Y, 1987, THROMB RES, V48, P179, DOI 10.1016/0049-3848(87)90414-2; Krebs M, 1999, J INVEST DERMATOL, V113, P32, DOI 10.1046/j.1523-1747.1999.00644.x; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LAURELL M, 1988, THROMB HAEMOSTASIS, V60, P334; LAURELL M, 1989, THROMB HAEMOSTASIS, V62, P885; Li W, 2008, P NATL ACAD SCI USA, V105, P4661, DOI 10.1073/pnas.0711055105; Li W, 2007, J BIOL CHEM, V282, P13759, DOI 10.1074/jbc.M701074200; Malleier JM, 2007, BLOOD, V109, P4769, DOI 10.1182/blood-2006-09-046953; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; Medzihradszky KF, 2005, METHOD ENZYMOL, V405, P116, DOI 10.1016/S0076-6879(05)05006-8; Nishii Y, 2006, J THROMB HAEMOST, V4, P2331, DOI 10.1111/j.1538-7836.2006.02174.x; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pike RN, 2005, FEBS J, V272, P4842, DOI 10.1111/j.1742-4658.2005.04880.x; Pike RN, 2002, IUBMB LIFE, V54, P1, DOI 10.1080/15216540213825; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PRATT CW, 1992, J BIOL CHEM, V267, P8789; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPIK G, 1991, European Journal of Biochemistry, V195, P397, DOI 10.1111/j.1432-1033.1991.tb15719.x; Strandberg K, 2000, BIOCHEMISTRY-US, V39, P15713, DOI 10.1021/bi001640h; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; Strukova S, 2006, FRONT BIOSCI-LANDMRK, V11, P59, DOI 10.2741/1780; SUZUKI K, 1983, J BIOL CHEM, V258, P163; SUZUKI K, 1984, SEMIN THROMB HEMOST, V10, P154, DOI 10.1055/s-2007-1004418; Yang LK, 2003, J BIOL CHEM, V278, P37465, DOI 10.1074/jbc.M307243200	42	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18601	18611		10.1074/jbc.M800608200	http://dx.doi.org/10.1074/jbc.M800608200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18467335	hybrid			2022-12-25	WOS:000257165600016
J	Mager, GM; Ward, RM; Srinivasan, R; Jang, SW; Wrabetz, L; Svaren, J				Mager, Gennifer M.; Ward, Rebecca M.; Srinivasan, Rajini; Jang, Sung-Wook; Wrabetz, Lawrence; Svaren, John			Active gene repression by the Egr2 center dot NAB complex during peripheral nerve myelination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; SCHWANN-CELL DIFFERENTIATION; NEGATIVE FEEDBACK LOOP; TRANSCRIPTION FACTORS; NAB PROTEINS; NGFI-A; RETINOBLASTOMA PROTEIN; NURD COMPLEX; ID PROTEINS; EXPRESSION	The Egr2/Krox20 transactivator is required for activation of many myelin-associated genes during peripheral nerve myelination by Schwann cells. However, recent work has indicated that Egr2 not only activates genes required for peripheral nerve myelination but may also be involved in gene repression. The NAB (NGFI-A/Egr-binding) corepressors interact with Egr2 and are required for proper coordination of myelin formation. Therefore, NAB proteins could mediate repression of some Egr2 target genes, although direct repression by Egr2 or NAB proteins during myelination has not been demonstrated. To define the physiological role of NAB corepression in gene repression by Egr2, we tested whether the Egr2 center dot NAB complex directly repressed specific target genes. A screen for NAB-regulated genes identified several (including Id2, Id4, and Rad) that declined during the course of peripheral nerve myelination. In vivo chromatin immunoprecipitation analysis of the myelinating sciatic nerve was used to show developmental association of both Egr2 and NAB2 on the Id2, Id4, and Rad promoters as they were repressed during the myelination process. In addition, NAB2 represses transcription by interaction with the chromodomain helicase DNA-binding protein 4 (CHD4) subunit of the nucleosome remodeling and deacetylase chromatin remodeling complex, and we demonstrate that CHD4 occupies NAB-repressed promoters in a developmentally regulated manner in vivo. These results illustrate a novel aspect of genetic regulation of peripheral nerve myelination by showing that Egr2 directly represses genes during myelination in conjunction with NAB corepressors. Furthermore, repression of Id2 was found to augment activation of Mpz (myelin protein zero) expression.	[Ward, Rebecca M.; Srinivasan, Rajini; Svaren, John] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; [Mager, Gennifer M.] Univ Wisconsin, Mol & Cellular Pharmacol Training Program, Madison, WI 53706 USA; [Jang, Sung-Wook] Univ Wisconsin, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA; [Svaren, John] Univ Wisconsin, Waisman Ctr, Madison, WI 53706 USA; [Wrabetz, Lawrence] Ist Sci San Raffaele, Dipartimento Ric Biol & Technol, I-20132 Milan, Italy	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Svaren, J (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055256] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 41590, P30 HD 03352] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08688] Funding Source: Medline; NINDS NIH HHS [R01 NS055256] Funding Source: Medline; Telethon [GGP07100] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bellone E, 1999, Hum Mutat, V14, P353, DOI 10.1002/(SICI)1098-1004(199910)14:4<353::AID-HUMU17>3.3.CO;2-W; Bolino A, 2004, J CELL BIOL, V167, P711, DOI 10.1083/jcb.200407010; Bolis A, 2005, J NEUROSCI, V25, P8567, DOI 10.1523/JNEUROSCI.2493-05.2005; Buchstaller J, 2004, J NEUROSCI, V24, P2357, DOI 10.1523/JNEUROSCI.4083-03.2004; D'Antonio M, 2006, GLIA, V53, P501, DOI 10.1002/glia.20309; Decker L, 2006, J NEUROSCI, V26, P9771, DOI 10.1523/JNEUROSCI.0716-06.2006; Dierick I, 2005, ANN MED, V37, P413, DOI 10.1080/07853890500296410; Fabrizi C, 1997, J NEUROSCI RES, V50, P291; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Giambonini-Brugnoli G, 2005, NEUROBIOL DIS, V18, P656, DOI 10.1016/j.nbd.2004.10.023; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Gokhan S, 2005, J NEUROSCI, V25, P8311, DOI 10.1523/JNEUROSCI.1850-05.2005; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Jang SW, 2006, J NEUROCHEM, V98, P1678, DOI 10.1111/j.1471-4159.2006.04069.x; Kondo T, 2000, EMBO J, V19, P1998, DOI 10.1093/emboj/19.9.1998; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; LeBlanc SE, 2005, J NEUROCHEM, V93, P737, DOI 10.1111/j.1471-4159.2005.03056.x; LeBlanc SE, 2006, J BIOL CHEM, V281, P5453, DOI 10.1074/jbc.M512159200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Marin-Husstege M, 2006, GLIA, V54, P285, DOI 10.1002/glia.20385; Mechta-Grigoriou F, 2000, DEVELOPMENT, V127, P119; Melendez-Vasquez CV, 2004, J NEUROSCI, V24, P3953, DOI 10.1523/JNEUROSCI.4920-03.2004; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; NARAYANAN V, 1988, J BIOL CHEM, V263, P8332; Niemann A, 2006, NEUROMOL MED, V8, P217, DOI 10.1385/NMM:8:1:217; Ogata T, 2004, J NEUROSCI, V24, P6724, DOI 10.1523/JNEUROSCI.5520-03.2004; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Parkinson DB, 2008, J CELL BIOL, V181, P625, DOI 10.1083/jcb.200803013; Parkinson DB, 2003, MOL CELL NEUROSCI, V23, P13, DOI 10.1016/S1044-7431(03)00024-1; Parkinson DB, 2004, J CELL BIOL, V164, P385, DOI 10.1083/jcb.200307132; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Previtali SC, 2003, HUM MOL GENET, V12, P1713, DOI 10.1093/hmg/ddg179; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Ryu EJ, 2007, J NEUROSCI, V27, P11552, DOI 10.1523/JNEUROSCI.5497-06.2007; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Sotelo-Silveira JR, 2000, J NEUROSCI RES, V62, P65, DOI 10.1002/1097-4547(20001001)62:1<65::AID-JNR7>3.0.CO;2-Z; Srinivasan R, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-117; Srinivasan R, 2006, J BIOL CHEM, V281, P15129, DOI 10.1074/jbc.M600775200; Stewart HJS, 2001, EUR J NEUROSCI, V14, P363, DOI 10.1046/j.0953-816x.2001.01650.x; Stewart HJS, 1996, EUR J NEUROSCI, V8, P553, DOI 10.1111/j.1460-9568.1996.tb01240.x; Stewart HJS, 1997, J NEUROSCI RES, V50, P684; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Thatikunta P, 1999, MOL CELL NEUROSCI, V14, P519, DOI 10.1006/mcne.1999.0799; Timmerman V, 1999, NEUROLOGY, V52, P1827, DOI 10.1212/WNL.52.9.1827; TODA K, 1994, J NEUROCHEM, V63, P1646; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Verheijen MHG, 2003, GENE DEV, V17, P2450, DOI 10.1101/gad.1116203; Vigo T, 2005, MOL CELL NEUROSCI, V28, P703, DOI 10.1016/j.mcn.2004.11.016; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; WRABETZ L, 2004, MYELIN BIOL DISORDER, P905; Yamauchi J, 2004, P NATL ACAD SCI USA, V101, P8774, DOI 10.1073/pnas.0402795101; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	73	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18187	18197		10.1074/jbc.M803330200	http://dx.doi.org/10.1074/jbc.M803330200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18456662	Green Published, hybrid			2022-12-25	WOS:000256949200047
J	Tomo, T; Kato, Y; Suzuki, T; Akimoto, S; Okubo, T; Noguchi, T; Hasegawa, K; Tsuchiya, T; Tanaka, K; Fukuya, M; Dohmae, N; Watanabe, T; Mimuro, M				Tomo, Tatsuya; Kato, Yuki; Suzuki, Takehiro; Akimoto, Seiji; Okubo, Tatsunori; Noguchi, Takumi; Hasegawa, Koji; Tsuchiya, Tohru; Tanaka, Kazunori; Fukuya, Michitaka; Dohmae, Naoshi; Watanabe, Tadashi; Mimuro, Mamoru			Characterization of highly purified photosystem I complexes from the chlorophyll d-dominated cyanobacterium Acaryochloris marina MBIC 11017	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY ELECTRON-DONOR; TIME-RESOLVED FLUORESCENCE; OXYGENIC PHOTOSYNTHETIC PROKARYOTE; GLOEOBACTER-VIOLACEUS PCC-7421; REACTION CENTERS; SPECIAL PAIR; PIGMENT COMPOSITION; CHARGE-DISTRIBUTION; ENERGY-TRANSFER; CORE ANTENNA	Photochemically active photosystem (PS) I complexes were purified from the chlorophyll (Chl) d-dominated cyanobacterium Acaryochloris marina MBIC 11017, and several of their properties were characterized. PS I complexes consist of 11 subunits, including PsaK1 and PsaK2; a new small subunit was identified and named Psa27. The new subunit might replace the function of PsaI that is absent in A. marina. The amounts of pigments per one molecule of Chld' were 97.0 +/- 11.0 Chl d, 1.9 +/- 0.5 Chl a, 25.2 +/- 2.4 alpha-carotene, and two phylloquinone molecules. The light-induced Fourier transform infrared difference spectroscopy and light-induced difference absorption spectra reconfirmed that the primary electron donor of PS I (P740) was the Chl d dimer. In addition to P740, the difference spectrum contained an additional band at 728 nm. The redox potentials of P740 were estimated to be 439mV by spectroelectrochemistry; thisvalue was comparable with the potential of P700 in other cyanobacteria and higher plants. This suggests that the overall energetics of the PS I reaction were adjusted to the electron acceptor side to utilize the lower light energy gained by P740. The distribution of charge in P740 was estimated by a density functional theory calculation, and a partial localization of charge was predicted to P1 Chl (special pair Chl on PsaA). Based on differences in the protein matrix and optical properties of P740, construction of the PS I core in A. marina was discussed.	[Tomo, Tatsuya; Tsuchiya, Tohru; Mimuro, Mamoru] Kyoto Univ, Dept Technol & Ecol, Kyoto 6068501, Japan; [Suzuki, Takehiro; Dohmae, Naoshi] RIKEN, Biomol Characterizat Team, Wako, Saitama 3510198, Japan; [Kato, Yuki; Watanabe, Tadashi] Univ Tokyo, Inst Ind Sci, Tokyo 1538505, Japan; [Akimoto, Seiji] Kobe Univ, Mol Photosci Res Ctr, Kobe, Hyogo 6578501, Japan; [Akimoto, Seiji] Kobe Univ, Grad Sch Sci, Kobe, Hyogo 6578501, Japan; [Okubo, Tatsunori; Noguchi, Takumi] Univ Tsukuba, Inst Mat Sci, Tsukuba, Ibaraki 3058573, Japan; [Hasegawa, Koji] Advancesoft Corp, Tokyo 1070052, Japan; [Tsuchiya, Tohru; Mimuro, Mamoru] Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan; [Tanaka, Kazunori; Fukuya, Michitaka] Kobe Univ, Fac Sci, Kobe, Hyogo 6578501, Japan	Kyoto University; RIKEN; University of Tokyo; Kobe University; Kobe University; University of Tsukuba; Kyoto University; Kobe University	Tomo, T (corresponding author), Kyoto Univ, Dept Technol & Ecol, Kyoto 6068501, Japan.	tomo@z05.mbox.media.kyoto-u.ac.jp	Noguchi, Takumi/I-7105-2014; Tomo, Tatsuya/K-7680-2012; Dohmae, Naoshi/C-2040-2011; Suzuki, Takehiro/B-3210-2013	Tomo, Tatsuya/0000-0002-9369-1941; Dohmae, Naoshi/0000-0002-5242-9410; 				Akimoto S, 2005, CHEM PHYS LETT, V409, P167, DOI 10.1016/j.cplett.2005.05.006; Akiyama M, 2002, PHOTOSYNTH RES, V74, P97, DOI 10.1023/A:1020915506409; Akiyama M, 2001, ANAL SCI, V17, P205, DOI 10.2116/analsci.17.205; AKIYAMA M, 2004, JPN J PHYCOL, V52, P67; Amunts A, 2007, NATURE, V447, P58, DOI 10.1038/nature05687; Battistuzzi G, 1999, J AM CHEM SOC, V121, P501, DOI 10.1021/ja982126q; Benjamin B, 2007, PHOTOSYNTH RES, V91, P155; BOOTH PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P141, DOI 10.1016/0005-2728(90)90053-7; Breton J, 1999, BIOCHEMISTRY-US, V38, P11585, DOI 10.1021/bi991216k; Breton J, 2001, BBA-BIOENERGETICS, V1507, P180, DOI 10.1016/S0005-2728(01)00206-7; Brettel K, 2001, BBA-BIOENERGETICS, V1507, P100, DOI 10.1016/S0005-2728(01)00202-X; Britton G., 1995, SPECTROSCOPY-US, V1B, P13; Cances E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; Diaz-Quintana A, 2003, PHOTOSYNTH RES, V75, P97, DOI 10.1023/A:1022841513592; FRENCH CS, 1960, HDB PFLANZENPHYSIOLO, V5, P252; Frisch M., 2016, GAUSSIAN 16 REVISION; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Fujimori T, 2005, J BIOL CHEM, V280, P22191, DOI 10.1074/jbc.M500369200; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; HASTINGS G, 1994, BIOCHEMISTRY-US, V33, P3193, DOI 10.1021/bi00177a008; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Holzwarth AR, 2006, BIOPHYS J, V90, P552, DOI 10.1529/biophysj.105.059824; Hu Q, 1998, P NATL ACAD SCI USA, V95, P13319, DOI 10.1073/pnas.95.22.13319; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; Inoue H, 2004, FEBS LETT, V578, P275, DOI 10.1016/j.febslet.2004.11.013; Itoh S, 2007, BIOCHEMISTRY-US, V46, P12473, DOI 10.1021/bi7008085; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KATO Y, 2008, PHOTOSYNTHE IN PRESS; KE B, 2002, PHOTOSYNTHESIS PHOTO, P463; Kuhl M, 2005, NATURE, V433, P820, DOI 10.1038/433820a; Kumazaki S, 2002, FEBS LETT, V530, P153, DOI 10.1016/S0014-5793(02)03446-4; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Lutz M., 1991, CHLOROPHYLLS, P855; Manning WM, 1943, J BIOL CHEM, V151, P1; Marquardt J, 1997, FEBS LETT, V410, P428, DOI 10.1016/S0014-5793(97)00631-5; Mennucci B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558; Mi DH, 2003, J PHYS CHEM B, V107, P1452, DOI 10.1021/jp0268260; Miller SR, 2005, P NATL ACAD SCI USA, V102, P850, DOI 10.1073/pnas.0405667102; Mimuro M, 2005, FEBS LETT, V579, P3493, DOI 10.1016/j.febslet.2005.05.029; Mimuro M, 2004, FEBS LETT, V556, P95, DOI 10.1016/S0014-5793(03)01383-8; Mimuro M, 1999, BBA-BIOENERGETICS, V1412, P37, DOI 10.1016/S0005-2728(99)00048-1; Mimuro M, 2007, BBA-BIOENERGETICS, V1767, P327, DOI 10.1016/j.bbabio.2007.02.012; Mino H, 2005, CHEM PHYS LETT, V411, P262, DOI 10.1016/j.cplett.2005.06.033; Miyachi S, 1997, Z NATURFORSCH C, V52, P636; Miyashita H, 1997, PLANT CELL PHYSIOL, V38, P274, DOI 10.1093/oxfordjournals.pcp.a029163; Miyashita H, 1996, NATURE, V383, P402, DOI 10.1038/383402a0; Muhiuddin IP, 2001, FEBS LETT, V503, P56, DOI 10.1016/S0014-5793(01)02696-5; Murakami A, 2004, SCIENCE, V303, P1633, DOI 10.1126/science.1095459; Nakamura A, 2005, FEBS LETT, V579, P2273, DOI 10.1016/j.febslet.2005.02.076; Nakamura A, 2004, CHEM LETT, V33, P688, DOI 10.1246/cl.2004.688; Nakamura A, 2003, EUR J BIOCHEM, V270, P2446, DOI 10.1046/j.1432-1033.2003.03616.x; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; Noguchi T, 1998, BIOCHEMISTRY-US, V37, P13614, DOI 10.1021/bi9812975; O'Connor D. V., 1984, TIME CORRELATED SING; Okubo T, 2007, BIOCHEMISTRY-US, V46, P4390, DOI 10.1021/bi700157n; OWENS TG, 1987, P NATL ACAD SCI USA, V84, P1532, DOI 10.1073/pnas.84.6.1532; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; Ramesh VM, 2007, BBA-BIOENERGETICS, V1767, P151, DOI 10.1016/j.bbabio.2006.12.013; SANDERSON DG, 1986, BIOCHIM BIOPHYS ACTA, V852, P269, DOI 10.1016/0005-2728(86)90232-X; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shevela D, 2006, PHYS CHEM CHEM PHYS, V8, P3460, DOI 10.1039/b604389e; SIGFRIDSSON K, 1995, BBA-BIOENERGETICS, V1228, P28, DOI 10.1016/0005-2728(94)00158-2; Sivakumar V, 2003, BIOPHYS J, V85, P3162, DOI 10.1016/S0006-3495(03)74734-1; Sun J, 1998, METHOD ENZYMOL, V297, P124; Swingley WD, 2008, P NATL ACAD SCI USA, V105, P2005, DOI 10.1073/pnas.0709772105; Telfer A, 2007, PHOTOSYNTH RES, V91, P143; Tomo T, 2005, PHOTOSYNTH RES, V84, P77, DOI 10.1007/s11120-005-1302-0; Tomo T, 2007, P NATL ACAD SCI USA, V104, P7283, DOI 10.1073/pnas.0701847104; Tomo T, 2006, CHEM PHYS LETT, V423, P282, DOI 10.1016/j.cplett.2006.03.091; WATANABE T, 1984, ANAL CHEM, V56, P251, DOI 10.1021/ac00266a030; Webber AN, 2001, BBA-BIOENERGETICS, V1507, P61, DOI 10.1016/S0005-2728(01)00198-0; Yamasaki H, 2007, CHEM PHYS LETT, V447, P324, DOI 10.1016/j.cplett.2007.08.101	78	53	55	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18198	18209		10.1074/jbc.M801805200	http://dx.doi.org/10.1074/jbc.M801805200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18458090	hybrid			2022-12-25	WOS:000256949200048
J	Uddin, MN; Horvat, D; Glaser, SS; Mitchell, BM; Puschett, JB				Uddin, Mohammad N.; Horvat, Darijana; Glaser, Shannon S.; Mitchell, Brett M.; Puschett, Jules B.			Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-B; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION; CARDIAC-GLYCOSIDES; INDUCED APOPTOSIS; VOLUME EXPANSION; BLOOD-PRESSURE; P38 MAPK; OUABAIN	Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid involved in the inhibition of Na+/K+-ATPase. Increased plasma levels have been reported in patients with volume expansion-related hypertension. We have recently demonstrated that MBG impairs first trimester cytotrophoblast (CTB) cell proliferation, migration, and invasion, which may play a role in the development of preeclampsia. However, whether apoptosis contributes to altered CTB cell function by MBG remains unknown. Using the human extravillous CTB cell line SGHPL-4, we examined the effect of MBG and a similar Na+/K+-ATPase inhibitor, ouabain, on the phosphorylation status of Jnk, p38, and Src. Additionally, we measured apoptosis by caspase 9 and 3/7 activity and by annexin-V staining. We also investigated interleukin-6 (IL-6) secretion with or without p38 and Jnk inhibition. MBG significantly increased the phosphorylation of Jnk, p38, and Src and increased the expression of caspase 9 and 3/7 indicating the activation of apoptosis. MBGtreatment also stimulated the expression of the early apoptosis marker, annexin-V, which was prevented by Jnk and p38 inhibition. MBG also stimulated the secretion of IL-6, which was attenuated by p38 inhibition. Ouabain had similar effects to those of MBG, suggesting that the apoptotic effects on CTB cells may be mediated by inhibition of Na+/K+-ATPase. In conclusion, the MBG-induced impairment of CTB function occurs via activation of Jnk, p38, and Src leading to increased apoptosis and IL-6 secretion. These observations may have clinical applicability with respect to the therapy of preeclampsia.	[Glaser, Shannon S.] Texas A&M Hlth Sci Ctr, Scott & White Clin, Dept Med, Div Gastroenterol, Temple, TX 76508 USA; [Uddin, Mohammad N.; Horvat, Darijana; Mitchell, Brett M.; Puschett, Jules B.] Texas A&M Hlth Sci Ctr, Scott & White Clin, Dept Med, Div Nephrol & Hypertens, Temple, TX 76508 USA	Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Puschett, JB (corresponding author), 2401 South 31st St,Rm 407L, Temple, TX 76508 USA.	jpuschett@swmail.sw.org						Abramowitz J, 2003, CIRCULATION, V108, P3048, DOI 10.1161/01.CIR.0000101919.00548.86; AGASTISA PK, 2004, AM J PHYSIOL-HEART C, V286, pH1389; Akimova OA, 2005, J BIOL CHEM, V280, P832, DOI 10.1074/jbc.M411011200; Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; Bagrov AY, 1998, J HYPERTENS, V16, P1953, DOI 10.1097/00004872-199816121-00015; BAGROV AY, 1995, EUR J PHARMACOL, V274, P151, DOI 10.1016/0014-2999(94)00735-P; Bagrov AY, 1996, CARDIOVASC RES, V31, P296; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BLAUSTEIN MP, 1977, AM J PHYSIOL, V232, pC165, DOI 10.1152/ajpcell.1977.232.5.C165; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cartwright JE, 1999, BRIT J PHARMACOL, V128, P181, DOI 10.1038/sj.bjp.0702757; Cartwright JE, 2002, PLACENTA, V23, P232, DOI 10.1053/plac.2001.0760; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARD IT, 1990, INTRO RADIOIMMUNOASS, P131; Choy M Y, 2000, Early Pregnancy, V4, P124; Choy MY, 1998, HUM REPROD, V13, P2941, DOI 10.1093/humrep/13.10.2941; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Crowther J R, 1995, Methods Mol Biol, V42, P1; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEWARDENER HE, 1985, CLIN EXP HYPERTENS A, V7, P647, DOI 10.3109/10641968509077218; Durst I, 2004, J INVEST MED, V52, pS318; Fedorova OV, 2005, J HYPERTENS, V23, P835, DOI 10.1097/01.hjh.0000163153.27954.33; Fedorova OV, 1998, CLIN EXP HYPERTENS, V20, P581, DOI 10.3109/10641969809053236; Fedorova OV, 2001, HYPERTENSION, V37, P462, DOI 10.1161/01.HYP.37.2.462; Fisher Susan J, 2004, Reprod Biol Endocrinol, V2, P53, DOI 10.1186/1477-7827-2-53; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gonick HC, 1998, CLIN EXP HYPERTENS, V20, P617, DOI 10.3109/10641969809053240; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; HIRONO T, 1998, INT REV IMMUNOL, V16, P249; KAVINEN J, 2002, J BIOMOL SCREEN, V7, P223; Kawazoe N, 1999, J BIOCHEM-TOKYO, V126, P278, DOI 10.1093/oxfordjournals.jbchem.a022446; Kharfi A, 2003, CLIN BIOCHEM, V36, P323, DOI 10.1016/S0009-9120(03)00060-2; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LaMarca HL, 2006, PLACENTA, V27, P984, DOI 10.1016/j.placenta.2005.12.004; Liu LJ, 2004, AM J PHYSIOL-HEART C, V287, pH2173, DOI 10.1152/ajpheart.00352.2004; Lopatin DA, 1999, J HYPERTENS, V17, P1179, DOI 10.1097/00004872-199917080-00018; Myatt L, 2002, ENDOCRINE, V19, P103, DOI 10.1385/ENDO:19:1:103; Nasu K, 2005, MOL HUM REPROD, V11, P817, DOI 10.1093/molehr/gah249; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; PAMNANI MB, 1994, HYPERTENSION, V23, pI106, DOI 10.1161/01.HYP.23.1_Suppl.I106; Pridjian G, 2002, OBSTET GYNECOL SURV, V57, P598, DOI 10.1097/00006254-200209000-00023; Puschett JB, 2006, MED HYPOTHESES, V67, P1125, DOI 10.1016/j.mehy.2006.04.059; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; REDLINE RW, 1995, HUM PATHOL, V26, P594, DOI 10.1016/0046-8177(95)90162-0; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Schoner W, 2007, AM J PHYSIOL-CELL PH, V293, pC509, DOI 10.1152/ajpcell.00098.2007; Thobe BM, 2006, AM J PHYSIOL-CELL PH, V291, pC476, DOI 10.1152/ajpcell.00076.2006; TIJSSEN P, 1985, PRACTICE THEORY ENZY, P331; Uddin MN, 2008, PLACENTA, V29, P266, DOI 10.1016/j.placenta.2007.12.009; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; Vu HV, 2005, AM J NEPHROL, V25, P520, DOI 10.1159/000088461; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738	68	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17946	17953		10.1074/jbc.M800958200	http://dx.doi.org/10.1074/jbc.M800958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434301	hybrid			2022-12-25	WOS:000256949200023
J	Yu, XL; Hu, T; Du, JM; Ding, JP; Yang, XM; Zhang, J; Yang, B; Shen, X; Zhang, Z; Zhong, WD; Wen, N; Jiang, HL; Zhu, P; Chen, ZN				Yu, Xiao-Ling; Hu, Tiancen; Du, Jia-Mu; Ding, Jian-Ping; Yang, Xiang-Min; Zhang, Jian; Yang, Bin; Shen, Xu; Zhang, Zheng; Zhong, Wei-De; Wen, Ning; Jiang, Hualiang; Zhu, Ping; Chen, Zhi-Nan			Crystal structure of HAb18g/CD147 - Implications for immunoglobulin superfamily homophilic adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INDUCER; CELL-SURFACE EXPRESSION; MOLECULAR-DYNAMICS; BINDING FRAGMENT; SOLUBLE FORM; RESOLUTION; BASIGIN; ANTIGEN; CD147; RECOGNITION	CD147, a member of the immunoglobulin superfamily (IgSF), plays fundamental roles in intercellular interactions in numerous pathological and physiological processes. Importantly, our previous studies have demonstrated that HAb18G/CD147 is a novel hepatocellular carcinoma (HCC)-associated antigen, and HAb18G/CD147 stimulates adjacent fibroblasts and HCC cells to produce elevated levels of several matrix metalloproteinases, facilitating invasion and metastasis of HCC cells. In addition, HAb18G/CD147 has also been shown to be a novel universal cancer biomarker for diagnosis and prognostic assessment of a wide range of cancers. However, the structural basis underlying the multifunctional character of CD147 remains unresolved. We report here the crystal structure of the extracellular portion of HAb18G/CD147 at 2.8 angstrom resolution. The structure comprises an N-terminal IgC2 domain and a C-terminal IgI domain, which are connected by a 5-residue flexible linker. This unique C2-I domain organization is distinct from those of other IgSF members. Four homophilic dimers exist in the crystal and adopt C2-C2 and C2-I dimerization rather than V-V dimerization commonly found in other IgSF members. This type of homophilic association thus presents a novel model for homophilic interaction between C2 domains of IgSF members. Moreover, the crystal structure of HAb18G/CD147 provides a good structural explanation for the established multifunction of CD147 mediated by homo/heterooligomerizations and should represent a general architecture of other CD147 family members.	[Zhu, Ping] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian 710032, Peoples R China; [Yu, Xiao-Ling; Yang, Xiang-Min; Yang, Bin; Zhang, Zheng; Chen, Zhi-Nan] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Cell Biol, Xian 710032, Peoples R China; [Yu, Xiao-Ling; Yang, Xiang-Min; Yang, Bin; Zhang, Zheng; Chen, Zhi-Nan] Fourth Mil Med Univ, Cell Engn Res Ctr, Xian 710032, Peoples R China; [Hu, Tiancen; Zhang, Jian; Shen, Xu; Jiang, Hualiang] Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China; [Du, Jia-Mu; Ding, Jian-Ping] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; [Zhong, Wei-De] Guangzhou First Municipal Peoples Hosp, Guangzhou Med Coll, Guangzhou 510182, Peoples R China; [Wen, Ning] Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Guangzhou Medical University; South China University of Technology; Chinese People's Liberation Army General Hospital	Zhu, P (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, 17 W Changle Rd, Xian 710032, Peoples R China.	zhuping@fmmu.edu.cn; zhinanchen@fmmu.edu.cn	YU, Xiaoling/M-8815-2018; Du, Jiamu/I-1334-2013; Zhang, Jian/GXA-1303-2022; Du, Jiamu/G-3308-2010	YU, Xiaoling/0000-0001-6035-3906; Du, Jiamu/0000-0002-1337-0786; Zhang, Jian/0000-0002-6558-791X; Yang, Bin/0000-0001-9687-5968; Zhong, Weide/0000-0002-0430-2845				BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; Chen ZN, 1999, J CELL MOL IMMUNOL, V15, P34; CHOTHIA C, 1985, J MOL BIOL, V182, P151, DOI 10.1016/0022-2836(85)90033-6; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Pushkarsky T, 2005, J BIOL CHEM, V280, P27866, DOI 10.1074/jbc.M503770200; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Reyes CM, 2000, J MOL BIOL, V297, P1145, DOI 10.1006/jmbi.2000.3629; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; Saxena DK, 2002, REPRODUCTION, V123, P435, DOI 10.1530/rep.0.1230435; SCHLOSSHAUER B, 1991, DEVELOPMENT, V113, P129; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; Srinivasan J, 1998, J BIOMOL STRUCT DYN, V16, P671, DOI 10.1080/07391102.1998.10508279; Sun JX, 2001, CANCER RES, V61, P2276; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu J, 2007, MOL CANCER RES, V5, P605, DOI 10.1158/1541-7786.MCR-06-0286; Xu J, 2007, HEPATOLOGY, V45, P269, DOI 10.1002/hep.21465; Yoshida S, 2000, EUR J BIOCHEM, V267, P4372, DOI 10.1046/j.1432-1327.2000.01482.x; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847; Zhu P, 2005, ARTHRITIS RES THER, V7, pR1023, DOI 10.1186/ar1778; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	53	101	112	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18056	18065		10.1074/jbc.M802694200	http://dx.doi.org/10.1074/jbc.M802694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18430721	hybrid			2022-12-25	WOS:000256949200035
J	Ouyang, MX; Lu, SY; Li, XY; Xu, J; Seong, J; Giepmans, BNG; Shyy, JYJ; Weiss, SJ; Wang, YX				Ouyang, Mingxing; Lu, Shaoying; Li, Xiao-Yan; Xu, Jing; Seong, Jihye; Giepmans, Ben N. G.; Shyy, John Y. -J.; Weiss, Stephen J.; Wang, Yingxiao			Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; 1-MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX; CERVICAL-CARCINOMA; KINASE ACTIVATION; ENDOTHELIAL-CELLS; LIVING CELLS; EGF RECEPTOR; MT1-MMP; SRC	Membrane type 1 matrix metalloproteinase (MT1-MMP) plays a critical role in cancer cell biology by proteolytically remodeling the extracellular matrix. Utilizing fluorescence resonance energy transfer ( FRET) imaging, we have developed a novel biosensor, with its sensing element anchoring at the extracellular surface of cell membrane, to visualize MT1-MMP activity dynamically in live cells with subcellular resolution. Epidermal growth factor (EGF) induced significant FRET changes in cancer cells expressing MT1-MMP, but not in MT1-MMP-deficient cells. EGF-induced FRET changes in MT1-MMP-deficient cells could be restored after reconstituting with wild-type MT1-MMP, but not MMP-2, MMP-9, or inactive MT1-MMP mutants. Deletion of the transmembrane domain in the biosensor or treatment with tissue inhibitor of metalloproteinase-2, a cell-impermeable MT1-MMP inhibitor, abolished the EGF-induced FRET response, indicating that MT1-MMP acts at the cell surface to generate FRET changes. In response to EGF, active MT1-MMP was directed to the leading edge of migrating cells along micropatterned fibronectin stripes, in tandem with the local accumulation of the EGF receptor, via a process dependent upon an intact cytoskeletal network. Hence, the MT1-MMP biosensor provides a powerful tool for characterizing the molecular processes underlying the spatiotemporal regulation of this critical class of enzymes.	[Li, Xiao-Yan; Weiss, Stephen J.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Li, Xiao-Yan; Weiss, Stephen J.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Giepmans, Ben N. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands; [Shyy, John Y. -J.] Univ Calif Riverside, Div Biomed Sci Program, Riverside, CA 92521 USA; [Ouyang, Mingxing; Lu, Shaoying; Xu, Jing; Wang, Yingxiao] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Ouyang, Mingxing; Lu, Shaoying; Xu, Jing; Wang, Yingxiao] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA; [Wang, Yingxiao] Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Seong, Jihye; Wang, Yingxiao] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Groningen; University of California System; University of California Riverside; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wang, YX (corresponding author), Univ Illinois, Beckman Inst, 405 N Mathews Ave, Urbana, IL 61801 USA.	yingxiao@uiuc.edu	Ouyang, Mingxing/F-8907-2019; Giepmans, Ben N.G./R-4564-2016; Seong, Jihye/N-2132-2017; Ouyang, Mingxing/AAF-5896-2019; Ouyang, Mingxing/C-9130-2011; Ouyang, Mingxing/J-4529-2013	Giepmans, Ben N.G./0000-0001-5105-5915; Seong, Jihye/0000-0001-8450-3315; Ouyang, Mingxing/0000-0002-2910-0713; 	NCI NIH HHS [CA71699] Funding Source: Medline; NHLBI NIH HHS [HL77448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071699] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Beningo KA, 2004, P NATL ACAD SCI USA, V101, P18024, DOI 10.1073/pnas.0405747102; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DEFAZIO A, 1992, J BIOL CHEM, V267, P18008; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Ghajar CM, 2006, TISSUE ENG, V12, P2875, DOI 10.1089/ten.2006.12.2875; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kinoshita T, 1996, CANCER RES, V56, P2535; Klein S, 1997, BIOCHEM J, V322, P937, DOI 10.1042/bj3220937; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lehti K, 2005, GENE DEV, V19, P979, DOI 10.1101/gad.1294605; Leu TH, 2003, FRONT BIOSCI-LANDMRK, V8, pS28, DOI 10.2741/980; Lidke DS, 2005, J CELL BIOL, V170, P619, DOI 10.1083/jcb.200503140; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nguyen AW, 2005, NAT BIOTECHNOL, V23, P355, DOI 10.1038/nbt1066; Nyalendo C, 2007, J BIOL CHEM, V282, P15690, DOI 10.1074/jbc.M608045200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pertz O, 2004, J CELL SCI, V117, P1313, DOI 10.1242/jcs.01117; Remacle AG, 2005, J CELL SCI, V118, P4975, DOI 10.1242/jcs.02610; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Santin AD, 2003, CANCER, V98, P1898, DOI 10.1002/cncr.11753; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Sato T, 1997, J CELL SCI, V110, P589; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Tan JL, 2004, TISSUE ENG, V10, P865, DOI 10.1089/1076327041348365; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Van Meter TE, 2004, NEURO-ONCOLOGY, V6, P188, DOI 10.1215/S1152851703000486; Varon C, 2006, MOL CELL BIOL, V26, P3582, DOI 10.1128/MCB.26.9.3582-3594.2006; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Wells A, 1999, CELL MOTIL CYTOSKEL, V44, P227, DOI 10.1002/(SICI)1097-0169(199912)44:4<227::AID-CM1>3.0.CO;2-B; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wolf K, 2006, BRIT J DERMATOL, V154, P11, DOI 10.1111/j.1365-2133.2006.07231.x; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Yang J, 2007, BBA-MOL CELL RES, V1773, P400, DOI 10.1016/j.bbamcr.2006.11.002; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	56	68	70	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17740	17748		10.1074/jbc.M709872200	http://dx.doi.org/10.1074/jbc.M709872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18441011	hybrid, Green Published			2022-12-25	WOS:000256720600080
J	Simockova, M; Holic, R; Tahotna, D; Patton-Vogt, J; Griac, P				Simockova, Maria; Holic, Roman; Tahotna, Dana; Patton-Vogt, Jana; Griac, Peter			Yeast Pgc1p (YPL206c) controls the amount of phosphatidylglycerol via a phospholipase C-type degradation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFECTING MITOCHONDRIAL DEVELOPMENT; SUPPRESSES TEMPERATURE SENSITIVITY; HIGH-EFFICIENCY TRANSFORMATION; PHOSPHATIDIC-ACID ANALOG; SACCHAROMYCES-CEREVISIAE; CARDIOLIPIN SYNTHASE; BIOCHEMICAL-CHARACTERIZATION; PEL1 GENE; MEMBRANE-PROTEINS; LIPID PARTICLES	The product of the open reading frame YPL206c, Pgc1p, of the yeast Saccharomyces cerevisiae displays homology to bacterial and mammalian glycerophosphodiester phosphodiesterases. Deletion of PGC1 causes an accumulation of the anionic phospholipid, phosphatidylglycerol (PG), especially under conditions of inositol limitation. This PG accumulation was not caused by increased production of phosphatidylglycerol phosphate or by decreased consumption of PG in the formation of cardiolipin, the end product of the pathway. PG accumulation in the pgc1 Delta strain was caused rather by inactivation of the PG degradation pathway. Our data demonstrate an existence of a novel regulatory mechanism in the cardiolipin biosynthetic pathway in which Pgc1p is required for the removal of excess PG via a phospholipase C-type degradation mechanism.	[Simockova, Maria; Holic, Roman; Tahotna, Dana; Griac, Peter] Slovak Acad Sci, Inst Anim Biochem & Genet, Ivanka Pri Dunaji 90028, Slovakia; [Patton-Vogt, Jana] Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	Slovak Academy of Sciences; Duquesne University	Griac, P (corresponding author), Slovak Acad Sci, Inst Anim Biochem & Genet, Moyzesova 61, Ivanka Pri Dunaji 90028, Slovakia.	Peter.Griac@savba.sk	Balazova, Maria/AAC-1280-2019; , Peter/ABA-9227-2020; Roman, Holic/X-7500-2018; Holic, Roman/AAC-8402-2019	Balazova, Maria/0000-0001-8113-6855; , Peter/0000-0003-3538-0405; Roman, Holic/0000-0003-1347-4785; Holic, Roman/0000-0003-1347-4785	NIGMS NIH HHS [GM59817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059817] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; Burke D., 2000, METHODS YEAST GENETI; Carman GM, 2007, J BIOL CHEM, V282, P37293, DOI 10.1074/jbc.R700038200; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Drawid A, 2000, J MOL BIOL, V301, P1059, DOI 10.1006/jmbi.2000.3968; Fernandez-Murray JP, 2005, J BIOL CHEM, V280, P38290, DOI 10.1074/jbc.M507700200; Fisher E, 2005, J BIOL CHEM, V280, P36110, DOI 10.1074/jbc.M507051200; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; Gu ZM, 2004, MOL MICROBIOL, V51, P149, DOI 10.1046/j.1365-2958.2003.03802.x; Gunther A, 2001, RESPIR RES, V2, P353, DOI 10.1186/rr86; HAID A, 1983, METHOD ENZYMOL, V96, P192; He Q, 2004, MOL MICROBIOL, V53, P1243, DOI 10.1111/j.1365-2958.2004.04202.x; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Li GL, 2007, BBA-MOL CELL BIOL L, V1771, P432, DOI 10.1016/j.bbalip.2006.06.007; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951; Milla P, 2002, J BIOL CHEM, V277, P2406, DOI 10.1074/jbc.M104195200; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; Sato N, 2004, J PLANT RES, V117, P495, DOI 10.1007/s10265-004-0183-1; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; Su XF, 2006, YEAST, V23, P279, DOI 10.1002/yea.1352; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; Trotter PJ, 2000, TRAFFIC, V1, P425, DOI 10.1034/j.1600-0854.2000.010507.x; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wilson D, 2007, NUCLEIC ACIDS RES, V35, pD308, DOI 10.1093/nar/gkl910; Wu SX, 2004, BIOTECHNIQUES, V36, P152, DOI 10.2144/04361DD02; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zhong Q, 2005, MOL BIOL CELL, V16, P665, DOI 10.1091/mbc.E04-09-0808; Zhong Q, 2003, J BIOL CHEM, V278, P33978, DOI 10.1074/jbc.M305242200; Zhong Q, 2007, J BIOL CHEM, V282, P15946, DOI 10.1074/jbc.M701055200; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	65	32	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17107	17115		10.1074/jbc.M800868200	http://dx.doi.org/10.1074/jbc.M800868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18434318	Green Published, hybrid			2022-12-25	WOS:000256720600018
J	Bikbaev, A; Neyman, S; Ngomba, RT; Conn, J; Nicoletti, F; Manahan-Vaughan, D				Bikbaev, Arthur; Neyman, Sergey; Ngomba, Richard Teke; Conn, Jeffrey; Nicoletti, Ferdinando; Manahan-Vaughan, Denise			MGluR5 Mediates the Interaction between Late-LTP, Network Activity, and Learning	PLOS ONE			English	Article								Hippocampal synaptic plasticity and learning are strongly regulated by metabotropic glutamate receptors (mGluRs) and particularly by mGluR5. Here, we investigated the mechanisms underlying mGluR5-modulation of these phenomena. Prolonged pharmacological blockade of mGluR5 with MPEP produced a profound impairment of spatial memory. Effects were associated with 1) a reduction of mGluR1a-expression in the dentate gyrus; 2) impaired dentate gyrus LTP; 3) enhanced CA1-LTP and 4) suppressed theta (5-10 Hz) and gamma (30-100 Hz) oscillations in the dentate gyrus. Allosteric potentiation of mGluR1 after mGluR5 blockade significantly ameliorated dentate gyrus LTP, as well as suppression of gamma oscillatory activity. CA3-lesioning prevented MPEP effects on CA1-LTP, suggesting that plasticity levels in CA1 are driven by mGluR5-dependent synaptic and network activity in the dentate gyrus. These data support the hypothesis that prolonged mGluR5-inactivation causes altered hippocampal LTP levels and network activity, which is mediated in part by impaired mGluR1-expression in the dentate gyrus. The consequence is impairment of long-term learning.	[Bikbaev, Arthur; Neyman, Sergey; Manahan-Vaughan, Denise] Ruhr Univ Bochum, Dept Expt Neurophysiol, Fac Med, Bochum, Germany; [Manahan-Vaughan, Denise] Ruhr Univ Bochum, Int Grad Sch Neurosci, Bochum, Germany; [Neyman, Sergey] Humboldt Univ, Inst Physiol Charite, Synaptic Plasticity Res Grp, Berlin, Germany; [Ngomba, Richard Teke; Nicoletti, Ferdinando] Inst Neurol Mediterraneo INM, Pozzilli, Italy; [Conn, Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN USA; [Nicoletti, Ferdinando] Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Rome, Italy	Ruhr University Bochum; Ruhr University Bochum; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; IRCCS Neuromed; Vanderbilt University; Sapienza University Rome	Bikbaev, A (corresponding author), Ruhr Univ Bochum, Dept Expt Neurophysiol, Fac Med, Bochum, Germany.	dmv-igsn@rub.de	Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/A-2446-2010	Ngomba, Richard/0000-0003-3825-3970; Manahan-Vaughan, Denise/0000-0002-9283-9609; NICOLETTI, Ferdinando/0000-0003-3366-7269; Nicoletti, Ferdinando/0000-0003-0917-443X	German Research Foundation (Deutsche Forschungsgemeinschaft)(DFG)	German Research Foundation (Deutsche Forschungsgemeinschaft)(DFG)(German Research Foundation (DFG))	This work was supported by a research grant the German Research Foundation (Deutsche Forschungsgemeinschaft)(DFG). The DFG was not involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Abraham WC, 2003, PHILOS T R SOC B, V358, P735, DOI 10.1098/rstb.2002.1222; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; Axmacher N, 2006, BRAIN RES REV, V52, P170, DOI 10.1016/j.brainresrev.2006.01.007; Balschun D, 1999, LEARN MEMORY, V6, P138; Balschun D, 2006, NEUROSCIENCE, V142, P691, DOI 10.1016/j.neuroscience.2006.06.043; BARNES CA, 1994, J NEUROSCI, V14, P5793; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; Bordi F, 1997, BRAIN RES, V761, P121, DOI 10.1016/S0006-8993(97)00320-X; BRAGIN A, 1995, J NEUROSCI, V15, P47; Braunewell KH, 2003, NEUROPHARMACOLOGY, V44, P707, DOI 10.1016/S0028-3908(03)00051-0; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; Casabona G, 1997, EUR J NEUROSCI, V9, P12, DOI 10.1111/j.1460-9568.1997.tb01348.x; Chen YL, 2007, MOL PHARMACOL, V71, P1389, DOI 10.1124/mol.106.032425; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; Chrobak JJ, 1998, J NEUROSCI, V18, P388; Cobb SR, 2000, NEUROPHARMACOLOGY, V39, P1933, DOI 10.1016/S0028-3908(00)00036-8; Cohen AS, 1998, HIPPOCAMPUS, V8, P160, DOI 10.1002/(SICI)1098-1063(1998)8:2<160::AID-HIPO8>3.3.CO;2-J; Cohen AS, 1996, J NEUROPHYSIOL, V76, P953, DOI 10.1152/jn.1996.76.2.953; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cozzi A, 2002, NEUROPHARMACOLOGY, V43, P119, DOI 10.1016/S0028-3908(02)00080-1; Csicsvari J, 2003, NEURON, V37, P311, DOI 10.1016/S0896-6273(02)01169-8; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1996, J PHYSIOL-LONDON, V490, P703, DOI 10.1113/jphysiol.1996.sp021179; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hemstapat K, 2006, MOL PHARMACOL, V70, P616, DOI 10.1124/mol.105.021857; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Holscher C, 1997, EUR J PHARMACOL, V322, P155, DOI 10.1016/S0014-2999(96)01000-X; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Hughes SW, 2004, NEURON, V42, P253, DOI 10.1016/S0896-6273(04)00191-6; Hughes SW, 2002, NEURON, V33, P947, DOI 10.1016/S0896-6273(02)00623-2; KEMP A, 2007, CEREB CORTE IN PRESS; Kemp A, 2007, TRENDS NEUROSCI, V30, P111, DOI 10.1016/j.tins.2007.01.002; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kocsis B, 1999, J NEUROSCI, V19, P6200, DOI 10.1523/JNEUROSCI.19-14-06200.1999; Kulla A, 2000, CEREB CORTEX, V10, P614, DOI 10.1093/cercor/10.6.614; Lanneau C, 2002, NEUROPHARMACOLOGY, V43, P131, DOI 10.1016/S0028-3908(02)00086-2; Lisman JE, 2001, HIPPOCAMPUS, V11, P551; Lu YM, 1997, J NEUROSCI, V17, P5196; Manahan-Vaughan D, 2005, CEREB CORTEX, V15, P1703, DOI 10.1093/cercor/bhi047; Manahan-Vaughan D, 2003, NEUROPHARMACOLOGY, V44, P17, DOI 10.1016/S0028-3908(02)00342-8; Manahan-Vaughan D, 1998, NEUROSCIENCE, V86, P709, DOI 10.1016/S0306-4522(98)00111-0; Manahan-Vaughan D, 1999, P NATL ACAD SCI USA, V96, P8739, DOI 10.1073/pnas.96.15.8739; Manahan-Vaughan D, 2000, J NEUROSCI, V20, P8572, DOI 10.1523/JNEUROSCI.20-22-08572.2000; ManahanVaughan D, 1997, J NEUROSCI, V17, P3303; Mannaioni G, 2001, J NEUROSCI, V21, P5925, DOI 10.1523/JNEUROSCI.21-16-05925.2001; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Moser EI, 1999, NEUROSCI BIOBEHAV R, V23, P661, DOI 10.1016/S0149-7634(98)00060-8; Naie K, 2005, EUR J NEUROSCI, V21, P411, DOI 10.1111/j.1460-9568.2005.03864.x; Naie K, 2004, CEREB CORTEX, V14, P189, DOI 10.1093/cercor/bhg118; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; Neyman S, 2008, EUR J NEUROSCI, V27, P1345, DOI 10.1111/j.1460-9568.2008.06109.x; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Queiroz CMT, 2007, EUR J NEUROSCI, V25, P3071, DOI 10.1111/j.1460-9568.2007.05573.x; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; Sourdet V, 2003, J NEUROSCI, V23, P10238; THOMAS MJ, 1995, BRAIN RES, V695, P45, DOI 10.1016/0006-8993(95)00757-H; Thuault SJ, 2002, NEUROPHARMACOLOGY, V43, P141, DOI 10.1016/S0028-3908(02)00095-3; Traub RD, 2005, J NEUROPHYSIOL, V94, P1225, DOI 10.1152/jn.00069.2005; Uzakov S, 2005, LEARN MEMORY, V12, P165, DOI 10.1101/lm.89305; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Wilsch VW, 1998, J NEUROSCI, V18, P6071	70	57	57	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2155	10.1371/journal.pone.0002155	http://dx.doi.org/10.1371/journal.pone.0002155			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478073	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000262172800020
J	Akchurin, T; Aissiou, T; Kemeny, N; Prosk, E; Nigam, N; Komarova, SV				Akchurin, Timur; Aissiou, Tayeb; Kemeny, Naomi; Prosk, Erin; Nigam, Nilima; Komarova, Svetlana V.			Complex Dynamics of Osteoclast Formation and Death in Long-Term Cultures	PLOS ONE			English	Article								Background: Osteoclasts, cells responsible for bone resorption, contribute to the development of degenerative, metabolic and neoplastic bone diseases, which are often characterized by persistent changes in bone microenvironment. We aimed to investigate the dynamics of osteoclast formation and death in cultures that considerably exceeded the length of standard protocol and to design a mathematical model describing osteoclastogenesis. Methodology/Principal Findings: RAW 264.7 monocytic cells fuse to form multinucleated osteoclasts upon treatment with pro-resorptive cytokine RANKL. We have found that in long-term experiments (15-26 days), the dynamics of changes in osteoclast numbers was remarkably complex and qualitatively variable in different experiments. Whereas 19 of 46 experiments exhibited single peak of osteoclast formation, in 27 experiments we observed development of successive waves of osteoclast formation and death. Periodic changes in osteoclast numbers were confirmed in long-term cultures of mouse bone marrow cells treated with M-CSF and RANKL. Because the dynamics of changes in osteoclast numbers was found to be largely independent of monocytes, a two-species model of ordinary differential equations describing the changes in osteoclasts and monocytes was ineffective in recapitulating the oscillations in osteoclast numbers. Following experimental observation that medium collected from mature osteoclasts inhibited osteoclastogenesis in fresh cultures, we introduced a third variable, factor f, to describe osteoclast-derived inhibitor. This model allowed us to simulate the oscillatory changes in osteoclasts, which were coupled to oscillatory changes in the factor f, whereas monocytes changed exponentially. Importantly, to achieve the experimentally observed oscillations with increasing amplitude, we also had to assume that osteoclast presence stimulates osteoclast formation. Conclusions/Significance: This study identifies the critical role for osteoclast autocrine regulation in controlling long-term dynamic of osteoclast formation and death and describes the complementary roles for negative and positive feedback mediators in determining the sharp dynamics of activation and inactivation of osteoclasts.	[Akchurin, Timur; Aissiou, Tayeb; Kemeny, Naomi; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ, Canada; [Aissiou, Tayeb; Prosk, Erin; Nigam, Nilima] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	McGill University; McGill University	Akchurin, T (corresponding author), McGill Univ, Fac Dent, Montreal, PQ, Canada.	svetlana.komarova@mcgill.ca			CIHR/IMHA; NSERC	CIHR/IMHA(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This study is supported by operating grants from CIHR/IMHA and NSERC. SVK holds Canada Research Chair in osteoclast biology.	Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Colijn C, 2005, J THEOR BIOL, V237, P133, DOI 10.1016/j.jtbi.2005.03.034; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P153; Defranoux NA, 2005, J BONE MINER RES, V20, P1079, DOI 10.1359/JBMR.050401; Espinosa L, 2002, J CELL SCI, V115, P3837, DOI 10.1242/jcs.00062; Go RS, 2005, BLOOD REV, V19, P53, DOI 10.1016/j.blre.2004.05.001; Goya M, 2006, PROSTATE, V66, P1573, DOI 10.1002/pros.20375; Grey A, 2007, EXPERT OPIN EMERG DR, V12, P493, DOI 10.1517/14728214.12.3.493; Horwitz M, 2004, TRENDS MOL MED, V10, P163, DOI 10.1016/j.molmed.2004.02.002; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109; Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004-1642; Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756-3282(03)00157-1; Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146; Lawson Jack, 2002, Semin Musculoskelet Radiol, V6, P285, DOI 10.1055/s-2002-36727; Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719; PEREVERZEV A, 2007, EXTRACELLULAR ACIDIF; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718; Reddy S V, 2001, Rev Endocr Metab Disord, V2, P195; REDDY SV, 1994, J BONE MINER RES, V9, P753; Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013; Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311; Takahashi Naoyuki, 2007, V135, P285; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; WISE GE, 1995, J DENT RES, V74, P1551, DOI 10.1177/00220345950740090801; WISE GE, 1989, J DENT RES, V68, P150, DOI 10.1177/00220345890680021001; Xiao ZJ, 2003, LEUKEMIA RES, V27, P89, DOI 10.1016/S0145-2126(02)00097-8; Yao SM, 2007, ARCH ORAL BIOL, V52, P228, DOI 10.1016/j.archoralbio.2006.10.008; Yun JH, 2007, J PERIODONTAL RES, V42, P212, DOI 10.1111/j.1600-0765.2006.00935.x; Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200	42	30	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2104	10.1371/journal.pone.0002104	http://dx.doi.org/10.1371/journal.pone.0002104			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461134	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400026
J	Brennan, LJ; Keddie, BA; Braig, HR; Harris, HL				Brennan, Lesley J.; Keddie, B. Andrew; Braig, Henk R.; Harris, Harriet L.			The Endosymbiont Wolbachia pipientis Induces the Expression of Host Antioxidant Proteins in an Aedes albopictus Cell Line	PLOS ONE			English	Article							CU/ZN SUPEROXIDE-DISMUTASE; GENOME-WIDE ANALYSIS; ESCHERICHIA-COLI; IMMUNE-RESPONSE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; LIFE-SPAN; DROSOPHILA; GENE	Wolbachia are obligate intracellular bacteria which commonly infect arthropods. They are maternally inherited and capable of altering host development, sex determination, and reproduction. Reproductive manipulations include feminization, male-killing, parthenogenesis, and cytoplasmic incompatibility. The mechanism by which Wolbachia avoid destruction by the host immune response is unknown. Generation of antimicrobial peptides (AMPs) and reactive oxygen species (ROS) by the host are among the first lines of traditional antimicrobial defense. Previous work shows no link between a Wolbachia infection and the induction of AMPs. Here we compare the expression of protein in a cell line naturally infected with Wolbachia and an identical cell line cured of the infection through the use of antibiotics. Protein extracts of each cell line were analyzed by two dimensional gel electrophoresis and LC/MS/MS. Our results show the upregulation of host antioxidant proteins, which are active against ROS generated by aerobic cell metabolism and during an immune response. Furthermore, flow cytometric and microscopic analysis demonstrates that ROS production is significantly greater in Wolbachia-infected mosquito cells and is associated with endosymbiont-containing vacuoles located in the host cell cytoplasm. This is the first empirical data supporting an association between Wolbachia and the insect antioxidant system.	[Brennan, Lesley J.; Keddie, B. Andrew; Harris, Harriet L.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada; [Braig, Henk R.] Univ Wales, Sch Biol Sci, Bangor, Gwynedd, Wales; [Brennan, Lesley J.; Harris, Harriet L.] Concordia Univ, Coll Alberta, Dept Biol & Env Sci, Edmonton, AB, Canada	University of Alberta; Bangor University; Concordia University - Canada	Brennan, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada.	hharris@concordia.ab.ca	Braig, Henk/I-5477-2013; Keddie, Andrew/A-2654-2014	Braig, Henk/0000-0001-9592-1141; Keddie, Andrew/0000-0002-0131-4306	Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work is supported by the Natural Sciences and Engineering Research Council of Canada.	Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; ANDREWS SC, 1989, J BACTERIOL, V171, P3940, DOI 10.1128/jb.171.7.3940-3947.1989; ARAI K, 1987, J BIOL CHEM, V262, P16969; BENOV LT, 1994, J BIOL CHEM, V269, P25310; Bourtzis K, 2000, INSECT MOL BIOL, V9, P635, DOI 10.1046/j.1365-2583.2000.00224.x; Braig HR, 1998, J BACTERIOL, V180, P2373, DOI 10.1128/JB.180.9.2373-2378.1998; CABISCOL E, 2000, INT MICROBIOL, V2, P3; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Carrondo MA, 2003, EMBO J, V22, P1959, DOI 10.1093/emboj/cdg215; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chen CY, 1999, MICROBIOL-SGM, V145, P2967, DOI 10.1099/00221287-145-10-2967; Csar XF, 2001, PROTEOMICS, V1, P435, DOI 10.1002/1615-9861(200103)1:3<435::AID-PROT435>3.3.CO;2-H; Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; DeJong RJ, 2007, P NATL ACAD SCI USA, V104, P2121, DOI 10.1073/pnas.0608407104; DEVAMANOHARAN PS, 1994, INFECT IMMUN, V62, P2619, DOI 10.1128/IAI.62.6.2619-2621.1994; Eremeeva ME, 1998, MICROBIOL-SGM, V144, P2037, DOI 10.1099/00221287-144-8-2037; Fares MA, 2004, TRENDS GENET, V20, P413, DOI 10.1016/j.tig.2004.07.001; FRANZON VL, 1990, INFECT IMMUN, V58, P529, DOI 10.1128/IAI.58.2.529-535.1990; Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Furukawa Y, 2006, ANTIOXID REDOX SIGN, V8, P847, DOI 10.1089/ars.2006.8.847; Geslin C, 2001, RES MICROBIOL, V152, P901, DOI 10.1016/S0923-2508(01)01273-6; Gort AS, 1999, MOL MICROBIOL, V32, P179, DOI 10.1046/j.1365-2958.1999.01343.x; Ha EM, 2005, SCIENCE, V310, P847, DOI 10.1126/science.1117311; Ha EM, 2005, DEV CELL, V8, P125, DOI 10.1016/j.devcel.2004.11.007; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Harris HL, 2003, BIOCHEM CELL BIOL, V81, P229, DOI [10.1139/o03-053, 10.1139/O03-053]; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; Hermans PG, 2001, J ANTIMICROB CHEMOTH, V47, P659, DOI 10.1093/jac/47.5.659; Ho YS, 1998, ENVIRON HEALTH PERSP, V106, P1219, DOI 10.2307/3433989; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hurst GDD, 2003, INSECT MOL BIOL, V12, P93, DOI 10.1046/j.1365-2583.2003.00380.x; Hurst GDD, 1999, P ROY SOC B-BIOL SCI, V266, P735, DOI 10.1098/rspb.1999.0698; Iiyama K, 2007, APPL ENVIRON MICROB, V73, P1569, DOI 10.1128/AEM.00981-06; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; Khelef N, 1996, FEMS MICROBIOL LETT, V142, P231; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; Manduzio H, 2003, AQUAT TOXICOL, V64, P73, DOI 10.1016/S0166-445X(03)00026-2; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Missirlis F, 2003, BIOL CHEM, V384, P463, DOI 10.1515/BC.2003.052; Mittapalli O, 2007, P NATL ACAD SCI USA, V104, P1889, DOI 10.1073/pnas.0604722104; Ni DJ, 2007, FISH SHELLFISH IMMUN, V23, P1032, DOI 10.1016/j.fsi.2007.04.008; ONeill SL, 1997, INSECT MOL BIOL, V6, P33, DOI 10.1046/j.1365-2583.1997.00157.x; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Parker JD, 2004, INSECT MOL BIOL, V13, P587, DOI 10.1111/j.0962-1075.2004.00515.x; Parkes TL, 1998, GENOME, V41, P642; Radyuk SN, 2001, FREE RADICAL BIO MED, V31, P1090, DOI 10.1016/S0891-5849(01)00692-X; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; SANTUCCI LA, 1992, INFECT IMMUN, V60, P5113, DOI 10.1128/IAI.60.12.5113-5118.1992; Sarto C, 1999, ELECTROPHORESIS, V20, P3458, DOI 10.1002/(SICI)1522-2683(19991101)20:17<3458::AID-ELPS3458>3.3.CO;2-X; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SILVERMAN DJ, 1988, INFECT IMMUN, V56, P3110, DOI 10.1128/IAI.56.12.3110-3115.1988; Singh OP, 2004, AM J TROP MED HYG, V70, P27, DOI 10.4269/ajtmh.2004.70.27; SMITH J, 1979, COMP BIOCHEM PHYS B, V63, P39, DOI 10.1016/0305-0491(79)90231-1; Stothard P, 2005, NUCLEIC ACIDS RES, V33, pD317, DOI 10.1093/nar/gki075; STOUTHAMER R, 1993, NATURE, V361, P66, DOI 10.1038/361066a0; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Whitten MMA, 1999, J INSECT PHYSIOL, V45, P667, DOI 10.1016/S0022-1910(99)00039-6; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Woodruff RC, 2004, GENOME, V47, P1029, DOI 10.1139/G04-083; Wu M, 2004, PLOS BIOL, V2, P327, DOI 10.1371/journal.pbio.0020069; XI ZY, 2008, BMC GENOMICS, V9; Zhou WG, 1998, P ROY SOC B-BIOL SCI, V265, P509, DOI 10.1098/rspb.1998.0324	77	112	115	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2083	10.1371/journal.pone.0002083	http://dx.doi.org/10.1371/journal.pone.0002083			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461124	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400007
J	Nayak, S; Salim, S; Luan, D; Zai, M; Varner, JD				Nayak, Satyaprakash; Salim, Saniya; Luan, Deyan; Zai, Michael; Varner, Jeffrey D.			A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials	PLOS ONE			English	Article							ANAPHASE-PROMOTING COMPLEX; SENSITIVITY-ANALYSIS; ROBUSTNESS PROPERTIES; RESTRICTION POINT; KINASE INHIBITOR; IN-VITRO; S-PHASE; PROTEIN; ACTIVATION; EXPRESSION	Robustness, a long-recognized property of living systems, allows function in the face of uncertainty while fragility, i.e., extreme sensitivity, can potentially lead to catastrophic failure following seemingly innocuous perturbations. Carlson and Doyle hypothesized that highly-evolved networks, e. g., those involved in cell-cycle regulation, can be resistant to some perturbations while highly sensitive to others. The "robust yet fragile'' duality of networks has been termed Highly Optimized Tolerance (HOT) and has been the basis of new lines of inquiry in computational and experimental biology. In this study, we tested the working hypothesis that cell-cycle control architectures obey the HOT paradigm. Three cell-cycle models were analyzed using monte-carlo sensitivity analysis. Overall state sensitivity coefficients, which quantify the robustness or fragility of a given mechanism, were calculated using a monte-carlo strategy with three different numerical techniques along with multiple parameter perturbation strategies to control for possible numerical and sampling artifacts. Approximately 65% of the mechanisms in the G1/S restriction point were responsible for 95% of the sensitivity, conversely, the G2-DNA damage checkpoint showed a much stronger dependence on a few mechanisms;,32% or 13 of 40 mechanisms accounted for 95% of the sensitivity. Our analysis predicted that CDC25 and cyclin E mechanisms were strongly implicated in G1/S malfunctions, while fragility in the G2/M checkpoint was predicted to be associated with the regulation of the cyclin B-CDK1 complex. Analysis of a third model containing both G1/S and G2/M checkpoint logic, predicted in addition to mechanisms already mentioned, that translation and programmed proteolysis were also key fragile subsystems. Comparison of the predicted fragile mechanisms with literature and current preclinical and clinical trials suggested a strong correlation between efficacy and fragility. Thus, when taken together, these results support the working hypothesis that cell-cycle control architectures are HOT networks and establish the mathematical estimation and subsequent therapeutic exploitation of fragile mechanisms as a novel strategy for anti-cancer lead generation.	[Nayak, Satyaprakash; Luan, Deyan; Zai, Michael; Varner, Jeffrey D.] Cornell Univ, Dept Chem & Biomol Engn, Ithaca, NY USA; [Salim, Saniya] Cornell Univ, Dept Biol & Env Engn, Ithaca, NY USA	Cornell University; Cornell University	Varner, JD (corresponding author), Cornell Univ, Dept Chem & Biomol Engn, Ithaca, NY USA.	jdv27@cornell.edu			Cornell University Center for Life Science Enterprise; New York State Center for Advanced Technology; Engineering Learning Initiatives Undergraduate Research Awards [ELI-650, ELI-895]	Cornell University Center for Life Science Enterprise; New York State Center for Advanced Technology; Engineering Learning Initiatives Undergraduate Research Awards	The authors acknowledge the gracious financial support of the Cornell University Center for Life Science Enterprise, a New York State Center for Advanced Technology grant (to J.V. for the support of S. N.) and Engineering Learning Initiatives Undergraduate Research Awards ELI-650 and ELI-895 to M.Z. and S.S. The Cornell University Center for Life Science Enterprise and the Engineering Learning Initiatives Undergraduate research program played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Aguda BD, 1999, ONCOGENE, V18, P2846, DOI 10.1038/sj.onc.1202462; Aguda BD, 1999, CELL PROLIFERAT, V32, P321, DOI 10.1046/j.1365-2184.1999.3250321.x; Aguda BD, 1999, P NATL ACAD SCI USA, V96, P11352, DOI 10.1073/pnas.96.20.11352; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; ASIEDU C, 1995, CANCER RES, V55, P3716; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Bang S, 2005, CLIN CANCER RES, V11, P1545, DOI 10.1158/1078-0432.CCR-04-1939; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Cagney G, 2000, METHOD ENZYMOL, V328, P3, DOI 10.1016/S0076-6879(00)28386-9; CARLSON JM, 2002, P NATL ACAD SCI USA, V99, P2358; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Cho KH, 2003, SIMUL-T SOC MOD SIM, V79, P726, DOI 10.1177/0037549703040943; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Cote RJ, 1998, CANCER RES, V58, P1090; Csete M, 2004, TRENDS BIOTECHNOL, V22, P446, DOI 10.1016/j.tibtech.2004.07.007; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; DOUGHERTY EP, 1979, INT J CHEM KINET, V11, P1237, DOI 10.1002/kin.550111203; Eissing T, 2005, IEE P SYST BIOL, V152, P221, DOI 10.1049/ip-syb:20050046; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gadkar KG, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-155; Gadkar KG, 2005, SYSTEMS BIOL, V2, P17, DOI 10.1049/sb:20045029; Garber K, 2005, J NATL CANCER I, V97, P166, DOI 10.1093/jnci/97.3.166; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gunawan R, 2005, BIOPHYS J, V88, P2530, DOI 10.1529/biophysj.104.053405; Gunawan R, 2007, J BIOL RHYTHM, V22, P180, DOI 10.1177/0748730407299194; Gunawan R, 2006, BIOPHYS J, V91, P2131, DOI 10.1529/biophysj.105.078006; Gutenkunst RN, 2007, PLOS COMPUT BIOL, V3, P1871, DOI 10.1371/journal.pcbi.0030189; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hayun M, 2007, LEUKEMIA, V21, P1504, DOI 10.1038/sj.leu.2404746; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HORNUNG RL, 1992, CANCER RES, V52, P101; HOUCHENS DP, 1983, EUR J CANCER CLIN ON, V19, P799, DOI 10.1016/0277-5379(83)90012-3; Kanungo T, 2002, IEEE T PATTERN ANAL, V24, P881, DOI 10.1109/TPAMI.2002.1017616; Kar S, 2006, MOL CANCER THER, V5, P1511, DOI 10.1158/1535-7163.MCT-05-0485; Keenan SM, 2004, J BIOL CHEM, V279, P5387, DOI 10.1074/jbc.M310383200; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kholodenko BN, 2002, P NATL ACAD SCI USA, V99, P12841, DOI 10.1073/pnas.192442699; Kitano H, 2004, NAT REV GENET, V5, P826, DOI 10.1038/nrg1471; Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; KRAMER MA, 1984, INT J CHEM KINET, V16, P559, DOI 10.1002/kin.550160506; Kremling A, 2004, GENOME RES, V14, P1773, DOI 10.1101/gr.1226004; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LEIS JR, 1985, COMPUT CHEM ENG, V9, P93, DOI 10.1016/0098-1354(85)87008-3; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Luan D, 2007, PLOS COMPUT BIOL, V3, P1347, DOI 10.1371/journal.pcbi.0030142; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mahdavi A, 2007, PLOS COMPUT BIOL, V3, P1257, DOI 10.1371/journal.pcbi.0030130; MCCORMICK J, 2003, P AN M AM SOC CLIN, V22, P208; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; *NCI, 2007, NCT00003690 NCI; *NCI, NCT00060567 NCI; *NCI, 2007, NCT00039455 NCI; *NCI, 2007, PHAS 2 STUD FLAV HMR; *NCI, 2007, NCT00002907 NCI; *NCI, 2007, NCT00112723 NCI; NEWSAM GN, 1983, SIAM J ALGEBRA DISCR, V4, P404, DOI 10.1137/0604041; Novak M, 2004, J THEOR BIOL, V230, P563, DOI 10.1016/j.jtbi.2004.04.039; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Qu ZL, 2003, AM J PHYSIOL-CELL PH, V284, pC349, DOI 10.1152/ajpcell.00066.2002; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Soderlund G, 2004, NEOPLASMA, V51, P1; Stelling J, 2004, P NATL ACAD SCI USA, V101, P13210, DOI 10.1073/pnas.0401463101; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Tamura K, 2000, CANCER RES, V60, P1317; van Kesteren C, 2002, ANTI-CANCER DRUG, V13, P989, DOI 10.1097/00001813-200211000-00002; Varterasian ML, 1998, J CLIN ONCOL, V16, P56, DOI 10.1200/JCO.1998.16.1.56; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Venkatasubramanian V, 2004, COMPUT CHEM ENG, V28, P1789, DOI 10.1016/j.compchemeng.2004.02.028; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.2307/2332510; You L, 2006, IEE P SYST BIOL, V153, P46, DOI 10.1049/ip-syb:20050026; You X, 2006, P NATL ACAD SCI USA, V103, P18458, DOI 10.1073/pnas.0605422103	90	13	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2016	10.1371/journal.pone.0002016	http://dx.doi.org/10.1371/journal.pone.0002016			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431497	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700032
J	Matta, H; Punj, V; Schamus, S; Mazzacurati, L; Chen, AM; Song, R; Yang, T; Chaudhary, PM				Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Yang, T.; Chaudhary, P. M.			A nuclear role for Kaposi's sarcoma-associated herpesvirus-encoded K13 protein in gene regulation	ONCOGENE			English	Article						K13; vFLIP; KSHV; RTA; IKK; NF-kappa B	NF-KAPPA-B; KINASE COMPLEX; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; KSHV VFLIP; IKK-GAMMA; ACTIVATION; EXPRESSION; ALPHA; PATHWAY	Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded viral FLICE inhibitory protein K13 interacts with a cytosolic I kappa B kinase (IKK) complex to activate nuclear factor-kappa B (NF-kappa B). We recently reported that K13 antagonizes KSHV lytic regulator RTA ( replication and transcription activator) and blocks lytic replication, but spares RTA-induced viral interleukin-6 (vIL6). Here we report that K13 is also present in the nuclear compartment, a property not shared by its structural homologs. K13 interacts with and activates the nuclear IKK complex, and binds to the I kappa B alpha promoter. K13 mutants that are retained in the cytosol lack NF-kappa B activity. However, neither the IKKs nor NF-kappa B activation is required for nuclear localization of K13. Instead, this ability is dependent on a nuclear localization signal located in its N-terminal 40 amino acids. Finally, K13, along with p65/RelA, binds to the promoters of a number of KSHV lytic genes, including RTA, ORF57 and vGPCR, but not to the promoter of the vIL6 gene. Thus, K13 has an unexpected nuclear role in viral and cellular gene regulation and its differential binding to the promoters of lytic genes may not only contribute to the inhibition of KSHV lytic replication, but may also account for the escape of vIL6 from K13-induced transcriptional suppression.	[Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Chaudhary, P. M.] Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, Pittsburgh, PA 15213 USA; [Yang, T.] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Spang Translat Res Core Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chaudhary, PM (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	ational Institutes of Health [CA85177, CA124621]; Leukemia and Lymphoma Society; Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE [R01CA124621, R01CA085177] Funding Source: NIH RePORTER	ational Institutes of Health; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Inder Verma for providing the IKK deficient MEFs, Dr Shao-Cong Sun for NEMO-deficient Jurkat cells and Dr Mary Collins for a K13 monoclonal antibody. This work was supported by grants from the National Institutes of Health (CA85177 and CA124621), the Leukemia and Lymphoma Society and the Mario Lemieux Foundation.	An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Ear T, 2005, J IMMUNOL, V175, P1834, DOI 10.4049/jimmunol.175.3.1834; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Han Z, 2006, J VIROL, V80, P5251, DOI 10.1128/JVI.02570-05; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nekorchuk M, 2007, J VIROL, V81, P9990, DOI 10.1128/JVI.00896-07; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Schulz TF, 2006, J PATHOL, V208, P187, DOI 10.1002/path.1904; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Wang SZE, 2004, J VIROL, V78, P4248, DOI 10.1128/JVI.78.8.4248-4267.2004; West JT, 2003, ONCOGENE, V22, P5150, DOI 10.1038/sj.onc.1206555; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067	40	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5243	5253		10.1038/onc.2008.150	http://dx.doi.org/10.1038/onc.2008.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469854				2022-12-25	WOS:000258915100008
J	Makkonen, H; Jaaskelainen, T; Pitkanen-Arsiola, T; Rytinki, M; Waltering, KK; Matto, M; Visakorpi, T; Palvimo, JJ				Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Waltering, K. K.; Matto, M.; Visakorpi, T.; Palvimo, J. J.			Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; ETS transcription factor; prostate cancer; FoxA1	ETS TRANSCRIPTION FACTOR; GENE-EXPRESSION; REGULATED ACTIVITY; OVEREXPRESSION; AMPLIFICATION; MICROARRAYS; PROTEINS; MUTATION; DOMAIN; ROLES	Transcriptional control by androgens via androgen receptor (AR) is strongly involved in prostate cancer development, but the critical target genes have remained elusive. We have characterized E twenty-six-like transcription factor 4 (ELK4) ( also known as serum response factor accessory protein 1) as a novel AR target in human prostate cancer cells. In-silico screening identified three putative AR response elements (AREs) within -10 kb from the transcription start site of ELK4. Both ARE1 at -167/-153 and ARE2 at -481/-467 bound AR in vitro and mediated androgen induction as isolated elements in transcription assays in non-prostate cells. However, merely the ARE2 that cooperates with a proximal forkhead box A1-binding site was critical for the AR-dependent activation of ELK4 promoter in prostate cancer cells. Preferential loading of holo-AR onto the ARE2 and concomitant recruitment of RNA polymerase II onto the ELK4 promoter was conformed in prostate cancer cells by chromatin immunoprecipitation. Database searches indicated that the expression of ELK4 is markedly increased in prostate cancers relative to normal prostates. Moreover, prostate cancer tissue immunostainings showed that nuclear ELK4 levels are significantly increased in androgen-refractory prostate cancers compared to untreated tumours. Reduction of the amount of ELK4 in LNCaP cells by RNAi retarded cell growth. In conclusion, ELK4 is a direct AR target in prostate cancer cells. Androgens may thus contribute to the growth of prostate cancer via influencing ELK4 levels.	[Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Palvimo, J. J.] Univ Kuopio, Inst Biomed Med Biochem, FI-70211 Kuopio, Finland; [Waltering, K. K.; Visakorpi, T.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Waltering, K. K.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [Matto, M.] Univ Kuopio, Inst Clin Med & Clin Microbiol, FI-70211 Kuopio, Finland	University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital; University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Kuopio, Inst Biomed Med Biochem, POB 1627, FI-70211 Kuopio, Finland.	Jorma.Palvimo@uku.fi		Palvimo, Jorma/0000-0003-2373-0578; Visakorpi, Tapio/0000-0002-5004-0364	Academy of Finland; Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation; Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	Academy of Finland(Academy of Finland); Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	This work was supported by grants from the Academy of Finland, Association for International Cancer Research, Finnish Cancer Foundation, Sigrid Juselius Foundation, Kuopio Naturalists' Society, Helena Vuorenmies Foundation, Karjalan Sivistysseura and Finnish Union of Experts in Science. We thank Merja Rasanen for skilful technical assistance.	Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cesari F, 2004, MOL CELL BIOL, V24, P294, DOI 10.1128/MCB.24.1.294-305.2004; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Costello PS, 2004, NAT IMMUNOL, V5, P289, DOI 10.1038/ni1038; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gregory CW, 2001, CANCER RES, V61, P4315; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huggins C, 1941, CANCER RES, V1, P293; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Linja MJ, 2001, CANCER RES, V61, P3550; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maroni Paul D, 2006, N C Med J, V67, P136; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Stewart Alistair B., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P603, DOI 10.2174/156801105774574658; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Welsh JB, 2001, CANCER RES, V61, P5974; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	46	34	45	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4865	4876		10.1038/onc.2008.125	http://dx.doi.org/10.1038/onc.2008.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469865				2022-12-25	WOS:000258596900001
J	Calvo, AC; Pey, AL; Ying, M; Loer, CM; Martinez, A				Calvo, Ana C.; Pey, Angel L.; Ying, Ming; Loer, Curtis M.; Martinez, Aurora			Anabolic function of phenylalanine hydroxylase in Caenorhabditis elegans	FASEB JOURNAL			English	Article						phenylketonuria; melanin; cuticle; oxygen radical scavenging; tetrahydrobiopterin	OXIDATIVE STRESS; ESCHERICHIA-COLI; C-ELEGANS; LIFE-SPAN; SYSTEM; FLUORESCENCE; TYROSINE; PROTEIN; FAMILY; GENE	In humans, liver phenylalanine hydroxylase (PAH) has an established catabolic function, and mutations in PAH cause phenylketonuria, a genetic disease characterized by neurological damage, if not treated. To obtain novel evolutionary insights and information on molecular mechanisms operating in phenylketonuria, we investigated PAH in the nematode Caenorhabditis elegans (cePAH), where the enzyme is coded by the pah-1 gene, expressed in the hypodermis. CePAH presents similar molecular and kinetic properties to human PAH [S-0.5(L-Phe) similar to 150 mu M; K-m for tetrahydrobiopterin (BH4) similar to 35 mu M and comparable V-max], but cePAH is devoid of positive cooperativity for L-Phe, an important regulatory mechanism of mammalian PAH that protects the nervous system from excess L-Phe. Pah-1 knockout worms show no obvious neurological defects, but in combination with a second cuticle synthesis mutation, they display serious cuticle abnormalities. We found that pah-1 knockouts lack a yellow-orange pigment in the cuticle, identified as melanin by spectroscopic techniques, and which is detected in C. elegans for the first time. Pah-1 mutants show stimulation of superoxide dismutase activity, suggesting that cuticle melanin functions as oxygen radical scavenger. Our results uncover both an important anabolic function of PAH and the change in regulation of the enzyme along evolution.	[Calvo, Ana C.; Pey, Angel L.; Ying, Ming; Martinez, Aurora] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; [Loer, Curtis M.] Univ San Diego, Dept Biol, San Diego, CA 92110 USA	University of Bergen; University of San Diego	Martinez, A (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	aurora.martinez@biomed.uib.no	Martinez, Aurora/M-3088-2019	Martinez, Aurora/0000-0003-1643-6506; Pey, Angel Luis/0000-0001-7706-3243				ABITA JP, 1984, J BIOL CHEM, V259, P4560; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; BEL Y, 1992, INSECT BIOCHEM MOLEC, V22, P633, DOI 10.1016/0965-1748(92)90041-C; Bilinska B, 2001, SPECTROCHIM ACTA A, V57, P2525, DOI 10.1016/S1386-1425(01)00519-4; BLAXTER M, 1999, C ELEGANS PRACTICAL, P15; Bowen RL, 2004, GERONTOLOGY, V50, P265, DOI 10.1159/000079125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1974, GENETICS, V77, P71; Cappitelli F, 2005, MACROMOL BIOSCI, V5, P49, DOI 10.1002/mabi.200400134; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Chavez V, 2007, GENETICS, V176, P1567, DOI 10.1534/genetics.107.072587; Chen YH, 2004, J GEN APPL MICROBIOL, V50, P183, DOI 10.2323/jgam.50.183; Christensen BM, 2005, TRENDS PARASITOL, V21, P192, DOI 10.1016/j.pt.2005.02.007; Cronin CJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-5; DAVIS BO, 1982, BIOCHEMISTRY-US, V21, P4089, DOI 10.1021/bi00260a027; Donko A, 2005, PHILOS T R SOC B, V360, P2301, DOI 10.1098/rstb.2005.1767; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Fisher AL, 2008, J BIOL CHEM, V283, P9127, DOI 10.1074/jbc.M708341200; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; FLATMARK T, 1980, ANAL BIOCHEM, V107, P71, DOI 10.1016/0003-2697(80)90494-7; Fossbakk A, 2005, ANAL BIOCHEM, V343, P100, DOI 10.1016/j.ab.2005.04.043; Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x; Hagen MEK, 2002, BBA-MOL BASIS DIS, V1586, P344, DOI 10.1016/S0925-4439(01)00112-0; Honda Y, 2002, ANN NY ACAD SCI, V959, P466, DOI 10.1111/j.1749-6632.2002.tb02117.x; Ikemoto K, 2002, BIOL CHEM, V383, P325, DOI 10.1515/BC.2002.035; Infanger LC, 2004, INSECT BIOCHEM MOLEC, V34, P1329, DOI 10.1016/j.ibmb.2004.09.004; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lints R, 1999, DEVELOPMENT, V126, P5819; LOER C, 2002, SOC NEUR ABSTR, V28, P231; Loer CM, 1999, J NEUROGENET, V13, P157, DOI 10.3109/01677069909083472; Malencik DA, 2003, AMINO ACIDS, V25, P233, DOI 10.1007/s00726-003-0014-z; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Meredith P, 2006, PIGM CELL RES, V19, P572, DOI 10.1111/j.1600-0749.2006.00345.x; MITNAUL LJ, 1995, P NATL ACAD SCI USA, V92, P885, DOI 10.1073/pnas.92.3.885; Nighswander-Rempel SP, 2006, BIOPOLYMERS, V82, P631, DOI 10.1002/bip.20518; O'Rourke D, 2006, GENOME RES, V16, P1005, DOI 10.1101/gr.50823006; Page AP, 2007, WORMBOOK, DOI [10.1895/wormbook.1.138.1, DOI 10.1895/W0RMB00K.1.138.1]; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Pardridge WM, 1998, NEUROCHEM RES, V23, P635, DOI 10.1023/A:1022482604276; Pey AL, 2007, AM J HUM GENET, V81, P1006, DOI 10.1086/521879; Pey AL, 2006, FASEB J, V20, P2130, DOI 10.1096/fj.06-5835fje; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; Plonka PM, 2006, ACTA BIOCHIM POL, V53, P429, DOI 10.18388/abp.2006_3314; Potterf SB, 1996, J BIOL CHEM, V271, P4002; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; Riesz J, 2006, J PHYS CHEM B, V110, P13985, DOI 10.1021/jp0548691; Schallreuter KU, 2005, MOL GENET METAB, V86, pS27, DOI 10.1016/j.ymgme.2005.07.023; SCRIVER CR, 1994, ANNU REV GENET, V28, P141; Scriver CR, 2003, HUM MUTAT, V21, P333, DOI 10.1002/humu.10200; SILVA FJ, 1992, BIOCHEM J, V287, P85, DOI 10.1042/bj2870085; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; Teigen K, 2007, CURR MED CHEM, V14, P455, DOI 10.2174/092986707779941023; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Thorolfsson M, 2002, BIOCHEMISTRY-US, V41, P7573, DOI 10.1021/bi0160720; van Spronsen FJ, 2001, J INHERIT METAB DIS, V24, P1, DOI 10.1023/A:1005689232358; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Veljkovic E, 2004, J BIOL CHEM, V279, P49268, DOI 10.1074/jbc.M404470200; Watts JL, 2003, GENETICS, V163, P581; Werner-Felmayer G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073; Wheeler JM, 2006, GENETICS, V174, P1327, DOI 10.1534/genetics.106.059089; Wiens M, 1998, DEV COMP IMMUNOL, V22, P469, DOI 10.1016/S0145-305X(98)00034-2; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5	69	26	30	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3046	3058		10.1096/fj.08-108522	http://dx.doi.org/10.1096/fj.08-108522			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18460651				2022-12-25	WOS:000258089300044
J	Hartz, AMS; Bauer, B; Block, ML; Hong, JS; Miller, DS				Hartz, Anika M. S.; Bauer, Bjoern; Block, Michelle L.; Hong, Jau-Shyong; Miller, David S.			Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier	FASEB JOURNAL			English	Article						NADPH oxidase; reactive oxygen species; TNF-alpha; TNF-receptor 1; JNK	NECROSIS-FACTOR-ALPHA; AIR-POLLUTION; EFFLUX TRANSPORTERS; DRUG-THERAPY; IN-VIVO; KAPPA-B; ACTIVATION; MACROPHAGE; EXPRESSION; PATHOLOGY	Here, we report that diesel exhaust particles (DEPs), a major constituent of urban air pollution, affect blood-brain barrier function at the tissue, cellular, and molecular levels. Isolated rat brain capillaries exposed to DEPs showed increased expression and transport activity of the key drug efflux transporter, P-glycoprotein (6 h EC(50) was similar to 5 mu g/ml). Upregulation of P-glycoprotein was abolished by blocking transcription or protein synthesis. Inhibition of NADPH oxidase or pretreatment of capillaries with radical scavengers ameliorated DEP-induced P-glycoprotein up-regulation, indicating a role for reactive oxygen species in signaling. DEP exposure also increased brain capillary tumor necrosis factor-alpha (TNF-alpha) levels. DEP-induced P-glycoprotein up-regulation was abolished when TNF-receptor 1 (TNF-R1) was blocked and was not evident in experiments with capillaries from TNF-R1 knockout mice. Inhibition of JNK, but not NF-kappa B, blocked DEP-induced P-glycoprotein up-regulation, indicating a role for AP-1 in the signaling pathway. Consistent with this, DEPs increased phosphorylation of c-jun. Together, our results show for the first time that a component of air pollution, DEPs, alters blood-brain barrier function through oxidative stress and proinflammatory cytokine production. These experiments disclose a novel blood-brain barrier signaling pathway, with clear implications for environmental toxicology, CNS pathology, and the pharmacotherapy of CNS disorders.	[Hartz, Anika M. S.; Bauer, Bjoern; Block, Michelle L.; Hong, Jau-Shyong; Miller, David S.] NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; [Hartz, Anika M. S.] Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA; [Bauer, Bjoern] Univ Minnesota, Coll Pharm, Dept Pharmaceut Sci, Duluth, MN 55812 USA; [Block, Michelle L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; Virginia Commonwealth University	Miller, DS (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	miller@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	Intramural NIH HHS Funding Source: Medline; NIEHS NIH HHS [R00 ES015409, R00 ES015409-02, R00ES015409] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090082, R00ES015409, Z01ES080060, Z01ES080048] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2002, EPA600890057F NAT CT; Bauer B, 2005, EXP BIOL MED, V230, P118; Bauer B, 2004, MOL PHARMACOL, V66, P413; Bauer B, 2007, MOL PHARMACOL, V71, P667, DOI 10.1124/mol.106.029512; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Block ML, 2004, FASEB J, V18, P1618, DOI 10.1096/fj.04-1945fje; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Calderon-Garciduenas L, 2004, TOXICOL PATHOL, V32, P650, DOI 10.1080/01926230490520232; Calderon-Garciduenas L, 2003, TOXICOL PATHOL, V31, P524, DOI 10.1080/01926230390226645; Calderon-Garciduenas L, 2007, TOXICOL PATHOL, V35, P154, DOI 10.1080/01926230601059985; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dazert P, 2006, NEUROSCIENCE, V142, P1071, DOI 10.1016/j.neuroscience.2006.07.056; Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X; Desai BS, 2007, CELL TRANSPLANT, V16, P285, DOI 10.3727/000000007783464731; DRAPER WM, 1986, CHEMOSPHERE, V15, P437, DOI 10.1016/0045-6535(86)90537-0; Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451; GREENE G, 1994, ENVIRONMENT, V36, P25, DOI 10.1080/00139157.1994.9929182; Hartz AMS, 2006, MOL PHARMACOL, V69, P462, DOI 10.1124/mol.105.017954; Hartz AMS, 2005, CURR NANOSCI, V1, P203, DOI 10.2174/157341305774642948; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JETTE L, 1993, ADV EXP MED BIOL, V331, P121; JOO F, 1986, NATURE, V321, P197, DOI 10.1038/321197a0; Kim RB, 2002, DRUG METAB REV, V34, P47, DOI 10.1081/DMR-120001389; Kyriakis JM, 2001, NATURE, V414, P265, DOI 10.1038/35104735; Lin JH, 2003, DRUG METAB REV, V35, P417, DOI 10.1081/DMR-120026871; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; *NAT I STAND TECHN, 2000, CERT AN STAND REF MA; National Institute of Standards and Technology, 2006, MAT SAF DAT SHEET SR; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Peters A, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-13; Rao KMK, 2005, ENVIRON HEALTH PERSP, V113, P612, DOI 10.1289/ehp.7696; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; SCHUETZLE D, 1983, ENVIRON HEALTH PERSP, V47, P65, DOI 10.2307/3429500; Singh P, 2004, ENVIRON HEALTH PERSP, V112, P820, DOI 10.1289/ehp.6579; Sugamata M, 2006, J HEALTH SCI, V52, P82, DOI 10.1248/jhs.52.82; Taylor EM, 2002, CLIN PHARMACOKINET, V41, P81, DOI 10.2165/00003088-200241020-00001; *UN ENV PROGR WHO, 1994, ENVIRONMENT, V36, P2; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang MY, 2005, ELECTROPHORESIS, V26, P2092, DOI 10.1002/elps.200410428; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200	46	197	203	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2723	2733		10.1096/fj.08-106997	http://dx.doi.org/10.1096/fj.08-106997			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18474546	Green Published			2022-12-25	WOS:000258089300012
J	Noda, K; She, H; Nakazawa, T; Hisatomi, T; Nakao, S; Almulki, L; Zandi, S; Miyahara, S; Ito, Y; Thomas, KL; Garland, RC; Miller, JW; Gragoudas, ES; Mashima, Y; Hafezi-Moghadam, A				Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Mashima, Yukihiko; Hafezi-Moghadam, Ali			Vascular adhesion protein-1 blockade suppresses choroidal neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; leukocyte recruitment; macrophage; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; GENE-EXPRESSION; BRUCHS MEMBRANE; INFLAMMATION; MACROPHAGES; ANGIOGENESIS; PATHOGENESIS; INDUCTION; MOLECULES	Vascular adhesion protein-1 (VAP-1) is an endothelial cell adhesion molecule involved in leukocyte recruitment. Leukocytes and, in particular, macrophages play an important role in the development of choroidal neovascularization (CNV), an integral component of age-related macular degeneration (AMD). Previously, we showed a role for VAP-1 in ocular inflammation. Here, we investigate the expression of VAP-1 in the choroid and its role in CNV development. VAP-1 was expressed in the choroid, exclusively in the vessels, and colocalized in the vessels of the CNV lesions. VAP-1 blockade with a novel and specific inhibitor significantly decreased CNV size, fluorescent angiographic leakage, and the accumulation of macrophages in the CNV lesions. Furthermore, VAP-1 blockade significantly reduced the expression of inflammation-associated molecules such as tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM) - 1. This work provides evidence for an important role of VAP-1 in the recruitment of macrophages to CNV lesions, establishing a novel link between VAP-1 and angiogenesis. Inhibition of VAP-1 may become a new therapeutic strategy in the treatment of AMD.	[Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Mashima, Yukihiko] R Tech Ueno Ltd, Tokyo, Japan	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Hafezi-Moghadam, A (corresponding author), Massachusetts Eye & Ear Infirm, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	Ali_Hafezi-Moghadam@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Zandi, Souska/0000-0001-9351-4278	NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY014104, EY14104] Funding Source: Medline; NHLBI NIH HHS [R01 HL086933, HL086933] Funding Source: Medline; NIAID NIH HHS [K08 AI050775, AI050775] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin E, 2001, INFECT IMMUN, V69, P1774, DOI 10.1128/IAI.69.3.1774-1780.2001; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353; Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013; DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716; ELNER SG, 1991, LAB INVEST, V64, P819; ELNER VM, 1990, AM J PATHOL, V136, P745; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914; Grossniklaus HE, 2002, MOL VIS, V8, P119; Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625; HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010; Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Lehr HA, 1999, J HISTOCHEM CYTOCHEM, V47, P119, DOI 10.1177/002215549904700113; Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112; Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058; Martelius T, 2000, AM J PATHOL, V157, P1229, DOI 10.1016/S0002-9440(10)64638-X; Matyus P, 2004, CURR MED CHEM, V11, P1285, DOI 10.2174/0929867043365305; Merinen M, 2005, AM J PATHOL, V166, P793, DOI 10.1016/S0002-9440(10)62300-0; Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe; Noda K, 2008, FASEB J, V22, P1094, DOI 10.1096/fj.07-9377com; Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891; PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255; SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983; She HC, 2007, INVEST OPHTH VIS SCI, V48, P2268, DOI 10.1167/iovs.06-0979; Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063; Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007; Singh B, 2003, VIRCHOWS ARCH, V442, P491, DOI 10.1007/s00428-003-0802-6; Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436; WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145; Yamashiro K, 2001, INVEST OPHTH VIS SCI, V42, P1553; Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05-0855; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	45	53	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2928	2935		10.1096/fj.07-105346	http://dx.doi.org/10.1096/fj.07-105346			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18436961	Green Published			2022-12-25	WOS:000258089300033
J	Ottenheijm, CAC; Fong, C; Vangheluwe, P; Wuytack, F; Babu, GJ; Periasamy, M; Witt, CC; Labeit, S; Granzier, H				Ottenheijm, Coen A. C.; Fong, Chi; Vangheluwe, Peter; Wuytack, Frank; Babu, Gopal J.; Periasamy, Muthu; Witt, Christian C.; Labeit, Siegfried; Granzier, Henk			Sarcoplasmic reticulum calcium uptake and speed of relaxation are depressed in nebulin-free skeletal muscle	FASEB JOURNAL			English	Article						sarcolipin; SERCA function; muscle contractility; nebulin KO model	CONTRACTILE FUNCTION; CARDIAC-FUNCTION; DEFICIENT MICE; CA2+ AFFINITY; SARCOLIPIN; OVEREXPRESSION; TRANSPORT; DISEASE; FIBERS; PHOSPHOLAMBAN	Previous work suggested that altered Ca2+ homeostasis might contribute to dysfunction of nebulin-free muscle, as gene expression analysis revealed that the sarco(endo) plasmic reticulum Ca2+-ATPase (SERCA)-inhibitor sarcolipin (SLN) is up-regulated > 70-fold in nebulin knockout mice, and here we tested this proposal. We investigated SLN protein expression in nebulin-free and wild-type skeletal muscle, as well as expression of other Ca2+-handling proteins. Ca2+ uptake capacity was determined in isolated sarcoplasmic reticulum vesicles and in intact myofibers by measuring Ca2+ transients. Muscle contractile performance was determined in skinned muscle activated with exogenous Ca2+, as well as in electrically stimulated intact muscle. We found profound up-regulation of SLN protein in nebulin-free skeletal muscle, whereas expression of other Ca2+-handling proteins was not (calsequestrin and phospholamban) or was minimally (SERCA) affected. Speed of Ca2(+) uptake was > 3-fold decreased in sarcoplasmic reticulum vesicles isolated from nebulin-free muscle as well as in nebulin-free intact myofibers. Ca2+-activated stress in skinned muscle and stress produced by intact nebulin-free muscle were reduced to a similar extent compared with wild type. Half-relaxation time was significantly longer in nebulin-free compared with wild-type muscle. Thus, the present study demonstrates for the first time that nebulin might also be involved in physiological Ca2+ handling of the SR-myofibrillar system.	[Ottenheijm, Coen A. C.; Fong, Chi; Granzier, Henk] Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; [Vangheluwe, Peter; Wuytack, Frank] Katholieke Univ Leuven, Lab Ca2 Transport ATPases, Leuven, Belgium; [Babu, Gopal J.; Periasamy, Muthu] Ohio State Univ, Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Witt, Christian C.; Labeit, Siegfried] Univ Hosp Mannheim, Inst Anaesthesiol & Intens Care, Mannheim, Germany	University of Arizona; KU Leuven; University System of Ohio; Ohio State University; Ruprecht Karls University Heidelberg	Granzier, H (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, POB 245217, Tucson, AZ 85724 USA.	granzier@email.arizona.edu	Babu, Gopal/AAB-7787-2021; Vangheluwe, Peter/P-5476-2017	Babu, Gopal/0000-0001-7833-5300; Vangheluwe, Peter/0000-0002-7822-2944; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062881, HL-062881] Funding Source: Medline; NIAMS NIH HHS [R01 AR053897, AR-053897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Babu GJ, 2006, J BIOL CHEM, V281, P3972, DOI 10.1074/jbc.M508998200; Babu GJ, 2007, P NATL ACAD SCI USA, V104, P17867, DOI 10.1073/pnas.0707722104; Babu GJ, 2007, J MOL CELL CARDIOL, V43, P215, DOI 10.1016/j.yjmcc.2007.05.009; Bang ML, 2006, J CELL BIOL, V173, P905, DOI 10.1083/jcb.200603119; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bruton JD, 2003, J PHYSIOL-LONDON, V552, P393, DOI 10.1113/jphysiol.org; Capote J, 2005, J PHYSIOL-LONDON, V564, P451, DOI 10.1113/jphysiol.2004.081034; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Han RZ, 2006, CELL CALCIUM, V40, P299, DOI 10.1016/j.ceca.2006.04.016; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; McElhinny AS, 2003, TRENDS CARDIOVAS MED, V13, P195, DOI 10.1016/S1050-1738(03)00076-8; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Ottenheijm CAC, 2006, AM J PHYSIOL-LUNG C, V290, pL127, DOI 10.1152/ajplung.00073.2005; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Periasamy M, 2007, MUSCLE NERVE, V35, P430, DOI 10.1002/mus.20745; Pinniger G, 2005, J MUSCLE RES CELL M, V26, P135, DOI 10.1007/s10974-005-2679-2; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Vangheluwe P, 2006, BBA-MOL CELL RES, V1763, P1216, DOI 10.1016/j.bbamcr.2006.08.025; Vangheluwe P, 2005, BIOCHEM J, V389, P151, DOI 10.1042/BJ20050068; Vangheluwe P, 2006, J MOL CELL CARDIOL, V41, P308, DOI 10.1016/j.yjmcc.2006.05.014; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Wang ZM, 2002, BIOPHYS J, V82, P1338, DOI 10.1016/S0006-3495(02)75489-1; Witt CC, 2006, EMBO J, V25, P3843, DOI 10.1038/sj.emboj.7601242	26	50	50	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2912	2919		10.1096/fj.07-104372	http://dx.doi.org/10.1096/fj.07-104372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434434	Green Published			2022-12-25	WOS:000258089300031
J	Sanderson-Smith, ML; Dinkla, K; Cole, JN; Cork, AJ; Maamary, PG; McArthur, JD; Chhatwal, GS; Walker, MJ				Sanderson-Smith, M. L.; Dinkla, K.; Cole, J. N.; Cork, A. J.; Maamary, P. G.; McArthur, J. D.; Chhatwal, G. S.; Walker, M. J.			M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate	FASEB JOURNAL			English	Article						plasmin; group A streptococcus; innate immunity	GROUP-A STREPTOCOCCI; SERUM OPACITY FACTOR; SURFACE PROTEIN; MOLECULAR EPIDEMIOLOGY; HISTIDINE-RESIDUES; BACTERIAL SURFACE; STREPTOKINASE; INFECTION; FIBRINOGEN; GENE	The human protease plasmin plays a crucial role in the capacity of the group A streptococcus (GAS; Streptococus pyogenes) to initiate invasive disease. The GAS strain NS88.2 was isolated from a case of bacteremia from the Northern Territory of Australia, a region with high rates of GAS invasive disease. Mutagenesis of the NS88.2 plasminogen binding M protein Prp was undertaken to examine the contribution of plasminogen binding and cell surface plasmin acquisition to virulence. The isogenic mutant NS88.2prp was engineered whereby four amino acid residues critical for plasminogen binding were converted to alanine codons in the GAS genome sequence. The mutated residues were reverse complemented to the wild-type sequence to construct GAS strain NS88.2prpRC. In comparison to NS88.2 and NS88.2prpRC, the NS88.2prp mutant exhibited significantly reduced ability to bind human plasminogen and accumulate cell surface plasmin activity during growth in human plasma. Utilizing a humanized plasminogen mouse model of invasive infection, we demonstrate that the capacity to bind plasminogen and accumulate surface plasmin activity plays an essential role in GAS virulence.	[Sanderson-Smith, M. L.; Cole, J. N.; Cork, A. J.; Maamary, P. G.; McArthur, J. D.; Walker, M. J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Sanderson-Smith, M. L.; Dinkla, K.; Chhatwal, G. S.] Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, Braunschweig, Germany	University of Wollongong; Helmholtz Association; Helmholtz-Center for Infection Research	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Cork, Amanda/C-3830-2012; Sanderson-Smith, Martina/O-9387-2019; Sanderson-Smith, Martina L/H-9614-2013; Walker, Mark J./F-6940-2011	Cork, Amanda/0000-0003-2207-6877; Sanderson-Smith, Martina L/0000-0002-6366-4993; Walker, Mark/0000-0001-7423-2769				Ashbaugh CD, 2001, INFECT IMMUN, V69, P6683, DOI 10.1128/IAI.69.11.6683-6686.2001; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; Baldassarri L, 2007, J CLIN MICROBIOL, V45, P1284, DOI 10.1128/JCM.02119-06; BENNASR A, 1994, EUR J BIOCHEM, V222, P267, DOI 10.1111/j.1432-1033.1994.tb18865.x; BERGE A, 1993, J BIOL CHEM, V268, P25417; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Delvecchio A, 2002, EPIDEMIOL INFECT, V128, P391, DOI 10.1017/S0950268802006787; Dinkla K, 2007, MICROBES INFECT, V9, P922, DOI 10.1016/j.micinf.2007.03.011; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; Gardiner D, 1997, ADV EXP MED BIOL, V418, P317; Gardiner DL, 1996, J CLIN MICROBIOL, V34, P1448, DOI 10.1128/JCM.34.6.1448-1452.1996; HOLLINGSHEAD SK, 1993, MOL MICROBIOL, V8, P707, DOI 10.1111/j.1365-2958.1993.tb01614.x; Johnson DR., 1996, LAB DIAGNOSIS GROUP; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; Khil J, 2003, J INFECT DIS, V188, P497, DOI 10.1086/377100; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; Ranson M, 2003, FRONT BIOSCI, V8, pS294, DOI 10.2741/1044; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Ringdahl U, 2000, METHODS, V21, P143, DOI 10.1006/meth.2000.0985; Sanderson-Smith M, 2006, J BIOL CHEM, V281, P3217, DOI 10.1074/jbc.M508758200; Sanderson-Smith ML, 2007, J BACTERIOL, V189, P1435, DOI 10.1128/JB.01218-06; Sanderson-Smith ML, 2006, J BIOL CHEM, V281, P25965, DOI 10.1074/jbc.M603846200; SIMON D, 1991, FEMS MICROBIOL LETT, V82, P219, DOI 10.1016/0378-1097(91)90336-9; Staali L, 2003, CELL MICROBIOL, V5, P253, DOI 10.1046/j.1462-5822.2003.00272.x; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; Svensson MD, 2002, MICROBIOL-SGM, V148, P3933, DOI 10.1099/00221287-148-12-3933; Tart AH, 2007, TRENDS MICROBIOL, V15, P318, DOI 10.1016/j.tim.2007.05.001; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Timmer AM, 2006, MOL MICROBIOL, V62, P15, DOI 10.1111/j.1365-2958.2006.05337.x; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WANG H, 1995, MICROB PATHOGENESIS, V18, P153, DOI 10.1016/S0882-4010(95)90013-6; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	52	61	64	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2715	2722		10.1096/fj.07-105643	http://dx.doi.org/10.1096/fj.07-105643			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18467595	Green Submitted			2022-12-25	WOS:000258089300011
J	Gautier, T; Klein, A; Deckert, V; Desrumaux, C; Ogier, N; Sberna, AL; Paul, C; Le Guern, N; Athias, A; Montange, T; Monier, S; Piard, F; Jiang, XC; Masson, D; Lagrost, L				Gautier, Thomas; Klein, Alexis; Deckert, Valerie; Desrumaux, Catherine; Ogier, Nicolas; Sberna, Anne-Laure; Paul, Catherine; Le Guern, Naig; Athias, Anne; Montange, Thomas; Monier, Serge; Piard, Francoise; Jiang, Xian-Cheng; Masson, David; Lagrost, Laurent			Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; HIGH-DENSITY-LIPOPROTEIN; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; 3-HYDROXY FATTY-ACIDS; LPS-BINDING; (LPS)-BINDING PROTEIN; IN-VITRO; CHYLOMICRONS ALTER; SOLUBLE CD14; CELLS	Lipopolysaccharides (LPS) are components of Gram-negative bacteria. The cellular response from the host to LPS is mediated through stepwise interactions involving the lipopolysaccharide-binding protein (LBP), CD14, and MD-2, which produces the rearrangement of TLR4. In addition to LBP, the lipid transfer/lipopolysaccharide- binding protein gene family includes the phospholipid transfer protein (PLTP). Here we show that the intravascular redistribution of LPS from the plasma lipoprotein-free fraction toward circulating lipoproteins is delayed in PLTP-deficient mice. In agreement with earlier in vitro studies, which predicted the neutralization of the endotoxic properties of LPS when associated with lipoproteins, significant increases in the plasma concentration of proinflammatory cytokines were found in PLTP-deficient as compared with wild type mice. Similar inflammatory damage occurred in tissues from wild type and PLTP-deficient mice 24 h after one single intraperitoneal injection of LPS but with a more severe accumulation of red blood cells in glomeruli of LPS-injected PLTP-deficient mice. Complementary ex vivo experiments on isolated splenocytes from wild type and PLTP-deficient mice further supported the ability of cell-derived PLTP to prevent LPS-mediated inflammation and cytotoxicity when combined with lipoprotein acceptors. Finally, PLTP deficiency in mice led to a significant increase in LPS-induced mortality. It is concluded that increasing circulating levels of PLTP may constitute a new and promising strategy in preventing endotoxic shock.	[Gautier, Thomas; Klein, Alexis; Deckert, Valerie; Desrumaux, Catherine; Ogier, Nicolas; Sberna, Anne-Laure; Paul, Catherine; Le Guern, Naig; Athias, Anne; Montange, Thomas; Monier, Serge; Piard, Francoise; Masson, David; Lagrost, Laurent] Univ Bourgogne, INSERM, Ctr Rech,UMR866, Fac Med,Inst Federatif Rech Sante STIC, F-21079 Dijon, France; [Piard, Francoise; Masson, David; Lagrost, Laurent] Hop Bocage, CHU Dijon, F-21034 Dijon, France; [Jiang, Xian-Cheng] Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Lagrost, L (corresponding author), Univ Bourgogne, INSERM, Ctr Rech,UMR866, Fac Med,Inst Federatif Rech Sante STIC, 7 Blvd Jeanne Arc,BP 87900, F-21079 Dijon, France.	laurent.lagrost@u-bourgogne.fr	MASSON, David/AAC-8896-2022; Masson, David/R-6633-2019; MASSON, David/R-4557-2017; Desrumaux, Catherine/O-1925-2018; Gautier, Thomas/Q-5371-2018; Paul, Catherine/F-8376-2019	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; Gautier, Thomas/0000-0003-1119-7382; DECKERT, Valerie/0000-0001-5728-1710; Paul, Catherine/0000-0002-7657-5535				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Alexander S, 2004, BLOOD, V103, P93, DOI 10.1182/blood-2003-02-0660; Birjmohun RS, 2007, ARTERIOSCL THROM VAS, V27, P1153, DOI 10.1161/ATVBAHA.106.136325; CAVAILLON JM, 1990, INFECT IMMUN, V58, P2375, DOI 10.1128/IAI.58.7.2375-2382.1990; Chaby R, 2004, CELL MOL LIFE SCI, V61, P1697, DOI 10.1007/s00018-004-4020-4; Chien JY, 2005, CRIT CARE MED, V33, P1688, DOI 10.1097/01.CCM.0000171183.79525.6B; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; DENTENER MA, 1995, J INFECT DIS, V171, P739, DOI 10.1093/infdis/171.3.739; DINARELLO CA, 1997, CHEST S, V112, P321, DOI DOI 10.1378/CHEST.112.6_SUPPLEMENT.321S; EMANCIPATOR K, 1992, INFECT IMMUN, V60, P596, DOI 10.1128/IAI.60.2.596-601.1992; FLEGEL WA, 1989, INFECT IMMUN, V57, P2237, DOI 10.1128/IAI.57.7.2237-2245.1989; FREUDENBERG M A, 1990, International Reviews of Immunology, V6, P207, DOI 10.3109/08830189009056632; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; Harris HW, 1998, HEPATOLOGY, V27, P1341, DOI 10.1002/hep.510270521; HEUMANN D, 1992, J IMMUNOL, V148, P3505; Hickey MJ, 1998, CIRC RES, V83, P1124, DOI 10.1161/01.RES.83.11.1124; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Jerala R, 2007, INT J MED MICROBIOL, V297, P353, DOI 10.1016/j.ijmm.2007.04.001; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jiang Z, 2004, INT IMMUNOPHARMACOL, V4, P527, DOI 10.1016/j.intimp.2004.02.004; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Klein A, 2006, ARTERIOSCL THROM VAS, V26, P2160, DOI 10.1161/01.ATV.0000235699.98024.11; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Levels JHM, 2005, INFECT IMMUN, V73, P2321, DOI 10.1128/IAI.73.4.2321-2326.2005; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; Oka T, 2000, J LIPID RES, V41, P1651; OLSSON NO, 1982, ANN INST PASTEUR IMM, VD133, P245; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; REDL H, 1993, IMMUNOBIOLOGY, V187, P330, DOI 10.1016/S0171-2985(11)80348-7; Reisser D, 1996, J LEUKOCYTE BIOL, V59, P728, DOI 10.1002/jlb.59.5.728; Saraf A, 1999, J ENVIRON MONITOR, V1, P163, DOI 10.1039/a809019j; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Settasatian N, 2001, J BIOL CHEM, V276, P26898, DOI 10.1074/jbc.M010708200; Sewnath ME, 2000, HEPATOLOGY, V32, P1289, DOI 10.1053/jhep.2000.20525; Szponar B, 2003, CLIN CHEM, V49, P1149, DOI 10.1373/49.7.1149; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; ULEVITCH RJ, 1979, J CLIN INVEST, V64, P1516, DOI 10.1172/JCI109610; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WILDE CG, 1994, J BIOL CHEM, V269, P17411; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051	57	54	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18702	18710		10.1074/jbc.M802802200	http://dx.doi.org/10.1074/jbc.M802802200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458077	hybrid			2022-12-25	WOS:000257165600027
J	Lyssand, JS; Defino, MC; Tang, XB; Hertz, AL; Feller, DB; Wacker, JL; Adams, ME; Hague, C				Lyssand, John S.; Defino, Mia C.; Tang, Xiao-Bo; Hertz, Angie L.; Feller, David B.; Wacker, Jennifer L.; Adams, Marvin E.; Hague, Chris			Blood pressure is regulated by an alpha(1D)-adrenergic receptor/dystrophin signalosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MYOCARDIAL CONTRACTILE RESPONSES; POSTTRAUMATIC-STRESS-DISORDER; CELL-SURFACE EXPRESSION; ALPHA(1B)-ADRENERGIC RECEPTOR; PDZ DOMAIN; ALPHA(1)-ADRENOCEPTOR SUBTYPES; NA+/PHOSPHATE-COTRANSPORTER; DYSTROPHIN COMPLEX; DIRECTLY INTERACTS	Hypertension is a cardiovascular disease associated with increased plasma catecholamines, overactivation of the sympathetic nervous system, and increased vascular tone and total peripheral resistance. A key regulator of sympathetic nervous system function is the alpha(1D)-adrenergic receptor (AR), which belongs to the adrenergic family of G-protein-coupled receptors (GPCRs). Endogenous catecholamines norepinephrine and epinephrine activate alpha(1D)-ARs on vascular smooth muscle to stimulate vasoconstriction, which increases total peripheral resistance and mean arterial pressure. Indeed, alpha(1D)-AR KO mice display a hypotensive phenotype and are resistant to salt-induced hypertension. Unfortunately, little information exists about how this important GPCR functions because of an inability to obtain functional expression in vitro. Here, we identified the dystrophin proteins, syntrophin, dystrobrevin, and utrophin as essential GPCR-interacting proteins for alpha(1D)-ARs. We found that dystrophins complex with alpha(1D)-AR both in vitro and in vivo to ensure proper functional expression. More importantly, we demonstrate that knock-out of multiple syntrophin isoforms results in the complete loss of alpha(1D)-AR function in mouse aortic smooth muscle cells and abrogation of alpha(1D)-AR-mediated increases in blood pressure. Our findings demonstrate that syntrophin and utrophin associate with alpha(1D)-ARs to create a functional signalosome, which is essential for alpha(1D)-AR regulation of vascular tone and blood pressure.	[Lyssand, John S.; Defino, Mia C.; Tang, Xiao-Bo; Hertz, Angie L.; Feller, David B.; Wacker, Jennifer L.; Hague, Chris] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; [Adams, Marvin E.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hague, C (corresponding author), 1959 NE Pacific St,Box 357280, Seattle, WA 98195 USA.	chague@u.washington.edu			NHLBI NIH HHS [T32 HL07312] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07750, T32 GM07270] Funding Source: Medline; NINDS NIH HHS [R01 NS033145, NS33145] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750, T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams ME, 2004, J NEUROSCI, V24, P10302, DOI 10.1523/JNEUROSCI.3408-04.2004; ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Battaglia G, 2003, J NEUROCHEM, V86, P413, DOI 10.1046/j.1471-4159.2003.01867.x; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chen HX, 2005, ANAL BIOCHEM, V338, P136, DOI 10.1016/j.ab.2004.11.015; Chen ZJ, 2006, J BIOL CHEM, V281, P12414, DOI 10.1074/jbc.M508651200; Daulat AM, 2007, MOL CELL PROTEOMICS, V6, P835, DOI 10.1074/mcp.M600298-MCP200; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Faber JE, 2001, J PHARMACOL EXP THER, V298, P441; Gee SH, 1998, J NEUROSCI, V18, P128; Guimaraes S, 2001, PHARMACOL REV, V53, P319; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hague C, 2006, MOL PHARMACOL, V69, P45, DOI 10.1124/mol.105.014985; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kuwasako K, 2001, J BIOL CHEM, V276, P49459, DOI 10.1074/jbc.M108369200; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; McCloskey DT, 2002, J MOL CELL CARDIOL, V34, P1007, DOI 10.1006/jmcc.2002.2049; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Onwochei MO, 1998, J CARDIOVASC PHARM, V31, P10, DOI 10.1097/00005344-199801000-00002; ONWOCHEI MO, 1995, J CARDIOVASC PHARM, V25, P833, DOI 10.1097/00005344-199505000-00021; ONWOCHEI MO, 1993, J CARDIOVASC PHARM, V22, P632, DOI 10.1097/00005344-199310000-00018; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; Pupo AS, 2003, J RECEPT SIG TRANSD, V23, P185, DOI 10.1081/RRS-120025200; Raskind MA, 2000, J CLIN PSYCHIAT, V61, P129, DOI 10.4088/JCP.v61n0208; Raskind MA, 2002, J CLIN PSYCHIAT, V63, P565, DOI 10.4088/JCP.v63n0705; Stanasila L, 2006, J BIOL CHEM, V281, P4354, DOI 10.1074/jbc.M511989200; Suzuki F, 2007, J BIOL CHEM, V282, P29563, DOI 10.1074/jbc.M702063200; Tanoue A, 2002, HYPERTENSION, V40, P101, DOI 10.1161/01.HYP.0000022062.70639.1C; Tanoue A, 2002, J CLIN INVEST, V109, P765, DOI 10.1172/JCI200214001; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Uberti MA, 2003, MOL PHARMACOL, V64, P1379, DOI 10.1124/mol.64.6.1379; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Williams JC, 2006, J BIOL CHEM, V281, P23341, DOI 10.1074/jbc.M513341200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Yamamoto Y, 2001, EUR J PHARMACOL, V424, P131, DOI 10.1016/S0014-2999(01)01134-7; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	51	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18792	18800		10.1074/jbc.M801860200	http://dx.doi.org/10.1074/jbc.M801860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18468998	hybrid, Green Published			2022-12-25	WOS:000257165600036
J	Nakaya, T; Kawai, T; Suzuki, T				Nakaya, Tadashi; Kawai, Tomoko; Suzuki, Toshiharu			Regulation of FE65 nuclear translocation and function by amyloid beta-protein precursor in osmotically stressed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; DEPENDENT REGULATION; CYTOPLASMIC DOMAIN; HISTONE H2AX; PHOSPHORYLATION; TRANSCRIPTION; APP; KINASE; BREAKS; FORMS	FE65, a neural adaptor protein, interacts with amyloid beta-protein precursor (APP) and is known to regulate amyloid beta generation from APP. FE65 also associates with nuclear proteins; however, its physiological function in the nucleus remains unclear. A fixed population of cytoplasmic FE65 is tethered to membranes by binding APP. This membrane-tethered FE65 is liberated from membranes by APP phosphorylation, which is facilitated by a stress-activated protein kinase in sorbitol-treated cells. Here we show that liberated FE65, which is distinct from "virgin" FE65 in the cytoplasm, translocates into the nucleus and accumulates in the nuclear matrix forming a patched structure. Targeting of FE65 into the nuclear matrix was suppressed by the APP intracellular domain fragment, which is generated by consecutive cleavages of APP. Thus, nuclear translocation of FE65 is under the regulation of APP. In the nucleus, FE65 induced gamma H2AX, which plays an important role in DNA repair as a cellular response by stress-damaged cells. These observations suggest that APP-regulated FE65 plays an important role in the early stress response of cells and that FE65 deregulated from APP induces apoptosis.	[Nakaya, Tadashi; Kawai, Tomoko; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Suzuki, Toshiharu/B-5342-2013					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Aplin AE, 1996, J NEUROCHEM, V67, P699; Araki Y, 2007, EMBO J, V26, P1475, DOI 10.1038/sj.emboj.7601609; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Dmitrieva NI, 2005, MUTAT RES-FUND MOL M, V569, P65, DOI 10.1016/j.mrfmmm.2004.06.053; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; McLoughlin DM, 2008, J NEUROSCI RES, V86, P744, DOI 10.1002/jnr.21532; Minopoli G, 2007, J BIOL CHEM, V282, P831, DOI 10.1074/jbc.C600276200; Muresan Z, 2004, HUM MOL GENET, V13, P475, DOI 10.1093/hmg/ddh054; Nakaya T, 2006, GENES CELLS, V11, P633, DOI 10.1111/j.1365-2443.2006.00968.x; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taru H, 2004, J BIOL CHEM, V279, P21628, DOI 10.1074/jbc.M312007200; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	29	31	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19119	19131		10.1074/jbc.M801827200	http://dx.doi.org/10.1074/jbc.M801827200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18468999	hybrid			2022-12-25	WOS:000257165600067
J	Naarmann, IS; Harnisch, C; Flach, N; Kremmer, E; Kuhn, H; Ostareck, DH; Ostareck-Lederer, A				Naarmann, Isabel S.; Harnisch, Christiane; Flach, Nadine; Kremmer, Elisabeth; Kuehn, Hartmut; Ostareck, Dirk H.; Ostareck-Lederer, Antje			mRNA silencing in human erythroid cell maturation - Heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNRNP-K; TERMINAL DIFFERENTIATION; LIPOXYGENASE; PROTEIN; RETICULOCYTES; ACTIVATION; COMPLEX; DOMAIN; PHOSPHORYLATION; ERYTHROPOIESIS	Erythroid precursor cells undergo nuclear extrusion and degradation of mitochondria when they mature to erythrocytes. It has been suggested before that the reticulocyte 15-lipoxygenase (r15-LOX) plays an important role in initiating the breakdown of mitochondria in rabbit reticulocytes. The expression of rabbit r15-LOX is regulated by the heterogeneous nuclear ribonucleoproteins (hnRNP)K and E1 at the translational level. However, this mechanism has never been confirmed in human erythropoiesis. Based on K562 cells we have set up an inducible human erythroid cell system. We show that, during induction, K562 cells exhibit changes in morphology and protein expression that are characteristic for terminal erythroid maturation: nuclear exclusion, expression of endogenous human r15-LOX regulated by hnRNP K and hnRNP E1, and loss of mitochondria. Importantly, induction of terminal erythroid maturation in primary human CD34(+) cells recapitulated the results obtained in K562 cells. Employing the physiologically relevant K562 cell system we uncovered a new mechanism of interdependent post-transcriptional regulation of gene expression. The timely expression of the tyrosine kinase c-Src, which phosphorylates hnRNP K in later stages, is controlled by hnRNP K in early stages of erythroid maturation. hnRNP K binds to the 3'-untranslated region of the c-Src mRNA and inhibits its translation by blocking 80 S ribosome formation. In premature erythroid cells, small interfering RNA-mediated knockdown of hnRNP K, but not of hnRNP E1, leads to the de-repression of c-Src synthesis.	[Naarmann, Isabel S.; Harnisch, Christiane; Flach, Nadine; Ostareck, Dirk H.; Ostareck-Lederer, Antje] Univ Halle Wittenberg, Inst Biochem & Biotechnol, D-06120 Halle, Germany; [Kremmer, Elisabeth] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Mol Immunol, D-81377 Munich, Germany; [Kuehn, Hartmut] Charite, Inst Biochem, D-10117 Berlin, Germany	Martin Luther University Halle Wittenberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ostareck, DH (corresponding author), Univ Halle Wittenberg, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.	dostareck@biochemtech.uni-halle.de; aostareck@biochemtech.uni-halle.de		Ostareck-Lederer, Antje/0000-0003-0733-7071; Ostareck, Dirk/0000-0001-9406-7190				Adolph D, 2007, MOL CELL BIOL, V27, P1758, DOI 10.1128/MCB.02014-06; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; Asatryan L, 2003, BLOOD, V102, P1732, DOI 10.1182/blood-2003-01-0293; Backe PH, 2005, STRUCTURE, V13, P1055, DOI 10.1016/j.str.2005.04.008; BADER M, 1986, EUR J BIOCHEM, V161, P103, DOI 10.1111/j.1432-1033.1986.tb10129.x; Belhacene N, 1998, FASEB J, V12, P531; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASTOLDI GL, 1988, ATLAS BLOOD CELLS FU, P49; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; CIOE L, 1981, CANCER RES, V41, P237; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; GAHMBERG CG, 1978, BLOOD, V52, P379; Gamarnik AV, 1997, RNA, V3, P882; GEBAUER F, 2001, RIBOSOME, P329; GREGORY CJ, 1978, BLOOD, V51, P527; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; HAMBERG M, 1983, BIOCHIM BIOPHYS ACTA, V752, P191, DOI 10.1016/0005-2760(83)90112-1; Hentze MW, 2007, TRANSLATIONAL CONTRO, P269; HOHNE M, 1988, BIOMED BIOCHIM ACTA, V47, P75; Hristoskova S, 2007, EXP CELL RES, V313, P1024, DOI 10.1016/j.yexcr.2006.12.018; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kie JH, 2003, ANN HEMATOL, V82, P278, DOI 10.1007/s00277-003-0629-x; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; Koury MJ, 2005, BLOOD, V105, P2168, DOI 10.1182/blood-2004-02-0616; KOURY ST, 1988, EXP HEMATOL, V16, P758; Krauss SW, 2005, BLOOD, V106, P2200, DOI 10.1182/blood-2005-04-1357; Leberbauer C, 2005, BLOOD, V105, P85, DOI 10.1182/blood-2004-03-1002; LOZZIO CB, 1979, NATURE, V281, P709, DOI 10.1038/281709b0; Messias AC, 2006, J MOL BIOL, V361, P470, DOI 10.1016/j.jmb.2006.06.025; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2006, J BIOL CHEM, V281, P11115, DOI 10.1074/jbc.M513053200; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Patterson Jr MK, 1973, TISSUE CULTURE METHO, P406; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; Schranzhofer M, 2006, BLOOD, V107, P4159, DOI 10.1182/blood-2005-05-1809; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; THIELE BJ, 1982, EUR J BIOCHEM, V129, P133, DOI 10.1111/j.1432-1033.1982.tb07031.x; THIELE BJ, 1981, ACTA BIOL MED GER, V40, P597; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thompson B, 2007, TRANSLATIONAL CONTRO, V48, P507; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295	52	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18461	18472		10.1074/jbc.M710328200	http://dx.doi.org/10.1074/jbc.M710328200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441016	hybrid			2022-12-25	WOS:000256949200074
J	Jagemann, LR; Perez-Rivas, LG; Ruiz, EJ; Ranea, JA; Sanchez-Jimenez, F; Nebreda, AR; Alba, E; Lozano, J				Jagemann, Lucas R.; Perez-Rivas, Luis G.; Ruiz, E. Josue; Ranea, Juan A.; Sanchez-Jimenez, Francisca; Nebreda, Angel R.; Alba, Emilio; Lozano, Jose			The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUPPRESSOR; STRUCTURAL BASIS; LIGAND-BINDING; EXOENZYME-S; IN-VIVO; RAS; PHOSPHORYLATION; IDENTIFICATION; 14-3-3-PROTEIN; RAF-1	Identifying 14-3-3 isoform-specific substrates and functions may be of broad relevance to cell signaling research because of the key role played by this family of proteins in many vital processes. A multitude of ligands have been identified, but the extent to which they are isoform-specific is a matter of debate. Herein we demonstrate, both in vitro and in vivo, a specific, functionally relevant interaction of human 14-3-3 gamma with the molecular scaffold KSR1, which is mediated by the C-terminal stretch of 14-3-3 gamma. Specific binding to 14-3-3 gamma protected KSR1 from epidermal growth factor-induced dephosphorylation and impaired its ability to activate ERK2 and facilitate Ras signaling in Xenopus oocytes. Furthermore, RNA interference-mediated inhibition of 14-3-3 gamma resulted in the accumulation of KSR1 in the plasma membrane, all in accordance with 14-3-3 gamma being the cytosolic anchor that keeps KSR1 inactive. We also provide evidence that KSR1-bound 14-3-3 gamma heterodimerized preferentially with selected isoforms and that KSR1 bound monomeric 14- 3-3 gamma. In sum, we have demonstrated ligand discrimination among 14-3-3 isoforms and shed light on molecular mechanisms of 14-3-3 functional specificity and KSR1 regulation.	[Jagemann, Lucas R.; Perez-Rivas, Luis G.; Ranea, Juan A.; Sanchez-Jimenez, Francisca; Lozano, Jose] Univ Malaga, Dept Bioquim & Biol Mol, E-29071 Malaga, Spain; [Sanchez-Jimenez, Francisca] CIBERER, Malaga 29071, Spain; [Ruiz, E. Josue; Nebreda, Angel R.] CNIO, Madrid 28029, Spain; [Alba, Emilio] Hosp Clin Univ Virgen Victoria, Med Oncol Serv, Malaga 29071, Spain	Universidad de Malaga; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Virgen de la Victoria	Lozano, J (corresponding author), Univ Malaga, Dept Bioquim & Biol Mol, Campus Teatinos S-N, E-29071 Malaga, Spain.	jlozano@uma.es	Nebreda, Angel Rodriguez/R-9594-2019; Lozano, José/C-2760-2014; Alba, Emilio/S-1435-2019; Jiménez, Francisca María Sánchez/H-2513-2015; jag, luc/B-2772-2011	Lozano, José/0000-0002-8187-2833; Alba, Emilio/0000-0002-3364-2603; Jiménez, Francisca María Sánchez/0000-0002-4958-6060; Garcia Ranea, Juan Antonio/0000-0003-0327-1837				Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Angrand PO, 2006, MOL CELL PROTEOMICS, V5, P2211, DOI 10.1074/mcp.M600147-MCP200; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carter P, 2003, NUCLEIC ACIDS RES, V31, P3293, DOI 10.1093/nar/gkg626; Chaudhri M, 2003, BIOCHEM BIOPH RES CO, V300, P679, DOI 10.1016/S0006-291X(02)02902-9; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Coblitz B, 2006, FEBS LETT, V580, P1531, DOI 10.1016/j.febslet.2006.02.014; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Gu YM, 2006, FEBS LETT, V580, P305, DOI 10.1016/j.febslet.2005.12.024; Hartsough MT, 2002, J BIOL CHEM, V277, P32389, DOI 10.1074/jbc.M203115200; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Liu MY, 2002, CANCER RES, V62, P6475; Lozano J, 2003, CANCER RES, V63, P4232; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Obsilova V, 2004, J BIOL CHEM, V279, P4531, DOI 10.1074/jbc.M306939200; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Ottmann C, 2007, EMBO J, V26, P902, DOI 10.1038/sj.emboj.7601530; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Perdiguero Eusebio, 2004, Methods Mol Biol, V250, P299; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Ritt DA, 2007, CURR BIOL, V17, P179, DOI 10.1016/j.cub.2006.11.061; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shen YH, 2003, MOL BIOL CELL, V14, P4721, DOI 10.1091/mbc.E02-12-0821; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; Silhan J, 2004, J BIOL CHEM, V279, P49113, DOI 10.1074/jbc.M408671200; Stewart S, 1999, MOL CELL BIOL, V19, P5523; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Truong AB, 2002, PROTEINS, V49, P321, DOI 10.1002/prot.10210; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang XW, 2006, P NATL ACAD SCI USA, V103, P17237, DOI 10.1073/pnas.0605779103; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	52	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17450	17462		10.1074/jbc.M709185200	http://dx.doi.org/10.1074/jbc.M709185200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426801	hybrid			2022-12-25	WOS:000256720600053
J	Willmund, F; Hinnenberger, M; Nick, S; Schulz-Raffelt, M; Muhlhaus, T; Schroda, M				Willmund, Felix; Hinnenberger, Manuela; Nick, Sabine; Schulz-Raffelt, Miriam; Muehlhaus, Timo; Schroda, Michael			Assistance for a chaperone - Chlamydomonas HEP2 activates plastidic HSP70B for cochaperone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST PROTEIN IMPORT; HEAT-SHOCK-PROTEIN; GRPE HOMOLOG; MITOCHONDRIAL; MATRIX; DNAK; HEAT-SHOCK-PROTEIN-70; IDENTIFICATION; TRANSLOCATION; PURIFICATION	Previous efforts aimed at the biochemical characterization of chloroplast HSP70B were hampered by the observation that recombinant HSP70B was inactive, i.e. incompetent of interacting with its nucleotide exchange factor CGE1. In addition, because heterologously expressed mitochondrial Hsp70 was inactive unless coexpressed with the escort protein Hep1, we wondered whether homologs of Hep1 existed in the chloroplast. Data base searches revealed that algae and higher plants indeed encode at least two HEP homologs, one predicted to be targeted to mitochondria, the others to chloroplasts. Using Chlamydomonas reinhardtii as plant model organism we demonstrate that this alga encodes an HEP homolog (termed HEP2) that is localized to the stroma. HEP2 is expressed constitutively as a low abundance protein with an apparent molecular mass of similar to 21 kDa. In cell extracts HEP2 interacts with HSP70B in an ATP-dependent fashion. Coexpression of HSP70B with HEP2 in Escherichia coli yielded high levels of CGE1-binding competent HSP70B, which also displayed ATPase activity. Inactive HSP70B was more prone to proteolysis than active HSP70B. Although inactive HSP70B interacted with HEP2, it could not be activated. Active HSP70B remained active for 48 h in the absence of HEP2, suggesting that HEP2 was not involved in maintaining HSP70B in an active state. However, some HSP70B expressed as a fusion protein with an N-terminal extension was activated when HEP2 was present during cleavage of the fusion protein, suggesting that in vivo HEP2 might be required for de novo folding of HSP70B after transit peptide cleavage.	[Willmund, Felix; Hinnenberger, Manuela; Nick, Sabine; Schulz-Raffelt, Miriam; Muehlhaus, Timo; Schroda, Michael] Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	University of Freiburg	Schroda, M (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	michael.schroda@biologie.uni-freiburg.de	Schroda, Michael/A-2651-2015	Schroda, Michael/0000-0001-6872-0483; Willmund, Felix/0000-0002-3988-4590; Muhlhaus, Timo/0000-0003-3925-6778				Bonk M, 1996, PLANT PHYSIOL, V111, P931, DOI 10.1104/pp.111.3.931; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; Burri L, 2004, J BIOL CHEM, V279, P50243, DOI 10.1074/jbc.M409194200; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; Craig EA, 2006, REV PHYSIOL BIOCH P, V156, P1, DOI 10.1007/s10254-005-0001-8; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Drzymalla C, 1996, PLANT MOL BIOL, V31, P1185, DOI 10.1007/BF00040835; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; ERIKSSON M, 1995, PLANT PHYSIOL, V107, P479, DOI 10.1104/pp.107.2.479; Eriksson M, 1996, P NATL ACAD SCI USA, V93, P12031, DOI 10.1073/pnas.93.21.12031; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P26; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Kourtz L, 1997, J BIOL CHEM, V272, P2808, DOI 10.1074/jbc.272.5.2808; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; Liu CM, 2005, MOL BIOL CELL, V16, P1165, DOI 10.1091/mbc.E04-08-0736; Liu CM, 2007, PLANT J, V50, P265, DOI 10.1111/j.1365-313X.2007.03047.x; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Miernyk JA, 1999, PLANT PHYSIOL, V121, P695, DOI 10.1104/pp.121.3.695; Momose T, 2007, EMBO REP, V8, P664, DOI 10.1038/sj.embor.7400990; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Schroda M, 2004, PHOTOSYNTH RES, V82, P221, DOI 10.1007/s11120-004-2216-y; Schroda M, 1999, PLANT CELL, V11, P1165, DOI 10.1105/tpc.11.6.1165; Schroda M, 2001, PLANT CELL, V13, P2823, DOI 10.1105/tpc.010202; Sichting M, 2005, EMBO J, V24, P1046, DOI 10.1038/sj.emboj.7600580; Szklarz LKS, 2005, J MOL BIOL, V351, P206, DOI 10.1016/j.jmb.2005.05.068; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; TSUGEKI R, 1993, FEBS LETT, V320, P198, DOI 10.1016/0014-5793(93)80585-I; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; von Janowsky B, 2006, J MOL BIOL, V357, P793, DOI 10.1016/j.jmb.2006.01.008; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Willmund F, 2005, PLANT PHYSIOL, V138, P2310, DOI 10.1104/pp.105.063578; Willmund F, 2007, J BIOL CHEM, V282, P11317, DOI 10.1074/jbc.M608854200; Yamamoto H, 2005, FEBS LETT, V579, P507, DOI 10.1016/j.febslet.2004.12.018; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	44	21	21	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16363	16373		10.1074/jbc.M708431200	http://dx.doi.org/10.1074/jbc.M708431200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420590	hybrid			2022-12-25	WOS:000256497100012
J	Haeberle, H; Bryan, LA; Vadakkan, TJ; Dickinson, ME; Lumpkin, EA				Haeberle, Henry; Bryan, Leigh A.; Vadakkan, Tegy J.; Dickinson, Mary E.; Lumpkin, Ellen A.			Swelling-Activated Ca2+ Channels Trigger Ca2+ Signals in Merkel Cells	PLOS ONE			English	Article								Merkel cell-neurite complexes are highly sensitive touch receptors comprising epidermal Merkel cells and sensory afferents. Based on morphological and molecular studies, Merkel cells are proposed to be mechanosensory cells that signal afferents via neurotransmission; however, functional studies testing this hypothesis in intact skin have produced conflicting results. To test this model in a simplified system, we asked whether purified Merkel cells are directly activated by mechanical stimulation. Cell shape was manipulated with anisotonic solution changes and responses were monitored by Ca2+ imaging with fura-2. We found that hypotonic-induced cell swelling, but not hypertonic solutions, triggered cytoplasmic Ca2+ transients. Several lines of evidence indicate that these signals arise from swelling-activated Ca2+-permeable ion channels. First, transients were reversibly abolished by chelating extracellular Ca2+, demonstrating a requirement for Ca2+ influx across the plasma membrane. Second, Ca2+ transients were initially observed near the plasma membrane in cytoplasmic processes. Third, voltage-activated Ca2+ channel (VACC) antagonists reduced transients by half, suggesting that swelling-activated channels depolarize plasma membranes to activate VACCs. Finally, emptying internal Ca2+ stores attenuated transients by 80%, suggesting Ca2+ release from stores augments swelling-activated Ca2+ signals. To identify candidate mechanotransduction channels, we used RT-PCR to amplify ion-channel transcripts whose pharmacological profiles matched those of hypotonic-evoked Ca2+ signals in Merkel cells. We found 11 amplicons, including PKD1, PKD2, and TRPC1, channels previously implicated in mechanotransduction in other cells. Collectively, these results directly demonstrate that Merkel cells are activated by hypotonic-evoked swelling, identify cellular signaling mechanisms that mediate these responses, and support the hypothesis that Merkel cells contribute to touch reception in the Merkel cell-neurite complex.	[Haeberle, Henry] Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA; [Haeberle, Henry; Bryan, Leigh A.; Lumpkin, Ellen A.] Baylor Coll Med, Dept Neurosci, Houston, TX USA; [Vadakkan, Tegy J.; Dickinson, Mary E.; Lumpkin, Ellen A.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX USA; [Lumpkin, Ellen A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX USA	University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Haeberle, H (corresponding author), Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.	lumpkin@bcm.edu		Lumpkin, Ellen/0000-0002-1166-3374	Gillson Longenbaugh Foundation; Sandler Program in Basic Sciences; NIH [R01AR051219, R01HL077187, P20EB007076]; NSF graduate research fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P20EB007076] Funding Source: NIH RePORTER	Gillson Longenbaugh Foundation; Sandler Program in Basic Sciences; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF graduate research fellowship(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by the Gillson Longenbaugh Foundation (E. A. L.), the Sandler Program in Basic Sciences (E. A. L.), the NIH (NIAMS R01AR051219 to E. A. L., NHLBI R01HL077187 and NIBIB P20EB007076 to M. E. D.) and the NSF (graduate research fellowship to H. H.). The funding agencies had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Altamirano J, 1998, J GEN PHYSIOL, V112, P145, DOI 10.1085/jgp.112.2.145; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Baumann KI, 1996, NEUROSCI LETT, V213, P1, DOI 10.1016/0304-3940(96)12813-5; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790, DOI 10.1152/ajpcell.1996.270.6.C1790; Cibulsky SM, 1999, J PHARMACOL EXP THER, V289, P1447; Colbert HA, 1997, J NEUROSCI, V17, P8259; CRIST JR, 1993, HEARING RES, V69, P194, DOI 10.1016/0378-5955(93)90107-C; DIETRICH A, 2007, PRESSURE INDUCED STO; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Dumont RA, 2002, JARO-J ASSOC RES OTO, V3, P375, DOI 10.1007/s101620020049; Fettiplace R, 2006, NAT REV NEUROSCI, V7, P19, DOI 10.1038/nrn1828; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Gong ZF, 2004, J NEUROSCI, V24, P9059, DOI 10.1523/JNEUROSCI.1645-04.2004; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GOTTSCHALDT KM, 1981, SCIENCE, V214, P183, DOI 10.1126/science.7280690; Haeberle H, 2004, P NATL ACAD SCI USA, V101, P14503, DOI 10.1073/pnas.0406308101; Halata Z, 2003, ANAT REC PART A, V271A, P225, DOI 10.1002/ar.a.10029; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hayashi Y, 1996, BIOPHYS J, V71, P1057, DOI 10.1016/S0006-3495(96)79306-2; Hitchcock IS, 2004, NEUROSCI LETT, V362, P196, DOI 10.1016/j.neulet.2004.02.071; Hudspeth AJ, 2000, CURR OPIN NEUROBIOL, V10, P631, DOI 10.1016/S0959-4388(00)00133-1; IGGO A, 1969, J PHYSIOL-LONDON, V200, P763, DOI 10.1113/jphysiol.1969.sp008721; IGGO A, 1984, SENSORY RECEPTOR MEC, P117; IKEDA I, 1994, J PHYSIOL-LONDON, V479, P247, DOI 10.1113/jphysiol.1994.sp020292; IKEDA K, 1991, ORL J OTO-RHINO-LARY, V53, P78, DOI 10.1159/000276192; Johnson KO, 2001, CURR OPIN NEUROBIOL, V11, P455, DOI 10.1016/S0959-4388(00)00234-8; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kim J, 2003, NATURE, V424, P81, DOI 10.1038/nature01733; Kinkelin I, 1999, EUR J NEUROSCI, V11, P3963, DOI 10.1046/j.1460-9568.1999.00822.x; Kung C, 2004, MOL MICROBIOL, V53, P373, DOI 10.1111/j.1365-2958.2004.04180.x; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; LUMPKIN EA, 1995, P NATL ACAD SCI USA, V92, P10297, DOI 10.1073/pnas.92.22.10297; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MILLS LR, 1995, J NEUROCYTOL, V24, P117, DOI 10.1007/BF01181555; NAGASAKI K, 1989, CELL CALCIUM, V10, P63, DOI 10.1016/0143-4160(89)90045-6; Nakafusa J, 2006, BRIT J DERMATOL, V155, P883, DOI 10.1111/j.1365-2133.2006.07441.x; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nunzi MG, 2004, J NEUROCYTOL, V33, P359, DOI 10.1023/B:NEUR.0000044196.45602.92; Ogawa H, 1996, PROG NEUROBIOL, V49, P317, DOI 10.1016/0301-0082(96)00018-4; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; Pacitti E G, 1988, Prog Brain Res, V74, P37; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tachibana T, 1997, ARCH HISTOL CYTOL, V60, P379, DOI 10.1679/aohc.60.379; Tazaki M, 1998, NEUROSCI LETT, V243, P69, DOI 10.1016/S0304-3940(98)00066-4; Toyoshima K, 1998, J HISTOCHEM CYTOCHEM, V46, P1329, DOI 10.1177/002215549804601113; Viana F, 2001, EUR J NEUROSCI, V13, P722, DOI 10.1046/j.0953-816x.2000.01441.x; Woodbury CJ, 2007, J COMP NEUROL, V505, P547, DOI 10.1002/cne.21517; YAMASHITA Y, 1992, J PHYSIOL-LONDON, V450, P143, DOI 10.1113/jphysiol.1992.sp019120; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	56	34	38	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2008	3	3							e1750	10.1371/journal.pone.0001750	http://dx.doi.org/10.1371/journal.pone.0001750			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369VW	18454189	gold, Green Published, Green Submitted			2022-12-25	WOS:000260723000004
J	Kargiotis, O; Chetty, C; Gondi, CS; Tsung, AJ; Dinh, DH; Gujrati, M; Lakka, SS; Kyritsis, AP; Rao, JS				Kargiotis, O.; Chetty, C.; Gondi, C. S.; Tsung, A. J.; Dinh, D. H.; Gujrati, M.; Lakka, S. S.; Kyritsis, A. P.; Rao, J. S.			Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma	ONCOGENE			English	Article						MMP-2; gliomas; invasion; angiogenesis; intracranial; siRNAs	MATRIX METALLOPROTEINASES; GLIOMA-CELLS; IV COLLAGENASE; MALIGNANT GLIOMAS; METASTASIS; EXPRESSION; MIGRATION; RECEPTOR; STRATEGIES; THERAPY	Invasive tumors, including gliomas, utilize proteinases to degrade extracellular matrix components and diffuse into the adjacent tissues or migrate toward distant ones. In addition, proteinase activity is required for the formation of new blood vessels within the tumor. Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased in gliomas. In this study, we examined the effect of the downregulation of MMP-2 via adenovirus-mediated siRNA in gliomas. Here, we show that siRNA delivery significantly decreased levels of MMP-2 in the glioblastoma cell lines U-87 and U-251. U-87 and U-251 cells showed impaired invasion through matrigel as well as decreased migration from tumor spheroids transfected with adenoviral vector expressing siRNA against MMP-2. Additionally, tumor-induced angiogenesis was decreased in in vitro experiments in cultured human microvascular endothelial cells (HMECs) in serum-free conditioned medium of glioblastoma cells transfected with these constructs and co-cultures of glioma cells with HMECs. We also observed decreased angiogenesis in the in vivo dorsal skin-fold chamber model. Moreover, MMP-2 inhibition induced apoptotic cell death in vitro, and suppressed tumor growth of preestablished U-251 intracranial xenografts in nude mice. Thus, specific targeting of MMP-2 may provide a novel, efficient approach for the treatment of gliomas and improve the poor outcomes of patients with these brain tumors.	[Kargiotis, O.; Chetty, C.; Gondi, C. S.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Tsung, A. J.; Dinh, D. H.; Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61605 USA; [Kyritsis, A. P.] Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Ioannina	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [R01 CA075557, R01 CA095058-04, CA 116708, R01 CA092393, R01 CA116708-02, R01 CA116708, CA 95058, CA 75557, R01 CA092393-04, R01 CA095058, R01 CA075557-09, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS057529, R01 NS047699-03, R01 NS047699, R01 NS061835, NS61835, NS57529, R01 NS057529-01, R01 NS061835-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092393, R01CA116708, R01CA095058, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS061835, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Belotti D, 2003, CANCER RES, V63, P5224; BENELLI R, 1994, ONCOL RES, V6, P251; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 1998, CANCER RES, V58, P3743; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Itoh T, 1998, CANCER RES, V58, P1048; Kaliski A, 2005, MOL CANCER THER, V4, P1717, DOI 10.1158/1535-7163.MCT-05-0179; Komatsu Kyoko, 2004, Brain Tumor Pathol, V21, P105, DOI 10.1007/BF02482184; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; RAY JM, 1994, EUR RESPIR J, V7, P2062; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Sawaya R, 1998, BIOCHEM BIOPH RES CO, V251, P632, DOI 10.1006/bbrc.1998.9466; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Wang JG, 2003, IEEE T MOBILE COMPUT, V2, P65, DOI 10.1109/TMC.2003.1195152; Wild-Bode C, 2001, CANCER RES, V61, P2744; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	43	99	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4830	4840		10.1038/onc.2008.122	http://dx.doi.org/10.1038/onc.2008.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438431	Green Accepted			2022-12-25	WOS:000258445100008
J	Mazauric, MH; Licznar, P; Prere, MF; Canal, I; Fayet, O				Mazauric, Marie-Helene; Licznar, Patricia; Prere, Marie-Francoise; Canal, Isabelle; Fayet, Olivier			Apical loop-internal loop RNA pseudoknots - A new type of stimulator of-1 translational frameshifting in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICOID MESSENGER-RNA; RIBOSOMAL FRAMESHIFT; ESCHERICHIA-COLI; GENE-EXPRESSION; SEQUENCE; SIGNAL; TRANSPOSITION; DIMERIZATION; INITIATION; MECHANISM	Nearly all members of a widespread family of bacterial transposable elements related to insertion sequence 3 (IS3), therefore called the IS3 family, very likely use programmed -1 ribosomal frameshifting to produce their transposase, a protein required for mobility. Comparative analysis of the potential frameshift signals in this family suggested that most of the insertion sequences from the IS51 group contain in their mRNA an elaborate pseudoknot that could act as a recoding stimulator. It results from a specific intramolecular interaction between an apical loop and an internal loop from two stem-loop structures. Directed mutagenesis, chemical probing, and gel mobility assays of the frameshift region of one element from the IS51 group, IS3411, provided clear evidences of the existence of the predicted structure. Modeling was used to generate a three-dimensional molecular representation of the apical loop-internal loop complex. We could demonstrate that mutations affecting the stability of the structure reduce both frameshifting and transposition, thus establishing the biological importance of this new type of RNA structure for the control of transposition level.	CNRS, UMR5100, Lab Microbiol & Genet Mol, F-31062 Toulouse 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Fayet, O (corresponding author), Univ Toulouse 3, CNRS, UMR5100, Bat IBCG,118 Route Narbonne, F-31062 Toulouse 9, France.	Olivier.Fayet@ibcg.biotoul.fr						Aldaz-Carroll L, 2002, BIOCHEMISTRY-US, V41, P5883, DOI 10.1021/bi0121508; Bao TH, 1997, EMBO J, V16, P3357, DOI 10.1093/emboj/16.11.3357; Baranov PV, 2006, TRENDS GENET, V22, P174, DOI 10.1016/j.tig.2006.01.005; Barry JK, 2002, P NATL ACAD SCI USA, V99, P11133, DOI 10.1073/pnas.162223099; Bertrand C, 2002, RNA, V8, P16, DOI 10.1017/S1355838202012086; Brierley I, 2001, COLD SPRING HARB SYM, V66, P233, DOI 10.1101/sqb.2001.66.233; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3; Chandler M, 2002, MOBILE DNA, V2, P305; Chen CC, 2006, J BIOL CHEM, V281, P21617, DOI 10.1074/jbc.M602437200; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Dulude D, 2002, NUCLEIC ACIDS RES, V30, P5094, DOI 10.1093/nar/gkf657; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Gaudin C, 2005, J MOL BIOL, V349, P1024, DOI 10.1016/j.jmb.2005.04.045; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Giedroc DP, 2000, J MOL BIOL, V298, P167, DOI 10.1006/jmbi.2000.3668; Gomes SD, 2004, BIOCHEM BIOPH RES CO, V322, P820, DOI 10.1016/j.bbrc.2004.07.185; Harger JW, 2002, TRENDS BIOCHEM SCI, V27, P448, DOI 10.1016/S0968-0004(02)02149-7; Horiya S, 2003, CHEM BIOL, V10, P645, DOI 10.1016/S1074-5521(03)00146-7; ISHIGURO N, 1988, J BACTERIOL, V170, P1902, DOI 10.1128/jb.170.4.1902-1906.1988; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Kanevsky I, 2003, NUCLEIC ACIDS RES, V31, P7070, DOI 10.1093/nar/gkg942; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162; Licznar P, 2003, EMBO J, V22, P4770, DOI 10.1093/emboj/cdg465; Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; Mejlhede N, 2004, J BACTERIOL, V186, P3274, DOI 10.1128/JB.186.10.3274-3277.2004; Michiels PJA, 2001, J MOL BIOL, V310, P1109, DOI 10.1006/jmbi.2001.4823; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Namy O, 2006, NATURE, V441, P244, DOI 10.1038/nature04735; Napthine S, 2003, EMBO J, V22, P3941, DOI 10.1093/emboj/cdg365; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; POLARD P, 1991, J MOL BIOL, V222, P465, DOI 10.1016/0022-2836(91)90490-W; Rettberg CC, 1999, J MOL BIOL, V286, P1365, DOI 10.1006/jmbi.1999.2546; ROMBY P, 1987, J MOL BIOL, V195, P193, DOI 10.1016/0022-2836(87)90336-6; SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097; SOMOGYI P, 1993, MOL CELL BIOL, V13, P6931, DOI 10.1128/MCB.13.11.6931; Staple DW, 2005, J MOL BIOL, V349, P1011, DOI 10.1016/j.jmb.2005.03.038; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; VOGELE K, 1991, NUCLEIC ACIDS RES, V19, P4377, DOI 10.1093/nar/19.16.4377; Wagner C, 2004, J BIOL CHEM, V279, P4560, DOI 10.1074/jbc.M306511200; ZHENG JH, 1995, MOL MICROBIOL, V16, P669, DOI 10.1111/j.1365-2958.1995.tb02429.x	50	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20421	20432		10.1074/jbc.M802829200	http://dx.doi.org/10.1074/jbc.M802829200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18474594	hybrid			2022-12-25	WOS:000257565300057
J	Perello, M; Stuart, R; Nillni, EA				Perello, Mario; Stuart, Ronald; Nillni, Eduardo A.			Prothyrotropin-releasing hormone targets its processing products to different vesicles of the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PITUITARY-TUMOR-CELLS; PRO-ACTH-ENDORPHIN; ATT20 CELLS; PARAVENTRICULAR NUCLEUS; ATT-20 CELLS; ENDOPROTEOLYTIC CLEAVAGE; HYPOTHALAMIC NEURONS; INTRACELLULAR SITES; FOOD-INTAKE	Prothyrotropin-releasing hormone (pro-TRH) is initially cleaved by the prohormone convertase-1/3 (PC1/3) in the transGolgi network generating N- and C-terminal intermediate forms that are then packed into secretory vesicles. However, it is not known whether these peptides are differentially sorted within the secretory pathway. This is of key importance because the processing products of several prohormones fulfill different biological functions. Using AtT20 cells stably transfected with prepro-TRH cDNA, we found that two specific N- and C-terminal peptides were located in different vesicles. Furthermore, the C-terminal pro-TRH-derived peptides were more efficiently released in response to KCl and norepinephrine, a natural secretagogue of TRH. Similar sorting and secretion of N- and C-terminal peptides occurs in vivo. When we blocked the initial proteolytic processing by a mutagenic approach, the differential sorting and secretion of these peptides were prevented. In summary, our data show that pro-TRH-derived peptides are differentially sorted within the secretory pathway and that the initial cleavage in the trans-Golgi network is key to this process. This could be a common mechanism used by neuroendocrine cells to regulate independently the secretion of different bioactive peptides derived from the same gene product.	[Perello, Mario; Stuart, Ronald; Nillni, Eduardo A.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch,Dept Med, Div Endocrinol, Providence, RI 02903 USA; [Nillni, Eduardo A.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Nillni, EA (corresponding author), 55 Claverick St,Rm 320, Providence, RI 02903 USA.	Eduardo_Nillni@brown.edu		Perello, Mario/0000-0003-2114-6765	NIDDK NIH HHS [R01 DK 58148] Funding Source: Medline; NINDS NIH HHS [R01 NS 045231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoki Y, 1997, ENDOCRINOLOGY, V138, P1923, DOI 10.1210/en.138.5.1923; Borgonovo B, 2006, CURR OPIN CELL BIOL, V18, P365, DOI 10.1016/j.ceb.2006.06.010; BULANT M, 1990, P NATL ACAD SCI USA, V87, P4439, DOI 10.1073/pnas.87.12.4439; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Cote-Velez A, 2005, J MOL ENDOCRINOL, V34, P177, DOI 10.1677/jme.1.01634; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; Diano S, 1998, J NEUROENDOCRINOL, V10, P647, DOI 10.1046/j.1365-2826.1998.00261.x; Dikeakos JD, 2007, J CELL BIOL, V177, P191, DOI 10.1083/jcb.200701024; FISHER JM, 1988, J BIOL CHEM, V263, P16515; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; Goldstein J, 2007, J MOL NEUROSCI, V31, P69, DOI 10.1007/BF02686119; Josic D, 2005, ELECTROPHORESIS, V26, P2809, DOI 10.1002/elps.200500060; Klumperman J, 1996, J NEUROSCI, V16, P7930; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MERIGHI A, 1992, ELECT MICROSCOPIC IM, P51; Mulcahy LR, 2005, J BIOL CHEM, V280, P39818, DOI 10.1074/jbc.M507193200; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 2002, J NEUROCHEM, V80, P874, DOI 10.1046/j.0022-3042.2002.00763.x; Nillni EA, 2001, ENDOCRINOLOGY, V142, P896, DOI 10.1210/en.142.2.896; Perello M, 2007, FRONT BIOSCI-LANDMRK, V12, P3554, DOI 10.2741/2334; Perello M, 2006, ENDOCRINOLOGY, V147, P3296, DOI 10.1210/en.2005-1533; Perello M, 2006, ENDOCRINOLOGY, V147, P2705, DOI 10.1210/en.2005-1609; Perone MJ, 1998, MOL CELL ENDOCRINOL, V142, P191, DOI 10.1016/S0303-7207(98)00104-X; REISINE TD, 1983, J NEUROSCI, V3, P725; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; SCHMIDT WK, 1994, J BIOL CHEM, V269, P27115; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Sobota JA, 2006, MOL BIOL CELL, V17, P5038, DOI 10.1091/mbc.E06-07-0626; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TANAKA S, 1991, J HISTOCHEM CYTOCHEM, V39, P809, DOI 10.1177/39.6.1851777; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; VANHEUMEN WRA, 1991, CELL TISSUE RES, V264, P185, DOI 10.1007/BF00305737; Villeneuve P, 2000, NEUROREPORT, V11, P3443; WATTENBERG BW, 1990, J CELL PHYSIOL, V143, P287, DOI 10.1002/jcp.1041430212; XU H, 1994, BIOCHIMIE, V76, P257, DOI 10.1016/0300-9084(94)90155-4; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					19936	19947		10.1074/jbc.M800732200	http://dx.doi.org/10.1074/jbc.M800732200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18474603	Green Published, hybrid			2022-12-25	WOS:000257565300009
J	Haring, SJ; Mason, AC; Binz, SK; Wold, MS				Haring, Stuart J.; Mason, Aaron C.; Binz, Sara K.; Wold, Marc S.			Cellular functions of human RPA1 - Multiple roles of domains in replication, repair, and checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROTEIN-A RPA; DAMAGE CHECKPOINTS; BINDING-PROTEIN; 32-KDA SUBUNIT; IN-VITRO; PHOSPHORYLATION; RECOMBINATION; COMPLEX; MECHANISM	In eukaryotes, the single strand DNA (ssDNA)-binding protein, replication protein A (RPA), is essential for DNA replication, repair, and recombination. RPA is composed of the following three subunits: RPA1, RPA2, and RPA3. The RPA1 subunit contains four structurally related domains and is responsible for high affinity ssDNA binding. This study uses a depletion/replacement strategy in human cells to reveal the contributions of each domain to RPA cellular functions. Mutations that substantially decrease ssDNA binding activity do not necessarily disrupt cellular RPA function. Conversely, mutations that only slightly affect ssDNA binding can dramatically affect cellular function. The N terminus of RPA1 is not necessary for DNA replication in the cell; however, this region is important for the cellular response to DNA damage. Highly conserved aromatic residues in the high affinity ssDNA-binding domains are essential for DNA repair and cell cycle progression. Our findings suggest that as long as a threshold of RPA-ssDNA binding activity is met, DNA replication can occur and that an RPA activity separate from ssDNA binding is essential for function in DNA repair.	[Haring, Stuart J.; Mason, Aaron C.; Binz, Sara K.; Wold, Marc S.] Univ Iowa, Dept Biochem, Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa	Wold, MS (corresponding author), Univ Iowa, Dept Biochem, Carver Coll Med, 3107 MERF, Iowa City, IA 52242 USA.	marc-wold@uiowa.edu	Wold, Marc/F-5806-2010; Haring, Stuart/E-7481-2012	Wold, Marc/0000-0002-4580-1624	NIGMS NIH HHS [GM44721, R01 GM044721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araya R, 2005, FEBS LETT, V579, P157, DOI 10.1016/j.febslet.2004.11.066; Arunkumar AI, 2003, J BIOL CHEM, V278, P41077, DOI 10.1074/jbc.M305871200; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Binz SK, 2006, METHOD ENZYMOL, V409, P11, DOI 10.1016/S0076-6879(05)09002-6; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Cuvier O, 2006, CURR BIOL, V16, P516, DOI 10.1016/j.cub.2006.01.059; Deng XY, 2007, J MOL BIOL, V374, P865, DOI 10.1016/j.jmb.2007.09.074; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Gao H, 2007, NAT STRUCT MOL BIOL, V14, P208, DOI 10.1038/nsmb1205; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; Grandin N, 2007, NUCLEIC ACIDS RES, V35, P822, DOI 10.1093/nar/gkl1081; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Ishibashi T, 2006, J BIOCHEM, V139, P99, DOI 10.1093/jb/mvj014; Kanoh Y, 2006, GENE, V377, P88, DOI 10.1016/j.gene.2006.03.019; Kantake N, 2003, J BIOL CHEM, V278, P23410, DOI 10.1074/jbc.M302995200; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Kumaran S, 2006, BIOCHEMISTRY-US, V45, P11958, DOI 10.1021/bi060994r; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; Lee SE, 2003, MOL CELL BIOL, V23, P8913, DOI 10.1128/MCB.23.23.8913-8923.2003; Liu LF, 1996, ANN NY ACAD SCI, V803, P44, DOI 10.1111/j.1749-6632.1996.tb26375.x; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; Liu YY, 2005, J BIOL CHEM, V280, P32775, DOI 10.1074/jbc.M505705200; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Majka J, 2006, J BIOL CHEM, V281, P27855, DOI 10.1074/jbc.M605176200; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pestryakov PE, 2004, NUCLEIC ACIDS RES, V32, P1894, DOI 10.1093/nar/gkh346; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Salas TR, 2006, NUCLEIC ACIDS RES, V34, P4857, DOI 10.1093/nar/gkl564; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schramke V, 2004, NAT GENET, V36, P46, DOI 10.1038/ng1284; Soustelle C, 2002, GENETICS, V161, P535; Sugiyama T, 2006, EMBO J, V25, P5539, DOI 10.1038/sj.emboj.7601412; Syljuasen RG, 2007, ONCOGENE, V26, P5833, DOI 10.1038/sj.onc.1210402; Tuteja N, 2001, CRIT REV BIOCHEM MOL, V36, P261, DOI 10.1080/20014091074192; Umezu K, 1998, GENETICS, V148, P989; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Wang X, 2004, PLOS BIOL, V2, P104, DOI 10.1371/journal.pbio.0020021; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Wu X, 2005, BIOCHEM J, V391, P473, DOI 10.1042/BJ20050379; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Wyka IM, 2003, BIOCHEMISTRY-US, V42, P12909, DOI 10.1021/bi034930h; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	70	88	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19095	19111		10.1074/jbc.M800881200	http://dx.doi.org/10.1074/jbc.M800881200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18469000	Green Published, hybrid			2022-12-25	WOS:000257165600065
J	Schwenk, J; Zolles, G; Kandias, NG; Neubauer, I; Kalbacher, H; Covarrubias, M; Fakler, B; Bentrop, D				Schwenk, Jochen; Zolles, Gerd; Kandias, Nikolaos G.; Neubauer, Isabel; Kalbacher, Hubert; Covarrubias, Manuel; Fakler, Bernd; Bentrop, Detlef			NMR analysis of KChIP4a reveals structural basis for control of surface expression of Kv4 channel complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE EXPERIMENTS; RESIDUAL DIPOLAR COUPLINGS; K+ CHANNELS; POTASSIUM CHANNELS; LARGE PROTEINS; BIOLOGICAL MACROMOLECULES; TERMINAL DOMAIN; MODULATION; BINDING; INACTIVATION	Potassium channel-interacting proteins ( KChIPs) are EF-hand calcium-binding proteins of the recoverin/neuronal calcium sensor 1 family that co-assemble with the pore-forming Kv4 alpha-subunits and thus control surface trafficking of the voltage-gated potassium channels mediating the neuronal IA and cardiac I-to currents. Different from the other KChIPs, KChIP4a largely reduces surface expression of the Kv4 channel complexes. Using solution NMR we show that the unique N terminus of KChIP4a forms a 6-turn alpha-helix that is connected to the highly conserved core of the KChIP protein via a solvent-exposed linker. As identified by chemical shift changes, N-terminal alpha-helix and core domain of KChIP4a interact with each other through the same hydrophobic surface pocket that is involved in intermolecular interaction between the N-terminal helix of Kv4 alpha and KChIP in Kv4-KChIP complexes. Electro-physiological recordings and biochemical interaction assays of complexes formed by wild-type and mutant Kv4 alpha and KChIP4a proteins suggest that competition of these two helical domains for the surface groove is responsible for the reduced trafficking of Kv4- KChIP4a complexes to the plasma membrane. Surface expression of Kv4 complexes may thus be controlled by an auto-inhibitory domain in the KChIP subunit.	[Schwenk, Jochen; Zolles, Gerd; Neubauer, Isabel; Fakler, Bernd; Bentrop, Detlef] Univ Freiburg, Inst Physiol 2, D-79104 Freiburg, Germany; [Kandias, Nikolaos G.] Univ Patras, Dept Pharm, Sch Hlth Sci, GR-26500 Patras, Greece; [Kalbacher, Hubert] Univ Tubingen, Interfacultary Inst Biochem, D-72074 Tubingen, Germany; [Kalbacher, Hubert] Univ Tubingen, Nat Sci Res Ctr, D-72074 Tubingen, Germany; [Covarrubias, Manuel] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of Freiburg; University of Patras; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Jefferson University	Bentrop, D (corresponding author), Hermann Herder Str 7, D-79104 Freiburg, Germany.	detlef.bentrop@physiologie.uni-freiburg.de		Schwenk, Jochen/0000-0003-3664-9795; Covarrubias, Manuel/0000-0002-0881-4143	NINDS NIH HHS [R01 NS032337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032337] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Baker KA, 2006, BIOCHEMISTRY-US, V45, P1663, DOI 10.1021/bi0516430; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Berjanskii M, 2006, NAT PROTOC, V1, P683, DOI 10.1038/nprot.2006.108; Berjanskii MV, 2005, J AM CHEM SOC, V127, P14970, DOI 10.1021/ja054842f; Berkefeld H, 2006, SCIENCE, V314, P615, DOI 10.1126/science.1132915; Callsen B, 2005, J PHYSIOL-LONDON, V568, P397, DOI 10.1113/jphysiol.2005.094359; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Gardner KH, 1997, BIOCHEMISTRY-US, V36, P1389, DOI 10.1021/bi9624806; Han W, 2006, J BIOL CHEM, V281, P27134, DOI 10.1074/jbc.M604843200; Hasdemir B, 2005, J CELL BIOL, V171, P459, DOI 10.1083/jcb.200506005; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jerng HH, 2004, BIOPHYS J, V87, P2380, DOI 10.1529/biophysj.104.042358; Keller R., 2004, COMPUTER AIDED RESON, V1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nietlispach D, 2002, J AM CHEM SOC, V124, P11199, DOI 10.1021/ja025865m; Osawa M, 2005, J BIOL CHEM, V280, P18008, DOI 10.1074/jbc.M500338200; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ou HD, 2001, J BIOMOL NMR, V21, P269, DOI 10.1023/A:1012920832184; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pioletti M, 2006, NAT STRUCT MOL BIOL, V13, P987, DOI 10.1038/nsmb1164; Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656; Reese ML, 2003, J AM CHEM SOC, V125, P14250, DOI 10.1021/ja037640x; Roosild TP, 2005, SCIENCE, V307, P1317, DOI 10.1126/science.1106392; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Venters RA, 1996, J MOL BIOL, V264, P1101, DOI 10.1006/jmbi.1996.0699; Wang HY, 2007, NAT NEUROSCI, V10, P32, DOI 10.1038/nn1822; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zhou P, 2001, J BIOMOL NMR, V20, P11, DOI 10.1023/A:1011258906244; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zhu G, 1999, J BIOMOL NMR, V13, P77, DOI 10.1023/A:1008398227519; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	49	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18937	18946		10.1074/jbc.M800976200	http://dx.doi.org/10.1074/jbc.M800976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458082	Green Published, hybrid			2022-12-25	WOS:000257165600050
J	Yamaguchi, H; Woods, NT; Dorsey, JF; Takahashi, Y; Gjertsen, NR; Yeatman, T; Wu, J; Wang, HG				Yamaguchi, Hirohito; Woods, Nicholas T.; Dorsey, Jay F.; Takahashi, Yoshinori; Gjertsen, Nicole R.; Yeatman, Timothy; Wu, Jie; Wang, Hong-Gang			Src directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CURVATURE; MITOCHONDRIAL APOPTOSIS; CONFORMATIONAL-CHANGE; BH3 DOMAINS; PROTEIN; ACTIVATION; INDUCTION; BCL-2; METASTASIS; MECHANISMS	Bif-1 interacts with Bax and enhances its conformational rearrangement, resulting in apoptosis. However, the molecular mechanism governing the interaction between Bif-1 and Bax is poorly defined. Here we provide evidence that Bif-1 is phosphorylated, an event that can be repressed by apoptotic stimuli. The protein kinase c-Src binds to and directly phosphorylates Bif-1 on tyrosine 80. Moreover, Src phosphorylation of Bif-1 suppresses the interaction between Bif-1 and Bax, resulting in the inhibition of Bax activation during anoikis. Together, these results suggest that phosphorylation of Bif-1 impairs its binding to Bax and represses apoptosis, providing another mechanism by which Src oncogenic signaling can prevent cell death.	[Yamaguchi, Hirohito; Woods, Nicholas T.; Dorsey, Jay F.; Takahashi, Yoshinori; Gjertsen, Nicole R.; Yeatman, Timothy; Wu, Jie; Wang, Hong-Gang] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Wang, HG (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Hong-Gang.Wang@Moffitt.org	Wu, Jie/R-2404-2019; Wang, Hong-Gang/A-3018-2015	Wu, Jie/0000-0002-2864-1606; Wang, Hong-Gang/0000-0003-0551-0571; Woods, Nicholas/0000-0002-4962-9083; Takahashi, Yoshinori/0000-0002-8004-4817	NCI NIH HHS [R01 CA090315, R01 CA077467, P01 CA118210, R01 CA082197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090315, P01CA118210, R01CA077467, R01CA082197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chung KC, 2001, J BIOL CHEM, V276, P2132, DOI 10.1074/jbc.M007492200; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Ott M, 2007, J BIOL CHEM, V282, P27633, DOI 10.1074/jbc.M703155200; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woods NT, 2007, CANCER RES, V67, P10744, DOI 10.1158/0008-5472.CAN-07-3148; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang JS, 2006, NAT CELL BIOL, V8, P1376, DOI 10.1038/ncb1503	34	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19112	19118		10.1074/jbc.M709882200	http://dx.doi.org/10.1074/jbc.M709882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474606	hybrid, Green Published			2022-12-25	WOS:000257165600066
J	Yang, YZ; Tetreault, MP; Yermolina, YA; Goldstein, BG; Katz, JP				Yang, Yizeng; Tetreault, Marie-Pier; Yermolina, Yuliya A.; Goldstein, Bree G.; Katz, Jonathan P.			Kruppel-like factor 5 controls keratinocyte migration via the integrin-linked kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR KLF5; CELL-MIGRATION; STEM-CELLS; EPITHELIAL-CELLS; ESOPHAGEAL EPITHELIUM; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; UP-REGULATION; RHO-GTPASES; ILK	Migration of epithelial cells is critical for normal homeostasis in gut and skin, but the factors regulating this process are not completely understood. The zinc finger transcription factor Klf5 (IKLF; BTEB2) is highly expressed in proliferating cells of esophagus, skin, and other organs. We hypothesized that Klf5 regulates keratinocyte migration via the integrin-linked kinase (ILK), which, like Klf5, is localized to basal keratinocytes. We stably transduced mouse primary esophageal keratinocytes to overexpress Klf5 or small interfering RNA against Klf5. Klf5 overexpression in keratinocytes increased migration and correlated directly with ILK expression and activation. ILK expression restored migratory capacity in keratinocytes with suppression of Klf5, whereas ILK small interfering RNA blocked the increased migration resulting from Klf5 overexpression. By chromatin immunoprecipitation, electromobility shift assay, and luciferase reporter assays, we confirmed that ILK was a direct target for Klf5. In addition, Klf5 induced the activation of the ILK targets Cdc42 and myosin light chain, which are critical for cell migration and motility but not Rac1, AKT, or GSK3 beta. Overall, these results demonstrate that Klf5 is a key regulator of cell migration via ILK and provide new insight into the regulation of epithelial cell migration.	[Yang, Yizeng; Tetreault, Marie-Pier; Yermolina, Yuliya A.; Goldstein, Bree G.; Katz, Jonathan P.] Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Katz, JP (corresponding author), 600 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jpkatz@mail.med.upenn.edu	Tetreault, Marie-Pier/K-7950-2013		NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073888, P30DK050306] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA098101] Funding Source: Medline; NIDDK NIH HHS [R21 DK073888, P30 DK050306] Funding Source: Medline; PHS HHS [P01 A098101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Cullen BR, 2006, NAT METHODS, V3, P677, DOI 10.1038/NMETH913; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dise RS, 2008, AM J PHYSIOL-GASTR L, V294, pG276, DOI 10.1152/ajpgi.00340.2007; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Goldstein BG, 2007, AM J PHYSIOL-GASTR L, V292, pG1784, DOI 10.1152/ajpgi.00541.2006; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kirfel G, 2004, PROTOPLASMA, V223, P67, DOI 10.1007/s00709-003-0031-5; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Nagai R, 2003, ADV EXP MED BIOL, V538, P57; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; RAJA SK, 2007, FRONT BIOSCI, V12, P2849, DOI DOI 10.2741/2277; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schug J, 2008, CURR PROTOC BIOINFOR, V21, P261, DOI DOI 10.1002/; Seery JP, 2002, J CELL SCI, V115, P1783; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Watanabe T, 2007, MOL BIOL CELL, V18, P605, DOI 10.1091/mbc.E06-07-0590; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WATT FM, 1993, J CELL SCI, V106, P175; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792	56	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18812	18820		10.1074/jbc.M801384200	http://dx.doi.org/10.1074/jbc.M801384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18450752	Green Published, hybrid			2022-12-25	WOS:000257165600038
J	Deikus, G; Condon, C; Bechhofer, DH				Deikus, Gintaras; Condon, Ciaran; Bechhofer, David H.			Role of Bacillus subtilis RNase J1 endonuclease and 5 '-exonuclease activities in trp leader RNA turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; RIBOSOMAL-RNA; DEGRADATION; DECAY; MATURATION; INITIATION; BACTERIA; ATTENUATION; CLEAVAGE	The 140-nucleotide trp leader RNA, which is formed by transcription termination under conditions of high intracellular tryptophan, was used to study RNA turnover in Bacillus subtilis. We showed in vivo that the amount of endonuclease cleavage at similar to nucleotide 100 is decreased under conditions where RNase J1 concentration is reduced. In addition, under these conditions the level of 3'-terminal RNA fragments, which contain the strong transcription terminator structure, increases dramatically. These results implicated RNase J1 in the initiation of trp leader RNA decay as well as in the subsequent steps leading to complete turnover of the terminator fragment. To confirm a direct role for RNase J1, experiments were performed in vitro with various forms of trp leader RNA and 3'-terminal RNA fragments. Specific endonuclease cleavages, which were restricted to single-stranded regions not bound by protein, were observed. Degradation of the 3'-terminal fragment by the 5' to 3'-exonuclease activity of RNase J1 was also demonstrated, although the presence of strong secondary structure impeded RNase J1 processivity to some extent. These results are consistent with a model for mRNA decay in Bacillus subtilis whereby the downstream products of RNase J1 endonucleolytic cleavage become substrates for the 5' to 3'-exoribonuclease activity of the enzyme.	[Deikus, Gintaras; Bechhofer, David H.] NYU, Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [Condon, Ciaran] Univ Paris 07, CNRS, Inst Biol Physicochim, UPR 9073, F-75005 Paris, France	Icahn School of Medicine at Mount Sinai; New York University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Bechhofer, DH (corresponding author), Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	david.bechhofer@mssm.edu	Condon, Ciaran/F-6798-2011	Condon, Ciaran/0000-0002-2199-9621	NIGMS NIH HHS [GM48804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Britton RA, 2007, MOL MICROBIOL, V63, P127, DOI 10.1111/j.1365-2958.2006.05499.x; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; Callaghan AJ, 2005, NATURE, V437, P1187, DOI 10.1038/nature04084; Celesnik H, 2007, MOL CELL, V27, P79, DOI 10.1016/j.molcel.2007.05.038; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; Condon C, 2003, MICROBIOL MOL BIOL R, V67, P157, DOI 10.1128/MMBR.67.2.157-174.2003; Condon C, 1997, J MOL BIOL, V268, P235, DOI 10.1006/jmbi.1997.0971; Condon C, 2007, CURR OPIN MICROBIOL, V10, P271, DOI 10.1016/j.mib.2007.05.008; de la Sierra-Gallay IL, 2008, NAT STRUCT MOL BIOL, V15, P206, DOI 10.1038/nsmb.1376; Deana A, 2008, NATURE, V451, P355, DOI 10.1038/nature06475; Deikus G, 2004, P NATL ACAD SCI USA, V101, P2747, DOI 10.1073/pnas.0307343101; Deikus G, 2007, J BIOL CHEM, V282, P20238, DOI 10.1074/jbc.M702747200; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; Even S, 2005, NUCLEIC ACIDS RES, V33, P2141, DOI 10.1093/nar/gki505; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; Jiang XQ, 2004, P NATL ACAD SCI USA, V101, P9211, DOI 10.1073/pnas.0401382101; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; Mathy N, 2007, CELL, V129, P681, DOI 10.1016/j.cell.2007.02.051; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Sharp JS, 2003, J BACTERIOL, V185, P5372, DOI 10.1128/JB.185.18.5372-5379.2003; Spickler C, 2000, J BACTERIOL, V182, P2422, DOI 10.1128/JB.182.9.2422-2427.2000; Yao SY, 2007, NUCLEIC ACIDS RES, V35, P4464, DOI 10.1093/nar/gkm460	29	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17158	17167		10.1074/jbc.M801461200	http://dx.doi.org/10.1074/jbc.M801461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445592	hybrid, Green Published			2022-12-25	WOS:000256720600024
J	Kuiper, HC; Miranda, CL; Sowell, JD; Stevens, JF				Kuiper, Heather C.; Miranda, Cristobal L.; Sowell, John D.; Stevens, Jan F.			Mercapturic acid conjugates of 4-hydroxy-2-nonenal and 4-oxo-2-nonenal metabolites are in vivo markers of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; REDUCTASE CATALYZES REDUCTION; MILD COGNITIVE IMPAIRMENT; CARBON-TETRACHLORIDE; DNA-DAMAGE; ALZHEIMERS-DISEASE; ALDOSE REDUCTASE; LINOLEIC-ACID; LIVER-INJURY; RAT	Oxidative stress-induced lipid peroxidation leads to the formation of cytotoxic and genotoxic 2-alkenals, such as 4-hydroxy-2-nonenal (HNE) and 4-oxo-2-nonenal (ONE). Lipid-derived reactive aldehydes are subject to phase-2 metabolism and are predominantly found as mercapturic acid (MA) conjugates in urine. This study shows evidence for the in vivo formation of ONE and its phase-1 metabolites, 4-oxo-2-nonen-1-ol (ONO) and 4-oxo-2-nonenoic acid (ONA). We have detected the MA conjugates of HNE, 1,4-dihydroxy-2-nonene (DHN), 4-hydroxy-2-nonenoic acid (HNA), the lactone of HNA, ONE, ONO, and ONA in rat urine by liquid chromatography-tandem mass spectrometry comparison with synthetic standards prepared in our laboratory. CCl4 treatment of rats, a widely accepted animal model of acute oxidative stress, resulted in a significant increase in the urinary levels of DHN-MA, HNA-MA lactone, ONE-MA, and ONA-MA. Our data suggest that conjugates of HNE and ONE metabolites have value as markers of in vivo oxidative stress and lipid peroxidation.	[Stevens, Jan F.] Oregon State Univ, Dept Pharmaceut Sci, Corvallis, OR 97331 USA; Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Stevens, JF (corresponding author), Oregon State Univ, Dept Pharmaceut Sci, 203 Pharm Bldg,1601 SW Jefferson, Corvallis, OR 97331 USA.	fred.stevens@oregonstate.edu		Stevens, Jan Frederik/0000-0002-6348-9347	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR022589, S10 RR022589] Funding Source: Medline; NHLBI NIH HHS [R01HL081721, R01 HL081721] Funding Source: Medline; NIEHS NIH HHS [P30 ES000210, P30ES000210] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abou-Raya A, 2004, CLIN INVEST MED, V27, P306; Agianian B, 2003, J MOL BIOL, V326, P151, DOI 10.1016/S0022-2836(02)01327-X; Alary J, 1998, CHEM RES TOXICOL, V11, P130, DOI 10.1021/tx970139w; ALARY J, 1995, CHEM RES TOXICOL, V8, P34, DOI 10.1021/tx00043a004; Alary Jacques, 2003, Molecular Aspects of Medicine, V24, P177, DOI 10.1016/S0098-2997(03)00012-8; Amunom I, 2007, ARCH BIOCHEM BIOPHYS, V464, P187, DOI 10.1016/j.abb.2007.05.019; Annangudi SP, 2005, SYNLETT, P1468, DOI 10.1055/s-2005-869833; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Blair IA, 2006, CURR DRUG METAB, V7, P853, DOI 10.2174/138920006779010601; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P173, DOI 10.3109/15563659309000384; Bruno RS, 2006, FREE RADICAL BIO MED, V40, P689, DOI 10.1016/j.freeradbiomed.2005.10.051; Butterfield DA, 2007, J ALZHEIMERS DIS, V12, P61; Chung FL, 2000, CANCER RES, V60, P1507; Chung H, 2005, TOXICOL APPL PHARM, V206, P27, DOI 10.1016/j.taap.2004.11.004; COMPORTI M, 1989, CHEM-BIOL INTERACT, V72, P1, DOI 10.1016/0009-2797(89)90016-1; deZwart LL, 1996, XENOBIOTICA, V26, P1087; Doorn JA, 2006, CHEM RES TOXICOL, V19, P102, DOI 10.1021/tx0501839; Doorn JA, 2004, BIOCHEMISTRY-US, V43, P13106, DOI 10.1021/bi049136q; Doorn JA, 2003, CHEM RES TOXICOL, V16, P1418, DOI 10.1021/tx0300378; Douki T, 2004, FREE RADICAL BIO MED, V37, P62, DOI 10.1016/j.freeradbiomed.2004.04.013; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gallagher EP, 2007, TOXICOL IN VITRO, V21, P1365, DOI 10.1016/j.tiv.2007.04.004; GARDNER HW, 1992, LIPIDS, V27, P686, DOI 10.1007/BF02536025; Halliwell B., 1999, FREE RADICAL BIO MED, P547; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P186; HOFF HF, 1993, J LIPID RES, V34, P1209; Jian WY, 2007, CHEM RES TOXICOL, V20, P1008, DOI 10.1021/tx700001t; Jian WY, 2005, FREE RADICAL BIO MED, V39, P1162, DOI 10.1016/j.freeradbiomed.2005.06.008; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; Knoll N, 2005, TOXICOL SCI, V86, P27, DOI 10.1093/toxsci/kfi171; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2001, TRENDS CARDIOVAS MED, V11, P148, DOI 10.1016/S1050-1738(01)00094-9; Lin D, 2005, CHEM RES TOXICOL, V18, P1219, DOI 10.1021/tx050080q; Lovell MA, 2007, NUCLEIC ACIDS RES, V35, P7497, DOI 10.1093/nar/gkm821; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; McGregor D, 1996, MUTAT RES-REV GENET, V366, P181; Milne GL, 2007, METHOD ENZYMOL, V433, P113, DOI 10.1016/S0076-6879(07)33006-1; MITCHELL DY, 1987, TOXICOL APPL PHARM, V87, P403, DOI 10.1016/0041-008X(87)90245-6; Oriolli M, 2007, ANAL CHEM, V79, P9174, DOI 10.1021/ac7016184; Picklo MJ, 2007, J ALZHEIMERS DIS, V12, P185; ROBERTS JD, 1977, BASIC PRINCIPLES ORG, P624; Schneider C, 2005, LIPIDS, V40, P1155, DOI 10.1007/s11745-005-1480-3; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Shishehbor MH, 2006, FREE RADICAL BIO MED, V41, P1678, DOI 10.1016/j.freeradbiomed.2006.09.001; Sicilia T, 2008, J CHROMATOGR B, V861, P48, DOI 10.1016/j.jchromb.2007.11.021; Spiteller G, 1998, CHEM PHYS LIPIDS, V95, P105, DOI 10.1016/S0009-3084(98)00091-7; Spiteller G, 2007, MOL BIOTECHNOL, V37, P5, DOI 10.1007/s12033-007-0057-6; Srinivasan R, 2007, J ETHNOPHARMACOL, V113, P284, DOI 10.1016/j.jep.2007.06.006; Srivastava S, 2000, FREE RADICAL BIO MED, V29, P642, DOI 10.1016/S0891-5849(00)00351-8; Stewart BJ, 2007, CHEM RES TOXICOL, V20, P1111, DOI 10.1021/tx700106v; Volkel W, 2005, FREE RADICAL BIO MED, V38, P1526, DOI 10.1016/j.freeradbiomed.2005.02.015; Wacker M, 2001, CHEM-BIOL INTERACT, V137, P269, DOI 10.1016/S0009-2797(01)00259-9; Wiswedel I, 2005, BIOFACTORS, V24, P201, DOI 10.1002/biof.5520240124; Yin HY, 2007, J BIOL CHEM, V282, P329, DOI 10.1074/jbc.M608975200; Zhang WH, 2003, CHEM RES TOXICOL, V16, P512, DOI 10.1021/tx020105a	57	37	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17131	17138		10.1074/jbc.M802797200	http://dx.doi.org/10.1074/jbc.M802797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442969	hybrid, Green Published			2022-12-25	WOS:000256720600021
J	Porto, I; Granados, C; Restrepo, JC; Sanchez, JA				Porto, Isabel; Granados, Camila; Restrepo, Juan C.; Sanchez, Juan A.			Macroalgal-Associated Dinoflagellates Belonging to the Genus Symbiodinium in Caribbean Reefs	PLOS ONE			English	Article							SPARISOMA-VIRIDE; CORAL; DIVERSITY; SPECIFICITY; ZOOXANTHELLAE; PREDATION; OCTOCORAL; SYMBIOSIS; DYNAMICS; PACIFIC	Coral-algal symbiosis has been a subject of great attention during the last two decades in response to global coral reef decline. However, the occurrence and dispersion of free-living dinoflagellates belonging to the genus Symbiodinium are less documented. Here ecological and molecular evidence is presented demonstrating the existence of demersal free-living Symbiodinium populations in Caribbean reefs and the possible role of the stoplight parrotfish (Sparisoma viride) as Symbiodinium spp. dispersers. Communities of free-living Symbiodinium were found within macroalgal beds consisting of Halimeda spp., Lobophora variegata, Amphiroa spp., Caulerpa spp. and Dictyota spp. Viable Symbiodinium spp. cells were isolated and cultured from macroalgal beds and S. viride feces. Further identification of Symbiodinium spp. type was determined by length variation in the Internal Transcribed Spacer 2 (ITS2, nuclear rDNA) and length variation in domain V of the chloroplast large subunit ribosomal DNA (cp23S-rDNA). Determination of free-living Symbiodinium and mechanisms of dispersal is important in understanding the life cycle of Symbiodinium spp.	[Porto, Isabel; Granados, Camila; Restrepo, Juan C.; Sanchez, Juan A.] Univ Los Andes, Dept Ciencias Biol, Fac Ciencias, Lab Biol Mol Marina BIOMMAR, Bogota, DC, Colombia	Universidad de los Andes (Colombia)	Porto, I (corresponding author), Univ Los Andes, Dept Ciencias Biol, Fac Ciencias, Lab Biol Mol Marina BIOMMAR, Bogota, DC, Colombia.	juansanc@uniandes.edu.co	sanchez, juan/GSD-8167-2022	Sanchez, Juan Armando/0000-0001-7149-8369	COLCIENCIAS [120409-16825]; Facultad de Ciencias, Department of Biological Sciences, Universidad de los Andes	COLCIENCIAS(Departamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias); Facultad de Ciencias, Department of Biological Sciences, Universidad de los Andes	This study was funded by COLCIENCIAS (No. 120409-16825), J. Dave Hardy Jr. (Tobago), and Facultad de Ciencias, Department of Biological Sciences, Universidad de los Andes (funding to J.A. Sanchez). These funding agencies granted the money without any commercial or unethical interest, other than providing support for this research. They did not have any role making the manuscript. The Minister of Environment, Household and Territorial Development of Colombia granted access to genetic resources to J.A.S. for the DNA analyses included in this paper (Contract 007, resolution 634, 14 March 2007).	ALLDREDGE AL, 1977, MAR BIOL, V41, P317, DOI 10.1007/BF00389098; BAKER A, 2003, EVOL SYST, V34, P661; Barnes D.J., 1990, P109; Bellwood DR, 2003, ECOL LETT, V6, P281, DOI 10.1046/j.1461-0248.2003.00432.x; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Bruckner AW, 2000, CORAL REEFS, V19, P50, DOI 10.1007/s003380050225; BRUGGEMANN JH, 1994, MAR ECOL PROG SER, V106, P41, DOI 10.3354/meps106041; Bruggemann JH, 1996, MAR ECOL PROG SER, V134, P59, DOI 10.3354/meps134059; BURRIS RH, 1983, MAR BIOL, V75, P151, DOI 10.1007/BF00405997; Carlos AA, 1999, J PHYCOL, V35, P1054, DOI 10.1046/j.1529-8817.1999.3551054.x; CHANG FH, 1983, NEW ZEAL J MAR FRESH, V17, P279, DOI 10.1080/00288330.1983.9516003; COFFROTH M, 2006, CURR BIOL, V16; COFFROTH MA, 1992, MAR BIOL, V114, P317, DOI 10.1007/BF00349534; Coffroth MA, 2001, MAR ECOL PROG SER, V222, P85, DOI 10.3354/meps222085; Elbrachter M, 2003, J PHYCOL, V39, P629, DOI 10.1046/j.1529-8817.2003.39041.x; Gomez-Cabrera MD, 2008, CORAL REEFS, V27, P219, DOI 10.1007/s00338-007-0315-x; Gou WL, 2003, J EXP MAR BIOL ECOL, V296, P135, DOI 10.1016/S0022-0981(03)00242-9; Goulet TL, 2003, MAR ECOL PROG SER, V250, P117, DOI 10.3354/meps250117; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; Hoegh-Guldberg O, 2002, NATURE, V415, P601, DOI 10.1038/415601a; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; LaJeunesse TC, 2005, J PHYCOL, V41, P880, DOI 10.1111/j.0022-3646.2005.04231.x; LaJeunesse TC, 2005, MOL BIOL EVOL, V22, P570, DOI 10.1093/molbev/msi042; LaJeunesse TC, 2003, LIMNOL OCEANOGR, V48, P2046, DOI 10.4319/lo.2003.48.5.2046; LaJeunesse TC, 2002, MAR BIOL, V141, P387, DOI 10.1007/s00227-002-0829-2; Lewis CL, 2004, SCIENCE, V304, P1490, DOI 10.1126/science.1097323; Littler MM, 2007, AQUAT CONSERV, V17, P195, DOI 10.1002/aqc.790; Miller MW, 1998, OECOLOGIA, V113, P231, DOI 10.1007/s004420050373; Muscatine L., 1990, P75; PARKER GM, 1984, BIOL BULL, V167, P159, DOI 10.2307/1541344; Parrow MW, 2004, J PHYCOL, V40, P664, DOI 10.1111/j.1529-8817.2004.03202.x; Pasternak Z, 2006, CORAL REEFS, V25, P201, DOI 10.1007/s00338-005-0085-2; PEARSE VB, 1971, BIOL BULL, V141, P350, DOI 10.2307/1540123; Pochon X, 2001, MAR BIOL, V139, P1069; POSADA D, 1998, BIOINFORMATICS, V17, P754; Rodriguez-Lanetty M, 2003, MAR BIOL, V143, P1193, DOI 10.1007/s00227-003-1165-x; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; Sanchez JA, 2004, CORAL REEFS, V23, P578, DOI 10.1007/s00338-004-0419-5; Santos SR, 2003, MAR BIOTECHNOL, V5, P130, DOI 10.1007/s10126-002-0076-9; Santos SR, 2001, J PHYCOL, V37, P900, DOI 10.1046/j.1529-8817.2001.00194.x; Stat M, 2006, PERSPECT PLANT ECOL, V8, P23, DOI 10.1016/j.ppees.2006.04.001; Thornhill DJ, 2006, J EXP MAR BIOL ECOL, V338, P50, DOI 10.1016/j.jembe.2006.06.032; van Oppen MJH, 2001, P ROY SOC B-BIOL SCI, V268, P1759, DOI 10.1098/rspb.2001.1733; Vila M, 2001, AQUAT MICROB ECOL, V26, P51, DOI 10.3354/ame026051; Yacobovitch T, 2004, J EXP MAR BIOL ECOL, V298, P35, DOI 10.1016/j.jembe.2003.08.003; Yahel R, 2005, CORAL REEFS, V24, P75, DOI 10.1007/s00338-004-0449-z; Zhang H, 2005, J PHYCOL, V41, P411, DOI 10.1111/j.1529-8817.2005.04168.x; [No title captured]	48	47	50	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2160	10.1371/journal.pone.0002160	http://dx.doi.org/10.1371/journal.pone.0002160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478069	Green Submitted, gold, Green Published			2022-12-25	WOS:000262172800025
J	Bassett, AR; Cooper, SE; Ragab, A; Travers, AA				Bassett, Andrew R.; Cooper, Sarah E.; Ragab, Anan; Travers, Andrew A.			The Chromatin Remodelling Factor dATRX Is Involved in Heterochromatin Formation	PLOS ONE			English	Article								Despite extensive study of heterochromatin, relatively little is known about the mechanisms by which such a structure forms. We show that the Drosophila homologue of the human alpha-thalassemia and mental retardation X-linked protein (dATRX), is important in the formation or maintenance of heterochromatin through modification of position effect variegation. We further show that there are two isoforms of the dATRX protein, the longer of which interacts directly with heterochromatin protein 1 (dHP-1) through a CxVxL motif both in vitro and in vivo. These two proteins co-localise at heterochromatin in a manner dependent on this motif. Consistent with this observation, the long isoform of the dATRX protein localises primarily to the heterochromatin at the chromocentre on salivary gland polytene chromosomes, whereas the short isoform binds to many sites along the chromosome arms. We suggest that the establishment of a regular nucleosomal organisation may be common to heterochromatin and transcriptionally repressed chromatin in other locations, and may require the action of ATP dependent chromatin remodelling factors.	[Bassett, Andrew R.] Univ Cambridge, Dept Plant Sci, Cambridge, England; [Cooper, Sarah E.; Travers, Andrew A.] Med Res Council MRC, Lab Mol Biol, Cambridge, England; [Ragab, Anan] German Canc Res Ctr, Signaling & Funct Genom, Heidelberg, Germany	University of Cambridge; MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Helmholtz Association; German Cancer Research Center (DKFZ)	Bassett, AR (corresponding author), Univ Cambridge, Dept Plant Sci, Cambridge, England.	arb43@cam.ac.uk		Bassett, Andrew/0000-0003-1632-9137	Medical Research Council [Studentship]; MRC [MC_U105184288] Funding Source: UKRI; Medical Research Council [MC_U105184288] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Medical Research Council Studentship	Cardoso C, 2005, DEV BIOL, V278, P49, DOI 10.1016/j.ydbio.2004.10.014; Collins N, 2002, NAT GENET, V32, P627, DOI 10.1038/ng1046; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; EISSENBERG JC, 1992, GENETICS, V131, P345; Eskeland R, 2007, MOL CELL BIOL, V27, P453, DOI 10.1128/MCB.01576-06; Fyodorov DV, 2004, GENE DEV, V18, P170, DOI 10.1101/gad.1139604; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; LI H, 2006, NATURE; Luciani JJ, 2006, J CELL SCI, V119, P2518, DOI 10.1242/jcs.02965; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Nan XS, 2007, P NATL ACAD SCI USA, V104, P2709, DOI 10.1073/pnas.0608056104; Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; Steensma DP, 2005, BLOOD, V105, P443, DOI 10.1182/blood-2004-07-2792; Stephens GE, 2006, BIOCHEMISTRY-US, V45, P14990, DOI 10.1021/bi060983y; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Sun XT, 2006, GENETICS, V173, P1397, DOI 10.1534/genetics.106.057893; Wallace J, 2005, CHROMOSOMA, V114, P389, DOI 10.1007/s00412-005-0024-6; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wu CY, 2007, EMBO REP, V8, P1129, DOI 10.1038/sj.embor.7401115; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100	25	28	29	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2099	10.1371/journal.pone.0002099	http://dx.doi.org/10.1371/journal.pone.0002099			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461125	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400021
J	Smagghe, BJ; Trent, JT; Hargrove, MS				Smagghe, Benoit J.; Trent, James T., III; Hargrove, Mark S.			NO Dioxygenase Activity in Hemoglobins Is Ubiquitous In Vitro, but Limited by Reduction In Vivo	PLOS ONE			English	Article								Genomics has produced hundreds of new hemoglobin sequences with examples in nearly every living organism. Structural and biochemical characterizations of many recombinant proteins reveal reactions, like oxygen binding and NO dioxygenation, that appear general to the hemoglobin superfamily regardless of whether they are related to physiological function. Despite considerable attention to "hexacoordinate'' hemoglobins, which are found in nearly every plant and animal, no clear physiological role(s) has been assigned to them in any species. One popular and relevant hypothesis for their function is protection against NO. Here we have tested a comprehensive representation of hexacoordinate hemoglobins from plants (rice hemoglobin), animals (neuroglobin and cytoglobin), and bacteria (Synechocystis hemoglobin) for their abilities to scavenge NO compared to myoglobin. Our experiments include in vitro comparisons of NO dioxygenation, ferric NO binding, NO-induced reduction, NO scavenging with an artificial reduction system, and the ability to substitute for a known NO scavenger (flavohemoglobin) in E. coli. We conclude that none of these tests reveal any distinguishing predisposition toward a role in NO scavenging for the hxHbs, but that any hemoglobin could likely serve this role in the presence of a mechanism for heme iron re-reduction. Hence, future research to test the role of Hbs in NO scavenging would benefit more from the identification of cognate reductases than from in vitro analysis of NO and O-2 binding.	[Smagghe, Benoit J.; Trent, James T., III; Hargrove, Mark S.] Iowa State Univ, Dept Biochem, Biophys, & Mol Biol, Ames, IA USA	Iowa State University	Smagghe, BJ (corresponding author), Iowa State Univ, Dept Biochem, Biophys, & Mol Biol, Ames, IA USA.	msh@iastate.edu			National Institutes of Health [R01-GM065948]; Iowa State University Plant Sciences Institute; Conseil Regional du Nord-Pas de Calais [doctoral fellowship]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065948] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Iowa State University Plant Sciences Institute; Conseil Regional du Nord-Pas de Calais(Region Hauts-de-FranceRegion Ile-de-France); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was made possible by the National Institutes of Health Award R01-GM065948, support from the Iowa State University Plant Sciences Institute, by a Contrat Plan-Etat-Region to the Laboratoire Stress abiotiques et differenciation des vegetaux cultives, and by a doctoral fellowship of the Conseil Regional du Nord-Pas de Calais.	ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; APPLEBY CA, 1992, SCI PROG, V76, P365; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BROWN WD, 1969, J BIOL CHEM, V244, P6702; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; de Sanctis D, 2004, J MOL BIOL, V336, P917, DOI 10.1016/j.jmb.2003.12.063; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Dordas C, 2004, PLANTA, V219, P66, DOI 10.1007/s00425-004-1212-y; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Fago A, 2006, FEBS LETT, V580, P4884, DOI 10.1016/j.febslet.2006.08.003; Fernandez BO, 2004, INORG CHEM, V43, P5393, DOI 10.1021/ic049532x; Flatley J, 2005, J BIOL CHEM, V280, P10065, DOI 10.1074/jbc.M410393200; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Ford PC, 2005, CHEM REV, V105, P2439, DOI 10.1021/cr0307289; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; Frey AD, 2002, APPL ENVIRON MICROB, V68, P4835, DOI 10.1128/AEM.68.10.4835-4840.2002; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner PR, 2008, METHOD ENZYMOL, V436, P217, DOI 10.1016/S0076-6879(08)36012-1; Gardner PR, 2006, J INORG BIOCHEM, V100, P542, DOI 10.1016/j.jinorgbio.2005.12.012; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 2005, J INORG BIOCHEM, V99, P247, DOI 10.1016/j.jinorgbio.2004.10.003; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Goncalves VL, 2006, FEBS LETT, V580, P1817, DOI 10.1016/j.febslet.2006.02.039; HALDER P, 2006, PROTEINS STRUCTURE F; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; Helmick RA, 2005, ANTIMICROB AGENTS CH, V49, P1837, DOI 10.1128/AAC.49.5.1837-1843.2005; Hernandez-Urzua E, 2003, J BIOL CHEM, V278, P34975, DOI 10.1074/jbc.M303629200; Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009; Herold S, 2005, BIOCHEMISTRY-US, V44, P6223, DOI 10.1021/bi0475929; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hoy JA, 2004, J BIOL CHEM, V279, P16535, DOI 10.1074/jbc.M313707200; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Igamberdiev AU, 2006, PLANTA, V223, P1033, DOI 10.1007/s00425-005-0146-3; Igamberdiev AU, 2004, J EXP BOT, V55, P2473, DOI 10.1093/jxb/erh272; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; JAKOB W, 1992, ARCH BIOCHEM BIOPHYS, V292, P29, DOI 10.1016/0003-9861(92)90046-Y; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kaur R, 2002, APPL ENVIRON MICROB, V68, P152, DOI 10.1128/AEM.68.1.152-160.2002; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; LEDO AFF, 2004, MOL ASPECTS MED, V24, P75; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 2004, FREE RADICAL BIO MED, V36, P685, DOI 10.1016/j.freeradbiomed.2003.11.030; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pathania R, 2002, MOL MICROBIOL, V45, P1303, DOI 10.1046/j.1365-2958.2002.03095.x; Perazzolli M, 2006, J EXP BOT, V57, P479, DOI 10.1093/jxb/erj051; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Sakamoto A, 2004, FEBS LETT, V572, P27, DOI 10.1016/j.febslet.2004.07.005; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Scott NL, 2002, BIOCHEMISTRY-US, V41, P6902, DOI 10.1021/bi025609m; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Smagghe BJ, 2006, BIOCHEMISTRY-US, V45, P561, DOI 10.1021/bi051902l; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trandafir F, 2007, GENE, V398, P103, DOI 10.1016/j.gene.2007.02.038; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200; Vidwans AS, 1999, J NEUROCHEM, V72, P1843, DOI 10.1046/j.1471-4159.1999.0721843.x; Weber RE, 2004, RESP PHYSIOL NEUROBI, V144, P141, DOI 10.1016/j.resp.2004.04.018; Weiland TR, 2004, J AM CHEM SOC, V126, P11930, DOI 10.1021/ja046990w; WITTENBERG JB, 1965, J GEN PHYSIOL, V49, P57; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	86	117	117	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2039	10.1371/journal.pone.0002039	http://dx.doi.org/10.1371/journal.pone.0002039			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446211	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300011
J	Lei, K; Townsend, DM; Tew, KD				Lei, K.; Townsend, D. M.; Tew, K. D.			Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response	ONCOGENE			English	Article						sulfiredoxin; redox; glutathione; thiols; phosphatases; regulatory kinases	TYROSINE PHOSPHATASES; S-GLUTATHIONYLATION; SIGNAL-TRANSDUCTION; REDOX REGULATION; TRANSCRIPTIONAL RESPONSE; LUNG-CANCER; ACTIVE-SITE; PEROXIREDOXIN; THIOREDOXIN; PHOSPHORYLATION	Sulfiredoxin (Srx) is one of a family of low molecular weight sulfur containing proteins linked with maintenance of cellular redox balance. One function of Srx is the reduction of cysteine sulfinic acid to sulfenic acid in proteins subject to oxidative stress. Other redox active protein families have multiple functions in regulating redox and controlling proliferation/death pathways; increased Srx has been linked with oncogenic transformation. To explore the biological functions of Srx in tumors, we established cell lines that overexpress Srx. Enhanced levels of Srx promoted cell proliferation and enhanced cell death following cisplatin. Srx overexpression triggered an alteration in expression and phosphorylation of cell cycle regulators p21, p27 and p53; stabilized the phosphatase PTEN and, importantly, interacted directly with, and enhanced the activity of, phosphatase PTP1B. In turn, this promoted Src kinase activity by dephosphorylating its inhibitory tyrosine residue (Y530). Srx expression was stimulated by cell exposure to certain growth factors. These data support a role for Srx in controlling the phosphorylation status of key regulatory kinases through effects upon phosphatase activity with an ultimate effect on pathways that influence cell proliferation.	[Lei, K.; Tew, K. D.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA; [Townsend, D. M.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tew, KD (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, 173 Ashley Ave,POB 250505, Charleston, SC 29425 USA.	tewk@musc.edu			KL [T32 CA119945-02]; KDT [CA08660]; NATIONAL CANCER INSTITUTE [R01CA085660, T32CA119945] Funding Source: NIH RePORTER	KL; KDT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Carola A Neumann for providing retroviral vectors and packaging cells. This work was supported by a postdoctoral fellowship grant (T32 CA119945-02) to KL and by CA08660 to KDT. We thank the Drug Metabolism and Pharmacokinetics facility for GSH measurements.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Basu MK, 2005, CELL CYCLE, V4, P947, DOI 10.4161/cc.4.7.1786; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bondareva AA, 2007, FREE RADICAL BIO MED, V43, P911, DOI 10.1016/j.freeradbiomed.2007.05.026; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; Demasi APD, 2006, FEBS J, V273, P805, DOI 10.1111/j.1742-4658.2006.05116.x; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Diet A, 2007, J BIOL CHEM, V282, P36199, DOI 10.1074/jbc.M706420200; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findlay VJ, 2006, CANCER RES, V66, P6800, DOI 10.1158/0008-5472.CAN-06-0484; Findlay VJ, 2005, BIOMED PHARMACOTHER, V59, P374, DOI 10.1016/j.biopha.2005.07.003; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Glauser DA, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-54; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hatahet F, 2007, FEBS J, V274, P5223, DOI 10.1111/j.1742-4658.2007.06058.x; Hirabayashi Hirohisa, 2002, Nihon Rinsho, V60 Suppl 5, P263; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob C, 2004, ORG BIOMOL CHEM, V2, P1953, DOI 10.1039/b406180b; Jeong W, 2006, J BIOL CHEM, V281, P14400, DOI 10.1074/jbc.M511082200; Jonsson A, 2008, J BACTERIOL, V190, P434, DOI 10.1128/JB.01058-07; Jonsson TJ, 2007, BIOCHEMISTRY-US, V46, P5709, DOI 10.1021/bi7001218; Jonsson TJ, 2005, BIOCHEMISTRY-US, V44, P8634, DOI 10.1021/bi050131i; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Lee DY, 2006, BIOCHEMISTRY-US, V45, P15301, DOI 10.1021/bi061824h; Lee HJ, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-15; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Liu XP, 2006, CELL RES, V16, P287, DOI 10.1038/sj.cr.7310036; Martinez-Ruiz A, 2007, CARDIOVASC RES, V75, P220, DOI 10.1016/j.cardiores.2007.03.016; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Rey P, 2007, PLANT J, V49, P505, DOI 10.1111/j.1365-313X.2006.02969.x; Rhee SG, 2007, KIDNEY INT, V72, pS3, DOI 10.1038/sj.ki.5002380; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Tew KD, 2007, BIOCHEM PHARMACOL, V73, P1257, DOI 10.1016/j.bcp.2006.09.027; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Townsend DM, 2007, MOL INTERV, V7, P313, DOI 10.1124/mi.7.6.7; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; TOWNSEND DM, 2008, CANC RES IN PRESS; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhu CQ, 2006, J CLIN PATHOL, V59, P790, DOI 10.1136/jcp.2005.031351	63	46	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4877	4887		10.1038/onc.2008.132	http://dx.doi.org/10.1038/onc.2008.132			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454177	Green Accepted			2022-12-25	WOS:000258596900002
J	Kukley, M; Kiladze, M; Tognatta, R; Hans, M; Swandulla, D; Schramm, J; Dietrich, D				Kukley, Maria; Kiladze, Maia; Tognatta, Reshmi; Hans, Michael; Swandulla, Dieter; Schramm, Johannes; Dietrich, Dirk			Glial cells are born with synapses	FASEB JOURNAL			English	Article						NG2; proliferation; mitosis; GABA; glutamate; patch clamp	OLIGODENDROCYTE PRECURSOR CELLS; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; WHITE-MATTER; GABAERGIC INTERNEURONS; SUBVENTRICULAR ZONE; NG2 PROTEOGLYCAN; OLFACTORY-BULB; BRAIN; CNS	In postnatal rodent brain, certain NG2-expressing oligodendroglial precursor cells (OPCs) are contacted by synaptic terminals from local neurons. However, it has remained elusive whether and when NG(2+) cells are integrated into neuronal circuits. Here we use patch-clamp recordings from mitotic cells in murine brain slices to show that, unlike any other cell in the central nervous system (CNS), cortical NG(2+) cells divide and relocate while being linked to synaptic junctions. Together with bromodeoxyuridine (BrdU) labeling, our recordings imply that cellular processes that bear synaptic junctions are surprisingly kept during cytokinesis and are inherited by the daughter cells. Cell cycle time (78 h) and relocation speed (5 mu m/day) are slowed, and NG(2+) cells largely divide symmetrically. Inheritance of synapses enables newborn glial cells to establish synaptic connections much faster than newborn neurons and ensures that the entire population of NG(2+) cells is exposed to synaptic signals from local axons. The results suggest that synapses do not only transmit neuronal activity but also act as environmental cues for the development of glial cells. Inheritance of synapses allows for the direct transfer of environmental interactions to clonal descendants of OPCs, which might be important for effective colonization and myelination of the developing brain.	[Hans, Michael; Swandulla, Dieter] Univ Bonn, Dept Physiol, D-5300 Bonn, Germany; [Kukley, Maria; Kiladze, Maia; Tognatta, Reshmi; Schramm, Johannes; Dietrich, Dirk] Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	University of Bonn; University of Bonn	Kukley, M (corresponding author), Univ Clin Bonn, Dept Neurosurg, NCH U1 R035,Sigmund Freud Str 25, D-53105 Bonn, Germany.	maria.kukley@gmx.de; dirk.dietrich@ukb.uni-bonn.de	Messier, Claude/A-2322-2008; Kukley, Maria/I-4064-2017	Messier, Claude/0000-0002-4791-1763; Kukley, Maria/0000-0002-4567-1241; Kiladze, Maia/0000-0002-0656-0821				Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BERGER T, 1991, J NEUROSCI, V11, P3008; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Brazel CY, 2003, PROG NEUROBIOL, V69, P49, DOI 10.1016/S0301-0082(03)00002-9; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Cherubini E, 2001, TRENDS NEUROSCI, V24, P155, DOI 10.1016/S0166-2236(00)01724-0; Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; Dietrich D, 2003, NEURON, V39, P483, DOI 10.1016/S0896-6273(03)00430-6; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kukley M, 2004, J NEUROSCI, V24, P7128, DOI 10.1523/JNEUROSCI.2093-04.2004; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lin SC, 2005, NEURON, V46, P773, DOI 10.1016/j.neuron.2005.04.025; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2007, NEUROSCIENTIST, V13, P62, DOI 10.1177/1073858406295586; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Petreanu L, 2002, J NEUROSCI, V22, P6106; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Yuan XQ, 1998, DEVELOPMENT, V125, P2901; ZAJICEK J, 1994, BRAIN, V117, P1333, DOI 10.1093/brain/117.6.1333; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	46	96	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2957	2969		10.1096/fj.07-090985	http://dx.doi.org/10.1096/fj.07-090985			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18467596				2022-12-25	WOS:000258089300036
J	Qin, K; Sethi, PR; Lambert, NA				Qin, Kou; Sethi, Pooja R.; Lambert, Nevin A.			Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins	FASEB JOURNAL			English	Article						FRAP; heterotrimers; precoupling; collision	RESONANCE ENERGY-TRANSFER; BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; 3RD-INTRACELLULAR LOOP; PLASMA-MEMBRANE; GIRK CHANNELS; GAMMA COMPLEX; IN-VIVO; BINDING; AGONIST	G protein-coupled receptors (GPCRs) interact directly with heterotrimeric G proteins to transduce physiological signals. Early studies of this interaction concluded that GPCRs (R) and G proteins (G) collide with each other randomly after receptor activation and that R-G complexes are transient. More recent studies have suggested that inactive R and G are preassembled (precoupled) as stable R-G complexes. Here we examine the stability of complexes formed between cyan fluorescent protein-labeled alpha(2A)-adrenore-ceptors (C-alpha 2ARs) and G proteins in cells using fluorescence recovery after photobleaching (FRAP). Labeled G proteins diffused in the plasma membrane with equal mobility in the absence and presence of immobile C-alpha 2ARs. Immobile C-alpha 2ARs activated labeled G proteins, demonstrating functional coupling without stable physical association. In contrast, a stable R-G interaction was detected when G proteins were deprived of nucleotides and C-alpha 2ARs were active, as predicted by the ternary complex model. Overexpression of regulator of G protein signaling 4 (RGS4) accelerated the onset of effector activation but did not detectably alter the interaction between C-alpha 2ARs and G proteins. We conclude that at most a small fraction of C-alpha 2ARs and G proteins exist as R-G complexes at any moment.	[Qin, Kou] Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30809 USA; Med Coll Georgia, Grad Program Neurosci, Augusta, GA 30809 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Qin, K (corresponding author), Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30809 USA.	nlambert@mcg.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078319] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200; Akgoz M, 2006, CELL SIGNAL, V18, P1758, DOI 10.1016/j.cellsig.2006.01.016; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Benians A, 2005, J BIOL CHEM, V280, P13383, DOI 10.1074/jbc.M410163200; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Carrero G, 2003, METHODS, V29, P14, DOI 10.1016/S1046-2023(02)00288-8; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Dushek O, 2008, J BIOCHEM BIOPH METH, V70, P1224, DOI 10.1016/j.jbbm.2007.07.002; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fernandez-Fernandez JM, 2001, EUR J NEUROSCI, V14, P283, DOI 10.1046/j.0953-816x.2001.01642.x; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAESER D, 1993, MOL PHARMACOL, V43, P434; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Philip F, 2007, J BIOL CHEM, V282, P19203, DOI 10.1074/jbc.M701558200; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; Vogel Steven S, 2006, Sci STKE, V2006, pre2; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	39	50	50	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2920	2927		10.1096/fj.08-105775	http://dx.doi.org/10.1096/fj.08-105775			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434433	Green Published, Green Accepted			2022-12-25	WOS:000258089300032
J	Zhou, S; Si, J; Liu, T; DeWille, JW				Zhou, Shanggen; Si, Junling; Liu, Tong; DeWille, James W.			PIASy represses CCAAT/enhancer-binding protein delta(C/EBP delta) transcriptional activity by sequestering C/EBP delta to the nuclear periphery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GROWTH ARREST; FAMILY-MEMBERS; EXPRESSION; GENE; ACTIVATION; PROLIFERATION; INTEGRIN; SUMO; SEQUESTRATION	CCAAT/enhancerbindingprotein delta(C/EBP delta) plays a key role in mammary epithelial cell G(0) growth arrest, and "loss of function" alterations in C/EBP delta have been reported in breast cancer and acute myeloidleukemia. C/EBP delta isregulatedatthetranscriptional, post-transcriptional, and post-translational levels, suggesting tight control of C/EBP delta content and function. Protein inhibitors of activated STATs (PIASs) regulate a growing number of transcription factors, including C/EBPs. HC11 nontransformed mammary epithelial cells express PIAS3, PIASx beta, and PIASy, and all three PIAS family members repress C/EBP delta transcriptional activity. PIASy is the most potent, however, repressing C/EBP delta transcriptional activity by > 80%. PIASy repression of C/EBP delta transcriptional activity is dependent upon interaction between the highly conserved PIASy N-terminal nuclear matrix binding domain (SAPD) and the C/EBP delta transactivation domain (TAD). PIASy repression of C/EBP delta transcriptional activity is independent of histone deacetylase activity, PIASy E3 SUMO ligase activity, and C/EBP delta sumoylation status. PIASy expression is associated with C/EBP delta translocation from nuclear foci, where C/EBP delta co-localizes with p300, to the nuclear periphery. PIASy- mediated translocation of C/EBP delta is dependent upon the PIASy SAPD and C/EBP delta TAD. PIASy reduces the expression of C/EBP delta adhesion-related target genes and enhances repopulation of open areas within a cell monolayer in the in vitro "scratch" assay. These results demonstrate that PIASy represses C/EBP delta by a mechanism that requires interaction between the PIASy SAPD and C/EBP delta TAD and does not require PIASy SUMO ligase activity or C/EBP delta sumoylation. PIASy alters C/EBP delta nuclear localization, reduces C/EBP delta transcriptional activity, and enhances cell proliferation/ migration.	[Zhou, Shanggen; Si, Junling; Liu, Tong; DeWille, James W.] Ohio State Univ, Dept Vet Biosci, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	DeWille, JW (corresponding author), Ohio State Univ, Dept Vet Biosci, Ohio State Biochem Program, 1925 Coffey Rd, Columbus, OH 43210 USA.	dewille.1@osu.edu			NCI NIH HHS [P30 CA 16058, CA 57607-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R29CA057607, R01CA057607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2007, BLOOD, V109, P3895, DOI 10.1182/blood-2006-08-040147; Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3; Barbaro V, 2007, J CELL BIOL, V177, P1037, DOI 10.1083/jcb.200703003; Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016; BOWCOCK A M, 1988, Genomics, V3, P8, DOI 10.1016/0888-7543(88)90152-8; Cambier S, 2000, CANCER RES, V60, P7084; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Dearth LR, 2003, J BIOL CHEM, V278, P11246, DOI 10.1074/jbc.M207930200; Diaz G, 2008, HISTOCHEM CELL BIOL, V129, P611, DOI 10.1007/s00418-008-0402-2; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Fjellbirkeland L, 2003, AM J PATHOL, V163, P533, DOI 10.1016/S0002-9440(10)63681-4; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Gery S, 2005, ONCOGENE, V24, P1589, DOI 10.1038/sj.onc.1208393; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; Hutt JA, 2002, MOL CANCER THER, V1, P601; Ikuzawa M, 2005, COMP BIOCHEM PHYS B, V140, P505, DOI 10.1016/j.cbpc.2004.11.015; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim JY, 2005, J BIOL CHEM, V280, P12246, DOI 10.1074/jbc.M413771200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu XW, 2007, J BIOL CHEM, V282, P20868, DOI 10.1074/jbc.M702547200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lyons SE, 2001, GENE, V281, P43, DOI 10.1016/S0378-1119(01)00774-0; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Nishida T, 2006, BIOCHEM BIOPH RES CO, V345, P1536, DOI 10.1016/j.bbrc.2006.05.065; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Porter D, 2003, MOL CANCER RES, V1, P362; Porter DA, 2001, CANCER RES, V61, P5697; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SCOTT LM, 1992, BLOOD, V80, P1725; Shaklai S, 2007, FEBS J, V274, P1383, DOI 10.1111/j.1742-4658.2007.05697.x; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Sivko GS, 2004, J CELL BIOCHEM, V93, P844, DOI 10.1002/jcb.20224; Sivko GS, 2004, J CELL BIOCHEM, V93, P830, DOI 10.1002/jcb.20223; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANG D, 2005, BREAST CANC RES TREA, P1; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang JM, 2006, NUCLEIC ACIDS RES, V34, P217, DOI 10.1093/nar/gkj422; Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356; Zhou SG, 2007, BIOCHEM J, V405, P341, DOI 10.1042/BJ20070082	64	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20137	20148		10.1074/jbc.M801307200	http://dx.doi.org/10.1074/jbc.M801307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18477566	hybrid, Green Published			2022-12-25	WOS:000257565300030
J	Allard, D; Figg, N; Bennett, MR; Littlewood, TD				Allard, David; Figg, Nichola; Bennett, Martin R.; Littlewood, Trevor D.			Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; FORKHEAD TRANSCRIPTION FACTOR; OXIDATIVE STRESS; ATHEROSCLEROTIC PLAQUES; SIGNALING PATHWAY; NEOINTIMAL HYPERPLASIA; KINASE ACTIVATION; DOWN-REGULATION; MYELOMA CELLS; APOPTOSIS	Apoptosis of vascular smooth muscle cells (VSMCs) may lead to atherosclerotic plaque instability and rupture, resulting in myocardial infarction, stroke, and sudden death. However, the molecular mechanisms mediating survival of VSMCs in atherosclerotic plaques remain unknown. Although plaque VSMCs exhibit increased susceptibility to apoptosis and reduced expression of the IGF1 receptor (IGF1R) when compared with normal VSMCs, a causative effect has not been established. Here we show that increased expression of the IGF1R can rescue plaque VSMCs from oxidative stress-induced apoptosis, demonstrating that IGF-1 signaling is a critical regulator of VSMC survival. Akt mediates the majority of the IGF1R survival signaling, and ectopic activation of Akt was sufficient to protect VSMCs in vitro. Both IGF1R and phospho-Akt expression were reduced in human plaque (intimal) VSMCs when compared with medial VSMCs, suggesting that Akt mediates survival signaling in atherosclerosis. Importantly, downstream targets of Akt were identified that mediate its protective effect as inhibition of FoxO3a or GSK3 by Akt-dependent phosphorylation protected VSMCs in vitro. We conclude that Akt and its downstream targets FoxO3a and GSK3 regulate a survival pathway in VSMCs and that their deregulation due to a reduction of IGF1R signaling may promote apoptosis in atherosclerosis.	[Allard, David; Figg, Nichola; Bennett, Martin R.; Littlewood, Trevor D.] Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Littlewood, TD (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Box 110, Cambridge CB2 2QQ, England.	tdl2@cam.ac.uk		Bennett, Martin/0000-0002-2565-1825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Alves NL, 2007, TRENDS IMMUNOL, V28, P26, DOI 10.1016/j.it.2006.11.003; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Clarke MCH, 2006, NAT MED, V12, P1075, DOI 10.1038/nm1459; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Higashi Y, 2005, J LIPID RES, V46, P1266, DOI 10.1194/jlr.M400478-JLR200; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; Kavurma MM, 2007, BIOCHEM J, V407, P79, DOI 10.1042/BJ20070380; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lawlor MA, 2001, J CELL SCI, V114, P2903; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Li MY, 2006, J BIOL CHEM, V281, P40429, DOI 10.1074/jbc.M606596200; LI SW, 1994, J BIOL CHEM, V269, P32558; Li YX, 2003, ARTERIOSCL THROM VAS, V23, P2178, DOI 10.1161/01.ATV.0000099788.31333.DB; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Okura Y, 2001, J MOL CELL CARDIOL, V33, P1777, DOI 10.1006/jmcc.2001.1441; Paik JH, 2006, BIOCHEM SOC T, V34, P731, DOI 10.1042/BST0340731; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park KW, 2005, ARTERIOSCL THROM VAS, V25, P742, DOI 10.1161/01.ATV.0000156288.70849.26; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Rosner D, 2006, AM J PATHOL, V168, P2054, DOI 10.2353/ajpath.2006.050473; Sandberg EM, 2004, J BIOL CHEM, V279, P34547, DOI 10.1074/jbc.M405045200; Scheidegger KJ, 2000, J BIOL CHEM, V275, P26864; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Song HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI 10.1124/jpet.104.074401; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stocker R, 2005, J THROMB HAEMOST, V3, P1825, DOI 10.1111/j.1538-7836.2005.01370.x; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Sukhanov S, 2007, ARTERIOSCL THROM VAS, V27, P2684, DOI 10.1161/ATVBAHA.107.156257; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Vantler M, 2005, J BIOL CHEM, V280, P14168, DOI 10.1074/jbc.M413310200; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	50	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19739	19747		10.1074/jbc.M710098200	http://dx.doi.org/10.1074/jbc.M710098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18458087	hybrid			2022-12-25	WOS:000257387600058
J	El-Mashtoly, SF; Nakashima, S; Tanaka, A; Shimizu, T; Kitagawa, T				El-Mashtoly, Samir F.; Nakashima, Satoru; Tanaka, Atsunari; Shimizu, Toru; Kitagawa, Teizo			Roles of Arg-97 and Phe-113 in regulation of distal ligand binding to heme in the sensor domain of Ec DOS protein - Resonance Raman and mutation study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT OXYGEN SENSOR; ESCHERICHIA-COLI; CARBON-MONOXIDE; CRYSTAL-STRUCTURE; DIGUANYLIC ACID; PAS DOMAINS; MYOGLOBIN; SPECTROSCOPY; MUTANTS; PHOSPHODIESTERASE	The direct oxygen sensor protein isolated from Escherichia coli (Ec DOS) is a heme-based signal transducer protein responsible for phosphodiesterase (PDE) activity. Binding of O-2, CO, or NO to a reduced heme significantly enhances the PDE activity toward 3',5'-cyclic diguanylic acid. We report stationary and time-resolved resonance Raman spectra of the wild-type and several mutants (Glu-93 -> Ile, Met-95 -> Ala, Arg-97 -> Ile, Arg-97 -> Ala, Arg-97 -> Glu, Phe-113 -> Leu, and Phe-113 -> Thr) of the heme-containing PAS domain of Ec DOS. For the CO-and NO-bound forms, both the hydrogen-bonded and non-hydrogen-bonded conformations were found, and in the former Arg-97 forms a hydrogen bond with the heme-bound external ligand. The resonance Raman results revealed significant interactions of Arg-97 and Phe-113 with a ligand bound to the sixth coordination site of the heme and profound structural changes in the heme propionates upon dissociation of CO. Mutation of Phe-113 perturbed the PDE activities, and the mutation of Arg-97 and Phe-113 significantly influenced the transient binding of Met-95 to the heme upon photodissociation of CO. This suggests that the electrostatic interaction of Arg-97 and steric interaction of Phe-113 are crucial for regulating the competitive recombination of Met-95 and CO to the heme. On the basis of these results, we propose a model for the role of the heme propionates in communicating the heme structural changes to the protein moiety.	[El-Mashtoly, Samir F.; Kitagawa, Teizo] Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; [Nakashima, Satoru] Hyogo Prefecture Univ, Grad Sch Sci, Dept Life Sci, Kamigori, Hyogo 6781201, Japan; [Tanaka, Atsunari; Shimizu, Toru] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Hyogo; Tohoku University	El-Mashtoly, SF (corresponding author), King Khalid Univ, Fac Sci, Dept Chem, Abha 9004, Saudi Arabia.		El-Mashtoly, Samir/C-8761-2014; Tanaka, Atsunari/F-4950-2013	El-Mashtoly, Samir/0000-0001-6087-8817; Nakashima, Satoru/0000-0001-8378-1153				Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; El-Mashtoly SF, 2008, J BIOL CHEM, V283, P6942, DOI 10.1074/jbc.M709209200; El-Mashtoly SF, 2007, J AM CHEM SOC, V129, P3556, DOI 10.1021/ja0669777; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; Gao Y, 2006, J BIOL CHEM, V281, P24637, DOI 10.1074/jbc.M603198200; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; Gonzalez G, 2002, BIOCHEMISTRY-US, V41, P8414, DOI 10.1021/bi025845x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; Huang SH, 2007, BIOCHEMISTRY-US, V46, P15115, DOI 10.1021/bi701771r; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Kruglik SG, 2007, P NATL ACAD SCI USA, V104, P7408, DOI 10.1073/pnas.0700445104; Kurokawa H, 2004, J BIOL CHEM, V279, P20186, DOI 10.1074/jbc.M314199200; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Liebl U, 2003, BIOCHEMISTRY-US, V42, P6527, DOI 10.1021/bi027359f; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; Mendez-Ortiz MM, 2006, J BIOL CHEM, V281, P8090, DOI 10.1074/jbc.M510701200; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Mizutani Y, 2001, J PHYS CHEM B, V105, P10992, DOI 10.1021/jp010923w; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Park ES, 2000, J AM CHEM SOC, V122, P12297, DOI 10.1021/ja0014741; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; SAKAN Y, 1993, BIOCHEMISTRY-US, V32, P5815, DOI 10.1021/bi00073a014; Sasakura Y, 2006, ACCOUNTS CHEM RES, V39, P37, DOI 10.1021/ar0501525; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Takahashi H, 2006, CHEM LETT, V35, P970, DOI 10.1246/cl.2006.970; Tanaka A, 2007, J BIOL CHEM, V282, P21301, DOI 10.1074/jbc.M701920200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tomita T, 1999, J PHYS CHEM B, V103, P7044, DOI 10.1021/jp991106n; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	43	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19000	19010		10.1074/jbc.M801262200	http://dx.doi.org/10.1074/jbc.M801262200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18450754	hybrid			2022-12-25	WOS:000257165600056
J	Wang, M; Tan, W; Zhou, J; Leow, J; Go, M; Lee, HS; Casey, PJ				Wang, Mei; Tan, Wanloo; Zhou, Jin; Leow, Jolene; Go, Meilin; Lee, How Sung; Casey, Patrick J.			A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT GLIOMA-CELLS; CARBOXYL METHYLTRANSFERASE; TRANSFERASE INHIBITORS; PROTEIN PRENYLATION; THERAPY; RAS; TRANSFORMATION; MECHANISM; APOPTOSIS; ENZYMES	A number of proteins involved in cell growth control, including members of the Ras family of GTPases, are modified at their C terminus by a three-step posttranslational process termed prenylation. The enzyme isoprenylcysteine carboxylmethyl-transferase (Icmt) catalyzes the last step in this process, and genetic and pharmacological suppression of Icmt activity significantly impacts on cell growth and oncogenesis. Screening of a diverse chemical library led to the identification of a specific small molecule inhibitor of Icmt, cysmethynil, that inhibited growth factor signaling and tumorigenesis in an in vitro cancer cell model (Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., and Casey, P. J. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 4336-4341). To further evaluate the mechanisms through which this Icmt inhibitor impacts on cancer cells, we developed both in vitro and in vivo models utilizing PC3 prostate cancer cells. Treatment of these cells with cysmethynil resulted in both an accumulation of cells in the G(1) phase and cell death. Treatment of mice harboring PC3 cell-derived xenograft tumors with cysmethynil resulted in markedly reduced tumor size. Analysis of cell death pathways unexpectedly showed minimal impact of cysmethynil treatment on apoptosis; rather, drug treatment significantly enhanced autophagy and autophagic cell death. Cysmethynil-treated cells displayed reduced mammalian target of rapamycin (mTOR) signaling, providing a potential mechanism for the excessive autophagy as well as G1 cell cycle arrest observed. These results identify a novel mechanism for the antitumor activity of Icmt inhibition. Further, the dual effects of cell death and cell cycle arrest by cysmethynil treatment strengthen the rationale for targeting Icmt in cancer chemotherapy.	[Wang, Mei; Tan, Wanloo; Zhou, Jin; Casey, Patrick J.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169547, Singapore; [Leow, Jolene; Go, Meilin] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore; [Lee, How Sung] Natl Univ Singapore, Dept Pharmacol, Singapore 117597, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Casey, PJ (corresponding author), 2 Jalan Bukit Merah, Singapore 169547, Singapore.	patrick.casey@gms.edu.sg		Casey, Patrick/0000-0002-7366-9309; Wang, Mei/0000-0001-6887-6840				Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Baron RA, 2007, BIOCHEMISTRY-US, V46, P554, DOI 10.1021/bi060344n; Baron Rudi A., 2004, BMC Biochemistry, V5, P19, DOI 10.1186/1471-2091-5-19; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bishop WR, 2003, CANCER BIOL THER, V2, pS96; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597; Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Leow JL, 2007, BIOORG MED CHEM LETT, V17, P1025, DOI 10.1016/j.bmcl.2006.11.030; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Sebti SM, 2005, CANCER CELL, V7, P297, DOI 10.1016/j.ccr.2005.04.005; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	30	90	94	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18678	18684		10.1074/jbc.M801855200	http://dx.doi.org/10.1074/jbc.M801855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18434300	hybrid			2022-12-25	WOS:000257165600024
J	Zhu, M; Wang, FS; Yan, F; Yao, PY; Du, J; Gao, XJ; Wang, XW; Wu, Q; Ward, T; Li, JJ; Kioko, S; Hu, RM; Xie, W; Ding, X; Yao, XB				Zhu, Mei; Wang, Fengsong; Yan, Feng; Yao, Phil Y.; Du, Jian; Gao, Xinjiao; Wang, Xiwei; Wu, Quan; Ward, Tarsha; Li, Jingjing; Kioko, Steve; Hu, Renming; Xie, Wei; Ding, Xia; Yao, Xuebiao			Septin 7 interacts with centromere-associated protein E and is required for its kinetochore localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-E; MITOTIC CHECKPOINT; MAMMALIAN SEPTINS; CHROMOSOME CONGRESSION; SPINDLE MICROTUBULES; BUDDING YEAST; FILAMENTS; ATTACHMENT; METAPHASE; PHOSPHORYLATION	Chromosome segregation in mitosis is orchestrated by dynamic interaction between spindle microtubules and the kinetochore. Septin (SEPT) belongs to a conserved family of polymerizing GTPases localized to the metaphase spindle during mitosis. Previous study showed that SEPT2 depletion results in chromosome mis-segregation correlated with a loss of centromere-associated protein E ( CENP-E) from the kinetochores of congressing chromosomes ( 1). However, it has remained elusive as to whether CENP-E physically interacts with SEPT and how this interaction orchestrates chromosome segregation in mitosis. Here we show that SEPT7 is required for a stable kinetochore localization of CENP-E in HeLa and MDCK cells. SEPT7 stabilizes the kinetochore association of CENP-E by directly interacting with its C-terminal domain. The region of SEPT7 binding to CENP- E was mapped to its C-terminal domain by glutathione S-transferase pull-down and yeast two-hybrid assays. Immunofluorescence study shows that SEPT7 filaments distribute along the mitotic spindle and terminate at the kinetochore marked by CENP-E. Remarkably, suppression of synthesis of SEPT7 by small interfering RNA abrogated the localization of CENP- E to the kinetochore and caused aberrant chromosome segregation. These mitotic defects and kinetochore localization of CENP- E can be successfully rescued by introducing exogenous GFP-SEPT7 into the SEPT7-depleted cells. These SEPT7-suppressed cells display reduced tension at kinetochores of bi- orientated chromosomes and activated mitotic spindle checkpoint marked by Mad2 and BubR1 labelings on these misaligned chromosomes. These findings reveal a key role for the SEPT7-CENP-E interaction in the distribution of CENP-E to the kinetochore and achieving chromosome alignment.	[Ding, Xia] Beijing Univ Chinese Med, Beijing 100029, Peoples R China; [Zhu, Mei; Wang, Fengsong; Yan, Feng; Du, Jian; Gao, Xinjiao; Wang, Xiwei; Wu, Quan; Li, Jingjing; Yao, Xuebiao] Hefei Natl Lab Phys Sci Microscale, Div Cellular Dynam, Hefei 230027, Peoples R China; [Zhu, Mei; Wang, Fengsong; Yan, Feng; Du, Jian; Gao, Xinjiao; Wang, Xiwei; Wu, Quan; Li, Jingjing; Yao, Xuebiao] Univ Sci & Technol China, Hefei 230027, Peoples R China; [Wang, Fengsong; Yan, Feng; Yao, Phil Y.; Wu, Quan; Ward, Tarsha; Kioko, Steve] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Hu, Renming] Fudan Univ, Sch Med, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China; [Xie, Wei] Southeast Univ, Sch Med, MOE Key Lab Dev Genes & Human Dis, Nanjing 210009, Peoples R China	Beijing University of Chinese Medicine; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Fudan University; Southeast University - China	Ding, X (corresponding author), Beijing Univ Chinese Med, Beijing 100029, Peoples R China.	xiading6@yahoo.com; yaoxb@ustc.edu.cn	Yao, Xuebiao/P-5771-2014	Li, Jingjing/0000-0003-4435-7573	NCI NIH HHS [CA92080, CA89019] Funding Source: Medline; NIDDK NIH HHS [DK-56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Cao XW, 2005, J BIOL CHEM, V280, P13584, DOI 10.1074/jbc.M411941200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Dou Z, 2004, FEBS LETT, V572, P51, DOI 10.1016/j.febslet.2004.06.092; Espeut J, 2008, MOL CELL, V29, P637, DOI 10.1016/j.molcel.2008.01.004; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Hall PA, 2005, J PATHOL, V206, P269, DOI 10.1002/path.1789; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Liu D, 2007, J BIOL CHEM, V282, P21415, DOI 10.1074/jbc.M609026200; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Low C, 2006, J BIOL CHEM, V281, P30697, DOI 10.1074/jbc.M605179200; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Peterson EA, 2007, MAMM GENOME, V18, P796, DOI 10.1007/s00335-007-9065-x; Sirajuddin M, 2007, NATURE, V449, P311, DOI 10.1038/nature06052; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Versele M, 2004, J CELL BIOL, V164, P701, DOI 10.1083/jcb.200312070; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Xue Y, 2006, CHINESE SCI BULL, V51, P1836, DOI 10.1007/s11434-006-2054-8; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Yu HJ, 2008, CELL RES, V18, P218, DOI 10.1038/cr.2008.20	33	59	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18916	18925		10.1074/jbc.M710591200	http://dx.doi.org/10.1074/jbc.M710591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460473	Green Published, hybrid			2022-12-25	WOS:000257165600048
J	DuBois, KN; Abodeely, M; Sakanari, J; Craik, CS; Lee, M; McKerrow, JH; Sajid, M				DuBois, Kelly N.; Abodeely, Marla; Sakanari, Judy; Craik, Charles S.; Lee, Malinda; McKerrow, James H.; Sajid, Mohammed			Identification of the major cysteine protease of Giardia and its role in encystation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I CATHEPSIN-C; PRIMITIVE EUKARYOTE; LAMBLIA; WALL; EXPRESSION; DIFFERENTIATION; EXCYSTATION; ORGANISMS; PROTOZOAN; CELL	Giardia lamblia is a protozoan parasite and the earliest branching clade of eukaryota. The Giardia life cycle alternates between an asexually replicating vegetative form and an infectious cyst form. Encystation and excystation are crucial processes for the survival and transmission of Giardia. Cysteine proteases in Giardia have been implicated in proteolytic processing events that enable the continuance of the life cycle throughout encystation and excystation. Using quantitative real-time PCR, the expression of twenty-seven clan CA cysteine protease genes in the Giardia genome was measured during both vegetative growth and encystation. Giardia cysteine protease 2 was the most highly expressed cysteine protease during both life cycle stages measured, with a dramatic expression increase during encystation. The mRNA transcript for Giardia cysteine protease 2 was 7-fold up-regulated during encystation and was greater than 3-fold higher than any other Giardia protease gene product. Recombinant Giardia cysteine protease 2 was expressed, purified, and biochemically characterized. The activity of the recombinant cysteine protease 2 protein was confirmed to be identical to the dominant cysteine protease activity found in G. lamblia lysates. Giardia cysteine protease 2 was co-localized with cyst wall protein in encystation-specific vesicles during encystation and processed cyst wall protein 2 to the size found in Giardia cyst walls. These data suggest that Giardia cysteine protease 2 is not only the major cysteine endoprotease expressed in Giardia, but is also central to the encystation process.	[DuBois, Kelly N.; Abodeely, Marla; Sakanari, Judy; Lee, Malinda; McKerrow, James H.; Sajid, Mohammed] Univ Calif San Francisco, Dept Pathol, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94158 USA; [DuBois, Kelly N.; Abodeely, Marla] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94158 USA; [Craik, Charles S.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sajid, M (corresponding author), 1700 4th St,QB3-UCSF 509, San Francisco, CA 94158 USA.	sajid@ucsf.edu			NIAID NIH HHS [AI 35707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abel ES, 2001, J BIOL CHEM, V276, P10320, DOI 10.1074/jbc.M006589200; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; HASHIMOTO T, 1994, MOL BIOL EVOL, V11, P65; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Jacobsen W, 2000, DRUG METAB DISPOS, V28, P1343; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; McKerrow JH, 1999, INT J PARASITOL, V29, P833, DOI 10.1016/S0020-7519(99)00044-2; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; MOTTRAM J, 1998, TRICHOMONAD GIARDIA, P1170; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Que XC, 2007, J BIOL CHEM, V282, P4994, DOI 10.1074/jbc.M606764200; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk D, 2001, EMBO J, V20, P6570, DOI 10.1093/emboj/20.23.6570; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; Yuan F, 2006, J AM CHEM SOC, V128, P5616, DOI 10.1021/ja060835v	28	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18024	18031		10.1074/jbc.M802133200	http://dx.doi.org/10.1074/jbc.M802133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18445589	hybrid, Green Published			2022-12-25	WOS:000256949200031
J	Schweiger, M; Schoiswohl, G; Lass, A; Radner, FPW; Haemmerle, G; Malli, R; Graier, W; Cornaciu, I; Oberer, M; Salvayre, R; Fischer, J; Zechner, R; Zimmermann, R				Schweiger, Martina; Schoiswohl, Gabriele; Lass, Achim; Radner, Franz P. W.; Haemmerle, Guenter; Malli, Roland; Graier, Wolfgang; Cornaciu, Irina; Oberer, Monika; Salvayre, Robert; Fischer, Judith; Zechner, Rudolf; Zimmermann, Robert			The C-terminal region of human adipose triglyceride lipase affects enzyme activity and lipid droplet binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANARIN-DORFMAN-SYNDROME; NEUROPATHY TARGET ESTERASE; HORMONE-SENSITIVE LIPASE; STORAGE DISEASE; HYDROLASE ACTIVITY; CRYSTAL-STRUCTURE; FAMILY-MEMBERS; LIPOLYSIS; PROTEIN; CGI-58	Adipose triglyceride lipase (ATGL) catalyzes the first step in the hydrolysis of triacylglycerol (TG) generating diacylglycerol and free fatty acids. The enzyme requires the activator protein CGI-58 (or ABHD5) for full enzymatic activity. Defective ATGL function causes a recessively inherited disorder named neutral lipid storage disease that is characterized by systemic TG accumulation and myopathy. In this study, we investigated the functional defects associated with mutations in the ATGL gene that cause neutral lipid storage disease. We show that these mutations lead to the expression of either inactive enzymes localizing to lipid droplets (LDs) or enzymatically active lipases with defective LD binding. Additionally, our studies assign important regulatory functions to the C-terminal part of ATGL. Truncated mutant ATGL variants lacking similar to 220 amino acids of the C-terminal protein region do not localize to LDs. Interestingly, however, these mutants exhibit substantially increased TG hydrolase activity in vitro (up to 20-fold) compared with the wild-type enzyme, indicating that the C-terminal region suppresses enzyme activity. Protein-protein interaction studies revealed an increased binding of truncated ATGL to CGI-58, suggesting that the C-terminal part interferes with CGI-58 interaction and enzyme activation. Compared with the human enzyme, the C-terminal region of mouse ATGL is much less effective in suppressing enzyme activity, implicating species-dependent differences in enzyme regulation. Together, our results demonstrate that the C-terminal region of ATGL is essential for proper localization of the enzyme and suppresses enzyme activity.	[Schweiger, Martina; Schoiswohl, Gabriele; Lass, Achim; Radner, Franz P. W.; Haemmerle, Guenter; Cornaciu, Irina; Oberer, Monika; Zechner, Rudolf; Zimmermann, Robert] Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; [Malli, Roland; Graier, Wolfgang] Med Univ Graz, Inst Mol Biol & Biochem, A-8010 Graz, Austria; [Salvayre, Robert] Univ Toulouse 3, CHU Rangueil, INSERM, Inst Federatif Rech 31,U 466, F-31432 Toulouse, France; [Fischer, Judith] Ctr Natl Genotypage, F-91057 Evry, France	University of Graz; Medical University of Graz; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CEA; UDICE-French Research Universities; Universite Paris Saclay	Zimmermann, R (corresponding author), Graz Univ, Inst Mol Biosci, Heinrichstr 31A, A-8010 Graz, Austria.	robert.zimmermann@uni-graz.at	Graier, Wolfgang F./B-7052-2008; Lass, Achim/C-3332-2008; Fischer, Judith/E-6327-2016	Graier, Wolfgang F./0000-0003-1871-3298; Lass, Achim/0000-0002-8190-7151; Fischer, Judith/0000-0002-8580-8118; Zechner, Rudolf/0000-0001-5483-1182; Oberer, Monika/0000-0003-2525-9513; Schweiger, Martina/0000-0002-3419-1007; Radner, Franz/0000-0003-3466-0181; Haemmerle, Guenter/0000-0001-9900-5896; Zimmermann, Robert/0000-0002-7354-870X; Schoiswohl, Gabriele/0000-0002-7346-2834; Malli, Roland/0000-0001-6327-8729	Austrian Science Fund FWF [P 18434, W 901] Funding Source: Medline; Austrian Science Fund (FWF) [Z 136, W 901, F 3002] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Akiyama M, 2007, MUSCLE NERVE, V36, P856, DOI 10.1002/mus.20869; Bartzt R, 2007, J PROTEOME RES, V6, P3256, DOI 10.1021/pr070158j; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; Fischer J, 2007, NAT GENET, V39, P28, DOI 10.1038/ng1951; Gao J, 2005, J INVEST DERMATOL, V124, P1259, DOI 10.1111/j.0022-202X.2005.23761.x; Granneman JG, 2007, J BIOL CHEM, V282, P5726, DOI 10.1074/jbc.M610580200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Holm C, 1999, METH MOL B, V109, P109; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kienesberger PC, 2008, J BIOL CHEM, V283, P5908, DOI 10.1074/jbc.M709598200; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Listenberger LL, 2007, J LIPID RES, V48, P2751, DOI 10.1194/jlr.M700359-JLR200; Mairal A, 2006, DIABETOLOGIA, V49, P1629, DOI 10.1007/s00125-006-0272-x; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Pena-Penabad C, 2001, BRIT J DERMATOL, V144, P430, DOI 10.1046/j.1365-2133.2001.04051.x; Quistad GB, 2003, P NATL ACAD SCI USA, V100, P7983, DOI 10.1073/pnas.1232473100; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; Schweiger M, 2006, J BIOL CHEM, V281, P40236, DOI 10.1074/jbc.M608048200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Trenker M, 2007, NAT CELL BIOL, V9, P445, DOI 10.1038/ncb1556; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	30	106	109	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17211	17220		10.1074/jbc.M710566200	http://dx.doi.org/10.1074/jbc.M710566200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445597	hybrid			2022-12-25	WOS:000256720600030
J	Beekwilder, J; van Leeuwen, W; van Dam, NM; Bertossi, M; Grandi, V; Mizzi, L; Soloviev, M; Szabados, L; Molthoff, JW; Schipper, B; Verbocht, H; de Vos, RCH; Morandini, P; Aarts, MGM; Bovy, A				Beekwilder, Jules; van Leeuwen, Wessel; van Dam, Nicole M.; Bertossi, Monica; Grandi, Valentina; Mizzi, Luca; Soloviev, Mikhail; Szabados, Laszlo; Molthoff, Jos W.; Schipper, Bert; Verbocht, Hans; de Vos, Ric C. H.; Morandini, Piero; Aarts, Mark G. M.; Bovy, Arnaud			The Impact of the Absence of Aliphatic Glucosinolates on Insect Herbivory in Arabidopsis	PLOS ONE			English	Article							THALIANA; DIVERSIFICATION; ISOTHIOCYANATES; IDENTIFICATION; BIOSYNTHESIS; MYROSINASE; RESISTANCE; BIOLOGY; GROWTH	Aliphatic glucosinolates are compounds which occur in high concentrations in Arabidopsis thaliana and other Brassicaceae species. They are important for the resistance of the plant to pest insects. Previously, the biosynthesis of these compounds was shown to be regulated by transcription factors MYB28 and MYB29. We now show that MYB28 and MYB29 are partially redundant, but in the absence of both, the synthesis of all aliphatic glucosinolates is blocked. Untargeted and targeted biochemical analyses of leaf metabolites showed that differences between single and double knock-out mutants and wild type plants were restricted to glucosinolates. Biosynthesis of long-chain aliphatic glucosinolates was blocked by the myb28 mutation, while short-chain aliphatic glucosinolates were reduced by about 50% in both the myb28 and the myb29 single mutants. Most remarkably, all aliphatic glucosinolates were completely absent in the double mutant. Expression of glucosinolate biosynthetic genes was slightly but significantly reduced by the single myb mutations, while the double mutation resulted in a drastic decrease in expression of these genes. Since the myb28myb29 double mutant is the first Arabidopsis genotype without any aliphatic glucosinolates, we used it to establish the relevance of aliphatic glucosinolate biosynthesis to herbivory by larvae of the lepidopteran insect Mamestra brassicae. Plant damage correlated inversely to the levels of aliphatic glucosinolates observed in those plants: Larval weight gain was 2.6 fold higher on the double myb28myb29 mutant completely lacking aliphatic glucosinolates and 1.8 higher on the single mutants with intermediate levels of aliphatic glucosinolates compared to wild type plants.	[Beekwilder, Jules; Molthoff, Jos W.; Schipper, Bert; Verbocht, Hans; de Vos, Ric C. H.; Bovy, Arnaud] Plant Res Int, Wageningen, Netherlands; [van Leeuwen, Wessel; Aarts, Mark G. M.] Wageningen Univ, Lab Genet, Wageningen, Netherlands; [van Dam, Nicole M.] Netherlands Inst Ecol, Heteren, Netherlands; [Bertossi, Monica; Grandi, Valentina; Morandini, Piero] Univ Milan, CNR Biophys Inst, Dept Biol, Milan, Italy; [Mizzi, Luca] Univ Milan, CNR Biophys Inst, Dept Biomol Sci & Biotechnol, Milan, Italy; [Soloviev, Mikhail] Royal Holloway Univ London, Sch Biol Sci, Egham, Surrey, England; [Szabados, Laszlo] Biol Res Ctr, Szeged, Hungary	Wageningen University & Research; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); University of Milan; University of Milan; University of London; Royal Holloway University London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Beekwilder, J (corresponding author), Plant Res Int, Wageningen, Netherlands.	jules.beekwilder@wur.nl	Aarts, Mark G.M./G-8929-2013; Beekwilder, Jules/A-6802-2011; Szabados, Laszlo/F-2078-2010; MORANDINI, PIERO ANGELO/AAZ-1880-2021; van Dam, Nicole M./B-3281-2008; De Vos, Ric/F-5012-2017; Morandini, Piero A/B-1394-2017; Aarts, Mark/O-1706-2019	Aarts, Mark G.M./0000-0001-5257-0740; Beekwilder, Jules/0000-0003-3238-4427; MORANDINI, PIERO ANGELO/0000-0002-7994-6426; van Dam, Nicole M./0000-0003-2622-5446; Morandini, Piero A/0000-0002-7994-6426; Aarts, Mark/0000-0001-5257-0740; Soloviev, Mikhail/0000-0002-3235-1134; Bovy, Arnaud/0000-0003-2643-7377; Szabados, Laszlo/0000-0002-9163-9875				Agrawal AA, 2003, J CHEM ECOL, V29, P1403, DOI 10.1023/A:1024265420375; Barth C, 2006, PLANT J, V46, P549, DOI 10.1111/j.1365-313X.2006.02716.x; Benderoth M, 2006, P NATL ACAD SCI USA, V103, P9118, DOI 10.1073/pnas.0601738103; Brown PD, 2003, PHYTOCHEMISTRY, V62, P471, DOI 10.1016/S0031-9422(02)00549-6; Celenza JL, 2005, PLANT PHYSIOL, V137, P253, DOI 10.1104/pp.104.054395; De Vos RCH, 2007, NAT PROTOC, V2, P778, DOI 10.1038/nprot.2007.95; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Gigolashvili T, 2008, NEW PHYTOL, V177, P627, DOI 10.1111/j.1469-8137.2007.02295.x; Gigolashvili T, 2007, PLANT J, V51, P247, DOI 10.1111/j.1365-313X.2007.03133.x; Gigolashvili T, 2007, PLANT J, V50, P886, DOI 10.1111/j.1365-313X.2007.03099.x; Gimsing AL, 2006, ENVIRON TOXICOL CHEM, V25, P2038, DOI 10.1897/05-610R.1; Gratwick M., 1992, CROP PESTS UK COLLEC; Grubb CD, 2006, TRENDS PLANT SCI, V11, P89, DOI 10.1016/j.tplants.2005.12.006; Halkier BA, 2006, ANNU REV PLANT BIOL, V57, P303, DOI 10.1146/annurev.arplant.57.032905.105228; Hemm MR, 2003, PLANT CELL, V15, P179, DOI 10.1105/tpc.006544; Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009; Hirai MY, 2007, P NATL ACAD SCI USA, V104, P6478, DOI 10.1073/pnas.0611629104; HOGGE LR, 1988, J CHROMATOGR SCI, V26, P551, DOI 10.1093/chromsci/26.11.551; Kelly PJ, 1998, PLANTA, V206, P370, DOI 10.1007/s004250050412; Keurentjes JJB, 2006, NAT GENET, V38, P842, DOI 10.1038/ng1815; Kliebenstein D, 2002, GENETICS, V161, P325; Kliebenstein DJ, 2004, PLANT CELL ENVIRON, V27, P675, DOI 10.1111/j.1365-3040.2004.01180.x; Kliebenstein DJ, 2001, PLANT PHYSIOL, V126, P811, DOI 10.1104/pp.126.2.811; Li Q, 2000, J CHEM ECOL, V26, P2401, DOI 10.1023/A:1005535129399; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MCCLOSKEY C, 1993, J CHEM ECOL, V19, P249, DOI 10.1007/BF00993693; Popova T. A., 1993, Entomological Review (English Translation of Entomologicheskoye Obozreniye), V72, P125; Reichelt M, 2002, PHYTOCHEMISTRY, V59, P663, DOI 10.1016/S0031-9422(02)00014-6; Rojas JC, 2000, J INSECT BEHAV, V13, P247, DOI 10.1023/A:1007792332046; Sonderby IE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001322; Szabados L, 2002, PLANT J, V32, P233, DOI 10.1046/j.1365-313X.2002.01417.x; Textor S, 2007, PLANT PHYSIOL, V144, P60, DOI 10.1104/pp.106.091579; Tocquin Pierre, 2003, BMC Plant Biology, V3, P2, DOI 10.1186/1471-2229-3-2; Windsor AJ, 2005, PHYTOCHEMISTRY, V66, P1321, DOI 10.1016/j.phytochem.2005.04.016; Wittstock U, 2003, RECENT ADV PHYTOCHEM, V37, P101	35	190	198	2	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2068	10.1371/journal.pone.0002068	http://dx.doi.org/10.1371/journal.pone.0002068			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446225	Green Published, gold			2022-12-25	WOS:000261572300037
J	Dan, JM; Wang, JP; Lee, CK; Levitz, SM				Dan, Jennifer M.; Wang, Jennifer P.; Lee, Chrono K.; Levitz, Stuart M.			Cooperative Stimulation of Dendritic Cells by Cryptococcus neoformans Mannoproteins and CpG Oligodeoxynucleotides	PLOS ONE			English	Article								While mannosylation targets antigens to mannose receptors on dendritic cells (DC), the resultant immune response is suboptimal. We hypothesized that the addition of toll-like receptor (TLR) ligands would enhance the DC response to mannosylated antigens. Cryptococcus neoformans mannoproteins (MP) synergized with CpG-containing oligodeoxynucleotides to stimulate enhanced production of proinflammatory cytokines and chemokines from murine conventional and plasmacytoid DC. Synergistic stimulation required the interaction of mannose residues on MP with the macrophage mannose receptor (MR), CD206. Moreover, synergy with MP was observed with other TLR ligands, including tripalmitoylated lipopeptide (Pam3CSK4), polyinosine-polycytidylic acid (pI: C), and imiquimod. Finally, CpG enhanced MP-specific MHC II-restricted CD4(+) T-cell responses by a mechanism dependent upon DC expression of CD206 and TLR9. These data suggest a rationale for vaccination strategies that combine mannosylated antigens with TLR ligands and imply that immune responses to naturally mannosylated antigens on pathogens may be greatly augmented if TLR and MR are cooperatively stimulated.	[Dan, Jennifer M.; Levitz, Stuart M.] Boston Univ, Sch Med, Dept Microbiol, Immunol Training Program, Boston, MA 02118 USA; [Dan, Jennifer M.; Wang, Jennifer P.; Lee, Chrono K.; Levitz, Stuart M.] Univ Massachusetts, Med Sch, Dept Med, Div Infect Dis, Worcester, MA USA	Boston University; University of Massachusetts System; University of Massachusetts Worcester	Dan, JM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Immunol Training Program, Boston, MA 02118 USA.	Stuart.Levitz@umassmed.edu		wang, jennifer/0000-0002-2556-9100	National Institutes of Health [RO1 AI25780, RO1 AI37532, K08 AI 53542]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025780, R01AI037532, R01AI066087, K08AI053542] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants RO1 AI25780 and RO1 AI37532 to SML and K08 AI 53542 to JPW. The funding agency had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Bicanic T, 2005, BRIT MED BULL, V72, P99, DOI 10.1093/bmb/ldh043; Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Edwards L, 2005, EUR J IMMUNOL, V35, P273, DOI 10.1002/eji.200425640; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hazeki K, 2007, BIOL PHARM BULL, V30, P1617, DOI 10.1248/bpb.30.1617; Herring AC, 2002, INFECT IMMUN, V70, P2959, DOI 10.1128/IAI.70.6.2959-2964.2002; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hochrein H, 2002, HUM IMMUNOL, V63, P1103, DOI 10.1016/S0198-8859(02)00748-6; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kinjo T, 2007, MICROBIOL IMMUNOL, V51, P741, DOI 10.1111/j.1348-0421.2007.tb03963.x; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Levitz SM, 2001, P NATL ACAD SCI USA, V98, P10422, DOI 10.1073/pnas.181331398; Levitz SM, 2006, FEMS YEAST RES, V6, P513, DOI 10.1111/j.1567-1364.2006.00071.x; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mansour MK, 2006, J IMMUNOL, V176, P3053, DOI 10.4049/jimmunol.176.5.3053; Mansour MK, 2004, INFECT IMMUN, V72, P1746, DOI 10.1128/IAI.72.3.1746-1754.2004; Mansour MK, 2002, J IMMUNOL, V168, P2872, DOI 10.4049/jimmunol.168.6.2872; Miyagi K, 2005, CLIN EXP IMMUNOL, V140, P220, DOI 10.1111/j.1365-2249.2005.02772.x; MURPHY JW, 1988, INFECT IMMUN, V56, P424, DOI 10.1128/IAI.56.2.424-431.1988; Netea MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pietrella D, 2005, INFECT IMMUN, V73, P820, DOI 10.1128/IAI.73.2.820-827.2005; Ramakrishna V, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-5; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Shoham S, 2005, BRIT J HAEMATOL, V129, P569, DOI 10.1111/j.1365-2141.2005.05397.x; Specht CA, 2007, J INFECT DIS, V196, P796, DOI 10.1086/520536; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Zhang JM, 2004, INFECT IMMUN, V72, P3147, DOI 10.1128/IAI.72.6.3147-3160.2004	40	49	50	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2046	10.1371/journal.pone.0002046	http://dx.doi.org/10.1371/journal.pone.0002046			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446192	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300018
J	Gustafsson, C; Mjosberg, J; Matussek, A; Geffers, R; Matthiesen, L; Berg, G; Sharma, S; Buer, J; Ernerudh, J				Gustafsson, Charlotte; Mjoesberg, Jenny; Matussek, Andreas; Geffers, Robert; Matthiesen, Leif; Berg, Goeran; Sharma, Surendra; Buer, Jan; Ernerudh, Jan			Gene Expression Profiling of Human Decidual Macrophages: Evidence for Immunosuppressive Phenotype	PLOS ONE			English	Article								Background: Although uterine macrophages are thought to play an important regulatory role at the maternal-fetal interface, their global gene expression profile is not known. Methodology/Principal Findings: Using micro-array comprising approximately 14,000 genes, the gene expression pattern of human first trimester decidual CD14+ monocytes/macrophages was characterized and compared with the expression profile of the corresponding cells in blood. Some of the key findings were confirmed by real time PCR or by secreted protein. A unique gene expression pattern intrinsic of first trimester decidual CD14+ cells was demonstrated. A large number of regulated genes were functionally related to immunomodulation and tissue remodelling, corroborating polarization patterns of differentiated macrophages mainly of the alternatively activated M2 phenotype. These include known M2 markers such as CCL-18, CD209, insulin-like growth factor (IGF)-1, mannose receptor c type (MRC)-1 and fibronectin-1. Further, the selective up-regulation of triggering receptor expressed on myeloid cells (TREM)-2, alpha-2-macroglobulin (A2M) and prostaglandin D2 synthase (PGDS) provides new insights into the regulatory function of decidual macrophages in pregnancy that may have implications in pregnancy complications. Conclusions/Significance: The molecular characterization of decidual macrophages presents a unique transcriptional profile replete with important components for fetal immunoprotection and provides several clues for further studies of these cells.	[Gustafsson, Charlotte; Mjoesberg, Jenny; Ernerudh, Jan] Linkoping Univ Hosp, Fac Hlth Sci, Dept Clin & Expt Med,Div Clin Immunol, Unit Autoimmunity & Immune Regulat AIR, S-58185 Linkoping, Sweden; [Matussek, Andreas] Cty Hosp Ryhov, Dept Clin Microbiol, Jonkoping, Sweden; [Geffers, Robert] Helmholtz Ctr Infect Res HCI, Braunschweig, Germany; [Matthiesen, Leif; Berg, Goeran] Univ Hosp, Fac Hlth Sci, Div Gynecol & Obstet, Linkoping, Sweden; [Sharma, Surendra] Brown Univ, Women & Infants Hosp Rhode Island, Dept Pediat, Providence, RI USA; [Sharma, Surendra] Brown Univ, Women & Infants Hosp Rhode Island, Dept Pathol, Providence, RI USA; [Buer, Jan] Univ Hosp Essen, Inst Med Microbiol, Essen, Germany	Linkoping University; Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; University of Duisburg Essen	Gustafsson, C (corresponding author), Linkoping Univ Hosp, Fac Hlth Sci, Dept Clin & Expt Med,Div Clin Immunol, Unit Autoimmunity & Immune Regulat AIR, S-58185 Linkoping, Sweden.	charlotte.gustafsson@imk.liu.se	Matussek, Andreas/AAB-3629-2021	Gustafsson, Charlotte/0000-0003-4997-6795; Buer, Jan/0000-0002-7602-1698	Swedish Research Council; Medical Research Council of South-east Sweden (FORSS); County Council of Ostergotland; National Institutes of Health, USA [HD-41701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041701] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Medical Research Council of South-east Sweden (FORSS); County Council of Ostergotland; National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was supported by grants from the Swedish Research Council, the Medical Research Council of South-east Sweden (FORSS), the County Council of Ostergotland and by a grant from the National Institutes of Health, USA (HD-41701).	Aoki S, 1998, HUM REPROD, V13, P2950, DOI 10.1093/humrep/13.10.2950; Baykal C, 2005, FETAL DIAGN THER, V20, P249, DOI 10.1159/000085079; Begum NA, 2004, INFECT IMMUN, V72, P937, DOI 10.1128/IAI.72.2.937-948.2004; Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361; Brown M, 2004, HUM IMMUNOL, V65, P1336, DOI 10.1016/j.humimm.2004.08.176; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Burk MR, 2001, PLACENTA, V22, P309, DOI 10.1053/plac.2001.0624; Chaouat G, 1999, AM J REPROD IMMUNOL, V42, P1; CHEUNG DL, 1992, BLOOD, V79, P1972; Clark DA, 2003, AM J REPROD IMMUNOL, V50, P187, DOI 10.1034/j.1600-0897.2003.00086.x; Coolman M, 2007, PLACENTA, V28, P709, DOI 10.1016/j.placenta.2006.06.017; Cupurdija K, 2004, AM J REPROD IMMUNOL, V51, P117, DOI 10.1046/j.8755-8920.2003.00128.x; Daly C, 2003, MICROCIRCULATION, V10, P247, DOI 10.1038/sj.mn.7800190; Dealtry GB, 1998, AM J REPROD IMMUNOL, V40, P283; Furugori K, 1997, J CLIN ENDOCR METAB, V82, P2726, DOI 10.1210/jc.82.8.2726; Gabinskaya T, 1998, AM J REPROD IMMUNOL, V40, P339; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gustafsson C, 2006, J REPROD IMMUNOL, V71, P41, DOI 10.1016/j.jri.2005.12.009; Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051; Hanna N, 2000, J IMMUNOL, V164, P5721, DOI 10.4049/jimmunol.164.11.5721; Hashimoto SI, 2003, SCAND J INFECT DIS, V35, P619, DOI 10.1080/00365540310015926; Heikkinen J, 2003, CLIN EXP IMMUNOL, V131, P498, DOI 10.1046/j.1365-2249.2003.02092.x; Hunt J S, 1992, Curr Top Microbiol Immunol, V181, P39; Ip WK, 2006, CLIN EXP IMMUNOL, V145, P162, DOI 10.1111/j.1365-2249.2006.03085.x; Kammerer U, 2005, CHEM IMMUNOL ALLERGY, V89, P96, DOI 10.1159/000087951; Kammerer U, 2003, AM J PATHOL, V162, P887, DOI 10.1016/S0002-9440(10)63884-9; Kodelja V, 1997, IMMUNOBIOLOGY, V197, P478, DOI 10.1016/S0171-2985(97)80080-0; Kodelja V, 1998, J IMMUNOL, V160, P1411; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Larin Sergei S, 2002, Russ J Immunol, V7, P34; Laskarin G, 2005, HUM REPROD, V20, P1057, DOI 10.1093/humrep/deh740; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lidstrom C, 2003, AM J REPROD IMMUNOL, V50, P444, DOI 10.1046/j.8755-8920.2003.00112.x; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Marvin KW, 2002, MOL HUM REPROD, V8, P399, DOI 10.1093/molehr/8.4.399; MIZUNO M, 1994, AM J REPROD IMMUNOL, V31, P180, DOI 10.1111/j.1600-0897.1994.tb00865.x; Mor Gil, 2003, Reprod Biol Endocrinol, V1, P119, DOI 10.1186/1477-7827-1-119; MUES B, 1989, IMMUNOLOGY, V67, P303; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nayak NR, 2003, PLACENTA, V24, P281, DOI 10.1053/plac.2002.0906; PARHAR RS, 1988, CELL IMMUNOL, V116, P392, DOI 10.1016/0008-8749(88)90240-7; Puig-Kroger A, 2004, J BIOL CHEM, V279, P25680, DOI 10.1074/jbc.M311516200; Rieger L, 2002, MOL HUM REPROD, V8, P255, DOI 10.1093/molehr/8.3.255; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; Sacks GP, 2001, PLACENTA, V22, P550, DOI 10.1053/plac.2001.0686; Saito S, 2002, AM J REPROD IMMUNOL, V47, P295, DOI 10.1034/j.1600-0897.2002.01113.x; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Takabayshi K, 2006, IMMUNITY, V24, P475, DOI 10.1016/j.immuni.2006.02.008; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tayade C, 2005, MOL CELL ENDOCRINOL, V245, P60, DOI 10.1016/j.mce.2005.10.004; Terness P, 2007, AM J REPROD IMMUNOL, V58, P238, DOI 10.1111/j.1600-0897.2007.00510.x; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; van Lieshout AWT, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-23; Volpe E, 2006, IMMUNOLOGY, V118, P449, DOI 10.1111/j.1365-2567.2006.02378.x; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357	60	261	274	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2078	10.1371/journal.pone.0002078	http://dx.doi.org/10.1371/journal.pone.0002078			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446208	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300046
J	Hong, SK; Tsang, M; Dawid, IB				Hong, Sung-Kook; Tsang, Michael; Dawid, Igor B.			The Mych Gene Is Required for Neural Crest Survival during Zebrafish Development	PLOS ONE			English	Article								Background: Among Myc family genes, c-Myc is known to have a role in neural crest specification in Xenopus and in craniofacial development in the mouse. There is no information on the function of other Myc genes in neural crest development, or about any developmental role of zebrafish Myc genes. Principal Findings: We isolated the zebrafish mych (myc homologue) gene. Knockdown of mych leads to severe defects in craniofacial development and in certain other tissues including the eye. These phenotypes appear to be caused by cell death in the neural crest and in the eye field in the anterior brain. Significance: Mych is a novel factor required for neural crest cell survival in zebrafish.	[Hong, Sung-Kook; Tsang, Michael; Dawid, Igor B.] NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; [Tsang, Michael] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hong, SK (corresponding author), NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA.	hongsk@mail.nih.gov	Tsang, Michael/AAG-9338-2020; Tsang, Michael W/I-9305-2014; Tsang, Michael/ABV-0504-2022; TSANG, Michael/E-2758-2013	Tsang, Michael W/0000-0001-7123-0063; Tsang, Michael/0000-0001-7123-0063; TSANG, Michael/0000-0001-6384-2422	National Institute of Child Health and Human Development, National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008809] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008809] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Intramural Research Program of the National Institute of Child Health and Human Development, National Institutes of Health	AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Barembaum M, 2005, SEMIN CELL DEV BIOL, V16, P642, DOI 10.1016/j.semcdb.2005.06.006; Barrallo-Gimeno A, 2004, DEVELOPMENT, V131, P1463, DOI 10.1242/dev.01033; Bellmeyer A, 2003, DEV CELL, V4, P827, DOI 10.1016/S1534-5807(03)00160-6; Chuang JC, 2002, BIOESSAYS, V24, P519, DOI 10.1002/bies.10097; Dang CV, 1999, MOL CELL BIOL, V19, P1; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hong SK, 2005, P NATL ACAD SCI USA, V102, P18473, DOI 10.1073/pnas.0509457102; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Kawahara A, 2002, DEV BIOL, V248, P107, DOI 10.1006/dbio.2002.0709; Kudoh T, 2001, GENOME RES, V11, P1979, DOI 10.1101/gr.209601; Kudoh T, 2001, MECH DEVELOP, V109, P95, DOI 10.1016/S0925-4773(01)00505-6; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Light W, 2005, DEVELOPMENT, V132, P1831, DOI 10.1242/dev.01734; Loeb-Hennard C, 2005, GENE EXPR PATTERNS, V5, P341, DOI 10.1016/j.modgep.2004.10.003; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; O'Brien EK, 2004, DEV BIOL, V265, P246, DOI 10.1016/j.ydbio.2003.09.029; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Phillips BT, 2006, DEV BIOL, V294, P376, DOI 10.1016/j.ydbio.2006.03.001; Piotrowski T, 2003, DEVELOPMENT, V130, P5043, DOI 10.1242/dev.00704; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Wei K, 2007, GENESIS, V45, P382, DOI 10.1002/dvg.20304; Westerfield M, 1995, ZEBRAFISH BOOK	32	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2029	10.1371/journal.pone.0002029	http://dx.doi.org/10.1371/journal.pone.0002029			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446220	Green Accepted, gold, Green Published			2022-12-25	WOS:000261572300003
J	Chiaraviglio, L; Brown, DA; Kirby, JE				Chiaraviglio, Lucius; Brown, Daniel A.; Kirby, James E.			Infection of Cultured Human Endothelial Cells by Legionella pneumophila	PLOS ONE			English	Article								Legionella pneumophila is a gram-negative pathogen that causes a severe pneumonia known as Legionnaires' disease. Here, we demonstrate for the first time that L. pneumophila infects and grows within cultured human endothelial cells. Endothelial infection may contribute to lung damage observed during Legionnaires' disease and to systemic spread of this organism.	[Chiaraviglio, Lucius; Brown, Daniel A.; Kirby, James E.] Beth Israel Deaconess Med Ctr, Div Canc Biol & Angiogenesis, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Chiaraviglio, L (corresponding author), Beth Israel Deaconess Med Ctr, Div Canc Biol & Angiogenesis, Dept Pathol, Boston, MA 02215 USA.	jekirby@bidmc.harvard.edu	Kirby, James/K-4438-2019	Chiaraviglio, Lucius/0000-0002-2613-6614	American Heart Association [Grant-In-Aid award]	American Heart Association(American Heart Association)	Supported in part by a Grant-In-Aid award from the American Heart Association. The sponsor did not have a role in design of studies or preparation of the manuscript	AbuKwaik Y, 1996, APPL ENVIRON MICROB, V62, P2022, DOI 10.1128/AEM.62.6.2022-2028.1996; Andrews HL, 1998, INFECT IMMUN, V66, P950, DOI 10.1128/IAI.66.3.950-958.1998; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BRIELAND J, 1994, AM J PATHOL, V145, P1537; CHASTRE J, 1987, CHEST, V91, P57, DOI 10.1378/chest.91.1.57; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; CIANCIOTTO NP, 1995, CURR MICROBIOL, V30, P247, DOI 10.1007/BF00293641; EVANS CP, 1981, AM J CLIN PATHOL, V76, P813; Fabbi M, 1998, J CLIN MICROBIOL, V36, P1942, DOI 10.1128/JCM.36.7.1942-1947.1998; Gao LY, 1998, MICROB PATHOGENESIS, V25, P291, DOI 10.1006/mpat.1998.0237; HORWITZ MA, 1980, J CLIN INVEST, V66, P441, DOI 10.1172/JCI109874; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; HUSMANN LK, 1994, INFECT IMMUN, V62, P2111, DOI 10.1128/IAI.62.5.2111-2114.1994; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Khelef N, 2001, INFECT IMMUN, V69, P5157, DOI 10.1128/IAI.69.8.5157-5161.2001; KING CH, 1991, INFECT IMMUN, V59, P758, DOI 10.1128/IAI.59.3.758-763.1991; Kirby JE, 1998, MOL MICROBIOL, V27, P323, DOI 10.1046/j.1365-2958.1998.00680.x; MARRA A, 1992, P NATL ACAD SCI USA, V89, P9607, DOI 10.1073/pnas.89.20.9607; Marruchella A, 2003, SARCOIDOSIS VASC DIF, V20, P77; Maruta K, 1998, AM J RESP CRIT CARE, V157, P1967, DOI 10.1164/ajrccm.157.6.9710108; Massey R, 2003, HEART, V89, DOI 10.1136/heart.89.5.e16; MCCABE RE, 1984, ANN INTERN MED, V100, P525, DOI 10.7326/0003-4819-100-4-525; MODY CH, 1993, J INFECT DIS, V167, P1138, DOI 10.1093/infdis/167.5.1138; NASH TW, 1984, J CLIN INVEST, V74, P771, DOI 10.1172/JCI111493; NEWSOME AL, 1985, INFECT IMMUN, V50, P449, DOI 10.1128/IAI.50.2.449-452.1985; Roy CR, 2002, J CELL BIOL, V158, P415, DOI 10.1083/jcb.200205011; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Segal G, 1997, INFECT IMMUN, V65, P5057, DOI 10.1128/IAI.65.12.5057-5066.1997; Stout JE, 1997, NEW ENGL J MED, V337, P682, DOI 10.1056/NEJM199709043371006; Sundar KM, 2004, SARCOIDOSIS VASC DIF, V21, P158; Swanson MS, 1996, INFECT IMMUN, V64, P2585, DOI 10.1128/IAI.64.7.2585-2594.1996; TOMPKINS LS, 1988, NEW ENGL J MED, V318, P530, DOI 10.1056/NEJM198803033180902; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Watarai M, 2001, J EXP MED, V194, P1081, DOI 10.1084/jem.194.8.1081	35	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2012	10.1371/journal.pone.0002012	http://dx.doi.org/10.1371/journal.pone.0002012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431493	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700028
J	Zybailov, B; Rutschow, H; Friso, G; Rudella, A; Emanuelsson, O; Sun, Q; van Wijk, KJ				Zybailov, Boris; Rutschow, Heidi; Friso, Giulia; Rudella, Andrea; Emanuelsson, Olof; Sun, Qi; van Wijk, Klaas J.			Sorting Signals, N-Terminal Modifications and Abundance of the Chloroplast Proteome	PLOS ONE			English	Article								Characterization of the chloroplast proteome is needed to understand the essential contribution of the chloroplast to plant growth and development. Here we present a large scale analysis by nanoLC-Q-TOF and nanoLC-LTQ-Orbitrap mass spectrometry (MS) of ten independent chloroplast preparations from Arabidopsis thaliana which unambiguously identified 1325 proteins. Novel proteins include various kinases and putative nucleotide binding proteins. Based on repeated and independent MS based protein identifications requiring multiple matched peptide sequences, as well as literature, 916 nuclear-encoded proteins were assigned with high confidence to the plastid, of which 86% had a predicted chloroplast transit peptide (cTP). The protein abundance of soluble stromal proteins was calculated from normalized spectral counts from LTQ-Obitrap analysis and was found to cover four orders of magnitude. Comparison to gel-based quantification demonstrates that 'spectral counting' can provide large scale protein quantification for Arabidopsis. This quantitative information was used to determine possible biases for protein targeting prediction by TargetP and also to understand the significance of protein contaminants. The abundance data for 550 stromal proteins was used to understand abundance of metabolic pathways and chloroplast processes. We highlight the abundance of 48 stromal proteins involved in post-translational proteome homeostasis (including aminopeptidases, proteases, deformylases, chaperones, protein sorting components) and discuss the biological implications. N-terminal modifications were identified for a subset of nuclear- and chloroplast-encoded proteins and a novel N-terminal acetylation motif was discovered. Analysis of cTPs and their cleavage sites of Arabidopsis chloroplast proteins, as well as their predicted rice homologues, identified new species-dependent features, which will facilitate improved subcellular localization prediction. No evidence was found for suggested targeting via the secretory system. This study provides the most comprehensive chloroplast proteome analysis to date and an expanded Plant Proteome Database (PPDB) in which all MS data are projected on identified gene models.	[Zybailov, Boris; Rutschow, Heidi; Friso, Giulia; Rudella, Andrea; van Wijk, Klaas J.] Cornell Univ, Dept Plant Biol, Ithaca, NY USA; [Emanuelsson, Olof] Stockholm Univ, AlbaNova, Stockholm Bioinformat Ctr, Stockholm, Sweden; [Sun, Qi] Cornell Univ, Cornell Theory Ctr, Computat Biol Serv Unit, Ithaca, NY USA	Cornell University; Stockholm University; Cornell University	van Wijk, KJ (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY USA.	kv35@cornell.edu		Zybailov, Boris/0000-0003-2432-9145	National Science Foundation [0343444]; U.S. Department of Energy [DE-FG02-04ER15560]; New York Science, Technology and Academic Research (NYSTAR); Microsoft Corporation; Knut and Alice Wallenberg Foundation	National Science Foundation(National Science Foundation (NSF)); U.S. Department of Energy(United States Department of Energy (DOE)); New York Science, Technology and Academic Research (NYSTAR); Microsoft Corporation(Microsoft); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation)	This project was supported by a grant from the National Science Foundation (MCB # 0343444), the U.S. Department of Energy (DE-FG02-04ER15560) and New York Science, Technology and Academic Research (NYSTAR) to K.J.v.W. QS was supported by resources of the Computational Biology Service Unit from Cornell University which is partially funded by the Microsoft Corporation. OE was supported by a grant from the Knut and Alice Wallenberg Foundation.	Adam Z, 2006, CURR OPIN PLANT BIOL, V9, P234, DOI 10.1016/j.pbi.2006.03.010; Amin P, 1999, PLANT PHYSIOL, V121, P61, DOI 10.1104/pp.121.1.61; Baginsky S, 2006, J EXP BOT, V57, P1485, DOI 10.1093/jxb/erj130; Baginsky S, 2004, J EXP BOT, V55, P1213, DOI 10.1093/jxb/erh104; Baker TA, 2006, TRENDS BIOCHEM SCI, V31, P647, DOI 10.1016/j.tibs.2006.10.006; Bantscheff M, 2007, ANAL BIOANAL CHEM, V389, P1017, DOI 10.1007/s00216-007-1486-6; Bellafiore S, 2005, NATURE, V433, P892, DOI 10.1038/nature03286; Bonardi V, 2005, NATURE, V437, P1179, DOI 10.1038/nature04016; Book AJ, 2005, PLANT PHYSIOL, V138, P1046, DOI 10.1104/pp.104.057406; Chen H, 2006, PLANT MOL BIOL, V61, P567, DOI 10.1007/s11103-006-0031-x; Dirk LMA, 2002, ARCH BIOCHEM BIOPHYS, V406, P135, DOI 10.1016/S0003-9861(02)00426-5; Dirk LMA, 2001, PLANT PHYSIOL, V127, P97, DOI 10.1104/pp.127.1.97; Elias JE, 2005, NAT METHODS, V2, P667, DOI 10.1038/NMETH785; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; Fernie AR, 2005, CURR OPIN PLANT BIOL, V8, P174, DOI 10.1016/j.pbi.2005.01.008; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Glinski M, 2006, MASS SPECTROM REV, V25, P173, DOI 10.1002/mas.20063; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Heazlewood JL, 2005, PLANT PHYSIOL, V139, P598, DOI 10.1104/pp.105.065532; Heazlewood JL, 2007, NUCLEIC ACIDS RES, V35, pD213, DOI 10.1093/nar/gkl863; Hennig L, 2007, TRENDS PLANT SCI, V12, P287, DOI 10.1016/j.tplants.2007.05.002; Hummel J, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-216; Jain R, 2007, BIOCHEM BIOPH RES CO, V359, P486, DOI 10.1016/j.bbrc.2007.05.142; Jensen ON, 2006, NAT REV MOL CELL BIO, V7, P391, DOI 10.1038/nrm1939; Kleffmann T, 2007, PLANT PHYSIOL, V143, P912, DOI 10.1104/pp.106.090738; Listgarten J, 2005, MOL CELL PROTEOMICS, V4, P419, DOI 10.1074/mcp.R500005-MCP200; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu Q, 2007, MOL CELL PROTEOMICS, V6, P1299, DOI 10.1074/mcp.M700054-MCP200; Lu P, 2007, NAT BIOTECHNOL, V25, P117, DOI 10.1038/nbt1270; Mallick P, 2007, NAT BIOTECHNOL, V25, P125, DOI 10.1038/nbt1275; Meinnel T, 2006, BIOL CHEM, V387, P839, DOI 10.1515/BC.2006.107; Mendenhall W, 1995, STAT ENG SCI; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1991, J BIOL CHEM, V266, P17584; Millar AH, 2006, CURR OPIN PLANT BIOL, V9, P610, DOI 10.1016/j.pbi.2006.09.002; Mogk A, 2007, TRENDS CELL BIOL, V17, P165, DOI 10.1016/j.tcb.2007.02.001; Nesvizhskii AI, 2007, NAT METHODS, V4, P787, DOI 10.1038/NMETH1088; Nowaczyk MM, 2006, PLANT CELL, V18, P3121, DOI 10.1105/tpc.106.042671; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; Olsen JV, 2007, NAT METHODS, V4, P709, DOI 10.1038/NMETH1060; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Peltier JB, 2006, MOL CELL PROTEOMICS, V5, P114, DOI 10.1074/mcp.M500180-MCP200; Peltier JB, 2004, J BIOL CHEM, V279, P49367, DOI 10.1074/jbc.M406763200; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Pesaresi P, 2003, PLANT CELL, V15, P1817, DOI 10.1105/tpc.012377; Pfalz J, 2006, PLANT CELL, V18, P176, DOI 10.1105/tpc.105.036392; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Reumann S, 2004, PLANT PHYSIOL, V136, P2587, DOI 10.1104/pp.104.043695; Richly E, 2004, GENE, V329, P11, DOI 10.1016/j.gene.2004.01.008; Rolland N, 2006, J EXP BOT, V57, P1579, DOI 10.1093/jxb/erj162; Roose JL, 2004, J BIOL CHEM, V279, P45417, DOI 10.1074/jbc.M408458200; Ross S, 2005, PLANT PHYSIOL, V137, P623, DOI 10.1104/pp.104.056861; Rudella A, 2006, PLANT CELL, V18, P1704, DOI 10.1105/tpc.106.042861; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Scigelova M, 2006, PROTEOMICS, P16, DOI 10.1002/pmic.200600528; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sjogren LLE, 2006, PLANT CELL, V18, P2635, DOI 10.1105/tpc.106.044594; SOKAL R, 2005, BIOMETRY, pCH5; Stahl A, 2005, J MOL BIOL, V349, P847, DOI 10.1016/j.jmb.2005.04.023; Stahl-Zeng J, 2007, MOL CELL PROTEOMICS, V6, P1809, DOI 10.1074/mcp.M700132-MCP200; Sun Q, 2004, PLANT PHYSIOL, V135, P723, DOI 10.1104/pp.104.040717; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; van Wijk KJ, 2004, PLANT PHYSIOL BIOCH, V42, P963, DOI 10.1016/j.plaphy.2004.10.015; van Wijk Klaas J., 2007, V355, P43; VANWIJK KJ, 2007, PHOTOSYNTHESIS COMPR, pCH8; Villarejo A, 2005, NAT CELL BIOL, V7, P1224, DOI 10.1038/ncb1330; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Wang BC, 2006, PROTEOMICS, V6, P2555, DOI 10.1002/pmic.200500657; Whitelegge JP, 2004, PLANT PHYSIOL BIOCH, V42, P919, DOI 10.1016/j.plaphy.2004.11.005; Wisniewski JR, 2007, MOL CELL PROTEOMICS, V6, P72, DOI 10.1074/mcp.M600255-MCP200; Ytterberg AJ, 2006, PLANT PHYSIOL, V140, P984, DOI 10.1104/pp.105.076083; Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273; Zybailov B, 2005, ANAL CHEM, V77, P6218, DOI 10.1021/ac050846r; Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n	80	509	645	3	96	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1994	10.1371/journal.pone.0001994	http://dx.doi.org/10.1371/journal.pone.0001994			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431481	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700016
J	Westhoff, MA; Zhou, S; Bachem, MG; Debatin, KM; Fulda, S				Westhoff, M. A.; Zhou, S.; Bachem, M. G.; Debatin, K. M.; Fulda, S.			Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells	ONCOGENE			English	Article						cell adhesion-mediated drug resistance; glioblastoma; apoptosis	GAP JUNCTIONAL COMMUNICATION; DE-NOVO; TUMOR MICROENVIRONMENT; GLYCYRRHETINIC ACID; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; STEM-CELLS; IN-VITRO; BRAIN; SURVIVAL	The failure of malignant cells to undergo apoptosis is a major obstacle in cancer therapy, and thus identifying the underlining molecules involved therein is imperative for improving patient survival. An important mechanism of drug resistance is cell adhesion-mediated drug resistance (CAM-DR). In this study we identify a novel switch by which glioblastoma multiforme (GBM) cells alter the mode of CAM-DR. In the absence of a microenvironmental cue provided by components of the extracellular matrix (ECM), GBM cells are able to employ an alternative, but equally effective, mode of CAM-DR by forming spheres via cell-cell interactions. Intriguingly, when inhibiting cell-cell interactions in the absence of ECM components, either by low cell density or by inhibition of gap junctions (intercellular connexin tunnels) through chemical inhibition with carbenoxyolone or coincubation with the connexin-mimicking Gap27 Cx37,43 peptide, GBM cells were sensitized to tumor necrosis factor-related apoptosis- inducing ligand- and CD95-induced apoptosis. By demonstrating that GBM cells can alternate from one form of CAM-DR (cell-substrate tethering) to another (homocellular cell-cell adhesion) and that inhibition of both forms is necessary for apoptosis sensitization, our findings not only have important implications for novel approaches to restore defective apoptosis programs, but also reveal a novel role of gap junctions in GBM.	[Westhoff, M. A.; Debatin, K. M.; Fulda, S.] Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; [Zhou, S.; Bachem, M. G.] Univ Ulm, Dept Clin Chem, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Ministry of Science; Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Ministry of Science(Ministry of Science, ICT & Future Planning, Republic of Korea); Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	We thank M Adam-Jager and S Piater for expert technical assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Ministry of Science, Research and Arts of Baden-Wurttemberg, IZKF Ulm, Wilhelm-Sander-Stiftung and Else-Kroner-Fresenius-Stiftung (to SF and KMD).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Calaora V, 2001, J NEUROSCI, V21, P4740, DOI 10.1523/JNEUROSCI.21-13-04740.2001; Cheng AW, 2004, DEV BIOL, V272, P203, DOI 10.1016/j.ydbio.2004.04.031; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Elliott Tony, 2002, Expert Rev Anticancer Ther, V2, P449, DOI 10.1586/14737140.2.4.449; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Fulda S, 1997, CANCER RES, V57, P3823; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; GLADSON CL, 1995, J CELL SCI, V108, P947; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; Green LM, 2005, RADIAT RES, V163, P172, DOI 10.1667/RR3297; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Hazlehurst LA, 2003, CANCER RES, V63, P7900; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Huang RP, 1998, CANCER RES, V58, P5089; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Krysko DV, 2005, APOPTOSIS, V10, P459, DOI 10.1007/s10495-005-1875-2; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Levin V A, 1999, Neuro Oncol, V1, P69, DOI 10.1093/neuonc/1.1.69; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Oloumi A, 2000, CANCER RES, V60, P5747; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Schmid-Kotsas A, 1999, AM J PATHOL, V155, P1749, DOI 10.1016/S0002-9440(10)65490-9; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; Shain KH, 2001, MOL CANCER THER, V1, P69; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; SUTHERLAND RM, 1972, BRIT J RADIOL, V45, P788, DOI 10.1259/0007-1285-45-538-788; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wei CJ, 2005, J BIOL CHEM, V280, P19925, DOI 10.1074/jbc.M412921200; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhang W, 1999, CANCER RES, V59, P1994	41	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5169	5181		10.1038/onc.2008.148	http://dx.doi.org/10.1038/onc.2008.148			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469856				2022-12-25	WOS:000258915100001
J	Tapia-Paez, I; Tammimies, K; Massinen, S; Roy, AL; Kere, J				Tapia-Paez, Isabel; Tammimies, Kristiina; Massinen, Satu; Roy, Ananda L.; Kere, Juha			The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia	FASEB JOURNAL			English	Article						complex disease; regulation of transcription; learning disability; reading impairment	FAMILY-BASED ASSOCIATION; DEVELOPMENTAL DYSLEXIA; CANDIDATE GENE; SUSCEPTIBILITY LOCUS; READING-DISABILITY; INITIATOR ELEMENT; CHROMOSOME 15Q; TERM-MEMORY; EXPRESSION; SUPPORT	DYX1C1 was first identified as a candidate gene for dyslexia susceptibility, and its role in controlling neuronal migration during embryogenesis and effect on learning in rodents have been verified. In contrast, genetic association studies have been ambiguous in replicating its effects on dyslexia. To better understand the regulation of DYX1C1 and the possible functional role of genetic variation in the promoter of DYX1C1, we selected three single-nucleotide polymorphisms (SNPs) with predicted functional consequences or suggested associations to dyslexia for detailed study. Electrophoretic mobility shift assays suggested the allele-specific binding of the transcription factors TFII-I (to rs3743205) and Sp1 (to rs16787 and rs12899331) that could be verified by competition assays. In addition, we purified a complex of protein factors binding to the previously suggested dyslexia-related SNP, -3G/A (rs3743205). Three proteins, TFII-I, PARP1, and SFPQ, were unambiguously identified by mass spectrometry and protein sequencing. Two SNPs, rs16787 and rs3743205, showed significant allelic differences in luciferase assays. Our results show that TFII-I, PARP1, and SFPQ proteins, each previously implicated in gene regulation, form a complex controlling transcription of DYX1C1. Furthermore, allelic differences in the promoter or 5' untranslated region of DYX1C1 may affect factor binding and thus regulation of the gene.	[Massinen, Satu; Kere, Juha] Univ Helsinki, Dept Med Genet, Helsinki, Finland; [Roy, Ananda L.] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; [Tapia-Paez, Isabel; Tammimies, Kristiina; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	University of Helsinki; Tufts University; Karolinska Institutet	Kere, J (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Halsovagen 7-9, S-14157 Stockholm, Sweden.	juha.kere@biosci.ki.se	Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Tapia-Páez, Isabel/N-1210-2013; Tapia-Páez, Isabel/ABD-7197-2021	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Tapia-Paez, Isabel/0000-0002-0535-4233; Tammimies, Kristiina/0000-0002-8324-4697	NICHD NIH HHS [R01 HD046034, HD046034] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046034] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; Anthoni H, 2007, HUM MOL GENET, V16, P667, DOI 10.1093/hmg/ddm009; Bellini G, 2005, J MOL NEUROSCI, V27, P311, DOI 10.1385/JMN:27:3:311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Cope NA, 2005, MOL PSYCHIATR, V10, P237, DOI 10.1038/sj.mp.4001596; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; GALABURDA AM, 1979, ANN NEUROL, V6, P94, DOI 10.1002/ana.410060203; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Grigorenko EL, 2003, P NATL ACAD SCI USA, V100, P11190, DOI 10.1073/pnas.2134926100; Grigorenko EL, 1997, AM J HUM GENET, V60, P27; Grigorenko EL, 2001, AM J MED GENET, V105, P120, DOI 10.1002/1096-8628(20010108)105:1<120::AID-AJMG1075>3.3.CO;2-K; Hannula-Jouppi K, 2005, PLOS GENET, V1, P467, DOI 10.1371/journal.pgen.0010050; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hatip-Al-Khatib I, 2004, LIFE SCI, V75, P1967, DOI 10.1016/j.lfs.2004.05.014; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lowery LA, 2007, DEV DYNAM, V236, P1347, DOI 10.1002/dvdy.21132; Marino C, 2007, GENES BRAIN BEHAV, V6, P640, DOI 10.1111/j.1601-183X.2006.00291.x; Marino C, 2005, EUR J HUM GENET, V13, P491, DOI 10.1038/sj.ejhg.5201356; Meng HY, 2005, P NATL ACAD SCI USA, V102, P17053, DOI 10.1073/pnas.0508591102; Miscimarra L, 2007, HUM HERED, V63, P47, DOI 10.1159/000098727; Morris DW, 2000, HUM MOL GENET, V9, P843, DOI 10.1093/hmg/9.5.843; Nopola-Hemmi J, 2000, J MED GENET, V37, P771, DOI 10.1136/jmg.37.10.771; Ogura Y, 2006, GENES CELLS, V11, P373, DOI 10.1111/j.1365-2443.2006.00952.x; Paracchini S, 2006, HUM MOL GENET, V15, P1659, DOI 10.1093/hmg/ddl089; Preuss TM, 2004, NAT REV GENET, V5, P850, DOI 10.1038/nrg1469; RABIN M, 1993, LANCET, V342, P178, DOI 10.1016/0140-6736(93)91384-X; Rico-Bautista E, 2004, EXP CELL RES, V294, P269, DOI 10.1016/j.yexcr.2003.11.017; Rosen GD, 2007, CEREB CORTEX, V17, P2562, DOI 10.1093/cercor/bhl162; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Sambrook J, 2001, MOL CLONING LAB MANU; Scerri TS, 2004, J MED GENET, V41, P853, DOI 10.1136/jmg.2004.018341; Schulte-Korne G, 1998, AM J HUM GENET, V63, P279, DOI 10.1086/301919; Schumacher J, 2006, AM J HUM GENET, V78, P52, DOI 10.1086/498992; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Taipale M, 2003, P NATL ACAD SCI USA, V100, P11553, DOI 10.1073/pnas.1833911100; Temple CM, 2003, J NEUROLINGUIST, V16, P457, DOI 10.1016/S0911-6044(01)00044-6; Threlkeld SW, 2007, BRAIN RES BULL, V71, P508, DOI 10.1016/j.brainresbull.2006.11.005; Tzenova J, 2004, AM J MED GENET B, V127B, P117, DOI 10.1002/ajmg.b.20139; Wang Y, 2006, NEUROSCIENCE, V143, P515, DOI 10.1016/j.neuroscience.2006.08.022; Wigg KG, 2004, MOL PSYCHIATR, V9, P1111, DOI 10.1038/sj.mp.4001543; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x	46	60	61	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3001	3009		10.1096/fj.07-104455	http://dx.doi.org/10.1096/fj.07-104455			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18445785	Green Published			2022-12-25	WOS:000258089300040
J	Fukaya, Y; Shimada, H; Wang, LC; Zandi, E; DeClerck, YA				Fukaya, Yasushi; Shimada, Hiroyuki; Wang, Ling-Chi; Zandi, Ebrahim; DeClerck, Yves A.			Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MAC-2-BINDING PROTEIN; EXTRACELLULAR-MATRIX; METASTASIS; NEUROBLASTOMA; ACTIVATOR; MOLECULE; 90K; MICROENVIRONMENT; MECHANISMS	We have previously demonstrated that neuroblastoma cells increase the expression of interleukin-6 by bone marrow stromal cells and that stimulation does not require cell-cell contact. In this study we report the purification and identification of a protein secreted by neuroblastoma cells that stimulates interleukin-6 production by stromal cells. Using a series of chromatographic purification steps including heparin-affinity, ion exchange, and molecular sieve chromatography followed by trypsin digestion and liquid chromatography tandem mass spectrometry, we identified in serum-free conditioned medium of neuroblastoma cells several secreted peptides including galectin-3-binding protein, also known as 90-kDa Mac-2-binding protein. We demonstrated the presence of the galectin-3-binding protein in the conditioned medium of several neuroblastoma cell lines and in chromatographic fractions with interleukin-6 stimulatory activity. Consistently, bone marrow stromal cells express galectin-3, the receptor for galectin-3-binding protein. Supporting a role for galectin-3-binding protein in stimulating interleukin-6 expression in bone marrow stromal cells, we observed that recombinant galectin-3-binding protein stimulated interleukin-6 expression in these cells and that interleukin-6 stimulation by neuroblastoma-conditioned medium was inhibited in the presence of lactose or a neutralizing anti-galectin-3 antibody. Down-regulation of galectin-3-binding protein expression in neuroblastoma cells also decreased the interleukin-6 stimulatory activity of the conditioned medium on bone marrow stromal cells. We also provide evidence that stimulation of interleukin-6 by galectin-3-binding protein involves activation of the Erk1/2 pathway. The data, thus, identifies galectin-3-binding protein as a factor secreted by neuroblastoma cells that stimulates the expression of interleukin-6 in bone marrow stromal cells and provides a novel function for this protein in cancer progression.	[DeClerck, Yves A.] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; [Fukaya, Yasushi; DeClerck, Yves A.] Univ So Calif, Keck Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA; [Fukaya, Yasushi; DeClerck, Yves A.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; [Shimada, Hiroyuki] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90027 USA; [Wang, Ling-Chi; Zandi, Ebrahim] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90027 USA; [DeClerck, Yves A.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	DeClerck, YA (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, 4650 Sunset Blvd,MailStop 54, Los Angeles, CA 90027 USA.	declerck@usc.edu		DeClerck, Yves/0000-0002-3688-0113				Akahani S, 1997, CANCER RES, V57, P5272; Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Bonfil RD, 2007, UROL ONCOL-SEMIN ORI, V25, P407, DOI 10.1016/j.urolonc.2007.05.008; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Fukumori T, 2006, CANCER RES, V66, P3114, DOI 10.1158/0008-5472.CAN-05-3750; Gordower L, 1999, NEUROPATH APPL NEURO, V25, P319; HAJTO T, 1990, CANCER RES, V50, P3322; Honjo Y, 2001, CLIN CANCER RES, V7, P661; Hurley MM, 1996, J BONE MINER RES, V11, P760; Inohara H, 1996, CANCER RES, V56, P4530; Kalayci O, 2004, ANN ALLERG ASTHMA IM, V93, P485, DOI 10.1016/S1081-1206(10)61417-2; Kobayashi D, 2007, EUR J PHARMACOL, V573, P249, DOI 10.1016/j.ejphar.2007.07.058; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Marchetti A, 2002, CANCER RES, V62, P2535; Michigami T, 2001, CANCER RES, V61, P1637; Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; PIENTA KJ, 1995, J NATL CANCER I, V87, P348, DOI 10.1093/jnci/87.5.348; POWELL TJ, 1995, J IMMUNOTHER, V17, P209, DOI 10.1097/00002371-199505000-00003; Rao SP, 2007, J IMMUNOL, V179, P7800, DOI 10.4049/jimmunol.179.11.7800; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Satelli A, 2008, ONCOL REP, V19, P587; Shalom-Feuerstein R, 2005, CANCER RES, V65, P7292, DOI 10.1158/0008-5472.CAN-05-0775; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008-5472.CAN-04-2853; Sohara Y, 2003, CANCER RES, V63, P3026; Sugiura Y, 1999, CANCER RES, V59, P1327; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; Ulmer TA, 2006, J CELL BIOCHEM, V98, P1351, DOI 10.1002/jcb.20784; Urashima M, 1997, BLOOD, V90, P279; van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008-5472.CAN-05-1448; Wang LC, 2008, PROTEOMICS, V8, P1758, DOI 10.1002/pmic.200700931	42	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18573	18581		10.1074/jbc.M803115200	http://dx.doi.org/10.1074/jbc.M803115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18450743	hybrid			2022-12-25	WOS:000257165600013
J	Rotem, S; Katz, C; Benyamini, H; Lebendiker, M; Veprintsev, D; Ruediger, S; Danieli, T; Friedler, A				Rotem, Shahar; Katz, Chen; Benyamini, Hadar; Lebendiker, Mario; Veprintsev, Dmitry; Ruediger, Stefan; Danieli, Tsafi; Friedler, Assaf			The structure and interactions of the proline-rich domain of ASPP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSICALLY UNSTRUCTURED PROTEINS; NATIVELY UNFOLDED PROTEINS; N-TERMINAL DOMAIN; PEPTIDE ARRAYS; SH3 DOMAINS; P53-BINDING PROTEIN; SECONDARY STRUCTURE; DISORDERED PROTEIN; APOPTOTIC FUNCTION; HIV-1 INTEGRASE	ASPP2 is a pro-apoptotic protein that stimulates the p53-mediated apoptotic response. The C terminus of ASPP2 contains ankyrin (Ank) repeats and a SH3 domain, which mediate its interactions with numerous partner proteins such as p53, NF kappa B, and Bcl-2. It also contains a proline-rich domain (ASPP2 Pro), whose structure and function are unclear. Here we used biophysical and biochemical methods to study the structure and the interactions of ASPP2 Pro, to gain insight into its biological role. We show, using biophysical and computational methods, that the ASPP2 Pro domain is natively unfolded. We found that the ASPP2 Pro domain interacts with the ASPP2 Ank-SH3 domains, and mapped the interaction sites in both domains. Using a combination of peptide array screening, biophysical and biochemical techniques, we found that ASPP2 Ank-SH3, but not ASPP2 Pro, mediates interactions of ASPP2 with peptides derived from its partner proteins. ASPP2 Pro-Ank-SH3 bound a peptide derived from its partner protein NF kappa B weaker than ASPP2 Ank-SH3 bound this peptide. This suggested that the presence of the proline-rich domain inhibited the interactions mediated by the Ank-SH3 domains. Furthermore, a peptide from ASPP2 Pro competed with a peptide derived from NF kappa B on binding to ASPP2 Ank-SH3. Based on our results, we propose a model in which the interaction between the ASPP2 domains regulates the intermolecular interactions of ASPP2 with its partner proteins.	[Rotem, Shahar; Katz, Chen; Benyamini, Hadar; Friedler, Assaf] Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Inst Chem, IL-91904 Jerusalem, Israel; [Lebendiker, Mario; Danieli, Tsafi] Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Prot Express & Purificat Facil, IL-91904 Jerusalem, Israel; [Veprintsev, Dmitry] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Ruediger, Stefan] Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands	Hebrew University of Jerusalem; Hebrew University of Jerusalem; MRC Laboratory Molecular Biology; Utrecht University	Friedler, A (corresponding author), Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Inst Chem, Safra Campus, IL-91904 Jerusalem, Israel.	assaf@chem.ch.huji.ac.il	Veprintsev, Dmitry B/H-2228-2012; Rüdiger, Stefan GD/G-4906-2012	Veprintsev, Dmitry B/0000-0002-3583-5409; Rüdiger, Stefan GD/0000-0002-1807-2972				Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Cao YH, 2004, BIOCHEM BIOPH RES CO, V315, P788, DOI 10.1016/j.bbrc.2004.01.124; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Cheng JL, 2005, DATA MIN KNOWL DISC, V11, P213, DOI 10.1007/s10618-005-0001-y; Cherny I, 2005, J BIOL CHEM, V280, P30063, DOI 10.1074/jbc.M506220200; Coeytaux K, 2005, BIOINFORMATICS, V21, P1891, DOI 10.1093/bioinformatics/bti266; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Ferron F, 2006, PROTEINS, V65, P1, DOI 10.1002/prot.21075; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; HAYOUKA Z, 2008, BIOPOLYMERS IN PRESS; Hayouka Z, 2007, P NATL ACAD SCI USA, V104, P8316, DOI 10.1073/pnas.0700781104; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Liu JF, 2003, NUCLEIC ACIDS RES, V31, P3833, DOI 10.1093/nar/gkg515; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Mondigler M, 1996, J BACTERIOL, V178, P2986, DOI 10.1128/jb.178.10.2986-2988.1996; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Obradovic Z, 2005, PROTEINS, V61, P176, DOI 10.1002/prot.20735; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Robinson RA, 2008, STRUCTURE, V16, P259, DOI 10.1016/j.str.2007.11.012; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525; Tidow H, 2007, J MOL BIOL, V371, P948, DOI 10.1016/j.jmb.2007.05.024; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Uversky VN, 2002, FEBS LETT, V522, P9, DOI 10.1016/S0014-5793(02)02883-1; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Weinberg RL, 2004, J MOL BIOL, V342, P801, DOI 10.1016/j.jmb.2004.07.042; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhao L, 2003, BIOORG MED CHEM LETT, V13, P1175, DOI 10.1016/S0960-894X(03)00040-4; Zhu ZY, 2005, J BIOL CHEM, V280, P34473, DOI 10.1074/jbc.M503736200	58	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18990	18999		10.1074/jbc.M708717200	http://dx.doi.org/10.1074/jbc.M708717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18448430	Green Published, hybrid			2022-12-25	WOS:000257165600055
J	Tetzlaff, JE; Putcha, P; Outeiro, TF; Ivanov, A; Berezovska, O; Hyman, BT; McLean, PJ				Tetzlaff, Julie E.; Putcha, Preeti; Outeiro, Tiago F.; Ivanov, Alexander; Berezovska, Oksana; Hyman, Bradley T.; McLean, Pamela J.			CHIP targets toxic alpha-synuclein oligomers for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PARKINSONS-DISEASE; IN-VITRO; CHAPERONE FUNCTIONS; CARBOXYL-TERMINUS; AGGREGATION; TAU; HSP70; UBIQUITINATION; NEUROTOXICITY	alpha-Synuclein (alpha Syn) can self-associate, forming oligomers, fibrils, and Lewy bodies, the pathological hallmark of Parkinson disease. Current dogma suggests that oligomeric alpha Syn intermediates may represent the most toxic alpha Syn species. Here, we studied the effect of a potent molecular chaperone, CHIP ( carboxyl terminus of Hsp70- interacting protein), on alpha Syn oligomerization using a novel bimolecular fluorescence complementation assay. CHIP is a multidomain chaperone, utilizing both a tetratricopeptide/Hsp70 binding domain and a U-box/ubiquitin ligase domain to differentially impact the fate of misfolded proteins. In the current study, we found that co-expression of CHIP selectively reduced alpha Syn oligomerization and toxicity in a tetratricopeptide domain-dependent, U-box-independent manner by specifically degrading toxic alpha Syn oligomers. We conclude that CHIP preferentially recognizes and mediates degradation of toxic, oligomeric forms of alpha Syn. Further elucidation of the mechanisms of CHIP-induced degradation of oligomeric alpha Syn may contribute to the successful development of drug therapies that target oligomeric alpha Syn by mimicking or enhancing the powerful effects of CHIP.	[Tetzlaff, Julie E.; Putcha, Preeti; Outeiro, Tiago F.; Ivanov, Alexander; Berezovska, Oksana; Hyman, Bradley T.; McLean, Pamela J.] Massachusetts Gen Hosp, Alzheimer Dis Res Unit, Dept Neurol, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	McLean, PJ (corresponding author), Massachusetts Gen Hosp, Alzheimer Dis Res Unit, Dept Neurol, MassGen Inst Neurodegenerat Dis, 114 16th St, Charlestown, MA 02129 USA.	pmclean@partners.org	Outeiro, Tiago/L-7351-2019; Outeiro, Tiago/M-8106-2019; Outeiro, Tiago F/C-1067-2008; Tetzlaff, Julie/ABA-3395-2021	Outeiro, Tiago/0000-0003-1679-1727; Outeiro, Tiago F/0000-0003-1679-1727; McLean, Pamela/0000-0003-4870-5715	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063963, P50NS038372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG005134, P30 AG062421] Funding Source: Medline; NINDS NIH HHS [P50 NS038372-080001, P50 NS038372, R01 NS063963, P50 NS038372-030001, R01 NS063963-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Choi JY, 2007, MOL CELL NEUROSCI, V34, P69, DOI 10.1016/j.mcn.2006.10.002; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Evans CG, 2006, J BIOL CHEM, V281, P33182, DOI 10.1074/jbc.M606192200; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kumar P, 2007, HUM MOL GENET, V16, P848, DOI 10.1093/hmg/ddm030; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Li WX, 2005, J NEUROCHEM, V93, P1542, DOI 10.1111/j.1471-4159.2005.03146.x; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Novoselova TV, 2005, J NEUROCHEM, V94, P597, DOI 10.1111/j.1471-4159.2005.03119.x; Outeiro TF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001867; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Rosser MFN, 2007, J BIOL CHEM, V282, P22267, DOI 10.1074/jbc.M700513200; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Tetzlaff J, 2007, J NEUROENDOCRINOL, V19, P383, DOI 10.1111/j.1365-2826.2007.01538.x; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j	30	133	135	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17962	17968		10.1074/jbc.M802283200	http://dx.doi.org/10.1074/jbc.M802283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18436529	Green Accepted, hybrid			2022-12-25	WOS:000256949200025
J	Gohler, A; Xiong, GM; Paulsen, S; Trentmann, G; Maser, E				Goehler, Andre; Xiong, Guangming; Paulsen, Simone; Trentmann, Gabriele; Maser, Edmund			Testosterone-inducible regulator is a kinase that drives steroid sensing and metabolism in Comamonas testosteroni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-ALPHA-HYDROXYSTEROID DEHYDROGENASE/CARBONYL REDUCTASE; DEGRADATION GENE-CLUSTER; PSEUDOMONAS-TESTOSTERONI; MICROBIOLOGICAL DEGRADATION; ANTIBIOTIC-RESISTANCE; HISTIDINE KINASE; SIDE-CHAIN; BACTERIA; IDENTIFICATION; CLEAVAGE	The mechanism of gene regulation by steroids in bacteria is still a mystery. We use steroid-inducible 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase (3 alpha-HSD/CR) as a reporter system to study steroid signaling in Comamonas testosteroni. In previous investigations we cloned and characterized the 3 alpha-HSD/CR-encoding gene, hsdA. In addition, we identified two negative regulator genes (repA and repB) in the vicinity of hsdA, the protein products which repress hsdA expression on the level of transcription and translation, respectively. Recently, a positive regulator of hsdA expression, TeiR (testosterone-inducible regulator), was found by transposon mutagenesis, but the mode of its action remained obscure. In the present work we produced a TeiR-green fluorescent fusion protein and showed that TeiR is a membrane protein with asymmetrical localization at one of the cell poles of C. testosteroni. Knock-out mutants of the teiR gene revealed that TeiR provides swimming and twitching motility of C. testosteroni to the steroid substrate source. TeiR also mediated an induced expression of 3 alpha-HSD/CR which was paralleled by an enhanced catabolism of testosterone. We also found that TeiR responds to a variety of different steroids other than testosterone. Biochemical analysis with several deletion mutants of the teiR gene revealed TeiR to consist of three different functional domains, an N-terminal domain important for membrane association, a central steroid binding site, and a C-terminal part mediating TeiR function. Finally, we could demonstrate that TeiR works as a kinase in the steroid signaling chain in C. testosteroni. Overall, we provide evidence that TeiR mediates steroid sensing and metabolism in C. testosteroni via its steroid binding and kinase activity.	[Goehler, Andre; Xiong, Guangming; Paulsen, Simone; Trentmann, Gabriele; Maser, Edmund] Univ Med Sch Schleswig Holstein, Inst Toxicol & Pharmacol Nat Scientists, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Maser, E (corresponding author), Univ Med Sch Schleswig Holstein, Inst Toxicol & Pharmacol Nat Scientists, Campus Kiel,Brunswiker Str 10, D-24105 Kiel, Germany.	maser@toxi.uni-kiel.de	Goehler, André/AAZ-7067-2020; Maser, Edmund/B-1728-2010	Goehler, André/0000-0002-4006-3511; 				AHMAD D, 1990, GENE, V86, P53, DOI 10.1016/0378-1119(90)90113-6; ARAI H, 1991, AGR BIOL CHEM TOKYO, V55, P2431; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Arda B, 2003, APMIS, V111, P474, DOI 10.1034/j.1600-0463.2003.1110404.x; BARBARO DJ, 1987, REV INFECT DIS, V9, P124; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bishop GJ, 2001, PLANT CELL PHYSIOL, V42, P114, DOI 10.1093/pcp/pce018; BOYER J, 1965, BIOCHEMISTRY-US, V4, P1825, DOI 10.1021/bi00885a020; BRADFORD MM, 1976, NATURE, V72, P248; BUSSE HJ, 1992, INT J SYST BACTERIOL, V42, P19, DOI 10.1099/00207713-42-1-19; COULTER AW, 1968, J BIOL CHEM, V243, P3238; Florin C, 1996, J BACTERIOL, V178, P3322, DOI 10.1128/jb.178.11.3322-3330.1996; GIBSON DT, 1966, J BIOL CHEM, V241, P551; Hefti MH, 2004, EUR J BIOCHEM, V271, P1198, DOI 10.1111/j.1432-1033.2004.04023.x; Horinouchi M, 2005, APPL ENVIRON MICROB, V71, P5275, DOI 10.1128/AEM.71.9.5275-5281.2005; Horinouchi M, 2004, J STEROID BIOCHEM, V92, P143, DOI 10.1016/j.jsbmb.2004.09.002; Horinouchi M, 2004, BIOCHEM BIOPH RES CO, V324, P597, DOI 10.1016/j.bbrc.2004.09.096; Horinouchi M, 2003, APPL ENVIRON MICROB, V69, P4421, DOI 10.1128/AEM.69.8.4421-4430.2003; Horinouchi M, 2003, APPL ENVIRON MICROB, V69, P2139, DOI 10.1128/AEM.69.4.2139-2152.2003; Khorchid A, 2006, INT J BIOCHEM CELL B, V38, P307, DOI 10.1016/j.biocel.2005.08.018; KIESLICH K, 1985, J BASIC MICROB, V25, P461, DOI 10.1002/jobm.3620250713; KOOLMAN J, 1990, PROG CLIN BIOL RES, V342, P704; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont R, 2007, ECOTOXICOLOGY, V16, P109, DOI 10.1007/s10646-006-0113-1; Lybarger SR, 2001, J BACTERIOL, V183, P3261, DOI 10.1128/JB.183.11.3261-3267.2001; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCUS PI, 1956, J BIOL CHEM, V218, P661; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; Morgan CA, 1996, CAN J MICROBIOL, V42, P423, DOI 10.1139/m96-058; OPPERMANN UCT, 1993, ADV EXP MED BIOL, V328, P379; Oppermann UCT, 1996, J STEROID BIOCHEM, V58, P217, DOI 10.1016/0960-0760(96)00021-0; Oppermann UCT, 1996, EUR J BIOCHEM, V241, P744, DOI 10.1111/j.1432-1033.1996.00744.x; Pruneda-Paz JL, 2004, J BACTERIOL, V186, P1430, DOI 10.1128/JB.186.5.1430-1437.2004; Sambrook J, 2001, MOL CLONING LAB MANU; SIH CJ, 1968, BIOCHEMISTRY-US, V7, P796, DOI 10.1021/bi00842a038; SIH CJ, 1966, J BIOL CHEM, V241, P540; Skowasch D, 2002, BIOCHEM BIOPH RES CO, V294, P560, DOI 10.1016/S0006-291X(02)00516-8; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TAMAOKA J, 1987, INT J SYST BACTERIOL, V37, P52, DOI 10.1099/00207713-37-1-52; WATANABE M, 1974, BIOCHIM BIOPHYS ACTA, P419; Xiong GM, 2003, J BIOL CHEM, V278, P47400, DOI 10.1074/jbc.M309210200; Xiong GM, 2001, J BIOL CHEM, V276, P9961, DOI 10.1074/jbc.M010962200; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	46	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17380	17390		10.1074/jbc.M710166200	http://dx.doi.org/10.1074/jbc.M710166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18424443	hybrid			2022-12-25	WOS:000256720600047
J	Yuen, EY; Jiang, Q; Chen, P; Feng, J; Yan, Z				Yuen, Eunice Y.; Jiang, Qian; Chen, Paul; Feng, Jian; Yan, Zhen			Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of N-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; SEROTONIN RECEPTORS; MEMBRANE EXCITABILITY; HIPPOCAMPAL-NEURONS; PROTEIN-2 MAP2; MESSENGER-RNAS; PHOSPHORYLATION; SCHIZOPHRENIA; KINASE; ANXIETY	Abnormal serotonin-glutamate interaction in prefrontal cortex (PFC) is implicated in the pathophysiology of many mental disorders, including schizophrenia and depression. However, the mechanisms by which this interaction occurs remain unclear. Our previous study has shown that activation of 5-HT1A receptors inhibits N-methyl-D-aspartate (NMDA) receptor (NMDAR) currents in PFC pyramidal neurons by disrupting microtubule-based transport of NMDARs. Here we found that activation of 5-HT2A/C receptors significantly attenuated the effect of 5-HT1A on NMDAR currents and microtubule depolymerization. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of synaptic NMDAR response was also observed in PFC pyramidal neurons from intact animals treated with various 5-HT-related drugs. Moreover, 5-HT2A/C stimulation triggered the activation of extracellular signal-regulated kinase (ERK) in dendritic processes. Inhibition of the beta-arrestin/Src/dynamin signaling blocked 5-HT2A/C activation of ERK and the counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR currents. Immunocytochemical studies showed that 5-HT2A/C treatment blocked the inhibitory effect of 5-HT1A on surface NR2B clusters on dendrites, which was prevented by cellular knockdown of beta-arrestins. Taken together, our study suggests that serotonin, via 5-HT1A and 5-HT2A/C receptor activation, regulates NMDAR functions in PFC neurons in a counteractive manner. 5-HT2A/C, by activating ERK via the beta-arrestin-dependent pathway, opposes the 5-HT1A disruption of microtubule stability and NMDAR transport. These findings provide a framework for understanding the complex interactions between serotonin and NMDARs in PFC, which could be important for cognitive and emotional control in which both systems are highly involved.	[Yuen, Eunice Y.; Jiang, Qian; Chen, Paul; Feng, Jian; Yan, Zhen] SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu			NIMH NIH HHS [MH63128, R01 MH063128] Funding Source: Medline; NINDS NIH HHS [NS48911, R01 NS048911] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048911] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aghajanian GK, 1999, BRAIN RES, V825, P161, DOI 10.1016/S0006-8993(99)01224-X; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Amargos-Bosch M, 2004, CEREB CORTEX, V14, P281, DOI 10.1093/cercor/bhg128; Andrade R, 1998, ANN NY ACAD SCI, V861, P190, DOI 10.1111/j.1749-6632.1998.tb10191.x; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; Artigas F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0; Arvanov VL, 1999, EUR J NEUROSCI, V11, P3064, DOI 10.1046/j.1460-9568.1999.00726.x; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Boyer PA, 1998, J MOL NEUROSCI, V10, P219, DOI 10.1007/BF02761776; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; Buhot MC, 1997, CURR OPIN NEUROBIOL, V7, P243, DOI 10.1016/S0959-4388(97)80013-X; Bunin MA, 1999, TRENDS NEUROSCI, V22, P377, DOI 10.1016/S0166-2236(99)01410-1; Burnet PWJ, 1996, NEUROPSYCHOPHARMACOL, V15, P442, DOI 10.1016/S0893-133X(96)00053-X; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; DEAKIN JFW, 1988, PHARMACOL BIOCHEM BE, V29, P819, DOI 10.1016/0091-3057(88)90215-8; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Guillaud L, 2003, J NEUROSCI, V23, P131; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; Jakab RL, 1998, P NATL ACAD SCI USA, V95, P735, DOI 10.1073/pnas.95.2.735; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8; Kia HK, 1996, J NEUROSCI RES, V46, P697; Law AJ, 2001, NEUROREPORT, V12, P2971, DOI 10.1097/00001756-200109170-00043; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mao LM, 2004, EUR J NEUROSCI, V19, P1207, DOI 10.1111/j.1460-9568.2004.03223.x; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; Miller EK, 1999, NEURON, V22, P15, DOI 10.1016/S0896-6273(00)80673-X; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENINGTON NJ, 1990, NEURON, V4, P751, DOI 10.1016/0896-6273(90)90201-P; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SCHREIBER R, 1993, PROG NEURO-PSYCHOPH, V17, P87, DOI 10.1016/0278-5846(93)90034-P; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Trantham-Davidson H, 2004, J NEUROSCI, V24, P10652, DOI 10.1523/JNEUROSCI.3179-04.2004; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wang X, 2003, J NEUROSCI, V23, P9852; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Yuen EY, 2005, J NEUROSCI, V25, P5488, DOI 10.1523/JNEUROSCI.1187-05.2005; Yuen EY, 2005, J BIOL CHEM, V280, P29420, DOI 10.1074/jbc.M504499200	52	100	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17194	17204		10.1074/jbc.M801713200	http://dx.doi.org/10.1074/jbc.M801713200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442977	Green Published, hybrid			2022-12-25	WOS:000256720600028
J	Coustou, V; Biran, M; Breton, M; Guegan, F; Riviere, L; Plazolles, N; Nolan, D; Barrett, MP; Franconi, JM; Bringaud, F				Coustou, Virginie; Biran, Marc; Breton, Marc; Guegan, Fabien; Riviere, Loic; Plazolles, Nicolas; Nolan, Derek; Barrett, Michael P.; Franconi, Jean-Michel; Bringaud, Frederic			Glucose-induced remodeling of intermediary and energy metabolism in procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE LEVEL PHOSPHORYLATION; DEPENDENT FUMARATE REDUCTASE; INDUCIBLE EXPRESSION SYSTEM; SUCCINATE COA-TRANSFERASE; RNA INTERFERENCE; RESPIRATORY-CHAIN; CULTURE FORMS; KREBS CYCLE; PROLINE; DEHYDROGENASE	The procyclic form of Trypanosoma brucei is a parasitic protozoan that normally dwells in the midgut of its insect vector. In vitro, this parasite prefers D-glucose to L-proline as a carbon source, although this amino acid is the main carbon source available in its natural habitat. Here, we investigated how L-proline is metabolized in glucose-rich and glucose-depleted conditions. Analysis of the excreted end products of C-13-enriched L-proline metabolism showed that the amino acid is converted into succinate or L-alanine depending on the presence or absence of D-glucose, respectively. The fact that the pathway of L-proline metabolism was truncated in glucose-rich conditions was confirmed by the analysis of 13 separate RNA interference-harboring or knock-out cell lines affecting different steps of this pathway. For instance, RNA interference studies revealed the loss of succinate dehydrogenase activity to be conditionally lethal only in the absence of D-glucose, confirming that in glucose-depleted conditions, L-proline needs to be converted beyond succinate. In addition, depletion of the F-0/F-1-ATP synthase activity by RNA interference led to cell death in glucose-depleted medium, but not in glucose-rich medium. This implies that, in the presence of D-glucose, the importance of the F-0/F-1-ATP synthase is diminished and ATP is produced by substrate level phosphorylation. We conclude that trypanosomes develop an elaborate adaptation of their energy production pathways in response to carbon source availability.	[Biran, Marc; Franconi, Jean-Michel; Bringaud, Frederic] Univ Bordeaux 2, Ctr Resonance Magnet Syst Biol, CNRS, UMR 5536, F-33076 Bordeaux, France; [Coustou, Virginie; Breton, Marc; Guegan, Fabien; Riviere, Loic; Plazolles, Nicolas; Bringaud, Frederic] Univ Bordeaux 2, Lab Microbiol Cellulaire & Mol & Pathogenicite, CNRS, UMR 5234, F-33076 Bordeaux, France; [Nolan, Derek] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland; [Barrett, Michael P.] Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Trinity College Dublin; University of Glasgow	Bringaud, F (corresponding author), Univ Bordeaux 2, Ctr Resonance Magnet Syst Biol, CNRS, UMR 5536, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@rmsb.u-bordeaux2.fr		Nolan, Derek/0000-0002-3742-4304; Guegan, Fabien Marc/0000-0001-9393-2920; Barrett, Mike/0000-0001-9447-3519				BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Besteiro S, 2005, TRENDS PARASITOL, V21, P185, DOI 10.1016/j.pt.2005.02.008; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Bringaud F, 2006, MOL BIOCHEM PARASIT, V149, P1, DOI 10.1016/j.molbiopara.2006.03.017; Brown JM, 2005, J NEUROCHEM, V95, P429, DOI 10.1111/j.1471-4159.2005.03379.x; Brown SV, 2006, EUKARYOT CELL, V5, P45, DOI 10.1128/EC.5.1.45-53.2006; BRUN R, 1979, ACTA TROP, V36, P289; BURSELL E, 1963, B WORLD HEALTH ORGAN, V28, P703; BURSELL E, 1981, ROLE PROLINE ENERGY, P183; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; CANNATA JJB, 1984, COMP BIOCHEM PHYS B, V79, P297, DOI 10.1016/0305-0491(84)90380-8; Coustou V, 2005, J BIOL CHEM, V280, P16559, DOI 10.1074/jbc.M500343200; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; Coustou V, 2006, J BIOL CHEM, V281, P26832, DOI 10.1074/jbc.M601377200; Denicola A, 2002, COMP BIOCHEM PHYS B, V133, P23, DOI 10.1016/S1096-4959(02)00094-5; Denise H, 1999, EUR J BIOCHEM, V259, P339, DOI 10.1046/j.1432-1327.1999.00048.x; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; Ebikeme CE, 2008, PARASITOLOGY, V135, P585, DOI 10.1017/S0031182008004241; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; Fairlamb Alan H., 1986, CARBOHYDRATE METABOL; Fang J, 2002, BIOCHEMISTRY-US, V41, P3065, DOI 10.1021/bi015989w; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Harlow E., 1988, ANTIBODIES LAB MANUA; Hernandez FR, 1998, MOL BIOCHEM PARASIT, V93, P135, DOI 10.1016/S0166-6851(98)00015-2; Inoue N, 2002, MOL BIOCHEM PARASIT, V120, P309, DOI 10.1016/S0166-6851(02)00015-4; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; KLEIN RA, 1975, PARASITOLOGY, V71, P93, DOI 10.1017/S003118200005318X; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; Obungu VH, 1999, COMP BIOCHEM PHYS B, V123, P59, DOI 10.1016/S0305-0491(99)00040-1; Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; ROSS CA, 1987, ACTA TROP, V44, P293; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaraffia PY, 2003, J INSECT PHYSIOL, V49, P591, DOI 10.1016/S0022-1910(03)00031-3; Schnaufer A, 2005, EMBO J, V24, P4029, DOI 10.1038/sj.emboj.7600862; Speijer D, 1997, MOL BIOCHEM PARASIT, V85, P171, DOI 10.1016/S0166-6851(96)02823-X; Takashima E, 2002, MOL BIOCHEM PARASIT, V122, P189, DOI 10.1016/S0166-6851(02)00100-7; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; Van Hellemond JJ, 2007, EUKARYOT CELL, V6, P1693, DOI 10.1128/EC.00130-07; van Hellemond JJ, 2005, ADV MICROB PHYSIOL, V50, P199, DOI 10.1016/S0065-2911(05)50005-5; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; Vedrenne C, 2000, EUR J BIOCHEM, V267, P4850, DOI 10.1046/j.1432-1327.2000.01543.x; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	60	102	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16342	16354		10.1074/jbc.M709592200	http://dx.doi.org/10.1074/jbc.M709592200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18430732	hybrid			2022-12-25	WOS:000256497100010
J	Farhana, A; Kumar, S; Rathore, SS; Ghosh, PC; Ehtesham, NZ; Tyagi, AK; Hasnain, SE				Farhana, Aisha; Kumar, Sandeep; Rathore, Shailendra S.; Ghosh, Prahlad C.; Ehtesham, Nasreen Z.; Tyagi, Anil K.; Hasnain, Seyed E.			Mechanistic Insights into a Novel Exporter-Importer System of Mycobacterium tuberculosis Unravel Its Role in Trafficking of Iron	PLOS ONE			English	Article								Background: Elucidation of the basic mechanistic and biochemical principles underlying siderophore mediated iron uptake in mycobacteria is crucial for targeting this principal survival strategy vis-a-vis virulence determinants of the pathogen. Although, an understanding of siderophore biosynthesis is known, the mechanism of their secretion and uptake still remains elusive. Methodology/Principal Findings: Here, we demonstrate an interplay among three iron regulated Mycobacterium tuberculosis (M. tb) proteins, namely, Rv1348 (IrtA), Rv1349 (IrtB) and Rv2895c in export and import of M. tb siderophores across the membrane and the consequent iron uptake. IrtA, interestingly, has a fused N-terminal substrate binding domain (SBD), representing an atypical subset of ABC transporters, unlike IrtB that harbors only the permease and ATPase domain. SBD selectively binds to non-ferrated siderophores whereas Rv2895c exhibits relatively higher affinity towards ferrated siderophores. An interaction between the permease domain of IrtB and Rv2895c is evident from GST pull-down assay. In vitro liposome reconstitution experiments further demonstrate that IrtA is indeed a siderophore exporter and the two-component IrtB-Rv2895c system is an importer of ferrated siderophores. Knockout of msmeg_6554, the irtA homologue in Mycobacterium smegmatis, resulted in an impaired M. tb siderophore export that is restored upon complementation with M. tb irtA. Conclusion: Our data suggest the interplay of three proteins, namely IrtA, IrtB and Rv2895c in synergizing the balance of siderophores and thus iron inside the mycobacterial cell.	[Farhana, Aisha; Kumar, Sandeep] Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad, Andhra Pradesh, India; [Rathore, Shailendra S.; Ghosh, Prahlad C.; Tyagi, Anil K.] Univ Delhi, Dept Biochem, New Delhi, India; [Ehtesham, Nasreen Z.] Natl Inst Nutrit, Mol Biol Unit, Hyderabad, Andhra Pradesh, India; [Hasnain, Seyed E.] Univ Hyderabad, Dept Biochem, Hyderabad, Andhra Pradesh, India; [Hasnain, Seyed E.] Hyderabad Univ Campus, Inst Life Sci, Hyderabad, Andhra Pradesh, India; [Hasnain, Seyed E.] Jawaharlal Nehru Ctr Advanced Sci Res, Bangalore, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); University of Delhi; Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN); University of Hyderabad; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Farhana, A (corresponding author), Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad, Andhra Pradesh, India.	seh@uohyd.ernet.in	EHTESHAM, NASREEN ZAFAR/AAI-3169-2020; Farhana, Aisha/AAR-7356-2020	Hasnain, Seyed/0000-0002-2967-0791; Kumar, Sandeep/0000-0003-1249-1743; Farhana, Aisha/0000-0002-4631-2769	Council of Scientific and Industrial Research (CSIR), India [Senior Research Fellowship]; CDFD	Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India); CDFD	Senior Research Fellowship of Council of Scientific and Industrial Research (CSIR), India to Aisha Farhana. Financial support from CDFD core grants is acknowledged.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Banerjee S, 2007, J BACTERIOL, V189, P4046, DOI 10.1128/JB.00026-07; BEISEL WR, 1977, AM J CLIN NUTR, V30, P1236, DOI 10.1093/ajcn/30.8.1236; Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1111/j.1574-6976.2000.tb00550.x; Brickman TJ, 2005, J BACTERIOL, V187, P3650, DOI 10.1128/JB.187.11.3650-3661.2005; Cronje L, 2005, FEMS IMMUNOL MED MIC, V45, P103, DOI 10.1016/j.femsim.2005.02.007; Crosa JH, 1997, MICROBIOL MOL BIOL R, V61, P319, DOI 10.1128/.61.3.319-336.1997; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; De Voss JJ, 1999, J BACTERIOL, V181, P4443, DOI 10.1128/JB.181.15.4443-4451.1999; Dhar N, 2000, FEMS MICROBIOL LETT, V190, P309, DOI 10.1111/j.1574-6968.2000.tb09304.x; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fiske CH, 1925, J BIOL CHEM, V66, P375; Furrer JL, 2002, MOL MICROBIOL, V44, P1225, DOI 10.1046/j.1365-2958.2002.02885.x; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; Hoegy FO, 2005, J BIOL CHEM, V280, P20222, DOI 10.1074/jbc.M500776200; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; Krithika R, 2006, P NATL ACAD SCI USA, V103, P2069, DOI 10.1073/pnas.0507924103; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Neilands J.B., 1991, CRC HDB MICROBIAL IR, P1; PARISH T, 1998, ELECTROPORATION MYCO, P129; Prakash P, 2005, J BIOL CHEM, V280, P19641, DOI 10.1074/jbc.M413026200; Prakash P, 2005, BIOINFORMATICS, V21, P2161, DOI 10.1093/bioinformatics/bti375; Ratledge C, 2004, TUBERCULOSIS, V84, P110, DOI 10.1016/j.tube.2003.08.012; Ratledge C, 1996, MICROBIOL-UK, V142, P2207, DOI 10.1099/13500872-142-8-2207; Rindi L, 1999, BIOCHEM BIOPH RES CO, V258, P94, DOI 10.1006/bbrc.1999.0591; Rodriguez GM, 2006, J BACTERIOL, V188, P424, DOI 10.1128/JB.188.2.424-430.2006; Rodriguez GM, 2003, MOL MICROBIOL, V47, P1485, DOI 10.1046/j.1365-2958.2003.03384.x; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; Schubert S, 1999, J BACTERIOL, V181, P6387, DOI 10.1128/JB.181.20.6387-6395.1999; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Tundup S, 2006, FEBS LETT, V580, P1285, DOI 10.1016/j.febslet.2006.01.042; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; Zhu WM, 1998, MOL MICROBIOL, V29, P629, DOI 10.1046/j.1365-2958.1998.00961.x	44	44	51	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2087	10.1371/journal.pone.0002087	http://dx.doi.org/10.1371/journal.pone.0002087			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461140	gold, Green Published			2022-12-25	WOS:000261642400010
J	Alonso-Magdalena, P; Ropero, AB; Carrera, MP; Cederroth, CR; Baquie, M; Gauthier, BR; Nef, S; Stefani, E; Nadal, A				Alonso-Magdalena, Paloma; Ropero, Ana B.; Carrera, M. Pilar; Cederroth, Christopher R.; Baquie, Mathurin; Gauthier, Benoit R.; Nef, Serge; Stefani, Enrico; Nadal, Angel			Pancreatic Insulin Content Regulation by the Estrogen Receptor ER alpha	PLOS ONE			English	Article								The function of pancreatic beta-cells is the synthesis and release of insulin, the main hormone involved in blood glucose homeostasis. Estrogen receptors, ER alpha and ER beta, are important molecules involved in glucose metabolism, yet their role in pancreatic beta-cell physiology is still greatly unknown. In this report we show that both ER alpha and ER beta are present in pancreatic beta-cells. Long term exposure to physiological concentrations of 17 beta-estradiol (E2) increased beta-cell insulin content, insulin gene expression and insulin release, yet pancreatic beta-cell mass was unaltered. The up-regulation of pancreatic beta-cell insulin content was imitated by environmentally relevant doses of the widespread endocrine disruptor Bisphenol-A (BPA). The use of ER alpha and ER beta agonists as well as ER alpha KO and ER beta KO mice suggests that the estrogen receptor involved is ER alpha. The up-regulation of pancreatic insulin content by ER alpha activation involves ERK1/2. These data may be important to explain the actions of E2 and environmental estrogens in endocrine pancreatic function and blood glucose homeostasis.	[Alonso-Magdalena, Paloma; Ropero, Ana B.; Carrera, M. Pilar; Nadal, Angel] Univ Miguel Hernandez Elche, Inst Bioingen, Alicante, Spain; [Ropero, Ana B.; Nadal, Angel] Inst Salud Carlos III, CIBERDEM, Alicante, Spain; [Cederroth, Christopher R.; Nef, Serge] Univ Geneva, Med Sch, Dept Genet Med & Development, Geneva, Switzerland; [Baquie, Mathurin; Gauthier, Benoit R.] Univ Geneva, Med Sch, Dept Cell Physiol & Metabolism, Geneva, Switzerland; [Stefani, Enrico] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Div Mol Med, Los Angeles, CA USA; [Stefani, Enrico] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA USA	Universidad Miguel Hernandez de Elche; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Instituto de Salud Carlos III; University of Geneva; University of Geneva; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Alonso-Magdalena, P (corresponding author), Univ Miguel Hernandez Elche, Inst Bioingen, Alicante, Spain.	nadal@umh.es	Cederroth, Christopher R./AAO-9501-2020; Cederroth, Christopher/B-9932-2011; Nadal, Angel/G-6721-2014; Nef, Serge/AAV-6445-2020; del Pilar Carrera González, María/K-2580-2018; ROPERO, ANA B./AAK-8342-2021; Alonso-Magdalena, Paloma/AAH-2076-2021; Gauthier, Benoit R/C-3138-2017; B, Ana/AAN-9680-2021	Nadal, Angel/0000-0003-4178-2152; Nef, Serge/0000-0001-5462-0676; del Pilar Carrera González, María/0000-0001-6575-8240; ROPERO, ANA B./0000-0002-6503-7598; Gauthier, Benoit R/0000-0001-8146-7486; ALONSO MAGDALENA, PALOMA/0000-0003-1065-5388; Cederroth, Christopher/0000-0001-7267-5136	Spanish Ministry of Education and Science [BFU2005-01052]; Instituto de Salud Carlos III-RETIC RD06; Ministry of Education and Science [studentship, SB2004-0044]; Swiss National Science Foundation [NRP50, 4050-104375]; The Sir Jules Thorn Charitable Overseas Trust Reg; Swiss National Research Foundation [3100A0-107682/1]	Spanish Ministry of Education and Science(Spanish Government); Instituto de Salud Carlos III-RETIC RD06(Instituto de Salud Carlos III); Ministry of Education and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); The Sir Jules Thorn Charitable Overseas Trust Reg; Swiss National Research Foundation(Swiss National Science Foundation (SNSF))	This study was supported by the Spanish Ministry of Education and Science, grant BFU2005-01052 and Instituto de Salud Carlos III-RETIC RD06 to AN. PA-M had a studentship from the Ministry of Education and Science. ABR had a postdoctoral fellowship from the Ministry of Education and Science (SB2004-0044). CRC and SN were funded by a grant from the Swiss National Science Foundation (NRP50, 4050-104375) and The Sir Jules Thorn Charitable Overseas Trust Reg., Schaan. MB and BRG are subsidized by a Swiss National Research Foundation Grant (#3100A0-107682/1 to BRG).	Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI [10.1289/ehp.8451, 10.1289/ehp.8062]; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; BARKLEY MS, 1979, BIOL REPROD, V20, P733, DOI 10.1095/biolreprod20.4.733; Barros RPA, 2006, P NATL ACAD SCI USA, V103, P1605, DOI 10.1073/pnas.0510391103; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Biles JE, 1997, J AGR FOOD CHEM, V45, P4697, DOI 10.1021/jf970518v; BONE AJ, 1976, NATURE, V262, P501, DOI 10.1038/262501a0; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Bryzgalova G, 2006, DIABETOLOGIA, V49, P588, DOI 10.1007/s00125-005-0105-3; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534; Cook R, 2006, ENVIRON HEALTH PERSP, V114, P1631, DOI 10.1289/ehp.8606; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8; Dupont S, 2000, DEVELOPMENT, V127, P4277; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Godsland IF, 2005, DIABETOLOGIA, V48, P2213, DOI 10.1007/s00125-005-1930-0; GREEN IC, 1973, BIOCHEM J, V134, P481, DOI 10.1042/bj1340481; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Le May C, 2006, P NATL ACAD SCI USA, V103, P9232, DOI 10.1073/pnas.0602956103; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc06-0543; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2007, INT J BIOCHEM CELL B, V39, P1343, DOI 10.1016/j.biocel.2006.12.009; Monje P, 2001, J CELL BIOCHEM, V82, P467, DOI 10.1002/jcb.1182; Morimoto S, 2001, LIFE SCI, V68, P2979, DOI 10.1016/S0024-3205(01)01100-6; Nadal A, 2005, PFLUG ARCH EUR J PHY, V449, P335, DOI 10.1007/s00424-004-1343-9; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Rochira V, 2002, MOL CELL ENDOCRINOL, V193, P19, DOI 10.1016/S0303-7207(02)00092-8; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Ropero AB, 2008, STEROIDS, V73, P874, DOI 10.1016/j.steroids.2007.12.018; Ropero AB, 2006, J STEROID BIOCHEM, V102, P163, DOI 10.1016/j.jsbmb.2006.09.019; Ropero AB, 2006, J MOL CELL CARDIOL, V41, P496, DOI 10.1016/j.yjmcc.2006.05.022; Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189; Sajiki J, 1999, J CHROMATOGR B, V736, P255, DOI 10.1016/S0378-4347(99)00471-5; Sheeler CQ, 2000, ENVIRON HEALTH PERSP, V108, P97, DOI 10.2307/3454506; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stahlhut RW, 2007, ENVIRON HEALTH PERSP, V115, P876, DOI 10.1289/ehp.9882; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V291, P76, DOI 10.1006/bbrc.2002.6407; Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; WAKELING AE, 1991, CANCER RES, V51, P3867; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565	55	289	301	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2069	10.1371/journal.pone.0002069	http://dx.doi.org/10.1371/journal.pone.0002069			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446233	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300038
J	Keller, DX; Franks, KM; Bartol, TM; Sejnowski, TJ				Keller, Daniel X.; Franks, Kevin M.; Bartol, Thomas M., Jr.; Sejnowski, Terrence J.			Calmodulin Activation by Calcium Transients in the Postsynaptic Density of Dendritic Spines	PLOS ONE			English	Article							NMDA RECEPTORS; HIPPOCAMPAL SPINES; SINGLE SPINES; CHANNELS; DYNAMICS; INFLUX; AMPA; MECHANISMS; NUCLEUS; SIGNAL	The entry of calcium into dendritic spines can trigger a sequence of biochemical reactions that begins with the activation of calmodulin (CaM) and ends with long-term changes to synaptic strengths. The degree of activation of CaM can depend on highly local elevations in the concentration of calcium and the duration of transient increases in calcium concentration. Accurate measurement of these local changes in calcium is difficult because the spaces are so small and the numbers of molecules are so low. We have therefore developed a Monte Carlo model of intracellular calcium dynamics within the spine that included calcium binding proteins, calcium transporters and ion channels activated by voltage and glutamate binding. The model reproduced optical recordings using calcium indicator dyes and showed that without the dye the free intracellular calcium concentration transient was much higher than predicted from the fluorescent signal. Excitatory postsynaptic potentials induced large, long-lasting calcium gradients across the postsynaptic density, which activated CaM. When glutamate was released at the synapse 10 ms before an action potential occurred, simulating activity patterns that strengthen hippocampal synapses, the calcium gradient and activation of CaM in the postsynaptic density were much greater than when the order was reversed, a condition that decreases synaptic strengths, suggesting a possible mechanism underlying the induction of long-term changes in synaptic strength. The spatial and temporal mechanisms for selectivity in CaM activation demonstrated here could be used in other signaling pathways.	[Keller, Daniel X.; Franks, Kevin M.; Bartol, Thomas M., Jr.; Sejnowski, Terrence J.] Salk Inst Biol Studies, Computat Neurobiol Lab, Howard Hughes Med Inst, La Jolla, CA USA; [Keller, Daniel X.; Franks, Kevin M.; Bartol, Thomas M., Jr.; Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA USA; [Keller, Daniel X.; Franks, Kevin M.; Bartol, Thomas M., Jr.; Sejnowski, Terrence J.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA USA; [Keller, Daniel X.] Univ Calif San Diego, Neurosci Grad Program, La Jolla, CA USA	Howard Hughes Medical Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Keller, DX (corresponding author), Salk Inst Biol Studies, Computat Neurobiol Lab, Howard Hughes Med Inst, La Jolla, CA USA.	dkeller@salk.edu	Sejnowski, Terrence/AAV-5558-2021		Howard Hughes Medical Institute [GM068630, P01-NS044306]; National Institutes of Health [GM068630, P01-NS044306]; National Science Foundation's Center for Theoretical Biological Physics [PHY0225630]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044306] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation's Center for Theoretical Biological Physics; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Howard Hughes Medical Institute and the National Institutes of Health (GM068630, P01-NS044306) and the National Science Foundation's Center for Theoretical Biological Physics (PHY0225630).	ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Bischofberger J, 2002, J NEUROSCI, V22, P10593; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bloodgood BL, 2005, SCIENCE, V310, P866, DOI 10.1126/science.1114816; Bloodgood BL, 2007, NEURON, V53, P249, DOI 10.1016/j.neuron.2006.12.017; Buldakova SL, 2007, NEUROSCIENCE, V144, P88, DOI 10.1016/j.neuroscience.2006.09.005; BURNASHEV N, 2005, J PHYSL, V485, P403; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Church PJ, 1996, J PHYSIOL-LONDON, V496, P59, DOI 10.1113/jphysiol.1996.sp021665; Cohen P, 1988, CALMODULIN; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; EBERHARD M, 1991, BIOCHEM BIOPH RES CO, V180, P209, DOI 10.1016/S0006-291X(05)81278-1; Franks KM, 2003, J NEUROSCI, V23, P3186; Franks KM, 2002, BIOPHYS J, V83, P2333, DOI 10.1016/S0006-3495(02)75248-X; FRANKS KM, 2002, THESIS U CALIFORNIA; Garaschuk O, 1996, J PHYSIOL-LONDON, V491, P757, DOI 10.1113/jphysiol.1996.sp021255; Graupner M, 2007, PLOS COMPUT BIOL, V3, P2299, DOI 10.1371/journal.pcbi.0030221; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; HAUGLAND RP, 1996, HDB BIOL FLUORESCENT; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holcman D, 2004, BIOPHYS J, V87, P81, DOI 10.1529/biophysj.103.035972; Holthoff K, 2002, NEURON, V33, P425, DOI 10.1016/S0896-6273(02)00576-7; JAHR CE, 1993, P NATL ACAD SCI USA, V90, P11573, DOI 10.1073/pnas.90.24.11573; JAHR CE, 1990, J NEUROSCI, V10, P3178; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KERR RA, 2008, SIAM J SCI COMPUTING; Kharazia VN, 1996, NEUROSCI LETT, V210, P37, DOI 10.1016/0304-3940(96)12658-6; KOCH C, 1993, J NEUROSCI, V13, P413; Koester HJ, 1998, P NATL ACAD SCI USA, V95, P9596, DOI 10.1073/pnas.95.16.9596; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; LLINAS R, 1995, NEUROPHARMACOLOGY, V34, P1443, DOI 10.1016/0028-3908(95)00150-5; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; Majewska A, 2000, J NEUROSCI, V20, P8262, DOI 10.1523/JNEUROSCI.20-22-08262.2000; Majewska A, 2000, J NEUROSCI, V20, P1722; Maravall M, 2000, BIOPHYS J, V78, P2655, DOI 10.1016/S0006-3495(00)76809-3; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MIHALAS S, 2006, THESIS CALTECH; MIHALAS S, 2005, QUANTITATIVE MODEL C; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Muller A, 2005, J NEUROSCI, V25, P558, DOI 10.1523/JNEUROSCI.3799-04.2005; Nagerl UV, 2000, BIOPHYS J, V79, P3009, DOI 10.1016/S0006-3495(00)76537-4; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Noguchi J, 2005, NEURON, V46, P609, DOI 10.1016/j.neuron.2005.03.015; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Popescu G, 2004, NATURE, V430, P790, DOI 10.1038/nature02775; Sabatini BL, 2000, NATURE, V408, P589, DOI 10.1038/35046076; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Sakmann B., 1995, SINGLE CHANNEL RECOR; Scheuss V, 2006, J NEUROSCI, V26, P8183, DOI 10.1523/JNEUROSCI.1962-06.2006; Schneggenburger R, 1996, BIOPHYS J, V70, P2165, DOI 10.1016/S0006-3495(96)79782-5; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shifman JM, 2006, P NATL ACAD SCI USA, V103, P13968, DOI 10.1073/pnas.0606433103; Sorra KE, 2000, HIPPOCAMPUS, V10, P501, DOI 10.1002/1098-1063(2000)10:5<501::AID-HIPO1>3.0.CO;2-T; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Stiles JR, 2001, METH NE FRO NEUROSCI, P87; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; Xia ZG, 2005, NAT REV NEUROSCI, V6, P267, DOI 10.1038/nrn1647; Yeung LC, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.011907; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 1999, J NEUROSCI, V19, P1976	75	62	63	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2045	10.1371/journal.pone.0002045	http://dx.doi.org/10.1371/journal.pone.0002045			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446197	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300017
J	Wanchu, A; Dong, YX; Sethi, S; Myneedu, VP; Nadas, A; Liu, ZT; Belisle, J; Laal, S				Wanchu, Ajay; Dong, Yuxin; Sethi, Sunil; Myneedu, V. P.; Nadas, Arthur; Liu, Zhentong; Belisle, John; Laal, Suman			Biomarkers for Clinical and Incipient Tuberculosis: Performance in a TB-Endemic Country	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CULTURE FILTRATE ANTIGENS; MYCOBACTERIUM-TUBERCULOSIS; UNDIAGNOSED TUBERCULOSIS; PRECLINICAL TUBERCULOSIS; PULMONARY TUBERCULOSIS; ANTIBODY-RESPONSES; MALATE SYNTHASE; HIV-INFECTION; DIAGNOSIS	Background: Simple biomarkers are required to identify TB in both HIV-TB+ and HIV+TB+ patients. Earlier studies have identified the M. tuberculosis Malate Synthase (MS) and MPT51 as immunodominant antigens in TB patients. One goal of these investigations was to evaluate the sensitivity and specificity of anti-MS and -MPT51 antibodies as biomarkers for TB in HIV-TB+ and HIV+TB+ patients from a TB-endemic setting. Earlier studies also demonstrated the presence of these biomarkers during incipient subclinical TB. If these biomarkers correlate with incipient TB, their prevalence should be higher in asymptomatic HIV+ subjects who are at a high-risk for TB. The second goal was to compare the prevalence of these biomarkers in asymptomatic, CD4(+) T cell-matched HIV+ TB 2 subjects from India who are at high-risk for TB with similar subjects from US who are at low-risk for TB. Methods and Results: Anti-MS and - MPT51 antibodies were assessed in sera from 480 subjects including PPD+ or PPD- healthy subjects, healthy community members, and HIV-TB+ and HIV+TB+ patients from India. Results demonstrate high sensitivity (similar to 80%) of detection of smear-positive HIV-TB+ and HIV+TB+ patients, and high specificity (>97%) with PPD+ subjects and endemic controls. While similar to 45% of the asymptomatic HIV+ TB 2 patients at high-risk for TB tested biomarker-positive, >97% of the HIV+TB- subjects at low risk for TB tested negative. Although the current studies are hampered by lack of knowledge of the outcome, these results provide strong support for the potential of these biomarkers to detect incipient, subclinical TB in HIV+ subjects. Conclusions: These biomarkers provide high sensitivity and specificity for TB diagnosis in a TB endemic setting. Their performance is not compromised by concurrent HIV infection, site of TB and absence of pulmonary manifestations in HIV+TB+ patients. Results also demonstrate the potential of these biomarkers for identifying incipient subclinical TB in HIV+TB- subjects at high-risk for TB.	[Wanchu, Ajay] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India; [Sethi, Sunil] Post Grad Inst Med Educ & Res, Dept Med Microbiol, Chandigarh, India; [Myneedu, V. P.] Lala Ram Sarup Inst Tuberculosis & Respiratory Dis, Dept Microbiol, New Delhi, India; [Liu, Zhentong; Belisle, John] Colorado State Univ, Dept Microbiol, Immunol & Pathol, Ft Collins, CO USA; [Dong, Yuxin; Laal, Suman] NYU, Sch Med, Dept Pathol, New York, NY USA; [Laal, Suman] NYU, Sch Med, Dept Microbiol, New York, NY USA; [Nadas, Arthur] NYU, Sch Med, Inst Env Med, New York, NY USA; [Laal, Suman] Veterans Affairs Med Ctr, New York, NY USA	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Colorado State University; New York University; New York University; New York University	Wanchu, A (corresponding author), Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India.	suman.laal@med.nyu.edu	Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798	AIDS International Training and Research Program (AITRP) [TW001409]; National Institutes of Health (NIH) [R01 AI056257]; VA Merit Review Award; NIH/NIAID [N01 AI75320]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320, R01AI056257] Funding Source: NIH RePORTER	AIDS International Training and Research Program (AITRP); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Review Award(US Department of Veterans Affairs); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A. Wanchu, S. Sethi, V.P. Myneedu and S. Laal are supported by the AIDS International Training and Research Program (AITRP) Grant TW001409. These studies were also supported by the National Institutes of Health (NIH) Grant R01 AI056257, by the VA Merit Review Award and by the NIH/NIAID Contract N01 AI75320 entitled TB Research Materials and Vaccine Testing. The sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe F, 2007, SCAND J IMMUNOL, V66, P176, DOI 10.1111/j.1365-3083.2007.01978.x; Achkar JM, 2006, CLIN VACCINE IMMUNOL, V13, P1291, DOI 10.1128/CVI.00158-06; Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; BARRERA L, 1992, TUBERCLE LUNG DIS, V73, P187, DOI 10.1016/0962-8479(92)90084-W; Cohen J, 2004, SCIENCE, V304, P504, DOI 10.1126/science.304.5670.504; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC; DANIEL TM, 1996, TUBERCULOSIS, P223; Foulds J, 1998, INT J TUBERC LUNG D, V2, P778; Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0; Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354; Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; JANOFF EN, 1991, J IMMUNOL, V147, P2130; Kinhikar AG, 2006, MOL MICROBIOL, V60, P999, DOI 10.1111/j.1365-2958.2006.05151.x; Laal S, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P71; Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015; Laal S, 1997, CLIN DIAGN LAB IMMUN, V4, P49, DOI 10.1128/CDLI.4.1.49-56.1997; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524; Mukherjee S, 2004, CLIN DIAGN LAB IMMUN, V11, P280, DOI 10.1128/CDLI.11.2.280-286.2004; Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656; Perkins MD, 2000, INT J TUBERC LUNG D, V4, pS182; Ramalingam B, 2003, SCAND J INFECT DIS, V35, P234, DOI 10.1080/00365540310000292; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; SALTINI C, 1992, American Review of Respiratory Disease, V145, pA686; Samanich K, 2001, INFECT IMMUN, V69, P4600, DOI 10.1128/IAI.69.7.4600-4609.2001; Samanich KM, 1998, J INFECT DIS, V178, P1534, DOI 10.1086/314438; Samanich KM, 2000, CLIN DIAGN LAB IMMUN, V7, P662, DOI 10.1128/CDLI.7.4.662-668.2000; Sartain MJ, 2006, MOL CELL PROTEOMICS, V5, P2102, DOI 10.1074/mcp.M600089-MCP200; Singh KK, 2005, INFECT IMMUN, V73, P5004, DOI 10.1128/IAI.73.8.5004-5014.2005; Singh KK, 2005, CLIN DIAGN LAB IMMUN, V12, P354, DOI 10.1128/CDLI.12.2.354-358.2005; Singh KK, 2003, J INFECT DIS, V188, P371, DOI 10.1086/376532; Singh KK, 2001, INFECT IMMUN, V69, P4185, DOI 10.1128/IAI.69.6.4185-4191.2001; Steingart KR, 2007, PLOS MED, V4, P1; *UNICEF UNDP WORLD, 2006, DIAGN TUB GLOB DEM M; VANDERWERF TS, 1992, MED MICROBIOL IMMUN, V181, P71, DOI 10.1007/BF00189425; Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005; Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC	43	31	33	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2071	10.1371/journal.pone.0002071	http://dx.doi.org/10.1371/journal.pone.0002071			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446210	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300040
J	Sakuntabhai, A; Ndiaye, R; Casademont, I; Peerapittayamonkol, C; Rogier, C; Tortevoye, P; Tall, A; Paul, R; Turbpaiboon, C; Phimpraphi, W; Trape, JF; Spiegel, A; Heath, S; Mercereau-Puijalon, O; Dieye, A; Julier, C				Sakuntabhai, Anavaj; Ndiaye, Rokhaya; Casademont, Isabelle; Peerapittayamonkol, Chayanon; Rogier, Christophe; Tortevoye, Patricia; Tall, Adama; Paul, Richard; Turbpaiboon, Chairat; Phimpraphi, Waraphon; Trape, Jean-Francois; Spiegel, Andre; Heath, Simon; Mercereau-Puijalon, Odile; Dieye, Alioune; Julier, Cecile			Genetic Determination and Linkage Mapping of Plasmodium falciparum Malaria Related Traits in Senegal	PLOS ONE			English	Article							BLOOD INFECTION LEVELS; INTERLEUKIN-7 RECEPTOR; PROMOTER POLYMORPHISM; SUSCEPTIBILITY LOCUS; SEGREGATION ANALYSIS; SCHISTOSOMA-MANSONI; GENOMEWIDE SCREEN; HOLOENDEMIC AREA; CHROMOSOME 13Q14; CLINICAL MALARIA	Plasmodium falciparum malaria episodes may vary considerably in their severity and clinical manifestations. There is good evidence that host genetic factors contribute to this variability. To date, most genetic studies aiming at the identification of these genes have used a case/control study design for severe malaria, exploring specific candidate genes. Here, we performed a family-based genetic study of falciparum malaria related phenotypes in two independent longitudinal survey cohorts, as a first step towards the identification of genes and mechanisms involved in the outcome of infection. We studied two Senegalese villages, Dielmo and Ndiop that differ in ethnicity, malaria transmission and endemicity. We performed genome-scan linkage analysis of several malaria-related phenotypes both during clinical attacks and asymptomatic infection. We show evidence for a strong genetic contribution to both the number of clinical falciparum malaria attacks and the asymptomatic parasite density. The asymptomatic parasite density showed linkage to chromosome 5q31 (LOD = 2.26, empirical p = 0.0014, Dielmo), confirming previous findings in other studies. Suggestive linkage values were also obtained at three additional chromosome regions: the number of clinical malaria attacks on chromosome 5p15 (LOD = 2.57, empirical p = 0.001, Dielmo) and 13q13 (LOD = 2.37, empirical p = 0.0014 Dielmo), and the maximum parasite density during asymptomatic infection on chromosome 12q21 (LOD = 3.1, empirical p, 10 24, Ndiop). While regions of linkage show little overlap with genes known to be involved in severe malaria, the four regions appear to overlap with regions linked to asthma or atopy related traits, suggesting that common immune related pathways may be involved.	[Sakuntabhai, Anavaj; Ndiaye, Rokhaya; Casademont, Isabelle; Peerapittayamonkol, Chayanon; Turbpaiboon, Chairat; Phimpraphi, Waraphon; Julier, Cecile] Inst Pasteur, Unite Genet Malad Infect & Autoimmunes, Paris, France; [Sakuntabhai, Anavaj; Ndiaye, Rokhaya; Casademont, Isabelle; Peerapittayamonkol, Chayanon; Turbpaiboon, Chairat; Phimpraphi, Waraphon; Julier, Cecile] INSERM U730, Paris, France; [Sakuntabhai, Anavaj; Casademont, Isabelle; Paul, Richard] Inst Pasteur, Lab Genet Reponse Infect homme, Paris, France; [Ndiaye, Rokhaya; Dieye, Alioune] Inst Pasteur, Unite Immunogenet, Dakar, Senegal; [Rogier, Christophe; Tall, Adama; Spiegel, Andre] Inst Pasteur, Unite Epidemiol, Dakar, Senegal; [Rogier, Christophe] Inst Med Trop Serv Sante Armees, Unite Rech Biol Epidemiol Parasit, IFR48, Marseille, France; [Tortevoye, Patricia] Inst Pasteur, Unite Epidemiol Physiopathol Virus Oncogenes, Paris, France; [Trape, Jean-Francois] Inst Rech Dev, Lab Paludol, BP 1386, Dakar, Senegal; [Spiegel, Andre] Ecole Val Grace, Dept Epidemiol Sante Publ, Paris, France; [Heath, Simon] Ctr Natl Genotypage, Evry, France; [Mercereau-Puijalon, Odile] Inst Pasteur, Unite Immunol Mol Parasites, CNRS URA 2581, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut de Recherche pour le Developpement (IRD); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sakuntabhai, A (corresponding author), Inst Pasteur, Unite Genet Malad Infect & Autoimmunes, Paris, France.	anavaj@pasteur.fr	Peerapittayamongkol, Chayanon/B-4920-2010; Mercereau-Puijalon, Odile/AAA-2242-2020; Heath, Simon C/J-4138-2012; JULIER, Cécile/M-9824-2017	Heath, Simon C/0000-0002-9550-0897; JULIER, Cécile/0000-0002-1538-0240	French Ministry of Research and Technology; Institut national de la sante et de la recherche medicale (INSERM) [post-doctoral fellowship]; BioMalPar European Network of Excellence [LSHP-CT-2004-503578]; Institut Pasteur de Dakar [studentship]; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand [post-doctoral fellowship]; Royal Golden Jubilee Program; Thailand Research Fund; French Embassy in Thailand	French Ministry of Research and Technology; Institut national de la sante et de la recherche medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); BioMalPar European Network of Excellence; Institut Pasteur de Dakar; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Royal Golden Jubilee Program; Thailand Research Fund(Thailand Research Fund (TRF)); French Embassy in Thailand	This work was funded in part by grants from the French Ministry of Research and Technology, the Institut Pasteur and Institut national de la sante et de la recherche medicale (INSERM) to C.J. Research in the laboratory of OMP is partly supported by the BioMalPar European Network of Excellence supported by a European grant (LSHP-CT-2004-503578) from the Priority 1 Life Sciences, Genomics and Biotechnology for Health in the 6th Framework Programme. We thank the Centre National de Genotypage for providing access to their genotyping facility. R.N. was supported by a studentship from the Institut Pasteur de Dakar. C.P. was supported by post-doctoral fellowships from Inserm and from the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. C.T. and W.P. were supported by the Royal Golden Jubilee Program, the Thailand Research Fund and the French Embassy in Thailand.	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; AMOS CI, 1994, AM J HUM GENET, V54, P535; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; BEGHDADI W, 2008, J EXP MED IN PRESS; Bereczky S, 2004, INT J PARASITOL, V34, P935, DOI 10.1016/j.ijpara.2004.04.007; Blangero J, 2001, ADV GENET, V42, P151, DOI 10.1016/S0065-2660(01)42021-9; Blangero J, 2000, GENET EPIDEMIOL, V19, pS8, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI2>3.0.CO;2-Y; Booth DR, 2005, J MOL MED, V83, P822, DOI 10.1007/s00109-005-0684-y; Cancre N, 2000, AM J EPIDEMIOL, V152, P760, DOI 10.1093/aje/152.8.760; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Caulfield LE, 2004, AM J TROP MED HYG, V71, P55, DOI 10.4269/ajtmh.2004.71.55; Concannon P, 2005, DIABETES, V54, P2995, DOI 10.2337/diabetes.54.10.2995; Elghazali G, 1997, CLIN EXP IMMUNOL, V109, P84, DOI 10.1046/j.1365-2249.1997.4401337.x; Falchi M, 2006, HUM MOL GENET, V15, P2975, DOI 10.1093/hmg/ddl227; Flori L, 2003, GENES IMMUN, V4, P265, DOI 10.1038/sj.gene.6363960; Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X; Fontenille D, 1997, AM J TROP MED HYG, V56, P247, DOI 10.4269/ajtmh.1997.56.247; Friberg C, 2006, J INVEST DERMATOL, V126, P998, DOI 10.1038/sj.jid.5700194; Garcia A, 1998, AM J TROP MED HYG, V58, P705, DOI 10.4269/ajtmh.1998.58.705; GOLDGAR DE, 1990, AM J HUM GENET, V47, P957; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; HALDANE JBS, 1950, ANN EUGENIC, V15, P15, DOI 10.1111/j.1469-1809.1949.tb02418.x; Hernandez-Valladares M, 2004, IMMUNOGENETICS, V56, P115, DOI 10.1007/s00251-004-0667-0; Iyengar SK, 2001, GENET EPIDEMIOL, V21, pS130, DOI 10.1002/gepi.2001.21.s1.s130; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; Jang N, 2005, GENES IMMUN, V6, P262, DOI 10.1038/sj.gene.6364169; JEPSON AP, 1995, J INFECT DIS, V172, P316, DOI 10.1093/infdis/172.1.316; Jeronimo SMB, 2007, GENES IMMUN, V8, P539, DOI 10.1038/sj.gene.6364422; Kohara Y, 2001, IMMUNOGENETICS, V53, P15, DOI 10.1007/s002510000286; Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519; Latiano A, 2007, J PEDIATR GASTR NUTR, V45, P180, DOI 10.1097/MPG.0b013e3180616bd2; Lee JK, 2002, BIOCHEM BIOPH RES CO, V295, P771, DOI 10.1016/S0006-291X(02)00679-4; Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106; Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journal.pmed.0020340; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206; Mombo LE, 2003, AM J TROP MED HYG, V68, P186, DOI 10.4269/ajtmh.2003.68.186; Morahan G, 2002, GENES IMMUN, V3, P414, DOI 10.1038/sj.gene.6363909; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; Morrot A, 2006, INFECT IMMUN, V74, P2495, DOI 10.1128/IAI.74.4.2495-2497.2006; Nacher M, 2000, PARASITE IMMUNOL, V22, P107, DOI 10.1046/j.1365-3024.2000.00284.x; Nacher M, 2001, AM J TROP MED HYG, V65, P834, DOI 10.4269/ajtmh.2001.65.834; Ndiaye R, 2005, TISSUE ANTIGENS, V65, P474, DOI 10.1111/j.1399-0039.2005.00388.x; Noranate N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000139; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ohno T, 2001, IMMUNOGENETICS, V53, P736, DOI 10.1007/s00251-001-0390-z; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Perlmann P, 1999, IMMUNOL LETT, V65, P29, DOI 10.1016/S0165-2478(98)00120-5; Perlmann P, 1997, INFECT IMMUN, V65, P116, DOI 10.1128/IAI.65.1.116-121.1997; Philippi A, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-74; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967; Rihet P, 1998, GENET EPIDEMIOL, V15, P435, DOI 10.1002/(SICI)1098-2272(1998)15:5<435::AID-GEPI1>3.0.CO;2-#; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rogier C, 1996, AM J TROP MED HYG, V54, P613, DOI 10.4269/ajtmh.1996.54.613; Rogier C, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P255; Rogier C, 1996, T ROY SOC TROP MED H, V90, P175, DOI 10.1016/S0035-9203(96)90128-5; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; SCHOFIELD L, 1993, ANN TROP MED PARASIT, V87, P617, DOI 10.1080/00034983.1993.11812820; SCHORK NJ, 1993, HUM HERED, V43, P1, DOI 10.1159/000154106; Sergent Ed., 1935, Arch Inst Pasteur Alger, V13, P279; Sham PC, 2002, AM J HUM GENET, V71, P238, DOI 10.1086/341560; Sklar P, 2004, MOL PSYCHIATR, V9, P213, DOI 10.1038/sj.mp.4001418; Sokhna C, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-43; Sokhna CS, 2000, AM J TROP MED HYG, V62, P266, DOI 10.4269/ajtmh.2000.62.266; Spiegel A, 2003, T ROY SOC TROP MED H, V97, P198, DOI 10.1016/S0035-9203(03)90117-9; Stirnadel HA, 1999, GENET EPIDEMIOL, V17, P16, DOI 10.1002/(SICI)1098-2272(1999)17:1<16::AID-GEPI2>3.0.CO;2-7; Sunyer J, 2001, THORAX, V56, P290, DOI [10.1136/thorax.56.4.290, 10.1136/thorax.56.11.897a]; Timmann C, 2007, PLOS GENET, V3, P393, DOI 10.1371/journal.pgen.0030048; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P181, DOI 10.1016/0035-9203(85)90329-3; TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; Walley AJ, 2004, EUR J HUM GENET, V12, P132, DOI 10.1038/sj.ejhg.5201084; WEATHERALL DJ, 1987, ANN TROP MED PARASIT, V81, P539, DOI 10.1080/00034983.1987.11812155; Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744; Williams TN, 1996, NATURE, V383, P522, DOI 10.1038/383522a0; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; Zhang Z, 2005, GENES IMMUN, V6, P145, DOI 10.1038/sj.gene.6364171	87	37	37	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2000	10.1371/journal.pone.0002000	http://dx.doi.org/10.1371/journal.pone.0002000			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431485	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700020
J	Wu, RQ; Dong, WF; Ji, YX; Zhou, M; Marini, CP; Ravikumar, TS; Wang, P				Wu, Rongqian; Dong, Weifeng; Ji, Youxin; Zhou, Mian; Marini, Corrado P.; Ravikumar, Thanjavur S.; Wang, Ping			Orexigenic Hormone Ghrelin Attenuates Local and Remote Organ Injury after Intestinal Ischemia-Reperfusion	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; GUT BARRIER DYSFUNCTION; SECRETAGOGUE RECEPTOR; ACYLATED PEPTIDE; PROGNOSTIC VALUE; STIMULATES GH; VAGAL NERVE; SECRETION; EXPRESSION; STOMACH	Background: Gut ischemia/reperfusion (I/R) injury is a serious condition in intensive care patients. Activation of immune cells adjacent to the huge endothelial cell surface area of the intestinal microvasculature produces initially local and then systemic inflammatory responses. Stimulation of the vagus nerve can rapidly attenuate systemic inflammatory responses through inhibiting the activation of macrophages and endothelial cells. Ghrelin, a novel orexigenic hormone, is produced predominately in the gastrointestinal system. Ghrelin receptors are expressed at a high density in the dorsal vagal complex of the brain stem. In this study, we investigated the regulation of the cholinergic anti-inflammatory pathway by the novel gastrointestinal hormone, ghrelin, after gut I/R. Methods and Findings: Gut ischemia was induced by placing a microvascular clip across the superior mesenteric artery for 90 min in male adult rats. Our results showed that ghrelin levels were significantly reduced after gut I/R and that ghrelin administration inhibited pro-inflammatory cytokine release, reduced neutrophil infiltration, ameliorated intestinal barrier dysfunction, attenuated organ injury, and improved survival after gut I/R. Administration of a specific ghrelin receptor antagonist worsened gut I/R-induced organ injury and mortality. To determine whether ghrelin's beneficial effects after gut I/R require the intact vagus nerve, vagotomy was performed in sham and gut I/R animals immediately prior to the induction of gut ischemia. Our result showed that vagotomy completely eliminated ghrelin's beneficial effect after gut I/R. To further confirm that ghrelin's beneficial effects after gut I/R are mediated through the central nervous system, intracerebroventricular administration of ghrelin was performed at the beginning of reperfusion after 90-min gut ischemia. Our result showed that intracerebroventricular injection of ghrelin also protected the rats from gut I/R injury. Conclusions: These findings suggest that ghrelin attenuates excessive inflammation and reduces organ injury after gut I/R through activation of the cholinergic anti-inflammatory pathway.	[Wu, Rongqian; Zhou, Mian; Ravikumar, Thanjavur S.; Wang, Ping] Feinstein Inst Med Res, Manhasset, NY USA; [Wu, Rongqian; Dong, Weifeng; Ji, Youxin; Zhou, Mian; Marini, Corrado P.; Ravikumar, Thanjavur S.; Wang, Ping] N Shore Univ Hosp, Long Island Jewish Med Ctr, Dept Surg, Manhasset, NY USA	Northwell Health; Northwell Health; North Shore University Hospital	Wu, RQ (corresponding author), Feinstein Inst Med Res, Manhasset, NY USA.	pwang@nshs.edu	Wu, Rongqian/I-3614-2012; ji, youxin/F-3802-2014; ji, youxin/F-3802-2014	Wu, Rongqian/0000-0003-0993-4531; ji, youxin/0000-0003-2895-4730; ji, youxin/0000-0003-2303-8784; Wang, Ping/0000-0002-1557-0394; Marini, Corrado Paolo/0000-0002-4155-8292	National Institutes of Health [R01 GM053008, R01 AG028352]; American Heart Association [0325802T]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028352] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by National Institutes of Health grants R01 GM053008 and R01 AG028352 (PW). Dr. Rongqian Wu was supported by a Postdoctoral Fellowship from the American Heart Association (the Heritage Affiliate) #0325802T.	Arvat E, 2000, J ENDOCRINOL INVEST, V23, P493, DOI 10.1007/BF03343763; Asakawa A, 2003, GUT, V52, P947, DOI 10.1136/gut.52.7.947; Balanescu S, 2004, MED SCI MONITOR, V10, pCR307; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Berlanga J, 2002, AM J PATHOL, V161, P373, DOI 10.1016/S0002-9440(10)64192-2; Bilchick KC, 2002, AM J CARDIOL, V90, P24, DOI 10.1016/S0002-9149(02)02380-9; Borovikova LV, 2000, AUTON NEUROSCI-BASIC, V85, P141, DOI 10.1016/S1566-0702(00)00233-2; Chang L, 2004, J CARDIOVASC PHARM, V43, P165, DOI 10.1097/00005344-200402000-00001; Chavez AM, 1999, CRIT CARE MED, V27, P2246, DOI 10.1097/00003246-199910000-00030; Chen WL, 2007, ACAD EMERG MED, V14, P392, DOI 10.1197/j.aem.2006.12.015; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Cowley MA, 2004, ENDOCRINOLOGY, V145, P2604, DOI 10.1210/en.2004-0346; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; Diano S, 2006, NAT NEUROSCI, V9, P381, DOI 10.1038/nn1656; Dwivedi AJ, 2007, J AM COLL SURGEONS, V205, P284, DOI 10.1016/j.jamcollsurg.2007.03.012; Evrengul H, 2004, RHEUMATOL INT, V24, P198, DOI 10.1007/s00296-003-0357-5; Fink M P, 1994, Semin Respir Infect, V9, P256; Hattori N, 2001, J CLIN ENDOCR METAB, V86, P4284, DOI 10.1210/jc.86.9.4284; Higuchi S, 2007, J SURG RES, V137, P46, DOI 10.1016/j.jss.2006.04.019; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004; Kong SE, 1998, AUST NZ J SURG, V68, P554, DOI 10.1111/j.1445-2197.1998.tb02099.x; Lanza GA, 1998, AM J CARDIOL, V82, P1323, DOI 10.1016/S0002-9149(98)00635-3; Laversuch CJ, 1997, J RHEUMATOL, V24, P1540; LINDGREN S, 1993, SCAND J GASTROENTERO, V28, P638, DOI 10.3109/00365529309096103; Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575; Nass R, 2000, J NEUROENDOCRINOL, V12, P1194, DOI 10.1046/j.1365-2826.2000.00586.x; Oldenburg WA, 2004, ARCH INTERN MED, V164, P1054, DOI 10.1001/archinte.164.10.1054; Papotti M, 2000, J CLIN ENDOCR METAB, V85, P3803, DOI 10.1210/jc.85.10.3803; Sakata I, 2003, NEUROSCI LETT, V342, P183, DOI 10.1016/S0304-3940(03)00294-5; Sakata I, 2002, J ENDOCRINOL, V174, P463, DOI 10.1677/joe.0.1740463; Sato N, 2003, JPN J PHYSIOL, V53, P443, DOI 10.2170/jjphysiol.53.443; Shuto YJ, 2001, LIFE SCI, V68, P991, DOI 10.1016/S0024-3205(00)01001-8; Soejima K, 2000, JPN CIRC J, V64, P32, DOI 10.1253/jcj.64.32; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2005, J EXP MED, V202, P1017, DOI 10.1084/jem.20051760; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Villareal Rollo P, 2002, Curr Atheroscler Rep, V4, P120, DOI 10.1007/s11883-002-0035-1; Wang GY, 2002, REGUL PEPTIDES, V105, P75, DOI 10.1016/S0167-0115(02)00012-5; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wu JT, 2004, ANN SURG, V239, P464, DOI 10.1097/01.sla.0000118561.54919.61; Wu R, 2007, AM J PHYSIOL-ENDOC M, V293, pE1697, DOI 10.1152/ajpendo.00098.2007; Wu R, 2007, AM J RESP CRIT CARE, V176, P805, DOI 10.1164/rccm.200604-511OC; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2003, INT J MOL MED, V12, P777; Yang RK, 2003, AM J PHYSIOL-GASTR L, V285, pG621, DOI 10.1152/ajpgi.00177.2003; Yang RK, 2006, MOL MED, V12, P105, DOI 10.2119/2006-00010.Yang	49	80	84	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2026	10.1371/journal.pone.0002026	http://dx.doi.org/10.1371/journal.pone.0002026			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431503	gold, Green Published, Green Submitted			2022-12-25	WOS:000261558700038
J	Maroto, B; Ye, MB; von Lohneysen, K; Schnelzer, A; Knaus, UG				Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.			P21-activated kinase is required for mitotic progression and regulates Plk1	ONCOGENE			English	Article						p21-activated kinase; Plk1; cell cycle	POLO-LIKE KINASE-1; BREAST-CANCER CELLS; SPINDLE POLES; HISTONE H3; AURORA-A; PHOSPHORYLATION; PAK1; ACTIVATION; LOCALIZATION; CYTOKINESIS	P21-activated kinases (Paks), a family of serine/threonine kinases, are effectors of the Rho GTPases Cdc42 and Rac1. Mammalian Pak1 and Pak homologs in simple eukaryotes are implicated in controlling G2/M transition and/or mitosis. Another serine/threonine kinase, polo-like kinase 1 (Plk1), is an important regulator of mitotic events, such as centrosome maturation, mitotic entry, spindle formation, sister chromatid cohesion and cytokinesis. Plk1 phosphorylation is thought to be one of the critical regulatory events leading to these Plk1-mediated functions. We show here that Pak1 is required for cell proliferation, mitotic progression and Plk1 activity in HeLa cells. Gain or loss of Pak function directly impacted phosphorylation and activity of Plk1. Phosphorylation of Plk1 on Ser 49 is important for metaphase-associated events. Inhibition of Pak activity leads to delay in G2/M progression and abnormal spindle formation, mirroring some attributes of Plk1 deregulation. Our results reveal a role for Pak in regulating Plk1 activity and mitotic progression, and connect Pak to the complex protein interaction network enabling cell division.	[Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol, IMM28,10550 N Torrey Pines Rd,R203, La Jolla, CA 92037 USA.	uknaus@scripps.edu		Schnelzer, Andreas/0000-0002-5410-3561	NIH [AI35947, AI24838, AI07244-22]; University of California [8FB-0026]; German Academic Exchange; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244, R01AI035947, R01AI024838] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); German Academic Exchange(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank E Nishida for Plk wild-type constructs, the laboratories of G Bokoch and S Reed for sharing antibodies, J Birkenfeld for advice and K Schreiber for illustrations and administrative assistance. This work was supported by NIH (AI35947, AI24838 to UGK), by funds from the California Breast Cancer Research Program of the University of California 8FB-0026 (BM), NIH training grant T32 AI07244-22 (MY) and a German Academic Exchange (DAAD) fellowship (AS).	Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; BODE AM, 2005, SCI STKE, pRE4; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; De Luca M, 2006, CELL CYCLE, V5, P296; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nheu T, 2004, CELL CYCLE, V3, P71; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2007, ONCOGENE, V26, P1820, DOI 10.1038/sj.onc.1209983; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	36	76	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4900	4908		10.1038/onc.2008.131	http://dx.doi.org/10.1038/onc.2008.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427546				2022-12-25	WOS:000258596900004
J	Han, GS; O'Hara, L; Carman, GM; Siniossoglou, S				Han, Gil-Soo; O'Hara, Laura; Carman, George M.; Siniossoglou, Symeon			An unconventional diacylglycerol kinase that regulates phospholipid synthesis and nuclear membrane growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG2+-DEPENDENT PHOSPHATIDATE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; LIPIN HOMOLOG; CELL-CYCLE; YEAST; ACID; CTP; PROLIFERATION	Changes in nuclear size and shape during the cell cycle or during development require coordinated nuclear membrane remodeling, but the underlying molecular events are largely unknown. We have shown previously that the activity of the conserved phosphatidate phosphatase Pah1p/Smp2p regulates nuclear structure in yeast by controlling phospholipid synthesis and membrane biogenesis at the nuclear envelope. Two screens for novel regulators of phosphatidate led to the identification of DGK1. We show that Dgk1p is a unique diacylglycerol kinase that uses CTP, instead of ATP, to generate phosphatidate. DGK1 counteracts the activity of PAH1 at the nuclear envelope by controlling phosphatidate levels. Overexpression of DGK1 causes the appearance of phosphatidate-enriched membranes around the nucleus and leads to its expansion, without proliferating the cortical endoplasmic reticulum membrane. Mutations that decrease phosphatidate levels decrease nuclear membrane growth in pah1 Delta cells. We propose that phosphatidate metabolism is a critical factor determining nuclear structure by regulating nuclear membrane biogenesis.	[O'Hara, Laura; Siniossoglou, Symeon] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Han, Gil-Soo; Carman, George M.] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; [Han, Gil-Soo; Carman, George M.] Rutgers State Univ, Rutgers Ctr Lipid Res, New Brunswick, NJ 08901 USA	University of Cambridge; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Siniossoglou, S (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 0XY, England.	ss560@cam.ac.uk		O'Hara, Laura/0000-0001-7790-9261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; Medical Research Council [G0701446] Funding Source: Medline; NIGMS NIH HHS [GM 28140, R01 GM028140] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0701446] Funding Source: UKRI	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BELENDIUK G, 1978, J BIOL CHEM, V253, P4555; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Carman GM, 2007, J BIOL CHEM, V282, P37293, DOI 10.1074/jbc.R700038200; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; De Craene JO, 2006, MOL BIOL CELL, V17, P3009, DOI 10.1091/mbc.e06-01-0080; Fagone P, 2007, J BIOL CHEM, V282, P7591, DOI 10.1074/jbc.M608175200; Gehrig K, 2008, MOL BIOL CELL, V19, P237, DOI 10.1091/mbc.E07-02-0179; Han GS, 2008, J BIOL CHEM, V283, P20443, DOI 10.1074/jbc.M802866200; Han GS, 2007, J BIOL CHEM, V282, P37026, DOI 10.1074/jbc.M705777200; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Kosodo Y, 2001, YEAST, V18, P1003, DOI 10.1002/yea.747.abs; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lagace TA, 2005, MOL BIOL CELL, V16, P1120, DOI 10.1091/mbc.E04-10-0874; Leitch AR, 2000, MICROBIOL MOL BIOL R, V64, P138, DOI 10.1128/MMBR.64.1.138-152.2000; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Luo B, 2004, CELL SIGNAL, V16, P983, DOI 10.1016/j.cellsig.2004.03.016; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Muller MO, 2000, J BIOL CHEM, V275, P19475, DOI 10.1074/jbc.M002575200; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; O'Hara L, 2006, J BIOL CHEM, V281, P34537, DOI 10.1074/jbc.M606654200; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PARRISH ML, 1995, MOL BIOL CELL, V6, P1535, DOI 10.1091/mbc.6.11.1535; Sakane F, 2007, BBA-MOL CELL BIOL L, V1771, P793, DOI 10.1016/j.bbalip.2007.04.006; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; Shridas P, 2006, J BIOL CHEM, V281, P31696, DOI 10.1074/jbc.M604087200; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; SZKOPINSKA A, 1988, ARCH BIOCHEM BIOPHYS, V266, P124, DOI 10.1016/0003-9861(88)90242-1; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; VERGERES G, 1993, J CELL SCI, V106, P249; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zeniou-Meyer M, 2007, J BIOL CHEM, V282, P21746, DOI 10.1074/jbc.M702968200; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	43	115	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20433	20442		10.1074/jbc.M802903200	http://dx.doi.org/10.1074/jbc.M802903200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18458075	Green Published, hybrid			2022-12-25	WOS:000257565300058
J	Svensson, LA; Bondensgaard, K; Norskov-Lauritsen, L; Christensen, L; Becker, P; Andersen, MD; Maltesen, MJ; Rand, KD; Breinholt, J				Svensson, L. Anders; Bondensgaard, Kent; Norskov-Lauritsen, Leif; Christensen, Leif; Becker, Peter; Andersen, Mette D.; Maltesen, Morten J.; Rand, Kasper D.; Breinholt, Jens			Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; BINDING-SITES; ERYTHROPOIETIN RECEPTOR; ACTIVATION; AFFINITY; COMPLEX; TRANSMEMBRANE; ROTATION; LACTOGEN; EXCHANGE	The crystal structure of the complex between an N-terminally truncated G129R human prolactin (PRL) variant and the extracellular domain of the human prolactin receptor (PRLR) was determined at 2.5 angstrom resolution by x-ray crystallography. This structure represents the first experimental structure reported for a PRL variant bound to its cognate receptor. The binding of PRL variants to the PRLR extracellular domain was furthermore characterized by the solution state techniques, hydrogen exchange mass spectrometry, and NMR spectroscopy. Compared with the binding interface derived from mutagenesis studies, the structural data imply that the definition of PRL binding site 1 should be extended to include residues situated in the N-terminal part of loop 1 and in the C terminus. Comparison of the structure of the receptor-bound PRL variant with the structure reported for the unbound form of a similar analogue (Jomain, J. B., Tallet, E., Broutin, I., Hoos, S., van Agthoven, J., Ducruix, A., Kelly, P. A., Kragelund, B. B., England, P., and Goffin, V. (2007) J. Biol. Chem. 282, 33118-33131) demonstrates that receptor-induced changes in the backbone of the four-helix bundle are subtle, whereas large scale rearrangements and structuring occur in the flexible N-terminal part of loop 1. Hydrogen exchange mass spectrometry data imply that the dynamics of the four-helix bundle in solution generally become stabilized upon receptor interaction at binding site 1.	[Svensson, L. Anders; Bondensgaard, Kent; Norskov-Lauritsen, Leif; Christensen, Leif; Becker, Peter; Andersen, Mette D.; Maltesen, Morten J.; Rand, Kasper D.; Breinholt, Jens] Novo Nordisk AS, Prot Engn, DK-2760 Malov, Denmark	Novo Nordisk	Breinholt, J (corresponding author), Novo Nordisk AS, Prot Engn, Novo Nordisk Pk, DK-2760 Malov, Denmark.	jbre@novonordisk.com	Rand, Kasper/ABG-7446-2021	Rand, Kasper/0000-0002-6337-5489				BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Chen NY, 2002, INT J ONCOL, V20, P813; Chen TJ, 1998, ENDOCRINOLOGY, V139, P609, DOI 10.1210/en.139.2.609; CHEN WY, 1994, J BIOL CHEM, V269, P20806; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Duda KM, 2003, J BIOL CHEM, V278, P22734, DOI 10.1074/jbc.M212550200; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Garcia RA, 2004, ASSAY DRUG DEV TECHN, V2, P81, DOI 10.1089/154065804322966342; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jomain JB, 2007, J BIOL CHEM, V282, P33118, DOI 10.1074/jbc.M704364200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Keeler C, 2003, J MOL BIOL, V328, P1105, DOI 10.1016/S0022-2836(03)00367-X; Kinet S, 1999, J BIOL CHEM, V274, P26033, DOI 10.1074/jbc.274.37.26033; Kinet S, 1996, J BIOL CHEM, V271, P14353, DOI 10.1074/jbc.271.24.14353; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; Peterson FC, 2004, PROTEIN ENG DES SEL, V17, P417, DOI 10.1093/protein/gzh051; Qazi AM, 2006, MOL ENDOCRINOL, V20, P1912, DOI 10.1210/me.2005-0291; Rand KD, 2006, J BIOL CHEM, V281, P23018, DOI 10.1074/jbc.M602968200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; Sivaprasad U, 2004, BIOCHEMISTRY-US, V43, P13755, DOI 10.1021/bi049333p; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Teilum K, 2005, J MOL BIOL, V351, P810, DOI 10.1016/j.jmb.2005.06.042; Ursby T, 2004, AIP CONF PROC, V705, P1241, DOI 10.1063/1.1758025; Walsh STR, 2004, P NATL ACAD SCI USA, V101, P17078, DOI 10.1073/pnas.0403336101; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623	35	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19085	19094		10.1074/jbc.M801202200	http://dx.doi.org/10.1074/jbc.M801202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18467331	hybrid			2022-12-25	WOS:000257165600064
J	Bove, PF; Hristova, M; Wesley, UV; Olson, N; Lounsbury, KM; van der Vliet, A				Bove, Peter F.; Hristova, Milena; Wesley, Umadevi V.; Olson, Nels; Lounsbury, Karen M.; van der Vliet, Albert			Inflammatory levels of nitric oxide inhibit airway epithelial cell migration by inhibition of the kinase ERK1/2 and activation of hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B; S-NITROSYLATION; FACTOR 1-ALPHA; WOUND REPAIR; TRANSCRIPTIONAL ACTIVITY; MESENCHYMAL TRANSITION	Increased synthesis of NO during airway inflammation, caused by induction of nitric-oxide synthase 2 in several lung cell types, may contribute to epithelial injury and permeability. To investigate the consequence of elevated NO production on epithelial function, we exposed cultured monolayers of human bronchial epithelial cells to the NO donor diethylenetriaamine NONOate. At concentrations generating high nanomolar levels of NO, representative of inflammatory conditions, diethylenetriaamine NONOate markedly reduced wound closure in an in vitro scratch injury model, primarily by inhibiting epithelial cell migration. Analysis of signaling pathways and gene expression profiles indicated a rapid induction of the mitogen-activated protein kinase phosphatase (MPK)-1 and decrease in extracellular signal-regulated kinase (ERK)1/2 activation, as well as marked stabilization of hypoxia-inducible factor (HIF)-1 alpha and activation of hypoxia-responsive genes, under these conditions. Inhibition of ERK1/2 signaling using U0126 enhanced HIF-1 alpha stabilization, implicating ERK1/2 dephosphorylation as a contributing mechanism in NO-mediated HIF-1 alpha activation. Activation of HIF-1 alpha by the hypoxia mimic cobalt chloride, or cell transfection with a degradation-resistant HIF-1 alpha mutant construct inhibited epithelial wound repair, implicating HIF- 1 alpha in NO-mediated inhibition of cell migration. Conversely, NO-mediated inhibition of epithelial wound closure was largely prevented after small interfering RNA suppression of HIF-1 alpha. Finally, NO-mediated inhibition of cell migration was associated with HIF-1 alpha-dependent induction of PAI-1 and activation of p53, both negative regulators of epithelial cell migration. Collectively, our results demonstrate that inflammatory levels of NO inhibit epithelial cell migration, because of suppression of ERK1/2 signaling, and activation of HIF-1 alpha and p53, with potential consequences for epithelial repair and remodeling during airway inflammation.	[Bove, Peter F.; Hristova, Milena; Olson, Nels; van der Vliet, Albert] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; [Wesley, Umadevi V.] Univ Vermont, Coll Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; [Lounsbury, Karen M.] Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	van der Vliet, A (corresponding author), Univ Vermont, Coll Med, Dept Pathol, 89 Beaumont Ave, Burlington, VT 05405 USA.	Albert.van-der-Vliet@uvm.edu						Amadeu TP, 2006, J CUTAN PATHOL, V33, P465, DOI 10.1111/j.1600-0560.2006.00472.x; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bove PF, 2007, AM J RESP CELL MOL, V36, P138, DOI 10.1165/rcmb.2006-0253SM; Bove PF, 2006, FREE RADICAL BIO MED, V41, P515, DOI 10.1016/j.freeradbiomed.2006.05.011; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Cetin S, 2007, AM J PHYSIOL-GASTR L, V292, pG1347, DOI 10.1152/ajpgi.00375.2006; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Corley KM, 2005, J CELL BIOCHEM, V96, P971, DOI 10.1002/jcb.20559; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Darling KEA, 2003, INFECT IMMUN, V71, P2341, DOI 10.1128/IAI.71.5.2341-2349.2003; Eriksson U, 2005, J IMMUNOL, V175, P2715, DOI 10.4049/jimmunol.175.4.2715; Ferlito M, 2006, P NATL ACAD SCI USA, V103, P11689, DOI 10.1073/pnas.0600275103; Fitsialos G, 2007, J BIOL CHEM, V282, P15090, DOI 10.1074/jbc.M606094200; Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839; Fujiwara S, 2007, INT J ONCOL, V30, P793; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Han XN, 2004, AM J PHYSIOL-GASTR L, V286, pG126, DOI 10.1152/ajpgi.00231.2003; Hardiman KA, 2004, AM J RESP CELL MOL, V30, P720, DOI 10.1165/rcmb.2003-0325OC; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Kilani MM, 2004, INFLAMMATION, V28, P245, DOI 10.1007/s10753-004-6047-y; Kim SJ, 2005, LUNG CANCER, V49, P325, DOI 10.1016/j.lungcan.2005.03.036; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kiviluoto T, 2001, AM J PHYSIOL-GASTR L, V281, pG1151, DOI 10.1152/ajpgi.2001.281.5.G1151; Lazar MH, 2004, AM J RESP CELL MOL, V31, P672, DOI 10.1165/rcmb.2004-0025OC; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Liang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992; Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315; Liu CJ, 2005, EXP CELL RES, V309, P410, DOI 10.1016/j.yexcr.2005.06.022; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; Pervin S, 2003, CANCER RES, V63, P8853; Polosukhin VV, 2007, VIRCHOWS ARCH, V451, P793, DOI 10.1007/s00428-007-0469-5; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Ridnour LA, 2007, P NATL ACAD SCI USA, V104, P16898, DOI 10.1073/pnas.0702761104; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Rose F, 2002, J IMMUNOL, V169, P1474, DOI 10.4049/jimmunol.169.3.1474; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Schwentker A, 2002, NITRIC OXIDE-BIOL CH, V7, P1, DOI 10.1016/S1089-8603(02)00002-2; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shukla A, 1999, MOL CELL BIOCHEM, V200, P27, DOI 10.1023/A:1006977513146; Sparkman L, 2004, AM J PHYSIOL-LUNG C, V287, pL764, DOI 10.1152/ajplung.00165.2004; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; Tzouvelekis A, 2007, AM J RESP CRIT CARE, V176, P1108, DOI 10.1164/rccm.200705-683OC; Vyas-Read S, 2007, AM J PHYSIOL-LUNG C, V293, pL212, DOI 10.1152/ajplung.00475.2006; Wang XX, 2007, CELL SIGNAL, V19, P1372, DOI 10.1016/j.cellsig.2007.03.013; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Weis M, 2002, ARTERIOSCL THROM VAS, V22, P1817, DOI 10.1161/01.ATV.0000036418.04998.D5; Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200; White SR, 2005, AM J RESP CELL MOL, V32, P301, DOI 10.1165/rcmb.2004-0118OC; Xu WL, 2006, FREE RADICAL BIO MED, V41, P19, DOI 10.1016/j.freeradbiomed.2006.01.037; Zheng S, 2003, IMMUNITY, V18, P619, DOI 10.1016/S1074-7613(03)00114-6; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	68	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17919	17928		10.1074/jbc.M709914200	http://dx.doi.org/10.1074/jbc.M709914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18424783	Green Published, hybrid			2022-12-25	WOS:000256949200020
J	Chang, MH; DiPiero, J; Sonnichsen, FD; Romero, MF				Chang, Min-Hwang; DiPiero, Jennifer; Soennichsen, Frank D.; Romero, Michael F.			Entry to "HCO3- tunnel" revealed by SLC4A4 human mutation and structural model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; ELECTROGENIC NA+-HCO3-COTRANSPORTER; NA+/HCO3-COTRANSPORTER; PH-SENSOR; OCULAR ABNORMALITIES; FUNCTIONAL-ANALYSIS; CYTOPLASMIC DOMAIN; MISSENSE MUTATION; MICE LACKING; SWISS-MODEL	Glaucoma, cataracts, and proximal renal tubular acidosis are diseases caused by point mutations in the human electrogenic Na+ bicarbonate cotransporter (NBCe1/SLC4A4) (1, 2). One such mutation, R298S, is located in the cytoplasmic N-terminal domain of NBCe1 and has only moderate (75%) function. As SLC transporters have high similarity in their membrane and N-terminal primary sequences, we homology-modeled NBCe1 onto the crystal structure coordinates of Band 3(AE1) (3). Arg-298 is predicted to be located in a solvent-inaccessible subsurface pocket and to associate with Glu-91 or Glu-295 via H-bonding and charge- charge interactions. We perturbed these putative interactions between Glu-91 and Arg-298 by site-directed mutagenesis and used expression in Xenopus oocyte to test our structural model. Mutagenesis of either residue resulted in reduced transport function. Function was "repaired" by charge reversal (E91R/R298E), implying that these two residues are interchangeable and interdependent. These results contrast the current understanding of the AE1 N terminus as protein-binding sites and propose that hkNBCe1 (and other SLC4) cytoplasmic N termini play roles in controlling HCO3- permeation.	[Chang, Min-Hwang; Romero, Michael F.] Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; [Chang, Min-Hwang; DiPiero, Jennifer; Soennichsen, Frank D.; Romero, Michael F.] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Mayo Clinic; Case Western Reserve University	Romero, MF (corresponding author), Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, 200 1st St SW,Guggenheim 9-21D, Rochester, MN 55905 USA.	romero.michael@mayo.edu	Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755	NEI NIH HHS [R01 EY017732, EY 017732] Funding Source: Medline; NIDDK NIH HHS [DK 056218] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY017732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056218] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Chernova MN, 2005, J BIOL CHEM, V280, P8564, DOI 10.1074/jbc.M411703200; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; Cunninghan R, 2004, J BIOL CHEM, V279, P37815, DOI 10.1074/jbc.M405893200; Demirci FYK, 2006, MOL VIS, V12, P324; Dinour D, 2004, J BIOL CHEM, V279, P52238, DOI 10.1074/jbc.M406591200; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Gawenis LR, 2007, J BIOL CHEM, V282, P9042, DOI 10.1074/jbc.M607041200; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gill HS, 2006, ACTA CRYSTALLOGR F, V62, P534, DOI 10.1107/S1744309106015181; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; Gross E, 2001, J PHYSIOL-LONDON, V531, P375, DOI 10.1111/j.1469-7793.2001.0375i.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Horita S, 2005, J AM SOC NEPHROL, V16, P2270, DOI 10.1681/ASN.2004080667; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Igarashi T, 1999, NAT GENET, V23, P264, DOI 10.1038/15440; Igarashi T, 2001, J AM SOC NEPHROL, V12, P713, DOI 10.1681/ASN.V124713; IGARASHI T, 2000, J AM SOC NEPHROL, V11; Inatomi J, 2004, PFLUG ARCH EUR J PHY, V448, P438, DOI 10.1007/s00424-004-1278-1; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McAlear SD, 2006, J GEN PHYSIOL, V127, P639, DOI 10.1085/jgp.200609520; Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Romero MF, 2005, CURR OPIN NEPHROL HY, V14, P495, DOI 10.1097/01.mnh.0000168333.01831.2c; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Romero MF, 2002, FASEB J, V16, pA52; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Shirakabe K, 2006, P NATL ACAD SCI USA, V103, P9542, DOI 10.1073/pnas.0602250103; Stewart AK, 2004, J BIOL CHEM, V279, P52664, DOI 10.1074/jbc.M408108200; Stroffekova K, 1998, AM J PHYSIOL-CELL PH, V275, pC1113, DOI 10.1152/ajpcell.1998.275.4.C1113; Takano J, 2002, NATURE, V420, P337, DOI 10.1038/nature01139; Tatishchev S, 2003, BIOCHEMISTRY-US, V42, P755, DOI 10.1021/bi026826q; Toye AM, 2006, AM J PHYSIOL-CELL PH, V291, pC788, DOI 10.1152/ajpcell.00094.2006; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; Willard L, 2003, NUCLEIC ACIDS RES, V31, P3316, DOI 10.1093/nar/gkg565; Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang DC, 2000, BLOOD, V96, P2925	51	44	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18402	18410		10.1074/jbc.M709819200	http://dx.doi.org/10.1074/jbc.M709819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441326	Green Published, hybrid			2022-12-25	WOS:000256949200068
J	Ignatev, A; Kravchenko, S; Rak, A; Goody, RS; Pylypenko, O				Ignatev, Alexander; Kravchenko, Sergey; Rak, Alexey; Goody, Roger S.; Pylypenko, Olena			A structural model of the GDP dissociation inhibitor rab membrane extraction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CHOROIDEREMIA DISEASE; COMPLEX; SUPERFAMILY; PRENYLATION; EVOLUTION	Rab GDP dissociation inhibitors (GDI)-facilitated extraction of prenylated Rab proteins from membranes plays an important role in vesicular membrane trafficking. The investigated thermodynamic properties of yeast Rab.GDI and Rab.MRS6 complexes demonstrated differences in the Rab binding properties of the closely related Rab GDI and MRS6 proteins, consistent with their functional diversity. The importance of the Rab C terminus and its prenylation for GDI/MRS6 binding was demonstrated using both biochemical and structural data. The presented structures of the apo-form yeast Rab GDI and its two complexes with unprenylated Rab proteins, together with the earlier published structures of the prenylated Ypt1.GDI, provide evidence of allosteric regulation of the GDI lipid binding site opening, which plays a key role in the proposed mechanism of GDI-mediated Rab extraction. We suggest a model for the interaction of GDI with prenylated Rab proteins that incorporates a stepwise increase in affinity as the three different partial interactions are successively formed.	[Ignatev, Alexander; Kravchenko, Sergey; Rak, Alexey; Goody, Roger S.; Pylypenko, Olena] Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; [Goody, Roger S.] Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	Max Planck Society; Ruhr University Bochum	Pylypenko, O (corresponding author), Max Planck Inst Mol Physiol, Dortmund Otto Hahn Str 11, D-44227 Dortmund, Germany.	pylypenk@mpi-dortmund.mpg.de	Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Pylypenko, Olena/0000-0001-7073-5238; Kravchenko, Sergey/0000-0002-1261-7919				Alory C, 2003, MOL BIOL CELL, V14, P3857, DOI 10.1091/mbc.E03-04-0227; Alory C, 2001, TRAFFIC, V2, P532, DOI 10.1034/j.1600-0854.2001.20803.x; An Y, 2003, STRUCTURE, V11, P347, DOI 10.1016/S0969-2126(03)00034-0; ARAKI S, 1990, J BIOL CHEM, V265, P13007; Calero M, 2003, MOL BIOL CELL, V14, P1852, DOI 10.1091/mbc.E02-11-0707; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Goody RS, 2005, CELL MOL LIFE SCI, V62, P1657, DOI 10.1007/s00018-005-4486-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ignatev A, 2007, J STRUCT BIOL, V159, P154, DOI 10.1016/j.jsb.2007.02.005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pylypenko O, 2006, EMBO J, V25, P13, DOI 10.1038/sj.emboj.7600921; Rak A, 2004, CELL, V117, P749, DOI 10.1016/j.cell.2004.05.017; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wu YW, 2007, P NATL ACAD SCI USA, V104, P12294, DOI 10.1073/pnas.0701817104	21	32	32	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18377	18384		10.1074/jbc.M709718200	http://dx.doi.org/10.1074/jbc.M709718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18426803	Green Published, hybrid			2022-12-25	WOS:000256949200065
J	Nojima, T; Murayama, S; Yoshida, M; Motojima, F				Nojima, Tatsuya; Murayama, Shigeto; Yoshida, Masasuke; Motojima, Fumihiro			Determination of the number of active GroES subunits in the fused heptamer GroES required for interactions with GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CRYSTAL-STRUCTURE; IN-VIVO; POLYPEPTIDE BINDING; SUBSTRATE PROTEIN; ESCHERICHIA-COLI; RELEASE; CAVITY; ATP; 2.8-ANGSTROM	A double-heptamer ring chaperonin GroEL binds denatured substrate protein, ATP, and GroES to the same heptamer ring and encapsulates substrate into the central cavity underneath GroES where productive folding occurs. GroES is a disk-shaped heptamer, and each subunit has a GroEL-binding loop. The residues of the GroEL subunit responsible for GroES binding largely overlap those involved in substrate binding, and the mechanism by which GroES can replace the substrate when GroES binds to GroEL/substrate complex remains to be clarified. To address this question, we generated single polypeptide GroES by fusing seven subunits with various combinations of active and GroEL binding-defective subunits. Functional tests of the fused GroES variants indicated that four active GroES subunits were required for efficient formation of the stable GroEL/GroES complex and five subunits were required for the productive GroEL/substrate/GroES complex. An increase in the number of defective GroES subunits resulted in a slowing of encapsulation and folding. These results indicate the presence of an intermediate GroEL/substrate/GroES complex in which the substrate and GroES bind to GroEL by sharing seven common binding sites.	[Nojima, Tatsuya; Murayama, Shigeto; Yoshida, Masasuke; Motojima, Fumihiro] Tokyo Inst Technol, Chem Resources Lab R1 7, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab R1 7, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp; fumihiro.motojima@res.titech.ac.jp	Nojima, Tatsuya/E-9741-2017; Motojima, Fumihiro/J-2389-2014; Nojima, Tatsuya/S-4325-2019	Nojima, Tatsuya/0000-0002-0422-0225; Motojima, Fumihiro/0000-0003-4461-8673; Nojima, Tatsuya/0000-0002-0422-0225				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Elad N, 2007, MOL CELL, V26, P415, DOI 10.1016/j.molcel.2007.04.004; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Koike-Takeshita A, 2006, J BIOL CHEM, V281, P962, DOI 10.1074/jbc.M506298200; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Sakane I, 2007, J MOL BIOL, V367, P1171, DOI 10.1016/j.jmb.2007.01.037; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Taguchi H, 2001, NAT BIOTECHNOL, V19, P861, DOI 10.1038/nbt0901-861; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	30	17	17	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18385	18392		10.1074/jbc.M709825200	http://dx.doi.org/10.1074/jbc.M709825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18430731	hybrid			2022-12-25	WOS:000256949200066
J	Fujii, S; Ito, K; Ito, Y; Ochiai, A				Fujii, Satoshi; Ito, Kosei; Ito, Yoshiaki; Ochiai, Atsushi			Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN EZH2; CANCER CELL-LINES; TUMOR-SUPPRESSOR; GASTRIC-CANCER; PROMOTER HYPERMETHYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; PROSTATE-CANCER; BREAST-CANCER; POLYCOMB	Overexpression of enhancer of zeste homologue 2 (EZH2) occurs in various malignancies and is associated with a poor prognosis, especially because of increased cancer cell proliferation. In this study we found an inverse correlation between EZH2 and RUNX3 gene expression in five cancer cell lines, i.e. gastric, breast, prostate, colon, and pancreatic cancer cell lines. Chromatin immunoprecipitation assay showed an association between EZH2 bound to the RUNX3 gene promoter, and trimethylated histone H3 at lysine 27, and HDAC1 (histone deacetylase 1) bound to the RUNX3 gene promoter in cancer cells. RNA interference-mediated knockdown of EZH2 resulted in a decrease in H3K27 trimethylation and unbound HDAC1 and an increase in expression of the RUNX3 gene. Restoration of RUNX3 expression was not associated with any change in DNA methylation status in the RUNX3 promoter region. RUNX3 was repressed by histone deacetylation and hypermethylation of a CpG island in the promoter region and restored by trichostatin A or/and 5-aza-2'-deoxycytidine. Immunofluorescence staining confirmed restoration of expression of the RUNX3 protein after knockdown of EZH2 and its restoration resulted in decreased cell proliferation. In vivo, an inverse relationship between expression of the EZH2 and RUNX3 proteins was observed at the individual cell level in gastric cancer patients in the absence of DNA methylation in the RUNX3 promoter region. The results showed that RUNX3 is a target for repression by EZH2 and indicated an underlying mechanism of the functional role of EZH2 overexpression on cancer cell proliferation.	[Fujii, Satoshi; Ochiai, Atsushi] Natl Canc Ctr, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba 2778577, Japan; [Ito, Kosei; Ito, Yoshiaki] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 138673, Singapore	National Cancer Center - Japan; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Ochiai, A (corresponding author), Natl Canc Ctr, Res Ctr Innovat Oncol, Div Pathol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp						Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	32	149	158	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17324	17332		10.1074/jbc.M800224200	http://dx.doi.org/10.1074/jbc.M800224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430739	hybrid, Green Published			2022-12-25	WOS:000256720600041
J	Upton, JW; Kaiser, WJ; Mocarski, ES				Upton, Jason W.; Kaiser, William J.; Mocarski, Edward S.			Cytomegalovirus m45 cell death suppression requires receptor-interacting protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; RIBONUCLEOTIDE REDUCTASE HOMOLOG; DOMAIN KINASE RIP; MURINE CYTOMEGALOVIRUS; LOCALIZED INHIBITOR; INDUCED APOPTOSIS; ADAPTER TRIF; IDENTIFICATION; ACTIVATION	Herpesviruses such as cytomegaloviruses encode functions that modulate the innate response in diverse ways to counteract host sensing and delay host clearance during infection. The murine cytomegalovirus M45 protein interacts with receptor-interacting protein (RIP) 1 and RIP3 via a RIP homotypic interaction motif. Cell death suppression by M45 requires RIP homotypic interaction motif-dependent interaction with RIP1. This interaction also underlies the cell tropism role of M45 in preventing premature death of endothelial cells during murine cytomegalovirus infection. Thus, M45 is a viral inhibitor of RIP activation that provides a direct cell type-dependent replication benefit to the virus while modulating other biological processes signaling via the RIP1 adaptor such as activation of Toll- like receptor (TLR)3 as well as other mediators of cell death.	[Upton, Jason W.; Kaiser, William J.; Mocarski, Edward S.] Emory Univ, Sch Med, Emory Vaccine Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Mocarski, ES (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Dept Microbiol & Immunol, 1462 Clifton Rd NE, Atlanta, GA 30322 USA.	mocarski@emory.edu	Mocarski, Edward/ABC-2893-2020	Upton, Jason/0000-0002-4218-4026	NHLBI NIH HHS [T32 HL069769] Funding Source: Medline; NIAID NIH HHS [R01 AI 030363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abate DA, 2004, J VIROL, V78, P10995, DOI 10.1128/JVI.78.20.10995-11006.2004; Brune W, 2003, J VIROL, V77, P11633, DOI 10.1128/JVI.77.21.11633-11643.2003; Brune W, 2001, SCIENCE, V291, P303, DOI 10.1126/science.291.5502.303; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Hahn G, 2002, J VIROL, V76, P9551, DOI 10.1128/JVI.76.18.9551-9555.2002; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Kattenhorn LM, 2004, J VIROL, V78, P11187, DOI 10.1128/JVI.78.20.11187-11197.2004; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Lembo D, 2004, J VIROL, V78, P4278, DOI 10.1128/JVI.78.8.4278-4288.2004; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Mack C, 2008, P NATL ACAD SCI USA, V105, P3094, DOI 10.1073/pnas.0800168105; MANNING WC, 1992, J VIROL, V66, P3794, DOI 10.1128/JVI.66.6.3794-3802.1992; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; McCormick AL, 2003, VIROLOGY, V316, P221, DOI 10.1016/j.virol.2003.07.003; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004; Orange JS, 1997, J VIROL, V71, P9248, DOI 10.1128/JVI.71.12.9248-9258.1997; PAVIC I, 1993, J GEN VIROL, V74, P2215, DOI 10.1099/0022-1317-74-10-2215; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; Popkin DL, 2003, J VIROL, V77, P10125, DOI 10.1128/JVI.77.18.10125-10130.2003; Roy CR, 2007, NAT IMMUNOL, V8, P1179, DOI 10.1038/ni1528; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Upton JW, 2005, VIROLOGY, V341, P271, DOI 10.1016/j.virol.2005.07.014; van Dommelen SLH, 2006, IMMUNITY, V25, P835, DOI 10.1016/j.immuni.2006.09.010; VANDENABEELE P, 2006, SCI STKE, pPE44; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; Zhou J, 2007, INVEST OPHTH VIS SCI, V48, P1691, DOI 10.1167/iovs.06-1040	38	150	157	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					16966	16970		10.1074/jbc.C800051200	http://dx.doi.org/10.1074/jbc.C800051200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18442983	hybrid, Green Published			2022-12-25	WOS:000256720600002
J	Inoue, O; Suzuki-Inoue, K; Ozaki, Y				Inoue, Osamu; Suzuki-Inoue, Katsue; Ozaki, Yukio			Redundant mechanism of platelet adhesion to laminin and collagen under flow - Involvement of von Willebrand factor and glycoprotein Ib-IX-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1; ACTIVATION; RECEPTOR; GPVI	Although the role of collagen in thrombosis has been extensively investigated, the contribution of other extracellular matrices is still unclear. We have recently reported that laminin stimulates platelet spreading through integrin alpha(6)beta(1)-dependent activation of the collagen receptor glycoprotein ( GP) VI under static condition. Under physiological high and low shear conditions, platelets adhered to laminin, and this was strongly inhibited by an antibody that blocks association between GPIb-IX-V and von Willebrand factor (VWF). Moreover, platelets of type III von Willebrand disease or Bernard-Soulier syndrome adhered to laminin at a low shear condition but not at a high shear condition. The specific binding of laminin to VWF was confirmed by surface plasmin resonance spectroscopy (BIAcore). These findings suggest that laminin supports platelet adhesion depending on the interaction of VWF and GPIb-IX-V under pathophysiological high shear flow. This mechanism is similar to that of collagen. We propose that integrins, GPVI, GPIb-IX-V, and VWF represent a general paradigm for the interaction between platelets and subendothelial matrices.	[Inoue, Osamu; Suzuki-Inoue, Katsue; Ozaki, Yukio] Univ Yamanashi, Dept Clin & Lab Med, Fac Med, Chuo Ku, Yamanashi 4093898, Japan	University of Yamanashi	Inoue, O (corresponding author), Univ Yamanashi, Dept Clin & Lab Med, Fac Med, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	oinoue@yamanashi.ac.jp						Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Eto K, 1999, ARTERIOSCL THROM VAS, V19, P877, DOI 10.1161/01.ATV.19.4.877; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; HINDRIKS G, 1992, BLOOD, V79, P928; Inoue O, 2006, BLOOD, V107, P1405, DOI 10.1182/blood-2005-06-2406; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jung SM, 2000, TRENDS CARDIOVAS MED, V10, P285, DOI 10.1016/S1050-1738(01)00064-0; Matsui T, 1997, J BIOCHEM-TOKYO, V121, P376; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; WAGNER DD, 1984, P NATL ACAD SCI-BIOL, V81, P471, DOI 10.1073/pnas.81.2.471	12	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16279	16282		10.1074/jbc.C700241200	http://dx.doi.org/10.1074/jbc.C700241200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18450753	hybrid			2022-12-25	WOS:000256497100003
J	Hendrickson, DG; Hogan, DJ; Herschlag, D; Ferrell, JE; Brown, PO				Hendrickson, David G.; Hogan, Daniel J.; Herschlag, Daniel; Ferrell, James E.; Brown, Patrick O.			Systematic Identification of mRNAs Recruited to Argonaute 2 by Specific microRNAs and Corresponding Changes in Transcript Abundance	PLOS ONE			English	Article							ANIMAL DEVELOPMENT; GENE-REGULATION; LET-7 MICRORNA; BINDING-SITES; IN-VIVO; MIRNAS; EXPRESSION; PROTEINS; DISCOVERY; CLEAVAGE	microRNAs (miRNAs) are small non-coding RNAs that regulate mRNA stability and translation through the action of the RNAi-induced silencing complex (RISC). Our current understanding of miRNA function is inferred largely from studies of the effects of miRNAs on steady-state mRNA levels and from seed match conservation and context in putative targets. Here we have taken a more direct approach to these issues by comprehensively assessing the miRNAs and mRNAs that are physically associated with Argonaute 2 (Ago2), which is a core RISC component. We transfected HEK293T cells with epitope-tagged Ago2, immunopurified Ago2 together with any associated miRNAs and mRNAs, and quantitatively determined the levels of these RNAs by microarray analyses. We found that Ago2 immunopurified samples contained a representative repertoire of the cell's miRNAs and a select subset of the cell's total mRNAs. Transfection of the miRNAs miR-1 and miR-124 caused significant changes in the association of scores of mRNAs with Ago2. The mRNAs whose association with Ago2 increased upon miRNA expression were much more likely to contain specific miRNA seed matches and to have their overall mRNA levels decrease in response to the miRNA transfection than expected by chance. Hundreds of mRNAs were recruited to Ago2 by each miRNA via seed sequences in 3'-untranslated regions and coding sequences and a few mRNAs appear to be targeted via seed sequences in 5'-untranslated regions. Microarray analysis of Ago2 immunopurified samples provides a simple, direct method for experimentally identifying the targets of miRNAs and for elucidating roles of miRNAs in cellular regulation.	[Hendrickson, David G.; Ferrell, James E.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Hogan, Daniel J.; Herschlag, Daniel; Ferrell, James E.; Brown, Patrick O.] Stanford Univ, Sch Med, Dept Biochem, Palo Alto, CA USA; [Hogan, Daniel J.; Brown, Patrick O.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Palo Alto, CA USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Hendrickson, DG (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA.	herschla@stanford.edu; pbrown@pmgm2.stanford.edu			Howard Hughes Medical Institute; National Cancer Institute; National Institutes of Health [GM61276]; NSF [predoctoral fellowship]; AHA [predoctoral fellowship]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061276] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); AHA(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Howard Hughes Medical Institute, by a grant from the National Cancer Institute to POB, and by a grant from the National Institutes of Health (GM61276) to JEF. POB is an investigator of the Howard Hughes Medical Institute. DGH was partially supported by an NSF predoctoral fellowship and DJH was partially supported by NSF and AHA predoctoral fellowships.	Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; *AMB, 2008, MIRVANA MIRNA PROB S; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Behm-Ansmant I, 2006, GENE DEV, V20, P1885, DOI 10.1101/gad.1424106; Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012; Chen PY, 2005, BIOL CHEM, V386, P1205, DOI 10.1515/BC.2005.139; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Demeter J, 2007, NUCLEIC ACIDS RES, V35, pD766, DOI 10.1093/nar/gkl1019; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Easow G, 2007, RNA, V13, P1198, DOI 10.1261/rna.563707; Efron B, 2002, GENET EPIDEMIOL, V23, P70, DOI 10.1002/gepi.1124; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enright AJ, 2004, GENOME BIOL, V5; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Eulalio A, 2007, GENE DEV, V21, P2558, DOI 10.1101/gad.443107; Fare TL, 2003, ANAL CHEM, V75, P4672, DOI 10.1021/ac034241b; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Ferea TL, 1999, CURR OPIN GENET DEV, V9, P715, DOI 10.1016/S0959-437X(99)00033-7; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hall TMT, 2005, STRUCTURE, V13, P1403, DOI 10.1016/j.str.2005.08.005; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; JACKSON RJ, 2007, SCI STKE, pRE1, DOI DOI 10.1126/STKE.3672007RE1; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Myers JW, 2005, METH MOL B, V309, P93; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Peters L, 2007, MOL CELL, V26, P611, DOI 10.1016/j.molcel.2007.05.001; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rehwinkel J, 2006, MOL CELL BIOL, V26, P2965, DOI 10.1128/MCB.26.8.2965-2975.2006; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schmitter D, 2006, NUCLEIC ACIDS RES, V34, P4801, DOI 10.1093/nar/gkl646; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; *SFGF, 2008, HUM EX EV BAS OL HEE; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu LG, 2005, MOL CELL BIOL, V25, P9198, DOI 10.1128/MCB.25.21.9198-9208.2005; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhang L, 2007, MOL CELL, V28, P598, DOI 10.1016/j.molcel.2007.09.014	76	148	153	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2126	10.1371/journal.pone.0002126	http://dx.doi.org/10.1371/journal.pone.0002126			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461144	Green Submitted, Green Published, gold			2022-12-25	WOS:000261642400047
J	Kim, JW; Roberts, CD; Berg, SA; Caicedo, A; Roper, SD; Chaudhari, N				Kim, Joung Woul; Roberts, Craig D.; Berg, Stephanie A.; Caicedo, Alejandro; Roper, Stephen D.; Chaudhari, Nirupa			Imaging Cyclic AMP Changes in Pancreatic Islets of Transgenic Reporter Mice	PLOS ONE			English	Article								Cyclic AMP (cAMP) and Ca(2+) are two ubiquitous second messengers in transduction pathways downstream of receptors for hormones, neurotransmitters and local signals. The availability of fluorescent Ca(2+) reporter dyes that are easily introduced into cells and tissues has facilitated analysis of the dynamics and spatial patterns for Ca(2+) signaling pathways. A similar dissection of the role of cAMP has lagged because indicator dyes do not exist. Genetically encoded reporters for cAMP are available but they must be introduced by transient transfection in cell culture, which limits their utility. We report here that we have produced a strain of transgenic mice in which an enhanced cAMP reporter is integrated in the genome and can be expressed in any targeted tissue and with tetracycline induction. We have expressed the cAMP reporter in beta-cells of pancreatic islets and conducted an analysis of intracellular cAMP levels in relation to glucose stimulation, Ca(2+) levels, and membrane depolarization. Pancreatic function in transgenic mice was normal. In induced transgenic islets, glucose evoked an increase in cAMP in beta-cells in a dose-dependent manner. The cAMP response is independent of (in fact, precedes) the Ca(2+) influx that results from glucose stimulation of islets. Glucose-evoked cAMP responses are synchronous in cells throughout the islet and occur in 2 phases suggestive of the time course of insulin secretion. Insofar as cAMP in islets is known to potentiate insulin secretion, the novel transgenic mouse model will for the first time permit detailed analyses of cAMP signals in beta-cells within islets, i.e. in their native physiological context. Reporter expression in other tissues (such as the heart) where cAMP plays a critical regulatory role, will permit novel biomedical approaches.	[Kim, Joung Woul; Berg, Stephanie A.; Roper, Stephen D.; Chaudhari, Nirupa] Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33152 USA; [Roberts, Craig D.; Caicedo, Alejandro; Roper, Stephen D.; Chaudhari, Nirupa] Univ Miami, Sch Med, Program Neurosci, Miami, FL USA; [Caicedo, Alejandro] Univ Miami, Sch Med, Diabetes Res Inst, Miami, FL USA	University of Miami; University of Miami; University of Miami	Kim, JW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33152 USA.	NChaudhari@med.miami.edu	Caicedo, Alejandro/F-1202-2010; Caicedo, Alejandro/AAC-8544-2020	Kim, Joung Woul/0000-0001-5456-8820; Roper, Stephen/0000-0001-6049-8320; Berg, Stephanie/0000-0001-6193-5350; Tilahin, Shimelis/0000-0001-8975-8026	National Institutes of Health [F31DC007591, R03DK075487, R01DC000374, R01DC006021, R01DC006308]; The Diabetes Research Institute, University of Miami; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK075487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006308, R01DC006021, F31DC007591, R01DC000374] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Diabetes Research Institute, University of Miami; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by grants from the National Institutes of Health: F31DC007591 (C.D.R.), R03DK075487 (A.C.), R01DC000374 (S.D.R.), R01DC006021 and R01DC006308 (N.C). The Diabetes Research Institute, University of Miami, also provided support for this project. The study sponsors were not involved in study design, data analysis, or manuscript preparation.	ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; Beauvois MC, 2006, AM J PHYSIOL-CELL PH, V290, pC1503, DOI 10.1152/ajpcell.00400.2005; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; Bozza T, 2004, NEURON, V42, P9, DOI 10.1016/S0896-6273(04)00144-8; CHARLES MA, 1975, J BIOL CHEM, V250, P6134; Dachicourt N, 1996, AM J PHYSIOL-ENDOC M, V271, pE725, DOI 10.1152/ajpendo.1996.271.4.E725; Dyachok O, 2006, NATURE, V439, P349, DOI 10.1038/nature04410; El-Kholy W, 2007, MOL ENDOCRINOL, V21, P753, DOI 10.1210/me.2006-0258; Ghil S, 2006, P NATL ACAD SCI USA, V103, P19158, DOI 10.1073/pnas.0609392103; GILON P, 1993, J BIOL CHEM, V268, P22265; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Hasan MT, 2004, PLOS BIOL, V2, P763, DOI 10.1371/journal.pbio.0020163; Hatakeyama H, 2007, J PHYSIOL-LONDON, V582, P1087, DOI 10.1113/jphysiol.2007.135228; Heim N, 2007, NAT METHODS, V4, P127, DOI 10.1038/nmeth1009; Henquin JC, 2006, DIABETES, V55, P441, DOI 10.2337/diabetes.55.02.06.db05-1051; Hisatomi M, 1996, ENDOCRINOLOGY, V137, P4644, DOI 10.1210/en.137.11.4644; Holz GG, 2006, J PHYSIOL-LONDON, V577, P5, DOI 10.1113/jphysiol.2006.119644; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; Kang GX, 2006, J PHYSIOL-LONDON, V573, P595, DOI 10.1113/jphysiol.2006.107391; Kim JW, 2006, CHEM SENSES, V31, P213, DOI 10.1093/chemse/bjj021; Klopotowska D, 2008, NEUROCHEM INT, V52, P221, DOI 10.1016/j.neuint.2007.05.014; LACY PE, 1975, LAB INVEST, V33, P570; Landa LR, 2005, J BIOL CHEM, V280, P31294, DOI 10.1074/jbc.M505657200; MacDonald PE, 2005, PHILOS T R SOC B, V360, P2211, DOI 10.1098/rstb.2005.1762; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Neary CL, 2001, ONCOGENE, V20, P8019, DOI 10.1038/sj.onc.1204992; Nikolaev VO, 2006, CIRC RES, V99, P1084, DOI 10.1161/01.RES.0000250046.69918.d5; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Nunemaker CS, 2006, AM J PHYSIOL-ENDOC M, V290, pE523, DOI 10.1152/ajpendo.00392.2005; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; Schonig Kai, 2003, Methods Mol Biol, V209, P69; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	35	26	26	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2127	10.1371/journal.pone.0002127	http://dx.doi.org/10.1371/journal.pone.0002127			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461145	Green Submitted, Green Published, gold			2022-12-25	WOS:000261642400048
J	Mori, I; Parizot, C; Dorgham, K; Demeret, S; Amoura, Z; Bolgert, F; Gorochov, G				Mori, Izumi; Parizot, Christophe; Dorgham, Karim; Demeret, Sophie; Amoura, Zahir; Bolgert, Francis; Gorochov, Guy			Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barre Syndrome	PLOS ONE			English	Article								Background: High doses of pooled polyclonal IgG are commonly used to treat numerous autoimmune diseases. Their mode of action nevertheless remains only partially explained. At the same time, until now, no early biological marker has been able to predict their efficacy. Methodology/Principal Findings: In a first pilot retrospective analysis, we reviewed white blood cell counts and blood smears in consecutive patients with autoimmune disease (n = 202) and non-autoimmune disease (n = 104). Autoimmune patients received either intravenous immunoglobulin (IVIg, n = 103), plasma exchange (n = 78) or no specific treatment (n = 21). We then prospectively monitored consecutive autoimmune patients with IVIg injection (n = 67), or without any specific treatment (n = 10) using the same routine laboratory tests, as well as flow cytometry. Both retrospective and prospective analyses identified large plasma-cell mobilization exclusively in IVIg-treated autoimmune patients 7 days after initiation of treatment. The majority of IVIg-mobilized plasma cells were immature HLA-DR(high)/CD138(low)/CXCR4(low) plasma cells expressing intracellular immunoglobulin G which were neither IVIg- nor human IgG-specific. Importantly, we found a strong negative correlation between the absolute number of IVIg- mobilized plasma cells and time to improve neurological function in both retrospective and prospective studies of Guillain-Barre syndrome (GBS), (r = -0.52, p = 0.0031, n = 30, r = 20.47, p = 0.0028, n = 40, respectively). Conclusions/Significance: IVIg promotes immature plasma-cell mobilization in patients with GBS, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis and inflammatory myopathy. Prominent day 7 plasma-cell mobilization is a favourable prognostic marker in patients with GBS receiving IVIg treatment.	[Mori, Izumi; Dorgham, Karim; Gorochov, Guy] INSERM, U543, Paris, France; [Parizot, Christophe; Gorochov, Guy] Assistance Publ Hop Paris AP HP, Hop Pitie Salpetriere, Lab Immunol Cellulaire Tissulaire, Paris, France; [Demeret, Sophie; Bolgert, Francis] Assistance Publ Hop Paris AP HP, Hop Pitie Salpetriere, Dept Neurol, Paris, France; [Amoura, Zahir] Assistance Publ Hop Paris AP HP, Hop Pitie Salpetriere, Dept Internal Med, Paris, France; [Mori, Izumi; Amoura, Zahir; Gorochov, Guy] Univ Pierre Marie Curie Paris 6 UPMC, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Mori, I (corresponding author), INSERM, U543, Paris, France.	guy.gorochov@psl.aphp.fr	AMOURA, Zahir/P-5324-2017; Dorgham, karim/A-2241-2016; Gorochov, Guy/P-2911-2017; Amoura, Zahir/P-5325-2017	AMOURA, Zahir/0000-0003-0292-9043; Dorgham, karim/0000-0001-9539-3203; PARIZOT, Christophe/0000-0001-5723-4471; Gorochov, Guy/0000-0003-2097-9677	Assistance Publique - Hopitaux de Paris (CIB Pitie-Salpetriere); INSERM; Laboratoire francais du Fractionnement et des Biotechnologies (LFB-Biomedicaments)	Assistance Publique - Hopitaux de Paris (CIB Pitie-Salpetriere); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Laboratoire francais du Fractionnement et des Biotechnologies (LFB-Biomedicaments)	This study was financially supported by Assistance Publique - Hopitaux de Paris (CIB Pitie-Salpetriere) and by grants from INSERM and Laboratoire francais du Fractionnement et des Biotechnologies (LFB-Biomedicaments).	Ahmed AR, 2004, EXPERT OPIN INV DRUG, V13, P1019, DOI 10.1517/13543784.13.8.1019; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; Cepok S, 2005, BRAIN, V128, P1667, DOI 10.1093/brain/awh486; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; de Grandmont MJ, 2003, BLOOD, V101, P3065, DOI 10.1182/blood-2002-06-1684; Gold R, 2007, NAT CLIN PRACT NEURO, V3, P36, DOI 10.1038/ncpneuro0376; Govoni V, 2001, CURR OPIN NEUROL, V14, P605, DOI 10.1097/00019052-200110000-00009; Gurcan HM, 2007, ANN PHARMACOTHER, V41, P812, DOI 10.1345/aph.1K037; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Hughes RAC, 1997, LANCET, V349, P225; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; HUGHES RAC, 1993, LANCET, V341, P586; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Muehlinghaus G, 2005, BLOOD, V105, P3965, DOI 10.1182/blood-2004-08-2992; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Nimmerjahn F, 2007, J EXP MED, V204, P11, DOI 10.1084/jem.20061788; Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507; Odendahl M, 2000, J IMMUNOL, V165, P5970, DOI 10.4049/jimmunol.165.10.5970; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Ravetch JV, 2007, NAT IMMUNOL, V8, P337, DOI 10.1038/ni0407-337; Siragam V, 2006, NAT MED, V12, P688, DOI 10.1038/nm1416; STEVENS RH, 1979, J IMMUNOL, V122, P2498; THOMSON PD, 1977, J IMMUNOL, V118, P1480; van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X; van Koningsveld R, 2007, LANCET NEUROL, V6, P589, DOI 10.1016/S1474-4422(07)70130-8; VANDERMECHE EF, 1992, NEW ENGL J MED, V326, P1123; Vassilev T, 1999, EUR J IMMUNOL, V29, P2436, DOI 10.1002/(SICI)1521-4141(199908)29:08<2436::AID-IMMU2436>3.3.CO;2-0; Victor M, 2001, ADAMS VICTORS PRINCI, P1536; Visser LH, 1999, NEUROLOGY, V53, P598, DOI 10.1212/WNL.53.3.598; Xiang Z, 2007, NAT IMMUNOL, V8, P419, DOI 10.1038/ni1440; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101	35	15	17	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2109	10.1371/journal.pone.0002109	http://dx.doi.org/10.1371/journal.pone.0002109			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461177	Green Published, gold			2022-12-25	WOS:000261642400031
J	Bogdanik, L; Framery, B; Froelich, A; Franco, B; Mornet, D; Bockaert, J; Sigrist, SJ; Grau, Y; Parmentier, ML				Bogdanik, Laurent; Framery, Berenice; Froelich, Andreas; Franco, Benedicte; Mornet, Dominique; Bockaert, Joel; Sigrist, Stephan J.; Grau, Yves; Parmentier, Marie-Laure			Muscle Dystroglycan Organizes the Postsynapse and Regulates Presynaptic Neurotransmitter Release at the Drosophila Neuromuscular Junction	PLOS ONE			English	Article								Background: The Dystrophin-glycoprotein complex (DGC) comprises dystrophin, dystroglycan, sarcoglycan, dystrobrevin and syntrophin subunits. In muscle fibers, it is thought to provide an essential mechanical link between the intracellular cytoskeleton and the extracellular matrix and to protect the sarcolemma during muscle contraction. Mutations affecting the DGC cause muscular dystrophies. Most members of the DGC are also concentrated at the neuromuscular junction (NMJ), where their deficiency is often associated with NMJ structural defects. Hence, synaptic dysfunction may also intervene in the pathology of dystrophic muscles. Dystroglycan is a central component of the DGC because it establishes a link between the extracellular matrix and Dystrophin. In this study, we focused on the synaptic role of Dystroglycan (Dg) in Drosophila. Methodology/Principal Findings: We show that Dg was concentrated postsynaptically at the glutamatergic NMJ, where, like in vertebrates, it controls the concentration of synaptic Laminin and Dystrophin homologues. We also found that synaptic Dg controlled the amount of postsynaptic 4.1 protein Coracle and alpha-Spectrin, as well as the relative subunit composition of glutamate receptors. In addition, both Dystrophin and Coracle were required for normal Dg concentration at the synapse. In electrophysiological recordings, loss of postsynaptic Dg did not affect postsynaptic response, but, surprisingly, led to a decrease in glutamate release from the presynaptic site. Conclusion/Significance: Altogether, our study illustrates a conservation of DGC composition and interactions between Drosophila and vertebrates at the synapse, highlights new proteins associated with this complex and suggests an unsuspected trans-synaptic function of Dg.	[Bogdanik, Laurent; Framery, Berenice; Franco, Benedicte; Bockaert, Joel; Grau, Yves; Parmentier, Marie-Laure] CNRS, Inst Genom Fonct, UMR 5203, Montpellier, France; [Bogdanik, Laurent; Framery, Berenice; Franco, Benedicte; Bockaert, Joel; Grau, Yves; Parmentier, Marie-Laure] INSERM, U661, Montpellier, France; [Bogdanik, Laurent; Framery, Berenice; Franco, Benedicte; Bockaert, Joel; Grau, Yves; Parmentier, Marie-Laure] Univ Montpellier, Montpellier, France; [Froelich, Andreas; Sigrist, Stephan J.] European Neurosci Inst Gottingen, Gottingen, Germany; [Sigrist, Stephan J.] Univ Wurzburg, Rudolf Virchow Zentrum, Inst Klin Neurobiol, Wurzburg, Germany; [Mornet, Dominique] Univ Montpellier 1, INSERM, ERI 25, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; University of Wurzburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Bogdanik, L (corresponding author), CNRS, Inst Genom Fonct, UMR 5203, Montpellier, France.	Marie-Laure.Parmentier@igf.cnrs.fr	Parmentier, Marie-Laure/N-9915-2017	Parmentier, Marie-Laure/0000-0001-6133-3413; Bogdanik, Laurent/0000-0001-7015-6631	AFM [10808]; ANR [JC05_56382]	AFM(Association Francaise contre les Myopathies); ANR(French National Research Agency (ANR))	This work was supported by AFM fellowships to L. Bogdanik and B. Franco, the AFM grant 10808 MNM2 2004 Subvention Groupe C and the ANR grant JC05_56382 to M.-L. Parmentier. Sponsors and funders played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; Balci B, 2005, NEUROMUSCULAR DISORD, V15, P271, DOI 10.1016/j.nmd.2005.01.013; Bartoli M, 2001, J BIOL CHEM, V276, P24911, DOI 10.1074/jbc.M103258200; Batchelor CL, 2007, CELL CYCLE, V6, P353, DOI 10.4161/cc.6.3.3819; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen K, 2005, J NEUROSCI, V25, P6667, DOI 10.1523/JNEUROSCI.1527-05.2005; Collins CA, 2007, CURR OPIN NEUROBIOL, V17, P35, DOI 10.1016/j.conb.2007.01.001; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Delhommeau F, 2005, CR BIOL, V328, P43, DOI 10.1016/j.crvi.2004.11.003; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; DiAntonio A, 1999, J NEUROSCI, V19, P3023; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Featherstone DE, 2005, J NEUROSCI, V25, P3199, DOI 10.1523/JNEUROSCI.4201-04.2005; FEHON RG, 1994, DEVELOPMENT, V120, P545; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Greener MJ, 2000, FEBS LETT, V482, P13, DOI 10.1016/S0014-5793(00)02018-4; HAINES N, 2007, MOL BIOL CELL; Hosaka Y, 2002, J CELL BIOL, V158, P1097, DOI 10.1083/jcb.200204076; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Kittel RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/science.1126308; Kueh SLL, 2008, CLIN EXP PHARMACOL P, V35, P207, DOI 10.1111/j.1440-1681.2007.04816.x; Lamb RS, 1998, MOL BIOL CELL, V9, P3505, DOI 10.1091/mbc.9.12.3505; Lisi MT, 2007, BBA-MOL BASIS DIS, V1772, P159, DOI 10.1016/j.bbadis.2006.09.006; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; Macleod GT, 2006, NEURON, V52, P569, DOI 10.1016/j.neuron.2006.11.006; Marchand S, 2001, EUR J NEUROSCI, V13, P221, DOI 10.1046/j.1460-9568.2001.01373.x; Marrus SB, 2004, J NEUROSCI, V24, P1406, DOI 10.1523/JNEUROSCI.1575-03.2004; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; NAGEL A, 1990, MUSCLE NERVE, V13, P742, DOI 10.1002/mus.880130813; Nishimune H, 2004, NATURE, V432, P580, DOI 10.1038/nature03112; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Petersen SA, 1997, NEURON, V19, P1237, DOI 10.1016/S0896-6273(00)80415-8; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Pielage J, 2006, J CELL BIOL, V175, P491, DOI 10.1083/jcb.200607036; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; Prokop A, 1998, DEV BIOL, V196, P58, DOI 10.1006/dbio.1997.8830; Qin G, 2005, J NEUROSCI, V25, P3209, DOI 10.1523/JNEUROSCI.4194-04.2005; Schmid A, 2006, J NEUROSCI, V26, P11267, DOI 10.1523/JNEUROSCI.2722-06.2006; Schneider M, 2006, DEVELOPMENT, V133, P3805, DOI 10.1242/dev.02549; Sciandra F, 2007, TRENDS BIOTECHNOL, V25, P262, DOI 10.1016/j.tibtech.2007.04.002; Shcherbata HR, 2007, EMBO J, V26, P481, DOI 10.1038/sj.emboj.7601503; Son YJ, 2000, J BIOL CHEM, V275, P451, DOI 10.1074/jbc.275.1.451; Spence HJ, 2004, HUM MOL GENET, V13, P1657, DOI 10.1093/hmg/ddh170; Taniguchi M, 2006, HUM MOL GENET, V15, P1279, DOI 10.1093/hmg/ddl045; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; Tremblay MR, 2006, J BIOL CHEM, V281, P13365, DOI 10.1074/jbc.M600912200; van der Plas MC, 2006, J NEUROSCI, V26, P333, DOI 10.1523/JNEUROSCI.4069-05.2006; Wagh DA, 2006, NEURON, V49, P833, DOI 10.1016/j.neuron.2006.02.008; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X	62	44	45	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2084	10.1371/journal.pone.0002084	http://dx.doi.org/10.1371/journal.pone.0002084			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446215	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300048
J	Osipo, C; Patel, P; Rizzo, P; Clementz, AG; Hao, L; Golde, TE; Miele, L				Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L.			ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor	ONCOGENE			English	Article						ErbB-2; trastuzumab; Notch-1; GSI; breast cancer	PHASE-II TRIAL; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE; MONOCLONAL-ANTIBODY; WEEKLY VINORELBINE; 1ST-LINE THERAPY; RECEPTOR; GROWTH; HER2; CHEMOTHERAPY	ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors. Trastuzumab plus chemotherapy is the standard of care for ErbB-2-positive breast cancer. A proportion of tumors are initially resistant to trastuzumab and acquired resistance to trastuzumab occurs in metastatic breast cancer and is associated with poor prognosis. Thus, we investigated whether Notch-1 contributes to trastuzumab resistance. ErbB-2-positive cells have low Notch transcriptional activity compared to non-overexpressing cells. Trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells. The increase in activity was abrogated by a Notch inhibitor, gamma-secretase inhibitor (GSI) or Notch-1 small-interfering RNA ( siRNA). Trastuzumab decreased Notch-1 (TM) precursor, increased amount and nuclear accumulation of active Notch-1(IC) and increased expression of targets, Hey1 and Deltex1 mRNAs, and Hes5, Hey1, Hes1 proteins. Importantly, trastuzumab-resistant BT474 cells treated with trastuzumab for 6 months expressed twofold higher Notch-1, twofold higher Hey1, ninefold higher Deltex1 mRNAs and threefold higher Notch-1 and Hes5 proteins, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs in resistant cells was abrogated by a Notch-1 siRNA. Cell proliferation was inhibited more effectively by trastuzumab or TKI plus a GSI than either agent alone. Decreased Notch-1 by siRNA increased efficacy of trastuzumab in BT474 sensitive cells and restored sensitivity in resistant cells. Trastuzumab plus a GSI increased apoptosis in sensitive cells by 20-30%. A GSI alone was sufficient to increase apoptosis in trastuzumab-resistant BT474 cells by 20%, which increased to 30% with trastuzumab. Notch-1 siRNA alone decreased cell growth by 30% in sensitive and more than 50% in resistant BT474 cells. Furthermore, growth of both trastuzumab sensitive and resistant cells was completely inhibited by combining trastuzumab plus Notch-1 siRNA. More importantly, Notch-1 siRNA or a GSI resensitized trastuzumab-resistant BT474 cells to trastuzumab. These results demonstrate that ErbB-2 overexpression suppresses Notch-1 activity, which can be reversed by trastuzumab or TKI. These results suggest that Notch-1 might play a novel role in resistance to trastuzumab, which could be prevented or reversed by inhibiting Notch-1.	[Osipo, C.; Rizzo, P.; Hao, L.; Miele, L.] Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, Maywood, IL 60153 USA; [Osipo, C.; Patel, P.; Clementz, A. G.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Mol & Cellular Biochem Program, Maywood, IL 60153 USA; [Hao, L.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Program Mol Biol, Maywood, IL 60153 USA; [Golde, T. E.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Miele, L.] Loyola Univ, Dept Pharmacol & Mol Therapeut, Cardinal Bernardin Canc Ctr, Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	cosipo@lumc.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674				Amar S, 2008, BREAST CANCER RES TR, V109, P1, DOI 10.1007/s10549-007-9636-2; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Calzavara E, 2008, J CELL BIOCHEM, V103, P1405, DOI 10.1002/jcb.21527; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Efstratiadis A, 2007, CELL CYCLE, V6, P418, DOI 10.4161/cc.6.4.3838; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Florena AM, 2007, PATHOBIOLOGY, V74, P317, DOI 10.1159/000110024; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jahanzeb M, 2002, ONCOLOGIST, V7, P410, DOI 10.1634/theoncologist.7-5-410; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menendez JA, 2006, J CLIN ONCOL, V24, P3735, DOI 10.1200/JCO.2005.04.3489; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nabholtz JM, 2001, SEMIN ONCOL, V28, P1; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osipo C, 2003, J NATL CANCER I, V95, P1597, DOI 10.1093/jnci/djg079; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Papaldo P, 2006, ANN ONCOL, V17, P630, DOI 10.1093/annonc/mdj110; Parks AL, 2000, DEVELOPMENT, V127, P1373; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yokoyama Goro, 2005, Int J Clin Oncol, V10, P139	67	169	181	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					5019	5032		10.1038/onc.2008.149	http://dx.doi.org/10.1038/onc.2008.149			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469855				2022-12-25	WOS:000258914800005
J	Hammes, GG				Hammes, Gordon G.			How do enzymes really work?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							LASER TEMPERATURE-JUMP; MECHANISM; KINETICS; ACID; RIBONUCLEASE; CATALYSIS; DYNAMICS; ENERGY		Duke Univ, Dept Biochem, Durham, NC 27710 USA	Duke University	Hammes, GG (corresponding author), Duke Univ, Dept Biochem, Durham, NC 27710 USA.	hamme001@mc.duke.edu						Antikainen NM, 2005, BIOCHEMISTRY-US, V44, P16835, DOI 10.1021/bi051378i; BAIRD BA, 1979, BIOCHIM BIOPHYS ACTA, V549, P31, DOI 10.1016/0304-4173(79)90017-X; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Benkovic SJ, 2008, BIOCHEMISTRY-US, V47, P3317, DOI 10.1021/bi800049z; Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; CHANCE B, 1956, CURRENTS BIOCH RES, P308; CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; DEWEY TG, 1981, P NATL ACAD SCI-BIOL, V78, P7422, DOI 10.1073/pnas.78.12.7422; DEWEY TG, 1979, BIOCHEMISTRY-US, V18, P5757, DOI 10.1021/bi00593a002; DEWEY TG, 1981, J BIOL CHEM, V256, P8941; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; EIGEN M, 1963, INVESTIGATION RATE 2, P895; ERMAN JE, 1966, J AM CHEM SOC, V88, P5607, DOI 10.1021/ja00975a046; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; FASELLA P, 1967, BIOCHEMISTRY-US, V6, P1798, DOI 10.1021/bi00858a031; Gloss LM, 1996, PROTEINS, V24, P195, DOI 10.1002/(SICI)1097-0134(199602)24:2<195::AID-PROT6>3.0.CO;2-I; GUTFREUND H, 1956, BIOCHEM J, V63, P656, DOI 10.1042/bj0630656; Hammes G., 1982, ENZYME CATALYSIS REG; Hammes G.G., 1970, ENZYMES, V2, P67; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; HAMMES GG, 1974, ANNU REV BIOPHYS BIO, V3, P1, DOI 10.1146/annurev.bb.03.060174.000245; Hammes GG, 1998, PROTEIN SCI, V7, P799, DOI 10.1002/pro.5560070331; HAMMES GG, 1969, J AM CHEM SOC, V91, P1812, DOI 10.1021/ja01035a036; HAMMES GG, 1970, BIOCHIM BIOPHYS ACTA, V198, P604, DOI 10.1016/0005-2744(70)90138-5; HAMMES GG, 1964, NATURE, V204, P342, DOI 10.1038/204342a0; HAMMES GG, 1969, BIOCHEMISTRY-US, V8, P1591, DOI 10.1021/bi00832a040; HAMMES GG, 1968, ACCOUNTS CHEM RES, V1, P321, DOI 10.1021/ar50011a001; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; HESS GP, 1971, ENZYMES, V3, P213; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KOSHLAND DE, 1960, ADV ENZYMOL REL S BI, V22, P45; LAD PM, 1973, BIOCHEMISTRY-US, V12, P4303, DOI 10.1021/bi00746a001; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Nagel ZD, 2006, CHEM REV, V106, P3095, DOI 10.1021/cr050301x; PELLER L, 1959, J AM CHEM SOC, V81, P5907, DOI 10.1021/ja01531a017; RICHARDS FM, 1971, ENZYMES, V4, P647; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; Watt ED, 2007, P NATL ACAD SCI USA, V104, P11981, DOI 10.1073/pnas.0702551104; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p	42	16	17	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2008	283	33					22337	22346		10.1074/jbc.X800005200	http://dx.doi.org/10.1074/jbc.X800005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335VR	18477561	hybrid			2022-12-25	WOS:000258321000001
J	Orso, F; Penna, E; Cimino, D; Astanina, E; Maione, F; Valdembri, D; Giraudo, E; Serini, G; Sismondi, P; De Bortoli, M; Taverna, D				Orso, Francesca; Penna, Elisa; Cimino, Daniela; Astanina, Elena; Maione, Federica; Valdembri, Donatella; Giraudo, Enrico; Serini, Guido; Sismondi, Piero; De Bortoli, Michele; Taverna, Daniela			AP-2 alpha and AP-2 gamma regulate tumor progression via specific genetic programs	FASEB JOURNAL			English	Article						transcription factor; migration; microarray	TRANSCRIPTION FACTOR AP-2; ACTIVATOR PROTEIN 2-ALPHA; BREAST-CANCER; EPITHELIAL-CELLS; PROSTATE-CANCER; DOWN-REGULATION; MAMMARY-CARCINOMA; DNA-BINDING; EXPRESSION; METASTASIS	The events occurring during tumor formation and progression display similarities to some of the steps in embryonic morphogenesis. The family of AP-2 proteins consists of five different transcription factors ( alpha,beta,gamma,delta, and epsilon) that play relevant roles in embryonic development, as demonstrated by the phenotypes of the corresponding knockout mice. Here, we show that AP-2 alpha and AP-2 gamma proteins play an essential role in tumorigenesis. Down-modulation of AP-2 expression in tumor cells by RNA interference (RNAi) led to enhanced tumor growth and reduced chemotherapy-induced cell death, as well as migration and invasion. Most of these biological modulations were rescued by AP-2 overexpression. We observed that increased xeno-transplant growth was mostly due to highly enhanced proliferation of the tumor cells together with reduced innate immune cell recruitment. Moreover, we showed that migration impairment was mediated, at least in part, by secreted factors. To identify the genetic programs involved in tumorigenesis, we performed whole genome microarray analysis of AP-2 alpha knockdown cells and observed that AP-2 alpha regulates specific genes involved in cell cycle, cell death, adhesion, and migration. In particular, we showed that ESDN, EREG, and CXCL2 play a major role in AP-2 controlled migration, as ablation of any of these genes severely altered migration.	[Orso, Francesca; Penna, Elisa; Cimino, Daniela; Taverna, Daniela] Univ Turin, Dept Oncol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Orso, Francesca; Penna, Elisa; Cimino, Daniela; Astanina, Elena; Maione, Federica; Valdembri, Donatella; Giraudo, Enrico; Serini, Guido; Sismondi, Piero; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, I-10126 Turin, Italy; [Giraudo, Enrico; Serini, Guido; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Ctr Complex Syst Mol Biol & Med, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	Taverna, D (corresponding author), Univ Turin, Dept Oncol Sci, Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy.	daniela.taverna@unito.it	Serini, Guido/AAF-2873-2021; taverna, daniela/J-8358-2016; De Bortoli, Michele/B-5418-2013; Giraudo, Enrico/K-3192-2016; Maione, Federica/K-6679-2016; Giraudo, Enrico/K-6441-2019; Orso, Francesca/B-1985-2014	Serini, Guido/0000-0002-3502-8367; taverna, daniela/0000-0002-6365-527X; De Bortoli, Michele/0000-0002-6666-9052; Giraudo, Enrico/0000-0003-4128-4786; Maione, Federica/0000-0003-2789-799X; Giraudo, Enrico/0000-0003-4128-4786; Valdembri, Donatella/0000-0003-4590-417X; Sismondi, Piero/0000-0002-2505-5716; Orso, Francesca/0000-0003-4706-6464	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chiorino G, 2004, EUR J CANCER, V40, P2592, DOI 10.1016/j.ejca.2004.07.029; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lazzarato F, 2004, BIOINFORMATICS, V20, P2848, DOI 10.1093/bioinformatics/bth287; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nagai H, 2007, ONCOGENE, V26, P4025, DOI 10.1038/sj.onc.1210183; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Orso F, 2004, BIOCHEM J, V377, P429, DOI 10.1042/BJ20031133; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SUYAMA E, 2002, NUCL ACIDS RES S, V2, P247; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Wajapeyee N, 2005, CANCER RES, V65, P8628, DOI 10.1158/0008-5472.CAN-05-1059; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Werling U, 2002, MOL CELL BIOL, V22, P3149, DOI 10.1128/MCB.22.9.3149-3156.2002; Werling Uwe, 2002, Genesis The Journal of Genetics and Development, V32, P127, DOI 10.1002/gene.10057; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	50	59	59	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2702	2714		10.1096/fj.08-106492	http://dx.doi.org/10.1096/fj.08-106492			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18443366				2022-12-25	WOS:000258089300010
J	Pal, A; Chu, UB; Ramachandran, S; Grawoig, D; Guo, LW; Hajipour, AR; Ruoho, AE				Pal, Arindam; Chu, Uyen B.; Ramachandran, Subramaniam; Grawoig, David; Guo, Lian-Wang; Hajipour, Abdol R.; Ruoho, Arnold E.			Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 SIGMA-RECEPTOR; TRANSDUCIN ALPHA-SUBUNIT; AMINO-ACID-RESIDUES; CGMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; LIMITED PROTEOLYSIS; LOCOMOTOR-ACTIVITY; MOLECULAR-CLONING; SELECTIVE LIGAND; OPIOID RECEPTOR	sigma-1 receptors represent unique binding sites that are capable of interacting with a wide range of compounds to mediate different cellular events. The composition of the ligand binding site of this receptor is unclear, since no NMR or crystal structures are available. Recent studies in our laboratory using radiolabeled photoreactive ligands suggested that the steroid binding domain-like I (SBDLI) (amino acids 91-109) and the steroid binding domain-like II (SBDLII) (amino acids 176-194) regions are involved in forming the ligand binding site(s) (Chen, Y., Hajipour, A. R., Sievert, M. K., Arbabian, M., and Ruoho, A. E. (2007) Biochemistry 46, 3532-3542; Pal, A., Hajipour, A. R., Fontanilla, D., Ramachandran, S., Chu, U. B., Mavlyutov, T., and Ruoho, A. E. (2007) Mol. Pharmacol. 72, 921-933). In this report, we have further addressed this issue by utilizing our previously developed sulfhydryl-reactive, cleavable, radioiodinated photocross-linking reagent: methanesulfonothioic acid, S-((4(4-amino-3-[I-125] iodobenzoyl) phenyl) methyl) ester (Guo, L. W., Hajipour, A. R., Gavala, M. L., Arbabian, M., Martemyanov, K. A., Arshavsky, V. Y., and Ruoho, A. E. (2005) Bioconjugate Chem. 16, 685-693). This photoprobe was shown to derivatize the single cysteine residues as mixed disulfides at position 94 in the SBDLI region of the wild type guinea pig sigma-1 receptor (Cys(94)) and at position 190 in the SBDLII region of a mutant guinea pig sigma-1 receptor (C94A, V190C), both in a sigma-ligand (haloperidol or (+)-pentazocine)-sensitive manner. Significantly, photocross-linking followed by Endo Lys-C cleavage under reducing conditions and intramolecular radiolabel transfer from the SBDLI to the SBDLII region in the wild type receptor and, conversely, from the SBDLII to the SBDLI region in the mutant receptor were observed. These data support a model in which the SBDLI and SBDLII regions are juxtaposed to form, at least in part, a ligand binding site of the sigma-1 receptor.	[Pal, Arindam; Chu, Uyen B.; Ramachandran, Subramaniam; Grawoig, David; Guo, Lian-Wang; Ruoho, Arnold E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53705 USA; [Hajipour, Abdol R.] Isfahan Univ Technol, Coll Chem, Pharmaceut Res Lab, Esfahan 84156, Iran	University of Wisconsin System; University of Wisconsin Madison; Isfahan University of Technology	Ruoho, AE (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@wisc.edu	Ramachandran, Subramaniam/B-8247-2013		NIMH NIH HHS [R01 MH065503] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065503] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aydar E, 2004, CANCER RES, V64, P5029, DOI 10.1158/0008-5472.CAN-03-2329; Aydar E, 2002, NEURON, V34, P399, DOI 10.1016/S0896-6273(02)00677-3; Bermack JE, 2005, J PHARMACOL SCI, V97, P317, DOI 10.1254/jphs.CRJ04005X; Bowen W D, 2000, Pharm Acta Helv, V74, P211; CAMPBELL BG, 1989, J NEUROSCI, V9, P3380; Chen YM, 2007, BIOCHEMISTRY-US, V46, P3532, DOI 10.1021/bi061727o; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONTRERAS PC, 1988, SYNAPSE, V2, P240, DOI 10.1002/syn.890020311; Dokudovskaya S, 2006, STRUCTURE, V14, P653, DOI 10.1016/j.str.2006.02.006; Esteban B, 2005, BIOCHEMISTRY-US, V44, P450, DOI 10.1021/bi0484365; Ganapathy ME, 1999, J PHARMACOL EXP THER, V289, P251; Guo LW, 2007, PROTEIN EXPRES PURIF, V51, P187, DOI 10.1016/j.pep.2006.07.012; Guo LW, 2006, J BIOL CHEM, V281, P15412, DOI 10.1074/jbc.M600595200; Guo LW, 2005, BIOCONJUGATE CHEM, V16, P685, DOI 10.1021/bc050016k; Guo LW, 2005, J BIOL CHEM, V280, P12585, DOI 10.1074/jbc.M410380200; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; Hayashi T, 2003, J PHARMACOL EXP THER, V306, P718, DOI 10.1124/jpet.103.051284; HAYASHI T, 2001, P NATL ACAD SCI US; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; HELLEWELL SB, 1994, EUR J PHARM-MOLEC PH, V268, P9, DOI 10.1016/0922-4106(94)90115-5; IWAMOTO ET, 1981, J PHARMACOL EXP THER, V217, P451; KAHOUN JR, 1992, P NATL ACAD SCI USA, V89, P1393, DOI 10.1073/pnas.89.4.1393; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; Langa F, 2003, EUR J NEUROSCI, V18, P2188, DOI 10.1046/j.1460-9568.2003.02950.x; Leoni M, 2004, J APPL CRYSTALLOGR, V37, P166, DOI 10.1107/S0021889803022787; Liu Y, 1999, BIOCHEM J, V337, P281, DOI 10.1042/0264-6021:3370281; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; LYSKO PG, 1992, STROKE, V23, P414, DOI 10.1161/01.STR.23.3.414; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MATSUNO K, 1993, J PHARMACOL EXP THER, V265, P851; McCracken KA, 1999, EUR J PHARMACOL, V370, P225, DOI 10.1016/S0014-2999(99)00113-2; McCracken KA, 1999, EUR J PHARMACOL, V365, P35, DOI 10.1016/S0014-2999(98)00876-0; Mei JF, 2001, BIOCHEM PHARMACOL, V62, P349, DOI 10.1016/S0006-2952(01)00666-9; Moebius FF, 1997, BRIT J PHARMACOL, V121, P1, DOI 10.1038/sj.bjp.0701079; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Nguyen EC, 2005, NEUROPHARMACOLOGY, V49, P638, DOI 10.1016/j.neuropharm.2005.04.016; Pal A, 2007, MOL PHARMACOL, V72, P921, DOI 10.1124/mol.107.038307; Palmer CP, 2007, CANCER RES, V67, P11166, DOI 10.1158/0008-5472.CAN-07-1771; Pan YX, 1998, J NEUROCHEM, V70, P2279; PAUL R, 1994, J NEUROIMMUNOL, V52, P183, DOI 10.1016/0165-5728(94)90112-0; de Laureto PP, 2006, BIOCHEMISTRY-US, V45, P11523, DOI 10.1021/bi052614s; Prasad PD, 1998, J NEUROCHEM, V70, P443; QUIRION R, 1992, TRENDS PHARMACOL SCI, V13, P85, DOI 10.1016/0165-6147(92)90030-A; Ramachandran S, 2007, PROTEIN EXPRES PURIF, V51, P283, DOI 10.1016/j.pep.2006.07.019; Seth P, 1997, BIOCHEM BIOPH RES CO, V241, P535, DOI 10.1006/bbrc.1997.7840; Seth P, 2001, BBA-MOL CELL RES, V1540, P59, DOI 10.1016/S0167-4889(01)00117-3; Seth P, 1998, J NEUROCHEM, V70, P922; SHARKEY J, 1988, EUR J PHARMACOL, V149, P171, DOI 10.1016/0014-2999(88)90058-1; SU TP, 1988, SCIENCE, V240, P219, DOI 10.1126/science.2832949; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; TAM SW, 1983, P NATL ACAD SCI-BIOL, V80, P6703, DOI 10.1073/pnas.80.21.6703; TorrenceCampbell C, 1996, EUR J PHARMACOL, V304, P201, DOI 10.1016/0014-2999(96)00109-4; VAUPEL DB, 1983, EUR J PHARMACOL, V92, P269; WALKER JM, 1990, PHARMACOL REV, V42, P355; WEBER E, 1986, P NATL ACAD SCI USA, V83, P8784, DOI 10.1073/pnas.83.22.8784; Wheeler KT, 2000, BRIT J CANCER, V82, P1223, DOI 10.1054/bjoc.1999.1067; Wilke RA, 1999, J BIOL CHEM, V274, P18387, DOI 10.1074/jbc.274.26.18387; Yamamoto H, 1999, FEBS LETT, V445, P19, DOI 10.1016/S0014-5793(99)00084-8	58	46	46	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19646	19656		10.1074/jbc.M802192200	http://dx.doi.org/10.1074/jbc.M802192200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18467334	Green Published, hybrid			2022-12-25	WOS:000257387600050
J	Vetrivel, KS; Zhang, XL; Meckler, X; Cheng, HP; Lee, SH; Gong, P; Lopes, KO; Chen, Y; Iwata, N; Yin, KJ; Lee, JM; Parent, AT; Saido, TC; Li, YM; Sisodia, SS; Thinakaran, G				Vetrivel, Kulandaivelu S.; Zhang, Xulun; Meckler, Xavier; Cheng, Haipeng; Lee, Sungho; Gong, Ping; Lopes, Kryslaine O.; Chen, Ying; Iwata, Nobuhisa; Yin, Ke-Jie; Lee, Jin-Moo; Parent, Angele T.; Saido, Takaomi C.; Li, Yue-Ming; Sisodia, Sangram S.; Thinakaran, Gopal			Evidence that CD147 modulation of beta-amyloid (A beta) levels is mediated by extracellular degradation of secreted A beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; GAMMA-SECRETASE; MATRIX METALLOPROTEINASES; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IG SUPERFAMILY; COMPLEX; NICASTRIN; PRESENILIN-1; PEPTIDE	Cerebral deposition of beta-amyloid (A beta)peptides is a pathological hallmark of Alzheimer disease. Intramembranous proteolysis of amyloid precursor protein by a multiprotein gamma-secretase complex generates A beta. Previously, it was reported that CD147, a glycoprotein that stimulates production of matrix metalloproteinases (MMPs), is a subunit of gamma-secretase and that the levels of secreted A beta inversely correlate with CD147 expression. Here, we show that the levels and localization of CD147 in fibroblasts, as well as postnatal expression and distribution in brain, are distinct from those of integral gamma-secretase subunits. Notably, we show that although depletion of CD147 increased extracellular A beta levels in intact cells, membranes isolated from CD147-depleted cells failed to elevate A beta production in an in vitro gamma-secretase assay. Consistent with an extracellular source that modulates A beta metabolism, synthetic A beta was degraded more rapidly in the conditioned medium of cells overexpressing CD147. Moreover, modulation of CD147 expression had no effect on epsilon-site cleavage of amyloid precursor protein and Notch1 receptor. Collectively, our results demonstrate that CD147 modulates A beta levels not by regulating gamma-secretase activity, but by stimulating extracellular degradation of A beta. In view of the known function of CD147 in MMP production, we postulate that CD147 expression influences A beta levels by an indirect mechanism involving MMPs that can degrade extracellular A beta.	[Vetrivel, Kulandaivelu S.; Zhang, Xulun; Meckler, Xavier; Cheng, Haipeng; Lee, Sungho; Gong, Ping; Lopes, Kryslaine O.; Chen, Ying; Parent, Angele T.; Sisodia, Sangram S.; Thinakaran, Gopal] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; [Vetrivel, Kulandaivelu S.; Zhang, Xulun; Meckler, Xavier; Cheng, Haipeng; Lee, Sungho; Gong, Ping; Lopes, Kryslaine O.; Chen, Ying; Parent, Angele T.; Sisodia, Sangram S.; Thinakaran, Gopal] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Iwata, Nobuhisa; Saido, Takaomi C.] RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; [Yin, Ke-Jie; Lee, Jin-Moo] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Yin, Ke-Jie; Lee, Jin-Moo] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Li, Yue-Ming] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA	University of Chicago; University of Chicago; RIKEN; Washington University (WUSTL); Washington University (WUSTL); Memorial Sloan Kettering Cancer Center	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol, Abbott 308,947 E 58th St, Chicago, IL 60637 USA.	ssisodia@bsd.uchicago.edu; gopal@uchicago.edu	LI, Yue/GRS-8071-2022; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Lee, Jin-Moo/K-2024-2015	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Lee, Jin-Moo/0000-0002-3979-0906; Lee, Sungho/0000-0003-2111-5504; Radomski, Kryslaine/0000-0001-9624-623X; Yin, Ke-Jie/0000-0002-7169-3858	NIA NIH HHS [AG021495, R01 AG019070, R01 AG021495, AG019070, AG026660] Funding Source: Medline; NINDS NIH HHS [P01 NS032636-139001, R01 NS048283-04, R01 NS048283-03, R01 NS048283, P01 NS032636] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048283, P01NS032636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021495, R01AG019070, R01AG026660] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Backstrom JR, 1996, J NEUROSCI, V16, P7910; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Cheng HP, 2007, NAT CLIN PRACT NEURO, V3, P374, DOI 10.1038/ncpneuro0549; Cho JY, 2001, BLOOD, V98, P374, DOI 10.1182/blood.V98.2.374; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Huang Y, 2005, EUR J CELL BIOL, V84, P59, DOI 10.1016/j.ejcb.2004.09.003; Iwata N, 2005, PHARMACOL THERAPEUT, V108, P129, DOI 10.1016/j.pharmthera.2005.03.010; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kodam A, 2008, NEUROBIOL AGING, V29, P724, DOI 10.1016/j.neurobiolaging.2006.12.005; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; Onishi M, 1996, EXP HEMATOL, V24, P324; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; Sato T, 2007, J BIOL CHEM, V282, P33985, DOI 10.1074/jbc.M705248200; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Spasic D, 2007, J CELL BIOL, V176, P629, DOI 10.1083/jcb.200609180; Staffler G, 2003, J IMMUNOL, V171, P1707, DOI 10.4049/jimmunol.171.4.1707; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Vetrivel KS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-4; Vetrivel KS, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-4; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; White AR, 2006, J BIOL CHEM, V281, P17670, DOI 10.1074/jbc.M602487200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; Yin KJ, 2006, J NEUROSCI, V26, P10939, DOI 10.1523/JNEUROSCI.2085-06.2006; Yoshimoto M, 1998, EXP EYE RES, V67, P331, DOI 10.1006/exer.1998.0525; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200; Zhou SX, 2005, P NATL ACAD SCI USA, V102, P7499, DOI 10.1073/pnas.0502768102	45	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19489	19498		10.1074/jbc.M801037200	http://dx.doi.org/10.1074/jbc.M801037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18456655	Green Published, hybrid			2022-12-25	WOS:000257387600035
J	Breloy, I; Schwientek, T; Gries, B; Razawi, H; Macht, M; Albers, C; Hanisch, FG				Breloy, Isabelle; Schwientek, Tilo; Gries, Barbara; Razawi, Hanieh; Macht, Marcus; Albers, Christian; Hanisch, Franz-Georg			Initiation of mammalian O-mannosylation in Vivo is independent of a consensus sequence and controlled by peptide regions within and upstream of the alpha-dystroglycan mucin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; LAMININ-BINDING; GENE FAMILY; UDP-GALNAC; GLYCOSYLATION; MANNOSE; PROTEINS; GLYCANS; BRAIN	To reveal insight into the initiation of mammalian O-mannosylation in vivo, recombinant glycosylation probes containing sections of human alpha-dystroglycan (hDG) were expressed in epithelial cell lines. We demonstrate that O-mannosylation within the mucin domain of hDG occurs preferentially at Thr/Ser residues that are flanked by basic amino acids. Protein O-mannosylation is independent of a consensus sequence, but strictly dependent on a peptide region located upstream of the mucin domain. This peptide region cannot be replaced by other N-terminal peptides, however, it is not sufficient to induce O-mannosylation on a structurally distinct mucin domain in hybrid constructs. The presented in vivo evidence for a more complex regulation of mammalian O-mannosylation contrasts with a recent in vitro study of O-mannosylation in human alpha-dystroglycan peptides indicating the existence of an 18-meric consensus sequence. We demonstrate in vivo that the entire region p377-417 is necessary and sufficient for O-mannosylation initiation of hDG, but not of MUC1 tandem repeats. The feature of a doubly controlled initiation process distinguishes mammalian O-mannosylation from other types of O-glycosylation, which are largely controlled by structural properties of the substrate positions and their local peptide environment.	[Breloy, Isabelle; Schwientek, Tilo; Gries, Barbara; Razawi, Hanieh; Hanisch, Franz-Georg] Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; [Macht, Marcus; Albers, Christian] Bruker Daltonics Inc, D-28359 Bremen, Germany; [Hanisch, Franz-Georg] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany	University of Cologne; Bruker Corporation; Bruker Daltonik GmbH; University of Cologne	Hanisch, FG (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	franz.hanisch@uni-koeln.de	Breloy, Isabelle/E-3804-2012					Akasaka-Manya K, 2006, J BIOL CHEM, V281, P19339, DOI 10.1074/jbc.M601091200; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; BUTLER WT, 1966, J BIOL CHEM, V241, P3882; Chai WG, 1999, EUR J BIOCHEM, V263, P879, DOI 10.1046/j.1432-1327.1999.00572.x; Chiba A, 1997, J BIOL CHEM, V272, P2156; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Combs AC, 2005, BIOCHEM J, V390, P303, DOI 10.1042/BJ20050375; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Hanisch FG, 2001, GLYCOBIOLOGY, V11, P731, DOI 10.1093/glycob/11.9.731; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Manya H, 2007, J BIOL CHEM, V282, P20200, DOI 10.1074/jbc.M702369200; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Martin PT, 2003, GLYCOBIOLOGY, V13, p55R, DOI 10.1093/glycob/cwg076; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Muntoni F, 2002, LANCET, V360, P1419, DOI 10.1016/S0140-6736(02)11397-3; Patnaik SK, 2005, J BIOL CHEM, V280, P20851, DOI 10.1074/jbc.M500069200; SASAKI T, 1998, BIOCHIM BIOPHYS ACTA, V27, P599; SETANDREU R, 1969, CARBOHYD RES, V10, P584; SILBERT JE, 1979, NEW COMPREHENSIVE B, V29, P1; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; van Reeuwijk J, 2005, J MED GENET, V42, P907, DOI 10.1136/jmg.2005.031963; Willer T, 2005, MOL MICROBIOL, V57, P156, DOI 10.1111/j.1365-2958.2005.04692.x; Yuen CT, 1997, J BIOL CHEM, V272, P8924	42	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18832	18840		10.1074/jbc.M802834200	http://dx.doi.org/10.1074/jbc.M802834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18456664	hybrid			2022-12-25	WOS:000257165600040
J	Linster, CL; Adler, LN; Webb, K; Christensen, KC; Brenner, C; Clarke, SG				Linster, Carole L.; Adler, Lital N.; Webb, Kristofor; Christensen, Kathryn C.; Brenner, Charles; Clarke, Steven G.			A second GDP-L-galactose phosphorylase in Arabidopsis en route to vitamin C - Covalent intermediate and substrate requirements for the conserved reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO BIOSYNTHESIS; L-ASCORBIC-ACID; MANNOSE 3'',5''-EPIMERASE; GENETIC-EVIDENCE; HIGHER-PLANTS; THALIANA; PATHWAY; ENZYME; IDENTIFICATION; PHOSPHATASE	The Arabidopsis thaliana VTC2 gene encodes an enzyme that catalyzes the conversion of GDP-L-galactose to L-galactose 1-phosphate in the first committed step of the Smirnoff-Wheeler pathway to plant vitamin C synthesis. Mutations in VTC2 had previously been found to lead to only partial vitamin C deficiency. Here we show that the Arabidopsis gene At5g55120 encodes an enzyme with high sequence identity to VTC2. Designated VTC5, this enzyme displays substrate specificity and enzymatic properties that are remarkably similar to those of VTC2, suggesting that it may be responsible for residual vitamin C synthesis in vtc2 mutants. The exact nature of the reaction catalyzed by VTC2/VTC5 is controversial because of reports that kiwifruit and Arabidopsis VTC2 utilize hexose 1-phosphates as phosphorolytic acceptor substrates. Using liquid chromatography-mass spectroscopy and a VTC2-H238N mutant, we provide evidence that the reaction proceeds through a covalent guanylylated histidine residue within the histidine triad motif. Moreover, we show that both the Arabidopsis VTC2 and VTC5 enzymes catalyze simple phosphorolysis of the guanylylated enzyme, forming GDP and L-galactose 1-phosphate from GDP-L-galactose and phosphate, with poor reactivity of hexose 1-phosphates as phosphorolytic acceptors. Indeed, the endogenous activities from Japanese mustard spinach, lemon, and spinach have the same substrate requirements. These results show that Arabidopsis VTC2 and VTC5 proteins and their homologs in other plants are enzymes that guanylylate a conserved active site His residue with GDP-L-galactose, forming L-galactose 1-phosphate for vitamin C synthesis, and regenerate the enzyme with phosphate to form GDP.	[Linster, Carole L.; Adler, Lital N.; Webb, Kristofor; Clarke, Steven G.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Linster, Carole L.; Adler, Lital N.; Webb, Kristofor; Clarke, Steven G.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Christensen, Kathryn C.; Brenner, Charles] Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; [Christensen, Kathryn C.; Brenner, Charles] Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Dartmouth College; Dartmouth College	Clarke, SG (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu	; Brenner, Charles/D-6339-2014	Webb, Kristofor/0000-0001-8111-9756; Brenner, Charles/0000-0002-4955-3226; Linster, Carole/0000-0001-7143-0719	NCI NIH HHS [CA75954] Funding Source: Medline; NIA NIH HHS [AG018000] Funding Source: Medline; NIGMS NIH HHS [GM026020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Conklin PL, 2006, J BIOL CHEM, V281, P15662, DOI 10.1074/jbc.M601409200; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1999, P NATL ACAD SCI USA, V96, P4198, DOI 10.1073/pnas.96.7.4198; Conklin PL, 2000, GENETICS, V154, P847; Dowdle J, 2007, PLANT J, V52, P673, DOI 10.1111/j.1365-313X.2007.03266.x; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Gatzek S, 2002, PLANT J, V30, P541, DOI 10.1046/j.1365-313X.2002.01315.x; Hancock RD, 2005, CRIT REV PLANT SCI, V24, P167, DOI 10.1080/07352680591002165; Jander G, 2002, PLANT PHYSIOL, V129, P440, DOI 10.1104/pp.003533; Laing WA, 2004, P NATL ACAD SCI USA, V101, P16976, DOI 10.1073/pnas.0407453101; Laing WA, 2007, P NATL ACAD SCI USA, V104, P9534, DOI 10.1073/pnas.0701625104; LEE RB, 1990, J EXP BOT, V41, P1063, DOI 10.1093/jxb/41.9.1063; Linster CL, 2007, J BIOL CHEM, V282, P18879, DOI 10.1074/jbc.M702094200; Qian WQ, 2007, PLANT J, V49, P399, DOI 10.1111/j.1365-313X.2006.02967.x; REBEILLE F, 1984, PLANT PHYSIOL, V74, P355, DOI 10.1104/pp.74.2.355; Sasaki-Sekimoto Y, 2005, PLANT J, V44, P653, DOI 10.1111/j.1365-313X.2005.02560.x; Smirnoff N, 2001, ANNU REV PLANT PHYS, V52, P437, DOI 10.1146/annurev.arplant.52.1.437; Valpuesta V, 2004, TRENDS PLANT SCI, V9, P573, DOI 10.1016/j.tplants.2004.10.002; Watanabe K, 2006, PHYTOCHEMISTRY, V67, P338, DOI 10.1016/j.phytochem.2005.12.003; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Wheeler GL, 1998, NATURE, V393, P365, DOI 10.1038/30728; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323; Wolucka BA, 2003, J BIOL CHEM, V278, P47483, DOI 10.1074/jbc.M309135200; Wolucka BA, 2001, P NATL ACAD SCI USA, V98, P14843, DOI 10.1073/pnas.011578198; Wolucka BA, 2007, PHYTOCHEMISTRY, V68, P2602, DOI 10.1016/j.phytochem.2007.08.034; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	28	36	45	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18483	18492		10.1074/jbc.M802594200	http://dx.doi.org/10.1074/jbc.M802594200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18463094	hybrid, Green Published			2022-12-25	WOS:000257165600003
J	Stensrud, KF; Adam, PR; La Mar, CD; Olive, AJ; Lushington, GH; Sudharsan, R; Shelton, NL; Givens, RS; Picking, WL; Picking, WD				Stensrud, Kenneth F.; Adam, Philip R.; La Mar, Cassandra D.; Olive, Andrew J.; Lushington, Gerald H.; Sudharsan, Raghavi; Shelton, Naomi L.; Givens, Richard S.; Picking, Wendy L.; Picking, William D.			Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID ANTIGEN-D; PROTEIN SECRETION; CHOLYL-LYSYLFLUORESCEIN; STRUCTURAL-ANALYSIS; LYSYL-FLUORESCEIN; EPITHELIAL-CELLS; SYSTEM NEEDLE; BILE-SALTS; INVASION; TRANSLOCON	Type III secretion (TTS) is an essential virulence function for Shigella flexneri that delivers effector proteins that are responsible for bacterial invasion of intestinal epithelial cells. The Shigella TTS apparatus (TTSA) consists of a basal body that spans the bacterial inner and outer membranes and a needle exposed at the pathogen surface. At the distal end of the needle is a "tip complex" composed of invasion plasmid antigen D(IpaD). IpaD not only regulates TTS, but is required for the recruitment and stable association of the translocator protein IpaB at the TTSA needle tip in the presence of deoxycholate or other bile salts. This phenomenon is not accompanied by induction of TTS or the recruitment of IpaC to the Shigella surface. We now show that IpaD specifically binds fluorescein-labeled deoxycholate and, based on energy transfer measurements and docking simulations, this interaction appears to occur where the N-terminal domain of IpaD meets its central coiled-coil, a region that may also be involved in needle-tip interactions. TTS is initiated as a series of distinct steps and that small molecules present in the bacterial milieu are capable of inducing the first step of TSS through interactions with the needle tip protein IpaD. Furthermore, the amino acids proposed to be important for deoxycholate binding by IpaD appear to have significant roles in regulating tip complex composition and pathogen entry into host cells.	[Stensrud, Kenneth F.; Lushington, Gerald H.; Givens, Richard S.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; [Adam, Philip R.; La Mar, Cassandra D.; Olive, Andrew J.; Sudharsan, Raghavi; Shelton, Naomi L.; Picking, Wendy L.; Picking, William D.] Univ Kansas, Dept Chem, Lawrence, KS 66045 USA	University of Kansas; University of Kansas	Picking, WD (corresponding author), 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	picking@ku.edu	Lushington, Gerald/AAH-3205-2020; Lushington, Gerald/P-8421-2019	Lushington, Gerald/0000-0001-5821-4253; Olive, Andrew/0000-0003-3441-3113	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI072510, R01AI034428, R29AI034428, R01AI067858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM062232, R01GM072910] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR016475] Funding Source: Medline; NIAID NIH HHS [AI034428, AI067858, AI072510] Funding Source: Medline; NIGMS NIH HHS [R25GM62232, R01 GM072910, R01 GM72910] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAXTER DJ, 1995, BBA-LIPID LIPID MET, V1256, P374, DOI 10.1016/0005-2760(95)00050-M; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Buttner D, 2002, TRENDS MICROBIOL, V10, P186, DOI 10.1016/S0966-842X(02)02331-4; CHANTALAT L, 1995, PROTEIN PEPTIDE LETT, V2, P333; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; DRUAR C, 2008, MED MICROBIOL, V52, P78; ELSEAIDY AZ, 1997, M AM J PHYSL, V272, pG298; Ermolenko DN, 2007, J MOL BIOL, V370, P530, DOI 10.1016/j.jmb.2007.04.042; Espina M, 2007, PROTEIN SCI, V16, P704, DOI 10.1110/ps.062645007; Espina M, 2006, BIOCHEMISTRY-US, V45, P9219, DOI 10.1021/bi060625v; Espina M, 2006, INFECT IMMUN, V74, P4391, DOI 10.1128/IAI.00440-06; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; GASTEIGER J, 1978, TETRAHEDRON LETT, P3181; Harrington A, 2006, BIOCHEMISTRY-US, V45, P626, DOI 10.1021/bi0512593; Harrington AT, 2003, INFECT IMMUN, V71, P1255, DOI 10.1128/IAI.71.3.1255-1264.2003; Hayward RD, 2005, MOL MICROBIOL, V56, P590, DOI 10.1111/j.1365-2958.2005.04568.x; Johnson S, 2007, J BIOL CHEM, V282, P4035, DOI 10.1074/jbc.M607945200; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MARQUART ME, 1995, BIOCHEM BIOPH RES CO, V214, P963, DOI 10.1006/bbrc.1995.2380; MENARD R, 1993, J BACTERIOL, V175, P5899; MILLS CO, 1991, BIOCHIM BIOPHYS ACTA, V1115, P151, DOI 10.1016/0304-4165(91)90024-B; Mills CO, 1997, BBA-GEN SUBJECTS, V1336, P485, DOI 10.1016/S0304-4165(97)00063-9; Mills CO, 1997, YALE J BIOL MED, V70, P447; MOHLEBOETANI JC, 1995, AM J PUBLIC HEALTH, V85, P812, DOI 10.2105/AJPH.85.6.812; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; Olive AJ, 2007, INFECT IMMUN, V75, P2626, DOI 10.1128/IAI.01599-06; Picking WL, 2005, INFECT IMMUN, V73, P1432, DOI 10.1128/IAI.73.3.1432-1440.2005; POPE LM, 1995, INFECT IMMUN, V63, P3642, DOI 10.1128/IAI.63.9.3642-3648.1995; Schroeder GN, 2008, CLIN MICROBIOL REV, V21, P134, DOI 10.1128/CMR.00032-07; Skoudy A, 2000, CELL MICROBIOL, V2, P19, DOI 10.1046/j.1462-5822.2000.00028.x; *TRIP ASS, SYBYL 7 1; van der Meer B W, 2002, J Biotechnol, V82, P181, DOI 10.1016/S1389-0352(01)00037-X; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Zhang L, 2007, J BIOL CHEM, V282, P32144, DOI 10.1074/jbc.M703403200	38	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18646	18654		10.1074/jbc.M802799200	http://dx.doi.org/10.1074/jbc.M802799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18450744	hybrid, Green Published			2022-12-25	WOS:000257165600021
J	Li, SH; Gorlatova, NV; Lawrence, DA; Schwartz, BS				Li, Shih-Hon; Gorlatova, Natalia V.; Lawrence, Daniel A.; Schwartz, Bradford S.			Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; CRYSTAL-STRUCTURE; LATENCY TRANSITION; BETA-SHEET; ALPHA-1-PROTEINASE INHIBITOR; SERPIN POLYMERIZATION; FUNCTIONAL STABILITY; ESCHERICHIA-COLI; HEPARIN-BINDING; SHUTTER REGION	Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (serpin) in which the reactive center loop (RCL) spontaneously inserts into a central beta-sheet, beta-sheet A, resulting in inactive inhibitor. Available x-ray crystallographic studies of PAI-1 in an active conformation relied on the use of stabilizing mutations. Recently it has become evident that these structural models do not adequately explain the behavior of wild-type PAI-1 (wtPAI-1) in solution. To probe the structure of native wtPAI-1, we used three conformationally sensitive ligands: the physiologic cofactor, vitronectin; a monoclonal antibody, 33B8, that binds preferentially to RCL-inserted forms of PAI-1; and RCL-mimicking peptides that insert into beta-sheet A. From patterns of interaction with wtPAI-1 and the stable mutant, 14-1B, we propose a model of the native conformation of wtPAI-1 in which the bottom of the central sheet is closed, whereas the top of the beta-sheet A is open to allow partial insertion of the RCL. Because the incorporation of RCL-mimicking peptides into wtPAI-1 is accelerated by vitronectin, we further propose that vitronectin alters the conformation of the RCL to allow increased accessibility to beta-sheet A, yielding a structural hypothesis that is contradictory to the current structural model of PAI-1 in solution and its interaction with vitronectin.	[Li, Shih-Hon; Schwartz, Bradford S.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Li, Shih-Hon; Schwartz, Bradford S.] Univ Illinois, Dept Med, Urbana, IL 61801 USA; [Li, Shih-Hon] Univ Illinois, Med Scholars Program, Urbana, IL 61801 USA; [Gorlatova, Natalia V.] Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; [Lawrence, Daniel A.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Michigan System; University of Michigan	Schwartz, BS (corresponding author), 190 Med Sci Bldg,MC-714,506 S Mathews Ave, Urbana, IL 61801 USA.	schwart2@uiuc.edu		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043506, R01HL055374, R01HL055747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS048780] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 055747, HL 055374, HL 43506] Funding Source: Medline; NINDS NIH HHS [F30 NS 048780] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P9487; Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Bodker JS, 2003, EUR J BIOCHEM, V270, P1672, DOI 10.1046/j.1432-1033.2003.03523.x; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; De Taeye B, 2003, J BIOL CHEM, V278, P23899, DOI 10.1074/jbc.M302226200; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dupont DM, 2006, J BIOL CHEM, V281, P36071, DOI 10.1074/jbc.M606851200; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gils A, 2003, THROMB HAEMOSTASIS, V90, P206, DOI 10.1160/TH03-01-0034; Gorlatova NV, 2003, J BIOL CHEM, V278, P16329, DOI 10.1074/jbc.M208420200; Hagglof P, 2004, J MOL BIOL, V335, P823, DOI 10.1016/j.jmb.2003.11.005; Hansen M, 2001, EUR J BIOCHEM, V268, P6274, DOI 10.1046/j.0014-2956.2001.02582.x; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jankova L, 2001, J BIOL CHEM, V276, P43374, DOI 10.1074/jbc.M103021200; Jensen S, 2002, BBA-PROTEIN STRUCT M, V1597, P301, DOI 10.1016/S0167-4838(02)00312-6; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, J BIOL CHEM, V281, P35478, DOI 10.1074/jbc.M607204200; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Li W, 2007, J BIOL CHEM, V282, P13759, DOI 10.1074/jbc.M701074200; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; MAGNOTTI RA, 1988, ANAL BIOCHEM, V170, P228, DOI 10.1016/0003-2697(88)90112-1; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; McGowan S, 2006, EMBO J, V25, P3144, DOI 10.1038/sj.emboj.7601201; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Naessens D, 2003, THROMB HAEMOSTASIS, V90, P52, DOI 10.1055/s-0037-1613598; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 2002, THROMB HAEMOSTASIS, V88, P288; OLSON ST, 1982, J BIOL CHEM, V257, P4891; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; Wind T, 2003, EUR J BIOCHEM, V270, P1680, DOI 10.1046/j.1432-1033.2003.03524.x; Wind T, 2002, BIOL CHEM, V383, P21, DOI 10.1515/BC.2002.003; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou A, 2004, J MOL BIOL, V342, P931, DOI 10.1016/j.jmb.2004.07.078; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhou AW, 2003, J BIOL CHEM, V278, P15116, DOI 10.1074/jbc.M211663200	67	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18147	18157		10.1074/jbc.M709455200	http://dx.doi.org/10.1074/jbc.M709455200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18436534	Green Published, hybrid			2022-12-25	WOS:000256949200043
J	Mori, S; Wu, CY; Yamaji, S; Saegusa, J; Shi, B; Ma, Z; Kuwabara, Y; Lam, KS; Isseroff, RR; Akada, YK; Takada, Y				Mori, Seiji; Wu, Chun-Yi; Yamaji, Satoshi; Saegusa, Jun; Shi, Biao; Ma, Zi; Kuwabara, Yasuko; Lam, Kit S.; Isseroff, R. Rivkah; Akada, Yoko K.; Takada, Yoshikazu			Direct binding of integrin alpha v beta 3 to FGF1 plays a role in FGF1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RECEPTOR SPECIFICITY; CELL-PROLIFERATION; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; FIBRINOGEN GAMMA; KINASE-ACTIVITY; FACTOR FAMILY; ANGIOGENESIS; ALPHA(V)BETA(3)	Integrins play a role in fibroblast growth factor (FGF) signaling through cross-talk with FGF receptors (FGFRs), but the mechanism underlying the cross-talk is unknown. We discovered that FGF1 directly bound to soluble and cell-surface integrin alpha v beta 3 (KD about 1 mu M). Antagonists to alpha v beta 3 (monoclonal antibody 7E3 and cyclic RGDfV) blocked this interaction. alpha v beta 3 was the predominant, if not the only, integrin that bound to FGF1, because FGF1 bound only weakly to several beta 1 integrins tested. We presented evidence that the CYDMKTTC sequence (the specificity loop) within the ligand-binding site of beta 3 plays a role in FGF1 binding. We found that the integrin-binding site of FGF1 overlaps with the heparin-binding site but is distinct from the FGFR-binding site using docking simulation and mutagenesis. We identified an FGF1 mutant (R50E) that was defective in integrin binding but still bound to heparin and FGFR. R50E was defective in inducing DNA synthesis, cell proliferation, cell migration, and chemotaxis, suggesting that the direct integrin binding to FGF1 is critical for FGF signaling. Nevertheless, R50E induced phosphorylation of FGFR1 and FRS2 alpha and activation of AKT and ERK1/2. These results suggest that the defect in R50E in FGF signaling is not in the initial activation of FGF signaling pathway components, but in the later steps in FGF signaling. We propose that R50E is a useful tool to identify the role of integrins in FGF signaling.	[Mori, Seiji; Yamaji, Satoshi; Saegusa, Jun; Shi, Biao; Ma, Zi; Kuwabara, Yasuko; Isseroff, R. Rivkah; Akada, Yoko K.; Takada, Yoshikazu] Univ Calif Davis, Dept Dermatol, Sch Med, Sacramento, CA 95817 USA; [Wu, Chun-Yi; Lam, Kit S.] Univ Calif Davis, Dept Hematol Oncol, Sch Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Takada, Y (corresponding author), Res 3 Ste 3300,4645 2nd Ave, Sacramento, CA 95817 USA.	ytakada@ucdavis.edu	Isseroff, Roslyn Rivkah/AAD-8478-2021	Isseroff, Roslyn Rivkah/0000-0001-7813-0858; takada, yoshikazu/0000-0001-5481-9589	NATIONAL CANCER INSTITUTE [U19CA113298, P30CA093373] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA093373-07, U19 CA113298-040002, P30 CA093373, CA 093373, U19 CA113298, CA 113298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akakura N, 2006, CANCER RES, V66, P9691, DOI 10.1158/0008-5472.CAN-06-1686; Artoni A, 2004, P NATL ACAD SCI USA, V101, P13114, DOI 10.1073/pnas.0404201101; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fleming FE, 2007, ARCH VIROL, V152, P1087, DOI 10.1007/s00705-007-0937-x; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Gan YB, 2006, PHARM RES-DORDR, V23, P1324, DOI 10.1007/s11095-006-0136-6; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Karajannis MA, 2006, LEUKEMIA, V20, P979, DOI 10.1038/sj.leu.2404203; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Paleolog EM, 2002, ARTHRITIS RES THER, V4, pS81, DOI 10.1186/ar575; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Sahni A, 2006, BLOOD, V107, P126, DOI 10.1182/blood-2005-06-2460; Sahni A, 2004, BLOOD, V104, P3635, DOI 10.1182/blood-2004-04-1358; Sahni A, 2003, J THROMB HAEMOST, V1, P1304, DOI 10.1046/j.1538-7836.2003.00250.x; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Schwartz MA, 2001, J CELL SCI, V114, P2553; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Sharrocks AD, 2006, CURR BIOL, V16, pR540, DOI 10.1016/j.cub.2006.06.038; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tanghetti E, 2002, ONCOGENE, V21, P3889, DOI 10.1038/sj.onc.1205407; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417	54	93	107	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18066	18075		10.1074/jbc.M801213200	http://dx.doi.org/10.1074/jbc.M801213200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441324	hybrid, Green Published			2022-12-25	WOS:000256949200036
J	Najy, AJ; Day, KC; Day, ML				Najy, Abdo J.; Day, Kathleen C.; Day, Mark L.			The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGFR SIGNAL TRANSACTIVATION; GROWTH-FACTOR RECEPTOR; CELL-CELL-ADHESION; N-CADHERIN; PROSTATE; DISINTEGRIN; EXPRESSION; CARCINOMA; DOMAIN; MIGRATION	The zinc-dependent disintegrin metalloproteinases (a disintegrin and metalloproteinases (ADAMs) have been implicated in several disease processes, including human cancer. Previously, we demonstrated that the expression of a catalytically active member of the ADAM family, ADAM15, is associated with the progression of prostate and breast cancer. The accumulation of the soluble ectodomain of E-cadherin in human serum has also been associated with the progression of prostate and breast cancer and is thought to be mediated by metalloproteinase shedding. Utilizing two complementary models, overexpression and stable short hairpin RNA-mediated knockdown of ADAM15 in breast cancer cells, we demonstrated that ADAM15 cleaves E-cadherin in response to growth factor deprivation. We also demonstrated that the extracellular shedding of E-cadherin was abrogated by a metalloproteinase inhibitor and through the introduction of a catalytically inactive mutation in ADAM15. We have made the novel observation that this soluble E-cadherin fragment was found in complex with the HER2 and HER3 receptors in breast cancer cells. These interactions appeared to stabilize HER2 heterodimerization with HER3 and induced receptor activation and signaling through the Erk pathway, supporting both cell migration and proliferation. In this study, we provide evidence that ADAM15 catalyzes the cleavage of E-cadherin to generate a soluble fragment that in turn binds to and stimulates ErbB receptor signaling.	[Najy, Abdo J.; Day, Kathleen C.; Day, Mark L.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Najy, Abdo J.; Day, Mark L.] Univ Michigan, Cell & Mol Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Day, ML (corresponding author), Univ Michigan, Dept Urol, 6219 CCGC 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NIDDK NIH HHS [R01 DK 56137] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Balazs M, 2001, CYTOMETRY, V46, P222, DOI 10.1002/cyto.1131; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bohm BB, 2005, ARTHRITIS RHEUM-US, V52, P1100, DOI 10.1002/art.20974; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Carl-McGrath S, 2005, INT J ONCOL, V26, P17; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; De Wever O, 2007, CLIN EXP METASTAS, V24, P685, DOI 10.1007/s10585-007-9104-8; Fedor-Chaiken M, 2003, CELL COMMUN ADHES, V10, P105, DOI 10.1080/714040416; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gilles C, 1996, INT J CANCER, V65, P209; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Horiuchi K, 2005, DEV BIOL, V283, P459, DOI 10.1016/j.ydbio.2005.05.004; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kuefer R, 2006, NEOPLASIA, V8, P319, DOI 10.1593/neo.05682; Lin JH, 2007, J VIROL, V81, P5705, DOI 10.1128/JVI.00076-07; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; MARETZKY T, 2008, J INVEST DE IN PRESS; Martin J, 2002, J BIOL CHEM, V277, P33683, DOI 10.1074/jbc.M200988200; Masterson J, 2007, CELLS TISSUES ORGANS, V185, P175, DOI 10.1159/000101318; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Najy AJ, 2008, CANCER RES, V68, P1092, DOI 10.1158/0008-5472.CAN-07-2432; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Noe V, 2001, J CELL SCI, V114, P111; Noe V, 1999, J CELL SCI, V112, P127; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rittie L, 2007, AM J PATHOL, V170, P2089, DOI 10.2353/ajpath.2007.060537; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schutz A, 2005, VIRCHOWS ARCH, V446, P421, DOI 10.1007/s00428-004-1193-z; Shah RB, 2006, PROSTATE, V66, P1437, DOI 10.1002/pros.20460; Shintani Y, 2004, CANCER RES, V64, P4190, DOI 10.1158/0008-5472.CAN-03-3235; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272; Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Wilmanns C, 2004, CLIN EXP METASTAS, V21, P75, DOI 10.1023/B:CLIN.0000017204.38807.22; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yasmeen Amber, 2006, Future Oncol, V2, P765, DOI 10.2217/14796694.2.6.765; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	55	145	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18393	18401		10.1074/jbc.M801329200	http://dx.doi.org/10.1074/jbc.M801329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434311	hybrid, Green Published			2022-12-25	WOS:000256949200067
J	Efendiev, R; Budu, CE; Bertorello, AM; Pedemonte, CH				Efendiev, Riad; Budu, Claudia E.; Bertorello, Alejandro M.; Pedemonte, Carlos H.			G-protein-coupled receptor-mediated traffic of Na,K-ATPase to the plasma membrane requires the binding of adaptor protein 1 to a Tyr-255-based sequence in the alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; POLARIZED EPITHELIAL-CELLS; ANGIOTENSIN-II RECEPTORS; PROXIMAL TUBULE; KINASE-C; DEPENDENT ENDOCYTOSIS; RENAL NA+,K+-ATPASE; DOPAMINE-RECEPTOR; SODIUM-TRANSPORT; SORTING SIGNALS	Motion of integral membrane proteins to the plasma membrane in response to G-protein-coupled receptor signals requires selective cargo recognition motifs that bind adaptor protein 1 and clathrin. Angiotensin II, through the activation of AT1 receptors, promotes the recruitment to the plasma membrane of Na,K-ATPase molecules from intracellular compartments. We present evidence to demonstrate that a tyrosine-based sequence (IVVY-255) present within the Na,K-ATPase alpha 1-subunit is involved in the binding of adaptor protein 1. Mutation of Tyr-255 to a phenylalanine residue in the Na,K-ATPase alpha 1-subunit greatly reduces the angiotensin II-dependent activation of Na,K-ATPase, recruitment of Na,K-ATPase molecules to the plasma membrane, and association of adaptor protein 1 with Na,K-ATPase alpha 1-subunit molecules. To determine protein-protein interaction, we used fluorescence resonance energy transfer between fluorophores attached to the Na,K-ATPase alpha 1-subunit and adaptor protein 1. Although angiotensin II activation of AT1 receptors induces a significant increase in the level of fluorescence resonance energy transfer between the two molecules, this effect was blunted in cells expressing the Tyr-255 mutant. Thus, results from different methods and techniques suggest that the Tyr-255-based sequence within the NKA alpha 1-subunit is the site of adaptor protein 1 binding in response to the G-protein-coupled receptor signals produced by angiotensin II binding to AT1 receptors.	[Efendiev, Riad; Budu, Claudia E.; Pedemonte, Carlos H.] Univ Houston, Coll Pharm, Houston, TX 77204 USA; [Bertorello, Alejandro M.] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Med, Atherosclerosis Res Unit,Membrane Signaling Netwo, S-17176 Stockholm, Sweden	University of Houston System; University of Houston; Karolinska Institutet; Karolinska University Hospital	Efendiev, R (corresponding author), Univ Texas Houston, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin,MSB-4-218, Houston, TX 77030 USA.	riad.efendi@uth.tmc.edu			NIDDK NIH HHS [DK62195] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062195] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achnine L, 2004, PLANT CELL, V16, P3098, DOI 10.1105/tpc.104.024406; APERIA A, 1994, FASEB J, V8, P436, DOI 10.1096/fasebj.8.6.8168694; Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Budu CE, 2002, BRIT J PHARMACOL, V137, P1380, DOI 10.1038/sj.bjp.0704962; CHEN CJ, 1992, PHARM TOXICOL S1, V70, P11; Cheng HF, 1996, J CLIN INVEST, V97, P2745, DOI 10.1172/JCI118729; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 2007, BRIT J PHARMACOL, V151, P1006, DOI 10.1038/sj.bjp.0707304; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Efendiev R, 2003, J BIOL CHEM, V278, P28719, DOI 10.1074/jbc.M303741200; Efendiev R, 2002, J BIOL CHEM, V277, P44108, DOI 10.1074/jbc.M205173200; Efendiev R, 2002, J BIOL CHEM, V277, P11489, DOI 10.1074/jbc.M108182200; Efendiev R, 2006, J AM SOC NEPHROL, V17, P31, DOI 10.1681/ASN.2005070681; Efendiev R, 2006, FEBS LETT, V580, P5067, DOI 10.1016/j.febslet.2006.08.035; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gidwani A, 2003, J CELL SCI, V116, P3177, DOI 10.1242/jcs.00621; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Guimaraes JT, 1997, INT J BIOCHEM CELL B, V29, P681, DOI 10.1016/S1357-2725(96)00166-5; Hussain T, 1998, HYPERTENSION, V32, P187, DOI 10.1161/01.HYP.32.2.187; Hussain T, 1997, CLIN EXP HYPERTENS, V19, P131, DOI 10.3109/10641969709080810; Hussain T, 1997, AM J PHYSIOL-RENAL, V272, pF339, DOI 10.1152/ajprenal.1997.272.3.F339; Inagami T, 1999, CLIN EXP PHARMACOL P, V26, P544, DOI 10.1046/j.1440-1681.1999.03086.x; Jose PA, 1998, PHARMACOL THERAPEUT, V80, P149, DOI 10.1016/S0163-7258(98)00027-8; KANSRA V, 1995, EUR J PHARM-MOLEC PH, V289, P391, DOI 10.1016/0922-4106(95)90119-1; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LANE LK, 1993, J BIOL CHEM, V268, P17930; Leong PKK, 2006, AM J PHYSIOL-RENAL, V290, pF854, DOI 10.1152/ajprenal.00353.2005; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; NASH SR, 1993, MOL PHARMACOL, V44, P918; Navar LG, 1999, J AM SOC NEPHROL, V10, pS266; NAVAR LG, 1994, J AM SOC NEPHROL, V5, P1153; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Pedemonte CH, 1997, MOL PHARMACOL, V52, P88, DOI 10.1124/mol.52.1.88; Pedemonte CH, 2005, SEMIN NEPHROL, V25, P322, DOI 10.1016/j.semnephrol.2005.03.007; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200; Zeng Chunyu, 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P69, DOI 10.2174/1568016052773289; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	44	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17561	17567		10.1074/jbc.M709260200	http://dx.doi.org/10.1074/jbc.M709260200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18420589	Green Published, hybrid			2022-12-25	WOS:000256720600063
J	Tubb, MR; Silva, RAGD; Fang, JW; Tso, P; Davidson, WS				Tubb, Matthew R.; Silva, R. A. Gangani D.; Fang, Jianwen; Tso, Patrick; Davidson, W. Sean			A three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOA-IV; EXCHANGEABLE APOLIPOPROTEINS; GENETIC-POLYMORPHISM; CIRCULAR-DICHROISM; AMPHIPATHIC HELIX; PLASMA-MEMBRANES; BINDING; RAT; SECRETION; SEQUENCE	Human apolipoprotein A-IV (apoA-IV) is a 46-kDa exchangeable plasma protein with many proposed functions. It is involved in chylomicron assembly and secretion, protection from atherosclerosis through a variety of mechanisms, and inhibition of food intake. There is little structural basis for these proposed functions due to the lack of a solved three-dimensional structure of the protein by x-ray crystallography or NMR. Based on previous studies, we hypothesized that lipid-free apoA-IV exists in a helical bundle, like other apolipoprotein family members and that regions near the N and C termini may interact. Utilizing a homobifunctional lysine cross-linking agent, we identified 21 intramolecular cross-links by mass spectrometry. These cross-links were used to constrain the building of a sequence threaded homology model using the I-TASSER server. Our results indicate that lipid-free apoA-IV does indeed exist as a complex helical bundle with the N and C termini in close proximity. This first structural model of lipid-free apoA-IV should prove useful for designing studies aimed at understanding how apoA-IV interacts with lipids and possibly with unknown protein partners.	[Tubb, Matthew R.; Silva, R. A. Gangani D.; Tso, Patrick; Davidson, W. Sean] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; [Fang, Jianwen] Univ Kansas, Bioinformat Core Facil, Lawrence, KS 66045 USA	University System of Ohio; University of Cincinnati; University of Kansas	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989; Tubb, Matthew/0000-0002-4543-2742	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082734, R01HL067093] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL82734, HL67093] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DUVERGER N, 1991, EUR J BIOCHEM, V201, P373, DOI 10.1111/j.1432-1033.1991.tb16294.x; DVORIN E, 1985, J LIPID RES, V26, P38; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; Ezeh B, 2003, J LIPID RES, V44, P1523, DOI 10.1194/jlr.M300060-JLR200; Fan DP, 2003, J BIOL CHEM, V278, P21212, DOI 10.1074/jbc.M208486200; FUJIMOTO K, 1992, AM J PHYSIOL, V262, pG1002, DOI 10.1152/ajpgi.1992.262.6.G1002; Gallagher JW, 2004, J LIPID RES, V45, P1826, DOI 10.1194/jlr.M400188-JLR200; GHISELLI G, 1986, BIOCHEM BIOPH RES CO, V139, P122, DOI 10.1016/S0006-291X(86)80088-2; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; JONAS A, 1993, J BIOL CHEM, V268, P1596; KALOGERIS TJ, 1997, J NUTR S, V127, P537; KAMBOH MI, 1994, HUM BIOL, V66, P625; Lagerstedt JO, 2007, J BIOL CHEM, V282, P9143, DOI 10.1074/jbc.M608717200; LOHSE P, 1990, J BIOL CHEM, V265, P10061; Lu S, 2006, J BIOL CHEM, V281, P3473, DOI 10.1074/jbc.M502501200; Main LA, 1996, BBA-LIPID LIPID MET, V1300, P17, DOI 10.1016/0005-2760(95)00228-6; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; PEARSON K, 2005, J BIOL CHEM; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; Recalde D, 2004, ARTERIOSCL THROM VAS, V24, P756, DOI 10.1161/01.ATV.0000119353.03690.22; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; Tubb MR, 2007, J BIOL CHEM, V282, P28385, DOI 10.1074/jbc.M704070200; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; WEINBERG RB, 1990, BIOCHIM BIOPHYS ACTA, V1044, P255, DOI 10.1016/0005-2760(90)90311-K; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEINBERG RB, 1994, J LIPID RES, V35, P2212; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WEINBERG RB, 1987, BIOCHIM BIOPHYS ACTA, V918, P299, DOI 10.1016/0005-2760(87)90234-7; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinstock PH, 1997, J LIPID RES, V38, P1782; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Zhang Y, 2007, PROTEINS, V69, P108, DOI 10.1002/prot.21702	44	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17314	17323		10.1074/jbc.M800036200	http://dx.doi.org/10.1074/jbc.M800036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430727	hybrid, Green Published			2022-12-25	WOS:000256720600040
J	Wahid, AM; Coventry, VK; Conn, GL				Wahid, Ahmed M.; Coventry, Veronica K.; Conn, Graeme L.			Systematic deletion of the adenovirus-associated RNA(I) terminal stem reveals a surprisingly active RNA inhibitor of double-stranded RNA-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ASSOCIATED RNA; CENTRAL DOMAIN; VAI RNA; TERTIARY STRUCTURE; STRUCTURAL FEATURES; TRIPLE-HELIX; PKR; BINDING; INTERFERON; DAI	Adenoviruses use the short noncoding RNA transcript virus-associated (VA) RNA(I) to counteract two critical elements of the host cell defense system, innate cellular immunity and RNA interference, mediated by the double-stranded RNA-activated protein kinase (PKR) and Dicer/RNA-induced silencing complex, respectively. We progressively shortened the VA RNA(I) terminal stem to examine its necessity for inhibition of PKR. Each deletion, up to 15 bp into the terminal stem, resulted in a cumulative decrease in PKR inhibitory activity. Remarkably, however, despite significant apparent destabilization of the RNA structure, the final RNA mutant that lacked the entire terminal stem (TS Delta 21 RNA) efficiently bound PKR and exhibited wild-type inhibitory activity. TS Delta 21 RNA stability was strongly influenced by solution pH, indicating the involvement of a protonated base within the VA RNA(I) central domain tertiary structure. Gel filtration chromatography and isothermal titration calorimetry analysis indicated that wild-type VA RNA(I) and TS Delta 21 RNA form similar 1:1 complexes with PKR but that the latter lacks secondary binding site(s) that might be provided by the terminal stem. Although TS Delta 21 RNA bound PKR with wild-type K-d, and overall change in free energy (Delta G), the thermodynamics of binding (Delta H and Delta S) were significantly altered. These results demonstrate that the VA RNA(I) terminal stem is entirely dispensable for inhibition of PKR. Potentially, VA RNA(I) is therefore a truly bi-functional RNA; Dicer processing of the VA RNA(I) terminal stem saturates the RNA interference system while generating a "mini-VA RNA(I)" molecule that remains fully active against PKR.	[Wahid, Ahmed M.; Conn, Graeme L.] Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England; [Wahid, Ahmed M.; Coventry, Veronica K.; Conn, Graeme L.] Univ Manchester, Fac Life Sci, Manchester M1 7DN, Lancs, England	University of Manchester; University of Manchester	Conn, GL (corresponding author), Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7DN, Lancs, England.	Graeme.L.Conn@manchester.ac.uk		Wahid, Ahmed/0000-0003-3613-2796; Conn, Graeme/0000-0002-2419-380X	Medical Research Council Funding Source: Medline; Wellcome Trust [061444] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Asensio JL, 1998, J MOL BIOL, V275, P811, DOI 10.1006/jmbi.1997.1520; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLARKE PA, 1994, NUCLEIC ACIDS RES, V22, P4364, DOI 10.1093/nar/22.21.4364; CLARKE PA, 1995, RNA, V1, P7; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Conn GL, 2003, BIOTECHNIQUES, V35, P682, DOI 10.2144/03354bm03; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; Coventry VK, 2008, NUCLEIC ACIDS RES, V36, P1645, DOI 10.1093/nar/gkn020; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; FURTADO MR, 1989, J VIROL, V63, P3423, DOI 10.1128/JVI.63.8.3423-3434.1989; GHADGE GD, 1994, J VIROL, V68, P4137, DOI 10.1128/JVI.68.7.4137-4151.1994; GHADGE GD, 1991, P NATL ACAD SCI USA, V88, P7140, DOI 10.1073/pnas.88.16.7140; Holland JA, 1996, NUCLEIC ACIDS RES, V24, P2841, DOI 10.1093/nar/24.14.2841; Ichetovkin IE, 1997, J BIOL CHEM, V272, P33009, DOI 10.1074/jbc.272.52.33009; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KLINCK R, 1995, EUR J BIOCHEM, V233, P544, DOI 10.1111/j.1432-1033.1995.544_2.x; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; Langland JO, 2006, VIRUS RES, V119, P100, DOI 10.1016/j.virusres.2005.10.014; Lemaire PA, 2005, J MOL BIOL, V345, P81, DOI 10.1016/j.jmb.2004.10.031; Ma YL, 1996, J VIROL, V70, P5083, DOI 10.1128/JVI.70.8.5083-5099.1996; MA YL, 1993, J VIROL, V67, P6605, DOI 10.1128/JVI.67.11.6605-6617.1993; Ma YL, 1996, RNA, V2, P937; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; McKenna SA, 2007, METHOD ENZYMOL, V430, P373, DOI 10.1016/S0076-6879(07)30014-1; McKenna SA, 2007, J MOL BIOL, V372, P103, DOI 10.1016/j.jmb.2007.06.028; McKenna SA, 2006, J MOL BIOL, V358, P1270, DOI 10.1016/j.jmb.2006.03.003; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MELLITS KH, 1992, J VIROL, V66, P2369, DOI 10.1128/JVI.66.4.2369-2377.1992; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Nixon PL, 2000, J MOL BIOL, V296, P659, DOI 10.1006/jmbi.1999.3464; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; Peery T, 1997, METHODS, V11, P371, DOI 10.1006/meth.1996.0435; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; RAHMAN A, 1995, J VIROL, V69, P4299, DOI 10.1128/JVI.69.7.4299-4307.1995; Roberts RW, 1996, P NATL ACAD SCI USA, V93, P4320, DOI 10.1073/pnas.93.9.4320; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SODERLUND H, 1976, CELL, V7, P585, DOI 10.1016/0092-8674(76)90209-9; WAGNER AF, 1971, BIOCHEM BIOPH RES CO, V45, P184, DOI 10.1016/0006-291X(71)90067-2; Walker SC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng082; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	46	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17485	17493		10.1074/jbc.M802300200	http://dx.doi.org/10.1074/jbc.M802300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430723	Green Published, hybrid			2022-12-25	WOS:000256720600056
J	Hansen, DM; Kaiser, CN; Muller, CB				Hansen, Dennis M.; Kaiser, Christopher N.; Mueller, Christine B.			Seed Dispersal and Establishment of Endangered Plants on Oceanic Islands: The Janzen-Connell Model, and the Use of Ecological Analogues	PLOS ONE			English	Article							TROPICAL FORESTS; INSECT HERBIVORES; PLEISTOCENE PARK; GIANT TORTOISE; RAIN-FOREST; CONSERVATION; TREE; ANIMALS; ANACHRONISMS; GERMINATION	Background: The Janzen-Connell model states that plant-specific natural enemies may have a disproportionately large negative effect on progeny close to maternal trees. The majority of experimental and theoretical studies addressing the Janzen-Connell model have explored how it can explain existing patterns of species diversity in tropical mainland areas. Very few studies have investigated how the model's predictions apply to isolated oceanic islands, or to the conservation management of endangered plants. Here, we provide the first experimental investigation of the predictions of the Janzen-Connell model on an oceanic island, in a conservation context. In addition, we experimentally evaluate the use of ecological analogue animals to resurrect the functional component of extinct frugivores that could have dispersed seeds away from maternal trees. Methodology/Principal Findings: In Mauritius, we investigated seed germination and seedling survival patterns of the critically endangered endemic plant Syzygium mamillatum (Myrtaceae) in relation to proximity to maternal trees. We found strong negative effects of proximity to maternal trees on growth and survival of seedlings. We successfully used giant Aldabran tortoises as ecological analogues for extinct Mauritian frugivores. Effects of gut-passage were negative at the seed germination stage, but seedlings from gut-passed seeds grew taller, had more leaves, and suffered less damage from natural enemies than any of the other seedlings. Conclusions/Significance: We provide the first experimental evidence of a distance-dependent Janzen-Connell effect on an oceanic island. Our results potentially have serious implications for the conservation management of rare plant species on oceanic islands, which harbour a disproportionately large fraction of the world's endemic and endangered plants. Furthermore, in contrast to recent controversy about the use of non-indigenous extant megafauna for re-wilding projects in North America and elsewhere, we argue that Mauritius and other oceanic islands are ideal study systems in which to empirically explore the use of ecological analogue species in restoration ecology.	[Hansen, Dennis M.; Kaiser, Christopher N.; Mueller, Christine B.] Univ Zurich, Inst Env Sci, Zurich, Switzerland	University of Zurich	Hansen, DM (corresponding author), Univ Zurich, Inst Env Sci, Zurich, Switzerland.	dmhansen@stanford.edu	Hansen, Dennis M/A-3307-2008; Kaiser-Bunbury, Christopher/C-5038-2012	Hansen, Dennis M/0000-0002-9584-2766; Kaiser-Bunbury, Christopher/0000-0001-7254-3491	NSF [631-065950]; University of Zurich	NSF(National Science Foundation (NSF)); University of Zurich	Swiss NSF grant #631-065950 to CBM. Research Fund of the University of Zurich to DMH during analysis and write-up	Arevalo JR, 2003, PLANT ECOL, V165, P1, DOI 10.1023/A:1021490715660; Bascompte J, 2006, SCIENCE, V312, P431, DOI 10.1126/science.1123412; BEARDSELL DV, 1993, AUST J BOT, V41, P511, DOI 10.1071/BT9930511; Bevill RL, 1999, CONSERV BIOL, V13, P1323, DOI 10.1046/j.1523-1739.1999.98450.x; BOND WJ, 1994, PHILOS T R SOC B, V344, P83, DOI 10.1098/rstb.1994.0055; Borges PAV, 1999, BIOL J LINN SOC, V66, P373, DOI 10.1111/j.1095-8312.1999.tb01897.x; BOSSER J, 1987, ADANSONIA, V9, P29; Caro T, 2007, TRENDS ECOL EVOL, V22, P281, DOI 10.1016/j.tree.2007.03.001; Cheke A.S., 1987, P5, DOI 10.1017/CBO9780511735769.003; CHEKE AS, LOST LAND D IN PRESS; CLARK DA, 1981, OECOLOGIA, V49, P73, DOI 10.1007/BF00376900; CLARK DA, 1984, AM NAT, V124, P769, DOI 10.1086/284316; Clout M., 2002, TURNING TIDE ERADICA; COLEY PD, 1985, SCIENCE, V230, P895, DOI 10.1126/science.230.4728.895; CONNELL J H, 1971, P298; Cordeiro NJ, 2001, CONSERV BIOL, V15, P1733, DOI 10.1046/j.1523-1739.2001.99579.x; COX PA, 1991, CONSERV BIOL, V5, P448, DOI 10.1111/j.1523-1739.1991.tb00351.x; Donlan CJ, 2006, AM NAT, V168, P660, DOI 10.1086/508027; Donlan J, 2005, NATURE, V436, P913, DOI 10.1038/436913a; Galetti M, 2006, BOT J LINN SOC, V151, P141, DOI 10.1111/j.1095-8339.2006.00529.x; Galetti M., 2004, NAT CONSERV, V2, P93; Garcia-Guzman G, 2001, AM J BOT, V88, P634, DOI 10.2307/2657063; Gilbert GS, 1996, BIOSCIENCE, V46, P98, DOI 10.2307/1312812; Gillespie RG, 2002, ANNU REV ENTOMOL, V47, P595, DOI 10.1146/annurev.ento.47.091201.145244; Grant P.R., 1998, EVOLUTION ISLANDS; Guimaraes Paulo R. Jr, 2008, PLoS ONE, V3, pUnpaginated, DOI 10.1371/journal.pone.0001745; HACHISUKA M, 1953, DODO KINDRED BIRDS E, P250; HAMBLER C, 1994, BIOL CONSERV, V69, P293, DOI 10.1016/0006-3207(94)90429-4; HAMILTON J, 1982, J ARID ENVIRON, V5, P127, DOI 10.1016/S0140-1963(18)31545-3; HNATIUK SH, 1978, OECOLOGIA, V36, P345, DOI 10.1007/BF00348060; Howe HF, 2000, TRENDS ECOL EVOL, V15, P434, DOI 10.1016/S0169-5347(00)01965-0; HOWE HF, 1982, ANNU REV ECOL SYST, V13, P201, DOI 10.1146/annurev.es.13.110182.001221; Hutton I, 2007, ANIM CONSERV, V10, P22, DOI 10.1111/j.1469-1795.2006.00077.x; IVERSON JB, 1987, J HERPETOL, V21, P229, DOI 10.2307/1564487; JANZEN DH, 1982, SCIENCE, V215, P19, DOI 10.1126/science.215.4528.19; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Jones CG, 2002, HANDBOOK OF ECOLOGICAL RESTORATION, VOL 1, P355; Kaiser CN, 2008, BIOTROPICA, V40, P86, DOI 10.1111/j.1744-7429.2007.00345.x; LAWTON JH, 1995, OIKOS, V73, P145, DOI 10.2307/3545902; LEE MAB, 1985, OIKOS, V45, P169, DOI 10.2307/3565702; LORENCE D H, 1986, Journal of Tropical Ecology, V2, P147; MARTIN PS, 2005, TWILIGHT MAMMOTHS IC, P250; Maunder M, 2002, ORYX, V36, P56, DOI 10.1017/S0030605302000091; Novotny V, 2005, P ROY SOC B-BIOL SCI, V272, P1083, DOI 10.1098/rspb.2004.3023; Nyhagen DF, 2005, BIOL CONSERV, V122, P491, DOI 10.1016/j.biocon.2004.08.012; Oliveira PS, 1995, BIOTROPICA, V27, P518, DOI 10.2307/2388966; Pinheiro J, 2000, MIXED EFFECTS MODELS; Pretorius JC, 2002, ANN APPL BIOL, V141, P117, DOI 10.1111/j.1744-7348.2002.tb00203.x; R Development Core Team, 2006, R LANG ENV STAT COMP; Ribeiro SP, 2005, ECOGRAPHY, V28, P315, DOI 10.1111/j.0906-7590.2005.04104.x; RICK CM, 1961, EVOLUTION, V15, P407, DOI 10.2307/2406309; Rodriguez-Perez J, 2005, FUNCT ECOL, V19, P699, DOI 10.1111/j.0269-8463.2005.00971.x; Rubenstein DR, 2006, BIOL CONSERV, V132, P232, DOI 10.1016/j.biocon.2006.04.003; Samuels IA, 2005, FUNCT ECOL, V19, P365, DOI 10.1111/j.1365-2435.2005.00973.x; Steadman DW, 2003, EARTH-SCI REV, V61, P133, DOI 10.1016/S0012-8252(02)00116-2; TEMPLE SA, 1977, SCIENCE, V197, P885, DOI 10.1126/science.197.4306.885; Traveset A, 2005, CONSERV BIOL, V19, P421, DOI 10.1111/j.1523-1739.2005.00019.x; VENABLES WN, 2002, MODERN APPL STAT S, P548; VITOUSEK PM, 1995, ISLANDS BIOL DIVERSI, V115, P238; Wiles GJ, 1996, BIOL CONSERV, V76, P229, DOI 10.1016/0006-3207(95)00078-X; Wills C, 1997, P NATL ACAD SCI USA, V94, P1252, DOI 10.1073/pnas.94.4.1252; WITMER MC, 1991, OIKOS, V61, P133, DOI 10.2307/3545415; Wright SJ, 2007, BIOTROPICA, V39, P289, DOI 10.1111/j.1744-7429.2007.00293.x; Wright SJ, 2002, OECOLOGIA, V130, P1, DOI 10.1007/s004420100809; WYSEJACKSON PS, 1988, TROP ECOL, V29, P98; Zimov SA, 2005, SCIENCE, V308, P796, DOI 10.1126/science.1113442	66	43	45	2	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2111	10.1371/journal.pone.0002111	http://dx.doi.org/10.1371/journal.pone.0002111			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461169	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400033
J	Li, M; Wang, CJ; Feng, YJ; Pan, XZ; Cheng, G; Wang, J; Ge, JC; Zheng, F; Cao, M; Dong, YQ; Liu, D; Wang, JF; Lin, Y; Du, HL; Gao, GF; Wang, XN; Hu, FQ; Tang, JQ				Li, Ming; Wang, Changjun; Feng, Youjun; Pan, Xiuzhen; Cheng, Gong; Wang, Jing; Ge, Junchao; Zheng, Feng; Cao, Min; Dong, Yaqing; Liu, Di; Wang, Jufang; Lin, Ying; Du, Hongli; Gao, George F.; Wang, Xiaoning; Hu, Fuquan; Tang, Jiaqi			SalK/SalR, a Two-Component Signal Transduction System, Is Essential for Full Virulence of Highly Invasive Streptococcus suis Serotype 2	PLOS ONE			English	Article							HORIZONTAL GENE-TRANSFER; MURAMIDASE-RELEASED PROTEIN; GROUP-A STREPTOCOCCUS; SURFACE PROTEIN; PATHOGENICITY ISLANDS; BACTERIAL VIRULENCE; REGULATORY SYSTEM; ABC TRANSPORTERS; RESPONSE-REGULATOR; DRUG-RESISTANCE	Background: Streptococcus suis serotype 2 (S. suis 2, SS2) has evolved into a highly infectious entity, which caused the two recent large-scale outbreaks of human SS2 epidemic in China, and is characterized by a toxic shock-like syndrome. However, the molecular pathogenesis of this new emerging pathogen is still poorly understood. Methodology/Principal Findings: 89K is a newly predicted pathogenicity island (PAI) which is specific to Chinese epidemic strains isolated from these two SS2 outbreaks. Further bioinformatics analysis revealed a unique two-component signal transduction system (TCSTS) located in the candidate 89K PAI, which is orthologous to the SalK/SalR regulatory system of Streptococcus salivarius. Knockout of salKR eliminated the lethality of SS2 in experimental infection of piglets. Functional complementation of salKR into the isogenic mutant DsalKR restored its soaring pathogenicity. Colonization experiments showed that the DsalKR mutant could not colonize any susceptible tissue of piglets when administered alone. Bactericidal assays demonstrated that resistance of the mutant to polymorphonuclear leukocyte (PMN)-mediated killing was greatly decreased. Expression microarray analysis exhibited a transcription profile alteration of 26 various genes down-regulated in the DsalKR mutant. Conclusions/Significance: These findings suggest that SalK/SalR is requisite for the full virulence of ethnic Chinese isolates of highly pathogenic SS2, thus providing experimental evidence for the validity of this bioinformatically predicted PAI.	[Li, Ming; Hu, Fuquan; Tang, Jiaqi] Third Mil Med Univ, Dept Microbiol, Chongqing, Peoples R China; [Li, Ming; Wang, Changjun; Pan, Xiuzhen; Cheng, Gong; Wang, Jing; Ge, Junchao; Zheng, Feng; Cao, Min; Dong, Yaqing; Hu, Fuquan; Tang, Jiaqi] Res Inst Med Nanjing Command, Dept Epidemiol, Nanjing, Peoples R China; [Feng, Youjun; Liu, Di; Gao, George F.] Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing, Peoples R China; [Wang, Jufang; Lin, Ying; Du, Hongli; Wang, Xiaoning] S China Univ Technol, Sch Biosci & Bioengn, Provincial Key Lab Biotechnol, Guangzhou, Peoples R China; [Feng, Youjun] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China	Army Medical University; Chinese Academy of Sciences; Institute of Microbiology, CAS; South China University of Technology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Li, M (corresponding author), Third Mil Med Univ, Dept Microbiol, Chongqing, Peoples R China.	xnwang@21.net; hufuquan@yahoo.com; tjq85@hotmail.com	Feng, Youjun/I-4134-2012; Feng, Youjun/E-8386-2010; Liu, Di/ABD-2729-2021; Gao, George Fu/ABD-5229-2021; Liu, Di/G-6135-2014	Liu, Di/0000-0003-3693-2726; Liu, Di/0000-0003-3693-2726	National High-Tech Research & Development Project 863 [2006AA0Z455]; National Natural Science Foundation of China [30670105, 30600533]; National Key Technologies R&D Programs [2006BAD06A01]; National Basic Research Program (973) of China [2005CB523001, 2007CB512402]; Natural Science Foundation of Jiangsu Province, China [BK2006014, BK2007013]	National High-Tech Research & Development Project 863(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technologies R&D Programs(National Key Technology R&D Program); National Basic Research Program (973) of China(National Basic Research Program of China); Natural Science Foundation of Jiangsu Province, China(Natural Science Foundation of Jiangsu Province)	The work was supported by National High-Tech Research & Development Project 863 (2006AA0Z455), National Natural Science Foundation of China (30670105 & 30600533), National Key Technologies R&D Programs (2006BAD06A01) and National Basic Research Program (973) of China (2005CB523001 & 2007CB512402), and Natural Science Foundation of Jiangsu Province, China (BK2006014 & BK2007013).	BALTIMORE RS, 1977, J IMMUNOL, V118, P673; Banu S, 2000, MOL MICROBIOL, V35, P854, DOI 10.1046/j.1365-2958.2000.01760.x; BaThein W, 1996, J BACTERIOL, V178, P2514, DOI 10.1128/jb.178.9.2514-2520.1996; Beier D, 2006, CURR OPIN MICROBIOL, V9, P143, DOI 10.1016/j.mib.2006.01.005; Berthelot-Herault F, 2000, VET RES, V31, P473, DOI 10.1051/vetres:2000133; Berthelot-Herault F, 2005, CAN J VET RES, V69, P236; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; Charland N, 1998, MICROBIOL-SGM, V144, P325, DOI 10.1099/00221287-144-2-325; Chen C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000315; DAIGLE F, 1995, INFECT IMMUN, V63, P4924, DOI 10.1128/IAI.63.12.4924-4927.1995; de Greeff A, 2002, MICROB PATHOGENESIS, V33, P185, DOI 10.1006/mpat.2002.0526; de Greeff A, 2002, INFECT IMMUN, V70, P1319, DOI 10.1128/IAI.70.3.1319-1325.2002; de Saizieu A, 2000, J BACTERIOL, V182, P4696, DOI 10.1128/JB.182.17.4696-4703.2000; Feng YJ, 2007, FEMS MICROBIOL LETT, V275, P80, DOI 10.1111/j.1574-6968.2007.00859.x; Gal-Mor O, 2006, CELL MICROBIOL, V8, P1707, DOI 10.1111/j.1462-5822.2006.00794.x; Gottschalk M, 1998, CAN J VET RES, V62, P75; Gottschalk M, 1999, J CLIN MICROBIOL, V37, P4202, DOI 10.1128/JCM.37.12.4202-4203.1999; Graham MR, 2002, P NATL ACAD SCI USA, V99, P13855, DOI 10.1073/pnas.202353699; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Jain R, 2002, THEOR POPUL BIOL, V61, P489, DOI 10.1006/tpbi.2002.1596; Jones PM, 2005, INT J PARASITOL, V35, P555, DOI 10.1016/j.ijpara.2005.01.012; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Kehoe MA, 1996, TRENDS MICROBIOL, V4, P436, DOI 10.1016/0966-842X(96)10058-5; Kobayashi SD, 2003, P NATL ACAD SCI USA, V100, P10948, DOI 10.1073/pnas.1833375100; Kurland CG, 2003, P NATL ACAD SCI USA, V100, P9658, DOI 10.1073/pnas.1632870100; Lamy MC, 2004, MOL MICROBIOL, V54, P1250, DOI 10.1111/j.1365-2958.2004.04365.x; Lee CA, 1996, INFECT AGENT DIS, V5, P1; Li YY, 2006, INFECT IMMUN, V74, P305, DOI 10.1128/IAI.74.1.305-312.2006; Liang XD, 2005, J BACTERIOL, V187, P5486, DOI 10.1128/JB.187.15.5486-5492.2005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lun SC, 2003, MICROB PATHOGENESIS, V34, P27, DOI 10.1016/S0882-4010(02)00192-4; Lun ZR, 2007, LANCET INFECT DIS, V7, P201, DOI 10.1016/S1473-3099(07)70001-4; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; McCluskey J, 2004, MOL MICROBIOL, V51, P1661, DOI 10.1111/j.1365-2958.2003.03917.x; Miller AA, 2001, MOL MICROBIOL, V40, P976, DOI 10.1046/j.1365-2958.2001.02441.x; Ng WL, 2005, J BACTERIOL, V187, P7444, DOI 10.1128/JB.187.21.7444-7459.2005; Normile D, 2005, SCIENCE, V309, P1308; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Roberts AP, 2006, PERIODONTOL 2000, V42, P36, DOI 10.1111/j.1600-0757.2006.00149.x; Sanders IR, 2006, TRENDS ECOL EVOL, V21, P656, DOI 10.1016/j.tree.2006.10.006; Schmidt H, 2004, CLIN MICROBIOL REV, V17, P14, DOI 10.1128/CMR.17.1.14-56.2004; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Shimizu T, 2002, J BACTERIOL, V184, P2587, DOI 10.1128/JB.184.10.2587-2594.2002; SHIMIZU T, 1994, J BACTERIOL, V176, P1616, DOI 10.1128/jb.176.6.1616-1623.1994; Shin NR, 2007, FEMS IMMUNOL MED MIC, V50, P94, DOI 10.1111/j.1574-695X.2007.00236.x; Sipos G, 2006, CURR DRUG TARGETS, V7, P471, DOI 10.2174/138945006776359403; Smith HE, 2000, MICROB PATHOGENESIS, V29, P127, DOI 10.1006/mpat.2000.0372; Smith HE, 1996, INFECT IMMUN, V64, P4409, DOI 10.1128/IAI.64.10.4409-4412.1996; SMITH HE, 1995, MICROBIOL-UK, V141, P181, DOI 10.1099/00221287-141-1-181; SMITH HE, 1992, INFECT IMMUN, V60, P2361, DOI 10.1128/IAI.60.6.2361-2367.1992; Sriskandan S, 2006, PLOS MED, V3, P595, DOI 10.1371/journal.pmed.0030187; Staats JJ, 1997, VET RES COMMUN, V21, P381, DOI 10.1023/A:1005870317757; Staats JJ, 1999, VET MICROBIOL, V70, P201, DOI 10.1016/S0378-1135(99)00147-9; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Takamatsu D, 2002, J BACTERIOL, V184, P2050, DOI 10.1128/JB.184.7.2050-2057.2002; Takamatsu D, 2001, PLASMID, V45, P101, DOI 10.1006/plas.2000.1510; TANG J, 2006, PLOS MED, V151, P2; Tarradas C, 2001, VET REC, V148, P183, DOI 10.1136/vr.148.6.183; Throup JP, 2000, MOL MICROBIOL, V35, P566, DOI 10.1046/j.1365-2958.2000.01725.x; Upton M, 2001, J BACTERIOL, V183, P3931, DOI 10.1128/JB.183.13.3931-3938.2001; VECHT U, 1992, INFECT IMMUN, V60, P550, DOI 10.1128/IAI.60.2.550-556.1992; Voyich JM, 2003, P NATL ACAD SCI USA, V100, P1996, DOI 10.1073/pnas.0337370100; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; Yazaki K, 2006, FEBS LETT, V580, P1183, DOI 10.1016/j.febslet.2005.12.009	65	114	138	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2080	10.1371/journal.pone.0002080	http://dx.doi.org/10.1371/journal.pone.0002080			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461172	Green Submitted, gold, Green Published			2022-12-25	WOS:000261642400004
J	Shalchian-Tabrizi, K; Minge, MA; Espelund, M; Orr, R; Ruden, T; Jakobsen, KS; Cavalier-Smith, T				Shalchian-Tabrizi, Kamran; Minge, Marianne A.; Espelund, Mari; Orr, Russell; Ruden, Torgeir; Jakobsen, Kjetill S.; Cavalier-Smith, Thomas			Multigene Phylogeny of Choanozoa and the Origin of Animals	PLOS ONE			English	Article							CAPSASPORA-OWCZARZAKI; EVOLUTIONARY ORIGIN; PROTEIN; SEQUENCE; GENE	Animals are evolutionarily related to fungi and to the predominantly unicellular protozoan phylum Choanozoa, together known as opisthokonts. To establish the sequence of events when animals evolved from unicellular ancestors, and understand those key evolutionary transitions, we need to establish which choanozoans are most closely related to animals and also the evolutionary position of each choanozoan group within the opisthokont phylogenetic tree. Here we focus on Ministeria vibrans, a minute bacteria-eating cell with slender radiating tentacles. Single-gene trees suggested that it is either the closest unicellular relative of animals or else sister to choanoflagellates, traditionally considered likely animal ancestors. Sequencing thousands of Ministeria protein genes now reveals about 14 with domains of key significance for animal cell biology, including several previously unknown from deeply diverging Choanozoa, e. g. domains involved in hedgehog, Notch and tyrosine kinase signaling or cell adhesion (cadherin). Phylogenetic trees using 78 proteins show that Ministeria is not sister to animals or choanoflagellates (themselves sisters to animals), but to Capsaspora, another protozoan with threadlike (filose) tentacles. The Ministeria/Capsaspora clade (new class Filasterea) is sister to animals and choanoflagellates, these three groups forming a novel clade (filozoa) whose ancestor presumably evolved filose tentacles well before they aggregated as a periciliary collar in the choanoflagellate/sponge common ancestor. Our trees show ichthyosporean choanozoans as sisters to filozoa; a fusion between ubiquitin and ribosomal small subunit S30 protein genes unifies all holozoa (filozoa plus Ichthyosporea), being absent in earlier branching eukaryotes. Thus, several successive evolutionary innovations occurred among their unicellular closest relatives prior to the origin of the multicellular body-plan of animals.	[Shalchian-Tabrizi, Kamran; Orr, Russell] Univ Oslo, Dept Biol, Microbial Evolut Res Grp, Oslo, Norway; [Minge, Marianne A.; Espelund, Mari; Jakobsen, Kjetill S.] Univ Oslo, Ctr Ecol & Evolut Synthesis, Oslo, Norway; [Ruden, Torgeir] Univ Oslo, Ctr Informat Technol Serv, Sci Comp Grp, Oslo, Norway; [Cavalier-Smith, Thomas] Univ Oxford, Dept Zool, Oxford, England	University of Oslo; University of Oslo; University of Oslo; University of Oxford	Shalchian-Tabrizi, K (corresponding author), Univ Oslo, Dept Biol, Microbial Evolut Res Grp, Oslo, Norway.	Kamran@bio.uio.no			NERC; Canadian Institute for Advanced Research Evolutionary Biology Program; Norwegian Research Council	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Canadian Institute for Advanced Research Evolutionary Biology Program(Canadian Institute for Advanced Research (CIFAR)); Norwegian Research Council(Research Council of NorwayEuropean Commission)	TC-S thanks NERC and the Canadian Institute for Advanced Research Evolutionary Biology Program for fellowship support and NERC for research grants, and KSJ the Norwegian Research Council for a research project and scholarships to KS, MAM and ME.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Adamska M, 2007, CURR BIOL, V17, pR836, DOI 10.1016/j.cub.2007.08.010; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Bayly RD, 2007, DEVELOPMENT, V134, P2115, DOI 10.1242/dev.02850; Cavalier-Smith T, 1998, BIOL REV, V73, P203, DOI 10.1017/S0006323198005167; Cavalier-Smith T, 2003, EUR J PROTISTOL, V39, P338, DOI 10.1078/0932-4739-00002; Cavalier-Smith T, 2003, J MOL EVOL, V56, P540, DOI 10.1007/s00239-002-2424-z; Cavalier-Smith T, 1998, SYST ASSOC SPEC VOL, V56, P375; Cavalier-Smith T, 2001, MYCOTA, V7, P3; Cavalier-Smith T., 1987, EVOLUTIONARY BIOL FU, P339; Dykova I, 2003, FOLIA PARASIT, V50, P161, DOI 10.14411/fp.2003.030; Gromov BV, 2000, ZOOL ZH, V79, P517; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hertel LA, 2002, INT J PARASITOL, V32, P1183, DOI 10.1016/S0020-7519(02)00066-8; Jimenez-Guri E, 2007, SCIENCE, V317, P116, DOI 10.1126/science.1142024; Karpov SA, 1998, J EUKARYOT MICROBIOL, V45, P361, DOI 10.1111/j.1550-7408.1998.tb04550.x; Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198; Keeling PJ, 2005, TRENDS ECOL EVOL, V20, P670, DOI 10.1016/j.tree.2005.09.005; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; Lartillot N, 2004, MOL BIOL EVOL, V21, P1095, DOI 10.1093/molbev/msh112; Medina M, 2003, INT J ASTROBIOL, V2, P203, DOI [DOI 10.1017/S1473550403001551), 10.1017/S1473550403001551, DOI 10.1017/S1473550403001551]; Nichols SA, 2006, P NATL ACAD SCI USA, V103, P12451, DOI 10.1073/pnas.0604065103; Pires-daSilva A, 2003, NAT REV GENET, V4, P39, DOI 10.1038/nrg977; Putnam NH, 2007, SCIENCE, V317, P86, DOI 10.1126/science.1139158; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Rodriguez-Ezpeleta N, 2005, CURR BIOL, V15, P1325, DOI 10.1016/j.cub.2005.06.040; Ruiz-Trillo I, 2008, MOL BIOL EVOL, V25, P664, DOI 10.1093/molbev/msn006; Ruiz-Trillo I, 2007, TRENDS GENET, V23, P113, DOI 10.1016/j.tig.2007.01.005; Ruiz-Trillo I, 2006, J EUKARYOT MICROBIOL, V53, P379, DOI 10.1111/j.1550-7408.2006.00118.x; Segawa Y, 2006, P NATL ACAD SCI USA, V103, P12021, DOI 10.1073/pnas.0600021103; Snell EA, 2006, P ROY SOC B-BIOL SCI, V273, P401, DOI 10.1098/rspb.2005.3263; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Steenkamp ET, 2006, MOL BIOL EVOL, V23, P93, DOI 10.1093/molbev/msj011; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Tong SM, 1997, OPHELIA, V47, P71, DOI 10.1080/00785236.1997.10427291; [No title captured]	38	165	171	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2098	10.1371/journal.pone.0002098	http://dx.doi.org/10.1371/journal.pone.0002098			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461162	Green Submitted, gold, Green Published			2022-12-25	WOS:000261642400020
J	Thomas, SH; Wagner, RD; Arakaki, AK; Skolnick, J; Kirby, JR; Shimkets, LJ; Sanford, RA; Loffler, FE				Thomas, Sara H.; Wagner, Ryan D.; Arakaki, Adrian K.; Skolnick, Jeffrey; Kirby, John R.; Shimkets, Lawrence J.; Sanford, Robert A.; Loeffler, Frank E.			The Mosaic Genome of Anaeromyxobacter dehalogenans Strain 2CP-C Suggests an Aerobic Common Ancestor to the Delta- Proteobacteria	PLOS ONE			English	Article							FRUITING BODY DEVELOPMENT; GEOBACTER-SULFURREDUCENS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; REDUCTIVE DEHALOGENASE; DESULFOVIBRIO-VULGARIS; PHYLOGENETIC ANALYSIS; FE(III) REDUCTION; ELECTRON-TRANSFER; ACETYL-COENZYME	Anaeromyxobacter dehalogenans strain 2CP-C is a versaphilic delta-Proteobacterium distributed throughout many diverse soil and sediment environments. 16S rRNA gene phylogenetic analysis groups A. dehalogenans together with the myxobacteria, which have distinguishing characteristics including strictly aerobic metabolism, sporulation, fruiting body formation, and surface motility. Analysis of the 5.01 Mb strain 2CP-C genome substantiated that this organism is a myxobacterium but shares genotypic traits with the anaerobic majority of the delta-Proteobacteria (i.e., the Desulfuromonadales). Reflective of its respiratory versatility, strain 2CP-C possesses 68 genes coding for putative c-type cytochromes, including one gene with 40 heme binding motifs. Consistent with its relatedness to the myxobacteria, surface motility was observed in strain 2CP-C and multiple types of motility genes are present, including 28 genes for gliding, adventurous (A-) motility and 17 genes for type IV pilus-based motility (i.e., social (S-) motility) that all have homologs in Myxococcus xanthus. Although A. dehalogenans shares many metabolic traits with the anaerobic majority of the delta-Proteobacteria, strain 2CP-C grows under microaerophilic conditions and possesses detoxification systems for reactive oxygen species. Accordingly, two gene clusters coding for NADH dehydrogenase subunits and two cytochrome oxidase gene clusters in strain 2CP-C are similar to those in M. xanthus. Remarkably, strain 2CP-C possesses a third NADH dehydrogenase gene cluster and a cytochrome cbb3 oxidase gene cluster, apparently acquired through ancient horizontal gene transfer from a strictly anaerobic green sulfur bacterium. The mosaic nature of the A. dehalogenans strain 2CP-C genome suggests that the metabolically versatile, anaerobic members of the delta-Proteobacteria may have descended from aerobic ancestors with complex lifestyles.	[Thomas, Sara H.; Loeffler, Frank E.] Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA; [Wagner, Ryan D.; Arakaki, Adrian K.; Skolnick, Jeffrey; Loeffler, Frank E.] Georgia Inst Technol, Sch Biol, Atlanta, GA USA; [Kirby, John R.] Univ Iowa, Dept Microbiol, Iowa City, IA USA; [Shimkets, Lawrence J.] Univ Georgia, Dept Microbiol, Athens, GA USA; [Sanford, Robert A.] Univ Illinois, Dept Geol, Urbana, IL USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Iowa; University System of Georgia; University of Georgia; University of Illinois System; University of Illinois Urbana-Champaign	Thomas, SH (corresponding author), Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA.	frank.loeffler@ce.gatech.edu	Sanford, Robert/C-1720-2019; Loeffler, Frank E/M-8216-2013	Sanford, Robert/0000-0002-9607-9897; 	Environmental Remediation Science Division (ERSD), Biological and Environmental Research (BER), U.S. Department of Energy; NSF IGERT [DGE 0114400]; NSF GK-12 [0338261]	Environmental Remediation Science Division (ERSD), Biological and Environmental Research (BER), U.S. Department of Energy(United States Department of Energy (DOE)); NSF IGERT(National Science Foundation (NSF)); NSF GK-12(National Science Foundation (NSF))	This research was supported by the Environmental Remediation Science Division (ERSD), Biological and Environmental Research (BER), U.S. Department of Energy and by NSF IGERT (Grant No. DGE 0114400) and NSF GK-12 (Grant No. 0338261) fellowships. The sponsoring agencies were not involved in the design and conduct of the study. The sponsoring agencies have not reviewed this manuscript, and therefore, agency approval of the views expressed herein should not be inferred.	Abdel-Hamid AM, 2007, J BACTERIOL, V189, P369, DOI 10.1128/JB.01373-06; Afkar E, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-41; Aguilar D, 2004, J MOL BIOL, V340, P491, DOI 10.1016/j.jmb.2004.04.059; Akiyama T, 2003, J BACTERIOL, V185, P3317, DOI 10.1128/JB.185.11.3317-3324.2003; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arakaki AK, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-315; Baughn AD, 2004, NATURE, V427, P441, DOI 10.1038/nature02285; Bellenger K, 2002, J BACTERIOL, V184, P5654, DOI 10.1128/JB.184.20.5654-5660.2002; Bergey DH., 2001, BERGEYS MANUAL SYSTE; Berleman JE, 2006, J BACTERIOL, V188, P5888, DOI 10.1128/JB.00559-06; Blaisdell BE, 1996, P NATL ACAD SCI USA, V93, P5854, DOI 10.1073/pnas.93.12.5854; Bohlendorf B, 1999, EUR J ORG CHEM, V1999, P2601; Bonner PJ, 2005, MOL MICROBIOL, V57, P1499, DOI 10.1111/j.1365-2958.2005.04785.x; Brioukhanov AL, 2002, MICROBIOLOGY+, V71, P281, DOI 10.1023/A:1015846409735; Brown JR, 2003, NAT REV GENET, V4, P121, DOI 10.1038/nrg1000; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; COLE JR, 1994, APPL ENVIRON MICROB, V60, P3536, DOI 10.1128/AEM.60.10.3536-3542.1994; Dagan T, 2007, P NATL ACAD SCI USA, V104, P870, DOI 10.1073/pnas.0606318104; de Bok FAM, 2002, ANTON LEEUW INT J G, V81, P283, DOI 10.1023/A:1020539323190; Dedysh SN, 2006, APPL ENVIRON MICROB, V72, P2110, DOI 10.1128/AEM.72.3.2110-2117.2006; Dolla A, 2006, J BIOTECHNOL, V126, P87, DOI 10.1016/j.jbiotec.2006.03.041; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Esteve-Nunez A, 2008, ENVIRON MICROBIOL, V10, P497, DOI 10.1111/j.1462-2920.2007.01470.x; Evans KJ, 2007, J BACTERIOL, V189, P4850, DOI 10.1128/JB.01942-06; Fung JM, 2007, APPL ENVIRON MICROB, V73, P4439, DOI 10.1128/AEM.00215-07; Gogarten JP, 2005, NAT REV MICROBIOL, V3, P679, DOI 10.1038/nrmicro1204; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Goldman BS, 2006, P NATL ACAD SCI USA, V103, P15200, DOI 10.1073/pnas.0607335103; Gorlenko VM, 2004, MICROBIOLOGY+, V73, P541, DOI 10.1023/B:MICI.0000044245.67298.9f; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Guiral M, 2005, BBA-GEN SUBJECTS, V1723, P45, DOI 10.1016/j.bbagen.2005.01.015; Haywood-Farmer E, 2003, EVOLUTION, V57, P1783; He JZ, 2003, NATURE, V424, P62, DOI 10.1038/nature01717; He Q, 2003, APPL ENVIRON MICROB, V69, P2712, DOI 10.1128/AEM.69.5.2712-2718.2003; *INT UN BIOCH MOL, 1992, ENZ NOM 1992 REC NOM, P862; Jelsbak L, 2000, CURR OPIN MICROBIOL, V3, P637, DOI 10.1016/S1369-5274(00)00153-3; Jelsbak L, 2005, J BACTERIOL, V187, P2105, DOI 10.1128/JB.187.6.2105-2112.2005; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kaiser D, 2004, ANNU REV MICROBIOL, V58, P75, DOI 10.1146/annurev.micro.58.030603.123620; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Karlin S, 1998, ANNU REV GENET, V32, P185, DOI 10.1146/annurev.genet.32.1.185; Karlin S, 2006, P NATL ACAD SCI USA, V103, P11352, DOI 10.1073/pnas.0604311103; Kimura Y, 2000, J BACTERIOL, V182, P5462, DOI 10.1128/JB.182.19.5462-5469.2000; Kimura Y, 2004, MICROBIOL-SGM, V150, P631, DOI 10.1099/mic.0.26786-0; Kirby JR, 2003, P NATL ACAD SCI USA, V100, P2008, DOI 10.1073/pnas.0330944100; Konstantinidis KT, 2005, P NATL ACAD SCI USA, V102, P2567, DOI 10.1073/pnas.0409727102; Krajmalnik-Brown R, 2004, APPL ENVIRON MICROB, V70, P6347, DOI 10.1128/AEM.70.10.6347-6351.2004; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Lin WC, 2004, APPL ENVIRON MICROB, V70, P2525, DOI 10.1128/AEM.70.4.2525-2528.2004; Loffler FE, 2006, CURR OPIN BIOTECH, V17, P274, DOI 10.1016/j.copbio.2006.05.001; Lombard M, 2000, J BIOL CHEM, V275, P27021; LOVLEY DR, 1993, APPL ENVIRON MICROB, V59, P3572, DOI 10.1128/AEM.59.11.3572-3576.1993; LOVLEY DR, 1993, ARCH MICROBIOL, V159, P336, DOI 10.1007/BF00290916; Lowe KL, 2000, GEOMICROBIOL J, V17, P163, DOI 10.1080/01490450050023836; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Madigan M.T., 2006, BROCK BIOL MICROORGA; Methe BA, 2003, SCIENCE, V302, P1967, DOI 10.1126/science.1088727; Mignot T, 2007, SCIENCE, V315, P853, DOI 10.1126/science.1137223; Mrazek J, 1998, P NATL ACAD SCI USA, V95, P3720, DOI 10.1073/pnas.95.7.3720; Pett-Ridge J, 2005, APPL ENVIRON MICROB, V71, P6998, DOI 10.1128/AEM.71.11.6998-7007.2005; PFENNIG N, 1967, ANNU REV MICROBIOL, V21, P285, DOI 10.1146/annurev.mi.21.100167.001441; Pfennig N, 1989, BERGEYS MANUAL SYSTE, P1635; Pham VD, 2005, MICROBIOL-SGM, V151, P1865, DOI 10.1099/mic.0.27824-0; Pitcher RS, 2004, BBA-BIOENERGETICS, V1655, P388, DOI 10.1016/j.bbabio.2003.09.017; Pradella S, 2002, ARCH MICROBIOL, V178, P484, DOI 10.1007/s00203-002-0479-2; Rahm BG, 2006, APPL ENVIRON MICROB, V72, P5486, DOI 10.1128/AEM.00855-06; Rao CV, 2004, PLOS BIOL, V2, P239, DOI 10.1371/journal.pbio.0020049; Reguera G, 2005, NATURE, V435, P1098, DOI 10.1038/nature03661; Reguera G, 2007, J BACTERIOL, V189, P2125, DOI 10.1128/JB.01284-06; REICHENB.H, 1969, J GEN MICROBIOL, V58, P3, DOI 10.1099/00221287-58-1-3; Reichenbach H, 1999, ENVIRON MICROBIOL, V1, P15, DOI 10.1046/j.1462-2920.1999.00016.x; Reichenbach H, 2001, J IND MICROBIOL BIOT, V27, P149, DOI 10.1038/sj.jim.7000025; Rodrigues ML, 2006, EMBO J, V25, P5951, DOI 10.1038/sj.emboj.7601439; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sait M, 2006, APPL ENVIRON MICROB, V72, P1852, DOI 10.1128/AEM.72.3.1852-1857.2006; Sanford RA, 2002, APPL ENVIRON MICROB, V68, P893, DOI 10.1128/AEM.68.2.893-900.2002; Sanford RA, 2007, ENVIRON MICROBIOL, V9, P2885, DOI 10.1111/j.1462-2920.2007.01405.x; Schneiker S, 2007, NAT BIOTECHNOL, V25, P1281, DOI 10.1038/nbt1354; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shi L, 2007, MOL MICROBIOL, V65, P12, DOI 10.1111/j.1365-2958.2007.05783.x; Shi SY, 2005, ACTA BIOCH BIOPH SIN, V37, P561, DOI 10.1111/j.1745-7270.2005.00075.x; SHIMKETS L, 1992, P NATL ACAD SCI USA, V89, P9459, DOI 10.1073/pnas.89.20.9459; STIEFEL EI, 1979, NATURE, V279, P81, DOI 10.1038/279081a0; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Stothard P, 2005, BIOINFORMATICS, V21, P537, DOI 10.1093/bioinformatics/bti054; Sun H, 2000, CURR BIOL, V10, P1143, DOI 10.1016/S0960-9822(00)00705-3; Suyama A, 2002, J BACTERIOL, V184, P3419, DOI 10.1128/JB.184.13.3419-3425.2002; THONYMEYER L, 1993, J BACTERIOL, V175, P7450; Tian WD, 2004, NUCLEIC ACIDS RES, V32, P6226, DOI 10.1093/nar/gkh956; Todorova SG, 2006, ENVIRON MICROBIOL, V8, P426, DOI 10.1111/j.1462-2920.2005.00908.x; Treude N, 2003, FEMS MICROBIOL ECOL, V44, P261, DOI 10.1016/S0168-6496(03)00048-5; Ulrich LE, 2005, TRENDS MICROBIOL, V13, P52, DOI 10.1016/j.tim.2004.12.006; van Eerde A, 2006, ACTA CRYSTALLOGR F, V62, P1061, DOI 10.1107/S1744309106039583; Velicer GJ, 2002, ANTON LEEUW INT J G, V81, P155, DOI 10.1023/A:1020546130033; Wu Q, 2006, APPL ENVIRON MICROB, V72, P3608, DOI 10.1128/AEM.72.5.3608-3614.2006; Zhou JP, 2007, J MICROBIOL, V45, P105	101	106	113	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2103	10.1371/journal.pone.0002103	http://dx.doi.org/10.1371/journal.pone.0002103			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461135	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400025
J	Lombaert, IMA; Brunsting, JF; Wierenga, PK; Faber, H; Stokman, MA; Kok, T; Visser, WH; Kampinga, HH; de Haan, G; Coppes, RP				Lombaert, Isabelle M. A.; Brunsting, Jeanette F.; Wierenga, Pieter K.; Faber, Hette; Stokman, Monique A.; Kok, Tineke; Visser, Willy H.; Kampinga, Harm H.; de Haan, Gerald; Coppes, Robert P.			Rescue of Salivary Gland Function after Stem Cell Transplantation in Irradiated Glands	PLOS ONE			English	Article								Head and neck cancer is the fifth most common malignancy and accounts for 3% of all new cancer cases each year. Despite relatively high survival rates, the quality of life of these patients is severely compromised because of radiation-induced impairment of salivary gland function and consequential xerostomia (dry mouth syndrome). In this study, a clinically applicable method for the restoration of radiation-impaired salivary gland function using salivary gland stem cell transplantation was developed. Salivary gland cells were isolated from murine submandibular glands and cultured in vitro as salispheres, which contained cells expressing the stem cell markers Sca-1, c-Kit and Musashi-1. In vitro, the cells differentiated into salivary gland duct cells and mucin and amylase producing acinar cells. Stem cell enrichment was performed by flow cytrometric selection using c-Kit as a marker. In vitro, the cells differentiated into amylase producing acinar cells. In vivo, intra-glandular transplantation of a small number of c-Kit(+) cells resulted in long-term restoration of salivary gland morphology and function. Moreover, donor-derived stem cells could be isolated from primary recipients, cultured as secondary spheres and after re-transplantation ameliorate radiation damage. Our approach is the first proof for the potential use of stem cell transplantation to functionally rescue salivary gland deficiency.	[Lombaert, Isabelle M. A.; Brunsting, Jeanette F.; Faber, Hette; Kok, Tineke; Visser, Willy H.; Kampinga, Harm H.; Coppes, Robert P.] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, Sect Radiat & Stress Cell Biol, Groningen, Netherlands; [Lombaert, Isabelle M. A.; Wierenga, Pieter K.; Visser, Willy H.; de Haan, Gerald] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, Sect Stem Cell Biol, Groningen, Netherlands; [Faber, Hette; Coppes, Robert P.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands; [Stokman, Monique A.] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	Lombaert, IMA (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, Sect Radiat & Stress Cell Biol, Groningen, Netherlands.	r.p.coppes@med.umcg.nl	Coppes, Robert P/B-4089-2008; de Haan, Gerald/AAF-8963-2019; de Haan, Gerald/D-2081-2015	Coppes, Robert P/0000-0001-5503-1064; de Haan, Gerald/0000-0001-9706-0138; de Haan, Gerald/0000-0001-9706-0138; Kampinga, Harm/0000-0002-8966-8466	Dutch Society for Cancer Research [RUG2003-2909]; European Union [503436]	Dutch Society for Cancer Research; European Union(European Commission)	This study was financially supported by grants of the Dutch Society for Cancer Research (RUG2003-2909) and the European Union (FP-6, contract 503436).	Baum BJ, 2006, PERIODONTOL 2000, V41, P218, DOI 10.1111/j.1600-0757.2006.00160.x; BURFORDMASON AP, 1993, J ORAL PATHOL MED, V22, P440, DOI 10.1111/j.1600-0714.1993.tb00122.x; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chen JH, 2005, ENDOCRINOLOGY, V146, P3985, DOI 10.1210/en.2005-0185; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Couzin J, 2006, SCIENCE, V313, P1715; Denny PC, 1999, ANAT REC, V254, P408, DOI 10.1002/(SICI)1097-0185(19990301)254:3<408::AID-AR12>3.0.CO;2-G; Denny PC, 1997, CRIT REV ORAL BIOL M, V8, P51, DOI 10.1177/10454411970080010301; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; GRESIK EW, 1994, MICROSC RES TECHNIQ, V27, P1, DOI 10.1002/jemt.1070270102; Hisatomi Y, 2004, HEPATOLOGY, V39, P667, DOI 10.1002/hep.20063; Kawase Y, 2004, EXP CELL RES, V295, P194, DOI 10.1016/j.yexcr.2003.12.027; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kishi T, 2006, BIOCHEM BIOPH RES CO, V340, P544, DOI 10.1016/j.bbrc.2005.12.031; Konings AWT, 2005, INT J RADIAT ONCOL, V62, P1187, DOI 10.1016/j.ijrobp.2004.12.051; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925; Lin AL, 2001, ARCH ORAL BIOL, V46, P1085, DOI 10.1016/S0003-9969(01)00063-2; Lombaert IMA, 2006, CLIN CANCER RES, V12, P1804, DOI 10.1158/1078-0432.CCR-05-2381; Ma XQ, 2002, STEM CELLS, V20, P514, DOI 10.1634/stemcells.20-6-514; Man YG, 2001, ANAT REC, V263, P202, DOI 10.1002/ar.1098; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Medina RJ, 2006, J CELL BIOCHEM, V98, P174, DOI 10.1002/jcb.20757; Nishida M, 2004, BIOCHEM BIOPH RES CO, V324, P341, DOI 10.1016/j.bbrc.2004.09.051; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Seaberg RM, 2004, NAT BIOTECHNOL, V22, P1115, DOI 10.1038/nbt1004; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Takahashi S, 2004, J ORAL PATHOL MED, V33, P23, DOI 10.1111/j.1600-0714.2004.00191.x; Takahashi S, 2000, TISSUE CELL, V32, P457, DOI 10.1016/S0040-8166(00)80002-6; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P213, DOI 10.1177/154411130301400306; Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P199, DOI 10.1177/154411130301400305; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532	38	308	325	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2063	10.1371/journal.pone.0002063	http://dx.doi.org/10.1371/journal.pone.0002063			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446241	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300032
J	Rai, M; Soragni, E; Jenssen, K; Burnett, R; Herman, D; Coppola, G; Geschwind, DH; Gottesfeld, JM; Pandolfo, M				Rai, Myriam; Soragni, Elisabetta; Jenssen, Kai; Burnett, Ryan; Herman, David; Coppola, Giovanni; Geschwind, Daniel H.; Gottesfeld, Joel M.; Pandolfo, Massimo			HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model	PLOS ONE			English	Article								Background: Friedreich ataxia, an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin, an essential mitochondrial protein. All Friedreich ataxia patients carry a GAA.TTC repeat expansion in the first intron of the frataxin gene, either in the homozygous state or in compound heterozygosity with other loss-of-function mutations. The GAA expansion inhibits frataxin expression through a heterochromatin-mediated repression mechanism. Histone modifications that are characteristic of silenced genes in heterochromatic regions occur at expanded alleles in cells from Friedreich ataxia patients, including increased trimethylation of histone H3 at lysine 9 and hypoacetylation of histones H3 and H4. Methodology/Principal Findings: By chromatin immunoprecipitation, we detected the same heterochromatin marks in homozygous mice carrying a (GAA)(230) repeat in the first intron of the mouse frataxin gene (KIKI mice). These animals have decreased frataxin levels and, by microarray analysis, show significant gene expression changes in several tissues. We treated KIKI mice with a novel histone deacetylase inhibitor, compound 106, which substantially increases frataxin mRNA levels in cells from Friedreich ataxia individuals. Treatment increased histone H3 and H4 acetylation in chromatin near the GAA repeat and restored wild-type frataxin levels in the nervous system and heart, as determined by quantitative RT-PCR and semiquantitative western blot analysis. No toxicity was observed. Furthermore, most of the differentially expressed genes in KIKI mice reverted towards wild-type levels. Conclusions/Significance: Lack of acute toxicity, normalization of frataxin levels and of the transcription profile changes resulting from frataxin deficiency provide strong support to a possible efficacy of this or related compounds in reverting the pathological process in Friedreich ataxia, a so far incurable neurodegenerative disease.	[Rai, Myriam; Pandolfo, Massimo] Free Univ Brussels, Hop Erasme, Lab Neurol Expt, Brussels, Belgium; [Soragni, Elisabetta; Jenssen, Kai; Burnett, Ryan; Herman, David; Gottesfeld, Joel M.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA; [Coppola, Giovanni; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, Los Angeles, CA USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rai, M (corresponding author), Free Univ Brussels, Hop Erasme, Lab Neurol Expt, Brussels, Belgium.	massimo.pandolfo@ulb.ac.be	Pandolfo, Massimo/B-2853-2010	Gottesfeld, Joel/0000-0002-4643-5777	GOFAR Foundation (Italy); Friedreich Ataxia Research Alliance (USA); Ataxia UK; Ataxia Ireland; Fondazione CRT (Italy); Belgian National Scientific Research Funds (FNRS); Belgian Ministry of Scientific Policy (Program IAP6); FARA; National Ataxia Foundation (NAF); National Institutes of Neurological Disorders and Stroke (NINDS)	GOFAR Foundation (Italy); Friedreich Ataxia Research Alliance (USA); Ataxia UK; Ataxia Ireland; Fondazione CRT (Italy); Belgian National Scientific Research Funds (FNRS)(Fonds de la Recherche Scientifique - FNRS); Belgian Ministry of Scientific Policy (Program IAP6); FARA; National Ataxia Foundation (NAF); National Institutes of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the GOFAR Foundation (Italy), the Friedreich Ataxia Research Alliance (USA), Ataxia UK, Ataxia Ireland, Fondazione CRT (Italy), the Belgian National Scientific Research Funds (FNRS), the Belgian Ministry of Scientific Policy (Program IAP6) to MP; from FARA, the National Ataxia Foundation (NAF), the National Institutes of Neurological Disorders and Stroke (NINDS) to JMG; and from NINDS to DG.	Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; COPPOLA G, 2007, ANN NEUROLOGY, V62, pS24; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Herman D, 2006, NAT CHEM BIOL, V2, P551, DOI 10.1038/nchembio815; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Miranda CJ, 2002, FEBS LETT, V512, P291, DOI 10.1016/S0014-5793(02)02251-2; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; O'Neill HA, 2005, J MOL BIOL, V345, P433, DOI 10.1016/j.jmb.2004.10.074; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Pandolfo M, 2002, MITOCHONDRION, V2, P87, DOI 10.1016/S1567-7249(02)00039-9; PANDOLFO M, 2007, MOL NEUROLOGY, pCH18; Pandolfo M., 2006, GENETIC INSTABILITIE, P277; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Simon D, 2004, J NEUROSCI, V24, P1987, DOI 10.1523/JNEUROSCI.4549-03.2004; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Vazzola V, 2007, FEBS LETT, V581, P667, DOI 10.1016/j.febslet.2007.01.030; Ventura N, 2006, FASEB J, V20, P1029, DOI 10.1096/fj.06-0505ufm; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200	29	170	174	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1958	10.1371/journal.pone.0001958	http://dx.doi.org/10.1371/journal.pone.0001958			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18463734	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500028
J	Granero-Molto, F; Sarmah, S; O'Rear, L; Spagnoli, A; Abrahamson, D; Saus, J; Hudson, BG; Knapik, EW				Granero-Molto, Froilan; Sarmah, Swapnalee; O'Rear, Lynda; Spagnoli, Anna; Abrahamson, Dale; Saus, Juan; Hudson, Billy G.; Knapik, Ela W.			Goodpasture antigen-binding protein and its spliced variant, ceramide transfer protein, have different functions in the modulation of apoptosis during zebrafish development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOSPHORYLATION; TRAFFICKING; EXPRESSION	Human Goodpasture antigen-binding protein (GPBP) is an atypical protein kinase that phosphorylates the Goodpasture auto-antigen, the alpha 3 chain of collagen IV. The COL4A3BP gene is alternatively spliced producing two protein isoforms: GPBP and GPBP Delta 26. The latter lacks a serine-rich domain composed of 26 amino acid residues. Both isoforms also function as ceramide transfer proteins (CERT). Here, we explored the function of Gpbp and Gpbp Delta 26/CERT during embryogenesis in zebrafish. We cloned both splice variants of the zebrafish gene and found that they are differentially expressed during development. We used antisense oligonucleotide-mediated loss-of-function and synthetic mRNA-based gain-of-function approaches. Our results show that the loss-of-function phenotype is linked to cell death, evident primarily in the muscle of the somites, extensive loss of myelinated tracks, and brain edema. These results indicate that disruption of the nonvesicular ceramide transport is detrimental to normal embryonic development of somites and brain because of increased apoptosis. Moreover, this phenotype is mediated by Gpbp but not Gpbp Delta 26/CERT, suggesting that Gpbp is an important factor for normal skeletal muscle and brain development.	[Granero-Molto, Froilan; Hudson, Billy G.] Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Dept Med,Div Nephrol, Nashville, TN 37232 USA; [Granero-Molto, Froilan; Hudson, Billy G.] Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Dept Biochem, Nashville, TN 37232 USA; [Granero-Molto, Froilan; Hudson, Billy G.] Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Dept Pathol, Nashville, TN 37232 USA; [Granero-Molto, Froilan; O'Rear, Lynda; Spagnoli, Anna] Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Div Pediat Endocrinol, Nashville, TN 37232 USA; [Granero-Molto, Froilan; Saus, Juan] Ctr Invest Principe Felipe, Dept Autoimmune Pathol, Valencia 46013, Spain; [Sarmah, Swapnalee; Knapik, Ela W.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Abrahamson, Dale] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Prince Felipe Research Center; Vanderbilt University; University of Kansas; University of Kansas Medical Center	Hudson, BG (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Dept Med,Div Nephrol, Nashville, TN 37232 USA.	billy.hudson@vanderbilt.edu	Granero-Moltó, Froilán/H-6975-2017; Knapik, Ela W./J-6172-2014	Granero-Moltó, Froilán/0000-0003-4817-5232; Knapik, Ela W./0000-0002-2977-3619; Saus, Juan/0000-0003-2082-1597; Hudson, Billy/0000-0002-5420-4100	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070929, R01DK018381, U2CDK059637, R37DK018381, P30DK058404, P30DK020593, P60DK020593, U24DK059637, P01DK065123] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485] Funding Source: Medline; NEI NIH HHS [EY 08126] Funding Source: Medline; NICHD NIH HHS [HD 15052] Funding Source: Medline; NIDCR NIH HHS [DE 018477] Funding Source: Medline; NIDDK NIH HHS [DK 20593, DK 70929-01A11, DK 58404, DK 065123, DK 18381, DK 59637] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; Fugmann T, 2007, J CELL BIOL, V178, P15, DOI 10.1083/jcb.200612017; GOEMZMUNOZ A, 2006, BIOCHIM BIOPHYS ACTA, V1758, P2049; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Henry CA, 2004, DEV CELL, V7, P917, DOI 10.1016/j.devcel.2004.09.017; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kumagai K, 2007, J BIOL CHEM, V282, P17758, DOI 10.1074/jbc.M702291200; Leinonen A, 1999, KIDNEY INT, V55, P926, DOI 10.1046/j.1523-1755.1999.055003926.x; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200; Rao RP, 2007, P NATL ACAD SCI USA, V104, P11364, DOI 10.1073/pnas.0705049104; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WILSON SW, 1990, DEVELOPMENT, V108, P121; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200	23	22	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20495	20504		10.1074/jbc.M801806200	http://dx.doi.org/10.1074/jbc.M801806200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18424781	hybrid, Green Published			2022-12-25	WOS:000257565300063
J	Han, GS; O'Hara, L; Siniossoglou, S; Carman, GM				Han, Gil-Soo; O'Hara, Laura; Siniossoglou, Symeon; Carman, George M.			Characterization of the yeast DGK1-encoded CTP-dependent diacylglycerol kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG2+-DEPENDENT PHOSPHATIDATE PHOSPHATASE; PHOSPHOLIPID BIOSYNTHETIC GENES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SN-1,2-DIACYLGLYCEROL KINASE; DOLICHOL KINASE; PHOSPHATIDYLINOSITOL 4-KINASES; TRANSCRIPTIONAL REGULATION; SPHINGOLIPID FUNCTIONS; MEMBRANE-PROTEIN	The Saccharomyces cerevisiae DGK1 gene encodes a diacylglycerol kinase enzyme that catalyzes the formation of phosphatidate from diacylglycerol. Unlike the diacylglycerol kinases from bacteria, plants, and animals, the yeast enzyme utilizes CTP, instead of ATP, as the phosphate donor in the reaction. Dgk1p contains a CTP transferase domain that is present in the SEC59-encoded dolichol kinase and CDS1-encoded CDP-diacylglycerol synthase enzymes. Deletion analysis showed that the CTP transferase domain was sufficient for diacylglycerol kinase activity. Point mutations (R76A, K77A, D177A, and G184A) of conserved residues within the CTP transferase domain caused a loss of diacylglycerol kinase activity. Analysis of DGK1 alleles showed that the in vivo functions of Dgk1p were specifically due to its diacylglycerol kinase activity. The DGK1-encoded enzyme had a pH optimum at 7.0-7.5, required Ca2(+) or Mg2(+) ions for activity, was potently inhibited by N-ethylmaleimide, and was labile at temperatures above 40 C. The enzyme exhibited positive cooperative (Hill number = 2.5) kinetics with respect to diacylglycerol (apparent K-m = 6.5 mol %) and saturation kinetics with respect to CTP (apparent K-m = 0.3mM). dCTP was both a substrate (apparent K-m = 0.4 mM) and competitive inhibitor (apparent K-i = 0.4 mM) of the enzyme. Diacylglycerol kinase activity was stimulated by major membrane phospholipids and was inhibited by CDP-diacylglycerol and sphingoid bases.	[Carman, George M.] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; [Han, Gil-Soo; Carman, George M.] Rutgers State Univ, Rutgers Ctr Lipid Res, New Brunswick, NJ 08901 USA; [O'Hara, Laura; Siniossoglou, Symeon] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Cambridge	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu		O'Hara, Laura/0000-0001-7790-9261	Medical Research Council [G0701446] Funding Source: Medline; NIGMS NIH HHS [R01 GM028140, GM 28140] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0701446] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAELEE MS, 1984, J BIOL CHEM, V259, P857; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BELENDIUK G, 1978, J BIOL CHEM, V253, P4555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2007, J BIOL CHEM, V282, P37293, DOI 10.1074/jbc.R700038200; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; CARMAN GM, 1991, EUR J BIOCHEM, V209, P305; CARTER JR, 1966, J LIPID RES, V7, P678; Chen M, 2007, BBA-MOL CELL BIOL L, V1771, P310, DOI 10.1016/j.bbalip.2006.05.017; Czabany T, 2007, BBA-MOL CELL BIOL L, V1771, P299, DOI 10.1016/j.bbalip.2006.07.001; DAWSON RMC, 1986, DATA BIOCH RES, P384; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DONAHUE TF, 1981, GENETICS, V98, P491; Fernandez F, 2002, GLYCOBIOLOGY, V12, P555, DOI 10.1093/glycob/cwf068; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2008, J BIOL CHEM, V283, P20433, DOI 10.1074/jbc.M802903200; Han GS, 2007, J BIOL CHEM, V282, P37026, DOI 10.1074/jbc.M705777200; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Harlow E., 1999, USING ANTIBODIES LAB; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENNEDY EP, 1959, J BIOL CHEM, V234, P1998; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; Kosodo Y, 2001, YEAST, V18, P1003, DOI 10.1002/yea.747.abs; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Li GL, 2007, BBA-MOL CELL BIOL L, V1771, P432, DOI 10.1016/j.bbalip.2006.06.007; LIN YP, 1989, J BIOL CHEM, V264, P8641; Loewen CJR, 2005, J BIOL CHEM, V280, P14097, DOI 10.1074/jbc.M500147200; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; Merida I, 2008, BIOCHEM J, V409, P1, DOI 10.1042/BJ20071040; MinSeok R, 1996, J BIOCHEM, V120, P1040; Muller MO, 2000, J BIOL CHEM, V275, P19475, DOI 10.1074/jbc.M002575200; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; O'Hara L, 2006, J BIOL CHEM, V281, P34537, DOI 10.1074/jbc.M606654200; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RODRIGUEZLINARES B, 1991, BIOCHEM PHARMACOL, V41, P835, DOI 10.1016/0006-2952(91)90089-N; Rose MD., 1990, METHODS YEAST GENETI; Sakane F, 2007, BBA-MOL CELL BIOL L, V1771, P793, DOI 10.1016/j.bbalip.2007.04.006; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; Shridas P, 2006, J BIOL CHEM, V281, P31696, DOI 10.1074/jbc.M604087200; SMITH SW, 1957, J BIOL CHEM, V228, P915; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SZKOPINSKA A, 1988, ARCH BIOCHEM BIOPHYS, V266, P124, DOI 10.1016/0003-9861(88)90242-1; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	87	73	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20443	20453		10.1074/jbc.M802866200	http://dx.doi.org/10.1074/jbc.M802866200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18458076	hybrid, Green Published			2022-12-25	WOS:000257565300059
J	Wu, WM; Sinha, D; Shikov, S; Yip, CK; Walz, T; Billings, PC; Lear, JD; Walsh, PN				Wu, Wenman; Sinha, Dipali; Shikov, Sergei; Yip, Calvin K.; Walz, Thomas; Billings, Paul C.; Lear, James D.; Walsh, Peter N.			Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XI; FACTOR-IX-ACTIVATION; PLASMA THROMBOPLASTIN ANTECEDENT; BLOOD-COAGULATION; BINDING-SITE; CHRISTMAS-FACTOR; APPLE-4 DOMAIN; NONCOVALENT INTERACTIONS; PROTEIN INTERACTIONS; IDENTIFICATION	Coagulation factor XI (FXI) is a covalent homodimer consisting of two identical subunits of 80 kDa linked by a disulfide bond formed by Cys-321 within the Apple 4 domain of each subunit. Because FXIC321S is a noncovalent dimer, residues within the interface between the two subunits must mediate its homodimeric structure. The crystal structure of FXI demonstrates formation of salt bridges between Lys-331 of one subunit and Glu-287 of the other subunit and hydrophobic interactions at the interface of the Apple 4 domains involving Ile-290, Leu-284, and Tyr-329. FXIC321S, FXIC321S,K331A, FXIC321S,E287A, FXIC321S,I290A, FXIC321S,Y329A, FXIC321S,L284A, FXIC321S,K331R, and FXIC321S,H343A were expressed in HEK293 cells and characterized using size exclusion chromatography, analytical ultracentrifugation, electron microscopy, and functional assays. Whereas FXIC321S and FXIC321S,H343A existed in monomer/dimer equilibrium (K-d similar to 40 nM), all other mutants were predominantly monomers with impaired dimer formation by analytical ultracentrifugation (K-d = 3-38 mu M). When converted to the active enzyme, FXIa, all the monomeric mutants activated FIX similarly to wild-type dimeric FXIa. In contrast, these monomeric mutants could not be activated efficiently by FXIIa, thrombin, or autoactivation in the presence of dextran sulfate. We conclude that salt bridges formed between Lys-331 of one subunit and Glu-287 of the other together with hydrophobic interactions at the interface, involving residues Ile-290, Leu-284, and Tyr-329, are essential for homodimer formation. The dimeric structure of FXI is essential for normal proteolytic activation of FXI by FXIIa, thrombin, or FXIa either in solution or on an anionic surface but not for FIX activation by FXIa in solution.	[Wu, Wenman; Sinha, Dipali; Walsh, Peter N.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; [Shikov, Sergei; Walsh, Peter N.] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; [Walsh, Peter N.] Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; [Yip, Calvin K.; Walz, Thomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Billings, Paul C.; Lear, James D.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Harvard University; Harvard Medical School; University of Pennsylvania	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@temple.edu		Yip, Calvin/0000-0003-1779-9501; Walz, Thomas/0000-0003-2606-2835	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, P01HL074124, R01HL046213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL74124, HL40387, HL46213] Funding Source: Medline; NIGMS NIH HHS [P01 GM062580] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Dorfman R, 2001, J BIOL CHEM, V276, P6429, DOI 10.1074/jbc.M010340200; Fairman R, 1999, ANAL BIOCHEM, V270, P286, DOI 10.1006/abio.1999.4095; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P7527, DOI 10.1073/pnas.0932632100; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Kogan AE, 2001, THROMB RES, V101, P299, DOI 10.1016/S0049-3848(00)00405-9; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martin DC, 1999, PROTEIN SCI, V8, P1152, DOI 10.1110/ps.8.5.1152; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NAITO K, 1991, J BIOL CHEM, V266, P7353; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Papagrigoriou E, 2006, NAT STRUCT MOL BIOL, V13, P557, DOI 10.1038/nsmb1095; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Riley PW, 2007, J MOL BIOL, V367, P558, DOI 10.1016/j.jmb.2006.12.066; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Samuel D, 2007, P NATL ACAD SCI USA, V104, P15693, DOI 10.1073/pnas.0703080104; Sinha D, 2005, BIOCHEMISTRY-US, V44, P10416, DOI 10.1021/bi050361x; Sinha D, 2002, BIOCHEM J, V367, P49, DOI 10.1042/BJ20020232; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; Sinha D, 2007, BIOCHEMISTRY-US, V46, P9830, DOI 10.1021/bi062296c; Smith SB, 2008, J BIOL CHEM, V283, P6696, DOI 10.1074/jbc.M707234200; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; VELOSO D, 1986, THROMB RES, V43, P153, DOI 10.1016/0049-3848(86)90056-3; WIGGINS RC, 1979, THROMB RES, V15, P487, DOI 10.1016/0049-3848(79)90154-3; WIGGINS RC, 1979, THROMB RES, V15, P475, DOI 10.1016/0049-3848(79)90153-1; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y; Xu D, 1998, PROTEIN SCI, V7, P533; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200; Zhou Y, 2003, J BIOL CHEM, V278, P10073, DOI 10.1074/jbc.M211907200	45	36	36	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18655	18664		10.1074/jbc.M802275200	http://dx.doi.org/10.1074/jbc.M802275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18441012	hybrid, Green Published			2022-12-25	WOS:000257165600022
J	Jahn, TR; Tennent, GA; Radford, SE				Jahn, Thomas R.; Tennent, Glenys A.; Radford, Sheena E.			A common beta-sheet architecture underlies in vitro and in vivo beta(2)-microglobulin amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; LIMITED PROTEOLYSIS; SECONDARY STRUCTURE; BETA-2-MICROGLOBULIN; STATE; PROTEINS; CONFORMATIONS; FIBRILLATION; AGGREGATION; CONSTRAINTS	Misfolding and aggregation of normally soluble proteins into amyloid fibrils and their deposition and accumulation underlies a variety of clinically significant diseases. Fibrillar aggregates with amyloid-like properties can also be generated in vitro from pure proteins and peptides, including those not known to be associated with amyloidosis. Whereas biophysical studies of amyloid-like fibrils formed in vitro have provided important insights into the molecular mechanisms of amyloid generation and the structural properties of the fibrils formed, amyloidogenic proteins are typically exposed to mild or more extreme denaturing conditions to induce rapid fibril formation in vitro. Whether the structure of the resulting assemblies is representative of their natural in vivo counterparts, thus, remains a fundamental unresolved issue. Here we show using Fourier transform infrared spectroscopy that amyloid-like fibrils formed in vitro from natively folded or unfolded beta(2)-microglobulin (the protein associated with dialysis-related amyloidosis) adopt an identical beta-sheet architecture. The same beta-strand signature is observed whether fibril formation in vitro occurs spontaneously or from seeded reactions. Comparison of these spectra with those of amyloid fibrils extracted from patients with dialysis-related amyloidosis revealed an identical amide I' absorbance maximum, suggestive of a characteristic and conserved amyloid fold. Our results endorse the relevance of biophysical studies for the investigation of the molecular mechanisms of beta(2)-microglobulin fibrillogenesis, knowledge about which may inform understanding of the pathobiology of this protein.	[Jahn, Thomas R.; Radford, Sheena E.] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; [Tennent, Glenys A.] UCL, Ctr Amyloidosis & Acute Phase Prot, London NW3 2PF, England	University of Leeds; University of London; University College London	Radford, SE (corresponding author), Univ Leeds, Astbury Ctr Struct Mol Biol, Garstang Bldg, Leeds LS2 9JT, W Yorkshire, England.	s.e.radford@leeds.ac.uk	Jahn, Thomas/F-8134-2013	Radford, Sheena/0000-0002-3079-8039; Jahn, Thomas/0000-0002-9266-6736	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andreola A, 2003, J BIOL CHEM, V278, P2444, DOI 10.1074/jbc.M204801200; Calamai M, 2005, BIOPHYS J, V89, P4201, DOI 10.1529/biophysj.105.068726; Cao AE, 2004, PROTEIN SCI, V13, P319, DOI 10.1110/ps.03183404; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Choo LP, 1996, BIOPHYS J, V71, P1672, DOI 10.1016/S0006-3495(96)79411-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Frare E, 2004, J MOL BIOL, V340, P1153, DOI 10.1016/j.jmb.2004.05.056; Giorgetti S, 2007, PROTEIN SCI, V16, P343, DOI 10.1110/ps.062563507; Goda S, 2000, PROTEIN SCI, V9, P369; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Groenning M, 2007, J STRUCT BIOL, V158, P358, DOI 10.1016/j.jsb.2006.12.010; Ha C, 2007, BIOCHEMISTRY-US, V46, P6118, DOI 10.1021/bi7000032; Jahn TR, 2008, ARCH BIOCHEM BIOPHYS, V469, P100, DOI 10.1016/j.abb.2007.05.015; Jahn TR, 2005, AMYLOID PROTEINS: THE BETA SHEET CONFORMATION AND DISEASE, VOLS 1 AND 2, P667, DOI 10.1002/9783527619344.ch26; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Jahn TR, 2005, FEBS J, V272, P5962, DOI 10.1111/j.1742-4658.2005.05021.x; Jimenez JL, 2001, J MOL BIOL, V311, P241, DOI 10.1006/jmbi.2001.4863; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kodali R, 2007, CURR OPIN STRUC BIOL, V17, P48, DOI 10.1016/j.sbi.2007.01.007; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; LINKE RP, 1989, KIDNEY INT, V36, P675, DOI 10.1038/ki.1989.245; Luca S, 2007, BIOCHEMISTRY-US, V46, P13505, DOI 10.1021/bi701427q; Makin OS, 2005, FEBS J, V272, P5950, DOI 10.1111/j.1742-4658.2005.05025.x; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Monti M, 2005, BBA-PROTEINS PROTEOM, V1753, P44, DOI 10.1016/j.bbapap.2005.09.004; Mukhopadhyay S, 2007, P NATL ACAD SCI USA, V104, P2649, DOI 10.1073/pnas.0611503104; Myers SL, 2006, RAPID COMMUN MASS SP, V20, P1628, DOI 10.1002/rcm.2482; Myers SL, 2006, BIOCHEMISTRY-US, V45, P2311, DOI 10.1021/bi052434i; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Nelson R, 2006, CURR OPIN STRUC BIOL, V16, P260, DOI 10.1016/j.sbi.2006.03.007; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Oberg KA, 1998, ANAL BIOCHEM, V256, P92, DOI 10.1006/abio.1997.2486; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; Plattt GW, 2005, J MOL BIOL, V346, P279, DOI 10.1016/j.jmb.2004.11.035; Relini A, 2008, J BIOL CHEM, V283, P4912, DOI 10.1074/jbc.M702712200; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Sciarretta KL, 2006, METHOD ENZYMOL, V413, P273, DOI 10.1016/S0076-6879(06)13015-3; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Smith AM, 2006, J MOL BIOL, V364, P9, DOI 10.1016/j.jmb.2006.08.081; Souillac PO, 2003, BIOCHEMISTRY-US, V42, P8094, DOI 10.1021/bi034652m; Stoppini M, 2005, BBA-PROTEINS PROTEOM, V1753, P23, DOI 10.1016/j.bbapap.2005.07.019; Surewicz WK, 2006, ACCOUNTS CHEM RES, V39, P654, DOI 10.1021/ar050226c; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Tennent GA, 1999, METHOD ENZYMOL, V309, P26; Tycko R, 2006, Q REV BIOPHYS, V39, P1, DOI 10.1017/S0033583506004173; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; van der Wel PCA, 2007, J AM CHEM SOC, V129, P5117, DOI 10.1021/ja068633m; Vernaglia BA, 2004, BIOMACROMOLECULES, V5, P1362, DOI 10.1021/bm0498979; Yamamoto S, 2004, BIOCHEMISTRY-US, V43, P11075, DOI 10.1021/bi049262u; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	59	47	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17279	17286		10.1074/jbc.M710351200	http://dx.doi.org/10.1074/jbc.M710351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18424782	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000256720600037
J	Doherty, CP; Cox, SE; Fulford, AJ; Austin, S; Hilmers, DC; Abrams, SA; Prentice, AM				Doherty, Conor P.; Cox, Sharon E.; Fulford, Antony J.; Austin, Steven; Hilmers, David C.; Abrams, Steven A.; Prentice, Andrew M.			Iron Incorporation and Post-Malaria Anaemia	PLOS ONE			English	Article								Background: Iron supplementation is employed to treat post-malarial anaemia in environments where iron deficiency is common. Malaria induces an intense inflammatory reaction that stalls reticulo-endothelial macrophagal iron recycling from haemolysed red blood cells and inhibits oral iron absorption, but the magnitude and duration of these effects are unclear. Methodology/Principal Findings: We examined the red blood cell incorporation of oral administered stable isotopes of iron and compared incorporation between age matched 18 to 36 months old children with either anaemia post-malaria (n = 37) or presumed iron deficiency anaemia alone (n = 36). All children were supplemented for 30 days with 2 mg/kg elemental iron as liquid iron sulphate and administered (57)Fe and (58)Fe on days 1 and 15 of supplementation respectively. (57)Fe and (58)Fe incorporation were significantly reduced (8% vs. 28%: p<0.001 and 14% vs. 26%: p=0.045) in the malaria vs. non-malaria groups. There was a significantly greater haemoglobin response in the malaria group at both day 15 (p = 0.001) and 30 (p<0.000) with a regression analysis estimated greater change in haemoglobin of 7.2 g/l (s.e. 2.0) and 10.1 g/l (s.e. 2.5) respectively. Conclusion/Significance: Post-malaria anaemia is associated with a better haemoglobin recovery despite a significant depressant effect on oral iron incorporation which may indicate that early erythropoetic iron need is met by iron recycling rather than oral iron. Supplemental iron administration is of questionable utility within 2 weeks of clinical malaria in children with mild or moderate anaemia.	[Doherty, Conor P.] MRC, Nutr Program, Keneba Field Stn, Fajara, Gambia; [Cox, Sharon E.; Fulford, Antony J.; Prentice, Andrew M.] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, Med Res Council Int Nutr Grp, London, England; [Austin, Steven] Elsie Widdowson Lab, Med Res Council Human Nutr Res, Cambridge, England; [Hilmers, David C.; Abrams, Steven A.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX USA	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Cambridge; Baylor College of Medicine	Doherty, CP (corresponding author), MRC, Nutr Program, Keneba Field Stn, Fajara, Gambia.	conor.doherty@yorkhill.scot.nhs.uk	Prentice, Andrew/AAG-1961-2019; Cox, Sharon E/ABA-7986-2020	Cox, Sharon E/0000-0002-9908-2936; Abrams, Steven/0000-0003-4972-9233	Medical Research Council	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Medical Research Council	Abrams S. A., 2002, Food and Nutrition Bulletin, V23, P158; Ames SK, 1999, AM J CLIN NUTR, V70, P44; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Asobayire FS, 2001, AM J CLIN NUTR, V74, P776; Beesley R, 2000, T ROY SOC TROP MED H, V94, P295, DOI 10.1016/S0035-9203(00)90329-8; Brock JH, 2000, P NUTR SOC, V59, P537, DOI 10.1017/S002966510000077X; Chen ZS, 2005, J NUTR, V135, P1790, DOI 10.1093/jn/135.7.1790; COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63; Das BS, 1997, BRIT J NUTR, V78, P751, DOI 10.1079/BJN19970192; Das BS, 1999, T ROY SOC TROP MED H, V93, P58, DOI 10.1016/S0035-9203(99)90180-3; Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Garibay EV, 2001, J AM COLL NUTR, V20, P286, DOI 10.1080/07315724.2001.10719049; Griffiths MJ, 2001, BRIT J HAEMATOL, V113, P486, DOI 10.1046/j.1365-2141.2001.02758.x; GUBLER CJ, 1950, J BIOL CHEM, V184, P563; Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; MASSA E, 1978, J PEDIATR-US, V93, P1045, DOI 10.1016/S0022-3476(78)81257-8; Menendez C, 2004, AM J TROP MED HYG, V71, P434, DOI 10.4269/ajtmh.2004.71.434; *NAT NUTR AG, 2001, GAMB; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; PHILLIPS RE, 1986, Q J MED, V58, P305; vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7; WHO, 2001, IRON DEFICIENCY ANAE; Williams TN, 1999, AM J TROP MED HYG, V60, P875, DOI 10.4269/ajtmh.1999.60.875; World Health Organization, 1999, MAN SEV MALN MAN PHY	26	44	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2133	10.1371/journal.pone.0002133	http://dx.doi.org/10.1371/journal.pone.0002133			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461143	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000261642400054
J	Behar, DM; Metspalu, E; Kivisild, T; Rosset, S; Tzur, S; Hadid, Y; Yudkovsky, G; Rosengarten, D; Pereira, L; Amorim, A; Kutuev, I; Gurwitz, D; Bonne-Tamir, B; Villems, R; Skorecki, K				Behar, Doron M.; Metspalu, Ene; Kivisild, Toomas; Rosset, Saharon; Tzur, Shay; Hadid, Yarin; Yudkovsky, Guennady; Rosengarten, Dror; Pereira, Luisa; Amorim, Antonio; Kutuev, Ildus; Gurwitz, David; Bonne-Tamir, Batsheva; Villems, Richard; Skorecki, Karl			Counting the Founders: The Matrilineal Genetic Ancestry of the Jewish Diaspora	PLOS ONE			English	Article								The history of the Jewish Diaspora dates back to the Assyrian and Babylonian conquests in the Levant, followed by complex demographic and migratory trajectories over the ensuing millennia which pose a serious challenge to unraveling population genetic patterns. Here we ask whether phylogenetic analysis, based on highly resolved mitochondrial DNA ( mtDNA) phylogenies can discern among maternal ancestries of the Diaspora. Accordingly, 1,142 samples from 14 different non-Ashkenazi Jewish communities were analyzed. A list of complete mtDNA sequences was established for all variants present at high frequency in the communities studied, along with high-resolution genotyping of all samples. Unlike the previously reported pattern observed among Ashkenazi Jews, the numerically major portion of the non-Ashkenazi Jews, currently estimated at 5 million people and comprised of the Moroccan, Iraqi, Iranian and Iberian Exile Jewish communities showed no evidence for a narrow founder effect, which did however characterize the smaller and more remote Belmonte, Indian and the two Caucasus communities. The Indian and Ethiopian Jewish sample sets suggested local female introgression, while mtDNAs in all other communities studied belong to a well-characterized West Eurasian pool of maternal lineages. Absence of sub-Saharan African mtDNA lineages among the North African Jewish communities suggests negligible or low level of admixture with females of the host populations among whom the African haplogroup (Hg) L0-L3 sub-clades variants are common. In contrast, the North African and Iberian Exile Jewish communities show influence of putative Iberian admixture as documented by mtDNA Hg HV0 variants. These findings highlight striking differences in the demographic history of the widespread Jewish Diaspora.	[Behar, Doron M.; Tzur, Shay; Hadid, Yarin; Skorecki, Karl] Mol Med Lab, Haifa, Israel; [Metspalu, Ene; Kivisild, Toomas; Kutuev, Ildus; Villems, Richard] Univ Tartu, Estonian Bioctr, Dept Evolut Biol, Tartu, Estonia; [Kivisild, Toomas] Univ Cambridge, Leverhulme Ctr Human Evolut Stud, Cambridge, England; [Rosset, Saharon] IBM TJ Watson Res Ctr, Data Analytics Res Grp, Yorktown Hts, NY USA; [Tzur, Shay; Hadid, Yarin; Yudkovsky, Guennady; Rosengarten, Dror; Skorecki, Karl] Israel Inst Technol, Res Inst, Rappaport Fac Med, Haifa, Israel; [Pereira, Luisa; Amorim, Antonio] IPATIMUP, Oporto, Portugal; [Pereira, Luisa] Univ Porto, Fac Med, Oporto, Portugal; [Amorim, Antonio] Univ Porto, Fac Ciencias, Oporto, Portugal; [Kutuev, Ildus] Russian Acad Sci, Ufa Res Ctr, Inst Biochem & Genet, Ufa, Russia; [Gurwitz, David; Bonne-Tamir, Batsheva] Sackler Sch Med, Dept Human Genet, Ramat Aviv, Israel	Rambam Health Care Campus; Estonian Biocentre; University of Tartu; University of Cambridge; International Business Machines (IBM); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Universidade do Porto; Universidade do Porto; Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS; Russian Academy of Sciences; Tel Aviv University; Sackler Faculty of Medicine	Behar, DM (corresponding author), Mol Med Lab, Rambam Hlth Care Campus, Haifa, Israel.	rvillems@ebc.ee	Amorim, Antonio/A-7938-2008; Pereira, Luisa/H-3050-2011; Gurwitz, David/E-7642-2013; Kivisild, Toomas/P-5889-2017	Amorim, Antonio/0000-0002-7518-6247; Pereira, Luisa/0000-0002-4271-1527; Gurwitz, David/0000-0002-9363-1869; Kivisild, Toomas/0000-0002-6297-7808	Israel Science Foundation; Legacy Heritage Fund; Annie Chutick Endowment; Canadian Technion Society; Milin Charitable Foundation; Estonian Science Foundation [5807]; Fundacao para a Ciencia e a Tecnologia through O Programa Operacional Ciencia, e Inovacao 2010	Israel Science Foundation(Israel Science Foundation); Legacy Heritage Fund; Annie Chutick Endowment; Canadian Technion Society; Milin Charitable Foundation; Estonian Science Foundation; Fundacao para a Ciencia e a Tecnologia through O Programa Operacional Ciencia, e Inovacao 2010	This research was supported in part by grants from the Israel Science Foundation and the Legacy Heritage Fund (to K.L.S.), by the Annie Chutick Endowment and the Canadian Technion Society (to K.L.S.), by a donation from the Milin Charitable Foundation (to D.M.B), by the Estonian Science Foundation grant 5807 (to E.M.), and by Fundacao para a Ciencia e a Tecnologia through O Programa Operacional Ciencia, e Inovacao 2010 (POCI 2010), VI Programa-Quadro (2002 to 2006) (to IPATIMUP).	Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590; Achilli A, 2005, AM J HUM GENET, V76, P883, DOI 10.1086/430073; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Behar DM, 2006, AM J HUM GENET, V78, P487, DOI 10.1086/500307; Behar DM, 2004, EUR J HUM GENET, V12, P355, DOI 10.1038/sj.ejhg.5201156; Behar DM, 2004, HUM GENET, V114, P354, DOI 10.1007/s00439-003-1073-7; Casella G, 2001, STAT INFERENCE, V2nd; Chaubey G, 2007, BIOESSAYS, V29, P91, DOI 10.1002/bies.20525; Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6; DellaPergola S., 2001, PAPERS JEWISH DEMOGR, V11, P11; Finnila S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Forster P, 1996, AM J HUM GENET, V59, P935; Haak W, 2005, SCIENCE, V310, P1016, DOI 10.1126/science.1118725; Hammer MF, 2000, P NATL ACAD SCI USA, V97, P6769, DOI 10.1073/pnas.100115997; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; Johnson NL, 1969, DISTRIBUTIONS STAT D; Kivisild T, 1999, GENOMIC DIVERSITY, P135; Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901; Kivisild T, 2004, AM J HUM GENET, V75, P752, DOI 10.1086/425161; Kivisild T, 2003, EXAMINING FARMING LA, P215; Loogvali EL, 2004, MOL BIOL EVOL, V21, P2012, DOI 10.1093/molbev/msh209; Metspalu M, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-26; MOUNTAIN JL, 1995, AM J HUM GENET, V56, P979; Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566; Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871; Pereira L, 2005, GENOME RES, V15, P19, DOI 10.1101/gr.3182305; Reidla M, 2003, AM J HUM GENET, V73, P1178, DOI 10.1086/379380; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Richards MB, 1998, ANN HUM GENET, V62, P241, DOI 10.1046/j.1469-1809.1998.6230241.x; Roostalu U, 2007, MOL BIOL EVOL, V24, P436, DOI 10.1093/molbev/msl173; Saillard J, 2000, AM J HUM GENET, V67, P718, DOI 10.1086/303038; Shen PD, 2004, HUM MUTAT, V24, P248, DOI 10.1002/humu.20077; Sun C, 2006, MOL BIOL EVOL, V23, P683, DOI 10.1093/molbev/msj078; Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74; Thomas MG, 2002, AM J HUM GENET, V70, P1411, DOI 10.1086/340609; Torroni A, 2001, AM J HUM GENET, V69, P844, DOI 10.1086/323485; Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001	39	81	81	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2062	10.1371/journal.pone.0002062	http://dx.doi.org/10.1371/journal.pone.0002062			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446216	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300031
J	Cahill, H; Nathans, J				Cahill, Hugh; Nathans, Jeremy			The Optokinetic Reflex as a Tool for Quantitative Analyses of Nervous System Function in Mice: Application to Genetic and Drug-Induced Variation	PLOS ONE			English	Article								The optokinetic reflex (OKR), which serves to stabilize a moving image on the retina, is a behavioral response that has many favorable attributes as a test of CNS function. The OKR requires no training, assesses the function of diverse CNS circuits, can be induced repeatedly with minimal fatigue or adaptation, and produces an electronic record that is readily and objectively quantifiable. We describe a new type of OKR test apparatus in which computer-controlled visual stimuli and streamlined data analysis facilitate a relatively high throughput behavioral assay. We used this apparatus, in conjunction with infrared imaging, to quantify basic OKR stimulus-response characteristics for C57BL/6J and 129/SvEv mouse strains and for genetically engineered lines lacking one or more photoreceptor systems or with an alteration in cone spectral sensitivity. A second generation (F2) cross shows that the characteristic difference in OKR frequency between C57BL/6J and 129/SvEv is inherited as a polygenic trait. Finally, we demonstrate the sensitivity and high temporal resolution of the OKR for quantitative analysis of CNS drug action. These experiments show that the mouse OKR is well suited for neurologic testing in the context of drug discovery and large-scale phenotyping programs.	[Cahill, Hugh; Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Cahill, Hugh; Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD USA; [Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD USA; [Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Cahill, H (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460	NIH; Howard Hughes Medical Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute)	H.C. and J.N. are funded by NIH Visual Neuroscience Training Grant and Howard Hughes Medical Institute.	ALPERN M, 1969, EYE, P1; BALKEMA GW, 1984, INVEST OPHTH VIS SCI, V25, P795; BALKEMA GW, 1982, J NEUROPHYSIOL, V48, P968, DOI 10.1152/jn.1982.48.4.968; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; Brunner D, 2002, DRUG DISCOV TODAY, V7, pS107, DOI 10.1016/S1359-6446(02)02423-6; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CANNON SC, 1987, J NEUROPHYSIOL, V57, P1383, DOI 10.1152/jn.1987.57.5.1383; CAVALLI S, 1971, GENETICS HUMAN POPUL, P508; COLLEWIJN H, 1969, VISION RES, V9, P117, DOI 10.1016/0042-6989(69)90035-2; Crabbe JC, 2004, NAT NEUROSCI, V7, P1175, DOI 10.1038/nn1343; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; Visser L, 2006, GENES BRAIN BEHAV, V5, P458, DOI 10.1111/j.1601-183X.2005.00181.x; De Zeeuw CI, 1998, OTOLARYNG HEAD NECK, V119, P193, DOI 10.1016/S0194-5998(98)70054-3; Dodge R, 1903, AM J PHYSIOL, V8, P307, DOI 10.1152/ajplegacy.1903.8.4.307; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Faulstich BM, 2004, VISION RES, V44, P3419, DOI 10.1016/j.visres.2004.09.006; GODAUX E, 1990, NEUROSCI LETT, V116, P162, DOI 10.1016/0304-3940(90)90403-V; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; HESS BJM, 1985, NEUROSCIENCE, V15, P97, DOI 10.1016/0306-4522(85)90126-5; Iwakabe H, 1997, NEUROPHARMACOLOGY, V36, P135, DOI 10.1016/S0028-3908(96)00167-0; Iwashita M, 2001, NEUROSCI RES, V39, P299, DOI 10.1016/S0168-0102(00)00228-5; Jacobs GH, 2007, SCIENCE, V315, P1723, DOI 10.1126/science.1138838; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; Katoh A, 1998, P NATL ACAD SCI USA, V95, P7705, DOI 10.1073/pnas.95.13.7705; Kitazawa H, 2000, NEUROSCI LETT, V280, P179, DOI 10.1016/S0304-3940(00)00779-5; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; Lipp HP, 1998, CURR OPIN NEUROBIOL, V8, P272, DOI 10.1016/S0959-4388(98)80151-7; Long JM, 2006, METHOD ENZYMOL, V417, P66, DOI 10.1016/S0076-6879(06)17006-8; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; MANCALL EM, 1982, ESSENTIALS NEUROLOGI, P228; MANGINI NJ, 1985, J COMP NEUROL, V241, P191, DOI 10.1002/cne.902410207; MARSHALL BE, 1996, GOODMAN GILMANS PHAR, P326; Moldin SO, 2001, MAMM GENOME, V12, P575, DOI 10.1007/s00335-001-4005-7; Picciotto MR, 1998, PHYSIOL REV, V78, P1131, DOI 10.1152/physrev.1998.78.4.1131; Pinto LH, 2007, DOC OPHTHALMOL, V115, P127, DOI 10.1007/s10633-007-9064-y; Pinto LH, 2000, MAMM GENOME, V11, P531, DOI 10.1007/s003350010102; Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X; Sakatani T, 2004, NEUROSCI RES, V49, P123, DOI 10.1016/j.neures.2004.02.002; Sakatani T, 2007, NEUROSCI RES, V58, P324, DOI 10.1016/j.neures.2007.04.003; Schmucker C, 2005, INVEST OPHTH VIS SCI, V46, P398, DOI 10.1167/iovs.04-0959; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; Smallwood PM, 2003, P NATL ACAD SCI USA, V100, P11706, DOI 10.1073/pnas.1934712100; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Stahl JS, 2000, J NEUROSCI METH, V99, P101, DOI 10.1016/S0165-0270(00)00218-1; Stahl JS, 2006, J NEUROPHYSIOL, V95, P1588, DOI 10.1152/jn.00318.2005; Stahl JS, 2004, VISION RES, V44, P3401, DOI 10.1016/j.visres.2004.09.011; Tecott LH, 2004, NAT NEUROSCI, V7, P462, DOI 10.1038/nn1225; Teller DY, 1996, VISION RES, V36, P955, DOI 10.1016/0042-6989(95)00170-0; Thaung C, 2002, NEUROSCI LETT, V325, P21, DOI 10.1016/S0304-3940(02)00223-9; van Alphen AM, 2001, BRAIN RES, V890, P296, DOI 10.1016/S0006-8993(00)03180-2; Vitaterna MH, 2006, TRENDS NEUROSCI, V29, P233, DOI 10.1016/j.tins.2006.02.006; Yoshida K, 2001, NEURON, V30, P771, DOI 10.1016/S0896-6273(01)00316-6	53	93	96	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2055	10.1371/journal.pone.0002055	http://dx.doi.org/10.1371/journal.pone.0002055			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446207	Green Published, Green Submitted, gold			2022-12-25	WOS:000261572300024
J	Doublet, B; Golding, GR; Mulvey, MR; Cloeckaert, A				Doublet, Benoit; Golding, George R.; Mulvey, Michael R.; Cloeckaert, Axel			Secondary Chromosomal Attachment Site and Tandem Integration of the Mobilizable Salmonella Genomic Island 1	PLOS ONE			English	Article							SEROVAR TYPHIMURIUM DT104; RESISTANCE GENE-CLUSTER; PROTEUS-MIRABILIS; SXT ELEMENT; VARIANT; SALMONELLA-GENOMIC-ISLAND-1; RECOMBINATION; SPECIFICITY; INSERTION; SEQUENCE	Background: The Salmonella genomic island 1 is an integrative mobilizable element (IME) originally identified in epidemic multidrug-resistant Salmonella enterica serovar Typhimurium (S. Typhimurium) DT104. SGI1 contains a complex integron, which confers various multidrug resistance phenotypes due to its genetic plasticity. Previous studies have shown that SGI1 integrates site-specifically into the S. enterica, Escherichia coli, or Proteus mirabilis chromosome at the 39 end of thdF gene (attB site). Methodology/Principal Findings: Here, we report the transfer of SGI1 to a Delta thdF mutant of S. Typhimurium LT2. In the absence of thdF, the frequency of transconjugant formation was reduced by around thirty times of magnitude. Through DNA sequencing SGI1 was shown to integrate specifically into a secondary attachment site (2(nd) attB), which is located in the intergenic region between the chromosomal sodB and purR genes. At this 2(nd) attB site, we found that a significant fraction of SGI1 transconjugants (43% of wild type and 100% of Delta thdF mutant) contained tandem SGI1 arrays. Moreover, in wild type S. Typhimurium LT2 transconjugants, SGI1 integrated into both attachment sites, i.e., thdF and sodB-purR. The formation of SGI1 tandem arrays occurred in both specific attB sites. There was heterogeneity in the size of the SGI1 tandem arrays detected in single transconjugant colonies. Some arrays consisted as far as six SGI1s arranged in tandem. These tandem arrays were shown to persist during serial passages with or without antibiotic selection pressure. Conclusions/Significance: The ability of integration into two distinct chromosomal sites and tandem array formation of SGI1 could contribute to its spread and persistence. The existence of a secondary attachment site in the Salmonella chromosome has potential implications for the mobility of SGI1, which may integrate in other attachment sites of other bacterial pathogens that do not possess the 1(st) or 2(nd) specific SGI1 attB sites of Salmonella.	[Doublet, Benoit; Cloeckaert, Axel] INRA, UR1282, F-37380 Nouzilly, France; [Golding, George R.; Mulvey, Michael R.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada	INRAE; Public Health Agency of Canada	Doublet, B (corresponding author), INRA, UR1282, F-37380 Nouzilly, France.	Benoit.Doublet@tours.inra.fr		Doublet, Benoit/0000-0003-0531-0967	French National Institute of Agronomic Research	French National Institute of Agronomic Research	This research was supported by public funds from the French National Institute of Agronomic Research.	Ahmed AM, 2007, J ANTIMICROB CHEMOTH, V59, P184, DOI 10.1093/jac/dkl471; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; BAUER CE, 1989, GENETICS, V122, P727; Boyd D, 2002, ANTIMICROB AGENTS CH, V46, P1714, DOI 10.1128/AAC.46.6.1714-1722.2002; Boyd D, 2001, J BACTERIOL, V183, P5725, DOI 10.1128/JB.183.19.5725-5732.2001; Boyd DA, 2008, ANTIMICROB AGENTS CH, V52, P340, DOI 10.1128/AAC.00902-07; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Burrus V, 2004, RES MICROBIOL, V155, P376, DOI 10.1016/j.resmic.2004.01.012; Burrus V, 2004, J BACTERIOL, V186, P2636, DOI 10.1128/JB.186.9.2636-2645.2004; Burrus V, 2003, J BACTERIOL, V185, P5045, DOI 10.1128/JB.185.17.5045-5054.2003; Burrus V, 2002, PLASMID, V48, P77, DOI 10.1016/S0147-619X(02)00102-6; Burrus V, 2002, MOL MICROBIOL, V46, P601, DOI 10.1046/j.1365-2958.2002.03191.x; Cloeckaert A, 2006, ANTIMICROB AGENTS CH, V50, P3944, DOI 10.1128/AAC.00697-06; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dobrindt U, 2004, NAT REV MICROBIOL, V2, P414, DOI 10.1038/nrmicro884; Doublet B, 2005, MOL MICROBIOL, V55, P1911, DOI 10.1111/j.1365-2958.2005.04520.x; Doublet B, 2003, EMERG INFECT DIS, V9, P585, DOI 10.3201/eid0905.020609; Doublet B, 2007, J ANTIMICROB CHEMOTH, V59, P801, DOI 10.1093/jac/dkl540; GAFFNEY DF, 1981, J GEN MICROBIOL, V125, P113; Golding GR, 2007, MICROBES INFECT, V9, P21, DOI 10.1016/j.micinf.2006.10.004; Hochhut B, 1999, MOL MICROBIOL, V32, P99, DOI 10.1046/j.1365-2958.1999.01330.x; Hochhut B, 2001, J BACTERIOL, V183, P1124, DOI 10.1128/JB.183.4.1124-1132.2001; Levings RS, 2005, J BACTERIOL, V187, P4401, DOI 10.1128/JB.187.13.4401-4409.2005; Malanowska K, 2006, MOL MICROBIOL, V60, P1228, DOI 10.1111/j.1365-2958.2006.05164.x; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Members of the SFM Antibiogram Committee, 2003, Int J Antimicrob Agents, V21, P364; Mulvey MR, 2006, MICROBES INFECT, V8, P1915, DOI 10.1016/j.micinf.2005.12.028; Ravatn R, 1998, J BACTERIOL, V180, P4360, DOI 10.1128/JB.180.17.4360-4369.1998; Rutkai E, 2006, J BACTERIOL, V188, P3409, DOI 10.1128/JB.188.9.3409-3411.2006; Rutkai E, 2003, J MOL BIOL, V329, P983, DOI 10.1016/S0022-2836(03)00442-X; Serra-Moreno R, 2007, J BACTERIOL, V189, P6645, DOI 10.1128/JB.00466-07; Song B, 2007, J BACTERIOL, V189, P6594, DOI 10.1128/JB.00668-07; Turner SA, 2004, ANTIMICROB AGENTS CH, V48, P1028, DOI 10.1128/AAC.48.3.1028-1031.2004; Turner SA, 2003, ANTIMICROB AGENTS CH, V47, P727, DOI 10.1128/AAC.47.2.727-734.2003; Vo ATT, 2007, J ANTIMICROB CHEMOTH, V59, P594, DOI 10.1093/jac/dkl531; Wesslund NA, 2007, J BACTERIOL, V189, P1072, DOI 10.1128/JB.01064-06; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	38	32	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2060	10.1371/journal.pone.0002060	http://dx.doi.org/10.1371/journal.pone.0002060			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446190	Green Submitted, Green Published, gold			2022-12-25	WOS:000261572300029
J	Mahanta, S; Fessler, SP; Park, J; Bamdad, C				Mahanta, Sanjeev; Fessler, Shawn P.; Park, Jaehong; Bamdad, Cynthia			A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells	PLOS ONE			English	Article								The MUC1 protein is aberrantly expressed on many solid tumor cancers. In contrast to its apical clustering on healthy epithelial cells, it is uniformly distributed over cancer cells. However, a mechanistic link between aberrant expression and cancer has remained elusive. Herein, we report that a membrane-bound MUC1 cleavage product, that we call MUC1*, is the predominant form of the protein on cultured cancer cells and on cancerous tissues. Further, we demonstrate that transfection of a minimal fragment of MUC1, MUC1* 1110, containing a mere forty-five (45) amino acids of the extracellular domain, is sufficient to confer the oncogenic activities that were previously attributed to the full-length protein. By comparison of molecular weight and function, it appears that MUC1* and MUC1* 1110 are approximately equivalent. Evidence is presented that strongly supports a mechanism whereby dimerization of the extracellular domain of MUC1* activates the MAP kinase signaling cascade and stimulates cell growth. These findings suggest methods to manipulate this growth mechanism for therapeutic interventions in cancer treatments.	[Mahanta, Sanjeev; Fessler, Shawn P.; Park, Jaehong; Bamdad, Cynthia] Minerva Biotechnol, Waltham, MA USA		Mahanta, S (corresponding author), Minerva Biotechnol, Waltham, MA USA.	cbamdad@minervabio.com						ABE M, 1989, CANCER RES, V49, P2834; Andren O, 2007, BRIT J CANCER, V97, P730, DOI 10.1038/sj.bjc.6603944; Bamdad C, 1998, BIOPHYS J, V75, P1989, DOI 10.1016/S0006-3495(98)77640-4; BAMDAD C, 2001, Patent No. 2001020232; BAMDAD C, 2005, Patent No. 20050112607; Baruch A, 1999, CANCER RES, V59, P1552; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HAYES DF, 1986, J CLIN ONCOL, V4, P1542, DOI 10.1200/JCO.1986.4.10.1542; Kim YI, 2003, BIOCHEM BIOPH RES CO, V307, P281, DOI 10.1016/S0006-291X(03)01195-1; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P227, DOI 10.1023/A:1005580828141; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEUVERING J H W, 1980, Journal of Immunoassay, V1, P77, DOI 10.1080/01971528008055777; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; MERLO GR, 1989, CANCER RES, V49, P6966; Okabe-Kado J, 2002, LEUKEMIA LYMPHOMA, V43, P859, DOI 10.1080/10428190290017006; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Thathiah A, 2004, BIOCHEM J, V382, P363, DOI 10.1042/BJ20040513; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Tsutsumida H, 2006, CLIN CANCER RES, V12, P2976, DOI 10.1158/1078-0432.CCR-05-1197; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	38	57	67	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2054	10.1371/journal.pone.0002054	http://dx.doi.org/10.1371/journal.pone.0002054			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446242	gold, Green Submitted, Green Published			2022-12-25	WOS:000261572300023
J	Reed, KD; Meece, JK; Archer, JR; Peterson, AT				Reed, Kurt D.; Meece, Jennifer K.; Archer, John R.; Peterson, A. Townsend			Ecologic Niche Modeling of Blastomyces dermatitidis in Wisconsin	PLOS ONE			English	Article							NORTH CENTRAL WISCONSIN; GEOGRAPHIC-DISTRIBUTION; PULMONARY BLASTOMYCOSIS; SPECIES DISTRIBUTIONS; EPIDEMIC; SOIL; DISEASE	Background: Blastomycosis is a potentially fatal mycosis that is acquired by inhaling infectious spores of Blastomyces dermatitidis present in the environment. The ecology of this pathogen is poorly understood, in part because it has been extremely difficult to identify the niche(s) it occupies based on culture isolation of the organism from environmental samples. Methodology/Principal Findings: We investigated the ecology of blastomycosis by performing maximum entropy modeling of exposure sites from 156 cases of human and canine blastomycosis to provide a regional-scale perspective of the geographic and ecologic distribution of B. dermatitidis in Wisconsin. Based on analysis with climatic, topographic, surface reflectance and other environmental variables, we predicted that ecologic conditions favorable for maintaining the fungus in nature occur predominantly within northern counties and counties along the western shoreline of Lake Michigan. Areas of highest predicted occurrence were often in proximity to waterways, especially in northcentral Wisconsin, where incidence of infection is highest. Ecologic conditions suitable for B. dermatitidis are present in urban and rural environments, and may differ at the extremes of distribution of the species in the state. Conclusions/Significance: Our results provide a framework for a more informed search for specific environmental factors modulating B. dermatitidis occurrence and transmission and will be useful for improving public health awareness of relative exposure risks.	[Reed, Kurt D.; Meece, Jennifer K.] Marshfield Clin Res Fdn, Marshfield, WI USA; [Archer, John R.] Wisconsin Dept Hlth & Family Serv, Madison, WI USA; [Peterson, A. Townsend] Univ Kansas, Biodivers Res Ctr, Natural History Museum, Lawrence, KS USA	University of Kansas	Reed, KD (corresponding author), Marshfield Clin Res Fdn, Marshfield, WI USA.	reed.kurt@northwestern.edu	Peterson, A. Townsend/I-5697-2013	Peterson, A. Townsend/0000-0003-0243-2379	Marshfield Clinic Research Foundation	Marshfield Clinic Research Foundation	This research was supported in part by grants from the Marshfield Clinic Research Foundation.	Anderson RP, 2003, ECOL MODEL, V162, P211, DOI 10.1016/S0304-3800(02)00349-6; [Anonymous], P 21 INT C MACH LEAR; BAKERSPIGEL A, 1986, J CLIN MICROBIOL, V24, P890, DOI 10.1128/JCM.24.5.890-891.1986; BAUMGARDNER DJ, 1995, J MED VET MYCOL, V33, P171; Baumgardner DJ, 2006, MYCOPATHOLOGIA, V161, P275, DOI 10.1007/s11046-006-0018-9; Baumgardner DJ, 1999, MED MYCOL, V37, P163, DOI 10.1046/j.1365-280X.1999.00214.x; Bradsher RW, 2003, INFECT DIS CLIN N AM, V17, P21, DOI 10.1016/S0891-5520(02)00038-7; Burgess JW, 2006, MED MYCOL, V44, P741, DOI 10.1080/13693780600954749; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P601; COCKERILL FR, 1984, CHEST, V86, P688, DOI 10.1378/chest.86.5.688; Curtis JT, 1959, VEGETATION WISCONSIN; DENTON JF, 1961, SCIENCE, V133, P1126, DOI 10.1126/science.133.3459.1126; DENTON JF, 1979, AM J TROP MED HYG, V28, P697, DOI 10.4269/ajtmh.1979.28.697; Disalvo Arthur F., 1992, P43; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; Hirzel AH, 2002, ECOLOGY, V83, P2027, DOI 10.1890/0012-9658(2002)083[2027:ENFAHT]2.0.CO;2; KITCHEN MS, 1977, AM REV RESPIR DIS, V115, P1063; KLEIN BS, 1987, AM REV RESPIR DIS, V136, P1333, DOI 10.1164/ajrccm/136.6.1333; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; Levine RS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000176; Levine RS, 2004, AM J TROP MED HYG, V70, P105, DOI 10.4269/ajtmh.2004.70.105; MacEachren AM, 2004, P NATL ACAD SCI USA, V101, P5279, DOI 10.1073/pnas.0307755101; Peterson AT, 2006, EMERG INFECT DIS, V12, P1822; Peterson AT, 2003, INT J PARASITOL, V33, P919, DOI 10.1016/S0020-7519(03)00094-8; Peterson AT, 2004, EMERG INFECT DIS, V10, P40, DOI 10.3201/eid1001.030125; Peterson AT, 2002, EMERG INFECT DIS, V8, P662, DOI 10.3201/eid0807.010454; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Proctor ME, 2002, MYCOPATHOLOGIA, V153, P113, DOI 10.1023/A:1014515230994; RIPPON JW, 1988, MED MYCOLOGY PATHOGE, P474; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; TOSH FE, 1974, AM REV RESPIR DIS, V109, P525; Watts B, 2007, NEW ENGL J MED, V356, P1456, DOI 10.1056/NEJMcps055322; *WI DEP NAT RES, EC LANDSC WISC	33	56	56	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2034	10.1371/journal.pone.0002034	http://dx.doi.org/10.1371/journal.pone.0002034			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446224	gold, Green Published			2022-12-25	WOS:000261572300007
J	Voigt, CC; Capps, KA; Dechmann, DKN; Michener, RH; Kunz, TH				Voigt, Christian C.; Capps, Krista A.; Dechmann, Dina K. N.; Michener, Robert H.; Kunz, Thomas H.			Nutrition or Detoxification: Why Bats Visit Mineral Licks of the Amazonian Rainforest	PLOS ONE			English	Article								Many animals in the tropics of Africa, Asia and South America regularly visit so-called salt or mineral licks to consume clay or drink clay-saturated water. Whether this behavior is used to supplement diets with locally limited nutrients or to buffer the effects of toxic secondary plant compounds remains unclear. In the Amazonian rainforest, pregnant and lactating bats are frequently observed and captured at mineral licks. We measured the nitrogen isotope ratio in wing tissue of omnivorous short-tailed fruit bats, Carollia perspicillata, and in an obligate fruit-eating bat, Artibeus obscurus, captured at mineral licks and at control sites in the rainforest. Carollia perspicillata with a plant-dominated diet were more often captured at mineral licks than individuals with an insect-dominated diet, although insects were more mineral depleted than fruits. In contrast, nitrogen isotope ratios of A. obscurus did not differ between individuals captured at mineral lick versus control sites. We conclude that pregnant and lactating fruit-eating bats do not visit mineral licks principally for minerals, but instead to buffer the effects of secondary plant compounds that they ingest in large quantities during periods of high energy demand. These findings have potential implications for the role of mineral licks for mammals in general, including humans.	[Voigt, Christian C.; Dechmann, Dina K. N.] Leibniz Inst Zoo & Wildlife Res, Berlin, Germany; [Capps, Krista A.] Cornell Univ, Dept Ecol & Evolut Biol, Ithaca, NY USA; [Dechmann, Dina K. N.] Smithsonian Trop Res Inst, Balboa, Panama; [Michener, Robert H.] Boston Univ, Dept Biol, Stable Isotope Lab, Boston, MA USA; [Kunz, Thomas H.] Boston Univ, Dept Biol, Ctr Ecol & Conserv Biol, Boston, MA USA	Leibniz Institut fur Zoo und Wildtierforschung; Cornell University; Smithsonian Institution; Smithsonian Tropical Research Institute; Boston University; Boston University	Voigt, CC (corresponding author), Leibniz Inst Zoo & Wildlife Res, Berlin, Germany.	voigt@izw-berlin.de	Vazquez-Dominguez, Guillermo GVD/L-7818-2014; Dechmann, Dina/A-1827-2010	Dechmann, Dina/0000-0003-0043-8267	Leibniz Institute for Zoo and Wildlife Research (Berlin, Germany); Department of Biology at Boston University (Boston, USA)	Leibniz Institute for Zoo and Wildlife Research (Berlin, Germany); Department of Biology at Boston University (Boston, USA)	Leibniz Institute for Zoo and Wildlife Research (Berlin, Germany) and Department of Biology at Boston University (Boston, USA). Both institutions played no role in any stage of the project.	Adams RA, 2003, J ZOOL, V260, P189, DOI 10.1017/S0952836903003613; Atwood TC, 2003, NORTHEAST NAT, V10, P409, DOI 10.1656/1092-6194(2003)010[0409:SPOMLP]2.0.CO;2; Atwood TC, 2002, AM MIDL NAT, V148, P289, DOI 10.1674/0003-0031(2002)148[0289:SAASPO]2.0.CO;2; Barclay RMR, 2002, BIOTROPICA, V34, P168, DOI 10.1111/j.1744-7429.2002.tb00252.x; BARCLAY RMR, 1994, AM NAT, V144, P1021, DOI 10.1086/285723; Bernard RTF, 1996, S AFR J ZOOL, V31, P218; Booher CM, 2008, J ZOOL, V274, P38, DOI 10.1111/j.1469-7998.2007.00354.x; Bravo A, 2008, BIOTROPICA, V40, P203, DOI 10.1111/j.1744-7429.2007.00362.x; Brightsmith DJ, 2004, BIOTROPICA, V36, P534, DOI 10.1646/1602; Diamond JM, 1999, NATURE, V400, P120, DOI 10.1038/22014; Dominy NJ, 2004, J EXP BIOL, V207, P319, DOI 10.1242/jeb.00758; EMMONS LH, 1979, BIOTROPICA, V4; Gilardi JD, 1999, J CHEM ECOL, V25, P897, DOI 10.1023/A:1020857120217; Haynes Michelle A., 2004, Mammalian Species, P1; Herrera LG, 2001, J MAMMAL, V82, P352, DOI 10.1644/1545-1542(2001)082&lt;0352:SOPITS&gt;2.0.CO;2; Houston DC, 2001, MAMMAL REV, V31, P249, DOI 10.1046/j.1365-2907.2001.00091.x; JOHNS T, 1991, AM J CLIN NUTR, V53, P448, DOI 10.1093/ajcn/53.2.448; JONES RC, 1985, MINERAL LIKCS GEOPHA; KEELER JO, 1992, J MAMMAL, V73, P426, DOI 10.2307/1382079; KENNEDY JF, 1995, AM MIDL NAT, V134, P324, DOI 10.2307/2426301; Ketch LA, 2001, SOIL BIOL BIOCHEM, V33, P199, DOI 10.1016/S0038-0717(00)00129-2; Klaus G, 1998, J TROP ECOL, V14, P829, DOI 10.1017/S0266467498000595; Korine C, 2004, ECOLOGY, V85, P220, DOI 10.1890/02-0632; KUNZ TH, 1995, OECOLOGIA, V101, P407, DOI 10.1007/BF00329419; KWIECINSKI GG, 1987, AM J ANAT, V178, P410, DOI 10.1002/aja.1001780410; Mahaney WC, 1997, PRIMATES, V38, P159, DOI 10.1007/BF02382006; Mahaney WC, 2005, INT J PRIMATOL, V26, P1375, DOI 10.1007/s10764-005-8857-7; Mahaney WC, 2003, J CHEM ECOL, V29, P1503, DOI 10.1023/A:1024263627606; Mclean JA, 1999, FUNCT ECOL, V13, P360, DOI 10.1046/j.1365-2435.1999.00321.x; NORBERG UM, 1987, PHILOS T R SOC B, V316, P337; REX K, 2005, BIOL J LINN IN PRESS; RISENHOOVER KL, 1986, OECOLOGIA, V71, P121, DOI 10.1007/BF00377330; Speakman J. R., 1987, RECENT ADV STUDY BAT; STUDIER EH, 1995, J MAMMAL, V76, P32, DOI 10.2307/1382312; STUDIER EH, 1992, COMP BIOCHEM PHYS A, V103, P579, DOI 10.1016/0300-9629(92)90293-Y; STUDIER EH, 1991, COMP BIOCHEM PHYS A, V100, P1035, DOI 10.1016/0300-9629(91)90333-8; TANKERSLEY NG, 1983, CAN J ZOOL, V61, P2242, DOI 10.1139/z83-296; TUTTLE M D, 1974, Mammalia, V38, P141; VITOUSEK PM, 1986, ANNU REV ECOL SYST, V17, P137, DOI 10.1146/annurev.es.17.110186.001033; Voigt CC, 2004, J EXP BIOL, V207, P1741, DOI 10.1242/jeb.00929; Voigt CC, 2003, J EXP BIOL, V206, P1419, DOI 10.1242/jeb.00274; Voigt CC, 2003, J COMP PHYSIOL B, V173, P79, DOI 10.1007/s00360-002-0316-6; Voigt Christian C., 2007, Research Letters in Ecology, V2007, P1, DOI 10.1155/2007/34212; Wakibara JV, 2001, INT J PRIMATOL, V22, P495, DOI 10.1023/A:1010763930475; Wendeln MC, 2000, BIOTROPICA, V32, P489, DOI 10.1111/j.1744-7429.2000.tb00495.x; Wiley AS, 1998, CURR ANTHROPOL, V39, P532; Wilson MJ, 2003, J CHEM ECOL, V29, P1525, DOI 10.1023/A:1024262411676; Yanai RD, 2005, WATER AIR SOIL POLL, V160, P109, DOI 10.1007/s11270-005-3940-4	48	46	48	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2011	10.1371/journal.pone.0002011	http://dx.doi.org/10.1371/journal.pone.0002011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431492	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700027
J	Yde, CW; Olsen, BB; Meek, D; Watanabe, N; Guerra, B				Yde, C. W.; Olsen, B. B.; Meek, D.; Watanabe, N.; Guerra, B.			The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis	ONCOGENE			English	Article						CK2 beta; Wee1; PLK1; CDC25A; cell cycle	NEGATIVE REGULATION; CDC25A PHOSPHATASE; SOMATIC WEE1; INDUCED S; PHOSPHORYLATION; CHECKPOINT; INACTIVATION; DEGRADATION; CHK1; LOCALIZATION	Cell-cycle transition from the G(2) phase into mitosis is regulated by the cyclin-dependent protein kinase 1 (CDK1) in complex with cyclin B. CDK1 activity is controlled by both inhibitory phosphorylation, catalysed by the Myt1 and Wee1 kinases, and activating dephosphorylation, mediated by the CDC25 dual-specificity phosphatase family members. In somatic cells, Wee1 is downregulated by phosphorylation and ubiquitin-mediated degradation to ensure rapid activation of CDK1 at the beginning of M phase. Here, we show that downregulation of the regulatory beta-subunit of protein kinase CK2 by RNA interference results in delayed cell-cycle progression at the onset of mitosis. Knockdown of CK2 beta causes stabilization of Wee1 and increased phosphorylation of CDK1 at the inhibitory Tyr15. PLK1-Wee1 association is an essential event in the degradation of Wee1 in unperturbed cell cycle. We have found that CK2 beta participates in PLK1-Wee1 complex formation whereas its cellular depletion leads to disruption of PLK1-Wee1 interaction and reduced Wee1 phosphorylation at Ser53 and 121. The data reported here reinforce the notion that CK2 beta has functions that are independent of its role as the CK2 regulatory subunit, identifying it as a new component of signaling pathways that regulate cell-cycle progression at the entry of mitosis.	[Yde, C. W.; Olsen, B. B.; Guerra, B.] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; [Meek, D.] Univ Dundee, Biomed Res Ctr, Ninewells Hosp, Dundee, Scotland; [Meek, D.] Univ Dundee, Sch Med, Dundee, Scotland; [Watanabe, N.] RIKEN, Antibiot Lab, Discovery Res Inst, Wako, Saitama, Japan	University of Southern Denmark; University of Dundee; University of Dundee; RIKEN	Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	bag@bmb.sdu.dk	Olsen, Birgitte B/U-2382-2017; Watanabe, Nobumoto/N-6959-2015	Olsen, Birgitte B/0000-0002-6130-0387; Watanabe, Nobumoto/0000-0002-2130-1334; Guerra, Barbara/0000-0003-1136-2413	Novo Nordisk Foundation [5373]; Danish Medical Research Council [271-07-0464]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T Holm for technical assistance. This study was supported by the Novo Nordisk Foundation, grant no. 5373 and the Danish Medical Research Council, grant no. 271-07-0464 to BG.	Bibby AC, 2005, INT J BIOL SCI, V1, P67; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; Kohn EA, 2003, CANCER RES, V63, P31; Kreutzer J, 2007, INT J ONCOL, V31, P1251; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Perry JA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-12; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Timofeeva OA, 2006, ONCOGENE, V25, P7555, DOI 10.1038/sj.onc.1209742; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamane K, 2005, CANCER RES, V65, P4362, DOI 10.1158/0008-5472.CAN-04-3941; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	34	43	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4986	4997		10.1038/onc.2008.146	http://dx.doi.org/10.1038/onc.2008.146			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469858				2022-12-25	WOS:000258914800002
J	LaFiura, KM; Edwards, H; Taub, JW; Matherly, LH; Fontana, JA; Mohamed, AN; Ravindranath, Y; Ge, Y				LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Mohamed, A. N.; Ravindranath, Y.; Ge, Y.			Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group	ONCOGENE			English	Article						t(8;21); AML1-ETO; acute myeloid leukemia; fusion transcripts	ACUTE MYELOBLASTIC-LEUKEMIA; HIGH-DOSE CYTARABINE; DOWN-SYNDROME; AML1/ETO; EXPRESSION; REMISSION; GENE; AML; INTENSIFICATION; PROMOTER	t(8;21)(q22;q22) results in the AML1-ETO (A1E) fusion gene and is a common cytogenetic abnormality in acute myeloid leukemia (AML). Although insertions at the breakpoint region of the A1E fusion transcripts have been reported, additional structural alterations are largely uncharacterized. By RT-PCR amplifications and DNA sequencing, numerous in-frame and out-of-frame AML1b-ETO and AML1c-ETO transcripts were identified in 13 pediatric t(8; 21) AMLs, likely resulting from alternate splicing, internal deletions and/or breakpoint region insertions involving both the AML1 (RUNX1) and ETO regions. The in-frame A1E fusion transcript forms represented minor forms. These structure alterations were found in AML1c-ETO but not AML1b-ETO transcripts in two adult t(8;21) AMLs. Although no analogous alterations were detected in native AML1b transcripts, identical alterations in native ETO transcripts were identified. When transfected into HeLa cells, only AML1b, and not the in-frame A1E forms, transactivated the GM-CSF promoter. In co-transfection experiments, the effects of A1E proteins on GM-CSF transactivation by AML1b ranged from repressive to activating. Our results demonstrate a remarkable and unprecedented heterogeneity in A1E fusion transcripts in t(8;21) myeloblasts and suggest that synthesis of alternate A1E transcript and protein forms can significantly impact the regulation of AML1 responsive genes.	[LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Ravindranath, Y.; Ge, Y.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Matherly, L. H.; Ge, Y.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Fontana, J. A.] John D Dingell Vet Affairs Med Ctr, Dept Med, Detroit, MI USA; [Mohamed, A. N.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Children's Hospital of Michigan; Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ge, Y (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	gey@karmanos.org		Ge, Yubin/0000-0002-8748-716X; Fontana, Joseph/0000-0003-3829-3358	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute [CA92308, CA76641]; Pediatric Oncology Group [CA30969]; Children's Oncology Group [CA98543]; NATIONAL CANCER INSTITUTE [P30CA022453, U10CA098543, R01CA076641, U10CA030969, R01CA092308] Funding Source: NIH RePORTER	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute; Pediatric Oncology Group; Children's Oncology Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert J Arceci and the Children's Oncology Group AML Biology Subcommittee for authorizing and providing the clinical specimens that made this study possible. This work was supported by grants from the Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute (CA92308 and CA76641), the Leukemia and Lymphoma Society, BPCT Golf Charity, the Sehn Family Foundation and the Dale Meyer Memorial Endowment for Leukemia Research. JW Taub is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. This work was also supported by the Pediatric Oncology Group Grant CA30969 and the Children's Oncology Group Grant CA98543.	Becton D, 2006, BLOOD, V107, P1315, DOI 10.1182/blood-2004-08-3218; Bloomfield CD, 1998, CANCER RES, V58, P4173; Byrd JC, 1999, J CLIN ONCOL, V17, P3767, DOI 10.1200/JCO.1999.17.12.3767; Chang M, 2000, LEUKEMIA, V14, P1201, DOI 10.1038/sj.leu.2401832; Entz-Werle N, 2005, LEUKEMIA, V19, P2072, DOI 10.1038/sj.leu.2403932; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Frank R, 1995, ONCOGENE, V11, P2667; Ge YB, 2005, JNCI-J NATL CANCER I, V97, P226, DOI 10.1093/jnci/dji026; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Kardos G, 2005, LEUKEMIA, V19, P2063, DOI 10.1038/sj.leu.2403873; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Leroy H, 2005, LEUKEMIA, V19, P367, DOI 10.1038/sj.leu.2403627; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; NUCIFORA G, 1993, BLOOD, V81, P883; Perel Y, 2005, LEUKEMIA, V19, P2082, DOI 10.1038/sj.leu.2403867; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Raimondi SC, 1999, BLOOD, V94, P3707; Rubnitz JE, 2002, LEUKEMIA, V16, P2072, DOI 10.1038/sj.leu.2402633; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Schnittger S, 2003, BLOOD, V102, P2746, DOI 10.1182/blood-2003-03-0880; Smith FO, 2005, LEUKEMIA, V19, P2054, DOI 10.1038/sj.leu.2403925; Strout MP, 1999, ANN HEMATOL, V78, P251, DOI 10.1007/s002770050511; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoo SJ, 2005, HAEMATOLOGICA, V90, P1493	34	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4933	4942		10.1038/onc.2008.134	http://dx.doi.org/10.1038/onc.2008.134			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469864	Green Accepted			2022-12-25	WOS:000258596900007
J	Lemberger, T; Parkitna, JR; Chai, M; Schuetz, G; Engblom, D				Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David			CREB has a context-dependent role in activity-regulated transcription and maintains neuronal cholesterol homeostasis	FASEB JOURNAL			English	Article						cocaine plasticity; microarray; Cre/loxP; neurodegeneration	GENOME-WIDE ANALYSIS; GENE-EXPRESSION; NERVOUS-SYSTEM; BINDING PROTEIN; CELL-SURVIVAL; IN-VIVO; PHOSPHORYLATION; STIMULATION; ACTIVATION; MUTATION	Induction of specific gene expression patterns in response to activity confers functional plasticity to neurons. A principal role in the regulation of these processes has been ascribed to the cAMP responsive element binding protein (CREB). Using genome-wide expression profiling in mice lacking CREB in the forebrain, accompanied by deletion of the cAMP responsive element modulator gene (CREM), we here show that the role of these proteins in activity-induced gene expression is surprisingly selective and highly context dependent. Thus, only a very restricted subset of activity-induced genes (i.e., Gadd45b or Nr4a2) requires these proteins for their induction in the hippocampus after kainic acid administration, while they are required for most of the cocaine-induced expression changes in the striatum. Interestingly, in the absence of CREB, CREM is able to rescue activity-regulated transcription, which strengthens the notion of overlapping functions of the two proteins. In addition, we show that cholesterol metabolism is dysregulated in the brains of mutant mice, as reflected coordinated expression changes in genes involved in cholesterol synthesis and neuronal accumulation of cholesterol. These findings provide novel insights into the role of CREB and CREM in stimulus-dependent transcription and neuronal homeostasis.	[Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Linkoping University	Schuetz, G (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	g.schuetz@dkfz.de	Lemberger, Thomas/A-7301-2008; Rodriguez, Jan/I-2910-2012	Lemberger, Thomas/0000-0002-2499-4025; Rodriguez, Jan/0000-0003-0367-2331				Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Cooper SJ, 2007, GENOME RES, V17, P136, DOI 10.1101/gr.5875007; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Funfschilling U, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-1; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; Guzowski JF, 2002, HIPPOCAMPUS, V12, P86, DOI 10.1002/hipo.10010; Halder SK, 2002, MOL ENDOCRINOL, V16, P1853, DOI 10.1210/me.2001-0262; Han JH, 2007, SCIENCE, V316, P457, DOI [10.1126/science.1139438, 10.1126/science.1134697]; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143; Michikawa Makoto, 2004, Current Alzheimer Research, V1, P271, DOI 10.2174/1567205043331983; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Valenza M, 2007, HUM MOL GENET, V16, P2187, DOI 10.1093/hmg/ddm170; Walton M, 1999, J NEUROCHEM, V73, P1836; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Xu W, 2007, EMBO J, V26, P2890, DOI 10.1038/sj.emboj.7601734; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	42	60	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2872	2879		10.1096/fj.08-107888	http://dx.doi.org/10.1096/fj.08-107888			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424767				2022-12-25	WOS:000258089300027
J	Sureban, SM; Ramalingam, S; Natarajan, G; May, R; Subramaniam, D; Bishnupuri, KS; Morrison, AR; Dieckgraefe, BK; Brackett, DJ; Postier, RG; Houchen, CW; Anant, S				Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.; Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.			Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe	ONCOGENE			English	Article						cyclooxygenase-2; RNA stability; transformation; mitosis; cell cycle	RNA-BINDING-PROTEIN; CYCLOOXYGENASE-2 GENE-EXPRESSION; COLON-CANCER CELLS; AU-RICH ELEMENTS; MESSENGER-RNA; PROSTAGLANDIN E-2; 3'-UNTRANSLATED REGION; OVARIAN-CARCINOMA; STABILITY FACTOR; CYCLE ARREST	RNA-binding proteins play a key role in post-transcriptional regulation of mRNA stability and translation. We have identified that RBM3, a translation regulatory protein, is significantly upregulated in human tumors, including a stage-dependent increase in colorectal tumors. Forced RBM3 overexpression in NIH3T3 mouse fibroblasts and SW480 human colon epithelial cells increases cell proliferation and development of compact multicellular spheroids in soft agar suggesting the ability to induce anchorage-independent growth. In contrast, down-regulating RBM3 in HCT116 colon cancer cells with specific siRNA decreases cell growth in culture, which was partially overcome when treated with prostaglandin E(2), a product of cyclooxygenase (COX)-2 enzyme activity. Knockdown also resulted in the growth arrest of tumor xenografts. We have also identified that RBM3 knockdown increases caspase-mediated apoptosis coupled with nuclear cyclin B1, and phosphorylated Cdc25c, Chk1 and Chk2 kinases, implying that under conditions of RBM3 downregulation, cells undergo mitotic catastrophe. RBM3 enhances COX-2, IL-8 and VEGF mRNA stability and translation. Conversely, RBM3 knockdown results in loss in the translation of these transcripts. These data demonstrate that the RNA stabilizing and translation regulatory protein RBM3 is a novel proto-oncogene that induces transformation when overexpressed and is essential for cells to progress through mitosis.	[Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Houchen, C. W.; Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73126 USA; [Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Brackett, D. J.; Postier, R. G.] Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73126 USA; [Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.] OU Canc Inst, Oklahoma City, OK USA; [Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73126 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Anant, S (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, 970 Stanton L Young Blvd,WP1360, Oklahoma City, OK 73126 USA.	shrikant-anant@ouhsc.edu	Anant, Shrikant/AAF-8020-2020; Ramalingam, Satish/H-1577-2018; Sureban, Sripathi/Q-8232-2019	Ramalingam, Satish/0000-0002-3076-279X; Sureban, Sripathi/0000-0001-5476-9593	NATIONAL CANCER INSTITUTE [R01CA135559, R01CA109269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109269-01A1, R01 CA109269, R01 CA135559, CA-109269] Funding Source: Medline; NIDDK NIH HHS [R01 DK062265-06, R01 DK062265, DK-62265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREIS PG, 1981, EXP CELL RES, V134, P265, DOI 10.1016/0014-4827(81)90425-0; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2006, MODERN PATHOL, V19, P1261, DOI 10.1038/modpathol.3800645; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; Deschenes-Furry J, 2005, J BIOL CHEM, V280, P25361, DOI 10.1074/jbc.M410929200; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Doree M, 2002, J CELL SCI, V115, P2461; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Hacker S, 2004, J BIOL CHEM, V279, P5049, DOI 10.1074/jbc.C300522200; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Mukhopadhyay D, 2003, ANN NY ACAD SCI, V1010, P504, DOI 10.1196/annals.1299.093; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 2001, CANCER RES, V61, P2154; Ning SC, 1999, RADIAT RES, V151, P659, DOI 10.2307/3580204; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Shao JY, 2003, CANCER RES, V63, P5218; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Smart F, 2007, J NEUROCHEM, V101, P1367, DOI 10.1111/j.1471-4159.2007.04521.x; Stark George R, 2004, Methods Mol Biol, V280, P51; Sureban SM, 2007, GASTROENTEROLOGY, V132, P1055, DOI 10.1053/j.gastro.2006.12.031; Sutherland LC, 2005, J CELL BIOCHEM, V94, P5, DOI 10.1002/jcb.20204; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wu Gaosong, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P42; Yamashita H, 2003, ANTICANCER RES, V23, P4671	56	98	110	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4544	4556		10.1038/onc.2008.97	http://dx.doi.org/10.1038/onc.2008.97			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18427544	Green Accepted			2022-12-25	WOS:000258077300004
J	Marro, ML; Peiro, C; Panayiotou, CM; Baliga, RS; Meurer, S; Schmidt, HHHW; Hobbs, AJ				Marro, Martin L.; Peiro, Concepcion; Panayiotou, Catherine M.; Baliga, Reshma S.; Meurer, Sabine; Schmidt, Harald H. H. W.; Hobbs, Adrian J.			Characterization of the human alpha(1)beta(1) soluble guanylyl cyclase promoter - Key role for NF-kappa B(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; SIGNAL-TRANSDUCTION SYSTEM; CYCLIC-GMP; DOWN-REGULATION; PULMONARY-HYPERTENSION; BETA(1) SUBUNIT; DNA-BINDING; NF-Y; GENES; RAT	Soluble guanylyl cyclase (sGC) is the principal receptor for NO and plays a ubiquitous role in regulating cellular function. This is exemplified in the cardiovascular system where sGC governs smooth muscle tone and growth, vascular permeability, leukocyte flux, and platelet aggregation. As a consequence, aberrant NO-sGC signaling has been linked to diseases including hypertension, atherosclerosis, and stroke. Despite these key (patho) physiological roles, little is known about the expressional regulation of sGC. To address this deficit, we have characterized the promoter activity of human alpha(1) and beta(1) sGC genes in a cell type relevant to cardiovascular (patho) physiology, primary human aortic smooth muscle cells. Luciferase reporter constructs revealed that the 0.3-and 0.5-kb regions upstream of the transcription start sites were optimal for alpha(1) and beta(1) sGC promoter activity, respectively. Deletion of consensus sites for c-Myb, GAGA, NFAT, NF-kappa B(p50), and CCAAT-binding factor(s) (CCAAT-BF) revealed that these are the principal transcription factors regulating basal sGC expression. In addition, under pro-inflammatory conditions, the effects of the strongest alpha(1) and beta(1) sGC repressors were enhanced, and enzyme expression and activity were reduced; in particular, NF-kappa B(p50) is pivotal in regulating enzyme expression under such conditions. NO itself also elicited a cGMP-independent negative feedback effect on sGC promoter activity that is mediated, in part, via CCAAT-BF activity. In sum, these data provide a systematic characterization of the promoter activity of human sGC alpha(1) and beta(1) subunits and identify key transcription factors that govern subunit expression under basal and pro-inflammatory (i.e. atherogenic) conditions and in the presence of ligand NO.	[Marro, Martin L.; Panayiotou, Catherine M.; Baliga, Reshma S.; Hobbs, Adrian J.] UCL, Dept Pharmacol, London WC1E 6BT, England; [Peiro, Concepcion] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, E-28029 Madrid, Spain; [Meurer, Sabine; Schmidt, Harald H. H. W.] Monash Univ, Fac Med, Dept Pharmacol, Melbourne, Vic 3168, Australia	University of London; University College London; Autonomous University of Madrid; Monash University	Hobbs, AJ (corresponding author), UCL, Dept Pharmacol, Med Sci Bldg,Gower St, London WC1E 6BT, England.	a.hobbs@ucl.ac.uk	Schmidt, Harald HHW/B-1549-2008; Peiro, Concepcion/B-9545-2017	Schmidt, Harald HHW/0000-0003-0419-5549; Peiro, Concepcion/0000-0002-9690-7816; Hobbs, Adrian/0000-0002-3589-7108	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahluwalia A, 2004, P NATL ACAD SCI USA, V101, P1386, DOI 10.1073/pnas.0304264101; Andreopoulos S, 2000, GEN PHARMACOL-VASC S, V34, P147, DOI 10.1016/S0306-3623(00)00062-8; Azam M, 1998, HYPERTENSION, V32, P149, DOI 10.1161/01.HYP.32.1.149; Bauersachs J, 1999, CIRCULATION, V100, P292, DOI 10.1161/01.CIR.100.3.292; Brandes RP, 2000, P NATL ACAD SCI USA, V97, P9747, DOI 10.1073/pnas.97.17.9747; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; Chen LH, 2000, CIRC RES, V86, P520, DOI 10.1161/01.RES.86.5.520; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIUILI G, 1993, HUM GENET, V91, P257; Guan HC, 2005, J BIOL CHEM, V280, P9957, DOI 10.1074/jbc.M412180200; Hassoun PM, 2004, AM J RESP CELL MOL, V30, P908, DOI 10.1165/rcmb.2003-0287OC; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Hobbs AJ, 2003, VASC PHARMACOL, V40, P149, DOI 10.1016/S1537-1891(03)00046-6; Hut QH, 2002, J BIOL CHEM, V277, P37191, DOI 10.1074/jbc.M205985200; Jin VX, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-114; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Kloss S, 2000, HYPERTENSION, V35, P43; KUBES P, 1993, AM J PHYSIOL, V265, pH1909, DOI 10.1152/ajpheart.1993.265.6.H1909; KUROSE I, 1993, CIRC RES, V73, P164, DOI 10.1161/01.RES.73.1.164; Madhani M, 2006, BRIT J PHARMACOL, V149, P797, DOI 10.1038/sj.bjp.0706920; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Melichar VO, 2004, P NATL ACAD SCI USA, V101, P16671, DOI 10.1073/pnas.0405509101; MORLEY D, 1993, P NATL ACAD SCI USA, V22, pS3; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Papapetropoulos A, 1996, BRIT J PHARMACOL, V118, P1359, DOI 10.1111/j.1476-5381.1996.tb15545.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RAPOPORT RM, 1983, J CYCLIC NUCL PROT, V9, P281; Ritter D, 2000, BIOCHEM J, V346, P811, DOI 10.1042/0264-6021:3460811; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; Sabrane K, 2003, J BIOL CHEM, V278, P17963, DOI 10.1074/jbc.M213113200; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Scott WS, 1998, J SURG RES, V79, P66, DOI 10.1006/jsre.1998.5382; Sharina IG, 2000, P NATL ACAD SCI USA, V97, P10878, DOI 10.1073/pnas.190331697; Sharina IG, 2003, P NATL ACAD SCI USA, V100, P11523, DOI 10.1073/pnas.1934338100; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Takata M, 2001, AM J PHYSIOL-LUNG C, V280, pL272, DOI 10.1152/ajplung.2001.280.2.L272; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; Tzao C, 2001, PEDIATR PULM, V31, P97, DOI 10.1002/1099-0496(200102)31:2<97::AID-PPUL1016>3.0.CO;2-K; Vazquez-Padron RI, 2004, BIOCHEM BIOPH RES CO, V314, P208, DOI 10.1016/j.bbrc.2003.12.078; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wedgwood S, 2005, AM J PHYSIOL-LUNG C, V289, pL660, DOI 10.1152/ajplung.00369.2004; Yamamoto T, 2002, BIOCHEM J, V361, P337, DOI 10.1042/0264-6021:3610337; You XM, 2003, CIRC RES, V92, P314, DOI 10.1161/01.RES.0000056758.73215.5A; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051	54	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20027	20036		10.1074/jbc.M801223200	http://dx.doi.org/10.1074/jbc.M801223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18474600	Green Published, hybrid			2022-12-25	WOS:000257565300018
J	Wen, YH; Pinto, JR; Gomes, AV; Xu, YY; Wang, YC; Wang, Y; Potter, JD; Kerrick, WGL				Wen, Yuhui; Pinto, Jose Renato; Gomes, Aldrin V.; Xu, Yuanyuan; Wang, Yingcai; Wang, Ying; Potter, James D.; Kerrick, W. Glenn L.			Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERATING CROSS-BRIDGES; SKINNED MUSCLE-FIBERS; SKELETAL-MUSCLE; GENETIC-BASIS; T MUTATIONS; FORCE; CA2+; CONTRACTION; ATPASE; EXPRESSION	In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca2+-activated force without changes in the maximal ATPase activity and an increase in the Ca2+ sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca2+ sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3mM 2,3-butanedione monoxime at pCa 9.0 showed that there was similar to 2-4% of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0% in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca2+] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca2+] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca2+ in Tg-R145G mice.	[Wen, Yuhui; Xu, Yuanyuan; Wang, Ying; Kerrick, W. Glenn L.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Pinto, Jose Renato; Wang, Yingcai; Potter, James D.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Gomes, Aldrin V.] Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA	University of Miami; University of Miami; University of California System; University of California Davis	Potter, JD (corresponding author), 1600 NW 10th Ave,R-189, Miami, FL 33136 USA.	jdpotter@miami.edu	Pinto, Jose Renato/H-2631-2017; Gomes, Aldrin V/I-6529-2018	Pinto, Jose Renato/0000-0001-9092-4976; Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325, R01HL067415] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL042325, R01 HL067415, HL 67415, HL 42325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abergel E, 2006, ARCH MAL COEUR VAISS, V99, P969; Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, V1, pCH8; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; DONALDSON SKB, 1975, J GEN PHYSIOL, V66, P427, DOI 10.1085/jgp.66.4.427; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; Gomes AV, 2004, ANN NY ACAD SCI, V1015, P214, DOI 10.1196/annals.1302.018; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; Harada K, 2004, J BIOL CHEM, V279, P14488, DOI 10.1074/jbc.M309355200; Hernandez OM, 2005, J BIOL CHEM, V280, P37183, DOI 10.1074/jbc.M508114200; Herron TJ, 2007, CIRC RES, V100, P1182, DOI 10.1161/01.RES.0000264102.00706.4e; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; Kerrick WGL, 2004, J MUSCLE RES CELL M, V25, P107, DOI 10.1023/B:JURE.0000035841.04314.16; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Kobayashi T, 2006, J BIOL CHEM, V281, P13471, DOI 10.1074/jbc.M509561200; Kohler J, 2003, PHYSIOL GENOMICS, V14, P117, DOI 10.1152/physiolgenomics.00101.2002; Kokado H, 2000, CIRCULATION, V102, P663, DOI 10.1161/01.CIR.102.6.663; Krenz M, 2004, J AM COLL CARDIOL, V44, P2390, DOI 10.1016/j.jacc.2004.09.044; Kruger M, 2005, J PHYSIOL-LONDON, V564, P347, DOI 10.1113/jphysiol.2004.079095; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Morner S, 2000, J MOL CELL CARDIOL, V32, P521, DOI 10.1006/jmcc.1999.1099; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OAKLEY CM, 1980, BRIT HEART J, V44, P672; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Robinson JM, 2002, J MOL BIOL, V322, P1065, DOI 10.1016/S0022-2836(02)00855-0; Sanbe A, 2005, CIRCULATION, V111, P2330, DOI 10.1161/01.CIR.0000164234.24957.75; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2000, J BIOCHEM-TOKYO, V127, P355, DOI 10.1093/oxfordjournals.jbchem.a022615; Takahashi-Yanaga F, 2001, J MOL CELL CARDIOL, V33, P2095, DOI 10.1006/jmcc.2001.1473; TAKASHI R, 1979, ANAL BIOCHEM, V92, P375, DOI 10.1016/0003-2697(79)90674-2; Van Driest SL, 2003, CIRCULATION, V108, P445, DOI 10.1161/01.CIR.0000080896.52003.DF; Wang Y, 2002, J APPL PHYSIOL, V92, P2409, DOI 10.1152/japplphysiol.00376.2001; Wang Y, 1999, J MUSCLE RES CELL M, V20, P645, DOI 10.1023/A:1005559613516; Wang Y, 2006, J MOL BIOL, V361, P286, DOI 10.1016/j.jmb.2006.06.018; WARD CW, 2004, J BIOL CHEM, V280, P37183; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0	45	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20484	20494		10.1074/jbc.M801661200	http://dx.doi.org/10.1074/jbc.M801661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18430738	Green Published, hybrid			2022-12-25	WOS:000257565300062
J	Luo, H; Li, Y; Mu, JJ; Zhang, J; Tonaka, T; Hamamori, Y; Jung, SY; Wang, Y; Qin, J				Luo, Hao; Li, Yehua; Mu, Jung-Jung; Zhang, Jinglan; Tonaka, Toru; Hamamori, Yasuo; Jung, Sung Yun; Wang, Yi; Qin, Jun			Regulation of intra-S phase checkpoint by ionizing radiation (IR)-dependent and IR-independent phosphorylation of SMC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND-BREAK; PROTEIN-KINASE CK2; DNA-DAMAGE RESPONSE; ATM-DEPENDENT PHOSPHORYLATION; COHESIN; COMPLEX; REPAIR; EXPRESSION; APOPTOSIS; FORMS	Structure maintenance of chromosome 1 (SMC1) is phosphorylated by ataxia telangiectasia-mutated (ATM) in response to ionizing radiation (IR) to activate intra-S phase checkpoint. A role of CK2 in DNA damage response has been implicated in many previous works, but the molecular mechanism for its activation is not clear. In the present work, we report that SMC3 is phosphorylated at Ser-1067 and Ser-1083 in vivo. Ser-1083 phosphorylation is IR-inducible, depends on ATM and Nijmegen breakage syndrome 1 (NBS1), and is required for intra-S phase checkpoint. Interestingly, Ser-1067 phosphorylation is constitutive and is not induced by IR but also affects intra-S phase checkpoint. Phosphorylation of Ser-1083 is weakened in cells expressing S1067A mutant, suggesting interplay between Ser-1067 and Ser-1083 phosphorylation in DNA damage response. Consistently, small interfering RNA knockdown of CK2 leads to attenuated phosphorylation of Ser-1067 as well as intra-S phase checkpoint defect. Our data provide evidence that phosphorylation of a core cohesin subunit SMC3 by ATM plays an important role in DNA damage response and suggest that a constitutive phosphorylation by CK2 may affect intra-S phase checkpoint by modulating SMC3 phosphorylation by ATM.	[Qin, Jun] Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Dept Mol & Cell Biol, Houston, TX 77030 USA; [Tonaka, Toru; Hamamori, Yasuo] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Qin, J (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	jqin@bcm.tmc.edu	Zhang, Jinglan/AAI-1793-2020; Zhang, Jinglan/D-4752-2011	Zhang, Jinglan/0000-0002-4600-7123	NATIONAL CANCER INSTITUTE [R01CA098500] Funding Source: NIH RePORTER; NCI NIH HHS [CA98500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Cheung WL, 2005, CURR BIOL, V15, P656, DOI 10.1016/j.cub.2005.02.049; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Gruber S, 2006, CELL, V127, P523, DOI 10.1016/j.cell.2006.08.048; Guillemain G, 2007, MOL CELL BIOL, V27, P3378, DOI 10.1128/MCB.00863-06; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Harvey EJ, 2007, ARTERIOSCL THROM VAS, V27, P806, DOI 10.1161/01.ATV.0000258867.79411.96; Homma MK, 2005, MOL CELL BIOCHEM, V274, P47, DOI 10.1007/s11010-005-3111-3; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lebrin F, 2001, ONCOGENE, V20, P2010, DOI 10.1038/sj.onc.1204307; Lengronne A, 2004, NATURE, V430, P573, DOI 10.1038/nature02742; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Schar P, 2004, NUCLEIC ACIDS RES, V32, P3921, DOI 10.1093/nar/gkh716; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Wang Y, 2000, GENE DEV, V14, P927; Weitzer S, 2003, CURR BIOL, V13, P1930, DOI 10.1016/j.cub.2003.10.030; Yamane K, 2005, CLIN CANCER RES, V11, P2355, DOI 10.1158/1078-0432.CCR-04-1734; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	39	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19176	19183		10.1074/jbc.M802299200	http://dx.doi.org/10.1074/jbc.M802299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18442975	hybrid, Green Published			2022-12-25	WOS:000257387600002
J	Kurata, S; Weixlbaumer, A; Ohtsuki, T; Shimazaki, T; Wada, T; Kirino, Y; Takai, K; Watanabe, K; Ramakrishnan, V; Suzuki, T				Kurata, Shinya; Weixlbaumer, Albert; Ohtsuki, Takashi; Shimazaki, Tomomi; Wada, Takeshi; Kirino, Yohei; Takai, Kazuyuki; Watanabe, Kimitsuna; Ramakrishnan, V.; Suzuki, Tsutomu			Modified uridines with c5-methylene substituents at the first position of the tRNA anticodon stabilize U center dot G wobble pairing during decoding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSFER-RNAS; ESCHERICHIA-COLI K-12; MUTANT TRANSFER-RNAS; CODON RECOGNITION; MODIFICATION DEFICIENCY; MYCOPLASMA-CAPRICOLUM; MODIFICATION DEFECT; MODIFIED NUCLEOSIDE; AGG CODONS; TRANSLATION	Post-transcriptional modifications at the first ( wobble) position of the tRNA anticodon participate in precise decoding of the genetic code. To decode codons that end in a purine (R) (i.e. NNR), tRNAs frequently utilize 5-methyluridine derivatives (xm(5)U) at the wobble position. However, the functional properties of the C5-substituents of xm(5)U in codon recognition remain elusive. We previously found that mitochondrial tRNAs(Leu(UUR)) with pathogenic point mutations isolated from MELAS ( mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) patients lacked the 5-taurinomethyluridine (tau m(5)U) modification and caused a decoding defect. Here, we constructed Escherichia coli tRNAs(Leu(UUR)) with or without xm(5)U modifications at the wobble position and measured their decoding activities in an in vitro translation as well as by A-site tRNA binding. In addition, the decoding properties of tRNA(Arg) lacking mnm(5)U modification in a knock-out strain of the modifying enzyme (Delta mnmE) were examined by pulse labeling using reporter constructs with consecutive AGR codons. Our results demonstrate that the xm(5)U modification plays a critical role in decoding NNG codons by stabilizing U center dot G pairing at the wobble position. Crystal structures of an anticodon stem-loop containing tau m(5)U interacting with a UUA or UUG codon at the ribosomal A-site revealed that the m(5)U center dot G base pair does not have classical U center dot G wobble geometry. These structures provide help to explain how the tau m(5)U modification enables efficient decoding of UUG codons.	[Kurata, Shinya; Kirino, Yohei; Suzuki, Tsutomu] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Weixlbaumer, Albert; Ramakrishnan, V.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Ohtsuki, Takashi] Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan; [Shimazaki, Tomomi; Wada, Takeshi] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan; [Takai, Kazuyuki] Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan; [Watanabe, Kimitsuna] Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tokyo 1350064, Japan	University of Tokyo; MRC Laboratory Molecular Biology; Okayama University; University of Tokyo; Ehime University; National Institute of Advanced Industrial Science & Technology (AIST)	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	ts@chembio.t.u-tokyo.ac.jp	Weixlbaumer, Albert/AAI-8474-2021; OHTSUKI, Takashi/B-1471-2011; Shimazaki, Tomomi/C-7405-2016; Weixlbaumer, Albert/P-3587-2016; Suzuki, Tsutomu/J-1776-2015	Weixlbaumer, Albert/0000-0001-9635-3844; OHTSUKI, Takashi/0000-0002-3183-5305; Weixlbaumer, Albert/0000-0001-9635-3844; Suzuki, Tsutomu/0000-0002-9731-1731; Ramakrishnan, V/0000-0002-4699-2194; Kirino, Yohei/0000-0001-5232-4742	Medical Research Council [MC_U105184332] Funding Source: Medline; MRC [MC_U105184332] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agris PF, 2007, J MOL BIOL, V366, P1, DOI 10.1016/j.jmb.2006.11.046; ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; ANDACHI Y, 1987, P NATL ACAD SCI USA, V84, P7398, DOI 10.1073/pnas.84.21.7398; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; BARRIO JR, 1978, BIOCHEMISTRY-US, V17, P2077, DOI 10.1021/bi00604a009; BJORK GR, 1995, BIOSYNTHESIS FUNCTIO, P165; BONITZ SG, 1980, P NATL ACAD SCI-BIOL, V77, P3167, DOI 10.1073/pnas.77.6.3167; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN GFT, 1994, GENE DEV, V8, P2641, DOI 10.1101/gad.8.21.2641; Clemons WM, 2001, J MOL BIOL, V310, P827, DOI 10.1006/jmbi.2001.4778; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Curran J. F., 1998, MODIFICATION EDITING, P493; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; HAGERVALL TG, 1987, J BIOL CHEM, V262, P8488; INAGAKI Y, 1995, J MOL BIOL, V251, P486, DOI 10.1006/jmbi.1995.0450; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Kirino Yohei, 2005, RNA Biol, V2, P41, DOI 10.4161/rna.2.2.1610; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kruger MK, 1998, J MOL BIOL, V284, P621, DOI 10.1006/jmbi.1998.2196; Kurata S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng145; MALKIEWICZ A, 1983, TETRAHEDRON LETT, V24, P5395, DOI 10.1016/S0040-4039(00)87878-8; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; Masquida B, 1999, RNA, V5, P1384, DOI 10.1017/S1355838299991173; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZUNO H, 1978, NUCLEIC ACIDS RES, V5, P4451, DOI 10.1093/nar/5.11.4451; MURAO K, 1978, NUCLEIC ACIDS RES SP, V5, pS333; Murphy FV, 2004, NAT STRUCT MOL BIOL, V11, P1186, DOI 10.1038/nsmb861; Nasvall SJ, 2004, RNA, V10, P1662, DOI 10.1261/rna.7106404; Noma A, 2006, EMBO J, V25, P2142, DOI 10.1038/sj.emboj.7601105; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Ohtsuki T, 1998, J BIOCHEM-TOKYO, V124, P28, DOI 10.1093/oxfordjournals.jbchem.a022092; Phelps SS, 2004, J MOL BIOL, V338, P439, DOI 10.1016/j.jmb.2004.02.070; ROSENBERG AH, 1993, J BACTERIOL, V175, P716, DOI 10.1128/JB.175.3.716-722.1993; SAMUELSSON T, 1980, J BIOL CHEM, V255, P4583; Shimada A, 2001, P NATL ACAD SCI USA, V98, P13537, DOI 10.1073/pnas.231267998; Sorensen MA, 2005, J MOL BIOL, V354, P16, DOI 10.1016/j.jmb.2005.08.076; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122; Suzuki T, 2005, TOP CURR GENET, V12, P23, DOI 10.1007/b106361; Suzuki T, 2007, METHOD ENZYMOL, V425, P211, DOI 10.1016/S0076-6876(07)25009-8; Takai K, 2003, NUCLEIC ACIDS RES, V31, P6383, DOI 10.1093/nar/gkg839; Takai K, 1996, NUCLEIC ACIDS RES, V24, P2894, DOI 10.1093/nar/24.15.2894; Tomita K, 2000, P NATL ACAD SCI USA, V97, P8278, DOI 10.1073/pnas.140213797; VARENNE S, 1982, J MOL BIOL, V159, P57, DOI 10.1016/0022-2836(82)90031-6; Watanabe Kimitsuna, 1995, P225; Yang JH, 1998, J AM CHEM SOC, V120, P9090, DOI 10.1021/ja981604u; Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905; Yokoyama S, 1995, MODIFIED NUCLEOSIDES, P207	63	100	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18801	18811		10.1074/jbc.M800233200	http://dx.doi.org/10.1074/jbc.M800233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18456657	Green Published, hybrid			2022-12-25	WOS:000257165600037
J	Miersch, S; Espey, MG; Chaube, R; Akarca, A; Tweten, R; Ananvoranich, S; Mutus, B				Miersch, Shane; Espey, Michael Graham; Chaube, Ruchi; Akarca, Arzu; Tweten, Rodney; Ananvoranich, Sirinart; Mutus, Bulent			Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; SOLUBLE GUANYLYL CYCLASE; LOW-DENSITY-LIPOPROTEIN; LIPID RAFTS; ENA/VASP PROTEINS; PROSTATE-CANCER; CELL-MEMBRANES; OXYGEN; DISEASE; INHIBITION	Nitric oxide (NO) signaling is inextricably linked to both its physical and chemical properties. Due to its preferentially hydrophobic solubility, NO molecules tend to partition from the aqueous milieu into biological membranes. We hypothesized that plasma membrane ordering provided by cholesterol further couples the physics of NO diffusion with cellular signaling. Fluorescence lifetime quenching studies with pyrene liposome preparations showed that the presence of cholesterol decreased apparent diffusion coefficients of NO similar to 20-40%, depending on the phospholipid composition. Electrochemical measurements indicated that the diffusion rate of NO across artificial bilayer membranes were inversely related to cholesterol content. Sterol transport-defective Niemann-Pick type C1 (NPC1) fibroblasts exhibited increased plasma membrane cholesterol content but decreased activation of both intracellular soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein (VASP) phosphorylation at Ser(239) induced by exogenous NO exposure relative to their normal human fibroblast (NHF) counterparts. Augmentation of plasma membrane cholesterol in NHF diminished production of both cGMP and VASP phosphorylation elicited by NO to NPC1-comparable levels. Conversely, decreasing membrane cholesterol in NPC1 resulted in the augmentation in both cGMP and VASP phosphorylation to a level similar to those observed in NHF. Increasing plasma membrane cholesterol contents in NHF, platelets, erythrocytes and tumor cells also resulted in an increased level of extracellular diaminofluorescein nitrosation following NO exposure. These findings suggest that the impact of cholesterol on membrane fluidity and microdomain structure contributes to the spatial heterogeneity of NO diffusion and signaling.	[Miersch, Shane; Chaube, Ruchi; Akarca, Arzu; Ananvoranich, Sirinart; Mutus, Bulent] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; [Tweten, Rodney] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; [Espey, Michael Graham] NIDDK, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA	University of Windsor; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mutus, B (corresponding author), 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	mutusb@uwindsor.ca			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI037657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bellamy TC, 2002, MOL CELL BIOCHEM, V230, P165, DOI 10.1023/A:1014204426331; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; Caccia S, 1999, BIOPHYS CHEM, V76, P63, DOI 10.1016/S0301-4622(98)00219-1; Chen LH, 2004, ARTERIOSCL THROM VAS, V24, P1403, DOI 10.1161/01.ATV.0000134705.39654.53; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; Chiang CY, 2006, J BIOL INORG CHEM, V11, P359, DOI 10.1007/s00775-006-0084-y; Christian AE, 1997, J LIPID RES, V38, P2264; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; FISCHKOFF S, 1975, J GEN PHYSIOL, V65, P663, DOI 10.1085/jgp.65.5.663; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Freeman MR, 2006, JAMA-J AM MED ASSOC, V295, P2720, DOI 10.1001/jama.295.23.2720-b; Freeman MR, 2005, TRENDS ENDOCRIN MET, V16, P273, DOI 10.1016/j.tem.2005.06.002; Gomes B, 2006, J BIOL CHEM, V281, P12421, DOI 10.1074/jbc.M510653200; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; ISSNER R, 1997, CHEM RES TOXICOL, V10, P1285; Khan N, 2003, BIOCHEMISTRY-US, V42, P23, DOI 10.1021/bi026039t; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Koike T, 1998, BBA-MOL BASIS DIS, V1406, P327, DOI 10.1016/S0925-4439(98)00019-2; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Lima ES, 2003, J LIPID RES, V44, P1660, DOI 10.1194/jlr.M200467-JLR200; Linder AE, 2005, J PHARMACOL EXP THER, V314, P9, DOI 10.1124/jpet.105.083634; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; Mason RP, 2003, BBA-BIOMEMBRANES, V1610, P198, DOI 10.1016/S0005-2736(03)00018-X; Massberg S, 2004, BLOOD, V103, P136, DOI 10.1182/blood-2002-11-3417; Mo E, 2004, J BIOL CHEM, V279, P26149, DOI 10.1074/jbc.M400916200; Moller M, 2005, J BIOL CHEM, V280, P8850, DOI 10.1074/jbc.M413699200; Moller MN, 2007, IUBMB LIFE, V59, P243, DOI 10.1080/15216540701311147; Ohno-Iwashita Y, 2004, ANAEROBE, V10, P125, DOI 10.1016/j.anaerobe.2003.09.003; Ostrowski SM, 2007, J BIOL CHEM, V282, P26832, DOI 10.1074/jbc.M702640200; Philippides A, 2000, J NEUROSCI, V20, P1199, DOI 10.1523/JNEUROSCI.20-03-01199.2000; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Pucadyil TJ, 2006, CHEM PHYS LIPIDS, V143, P11, DOI 10.1016/j.chemphyslip.2006.04.003; Qin CB, 2006, ARTERIOSCL THROM VAS, V26, P372, DOI 10.1161/01.ATV.0000197848.67999.e1; Radhakrishnan A, 2005, P NATL ACAD SCI USA, V102, P12662, DOI 10.1073/pnas.0506043102; Reid PC, 2007, J CELL MOL MED, V11, P383, DOI 10.1111/j.1582-4934.2007.00054.x; Rukmini R, 2001, BIOPHYS J, V81, P2122, DOI 10.1016/S0006-3495(01)75860-2; Sagin FG, 2008, CURR ALZHEIMER RES, V5, P4, DOI 10.2174/156720508783884648; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; SUBCZYNSKI WK, 1989, P NATL ACAD SCI USA, V86, P4474, DOI 10.1073/pnas.86.12.4474; Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhuang LY, 2005, J CLIN INVEST, V115, P959	61	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18513	18521		10.1074/jbc.M800440200	http://dx.doi.org/10.1074/jbc.M800440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18445594	Green Published, hybrid			2022-12-25	WOS:000257165600006
J	Coutu, DL; Wu, JH; Monette, A; Rivard, GE; Blostein, MD; Galipeau, J				Coutu, Daniel L.; Wu, Jian Hui; Monette, Anne; Rivard, Georges-Etienne; Blostein, Mark D.; Galipeau, Jacques			Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; GAMMA-CARBOXYGLUTAMIC ACID; STEM-CELLS; BONE; CLONING; IDENTIFICATION; RECOGNITION; OSTEOCALCIN; CARTILAGE; ADHESION	The modification of glutamic acid residues to gamma-carboxyglutamic acid (Gla) is a post-translational modification catalyzed by the vitamin K-dependent enzyme gamma-glutamylcarboxylase. Despite ubiquitous expression of the gamma-carboxylation machinery in mammalian tissues, only 12 Gla-containing proteins have so far been identified in humans. Because bone tissue is the second most abundant source of Gla-containing proteins after the liver, we sought to identify Gla proteins secreted by bone marrow-derived mesenchymal stromal cells (MSCs). We used a proteomics approach to screen the secretome of MSCs with a combination of two-dimensional gel electrophoresis and tandem mass spectrometry. The most abundant Gla-containing protein secreted by MSCs was identified as periostin, a previously unrecognized gamma-carboxylated protein. In silico amino acid sequence analysis of periostin demonstrated the presence of four consensus gamma-carboxylase recognition sites embedded within fasciclin-like protein domains. The carboxylation of periostin was confirmed by immunoprecipitation and purification of the recombinant protein. Carboxylation of periostin could be inhibited by warfarin in MSCs, demonstrating its dependence on the presence of vitamin K. We were able to demonstrate localization of carboxylated periostin to bone nodules formed by MSCs in vitro, suggesting a role in extracellular matrix mineralization. Our data also show that another fasciclin I-like protein, beta ig-h3, contains Gla. In conclusion, periostin is a member of a novel vitamin K-dependent gamma-carboxylated protein family characterized by the presence of fasciclin domains. Furthermore, carboxylated periostin is produced by bone-derived cells of mesenchymal lineage and is abundantly found in mineralized bone nodules in vitro.	[Blostein, Mark D.; Galipeau, Jacques] McGill Univ, Jewish Gen Hosp, SMBD, Div Hematol, Montreal, PQ H3T 1E2, Canada; [Coutu, Daniel L.; Monette, Anne; Galipeau, Jacques] McGill Univ, Div Expt Med, Montreal, PQ H3A 1A3, Canada; [Coutu, Daniel L.; Wu, Jian Hui; Monette, Anne; Blostein, Mark D.; Galipeau, Jacques] Univ Montreal, Lady Davis Inst Med Res, Montreal, PQ H3T 1C5, Canada; [Monette, Anne] Univ Montreal, HIV RNA Trafficking Lab 1, Montreal, PQ H3T 1C5, Canada; [Rivard, Georges-Etienne] Univ Montreal, Serv Hematol Oncol, Ctr Hosp Univ Ste Justine, Montreal, PQ H3T 1C5, Canada	McGill University; McGill University; Lady Davis Institute; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Galipeau, J (corresponding author), McGill Univ, Jewish Gen Hosp, SMBD, Div Hematol, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	jacques.galipeau@mcgill.ca	Coutu, Daniel/AAD-5292-2022; Galipeau, Jacques/R-9909-2019	Coutu, Daniel/0000-0002-4641-0115; Galipeau, Jacques/0000-0002-9374-1996				Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Blumer MJF, 2006, J ANAT, V208, P695, DOI 10.1111/j.1469-7580.2006.00578.x; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Clout N, 2003, MOL VIS, V9, P440; Cranenburg ECM, 2007, THROMB HAEMOSTASIS, V98, P120, DOI 10.1160/TH07-04-0266; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Eliopoulos N, 2005, BLOOD, V106, P4057, DOI 10.1182/blood-2005-03-1004; FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890-197404000-00001; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Gillan L, 2002, CANCER RES, V62, P5358; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH-22.1167; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Levesque K, 2006, TRAFFIC, V7, P1177, DOI 10.1111/j.1600-0854.2006.00461.x; Lindner V, 2005, ARTERIOSCL THROM VAS, V25, P77, DOI 10.1161/01.ATV.0000149141.81230.c6; Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115; LOESER RF, 1992, J BIOL CHEM, V267, P9459; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Nakazawa T, 2004, J ORTHOP RES, V22, P520, DOI 10.1016/j.orthres.2003.10.007; NISHIMOTO SK, 1979, J BIOL CHEM, V254, P437; Oka T, 2007, CIRC RES, V101, P313, DOI 10.1161/CIRCRESAHA.107.149047; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TUAN RS, 2004, CLIN ORTHOP RELAT R, V427, P105; VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039	43	125	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17991	18001		10.1074/jbc.M708029200	http://dx.doi.org/10.1074/jbc.M708029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450759	hybrid			2022-12-25	WOS:000256949200028
J	Fiuza, M; Canova, MJ; Zanella-Cleon, I; Becchi, M; Cozzone, AJ; Mateos, LM; Kremer, L; Gil, JA; Molle, V				Fiuza, Maria; Canova, Marc J.; Zanella-Cleon, Isabelle; Becchi, Michel; Cozzone, Alain J.; Mateos, Luis M.; Kremer, Laurent; Gil, Jose A.; Molle, Virginie			From the characterization of the four serine/threonine protein kinases (PknA/B/G/L) of Corynebacterium glutamicum toward the role of PknA and PknB in cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; STREPTOMYCES-COELICOLOR A3(2); MYCOBACTERIUM-TUBERCULOSIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; CORYNEFORM BACTERIA; BACILLUS-SUBTILIS; PHOSPHORYLATION SITES; SER/THR KINASE; POLAR GROWTH	Corynebacterium glutamicum contains four serine/threonine protein kinases (STPKs) named PknA, PknB, PknG, and PknL. Here we present the first biochemical and comparative analysis of all four C. glutamicum STPKs and investigate their potential role in cell shape control and peptidoglycan synthesis during cell division. In vitro assays demonstrated that, except for PknG, all STPKs exhibited autokinase activity. We provide evidence that activation of PknG is part of a phosphorylation cascade mechanism that relies on PknA activity. Following phosphorylation by PknA, PknG could transphosphorylate its specific substrate OdhI in vitro. A mass spectrometry profiling approach was also used to identify the phosphoresidues in all four STPKs. The results indicate that the nature, number, and localization of the phosphoacceptors varies from one kinase to the other. Disruption of either pknL or pknG in C. glutamicum resulted in viable mutants presenting a typical cell morphology and growth rate. In contrast, we failed to obtain null mutants of pknA or pknB, supporting the notion that these genes are essential. Conditional mutants of pknA or pknB were therefore created, leading to partial depletion of PknA or PknB. This resulted in elongated cells, indicative of a cell division defect. Moreover, overexpression of PknA or PknB in C. glutamicum resulted in a lack of apical growth and therefore a coccoid- like morphology. These findings indicate that pknA and pknB are key players in signal transduction pathways for the regulation of the cell shape and both are essential for sustaining corynebacterial growth.	[Canova, Marc J.; Zanella-Cleon, Isabelle; Becchi, Michel; Cozzone, Alain J.; Molle, Virginie] Univ Lyon 1, CNRS, IFR BioSci 128, UMR 5086,Inst Biol & Chim Prot, F-69367 Lyon 07, France; [Fiuza, Maria; Mateos, Luis M.; Gil, Jose A.] Univ Leon, Fac Biol, Area Microbiol, Dept Biol Mol, E-24071 Leon, Spain; [Kremer, Laurent] Univ Montpellier 2, Lab Dynam Interact Membranaires Normales & Pathol, CNRS, UMR 5235, F-34095 Montpellier 05, France; [Kremer, Laurent] Univ Montpellier 1, Lab Dynam Interact Membranaires Normales & Pathol, CNRS, UMR 5235, F-34095 Montpellier 05, France; [Kremer, Laurent] DIMNP, INSERM, F-34095 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universidad de Leon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Molle, V (corresponding author), Univ Lyon 1, CNRS, IFR BioSci 128, UMR 5086,Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	vmolle@ibcp.fr	Gil, José A./L-1800-2019; MOLLE, Virginie/D-4050-2019; MATEOS DELGADO, LUIS MARIANO/ABB-8848-2021; Kremer, Laurent/M-4935-2017; Gil, Jose A./C-3902-2009	Gil, José A./0000-0002-5069-2637; MOLLE, Virginie/0000-0002-6573-3411; MATEOS DELGADO, LUIS MARIANO/0000-0001-7763-582X; Kremer, Laurent/0000-0002-6604-4458; Gil, Jose A./0000-0002-5069-2637				Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Bendt AK, 2003, PROTEOMICS, V3, P1637, DOI 10.1002/pmic.200300494; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x; Canova MJ, 2008, PROTEOMICS, V8, P521, DOI 10.1002/pmic.200700442; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; Cohen-Gonsaud M, 2004, J BIOMOL NMR, V30, P373, DOI 10.1007/s10858-004-3466-x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cowley S, 2004, MOL MICROBIOL, V52, P1691, DOI 10.1111/j.1365-2958.2004.04085.x; Daniel RA, 2000, MOL MICROBIOL, V35, P299, DOI 10.1046/j.1365-2958.2000.01724.x; Daniel RA, 2003, CELL, V113, P767, DOI 10.1016/S0092-8674(03)00421-5; Dasgupta A, 2006, MICROBIOL-SGM, V152, P493, DOI 10.1099/mic.0.28630-0; Duran R, 2005, BIOCHEM BIOPH RES CO, V333, P858, DOI 10.1016/j.bbrc.2005.05.173; Fadda D, 2007, J BACTERIOL, V189, P1288, DOI 10.1128/JB.01168-06; Fernandez P, 2006, J BACTERIOL, V188, P7778, DOI 10.1128/JB.00963-06; Flardh K, 2003, MOL MICROBIOL, V49, P1523, DOI 10.1046/j.1365-2958.2003.03660.x; Grangeasse C, 2007, TRENDS BIOCHEM SCI, V32, P86, DOI 10.1016/j.tibs.2006.12.004; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hanlon WA, 1997, MOL MICROBIOL, V23, P459, DOI 10.1046/j.1365-2958.1997.d01-1871.x; Hermann T, 2003, J BIOTECHNOL, V104, P155, DOI 10.1016/S0168-1656(03)00149-4; Hett EC, 2008, MICROBIOL MOL BIOL R, V72, P126, DOI 10.1128/MMBR.00028-07; JAGER W, 1992, J BACTERIOL, V174, P5462; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kang CM, 2008, MICROBIOL-SGM, V154, P725, DOI 10.1099/mic.0.2007/014076-0; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Karczmarek A, 2007, MOL MICROBIOL, V65, P51, DOI 10.1111/j.1365-2958.2007.05777.x; Kieser T, 2000, PRACTICAL STREPTOMYC, P161; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Letek M, 2006, J BACTERIOL, V188, P409, DOI 10.1128/JB.188.2.409-423.2006; Letek M, 2008, J BACTERIOL, V190, P3283, DOI 10.1128/JB.01934-07; Letek M, 2007, INT MICROBIOL, V10, P271, DOI 10.2436/20.1501.01.36; Mateos LM, 1996, J BACTERIOL, V178, P5768, DOI 10.1128/jb.178.19.5768-5775.1996; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Molle V, 2003, BIOCHEM BIOPH RES CO, V308, P820, DOI 10.1016/S0006-291X(03)01476-1; Molle V, 2006, J BIOL CHEM, V281, P30094, DOI 10.1074/jbc.M601691200; Molle V, 2006, PROTEOMICS, V6, P3754, DOI 10.1002/pmic.200500900; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; Narayan A, 2007, PHYSIOL GENOMICS, V29, P66, DOI 10.1152/physiolgenomics.00221.2006; Nariya H, 2005, MOL MICROBIOL, V58, P367, DOI 10.1111/j.1365-2958.2005.04826.x; Niebisch A, 2006, J BIOL CHEM, V281, P12300, DOI 10.1074/jbc.M512515200; Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603; Peirs P, 1997, EUR J BIOCHEM, V244, P604, DOI 10.1111/j.1432-1033.1997.00604.x; Ramos A, 2005, MICROBIOL-SGM, V151, P2563, DOI 10.1099/mic.0.28036-0; SANTAMARIA RI, 1985, J BACTERIOL, V162, P463, DOI 10.1128/JB.162.1.463-467.1985; SCHAFER A, 1990, J BACTERIOL, V172, P1663, DOI 10.1128/jb.172.3.1663-1666.1990; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Scheffers DJ, 2004, MOL MICROBIOL, V51, P749, DOI 10.1046/j.1365-2958.2003.03854.x; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Shirai T, 2005, METAB ENG, V7, P59, DOI 10.1016/j.ymben.2004.10.001; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tauch A, 2005, J BACTERIOL, V187, P4671, DOI 10.1128/JB.187.13.4671-4682.2005; Thakur M, 2006, J BIOL CHEM, V281, P40107, DOI 10.1074/jbc.M607216200; Valbuena N, 2007, MOL MICROBIOL, V66, P643, DOI 10.1111/j.1365-2958.2007.05943.x; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Wehenkel A, 2006, FEBS LETT, V580, P3018, DOI 10.1016/j.febslet.2006.04.046; Yeats C, 2002, TRENDS BIOCHEM SCI, V27, P438, DOI 10.1016/S0968-0004(02)02164-3; Young KD, 2006, MICROBIOL MOL BIOL R, V70, P660, DOI 10.1128/MMBR.00001-06; Zhang WD, 1996, MOL MICROBIOL, V20, P435, DOI 10.1111/j.1365-2958.1996.tb02630.x; ZHANG WD, 1992, J BACTERIOL, V174, P5450, DOI 10.1128/JB.174.16.5450-5453.1992	64	80	81	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18099	18112		10.1074/jbc.M802615200	http://dx.doi.org/10.1074/jbc.M802615200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18442973	hybrid, Green Published			2022-12-25	WOS:000256949200039
J	Li, HT; Cui, HM; Kundu, TK; Alzawahra, W; Zweier, JL				Li, Haitao; Cui, Hongmei; Kundu, Tapan Kumar; Alzawahra, Wael; Zweier, Jay L.			Nitric oxide production from nitrite occurs primarily in tissues not in the blood - Critical role of xanthine oxidase and aldehyde oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HYPOXIC VASODILATION; PRIMARY CARDIAC FIBROBLASTS; BIOLOGICAL TISSUES; POSTISCHEMIC HEART; REDUCTASE-ACTIVITY; SYNTHASE ACTIVITY; ANOXIC TISSUES; CDNA CLONING; GUINEA-PIGS; RED-CELL	Recent studies have shown that nitrite is an important storage form and source of NO in biological systems. Controversy remains, however, regarding whether NO formation from nitrite occurs primarily in tissues or in blood. Questions also remain regarding the mechanism, magnitude, and contributions of several alternative pathways of nitrite-dependent NO generation in biological systems. To characterize the mechanism and magnitude of NO generation from nitrite, electron paramagnetic resonance spectroscopy, chemiluminescence NO analyzer, and immunoassays of cGMP formation were performed. The addition of nitrite triggered a large amount of NO generation in tissues such as heart and liver, but only trace NO production in blood. Carbon monoxide increased NO release from blood, suggesting that hemoglobin acts to scavenge NO not to generate it. Administration of the xanthine oxidase (XO) inhibitor oxypurinol or aldehyde oxidase (AO) inhibitor raloxifene significantly decreased NO generation from nitrite in heart or liver. NO formation rates increased dramatically with decreasing pH or with decreased oxygen tension. Isolated enzyme studies further confirm that XO and AO, but not hemoglobin, are critical nitrite reductases. Overall, NO generation from nitrite mainly occurs in tissues not in the blood, with XO and AO playing critical roles in nitrite reduction, and this process is regulated by pH, oxygen tension, nitrite, and reducing substrate concentrations.	Ohio State Univ, Coll Med, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA; Davis Heart & Lung Res Inst, Ctr Biomed EPR Spect & Imaging, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Li, HT (corresponding author), 110 G Davis Heart & Lung Res Inst, 473 West 12th Ave, Columbus, OH 43210 USA.	haitao.li@osumc.edu; jay.zweier@osumc.edu			NHLBI NIH HHS [HL 65608, HL 38324, HL 63744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R01HL038324, R29HL038324, R01HL063744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beedham C, 1987, Prog Med Chem, V24, P85, DOI 10.1016/S0079-6468(08)70420-X; BEEDHAM C, 1987, EUR J DRUG METAB PH, V12, P303, DOI 10.1007/BF03189918; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; Calzi ML, 1995, J BIOL CHEM, V270, P31037, DOI 10.1074/jbc.270.52.31037; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; DUTHU GS, 1979, DRUG METAB DISPOS, V7, P263; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; Gladwin MT, 2005, AM J RESP CELL MOL, V32, P363, DOI 10.1165/rcmb.F294; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Grubina R, 2007, J BIOL CHEM, V282, P12916, DOI 10.1074/jbc.M700546200; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Keszler A, 2006, FREE RADICAL BIO MED, V40, P507, DOI 10.1016/j.freeradbiomed.2005.09.005; KINGENBERG M, 1960, BEDEUTUNG FREIEN NUC, V2, P82; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Kundu TK, 2007, ARCH BIOCHEM BIOPHYS, V460, P113, DOI 10.1016/j.abb.2006.12.032; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Li HT, 2004, J BIOL CHEM, V279, P16939, DOI 10.1074/jbc.M314336200; Li HT, 2006, J BIOL CHEM, V281, P12546, DOI 10.1074/jbc.M511803200; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Liu XP, 2007, J BIOL CHEM, V282, P8831, DOI 10.1074/jbc.M611684200; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; Maia L, 2002, ARCH BIOCHEM BIOPHYS, V400, P48, DOI 10.1006/abbi.2002.2781; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Moriwaki Y, 1996, HISTOCHEM CELL BIOL, V105, P71, DOI 10.1007/BF01450880; MUXFELDT M, 1987, BASIC RES CARDIOL, V82, P486, DOI 10.1007/BF01907096; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; RAIKHMAN L M, 1971, Biofizika, V16, P1135; REISS PD, 1984, ANAL BIOCHEM, V140, P162, DOI 10.1016/0003-2697(84)90148-9; Robinson JM, 2005, AM J RESP CELL MOL, V32, P257, DOI 10.1165/rcmb.F292; Roy S, 2003, J BIOL CHEM, V278, P47129, DOI 10.1074/jbc.M308703200; Roy S, 2003, CIRC RES, V92, P264, DOI 10.1161/01.RES.0000056770.30922.E6; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sarnesto A, 1996, LAB INVEST, V74, P48; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Wink DA, 2003, NAT MED, V9, P1460, DOI 10.1038/nm1203-1460; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	55	214	216	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17855	17863		10.1074/jbc.M801785200	http://dx.doi.org/10.1074/jbc.M801785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18424432	Green Published, hybrid			2022-12-25	WOS:000256949200013
J	Patino-Lopez, G; Dong, XY; Ben-Aissa, K; Bernot, KM; Itoh, T; Fukuda, M; Kruhlak, MJ; Samelson, LE; Shaw, S				Patino-Lopez, Genaro; Dong, Xiaoyun; Ben-Aissa, Khadija; Bernot, Kelsie M.; Itoh, Takashi; Fukuda, Mitsunori; Kruhlak, Michael J.; Samelson, Lawrence E.; Shaw, Stephen			Rab35 and its GAP EPI64C in T cells regulate receptor recycling and immunological synapse formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; DOMAIN; IDENTIFICATION; COSTIMULATION; BINDING; TCR; REORGANIZATION; ENDOCYTOSIS; DYNAMICS; MUTANTS	Upon antigen recognition, T-cell receptor (TCR/CD3) and other signaling molecules become enriched in a specialized contact site between the T cell and antigen-presenting cell, i.e. the immunological synapse (IS). Enrichment occurs via mechanisms that include polarized secretion from recycling endosomes, but the Rabs and RabGAPs that regulate this are unknown. EPI64C (TBC1D10C) is an uncharacterized candidate RabGAP we identified by mass spectrometry as abundant in human peripheral blood T cells that is preferentially expressed in hematopoietic cells. EPI64C is a Rab35-GAP based both on in vitro Rab35-specific GAP activity and findings in transfection assays. EPI64C and Rab35 dominant negative (DN) constructs each impaired transferrin export from a recycling pathway in Jurkat T-cells and induced large vacuoles marked by transferrin receptor, TCR, and SNAREs implicated in TCR-polarized secretion. Rab35 localized to the plasma membrane and to intracellular vesicles where it substantially colocalized with TfR and with TCR. Rab35 was strongly recruited to the IS. Conjugate formation was impaired by transfection with Rab35-DN or EPI64C and by EPI64C knock down. TCR enrichment at the IS was impaired by Rab35-DN. Thus, EPI64C and Rab35 regulate a recycling pathway in T cells and contribute to IS formation, most likely by participating in TCR transport to the IS.	[Patino-Lopez, Genaro; Dong, Xiaoyun; Ben-Aissa, Khadija; Kruhlak, Michael J.; Shaw, Stephen] NIH, NCI, Expt Immunol Branch, Bethesda, MD 20892 USA; [Bernot, Kelsie M.; Samelson, Lawrence E.] NIH, NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; [Itoh, Takashi; Fukuda, Mitsunori] RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; [Itoh, Takashi; Fukuda, Mitsunori] Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Lab Membrane Trafficking Mech, Sendai, Miyagi 9808578, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); RIKEN; Tohoku University	Shaw, S (corresponding author), NIH, NCI, Expt Immunol Branch, Bldg 10,Rm 4B36,10 Ctr Dr,MSC 1360, Bethesda, MD 20892 USA.	sshaw@nih.gov	Patino-Lopez, Genaro/O-3484-2018; Patiño López, Genaro/GQI-4414-2022; Fukuda, MItsunori/I-1511-2015	Patino-Lopez, Genaro/0000-0002-8716-722X; Fukuda, MItsunori/0000-0002-8620-5853	NATIONAL CANCER INSTITUTE [ZICBC009255, Z01BC010304, ZIABC009257, ZIABC010993, Z01BC009255, ZICBC010915, Z01BC010993, Z01BC010915, ZIABC010304, Z01BC009257] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arkhipov SN, 2006, BIOPHYS J, V91, P4306, DOI 10.1529/biophysj.106.083204; Band AM, 2002, FEBS LETT, V531, P513, DOI 10.1016/S0014-5793(02)03605-0; Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Cemerski S, 2006, CURR OPIN IMMUNOL, V18, P298, DOI 10.1016/j.coi.2006.03.011; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; Dustin ML, 2005, SEMIN IMMUNOL, V17, P400, DOI 10.1016/j.smim.2005.09.002; Favier B, 2001, INT IMMUNOL, V13, P1525, DOI 10.1093/intimm/13.12.1525; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fuchs E, 2007, J CELL BIOL, V177, P1133, DOI 10.1083/jcb.200612068; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; Goody RS, 2005, CELL MOL LIFE SCI, V62, P1657, DOI 10.1007/s00018-005-4486-8; Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103; Hanono A, 2006, J CELL BIOL, V175, P803, DOI 10.1083/jcb.200604046; Heo WD, 2003, CELL, V113, P315; Huang YP, 2007, J CELL SCI, V120, P723, DOI 10.1242/jcs.000786; Itoh T, 2006, J BIOL CHEM, V281, P31823, DOI 10.1074/jbc.M603808200; Itoh T, 2006, GENES CELLS, V11, P1023, DOI 10.1111/j.1365-2443.2006.00997.x; Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x; Kouranti I, 2006, CURR BIOL, V16, P1719, DOI 10.1016/j.cub.2006.07.020; Kuroda TS, 2005, METHOD ENZYMOL, V403, P431, DOI 10.1016/S0076-6879(05)03038-7; Le Roy C, 2005, DEV CELL, V9, P167, DOI 10.1016/j.devcel.2005.07.007; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Matsumoto Y, 2004, FEBS LETT, V572, P135, DOI 10.1016/j.febslet.2004.07.023; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; Pan XJ, 2006, NATURE, V442, P303, DOI 10.1038/nature04847; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Saito T, 2006, CURR OPIN IMMUNOL, V18, P305, DOI 10.1016/j.coi.2006.03.014; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tskvitaria-Fuller I, 2003, J IMMUNOL, V171, P2287, DOI 10.4049/jimmunol.171.5.2287; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WAHL SM, 1984, CELL IMMUNOL, V85, P384, DOI 10.1016/0008-8749(84)90252-1; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang XM, 2005, BIOCHEM BIOPH RES CO, V335, P154, DOI 10.1016/j.bbrc.2005.07.070	40	112	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18323	18330		10.1074/jbc.M800056200	http://dx.doi.org/10.1074/jbc.M800056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450757	hybrid, Green Published			2022-12-25	WOS:000256949200060
J	Strehl, B; Textoris-Taube, K; Jakel, S; Voigt, A; Henklein, P; Steinhoff, U; Kloetzel, PM; Kuckelkorn, U				Strehl, Britta; Textoris-Taube, Kathrin; Jakel, Sandra; Voigt, Antje; Henklein, Peter; Steinhoff, Ulrich; Kloetzel, Peter-Michael; Kuckelkorn, Ulrike			Antitopes define preferential proteasomal cleavage site usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CD8(+) T-CELLS; INTERFERON-GAMMA; ANTIGENIC PEPTIDE; 20S PROTEASOME; IMMUNOPROTEASOMES; EPITOPE; PA28-ALPHA/BETA; GENERATION; SUBUNITS	Protein degradation by proteasomes is a major source of peptides presented by major histocompatibility v complex class I proteins. Importantly, interferon gamma-induced immunoproteasomes in many cases strongly enhance the generation of antigenic peptides both in vitro and in vivo. Whether this is due to enhanced substrate turnover or to a change in proteasomal cleavage specificity is, however, largely unresolved. To overcome the problems of peptide quantification inherent to mass spectrometry, we introduced the "antitope" as substrate-specific internal standard. The antitope is a non-functional peptide that is generated by proteasomal cleavage within the epitope, resulting in partial overlaps with the functional epitope. Using antitopes as internal standards we demonstrate that the observed enhanced immunoproteasome-dependent presentation of the bacterial listeriolysin OT-cell epitope LLO(296-304) is indeed due to altered cleavage preferences. This method is also applicable to other major histocompatibility class I epitopes as is shown for two potential epitopes derived from Coxsackievirus.	[Steinhoff, Ulrich] Max Planck Inst Infekt Biol, D-10117 Berlin, Germany; [Voigt, Antje] Charite Univ Med Berlin, Klin Kardiol & Pulmol, D-10117 Berlin, Germany; [Strehl, Britta; Textoris-Taube, Kathrin; Jakel, Sandra; Henklein, Peter; Kloetzel, Peter-Michael; Kuckelkorn, Ulrike] Charite Univ Med Berlin, Inst Biochem, D-10117 Berlin, Germany	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kloetzel, PM (corresponding author), Monbijoustr 2, D-10117 Berlin, Germany.	p-m.kloetzel@charite.de	Beling, Antje/AAW-5380-2020; Voigt, Antje/E-4332-2013	Beling, Antje/0000-0002-1826-5248; Steinhoff, Ulrich/0000-0003-2141-7756; Kuckelkorn, Ulrike/0000-0002-3085-9161				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Basler M, 2004, J IMMUNOL, V173, P3925, DOI 10.4049/jimmunol.173.6.3925; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Chen WS, 2001, J EXP MED, V193, P1319, DOI 10.1084/jem.193.11.1319; Deol P, 2007, J IMMUNOL, V178, P7557, DOI 10.4049/jimmunol.178.12.7557; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kuckelkorn U, 2002, EUR J IMMUNOL, V32, P1368, DOI 10.1002/1521-4141(200205)32:5<1368::AID-IMMU1368>3.0.CO;2-Z; Kuckelkorn U, 2002, J EXP MED, V195, P983, DOI 10.1084/jem.20011199; Levy F, 2002, J IMMUNOL, V169, P4161, DOI 10.4049/jimmunol.169.8.4161; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Palmowski MJ, 2006, J IMMUNOL, V177, P983, DOI 10.4049/jimmunol.177.2.983; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Schultz ES, 2002, J EXP MED, V195, P391, DOI 10.1084/jem.20011974; Schwarz K, 2000, J IMMUNOL, V165, P768, DOI 10.4049/jimmunol.165.2.768; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; Sijts AJAM, 2000, J EXP MED, V191, P503, DOI 10.1084/jem.191.3.503; Sijts AJAM, 2000, J IMMUNOL, V164, P4500, DOI 10.4049/jimmunol.164.9.4500; Strehl B, 2005, IMMUNOL REV, V207, P19, DOI 10.1111/j.0105-2896.2005.00308.x; Strehl B, 2006, J IMMUNOL, V177, P6238, DOI 10.4049/jimmunol.177.9.6238; Textoris-Taube K, 2007, J BIOL CHEM, V282, P12749, DOI 10.1074/jbc.M611644200; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015	27	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17891	17897		10.1074/jbc.M710042200	http://dx.doi.org/10.1074/jbc.M710042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18424434	hybrid			2022-12-25	WOS:000256949200017
J	Qiu, LX; Wu, XC; Chau, JFL; Szeto, IYY; Tam, WY; Guo, ZS; Chung, SK; Oates, PJ; Chung, SSM; Yang, JY				Qiu, Longxin; Wu, Xiaochun; Chau, Jenny F. L.; Szeto, Irene Y. Y.; Tam, Wing Yip; Guo, Zongsheng; Chung, Sookja K.; Oates, Peter J.; Chung, Stephen S. M.; Yang, James Y.			Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PPAR-ALPHA; POLYOL PATHWAY; HIGH GLUCOSE; METABOLISM; EXPRESSION; IDENTIFICATION; INHIBITION; MODULATION; PLASMA	Aldose reductase (AR) is implicated in the development of a number of diabetic complications, but the underlying mechanisms remain to be fully elucidated. We performed this study to determine whether and how AR might influence hepatic peroxisome proliferator-activated receptor alpha (PPAR alpha) activity and lipid metabolism. Our results in mouse hepatocyte AML12 cells show that AR overexpression caused strong suppression of PPAR alpha/delta activity (74%, p < 0.001) together with significant down-regulation of mRNA expression for acetyl-CoA oxidase and carnitine palmitoyltransferase-1. These suppressive effects were attenuated by the selective AR inhibitor zopolrestat. Furthermore, AR overexpression greatly increased the levels of phosphorylated PPAR alpha and ERK1/2. Moreover, AR-induced suppression of PPAR alpha activity was attenuated by treatment with an inhibitor for ERK1/2 but not that for phosphoinositide 3-kinase, p38, or JNK. Importantly, similar effects were observed for cells exposed to 25 mM glucose. In streptozotocin-diabetic mice, AR inhibitor treatment or genetic deficiency of AR resulted in significant dephosphorylation of both PPAR alpha and ERK1/2. With the dephosphorylation of PPAR alpha, hepatic acetyl-CoA oxidase and apolipoprotein C-III mRNA expression was greatly affected and that was associated with substantial reductions in blood triglyceride and nonesterified fatty acid levels. These data indicate that AR plays an important role in the regulation of hepatic PPAR alpha phosphorylation and activity and lipid homeostasis. A significant portion of the AR-induced modulation is achieved through ERK1/2 signaling.	[Wu, Xiaochun; Chau, Jenny F. L.; Szeto, Irene Y. Y.; Tam, Wing Yip; Chung, Sookja K.; Chung, Stephen S. M.; Yang, James Y.] Univ Hong Kong, Dept Physiol, Pokfulam, Hong Kong, Peoples R China; [Wu, Xiaochun; Chau, Jenny F. L.; Szeto, Irene Y. Y.; Tam, Wing Yip; Chung, Sookja K.; Chung, Stephen S. M.; Yang, James Y.] Univ Hong Kong, Inst Mol Biol, Pokfulam, Hong Kong, Peoples R China; [Qiu, Longxin; Guo, Zongsheng; Yang, James Y.] Xiamen Univ, Sch Life Sci, Minist Educ, Key Lab Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China; [Qiu, Longxin; Guo, Zongsheng; Yang, James Y.] Xiamen Univ, Sch Life Sci, Dept Biomed Sci, Xiamen 361005, Peoples R China; [Qiu, Longxin] Longyan Univ, Sch Life Sci, Longyan 364000, Peoples R China; [Oates, Peter J.] Pfizer Inc, Global Res & Dev, Dept Cardiovasc Metab & Endocrine Dis, Groton, CT 06340 USA	University of Hong Kong; University of Hong Kong; Xiamen University; Xiamen University; Longyan University; Pfizer	Chung, SSM (corresponding author), Univ Hong Kong, Dept Physiol, Pokfulam, Hong Kong, Peoples R China.	smchung@hkucc.hku.hk; jyy6127@yahoo.com	Guo, Zong Sheng/H-3098-2019	Guo, Zong Sheng/0000-0002-4624-9907				Auwerx J, 1996, ATHEROSCLEROSIS, V124, pS29, DOI 10.1016/0021-9150(96)05854-6; Balendiran GK, 2005, BIOCHEM PHARMACOL, V70, P1653, DOI 10.1016/j.bcp.2005.06.029; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Blanquart C, 2004, MOL ENDOCRINOL, V18, P1906, DOI 10.1210/me.2003-0327; Brown KE, 2005, HISTOL HISTOPATHOL, V20, P429, DOI 10.14670/HH-20.429; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018; Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429; CHENG HM, 1986, METABOLISM, V35, P10, DOI 10.1016/0026-0495(86)90180-0; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; CLEMENTS RS, 1969, BIOCHEM BIOPH RES CO, V37, P347, DOI 10.1016/0006-291X(69)90741-4; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Duval C, 2007, BBA-MOL CELL BIOL L, V1771, P961, DOI 10.1016/j.bbalip.2007.05.003; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Gray JP, 2005, BIOCHEMISTRY-US, V44, P10313, DOI 10.1021/bi050721g; Haneda M, 2001, AM J KIDNEY DIS, V38, pS178, DOI 10.1053/ajkd.2001.27438; HERS HG, 1956, BIOCHIM BIOPHYS ACTA, V22, P202, DOI 10.1016/0006-3002(56)90247-5; Ho HTB, 2000, MOL CELL BIOL, V20, P5840, DOI 10.1128/MCB.20.16.5840-5846.2000; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; Julius UA, 2007, DIABETES, V56, pA233; KALLAISANFACON M, 1985, Patent No. 4492706; Kawamura I, 1999, ANTICANCER RES, V19, P341; Kawasaki T, 2002, DIABETES CARE, V25, P353, DOI 10.2337/diacare.25.2.353; Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Klemin S, 2006, J ENZYM INHIB MED CH, V21, P569, DOI 10.1080/14756360600720887; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LEE FK, 1995, EUR J BIOCHEM, V230, P1059, DOI 10.1111/j.1432-1033.1995.tb20656.x; Lee KWY, 2001, ANTI-CANCER DRUG, V12, P129, DOI 10.1097/00001813-200102000-00005; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MARKUS HB, 1983, BIOCHEM MED METAB B, V29, P31, DOI 10.1016/0006-2944(83)90051-0; MORRISON AD, 1970, BIOCHEM BIOPH RES CO, V40, P199, DOI 10.1016/0006-291X(70)91066-1; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Oates PJ, 2008, CURR DRUG TARGETS, V9, P14, DOI 10.2174/138945008783431781; Oates PJ, 2002, INT REV NEUROBIOL, V50, P325; PETERSON MJ, 1995, Patent No. 5391551; POLI T, 1985, ACTA DIABETOL LAT, V22, P17, DOI 10.1007/BF02591088; Ramana KV, 2007, ENDOCRINOLOGY, V148, P4371, DOI 10.1210/en.2007-0512; Roglans N, 2007, HEPATOLOGY, V45, P778, DOI 10.1002/hep.21499; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; STEINERSTAUCH P, 1989, BIOCHEM BIOPH RES CO, V164, P1130, DOI 10.1016/0006-291X(89)91786-5; Takahashi M, 1996, JPN J CANCER RES, V87, P337, DOI 10.1111/j.1349-7006.1996.tb00227.x; Tamasi V, 2008, MOL PHARMACOL, V73, P968, DOI 10.1124/mol.107.036780; Vikramadithyan RK, 2005, J CLIN INVEST, V115, P2434, DOI 10.1172/JCI24819; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Wirth H P, 1985, Prog Clin Biol Res, V174, P231; Yaacob NS, 2001, TOXICOL LETT, V125, P133, DOI 10.1016/S0378-4274(01)00433-7; Yang JY, 2006, AM J PHYSIOL-RENAL, V291, pF186, DOI 10.1152/ajprenal.00506.2005; Yoshii H, 2001, DIABETES RES CLIN PR, V51, P115, DOI 10.1016/S0168-8227(00)00221-7; Zeindl-Eberhart E, 2004, HEPATOLOGY, V39, P540, DOI 10.1002/hep.20060	52	37	37	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17175	17183		10.1074/jbc.M801791200	http://dx.doi.org/10.1074/jbc.M801791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445591	hybrid			2022-12-25	WOS:000256720600026
J	Li, L; Norrelykke, SF; Cox, EC				Li, Liang; Norrelykke, Simon F.; Cox, Edward C.			Persistent Cell Motion in the Absence of External Signals: A Search Strategy for Eukaryotic Cells	PLOS ONE			English	Article								Background: Eukaryotic cells are large enough to detect signals and then orient to them by differentiating the signal strength across the length and breadth of the cell. Amoebae, fibroblasts, neutrophils and growth cones all behave in this way. Little is known however about cell motion and searching behavior in the absence of a signal. Is individual cell motion best characterized as a random walk? Do individual cells have a search strategy when they are beyond the range of the signal they would otherwise move toward? Here we ask if single, isolated, Dictyostelium and Polysphondylium amoebae bias their motion in the absence of external cues. Methodology: We placed single well-isolated Dictyostelium and Polysphondylium cells on a nutrient-free agar surface and followed them at 10 sec intervals for similar to 10 hr, then analyzed their motion with respect to velocity, turning angle, persistence length, and persistence time, comparing the results to the expectation for a variety of different types of random motion. Conclusions: We find that amoeboid behavior is well described by a special kind of random motion: Amoebae show a long persistence time (similar to 10 min) beyond which they start to lose their direction; they move forward in a zig-zag manner; and they make turns every 1-2 min on average. They bias their motion by remembering the last turn and turning away from it. Interpreting the motion as consisting of runs and turns, the duration of a run and the amplitude of a turn are both found to be exponentially distributed. We show that this behavior greatly improves their chances of finding a target relative to performing a random walk. We believe that other eukaryotic cells may employ a strategy similar to Dictyostelium when seeking conditions or signal sources not yet within range of their detection system.	[Li, Liang] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; [Norrelykke, Simon F.; Cox, Edward C.] Princeton Univ, Dept Mol Biol, Princeton, NJ USA	Princeton University; Princeton University	Li, L (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	ecox@princeton.edu	Nørrelykke, Simon F/M-4722-2014; Nørrelykke, Simon/C-9405-2009	Nørrelykke, Simon F/0000-0001-8302-526X; 	NIH; Burroughs Welcome [Fellowship]; NIH/NIGMS [P50 071508]; Carlsberg Foundation; Lundbeck Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Welcome(Burroughs Wellcome Fund); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Carlsberg Foundation(Carlsberg Foundation); Lundbeck Foundation(Lundbeckfonden)	This work was supported by the NIH, a Burroughs Welcome Fellowship and a stipend from the NIH/NIGMS (P50 071508) to L.L., and support from the Carlsberg Foundation and the Lundbeck Foundation to S.F.N. There is no participation by funding agencies.	Andrew N, 2007, NAT CELL BIOL, V9, P193, DOI 10.1038/ncb1536; Arrieumerlou C, 2005, DEV CELL, V8, P215, DOI 10.1016/j.devcel.2004.12.007; Bartumeus F, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.097901; Benichou O, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.020102; Benichou O, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.198101; Berg-Sorensen K, 2004, REV SCI INSTRUM, V75, P594, DOI 10.1063/1.1645654; Boyer D, 2008, ARXIV08021762V1; COX EC, 1990, P NATL ACAD SCI USA, V87, P8247, DOI 10.1073/pnas.87.21.8247; Czirok A, 1998, PHYS REV LETT, V81, P3038, DOI 10.1103/PhysRevLett.81.3038; Edwards AM, 2007, NATURE, V449, P1044, DOI 10.1038/nature06199; Erdmann U, 2000, EUR PHYS J B, V15, P105, DOI 10.1007/s100510051104; Flanagan JG, 2006, CURR OPIN NEUROBIOL, V16, P59, DOI 10.1016/j.conb.2006.01.010; Garcia R, 2007, MATH BIOSCI, V207, P165, DOI 10.1016/j.mbs.2006.11.014; HARTMAN RS, 1994, BIOPHYS J, V67, P2535, DOI 10.1016/S0006-3495(94)80743-X; Kramer DL, 2001, AM ZOOL, V41, P137, DOI 10.1668/0003-1569(2001)041[0137:TBEOIL]2.0.CO;2; OBRIEN WJ, 1990, AM SCI, V78, P152; POTEL MJ, 1979, J CELL SCI, V36, P281; Raposo EP, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.240601; Rubinstein M, 2003, POLYM PHYS; Santos MC, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.046143; Schaap P, 2006, SCIENCE, V314, P661, DOI 10.1126/science.1130670; Shlesinger MF, 2006, NATURE, V443, P281, DOI 10.1038/443281a; UHLENBECK GE, 1930, PHYS REV, V36; Viswanathan GM, 1999, NATURE, V401, P911, DOI 10.1038/44831; Willard SS, 2006, EUR J CELL BIOL, V85, P897, DOI 10.1016/j.ejcb.2006.06.003; Xu JS, 2007, P NATL ACAD SCI USA, V104, P9296, DOI 10.1073/pnas.0703153104	26	187	188	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2093	10.1371/journal.pone.0002093	http://dx.doi.org/10.1371/journal.pone.0002093			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461173	Green Published, Green Submitted, gold			2022-12-25	WOS:000261642400015
J	Ward, RM; Erdin, S; Tran, TA; Kristensen, DM; Lisewski, AM; Lichtarge, O				Ward, R. Matthew; Erdin, Serkan; Tran, Tuan A.; Kristensen, David M.; Lisewski, Andreas Martin; Lichtarge, Olivier			De-Orphaning the Structural Proteome through Reciprocal Comparison of Evolutionarily Important Structural Features	PLOS ONE			English	Article							3D COORDINATE TEMPLATES; FUNCTIONAL SITES; FUNCTION PREDICTION; SECONDARY-STRUCTURE; FAMILY RESOURCE; GENOMICS; SEQUENCE; DATABASE; ANNOTATION; PROTEINS	Function prediction frequently relies on comparing genes or gene products to search for relevant similarities. Because the number of protein structures with unknown function is mushrooming, however, we asked here whether such comparisons could be improved by focusing narrowly on the key functional features of protein structures, as defined by the Evolutionary Trace (ET). Therefore a series of algorithms was built to (a) extract local motifs (3D templates) from protein structures based on ET ranking of residue importance; (b) to assess their geometric and evolutionary similarity to other structures; and (c) to transfer enzyme annotation whenever a plurality was reached across matches. Whereas a prototype had only been 80% accurate and was not scalable, here a speedy new matching algorithm enabled large-scale searches for reciprocal matches and thus raised annotation specificity to 100% in both positive and negative controls of 49 enzymes and 50 non-enzymes, respectively-in one case even identifying an annotation error-while maintaining sensitivity (similar to 60%). Critically, this Evolutionary Trace Annotation (ETA) pipeline requires no prior knowledge of functional mechanisms. It could thus be applied in a large-scale retrospective study of 1218 structural genomics enzymes and reached 92% accuracy. Likewise, it was applied to all 2935 unannotated structural genomics proteins and predicted enzymatic functions in 320 cases: 258 on first pass and 62 more on second pass. Controls and initial analyses suggest that these predictions are reliable. Thus the large-scale evolutionary integration of sequence-structure-function data, here through reciprocal identification of local, functionally important structural features, may contribute significantly to de-orphaning the structural proteome.	[Ward, R. Matthew; Erdin, Serkan; Tran, Tuan A.; Kristensen, David M.; Lisewski, Andreas Martin; Lichtarge, Olivier] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Ward, R. Matthew; Kristensen, David M.; Lichtarge, Olivier] Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Ward, RM (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	lichtarge@bcm.edu	Erdin, Serkan/B-4988-2008; Erdin, Serkan/AAE-4288-2019	Erdin, Serkan/0000-0001-6587-2625; Tran, Tuan/0000-0003-3137-5035	NSF [DBI-0547695]; NIH [R01-GM066099, R01-GM079656, 5 T32 GM07526-29]; March of Dimes [1-FY06-371]; Keck Center for Interdisciplinary Bioscience Training [5T15LM07093]; W.M. Keck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066099, R01GM079656, T32GM007526] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Keck Center for Interdisciplinary Bioscience Training; W.M. Keck Foundation(W.M. Keck Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We wish to gratefully acknowledge partial support from NSF DBI-0547695 (OL), NIH R01-GM066099 and R01-GM079656, as well as from March of Dimes (1-FY06-371). This work was also supported by training fellowships from the Keck Center for Interdisciplinary Bioscience Training NLM Grant No. 5T15LM07093 (RMW and DMK) and from the W.M. Keck Foundation (AML). SE was supported by the NIH institutional postdoctoral fellowship program in a medical genetics training program NIH 5 T32 GM07526-29.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; ARTYMIUK PJ, 1994, J MOL BIOL, V243, P327, DOI 10.1006/jmbi.1994.1657; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Attwood TK, 2000, NUCLEIC ACIDS RES, V28, P225, DOI 10.1093/nar/28.1.225; Ausiello G, 2005, NUCLEIC ACIDS RES, V33, pW133, DOI 10.1093/nar/gki499; Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541; Bairoch A, 2007, NUCLEIC ACIDS RES, V35, pD193, DOI 10.1093/nar/gkl929; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Barker JA, 2003, BIOINFORMATICS, V19, P1644, DOI 10.1093/bioinformatics/btg226; Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Binkowski TA, 2004, NUCLEIC ACIDS RES, V32, pW555, DOI 10.1093/nar/gkh390; Brenner SE, 2001, NAT REV GENET, V2, P801, DOI 10.1038/35093574; Burley SK, 2000, NAT STRUCT BIOL, V7, P932, DOI 10.1038/80697; Cammer SA, 2003, J MOL BIOL, V334, P387, DOI 10.1016/j.jmb.2003.09.062; Chance MR, 2002, PROTEIN SCI, V11, P723, DOI 10.1110/ps.4570102; Chandonia JM, 2006, SCIENCE, V311, P347, DOI 10.1126/science.1121018; Cokus S, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S4-S7; Copley SD, 2004, BIOCHEMISTRY-US, V43, P13981, DOI 10.1021/bi048947r; de Rinaldis M, 1998, J MOL BIOL, V284, P1211, DOI 10.1006/jmbi.1998.2248; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Devos D, 2000, PROTEINS, V41, P98, DOI 10.1002/1097-0134(20001001)41:1<98::AID-PROT120>3.3.CO;2-J; Devos D, 2001, TRENDS GENET, V17, P429, DOI 10.1016/S0168-9525(01)02348-4; Ferre F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-194; FISCHER D, 1993, PROTEINS, V16, P278, DOI 10.1002/prot.340160306; Friedberg I, 2006, NUCLEIC ACIDS RES, V34, pW379, DOI 10.1093/nar/gkl045; Galperin M Y, 1998, In Silico Biol, V1, P55; Gilbert D, 1999, BIOINFORMATICS, V15, P317, DOI 10.1093/bioinformatics/15.4.317; Glaser F, 2006, PROTEINS, V62, P479, DOI 10.1002/prot.20769; Haft DH, 2001, NUCLEIC ACIDS RES, V29, P41, DOI 10.1093/nar/29.1.41; Harrison A, 2003, BIOINFORMATICS, V19, P1748, DOI 10.1093/bioinformatics/btg240; HOBOHM U, 1992, PROTEIN SCI, V1, P409; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ivanisenko VA, 2005, NUCLEIC ACIDS RES, V33, pD183, DOI 10.1093/nar/gki105; Ivanisenko VA, 2004, NUCLEIC ACIDS RES, V32, pW549, DOI 10.1093/nar/gkh439; Jambon M, 2005, BIOINFORMATICS, V21, P3929, DOI 10.1093/bioinformatics/bti645; Jambon M, 2003, PROTEINS, V52, P137, DOI 10.1002/prot.10339; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kinoshita Kengo, 2002, Journal of Structural and Functional Genomics, V2, P9, DOI 10.1023/A:1011318527094; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kristensen DM, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-17; Kristensen DM, 2006, PROTEIN SCI, V15, P1530, DOI 10.1110/ps.062152706; Kuznetsova E, 2005, FEMS MICROBIOL REV, V29, P263, DOI 10.1016/j.femsre.2004.12.006; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414; Laskowski RA, 2005, J MOL BIOL, V351, P614, DOI 10.1016/j.jmb.2005.05.067; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pD266, DOI 10.1093/nar/gki001; Laskowski RA, 1995, J MOL GRAPHICS, V13, P328; Lee I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000988; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Leulliot N, 2005, ACTA CRYSTALLOGR D, V61, P664, DOI 10.1107/S0907444905000028; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lisewski AM, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl788; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Madabushi S, 2002, J MOL BIOL, V316, P139, DOI 10.1006/jmbi.2001.5327; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Mihalek I, 2004, J MOL BIOL, V336, P1265, DOI 10.1016/j.jmb.2003.12.078; Morgan DH, 2006, BIOINFORMATICS, V22, P2049, DOI 10.1093/bioinformatics/btl285; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; Nocek B, 2005, J MOL BIOL, V354, P91, DOI 10.1016/j.jmb.2005.08.036; NUSSINOV R, 1991, P NATL ACAD SCI USA, V88, P10495, DOI 10.1073/pnas.88.23.10495; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; O'Toole N, 2004, PROTEINS, V56, P201, DOI 10.1002/prot.20060; Overbeek R, 1999, In Silico Biol, V1, P93; Pearl FMG, 2003, NUCLEIC ACIDS RES, V31, P452, DOI 10.1093/nar/gkg062; Polacco BJ, 2006, BIOINFORMATICS, V22, P723, DOI 10.1093/bioinformatics/btk038; Porter CT, 2004, NUCLEIC ACIDS RES, V32, pD129, DOI 10.1093/nar/gkh028; Quan XJ, 2004, DEVELOPMENT, V131, P1679, DOI 10.1242/dev.01055; Rajagopalan L, 2006, J NEUROSCI, V26, P12727, DOI 10.1523/JNEUROSCI.2734-06.2006; Ribes-Zamora A, 2007, NAT STRUCT MOL BIOL, V14, P301, DOI 10.1038/nsmb1214; Rosen M, 1998, PROTEIN ENG, V11, P263, DOI 10.1093/protein/11.4.263; Schmitt S, 2002, J MOL BIOL, V323, P387, DOI 10.1016/S0022-2836(02)00811-2; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shima S, 2000, J MOL BIOL, V300, P935, DOI 10.1006/jmbi.2000.3909; SHIN D, 2007, J STRUCT FUNCT GENOM; Shin HJ, 2007, BIOINFORMATICS, V23, P3217, DOI 10.1093/bioinformatics/btm511; Shulman-Peleg A, 2004, J MOL BIOL, V339, P607, DOI 10.1016/j.jmb.2004.04.012; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Sjolander K, 2004, BIOINFORMATICS, V20, P170, DOI 10.1093/bioinformatics/bth021; Skolnick J, 2000, TRENDS BIOTECHNOL, V18, P34, DOI 10.1016/S0167-7799(99)01398-0; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; Stark A, 2003, NUCLEIC ACIDS RES, V31, P3341, DOI 10.1093/nar/gkg506; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tian WD, 2003, J MOL BIOL, V333, P863, DOI 10.1016/j.jmb.2003.08.057; Todd AE, 2005, J MOL BIOL, V348, P1235, DOI 10.1016/j.jmb.2005.03.037; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Vazquez A, 2003, NAT BIOTECHNOL, V21, P697, DOI 10.1038/nbt825; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; von Grotthuss M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-53; Wallace AC, 1996, PROTEIN SCI, V5, P1001; Wallace AC, 1997, PROTEIN SCI, V6, P2308; Wangikar PP, 2003, J MOL BIOL, V326, P955, DOI 10.1016/S0022-2836(02)01384-0; Watson JD, 2007, J MOL BIOL, V367, P1511, DOI 10.1016/j.jmb.2007.01.063; Watson JD, 2005, CURR OPIN STRUC BIOL, V15, P275, DOI 10.1016/j.sbi.2005.04.003; Webb E. C., 1992, Enzyme nomenclature 1992. Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes.; Whisstock JC, 2003, Q REV BIOPHYS, V36, P307, DOI 10.1017/S0033583503003901; Wilson CA, 2000, J MOL BIOL, V297, P233, DOI 10.1006/jmbi.2000.3550; Xie L, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S4-S9; Yao H, 2003, J MOL BIOL, V326, P255, DOI 10.1016/S0022-2836(02)01336-0; Zhang BH, 1999, PROTEIN SCI, V8, P1104, DOI 10.1110/ps.8.5.1104	107	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2136	10.1371/journal.pone.0002136	http://dx.doi.org/10.1371/journal.pone.0002136			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461181	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400056
J	Wong, CM; Lai, HK; Ou, CQ; Ho, SY; Chan, KP; Thach, TQ; Yang, L; Chau, YK; Lam, TH; Hedley, AJ; Peiris, JSM				Wong, Chit-Ming; Lai, Hak-Kan; Ou, Chun-Quan; Ho, Sai-Yin; Chan, King-Pan; Thach, Thuan-Quoc; Yang, Lin; Chau, Yuen-Kwan; Lam, Tai-Hing; Hedley, Anthony Johnson; Peiris, Joseph Sriyal Malik			Is Exercise Protective Against Influenza-Associated Mortality?	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; MODERATE EXERCISE; HONG-KONG; IMMUNE-SYSTEM; ADULT DEATHS; ANTIBODY-RESPONSE; VACCINE; PREVENTION; SUSCEPTIBILITY; INFECTION	Background: Little is known about the effect of physical exercise on influenza-associated mortality. Methods and Findings: We collected information about exercise habits and other lifestyles, and socioeconomic and demographic status, the underlying cause of death of 24,656 adults (21% aged 30-64, 79% aged 65 or above) who died in 1998 in Hong Kong, and the weekly proportion of specimens positive for influenza A (H3N1 and H1N1) and B isolations during the same period. We assessed the excess risks (ER) of influenza-associated mortality due to all-natural causes, cardiovascular diseases, or respiratory disease among different levels of exercise: never/seldom (less than once per month), low/moderate (once per month to three times per week), and frequent (four times or more per week) by Poisson regression. We also assessed the differences in ER between exercise groups by case-only logistic regression. For all the mortality outcomes under study in relation to each 10% increase in weekly proportion of specimens positive for influenza A+B, never/seldom exercise (as reference) was associated with 5.8% to 8.5% excess risks (ER) of mortality (P < 0.0001), while low/moderate exercise was associated with ER which were 4.2% to 6.4% lower than those of the reference (P < 0.001 for all-natural causes; P = 0.001 for cardiovascular; and P = 0.07 for respiratory mortality). Frequent exercise was not different from the reference (change in ER -0.8% to 1.7%, P = 0.30 to 0.73). Conclusion: When compared with never or seldom exercise, exercising at low to moderate frequency is beneficial with lower influenza-associated mortality.	[Wong, Chit-Ming; Lai, Hak-Kan; Ou, Chun-Quan; Ho, Sai-Yin; Chan, King-Pan; Thach, Thuan-Quoc; Yang, Lin; Chau, Yuen-Kwan; Lam, Tai-Hing; Hedley, Anthony Johnson] Univ Hong Kong, Sch Publ Hlth, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; [Peiris, Joseph Sriyal Malik] Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wong, CM (corresponding author), Univ Hong Kong, Sch Publ Hlth, Dept Community Med, Hong Kong, Hong Kong, Peoples R China.	commed@hkucc.hku.hk	Thach, Thuan-Quoc/C-4416-2009; Hedley, Anthony J/A-9113-2013; YANG, Lin/F-9601-2014; Yang, Lin/E-5183-2011; Lam, Tai Hing/C-4317-2009; Ho, Daniel Sai Yin/C-4307-2009	Thach, Thuan-Quoc/0000-0003-3404-3888; YANG, Lin/0000-0002-5964-3233; Lam, Tai Hing/0000-0002-2033-9971; Ou, Chun-Quan/0000-0001-6866-7213; Ho, Daniel Sai Yin/0000-0001-9485-0273	Health and Health Services Research Fund [631012]; Research Fund for the Control of Infectious Diseases [HKU-AA-008]	Health and Health Services Research Fund; Research Fund for the Control of Infectious Diseases	This study was funded by the Health and Health Services Research Fund (#631012), who provided the Lifestyle and Mortality Study (LIMOR), and the Research Fund for the Control of Infectious Diseases (#HKU-AA-008) funding.	Armstrong BG, 2003, EPIDEMIOLOGY, V14, P467, DOI 10.1097/01.ede.0000071408.39011.99; Brown AS, 2004, MED SCI SPORT EXER, V36, P1290, DOI 10.1249/01.MSS.0000135798.72735.B3; Chow A, 2006, EMERG INFECT DIS, V12, P114, DOI 10.3201/eid1201.050826; Davis JM, 1997, J APPL PHYSIOL, V83, P1461, DOI 10.1152/jappl.1997.83.5.1461; Davis JM, 2004, AM J PHYSIOL-REG I, V286, pR366, DOI 10.1152/ajpregu.00304.2003; Demicheli V, 2000, VACCINE, V18, P957, DOI 10.1016/S0264-410X(99)00332-1; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hastie TJ., 1990, GEN ADDITIVE MODELS; HEATH GW, 1991, MED SCI SPORT EXER, V23, P152; *HKSAR GOV, 2006, HONG KONG FACTS POP; Ho SY, 2006, PREV MED, V43, P20, DOI 10.1016/j.ypmed.2006.03.007; HOFFMANGOETZ L, 1994, IMMUNOL TODAY, V15, P382, DOI 10.1016/0167-5699(94)90177-5; Kapasi ZF, 2001, PHYS THER, V81, P1801, DOI 10.1093/ptj/81.11.1801; Kohut ML, 2004, VACCINE, V22, P2298, DOI 10.1016/j.vaccine.2003.11.023; Kohut ML, 2002, J GERONTOL A-BIOL, V57, pM557, DOI 10.1093/gerona/57.9.M557; Lam TH, 2004, ANN EPIDEMIOL, V14, P391, DOI 10.1016/j.annepidem.2003.09.005; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361; MACNEIL B, 1991, J APPL PHYSIOL, V70, P179, DOI 10.1152/jappl.1991.70.1.179; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Matthews CE, 2002, MED SCI SPORT EXER, V34, P1242, DOI 10.1097/00005768-200208000-00003; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Nieman DC, 2000, IMMUNOL CELL BIOL, V78, P496, DOI 10.1046/j.1440-1711.2000.00950.x; NIEMAN DC, 1990, J SPORT MED PHYS FIT, V30, P316; NIEMAN DC, 1990, INT J SPORTS MED, V11, P467, DOI 10.1055/s-2007-1024839; NIEMAN DC, 1993, MED SCI SPORT EXER, V25, P823, DOI 10.1249/00005768-199307000-00011; NIEMAN DC, 1994, SEMIN HEMATOL, V31, P166; NIEMAN DC, 1994, INT J SPORTS MED, V15, pS131, DOI 10.1055/s-2007-1021128; NIEMAN DC, 1991, SPORTS MED, V11, P183, DOI 10.2165/00007256-199111030-00003; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; PEDERSEN BK, 1995, SPORTS MED, V19, P393, DOI 10.2165/00007256-199519060-00003; Pedersen BK, 1998, ACTA PHYSIOL SCAND, V162, P325, DOI 10.1046/j.1365-201X.1998.0325e.x; Rockhill B, 2001, AM J PUBLIC HEALTH, V91, P578, DOI 10.2105/AJPH.91.4.578; Roubenoff R, 2007, NUTR REV, V65, pS208, DOI 10.1111/j.1753-4887.2007.tb00364.x; Schooling CM, 2006, INT J EPIDEMIOL, V35, P418, DOI 10.1093/ije/dyi296; Schuler PB, 2003, J SPORT MED PHYS FIT, V43, P404; Schwartz J, 2005, EPIDEMIOLOGY, V16, P67, DOI 10.1097/01.ede.0000147114.25957.71; SHINKAI S, 1995, MED SCI SPORT EXER, V27, P1516; Stephenson I, 2001, EUR RESPIR J, V17, P1282, DOI 10.1183/09031936.01.00084301; Thomas LA, 2005, BRAIN BEHAV IMMUN, V19, P377, DOI 10.1016/j.bbi.2005.04.002; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; U.S. Department of Health and Human Services, 2002, PHYS ACT OLD AM BEN; *UK DEP HLTH, 2004, PHYS ACT HLTH IMPR P; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; Wong CM, 2006, PLOS MED, V3, P485, DOI 10.1371/journal.pmed.0030121; Wong CM, 2007, PREV MED, V44, P386, DOI 10.1016/j.ypmed.2006.12.012; Wong CM, 2004, CLIN INFECT DIS, V39, P1611, DOI 10.1086/425315	49	49	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2108	10.1371/journal.pone.0002108	http://dx.doi.org/10.1371/journal.pone.0002108			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461130	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400030
J	Yaghmur, A; Laggner, P; Sartori, B; Rappolt, M				Yaghmur, Anan; Laggner, Peter; Sartori, Barbara; Rappolt, Michael			Calcium Triggered L-alpha-H-2 Phase Transition Monitored by Combined Rapid Mixing and Time-Resolved Synchrotron SAXS	PLOS ONE			English	Article							X-RAY-SCATTERING; LIQUID-CRYSTALLINE PHASES; ALKALINE-EARTH CATIONS; MEMBRANE-FUSION; CUBIC PHASES; DIVALENT-CATIONS; LIPID-BILAYERS; BINDING; LAMELLAR; SYSTEMS	Background: Awad et al. [1] reported on the Ca2+-induced transitions of dioleoyl-phosphatidylglycerol (DOPG)/monoolein (MO) vesicles to bicontinuous cubic phases at equilibrium conditions. In the present study, the combination of rapid mixing and time-resolved synchrotron small-angle X-ray scattering (SAXS) was applied for the in-situ investigations of fast structural transitions of diluted DOPG/MO vesicles into well-ordered nanostructures by the addition of low concentrated Ca2+ solutions. Methodology/Principal Findings: Under static conditions and the in absence of the divalent cations, the DOPG/MO system forms large vesicles composed of weakly correlated bilayers with a d-spacing of similar to 140 angstrom (L-alpha-phase). The utilization of a stopped-flow apparatus allowed mixing these DOPG/MO vesicles with a solution of Ca2+ ions within 10 milliseconds (ms). In such a way the dynamics of negatively charged PG to divalent cation interactions, and the kinetics of the induced structural transitions were studied. Ca2+ ions have a very strong impact on the lipidic nanostructures. Intriguingly, already at low salt concentrations (DOPG/Ca2+ >2), Ca2+ ions trigger the transformation from bilayers to monolayer nanotubes (inverted hexagonal phase, H-2). Our results reveal that a binding ratio of 1 Ca2+ per 8 DOPG is sufficient for the formation of the H-2 phase. At 50 degrees C a direct transition from the vesicles to the H-2 phase was observed, whereas at ambient temperature (20 degrees C) a short lived intermediate phase (possibly the cubic Pn3m phase) coexisting with the H-2 phase was detected. Conclusions/Significance: The strong binding of the divalent cations to the negatively charged DOPG molecules enhances the negative spontaneous curvature of the monolayers and causes a rapid collapsing of the vesicles. The rapid loss of the bilayer stability and the reorganization of the lipid molecules within ms support the argument that the transition mechanism is based on a leaky fusion of the vesicles.	[Yaghmur, Anan; Laggner, Peter; Sartori, Barbara; Rappolt, Michael] Austrian Acad Sci, Inst Biophys & Nanosyst Res IBN, Graz, Austria	Austrian Academy of Sciences	Yaghmur, A (corresponding author), Austrian Acad Sci, Inst Biophys & Nanosyst Res IBN, Graz, Austria.	anan.yaghmur@oeaw.ac.at	Yaghmur, Anan/AGU-9381-2022	Yaghmur, Anan/0000-0003-1608-773X; Rappolt, Michael/0000-0001-9942-3035				Allen SJ, 2004, J MOL BIOL, V342, P1279, DOI 10.1016/j.jmb.2004.07.040; Almsherqi ZA, 2006, J CELL BIOL, V173, P839, DOI 10.1083/jcb.200603055; Amenitsch H, 2004, LANGMUIR, V20, P4621, DOI 10.1021/la036319p; Amenitsch H, 1998, J SYNCHROTRON RADIAT, V5, P506, DOI 10.1107/S090904959800137X; Andersson AS, 1998, BIOPHYS J, V75, P2877, DOI 10.1016/S0006-3495(98)77730-6; Angelova A, 2005, J PHYS CHEM B, V109, P3089, DOI 10.1021/jp044216p; Arseneault M, 2006, CHEM PHYS LIPIDS, V142, P84, DOI 10.1016/j.chemphyslip.2006.03.003; Awad TS, 2005, LANGMUIR, V21, P11556, DOI 10.1021/la051782i; Bernstorff S, 1998, J SYNCHROTRON RADIAT, V5, P1215, DOI 10.1107/S0909049597019110; Bockmann RA, 2004, ANGEW CHEM INT EDIT, V43, P1021, DOI 10.1002/anie.200352784; BOGGS JM, 1983, BIOCHEMISTRY-US, V22, P5425, DOI 10.1021/bi00292a026; Bolze J, 2004, J COLLOID INTERF SCI, V277, P84, DOI 10.1016/j.jcis.2004.04.029; BOYD BJ, 2005, DRUG DELIV REP   AUT, P63; Briggs J, 1996, J PHYS II, V6, P723, DOI 10.1051/jp2:1996208; CAFFREY M, 1985, BIOCHEMISTRY-US, V24, P4826, DOI 10.1021/bi00339a017; CAILLE A, 1972, CR ACAD SCI B PHYS, V274, P891; Chasserot-Golaz S, 2005, MOL BIOL CELL, V16, P1108, DOI 10.1091/mbc.E04-07-0627; Chernik GG, 1999, CURR OPIN COLLOID IN, V4, P381, DOI 10.1016/S1359-0294(00)00023-6; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; Couvreur P, 2006, PHARM RES-DORDR, V23, P1417, DOI 10.1007/s11095-006-0284-8; Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200; de Campo L, 2004, LANGMUIR, V20, P5254, DOI 10.1021/la0499416; deKruijff B, 1997, CURR TOP MEMBR, V44, P477; deKruijff B, 1997, NATURE, V386, P129, DOI 10.1038/386129a0; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; Epand RM, 1997, CURR TOP MEMBR, V44, P237; Faraudo J, 2007, BIOPHYS J, V92, P2806, DOI 10.1529/biophysj.106.092015; Garidel P, 2000, BBA-BIOMEMBRANES, V1466, P245, DOI 10.1016/S0005-2736(00)00166-8; Garidel P, 1999, LANGMUIR, V15, P5526, DOI 10.1021/la990217a; Garidel P, 2000, LANGMUIR, V16, P1662, DOI 10.1021/la990922j; Garidel P, 2000, PHYS CHEM CHEM PHYS, V2, P4537, DOI 10.1039/b003276j; GOODSELL DS, 2004, BIONANOTECHNOLOGY LE, P227; Gradzielski M, 2004, PROG COLL POL SCI S, V129, P32, DOI 10.1007/b100300; Gradzielski M, 2000, J PHYS CHEM B, V104, P11594, DOI 10.1021/jp0028913; GRADZIELSKI M, 2004, CURR OPIN COLLOID IN, V4, P381; Grillo I, 2003, LANGMUIR, V19, P4573, DOI 10.1021/la0208732; Gustafsson J, 1996, LANGMUIR, V12, P4611, DOI 10.1021/la960318y; HONG K, 1982, BIOPHYS J, V37, P297, DOI 10.1016/S0006-3495(82)84678-X; Hu MZC, 2000, J MATER SCI, V35, P1957, DOI 10.1023/A:1004722603945; HUANG TC, 1993, J APPL CRYSTALLOGR, V26, P180, DOI 10.1107/S0021889892009762; HUI SW, 1981, SCIENCE, V212, P921, DOI 10.1126/science.7233185; HUI SW, 1983, CHEM PHYS LIPIDS, V33, P113, DOI 10.1016/0009-3084(83)90015-4; HYDE S, 1997, ELSEVIER BOOK SERIES; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; Kamo T, 2003, LANGMUIR, V19, P9191, DOI 10.1021/la035313x; Kharakoz DP, 2003, MEMBR SCI T, V7, P239, DOI 10.1016/S0927-5193(03)80031-1; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Krebs J, 1995, ENCY MOL BIOL MOL ME, V1, P237; Kriechbaum M, 1996, PROG SURF SCI, V51, P233, DOI 10.1016/0079-6816(96)00003-2; LAGGNER P, 1991, CHEM PHYS LIPIDS, V57, P121, DOI 10.1016/0009-3084(91)90072-J; Laggner P, 1998, FARADAY DISCUSS, V111, P31; Larsson K, 2000, CURR OPIN COLLOID IN, V5, P64, DOI 10.1016/S1359-0294(00)00040-6; LARSSON K, 1983, NATURE, V304, P664, DOI 10.1038/304664c0; LEHRMANN R, 1994, BBA-BIOMEMBRANES, V1189, P89, DOI 10.1016/0005-2736(94)90284-4; Li SJ, 2001, BIOPHYS J, V81, P983, DOI 10.1016/S0006-3495(01)75756-6; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LUTTON ES, 1965, J AM OIL CHEM SOC, V42, P1068, DOI 10.1007/BF02636909; Luzzati V, 1997, CURR OPIN STRUC BIOL, V7, P661, DOI 10.1016/S0959-440X(97)80075-9; Masum SM, 2003, LANGMUIR, V19, P4745, DOI 10.1021/la026847l; Moitzi C, 2007, ADV MATER, V19, P1352, DOI 10.1002/adma.200601679; Nakano M, 2005, J PHYS CHEM B, V109, P4754, DOI 10.1021/jp046181z; NILSSON A, 1994, CHEM PHYS LIPIDS, V71, P119, DOI 10.1016/0009-3084(94)90065-5; Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4; Pabst G, 2000, PHYS REV E, V62, P4000, DOI 10.1103/PhysRevE.62.4000; Pabst G, 2003, J APPL CRYSTALLOGR, V36, P1378, DOI 10.1107/S0021889803017527; Pabst G, 2007, BIOPHYS J, V93, P2688, DOI 10.1529/biophysj.107.112615; Pabst Georg, 2006, Biophysical Reviews and Letters, V1, P57, DOI 10.1142/S1793048006000069; Panine P, 2006, ADV COLLOID INTERFAC, V127, P9, DOI 10.1016/j.cis.2006.06.003; PAPAHADJOPOULOS D, 1975, BIOPHYS J, V15, P945, DOI 10.1016/S0006-3495(75)85872-3; PATTON JS, 1979, SCIENCE, V204, P145, DOI 10.1126/science.432636; Pedersen UR, 2006, BBA-BIOMEMBRANES, V1758, P573, DOI 10.1016/j.bbamem.2006.03.035; Pitzalis P, 2000, LANGMUIR, V16, P6358, DOI 10.1021/la0002031; Qiu H, 2000, BIOMATERIALS, V21, P223, DOI 10.1016/S0142-9612(99)00126-X; Rappolt M, 2006, EUROPHYS LETT, V75, P267, DOI 10.1209/epl/i2006-10104-y; Rappolt M, 2001, COLLOID SURFACE A, V183, P171, DOI 10.1016/S0927-7757(01)00568-4; Rappolt M, 1998, BBA-BIOMEMBRANES, V1372, P389, DOI 10.1016/S0005-2736(98)00079-0; RAPPOLT M, 2008, CHEM PHYS L IN PRESS; RAPPOLT M, 2007, ELSEVIER BOOK SERIES, V5, P253; ROUX M, 1990, BIOCHEMISTRY-US, V29, P7077, DOI 10.1021/bi00482a019; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; Shearman GC, 2006, J PHYS-CONDENS MAT, V18, pS1105, DOI 10.1088/0953-8984/18/28/S01; Siegel DP, 1999, BIOPHYS J, V76, P291, DOI 10.1016/S0006-3495(99)77197-3; SIEGEL DP, 1986, BIOPHYS J, V49, P1155, DOI 10.1016/S0006-3495(86)83744-4; Simidjiev I, 2000, P NATL ACAD SCI USA, V97, P1473, DOI 10.1073/pnas.97.4.1473; Sinn CG, 2006, COLLOID SURFACE A, V282, P410, DOI 10.1016/j.colsurfa.2005.10.014; Spicer PT., 2004, DEKKER ENCY NANOSCIE, P881; Szule JA, 2003, J BIOL CHEM, V278, P24251, DOI 10.1074/jbc.C300197200; VanScyoc WS, 2002, BIOPHYS J, V83, P2767, DOI 10.1016/S0006-3495(02)75286-7; VERKLEIJ AJ, 1982, BIOCHIM BIOPHYS ACTA, V684, P255, DOI 10.1016/0005-2736(82)90014-1; VERKLEIJ AJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P620, DOI 10.1016/0005-2736(80)90465-4; Vest RS, 2004, BIOPHYS J, V86, P2251, DOI 10.1016/S0006-3495(04)74283-6; Weiss TM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.038303; Yaghmur A, 2006, LANGMUIR, V22, P517, DOI 10.1021/la052109w; Yaghmur A, 2002, COLLOID SURFACE A, V209, P71, DOI 10.1016/S0927-7757(02)00168-1; Yaghmur A, 2005, LANGMUIR, V21, P569, DOI 10.1021/la0482711; Yaghmur A, 2006, LANGMUIR, V22, P9919, DOI 10.1021/la061303v; Yaghmur A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000479; ZHANG J, 2002, NANOSTRUCTURE SCI TE; Zhang RT, 1996, BIOPHYS J, V70, P349, DOI 10.1016/S0006-3495(96)79576-0; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i	102	62	62	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2072	10.1371/journal.pone.0002072	http://dx.doi.org/10.1371/journal.pone.0002072			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446202	Green Accepted, gold, Green Published			2022-12-25	WOS:000261572300041
J	Tribouillard-Tanvier, D; Beringue, V; Desban, N; Gug, F; Bach, S; Voisset, C; Galons, H; Laude, H; Vilette, D; Blondel, M				Tribouillard-Tanvier, Deborah; Beringue, Vincent; Desban, Nathalie; Gug, Fabienne; Bach, Stephane; Voisset, Cecile; Galons, Herve; Laude, Hubert; Vilette, Didier; Blondel, Marc			Antihypertensive Drug Guanabenz Is Active In Vivo against both Yeast and Mammalian Prions	PLOS ONE			English	Article								Background: Prion-based diseases are incurable transmissible neurodegenerative disorders affecting animals and humans. Methodology/Principal Findings: Here we report the discovery of the in vivo antiprion activity of Guanabenz (GA), an agonist of alpha 2-adrenergic receptors routinely used in human medicine as an antihypertensive drug. We isolated GA in a screen for drugs active in vivo against two different yeast prions using a previously described yeast-based two steps assay. GA was then shown to promote ovine PrPSc clearance in a cell-based assay. These effects are very specific as evidenced by the lack of activity of some GA analogues that we generated. GA antiprion activity does not involve its agonist activity on alpha 2-adrenergic receptors as other chemically close anti-hypertensive agents possessing related mechanism of action were found inactive against prions. Finally, GA showed activity in a transgenic mouse-based in vivo assay for ovine prion propagation, prolonging slightly but significantly the survival of treated animals. Conclusion/Significance: GA thus adds to the short list of compounds active in vivo in animal models for the treatment of prion-based diseases. Because it has been administrated for many years to treat hypertension on a daily basis, without major side-effects, our results suggest that it could be evaluated in human as a potential treatment for prion-based diseases.	[Tribouillard-Tanvier, Deborah; Voisset, Cecile; Blondel, Marc] INSERM, U613, Brest, France; [Tribouillard-Tanvier, Deborah; Voisset, Cecile; Blondel, Marc] Univ Brest, Fac Med Sci Sante, UMR S613, Brest, France; [Tribouillard-Tanvier, Deborah; Voisset, Cecile; Blondel, Marc] Etab Francais Sang EFS Bretagne, Brest, France; [Tribouillard-Tanvier, Deborah; Voisset, Cecile; Blondel, Marc] Lab Genet Mol, Hop Morvan, CHU Brest, Brest, France; [Tribouillard-Tanvier, Deborah; Desban, Nathalie; Bach, Stephane] Place Georges Teissier, Protein Phosphorylat & Dis Lab, Stn Biol, CNRS UPS2682, Roscoff, France; [Beringue, Vincent; Laude, Hubert; Vilette, Didier] Virol Immunol Mol, UR892, Inst Natl Rech Agronom INRA, Jouy En Josas, France; [Gug, Fabienne; Galons, Herve] Univ Paris 05, Lab Chim Organ 2, INSERM U648, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; Universite de Bretagne Occidentale; CHU Brest; Universite de Bretagne Occidentale; UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blondel, M (corresponding author), INSERM, U613, Brest, France.	marc.blondel@univ-brest.fr	BACH, Stéphane/ABD-5865-2020; Voisset, Cecile/AAK-1636-2020; Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Tribouillard-Tanvier, Deborah/0000-0002-2290-5375; Voisset, Cecile/0000-0001-7505-1927	GIS Infections a prion; ACI Jeune Chercheur from the French government; CRITT Sante Bretagne; Ministere de la Recherche; FRM; CNRS [Ingenieur de valorisation fellowship]; ANR blanche from the French government; INSERM	GIS Infections a prion; ACI Jeune Chercheur from the French government; CRITT Sante Bretagne; Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); FRM(Fondation pour la Recherche Medicale); CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR blanche from the French government(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This work was supported by the following grants: GIS Infections a prion, ACI Jeune Chercheur from the French government, CRITT Sante Bretagne to MB, Ministere de la Recherche and FRM grants (to DTT), Ingenieur de valorisation fellowship from the CNRS, ANR blanche from the French government to MB, CV, VB, HL, DV and HG and INSERM junior contract to CV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Archer F, 2004, J VIROL, V78, P482, DOI 10.1128/JVI.78.1.482-490.2004; Bach S, 2003, NAT BIOTECHNOL, V21, P1075, DOI 10.1038/nbt855; Bach S, 2006, METHODS, V39, P72, DOI 10.1016/j.ymeth.2006.04.005; Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; BENKEMOUN L, 2006, FUNGAL GENET BIOL; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Bertsch U, 2005, J VIROL, V79, P7785, DOI 10.1128/JVI.79.12.7785-7791.2005; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Cronier S, 2007, J VIROL, V81, P13794, DOI 10.1128/JVI.01502-07; Dirikoc S, 2007, J NEUROSCI, V27, P9537, DOI 10.1523/JNEUROSCI.1942-07.2007; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; Gilch S, 2007, J MOL BIOL, V371, P362, DOI 10.1016/j.jmb.2007.05.052; HOLMES B, 1983, DRUGS, V26, P212, DOI 10.2165/00003495-198326030-00003; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HOUSTON MC, 1982, SOUTH MED J, V75, P713, DOI 10.1097/00007611-198206000-00022; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Le Dur A, 2005, P NATL ACAD SCI USA, V102, P16031, DOI 10.1073/pnas.0502296102; LEVY R, 1989, LANCET, V2, P329; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2007, NEURON, V53, P325, DOI 10.1016/j.neuron.2007.01.005; Schafer S G, 1995, Ann N Y Acad Sci, V763, P659, DOI 10.1111/j.1749-6632.1995.tb32460.x; Sica Domenic A, 2007, J Clin Hypertens (Greenwich), V9, P399, DOI 10.1111/j.1524-6175.2007.07161.x; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Taguchi Y, 2003, AM J PATHOL, V163, P2585, DOI 10.1016/S0002-9440(10)63613-9; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/awl150; Tribouillard Deborah, 2006, Biotechnology Journal, V1, P58, DOI 10.1002/biot.200500001; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Vilette D, 2008, VET RES, V39, DOI 10.1051/vetres:2007049; Vilotte JL, 2001, J VIROL, V75, P5977, DOI 10.1128/JVI.75.13.5977-5984.2001; Wermuth CG, 2004, J MED CHEM, V47, P1303, DOI 10.1021/jm030480f; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	41	63	74	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1981	10.1371/journal.pone.0001981	http://dx.doi.org/10.1371/journal.pone.0001981			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431471	Green Submitted, gold, Green Published			2022-12-25	WOS:000261558700006
J	Lavery, K; Swain, P; Falb, D; Alaoui-Ismaili, MH				Lavery, Karen; Swain, Pamela; Falb, Dean; Alaoui-Ismaili, Moulay Hicham			BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER BRET; MORPHOGENETIC PROTEINS; OSTEOGENIC PROTEIN-1; II-RECEPTOR; HETERO-OLIGOMERIZATION; HOMO-OLIGOMERIZATION; SIGNALING PATHWAYS; STROMAL CELLS; TRANSITION; FIBROBLASTS	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily of growth factors and are used clinically to induce new bone formation. The purpose of this study was to evaluate receptor utilization by BMP-2, BMP-4, BMP-6, and BMP-7 in primary human mesenchymal stem cells (hMSC), a physiologically relevant cell type that probably mediates the in vivo effects of BMPs. RNA interference-mediated gene knockdown revealed that osteoinductive BMP activities in hMSC are elicited through the type I receptors ACVR1A and BMPR1A and the type II receptors ACVR2A and BMPR2. BMPR1B and ACVR2B were expressed at low levels and were not found to play a significant role in signaling by any of the BMPs evaluated in this study. Type II receptor utilization differed significantly between BMP-2/4 and BMP-6/7. A greater reliance on BMPR2 was observed for BMP-2/4 relative to BMP-6/7, whereas ACVR2A was more critical to signaling by BMP-6/7 than BMP-2/4. Significant differences were also observed for the type I receptors. Although BMP-2/4 used predominantly BMPR1A for signaling, ACVR1A was the preferred type I receptor for BMP-6/7. Signaling by both BMP-2/4 and BMP-6/7 was mediated by homodimers of ACVR1A or BMPR1A. A portion of BMP-2/4 signaling also required concurrent BMPR1A and ACVR1A expression, suggesting that BMP-2/4 signal in part through ACVR1A/BMPR1A heterodimers. The capacity of ACVR1A and BMPR1A to form homodimers and heterodimers was confirmed by bioluminescence resonance energy transfer analyses. These results suggest different mechanisms for BMP-2/4- and BMP-6/7-induced osteoblastic differentiation in primary hMSC.			Alaoui-Ismaili, MH (corresponding author), Stryker Biotech, 35 South St, Hopkinton, MA 01748 USA.	hicham.alaoui@stryker.com						Aoki H, 2001, J CELL SCI, V114, P1483; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719; Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1; Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445-2197.2007.04175.x; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c; Izumi N, 2006, AM J PHYSIOL-LUNG C, V290, pL120, DOI 10.1152/ajplung.00171.2005; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Krishnaveni MS, 2006, BIOCHEM BIOPH RES CO, V351, P651, DOI 10.1016/j.bbrc.2006.10.083; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; LI X, 2008, ATHEROSCLER IN PRESS; LIU F, 1995, MOL CELL BIOL, V15, P3479; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; O'Connor MB, 2006, DEVELOPMENT, V133, P183; Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005-0303; Pfleger KDG, 2006, NAT PROTOC, V1, P337, DOI 10.1038/nprot.2006.52; Piscione TD, 1997, AM J PHYSIOL-RENAL, V273, pF961, DOI 10.1152/ajprenal.1997.273.6.F961; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200; Singhatanadgit W, 2006, J CELL PHYSIOL, V209, P912, DOI 10.1002/jcp.20799; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103; Wordinger RJ, 2007, EXP BIOL MED, V232, P979, DOI 10.3181/0510-MR-345; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	41	211	227	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					20948	20958		10.1074/jbc.M800850200	http://dx.doi.org/10.1074/jbc.M800850200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18436533	hybrid, Green Published			2022-12-25	WOS:000257746100037
J	Stowell, SR; Arthur, CM; Slanina, KA; Horton, JR; Smith, DF; Cummings, RD				Stowell, Sean R.; Arthur, Connie M.; Slanina, Kristin A.; Horton, John R.; Smith, David F.; Cummings, Richard D.			Dimeric galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ASPARAGINE-LINKED OLIGOSACCHARIDES; CARBOHYDRATE-BINDING PROTEIN-35; POLY-N-ACETYLLACTOSAMINE; RAY CRYSTAL-STRUCTURE; HAMSTER OVARY CELLS; HIGH-AFFINITY; DIFFERENTIAL GLYCOSYLATION; STRUCTURAL DETERMINANTS; PULMONARY-FIBROSIS	Human galectins have distinct and overlapping biological roles in immunological homeostasis. However, the underlying differences among galectins in glycan binding specificity regulating these functions are unclear. Galectin-8 (Gal-8), a tandem repeat galectin, has two distinct carbohydrate recognition domains (CRDs) that may cross-link cell surface counter receptors. Here we report that each Gal-8 CRD has differential glycan binding specificity and that cell signaling activity resides in the C-terminal CRD. Full-length Gal-8 and recombinant individual domains (Gal-8N and Gal-8C) bound to human HL60 cells, but only full-length Gal-8 signaled phosphatidylserine (PS) exposure in cells, which occurred independently of apoptosis. Although desialylation of cells did not alter Gal-8 binding, it enhanced cellular sensitivity to Gal-8-induced PS exposure. By contrast, HL60 cell desialylation increased binding by Gal-8C but reduced Gal-8N binding. Enzymatic reduction in surface poly-N-acetyllactosamine (polyLacNAc) glycans in HL60 cells reduced cell surface binding by Gal-8C but did not alter Gal-8N binding. Cross-linking and light scattering studies showed that Gal-8 is dimeric, and studies on individual subunits indicate that dimerization occurs through the Gal-8N domain. Mutations of individual domains within full-length Gal-8 showed that signaling activity toward HL60 cells resides in the C-terminal domain. In glycan microarray analyses, each CRD of Gal-8 showed different binding, with Gal-8N recognizing sulfated and sialylated glycans and Gal-8C recognizing blood group antigens and polyLacNAc glycans. These results demonstrate that Gal-8 dimerization promotes functional bivalency of each CRD, which allows Gal-8 to signal PS exposure in leukocytes entirely through C-terminal domain recognition of polyLacNAc glycans.	[Stowell, Sean R.; Arthur, Connie M.; Slanina, Kristin A.; Horton, John R.; Smith, David F.; Cummings, Richard D.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Cummings, RD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	rdcummi@emory.edu	Horton, John R/ABB-4770-2020; Horton, John/F-2375-2010	Horton, John/0000-0001-9749-8068	NHLBI NIH HHS [P01 HL085607, HL 085607] Funding Source: Medline; NIGMS NIH HHS [GM 62116, T32 GM008169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, T32GM008169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bax M, 2007, J IMMUNOL, V179, P8216, DOI 10.4049/jimmunol.179.12.8216; Bidon N, 2001, INT J MOL MED, V8, P245; Bidon-Wagner N, 2002, GLYCOCONJUGATE J, V19, P557, DOI 10.1023/B:GLYC.0000014086.38343.98; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Blois SM, 2007, NAT MED, V13, P1450, DOI 10.1038/nm1680; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Carlsson S, 2007, GLYCOBIOLOGY, V17, P906, DOI 10.1093/glycob/cwm059; Carlsson S, 2007, GLYCOBIOLOGY, V17, P663, DOI 10.1093/glycob/cwm026; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Fecho K, 1998, J LEUKOCYTE BIOL, V64, P373, DOI 10.1002/jlb.64.3.373; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hagimoto N, 1997, AM J RESP CELL MOL, V17, P272, DOI 10.1165/ajrcmb.17.3.2893; HSU DK, 1992, J BIOL CHEM, V267, P14167; IWAI K, 1994, BLOOD, V84, P1201; Jackson CE, 1999, AM J HUM GENET, V64, P1002, DOI 10.1086/302333; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; Kwon SW, 2003, VOX SANG, V85, P307, DOI 10.1111/j.0042-9007.2003.00374.x; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Leppanen A, 2005, J BIOL CHEM, V280, P5549, DOI 10.1074/jbc.m412019200; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Misawa R, 2001, APOPTOSIS, V6, P411, DOI 10.1023/A:1012406121993; Nagae M, 2006, J BIOL CHEM, V281, P35884, DOI 10.1074/jbc.M606648200; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Nieminen J, 2007, J BIOL CHEM, V282, P1374, DOI 10.1074/jbc.M604506200; Nishi N, 2003, GLYCOBIOLOGY, V13, P755, DOI 10.1093/glycob/cwg102; Nishi N, 2006, GLYCOBIOLOGY, V16, p15C, DOI 10.1093/glycob/cwl028; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Patnaik SK, 2006, GLYCOBIOLOGY, V16, P305, DOI 10.1093/glycob/cwj063; Rabinovich GA, 2007, SCAND J IMMUNOL, V66, P143, DOI 10.1111/j.1365-3083.2007.01986.x; Rabinovich GA, 2002, J LEUKOCYTE BIOL, V71, P741; Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P383, DOI 10.1590/S0100-879X1999000400002; Rajagopalan L, 2006, BIOSCIENCE REP, V26, P325, DOI 10.1007/s10540-006-9025-9; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Sato M, 2002, GLYCOBIOLOGY, V12, P191, DOI 10.1093/glycob/12.3.191; Sebban LE, 2007, J IMMUNOL, V179, P1225, DOI 10.4049/jimmunol.179.2.1225; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Stowell SR, 2008, J IMMUNOL, V180, P3091, DOI 10.4049/jimmunol.180.5.3091; Stowell SR, 2008, J BIOL CHEM, V283, P10109, DOI 10.1074/jbc.M709545200; Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153; Stowell SR, 2004, GLYCOBIOLOGY, V14, P157, DOI 10.1093/glycob/cwh018; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Thijssen VL, 2008, AM J PATHOL, V172, P545, DOI 10.2353/ajpath.2008.070938; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Tribulatti MV, 2007, GLYCOBIOLOGY, V17, P1404, DOI 10.1093/glycob/cwm104; Umemoto K, 2003, BIOCHEMISTRY-US, V42, P3688, DOI 10.1021/bi026671m; VIITALA J, 1984, EUR J BIOCHEM, V138, P393, DOI 10.1111/j.1432-1033.1984.tb07928.x; WOO HJ, 1990, J BIOL CHEM, V265, P7097	67	113	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20547	20559		10.1074/jbc.M802495200	http://dx.doi.org/10.1074/jbc.M802495200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18456665	Green Published, hybrid			2022-12-25	WOS:000257565300067
J	Radu, RA; Hu, J; Peng, J; Bok, D; Mata, NL; Travis, GH				Radu, Roxana A.; Hu, Jane; Peng, Jennifer; Bok, Dean; Mata, Nathan L.; Travis, Gabriel H.			Retinal pigment epithelium-retinal G protein receptor-opsin mediates light-dependent translocation of all-trans-retinyl esters for synthesis of visual chromophore in retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; LIPID DROPLETS; VERTEBRATE RETINA; DARK-ADAPTATION; KNOCKOUT MICE; CYCLE; ACYLTRANSFERASE; RHODOPSIN; LECITHIN; RPE65	Visual perception begins with the absorption of a photon by an opsin pigment, inducing isomerization of its 11-cis-retinaldehyde chromophore. After a brief period of activation, the resulting all-trans-retinaldehyde dissociates from the opsin apoprotein rendering it insensitive to light. Restoring light sensitivity to apo-opsin requires thermal re-isomerization of all-trans-retinaldehyde to 11-cis-retinaldehyde via an enzyme pathway called the visual cycle in retinal pigment epithelial (RPE) cells. Vertebrates can see over a 108-fold range of background illumination. This implies that the visual cycle can regenerate a visual chromophore over a similarly broad range. However, nothing is known about how the visual cycle is regulated. Here we show that RPE cells, functionally or physically separated from photoreceptors, respond to light by mobilizing all-trans-retinyl esters. These retinyl esters are substrates for the retinoid isomerase and hence critical for regenerating visual chromophore. We show in knock-out mice and by RNA interference in human RPE cells that this mobilization is mediated by a protein called "RPE-retinal G protein receptor" (RGR) opsin. These data establish that RPE cells are intrinsically sensitive to light. Finally, we show that in the dark, RGR-opsin inhibits lecithin: retinol acyltransferase and all-trans-retinyl ester hydrolase in vitro and that this inhibition is released upon exposure to light. The results of this study suggest that RGR-opsin mediates light-dependent translocation of all-trans-retinyl esters from a storage pool in lipid droplets to an "isomerase pool" in membranes of the endoplasmic reticulum. This translocation permits insoluble all-trans-retinyl esters to be utilized as substrate for the synthesis of a new visual chromophore.	[Radu, Roxana A.; Hu, Jane; Peng, Jennifer; Bok, Dean; Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; [Bok, Dean] Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Bok, Dean; Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; [Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Mata, Nathan L.] Sirion Therapeut, San Diego, CA 92121 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	travis@jsei.ucla.edu	Radu, Roxana A./K-8924-2019; Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Radu, Roxana/0000-0002-5064-6403	NATIONAL EYE INSTITUTE [R01EY011713] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011713-14, R01 EY011713-16, R01 EY011713-15, R01 EY011713, R01-EY01584] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Blackshaw S, 1999, J NEUROSCI, V19, P3681; Bok D, 2003, BIOCHEMISTRY-US, V42, P6090, DOI 10.1021/bi0342416; BOK D, 1992, EXP EYE RES, V55, P853, DOI 10.1016/0014-4835(92)90011-G; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Fu YB, 2005, CURR OPIN NEUROBIOL, V15, P415, DOI 10.1016/j.conb.2005.06.011; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; HAMSDORF K, 1979, HDB SENSORY PHYSL, V7, P45; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T; HO MTP, 1989, J BIOL CHEM, V264, P17759; Hu J, 2001, MOL VIS, V7, P14; HUBBARD R, 1962, NATURE, V193, P341, DOI 10.1038/193341a0; HUBBARD R, 1958, J GEN PHYSIOL, V41, P501, DOI 10.1085/jgp.41.3.501; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Mata JR, 1998, J LIPID RES, V39, P604; MATA NL, 1992, J BIOL CHEM, V267, P9794; Mata NL, 1996, J LIPID RES, V37, P1947; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Moise AR, 2007, J BIOL CHEM, V282, P2081, DOI 10.1074/jbc.M608315200; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; Nayak SK, 2007, CELL MOL LIFE SCI, V64, P144, DOI 10.1007/s00018-006-5581-1; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; SCHWEMER J, 1985, MOL MECH PHOTORECEPT, P326; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; Simon A, 1999, J CELL SCI, V112, P549; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; Tarttelin EE, 2003, FEBS LETT, V554, P410, DOI 10.1016/S0014-5793(03)01212-2; Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225; Tsuiki E, 2007, INVEST OPHTH VIS SCI, V48, P2858, DOI 10.1167/iovs.06-0768; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wenzel A, 2005, J BIOL CHEM, V280, P29874, DOI 10.1074/jbc.M503603200; Yang M, 2002, J BIOL CHEM, V277, P3318, DOI 10.1074/jbc.M108946200	59	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19730	19738		10.1074/jbc.M801288200	http://dx.doi.org/10.1074/jbc.M801288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18474598	Green Published, hybrid			2022-12-25	WOS:000257387600057
J	Christoffersen, C; Ahnstrom, J; Axler, O; Christensen, EI; Dahlback, B; Nielsen, LB				Christoffersen, Christina; Ahnstrom, Josefin; Axler, Olof; Christensen, Erik Ilso; Dahlback, Bjorn; Nielsen, Lars Bo			The signal peptide anchors apolipoprotein m in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAPTOGLOBIN-RELATED PROTEIN; TRYPANOSOME LYTIC FACTOR; ANTIINFLAMMATORY PROPERTIES; EXPRESSION; IDENTIFICATION; DEGRADATION; CHOLESTEROL; SECRETION; LIGAND	Lipoproteins consist of lipids solubilized by apolipoproteins. The lipid-binding structural motifs of apolipoproteins include amphipathic alpha-helixes and beta-sheets. Plasma apolipoprotein (apo) M lacks an external amphipathic motif but, nevertheless, is exclusively associated with lipoproteins ( mainly high density lipoprotein). Uniquely, however, apoM is secreted to plasma without cleavage of its hydrophobic NH2-terminal signal peptide. To test whether the signal peptide serves as a lipoprotein anchor for apoM in plasma, we generated mice expressing a mutated apoM(Q22A) cDNA in the liver ( apoM(Q22A)-Tg mice (transgenic mice)) and compared them with mice expressing wild-type human apoM( apoM-Tg mice). The substitution of the amino acid glutamine 22 with alanine in apoMQ22A results in secretion of human apoM without a signal peptide. The human apoM mRNA level in liver and the amount of human apoM protein secretion from hepatocytes were similar in apoM-Tg and apoMQ22A-Tg mice. Nevertheless, human apoM was not detectable in plasma of apoMQ22A-Tg mice, whereas it was easily measured in the apoM-Tg mice. To examine the plasma metabolism, recombinant apoM lacking the signal peptide was produced in Escherichia coli and injected into wild-type mice. The apoM without signal peptide did not associate with lipoproteins and was rapidly cleared in the kidney. Accordingly, ligation of the kidney arteries in apoMQ22A-Tg mice resulted in rapid accumulation of human apoM in plasma. The data suggest that hydrophobic signal peptide sequences, if preserved upon secretion, can anchor plasma proteins in lipoproteins. In the case of apoM, this mechanism prevents rapid loss by filtration in the kidney.	[Christoffersen, Christina; Nielsen, Lars Bo] Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; [Ahnstrom, Josefin; Axler, Olof; Dahlback, Bjorn] Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem, S-21401 Malmo, Sweden; [Christensen, Erik Ilso] Univ Aarhus, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark; [Nielsen, Lars Bo] Univ Copenhagen, Dept Biomed Sci, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Lund University; Skane University Hospital; Aarhus University; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem, KB3011,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk		Dahlback, Bjorn/0000-0003-1546-0328; Christoffersen, Christina/0000-0003-3751-5203				Ahnstrom J, 2007, J LIPID RES, V48, P1754, DOI 10.1194/jlr.M700103-JLR200; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; Axler O, 2008, FEBS LETT, V582, P826, DOI 10.1016/j.febslet.2008.02.007; Axler O, 2007, J LIPID RES, V48, P1772, DOI 10.1194/jlr.M700113-JLR200; Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Bro S, 2004, J AM SOC NEPHROL, V15, P1495, DOI 10.1097/01.ASN.0000128371.33195.7B; Carr SM, 2006, VIROLOGY, V344, P492, DOI 10.1016/j.virol.2005.08.041; CHEUNG MC, 1986, J LIPID RES, V27, P1135; Christoffersen C, 2008, J BIOL CHEM, V283, P1839, DOI 10.1074/jbc.M704576200; Christoffersen C, 2006, J LIPID RES, V47, P1833, DOI 10.1194/jlr.M600055-JLR200; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Deakin JE, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-281; Duan JX, 2001, FEBS LETT, V499, P127, DOI 10.1016/S0014-5793(01)02544-3; Faber K, 2006, MOL ENDOCRINOL, V20, P212, DOI 10.1210/me.2005-0209; Faber K, 2004, J LIPID RES, V45, P1272, DOI 10.1194/jlr.M300451-JLR200; Juul K, 1996, CIRCULATION, V94, P1698, DOI 10.1161/01.CIR.94.7.1698; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Nielsen MJ, 2006, BLOOD, V108, P2846, DOI 10.1182/blood-2006-05-022327; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; Raper J, 1999, INFECT IMMUN, V67, P1910; Sabol SL, 2005, J LIPID RES, V46, P2151, DOI 10.1194/jlr.M500080-JLR200; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; Segrest JP, 2001, J LIPID RES, V42, P1346; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Szabady RL, 2005, P NATL ACAD SCI USA, V102, P221, DOI 10.1073/pnas.0406055102; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Vanhollebeke B, 2007, P NATL ACAD SCI USA, V104, P4118, DOI 10.1073/pnas.0609902104; VON HG, 1991, J BIOL CHEM, V266, P15240; Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286; YE RD, 1988, J BIOL CHEM, V263, P4869	36	60	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18765	18772		10.1074/jbc.M800695200	http://dx.doi.org/10.1074/jbc.M800695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460466	hybrid			2022-12-25	WOS:000257165600033
J	Wei, YY; Jiang, JH; Liu, D; Zhou, J; Chen, XN; Zhang, S; Zong, HL; Yun, XJ; Gu, JX				Wei, Yuanyan; Jiang, Jianhai; Liu, Dan; Zhou, Jin; Chen, Xiaoning; Zhang, Si; Zong, Hongliang; Yun, Xiaojing; Gu, Jianxin			Cdc34-mediated degradation of ATF5 is blocked by cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL RESIDUE; ACTIVATING TRANSCRIPTION FACTOR-5; UBIQUITIN-PROTEASOME SYSTEM; NEURAL PROGENITOR CELLS; INDUCED APOPTOSIS; FUNCTIONAL INTERACTION; ATF/CREB FAMILY; CARCINOMA-CELLS; UP-REGULATION; HUMAN CDC34	ATF5, a member of activating transcription factor (ATF)/cAMP-response element-binding protein ( CREB) family of b-ZIP transcription factors, contributes to neural cell differentiation and is involved in cell apoptosis in response to cisplatin and a number of environment factors. However, the mechanisms governing the regulation of ATF5 protein during apoptosis are largely unknown. In this study we reported that ATF5 protein was a substrate of the ubiquitin-proteasome pathway. Interestingly, the ubiquitin-dependent degradation of exogenous ATF5 protein was independent of lysine residues. Instead, the addition of a large N-terminal enhanced green fluorescence protein tag increased the stability of ATF5 protein, and the free amino acid group of the N-terminal methionine of ATF5 protein was a site for ubiquitinylation, indicating that exogenous ATF5 was degraded via the ubiquitin-proteasome system through N-terminal ubiquitinylation. Furthermore, cisplatin increased ATF5 protein expression via preventing its ubiquitin-dependent degradation, which might be associated with its promoting the nucleus-to-cytoplasm translocation of E2 ubiquitin-conjugating enzyme Cdc34 and reducing the interaction between ATF5 and Cdc34. In summary, a down-regulation of proteasome-mediated degradation of ATF5 might contribute to cisplatin-induced apoptosis, providing a new mechanism of cisplatin-induced apoptosis.	[Gu, Jianxin] Fudan Univ, Ctr Gene Res, Key Lab Med Mol Virol, Minist Educ & Hlth, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Key Lab Glycoconjuates Res, Minist Publ Hlth, Shanghai 200032, Peoples R China; Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Ctr Gene Res, Key Lab Med Mol Virol, Minist Educ & Hlth, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	Zong, Hongliang/F-9366-2013; zhang, si/AAG-9094-2021	Zong, Hongliang/0000-0002-5855-5733; zhang, Si/0000-0002-5682-4995				ALBERTS DS, 1991, SEMIN ONCOL, V18, P11; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2006, ONCOGENE, V25, P907, DOI 10.1038/sj.onc.1209116; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Ben-Saadon R, 2004, J BIOL CHEM, V279, P41414, DOI 10.1074/jbc.M407201200; Block K, 2005, CELL CYCLE, V4, P1421, DOI 10.4161/cc.4.10.2054; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Collingwood TS, 2007, J BIOL CHEM, V282, P30920, DOI 10.1074/jbc.M706870200; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200; Funaoka K, 1996, CANCER LETT, V108, P15, DOI 10.1016/S0304-3835(96)04362-5; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOPALAN B, 2006, AACR M WASH APR 2006, P880; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoff Henry, 2004, Methods Mol Biol, V285, P79; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Hwang GW, 2007, BIOCHEM BIOPH RES CO, V363, P873, DOI 10.1016/j.bbrc.2007.09.064; Johnson CL, 2002, MOL CANCER THER, V1, P861; Jones NA, 1998, MOL PHARMACOL, V53, P819; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Liu WJ, 2004, BIOCHEM BIOPH RES CO, V321, P954, DOI 10.1016/j.bbrc.2004.07.053; Macdonald M, 2004, ONCOGENE, V23, P5643, DOI 10.1038/sj.onc.1207733; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; Monaco SE, 2007, INT J CANCER, V120, P1883, DOI 10.1002/ijc.22469; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Pati D, 1999, MOL CELL BIOL, V19, P5001; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Pintard L, 2003, NAT CELL BIOL, V5, P856, DOI 10.1038/ncb1003-856; Raymond F, 2000, J CELL SCI, V113, P1687; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Scaglione KM, 2007, MOL CELL BIOL, V27, P5860, DOI 10.1128/MCB.01555-06; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sun MY, 2006, BIOCHEM BIOPH RES CO, V340, P209, DOI 10.1016/j.bbrc.2005.12.003; Wei YY, 2006, BIOCHEM BIOPH RES CO, V339, P591, DOI 10.1016/j.bbrc.2005.11.054; Wood A, 2007, J BIOL CHEM, V282, P20256, DOI 10.1074/jbc.M702366200; Yang YZ, 2007, J CELL BIOCHEM, V101, P167, DOI 10.1002/jcb.21164	43	20	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18773	18781		10.1074/jbc.M707879200	http://dx.doi.org/10.1074/jbc.M707879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18458088	hybrid			2022-12-25	WOS:000257165600034
J	Belton, RJ; Chen, L; Mesquita, FS; Nowak, RA				Belton, Robert J., Jr.; Chen, Li; Mesquita, Fernando S.; Nowak, Romana A.			Basigin-2 is a cell surface receptor for soluble basigin ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INDUCER; COLLAGENASE STIMULATORY FACTOR; LEUKOCYTE ACTIVATION ANTIGEN; IMMUNOGLOBULIN SUPERFAMILY; STROMAL INTERACTIONS; HOMOPHILIC ADHESION; IG SUPERFAMILY; MOUSE BASIGIN; TUMOR; EMMPRIN	Themetastatic spread of a tumor is dependent upon the ability of the tumor to stimulate surrounding stromal cells to express enzymes required for tissue remodeling. The immunoglobulin superfamily protein basigin (EMMPRIN/CD147) is a cell surface glycoprotein expressed by tumor cells that stimulates matrix metalloproteinase and vascular endothelial growth factor expression in stromal cells. The ability of basigin to stimulate expression of molecules involved in tissue remodeling and angiogenesis makes basigin a potential target for the development of strategies to block metastasis. However, the identity of the cell surface receptor for basigin remains controversial. The goal of this study was to determine the identity of the receptor for basigin. Using a novel recombinant basigin protein (rBSG) corresponding to the extracellular domain of basigin, it was demonstrated that the native, nonglycosylated rBSG protein forms dimers in solution. Furthermore, rBSG binds to the surface of uterine fibroblasts, activates the ERK1/2 signaling pathway, and induces expression of matrix metalloproteinases 1, 2, and 3. Proteins that interact with rBSG were isolated using a biotin label transfer technique and sequenced by matrix-assisted laser desorption ionization tandem mass spectrophotometry. The results demonstrate that rBSG interacts with basigin expressed on the surface of fibroblasts and is subsequently internalized. During internalization, rBSG associates with a novel form of human basigin (basigin-3). It was concluded that cell surface basigin functions as a membrane receptor for soluble basigin and this homophilic interaction is not dependent upon glycosylation of the basigin ligand.	[Belton, Robert J., Jr.; Chen, Li; Mesquita, Fernando S.; Nowak, Romana A.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Belton, RJ (corresponding author), Univ Illinois, Dept Anim Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	rbelton@uiuc.edu	, Proteomics Core UNC/AFQ-7201-2022; MESQUITA, FERNANDO SILVEIRA/J-9978-2012; Belton, Robert/M-8591-2016	MESQUITA, FERNANDO SILVEIRA/0000-0002-4433-0832; Belton, Robert/0000-0002-6615-0517	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD040093] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 40093] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTRUDA F, 1989, GENE, V85, P445, DOI 10.1016/0378-1119(89)90438-1; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1982, BIOCHEM BIOPH RES CO, V109, P1026, DOI 10.1016/0006-291X(82)92042-3; BISWAS C, 1995, CANCER RES, V55, P434; BISWAS C, 1984, CANCER LETT, V24, P201, DOI 10.1016/0304-3835(84)90137-X; Caudroy S, 2002, CLIN EXP METASTAS, V19, P697, DOI 10.1023/A:1021350718226; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; Guo HM, 1997, J BIOL CHEM, V272, P24; Hanna S Melanie, 2003, BMC Biochem, V4, P17, DOI 10.1186/1471-2091-4-17; KANAME T, 1993, CYTOGENET CELL GENET, V64, P195, DOI 10.1159/000133573; KASINRERK W, 1992, J IMMUNOL, V149, P847; Krikun G, 2004, ENDOCRINOLOGY, V145, P2291, DOI 10.1210/en.2003-1606; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; McNiven MA, 2006, TRENDS CELL BIOL, V16, P487, DOI 10.1016/j.tcb.2006.08.007; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; Nabeshima K, 2004, J PATHOL, V202, P341, DOI 10.1002/path.1518; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; NEHME CL, 1993, J CELL BIOL, V120, P687, DOI 10.1083/jcb.120.3.687; Ochrietor JD, 2003, INVEST OPHTH VIS SCI, V44, P4086, DOI 10.1167/iovs.02-0995; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; SEULBERGER H, 1990, EMBO J, V9, P2151, DOI 10.1002/j.1460-2075.1990.tb07384.x; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Spring FA, 1997, EUR J IMMUNOL, V27, P891, DOI 10.1002/eji.1830270414; Sun JX, 2001, CANCER RES, V61, P2276; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yoshida S, 2000, EUR J BIOCHEM, V267, P4372, DOI 10.1046/j.1432-1327.2000.01482.x; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951; 1996, TISSUE ANTIGENS, V48, P352	42	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17805	17814		10.1074/jbc.M801876200	http://dx.doi.org/10.1074/jbc.M801876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434307	hybrid, Green Published			2022-12-25	WOS:000256949200008
J	Gebauer, JM; Murller, S; Hanisch, FG; Paulsson, M; Wagener, R				Gebauer, Jan M.; Mueller, Stefan; Hanisch, Franz-Georg; Paulsson, Mats; Wagener, Raimund			O-glucosylation and O-fucosylation occur together in close proximity on the first epidermal growth factor repeat of AMACO (VWA2 protein)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOSPONDIN TYPE-1 REPEATS; NOTCH-DELTA INTERACTIONS; LIGAND-BINDING; LINKED FUCOSE; FACTOR-VII; C-MANNOSYLATION; SERINE RESIDUE; FACTOR-IX; FRINGE; GLYCOSYLATION	AMACO(VWA2protein) is an extracellular matrix protein of unknown function associated with certain basement membranes in skin, lung, and kidney. AMACO is a member of the von Willebrand factor A-like (VWA) domain containing protein superfamily and in addition to three VWA domains it also contains two epidermal growth factor-like domains. One of these contains the rare, overlapping consensus sequences for both O-glucosylation and O-fucosylation. In earlier studies of other proteins the attachment of either core glucose and fucose moieties or of the respective elongated glycans starting with these monosaccharides has been described. By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain. It has been reported that the lack of O-fucosylation can markedly decrease secretion of proteins. However, the secretion of AMACO is not significantly affected when the glycosylation sites are mutated. The number of extracellular matrix proteins carrying the overlapping consensus sequence is very limited and it could be that these modifications have a new, yet unknown function.	[Gebauer, Jan M.; Hanisch, Franz-Georg; Paulsson, Mats; Wagener, Raimund] Univ Cologne, Ctr Biochem, Fac Med, D-50931 Cologne, Germany; [Mueller, Stefan; Hanisch, Franz-Georg; Paulsson, Mats] Univ Cologne, Ctr Mol Med, Fac Med, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Wagener, R (corresponding author), Univ Cologne, Ctr Biochem, Fac Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Gebauer, Jan/B-8115-2008; Gebauer, Jan M/C-3085-2009	Gebauer, Jan M/0000-0002-3989-4748				ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Eller E, 2004, ANN NY ACAD SCI, V1037, P145, DOI 10.1196/annals.1337.024; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Gara SK, 2008, J BIOL CHEM, V283, P10658, DOI 10.1074/jbc.M709540200; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Krogh TN, 1997, EUR J BIOCHEM, V244, P334, DOI 10.1111/j.1432-1033.1997.00334.x; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Maertens B, 2007, J BIOL CHEM, V282, P10647, DOI 10.1074/jbc.M611339200; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOCHEM-TOKYO, V111, P460, DOI 10.1093/oxfordjournals.jbchem.a123780; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Peter-Katalinic J, 2005, METHOD ENZYMOL, V405, P139, DOI 10.1016/S0076-6879(05)05007-X; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Ricketts LM, 2007, J BIOL CHEM, V282, P17014, DOI 10.1074/jbc.M700317200; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Schulz BL, 2002, ANAL CHEM, V74, P6088, DOI 10.1021/ac025890a; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Wang LW, 2007, J BIOL CHEM, V282, P17024, DOI 10.1074/jbc.M701065200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Xin BZ, 2005, ONCOGENE, V24, P724, DOI 10.1038/sj.onc.1208134; Xu AG, 2007, J BIOL CHEM, V282, P35153, DOI 10.1074/jbc.M707040200	37	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17846	17854		10.1074/jbc.M704820200	http://dx.doi.org/10.1074/jbc.M704820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434322	hybrid			2022-12-25	WOS:000256949200012
J	Kukreti, P; Singh, K; Ketkar, A; Modak, MJ				Kukreti, Pinky; Singh, Kamalendra; Ketkar, Amit; Modak, Mukund J.			Identification of a new motif required for the 3 '-5 ' exonuclease activity of Escherichia coli DNA polymerase I (Klenow fragment) - The RRRY motif is necessary for the binding of single-stranded DNA substrate and the template strand of the mismatched duplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							J-HELIX; COMPLEX; SITE; STABILIZATION; REPLICATION; EXONUCLEASE; CRYSTAL; 3'->5'-EXONUCLEASE; PATHWAYS; RESIDUES	The Klenow fragment of Escherichia coli DNA polymerase I houses catalytic centers for both polymerase and 3'-5' exonuclease activities that are separated by about 35 A. Upon the incorporation of a mismatched nucleotide, the primer terminus is transferred from the polymerase site to an exonuclease site designed for excision of the mismatched nucleotides. The structural comparison of the binary complexes of DNA polymerases in the polymerase and the exonuclease modes, together with a molecular modeling of the template strand overhang in Klenow fragment, indicated its binding in the region spanning residues 821-824. Since these residues are conserved in the "A" family DNA polymerases, we have designated this region as the RRRY motif. The alanine substitution of individual amino acid residues of this motif did not change the polymerase activity; however, the 3'-5' exonuclease activity was reduced 2 -29-fold, depending upon the site of mutation. The R821A and R822A/Y824A mutant enzymes showed maximum cleavage defect with single-stranded DNA, mainly due to a large decrease in the ssDNA binding affinity of these enzymes. Mismatch removal by these enzymes was only moderately affected. However, data from the exonuclease-polymerase balance assays with mismatched template-primer suggest that the mutant enzymes are defective in switching mismatched primer from the polymerase to the exonuclease site. Thus, the RRRY motif provides a binding track for substrate ssDNA and for nonsubstrate single-stranded template overhang, in a polarity-dependent manner. This binding then facilitates cleavage of the substrate at the exonuclease site.	[Modak, Mukund J.] Univ Med & Dent New Jersey, Sch Med, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, MJ (corresponding author), Univ Med & Dent New Jersey, Sch Med, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	modak@umdnj.edu	Ketkar, Amit/H-8022-2019	ketkar, amit/0000-0002-6536-7415	NIAID NIH HHS [AI 064477] Funding Source: Medline; NIGMS NIH HHS [GM 36307] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI064477] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BROWN T, 1992, CURR BIOL, V2, P299; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Hogg M, 2007, J BIOL CHEM, V282, P1432, DOI 10.1074/jbc.M605675200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KORNBERG A, 1992, DNA REPLICATION, P130; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUKRETI P, 2007, FASEB ANN M WASH DC; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MENDEZ J, 1994, J BIOL CHEM, V269, P30030; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Rossi ML, 2006, J BIOL CHEM, V281, P26051, DOI 10.1074/jbc.M604805200; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Singh K, 2005, BIOCHEMISTRY-US, V44, P8101, DOI 10.1021/bi050140r; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; Srivastava A, 2003, BIOCHEMISTRY-US, V42, P3645, DOI 10.1021/bi026699y; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200	29	11	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17979	17990		10.1074/jbc.M801053200	http://dx.doi.org/10.1074/jbc.M801053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18448432	Green Published, hybrid			2022-12-25	WOS:000256949200027
J	Bren, GD; Whitman, J; Cummins, N; Shepard, B; Rizza, SA; Trushin, SA; Badley, AD				Bren, Gary D.; Whitman, Joe; Cummins, Nathan; Shepard, Brett; Rizza, Stacey A.; Trushin, Sergey A.; Badley, Andrew D.			Infected Cell Killing by HIV-1 Protease Promotes NF-kappa B Dependent HIV-1 Replication	PLOS ONE			English	Article								Acute HIV-1 infection of CD4 T cells often results in apoptotic death of infected cells, yet it is unclear what evolutionary advantage this offers to HIV-1. Given the independent observations that acute T cell HIV-1 infection results in (1) NF-kappa B activation, (2) caspase 8 dependent apoptosis, and that (3) caspase 8 directly activates NF-kappa B, we questioned whether these three events might be interrelated. We first show that HIV-1 infected T cell apoptosis, NF-kappa B activation, and caspase 8 cleavage by HIV-1 protease are coincident. Next we show that HIV-1 protease not only cleaves procaspase 8, producing Casp8p41, but also independently stimulates NF-kappa B activity. Finally, we demonstrate that the HIV protease cleavage of caspase 8 is necessary for optimal NF-kappa B activation and that the HIV-1 protease specific cleavage fragment Casp8p41 is sufficient to stimulate HIV-1 replication through NF-kappa B dependent HIV-LTR activation both in vitro as well as in cells from HIV infected donors. Consequently, the molecular events which promote death of HIV-1 infected T cells function dually to promote HIV-1 replication, thereby favoring the propagation and survival of HIV-1.	[Bren, Gary D.; Whitman, Joe; Cummins, Nathan; Shepard, Brett; Rizza, Stacey A.; Trushin, Sergey A.; Badley, Andrew D.] Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA; [Rizza, Stacey A.; Badley, Andrew D.] Mayo Clin, Program Translat Immunovirol & Biodefense, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Bren, GD (corresponding author), Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA.	badley.andrew@mayo.edu	badley, andrew d/O-9022-2014	Badley, Andrew/0000-0001-7796-7680	National Institutes of Health [R01 AI62261, R01 AI40384, R21DK 77575-1]; Burroughs Wellcome Fund's Clinical Scientist Award in Translational Research [1005160]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062261, R01AI040384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077575] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund's Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr. Andrew Badley is supported by grants from the National Institutes of Health (R01 AI62261 and R01 AI40384), and the Burroughs Wellcome Fund's Clinical Scientist Award in Translational Research (ID#1005160). Dr. Stacey Rizza is supported by a grant from the National Institute of Health (R21DK 77575-1).	Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; Gil J, 2004, PROG MOL SUBCELL BIO, V36, P117; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Lemmers B, 2007, J BIOL CHEM, V282, P7416, DOI 10.1074/jbc.M606721200; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Nie Z, 2002, CELL DEATH DIFFER, V9, P1172, DOI 10.1038/sj.cdd.4401094; NIE Z, 2006, CELL DEATH HIV INFEC, P421; Nie Z, 2007, J VIROL, V81, P6947, DOI 10.1128/JVI.02798-06; Nie Zilin, 2008, Open Virol J, V2, P1, DOI 10.2174/1874357900802010001; PEREZ VL, 1991, J IMMUNOL, V147, P3145; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Swingler S, 2007, PLOS PATHOG, V3, P1281, DOI 10.1371/journal.ppat.0030134	16	22	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2112	10.1371/journal.pone.0002112	http://dx.doi.org/10.1371/journal.pone.0002112			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461165	gold, Green Submitted, Green Published			2022-12-25	WOS:000261642400034
J	Cauchi, S; Meyre, D; Durand, E; Proenca, C; Marre, M; Hadjadj, S; Choquet, H; De Graeve, F; Gaget, S; Allegaert, F; Delplanque, J; Permutt, MA; Wasson, J; Blech, I; Charpentier, G; Balkau, B; Vergnaud, AC; Czernichow, S; Patsch, W; Chikri, M; Glaser, B; Sladek, R; Froguel, P				Cauchi, Stephane; Meyre, David; Durand, Emmanuelle; Proenca, Christine; Marre, Michel; Hadjadj, Samy; Choquet, Helene; De Graeve, Franck; Gaget, Stefan; Allegaert, Frederic; Delplanque, Jerome; Permutt, Marshall Alan; Wasson, Jon; Blech, Ilana; Charpentier, Guillaume; Balkau, Beverley; Vergnaud, Anne-Claire; Czernichow, Sebastien; Patsch, Wolfgang; Chikri, Mohamed; Glaser, Benjamin; Sladek, Robert; Froguel, Philippe			Post Genome-Wide Association Studies of Novel Genes Associated with Type 2 Diabetes Show Gene-Gene Interaction and High Predictive Value	PLOS ONE			English	Article							ANTIOXIDANT VITAMINS; COMPLEX DISEASES; RISK LOCI; OBESITY; POPULATION; SU.VI.MAX; TRIAL	Background: Recently, several Genome Wide Association (GWA) studies in populations of European descent have identified and validated novel single nucleotide polymorphisms (SNPs), highly associated with type 2 diabetes (T2D). Our aims were to validate these markers in other European and non-European populations, then to assess their combined effect in a large French study comparing T2D and normal glucose tolerant (NGT) individuals. Methodology/Principal Findings: In the same French population analyzed in our previous GWA study (3,295 T2D and 3,595 NGT), strong associations with T2D were found for CDKAL1 (ORrs7756992 = 1.30[1.19-1.42], P = 2.3 x 10(-9)), CDKN2A/2B (ORrs10811661 = 0.74[0.66-0.82], P = 3.5 x 10(-8)) and more modestly for IGFBP2 (ORrs1470579 = 1.17[1.07-1.27], P = 0.0003) SNPs. These results were replicated in both Israeli Ashkenazi (577 T2D and 552 NGT) and Austrian (504 T2D and 753 NGT) populations (except for CDKAL1) but not in the Moroccan population (521 T2D and 423 NGT). In the overall group of French subjects (4,232 T2D and 4,595 NGT), IGFBP2 and CXCR4 synergistically interacted with (LOC38776, SLC30A8, HHEX) and (NGN3, CDKN2A/2B), respectively, encoding for proteins presumably regulating pancreatic endocrine cell development and function. The T2D risk increased strongly when risk alleles, including the previously discovered T2D-associated TCF7L2 rs7903146 SNP, were combined (8.68-fold for the 14% of French individuals carrying 18 to 30 risk alleles with an allelic OR of 1.24). With an area under the ROC curve of 0.86, only 15 novel loci were necessary to discriminate French individuals susceptible to develop T2D. Conclusions/Significance: In addition to TCF7L2, SLC30A8 and HHEX, initially identified by the French GWA scan, CDKAL1, IGFBP2 and CDKN2A/2B strongly associate with T2D in French individuals, and mostly in populations of Central European descent but not in Moroccan subjects. Genes expressed in the pancreas interact together and their combined effect dramatically increases the risk for T2D, opening avenues for the development of genetic prediction tests.	[Cauchi, Stephane; Meyre, David; Durand, Emmanuelle; Proenca, Christine; Choquet, Helene; De Graeve, Franck; Gaget, Stefan; Allegaert, Frederic; Delplanque, Jerome; Froguel, Philippe] Inst Pasteur, Inst Biol, CNRS 8090, F-59019 Lille, France; [Marre, Michel] INSERM U695, Paris, France; [Marre, Michel] Rene Diderot Paris 7 Univ, Paris, France; [Marre, Michel] Bichat Claude Bernard Hosp, Dept Endocrinol Diabetol & Nutrit, Paris, France; [Hadjadj, Samy] UFR Med Pharm, Univ Poitiers, INSERM U927, CIC INSERM 0801,CHU Poitiers, Poitiers, France; [Permutt, Marshall Alan; Wasson, Jon] Washington Univ, Sch Med, St Louis, MO USA; [Blech, Ilana; Glaser, Benjamin] Hadassah Hebrew Univ, Med Ctr, Dept Internal Med, Endocrinol & Metabolism Serv, Jerusalem, Israel; [Charpentier, Guillaume] Corbeil Essonnes Hosp, Endocrinol Diabetol Unit, Corbeil Essonnes, France; [Balkau, Beverley] INSERM U780 IFR69, Villejuif, France; [Balkau, Beverley] Univ Paris Sud, Paris, France; [Vergnaud, Anne-Claire; Czernichow, Sebastien] PARIS 13 CRNH IdF, CNAM, U1125 INRA, UMR U557 INSERM, Bobigny, France; [Czernichow, Sebastien] Assistance Publ Hop Paris AP HP, Dept Sante Publ, Hop Avicenne, Bobigny, France; [Patsch, Wolfgang] Paracelsus Med Univ, Landeskrankenhaus Salzburg, Dept Lab Med, Salzburg, Austria; [Chikri, Mohamed] Route Sidi Harazem, Pharm Fez, Fac Med, Lab Biochem, Fes, Morocco; [Sladek, Robert] McGill Univ, Fac Med, Dept Human Genet, Montreal, PQ, Canada; [Sladek, Robert] McGill Univ, Fac Med, Dept Med, Montreal, PQ, Canada; [Sladek, Robert] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Froguel, Philippe] Imperial Coll London, Hammersmith Hosp, Genom Med, London, England	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Washington University (WUSTL); Hebrew University of Jerusalem; Hadassah University Medical Center; Centre Hospitalier Sud Francilien; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; heSam Universite; Conservatoire National Arts & Metiers (CNAM); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Paracelsus Private Medical University; Mohammed First University of Oujda; Sidi Mohamed Ben Abdellah University of Fez; McGill University; McGill University; McGill University; Imperial College London	Cauchi, S (corresponding author), Inst Pasteur, Inst Biol, CNRS 8090, F-59019 Lille, France.	p.froguel@imperial.ac.uk	Glaser, Benjamin/F-8411-2017; Sladek, Robert/R-2391-2019; FROGUEL, Philippe/O-6799-2017; Meyre, David/D-7315-2011	Glaser, Benjamin/0000-0003-4711-5000; Sladek, Robert/0000-0002-2730-1204; FROGUEL, Philippe/0000-0003-2972-0784; Meyre, David/0000-0003-4850-7444; Gueranger, Anne-Claire/0000-0003-0728-9313; Marre, Michel/0000-0002-3071-1837; Choquet, Helene/0000-0001-9839-8667	French Governmental Agence Nationale de la Recherche; European Union [LSHM-CT-2006-518153]; Association Francaise des Diabetiques; Programme National de Recherche sur le Diabete; Medical Research Council [G0600331] Funding Source: researchfish; MRC [G0600331] Funding Source: UKRI	French Governmental Agence Nationale de la Recherche(French National Research Agency (ANR)); European Union(European Commission); Association Francaise des Diabetiques; Programme National de Recherche sur le Diabete; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by the French Governmental Agence Nationale de la Recherche, the European Union (Integrated Project EuroDia LSHM-CT-2006-518153 in the Framework Programme 6 [FP6] of the European-Community, to PF), and the charities Association Francaise des Diabetiques and Programme National de Recherche sur le Diabete.	Cauchi S, 2007, J MOL MED, V85, P777, DOI 10.1007/s00109-007-0203-4; Chimienti F, 2005, BIOMETALS, V18, P313, DOI 10.1007/s10534-005-3687-9; Chimienti F, 2006, J CELL SCI, V119, P4199, DOI 10.1242/jcs.03164; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; FLOREZ JC, 2007, DIABETES, DOI DOI 10.2337/DB07-0451; Frayling TM, 2007, NAT REV GENET, V8, P657, DOI 10.1038/nrg2178; Furukawa Y, 2008, J CLIN ENDOCR METAB, V93, P310, DOI 10.1210/jc.2007-1029; GRARUP N, 2007, DIABETES; HADJADJ S, PROGNOSTIC VAL UNPUB; HANSON RL, 2007, DIABETES; HAYES MG, 2007, DIABETES; HELGASON A, 2007, NAT GENET; Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335; Hercberg S, 1998, CONTROL CLIN TRIALS, V19, P336, DOI 10.1016/S0197-2456(98)00015-4; HORIKOSHI M, 2007, DIABETOLOGIA; Janssens ACJW, 2004, AM J HUM GENET, V74, P585, DOI 10.1086/382052; Koblas T, 2007, FOLIA BIOL-PRAGUE, V53, P13; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Meyre D, 2005, NAT GENET, V37, P863, DOI 10.1038/ng1604; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Oberkofler H, 2004, DIABETES, V53, P1385, DOI 10.2337/diabetes.53.5.1385; Omori S, 2007, DIABETES; RAMPERSAUD E, 2007, DIABETES; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Schulze MB, 2007, DIABETOLOGIA, V50, P2405, DOI 10.1007/s00125-007-0766-1; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Weedon MN, 2006, PLOS MED, V3, P1877, DOI 10.1371/journal.pmed.0030374; Yang QH, 2005, INT J EPIDEMIOL, V34, P1129, DOI 10.1093/ije/dyi130; Yang QH, 2003, AM J HUM GENET, V72, P636, DOI 10.1086/367923; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	33	123	130	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2031	10.1371/journal.pone.0002031	http://dx.doi.org/10.1371/journal.pone.0002031			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461161	gold, Green Published			2022-12-25	WOS:000261642400001
J	Jayapal, KP; Philp, RJ; Kok, YJ; Yap, MGS; Sherman, DH; Griffin, TJ; Hu, WS				Jayapal, Karthik P.; Philp, Robin J.; Kok, Yee-Jiun; Yap, Miranda G. S.; Sherman, David H.; Griffin, Timothy J.; Hu, Wei-Shou			Uncovering Genes with Divergent mRNA-Protein Dynamics in Streptomyces coelicolor	PLOS ONE			English	Article							ABSOLUTE PROTEIN; GLOBAL ANALYSIS; EXPRESSION; ABUNDANCE; SEQUENCE; CODON; TRANSCRIPTOME; QUANTITATION; PEPTIDES; PATHWAY	Many biological processes are intrinsically dynamic, incurring profound changes at both molecular and physiological levels. Systems analyses of such processes incorporating large-scale transcriptome or proteome profiling can be quite revealing. Although consistency between mRNA and proteins is often implicitly assumed in many studies, examples of divergent trends are frequently observed. Here, we present a comparative transcriptome and proteome analysis of growth and stationary phase adaptation in Streptomyces coelicolor, taking the time-dynamics of process into consideration. These processes are of immense interest in microbiology as they pertain to the physiological transformations eliciting biosynthesis of many naturally occurring therapeutic agents. A shotgun proteomics approach based on mass spectrometric analysis of isobaric stable isotope labeled peptides (iTRAQ (TM)) enabled identification and rapid quantification of approximately 14% of the theoretical proteome of S. coelicolor. Independent principal component analyses of this and DNA microarray-derived transcriptome data revealed that the prominent patterns in both protein and mRNA domains are surprisingly well correlated. Despite this overall correlation, by employing a systematic concordance analysis, we estimated that over 30% of the analyzed genes likely exhibited significantly divergent patterns, of which nearly one-third displayed even opposing trends. Integrating this data with biological information, we discovered that certain groups of functionally related genes exhibit mRNA-protein discordance in a similar fashion. Our observations suggest that differences between mRNA and protein synthesis/degradation mechanisms are prominent in microbes while reaffirming the plausibility of such mechanisms acting in a concerted fashion at a protein complex or sub-pathway level.	[Jayapal, Karthik P.; Hu, Wei-Shou] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; [Philp, Robin J.; Kok, Yee-Jiun; Yap, Miranda G. S.] Agcy Sci Technol & Res, Bioprocessing Technol Inst, Singapore, Singapore; [Sherman, David H.] Univ Michigan, Dept Med Chem, Life Sci Inst, Ann Arbor, MI USA; [Sherman, David H.] Univ Michigan, Dept Chem, Life Sci Inst, Ann Arbor, MI USA; [Sherman, David H.] Univ Michigan, Dept Microbiol & Immunol, Life Sci Inst, Ann Arbor, MI USA; [Griffin, Timothy J.] Univ Minnesota, Dept Biochem, Mol Biol & Biophys, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Jayapal, KP (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	acre@cems.umn.edu	Kok, Yee Jiun/HCH-9659-2022	Kok, Yee Jiun/0000-0001-6875-8262; Griffin, Timothy/0000-0001-6801-2559	National Institutes of Health [GM55850]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded in part by a grant from the National Institutes of Health (GM55850). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Challis GL, 2003, P NATL ACAD SCI USA, V100, P14555, DOI 10.1073/pnas.1934677100; Charaniya S, 2007, NUCLEIC ACIDS RES, V35, P7222, DOI 10.1093/nar/gkm501; Chong PK, 2006, J PROTEOME RES, V5, P1232, DOI 10.1021/pr060018u; de Crecy-Lagard V, 1999, MOL MICROBIOL, V32, P505, DOI 10.1046/j.1365-2958.1999.01364.x; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hesketh AR, 2002, MOL MICROBIOL, V46, P917, DOI 10.1046/j.1365-2958.2002.03219.x; Huang JQ, 2001, GENE DEV, V15, P3183, DOI 10.1101/gad.943401; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Jansen R, 2003, NUCLEIC ACIDS RES, V31, P2242, DOI 10.1093/nar/gkg306; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; LI W, 2006, FEMS MICROBIOL LETT; Lithwick G, 2003, GENOME RES, V13, P2665, DOI 10.1101/gr.1485203; Lu P, 2007, NAT BIOTECHNOL, V25, P117, DOI 10.1038/nbt1270; Martin-Galiano AJ, 2004, MICROBIOL-SGM, V150, P2313, DOI 10.1099/mic.0.27097-0; Mehra S, 2006, J IND MICROBIOL BIOT, V33, P159, DOI 10.1007/s10295-005-0034-7; Mogk A, 2007, TRENDS CELL BIOL, V17, P165, DOI 10.1016/j.tcb.2007.02.001; Molloy MP, 2003, PROTEOMICS, V3, P1912, DOI 10.1002/pmic.200300534; Nie L, 2006, GENETICS, V174, P2229, DOI 10.1534/genetics.106.065862; Price B, 1999, J BACTERIOL, V181, P6142, DOI 10.1128/JB.181.19.6142-6151.1999; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Schmidt MW, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100117; Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050-MCP200; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; Takano E, 2003, MOL MICROBIOL, V50, P475, DOI 10.1046/j.1365-2958.2003.03728.x; Vohradsky J, 2007, PROTEOMICS, V7, P3853, DOI 10.1002/pmic.200700005; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Wu G, 2005, MICROBIOL-SGM, V151, P2175, DOI 10.1099/mic.0.27833-0	34	75	76	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2097	10.1371/journal.pone.0002097	http://dx.doi.org/10.1371/journal.pone.0002097			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461186	Green Submitted, gold, Green Published			2022-12-25	WOS:000261642400019
J	Sun, T; McMinn, P; Holcombe, M; Smallwood, R; MacNeil, S				Sun, Tao; McMinn, Phil; Holcombe, Mike; Smallwood, Rod; MacNeil, Sheila			Agent Based Modelling Helps in Understanding the Rules by Which Fibroblasts Support Keratinocyte Colony Formation	PLOS ONE			English	Article							CELL-CELL INTERACTIONS; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; IN-VITRO; EPIDERMAL INTERACTION; INDUCED APOPTOSIS; FEEDER CELLS; STEM-CELLS; SKIN; PROLIFERATION	Background: Autologous keratincoytes are routinely expanded using irradiated mouse fibroblasts and bovine serum for clinical use. With growing concerns about the safety of these xenobiotic materials, it is desirable to culture keratinocytes in media without animal derived products. An improved understanding of epithelial/mesenchymal interactions could assist in this. Methodology/Principal Findings: A keratincyte/fibroblast o-culture model was developed by extending an agent-based keratinocyte colony formation model to include the response of keratinocytes to both fibroblasts and serum. The model was validated by comparison of the in virtuo and in vitro multicellular behaviour of keratinocytes and fibroblasts in single and co-culture in Greens medium. To test the robustness of the model, several properties of the fibroblasts were changed to investigate their influence on the multicellular morphogenesis of keratinocyes and fibroblasts. The model was then used to generate hypotheses to explore the interactions of both proliferative and growth arrested fibroblasts with keratinocytes. The key predictions arising from the model which were confirmed by in vitro experiments were that 1) the ratio of fibroblasts to keratinocytes would critically influence keratinocyte colony expansion, 2) this ratio needed to be optimum at the beginning of the co-culture, 3) proliferative fibroblasts would be more effective than irradiated cells in expanding keratinocytes and 4) in the presence of an adequate number of fibroblasts, keratinocyte expansion would be independent of serum. Conclusions: A closely associated computational and biological approach is a powerful tool for understanding complex biological systems such as the interactions between keratinocytes and fibroblasts. The key outcome of this study is the finding that the early addition of a critical ratio of proliferative fibroblasts can give rapid keratinocyte expansion without the use of irradiated mouse fibroblasts and bovine serum.	[Sun, Tao; MacNeil, Sheila] Univ Sheffield, Dept Mat Engn, Sheffield, S Yorkshire, England; [McMinn, Phil; Holcombe, Mike; Smallwood, Rod] Univ Sheffield, Dept Comp Sci, Sheffield, S Yorkshire, England	University of Sheffield; University of Sheffield	Sun, T (corresponding author), Univ Sheffield, Dept Mat Engn, Sheffield, S Yorkshire, England.	tao@sheffield.ac.uk; s.macneil@sheffield.ac.uk	Smallwood, Rod/C-5583-2011	Smallwood, Rod/0000-0003-0134-0632	EPSRC(UK)	EPSRC(UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	Funding from EPSRC(UK). The funder did not play a role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation of the manuscript.	ABSHER M, 1981, ENVIRON RES, V26, P438, DOI 10.1016/0013-9351(81)90219-X; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; Angel P, 2002, BIOCHEM PHARMACOL, V64, P949, DOI 10.1016/S0006-2952(02)01158-9; Ashkenas J, 1996, DEV BIOL, V180, P433, DOI 10.1006/dbio.1996.0317; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Beyer TA, 2003, EXP CELL RES, V287, P228, DOI 10.1016/S0014-4827(03)00139-3; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; Blomme EAG, 1999, MOL CELL ENDOCRINOL, V152, P189, DOI 10.1016/S0303-7207(98)00252-4; BOGAERDT AJ, 2004, BIOCHEM BIOPH RES CO, V315, P428, DOI DOI 10.1016/J.BBRC.2004.01.069; Bowers W, 1999, J DERMATOL SCI, V20, P172, DOI 10.1016/S0923-1811(98)00079-6; Bullock AJ, 2006, TISSUE ENG, V12, P245, DOI 10.1089/ten.2006.12.245; Casella GTB, 2000, GLIA, V30, P165, DOI 10.1002/(SICI)1098-1136(200004)30:2<165::AID-GLIA6>3.0.CO;2-L; Chang CC, 1995, J SURG RES, V59, P705, DOI 10.1006/jsre.1995.1227; CLAVEL C, 2005, IL FARMACO, V60, P721; COAKLEY S, 2006, P AG DIR SIM ADS 06; Dai NT, 2004, BIOMATERIALS, V25, P4263, DOI 10.1016/j.biomaterials.2003.11.022; Dawson RA, 1996, BURNS, V22, P93, DOI 10.1016/0305-4179(95)00092-5; Dilley TK, 2003, EXP CELL RES, V290, P38, DOI 10.1016/S0014-4827(03)00308-2; Drasdo D, 2005, PHYS BIOL, V2, P133, DOI 10.1088/1478-3975/2/3/001; Fleischmajer R, 2000, MATRIX BIOL, V19, P637, DOI 10.1016/S0945-053X(00)00092-5; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Galle J, 2005, BIOPHYS J, V88, P62, DOI 10.1529/biophysj.104.041459; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GIZELDA TB, 2000, GLIA, V30, P165; GORELIK JV, 1995, CELL BIOL INT, V19, P59, DOI 10.1006/cbir.1995.1008; Goulet F, 1996, BURNS, V22, P107, DOI 10.1016/0305-4179(95)00098-4; Grabe N, 2005, BIOINFORMATICS, V21, P3541, DOI 10.1093/bioinformatics/bti585; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Harrison CA, 2005, WOUND REPAIR REGEN, V13, P543, DOI 10.1111/j.1524-475X.2005.00076.x; Higham MC, 2003, TISSUE ENG, V9, P919, DOI 10.1089/107632703322495565; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kanzaki Y, 2002, EXP CELL RES, V279, P321, DOI 10.1006/excr.2002.5607; Keller UAD, 2004, EUR J CELL BIOL, V83, P607; Kim BM, 1999, BRIT J PLAST SURG, V52, P573, DOI 10.1054/bjps.1999.3162; Kolettas E, 2006, ARCH BIOCHEM BIOPHYS, V445, P184, DOI 10.1016/j.abb.2005.10.006; Kopp J, 2004, MOL THER, V10, P86, DOI 10.1016/j.ymthe.2004.04.016; MACIEIRACOELHO A, 1982, EXP CELL RES, V141, P325, DOI 10.1016/0014-4827(82)90220-8; MacNeil S, 2007, NATURE, V445, P874, DOI 10.1038/nature05664; Matsuyoshi N, 1997, BIOCHEM BIOPH RES CO, V235, P355, DOI 10.1006/bbrc.1997.6707; Meineke FA, 2001, CELL PROLIFERAT, V34, P253, DOI 10.1046/j.0960-7722.2001.00216.x; Mirastschijski U, 2004, EXP CELL RES, V299, P465, DOI 10.1016/j.yexcr.2004.06.007; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Morel D, 2001, ACTA BIOTHEOR, V49, P219, DOI 10.1023/A:1014201805222; Nelson CM, 2002, FEBS LETT, V514, P238, DOI 10.1016/S0014-5793(02)02370-0; Okazaki M, 2002, J DERMATOL SCI, V30, P108, DOI 10.1016/S0923-1811(02)00066-X; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Osborne CS, 1999, BIOMATERIALS, V20, P283, DOI 10.1016/S0142-9612(98)00179-3; Owen MR, 1998, MATH BIOSCI, V153, P125, DOI 10.1016/S0025-5564(98)10034-2; Ponciano JM, 2005, APPL ENVIRON MICROB, V71, P2355, DOI 10.1128/AEM.71.5.2355-2364.2005; Rashbass J, 1996, TRENDS CELL BIOL, V6, P280, DOI 10.1016/0962-8924(96)60028-2; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Roguet R, 1997, TOXICOL IN VITRO, V11, P591, DOI 10.1016/S0887-2333(97)00062-3; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Scheffrahn I, 2005, EXP CELL RES, V307, P427, DOI 10.1016/j.yexcr.2005.03.030; Sher I, 2003, FEBS LETT, V552, P150, DOI 10.1016/S0014-5793(03)00909-8; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; Sorrell JM, 2004, J CELL SCI, V117, P667, DOI 10.1242/jcs.01005; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stark HJ, 2004, EUR J CELL BIOL, V83, P631, DOI 10.1078/0171-9335-00435; Sun T, 2007, J MATER SCI-MATER M, V18, P321, DOI 10.1007/s10856-006-0696-3; Sun T, 2005, TISSUE ENG, V11, P1023, DOI 10.1089/ten.2005.11.1023; Sun T, 2004, WOUND REPAIR REGEN, V12, P626, DOI 10.1111/j.1067-1927.2004.12609.x; Sun T, 2007, J R SOC INTERFACE, V4, P1077, DOI 10.1098/rsif.2007.0227; Suzuki K, 2003, PROG RETIN EYE RES, V22, P113, DOI 10.1016/S1350-9462(02)00042-3; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; SZABOWSKI MN, 1999, J CELL SCI, V112, P1843; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; TAKEUCHI F, 1982, EXP GERONTOL, V17, P473, DOI 10.1016/S0531-5565(82)80009-0; Tepper CG, 2000, EXP CELL RES, V260, P9, DOI 10.1006/excr.2000.4990; Uchi H, 2000, J DERMATOL SCI, V24, pS29, DOI 10.1016/S0923-1811(00)00138-9; WAELTI ER, 1992, J INVEST DERMATOL, V98, P805, DOI 10.1111/1523-1747.ep12499961; Walker JL, 2005, CYTOKINE GROWTH F R, V16, P395, DOI 10.1016/j.cytogfr.2005.03.003; Wearing HJ, 2000, MATH BIOSCI, V165, P41, DOI 10.1016/S0025-5564(00)00008-0; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Williams IR, 1996, LIFE SCI, V58, P1485, DOI 10.1016/0024-3205(96)00042-2; Witte RP, 2005, BIOMATERIALS, V26, P3673, DOI 10.1016/j.biomaterials.2004.09.054; Yamaguchi Y, 2005, J DERMATOL SCI, V40, P1, DOI 10.1016/j.jdermsci.2005.04.006; Zhang LY, 1999, J DERMATOL SCI, V20, P191, DOI 10.1016/S0923-1811(98)00081-4	85	24	25	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2129	10.1371/journal.pone.0002129	http://dx.doi.org/10.1371/journal.pone.0002129			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461132	Green Published, Green Accepted, gold			2022-12-25	WOS:000261642400050
J	Garforth, SJ; Parniak, MA; Prasad, VR				Garforth, Scott J.; Parniak, Michael A.; Prasad, Vinayaka R.			Utilization of a Deoxynucleoside Diphosphate Substrate by HIV Reverse Transcriptase	PLOS ONE			English	Article								Background: Deoxynucleoside triphosphates (dNTPs) are the normal substrates for DNA synthesis catalyzed by polymerases such as HIV-1 reverse transcriptase (RT). However, substantial amounts of deoxynucleoside diphosphates (dNDPs) are also present in the cell. Use of dNDPs in HIV-1 DNA synthesis could have significant implications for the efficacy of nucleoside RT inhibitors such as AZT which are first line therapeutics for treatment of HIV infection. Our earlier work on HIV-1 reverse transcriptase (RT) suggested that the interaction between the gamma-phosphate of the incoming dNTP and RT residue K65 in the active site is not essential for dNTP insertion, implying that this polymerase may be able to insert dNDPs in addition to dNTPs. Methodology/Principal Findings: We examined the ability of recombinant wild type (wt) and mutant RTs with substitutions at residue K65 to utilize a dNDP substrate in primer extension reactions. We found that wild type HIV-1 RT indeed catalyzes incorporation of dNDP substrates whereas RT with mutations of residue K65 were unable to catalyze this reaction. Wild type HIV-1 RT also catalyzed the reverse reaction, inorganic phosphate-dependent phosphorolysis. Nucleotide-mediated phosphorolytic removal of chain-terminating 3'-terminal nucleoside inhibitors such as AZT forms the basis for HIV-1 resistance to such drugs, and this removal is enhanced by thymidine analog mutations (TAMs). We found that both wt and TAM-containing RTs were able to catalyze Pi-mediated phosphorolysis of 3'-terminal AZT at physiological levels of Pi with an efficacy similar to that for ATP-dependent AZT-excision. Conclusions: We have identified two new catalytic functions of HIV-1 RT, the use of dNDPs as substrates for DNA synthesis, and the use of Pi as substrate for phosphorolytic removal of primer 3'-terminal nucleotides. The ability to insert dNDPs has been documented for only one other DNA polymerase, the RB69 DNA polymerase and the reverse reaction employing inorganic phosphate has not been documented for any DNA polymerase. Importantly, our results show that Pi-mediated phosphorolysis can contribute to AZT resistance and indicates that factors that influence HIV resistance to AZT are more complex than previously appreciated.	[Garforth, Scott J.; Prasad, Vinayaka R.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; [Parniak, Michael A.] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA USA	Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Garforth, SJ (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.	prasad@aecom.yu.edu	Prasad, Vinayaka R./A-1029-2011; Garforth, Scott/B-5701-2011	Prasad, Vinayaka/0000-0002-9461-0189	National Institute of Allergy and Infectious Diseases, NIH [R37AI030861]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030861] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The research described here was supported by grant number R37AI030861 from the National Institute of Allergy and Infectious Diseases. The funder of this study, the National Institutes of Health have played no part in the conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Bagnis CI, 2006, NEPHRON PHYSIOL, V103, P131, DOI 10.1159/000092247; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BESSMAN MJ, 1958, J BIOL CHEM, V233, P171; BEVINGTON A, 1986, CLIN SCI, V71, P729, DOI 10.1042/cs0710729; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; BURGERS PMJ, 1980, J BIOL CHEM, V255, P8229; Cruchaga C, 2006, J BIOL CHEM, V281, P27744, DOI 10.1074/jbc.M603360200; Dharmasena S, 2007, BIOCHEMISTRY-US, V46, P828, DOI 10.1021/bi061364s; DORONIN SV, 1989, FEBS LETT, V259, P83, DOI 10.1016/0014-5793(89)81500-5; DORONIN SV, 1987, FEBS LETT, V216, P221, DOI 10.1016/0014-5793(87)80693-2; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garforth SJ, 2007, J MOL BIOL, V365, P38, DOI 10.1016/j.jmb.2006.09.057; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KEMP GJ, 1993, J THEOR BIOL, V161, P77, DOI 10.1006/jtbi.1993.1041; KORNBERG, 1992, DNA REPLICATION; Kukhanova MK, 2005, BIOCHEM BIOPH RES CO, V338, P1335, DOI 10.1016/j.bbrc.2005.10.092; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Meyer PR, 2006, ANTIMICROB AGENTS CH, V50, P3607, DOI 10.1128/AAC.00537-06; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Mulder BA, 2005, NUCLEIC ACIDS RES, V33, P4865, DOI 10.1093/nar/gki779; NAZARENKO IA, 1979, NUCLEIC ACIDS RES, V6, P2545, DOI 10.1093/nar/6.7.2545; Parikh UM, 2007, AIDS, V21, P1405, DOI 10.1097/QAD.0b013e3281ac229b; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200; Rigourd M, 2000, J BIOL CHEM, V275, P26944; Rothwell PJ, 2005, ADV PROTEIN CHEM, V71, P401, DOI 10.1016/S0065-3233(04)71011-6; ROZOVSKAYA TA, 1984, BIOCHEM J, V224, P645, DOI 10.1042/bj2240645; SCHACHMAN HK, 1960, J BIOL CHEM, V235, P3242; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Smith AJ, 2005, ANTIMICROB AGENTS CH, V49, P1761, DOI 10.1128/AAC.49.5.1761-1769.2005; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; White KL, 2006, ANTIVIR THER, V11, P155; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w	50	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2074	10.1371/journal.pone.0002074	http://dx.doi.org/10.1371/journal.pone.0002074			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446195	Green Published, Green Accepted, gold			2022-12-25	WOS:000261572300043
J	Surlykke, A; Kalko, EKV				Surlykke, Annemarie; Kalko, Elisabeth K. V.			Echolocating Bats Cry Out Loud to Detect Their Prey	PLOS ONE			English	Article								Echolocating bats have successfully exploited a broad range of habitats and prey. Much research has demonstrated how time-frequency structure of echolocation calls of different species is adapted to acoustic constraints of habitats and foraging behaviors. However, the intensity of bat calls has been largely neglected although intensity is a key factor determining echolocation range and interactions with other bats and prey. Differences in detection range, in turn, are thought to constitute a mechanism promoting resource partitioning among bats, which might be particularly important for the species-rich bat assemblages in the tropics. Here we present data on emitted intensities for 11 species from 5 families of insectivorous bats from Panama hunting in open or background cluttered space or over water. We recorded all bats in their natural habitat in the field using a multi-microphone array coupled with photographic methods to assess the bats' position in space to estimate emitted call intensities. All species emitted intense search signals. Output intensity was reduced when closing in on background by 4-7 dB per halving of distance. Source levels of open space and edge space foragers (Emballonuridae, Mormoopidae, Molossidae, and Vespertilionidae) ranged between 122-134 dB SPL. The two Noctilionidae species hunting over water emitted the loudest signals recorded so far for any bat with average source levels of ca. 137 dB SPL and maximum levels above 140 dB SPL. In spite of this ten-fold variation in emitted intensity, estimates indicated, surprisingly, that detection distances for prey varied far less; bats emitting the highest intensities also emitted the highest frequencies, which are severely attenuated in air. Thus, our results suggest that bats within a local assemblage compensate for frequency dependent attenuation by adjusting the emitted intensity to achieve comparable detection distances for prey across species. We conclude that for bats with similar hunting habits, prey detection range represents a unifying constraint on the emitted intensity largely independent of call shape, body size, and close phylogenetic relationships.	[Surlykke, Annemarie] Univ So Denmark, Inst Biol, Odense, Denmark; [Kalko, Elisabeth K. V.] Univ Ulm, Inst Expt Ecol, Ulm, Germany; [Kalko, Elisabeth K. V.] Smithsonian Trop Res Inst, Balboa, Panama	University of Southern Denmark; Ulm University; Smithsonian Institution; Smithsonian Tropical Research Institute	Surlykke, A (corresponding author), Univ So Denmark, Inst Biol, Odense, Denmark.	ams@biology.sdu.dk			Danish National Research Foundation; Danish Natural Science Research Foundation; Smithsonian Tropical Research Institute (STRI); German Science Foundation (DFG)	Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Natural Science Research Foundation(Danish Natural Science Research Council); Smithsonian Tropical Research Institute (STRI)(Smithsonian InstitutionSmithsonian Tropical Research Institute); German Science Foundation (DFG)(German Research Foundation (DFG))	The research was funded by the Danish National Research Foundation and the Danish Natural Science Research Foundation (to AS) and Smithsonian Tropical Research Institute (STRI) and the German Science Foundation (DFG) (to EKVK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*ANSI, 1978, 261978 ANSI SI; Au WWL, 2003, NATURE, V423, P861, DOI 10.1038/nature01727; Boonman A, 2002, J EXP BIOL, V205, P2865; Fenton MB, 2001, J TROP ECOL, V17, P511, DOI 10.1017/S0266467401001389; Fullard JH, 1997, J COMP PHYSIOL A, V181, P477, DOI 10.1007/s003590050131; Ghose K, 2003, J ACOUST SOC AM, V114, P1120, DOI 10.1121/1.1589754; Griffin D.R., 1986, LISTENING DARK; HARTLEY DJ, 1992, J ACOUST SOC AM, V91, P1120, DOI 10.1121/1.402639; HARTLEY DJ, 1992, J ACOUST SOC AM, V91, P1133, DOI 10.1121/1.402640; HARTLEY DJ, 1989, J ACOUST SOC AM, V85, P1348, DOI 10.1121/1.397466; HELLER KG, 1989, OECOLOGIA, V80, P178, DOI 10.1007/BF00380148; Holderied MW, 2005, J EXP BIOL, V208, P1321, DOI 10.1242/jeb.01528; Holderied MW, 2003, P ROY SOC B-BIOL SCI, V270, P2293, DOI 10.1098/rspb.2003.2487; Jensen ME, 1999, BEHAV ECOL SOCIOBIOL, V47, P60, DOI 10.1007/s002650050650; Jones G, 2006, TRENDS ECOL EVOL, V21, P149, DOI 10.1016/j.tree.2006.01.001; Jung K, 2007, J ZOOL, V272, P125, DOI 10.1111/j.1469-7998.2006.00250.x; KALKO E K V, 1989, Journal of the Acoustical Society of America, V85, P961, DOI 10.1121/1.397569; Kalko EKV, 1998, BEHAV ECOL SOCIOBIOL, V42, P305, DOI 10.1007/s002650050443; Kalko Elisabeth K.V., 1998, P197; Kalko Elisabeth K. V., 1997, P13; KICK SA, 1984, J NEUROSCI, V4, P2725; LEIGH EG, 1999, TROPICAL FOREST ECOL; Madsen PT, 2007, DEEP-SEA RES PT I, V54, P1421, DOI 10.1016/j.dsr.2007.04.020; Moss CF, 2006, PLOS BIOL, V4, P615, DOI 10.1371/journal.pbio.0040079; O'Farrell MJ, 1999, BIOTROPICA, V31, P507, DOI 10.1111/j.1744-7429.1999.tb00394.x; Rasmussen MH, 2002, J ACOUST SOC AM, V111, P1122, DOI 10.1121/1.1433814; ROEDER KD, 1966, J INSECT PHYSIOL, V12, P843, DOI 10.1016/0022-1910(66)90035-7; Rydell J, 2002, J ZOOL, V257, P27, DOI 10.1017/S0952836902000626; Schnitzler HU, 2003, TRENDS ECOL EVOL, V18, P386, DOI 10.1016/S0169-5347(03)00185-X; Schnitzler HU, 2001, BIOSCIENCE, V51, P557, DOI 10.1641/0006-3568(2001)051[0557:EBIEB]2.0.CO;2; SCHNITZLER HU, 1994, BEHAV ECOL SOCIOBIOL, V35, P327, DOI 10.1007/BF00184422; Siemers BM, 2001, J EXP BIOL, V204, P3843; Siemers BM, 2001, BEHAV ECOL SOCIOBIOL, V50, P317, DOI 10.1007/s002650100379; SIMMONS JA, 1980, J COMP PHYSIOL, V135, P61, DOI 10.1007/BF00660182; Simmons NB, 2008, NATURE, V451, P818, DOI 10.1038/nature06549; Simmons NB, 2005, MAMMAL SPECIES WORLD, P312, DOI DOI 10.1007/S10914-006-9022-6; SURLYKKE A, 1993, BEHAV ECOL SOCIOBIOL, V33, P1, DOI 10.1007/BF00164341; Surlykke A, 2000, J ACOUST SOC AM, V108, P2419, DOI 10.1121/1.1315295; Surlykke A, 1999, NATURWISSENSCHAFTEN, V86, P238, DOI 10.1007/s001140050607; VONSTAADEN MJ, 1997, J EXP BIOL, V200, P2597; Zar JH., 1999, BIOSTAT ANAL	41	167	174	2	73	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2036	10.1371/journal.pone.0002036	http://dx.doi.org/10.1371/journal.pone.0002036			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446226	gold, Green Published, Green Submitted			2022-12-25	WOS:000261572300009
J	Jovani, R; Serrano, D; Ursua, E; Tella, JL				Jovani, Roger; Serrano, David; Ursua, Esperanza; Tella, Jose L.			Truncated Power Laws Reveal a Link between Low-Level Behavioral Processes and Grouping Patterns in a Colonial Bird	PLOS ONE			English	Article							LESSER KESTREL; DISPERSAL; SIZE; AVAILABILITY; POPULATION; COMPLEXITY; SELECTION; DYNAMICS; SUCCESS	Background: Departures from power law group size frequency distributions have been proposed as a useful tool to link individual behavior with population patterns and dynamics, although examples are scarce for wild animal populations. Methodology/Principal Findings: We studied a population of Lesser kestrels (Falco naumanni) breeding in groups (colonies) from one to ca. 40 breeding pairs in 10,000 km(2) in NE Spain. A 3.5 fold steady population increase occurred during the eight-year study period, accompanied by a geographical expansion from an initial subpopulation which in turn remained stable in numbers. This population instability was mainly driven by first-breeders, which are less competitive at breeding sites, being relegated to breed solitarily or in small colony sizes, and disperse farther than adults. Colony size frequency distributions shifted from an initial power law to a truncated power law mirroring population increase. Thus, we hypothesized that population instability was behind the truncation of the power law. Accordingly, we found a power law distribution through years in the initial subpopulation, and a match between the power law breakpoint ( at ca. ten pairs) and those colony sizes from which the despotic behavior of colony owners started to impair the settlement of newcomers. Moreover, the instability hypothesis was further supported by snapshot data from another population of Lesser kestrels in SW Spain suffering a population decline. Conclusions/Significance: Appropriate analysis of the scaling properties of grouping patterns has unraveled the link between local agonistic processes and large-scale (population) grouping patterns in a wild bird population.	[Jovani, Roger; Serrano, David; Ursua, Esperanza; Tella, Jose L.] Pabellon Peru, Consejo Superior Investigaciones Cient CSIC, Estac Biol Donana, Dept Conservat Biol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD)	Jovani, R (corresponding author), Pabellon Peru, Consejo Superior Investigaciones Cient CSIC, Estac Biol Donana, Dept Conservat Biol, Seville, Spain.	jovani@ebd.csic.es	Serrano, David/B-5352-2013; Jovani, Roger/C-7080-2013; Tella, José L/I-3707-2015	Serrano, David/0000-0001-6205-386X; Jovani, Roger/0000-0002-8693-9742; Tella, José L/0000-0002-3038-7424	Consejo Superior de Investigaciones Cientificas; Gobierno de Aragon; SEO/BirdLife; DGICYT; DGES [PB93-0040, PB96-0834, BOS2003-01960]	Consejo Superior de Investigaciones Cientificas; Gobierno de Aragon(Gobierno de Aragon); SEO/BirdLife; DGICYT(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); DGES	D. Serrano was supported by a I3P postdoctoral contract from the Consejo Superior de Investigaciones Cientificas. Financial support was partially provided by collaborative projects with Gobierno de Aragon (1994-95 and 2000), SEO/BirdLife (1998-99) and DGICYT and DGES Projects PB93-0040, PB96-0834 and BOS2003-01960.	Ainley DG, 2002, ADELIE PENGUIN; Ame JM, 2006, P NATL ACAD SCI USA, V103, P5835, DOI 10.1073/pnas.0507877103; Arroyo B, 2001, BEHAV ECOL SOCIOBIOL, V50, P109, DOI 10.1007/s002650100342; Batty M., 1994, FRACTAL CITIES GEOME; BERG A, 1992, J ANIM ECOL, V61, P469, DOI 10.2307/5337; Bonabeau E, 1999, P NATL ACAD SCI USA, V96, P4472, DOI 10.1073/pnas.96.8.4472; Brown C. R., 1996, COLONIALITY CLIFF SW; BROWN CR, 1990, TRENDS ECOL EVOL, V5, P398, DOI 10.1016/0169-5347(90)90023-7; Brown J. H., 1995, MACROECOLOGY; Brown JH, 2002, PHILOS T R SOC B, V357, P619, DOI 10.1098/rstb.2001.0993; Buhl J, 2006, SCIENCE, V312, P1402, DOI 10.1126/science.1125142; Buldyrev SV, 2003, PHYSICA A, V330, P653, DOI 10.1016/j.physa.2003.09.041; Collett M, 1998, P NATL ACAD SCI USA, V95, P13052, DOI 10.1073/pnas.95.22.13052; Forero MG, 1996, BIOL CONSERV, V78, P289, DOI 10.1016/S0006-3207(96)00011-0; GOUMARK F, 1982, ORNIS SCAND, V13, P211; Halley JM, 2004, ECOL LETT, V7, P254, DOI 10.1111/j.1461-0248.2004.00568.x; Hiraldo F, 1996, J APPL ECOL, V33, P1085, DOI 10.2307/2404688; HIRALDO F, 1995, COLONIAS NIDIFICACIO; Jovani R, 2007, P ROY SOC B-BIOL SCI, V274, P2465, DOI 10.1098/rspb.2007.0527; Krause J., 2002, LIVING GROUPS OXFORD; Lenth R., 2019, Journal of Statistical Software, V60, P1; Lusseau D, 2004, ECOL LETT, V7, P1068, DOI 10.1111/j.1461-0248.2004.00669.x; Manrubia SC, 1999, FRACTALS, V7, P1, DOI 10.1142/S0218348X99000025; May R, 1999, PHILOS T R SOC B, V354, P1951, DOI 10.1098/rstb.1999.0534; Parrish J., 1997, ANIMAL GROUPS 3 DIME; Pascual M, 2002, PHILOS T ROY SOC B, V357, P657, DOI 10.1098/rstb.2001.0983; Pueyo S, 2006, OIKOS, V112, P392, DOI 10.1111/j.0030-1299.2006.14188.x; PUEYO S, 2003, THESIS U BARCELONA S; Pueyo S, 2006, SCIENCE, V313, DOI 10.1126/science.1129595; Rodriguez C, 2006, J APPL ECOL, V43, P587, DOI 10.1111/j.1365-2664.2006.01152.x; Schneider DC, 2002, ECOSYSTEMS, V5, P736, DOI 10.1007/s10021-002-0156-y; Serrano D, 2005, AM NAT, V166, pE22, DOI 10.1086/431255; Serrano D, 2004, ECOLOGY, V85, P3438, DOI 10.1890/04-0463; Serrano D, 2003, ECOLOGY, V84, P3044, DOI 10.1890/02-0231; Serrano D, 2003, J ANIM ECOL, V72, P400, DOI 10.1046/j.1365-2656.2003.00707.x; Serrano D, 2001, J ANIM ECOL, V70, P568, DOI 10.1046/j.1365-2656.2001.00512.x; Serrano D, 2007, AM NAT, V169, pE53, DOI 10.1086/510598; Sjoberg M, 2000, ECOL LETT, V3, P90, DOI 10.1046/j.1461-0248.2000.00113.x; Sole R.V., 2001, SIGNS LIFE COMPLEXIT; Sutherland W.J., 1996, INDIVIDUAL BEHAV POP; Tella JL, 1998, CONSERV BIOL, V12, P593, DOI 10.1046/j.1523-1739.1998.96288.x; TELLA JL, 1996, THESIS U BARCELONA S; Theraulaz G, 2002, P NATL ACAD SCI USA, V99, P9645, DOI 10.1073/pnas.152302199; Vandermeer J, 2006, SCIENCE, V311, P1000, DOI 10.1126/science.1121432	45	20	20	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1992	10.1371/journal.pone.0001992	http://dx.doi.org/10.1371/journal.pone.0001992			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431479	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700014
J	Toth, C; Shim, SY; Wang, J; Jiang, Y; Neumayer, G; Belzil, C; Liu, WQ; Martinez, J; Zochodne, D; Nguyen, MD				Toth, Cory; Shim, Su Yeon; Wang, Jian; Jiang, Yulan; Neumayer, Gernot; Belzil, Camille; Liu, Wei-Qiao; Martinez, Jose; Zochodne, Douglas; Nguyen, Minh Dang			Ndel1 Promotes Axon Regeneration via Intermediate Filaments	PLOS ONE			English	Article								Failure of axons to regenerate following acute or chronic neuronal injury is attributed to both the inhibitory glial environment and deficient intrinsic ability to re-grow. However, the underlying mechanisms of the latter remain unclear. In this study, we have investigated the role of the mammalian homologue of aspergillus nidulans NudE, Ndel1, emergently viewed as an integrator of the cytoskeleton, in axon regeneration. Ndel1 was synthesized de novo and upregulated in crushed and transected sciatic nerve axons, and, upon injury, was strongly associated with neuronal form of the intermediate filament (IF) Vimentin while dissociating from the mature neuronal IF (Neurofilament) light chain NF-L. Consistent with a role for Ndel1 in the conditioning lesion-induced neurite outgrowth of Dorsal Root Ganglion (DRG) neurons, the long lasting in vivo formation of the neuronal Ndel1/Vimentin complex was associated with robust axon regeneration. Furthermore, local silencing of Ndel1 in transected axons by siRNA severely reduced the extent of regeneration in vivo. Thus, Ndel1 promotes axonal regeneration; activating this endogenous repair mechanism may enhance neuroregeneration during acute and chronic axonal degeneration.	[Toth, Cory; Shim, Su Yeon; Wang, Jian; Neumayer, Gernot; Belzil, Camille; Liu, Wei-Qiao; Martinez, Jose; Zochodne, Douglas; Nguyen, Minh Dang] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada; [Shim, Su Yeon; Wang, Jian; Neumayer, Gernot; Belzil, Camille; Nguyen, Minh Dang] Univ Calgary, Hotchkiss Brain Inst, Dept Cell Biol & Anat, Calgary, AB, Canada; [Shim, Su Yeon; Wang, Jian; Jiang, Yulan; Neumayer, Gernot; Belzil, Camille; Nguyen, Minh Dang] Univ Calgary, Hotchkiss Brain Inst, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary	Nguyen, MD (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada.	mdnguyen@ucalgary.ca			Amyotrophic Lateral Sclerosis Societies of Canada/USA; Multiple Sclerosis Society of Canada; Canadian Institutes of Health Research (CIHR) [New Investigator Award]; Human Frontier Science Program Organization (HFSPO) [Career Development Award]; Alberta Heritage Foundation for Medical Research (AHFMR) [Scholarship]; Brenda Strafford Foundation Chair in Alzheimer research	Amyotrophic Lateral Sclerosis Societies of Canada/USA; Multiple Sclerosis Society of Canada; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Human Frontier Science Program Organization (HFSPO)(Human Frontier Science Program); Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); Brenda Strafford Foundation Chair in Alzheimer research	This work was supported by the Amyotrophic Lateral Sclerosis Societies of Canada/USA, the Multiple Sclerosis Society of Canada, the Canadian Institutes of Health Research (CIHR) (MDN). M.D.N. holds a Career Development Award from the Human Frontier Science Program Organization (HFSPO), a New Investigator Award from the CIHR, a Scholarship from the Alberta Heritage Foundation for Medical Research (AHFMR) and the Brenda Strafford Foundation Chair in Alzheimer research.	Boyne LJ, 1996, INT J DEV NEUROSCI, V14, P739, DOI 10.1016/S0736-5748(96)00053-6; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; Chen YY, 2005, J NEUROPATH EXP NEUR, V64, P613, DOI 10.1097/01.jnen.0000171650.94341.46; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DELEON M, 1991, J NEUROSCI RES, V29, P437; DENECHAUD B, 1986, J NEUROCHEM, V46, P708; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dubey M, 2004, J NEUROSCI RES, V78, P245, DOI 10.1002/jnr.20146; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; GILLEN C, 1995, J NEUROSCI RES, V42, P159, DOI 10.1002/jnr.490420203; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; Hanz S, 2006, J NEUROCHEM, V99, P13, DOI 10.1111/j.1471-4159.2006.04089.x; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Kamiya A, 2005, NAT CELL BIOL, V7, P1167, DOI 10.1038/ncb1328; Kamiya A, 2006, HUM MOL GENET, V15, P3313, DOI 10.1093/hmg/ddl407; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Mackie S, 2007, CURR OPIN NEUROBIOL, V17, P95, DOI 10.1016/j.conb.2007.01.007; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; McDonald DS, 2003, J NEUROSCI METH, V122, P171, DOI 10.1016/S0165-0270(02)00319-9; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Nguyen MD, 2004, NAT CELL BIOL, V6, P595, DOI 10.1038/ncb1139; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; OBLINGER MM, 1989, J NEUROSCI, V9, P2645; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2001, Prog Brain Res, V132, P23; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Sasaki S, 2005, MOL CELL BIOL, V25, P7812, DOI 10.1128/MCB.25.17.7812-7827.2005; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SHIM SY, 2008, J BIOL CHEM; Shu TZ, 2004, NEURON, V44, P263, DOI 10.1016/j.neuron.2004.09.030; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Taya S, 2007, J NEUROSCI, V27, P15, DOI 10.1523/JNEUROSCI.3826-06.2006; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; TROY CM, 1990, BRAIN RES, V529, P232, DOI 10.1016/0006-8993(90)90832-V; Vita G, 1998, NEUROREPORT, V9, P697, DOI 10.1097/00001756-199803090-00025; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	47	33	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2014	10.1371/journal.pone.0002014	http://dx.doi.org/10.1371/journal.pone.0002014			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431495	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700030
J	Geiger, BM; Behr, GG; Frank, LE; Caldera-Siu, AD; Beinfeld, MC; Kokkotou, EG; Pothos, EN				Geiger, Brenda M.; Behr, Gerald G.; Frank, Lauren E.; Caldera-Siu, Angela D.; Beinfeld, Margery C.; Kokkotou, Efi G.; Pothos, Emmanuel N.			Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats	FASEB JOURNAL			English	Article						body weight; nucleus accumbens; striatum; prefrontal cortex; vesicular monoamine transporter 2; tyrosine hydroxylase	DECREASES EXTRACELLULAR DOPAMINE; DIET-INDUCED OBESITY; NUCLEUS-ACCUMBENS; QUANTAL SIZE; PREFRONTAL CORTEX; FOOD-DEPRIVATION; WEIGHT-LOSS; OB/OB MICE; NEURONS; REWARD	The association between dietary obesity and mesolimbic systems that regulate hedonic aspects of feeding is currently unresolved. In the present study, we examined differences in baseline and stimulated central dopamine levels in obesity-prone (OP) and obesity-resistant ( OR) rats. OP rats were hyperphagic and showed a 20% weight gain over OR rats at wk 15 of age, when fed a standard chow diet. This phenotype was associated with a 50% reduction in basal extracellular dopamine, as measured by a microdialysis probe in the nucleus accumbens, a projection site of the mesolimbic dopamine system that has been implicated in food reward. Similar defects were also observed in younger animals ( 4 wk old). In electrophysiology studies, electrically evoked dopamine release in slice preparations was significantly attenuated in OP rats, not only in the nucleus accumbens but also in additional terminal sites of dopamine neurons such as the accumbens shell, dorsal striatum, and medial prefrontal cortex, suggesting that there may be a widespread dysfunction in mechanisms regulating dopamine release in this obesity model. Moreover, dopamine impairment in OP rats was apparent at birth and associated with changes in expression of several factors regulating dopamine synthesis and release: vesicular monoamine transporter-2, tyrosine hydroxylase, dopamine transporter, and dopamine receptor-2 short-form. Taken together, these results suggest that an attenuated central dopamine system would reduce the hedonic response associated with feeding and induce compensatory hyperphagia, leading to obesity.	[Geiger, Brenda M.; Behr, Gerald G.; Frank, Lauren E.; Caldera-Siu, Angela D.; Beinfeld, Margery C.; Pothos, Emmanuel N.] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; [Pothos, Emmanuel N.] Tufts Univ, Sch Med, Program Neurosci, Boston, MA 02111 USA; [Kokkotou, Efi G.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Tufts University; Tufts University; Harvard University; Beth Israel Deaconess Medical Center	Pothos, EN (corresponding author), Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Med & Vet Bldg,Rm 201,136 Harrison Ave, Boston, MA 02111 USA.	emmanuel.pothos@tufts.edu	behr, gerald/R-4996-2019	behr, gerald/0000-0002-2987-0005; Pothos, Emmanuel/0000-0001-8825-7852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065872, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA023760] Funding Source: NIH RePORTER; NIDA NIH HHS [DA023760, F31 DA023760] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928, DK065872, R01 DK065872, P30 DK034928] Funding Source: Medline; NINDS NIH HHS [P30 NS047243] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2002, J NEUROSCI, V22, P10958; Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019; Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x; Berthoud HR, 2008, ANNU REV PSYCHOL, V59, P55, DOI 10.1146/annurev.psych.59.103006.093551; Berthoud HR, 2005, PHYSIOL BEHAV, V85, P1, DOI 10.1016/j.physbeh.2005.04.006; Bina KG, 2000, NEUROENDOCRINOLOGY, V71, P68, DOI 10.1159/000054522; CARROLL ME, 1985, DRUG ALCOHOL DEPEN, V16, P95, DOI 10.1016/0376-8716(85)90109-7; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Dijk F, 2004, BRAIN RES, V1026, P194, DOI 10.1016/j.brainres.2004.08.034; Farooqi IS, 2007, SCIENCE, V317, P1355, DOI 10.1126/science.1144599; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Fulton S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006; Harris GC, 2007, BEHAV BRAIN RES, V183, P43, DOI 10.1016/j.bbr.2007.05.025; HERNANDEZ L, 1990, BRAIN RES BULL, V25, P975, DOI 10.1016/0361-9230(90)90197-8; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, MESOCORTICOLIMBIC DO, P508; Holtje M, 2003, J BIOL CHEM, V278, P15850, DOI 10.1074/jbc.M212816200; Holtje M, 2000, J NEUROSCI, V20, P2131; Hommel JD, 2006, NEURON, V51, P801, DOI 10.1016/j.neuron.2006.08.023; Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066; Leinninger GM, 2008, ACTA PHYSIOL, V192, P49, DOI 10.1111/j.1748-1716.2007.01784.x; Levin BE, 1997, AM J PHYSIOL-REG I, V273, pR725, DOI 10.1152/ajpregu.1997.273.2.R725; Levin BE, 2002, AM J PHYSIOL-REG I, V283, pR941, DOI 10.1152/ajpregu.00245.2002; MARK GP, 1992, J NEUROCHEM, V58, P2269, DOI 10.1111/j.1471-4159.1992.tb10973.x; Martel P, 1996, PHARMACOL BIOCHEM BE, V53, P221, DOI 10.1016/0091-3057(95)00187-5; Mutch DM, 2006, PLOS GENET, V2, P1956, DOI 10.1371/journal.pgen.0020188; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pothos EN, 1995, OBES RES, V3, pS525, DOI 10.1002/j.1550-8528.1995.tb00222.x; POTHOS EN, 1995, J NEUROSCI, V15, P6640; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Pothos EN, 1998, APPETITE, V31, P405, DOI 10.1006/appe.1998.0210; Salamone JD, 2005, CURR OPIN PHARMACOL, V5, P34, DOI 10.1016/j.coph.2004.09.004; Scislowski PWD, 1999, INT J OBESITY, V23, P425, DOI 10.1038/sj.ijo.0800893; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; Walker QD, 2000, NEUROSCIENCE, V95, P1061; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; YOSHIDA M, 1992, NEUROSCI LETT, V139, P73, DOI 10.1016/0304-3940(92)90861-Z	39	139	140	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2740	2746		10.1096/fj.08-110759	http://dx.doi.org/10.1096/fj.08-110759			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18477764	Green Published			2022-12-25	WOS:000258089300014
J	Perra, A; Simbula, G; Simbula, M; Pibiri, M; Kowalik, MA; Sulas, P; Cocco, MT; Ledda-Columbano, GM; Columbano, A				Perra, Andrea; Simbula, Gabriella; Simbula, Michela; Pibiri, Monica; Kowalik, Marta A.; Sulas, Pia; Cocco, Maria T.; Ledda-Columbano, Giovanna M.; Columbano, Amedeo			Thyroid hormone (T3) and TR beta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats	FASEB JOURNAL			English	Article						hepatic steatosis; choline deficient diet; beta-oxidation	PROLIFERATOR-ACTIVATED RECEPTOR; ACID-BINDING PROTEIN; PPAR-ALPHA; HEPATIC STEATOSIS; HEPATOCYTE PROLIFERATION; UNCOUPLING PROTEIN-3; GENE-EXPRESSION; STEATOHEPATITIS; DEFICIENT; SECRETION	Nonalcoholic fatty liver disease is the most common noninfectious liver disease in clinical practice, and there is an increasing need for new therapeutic approaches for the treatment of this liver disease. Here, we examined the effect of the thyroid hormone triiodothyronine (T3) and the agonist of the thyroid hormone receptor beta isoform (TR beta), GC-1, on fatty liver and steatohepatitis induced in rodents by a choline-methionine deficient (CMD) diet. Male Fischer 344 rats fed a CMD diet for 1 wk developed a marked fatty liver and mild hepatitis. Concurrent administration of T3 resulted in a complete prevention of the fatty change associated with increased fatty acid mitochondrial and peroxisomal beta-oxidation. To investigate whether T3 could also reverse fully established fatty liver, rats were fed a CMD diet for 10 wk and then cofed T3 for 1 wk. Coadministration of T3 resulted in a complete regression of liver steatosis associated with a decrease of lipid peroxidation, cyclooxygenase-2 expression, and activation of phospho-STAT3 and phospho-SAPK/JNK. Finally, additional experiments showed that GC-1, which has no significant side effects on heart rate, prevented and reverted CMD-induced fat accumulation, and ameliorated steatohepatitis. These results indicate that TR agonists have the potential to inhibit or reverse hepatic steatosis induced by a nutritional model.	[Perra, Andrea; Simbula, Gabriella; Simbula, Michela; Pibiri, Monica; Kowalik, Marta A.; Sulas, Pia; Cocco, Maria T.; Ledda-Columbano, Giovanna M.; Columbano, Amedeo] Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy	University of Cagliari	Columbano, A (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	columbano@unica.it	Simbula, Gabriella/AAN-4390-2020; Columbano, Amedeo/C-7463-2011; simbula, michela/P-6171-2018	Simbula, Gabriella/0000-0003-4946-532X; Columbano, Amedeo/0000-0002-6956-9030; simbula, michela/0000-0002-7473-5494; PIBIRI, MONICA/0000-0002-9660-9616	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Baskin-Bey ES, 2007, WORLD J GASTROENTERO, V13, P5635, DOI 10.3748/wjg.v13.i42.5635; BASS NM, 1990, MOL CELL BIOCHEM, V98, P167; Baxter JD, 2004, TRENDS ENDOCRIN MET, V15, P154, DOI 10.1016/j.tem.2004.03.008; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; CASTELLANI LW, 1991, BIOCHIM BIOPHYS ACTA, V1086, P197, DOI 10.1016/0005-2760(91)90008-6; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; CRABB DW, 2003, TXB GASTROENTEROLOGY, V2, P2415; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Han XN, 2005, GASTROENTEROLOGY, V129, P185, DOI 10.1053/j.gastro.2005.05.018; Hulbert AJ, 2000, BIOL REV, V75, P519, DOI 10.1017/S146479310000556X; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Ip E, 2004, HEPATOLOGY, V39, P1286, DOI 10.1002/hep.20170; Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Kawaguchi K, 2004, BIOCHEM BIOPH RES CO, V315, P187, DOI 10.1016/J.BBRC.2004.01.038; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Koteish A, 2002, BEST PRACT RES CL GA, V16, P679, DOI 10.1053/bega.2002.0332; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Linden D, 2001, J LIPID RES, V42, P1831; Liu HL, 2002, AM J PHYSIOL-GASTR L, V282, pG257, DOI 10.1152/ajpgi.00304.2001; LOMBARDI B, 1968, J LIPID RES, V9, P437; Mangelsdorf David J., 1994, P319; MEIERHEUSLER SC, 1995, MOL CELL ENDOCRINOL, V107, P55, DOI 10.1016/0303-7207(94)03422-P; Mudter J, 2005, AM J GASTROENTEROL, V100, P64, DOI 10.1111/j.1572-0241.2005.40615.x; Nagasawa T, 2006, EUR J PHARMACOL, V536, P182, DOI 10.1016/j.ejphar.2006.02.028; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; Newberry EP, 2006, HEPATOLOGY, V44, P1191, DOI 10.1002/hep.21369; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Rao MS, 2004, HEPATOLOGY, V40, P783, DOI 10.1002/hep.20453; Rao MS, 2002, IN VIVO, V16, P145; Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333, DOI 10.1152/ajpgi.2001.281.6.G1333; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Schroeder-Gloeckler JM, 2007, J BIOL CHEM, V282, P15717, DOI 10.1074/jbc.M701329200; SHINOZUKA H, 1978, CANCER RES, V38, P1092; SHINOZUKA H, 1985, NUTRITIONAL PATHOLOG, P279; Spann NJ, 2006, J BIOL CHEM, V281, P33066, DOI 10.1074/jbc.M607148200; TAKEDA T, 1992, BIOCHEM BIOPH RES CO, V185, P211, DOI 10.1016/S0006-291X(05)80977-5; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yu J, 2006, HEPATOLOGY, V43, P826, DOI 10.1002/hep.21108; Zafrani ES, 2004, VIRCHOWS ARCH, V444, P3, DOI 10.1007/s00428-003-0943-7; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	55	95	102	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2981	2989		10.1096/fj.08-108464	http://dx.doi.org/10.1096/fj.08-108464			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434432				2022-12-25	WOS:000258089300038
J	Chinnaswamy, S; Yarbrough, I; Palaninathan, S; Kumar, CTR; Vijayaraghavan, V; Demeler, B; Lemon, SM; Sacchettini, JC; Kao, CC				Chinnaswamy, Sreedhar; Yarbrough, Ian; Palaninathan, Satheesh; Kumar, C. T. Ranjith; Vijayaraghavan, Vinodhini; Demeler, Borries; Lemon, Stanley M.; Sacchettini, James C.; Kao, C. Cheng			A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; RETINOBLASTOMA TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; IN-VITRO; TRYPTOPHAN FLUORESCENCE; 2 CONFORMATIONS; CYCLOSPORINE-A; NS3 HELICASE; BINDING-SITE; GENOTYPE 2A	Mutational analysis of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) template channel identified two residues, Trp(397) and His(428), which are required for de novo initiation but not for extension from a primer. These two residues interact with the Delta 1 loop on the surface of the RdRp. A deletion within the Delta 1 loop also resulted in comparable activities. The mutant proteins exhibit increased double-stranded RNA binding compared with the wild type, suggesting that the Delta 1 loop serves as a flexible locking mechanism to regulate the conformations needed for de novo initiation and for elongative RNA synthesis. A similar locking motif can be found in other viral RdRps. Products associated with the open conformation of the HCV RdRp were inhibited by interaction with the retinoblastoma protein but not cyclophilin A. Different conformations of the HCV RdRp can thus affect RNA synthesis and interaction with cellular proteins.	[Chinnaswamy, Sreedhar; Yarbrough, Ian; Palaninathan, Satheesh; Kumar, C. T. Ranjith; Vijayaraghavan, Vinodhini; Sacchettini, James C.; Kao, C. Cheng] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Demeler, Borries] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Lemon, Stanley M.] Univ Texas Galveston, Med Branch, Ctr Hepatitis Res,Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA	Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Medical Branch Galveston	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Chinnaswamy, Sreedhar/GMX-0166-2022; Kumar CT, Ranjith/J-5701-2016	Demeler, Borries/0000-0002-2414-9518; Chinnaswamy, Sreedhar/0000-0003-0095-3453	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035, R01AI073335] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI 40035, N01 AI 25488, 1 R01 AI 073335, R01 AI073335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; An P, 2007, PLOS PATHOG, V3, P849, DOI 10.1371/journal.ppat.0030088; Anand VS, 2006, J BIOL CHEM, V281, P35677, DOI 10.1074/jbc.M608180200; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; BROOKES E, 2006, SUP 06 P 2006 ACM IE; Brookes E.H., 2007, P 9 ANN C GEN EV COM, P361; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cai ZH, 2005, J VIROL, V79, P11607, DOI 10.1128/JVI.79.18.11607-11617.2005; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; Demeler B, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P210; Di Marco S, 2005, J BIOL CHEM, V280, P29765, DOI 10.1074/jbc.M505423200; Dick FA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-26; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Dutartre H, 2005, J BIOL CHEM, V280, P6359, DOI 10.1074/jbc.M410191200; El-Farrash MA, 2007, MICROBIOL IMMUNOL, V51, P127, DOI 10.1111/j.1348-0421.2007.tb03883.x; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GRIMSLEY GR, 2003, PURIFYING PROTEINS P, P535; Gu BH, 2003, J BIOL CHEM, V278, P16602, DOI 10.1074/jbc.M210891200; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Howe AYM, 2006, ANTIMICROB AGENTS CH, V50, P4103, DOI 10.1128/AAC.00365-06; Jennings TA, 2008, BIOCHEMISTRY-US, V47, P1126, DOI 10.1021/bi701048a; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kaushik-Basu N, 2008, NUCLEIC ACIDS RES, V36, P1482, DOI 10.1093/nar/gkm1178; Kim MJ, 2001, P NATL ACAD SCI USA, V98, P4972, DOI 10.1073/pnas.081077198; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Kukolj G, 2005, J BIOL CHEM, V280, P39260, DOI 10.1074/jbc.M506407200; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Li Jiebo, 2007, Infectious Disorders - Drug Targets, V7, P238, DOI 10.2174/187152607782110013; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Love RA, 2004, STRUCTURE, V12, P1533, DOI 10.1016/j.str.2004.05.024; Ma H, 2005, VIROLOGY, V332, P8, DOI 10.1016/j.virol.2004.11.024; Malet H, 2007, J BIOL CHEM, V282, P10678, DOI 10.1074/jbc.M607273200; McKercher G, 2004, NUCLEIC ACIDS RES, V32, P422, DOI 10.1093/nar/gkh160; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Nakagawa M, 2005, GASTROENTEROLOGY, V129, P1031, DOI 10.1053/j.gastro.2005.06.031; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Nomaguchi M, 2003, J VIROL, V77, P8831, DOI 10.1128/JVI.77.16.8831-8842.2003; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Pertzev AV, 2006, NUCLEIC ACIDS RES, V34, P3708, DOI 10.1093/nar/gkl459; Pogany J, 2003, EMBO J, V22, P5602, DOI 10.1093/emboj/cdg523; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005; Ranjith-Kumar CT, 2006, RNA, V12, P303, DOI 10.1261/rna.2163106; Ranjith-Kumar CT, 2004, J VIROL, V78, P12207, DOI 10.1128/JVI.78.22.12207-12217.2004; Ranjith-Kumar CT, 2003, VIROLOGY, V312, P270, DOI 10.1016/S0042-6822(03)00247-2; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Robida JM, 2007, J VIROL, V81, P5829, DOI 10.1128/JVI.02524-06; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Tomei L, 2004, J VIROL, V78, P938, DOI 10.1128/JVI.78.2.938-946.2004; Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003; Tsai CH, 2006, CURR PHARM DESIGN, V12, P1339, DOI 10.2174/138161206776361156; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; Watashi K, 2007, REV MED VIROL, V17, P245, DOI 10.1002/rmv.534; Wu JZ, 2005, MINI-REV MED CHEM, V5, P1103, DOI 10.2174/138955705774933310; Yap TL, 2007, J VIROL, V81, P4753, DOI 10.1128/JVI.02283-06; Zhang C, 2005, J VIROL, V79, P8687, DOI 10.1128/JVI.79.14.8687-8697.2005; Zhu J, 2007, P NATL ACAD SCI USA, V104, P3129, DOI 10.1073/pnas.0611617104	78	57	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20535	20546		10.1074/jbc.M801490200	http://dx.doi.org/10.1074/jbc.M801490200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18442978	Green Published, hybrid			2022-12-25	WOS:000257565300066
J	Sanggaard, KW; Sonne-Schmidt, CS; Krogager, TP; Lorentzen, KA; Wisniewski, HG; Thogersen, IB; Enghild, JJ				Sanggaard, Kristian W.; Sonne-Schmidt, Carsten S.; Krogager, Toke P.; Lorentzen, Karen A.; Wisniewski, Hans-Georg; Thogersen, Ida B.; Enghild, Jan J.			The transfer of heavy chains from bikunin proteins to hyaluronan requires both TSG-6 and HC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; FACTOR-STIMULATED GENE-6; EXTRACELLULAR-MATRIX; TRYPSIN-INHIBITOR; BINDING; EXPRESSION; COMPLEXES; SEQUENCE; PLASMIN; FAMILY	Tumor necrosis factor-stimulated gene-6 protein (TSG-6) is involved in the transfer of heavy chains (HCs) from inter-alpha-inhibitor (I alpha I), pre-alpha-inhibitor, and as shown here HC2(.)bikunin to hyaluronan through the formation of covalent HC(.)TSG-6 intermediates. In contrast to I alpha I and HC2(.)bikunin, pre-alpha-inhibitor does not form a covalent complex in vitro using purified proteins but needs the presence of another factor (Rugg, M. S., Willis, A. C., Mukhopadhyay, D., Hascall, V. C., Fries, E., Fulop, C., Milner, C. M., and Day, A. J. (2005) J. Biol. Chem. 280, 25674 25686). In the present study we purified the required component from human plasma and identified it as HC2. Proteins containing HC2 including I alpha I, HC2(.)bikunin, and free HC2 promoted the formation of HC3(.)TSG-6 and subsequently HC3(.)hyaluronan complexes. HC1 or HC3 did not possess this activity. The presented data reveal that both HC2 and TSG-6 are required for the transesterification reactions to occur.	[Sanggaard, Kristian W.; Sonne-Schmidt, Carsten S.; Krogager, Toke P.; Lorentzen, Karen A.; Thogersen, Ida B.; Enghild, Jan J.] Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Struct inSPIN, DK-8000 Aarhus C, Denmark; [Sanggaard, Kristian W.; Sonne-Schmidt, Carsten S.; Krogager, Toke P.; Lorentzen, Karen A.; Thogersen, Ida B.; Enghild, Jan J.] Univ Aarhus, Dept Mol Biol, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus C, Denmark; [Wisniewski, Hans-Georg] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	Aarhus University; Aarhus University; New York University	Enghild, JJ (corresponding author), Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Struct inSPIN, Sci Pk,Gustav Wiedsvej 10C, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk	; Scavenius, Carsten/Q-5941-2017	Lorentzen, Karen Axelgaard/0000-0002-5456-9871; Enghild, Jan Johannes/0000-0001-9292-9172; Scavenius, Carsten/0000-0002-4304-0681				BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; BUTLER DM, 1988, ARTHRITIS RHEUM, V31, P1281, DOI 10.1002/art.1780311010; Chi LL, 2008, J AM CHEM SOC, V130, P2617, DOI 10.1021/ja0778500; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; Forteza R, 2007, AM J RESP CELL MOL, V36, P20, DOI 10.1165/rcmb.2006-0018OC; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; Kuznetsova SA, 2008, MATRIX BIOL, V27, P201, DOI 10.1016/j.matbio.2007.10.003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2005, BIOCHEM BIOPH RES CO, V330, P737, DOI 10.1016/j.bbrc.2005.03.040; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Sanggaard KW, 2006, BIOCHEMISTRY-US, V45, P7661, DOI 10.1021/bi060106s; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669; Wisniewski HG, 2005, J BIOL CHEM, V280, P14476, DOI 10.1074/jbc.M411734200; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609	32	33	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18530	18537		10.1074/jbc.M800874200	http://dx.doi.org/10.1074/jbc.M800874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18448433	hybrid			2022-12-25	WOS:000257165600008
J	Lau, P; Fitzsimmons, RL; Raichur, S; Wang, SCM; Lechtken, A; Muscat, GEO				Lau, Patrick; Fitzsimmons, Rebecca L.; Raichur, Suryaprakash; Wang, Shu-Ching M.; Lechtken, Adriane; Muscat, George E. O.			The orphan nuclear receptor, ROR alpha, regulates gene expression that controls lipid metabolism - Staggerer (sg/sg) mice are resistant to diet-induced obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; LIVER-X-RECEPTOR; FATTY-ACID SYNTHASE; SKELETAL-MUSCLE; TRANSCRIPTIONAL REGULATION; MUTANT MOUSE; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; SREBP-1C PROMOTER; DEFICIENT MICE	Homozygous staggerer mice (sg/sg) display decreased and dysfunctional retinoic acid receptor-related orphan receptor alpha (ROR alpha) expression. We observed decreases in serum (and liver) triglycerides and total and high density lipoprotein serum cholesterol in sg/sg mice. Moreover, the sg/sg mice were characterized by reduced adiposity (associated with decreased fat pad mass and adipocyte size). Candidate-based expression profiling demonstrated that the dyslipidemia in sg/sg mice is associated with decreased hepatic expression of SREBP-1c, and the reverse cholesterol transporters, ABCA1 and ABCG1. This is consistent with the reduced serum lipids. The molecular mechanism did not involve aberrant expression of LXR and/or ChREBP. However, ChIP and transfection analyses revealed that ROR alpha is recruited to and regulates the activity of the SREBP-1c promoter. Furthermore, the lean phenotype in sg/sg mice is also characterized by significantly increased expression of PGC-1 alpha, PGC-1 alpha, and lipin1 mRNA in liver and white and brown adipose tissue from sg/sg mice. In addition, we observed a significant 4-fold increase in beta(2)-adrenergic receptor mRNA in brown adipose tissue. Finally, dysfunctional ROR alpha expression protects against diet-induced obesity. Following a 10-week high fat diet, wild-type but not sg/sg mice exhibited a similar to 20% weight gain, increased hepatic triglycerides, and notable white and brown adipose tissue accumulation. In summary, these changes in gene expression (that modulate lipid homeostasis) in metabolic tissues are involved in decreased adiposity and resistance to diet-induced obesity in the sg/sg mice, despite hyperphagia. In conclusion, we suggest this orphan nuclear receptor is a key modulator of fat accumulation and that selective ROR modulators may have utility in the treatment of obesity.	[Lau, Patrick; Fitzsimmons, Rebecca L.; Raichur, Suryaprakash; Wang, Shu-Ching M.; Lechtken, Adriane; Muscat, George E. O.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	Fitzsimmons, Rebecca/C-9769-2017; Muscat, George/A-6401-2017; Wang, Shu-Ching/C-6082-2017	Fitzsimmons, Rebecca/0000-0002-0497-8212; Muscat, George/0000-0002-5829-5695; Lau, Patrick/0000-0002-9693-390X; Wang, Shu-Ching/0000-0002-7871-3735				Akashi M, 2005, NAT STRUCT MOL BIOL, V12, P441, DOI 10.1038/nsmb925; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Auwerx J, 1999, CELL, V97, P161; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BERTIN R, 1990, PHYSIOL BEHAV, V47, P377, DOI 10.1016/0031-9384(90)90157-Y; Biddinger SB, 2008, CELL METAB, V7, P125, DOI 10.1016/j.cmet.2007.11.013; Buchmann J, 2007, ENDOCRINOLOGY, V148, P1561, DOI 10.1210/en.2006-1244; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200; Chao LC, 2007, MOL ENDOCRINOL, V21, P2152, DOI 10.1210/me.2007-0169; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200; Dif N, 2006, BIOCHEM J, V400, P179, DOI 10.1042/BJ20060499; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; GENT PM, 2006, TRANSCRIPTION FACTOR, P307; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gosmain Y, 2005, J LIPID RES, V46, P697, DOI 10.1194/jlr.M400261-JLR200; GUASTAVINO JM, 1978, CR ACAD SCI D NAT, V286, P137; GUASTAVINO JM, 1991, PHYSIOL BEHAV, V49, P405, DOI 10.1016/0031-9384(91)90064-U; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kallen J, 2004, J BIOL CHEM, V279, P14033, DOI 10.1074/jbc.M400302200; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kanzleiter T, 2005, PHYSIOL GENOMICS, V24, P37, DOI 10.1152/physiolgenomics.00204.2005; Kim HK, 2004, J NUTR BIOCHEM, V15, P485, DOI 10.1016/j.jnutbio.2004.02.010; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kumar N, 2008, MOL ENDOCRINOL, V22, P1057, DOI 10.1210/me.2007-0464; Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIM RW, 1995, BIOCHEM J, V308, P785, DOI 10.1042/bj3080785; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MatysiakScholze U, 1997, GENOMICS, V43, P78, DOI 10.1006/geno.1997.4757; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pearen MA, 2008, ENDOCRINOLOGY, V149, P2853, DOI 10.1210/en.2007-1202; Pearen MA, 2006, ENDOCRINOLOGY, V147, P5217, DOI 10.1210/en.2006-0447; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Qiu CH, 2007, ENDOCRINOLOGY, V148, P1745, DOI 10.1210/en.2006-1131; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; SAX DS, 1968, NEUROLOGY, V18, P1093, DOI 10.1212/WNL.18.11.1093; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; van Harmelen V, 2007, J LIPID RES, V48, P201, DOI 10.1194/jlr.M600272-JLR200; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; Xavier GD, 2006, J LIPID RES, V47, P2482, DOI 10.1194/jlr.M600289-JLR200	61	133	145	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18411	18421		10.1074/jbc.M710526200	http://dx.doi.org/10.1074/jbc.M710526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18441015	hybrid			2022-12-25	WOS:000256949200069
J	Lopez, JA; Kwan, EP; Xie, L; He, Y; James, DE; Gaisano, HY				Lopez, Jamie A.; Kwan, Edwin P.; Xie, Li; He, Yu; James, David E.; Gaisano, Herbert Y.			The RalA GTPase is a central regulator of insulin exocytosis from pancreatic islet beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							READILY RELEASABLE POOL; SECRETORY GRANULES; SYNAPTIC VESICLES; EXOCYST COMPLEX	RalA is a small GTPase that is thought to facilitate exocytosis through its direct interaction with the mammalian exocyst complex. In this study, we report an essential role for RalA in regulated insulin secretion from pancreatic beta cells. We employed lentiviral-mediated delivery of RalA short hairpin RNAs to deplete endogenous RalA protein in mouse pancreatic islets and INS-1 beta cells. Perifusion of mouse islets depleted of RalA protein exhibited inhibition of both first and second phases of glucose- stimulated insulin secretion. Consistently, INS-1 cells depleted of RalA caused a severe inhibition of depolarization-induced insulin exocytosis determined by membrane capacitance, including a reduction in the size of the ready-releasable pool of insulin granules and a reduction in the subsequent mobilization and exocytosis of the reserve pool of granules. Collectively, these data suggest that RalA is a critical component in biphasic insulin release from pancreatic beta cells.	[Lopez, Jamie A.; James, David E.] Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia; [Kwan, Edwin P.; Xie, Li; He, Yu; Gaisano, Herbert Y.] Univ Toronto, Dept Physiol & Med, Toronto, ON M5S 1A8, Canada	Garvan Institute of Medical Research; University of Toronto	James, DE (corresponding author), Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia.	d.james@garvan.org.au; herbert.gaisano@utoronto.ca		Lopez Bernal, Jamie/0000-0002-1301-5653; James, David/0000-0001-5946-5257				Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Jin RS, 2005, EMBO J, V24, P2064, DOI 10.1038/sj.emboj.7600699; Kwan EP, 2007, DIABETES, V56, P2579, DOI 10.2337/db06-1207; Li MJ, 2005, METHOD ENZYMOL, V392, P218, DOI 10.1016/S0076-6879(04)92013-7; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Tsuboi T, 2005, J BIOL CHEM, V280, P25565, DOI 10.1074/jbc.M501674200; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200	20	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17939	17945		10.1074/jbc.M800321200	http://dx.doi.org/10.1074/jbc.M800321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18426794	hybrid			2022-12-25	WOS:000256949200022
J	Miyamoto, N; Izumi, H; Noguchi, T; Nakajima, Y; Ohmiya, Y; Shiota, M; Kidani, A; Tawara, A; Kohno, K				Miyamoto, Naoya; Izumi, Hiroto; Noguchi, Takako; Nakajima, Yoshihiro; Ohmiya, Yoshihiro; Shiota, Masaki; Kidani, Akihiko; Tawara, Akihiko; Kohno, Kimitoshi			Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELL-LINES; ADENOSINE-TRIPHOSPHATASE ATP7B; DNA-REPAIR; DRUG-RESISTANCE; HISTONE ACETYLTRANSFERASE; LUNG-CANCER; ACETYLATION; PROTEIN; CHEMOTHERAPY; GLUTATHIONE	Histone modification is important for maintaining chromatin structure and function. Recently, histone acetylation has been shown to have a critical regulatory role in both transcription and DNA repair. Wereport here that expression of histone acetyltransferase (HAT) genes is associated with cisplatin resistance. We found that Tip60 is overexpressed in cisplatin-resistant cells. The expression of two other HAT genes, HAT1 and MYST1, did not differ between drug-sensitive and -resistant cells. Knockdown of Tip60 expression rendered cells sensitive to cisplatin but not to oxaliplatin, vincristine, and etoposide. Tip60 expression is significantly correlated with cisplatin sensitivity in human lung cancer cell lines. Interestingly, the promoter region of the Tip60 gene contains several E boxes, and its expression was regulated by the E-box binding circadian transcription factor Clock but not by other E-box binding transcription factors such as c-Myc, Twist, and USF1. Hyperacetylation of H3K14 and H4K16 was found in cisplatin-resistant cells. The microarray study reveals that several genes for DNA repair are down-regulated by the knockdown of Tip60 expression. Our data show that HAT gene expression is required for cisplatin resistance and suggest that Clock and Tip60 regulate not only transcription, but also DNA repair, through periodic histone acetylation.	[Miyamoto, Naoya; Izumi, Hiroto; Shiota, Masaki; Kidani, Akihiko; Kohno, Kimitoshi] Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 8078555, Japan; [Miyamoto, Naoya; Tawara, Akihiko] Univ Occupat & Environm Hlth, Sch Med, Dept Ophthalmol, Kitakyushu, Fukuoka 8078555, Japan; [Noguchi, Takako; Nakajima, Yoshihiro; Ohmiya, Yoshihiro] Natl Inst Adv Ind Sci & Technol, Osaka 5638577, Japan; [Ohmiya, Yoshihiro] Hokkaido Univ, Grad Sch Med, Dept Photobiol, Sapporo, Hokkaido 0608633, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp	Ohmiya, Yoshihiro/J-7143-2013; Shiota, Masaki/Q-9387-2019; Nakajima, Yoshihiro/M-6935-2018	Ohmiya, Yoshihiro/0000-0002-4944-509X; Nakajima, Yoshihiro/0000-0002-7422-730X; Shiota, Masaki/0000-0002-3306-4858				Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; DANIEL RM, 2007, MOL CANCER RES, V5, P61; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Husain A, 1998, CANCER RES, V58, P1120; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kimura A, 2005, J BIOCHEM, V138, P647, DOI 10.1093/jb/mvi184; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Komatsu M, 2000, CANCER RES, V60, P1312; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nakahata Y, 2007, CURR OPIN CELL BIOL, V19, P230, DOI 10.1016/j.ceb.2007.02.016; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Takenaka T, 2007, INT J CANCER, V121, P895, DOI 10.1002/ijc.22738; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wakasugi T, 2007, ONCOGENE, V26, P5194, DOI 10.1038/sj.onc.1210326; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	30	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18218	18226		10.1074/jbc.M802332200	http://dx.doi.org/10.1074/jbc.M802332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18458078	hybrid			2022-12-25	WOS:000256949200050
J	Siroy, A; Mailaender, C; Harder, D; Koerber, S; Wolschendorf, F; Danilchanka, O; Wang, Y; Heinz, C; Niederweis, M				Siroy, Axel; Mailaender, Claudia; Harder, Daniel; Koerber, Stephanie; Wolschendorf, Frank; Danilchanka, Olga; Wang, Ying; Heinz, Christian; Niederweis, Michael			Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; ESCHERICHIA-COLI; STRUCTURE PREDICTION; PORIN; MSPA; GENE; TRANSLOCATION; BIOSYNTHESIS; PERMEABILITY; TOPOLOGY	Mycobacteria contain an outer membrane composed of mycolic acids and a large variety of other lipids. Its protective function is an essential virulence factor of Mycobacterium tuberculosis. Only OmpA, which has numerous homologs in Gram-negative bacteria, is known to form channels in the outer membrane of M. tuberculosis so far. Rv1698 was predicted to be an outer membrane protein of unknown function. Expression of rv1698 restored the sensitivity to ampicillin and chloramphenicol of a Mycobacterium smegmatis mutant lacking the main porin MspA. Uptake experiments showed that Rv1698 partially complemented the permeability defect of the M. smegmatis porin mutant for glucose. These results indicated that Rv1698 provides an unspecific pore that can partially substitute for MspA. Lipid bilayer experiments demonstrated that purified Rv1698 is an integral membrane protein that indeed produces channels. The main single channel conductance is 4.5 +/- 0.3 nanosiemens in 1 M KCl. Zero current potential measurements revealed a weak preference for cations. Whole cell digestion of recombinant M. smegmatis with proteinase K showed that Rv1698 is surface-accessible. Taken together, these experiments demonstrated that Rv1698 is a channel protein that is likely involved in transport processes across the outer membrane of M. tuberculosis. Rv1698 has single homologs of unknown functions in Corynebacterineae and thus represents the first member of a new class of channel proteins specific for mycolic acid-containing outer membranes.	[Siroy, Axel; Wolschendorf, Frank; Danilchanka, Olga; Wang, Ying; Niederweis, Michael] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Mailaender, Claudia; Harder, Daniel; Koerber, Stephanie; Heinz, Christian; Niederweis, Michael] Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; [Koerber, Stephanie] Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany; [Harder, Daniel] Tech Univ Munich, Lehrstuhl Ernahrungsphysiol, Wissensch Zentrum Weihenstephan, D-85350 Freising Weihenstephan, Germany	University of Alabama System; University of Alabama Birmingham; University of Erlangen Nuremberg; Goethe University Frankfurt; Technical University of Munich	Niederweis, M (corresponding author), Univ Alabama Birmingham, Dept Microbiol, 613 Bevill Biomed Res Bldg,845 19th St S, Birmingham, AL 35294 USA.	mnieder@uab.edu		Harder, Daniel/0000-0003-4226-9748; Niederweis, Michael/0000-0003-4068-8092; Siroy, Axel/0000-0002-8013-3596	NIAID NIH HHS [AI 063432] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alahari A, 2007, J BACTERIOL, V189, P6351, DOI 10.1128/JB.00509-07; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Basle A, 2004, BBA-BIOMEMBRANES, V1664, P100, DOI 10.1016/j.bbamem.2004.04.009; Bauer FJ, 1999, MOL MICROBIOL, V31, P903, DOI 10.1046/j.1365-2958.1999.01230.x; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cascales E, 2007, MICROBIOL MOL BIOL R, V71, P158, DOI 10.1128/MMBR.00036-06; Cascioferro A, 2007, MOL MICROBIOL, V66, P1536, DOI 10.1111/j.1365-2958.2007.06023.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; Delogu G, 2004, MOL MICROBIOL, V52, P725, DOI 10.1111/j.1365-2958.2004.04007.x; EISENBERG D, 1986, J CELL BIOCHEM, V31, P11, DOI 10.1002/jcb.240310103; Faller M, 2004, SCIENCE, V303, P1189, DOI 10.1126/science.1094114; Guilvout I, 2006, EMBO J, V25, P5241, DOI 10.1038/sj.emboj.7601402; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; Heinz C, 2003, J BIOL CHEM, V278, P8678, DOI 10.1074/jbc.M212280200; Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105; Kartmann B, 1999, J BACTERIOL, V181, P6543, DOI 10.1128/JB.181.20.6543-6546.1999; Kartmann B, 1999, J BACTERIOL, V181, P7650, DOI 10.1128/JB.181.24.7650-7650.1999; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lichtinger T, 1999, FEBS LETT, V454, P349, DOI 10.1016/S0014-5793(99)00844-3; Liu NZ, 1998, FEBS LETT, V434, P160, DOI 10.1016/S0014-5793(98)00975-2; Massari P, 2003, TRENDS MICROBIOL, V11, P87, DOI 10.1016/S0966-842X(02)00037-9; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Molle V, 2006, MOL MICROBIOL, V61, P826, DOI 10.1111/j.1365-2958.2006.05277.x; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2003, MOL MICROBIOL, V49, P1167, DOI 10.1046/j.1365-2958.2003.03662.x; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Ojha A, 2005, CELL, V123, P861, DOI 10.1016/j.cell.2005.09.012; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rauch G, 1995, COMPUT METH PROG BIO, V48, P193, DOI 10.1016/0169-2607(95)01698-8; Rezwan M, 2007, J MICROBIOL METH, V68, P32, DOI 10.1016/j.mimet.2006.05.016; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Senaratne RH, 1998, J BACTERIOL, V180, P3541, DOI 10.1128/JB.180.14.3541-3547.1998; Song H, 2008, TUBERCULOSIS, V88, P526, DOI 10.1016/j.tube.2008.02.004; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; STAHL C, 2001, MOL MICROBIOL, V457, P1509; Stephan J, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-45; Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x; Stephan J, 2004, ANTIMICROB AGENTS CH, V48, P4163, DOI 10.1128/AAC.48.11.4163-4170.2004; Tansel B, 2006, SEP PURIF TECHNOL, V51, P40, DOI 10.1016/j.seppur.2005.12.020; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; Varma S, 2006, BIOPHYS J, V90, P112, DOI 10.1529/biophysj.105.059329; Wen KK, 2000, BIOCHEMISTRY-US, V39, P8638, DOI 10.1021/bi000241j; Wolschendorf F, 2007, J BACTERIOL, V189, P2435, DOI 10.1128/JB.01600-06	58	54	58	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17827	17837		10.1074/jbc.M800866200	http://dx.doi.org/10.1074/jbc.M800866200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434314	Green Published, hybrid			2022-12-25	WOS:000256949200010
J	Lightbody, KL; Ilghari, D; Waters, LC; Carey, G; Bailey, MA; Williamson, RA; Renshaw, PS; Carr, MD				Lightbody, Kirsty L.; Ilghari, Dariush; Waters, Lorna C.; Carey, Gemma; Bailey, Mark A.; Williamson, Richard A.; Renshaw, Philip S.; Carr, Mark D.			Molecular features governing the stability and specificity of functional complex formation by Mycobacterium tuberculosis CFP-10/ESAT-6 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; T-CELL ANTIGENS; ESAT-6-CFP-10 COMPLEX; SECRETION SYSTEM; ESAT-6 FAMILY; VIRULENCE; CFP-10; GENE; IMMUNOGENICITY; EXPRESSION	The Mycobacterium tuberculosis complex CFP-10/ESAT-6 family proteins play essential but poorly defined roles in tuberculosis pathogenesis. In this article we report the results of detailed spectroscopic studies of several members of the CFP10/ESAT-6 family. This work shows that the CFP-10/ESAT-6 related proteins, Rv0287 and Rv0288, form a tight 1:1 complex, which is predominantly helical in structure and is predicted to closely resemble the complex formed by CFP-10 and ESAT-6. In addition, the Rv0287.Rv0288 complex was found to be significantly more stable to both chemical and temperature induced denaturation than CFP-10.ESAT-6. This approach demonstrated that neither Rv0287.Rv0288 nor the CFP-10.ESAT-6 complexes are destabilized at low pH (4.5), indicating that even in low pH environments, such as the mature phagosome, both Rv0287.Rv0288 and CFP-10.ESAT-6 undoubtedly function as complexes rather than individual proteins. Analysis of the structure of the CFP-10.ESAT-6 complex and optimized amino acid sequence alignments of M. tuberculosis CFP-10/ESAT-6 family proteins revealed that residues involved in the intramolecular contacts between helices are conserved across the CFP-10/ ESAT-6 family, but not those involved in primarily intermolecular contacts. This analysis identified the molecular basis for the specificity and stability of complex formation between CFP-10/ ESAT-6 family proteins, and indicates that the formation of functional complexes with key roles in pathogenesis will be limited to genome partners, or very closely related family members, such as Rv0287/Rv0288 and Rv3019c/Rv3020c.	[Lightbody, Kirsty L.; Ilghari, Dariush; Waters, Lorna C.; Carey, Gemma; Bailey, Mark A.; Renshaw, Philip S.; Carr, Mark D.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Ilghari, Dariush] Iran Minist Hlth & Med Educ, Tehran 1467664961, Iran; [Williamson, Richard A.] Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Leicester; Ministry of Health & Medical Education (MOHME); University of Kent	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk		Carr, Mark/0000-0002-3939-0996	Wellcome Trust [080085/Z/06/Z, 0786607/Z/05/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alderson MR, 2000, J EXP MED, V191, P551, DOI 10.1084/jem.191.3.551; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Betz SF, 1997, BIOCHEMISTRY-US, V36, P2450, DOI 10.1021/bi961704h; Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006; Brodin P, 2005, J BIOL CHEM, V280, P33953, DOI 10.1074/jbc.M503515200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Converse SE, 2005, J BACTERIOL, V187, P1238, DOI 10.1128/JB.187.4.1238-1245.2005; de Jonge MI, 2007, J BACTERIOL, V189, P6028, DOI 10.1128/JB.00469-07; Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285, DOI 10.1128/JCM.38.9.3285-3290.2000; Fortune SM, 2005, P NATL ACAD SCI USA, V102, P10676, DOI 10.1073/pnas.0504922102; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Lightbody KL, 2004, FEMS MICROBIOL LETT, V238, P255, DOI 10.1016/j.femsle.2004.07.043; MacGurn JA, 2005, MOL MICROBIOL, V57, P1653, DOI 10.1111/j.1365-2958.2005.04800.x; Maciag A, 2007, J BACTERIOL, V189, P730, DOI 10.1128/JB.01190-06; MALEN H, 2007, MICROBIOLOGY, V7, P1702; Marei A, 2005, INT IMMUNOL, V17, P1439, DOI 10.1093/intimm/dxh322; Meher AK, 2006, FEBS J, V273, P1445, DOI 10.1111/j.1742-4658.2006.05166.x; Meher AK, 2007, VACCINE, V25, P6098, DOI 10.1016/j.vaccine.2007.05.016; Okkels LM, 2004, J BACTERIOL, V186, P2487, DOI 10.1128/JB.186.8.2487-2491.2004; Pace C N, 1986, Methods Enzymol, V131, P266; Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Rosenkrands I, 2000, ELECTROPHORESIS, V21, P935, DOI 10.1002/(SICI)1522-2683(20000301)21:5<935::AID-ELPS935>3.3.CO;2-G; Russell DG, 2005, ASM NEWS, V71, P459; Skjot RLV, 2002, INFECT IMMUN, V70, P5446, DOI 10.1128/IAI.70.10.5446-5453.2002; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Sreerama N, 2004, PROTEIN SCI, V13, P100, DOI 10.1110/ps.03258404; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749; Van Pittius NG, 2001, GENOME BIOL, V2; WHO, 2007, WHOHTMTB2007376	40	38	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17681	17690		10.1074/jbc.M800123200	http://dx.doi.org/10.1074/jbc.M800123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430736	hybrid			2022-12-25	WOS:000256720600074
J	Cabreiro, F; Picot, CR; Perichon, M; Castel, J; Friguet, B; Petropoulos, I				Cabreiro, Filipe; Picot, Cedric R.; Perichon, Martine; Castel, Julien; Friguet, Bertrand; Petropoulos, Isabelle			Overexpression of mitochondrial methionine sulfoxide reductase B2 protects leukemia cells from oxidative stress-induced cell death and protein damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT DEFENSE; LENS CELLS; IN-VIVO; PROTEASOME; RESIDUES; REPAIR; MSRA; INACTIVATION; FIBROBLASTS; EXPRESSION	According to the mitochondrial theory of aging, mitochondrial dysfunction increases intracellular reactive oxidative species production, leading to the oxidation of macromolecules and ultimately to cell death. In this study, we investigated the role of the mitochondrial methionine sulfoxide reductase B2 in the protection against oxidative stress. We report, for the first time, that overexpression of methionine sulfoxide reductase B2 in mitochondria of acute T-lymphoblastic leukemia MOLT-4 cell line, in which methionine sulfoxide reductase A is missing, markedly protects against hydrogen peroxide-induced oxidative stress by scavenging reactive oxygen species. The addition of hydrogen peroxide provoked a time-gradual increase of intracellular reactive oxygen species, leading to a loss in mitochondrial membrane potential and to protein carbonyl accumulation, whereas in methionine sulfoxide reductase B2-overexpressing cells, intracellular reactive oxygen species and protein oxidation remained low with the mitochondrial membrane potential highly maintained. Moreover, in these cells, delayed apoptosis was shown by a decrease in the cleavage of the apoptotic marker poly(ADP-ribose) polymerase-1 and by the lower percentage of Annexin-V-positive cells in the late and early apoptotic stages. We also provide evidence for the protective mechanism of methionine sulfoxide reductase B2 against protein oxidative damages. Our results emphasize that upon oxidative stress, the overexpression of methionine sulfoxide reductase B2 leads to the preservation of mitochondrial integrity by decreasing the intracellular reactive oxygen species build-up through its scavenging role, hence contributing to cell survival and protein maintenance.	[Cabreiro, Filipe; Picot, Cedric R.; Perichon, Martine; Friguet, Bertrand; Petropoulos, Isabelle] Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, F-75251 Paris 05, France; [Castel, Julien] Univ Paris 07, CNRS, UMR 7059, Lab Physiopathol Nutr, F-75251 Paris 05, France; [Friguet, Bertrand; Petropoulos, Isabelle] Univ Paris 06, CNRS, UMR 7059, Lab Physiol & Physiopathol, F-75252 Paris 05, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Friguet, B (corresponding author), Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, 2 Pl Jussieu,Tour 33-23,1er Etage,CC 7128, F-75251 Paris 05, France.	bertrand.friguet@snv.jussieu.fr; isabelle.petropoulos@snv.jussieu.fr		CASTEL, JULIEN/0000-0003-4309-701X; Friguet, Bertrand/0000-0001-8085-1961; Picot, cedric/0000-0002-2884-1237; Cabreiro, Filipe/0000-0002-3696-4843; Petropoulos, Isabelle/0000-0001-9205-7458				Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BROT N, 1982, ANAL BIOCHEM, V122, P291, DOI 10.1016/0003-2697(82)90283-4; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Cabreiro F, 2006, ANN NY ACAD SCI, V1067, P37, DOI 10.1196/annals.1354.006; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P163, DOI 10.1089/ars.2006.8.163; Farout L, 2006, ARCH BIOCHEM BIOPHYS, V453, P135, DOI 10.1016/j.abb.2006.02.003; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X; Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Marchetti MA, 2005, INVEST OPHTH VIS SCI, V46, P2107, DOI 10.1167/iovs.05-0018; Marchetti MA, 2006, EXP EYE RES, V83, P1281, DOI 10.1016/j.exer.2006.07.005; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; Petropoulos I, 2006, FREE RADICAL RES, V40, P1269, DOI 10.1080/10715760600917144; Picot CR, 2005, FREE RADICAL BIO MED, V39, P1332, DOI 10.1016/j.freeradbiomed.2005.06.017; Picot CR, 2004, FEBS LETT, V558, P74, DOI 10.1016/S0014-5793(03)01530-8; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081; Vougier S, 2004, J BIOL CHEM, V279, P30210, DOI 10.1074/jbc.M400604200; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P1159, DOI 10.1073/pnas.0308215100	38	74	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16673	16681		10.1074/jbc.M708580200	http://dx.doi.org/10.1074/jbc.M708580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424444	hybrid			2022-12-25	WOS:000256497100044
J	Marshall, RS; Jolliffe, NA; Ceriotti, A; Snowden, CJ; Lord, JM; Frigerio, L; Roberts, LM				Marshall, Richard S.; Jolliffe, Nicholas A.; Ceriotti, Aldo; Snowden, Christopher J.; Lord, J. Michael; Frigerio, Lorenzo; Roberts, Lynne M.			The role of CDC48 in the retro-translocation of non-ubiquitinated toxin substrates in plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; ER QUALITY-CONTROL; RETICULUM-ASSOCIATED DEGRADATION; RECOGNIZES SUGAR CHAINS; ENDOPLASMIC-RETICULUM; AAA-ATPASE; PROTEIN-DEGRADATION; SECRETORY PATHWAY; COMMUNIS AGGLUTININ; TOBACCO PROTOPLASTS	When the catalytic A subunits of the castor bean toxins ricin and Ricinus communis agglutinin (denoted as RTA and RCA A, respectively) are delivered into the endoplasmic reticulum (ER) of tobacco protoplasts, they become substrates for ER-associated protein degradation (ERAD). As such, these orphan polypeptides are retro-translocated to the cytosol, where a significant proportion of each protein is degraded by proteasomes. Here we begin to characterize the ERAD pathway in plant cells, showing that retro-translocation of these lysine-deficient glycoproteins requires the ATPase activity of cytosolic CDC48. Lysine polyubiquitination is not obligatory for this step. We also show that although RCA A is found in a mannose-untrimmed form prior to its retro-translocation, a significant proportion of newly synthesized RTA cycles via the Golgi and becomes modified by downstream glycosylation enzymes. Despite these differences, both proteins are similarly retro-translocated.	[Marshall, Richard S.; Jolliffe, Nicholas A.; Snowden, Christopher J.; Lord, J. Michael; Frigerio, Lorenzo; Roberts, Lynne M.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Ceriotti, Aldo] CNR, Ist Biol & Biotecnol Agraria, Milan, Italy	University of Warwick; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Biotecnologia Agraria (IBBA-CNR)	Roberts, LM (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	lynne.roberts@warwick.ac.uk	Frigerio, Lorenzo/D-2685-2009; Ceriotti, Aldo/A-1448-2016; Frigerio, Lorenzo/M-6013-2019	Frigerio, Lorenzo/0000-0003-4100-6022; Ceriotti, Aldo/0000-0002-8230-8863; Frigerio, Lorenzo/0000-0003-4100-6022	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen SCH, 2007, FEBS J, V274, P5586, DOI 10.1111/j.1742-4658.2007.06080.x; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Brandizzi F, 2003, PLANT J, V34, P269, DOI 10.1046/j.1365-313X.2003.01728.x; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Ceriotti A, 2006, PLANT CELL MONOGR, V4, P75, DOI 10.1007/7089_066; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; Contento AL, 2004, PLANT PHYSIOL, V135, P2330, DOI 10.1104/pp.104.044362; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; DENECKE J, 1995, PLANT CELL, V7, P391, DOI 10.1105/tpc.7.4.391; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Di Cola A, 2005, PLANT PHYSIOL, V137, P287, DOI 10.1104/pp.104.055434; Di Cola A, 2001, P NATL ACAD SCI USA, V98, P14726, DOI 10.1073/pnas.251386098; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Hunter PR, 2007, PLANT PHYSIOL, V145, P1371, DOI 10.1104/pp.107.103945; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jolliffe NA, 2006, J BIOL CHEM, V281, P23377, DOI 10.1074/jbc.M602678200; Kirst ME, 2005, PLANT PHYSIOL, V138, P218, DOI 10.1104/pp.105.060087; Klein EM, 2006, PLANT J, V48, P657, DOI 10.1111/j.1365-313X.2006.02904.x; Kothe M, 2005, J BIOL CHEM, V280, P28127, DOI 10.1074/jbc.M503138200; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006; MALIGA P, 1973, NATURE-NEW BIOL, V244, P29, DOI 10.1038/newbio244029a0; Martinez IM, 2003, PLANT CELL, V15, P561, DOI 10.1105/tpc.007609; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Muller J, 2005, PLANT CELL, V17, P149, DOI 10.1105/tpc.104.026625; Pedrazzini E, 1997, PLANT CELL, V9, P1869, DOI 10.1105/tpc.9.10.1869; Pimpl P, 2006, PLANT CELL, V18, P198, DOI 10.1105/tpc.105.036665; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Roberts LM, 2004, TOXICON, V44, P469, DOI 10.1016/j.toxicon.2004.07.002; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; SIMPSON JC, 1995, EUR J BIOCHEM, V232, P458; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; TABE LM, 1995, J ANIM SCI, V73, P2752; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Vitale A, 2001, PLANT CELL, V13, P1260; Wahlman J, 2007, CELL, V129, P943, DOI 10.1016/j.cell.2007.03.046; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wojcik C, 2006, MOL BIOL CELL, V17, P4606, DOI 10.1091/mbc.E06-05-0432; Worthington ZEV, 2007, INFECT IMMUN, V75, P2946, DOI 10.1128/IAI.02011-06; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200	64	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15869	15877		10.1074/jbc.M709316200	http://dx.doi.org/10.1074/jbc.M709316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18420588	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000256332500045
J	Arnon, TI; Markel, G; Bar-Ilan, A; Hanna, J; Fima, E; Benchetrit, F; Galili, R; Cerwenka, A; Benharroch, D; Sion-Vardy, N; Porgador, A; Mandelboim, O				Arnon, Tal I.; Markel, Gal; Bar-Ilan, Ahuva; Hanna, Jacob; Fima, Eyal; Benchetrit, Fabrice; Galili, Ruth; Cerwenka, Adelheid; Benharroch, Daniel; Sion-Vardy, Netta; Porgador, Angel; Mandelboim, Ofer			Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy	PLOS ONE			English	Article								The natural cytotoxic receptors (NCRs) are a unique set of activating proteins expressed mainly on the surface of natural killer (NK) cells. The NCRs, which include three members; NKp46, NKp44 and NKp30, are critically involved in NK cytotoxicity against different targets, including a wide range of tumor cells derived from various origins. Even though the tumor ligands of the NCRs have not been identified yet, the selective manner by which these receptors target tumor cells may provide an excellent basis for the development of novel anti-tumor therapies. To test the potential use of the NCRs as anti-tumor agents, we generated soluble NCR-Ig fusion proteins in which the constant region of human IgG1 was fused to the extracellular portion of the receptor. We demonstrate, using two different human prostate cancer cell lines, that treatment with NKp30-Ig, dramatically inhibits tumor growth in vivo. Activated macrophages were shown to mediate an ADCC response against the NKp30-Ig coated prostate cell lines. Finally, the Ig fusion proteins were also demonstrated to discriminate between benign prostate hyperplasia and prostate cancer. This may provide a novel diagnostic modality in the difficult task of differentiating between these highly common pathological conditions.	[Arnon, Tal I.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Markel, Gal] Sheba Med Ctr, Sheba Canc Res Ctr, Tel Hashomer, Israel; [Bar-Ilan, Ahuva; Fima, Eyal; Benchetrit, Fabrice; Porgador, Angel] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Shraga Segal Dept Microbiol & Immunol, Beer Sheva, Israel; [Hanna, Jacob] Whitehead Inst Biomed Res, Cambridge, MA USA; [Galili, Ruth; Mandelboim, Ofer] Hebrew Univ Hadassah Med Sch, Lautenberg Ctr General & Tumor Immunol, Jerusalem, Israel; [Cerwenka, Adelheid] German Canc Res Ctr, Div Innate Immun, Heidelberg, Germany; [Benharroch, Daniel; Sion-Vardy, Netta] Soroka Hosp, Pathol Dept, Beer Sheva, Israel	California Institute of Technology; Chaim Sheba Medical Center; Ben Gurion University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Hebrew University of Jerusalem; Helmholtz Association; German Cancer Research Center (DKFZ); Ben Gurion University; Soroka Medical Center	Arnon, TI (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	angel@bgu.ac.il; oferman@md2.huji.ac.il	Hanna, Jacob/K-1339-2012	Hanna, Jacob/0000-0003-2042-9974; Mandelboim, Ofer/0000-0002-9354-1855; Porgador, Angel/0000-0003-1540-4449; Cerwenka, Adelheid/0000-0001-6977-3536				Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2004, BLOOD, V103, P664, DOI 10.1182/blood-2003-05-1716; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bloushtain N, 2004, J IMMUNOL, V173, P2392, DOI 10.4049/jimmunol.173.4.2392; Caplan Aaron, 2002, Am J Clin Pathol, V117 Suppl, pS104; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Coiffier B, 2003, BLOOD REV, V17, P25, DOI 10.1016/S0268-960X(02)00059-0; Costello RT, 2004, TRENDS IMMUNOL, V25, P328, DOI 10.1016/j.it.2004.04.005; Costello RT, 2002, BLOOD, V99, P3661, DOI 10.1182/blood.V99.10.3661; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Glennie MJ, 2003, DRUG DISCOV TODAY, V8, P503, DOI 10.1016/S1359-6446(03)02714-4; HERSHKOVITZ O, 2007, GLYCOBIOLOGY    1115; Hershkovitz O, 2007, BIOCHEMISTRY-US, V46, P7426, DOI 10.1021/bi7000455; Iannello A, 2005, CANCER METAST REV, V24, P487, DOI 10.1007/s10555-005-6192-2; Liossis SNC, 2005, J ALLERGY CLIN IMMUN, V116, P721, DOI 10.1016/j.jaci.2005.06.035; Lodoen MB, 2005, NAT REV MICROBIOL, V3, P59, DOI 10.1038/nrmicro1066; Lowe FC, 2005, DRUG TODAY, V41, P179, DOI 10.1358/dot.2005.41.3.892523; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Milas L, 2000, CLIN CANCER RES, V6, P701; Moretta L, 2002, SCAND J IMMUNOL, V55, P229, DOI 10.1046/j.1365-3083.2002.01055.x; Moretta L, 2002, EUR J IMMUNOL, V32, P1205, DOI 10.1002/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y; Moretta Lorenzo, 2001, Current Opinion in Pharmacology, V1, P387, DOI 10.1016/S1471-4892(01)00067-4; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Porgador A, 2005, THESCIENTIFICWORLDJO, V5, P151, DOI 10.1100/tsw.2005.22; PRESS OW, 2001, IMMUNOTHERAPY NONHOD, P221; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Shaffer DR, 2003, LANCET ONCOL, V4, P407, DOI 10.1016/S1470-2045(03)01138-0; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Swindle P, 2003, RADIOLOGY, V228, P144, DOI 10.1148/radiol.2281011808; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Yokoyama WM, 2005, ADV EXP MED BIOL, V560, P57; Zilka A, 2005, BIOCHEMISTRY-US, V44, P14477, DOI 10.1021/bi051241s	42	27	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2150	10.1371/journal.pone.0002150	http://dx.doi.org/10.1371/journal.pone.0002150			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478075	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000262172800015
J	Movsesyan, N; Ghochikyan, A; Mkrtichyan, M; Petrushina, I; Davtyan, H; Olkhanud, PB; Head, E; Biragyn, A; Cribbs, DH; Agadjanyan, MG				Movsesyan, Nina; Ghochikyan, Anahit; Mkrtichyan, Mikayel; Petrushina, Irina; Davtyan, Hayk; Olkhanud, Purevdorj B.; Head, Elizabeth; Biragyn, Arya; Cribbs, David H.; Agadjanyan, Michael G.			Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine - A Novel Immunotherapeutic Strategy	PLOS ONE			English	Article								Background: The development of a safe and effective AD vaccine requires a delicate balance between providing an adequate anti-A beta antibody response sufficient to provide therapeutic benefit, while eliminating an adverse T cell-mediated proinflammatory autoimmune response. To achieve this goal we have designed a prototype chemokine-based DNA epitope vaccine expressing a fusion protein that consists of 3 copies of the self-B cell epitope of A beta(42) (A beta(1-11)), a non-self T helper cell epitope (PADRE), and macrophage-derived chemokine (MDC/CCL22) as a molecular adjuvant to promote a strong anti-inflammatory Th2 phenotype. Methods and Findings: We generated pMDC-3A beta(1-11)-PADRE construct and immunized 3xTg-AD mouse model starting at age of 3-4 months old. We demonstrated that prophylactic immunizations with the DNA epitope vaccine generated a robust Th2 immune response that induced high titers of anti-A beta antibody, which in turn inhibited accumulation of A beta pathology in the brains of older mice. Importantly, vaccination reduced glial activation and prevented the development of behavioral deficits in aged animals without increasing the incidence of microhemorrhages. Conclusions: Data from this transitional pre-clinical study suggest that our DNA epitope vaccine could be used as a safe and effective strategy for AD therapy. Future safety and immunology studies in large animals with the goal to achieve effective humoral immunity without adverse effects should help to translate this study to human clinical trials.	[Movsesyan, Nina; Ghochikyan, Anahit; Mkrtichyan, Mikayel; Davtyan, Hayk; Agadjanyan, Michael G.] Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA USA; [Movsesyan, Nina; Petrushina, Irina; Head, Elizabeth; Cribbs, David H.; Agadjanyan, Michael G.] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA; [Olkhanud, Purevdorj B.; Biragyn, Arya] NIA, Lab Immunol, Immunotherapeut Unit, Baltimore, MD USA; [Head, Elizabeth; Cribbs, David H.] Univ Calif Irvine, Dept Neurol, Irvine, CA USA	University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California Irvine	Movsesyan, N (corresponding author), Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA USA.	magadjanyan@immed.org		Ghochikyan, Anahit/0000-0001-5436-0616	NIH [AG20241, NS50895, NS057395, AG00538, AG00096, P50 AG16573]; Alzheimers Association [IIRG036279, IIRG0728314]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057395, R01NS050895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538, R01AG020241, P50AG016573, ZIAAG000770] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimers Association(Alzheimer's Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funding from the NIH: AG20241 (DHC & MGA), NS50895 (DHC & MGA), NS057395 (MGA), AG00538(DHC) and from the Alzheimers Association IIRG036279 (MGA & DHC), IIRG0728314 (AG). NM was supported by NIA training grant AG00096. The 3xTg-AD homozygous mice and amyloid peptides were provided by UCI-Alzheimers Disease Research Center (ADRC) under the NIH/NIA P50 AG16573 grant.	Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Biragyn A, 2004, BLOOD, V104, P1961, DOI 10.1182/blood-2004-02-0637; Biragyn A, 2002, BLOOD, V100, P1153, DOI 10.1182/blood-2002-01-0086; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chen GQ, 2007, J NEUROSCI, V27, P2654, DOI 10.1523/JNEUROSCI.3710-06.2007; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; CRIBBS DH, 2005, CURR IMMUNOL REV, V1, P139; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Ghochikyan A, 2006, VACCINE, V24, P2275, DOI 10.1016/j.vaccine.2005.11.039; Ghochikyan A, 2003, EUR J IMMUNOL, V33, P3232, DOI 10.1002/eji.200324000; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kim HD, 2007, IMMUNOL LETT, V112, P30, DOI 10.1016/j.imlet.2007.06.006; Kutzler MA, 2006, VACCINE, V24, P4630, DOI 10.1016/j.vaccine.2005.08.036; Lemere CA, 2006, REJUV RES, V9, P77, DOI 10.1089/rej.2006.9.77; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li QY, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-22; Mamikonyan G, 2007, J BIOL CHEM, V282, P22376, DOI 10.1074/jbc.M700088200; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2006, J NEUROPATH EXP NEUR, V65, P1040, DOI 10.1097/01.jnen.0000240466.10758.ce; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Oddo S., 2006, J BIOL CHEM; Okura Y, 2006, P NATL ACAD SCI USA, V103, P9619, DOI 10.1073/pnas.0600966103; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pasquali JL, 2007, J AUTOIMMUN, V29, P250, DOI 10.1016/j.jaut.2007.07.006; Patton RL, 2006, AM J PATHOL, V169, P1048, DOI 10.2353/ajpath.2006.060269; Petrushina I, 2003, NEUROSCI LETT, V338, P5, DOI 10.1016/S0304-3940(02)01357-5; Petrushina I, 2007, J NEUROSCI, V27, P12721, DOI 10.1523/JNEUROSCI.3201-07.2007; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Qu BX, 2004, ARCH NEUROL-CHICAGO, V61, P1859, DOI 10.1001/archneur.61.12.1859; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Schiavo R, 2006, BLOOD, V107, P4597, DOI 10.1182/blood-2005-08-3207; Schultz JG, 2004, J MOL MED, V82, P706, DOI 10.1007/s00109-004-0570-z; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; WILCOCK DM, 2007, NEUROSCIENC IN PRESS; Zaliauskiene L, 2002, J IMMUNOL, V169, P2337, DOI 10.4049/jimmunol.169.5.2337	53	97	111	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2124	10.1371/journal.pone.0002124	http://dx.doi.org/10.1371/journal.pone.0002124			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461171	gold, Green Published			2022-12-25	WOS:000261642400045
J	Opatowski, L; Temime, L; Varon, E; Leclerc, R; Drugeon, H; Boelle, PY; Guillemot, D				Opatowski, Lulla; Temime, Laura; Varon, Emmanuelle; Leclerc, Roland; Drugeon, Henri; Boelle, Pierre-Yves; Guillemot, Didier			Antibiotic Innovation May Contribute to Slowing the Dissemination of Multiresistant Streptococcus pneumoniae: The Example of Ketolides	PLOS ONE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; PENICILLIN-BINDING PROTEINS; BETA-LACTAM RESISTANCE; NASOPHARYNGEAL CARRIAGE; ANTIMICROBIAL RESISTANCE; BACTERIAL-RESISTANCE; INFECTIOUS-DISEASES; ANTIBACTERIAL; TRANSMISSION; CHILDREN	Background: Despite increasingly frequent bacterial resistance to antibiotics, antibacterial innovation is rare. Ketolides constitute one of the very few new antibiotic classes active against Streptococcus pneumoniae developed during the last 25 years. Their mechanism of action resembles that of macrolides, but they are unaffected by common resistance mechanisms. However, cross-resistance to ketolides has been observed in some macrolide-resistant strains. We examined how new antibiotic exposure may affect overall pneumococcal resistance patterns in the population. The aims of this study were to assess the potential dissemination of newly emerged resistances and to control the selection of strains already multiresistant to existing antimicrobials. Methodology/Principal Findings: We developed an age-structured population model for S. pneumoniae transmission in a human community exposed to heptavalent vaccine, and beta-lactams, macrolides and ketolides. The dynamics of intraindividual selection of resistant strains under antibiotic exposure and interindividual transmission were simulated, with antibiotic-specific resistance mechanisms defining the path to co-resistances and cross-resistances, and parameters concerning the French situation. Results of this simulation study suggest that new antibiotic consumption could markedly slow the diffusion of multiresistant strains. Wider use was associated with slower progression of multiresistance. When ketolides were prescribed to all ages, resistance to them reached 10% after > 15 years, while it took > 40 years when they were prescribed only to adults. In the scenario according to which new antibiotics totally replaced former antimicrobials, the beta-lactam resistance rate was limited at 70%. Conclusions: In a context of widespread vaccination and rational use of antibiotics, innovative antibiotic, prescribed to all age groups, may have an added impact on multiresistant-strain dissemination in the population.	[Opatowski, Lulla; Guillemot, Didier] Inst Pasteur, Unite Pharmacoepidemiol & Malad Infect, Paris, France; [Opatowski, Lulla; Guillemot, Didier] INSERM, U657, Paris, France; [Temime, Laura] Conserv Natl Arts Metiers, Chaire Hygi & Secur, Paris, France; [Varon, Emmanuelle] Hop Europeen Georges Pompidou, Assistance Publs Hop Paris, Ctr Natl Reference Pneumocoques, Paris, France; [Leclerc, Roland] CHU Cote Nacre, Univ Caen, Serv Microbiol, Interactions hote microorganismes epitheliums, Caen, France; [Drugeon, Henri] Hop G&R Laennec, Hyg Hosp, Lab Bacteriol, Nantes, France; [Boelle, Pierre-Yves] INSERM, U707, Paris, France; [Boelle, Pierre-Yves] UPMC Paris6, UMR S 707, Paris, France; [Boelle, Pierre-Yves] Assistance Publ Hop Paris, Hop Saint Antoine, Paris, France; [Guillemot, Didier] Univ Versailles St Quentin, Versailles, France; [Guillemot, Didier] Assistance Publ Hop Paris, Hop Raymond Poincare, Unite Sant Publ, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); heSam Universite; Conservatoire National Arts & Metiers (CNAM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Opatowski, L (corresponding author), Inst Pasteur, Unite Pharmacoepidemiol & Malad Infect, Paris, France.	lopatows@pasteur.fr	Guillemot, Didier/AAN-3051-2020; Temime, Laura/G-7010-2011; Opatowski, Lulla/I-3143-2015	Opatowski, Lulla/0000-0001-8348-700X; Guillemot, Didier/0000-0002-8497-1765; Boelle, Pierre-Yves/0000-0002-5367-8232; Temime, Laura/0000-0002-8850-5403	Sanofi-Aventis	Sanofi-Aventis(Sanofi-Aventis)	Sanofi-Aventis accorded funding for this study. The funders had no role in model and simulations design and analysis, decision to publish or preparation of the manuscript.	Andersson DI, 2006, CURR OPIN MICROBIOL, V9, P461, DOI 10.1016/j.mib.2006.07.002; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Cassell GH, 2001, JAMA-J AM MED ASSOC, V285, P601, DOI 10.1001/jama.285.5.601; Cauchemez S, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-14; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P177; Davis SR, 2000, MIL MED, V165, P35, DOI 10.1093/milmed/165.suppl_2.35; Decousser JW, 2004, EUR J CLIN MICROBIOL, V23, P27, DOI 10.1007/s10096-003-1032-1; Desenclos JC, 2004, EMERG INFECT DIS, V10, P759, DOI 10.3201/eid1004.030754; *EARSS, 2006, ANN REP 2005; Ekdahl K, 1997, CLIN INFECT DIS, V25, P1113, DOI 10.1086/516103; Farrell DJ, 2007, J CLIN MICROBIOL, V45, P290, DOI 10.1128/JCM.01653-06; Farrell DJ, 2005, EMERG INFECT DIS, V11, P851, DOI 10.3201/eid1106.050222; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; *FRENCH NAT HLTH I, FRENCH SURV ANT CONS; GESLIN P, 1992, CTR NAT REF PNEUM; Goldstein F, 2005, EMERG INFECT DIS, V11, P1489, DOI 10.3201/eid1109.050415; Hakenbeck R, 1999, MOL MICROBIOL, V33, P673, DOI 10.1046/j.1365-2958.1999.01521.x; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; Hogberg L, 2007, J CLIN MICROBIOL, V45, P948, DOI 10.1128/JCM.01913-06; *INSEE, 2007, IND SER STAT INSEE; *INVS, 2006, B EP HEBD INVS, V2930, P212; Jorgensen JH, 2004, ANTIMICROB AGENTS CH, V48, P605, DOI 10.1128/AAC.48.2.605-607.2004; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Leclercq R, 2002, J INFECTION, V44, P11, DOI 10.1053/jinf.2001.0940; Leclercq R, 2001, J ANTIMICROB CHEMOTH, V48, P9, DOI 10.1093/jac/48.suppl_2.9; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; Lipsitch M, 2001, CLIN INFECT DIS, V32, P1044, DOI 10.1086/319604; Malley R, 2006, INFECT IMMUN, V74, P2187, DOI 10.1128/IAI.74.4.2187-2195.2006; McGowan JE, 2001, EMERG INFECT DIS, V7, P286, DOI 10.3201/eid0702.010228; Melegaro A, 2004, EPIDEMIOL INFECT, V132, P433, DOI 10.1017/S0950268804001980; Moroney JF, 2001, CLIN INFECT DIS, V33, P797, DOI 10.1086/322623; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772; Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547; Riedel S, 2007, EUR J CLIN MICROBIOL, V26, P485, DOI 10.1007/s10096-007-0321-5; Ross DB, 2007, NEW ENGL J MED, V356, P1601, DOI 10.1056/NEJMp078032; Rozen DE, 2007, ANTIMICROB AGENTS CH, V51, P412, DOI 10.1128/AAC.01161-06; Sommet A, 2004, J ANTIMICROB CHEMOTH, V54, P524, DOI 10.1093/jac/dkh342; Soreth J, 2007, NEW ENGL J MED, V356, P1675, DOI 10.1056/NEJMc076135; Stephens DS, 2005, LANCET, V365, P855, DOI 10.1016/S0140-6736(05)71043-6; Talbot GH, 2006, CLIN INFECT DIS, V42, P657, DOI 10.1086/499819; Temime L, 2006, PEDIATR INFECT DIS J, V25, P382, DOI 10.1097/01.inf.0000210460.21966.f1; Temime L, 2004, ANTIMICROB AGENTS CH, V48, P2206, DOI 10.1128/AAC.48.6.2206-2213.2004; Temime L, 2003, EMERG INFECT DIS, V9, P411, DOI 10.3201/eid0904.020213; Tomasz A, 1997, CLIN INFECT DIS, V24, pS85, DOI 10.1093/clinids/24.Supplement_1.S85; Trzcinski K, 2006, J INFECT DIS, V193, P1296, DOI 10.1086/501367; *US FDA, 2007, UPD LAB KET; VARON E, 2005, CTR NAT REF PNEUM RA; VARON E, 2003, CTR NATL REFERENCE P; Wang YC, 2006, P NATL ACAD SCI USA, V103, P9655, DOI 10.1073/pnas.0600636103; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Wierzbowski AK, 2005, ANTIMICROB AGENTS CH, V49, P4635, DOI 10.1128/AAC.49.11.4635-4640.2005; 2002, ARCH PEDIAT, V9, P862	55	10	11	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2089	10.1371/journal.pone.0002089	http://dx.doi.org/10.1371/journal.pone.0002089			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461139	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400012
J	Tran, PT; Fan, AC; Bendapudi, PK; Koh, S; Komatsubara, K; Chen, J; Horng, G; Bellovin, DI; Giuriato, S; Wang, CS; Whitsett, JA; Felsher, DW				Tran, Phuoc T.; Fan, Alice C.; Bendapudi, Pavan K.; Koh, Shan; Komatsubara, Kim; Chen, Joy; Horng, George; Bellovin, David I.; Giuriato, Sylvie; Wang, Craig S.; Whitsett, Jeffrey A.; Felsher, Dean W.			Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas	PLOS ONE			English	Article							KINASE DOMAIN MUTATION; C-MYC; TYROSINE KINASE; TRANSGENIC MICE; NEOPLASTIC PHENOTYPE; SOMATIC MUTATIONS; STAT3 ACTIVATION; MUTANT EGFR; BCR-ABL; IN-VIVO	Background: Conditional transgenic models have established that tumors require sustained oncogene activation for tumor maintenance, exhibiting the phenomenon known as "oncogene-addiction.'' However, most cancers are caused by multiple genetic events making it difficult to determine which oncogenes or combination of oncogenes will be the most effective targets for their treatment. Methodology/Principal Findings: To examine how the MYC and K-ras(G12D) oncogenes cooperate for the initiation and maintenance of tumorigenesis, we generated double conditional transgenic tumor models of lung adenocarcinoma and lymphoma. The ability of MYC and K-ras(G12D) to cooperate for tumorigenesis and the ability of the inactivation of these oncogenes to result in tumor regression depended upon the specific tissue context. MYC-, K-ras(G12D)- or MYC/K-ras(G12D)-induced lymphomas exhibited sustained regression upon the inactivation of either or both oncogenes. However, in marked contrast, MYC-induced lung tumors failed to regress completely upon oncogene inactivation; whereas K-ras(G12D)-induced lung tumors regressed completely. Importantly, the combined inactivation of both MYC and K-ras(G12D) resulted more frequently in complete lung tumor regression. To account for the different roles of MYC and K-ras(G12D) in maintenance of lung tumors, we found that the down-stream mediators of K-ras(G12D) signaling, Stat3 and Stat5, are dephosphorylated following conditional K-ras(G12D) but not MYC inactivation. In contrast, Stat3 becomes dephosphorylated in lymphoma cells upon inactivation of MYC and/or K-ras(G12D). Interestingly, MYC-induced lung tumors that failed to regress upon MYC inactivation were found to have persistent Stat3 and Stat5 phosphorylation. Conclusions/Significance: Taken together, our findings point to the importance of the K-Ras and associated down-stream Stat effector pathways in the initiation and maintenance of lymphomas and lung tumors. We suggest that combined targeting of oncogenic pathways is more likely to be effective in the treatment of lung cancers and lymphomas.	[Tran, Phuoc T.] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA; [Tran, Phuoc T.; Fan, Alice C.; Bendapudi, Pavan K.; Koh, Shan; Komatsubara, Kim; Chen, Joy; Horng, George; Bellovin, David I.; Wang, Craig S.; Felsher, Dean W.] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA; [Tran, Phuoc T.; Fan, Alice C.; Bendapudi, Pavan K.; Koh, Shan; Komatsubara, Kim; Chen, Joy; Horng, George; Bellovin, David I.; Wang, Craig S.; Felsher, Dean W.] Stanford Univ, Sch Med, Dept Pathol, Div Oncol, Stanford, CA USA; [Giuriato, Sylvie] INSERM U563, Ctr Physiopathol Toulouse Purpan, Toulouse, France; [Giuriato, Sylvie] Univ Paul Sabatier, Toulouse, France; [Whitsett, Jeffrey A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Pulmonary Biol, Cincinnati, OH USA	Stanford University; Stanford University; Stanford University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Tran, PT (corresponding author), Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA.	dfelsher@stanford.edu	Tran, Phuoc/W-2084-2019; Giuriato, Sylvie/A-9113-2010	Tran, Phuoc/0000-0002-0147-0376; Giuriato, Sylvie/0000-0003-3274-3397; Horng, George/0000-0003-0896-2557	RSNA [RR0601]; Henry S. Kaplan Research Fellow award [1046297-100-KAVWO]; Leukemia and Lymphoma Society Career Development Special Fellow in Clinical Research Award; Howard Hughes Medical Institute Medical Student Research Fellowship; NIH, NCI [R01-CA85610, R01-CA105102, 3R01CA089305-03S1, P50, 1P20 CA112973]; Burroughs Wellcome Fund; Damon Runyon Lilly Clinical Investigator Award; NATIONAL CANCER INSTITUTE [U56CA112973, R01CA105102, R01CA085610, R01CA089305] Funding Source: NIH RePORTER	RSNA; Henry S. Kaplan Research Fellow award; Leukemia and Lymphoma Society Career Development Special Fellow in Clinical Research Award; Howard Hughes Medical Institute Medical Student Research Fellowship(Howard Hughes Medical Institute); NIH, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Damon Runyon Lilly Clinical Investigator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by an RSNA Resident Research grant (RR0601) and the Henry S. Kaplan Research Fellow award (SUMC grant 1046297-100-KAVWO) (to P.T.T.); the Leukemia and Lymphoma Society Career Development Special Fellow in Clinical Research Award (to A.C.F.); the Howard Hughes Medical Institute Medical Student Research Fellowship (to P.K.B.); and National Cancer Institute (NCI) Grants R01-CA85610, R01-CA105102, 3R01CA089305-03S1; National Institutes of Health (NIH)_NCI In Vivo Cellular and Molecular Imaging Center Grant P50; NIH_NCI Grant 1P20 CA112973; the Leukemia and Lymphoma Society; the Burroughs Wellcome Fund; and the Damon Runyon Lilly Clinical Investigator Award (to D.W.F.). None of the above funding sources were involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; Arteaga CL, 2007, NAT MED, V13, P675, DOI 10.1038/nm0607-675; Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012; Bachireddy P, 2005, CLIN CANCER RES, V11, P4278, DOI 10.1158/1078-0432.CCR-05-0534; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Brose MS, 2002, CANCER RES, V62, P6997; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRITSCH TME, 1982, MOL CLONING COLD SPR; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Giuriato S, 2004, SEMIN CANCER BIOL, V14, P3, DOI 10.1016/j.semcancer.2003.11.002; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jang JW, 2006, MOL CELL BIOL; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee JW, 2006, CANCER LETT, V237, P89, DOI 10.1016/j.canlet.2005.05.026; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014; Marks JL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000426; Milton DT, 2006, J CLIN ONCOL, V24, P4940, DOI 10.1200/JCO.2006.06.4410; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Naoki K, 2002, CANCER RES, V62, P7001; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Sasaki H, 2006, INT J CANCER, V118, P180, DOI 10.1002/ijc.21301; Sasaki H, 2006, J SURG RES, V133, P203, DOI 10.1016/j.jss.2005.10.022; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wittig Ilka, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P449, DOI 10.2174/156800805774912999; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	67	61	62	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2125	10.1371/journal.pone.0002125	http://dx.doi.org/10.1371/journal.pone.0002125			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461184	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400046
J	Dahl, L; Richter, K; Hagglund, AC; Carlsson, L				Dahl, Lina; Richter, Karin; Haegglund, Anna-Carin; Carlsson, Leif			Lhx2 Expression Promotes Self-Renewal of a Distinct Multipotential Hematopoietic Progenitor Cell in Embryonic Stem Cell-Derived Embryoid Bodies	PLOS ONE			English	Article							LIM HOMEOBOX GENE; W-MUTANT MICE; C-KIT; YOLK-SAC; IN-VITRO; DEVELOPMENTAL REGULATORS; PRIMITIVE STREAK; COLONY FORMATION; PROTEIN RBTN2; ANEMIC MICE	The molecular mechanisms regulating the expansion of the hematopoietic system including hematopoietic stem cells (HSCs) in the fetal liver during embryonic development are largely unknown. The LIM-homeobox gene Lhx2 is a candidate regulator of fetal hematopoiesis since it is expressed in the fetal liver and Lhx2(-/-) mice die in utero due to severe anemia. Moreover, expression of Lhx2 in embryonic stem (ES) cell-derived embryoid bodies (EBs) can lead to the generation of HSC-like cell lines. To further define the role of this transcription factor in hematopoietic regulation, we generated ES cell lines that enabled tet-inducible expression of Lhx2. Using this approach we observed that Lhx2 expression synergises with specific signalling pathways, resulting in increased frequency of colony forming cells in developing EB cells. The increase in growth factor-responsive progenitor cells directly correlates to the efficiency in generating HSC-like cell lines, suggesting that Lhx2 expression induce self-renewal of a distinct multipotential hematopoietic progenitor cell in EBs. Signalling via the c-kit tyrosine kinase receptor and the gp130 signal transducer by IL-6 is necessary and sufficient for the Lhx2 induced self-renewal. While inducing self-renewal of multipotential progenitor cells, expression of Lhx2 inhibited proliferation of primitive erythroid precursor cells and interfered with early ES cell commitment, indicating striking lineage specificity of this effect.	[Dahl, Lina; Richter, Karin; Haegglund, Anna-Carin; Carlsson, Leif] Umea Univ, Umea Ctr Mol Med, Umea, Sweden	Umea University	Dahl, L (corresponding author), Umea Univ, Umea Ctr Mol Med, Umea, Sweden.	leif.carlsson@ucmm.umu.se			Swedish Cancer Society; Swedish Medical Research Council; Vasterbotten County; Swedish Foundation for Strategic Research; Tobias Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Vasterbotten County; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Tobias Foundation	This work was supported by the Swedish Cancer Society, in part by the Swedish Medical Research Council and a grant from the Vasterbotten County. KR was supported by the Swedish Foundation for Strategic Research. LC was supported by the Tobias Foundation.	Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Baba Y, 2006, J IMMUNOL, V177, P2294, DOI 10.4049/jimmunol.177.4.2294; BARKER JE, 1968, DEV BIOL, V18, P14, DOI 10.1016/0012-1606(68)90020-1; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; Carlsson L, 2003, METHOD ENZYMOL, V365, P202; Choi K, 1998, DEVELOPMENT, V125, P725; DOPINTO OP, 2001, EXP HEMATOL, V29, P1019; Ema H, 2000, BLOOD, V95, P2284, DOI 10.1182/blood.V95.7.2284.007k14_2284_2288; Fleischman RA, 1996, EXP HEMATOL, V24, P209; Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1991, EXP HEMATOL, V19, P374; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Helgason CD, 1996, BLOOD, V87, P2740, DOI 10.1182/blood.V87.7.2740.bloodjournal8772740; Hirota J, 2004, P NATL ACAD SCI USA, V101, P8751, DOI 10.1073/pnas.0400940101; Huber TL, 2004, NATURE, V432, P625, DOI 10.1038/nature03122; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Kolterud A, 2004, DEVELOPMENT, V131, P5319, DOI 10.1242/dev.01416; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Kyba M, 2003, P NATL ACAD SCI USA, V100, P11904, DOI 10.1073/pnas.1734140100; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Laker C, 1998, J VIROL, V72, P339, DOI 10.1128/JVI.72.1.339-348.1998; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; Miller CL, 1996, EXP HEMATOL, V24, P185; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; Palis J, 1999, DEVELOPMENT, V126, P5073; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Pilat S, 2005, P NATL ACAD SCI USA, V102, P12101, DOI 10.1073/pnas.0505624102; Pinto do O P, 1998, EMBO J, V17, P5744, DOI 10.1093/emboj/17.19.5744; Porter FD, 1997, DEVELOPMENT, V124, P2935; Rhee H, 2006, SCIENCE, V312, P1946, DOI 10.1126/science.1128004; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-75; Richter K, 2003, HAEMATOLOGICA, V88, P1336; Richter K., 2002, BLOOD, V99, P3939; Rodriguez-Esteban C, 1998, DEVELOPMENT, V125, P3925; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sabin FR, 1920, CONTRIB EMBRYOL, V9, P215; Samokhvalov IM, 2007, NATURE, V446, P1056, DOI 10.1038/nature05725; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Sui XW, 1999, BLOOD, V93, P2525, DOI 10.1182/blood.V93.8.2525.408k11_2525_2532; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; Sui XW, 1996, J EXP MED, V183, P837, DOI 10.1084/jem.183.3.837; Takizawa M, 2003, EXP HEMATOL, V31, P283, DOI 10.1016/S0301-472X(03)00025-0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Wandzioch E, 2004, P NATL ACAD SCI USA, V101, P16549, DOI 10.1073/pnas.0404678101; Wang Y, 2005, P NATL ACAD SCI USA, V102, P19081, DOI 10.1073/pnas.0506127102; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Willey S, 2006, BLOOD, V107, P3122, DOI 10.1182/blood-2005-10-4120; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zafonte BT, 2007, BLOOD, V109, P516, DOI 10.1182/blood-2006-02-004564	81	22	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2025	10.1371/journal.pone.0002025	http://dx.doi.org/10.1371/journal.pone.0002025			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431502	gold, Green Published, Green Submitted			2022-12-25	WOS:000261558700037
J	Kirschner, KM; Hagen, P; Hussels, CS; Ballmaier, M; Scholz, H; Dame, C				Kirschner, Karin M.; Hagen, Patricia; Hussels, Christiane S.; Ballmaier, Matthias; Scholz, Holger; Dame, Christof			The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells	FASEB JOURNAL			English	Article						erythropoiesis; colony-forming; unit-erythroid; gene expression; development; oncogene	GENE WT1; SUBNUCLEAR LOCALIZATION; FUNCTIONAL INTERACTION; REGULATED EXPRESSION; EPO RECEPTOR; HUMAN FETAL; GATA-1; DIFFERENTIATION; LIVER; DISRUPTION	The Wilms' tumor protein Wt1 is required for embryonic development and has been implicated in hematologic disorders. Since Wt1 deficiency may compromise the proliferation and differentiation of erythroid progenitor cells, we analyzed the possible role of the transcriptionally active Wt1 isoform, Wt1(- KTS), in regulating the expression of the erythropoietin receptor (EpoR). Wt1 and EpoR were coexpressed in CD117(+) hematopoietic progenitor cells and in several hematopoietic cell lines. CD117(+) cells of Wt1-deficient murine embryos (Wt1(-/-)) exhibited a significantly lower proliferation response to recombinant erythropoietin than CD117(+) cells of heterozygous (Wt1(+/-)) and wild-type littermates (Wt1(+/+)). EpoR expression was significantly diminished in hematopoietic progenitors ( CD117(+)) that lacked Wt1, and the erythroid colony-forming capacity was reduced by more than 50% in fetal liver cells of Wt1-deficient embryonic mice. Wt1(- KTS) significantly increased endogenous EpoR transcripts in transfected cells. The proximal EpoR promoter of human and mouse was stimulated more than 10-fold by Wt1(- KTS) in transiently cotransfeced K562 erythroleukemia cells. A responsible cis-element, which is highly conserved in the EpoR promoter of human and mouse, was identified by mutation analysis, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay. In conclusion, activation of the EpoR gene by Wt1 may represent an important mechanism in normal hematopoiesis.	[Hussels, Christiane S.; Dame, Christof] Charite, Dept Neonatol, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Kirschner, Karin M.; Hagen, Patricia; Scholz, Holger] Charite, Inst Vegetat Physiol, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Ballmaier, Matthias] Hannover Med Sch, Dept Pediat Hematol, D-30623 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Dame, C (corresponding author), Charite, Dept Neonatol, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany.	christof.dame@charite.de	Ballmaier, Matthias/J-4175-2014	Ballmaier, Matthias/0000-0002-1352-5995; Kirschner, Karin/0000-0003-0226-8636; Krause, Patricia/0000-0001-9063-0556				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Baird PN, 1997, EXP HEMATOL, V25, P312; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Brown WM, 2007, STEM CELLS, V25, P718, DOI 10.1634/stemcells.2006-0687; Chen D, 2001, EXP HEMATOL, V29, P971, DOI 10.1016/S0301-472X(01)00670-1; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Dame C, 1998, BLOOD, V92, P3218, DOI 10.1182/blood.V92.9.3218; Dame C, 2003, MIL DRUG TH, P35; Dame C, 2002, BRIT J HAEMATOL, V119, P510, DOI 10.1046/j.1365-2141.2002.03816.x; Dame C, 2006, BLOOD, V107, P4282, DOI 10.1182/blood-2005-07-2889; Dan YY, 2006, P NATL ACAD SCI USA, V103, P9912, DOI 10.1073/pnas.0603824103; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Fandrey J, 2006, CARDIOVASC RES, V72, P1, DOI 10.1016/j.cardiores.2006.07.024; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Hosen N, 2002, BRIT J HAEMATOL, V116, P409, DOI 10.1046/j.1365-2141.2002.03261.x; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; King-Underwood L, 2005, LEUKEMIA RES, V29, P803, DOI 10.1016/j.leukres.2004.11.020; Kirkeby A, 2007, J NEUROSCI METH, V164, P50, DOI 10.1016/j.jneumeth.2007.03.026; Komatsu N, 1997, BLOOD, V89, P1182, DOI 10.1182/blood.V89.4.1182; KOMATSU N, 1993, CANCER RES, V53, P1156; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; LEONARD M, 1993, BLOOD, V82, P1071; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; Maurer U, 1997, EXP HEMATOL, V25, P945; MIGLIACCIO AR, 1993, BLOOD, V82, P3760; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; Minguet S, 2003, J CLIN INVEST, V112, P1152, DOI 10.1172/JCI200317409; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; Svedberg H, 2001, LEUKEMIA, V15, P1914, DOI 10.1038/sj.leu.2402303; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	57	19	19	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2690	2701		10.1096/fj.07-097576	http://dx.doi.org/10.1096/fj.07-097576			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424770				2022-12-25	WOS:000258089300009
J	Chen, S; Gluhak-Heinrich, J; Martinez, M; Li, T; Wu, Y; Chuang, HH; Chen, L; Dong, J; Gay, I; MacDougall, M				Chen, Shuo; Gluhak-Heinrich, Jelica; Martinez, Marcos; Li, Tong; Wu, Yimin; Chuang, Hui-Hsiu; Chen, Lei; Dong, Juan; Gay, Isabel; MacDougall, Mary			Bone morphogenetic protein 2 mediates dentin sialophosphoprotein expression and odontoblast differentiation via NF-Y signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTOR; SIALOPROTEIN GENE; MATRIX PROTEIN-1; INVERTED-CCAAT; CDK2-DEPENDENT PHOSPHORYLATION; HISTONE ACETYLTRANSFERASES; B-SUBUNIT; CBF/NF-Y; BINDING	Dentin sialophosphoprotein (DSPP), an important odontoblast differentiation marker, is necessary for tooth development and mineralization. Bone morphogenetic protein 2 (BMP2) plays a vital role in odontoblast function via diverse signal transduction systems. We hypothesize that BMP2 regulates DSPP gene transcription and thus odontoblast differentiation. Here we report that expression of BMP2 and DSPP is detected during mouse odontogenesis by in situ hybridization assay, and BMP2 up-regulates DSPP mRNA and protein expression as well as DSPP-luciferase promoter activity in mouse preodontoblasts. By sequentially deleting fragments of the mouse DSPP promoter, we show that a BMP2-response element is located between nucleotides -97 and -72. By using antibody and oligonucleotide competition assays in electrophoretic mobility shift analysis and chromatin immunoprecipitation experiments, we show that the heterotrimeric transcription factor Y (NF-Y) complex physically interacts with the inverted CCAAT box within the BMP2-response element. BMP2 induces NF-Y accumulation into the nucleus increasing its recruitment to the mouse DSPP promoter in vivo. Furthermore, forced overexpression of NF-Y enhances promoter activity and increases endogenous DSPP protein levels. In contrast, mutations in the NF-Y binding motif reduce BMP2-induced DSPP transcription. Moreover, inhibiting BMP2 signaling by Noggin, a BMP2 antagonist, results in significant inhibition of DSPP gene expression in preodontoblasts. Taken together, these results indicate that BMP2 mediates DSPP gene expression and odontoblast differentiation via NF-Y signaling during tooth development.	[Dong, Juan; Gay, Isabel; MacDougall, Mary] Univ Alabama Birmingham, Dept Oral Maxillofacial Surg, Sch Dent, Birmingham, AL 35294 USA; [Chen, Shuo; Martinez, Marcos; Li, Tong] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat Dent, San Antonio, TX 78229 USA; [Gluhak-Heinrich, Jelica; Chuang, Hui-Hsiu] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA; [Wu, Yimin] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA; [Chen, Lei] Fujian Med Univ, Dept Orthodont, Fujian 350005, Peoples R China	University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Fujian Medical University	MacDougall, M (corresponding author), Univ Alabama Birmingham, Dept Oral Maxillofacial Surg, Sch Dent, 1919 7th Ave,S,SDB 702, Birmingham, AL 35294 USA.	MacDougall@uab.edu	MacDougall, Mary/ABG-8212-2021		NIDCR NIH HHS [P01 DE113221, R03 DE014484-01A2, R03 DE014484, DE01448401A2] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014484] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bhattacharya A, 2003, CANCER RES, V63, P8167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen S, 2005, J BIOL CHEM, V280, P29717, DOI 10.1074/jbc.M502929200; Chen S, 2004, J BIOL CHEM, V279, P42182, DOI 10.1074/jbc.M402476200; Chen S, 2004, J CELL BIOCHEM, V92, P332, DOI 10.1002/jcb.20051; Chen S, 2002, CONNECT TISSUE RES, V43, P338, DOI 10.1080/03008200290000691; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong J, 2005, AM J MED GENET A, V132A, P305, DOI 10.1002/ajmg.a.30460; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Frontini M, 2004, CELL CYCLE, V3, P217; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; He G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Iohara K, 2006, STEM CELLS, V24, P2493, DOI 10.1634/stemcells.2006-0161; Irace C, 2007, LIFE SCI, V80, P1282, DOI 10.1016/j.lfs.2006.12.008; Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200; Jadlowiec JA, 2006, J BIOL CHEM, V281, P5341, DOI 10.1074/jbc.M506158200; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; Kim RH, 1999, CANCER RES, V59, P565; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; LYONS KM, 1990, DEVELOPMENT, V109, P833; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1995, Connect Tissue Res, V33, P97, DOI 10.3109/03008209509016988; MAITY SN, 1990, TRENDS BIOCHEM SCI, V23, P174; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Miletich I, 2003, HUM MOL GENET, V12, pR69, DOI 10.1093/hmg/ddg085; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 2002, CONNECT TISSUE RES, V43, P331, DOI 10.1080/03008200290001041; Sambrok J.A. D.W.R., 2001, MOL CLONING LAB MANU, V3rd; Sjin RMTT, 2002, BLOOD, V100, P80; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Su M, 2006, J BIOL CHEM, V281, P9882, DOI 10.1074/jbc.M508364200; Su M, 2005, J BIOL CHEM, V280, P38365, DOI 10.1074/jbc.M501609200; Thesleff I, 2003, J CELL SCI, V116, P1647, DOI 10.1242/jcs.00410; Thomadakis G, 1999, EUR J ORAL SCI, V107, P368, DOI 10.1046/j.0909-8836.1999.eos107508.x; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Venezian R, 1998, J CELL PHYSIOL, V174, P331; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Xiao S, 2001, NAT GENET, V27, P345; Yamakoshi Y, 2005, J BIOL CHEM, V280, P17472, DOI 10.1074/jbc.M413220200; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441	76	86	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19359	19370		10.1074/jbc.M709492200	http://dx.doi.org/10.1074/jbc.M709492200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18424784	Green Published, hybrid			2022-12-25	WOS:000257387600022
J	Gomes, MPB; Millen, TA; Ferreira, PS; Silva, NLCE; Vieira, TCRG; Almeida, MS; Silva, JL; Cordeiro, Y				Gomes, Mariana P. B.; Millen, Thiago A.; Ferreira, Priscila S.; Cunha E Silva, Narcisa L.; Vieira, Tuane C. R. G.; Almeida, Marcius S.; Silva, Jerson L.; Cordeiro, Yraima			Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET CONVERSION; NUCLEIC-ACID; IN-VITRO; NUCLEOCAPSID PROTEIN; SCRAPIE; BINDING; PRP; APTAMERS; CONFORMATION; RESISTANT	Conversion of the cellular prion protein (PrPC) into its altered conformation, PrPSc, is believed to be the major cause of prion diseases. Although PrP is the only identified agent for these diseases, there is increasing evidence that other molecules can modulate the conversion. We have found that interaction of PrP with double-stranded DNA leads to a protein with higher beta-sheet content and characteristics similar to those of PrPSc. RNA molecules can also interact with PrP and potentially modulate PrPC to PrPSc conversion or even bind differentially to both PrP isoforms. Here, we investigated the interaction of recombinant murine PrP with synthetic RNA sequences and with total RNA extracted from cultured neuroblastoma cells (N2aRNA). We found that PrP interacts with N2aRNA with nanomolar affinity, aggregates upon this interaction, and forms species partially resistant to proteolysis. RNA does not bind to N-terminal deletion mutants of PrP, indicating that the N-terminal region is important for this process. Cell viability assays showed that only the N2aRNA extract induces PrP-RNA aggregates that can alter the homeostasis of cultured cells. Small RNAs bound to PrP give rise to nontoxic small oligomers. Nuclear magnetic resonance measurements of the PrP-RNA complex revealed structural changes in PrP, but most of its native fold is maintained. These results indicate that there is selectivity in the species generated by interaction with different molecules of RNA. The catalytic effect of RNA on the PrPC --> PrPSc conversion depends on the RNA sequence, and small RNA molecules may exert a protective effect.	[Gomes, Mariana P. B.; Millen, Thiago A.; Ferreira, Priscila S.; Vieira, Tuane C. R. G.; Almeida, Marcius S.; Silva, Jerson L.] Inst Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Jiri Jonas, Programa Biol Estrutural, BR-21491590 Rio De Janeiro, Brazil; [Cordeiro, Yraima] Univ Fed Rio de Janeiro, Fac Farm, BR-21491590 Rio De Janeiro, Brazil; [Cunha E Silva, Narcisa L.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21491590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Inst Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Jiri Jonas, Programa Biol Estrutural, BE S10, BR-21491590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br; yraima@pharma.ufrj.br	Silva, Jerson/J-8984-2014; SILVA, JERSON Lima/GRF-1442-2022; Vieira, Tuane CRG/F-4550-2014; Cordeiro, Yraima/J-7619-2012	Silva, Jerson/0000-0001-9523-9441; SILVA, JERSON Lima/0000-0001-9523-9441; Vieira, Tuane CRG/0000-0002-3574-5411; Cordeiro, Yraima/0000-0003-4278-212X; almeida, marcius/0000-0003-4921-8185				Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Caughey B, 2003, NATURE, V425, P673, DOI 10.1038/425673a; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cordeiro Y, 2005, BIOPHYS J, V89, P2667, DOI 10.1529/biophysj.105.067603; Cordeiro Y, 2005, PROTEIN PEPTIDE LETT, V12, P251, DOI 10.2174/0929866053587138; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Cordeiro Y, 2004, J BIOL CHEM, V279, P32354, DOI 10.1074/jbc.M404295200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Horonchik L, 2005, J BIOL CHEM, V280, P17062, DOI 10.1074/jbc.M500122200; Keller R. L. J., 2005, THESIS ETH ZURICH; King DJ, 2007, J MOL BIOL, V369, P1001, DOI 10.1016/j.jmb.2007.02.004; Kocisko DA, 2006, ANTIMICROB AGENTS CH, V50, P1034, DOI 10.1128/AAC.50.3.1034-1044.2006; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lim F, 2001, J BIOL CHEM, V276, P22507, DOI 10.1074/jbc.M102411200; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; Loske C, 1998, J NEURAL TRANSM, V105, P1005, DOI 10.1007/s007020050108; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Nandi PK, 2004, J MOL BIOL, V344, P827, DOI 10.1016/j.jmb.2004.09.080; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Novitskaya V, 2006, J BIOL CHEM, V281, P13828, DOI 10.1074/jbc.M511174200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200; Sekiya S, 2006, J BIOCHEM, V139, P383, DOI 10.1093/jb/mvj046; Silva JL, 2008, TRENDS BIOCHEM SCI, V33, P132, DOI 10.1016/j.tibs.2007.11.003; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; Takemura K, 2006, EXP BIOL MED, V231, P204; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Lima LMTR, 2006, BIOCHEMISTRY-US, V45, P9180, DOI 10.1021/bi060532d; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Windl O, 1999, J GEN VIROL, V80, P15, DOI 10.1099/0022-1317-80-1-15; Zou WQ, 2005, CELL, V121, P155, DOI 10.1016/j.cell.2005.04.002; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100	49	73	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19616	19625		10.1074/jbc.M802102200	http://dx.doi.org/10.1074/jbc.M802102200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18456654	Green Published, hybrid			2022-12-25	WOS:000257387600047
J	Kim, MH; Choi, BH; Jung, SR; Sernka, TJ; Kim, S; Kim, KT; Hille, B; Nguyen, TD; Koh, DS				Kim, Mean-Hwan; Choi, Bo-Hwa; Jung, Seung-Ryoung; Sernka, Thomas J.; Kim, Seunghwan; Kim, Kyong-Tai; Hille, Bertil; Nguyen, Toan D.; Koh, Duk-Su			Protease-activated receptor-2 increases exocytosis via multiple signal transduction pathways in pancreatic duct epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SECRETION; AMPEROMETRY; CA2+; MECHANISMS; PROTECTION	Protease-activated receptor-2 (PAR-2) is activated when trypsin cleaves its NH2 terminus to expose a tethered ligand. We previously demonstrated that PAR-2 activates ion channels in pancreatic duct epithelial cells (PDEC). Using real-time optical fluorescent probes, cyan fluorescence protein-Epac1-yellow fluorescence protein for cAMP, PHPLC-delta 1-enhanced green fluorescent protein for phosphatidylinositol 4,5-bisphosphate, and protein kinase C gamma (PKC gamma)-C1-yellow fluorescence protein for diacylglycerol, we now define the signaling pathways mediating PAR-2 effect in dog PDEC. Although PAR-2 activation does not stimulate acAMPincrease, it induces phospholipase C to hydrolyze phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol. Intracellular Ca2+ mobilization from inositol 1,4,5-trisphosphate- sensitive Ca2+ stores and a subsequent Ca2+ influx through store-operated Ca2+ channels cause a biphasic increase in intracellular Ca2+ concentration ([Ca2+](i)), measured with Indo-1 dye. Single-cell amperometry demonstrated that this increase in [Ca2+] i in turn causes a biphasic increase in exocytosis. A protein kinase assay revealed that trypsin also activates PKC isozymes to stimulate additional exocytosis. Paralleling the increased exocytosis, mucin secretion from PDEC was also induced by trypsin or the PAR-2 activating peptide. Consistent with the serosal localization of PAR-2, 1 mu M luminal trypsin did not induce exocytosis in polarized PDEC monolayers; on the other hand, 10 mu M trypsin at 37 degrees C damaged the epithelial barrier sufficiently so that it could reach and activate the serosal PAR-2 to stimulate exocytosis. Thus, in PDEC, PAR-2 activation increases [Ca2+](i) and activates PKC to stimulate exocytosis and mucin secretion. These functions may mediate the reported protective role of PAR-2 in different models of pancreatitis.	[Koh, Duk-Su] Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA; [Kim, Mean-Hwan; Jung, Seung-Ryoung; Kim, Seunghwan; Koh, Duk-Su] POSTECH, Dept Phys, Pohang 790784, South Korea; [Choi, Bo-Hwa; Kim, Kyong-Tai] POSTECH, Dept Life Sci, Pohang 790784, South Korea; [Sernka, Thomas J.; Nguyen, Toan D.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; [Nguyen, Toan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Koh, DS (corresponding author), Univ Washington, Sch Med, Dept Physiol & Biophys, Hlth Sci Bldg, Seattle, WA 98195 USA.	koh@u.washington.edu		KIM, KYONG-TAI/0000-0001-7292-2627; KIM, Seunghwan/0000-0002-0563-3902	NIDDK NIH HHS [DK55885] Funding Source: Medline; NIGMS NIH HHS [GM083913] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083913] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; Amadesi S, 2006, J PHYSIOL-LONDON, V575, P555, DOI 10.1113/jphysiol.2006.111534; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Gatti R, 2006, J APPL PHYSIOL, V101, P506, DOI 10.1152/japplphysiol.01558.2005; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Horowitz LF, 2005, J GEN PHYSIOL, V126, P243, DOI 10.1085/jgp.200509309; Jung SR, 2004, AM J PHYSIOL-CELL PH, V286, pC573, DOI 10.1152/ajpcell.00350.2003; Kawabata A, 2002, LIFE SCI, V71, P2435, DOI 10.1016/S0024-3205(02)02044-1; Kim KT, 2000, J NEUROSCI, V20, part. no.; Koh DS, 2000, J GEN PHYSIOL, V116, P507, DOI 10.1085/jgp.116.4.507; Koh DS, 1997, P NATL ACAD SCI USA, V94, P1506, DOI 10.1073/pnas.94.4.1506; Koh DS, 1999, J NEUROSCI METH, V88, P83, DOI 10.1016/S0165-0270(99)00020-5; Namkung W, 2004, GASTROENTEROLOGY, V126, P1844, DOI 10.1053/j.gastro.2004.03.019; Nguyen TD, 2004, GASTROENTEROLOGY, V126, pA763, DOI 10.1053/j.gastro.2004.04.026; Nguyen TD, 2001, AM J PHYSIOL-GASTR L, V280, pG795, DOI 10.1152/ajpgi.2001.280.5.G795; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG104, DOI 10.1152/ajpgi.1998.275.1.G104; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Oda D, 1996, AM J PATHOL, V148, P977; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Rychkov GY, 2005, CELL CALCIUM, V37, P183, DOI 10.1016/j.ceca.2004.09.001; Scott G, 2003, J INVEST DERMATOL, V121, P529, DOI 10.1046/j.1523-1747.2003.12427.x; Sharma A, 2005, AM J PHYSIOL-GASTR L, V288, pG388, DOI 10.1152/ajpgi.00341.2004; Singh VP, 2007, GUT, V56, P958, DOI 10.1136/gut.2006.094268; Vergnolle N, 2000, ALIMENT PHARM THER, V14, P257; VILLANGER O, 1995, GASTROENTEROLOGY, V108, P850, DOI 10.1016/0016-5085(95)90460-3	29	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18711	18720		10.1074/jbc.M801655200	http://dx.doi.org/10.1074/jbc.M801655200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18448425	Green Published, hybrid			2022-12-25	WOS:000257165600028
J	Narayanan, U; Nalavadi, V; Nakamoto, M; Thomas, G; Ceman, S; Bassell, GJ; Warren, ST				Narayanan, Usha; Nalavadi, Vijayalaxmi; Nakamoto, Mika; Thomas, George; Ceman, Stephanie; Bassell, Gary J.; Warren, Stephen T.			S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; MESSENGER-RNA TRANSLATION; RECEPTOR ACTIVATION; KINASE-ACTIVITY; MOUSE MODEL; LOCALIZATION; PATHWAY; MICE; IDENTIFICATION; INACTIVATION	Fragile X syndrome is a common form of cognitive deficit caused by the functional absence of fragile X mental retardation protein (FMRP), a dendritic RNA-binding protein that represses translation of specific messages. Although FMRP is phosphorylated in a group I metabotropic glutamate receptor (mGluR) activity-dependent manner following brief protein phosphatase 2A (PP2A)-mediated dephosphorylation, the kinase regulating FMRP function in neuronal protein synthesis is unclear. Here we identify ribosomal protein S6 kinase (S6K1) as a major FMRP kinase in the mouse hippocampus, finding that activity-dependent phosphorylation of FMRP by S6K1 requires signaling inputs from mammalian target of rapamycin (mTOR), ERK1/2, and PP2A. Further, the loss of hippocampal S6K1 and the subsequent absence of phospho-FMRP mimic FMRP loss in the increased expression of SAPAP3, a synapse-associated FMRP target mRNA. Together these data reveal a S6K1-PP2A signaling module regulating FMRP function and place FMRP phosphorylation in the mGluR-triggered signaling cascade required for protein-synthesis-dependent synaptic plasticity.	[Warren, Stephen T.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; [Nalavadi, Vijayalaxmi; Bassell, Gary J.] Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; [Warren, Stephen T.] Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; [Warren, Stephen T.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Thomas, George] Genome Res Inst, Cincinnati, OH 45215 USA; [Ceman, Stephanie] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	Emory University; Emory University; Emory University; Emory University; University of Illinois System; University of Illinois Urbana-Champaign	Warren, ST (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Ste 305E, Atlanta, GA 30322 USA.	swarren@genetics.emory.edu	Warren, Stephen T/A-2498-2012; Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD041591, R01HD020521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051127] Funding Source: NIH RePORTER; NICHD NIH HHS [HD41591, HD24064, HD020521] Funding Source: Medline; NINDS NIH HHS [NS051127] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antar LN, 2004, J NEUROSCI, V24, P2648, DOI 10.1523/JNEUROSCI.0099-04.2004; Antion MD, 2008, LEARN MEMORY, V15, P29, DOI 10.1101/lm.661908; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Ceman S, 2003, HUM MOL GENET, V12, P3295, DOI 10.1093/hmg/ddg350; Daw MI, 2002, NAT NEUROSCI, V5, P835, DOI 10.1038/nn903; Dell'Acqua ML, 2006, EUR J CELL BIOL, V85, P627, DOI 10.1016/j.ejcb.2006.01.010; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kimball SR, 2002, J NUTR, V132, P883; Kindler S, 2004, MOL BRAIN RES, V126, P14, DOI 10.1016/j.molbrainres.2004.03.014; Kosik KS, 2005, BBA-MOL BASIS DIS, V1739, P298, DOI 10.1016/j.bbadis.2004.10.011; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nakamoto M, 2007, P NATL ACAD SCI USA, V104, P15537, DOI 10.1073/pnas.0707484104; Namboodiripad AN, 1996, AM J PHYSIOL-CELL PH, V270, pC449, DOI 10.1152/ajpcell.1996.270.2.C449; Narayanan U, 2007, J NEUROSCI, V27, P14349, DOI 10.1523/JNEUROSCI.2969-07.2007; Nosyreva ED, 2006, J NEUROPHYSIOL, V95, P3291, DOI 10.1152/jn.01316.2005; NOVAKHOFER I, 1985, J BIOL CHEM, V260, P314; O'Donnell WT, 2002, ANNU REV NEUROSCI, V25, P315, DOI 10.1146/annurev.neuro.25.112701.142909; Page G, 2006, NEUROCHEM INT, V49, P413, DOI 10.1016/j.neuint.2006.01.020; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Phin S, 2003, BIOCHEM J, V373, P583, DOI 10.1042/BJ20021794; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Routtenberg A, 2005, TRENDS NEUROSCI, V28, P12, DOI 10.1016/j.tins.2004.11.006; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Siomi MC, 2002, MOL CELL BIOL, V22, P8438, DOI 10.1128/MCB.22.24.8438-8447.2002; Smith KE, 2006, J NEUROSCI, V26, P2391, DOI 10.1523/JNEUROSCI.3092-05.2006; Spencer CM, 2005, GENES BRAIN BEHAV, V4, P420, DOI 10.1111/j.1601-183X.2005.00123.x; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Welch JM, 2007, NATURE, V448, P894, DOI 10.1038/nature06104; Welch JM, 2004, J COMP NEUROL, V472, P24, DOI 10.1002/cne.20060; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93	46	170	172	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18478	18482		10.1074/jbc.C800055200	http://dx.doi.org/10.1074/jbc.C800055200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474609	Green Published, hybrid			2022-12-25	WOS:000257165600002
J	Reineke, LC; Komar, AA; Caprara, MG; Merrick, WC				Reineke, Lucas C.; Komar, Anton A.; Caprara, Mark G.; Merrick, William C.			A small stem loop element directs internal initiation of the URE2 internal ribosome entry site in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-INDEPENDENT TRANSLATION; MESSENGER-RNAS; SECONDARY STRUCTURE; GENE-EXPRESSION; YEAST-CELLS; IRES; LOCALIZATION; PREDICTION; PROMOTER; SEQUENCE	Internal initiation of translation is the process of beginning protein synthesis independent of the m(7)G cap structure at the 5'-end of an mRNA molecule. We have previously shown that the URE2 mRNA in the yeast Saccharomyces cerevisiae contains an internal ribosome entry site (IRES) whose activity is suppressed by eukaryotic initiation factor 2A (eIF2A; YGR054W). In this study, the minimal sequence required to efficiently direct internal initiation was determined using a system that abrogates cap-dependent scanning of the 40 S ribosomal subunit in both wild-type and eIF2A knock-out cells. Subsequently, secondary structural elements within the minimal sequence were determined by probing with RNases T1 and V1 and the small molecule diethylpyrocarbonate. It was found that the URE2 minimal IRES comprises a 104 nucleotide A-rich stem loop element encompassing the internal AUG codon. Interestingly, the internal AUG seems to be involved in base-pairing interactions that would theoretically hamper its ability to interact with incoming initiator tRNA molecules. Furthermore, none of the truncations used to identify the minimal IRES element were capable of abrogating the suppressive effect of eIF2A. Our data provide the first insight into the RNA structural requirements of the yeast translational machinery for cap-independent initiation of protein synthesis.	[Reineke, Lucas C.; Merrick, William C.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Caprara, Mark G.] Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; [Komar, Anton A.] Cleveland State Univ, Biol Geol & Environm Sci Dept, Cleveland, OH 44115 USA	Case Western Reserve University; Case Western Reserve University; University System of Ohio; Cleveland State University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wcm2@case.edu		Komar, Anton/0000-0003-4188-0633	NIGMS NIH HHS [GM-68079, GM-62853, T32 GM-08056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062853, R01GM068079, T32GM008056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; Chappell SA, 2004, P NATL ACAD SCI USA, V101, P9590, DOI 10.1073/pnas.0308759101; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Garlapati S, 2004, J BIOL CHEM, V279, P3389, DOI 10.1074/jbc.M307565200; Gilbert WV, 2007, SCIENCE, V317, P1224, DOI 10.1126/science.1144467; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hecht K, 2002, FEMS YEAST RES, V2, P215, DOI 10.1111/j.1567-1364.2002.tb00086.x; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Komar AA, 2003, EMBO J, V22, P1199, DOI 10.1093/emboj/cdg103; Komar AA, 2005, J BIOL CHEM, V280, P15601, DOI 10.1074/jbc.M413728200; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Raychaudhuri S, 2006, BIOCHEM BIOPH RES CO, V350, P788, DOI 10.1016/j.bbrc.2006.09.124; Rosenfeld AB, 2005, J VIROL, V79, P10126, DOI 10.1128/JVI.79.16.10126-10137.2005; Seino A, 2005, BBA-GENE STRUCT EXPR, V1681, P166, DOI 10.1016/j.bbaexp.2004.11.009; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; Thompson SR, 2001, P NATL ACAD SCI USA, V98, P12972, DOI 10.1073/pnas.241286698; Verge V, 2004, RNA, V10, P277, DOI 10.1261/rna.5910104; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Zhou W, 2001, P NATL ACAD SCI USA, V98, P1531, DOI 10.1073/pnas.98.4.1531; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	34	21	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19011	19025		10.1074/jbc.M803109200	http://dx.doi.org/10.1074/jbc.M803109200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18460470	hybrid, Green Published			2022-12-25	WOS:000257165600057
J	Pani, B; Ong, HL; Liu, XB; Rauser, K; Ambudkar, IS; Singh, BB				Pani, Biswaranjan; Ong, Hwei Ling; Liu, Xibao; Rauser, Kristina; Ambudkar, Indu S.; Singh, Brij B.			Lipid rafts determine clustering of STIM1 in endoplasmic reticulum-plasma membrane junctions and regulation of store-operated Ca2+ entry (SOCE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; TRPC CHANNELS; SIGNAL-TRANSDUCTION; CRAC CHANNELS; I-CRAC; CAVEOLAE; ACTIVATION; COMPLEX; INFLUX; ORAI1	Store depletion induces STIM1 to aggregate and relocate into clusters at ER-plasma membrane junctions where it functionally interacts with and activates plasma membrane channels that mediate store-operated Ca2+ entry (SOCE). Thus, the site of peripheral STIM1 clusters is critical for the regulation of SOCE. However, what determines the location of the STIM1 clusters in the ER-PM junctional regions, and whether these represent specific sites in the cell is not yet known. Here we report that clustering of STIM1 in the sub-plasma membrane region of the cell and activation of TRPC1-dependent SOCE are determined by lipid raft domains (LRD). We show that store depletion increased partitioning of TRPC1 and STIM1 into plasma membrane LRD. TRPC1 and STIM1 associated with each other within the LRD, and this association was dynamically regulated by the status of the ER Ca2+ store. Peripheral STIM1 clustering was independent of TRPC1. However, sequestration of membrane cholesterol attenuated thapsigargin-induced clustering of STIM1 as well as SOCE in HSG and HEK293 cells. Recruitment and association of STIM1 and TRPC1 in LRD was also decreased. Additionally STIM1(D76A), which is peripherally localized and constitutively activates SOCE in unstimulated cells, displayed a relatively higher partitioning into LRD and interaction with TRPC1, as compared with STIM1. Disruption of membrane rafts decreased peripheral STIM1(D76A) puncta, its association with TRPC1 and the constitutive SOCE. Together, these data demonstrate that intact LRD determine targeting of STIM1 clusters to ER-plasma membrane junctions following store depletion. This facilitates the functional interaction of STIM1 with TRPC1 and activation of SOCE.	[Ong, Hwei Ling; Liu, Xibao; Ambudkar, Indu S.] NIDCR, Secretory Physiol Sect, MPTB, NIH, Bethesda, MD 20892 USA; [Pani, Biswaranjan; Rauser, Kristina; Singh, Brij B.] Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Dakota Grand Forks	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, MPTB, NIH, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov; bsingh@medicine.nodak.edu	Pani, Biswaranjan/GLT-9217-2022	Singh, Brij/0000-0003-0535-5997; Ong, Hwei Ling/0000-0002-7551-6883	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017102, ZIADE000438] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [P20 RR017699-077011, 5P20RR017699, P20 RR017699] Funding Source: Medline; NIDCR NIH HHS [R01 DE017102-01A1, DE017102, R01 DE017102-02, R01 DE017102, R01 DE017102-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2007, CELL CALCIUM, V42, P213, DOI 10.1016/j.ceca.2007.01.013; Ambudkar IS, 2006, TRENDS PHARMACOL SCI, V27, P25, DOI 10.1016/j.tips.2005.11.008; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Hogan PG, 2007, TRENDS BIOCHEM SCI, V32, P235, DOI 10.1016/j.tibs.2007.03.009; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Li ZZ, 2007, J BIOL CHEM, V282, P29448, DOI 10.1074/jbc.M703573200; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Liu XB, 2007, P NATL ACAD SCI USA, V104, P17542, DOI 10.1073/pnas.0701254104; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ong HL, 2007, J BIOL CHEM, V282, P9105, DOI 10.1074/jbc.M608942200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney JW, 2007, CELL CALCIUM, V42, P103, DOI 10.1016/j.ceca.2007.01.011; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Varnai P, 2007, J BIOL CHEM, V282, P29678, DOI 10.1074/jbc.M704339200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Worley PF, 2007, CELL CALCIUM, V42, P205, DOI 10.1016/j.ceca.2007.03.004; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yuan JP, 2007, NAT CELL BIOL, V9, P636, DOI 10.1038/ncb1590; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	35	149	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17333	17340		10.1074/jbc.M800107200	http://dx.doi.org/10.1074/jbc.M800107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430726	Green Published, hybrid			2022-12-25	WOS:000256720600042
J	Scorah, J; Dong, MQ; Yates, JR; Scott, M; Gillespie, D; McGowan, CH				Scorah, Jennifer; Dong, Meng-Qiu; Yates, John R., III; Scott, Mary; Gillespie, David; McGowan, Clare H.			A conserved proliferating cell nuclear antigen-interacting protein sequence in Chk1 is required for checkpoint function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION CHECKPOINT; S-PHASE CHECKPOINT; XENOPUS EGG EXTRACTS; C-TERMINAL REGION; DAMAGE CHECKPOINT; CHROMATIN ASSOCIATION; CRYSTAL-STRUCTURE; FORK PROGRESSION; HUMAN CLASPIN; KINASE CHK1	Human checkpoint kinase 1 (Chk1) is an essential kinase required for cell cycle checkpoints and for coordination of DNA synthesis. To gain insight into the mechanisms by which Chk1 carries out these functions, we used mass spectrometry to identify previously uncharacterized interacting partners of Chk1. We describe a novel interaction between Chk1 and proliferating cell nuclear antigen (PCNA), an essential component of the replication machinery. Binding between Chk1 and PCNA was reduced in the presence of hydroxyurea, suggesting that the interaction is regulated by replication stress. A highly conserved PCNA-interacting protein (PIP) box motif was identified in Chk1. The intact PIP box is required for efficient DNA damage-induced phosphorylation and release of activated Chk1 from chromatin. We find that the PIP box of Chk1 is crucial for Chk1-mediated S-M and G(2)-M checkpoint responses. In addition, we show that mutations in the PIP box of Chk1 lead to decreased rates of replication fork progression and increased aberrant replication. These findings suggest an additional mechanism by which essential components of the DNA replication machinery interact with the replication checkpoint apparatus.	[Scorah, Jennifer; McGowan, Clare H.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Dong, Meng-Qiu; Yates, John R., III; McGowan, Clare H.] Scripps Res Inst, Dept Cellular Biol, La Jolla, CA 92037 USA; [Scott, Mary; Gillespie, David] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Scripps Research Institute; Scripps Research Institute; Beatson Institute	McGowan, CH (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chmcg@scripps.edu		Gillespie, David/0000-0002-6338-0544; Scott, Mary/0000-0002-7177-6960	Cancer Research UK Funding Source: Medline; NCI NIH HHS [CA077254] Funding Source: Medline; NCRR NIH HHS [P41 RR011823] Funding Source: Medline; NIDDK NIH HHS [R01 DK074798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077254] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074798] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Brondello JM, 2007, BIOCHEM BIOPH RES CO, V354, P1028, DOI 10.1016/j.bbrc.2007.01.091; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen ZH, 2003, MOL CANCER THER, V2, P543; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Conti C, 2007, CELL CYCLE, V6, P2760, DOI 10.4161/cc.6.22.4932; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; DePamphilis ML, 2006, CURR OPIN CELL BIOL, V18, P231, DOI 10.1016/j.ceb.2006.04.001; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Errico A, 2007, P NATL ACAD SCI USA, V104, P14929, DOI 10.1073/pnas.0706347104; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gotter AL, 2007, J MOL BIOL, V366, P36, DOI 10.1016/j.jmb.2006.10.097; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Liu QH, 2000, GENE DEV, V14, P1448; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Loffler H, 2007, CELL CYCLE, V6, P2541; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Maya-Mendoza A, 2007, EMBO J, V26, P2719, DOI 10.1038/sj.emboj.7601714; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Ng CP, 2004, J BIOL CHEM, V279, P8808, DOI 10.1074/jbc.M312215200; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sorensen CS, 2004, CELL CYCLE, V3, P941; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Takai H, 2000, GENE DEV, V14, P1439; Unsal-Kacmaz K, 2007, MOL CELL BIOL, V27, P3131, DOI 10.1128/MCB.02190-06; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang SX, 2000, FEBS LETT, V487, P277, DOI 10.1016/S0014-5793(00)02370-X; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	70	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17250	17259		10.1074/jbc.M800369200	http://dx.doi.org/10.1074/jbc.M800369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18448427	Green Published, hybrid			2022-12-25	WOS:000256720600034
J	Thornton, C; Sardini, A; Carling, D				Thornton, Claire; Sardini, Alessandro; Carling, David			Muscarinic receptor activation of AMP-activated protein kinase inhibits orexigenic neuropeptide mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; FOOD-INTAKE; METABOLIC SENSOR; UPSTREAM KINASE; IN-VITRO; BETA; SH-SY5Y; CASCADE; BRAIN; IDENTIFICATION	AMP-activated protein kinase (AMPK) plays a crucial role in both cellular and whole body energy homeostasis. Here we demonstrate that the muscarinic receptor agonist carbachol activates AMPK alpha 1-containing complexes in the human SH-SY5Y cell line via a mechanism specific for the AMPK upstream kinase, Ca2+/calmodulin-dependent protein kinase kinase beta. Activation of AMPK inhibits mRNA expression of the orexigenic neuropeptides Agouti-related peptide and melanin-concentrating hormone but surprisingly has no effect on neuropeptide Y mRNA, a neuropeptide previously shown to be regulated by AMPK. Rather than restoring mRNA levels to baseline, pharmacological inhibition of Ca2+/calmodulin-dependent protein kinase kinase beta or AMPK greatly increases Agouti-related peptide and melanin-concentrating hormone mRNA expression. These data support a hypothesis that modulating basal AMPK activity in the hypothalamus is essential for maintaining tight regulation of pathways contributing to food intake.	[Thornton, Claire; Sardini, Alessandro; Carling, David] Ctr Clin Sci, MRC, Cellular Stress Grp, London W12 0NN, England		Thornton, C (corresponding author), Ctr Clin Sci, MRC, Cellular Stress Grp, Du Cane Rd, London W12 0NN, England.	claire.thornton@imperial.ac.uk	Thornton, Claire/AAF-7481-2019; Carling, David/F-1943-2014	Thornton, Claire/0000-0001-7676-3272; Carling, David/0000-0002-2316-1830	Medical Research Council [MC_U120027537] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; GOULD J, 1992, NEUROSCI LETT, V145, P201, DOI 10.1016/0304-3940(92)90022-Y; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Hardie DG, 2007, NEURON, V53, P159, DOI 10.1016/j.neuron.2007.01.004; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim MS, 2005, J MOL MED, V83, P514, DOI 10.1007/s00109-005-0659-z; King TD, 2006, BIOCHEM PHARMACOL, V71, P1637, DOI 10.1016/j.bcp.2006.03.005; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; Lee K, 2005, ENDOCRINOLOGY, V146, P3, DOI 10.1210/en.2004-0968; Magni P, 1998, BRAIN RES, V798, P75, DOI 10.1016/S0006-8993(98)00471-5; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Mookherjee P, 2007, J CELL BIOCHEM, V102, P196, DOI 10.1002/jcb.21287; MOUNT PF, 2008, ATHEROSCLER IN PRESS; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Plaschke K, 1999, BRAIN RES, V830, P320, DOI 10.1016/S0006-8993(99)01427-4; Ramamurthy S, 2006, J PHYSIOL-LONDON, V574, P85, DOI 10.1113/jphysiol.2006.110122; Rowan A, 2000, J PATHOL, V192, P203; Sanders MJ, 2007, J BIOL CHEM, V282, P32539, DOI 10.1074/jbc.M706543200; Schneider A, 2004, J NEUROCHEM, V88, P1114, DOI 10.1046/j.1471-4159.2003.02228.x; Soltoff SP, 2004, J BIOL CHEM, V279, P10910, DOI 10.1074/jbc.M305396200; Stahmann N, 2006, MOL CELL BIOL, V26, P5933, DOI 10.1128/MCB.00383-06; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Turner N, 2008, DIABETES, V57, P1414, DOI 10.2337/db07-1552; Wahl M, 2004, AM J PHYSIOL-CELL PH, V287, pC1697, DOI 10.1152/ajpcell.00214.2004; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wynne K, 2005, J ENDOCRINOL, V184, P291, DOI 10.1677/joe.1.05866; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Yamada M, 2001, NATURE, V410, P207, DOI 10.1038/35065604	46	28	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17116	17122		10.1074/jbc.M708987200	http://dx.doi.org/10.1074/jbc.M708987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18436530	hybrid			2022-12-25	WOS:000256720600019
J	Gale, AJ; Cramer, TJ; Rozenshteyn, D; Cruz, JR				Gale, Andrew J.; Cramer, Thomas J.; Rozenshteyn, Diana; Cruz, Jason R.			Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; COAGULATION FACTOR-V; FACTOR VA(R506Q); A1 SUBUNIT; FACTOR XA; RESISTANCE; THROMBIN; MUTATION	Factor VIIIa is inactivated by a combination of two mechanisms. Activation of factor VIII by thrombin results in a heterotrimeric factor VIIIa that spontaneously inactivates due to dissociation of the A2 subunit. Additionally, factor VIIIa is cleaved by the anticoagulant serine protease, activated protein C, at two cleavage sites, Arg(336) in the A1 subunit and Arg(562) in the A2 subunit. We previously characterized an engineered variant of factor VIII which contains a disulfide bond between the A2 and the A3 subunits that prevents the spontaneous dissociation of the A2 subunit following thrombin activation. Thus, in the absence of activated protein C, this variant has stable activity following activation by thrombin. To isolate the effects of the individual activated protein C cleavage sites on factor VIIIa, we engineered mutations of the activated protein C cleavage sites into the disulfide bond-cross-linked factor VIII variant. Arg(336) cleavage is 6-fold faster than Arg(562) cleavage, and the Arg(336) cleavage does not fully inactivate factor VIIIa when A2 subunit dissociation is blocked. Protein S enhances both cleavage rates but enhances Arg(562) cleavage more than Arg(336) cleavage. Factor V also enhances both cleavage rates when protein S is present. Factor V enhances Arg(562) cleavage more than Arg(336) cleavage as well. As a result, in the presence of both activated protein C cofactors, Arg(336) cleavage is only twice as fast as Arg(562) cleavage. Therefore, both cleavages contribute significantly to factor VIIIa inactivation.	[Gale, Andrew J.; Cramer, Thomas J.; Rozenshteyn, Diana; Cruz, Jason R.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Gale, AJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 286,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	agale@scripps.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082588] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL82588] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, THROMB HAEMOSTASIS, V79, P557; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P8957; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gale AJ, 2006, J THROMB HAEMOST, V4, P1315, DOI 10.1111/j.1538-7836.2006.01951.x; Gale AJ, 2000, BLOOD, V96, P585; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Gale AJ, 2003, J THROMB HAEMOST, V1, P1966, DOI 10.1046/j.1538-7836.2003.00348.x; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; KANE WH, 1988, BLOOD, V71, P539; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; O'Brien LM, 2000, BLOOD, V95, P1714, DOI 10.1182/blood.V95.5.1714.005k40_1714_1720; OBRIEN DP, 1990, BLOOD, V75, P1664; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SHEN L, 1994, J BIOL CHEM, V269, P18735; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Varfaj F, 2006, BIOCHEM J, V396, P355, DOI 10.1042/BJ20060117; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521	33	34	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16355	16362		10.1074/jbc.M708985200	http://dx.doi.org/10.1074/jbc.M708985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424440	Green Published, hybrid			2022-12-25	WOS:000256497100011
J	Joo, JH; Jetten, AM				Joo, Joung Hyuck; Jetten, Anton M.			NF-kappa Beta-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser(276)) phosphorylation via the MEK-MSK1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ISOPRENOIDS PERILLYL ALCOHOL; B P65 SUBUNIT; INDUCED APOPTOSIS; SACCHAROMYCES-CEREVISIAE; ADENOCARCINOMA CELLS; NSC 641066; ER STRESS; CANCER	In this study, we demonstrate that treatment of human lung adenocarcinoma H460 cells with farnesol induces the expression of a number of immune response and inflammatory genes, including IL-6, CXCL3, IL-1 alpha, and COX-2. This response was dependent on the activation of the NF-kappa B signaling pathway. Farnesol treatment reduces the level of I kappa B alpha and induces translocation of p65/RelA to the nucleus, its phosphorylation at Ser(276), and transactivation of NF-kappa B-dependent transcription. Moreover, overexpression of I kappa B alpha or treatment with the NF-kappa B inhibitor caffeic acid phenethyl ester greatly diminishes the induction of inflammatory gene expression by farnesol. We provide evidence indicating that the farnesol-induced phosphorylation of p65/RelA at Ser(276) is important for optimal transcriptional activity of NF-kappa B. The MEK1/2 inhibitor U0126 and knockdown of MEK1/2 expression with small interfering RNAs effectively blocked the phosphorylation of p65/RelA(Ser(276)) but not that of Ser(536), suggesting that this phosphorylation is dependent on the activation of the MEK1/2-ERK1/2 pathway. We further show that inhibition of MSK1, a kinase acting downstream of MEK1/2-ERK1/2, by H89 or knockdown of MSK1 expression also inhibited phosphorylation of p65/RelA(Ser(276)), suggesting that this phosphorylation is dependent on MSK1. Knockdown of MEK1/2 or MSK1 expression inhibits farnesol-induced expression of CXCL3, IL-1 alpha, and COX-2 mRNA. Our results indicate that the induction of inflammatory genes by farnesol is mediated by the activation of the NF-kappa B pathway and involves MEK1/2-ERK1/2-MSK1-dependent phosphorylation of p65/RelA(Ser(276)). The activation of the NF-kappa B pathway by farnesol might be part of a prosurvival response during farnesol-induced ER stress.	[Joo, Joung Hyuck; Jetten, Anton M.] NIEHS, Cell Biol Sect, LRB, Div Intramural Res,Natl Inst Hlth, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, LRB, Div Intramural Res,Natl Inst Hlth, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	jetten@niehs.nih.gov	Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101586, Z01ES101586] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; Alique M, 2006, BRIT J PHARMACOL, V149, P215, DOI 10.1038/sj.bjp.0706842; Arai K, 2004, J NEUROCHEM, V89, P232, DOI 10.1111/j.1471-4159.2004.02317.x; Azzoli CG, 2003, CANCER CHEMOTH PHARM, V51, P493, DOI 10.1007/s00280-003-0599-7; Bailey HH, 2008, CANCER CHEMOTH PHARM, V62, P149, DOI 10.1007/s00280-007-0585-6; Bifulco M, 2005, LIFE SCI, V77, P1740, DOI 10.1016/j.lfs.2005.05.017; Burke YD, 2002, ANTICANCER RES, V22, P3127; Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745-997-0019-y; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen YJ, 2005, MOL CANCER RES, V3, P669, DOI 10.1158/1541-7786.MCR-05-0181; Crowell PL, 1999, J NUTR, V129, p775S, DOI 10.1093/jn/129.3.775S; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Fairn GD, 2007, J BIOL CHEM, V282, P4868, DOI 10.1074/jbc.M610575200; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Gambichler T, 2006, ARCH DERMATOL RES, V298, P139, DOI 10.1007/s00403-006-0673-1; Gibbs BS, 1999, J MED CHEM, V42, P3800, DOI 10.1021/jm9902786; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hanley K, 2000, J BIOL CHEM, V275, P11484, DOI 10.1074/jbc.275.15.11484; He L, 1997, J NUTR, V127, P668, DOI 10.1093/jn/127.5.668; Huang SJ, 2006, J REPROD IMMUNOL, V72, P60, DOI 10.1016/j.jri.2006.03.002; Hudes GR, 2000, CLIN CANCER RES, V6, P3071; Joo JH, 2007, CANCER RES, V67, P7929, DOI 10.1158/0008-5472.CAN-07-0931; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kim YM, 2007, CELL SIGNAL, V19, P538, DOI 10.1016/j.cellsig.2006.08.003; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Miquel K, 1996, BIOCHEM BIOPH RES CO, V225, P869, DOI 10.1006/bbrc.1996.1265; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u; Ong TP, 2006, CARCINOGENESIS, V27, P1194, DOI 10.1093/carcin/bgi291; Rao CV, 2002, CANCER DETECT PREV, V26, P419, DOI 10.1016/S0361-090X(02)00119-8; Rioja A, 2000, FEBS LETT, V467, P291, DOI 10.1016/S0014-5793(00)01168-6; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Taylor MM, 2005, FEBS J, V272, P5056, DOI 10.1111/j.1742-4658.2005.04914.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wiseman DA, 2007, J PHARMACOL EXP THER, V320, P1163, DOI 10.1124/jpet.106.111666; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Zhuang SG, 2007, AM J PHYSIOL-RENAL, V292, pF440, DOI 10.1152/ajprenal.00170.2006; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	50	54	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16391	16399		10.1074/jbc.M800945200	http://dx.doi.org/10.1074/jbc.M800945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18424438	Green Published, hybrid			2022-12-25	WOS:000256497100015
J	Young, RM; Wang, SJ; Gordan, JD; Ji, XJ; Liebhaber, SA; Simon, MC				Young, Regina M.; Wang, Shang-Jui; Gordan, John D.; Ji, Xinjun; Liebhaber, Stephen A.; Simon, M. Celeste			Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PREINITIATION COMPLEX; IRES ACTIVITY; HIF-ALPHA; GROWTH; HIF-1-ALPHA; INITIATION; STRESS; PHOSPHORYLATION; TRANSCRIPTION	Although it is advantageous for hypoxic cells to inhibit protein synthesis and conserve energy, it is also important to translate mRNAs critical for adaptive responses to hypoxic stress. Because internal ribosome entry sites (IRES) have been postulated to mediate this preferential synthesis, we analyzed the 5'-untranslated regions from a panel of stress-regulated mRNAs for m(7) GTP cap-independent translation and identified putative IRES elements in encephalomyocarditis virus, vascular endothelial growth factor, hypoxia-inducible factors (HIFs) 1 alpha and 2 alpha, glucose transporter- like protein 1, p57(Kip2), La, BiP, and triose phosphate isomerase transcripts. However, when capped and polyadenylated dicistronic RNAs were synthesized in vitro and transfected into cells, cellular IRES-mediated translation accounted for less than 1% that of the level of cap-dependent translation. Moreover, hypoxic stress failed to activate cap-independent synthesis, indicating that it is unlikely that this is the primary mechanism for the maintenance of the translation of these mRNAs under low O-2. Furthermore, although HIF-1 alpha is frequently cited as an example of an mRNA that is preferentially translated, we demonstrate that under different levels and durations of hypoxic stress, changes in newly synthesized HIF-1 alpha and beta-actin protein levels mirror alterations in corresponding mRNA abundance. In addition, our data suggest that cyclin-dependent kinase inhibitor p57(Kip2) and vascular endothelial growth factor mRNAs are selectively translated by an IRES-independent mechanism under hypoxic stress.	[Young, Regina M.; Wang, Shang-Jui; Gordan, John D.; Simon, M. Celeste] Abramson Family Canc Res Inst, Dept Genet, Philadelphia, PA 19104 USA; [Young, Regina M.; Wang, Shang-Jui; Gordan, John D.; Simon, M. Celeste] Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA; [Ji, Xinjun; Liebhaber, Stephen A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Simon, M. Celeste] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), 421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [P01CA104838, P01CA072765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL065449, P60HL038632] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P01 CA104838, CA1048387-03S1, P01 CA072765] Funding Source: Medline; NHLBI NIH HHS [R37 HL065449, R37 HL65449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Bornes S, 2004, J BIOL CHEM, V279, P18717, DOI 10.1074/jbc.M308410200; Bornes S, 2007, CIRC RES, V100, P305, DOI 10.1161/01.RES.0000258873.08041.c9; Carter MS, 2000, J BIOL CHEM, V275, P28301; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Denko N, 2003, J BIOL CHEM, V278, P5744, DOI 10.1074/jbc.M212534200; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197; Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com; Ji XJ, 2003, MOL CELL BIOL, V23, P899, DOI 10.1128/MCB.23.3.899-907.2003; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaufman Bennett, 2004, Cancer Res, V64, P3350, DOI 10.1158/0008-5472.CAN-03-2611; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Koritzinsky M, 2007, RADIOTHER ONCOL, V83, P353, DOI 10.1016/j.radonc.2007.04.031; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mokrejs M, 2006, NUCLEIC ACIDS RES, V34, pD125, DOI 10.1093/nar/gkj081; Park EH, 2005, J BIOL CHEM, V280, P20945, DOI 10.1074/jbc.M412744200; PETTERSEN EO, 1986, CANCER RES, V46, P4346; Schepens B, 2005, NUCLEIC ACIDS RES, V33, P6884, DOI 10.1093/nar/gki1000; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Thomas JD, 2007, RNA, V13, P1116, DOI 10.1261/rna.534807; van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972; WALDEN WE, 1981, J BIOL CHEM, V256, P1739; Wouters BG, 2004, DRUG RESIST UPDATE, V7, P25, DOI 10.1016/j.drup.2003.12.004; Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	51	96	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16309	16319		10.1074/jbc.M710079200	http://dx.doi.org/10.1074/jbc.M710079200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18430730	Green Published, hybrid			2022-12-25	WOS:000256497100007
J	Brodersen, J; Nilsson, PA; Ammitzboll, J; Hansson, LA; Skov, C; Bronmark, C				Brodersen, Jakob; Nilsson, P. Anders; Ammitzboll, Jeppe; Hansson, Lars-Anders; Skov, Christian; Bronmark, Christer			Optimal Swimming Speed in Head Currents and Effects on Distance Movement of Winter-Migrating Fish	PLOS ONE			English	Article							TIDAL-STREAM TRANSPORT; PLEURONECTES-PLATESSA L; GAIT TRANSITION; PREDATION RISK; ENERGETICS; BIRDS; CONSEQUENCES; METABOLISM; BEHAVIOR; REFUGES	Migration is a commonly described phenomenon in nature that is often caused by spatial and temporal differences in habitat quality. However, as migration requires energy, the timing of migration may depend not only on differences in habitat quality, but also on temporal variation in migration costs. Such variation can, for instance, arise from changes in wind or current velocity for migrating birds and fish, respectively. Whereas behavioural responses of birds to such changing environmental conditions have been relatively well described, this is not the case for fish, although fish migrations are both ecologically and economically important. We here use passive and active telemetry to study how winter migrating roach regulate swimming speed and distance travelled per day in response to variations in head current velocity. Furthermore, we provide theoretical predictions on optimal swimming speeds in head currents and relate these to our empirical results. We show that fish migrate farther on days with low current velocity, but travel at a greater ground speed on days with high current velocity. The latter result agrees with our predictions on optimal swimming speed in head currents, but disagrees with previously reported predictions suggesting that fish ground speed should not change with head current velocity. We suggest that this difference is due to different assumptions on fish swimming energetics. We conclude that fish are able to adjust both swimming speed and timing of swimming activity during migration to changes in head current velocity in order to minimize energy use.	[Brodersen, Jakob; Nilsson, P. Anders; Ammitzboll, Jeppe; Hansson, Lars-Anders; Bronmark, Christer] Lund Univ, Dept Ecol Limnol, Lund, Sweden; [Skov, Christian] Natl Inst Aquat Resources, DTU Aqua, Silkeborg, Denmark	Lund University; Technical University of Denmark	Brodersen, J (corresponding author), Lund Univ, Dept Ecol Limnol, Lund, Sweden.	jakob.brodersen@limnol.lu.se	Hansson, Lars-Anders/HCI-2735-2022; Nilsson, Anders/H-6836-2014; Skov, Christian/X-6511-2019	Nilsson, Anders/0000-0002-3541-9835; Skov, Christian/0000-0002-8547-6520; Hansson, Lars-Anders/0000-0002-3035-1317	Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)	Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)(Swedish Research Council Formas)	The study was supported by the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alerstam T., 1990, P331; Alerstam T, 1999, ARCTIC, V52, P346; BERNATCHEZ L, 1987, CAN J FISH AQUAT SCI, V44, P399, DOI 10.1139/f87-049; Borcherding J, 2002, J FISH BIOL, V61, P1154, DOI 10.1006/jfbi.2002.2129; BRODERSEN J, 2008, ECOLOGY IN PRESS; BRONMARK C, 2008, PLOS ONE IN PRESS; Castro-Santos T, 2006, T AM FISH SOC, V135, P1230, DOI 10.1577/T05-262.1; Clough S, 1998, J FISH BIOL, V53, P1060, DOI 10.1111/j.1095-8649.1998.tb00463.x; Copp GH, 1997, REGUL RIVER, V13, P303, DOI 10.1002/(SICI)1099-1646(199705)13:3<303::AID-RRR458>3.0.CO;2-E; Dingle H, 2007, BIOSCIENCE, V57, P113, DOI 10.1641/B570206; Forward RB, 2001, OCEANOGR MAR BIOL, V39, P305; Hansson LA, 1996, P ROY SOC B-BIOL SCI, V263, P1241, DOI 10.1098/rspb.1996.0182; Hansson LA, 2007, LIMNOL OCEANOGR, V52, P696, DOI 10.4319/lo.2007.52.2.0696; HEDENSTROM A, 1995, PHILOS T ROY SOC B, V348, P471, DOI 10.1098/rstb.1995.0082; Hedenstrom A, 2002, BEHAV ECOL SOCIOBIOL, V52, P308, DOI 10.1007/s00265-002-0504-0; Hedenstrom A, 1996, BEHAV ECOL, V7, P121, DOI 10.1093/beheco/7.2.121; Hinch Scott G., 2006, Fish Physiology, V24, P239; Hinch SG, 2000, CAN J FISH AQUAT SCI, V57, P2470, DOI 10.1139/cjfas-57-12-2470; Holker F, 2003, J FISH BIOL, V62, P565, DOI 10.1046/j.1095-8649.2003.00048.x; Jepsen N, 2002, HYDROBIOLOGIA, V483, P239, DOI 10.1023/A:1021356302311; Jepsen N, 2002, HYDROBIOLOGIA, V483, P167, DOI 10.1023/A:1021379528719; JONES FRH, 1979, J CONSEIL, V38, P331; JONSSON B, 1993, REV FISH BIOL FISHER, V3, P348, DOI 10.1007/BF00043384; Korsmeyer KE, 2002, J EXP BIOL, V205, P1253; Liechti F, 2006, J ORNITHOL, V147, P202, DOI 10.1007/s10336-006-0061-9; McNamara JM, 1998, J AVIAN BIOL, V29, P416, DOI 10.2307/3677160; METCALFE JD, 1990, J MAR BIOL ASSOC UK, V70, P149, DOI 10.1017/S0025315400034275; Ohlberger J, 2006, J COMP PHYSIOL B, V176, P17, DOI 10.1007/s00360-005-0024-0; Ohlberger J, 2005, J EXP ZOOL PART A, V303A, P657, DOI 10.1002/jez.a.181; Peake SJ, 2004, J EXP BIOL, V207, P1563, DOI 10.1242/jeb.00927; Pettersson LB, 2000, P ROY SOC B-BIOL SCI, V267, P759, DOI 10.1098/rspb.2000.1068; Salinger DH, 2006, T AM FISH SOC, V135, P188, DOI 10.1577/T04-181.1; Skov C, 2005, J FISH BIOL, V67, P1195, DOI 10.1111/j.1095-8649.2005.00814.x; SKOV C, 2008, ECOL FRESHW IN PRESS; TRUMP CL, 1980, CAN J FISH AQUAT SCI, V37, P1086, DOI 10.1139/f80-141; Videler JJ, 1993, FISH SWIMMING, P1, DOI [10.1007/978-94-011-1580-3, DOI 10.1007/978-94-011-1580-3]; WALKER MG, 1978, J CONSEIL, V38, P58; Wardle CS, 1996, J FISH BIOL, V49, P854, DOI 10.1111/j.1095-8649.1996.tb00084.x; Weber TP, 2000, J THEOR BIOL, V205, P95, DOI 10.1006/jtbi.2000.2047; WEIHS D, 1978, J CONSEIL, V38, P92; WERNER EE, 1988, ECOLOGY, V69, P1352, DOI 10.2307/1941633; WERNER EE, 1983, ECOLOGY, V64, P1540, DOI 10.2307/1937508	42	20	20	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2156	10.1371/journal.pone.0002156	http://dx.doi.org/10.1371/journal.pone.0002156			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478053	Green Published, Green Submitted, gold			2022-12-25	WOS:000262172800021
J	Pfenninger, M; Nowak, C				Pfenninger, Markus; Nowak, Carsten			Reproductive Isolation and Ecological Niche Partition among Larvae of the Morphologically Cryptic Sister Species Chironomus riparius and C. piger	PLOS ONE			English	Article							GENE FLOW; DNA; DIPTERA; THUMMI; COEXISTENCE; HAPLOTYPES; SETTLEMENT; EVOLUTION; SEQUENCES	Background: One of the central issues in ecology is the question what allows sympatric occurrence of closely related species in the same general area? The non-biting midges Chironomus riparius and C. piger, interbreeding in the laboratory, have been shown to coexist frequently despite of their close relatedness, similar ecology and high morphological similarity. Methodology/Principal Findings: In order to investigate factors shaping niche partitioning of these cryptic sister species, we explored the actual degree of reproductive isolation in the field. Congruent results from nuclear microsatellite and mitochondrial haplotype analyses indicated complete absence of interspecific gene-flow. Autocorrelation analysis showed a non-random spatial distribution of the two species. Though not dispersal limited at the scale of the study area, the sister species occurred less often than expected at the same site, indicating past or present competition. Correlation and multiple regression analyses suggested the repartition of the available habitat along water chemistry gradients (nitrite, conductivity, CaCO3), ultimately governed by differences in summer precipitation regime. Conclusions: We show that these morphologically cryptic sister species partition their niches due to a certain degree of ecological distinctness and total reproductive isolation in the field. The coexistence of these species provides a suitable model system for the investigation of factors shaping the distribution of closely related, cryptic species.	Goethe Univ Frankfurt, Abt Okol & Evolut, Frankfurt, Germany	Goethe University Frankfurt	Pfenninger, M (corresponding author), Goethe Univ Frankfurt, Abt Okol & Evolut, Frankfurt, Germany.	Pfenninger@bio.uni-frankfurt.de	Nowak, Carsten/A-4466-2014; Pfenninger, Markus/A-8230-2012	Nowak, Carsten/0000-0002-3139-1951; 	programme Environmental Quality and its Security and Sustainment (BW-Plus); Baden-Wurttemberg [BWR 22018]	programme Environmental Quality and its Security and Sustainment (BW-Plus); Baden-Wurttemberg	This research has been supported by the programme Environmental Quality and its Security and Sustainment (BW-Plus) with funding of the state Baden-Wurttemberg (project number BWR 22018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amarasekare P, 2003, ECOL LETT, V6, P1109, DOI 10.1046/j.1461-0248.2003.00530.x; Armitage P.D., 1995, P194; ARNOLD ML, 1992, ANNU REV ECOL SYST, V23, P237, DOI 10.1146/annurev.es.23.110192.001321; Belkhir K, 1996, GENETIX 4 04 LOGICIE; Blaxter ML, 2004, PHILOS T R SOC B, V359, P669, DOI 10.1098/rstb.2003.1447; CAREW ME, 2003, B ENTEMOLOGICAL RES, V8, P287; CHESSON P, 1991, TRENDS ECOL EVOL, V6, P26, DOI 10.1016/0169-5347(91)90144-M; Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; CONNELL JH, 1980, OIKOS, V35, P131, DOI 10.2307/3544421; Crandall KA, 1996, MOL BIOL EVOL, V13, P115, DOI 10.1093/oxfordjournals.molbev.a025550; Darwin C, 1859, ORIGINS SPECIES MEAN; De Meester L, 2002, ACTA OECOL, V23, P121, DOI 10.1016/S1146-609X(02)01145-1; EXCOFFIER L, 1992, GENETICS, V131, P479; Gunderina LI, 2005, RUSS J GENET+, V41, P130, DOI 10.1007/s11177-005-0107-8; Guryev V, 2001, MOL PHYLOGENET EVOL, V19, P9, DOI 10.1006/mpev.2001.0898; Haas H., 1957, Biologisches Zentralblatt Leipzig, V76, P513; Hagele K, 1999, J ZOOL SYST EVOL RES, V37, P161; Hijmans R.J., 2001, PLANT GENETIC RESOUR, V127, P15, DOI DOI 10.1016/j.compositesa.2008.10.018; HILSENHOFF WL, 1968, ANN ENTOMOL SOC AM, V61, P1173, DOI 10.1093/aesa/61.5.1173; Hubbell Stephen P., 2001, V32, pi; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; JOHNSON RK, 1987, ENTOMOL SCAND, P233; Kelly A, 2004, J N AM BENTHOL SOC, V23, P287, DOI 10.1899/0887-3593(2004)023&lt;0287:SIAPFI&gt;2.0.CO;2; Keyl H. G., 1959, Archiv fuer Hydrobiologie Stuttgart, V56, P43; KEYL HG, 1956, Z NATURFORSCH PT B, V11, P727; MACARTHUR R, 1967, AM NAT, V101, P377, DOI 10.1086/282505; MAYR E., 1942, Systematics and the origin of species from the viewpoint of a zoologist.; MCLACHLAN A, 1993, HYDROBIOLOGIA, V259, P1, DOI 10.1007/BF00005959; Meszena G, 2006, THEOR POPUL BIOL, V69, P68, DOI 10.1016/j.tpb.2005.07.001; MIEHLBRADT J, 1976, BEHAVIOUR, V58, P272, DOI 10.1163/156853976X00190; Neumann D, 2001, ARCH HYDROBIOL, V153, P103; NOWAK C, 2006, MOL ECOLOGY IN PRESS; Peakall R, 2006, MOL ECOL NOTES, V6, P288, DOI 10.1111/j.1471-8286.2005.01155.x; Pfenninger M, 2007, MOL ECOL, V16, P1957, DOI 10.1111/j.1365-294X.2006.03136.x; Ross R, 1997, J MOL EVOL, V44, P321, DOI 10.1007/PL00006149; Sawada M, 1999, B ECOL SOC AM, V80, P231, DOI DOI 10.1890/0012-9623(1999)080[0231:TT]2.0.CO;2; SCHARF BW, 1973, ARCH HYDROBIOL, V72, P225; Servia MJ, 2004, HYDROBIOLOGIA, V523, P137, DOI 10.1023/B:HYDR.0000033101.78277.8b; Stevens MM, 2003, J CHEM ECOL, V29, P911, DOI 10.1023/A:1022983800421; STRENZKE K, 1957, ANALLES ENTOMOL FENN, V26, P111; Suemoto T, 2004, HYDROBIOLOGIA, V515, P107, DOI 10.1023/B:HYDR.0000027322.11005.20; Templeton AR, 1998, MOL ECOL, V7, P381, DOI 10.1046/j.1365-294x.1998.00308.x; TEMPLETON AR, 1992, GENETICS, V132, P619; Tokeshi M., 1995, P225; Tokeshi M., 1995, P297; TOKESHI M, 1995, FRESHWATER BIOL, V33, P567, DOI 10.1111/j.1365-2427.1995.tb00414.x; Vos JH, 2002, ARCH HYDROBIOL, V154, P103; Wiens JJ, 2005, ANNU REV ECOL EVOL S, V36, P519, DOI 10.1146/annurev.ecolsys.36.102803.095431; Zhang DY, 2004, ECOL LETT, V7, P165, DOI 10.1111/j.1461-0248.2004.00569.x	50	25	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2157	10.1371/journal.pone.0002157	http://dx.doi.org/10.1371/journal.pone.0002157			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478074	Green Submitted, Green Published, gold			2022-12-25	WOS:000262172800022
J	Yu, Z; Li, P; Zhang, M; Hannink, M; Stamler, JS; Yan, Z				Yu, Zengli; Li, Ping; Zhang, Mei; Hannink, Mark; Stamler, Jonathan S.; Yan, Zhen			Fiber Type-Specific Nitric Oxide Protects Oxidative Myofibers against Cachectic Stimuli	PLOS ONE			English	Article								Oxidative skeletal muscles are more resistant than glycolytic muscles to cachexia caused by chronic heart failure and other chronic diseases. The molecular mechanism for the protection associated with oxidative phenotype remains elusive. We hypothesized that differences in reactive oxygen species (ROS) and nitric oxide (NO) determine the fiber type susceptibility. Here, we show that intraperitoneal injection of endotoxin (lipopolysaccharide, LPS) in mice resulted in higher level of ROS and greater expression of muscle-specific E3 ubiqitin ligases, muscle atrophy F-box (MAFbx)/atrogin-1 and muscle RING finger-1 (MuRF1), in glycolytic white vastus lateralis muscle than in oxidative soleus muscle. By contrast, NO production, inducible NO synthase (iNos) and antioxidant gene expression were greatly enhanced in oxidative, but not in glycolytic muscles, suggesting that NO mediates protection against muscle wasting. NO donors enhanced iNos and antioxidant gene expression and blocked cytokine/endotoxin-induced MAFbx/atrogin-1 expression in cultured myoblasts and in skeletal muscle in vivo. Our studies reveal a novel protective mechanism in oxidative myofibers mediated by enhanced iNos and antioxidant gene expression and suggest a significant value of enhanced NO signaling as a new therapeutic strategy for cachexia.	[Yu, Zengli; Li, Ping; Stamler, Jonathan S.; Yan, Zhen] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Stamler, Jonathan S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC USA; [Zhang, Mei; Yan, Zhen] Duke NUS Grad Med Sch, Singapore, Singapore; [Hannink, Mark] Univ Missouri Columbia, Life Sci Ctr, Dept Biochem, Columbia, MO USA	Duke University; Duke University; National University of Singapore; University of Missouri System; University of Missouri Columbia	Yu, Z (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	zhen.yan@duke.edu		Li, Ping/0000-0002-4549-9517; Stamler, Jonathan/0000-0002-6866-1572; Yan, Zhen/0000-0002-4826-9813	American Heart Association-Mid-Atlantic Affiliate Post-doctoral Fellowship [0625518]; National Institutes of Health [R01-HLO59130]; Grant-in-Aid [0555426U]	American Heart Association-Mid-Atlantic Affiliate Post-doctoral Fellowship(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grant-in-Aid	This study is supported by the American Heart Association-Mid-Atlantic Affiliate Post-doctoral Fellowship 0625518 (to P.L.), National Institutes of Health R01-HLO59130 (to J.S.S), and Grant-in-Aid 0555426U (to Z.Y.).	Abraham RZ, 1998, COMP BIOCHEM PHYS A, V119, P177, DOI 10.1016/S1095-6433(97)00421-2; Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Adams V, 1997, BIOCHEM MOL MED, V61, P152, DOI 10.1006/bmme.1997.2598; Agusti A, 2004, THORAX, V59, P483, DOI 10.1136/thx.2003.017640; Anderson EJ, 2006, AM J PHYSIOL-CELL PH, V290, pC844, DOI 10.1152/ajpcell.00402.2005; Appell HJ, 1997, INT J SPORTS MED, V18, P157; AriasDiaz J, 1997, EUR J SURG, V163, P619; Barreiro E, 2005, FEBS LETT, V579, P1646, DOI 10.1016/j.febslet.2005.02.017; BIANCA R, 2002, MED SCI MONITOR, V8, P1; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Borniquel S, 2006, FASEB J, V20, P1889, DOI 10.1096/fj.05-5189fje; Boveris A, 2002, FREE RADICAL BIO MED, V33, P1186, DOI 10.1016/S0891-5849(02)01009-2; Butori C, 1995, ANN PATHOL, V15, P424; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Comtois AS, 2001, AM J RESP CRIT CARE, V163, P977, DOI 10.1164/ajrccm.163.4.9912057; Das A, 2005, J BIOL CHEM, V280, P12944, DOI 10.1074/jbc.M404706200; Davila HH, 2004, BIOL REPROD, V71, P1568, DOI 10.1095/biolreprod.104.030833; Escames G, 2006, J PINEAL RES, V40, P71, DOI 10.1111/j.1600-079X.2005.00281.x; Escames G, 2007, FEBS J, V274, P2135, DOI 10.1111/j.1742-4658.2007.05755.x; Fagan JM, 1996, ARCH SURG-CHICAGO, V131, P1326; FAGAN JM, 1996, ARCH SURG-CHICAGO, V131, P1331; Fielitz J, 2007, J CLIN INVEST, V117, P2486, DOI 10.1172/JCI32827; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grozdanovic Z, 1999, HISTOL HISTOPATHOL, V14, P243, DOI 10.14670/HH-14.243; Hollander J, 1999, AM J PHYSIOL-REG I, V277, pR856, DOI 10.1152/ajpregu.1999.277.3.R856; JI LL, 1992, J APPL PHYSIOL, V73, P1854, DOI 10.1152/jappl.1992.73.5.1854; KAWANO T, 2007, J CEREB BLOOD FLOW M; Krolick KA, 2006, CLIN IMMUNOL, V121, P286, DOI 10.1016/j.clim.2006.07.005; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li P, 2007, AM J PATHOL, V170, P599, DOI 10.2353/ajpath.2007.060505; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Linke A, 2005, CIRCULATION, V111, P1763, DOI 10.1161/01.CIR.0000165503.08661.E5; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Minnaard R, 2005, MUSCLE NERVE, V31, P339, DOI 10.1002/mus.20268; MULLER FL, 2007, AM J PHYSL REGUL INT; Nin N, 2004, INTENS CARE MED, V30, P2271, DOI 10.1007/s00134-004-2427-x; Obasanjo-Blackshire K, 2006, CARDIOVASC RES, V71, P672, DOI 10.1016/j.cardiores.2006.05.026; Ockaili R, 2002, AM J PHYSIOL-HEART C, V283, pH1263, DOI 10.1152/ajpheart.00324.2002; Reid MB, 1998, COMP BIOCHEM PHYS A, V119, P211, DOI 10.1016/S1095-6433(97)00417-0; Salloum F, 2003, CIRC RES, V92, P595, DOI 10.1161/01.RES.0000066853.09821.98; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SHAH AJ, 1983, CLIN NEUROPATHOL, V2, P83; Wang MX, 2001, NITRIC OXIDE-BIOL CH, V5, P219, DOI 10.1006/niox.2001.0348; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	46	63	64	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2086	10.1371/journal.pone.0002086	http://dx.doi.org/10.1371/journal.pone.0002086			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461174	Green Published, gold			2022-12-25	WOS:000261642400009
J	Arredondo, J; Chernyavsky, AI; Jolkovsky, DL; Pinkerton, KE; Grando, SA				Arredondo, Juan; Chernyavsky, Alexander I.; Jolkovsky, David L.; Pinkerton, Kent E.; Grando, Sergei A.			Receptor-mediated tobacco toxicity: acceleration of sequential expression of alpha 5 and alpha 7 nicotinic receptor subunits in oral keratinocytes exposed to cigarette smoke	FASEB JOURNAL			English	Article						nicotinic acetylcholine receptors; Akt; PKC; p38; JAK-2; GATA-2	ACETYLCHOLINE-RECEPTOR; EPITHELIAL-CELLS; UP-REGULATION; IN-VITRO; BINDING-SITES; DIFFERENTIAL REGULATION; HIPPOCAMPAL-NEURONS; CHOLINERGIC SYSTEM; ENDOTHELIAL-CELLS; CALCIUM INFLUX	Tobacco products and nicotine alter the cell cycle and lead to squamatization of oral keratinocytes (KCs) and squamous cell carcinoma. Activation of nicotinic acetylcholine receptors (nAChRs) elicits Ca(2+) influx that varies in magnitude between different nAChR subtypes. Normal differentiation of KCs is associated with sequential expression of the nAChR subtypes with increasing Ca(2+) permeability, such as alpha 5-containing alpha 3 nAChR and alpha 7 nAChR. Exposure to environmental tobacco smoke (ETS) or an equivalent concentration of nicotine accelerated by severalfold the alpha 5 and alpha 7 expression in KCs, which could be abolished by mecamylamine and et-bungarotoxin with different efficacies, suggesting the following sequence of autoregulation of the expression of nAChR subtypes: alpha 3(beta 2/beta 4) > alpha 3(beta 2/beta 4)alpha 5 > alpha 7 > alpha 7. This conjecture was corroborated by results of quantitative assays of subunit mRNA and protein levels, using nAChR-specific pharmacologic antagonists and small interfering RNAs. The genomic effects of ETS and nicotine involved the transcription factor GATA-2 that showed a multifold increase in quantity and activity in exposed KCs. Using protein kinase inhibitors and dominant negative and constitutively active constructs, we characterized the principal signaling cascades mediating a switch in the nAChR subtype. Cumulative results indicated that the alpha 3(beta 2/beta 4) to alpha 3(beta 2/beta 4)alpha 5 nAChR transition predominantly involved protein kinase C, alpha 3(beta 2/beta 4)alpha 5 to alpha 7 nAChR transition-Ca(2+)/calmodulin-dependent protein kinase II and p38 MAPK, and alpha 7 self-up-regulation-the p38 MAPK/Akt pathway, and JAK-2. These results provide a mechanistic insight into the genomic effects of ETS and nicotine on KCs and characterize signaling pathways mediating autoregulation of stepwise overexpression of nAChR subtypes with increasing Ca(2+) permeability in exposed cells. These observations have salient clinical implications, because a switch in the nAChR subunit composition can bring about a corresponding switch in receptor function, leading to profound pathobiologic effects observed in KCs exposed to tobacco products.	[Arredondo, Juan; Chernyavsky, Alexander I.; Grando, Sergei A.] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92697 USA; [Jolkovsky, David L.] Univ Calif Los Angeles, Sch Dent, Ctr Periodont, Los Angeles, CA 90024 USA; [Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Davis	Grando, SA (corresponding author), Univ Calif Irvine, Dept Dermatol, C340 Med Sci I, Irvine, CA 92697 USA.	sgrando@uci.edu			NATIONAL CANCER INSTITUTE [R03CA117327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES014384] Funding Source: NIH RePORTER; NCI NIH HHS [CA117327] Funding Source: Medline; NIDCR NIH HHS [DE14173] Funding Source: Medline; NIEHS NIH HHS [ES014384] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON G, 1989, J ORAL PATHOL MED, V18, P491, DOI 10.1111/j.1600-0714.1989.tb01349.x; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Arredondo J, 2005, J INVEST DERMATOL, V125, P1236, DOI 10.1111/j.0022-202X.2005.23973.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Arredondo J, 2007, LIFE SCI, V80, P2191, DOI 10.1016/j.lfs.2007.01.013; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, CANCER BIOL THER, V5, P511, DOI 10.4161/cbt.5.5.2601; Bairam A, 2007, NEUROSCIENCE, V146, P1841, DOI 10.1016/j.neuroscience.2007.03.034; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Charpantier E, 2005, J NEUROSCI, V25, P9836, DOI 10.1523/JNEUROSCI.3497-05.2005; Cheng YH, 2005, BIOL REPROD, V73, P500, DOI 10.1095/biolreprod.105.039941; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Dajas-Bailador FA, 2002, J NEUROCHEM, V81, P606, DOI 10.1046/j.1471-4159.2002.00846.x; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; Davila-Garcia MI, 2003, J NEUROCHEM, V85, P1237, DOI 10.1046/j.1471-4159.2003.01774.x; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; delToro ED, 1997, DEV BRAIN RES, V98, P125; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Fischer H, 2005, J NEUROSCI, V25, P3571, DOI 10.1523/JNEUROSCI.4971-04.2005; Flores CM, 1997, J NEUROCHEM, V69, P2216; Fluck CE, 2004, MOL ENDOCRINOL, V18, P1144, DOI 10.1210/me.2003-0342; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Girod R, 1999, ANN NY ACAD SCI, V868, P578, DOI 10.1111/j.1749-6632.1999.tb11331.x; Grando SA, 2007, J INVEST DERMATOL, V127, pS31; GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606; Grando SA, 2007, LIFE SCI, V80, P2181, DOI 10.1016/j.lfs.2007.03.015; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Gray AC, 2001, TOXICOL IN VITRO, V15, P427, DOI 10.1016/S0887-2333(01)00047-9; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Hellstrom-Lindahl E, 2001, NEUROSCIENCE, V105, P527, DOI 10.1016/S0306-4522(01)00209-3; HIRSCH JM, 1982, J ORAL PATHOL MED, V11, P387, DOI 10.1111/j.1600-0714.1982.tb00180.x; Huang LZ, 2006, BRAIN RES, V1113, P94, DOI 10.1016/j.brainres.2006.06.084; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAUGARS GE, 1989, CANCER, V64, P1527, DOI 10.1002/1097-0142(19891001)64:7<1527::AID-CNCR2820640728>3.0.CO;2-N; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; KUES WA, 1995, EUR J NEUROSCI, V7, P1376, DOI 10.1111/j.1460-9568.1995.tb01129.x; Kumar P, 2005, J BIOL CHEM, V280, P25928, DOI 10.1074/jbc.M502435200; Kurzen H, 2004, J INVEST DERMATOL, V123, P937, DOI 10.1111/j.0022-202X.2004.23425.x; Kwon OS, 1999, SKIN PHARMACOL APPL, V12, P227, DOI 10.1159/000066247; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; LECOINTE N, 1994, ONCOGENE, V9, P2623; LINDSTROM J, 1995, ADV PHAR SC, P45; Liu W, 2007, THROMB HAEMOSTASIS, V97, P839, DOI 10.1160/TH06-09-0536; LUKAS RJ, 1998, NICOTINIC ACETYLCHOL, P145; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; MURRAH VA, 1993, ORAL SURG ORAL MED O, V75, P323, DOI 10.1016/0030-4220(93)90145-T; Nagavarapu U, 2001, J BIOL CHEM, V276, P16749, DOI 10.1074/jbc.M009712200; Nakayama H, 2002, J NEUROCHEM, V83, P1372, DOI 10.1046/j.1471-4159.2002.01248.x; Ndoye A, 1998, J INVEST DERMATOL, V111, P410, DOI 10.1046/j.1523-1747.1998.00299.x; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Nguyen VT, 2001, J CELL SCI, V114, P1189; Nuutinen S, 2006, EUR J PHARMACOL, V544, P21, DOI 10.1016/j.ejphar.2006.06.038; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; Quik M, 1997, MOL PHARMACOL, V51, P499; Ridley DL, 2001, BRIT J PHARMACOL, V133, P1286, DOI 10.1038/sj.bjp.0704207; Riganti L, 2005, BRIT J PHARMACOL, V146, P1096, DOI 10.1038/sj.bjp.0706434; Salas R, 2003, MOL PHARMACOL, V63, P1059, DOI 10.1124/mol.63.5.1059; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Slotkin TA, 2004, BRAIN RES, V1030, P159, DOI 10.1016/j.brainres.2004.10.009; SUNDSTROM B, 1982, J ORAL PATHOL MED, V11, P245, DOI 10.1111/j.1600-0714.1982.tb00162.x; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Teaktong T, 2004, NEUROPATH APPL NEURO, V30, P243, DOI 10.1046/j.0305-1846.2003.00528.x; THEILIG C, 1994, SKIN PHARMACOL, V7, P307; Tsuneki H, 2000, EUR J NEUROSCI, V12, P2475, DOI 10.1046/j.1460-9568.2000.00138.x; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Utsugisawa K, 2002, MOL BRAIN RES, V106, P88, DOI 10.1016/S0169-328X(02)00415-1; vanHoek ML, 1997, BIOCHEM J, V326, P271, DOI 10.1042/bj3260271; Vincler MA, 2005, PHARMACOL BIOCHEM BE, V80, P135, DOI 10.1016/j.pbb.2004.10.011; Wada T, 2007, ENDOCRINOLOGY, V148, P790, DOI 10.1210/en.2006-0907; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; Wang N, 2002, J PHYSIOL-LONDON, V542, P347, DOI 10.1113/jphysiol.2001.013456; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Winzer-Serhan UH, 2005, J COMP NEUROL, V481, P19, DOI 10.1002/cne.20357; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zia S, 1999, J INVEST DERMATOL, V112, P613; Zia S, 1997, RES COMMUN MOL PATH, V97, P243; Zia SH, 2000, J PHARMACOL EXP THER, V293, P973	92	65	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1356	1368		10.1096/fj.07-9965.com	http://dx.doi.org/10.1096/fj.07-9965.com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18450646				2022-12-25	WOS:000255898700009
J	Buhimschi, IA; Zhao, G; Rosenberg, VA; Abdel-Razeq, S; Thung, S; Buhimschi, CS				Buhimschi, Irina A.; Zhao, Guomao; Rosenberg, Victor A.; Abdel-Razeq, Sonya; Thung, Stephen; Buhimschi, Catalin S.			Multidimensional Proteomics Analysis of Amniotic Fluid to Provide Insight into the Mechanisms of Idiopathic Preterm Birth	PLOS ONE			English	Article							URINARY TRYPSIN-INHIBITOR; PREMATURE RUPTURE; FETAL-GROWTH; A-II; BIKUNIN; APOLIPOPROTEINS; INFLAMMATION; CONTRACTION; EXPRESSION; BIOMARKERS	Background: Though recent advancement in proteomics has provided a novel perspective on several distinct pathogenetic mechanisms leading to preterm birth (inflammation, bleeding), the etiology of most preterm births still remains elusive. We conducted a multidimensional proteomic analysis of the amniotic fluid to identify pathways related to preterm birth in the absence of inflammation or bleeding. Methodology/Principal Findings: A proteomic fingerprint was generated from fresh amniotic fluid using surface-enhanced laser desorbtion ionization time of flight (SELDI-TOF) mass spectrometry in a total of 286 consecutive samples retrieved from women who presented with signs or symptoms of preterm labor or preterm premature rupture of the membranes. Inflammation and/or bleeding proteomic patterns were detected in 32% (92/286) of the SELDI tracings. In the remaining tracings, a hierarchical algorithm was applied based on descriptors quantifying similarity/dissimilarity among proteomic fingerprints. This allowed identification of a novel profile (Q-profile) based on the presence of 5 SELDI peaks in the 10-12.5 kDa mass area. Women displaying the Q-profile(mean +/- SD, gestational age: 25 +/- 4 weeks, n = 40) were more likely to deliver preterm despite expectant management in the context of intact membranes and normal amniotic fluid clinical results. Utilizing identification-centered proteomics techniques (fluorescence two-dimensional differential gel electrophoresis, robotic tryptic digestion and mass spectrometry) coupled with Protein ANalysis THrough Evolutionary Relationships (PANTHER) ontological classifications, we determined that in amniotic fluids with Q-profile the differentially expressed proteins are primarily involved in non-inflammatory biological processes such as protein metabolism, signal transduction and transport. Conclusion/Significance: Proteomic profiling of amniotic fluid coupled with non-hierarchical bioinformatics algorithms identified a subgroup of patients at risk for preterm birth in the absence of intra-amniotic inflammation or bleeding, suggesting a novel pathogenetic pathway leading to preterm birth. The altered proteins may offer opportunities for therapeutical intervention and future drug development to prevent prematurity.	[Buhimschi, Irina A.; Zhao, Guomao; Rosenberg, Victor A.; Abdel-Razeq, Sonya; Thung, Stephen; Buhimschi, Catalin S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA	Yale University	Buhimschi, IA (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.	irina.buhimschi@yale.edu	Buhimschi, Irina/AAY-6619-2021	Buhimschi, Irina/0000-0002-1701-1326	National Institutes of Child Health and Development [RO1 HD 047321 IAB]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047321] Funding Source: NIH RePORTER	National Institutes of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The study was funded by a grant from the National Institutes of Child Health and Development (RO1 HD 047321 IAB). The funding source had no involvement in study design, interpretation of data, writing of the report or decision to submit the paper for publication.	ACOG Committee on Practice Bulletins-Obstetrics, 2007, OBSTET GYNECOL, V109, P1007, DOI DOI 10.1097/01.AOG.0000263888.69178.1F; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; Buhimschi CS, 2007, PLOS MED, V4, P84, DOI 10.1371/journal.pmed.0040018; Buhimschi CS, 2007, PEDIATR RES, V61, P318, DOI 10.1203/01.pdr.0000252439.48564.37; Buhimsehi CS, 2006, OBSTET GYNECOL SURV, V61, P481, DOI 10.1097/01.ogx.0000224617.11789.ab; Buhimschi IA, 2005, BJOG-INT J OBSTET GY, V112, P173, DOI 10.1111/j.1471-0528.2004.00340.x; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chevallier B, 1998, BIOL NEONATE, V73, P404, DOI 10.1159/000014003; ElMaradny E, 1996, GYNECOL OBSTET INVES, V41, P96, DOI 10.1159/000292051; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Gettins PGW, 2002, BIOL CHEM, V383, P1677, DOI 10.1515/BC.2002.188; Heffner LJ, 1998, GROWTH HORM IGF RES, V8, P33, DOI 10.1016/S1096-6374(98)80319-5; Kaga N, 1996, OBSTET GYNECOL, V88, P872, DOI 10.1016/0029-7844(96)00268-2; Kalopissis AD, 2000, INT J TISSUE REACT, V22, P67; KANAYAMA N, 1986, AM J OBSTET GYNECOL, V155, P1043, DOI 10.1016/0002-9378(86)90343-1; KANAYAMA N, 1995, AM J OBSTET GYNECOL, V173, P192, DOI 10.1016/0002-9378(95)90189-2; KANAYAMA N, 1995, EUR J OBSTET GYN R B, V60, P181, DOI 10.1016/0028-2243(95)02087-9; Kobayashi H, 2003, BIOL CHEM, V384, P749, DOI 10.1515/BC.2003.083; Kobayashi H, 1999, MOL HUM REPROD, V5, P662, DOI 10.1093/molehr/5.7.662; LEBOEUF RC, 1994, J LIPID RES, V35, P121; Lockwood CJ, 2003, CLIN LAB MED, V23, P345, DOI 10.1016/S0272-2712(03)00029-5; Marko-Varga G, 2007, J PROTEOME RES, V6, P2925, DOI 10.1021/pr070046s; Matsuzaki H, 2004, CLIN DIAGN LAB IMMUN, V11, P1140, DOI 10.1128/CDLI.11.6.1140-1147.2004; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; Mi HY, 2007, NUCLEIC ACIDS RES, V35, pD247, DOI 10.1093/nar/gkl869; Michaels JEA, 2007, J PROTEOME RES, V6, P1277, DOI 10.1021/pr060543t; Minino Arialdi M, 2007, Natl Vital Stat Rep, V55, P1; Moutquin JM, 2003, BJOG-INT J OBSTET GY, V110, P30, DOI 10.1016/S1470-0328(03)00021-1; Naef RW, 1998, AM J OBSTET GYNECOL, V178, P126, DOI 10.1016/S0002-9378(98)70638-6; Naeye RL., 1992, DISORDERS PLACENTA F, P118; Nesvizhskii AI, 2007, METHOD MOL BIOL, V367, P87, DOI DOI 10.1385/1-59745-275-0:87; Ngoc NTN, 2006, B WORLD HEALTH ORGAN, V84, P699, DOI 10.2471/BLT.05.027300; OBRIEN WF, 1990, AM J OBSTET GYNECOL, V162, P756, DOI 10.1016/0002-9378(90)91002-T; Petricoin EF, 2002, J MAMMARY GLAND BIOL, V7, P433, DOI 10.1023/A:1024042200521; Popovici RM, 2001, J CLIN ENDOCR METAB, V86, P2653, DOI 10.1210/jc.86.6.2653; SALAFIA CM, 1989, OBSTET GYNECOL, V73, P383; Sherer DM, 2000, GYNECOL OBSTET INVES, V50, P92, DOI 10.1159/000010289; STEINMETZ A, 1989, GYNECOL OBSTET INVES, V28, P127, DOI 10.1159/000293547; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; Vij N, 2004, EXP EYE RES, V78, P957, DOI 10.1016/j.exer.2003.12.006; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; Weiner CP, 2005, AM J OBSTET GYNECOL, V192, P710, DOI 10.1016/j.ajog.2004.10.588	42	42	44	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2049	10.1371/journal.pone.0002049	http://dx.doi.org/10.1371/journal.pone.0002049			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431506	Green Published, Green Submitted, gold			2022-12-25	WOS:000261558700041
J	Martins, PM; Rocha, F; Damas, AM				Martins, Pedro M.; Rocha, Fernando; Damas, Ana M.			Understanding Water Equilibration Fundamentals as a Step for Rational Protein Crystallization	PLOS ONE			English	Article								Background: Vapor diffusion is the most widely used technique for protein crystallization and the rate of water evaporation plays a key role on the quality of the crystals. Attempts have been made in the past to solve the mass transfer problem governing the evaporation process, either analytically or by employing numerical methods. Despite these efforts, the methods used for protein crystallization remain based on trial and error techniques rather than on fundamental principles. Methodology/Principal Findings: Here we present a new theoretical model which describes the hanging drop method as a function of the different variables that are known to influence the evaporation process. The model is extensively tested against experimental data published by other authors and considering different crystallizing conditions. Aspects responsible for the discrepancies between the existing theories and the measured evaporation kinetics are especially discussed; they include the characterization of vapor-liquid equilibrium, the role of mass transfer within the evaporating droplet, and the influence of the droplet-reservoir distance. Conclusions/Significance: The validation tests show that the proposed model can be used to predict the water evaporation rates under a wide range of experimental conditions used in the hanging drop vapor-diffusion method, with no parameter fitting or computational requirements. This model combined with protein solubility data is expected to become a useful tool for a priori screening of crystallization conditions.	[Martins, Pedro M.; Damas, Ana M.] Univ Porto, IBMC, Grp Estrutura Mol, P-4100 Oporto, Portugal; [Martins, Pedro M.; Rocha, Fernando] Univ Porto, Fac Engenharia, Dept Engenharia Quim, Oporto, Portugal; [Damas, Ana M.] Univ Porto, ICBAS, Oporto, Portugal	Universidade do Porto; Universidade do Porto; Universidade do Porto	Martins, PM (corresponding author), Univ Porto, IBMC, Grp Estrutura Mol, Rua Campo Alegre 823, P-4100 Oporto, Portugal.	amdamas@ibmc.up.pt	Martins, Pedro/GWC-7702-2022; Martins, Pedro M/J-3765-2013; Rocha, Fernando A/D-4324-2014	Rocha, Fernando A/0000-0002-2778-8374; Martins, Pedro Miguel/0000-0002-6908-1828	Fundacao para a Ciencia e a Tecnologia, Portugal [FEDER FCT POCI/SAU-NEU/69123/2006, PTDC/EQU-FTT/81496/2006]; EU [EURAMY(FP6-LIFESCIHEALTH-6)]; FCT [SFRH/BPD/34556/2007]	Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); EU(European Commission); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by the projects FEDER FCT POCI/SAU-NEU/69123/2006 and PTDC/EQU-FTT/81496/2006 from Fundacao para a Ciencia e a Tecnologia, Portugal, and project EURAMY(FP6-LIFESCIHEALTH-6) from EU. PMM is funded by a FCT grant with reference SFRH/BPD/34556/2007. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.	Asherie N, 2004, METHODS, V34, P266, DOI 10.1016/j.ymeth.2004.03.028; Baird JK, 1999, J CRYST GROWTH, V204, P553, DOI 10.1016/S0022-0248(99)00134-7; Capuano F, 2006, J SOLUTION CHEM, V35, P1525, DOI 10.1007/s10953-006-9077-2; Chayen NE, 2004, CURR OPIN STRUC BIOL, V14, P577, DOI 10.1016/j.sbi.2004.08.002; Chayen NE, 1997, STRUCTURE, V5, P1269, DOI 10.1016/S0969-2126(97)00279-7; Diller DJ, 1999, ACTA CRYSTALLOGR D, V55, P656, DOI 10.1107/S0907444998014589; DUCRUIX A, 1999, CRYSTALLISATION NUCL; Falini G, 2002, ACTA CRYSTALLOGR D, V58, P1649, DOI 10.1107/S0907444902012763; Fernandez-Serra MV, 2004, J CHEM PHYS, V121, P11136, DOI 10.1063/1.1813431; FOWLIS WW, 1988, J CRYST GROWTH, V90, P117, DOI 10.1016/0022-0248(88)90306-5; Luft JR, 1996, ACTA CRYSTALLOGR D, V52, P1098, DOI 10.1107/S0907444996006932; MIKOL V, 1990, ANAL BIOCHEM, V186, P332, DOI 10.1016/0003-2697(90)90091-M; Nakamura H, 2003, J CRYST GROWTH, V259, P149, DOI 10.1016/S0022-0248(03)01571-9; Saridakis E, 2000, PROTEIN SCI, V9, P755; SIBILLE L, 1991, J CRYST GROWTH, V110, P72, DOI 10.1016/0022-0248(91)90868-6; SIBILLE L, 1991, J CRYST GROWTH, V110, P80, DOI 10.1016/0022-0248(91)90869-7; Talreja S, 2007, LANGMUIR, V23, P4516, DOI 10.1021/la063734j; Tang L, 2005, ACTA CRYSTALLOGR D, V61, P53, DOI 10.1107/S0907444904026009	18	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1998	10.1371/journal.pone.0001998	http://dx.doi.org/10.1371/journal.pone.0001998			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431483	Green Published, gold, Green Submitted			2022-12-25	WOS:000261558700018
J	Chekenya, M; Krakstad, C; Svendsen, A; Netland, IA; Staalesen, V; Tysnes, BB; Selheim, F; Wang, J; Sakariassen, PO; Sandal, T; Lonning, PE; Flatmark, T; Enger, PO; Bjerkvig, R; Sioud, M; Stallcup, WB				Chekenya, M.; Krakstad, C.; Svendsen, A.; Netland, I. A.; Staalesen, V.; Tysnes, B. B.; Selheim, F.; Wang, J.; Sakariassen, P. O.; Sandal, T.; Lonning, P. E.; Flatmark, T.; Enger, P. O.; Bjerkvig, R.; Sioud, M.; Stallcup, W. B.			The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling	ONCOGENE			English	Article						apoptosis; chemoresistance; integrin; NG2/MPG	CHONDROITIN SULFATE PROTEOGLYCAN; ACUTE MYELOID-LEUKEMIA; PDGF ALPHA-RECEPTOR; NG2 PROTEOGLYCAN; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; HUMAN HOMOLOG; BRAIN-TUMORS; EXPRESSION; PHOSPHORYLATION	Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MPG) is aberrantly expressed by various tumors, but its role in cell death signaling and its potential as a therapeutic target are largely unexplored. We have assessed cytotoxic drug-induced cell death in glioblastoma spheroids from 15 patients, as well as in five cancer cell lines that differ with respect to NG2/MPG expression. The tumors were treated with doxorubicin, etoposide, carboplatin, temodal, cisplatin and tumor necrosis factor (TNF)alpha. High NG2/MPG expression correlated with multidrug resistance mediated by increased activation of alpha 3 beta 1 integrin/PI3K signaling and their downstream targets, promoting cell survival. NG2/MPG knockdown with shRNAs incorporated into lentiviral vectors attenuated beta 1 integrin signaling revealing potent antitumor effects and further sensitized neoplastic cells to cytotoxic treatment in vitro and in vivo. Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes.	[Chekenya, M.; Svendsen, A.; Netland, I. A.; Tysnes, B. B.; Wang, J.; Sakariassen, P. O.; Enger, P. O.; Bjerkvig, R.] Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, N-5009 Bergen, Norway; [Staalesen, V.] Univ Bergen, Dept Mol Biol, N-5009 Bergen, Norway; [Lonning, P. E.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Flatmark, T.] Univ Bergen, Dept Biomed, Sect Biochem & Mol Biol, N-5009 Bergen, Norway; [Enger, P. O.] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Bjerkvig, R.] CRP Sante, Norlux Neuro Oncol Grp, Luxembourg, Luxembourg; [Sioud, M.] Norwegian Radium Hosp, Dept Immunol, Mol Med Grp, Oslo, Norway; [Stallcup, W. B.] Tumor Microenvironm Program, Canc Res Ctr, Burnham Med Res Inst, La Jolla, CA USA	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; Luxembourg Institute of Health; University of Oslo; Sanford Burnham Prebys Medical Discovery Institute	Chekenya, M (corresponding author), Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, Jonas Lies Vei 91, N-5009 Bergen, Norway.	martha.chekenya@biomed.uib.no	Krakstad, Camilla/AAB-5138-2020	Krakstad, Camilla/0000-0002-0174-8139; Lonning, Per Eystein/0000-0002-8890-6303; Chekenya, PhD, Dr Philos, Dr. Martha/0000-0001-7241-3451	The Norwegian Cancer Society; The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health [RO1 CA95287]; Sixth EU Framework Programme; Helse-Vest; NATIONAL CANCER INSTITUTE [R01CA095287] Funding Source: NIH RePORTER	The Norwegian Cancer Society(Norwegian Cancer SocietyEuropean Commission); The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sixth EU Framework Programme(European Commission); Helse-Vest; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by research grants from The Norwegian Cancer Society, The Bergen Translational Research Group, Familien Blix Fond, The University of Bergen, and a RO1 CA95287 grant from the National Institutes of Health. This study was also supported by the Sixth EU Framework Programme and Helse-Vest. We thank Narve Brekka, Tove Johansen, Christine Eriksen, Erna Finsas and Nina Lied Larsen for their technical assistance. We thank Jesus Planaguma for assistance with image analysis.	ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEG AA, 1996, SCIENCE, V274, P784; Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chekenya M, 2002, NEUROPATH APPL NEURO, V28, P367, DOI 10.1046/j.1365-2990.2002.00412.x; Chekenya M, 2002, FASEB J, V16, P586, DOI 10.1096/fj.01-0632fje; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hilden JM, 1997, BLOOD, V89, P3801, DOI 10.1182/blood.V89.10.3801.3801_3801_3805; Joo NE, 2008, CELL DEATH DIFFER, V15, P899, DOI 10.1038/cdd.2008.22; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Li Y, 2003, BRIT J OPHTHALMOL, V87, P629, DOI 10.1136/bjo.87.5.629; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Makagiansar IT, 2007, J CELL BIOL, V178, P155, DOI 10.1083/jcb.200612084; Makagiansar IT, 2004, J BIOL CHEM, V279, P55262, DOI 10.1074/jbc.M411045200; Mauvieux L, 1999, BRIT J HAEMATOL, V107, P674; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Smith FO, 1996, BLOOD, V87, P1123, DOI 10.1182/blood.V87.3.1123.bloodjournal8731123; Stallcup WB, 2002, J NEUROCYTOL, V31, P423, DOI 10.1023/A:1025731428581; Stallcup WB, 2001, J CELL SCI, V114, P2315; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wewer UM, 1997, AM J PATHOL, V151, P1191; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	45	115	120	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5182	5194		10.1038/onc.2008.157	http://dx.doi.org/10.1038/onc.2008.157			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469852	Green Accepted			2022-12-25	WOS:000258915100002
J	Kouzmenko, AP; Takeyama, K; Kawasaki, Y; Akiyama, T; Kato, S				Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.			Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli	ONCOGENE			English	Article						adenomatous polyposis coli; chromatin; nuclear protein complexes; DNA repair	DOUBLE-STRAND BREAKS; BETA-CATENIN DEGRADATION; COLORECTAL TUMOR-CELLS; GENETIC INSTABILITY; APC MUTATIONS; SUBCELLULAR-LOCALIZATION; CHROMOSOMAL INSTABILITY; NUCLEAR RECEPTOR; UBIQUITIN LIGASE; DIOXIN RECEPTOR	The adenomatous polyposis coli (APC) is a tumor suppressor whose loss of function leads to colon cancer. APC shuttles between the nucleus and cytoplasm, however its role in the nucleus remains elusive. We have found that nuclear APC specifically associates with transcriptionally active chromatin through structural elements located downstream to the region of frequent truncation mutations found in colorectal tumors. We show that a recombinant APC fragment comprising such elements associates in vivo with euchromatin and preferentially binds in vitro to acetylated histone H3. Induction of DNA double-strand breaks (DSB) stimulates accumulation of APC at the damaged DNA chromatin marked by histone H2AX and S139-phosphorylated histone H2AX. A nuclear complex containing the DNA-dependent protein kinase catalytic subunit (DNAPKcs) and APC associates with chromatin in response to DNA DSB. APC knockdown with siRNA decreased the rate of DNA DSB-induced S139 histone H2AX phosphorylation in cells expressing endogenous full-length APC, but not in colon cancer cells with its truncation mutants, whereas ectopic APC expression stimulated the H2AX phosphorylation regardless of the type of endogenous APC. Our data suggest that APC involves in the DSB DNA repair and that truncation mutations impair chromatin-associated functions of APC.	[Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.] Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; [Kouzmenko, A. P.; Kato, S.] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	alexk@iam.u-tokyo.ac.jp; uskato@mail.ecc.u-tokyo.ac.jp			Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology; Exploratory Research for Advanced Technology (ERATO); Japan Science and Technology Agency (JST)	Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Exploratory Research for Advanced Technology (ERATO)(Japan Science & Technology Agency (JST)); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	We thank Professor AW Burgess (Ludwig Institute for Cancer Research, Melbourne Branch) for critical reading of the paper and members of the Department of Nuclear Signaling for constructive discussions, advice and support. This study was funded in part by the Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN) and priority areas from the Ministry of Education, Culture, Sports, Science and Technology (to SK), and by the Kato Nuclear Complex Project grant from the Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency (JST).	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; KOUZMENKO AP, 2008, GENES CELLS IN PRESS; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrison AJ, 2005, CELL CYCLE, V4, P568; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Neufeld KL, 2000, EMBO REP, V1, P519; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Steffensen IL, 2005, MUTAT RES-GEN TOX EN, V587, P73, DOI 10.1016/j.mrgentox.2005.07.004; Steffensen IL, 2006, MUTAT RES-GEN TOX EN, V611, P71, DOI 10.1016/j.mrgentox.2006.07.004; Strom A, 2007, DEVELOPMENT, V134, P2719, DOI 10.1242/dev.02875; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	65	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4888	4899		10.1038/onc.2008.127	http://dx.doi.org/10.1038/onc.2008.127			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454178				2022-12-25	WOS:000258596900003
J	Nam, CH; Lobato, MN; Appert, A; Drynan, LF; Tanaka, T; Rabbitts, TH				Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Tanaka, T.; Rabbitts, T. H.			An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions	ONCOGENE			English	Article						antibody; leukaemia; LMO2; scFv; gene therapy; X-SCID	T-CELL PROLIFERATION; TRANSGENIC MICE; CHROMOSOMAL TRANSLOCATION; INTRACELLULAR ANTIBODIES; PROTEIN RBTN2; HIGH-AFFINITY; DOMAIN; GENE; LMO2; EXPRESSION	The LIM-domain protein LMO2 is a T-cell oncogenic protein first recognized by gene activation through chromosomal translocations, but it is also responsible for leukaemias arising as secondary, adverse effects in an X-SCID gene therapy trial. There are no specific reagents currently available to analyse the LMO2 multiprotein complex or to combat LMO2-dependent leukaemias. Accordingly, we have isolated an anti-LMO2 single chain Fv antibody fragment to determine if intracellular interference with LMO2-protein complexes can avert LMO2-dependent functions in normal and cancer settings. The anti-LMO2 single chain Fv, obtained using Intracellular Antibody Capture (IAC) technology, is specifc for LMO2 among the LIM-only protein family and binds LMO2 through the third and fourth LIM fingers. Using vector-mediated expression of anti-LMO2 scFv, we show inhibition of Lmo2-dependent erythropoiesis but not endothelial development. We also demonstrate inhibition of Lmo2-dependent leukaemia in a mouse T-cell tumour-igenesis transplantation assay with retroviral-mediated expression of anti-LMO2 scFv. Our studies establish that interference with the LMO2 multiprotein complex inhibits both normal and tumourigenic roles. The antibody fragment is a tool for dissecting LMO2 function in haematopoiesis and leukaemia and is a lead for development of therapeutics against LMO2-dependent T-ALL.	[Tanaka, T.; Rabbitts, T. H.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Leeds LS9 7TF, W Yorkshire, England; [Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Rabbitts, T. H.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Saint James's University Hospital; University of Leeds; MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Wellcome Trust Brenner Bldg, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council; MRC [G0600914] Funding Source: UKRI; Medical Research Council [G0600914, MC_U105178807] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. CHN was supported by a fellowship from the Lady Tata Memorial Trust. We would like to thank Dr T Kitamura ( University of Tokyo) for PlatE packaging cells and Dr D Baltimore ( California Institute of Technology) for pMIG vector.	ALDERTON G, 2007, NATURE REV CANC, V7, P570; Bai SH, 2006, CRIT REV THER DRUG, V23, P437, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i6.10; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; Forster A, 2005, COLD SH Q B, V70, P275, DOI 10.1101/sqb.2005.70.008; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Holt L J, 2000, Nucleic Acids Res, V28, pE72, DOI 10.1093/nar/28.15.e72; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; NEALE GAM, 1995, BLOOD, V86, P3060; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; Tanaka T, 2003, EMBO J, V22, P1025, DOI 10.1093/emboj/cdg106; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	26	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4962	4968		10.1038/onc.2008.130	http://dx.doi.org/10.1038/onc.2008.130			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438427				2022-12-25	WOS:000258596900010
J	Frederick, LA; Matthews, JA; Jamieson, L; Justilien, V; Thompson, EA; Radisky, DC; Fields, AP				Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.			Matrix metalloproteinase-10 is a critical effector of protein kinase C iota-Par6 alpha-mediated lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; Rac1; PB1 domain; cellular invasion; anchorage-independent growth	SQUAMOUS-CELL CARCINOMA; C-IOTA; TRANSFORMED GROWTH; EXPRESSION; INVASION; TARGET; CDC42; LINKS; HEAD; NECK	Protein kinase C iota (PKC iota) drives transformed growth of non-small cell lung cancer (NSCLC) cells through the Rho family GTPase Rac1. We show here that PKC iota activates Rac1 in NSCLC cells by formation of a PKC iota-Par6 alpha complex that drives anchorage-independent growth and invasion through activation of matrix metalloproteinase-10 (MMP-10) expression. RNAi-mediated knockdown of PKC iota, Par6 alpha or Rac1 expression inhibits NSCLC transformation and MMP-10 expression in vitro. Expression of wild-type Par6 alpha in Par6 alpha-deficient cells restores transformation and MMP-10 expression, whereas expression of Par6 alpha mutants that either cannot bind PKC iota (Par6 alpha-K19A) or couple to Rac1 (Par6 alpha-Delta CRIB) do not. Knockdown of MMP-10 expression blocks anchorage-independent growth and invasion of NSCLC cells and addition of catalytically active MMP-10 to PKC iota- or Par6 alpha-deficient cells restores anchorage-independent growth and invasion. Dominant-negative PKC iota inhibits tumorigenicity and MMP-10 expression in subcutaneous NSCLC tumors. MMP-10 and PKC iota are coordinately overexpressed in primary NSCLC tumors, and tumor MMP-10 expression predicts poor survival in NSCLC patients. Our data define a PKC iota-Par6 alpha-Rac1 signaling axis that drives anchorage-independent growth and invasion of NSCLC cells through induction of MMP-10 expression.	[Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	NCI NIH HHS [R01 CA081436-11, R01 CA081436, CA081436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bodey B, 2001, IN VIVO, V15, P175; Cho NH, 2004, ONCOGENE, V23, P845, DOI 10.1038/sj.onc.1207140; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Impola U, 2004, J PATHOL, V202, P14, DOI 10.1002/path.1479; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Kren L, 2006, Cesk Patol, V42, P16; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; O-charoenrat P, 2001, ARCH OTOLARYNGOL, V127, P813; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Snaddon J, 2001, BRIT J CANCER, V84, P1630, DOI 10.1054/bjoc.2001.1848; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Van Themsche C, 2004, J IMMUNOL, V173, P3605, DOI 10.4049/jimmunol.173.6.3605; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	26	71	79	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4841	4853		10.1038/onc.2008.119	http://dx.doi.org/10.1038/onc.2008.119			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427549	Green Accepted			2022-12-25	WOS:000258445100009
J	Ng, AN; Toresson, H				Ng, Ai Na; Toresson, Hakan			gamma-secretase and metalloproteinase activity regulate the distribution of endoplasmic reticulum to hippocampal neuron dendritic spines	FASEB JOURNAL			English	Article						synapse; primary culture; live cell imaging	CAPACITATIVE CALCIUM-ENTRY; AMYLOID PRECURSOR PROTEIN; SERIAL ELECTRON-MICROSCOPY; CEREBELLAR PURKINJE-CELLS; PRESENILIN/GAMMA-SECRETASE; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; BIOPHYSICAL CHARACTERISTICS; 3-DIMENSIONAL ORGANIZATION	The neuronal endoplasmic reticulum (ER) contributes to many physiological and pathological processes in the brain. A subset of dendritic spines on hippocampal neurons contains ER that may contribute to synapse-specific intracellular signaling. Distribution of ER to spines is dynamic, but knowledge of the regulatory mechanisms is lacking. In live cell imaging experiments we now show that cultured hippocampal neurons rapidly lost ER from spines after phorbol ester treatment. ER loss was reduced by inhibiting gamma-secretase (DAPT at 2 mu M) and metalloproteinase (TAPI-0 and GM6001 at 4 mu M) activity. Inhibition of protein kinase C also diminished loss of ER by preventing exit of ER from spines. Furthermore, gamma-secretase and metalloproteinase inhibition, in the absence of phorbol ester, triggered a dramatic increase in spine ER content. Metalloproteinases and gamma-secretase cleave several transmembrane proteins. Many of these substrates are known to localize to adherens junctions, a structural specialization with which spine ER interacts. One interesting possibility is thus that ER content within spines may be regulated by proteolytic activity affecting adherens junctions. Our data demonstrate a hitherto unknown role for these two proteolytic activities in regulating dynamic aspects of cellular ultrastructure, which is potentially important for cellular calcium homeostasis and several intracellular signaling pathways.	[Ng, Ai Na; Toresson, Hakan] Lund Univ, Fac Med, Wallenberg Neurosci Ctr, Expt Brain Res Lab, S-22184 Lund, Sweden	Lund University	Toresson, H (corresponding author), Lund Univ, Fac Med, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, S-22184 Lund, Sweden.	hakan.toresson@med.lu.se		Ng, Ai Na/0000-0002-6219-5523				Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Bardo S, 2006, TRENDS PHARMACOL SCI, V27, P78, DOI 10.1016/j.tips.2005.12.008; Begley JG, 1999, J NEUROCHEM, V72, P1030, DOI 10.1046/j.1471-4159.1999.0721030.x; Berridge Michael, 2004, Sci STKE, V2004, ppe33; Bonn S, 2007, MOL CELL BIOL, V27, P4121, DOI 10.1128/MCB.01708-06; Calabrese B, 2005, NEURON, V48, P77, DOI 10.1016/j.neuron.2005.08.027; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Deller T, 2003, P NATL ACAD SCI USA, V100, P10494, DOI 10.1073/pnas.1832384100; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HOLBRO N, 2007, 37 ANN M SOC NEUR; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Huschenbett J, 1998, BBA-BIOMEMBRANES, V1374, P34, DOI 10.1016/S0005-2736(98)00121-7; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kovalchuk Y, 2000, J NEUROSCI, V20, P1791; Kume H, 2003, INT J MOL MED, V12, P57; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; Levine T, 2006, CURR OPIN CELL BIOL, V18, P371, DOI 10.1016/j.ceb.2006.06.011; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Mainen ZF, 1999, NATURE, V399, P151, DOI 10.1038/20187; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Moriguchi S, 2006, P NATL ACAD SCI USA, V103, P10811, DOI 10.1073/pnas.0509863103; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Pierce JP, 2000, NAT NEUROSCI, V3, P311, DOI 10.1038/73868; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Pilpel Y, 2004, EUR J NEUROSCI, V19, P3151, DOI 10.1111/j.0953-816X.2004.03380.x; Putney JW, 2007, CELL CALCIUM, V42, P103, DOI 10.1016/j.ceca.2007.01.011; Rauch U, 2007, BIOCHEM SOC T, V35, P656, DOI 10.1042/BST0350656; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Ris L, 2003, J BIOL CHEM, V278, P44393, DOI 10.1074/jbc.M300971200; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Selkoe DJ, 2007, CELL, V131, P215, DOI 10.1016/j.cell.2007.10.012; SHARP AH, 1993, J NEUROSCI, V13, P3051; Smith IF, 2005, CELL CALCIUM, V38, P427, DOI 10.1016/j.ceca.2005.06.021; Spacek J, 1998, J COMP NEUROL, V393, P58, DOI 10.1002/(SICI)1096-9861(19980330)393:1<58::AID-CNE6>3.0.CO;2-P; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STEWARD O, 1988, J NEUROSCI, V8, P176; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; TAKEI K, 1992, J NEUROSCI, V12, P489; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; Toresson H, 2005, EUR J NEUROSCI, V22, P1793, DOI 10.1111/j.1460-9568.2005.04342.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; WATANABE H, 1976, J NEUROCYTOL, V5, P125, DOI 10.1007/BF01176186; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zatti G, 2006, CELL CALCIUM, V39, P539, DOI 10.1016/j.ceca.2006.03.002; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang M, 2006, FASEB J, V20, P1176, DOI 10.1096/fj.05-5531fje	74	10	10	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2832	2842		10.1096/fj.07-103903	http://dx.doi.org/10.1096/fj.07-103903			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424769				2022-12-25	WOS:000258089300023
J	Inoue, N; Yahagi, N; Yamamoto, T; Ishikawa, M; Watanabe, K; Matsuzaka, T; Nakagawa, Y; Takeuchi, Y; Kobayashi, K; Takahashi, A; Suzuki, H; Hasty, AH; Toyoshima, H; Yamada, N; Shimano, H				Inoue, Noriyuki; Yahagi, Naoya; Yamamoto, Takashi; Ishikawa, Mayumi; Watanabe, Kazuhisa; Matsuzaka, Takashi; Nakagawa, Yoshimi; Takeuchi, Yoshinori; Kobayashi, Kazuto; Takahashi, Akimitsu; Suzuki, Hiroaki; Hasty, Alyssa H.; Toyoshima, Hideo; Yamada, Nobuhiro; Shimano, Hitoshi			Cyclin-dependent kinase inhibitor, p21(WAF1/CIP1), is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-CELLS; TRANSCRIPTION FACTOR; 3T3-L1 PREADIPOCYTES; GROWTH-ARREST; P53; EXPRESSION; MICE; GENE; P21; HYPERPLASIA	Both adipocyte hyperplasia and hypertrophy are determinant factors for adipocyte differentiation during the development of obesity. p21(WAF1/CIP1), a cyclin-dependent kinase inhibitor, is induced during adipocyte differentiation; however, its precise contribution to this process is unknown. Using both in vitro and in vivo systems, we show that p21 is crucial for maintaining adipocyte hypertrophy and obesity-induced insulin resistance. The absence of p21 in 3T3-L1 fibroblasts by RNA-mediated interference knockdown or in embryonic fibroblasts from p21(-/-) mice impaired adipocyte differentiation, resulting in smaller adipocytes. Despite normal adipose tissue mass on a normal diet, p21(-/-) mice fed high energy diets had reduced adipose tissue mass and adipocyte size accompanied by a marked improvement in insulin sensitivity. Knockdown of p21 in enlarged epididymal fat of diet-induced obese mice and also in fully differentiated 3T3-L1 adipocytes caused vigorous apoptosis by activating p53. Thus, p21 is involved in both adipocyte differentiation and in protecting hypertrophied adipocytes against apoptosis. Via both of these mechanisms, p21 promotes adipose tissue expansion during high fat diet feeding, leading to increased downstream pathophysiological consequences such as insulin resistance.	[Inoue, Noriyuki; Yamamoto, Takashi; Ishikawa, Mayumi; Watanabe, Kazuhisa; Nakagawa, Yoshimi; Takeuchi, Yoshinori; Kobayashi, Kazuto; Takahashi, Akimitsu; Suzuki, Hiroaki; Toyoshima, Hideo; Yamada, Nobuhiro; Shimano, Hitoshi] Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Tsukuba, Ibaraki 3058575, Japan; [Yahagi, Naoya; Matsuzaka, Takashi; Shimano, Hitoshi] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; [Yahagi, Naoya; Matsuzaka, Takashi; Shimano, Hitoshi] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; [Hasty, Alyssa H.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Tsukuba; University of Tsukuba; University of Tsukuba; Vanderbilt University	Shimano, H (corresponding author), Univ Tsukuba, Dept Internal Med Metab & Endocrinol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Yahagi, Naoya/D-2360-2014; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Hasty, Alyssa/0000-0001-7302-8045; Shimano, Hitoshi/0000-0002-5562-5572; Watanabe, Kazuhisa/0000-0002-5640-0818				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Auld CA, 2006, OBESITY, V14, P2136, DOI 10.1038/oby.2006.250; Auld CA, 2006, BIOCHEM BIOPH RES CO, V346, P314, DOI 10.1016/j.bbrc.2006.05.117; Berberich SJ, 1999, DIFFERENTIATION, V64, P205, DOI 10.1046/j.1432-0436.1999.6440205.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Constance CM, 1996, MOL CELL BIOL, V16, P3878; Cozar-Castellano I, 2006, DIABETES, V55, P3271, DOI 10.2337/db06-0627; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CUSHMAN SW, 1978, J LIPID RES, V19, P269; EL DW, 1993, CELL, V75, P817; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HARPER JW, 1993, CELL, V75, P805; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; HIRSCH J, 1968, J LIPID RES, V9, P110; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Inoue N, 2005, MOL CELL BIOL, V25, P8938, DOI 10.1128/MCB.25.20.8938-8947.2005; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Naaz A, 2004, FASEB J, V18, P1925, DOI 10.1096/fj.04-2631fje; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakagawa Y, 2006, NAT MED, V12, P107, DOI 10.1038/nm1334; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sakai T, 2007, J BIOL CHEM, V282, P2038, DOI 10.1074/jbc.M608144200; Shieh SY, 2000, GENE DEV, V14, P289; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Uchida T, 2005, NAT MED, V11, P175, DOI 10.1038/nm1187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yahagi N, 2004, J BIOL CHEM, V279, P20571, DOI 10.1074/jbc.M400884200; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Yamada T, 2006, CELL METAB, V3, P223, DOI 10.1016/j.cmet.2006.02.001	42	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					21220	21229		10.1074/jbc.M801824200	http://dx.doi.org/10.1074/jbc.M801824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18445590	hybrid, Green Published			2022-12-25	WOS:000257746100064
J	Yamamoto, M; Unzai, S; Saijo, S; Ito, K; Mizutani, K; Suno-Ikeda, C; Yabuki-Miyata, Y; Terada, T; Toyama, M; Shirouzu, M; Kobayashi, T; Kakinuma, Y; Yamato, I; Yokoyama, S; Iwata, S; Murata, T				Yamamoto, Misaki; Unzai, Satoru; Saijo, Shinya; Ito, Kazuki; Mizutani, Kenji; Suno-Ikeda, Chiyo; Yabuki-Miyata, Yukako; Terada, Takaho; Toyama, Mitsutoshi; Shirouzu, Mikako; Kobayashi, Takuya; Kakinuma, Yoshimi; Yamato, Ichiro; Yokoyama, Shigeyuki; Iwata, So; Murata, Takeshi			Interaction and stoichiometry of the peripheral stalk subunits NtpE and NtpF and the N-terminal hydrophilic domain of NtpI of Enterococcus hirae V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SIZE-DISTRIBUTION ANALYSIS; NA+-TRANSLOCATING ATPASE; ANALYTICAL ULTRACENTRIFUGATION; STATOR; SCATTERING; COMPLEX; ATPASE/SYNTHASE; MACROMOLECULES; BINDING	The vacuolar ATPase (V-ATPase) is composed of a soluble catalytic domain and an integral membrane domain connected by a central stalk and a few peripheral stalks. The number and arrangement of the peripheral stalk subunits remain controversial. The peripheral stalk of Na+-translocating V-ATPase from Enterococcus hirae is likely to be composed of NtpE and NtpF(corresponding to subunit G of eukaryotic V-ATPase) subunits together with the N-terminal hydrophilic domain of NtpI (corresponding to subunit a of eukaryotic V-ATPase). Here we purified NtpE, NtpF, and the N-terminal hydrophilic domain of NtpI (NtpI(Nterm)) as separate recombinant His-tagged proteins and examined interactions between these three subunits by pulldown assay using one tagged subunit, CD spectroscopy, surface plasmon resonance, and analytical ultracentrifugation. NtpI(Nterm) directly bound NtpF, but not NtpE. NtpE bound NtpF tightly. NtpI(Nterm) bound the NtpE-F complex stronger than NtpF only, suggesting that NtpE increases the binding affinity between NtpI(Nterm) and NtpF. Purified NtpE-F-I-Nterm complex appeared to be monodisperse, and the molecular masses estimated from analytical ultracentrifugation and small-angle x-ray scattering (SAXS) indicated that the ternary complex is formed with a 1:1:1 stoichiometry. A low resolution structure model of the complex produced from the SAXS data showed an elongated "L" shape.	[Mizutani, Kenji; Kobayashi, Takuya; Iwata, So; Murata, Takeshi] Kyoto Univ, Dept Cell Biol, Fac Med, Sakyo Ku, Kyoto 6068501, Japan; [Yamamoto, Misaki] Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; [Yamamoto, Misaki; Yabuki-Miyata, Yukako; Terada, Takaho; Toyama, Mitsutoshi; Shirouzu, Mikako; Kakinuma, Yoshimi; Yokoyama, Shigeyuki; Iwata, So; Murata, Takeshi] RIKEN, Genom Sci Ctr, Prot Res Grp, Yokohama, Kanagawa 2300045, Japan; [Unzai, Satoru] Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; [Saijo, Shinya] Japan Synchrotron Radiat Res Inst, Res & Utilizat Div, SPring 8, Sayo, Hyogo 6795198, Japan; [Ito, Kazuki] RIKEN, SPring 8 Ctr, Struct Mat Sci Lab, Sayo, Hyogo 6795198, Japan; [Suno-Ikeda, Chiyo; Kobayashi, Takuya; Iwata, So; Murata, Takeshi] Japan Sci & Technol Agcy, ERATO, Iwata Human Receptor Crystallog Project, Sakyo Ku, Kyoto 6068501, Japan; [Kakinuma, Yoshimi] Ehime Univ, Fac Agr, Lab Mol Physiol & Genet, Matsuyama, Ehime 7908566, Japan; [Yokoyama, Shigeyuki] Univ Tokyo, Dept Biophys & Biochem, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Tokyo University of Science; RIKEN; Yokohama City University; Japan Synchrotron Radiation Research Institute; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Science & Technology Agency (JST); Ehime University; University of Tokyo	Murata, T (corresponding author), Kyoto Univ, Dept Cell Biol, Fac Med, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.	t.murata@mfour.med.kyoto-u.ac.jp	Yamamoto, Masaki/B-7844-2015; Murata, Takeshi/J-6181-2017; Shirouzu, Mikako/A-6521-2016; Ito, Kazuki/A-8776-2015; Yokoyama, Shigeyuki/N-6911-2015; Murata, Takeshi/F-6114-2011	Yamamoto, Masaki/0000-0002-1311-1768; Murata, Takeshi/0000-0002-5748-4670; Ito, Kazuki/0000-0002-8550-6937; Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Bernal RA, 2004, STRUCTURE, V12, P1789, DOI 10.1016/j.str.2004.07.017; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Esteban O, 2008, J BIOL CHEM, V283, P2595, DOI 10.1074/jbc.M704941200; Fethiere J, 2005, BIOCHEMISTRY-US, V44, P15906, DOI 10.1021/bi051762f; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Fujisawa T, 2000, J APPL CRYSTALLOGR, V33, P797, DOI 10.1107/S002188980000131X; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Kakinuma Y, 1999, J BIOENERG BIOMEMBR, V31, P7, DOI 10.1023/A:1005499126939; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; Kawano M, 2002, J BIOL CHEM, V277, P24405, DOI 10.1074/jbc.M200973200; Kigawa Takanori, 2004, Journal of Structural and Functional Genomics, V5, P63, DOI 10.1023/B:JSFG.0000029204.57846.7d; Kish-Trier E, 2008, J MOL BIOL, V375, P673, DOI 10.1016/j.jmb.2007.10.063; Kitagawa N, 2008, J BIOL CHEM, V283, P3329, DOI 10.1074/jbc.M707924200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lolkema JS, 2003, J BIOENERG BIOMEMBR, V35, P323, DOI 10.1023/A:1025776831494; Murata T, 2005, J BIOENERG BIOMEMBR, V37, P411, DOI 10.1007/s10863-005-9481-0; Murata T, 2000, J BIOL CHEM, V275, P13415, DOI 10.1074/jbc.275.18.13415; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 2001, J BIOL CHEM, V276, P48337, DOI 10.1074/jbc.M106821200; Murata T, 2001, BBA-BIOENERGETICS, V1505, P75, DOI 10.1016/S0005-2728(00)00278-4; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; Norgett EE, 2007, J BIOL CHEM, V282, P14421, DOI 10.1074/jbc.M701226200; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Yokoyama K, 2005, J BIOENERG BIOMEMBR, V37, P405, DOI 10.1007/s10863-005-9480-1	39	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19422	19431		10.1074/jbc.M801772200	http://dx.doi.org/10.1074/jbc.M801772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18460472	hybrid			2022-12-25	WOS:000257387600028
J	Gakovic, M; Ragimbeau, J; Francois, V; Constantinescu, SN; Pellegrini, S				Gakovic, Milica; Ragimbeau, Josiane; Francois, Veronique; Constantinescu, Stefan N.; Pellegrini, Sandra			The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE TYK2; ERYTHROPOIETIN RECEPTOR; POLYCYTHEMIA-VERA; CYTOKINE RECEPTOR; MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; PSEUDOKINASE DOMAIN; JAK2 MUTATION; CANCER CELLS; DUAL ROLE	Tyk2 is a Jak family member involved in cytokine signaling through heterodimeric-type receptors. Here, we analyzed the impact of the Val(678)-to-Phe substitution on Tyk2 functioning. This mutation is homologous to the Jak2 Val(617)-to-Phe mutation, implicated in myeloproliferative disorders. We studied ligand-independent and ligand-dependent Jak/Stat signaling in cells expressing Tyk2 V678F. Moreover, the effect of Tyk2 V678F was monitored in the context of the native heterodimeric interferon alpha receptor and in the context of a homodimeric receptor chimera, EpoR/R1, containing the ectodomain of the erythropoietin receptor. We show that Tyk2 V678F has increased catalytic potential in vivo and in vitro and more so when it is anchored to the homodimeric receptor. Tyk2 V678F leads to constitutive Stat3 phosphorylation but has no notable effect on the canonical interferon alpha-induced signaling. However, if anchored to the homodimeric EpoR/R1, the mutant confers to the cell increased sensitivity to erythropoietin. Thus, despite the catalytic gain of function of Tyk2 V678F, the effect on ligand-induced signaling is manifest only when two mutant enzymes are juxtaposed via the homodimeric receptor.	[Gakovic, Milica; Ragimbeau, Josiane; Francois, Veronique; Pellegrini, Sandra] Inst Pasteur, Cytokine Signaling Unit, CNRS, URA 1961, F-75724 Paris, France; [Constantinescu, Stefan N.] Ludwig Inst Canc Res, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ludwig Institute for Cancer Research	Pellegrini, S (corresponding author), Inst Pasteur, Cytokine Signaling Unit, CNRS, URA 1961, 25 Rue Docteur Roux, F-75724 Paris, France.	pellegri@pasteur.fr	Constantinescu, Stefan N/E-5277-2012; Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Constantinescu, Stefan N./0000-0002-8599-2699				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Chen M, 2000, MOL CELL BIOL, V20, P947, DOI 10.1128/MCB.20.3.947-956.2000; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Donnelly RP, 2004, J LEUKOCYTE BIOL, V76, P314, DOI 10.1189/jlb.0204117; Funakoshi-Tago M, 2008, MOL CELL BIOL, V28, P1792, DOI 10.1128/MCB.01447-07; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Haan S, 2008, J IMMUNOL, V180, P998, DOI 10.4049/jimmunol.180.2.998; Ide H, 2008, BIOCHEM BIOPH RES CO, V369, P292, DOI 10.1016/j.bbrc.2007.08.160; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Knoops L, 2008, ONCOGENE, V27, P1511, DOI 10.1038/sj.onc.1210800; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levy DE, 2006, P NATL ACAD SCI USA, V103, P10151, DOI 10.1073/pnas.0604042103; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Lindauer K, 2001, PROTEIN ENG, V14, P27, DOI 10.1093/protein/14.1.27; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Marijanovic Z, 2006, BIOCHEM J, V397, P31, DOI 10.1042/BJ20060272; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Pattyn E, 1999, J BIOL CHEM, V274, P34838, DOI 10.1074/jbc.274.49.34838; Pradhan A, 2007, P NATL ACAD SCI USA, V104, P18502, DOI 10.1073/pnas.0702388104; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shide K, 2007, LEUKEMIA RES, V31, P1077, DOI 10.1016/j.leukres.2006.08.018; Song XC, 2008, MOL CELL PROTEOMICS, V7, P163, DOI 10.1074/mcp.M700115-MCP200; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Uze G, 2007, CURR TOP MICROBIOL, V316, P71; Uze G, 2007, BIOCHIMIE, V89, P729, DOI 10.1016/j.biochi.2007.01.008; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Walters DK, 2006, LEUKEMIA RES, V30, P1097, DOI 10.1016/j.leukres.2006.01.001; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; Zheng HY, 2005, MOL CELL PROTEOMICS, V4, P721, DOI 10.1074/mcp.M400077-MCP200; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	41	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18522	18529		10.1074/jbc.M801427200	http://dx.doi.org/10.1074/jbc.M801427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18456658	hybrid			2022-12-25	WOS:000257165600007
J	Hauptmann, P; Lehle, L				Hauptmann, Peter; Lehle, Ludwig			Kex1 protease is involved in yeast cell death induced by defective N-glycosylation, acetic acid, and chronological aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; SACCHAROMYCES-CEREVISIAE; OLIGOSACCHARYLTRANSFERASE COMPLEX; INDUCED APOPTOSIS; MITOCHONDRIAL FISSION; REGULATES APOPTOSIS; MEDIATED APOPTOSIS; CYSTEINE PROTEASES; MESSENGER-RNA; BUDDING YEAST	N-Glycosylation in the endoplasmic reticulum is an essential protein modification and highly conserved in evolution from yeast to humans. The key step of this pathway is the transfer of the lipid-linked core oligosaccharide to the nascent polypeptide chain, catalyzed by the oligosaccharyltransferase complex. Temperature-sensitive oligosaccharyltransferase mutants of Saccharomyces cerevisiae at the restrictive temperature, such as wbp1-1, as well as wild-type cells in the presence of the N-glycosylation inhibitor tunicamycin display typical apoptotic phenotypes like nuclear condensation, DNA fragmentation, phosphatidylserine translocation, caspase-like activity, and reactive oxygen species accumulation. Since deletion of the yeast metacaspase YCA1 did not abrogate this death pathway, we postulated a different proteolytic process to be responsible. Here, we show that Kex1 protease is involved in the programmed cell death caused by defective N-glycosylation. Its disruption decreases caspase-like activity, production of reactive oxygen species, and fragmentation of mitochondria and, conversely, improves growth and survival of cells. Moreover, we demonstrate that Kex1 contributes also to the active cell death program induced by acetic acid stress or during chronological aging, suggesting that Kex1 plays a more general role in cellular suicide of yeast.	[Hauptmann, Peter; Lehle, Ludwig] Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany	University of Regensburg	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	ludwig.lehle@biologie.uni-regensburg.de						Almeida B, 2007, J CELL SCI, V120, P3279, DOI 10.1242/jcs.010926; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bettiga M, 2004, FEMS YEAST RES, V5, P141, DOI 10.1016/j.femsyr.2004.07.005; Boise LH, 2001, TRENDS MICROBIOL, V9, P64, DOI 10.1016/S0966-842X(00)01937-5; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Burhans WC, 2003, MUTAT RES-FUND MOL M, V532, P227, DOI 10.1016/j.mrfmmm.2003.08.019; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fahrenkrog B, 2004, J CELL SCI, V117, P115, DOI 10.1242/jcs.00848; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Flower TR, 2005, J MOL BIOL, V351, P1081, DOI 10.1016/j.jmb.2005.06.060; Frohlich KU, 2007, SEMIN CANCER BIOL, V17, P112, DOI 10.1016/j.semcancer.2006.11.006; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Giannattasio S, 2005, GENE, V354, P93, DOI 10.1016/j.gene.2005.03.030; GOURLAY C, 2006, MOL MICROBIOL; Granot D, 2003, FEMS YEAST RES, V4, P7, DOI 10.1016/S1567-1356(03)00154-5; Guaragnella N, 2006, FEBS LETT, V580, P6880, DOI 10.1016/j.febslet.2006.11.050; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hardwick JM, 2004, DEV CELL, V7, P630, DOI 10.1016/j.devcel.2004.10.013; Hauptmann P, 2006, MOL MICROBIOL, V59, P765, DOI 10.1111/j.1365-2958.2005.04981.x; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Huh GH, 2002, PLANT J, V29, P649, DOI 10.1046/j.0960-7412.2001.01247.x; Jaeken J, 2004, CURR OPIN PEDIATR, V16, P434, DOI 10.1097/01.mop.0000133636.56790.4a; Kerr JFR, 2002, TOXICOLOGY, V181, P471, DOI 10.1016/S0300-483X(02)00457-2; Khan MAS, 2005, P NATL ACAD SCI USA, V102, P17326, DOI 10.1073/pnas.0508120102; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; LATCHINIANSADEK L, 1993, J BIOL CHEM, V268, P534; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; Lehle L, 2006, ANGEW CHEM INT EDIT, V45, P6802, DOI 10.1002/anie.200601645; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Lesage G, 2006, MICROBIOL MOL BIOL R, V70, P317, DOI 10.1128/MMBR.00038-05; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Li W, 2006, MOL BIOL CELL, V17, P1802, DOI 10.1091/mbc.E05-04-0333; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Ludovico P, 2005, IUBMB LIFE, V57, P129, DOI 10.1080/15216540500090553; Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mazzoni C, 2005, EMBO REP, V6, P1076, DOI 10.1038/sj.embor.7400514; Mitsui K, 2005, FEBS LETT, V579, P723, DOI 10.1016/j.febslet.2004.12.051; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Narasimhan ML, 2001, MOL CELL, V8, P921, DOI 10.1016/S1097-2765(01)00365-3; Niederer KE, 2005, CELL SIGNAL, V17, P177, DOI 10.1016/j.cellsig.2004.06.009; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Qiu JZ, 2005, J BIOL CHEM, V280, P15370, DOI 10.1074/jbc.M413547200; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Reiter J, 2005, J CELL BIOL, V168, P353, DOI 10.1083/jcb.200408071; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Saraiva L, 2006, J CELL SCI, V119, P3171, DOI 10.1242/jcs.03033; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schulz JB, 1996, J NEUROSCI, V16, P4696; Silva RD, 2005, MOL MICROBIOL, V58, P824, DOI 10.1111/j.1365-2958.2005.04868.x; Skulachev VP, 2002, FEBS LETT, V528, P23, DOI 10.1016/S0014-5793(02)03319-7; Sugiura M, 2006, BIOSCI BIOTECH BIOCH, V70, P1234, DOI 10.1271/bbb.70.1234; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vachova L, 2005, J CELL BIOL, V169, P711, DOI 10.1083/jcb.200410064; Vachova L, 2004, J BIOL CHEM, V279, P37973, DOI 10.1074/jbc.M404594200; Vachova L, 2007, FEMS YEAST RES, V7, P12, DOI 10.1111/j.1567-1364.2006.00137.x; Vercammen D, 2007, J CELL BIOL, V179, P375, DOI 10.1083/jcb.200705193; Wadskog I, 2004, MOL BIOL CELL, V15, P1436, DOI 10.1091/mbc.E03-02-0114; Walter D, 2006, J CELL SCI, V119, P1843, DOI 10.1242/jcs.02902; Watanabe N, 2005, J BIOL CHEM, V280, P14691, DOI 10.1074/jbc.M413527200; Weinberger M, 2005, J CELL SCI, V118, P3543, DOI 10.1242/jcs.02477; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wysocki R, 2004, J CELL BIOL, V166, P311, DOI 10.1083/jcb.200405016; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697	89	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					19151	19163		10.1074/jbc.M801303200	http://dx.doi.org/10.1074/jbc.M801303200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474590	hybrid			2022-12-25	WOS:000257165600070
J	Lee, AM; Rojek, JM; Spiropoulou, CF; Gundersen, AT; Jin, W; Shaginian, A; York, J; Nunberg, JH; Boger, DL; Oldstone, MBA; Kunz, S				Lee, Andrew M.; Rojek, Jillian M.; Spiropoulou, Christina F.; Gundersen, Anette T.; Jin, Wei; Shaginian, Alex; York, Joanne; Nunberg, Jack H.; Boger, Dale L.; Oldstone, Michael B. A.; Kunz, Stefan			Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PHASE COMBINATORIAL LIBRARIES; STABLE SIGNAL PEPTIDE; LASSA FEVER; ENVELOPE GLYCOPROTEIN; ALPHA-DYSTROGLYCAN; CELLULAR RECEPTOR; INTEGRIN ALPHA(V)BETA(3); IMINODIACETIC ACID; PROTEIN-PROTEIN	Viral hemorrhagic fevers caused by the arenaviruses Lassa virus in Africa and Machupo, Guanarito, Junin, and Sabia virus in South America are among the most devastating emerging human diseases with fatality rates of 15-35% and a limited antiviral therapeutic repertoire available. Here we used high throughput screening of synthetic combinatorial small molecule libraries to identify inhibitors of arenavirus infection using pseudotyped virion particles bearing the glycoproteins (GPs) of highly pathogenic arenaviruses. Our screening efforts resulted in the discovery of a series of novel small molecule inhibitors of viral entry that are highly active against both Old World and New World hemorrhagic arenaviruses. We observed potent inhibition of infection of human and primate cells with live hemorrhagic arenaviruses (IC50 = 500-800 nM). Investigations of the mechanism of action revealed that the candidate compounds efficiently block pH-dependent fusion by the arenavirus GPs (IC50 of 200-350 nM). Although our lead compounds were potent against phylogenetically distant arenaviruses, they did not show activity against other enveloped viruses with class I viral fusion proteins, indicating specificity for arenavirus GP-mediated membrane fusion.	[Kunz, Stefan] Univ Hosp Ctr, Inst Microbiol, CH-1011 Lausanne, Switzerland; [Kunz, Stefan] Univ Lausanne, CH-1011 Lausanne, Switzerland; [Lee, Andrew M.; Rojek, Jillian M.; Gundersen, Anette T.; Oldstone, Michael B. A.; Kunz, Stefan] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Jin, Wei; Shaginian, Alex; Boger, Dale L.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Oldstone, Michael B. A.] Scripps Res Inst, Dept Infectol, La Jolla, CA 92037 USA; [Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA; [York, Joanne; Nunberg, Jack H.] Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA	University of Lausanne; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Centers for Disease Control & Prevention - USA; University of Montana System; University of Montana	Kunz, S (corresponding author), Univ Hosp Ctr, Inst Microbiol, CH-1011 Lausanne, Switzerland.	Stefan.Kunz@chuv.ch	Pacific-Southwest, RCE/B-6155-2009; Lee, Andrew/G-5470-2011; Kunz, Stefan/K-5840-2017	Kunz, Stefan/0000-0001-6030-9550	NATIONAL CANCER INSTITUTE [P01CA078045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074818, U54AI065359, R21AI055540, R01AI055540] Funding Source: NIH RePORTER; NCI NIH HHS [CA78045] Funding Source: Medline; NIAID NIH HHS [1U54 AI065359, AI55540, R01 AI074818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Boger DL, 2003, ANGEW CHEM INT EDIT, V42, P4138, DOI 10.1002/anie.200300574; Boger DL, 1998, BIOORGAN MED CHEM, V6, P1347, DOI 10.1016/S0968-0896(98)00128-X; Boger DL, 2001, J AM CHEM SOC, V123, P1280, DOI 10.1021/ja003579+; Boger DL, 2000, HELV CHIM ACTA, V83, P1825, DOI 10.1002/1522-2675(20000809)83:8<1825::AID-HLCA1825>3.0.CO;2-4; Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; BORROW P, 1992, J VIROL, V66, P7270, DOI 10.1128/JVI.66.12.7270-7281.1992; BORROW P, 1994, VIROLOGY, V198, P1, DOI 10.1006/viro.1994.1001; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; CASTILLA V, 1994, ARCH VIROL, V136, P363, DOI 10.1007/BF01321064; Cheng S, 1996, BIOORGAN MED CHEM, V4, P727, DOI 10.1016/0968-0896(96)00069-7; Cianci C, 2004, P NATL ACAD SCI USA, V101, P15046, DOI 10.1073/pnas.0406696101; Clegg JCS, 2002, CURR TOP MICROBIOL, V262, P1; Eichler R, 2003, EMBO REP, V4, P1084, DOI 10.1038/sj.embor.7400002; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; Eschli B, 2006, J VIROL, V80, P5897, DOI 10.1128/JVI.00008-06; Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6; Flanagan ML, 2008, J VIROL, V82, P938, DOI 10.1128/JVI.01397-07; Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Goldberg J, 2002, J AM CHEM SOC, V124, P544, DOI 10.1021/ja0118789; Isaacson M, 2001, CLIN INFECT DIS, V33, P1707, DOI 10.1086/322620; Kunz S, 2005, J VIROL, V79, P5979, DOI 10.1128/JVI.79.10.5979-5987.2005; Martinez MG, 2007, J GEN VIROL, V88, P1776, DOI 10.1099/vir.0.82808-0; McCormick JB, 2002, CURR TOP MICROBIOL, V262, P75; Peters CJ, 2002, CURR TOP MICROBIOL, V262, P65; Plemper RK, 2004, P NATL ACAD SCI USA, V101, P5628, DOI 10.1073/pnas.0308520101; Radoshitzky SR, 2007, NATURE, V446, P92, DOI 10.1038/nature05539; Reignier T, 2008, VIROLOGY, V371, P439, DOI 10.1016/j.virol.2007.10.004; Roche S, 2007, SCIENCE, V315, P843, DOI 10.1126/science.1135710; Rojek JA, 2007, J VIROL, V81, P5685, DOI 10.1128/JVI.02574-06; Rojek JM, 2008, J VIROL, V82, P1505, DOI 10.1128/JVI.01331-07; Rojek JM, 2006, VIROLOGY, V349, P476, DOI 10.1016/j.virol.2006.02.033; Rose JK, 2001, FIELDS VIROLOGY, P1221; Schmitz H, 2002, MICROBES INFECT, V4, P43, DOI 10.1016/S1286-4579(01)01508-8; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Spiropoulou CF, 2002, J VIROL, V76, P5140, DOI 10.1128/JVI.76.10.5140-5146.2002; Weissenbacher M C, 1987, Curr Top Microbiol Immunol, V134, P79; Weissenhorn W, 2007, FEBS LETT, V581, P2150, DOI 10.1016/j.febslet.2007.01.093; York J, 2004, J VIROL, V78, P10783, DOI 10.1128/JVI.78.19.10783-10792.2004; York J., 2007, J VIROL, V10, P10; York J, 2007, VIROLOGY, V359, P72, DOI 10.1016/j.virol.2006.08.048; York J, 2006, J VIROL, V80, P7775, DOI 10.1128/JVI.00642-06	44	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18734	18742		10.1074/jbc.M802089200	http://dx.doi.org/10.1074/jbc.M802089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18474596	hybrid, Green Published			2022-12-25	WOS:000257165600030
J	Huang, HS; Lee, EYC				Huang, Hua-Shan; Lee, Ernest Y. C.			Protein phosphatase-1 inhibitor-3 is an in vivo target of caspase-3 and participates in the apoptotic response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPRIVATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; CATALYTIC SUBUNIT; HL-60 CELLS; DNA-DAMAGE; PHOSPHORYLASE-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; PROTEOLYTIC ACTIVATION; BAD; BCL-2	Inh3 (inhibitor-3) is a potent inhibitor of protein phosphatase-1 that selectively associates with PP1 gamma 1 and PP1 alpha but not the PP1 beta isoform. We demonstrate that Inh3 is a novel substrate for caspase-3 and is degraded in vivo during apoptosis induced by actinomycin D. Inh3 was not degraded in apoptotic MCF-7 cells, which lack caspase-3. These experiments establish that Inh3 is a novel physiological substrate of caspase-3. Electroporation of the caspase-3-resistant Inh3-D49A mutant into HL-60 cells resulted in a significant attenuation of apoptosis induced by actinomycin D. These results show that Inh3 degradation contributes to the apoptotic process. Immunofluorescence based examination of the subcellular localizations of Inh3 and PP1 gamma 1 revealed a major relocalization of the cellular pool of PP1 gamma 1 from the nucleolus to the nucleus and then to the cytoplasm during actinomycin D-induced apoptosis. A similar redistribution of PP1 alpha from the nucleus to the cytoplasm occurred. These results are consistent with an unexpected discovery that significant fractions of the cellular pools of PP1 gamma 1 and PP1 alpha are associated with Inh3 in HL-60 cells. Thus, Inh3 is a major factor in the cellular economy of PP1 gamma 1 and PP1 alpha subunits. The unscheduled relocalization of this large a pool of PP1 subunits and their release from a potent inhibitor could deregulate a diverse range of essential cellular processes and signaling pathways. We discuss the significance of these findings in relation to working hypotheses whereby Inh3 destruction could contribute to the apoptotic process.	[Huang, Hua-Shan; Lee, Ernest Y. C.] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, EYC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Ernest_Lee@NYMC.edu			PHS HHS [18512] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Ayllon V, 2002, EUR J IMMUNOL, V32, P1847, DOI 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7; Ayllon V, 2001, J IMMUNOL, V166, P7345, DOI 10.4049/jimmunol.166.12.7345; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; BRANDT H, 1975, BIOCHEM BIOPH RES CO, V63, P950, DOI 10.1016/0006-291X(75)90661-0; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Connor JH, 1998, METH MOL B, V93, P41; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; Dessauge F, 2006, J IMMUNOL, V177, P2441, DOI 10.4049/jimmunol.177.4.2441; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Ferguson HA, 2003, J BIOL CHEM, V278, P45793, DOI 10.1074/jbc.M307979200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Huang HS, 2005, ARCH BIOCHEM BIOPHYS, V443, P33, DOI 10.1016/j.abb.2005.08.021; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee Ernest Y. C., 1999, Frontiers in Bioscience, V4, pD270, DOI 10.2741/Lee; Lesage B, 2007, BIOCHEMISTRY-US, V46, P8909, DOI 10.1021/bi7003119; Li MG, 2007, BIOCHEMISTRY-US, V46, P2380, DOI 10.1021/bi602369m; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lu Q, 1996, ARCH BIOCHEM BIOPHYS, V334, P175, DOI 10.1006/abbi.1996.0443; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186; Martelli AM, 2000, J CELL BIOCHEM, V78, P264, DOI 10.1002/(SICI)1097-4644(20000801)78:2<264::AID-JCB9>3.0.CO;2-3; MARTIN SJ, 1990, BIOCHEM SOC T, V18, P634, DOI 10.1042/bst0180634; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Satinover DL, 2006, CELL CYCLE, V5, P2268, DOI 10.4161/cc.5.19.3316; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Tamura S, 2006, CANCER SCI, V97, P563, DOI 10.1111/j.1349-7006.2006.00219.x; Tembe V, 2007, CELL SIGNAL, V19, P1113, DOI 10.1016/j.cellsig.2007.03.001; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Tsiftsoglou AS, 2003, PHARMACOL THERAPEUT, V100, P257, DOI 10.1016/j.pharmthera.2003.09.002; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829; Wen LP, 1998, CELL DEATH DIFFER, V5, P729, DOI 10.1038/sj.cdd.4400409; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	74	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18135	18146		10.1074/jbc.M709735200	http://dx.doi.org/10.1074/jbc.M709735200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450750	Green Published, hybrid			2022-12-25	WOS:000256949200042
J	Kad, NM; Trybus, KM; Warshaw, DM				Kad, Neil M.; Trybus, Kathleen M.; Warshaw, David M.			Load and P-i control flux through the branched kinetic cycle of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEVER-ARM; DEPENDENT KINETICS; STEPPING KINETICS; PROCESSIVE MYOSIN; SMOOTH-MUSCLE; LASER TRAP; ACTIN; MOTOR; BINDING; CELLS	Myosin V is a processive actin-based motor protein that takes multiple 36-nm steps to deliver intracellular cargo to its destination. In the laser trap, applied load slows myosin V heavy meromyosin stepping and increases the probability of backsteps. In the presence of 40 mM phosphate (P-i), both forward and backward steps become less load-dependent. From these data, we infer that P-i release commits myosin V to undergo a highly load-dependent transition from a state in which ADP is bound to both heads and its lead head trapped in a pre-powerstroke conformation. Increasing the residence time in this state by applying load increases the probability of backstepping or detachment. The kinetics of detachment indicate that myosin V can detach from actin at two distinct points in the cycle, one of which is turned off by the presence of P-i. We propose a branched kinetic model to explain these data. Our model includes P-i release prior to the most load-dependent step in the cycle, implying that P-i release and load both act as checkpoints that control the flux through two parallel pathways.	[Kad, Neil M.; Trybus, Kathleen M.; Warshaw, David M.] Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Warshaw, DM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.	warshaw@physiology.med.uvm.edu	Kad, Neil/G-6746-2012	Kad, Neil/0000-0002-3491-8595	NHLBI NIH HHS [HL085489, HL059408] Funding Source: Medline; NIGMS NIH HHS [GM078097] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085489, P01HL059408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078097] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali MY, 2007, P NATL ACAD SCI USA, V104, P4332, DOI 10.1073/pnas.0611471104; Ali MY, 2002, NAT STRUCT BIOL, V9, P464, DOI 10.1038/nsb803; Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Carter NJ, 2005, NATURE, V435, P308, DOI 10.1038/nature03528; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Clemen AEM, 2005, BIOPHYS J, V88, P4402, DOI 10.1529/biophysj.104.053504; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Forgacs E, 2008, J BIOL CHEM, V283, P766, DOI 10.1074/jbc.M704313200; Gebhardt JCM, 2006, P NATL ACAD SCI USA, V103, P8680, DOI 10.1073/pnas.0510191103; Gennerich A, 2007, CELL, V131, P952, DOI 10.1016/j.cell.2007.10.016; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Kad NM, 2007, BIOPHYS J, V92, P1623, DOI 10.1529/biophysj.106.097618; Kad NM, 2003, J CELL BIOL, V162, P481, DOI 10.1083/jcb.200304023; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LI SJ, 1992, J BIOL CHEM, V267, P855; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Nishiyama M, 2002, NAT CELL BIOL, V4, P790, DOI 10.1038/ncb857; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schott DH, 2002, J CELL BIOL, V156, P35, DOI 10.1083/jcb.200110086; Steffen W, 2001, P NATL ACAD SCI USA, V98, P14949, DOI 10.1073/pnas.261560698; Takagi Y, 2004, PHILOS T R SOC B, V359, P1913, DOI 10.1098/rstb.2004.1561; Thirumurugan K, 2006, NATURE, V442, P212, DOI 10.1038/nature04865; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Vilfan A, 2005, BIOPHYS J, V88, P3792, DOI 10.1529/biophysj.104.046763; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Warshaw DM, 2005, BIOPHYS J, V88, pL30, DOI 10.1529/biophysj.105.061903; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124	43	52	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17477	17484		10.1074/jbc.M800539200	http://dx.doi.org/10.1074/jbc.M800539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18441369	Green Published, hybrid			2022-12-25	WOS:000256720600055
J	Wegner, AM; Nebhan, CA; Hu, L; Majumdar, D; Meier, KM; Weaver, AM; Webb, DJ				Wegner, Adam M.; Nebhan, Caroline A.; Hu, Lan; Majumdar, Devi; Meier, Kristen M.; Weaver, Alissa M.; Webb, Donna J.			N-WASP and the Arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; POSTSYNAPTIC DENSITIES; MOLECULAR-MECHANISMS; GROWTH-FACTOR; POLYMERIZATION; MORPHOGENESIS; CDC42; NUCLEATION; PLASTICITY; FILAMENTS	Changes in the number, size, and shape of dendritic spines are associated with synaptic plasticity, which underlies cognitive functions such as learning and memory. This plasticity is attributed to reorganization of actin, but the molecular signals that regulate this process are poorly understood. In this study, we show neural Wiskott-Aldrich syndrome protein (N-WASP) regulates the formation of dendritic spines and synapses in hippocampal neurons. N-WASP localized to spines and active, functional synapses as shown by loading with FM4-64 dye. Knock down of endogenous N-WASP expression by RNA interference or inhibition of its activity by treatment with a specific inhibitor, wiskostatin, caused a significant decrease in the number of spines and excitatory synapses. Deletion of the C-terminal VCA region of N-WASP, which binds and activates the actin-related protein 2/3 (Arp2/3) complex, dramatically decreased the number of spines and synapses, suggesting activation of the Arp2/3 complex is critical for spine and synapse formation. Consistent with this, Arp3, likeN-WASP, was enriched in spines and excitatory synapses and knock down of Arp3 expression impaired spine and synapse formation. A similar defect in spine and synapse formation was observed when expression of an N-WASP activator, Cdc42, was knocked down. Thus, activation of N-WASP and, subsequently, the Arp2/3 complex appears to be an important molecular signal for regulating spines and synapses. Arp2/3-mediated branching of actin could be a mechanism by which dendritic spine heads enlarge and subsequently mature. Collectively, our results point to a critical role for N-WASP and the Arp2/3 complex in spine and synapse formation.	[Weaver, Alissa M.; Webb, Donna J.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [Nebhan, Caroline A.; Hu, Lan; Majumdar, Devi; Meier, Kristen M.; Webb, Donna J.] Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37235 USA; [Wegner, Adam M.] Vanderbilt Univ, Grad Program Neurosci, Nashville, TN 37235 USA; [Nebhan, Caroline A.; Hu, Lan; Majumdar, Devi; Meier, Kristen M.; Webb, Donna J.] Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Webb, DJ (corresponding author), VU Stn B,Box 35-1634, Nashville, TN 37235 USA.	donna.webb@vanderbilt.edu		Wegner, Adam/0000-0001-5862-800X; Sochol, Kristen/0000-0003-4865-6909	NIGMS NIH HHS [T32 GM007347] Funding Source: Medline; NIMH NIH HHS [R01 MH071674, MH071674] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allison DW, 1998, J NEUROSCI, V18, P2423; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Dailey ME, 1996, J NEUROSCI, V16, P2983; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GASLIN K, 1998, RAT HIPPOCAMPAL NEUR, P339; Govek EE, 2004, NAT NEUROSCI, V7, P364, DOI 10.1038/nn1210; Harris KM, 1999, CURR OPIN NEUROBIOL, V9, P343, DOI 10.1016/S0959-4388(99)80050-6; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Kempiak SJ, 2005, J BIOL CHEM, V280, P5836, DOI 10.1074/jbc.M410713200; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nishimura T, 2006, MOL BIOL CELL, V17, P1273, DOI 10.1091/mbc.E05-07-0700; Node-Langlois R, 2006, J CELL SCI, V119, P4986, DOI 10.1242/jcs.03273; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Saito T, 2007, J BIOL CHEM, V282, P32280, DOI 10.1074/jbc.M704150200; Scott EK, 2003, J NEUROSCI, V23, P3118; Shen WH, 2006, NEURON, V50, P401, DOI 10.1016/j.neuron.2006.03.017; Steffen A, 2006, MOL BIOL CELL, V17, P2581, DOI 10.1091/mbc.E05-11-1088; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Tsuchiya D, 2006, NEUROSCI RES, V56, P459, DOI 10.1016/j.neures.2006.09.007; Udo H, 2005, NEURON, V45, P887, DOI 10.1016/j.neuron.2005.01.044; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zhang HY, 2008, DEV CELL, V14, P216, DOI 10.1016/j.devcel.2007.11.020; Zhang HY, 2003, J CELL BIOL, V161, P131, DOI 10.1083/jcb.200211002; Zhang HY, 2005, J NEUROSCI, V25, P3379, DOI 10.1523/JNEUROSCI.3553-04.2005; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	49	161	165	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15912	15920		10.1074/jbc.M801555200	http://dx.doi.org/10.1074/jbc.M801555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18430734	hybrid, Green Published			2022-12-25	WOS:000256332500050
J	Bowlin, MS; Wikelski, M				Bowlin, Melissa S.; Wikelski, Martin			Pointed Wings, Low Wingloading and Calm Air Reduce Migratory Flight Costs in Songbirds	PLOS ONE			English	Article							METABOLIC-RATE; BIRDS; SHAPE; PERFORMANCE; FIELD	Migratory bird, bat and insect species tend to have more pointed wings than non-migrants. Pointed wings and low wingloading, or body mass divided by wing area, are thought to reduce energy consumption during long-distance flight, but these hypotheses have never been directly tested. Furthermore, it is not clear how the atmospheric conditions migrants encounter while aloft affect their energy use; without such information, we cannot accurately predict migratory species' response(s) to climate change. Here, we measured the heart rates of 15 free-flying Swainson's Thrushes (Catharus ustulatus) during migratory flight. Heart rate, and therefore rate of energy expenditure, was positively associated with individual variation in wingtip roundedness and wingloading throughout the flights. During the cruise phase of the flights, heart rate was also positively associated with wind speed but not wind direction, and negatively but not significantly associated with large-scale atmospheric stability. High winds and low atmospheric stability are both indicative of the presence of turbulent eddies, suggesting that birds may be using more energy when atmospheric turbulence is high. We therefore suggest that pointed wingtips, low wingloading and avoidance of high winds and turbulence reduce flight costs for small birds during migration, and that climate change may have the strongest effects on migrants' in-flight energy use if it affects the frequency and/or severity of high winds and atmospheric instability.	[Bowlin, Melissa S.; Wikelski, Martin] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ USA	Princeton University	Bowlin, MS (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ USA.	melissa.bowlin@mso.umt.edu			Society for Integrative and Comparative Biology; Cooper Ornithological Society; American Ornithologists' Union; Princeton University's Department of Ecology and Evolutionary Biology; National Geographic Society; NSF DDIG [IOB-0608252]	Society for Integrative and Comparative Biology; Cooper Ornithological Society; American Ornithologists' Union; Princeton University's Department of Ecology and Evolutionary Biology(Princeton University); National Geographic Society(National Geographic Society); NSF DDIG(National Science Foundation (NSF))	Financial assistance was provided by the Society for Integrative and Comparative Biology, the Cooper Ornithological Society, the American Ornithologists' Union, Princeton University's Department of Ecology and Evolutionary Biology, the National Geographic Society, and an NSF DDIG (#IOB-0608252). None of these funding organizations played any role in designing, carrying out, or writing up the study.	BIEBACH H, 1992, IBIS, V134, P47; Bowlin MS, 2007, AUK, V124, P1388, DOI 10.1642/0004-8038(2007)124[1388:SWSAWP]2.0.CO;2; Bowlin MS, 2005, INTEGR COMP BIOL, V45, P295, DOI 10.1093/icb/45.2.295; Burns JG, 2002, BEHAV ECOL SOCIOBIOL, V52, P128, DOI 10.1007/s00265-002-0494-y; Butler PJ, 2004, FUNCT ECOL, V18, P168, DOI 10.1111/j.0269-8463.2004.00821.x; Cochran W.W., 1985, Illinois Natural History Survey Bulletin, V33, P297; Cochran William W., 2005, P274; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed., DOI DOI 10.4324/9780203771587; Hedenstrom A, 2002, BEHAV ECOL SOCIOBIOL, V52, P308, DOI 10.1007/s00265-002-0504-0; Jonzen N, 2006, SCIENCE, V312, P1959, DOI 10.1126/science.1126119; Keller LF, 2001, HEREDITY, V87, P325, DOI 10.1046/j.1365-2540.2001.00900.x; Kerlinger P., 1989, Current Ornithology, V6, P109; Klaassen M, 2000, CONDOR, V102, P444, DOI 10.1650/0010-5422(2000)102[0444:FCAFCO]2.0.CO;2; Klaassen M, 2004, J AVIAN BIOL, V35, P4; Klaassen M, 1996, J EXP BIOL, V199, P57; Kvist A, 2001, NATURE, V413, P730, DOI 10.1038/35099556; Liechti F, 2006, J ORNITHOL, V147, P202, DOI 10.1007/s10336-006-0061-9; LINCOLN FC, 1952, MIGRATION BIRDS; Lindstrom A, 1999, FUNCT ECOL, V13, P352, DOI 10.1046/j.1365-2435.1999.00320.x; Lockwood R, 1998, J AVIAN BIOL, V29, P273, DOI 10.2307/3677110; Lutgens F. K., 1998, ATMOSPHERE INTRO MET; Mesinger F, 2006, B AM METEOROL SOC, V87, P343, DOI 10.1175/BAMS-87-3-343; Nisbet I. C. T., 1955, British Birds, V48, P557; Norberg UML, 1990, VERTEBRATE FLIGHT; PENNYCUICK CJ, 1978, OIKOS, V30, P165, DOI 10.2307/3543476; Pennycuick CJ, 1997, J EXP BIOL, V200, P2355; PENNYCUICK CJ, 1972, ANIMAL FLIGHT; Richardson W.J., 1990, P78; Schmaljohann H, 2007, P R SOC B, V274, P735, DOI 10.1098/rspb.2006.0011; SCHMIDTWELLENBU.CA, 2007, THESIS U GRONINGEN N; Sillett TS, 2002, J ANIM ECOL, V71, P296, DOI 10.1046/j.1365-2656.2002.00599.x; Smith RJ, 2005, BEHAV ECOL SOCIOBIOL, V57, P231, DOI 10.1007/s00265-004-0855-9; Stull R.B., 1988, INTRO BOUNDARY LAYER, DOI 10.1007/978-94-009-3027-8; Swaddle JP, 2003, IBIS, V145, P457, DOI 10.1046/j.1474-919X.2003.00189.x; Weimerskirch H, 2001, NATURE, V413, P697, DOI 10.1038/35099670; Wikelski M, 2003, NATURE, V423, P704, DOI 10.1038/423704a; Winkler Hans, 2005, P79; YONG W, 1994, AUK, V111, P683	38	127	134	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2154	10.1371/journal.pone.0002154	http://dx.doi.org/10.1371/journal.pone.0002154			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478072	gold, Green Submitted, Green Published			2022-12-25	WOS:000262172800019
J	Salim, O; Clarke, IN; Lambden, PR				Salim, Omar; Clarke, Ian N.; Lambden, Paul R.			Functional Analysis of the 5 ' Genomic Sequence of a Bovine Norovirus	PLOS ONE			English	Article								Background: Jena Virus (JV), a bovine Norovirus, causes enteric disease in cattle and represents a potential model for the study of enteric norovirus infection and pathogenesis. The positive sense RNA genome of JV is organised into ORF1 (nonstructural proteins), ORF2 (major capsid protein) and ORF3 (minor capsid protein). The lack of a cell culture system for studying JV replication has meant that work to date has relied upon in vitro systems to study non-structural protein synthesis and processing. Principal Findings: Only two of the three major ORF1 proteins were identified (p110 and 2C) following in vitro translation of JV RNA, the N-term protein was not detected. The N-term encoding genomic sequence (5'GS) was tested for IRES-like function in a bi-cistronic system and displayed no evidence of IRES-like activity. The site of translation initiation in JV was determined to be at the predicted nucleotide 22. Following the insertion of an epitope within the 59GS the JV N-term protein was identified in vitro and within RNA transfected cells. Conclusions: The in vitro transcription/translation system is currently the best system for analysing protein synthesis and processing in JV. Unlike similarly studied human noroviruses JV initially did not appear to express the N-terminal protein, presenting the possibility that the encoding RNA sequence had a regulatory function, most likely involved in translation initiation in an IRES-like manner. This was not the case and, following determination of the site of translation initiation the N-term protein was detected using an epitope tag, both in vitro and in vivo. Although slightly larger than predicted the N-term protein was detected in a processed form in vivo, thus not only demonstrating initial translation of the ORF1 polyprotein but also activity of the viral protease. These findings indicate that the block to noroviral replication in cultured cells lies elsewhere.	[Salim, Omar; Clarke, Ian N.; Lambden, Paul R.] Univ Southampton, Southampton Gen Hosp, Sch Med, Mol Mikrobiol Grp, Southampton, Hants, England	University of Southampton	Salim, O (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Mol Mikrobiol Grp, Southampton, Hants, England.	O.Salim@soton.ac.uk		Clarke, Ian/0000-0002-4938-1620; Salim, Omar/0000-0002-2562-4827	Medical Research Council; Wellcome Trust [069233]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)	OS would like to thank the Medical Research Council for providing a studentship to support this work, which was also supported by Wellcome Trust Grant 069233.	Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BRIDGER JC, 1984, INFECT IMMUN, V43, P133, DOI 10.1128/IAI.43.1.133-138.1984; Clarke IN, 2000, J INFECT DIS, V181, pS309, DOI 10.1086/315575; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DAUGHENBAUGH KF, 2006, VIROLOGY J, V23; Ettayebi K, 2003, J VIROL, V77, P11790, DOI 10.1128/JVI.77.21.11790-11797.2003; Fernandez-Vega V, 2004, J VIROL, V78, P4827, DOI 10.1128/JVI.78.9.4827-4837.2004; Glass PJ, 2003, J VIROL, V77, P3569, DOI 10.1128/JVI.77.6.3569-3577.2003; GUNTHER H, 1984, ARCH EXP VET MED, V38, P781; GUNTHER H, 1987, LEIPZIG, V41, P934; Gutierrez-Escolano AL, 2003, BIOCHEM BIOPH RES CO, V311, P759, DOI 10.1016/j.bbrc.2003.10.066; Gutierrez-Escolano AL, 2000, J VIROL, V74, P8558, DOI 10.1128/JVI.74.18.8558-8562.2000; HALLER AA, 1995, VIROLOGY, V206, P923, DOI 10.1006/viro.1995.1015; Hardy ME, 2005, FEMS MICROBIOL LETT, V253, P1, DOI 10.1016/j.femsle.2005.08.031; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; Kaminski A, 1995, RNA, V1, P924; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Liu BL, 1999, J VIROL, V73, P819, DOI 10.1128/JVI.73.1.819-825.1999; LIU BL, 1997, POLYPROTEIN PROCESSI, P66; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; LOVE DN, 1975, ARCH VIROL, V48, P213, DOI 10.1007/BF01317964; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Meyers G, 2000, VIROLOGY, V276, P349, DOI 10.1006/viro.2000.0545; Oliver SL, 2007, ARCH VIROL, V152, P257, DOI 10.1007/s00705-006-0856-2; Oliver SL, 2006, J CLIN MICROBIOL, V44, P992, DOI 10.1128/JCM.44.3.992-998.2006; Pelosi E, 1999, J MED VIROL, V58, P93, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;93::AID-JMV15&gt;3.0.CO;2-P; Seah EEL, 1999, J VIROL, V73, P10531, DOI 10.1128/JVI.73.12.10531-10535.1999; Seah EL, 2003, J VIROL, V77, P7150, DOI 10.1128/JVI.77.12.7150-7155.2003; Sosnovtsev SV, 2006, J VIROL, V80, P7816, DOI 10.1128/JVI.00532-06; Sosnovtsev SV, 2002, J VIROL, V76, P7060, DOI 10.1128/JVI.76.14.7060-7072.2002; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551	31	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2169	10.1371/journal.pone.0002169	http://dx.doi.org/10.1371/journal.pone.0002169			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478070	Green Submitted, Green Published, Green Accepted, gold			2022-12-25	WOS:000262172800034
J	Cheng, YW; Lee, PL; Yang, CY; Lin, CP; Hung, D; Decety, J				Cheng, Yawei; Lee, Po-Lei; Yang, Chia-Yen; Lin, Ching-Po; Hung, Daisy; Decety, Jean			Gender Differences in the Mu Rhythm of the Human Mirror-Neuron System	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; AUTISM SPECTRUM DISORDERS; HIGH-FUNCTIONING AUTISM; NORMAL SEX-DIFFERENCES; SOCIAL NEUROSCIENCE; FACIAL EXPRESSIONS; ASPERGER-SYNDROME; PREMOTOR CORTEX; HUMAN EMPATHY; ACTIVATION	Background: Psychologically, females are usually thought to be superior in interpersonal sensitivity than males. The human mirror-neuron system is considered to provide the basic mechanism for social cognition. However, whether the human mirror-neuron system exhibits gender differences is not yet clear. Methodology/Principal Findings: We measured the electroencephalographic mu rhythm, as a reliable indicator of the human mirror-neuron system activity, when female (N = 20) and male (N = 20) participants watched either hand actions or a moving dot. The display of the hand actions included androgynous, male, and female characteristics. The results demonstrate that females displayed significantly stronger mu suppression than males when watching hand actions. Instead, mu suppression was similar across genders when participants observed the moving dot and between the perceived sex differences (same-sex vs. opposite-sex). In addition, the mu suppressions during the observation of hand actions positively correlated with the personal distress subscale of the interpersonal reactivity index and negatively correlated with the systemizing quotient. Conclusions/Significance: The present findings indirectly lend support to the extreme male brain theory put forward by Baron-Cohen (2005), and may cast some light on the mirror-neuron dysfunction in autism spectrum disorders. The mu rhythm in the human mirror-neuron system can be a potential biomarker of empathic mimicry.	[Cheng, Yawei; Lin, Ching-Po] Natl Yang Ming Univ, Sch Life Sci, Inst Neurosci, Taipei 112, Taiwan; [Cheng, Yawei] Natl Yang Ming Univ Hosp, Dept Rehabil, Yilan, Taiwan; [Lee, Po-Lei] Natl Cent Univ, Dept Elect Engn, Taoyuan, Taiwan; [Yang, Chia-Yen] Ching Yun Univ, Inst Comp, Commun & Syst Engn, Chungli, Taiwan; [Hung, Daisy] Natl Cent Univ, Coll Sci, Inst Cognitive Neurosci, Taoyuan, Taiwan; [Decety, Jean] Univ Chicago, Ctr Cognitive & Social Neurosci, Dept Psychiat, Chicago, IL USA; [Decety, Jean] Univ Chicago, Ctr Cognitive & Social Neurosci, Dept Psychol, Chicago, IL USA	National Yang Ming Chiao Tung University; National Central University; Chien Hsin University of Science & Technology; National Central University; University of Chicago; University of Chicago	Cheng, YW (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Neurosci, Taipei 112, Taiwan.	decety@uchicago.edu			National Science Council [95-2752-H-010-004-PAE, 96-2314-B-532-001, 96-2221-E-008-122-MY3]; Department of Health, Taipei City Government [96001-62-044]; Ministry of Education, Taiwan [96-2752-B-010-008-PAE]; NSF [BCS- 0718480]	National Science Council(Ministry of Science and Technology, Taiwan); Department of Health, Taipei City Government; Ministry of Education, Taiwan(Ministry of Education, Taiwan); NSF(National Science Foundation (NSF))	This study was sponsored by the National Science Council (95-2752-H-010-004-PAE; 96-2314-B-532-001; 96-2221-E-008-122-MY3), the Department of Health, Taipei City Government (96001-62-044), and Ministry of Education (96-2752-B-010-008-PAE), Taiwan. Dr. Jean Decety was supported by an NSF grant (BCS- 0718480).	Baron-Cohen S, 2003, PHILOS T ROY SOC B, V358, P361, DOI 10.1098/rstb.2002.1206; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Baron-Cohen S, 2005, SCIENCE, V310, P819, DOI 10.1126/science.1115455; CHENG Y, 2008, NEUROIMAGE IN PRESS; Cheng YW, 2006, NEUROREPORT, V17, P1115, DOI 10.1097/01.wnr.0000223393.59328.21; Cheng YW, 2007, CURR BIOL, V17, P1708, DOI 10.1016/j.cub.2007.09.020; Cheng YW, 2007, NEUROREPORT, V18, P887, DOI 10.1097/WNR.0b013e3280ebb486; CIALDINI RB, 1987, J PERS SOC PSYCHOL, V52, P749, DOI 10.1037/0022-3514.52.4.749; Cochin S, 1998, ELECTROEN CLIN NEURO, V107, P287, DOI 10.1016/S0013-4694(98)00071-6; Cochin S, 1999, EUR J NEUROSCI, V11, P1839, DOI 10.1046/j.1460-9568.1999.00598.x; Dapretto M, 2006, NAT NEUROSCI, V9, P28, DOI 10.1038/nn1611; Davis M., 1996, EMPATHY SOCIAL PSYCH; Decety J, 2003, TRENDS COGN SCI, V7, P527, DOI 10.1016/j.tics.2003.10.004; Decety J, 2007, SOC NEUROSCI, V2, P151, DOI 10.1080/17470910701506060; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; Doherty RW, 1997, J NONVERBAL BEHAV, V21, P131, DOI 10.1023/A:1024956003661; EISENBERG N, 1990, MOTIV EMOTION, V14, P131, DOI 10.1007/BF00991640; Fadiga L, 2004, J CLIN NEUROPHYSIOL, V21, P157, DOI 10.1097/00004691-200405000-00004; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; GASTAUT HJ, 1954, ELECTROEN CLIN NEURO, V6, P433, DOI 10.1016/0013-4694(54)90058-9; GASTAUT MH, 1952, REV NEUROL, V87, P176; Gazzola V, 2006, CURR BIOL, V16, P1824, DOI 10.1016/j.cub.2006.07.072; Geary DC, 2021, MALE, FEMALE, 3 EDITION, P1, DOI 10.1037/0000181-000; Hadjikhani N, 2007, HUM BRAIN MAPP, V28, P441, DOI 10.1002/hbm.20283; Hadjikhani N, 2006, CEREB CORTEX, V16, P1276, DOI 10.1093/cercor/bh069; Hall J. A., 1984, NONVERBAL SEX DIFFER; Hari R, 1998, P NATL ACAD SCI USA, V95, P15061, DOI 10.1073/pnas.95.25.15061; Jackson PL, 2005, NEUROIMAGE, V24, P771, DOI 10.1016/j.neuroimage.2004.09.006; Jarvelainen J, 2004, NEUROIMAGE, V23, P187, DOI 10.1016/j.neuroimage.2004.06.010; Jarvelainen J, 2001, NEUROREPORT, V12, P3493; Kemp AH, 2004, NEUROIMAGE, V21, P632, DOI 10.1016/j.neuroimage.2003.09.055; Klimesch W, 1998, NEUROSCI LETT, V244, P73, DOI 10.1016/S0304-3940(98)00122-0; Lamm C, 2007, J COGNITIVE NEUROSCI, V19, P42, DOI 10.1162/jocn.2007.19.1.42; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; McIntosh DN, 2006, DEVELOPMENTAL SCI, V9, P295, DOI 10.1111/j.1467-7687.2006.00492.x; Muthukumaraswamy SD, 2004, CLIN NEUROPHYSIOL, V115, P1760, DOI 10.1016/j.clinph.2004.03.004; Muthukumaraswamy SD, 2004, COGNITIVE BRAIN RES, V19, P195, DOI 10.1016/j.cogbrainres.2003.12.001; Nishitani N, 2004, ANN NEUROL, V55, P558, DOI 10.1002/ana.20031; Oberman LM, 2007, SOC COGN AFFECT NEUR, V2, P62, DOI 10.1093/scan/nsl022; Oberman LM, 2005, COGNITIVE BRAIN RES, V24, P190, DOI 10.1016/j.cogbrainres.2005.01.014; Pfurtscheller G, 1997, INT J PSYCHOPHYSIOL, V26, P121, DOI 10.1016/S0167-8760(97)00760-5; Pineda JA, 2005, BRAIN RES REV, V50, P57, DOI 10.1016/j.brainresrev.2005.04.005; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; SALMELIN R, 1994, NEUROSCIENCE, V60, P537, DOI 10.1016/0306-4522(94)90263-1; Seifritz E, 2003, BIOL PSYCHIAT, V54, P1367, DOI 10.1016/S0006-3223(03)00697-8; Siu AMH, 2005, RES SOCIAL WORK PRAC, V15, P118, DOI 10.1177/1049731504270384; Theoret H, 2005, CURR BIOL, V15, pR84, DOI 10.1016/j.cub.2005.01.022; Williams JHG, 2001, NEUROSCI BIOBEHAV R, V25, P287, DOI 10.1016/S0149-7634(01)00014-8	56	101	105	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2113	10.1371/journal.pone.0002113	http://dx.doi.org/10.1371/journal.pone.0002113			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	382YX	18461176	Green Published, gold, Green Submitted			2022-12-25	WOS:000261642400035
J	Legrand, J; Sanchez, A; Le Pont, F; Camacho, L; Larouze, B				Legrand, Judith; Sanchez, Alexandra; Le Pont, Francoise; Camacho, Luiz; Larouze, Bernard			Modeling the Impact of Tuberculosis Control Strategies in Highly Endemic Overcrowded Prisons	PLOS ONE			English	Article								Background: Tuberculosis (TB) in prisons is a major health problem in countries of high and intermediate TB endemicity such as Brazil. For operational reasons, TB control strategies in prisons cannot be compared through population based intervention studies. Methodology/Principal Findings: A mathematical model is proposed to simulate the TB dynamics in prison and evaluate the potential impact on active TB prevalence of several intervention strategies. The TB dynamics with the ongoing program was simulated over a 10 year period in a Rio de Janeiro prison (TB prevalence 4.6 %). Then, a simulation of the DOTS strategy reaching the objective of 70 % of bacteriologically-positive cases detected and 85 % of detected cases cured was performed; this strategy reduced only to 2.8% the average predicted TB prevalence after 5 years. Adding TB detection at entry point to DOTS strategy had no major effect on the predicted active TB prevalence. But, adding further a yearly X-ray mass screening of inmates reduced the predicted active TB prevalence below 1%. Furthermore, according to this model, after applying this strategy during 2 years (three annual screenings), the TB burden would be reduced and the active TB prevalence could be kept at a low level by associating X-ray screening at entry point and DOTS. Conclusions/Significance: We have shown that X-ray mass screenings should be considered to control TB in highly endemic prison. Prisons with different levels of TB prevalence could be examined thanks to this model which provides a rational tool for public health deciders.	[Legrand, Judith; Le Pont, Francoise; Larouze, Bernard] INSERM, U707, Paris, France; [Legrand, Judith; Le Pont, Francoise; Larouze, Bernard] Univ Pierre Marie Curie Paris 6, UMR S 707, Paris, France; [Legrand, Judith] Imperial Coll, Dept Infect Dis Epidemiol, London, England; [Sanchez, Alexandra] Secretaria Estado Adm Penitenciaria Rio de Janeiro, Coordenacso Gestao Saude, Rio De Janeiro, Brazil; [Camacho, Luiz] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Dept Epidemiol Metodos Quantit, Rio De Janeiro, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Imperial College London; Fundacao Oswaldo Cruz	Legrand, J (corresponding author), INSERM, U707, Paris, France.	j.legrand@imperial.ac.uk			Institut National de la Sante et de la Recherche Medicale, France; Fondation Oswaldo Cruz, Brazil	Institut National de la Sante et de la Recherche Medicale, France(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation Oswaldo Cruz, Brazil	This work was partially supported by the joined program Institut National de la Sante et de la Recherche Medicale, France/Fondation Oswaldo Cruz, Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts A, 2000, INT J TUBERC LUNG D, V4, P1104; Aerts A, 2006, INT J TUBERC LUNG D, V10, P1215; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; Bone A., 2000, TUBERCULOSIS CONTROL; Chaves F, 1997, AM J RESP CRIT CARE, V155, P719, DOI 10.1164/ajrccm.155.2.9032218; Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110; Coninx R, 2000, BRIT MED J, V320, P440, DOI 10.1136/bmj.320.7232.440; den Boon S, 2006, INT J TUBERC LUNG D, V10, P876; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328; Fournet N, 2006, PUBLIC HEALTH, V120, P976, DOI 10.1016/j.puhe.2006.06.004; GILLEPSIE DT, 1976, J COMPUTATIONAL PHYS, V22; Jones TF, 2001, AM J RESP CRIT CARE, V164, P77, DOI 10.1164/ajrccm.164.1.2010108; Kimerling ME, 2005, INT J TUBERC LUNG D, V9, P589; Layton MC, 1997, AM J PUBLIC HEALTH, V87, P1335, DOI 10.2105/AJPH.87.8.1335; Leung CC, 2005, INT J TUBERC LUNG D, V9, P627; MacIntyre CR, 1997, CLIN INFECT DIS, V24, P1060, DOI 10.1086/513632; Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X; Porco TC, 1998, THEOR POPUL BIOL, V54, P117, DOI 10.1006/tpbi.1998.1366; Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC, 2006, MMWR RECOMM REP, V55, P1; Sanchez A, 2005, INT J TUBERC LUNG D, V9, P633; Sanchez AR, 2007, CAD SAUDE PUBLICA, V23, P545, DOI 10.1590/S0102-311X2007000300013; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; *SECR EST AD PEN R, 2006, REL TECN AN PROGR CO; *SECR EST AD PEN R, 2006, REL TECN AN PROGR PN; STANSELL J, 1994, TXB RESP MED, P2333; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; 2001, INT J TUBERC LUNG DI, V5, P213; 2003, MMWR MORB MORTAL WKL, V52, P250	34	45	49	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2100	10.1371/journal.pone.0002100	http://dx.doi.org/10.1371/journal.pone.0002100			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461123	Green Published, gold			2022-12-25	WOS:000261642400022
J	Vissers, DCJ; Voeten, HACM; Nagelkerke, NJD; Habbema, JDF; de Vlas, SJ				Vissers, Debby C. J.; Voeten, Helene A. C. M.; Nagelkerke, Nico J. D.; Habbema, J. Dik F.; de Vlas, Sake J.			The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study	PLOS ONE			English	Article							TENOFOVIR DISOPROXIL FUMARATE; ACTIVE ANTIRETROVIRAL THERAPY; RISK BEHAVIOR; SOUTH-INDIA; PREVENTION; INFECTION; CHEMOPROPHYLAXIS; TRANSMISSION; INTERVENTIONS; PREVALENCE	Background: Pre-exposure prophylaxis (PrEP) is a promising new HIV prevention method, especially for women. An urgent demand for implementation of PrEP is expected at the moment efficacy has been demonstrated in clinical trials. We explored the long-term impact of PrEP on HIV transmission in different HIV epidemics. Methodology/Principal Findings: We used a mathematical model that distinguishes the general population, sex workers and their clients. PrEP scenarios varying in effectiveness, coverage and target group were modeled in the epidemiological settings of Botswana, Nyanza Province in Kenya, and Southern India. We also studied the effect of condom addition or condom substitution during PrEP use. Main outcome was number of HIV infections averted over ten years of PrEP use. PrEP strategies with high effectiveness and high coverage can have a substantial impact in African settings. In Southern India, by contrast, the number of averted HIV infections in different PrEP scenarios would be much lower. The impact of PrEP may be strongly diminished or even reversed by behavioral disinhibition, especially in scenarios with low coverage and low effectiveness. However, additional condom use during low coverage and low effective PrEP doubled the amount of averted HIV infections. Conclusions/Significance: The public health impact of PrEP can be substantial. However, this impact may be diminished, or even reversed, by changes in risk behavior. Implementation of PrEP strategies should therefore come on top of current condom campaigns, not as a substitution.	[Vissers, Debby C. J.; Voeten, Helene A. C. M.; Habbema, J. Dik F.; de Vlas, Sake J.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Nagelkerke, Nico J. D.] United Arab Emirates Univ, Dept Community Med, Al Ain, U Arab Emirates	Erasmus University Rotterdam; Erasmus MC; United Arab Emirates University	Vissers, DCJ (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.	d.vissers@erasmusmc.nl		Voeten, Helene/0000-0003-1358-6752; de Vlas, Sake J./0000-0002-1830-5668				ABBAS UL, 2007, PLOS ONE, V875, P1; [Anonymous], 2007, MANUAL ESTIMATING NA; [Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; Becker ML, 2007, AIDS, V21, P739, DOI 10.1097/QAD.0b013e328012b885; Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Cohen J, 2007, SCIENCE, V318, P1048, DOI 10.1126/science.318.5853.1048; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; EISELE TP, 2007, AIDS BEHAV; Grant RM, 2005, SCIENCE, V309, P2170, DOI 10.1126/science.1116204; Grant RM, 2006, J INFECT DIS, V194, P874, DOI 10.1086/507314; Hallett T B, 2006, Sex Transm Infect, V82 Suppl 1, pi1; Kaona FAD, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-68; Kumar R, 2006, LANCET, V367, P1164, DOI 10.1016/S0140-6736(06)68435-3; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; Liu AY, 2006, JAMA-J AM MED ASSOC, V296, P863, DOI 10.1001/jama.296.7.863; Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010; MARUM L, 2003, KENYA DEMOGRAPHIC HL, pCH13; *NACO, 2005, NAT AIDS CONTR ORG F; *NACO, 2005, BEH SURV SURV REP; Nagelkerke NJD, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-16; Nagelkerke NJD, 2002, B WORLD HEALTH ORGAN, V80, P89; Padian NS, 2007, LANCET, V370, P251, DOI 10.1016/S0140-6736(07)60950-7; Paxton LA, 2007, LANCET, V370, P89, DOI 10.1016/S0140-6736(07)61053-8; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; *PREP WATCH, 2007, CLEAR AV PREP WATCH; Ramjee G, 2007, PLOS MED, V4, P1167, DOI 10.1371/journal.pmed.0040235; Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010; Smith Stephen M, 2004, Retrovirology, V1, P16, DOI 10.1186/1742-4690-1-16; Stephenson J, 2004, JAMA-J AM MED ASSOC, V292, P1163, DOI 10.1001/jama.292.10.1163; Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; UNAIDS, 2006, REP GLOB AIDS EP; *UNAIDS WHO, 2004, IND EP FACT SHEET HI; Voeten HACM, 2002, SEX TRANSM DIS, V29, P444, DOI 10.1097/00007435-200208000-00003; Youle M, 2003, AIDS, V17, P937, DOI 10.1097/00002030-200304110-00027; Youle Mike, 2003, J Int Assoc Physicians AIDS Care (Chic), V2, P102, DOI 10.1177/154510970300200302; 2007, NATURE, V446, P1	41	85	93	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2077	10.1371/journal.pone.0002077	http://dx.doi.org/10.1371/journal.pone.0002077			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461185	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400003
J	Kondo, Y; Shen, L; Ahmed, S; Boumber, Y; Sekido, Y; Haddad, BR; Issa, JPJ				Kondo, Yutaka; Shen, Lanlan; Ahmed, Saira; Boumber, Yanis; Sekido, Yoshitaka; Haddad, Bassem R.; Issa, Jean-Pierre J.			Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells	PLOS ONE			English	Article								Background: Modifications of the histone amino-terminal tails affect access of regulatory factors and complexes to chromatin and thereby influence biological processes. Cancer cells are characterized by prominent epigenetic dysregulation, including histone modifications. However, the functional roles of the histone methyltransferases (HMT) in cancer remain unclear. Methodology/Principal Findings: We studied RNAi-based inhibition (knockdown, KD) of 2 different H3K9 HMTs, SUV39H1 and G9a. Knockdown of the 2 HMTs in PC3 cancer cell line markedly inhibited cell growth and caused profound morphological changes with loss of telomerase activity and shortened telomeres. SUV39H1 KD cells showed substantial increase in G2/M fraction. G9a KD cells showed increased DNA content (1.7-fold in 2 independent clones) compared with FACS analyses to control. Karyotype analyses showed that this was due to an increased number of chromosomes (from 61 to 102) in G9a KD cells compared to parental PC3. Intriguingly, we found abnormal centrosome morphology and number in about 25% of the G9a KD cells, while centrosomes were morphologically normal in control cells. Microarray analyses after KD of SUV39H1 or G9a showed very few genes up-regulated among the 39,000 genes. The silenced tumor-suppressor genes p16 and RASSF1A were not activated in KD cells. Conclusions/Significance: These data suggest that the 2 HMTs, SUV39H1 and G9a are required to perpetuate the malignant phenotype. Furthermore, G9a plays a critical role in regulating centrosome duplication presumably through chromatin structure rather than through affecting gene expression in cancer cells. Targeting these histone methyltransferases may be of therapeutic benefit in cancers.	[Kondo, Yutaka; Sekido, Yoshitaka] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Kondo, Yutaka; Shen, Lanlan; Ahmed, Saira; Boumber, Yanis; Issa, Jean-Pierre J.] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA; [Haddad, Bassem R.] Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehensive Canc Ctr, Washington, DC USA; [Haddad, Bassem R.] Georgetown Univ, Med Ctr, Dept Obstet & Gynecol, Lombardi Comprehensive Canc Ctr, Washington, DC USA	Aichi Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Georgetown University; Georgetown University	Kondo, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan.	ykondo@aichi-cc.jp	Sekido, Yoshitaka/P-9756-2015; Boumber, Yanis/AAP-8901-2021	Sekido, Yoshitaka/0000-0002-2428-3848; Boumber, Yanis/0000-0001-5003-248X; Issa, Jean-Pierre/0000-0003-2258-5030	NIH [CA098006, CA100632]; Japan Society for the Promotion of Science; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA098006] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants CA098006 and CA100632 from the NIH (JPJI) and a grant from the Japan Society for the Promotion of Science (YK).	Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernard P, 2002, TRENDS CELL BIOL, V12, P419, DOI 10.1016/S0962-8924(02)02344-9; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi Judith, 2003, Methods Mol Biol, V223, P155; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01; Fahrner JA, 2002, CANCER RES, V62, P7213; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Nguyen CT, 2002, CANCER RES, V62, P6456; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Zhang XQ, 2003, CANCER RES, V63, P760	27	192	196	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2037	10.1371/journal.pone.0002037	http://dx.doi.org/10.1371/journal.pone.0002037			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446223	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300010
J	Peirce, JL; Broman, KW; Lu, L; Chesler, EJ; Zhou, G; Airey, DC; Birmingham, AE; Williams, RW				Peirce, Jeremy L.; Broman, Karl W.; Lu, Lu; Chesler, Elissa J.; Zhou, Guomin; Airey, David C.; Birmingham, Amanda E.; Williams, Robert W.			Genome Reshuffling for Advanced Intercross Permutation (GRAIP): Simulation and Permutation for Advanced Intercross Population Analysis	PLOS ONE			English	Article							QUANTITATIVE TRAIT LOCI; INBRED MOUSE STRAINS; GENE LOCI; MARKER LOCI; IDENTIFICATION; LINES; MICE; HIPPOCAMPUS; EXPRESSION; RESOURCE	Background: Advanced intercross lines (AIL) are segregating populations created using a multi-generation breeding protocol for fine mapping complex trait loci (QTL) in mice and other organisms. Applying QTL mapping methods for intercross and backcross populations, often followed by naive permutation of individuals and phenotypes, does not account for the effect of AIL family structure in which final generations have been expanded and leads to inappropriately low significance thresholds. The critical problem with naive mapping approaches in AIL populations is that the individual is not an exchangeable unit. Methodology/Principal Findings: The effect of family structure has immediate implications for the optimal AIL creation (many crosses, few animals per cross, and population expansion before the final generation) and we discuss these and the utility of AIL populations for QTL fine mapping. We also describe Genome Reshuffling for Advanced Intercross Permutation, (GRAIP) a method for analyzing AIL data that accounts for family structure. GRAIP permutes a more interchangeable unit in the final generation crosses - the parental genome - and simulating regeneration of a permuted AIL population based on exchanged parental identities. GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures. We contrast GRAIP with naive permutation using a large densely genotyped mouse AIL population (1333 individuals from 32 crosses). A naive permutation using coat color as a model phenotype demonstrates high false-positive locus identification and uncertain significance levels, which are corrected using GRAIP. GRAIP also detects an established hippocampus weight locus and a new locus, Hipp9a. Conclusions and Significance: GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures. The effect of family structure has immediate implications for the optimal AIL creation and we discuss these and the utility of AIL populations.	[Peirce, Jeremy L.; Lu, Lu; Chesler, Elissa J.; Zhou, Guomin; Airey, David C.; Williams, Robert W.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Ctr Neurosci, Memphis, TN 38163 USA; [Peirce, Jeremy L.; Lu, Lu; Chesler, Elissa J.; Williams, Robert W.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Ctr Genom & Bioinformat, Memphis, TN USA; [Broman, Karl W.] Johns Hopkins Univ, Dept Biostat, Baltimore, MD USA; [Birmingham, Amanda E.] Dharmacon Inc, Lafayette, CO USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University	Peirce, JL (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Ctr Neurosci, Memphis, TN 38163 USA.	jpeirce@utmem.edu	Chesler, Elissa/K-4641-2019; zhou, guomin/M-2871-2016; Williams, Robert W./H-8789-2016	Chesler, Elissa/0000-0002-5642-5062; Williams, Robert W./0000-0001-8924-4447; Broman, Karl/0000-0002-4914-6671	The Informatics Center for Mouse Neurogenetics; NIMH [P20-MH62009]; NIDA [P20-MH62009]; NSF [P20-MH62009]; NIAAA [U01AA13499, U24AA135B, U01AA01442501]; National Heart, Lung, and Blood Institute (NHLBI) [HV48141]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV048141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P20MH062009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA013499] Funding Source: NIH RePORTER	The Informatics Center for Mouse Neurogenetics; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NSF(National Science Foundation (NSF)); NIAAA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Our thanks for financial support from (1) The Informatics Center for Mouse Neurogenetics; (2) P20-MH62009 from NIMH, NIDA, and NSF to RWW. (2) INIA grants U01AA13499 and U24AA135B from NIAAA to RWW, and INIA grant U01AA01442501 from NIAAA to LL. As mentioned in the text, genotypes were provided for 1333 AIL mice by the Mammalian Genotyping Service (MGS; National Heart, Lung, and Blood Institute (NHLBI) Contract Number HV48141), for which we would like to express our gratitude to Dr. James Weber and colleagues. Except for MGS contribution of genotypes, no funding agency had a role in design, conduct, data collection, analysis, or interpretation or in preparation of the manuscript.	Abiola O, 2003, NAT REV GENET, V4, P911, DOI 10.1038/nrg1206; Abney M, 2002, AM J HUM GENET, V70, P920, DOI 10.1086/339705; Broman KW, 2005, GENETICS, V169, P1133, DOI 10.1534/genetics.104.035212; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Broman KW, 2002, GENETICS, V160, P1123; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Chesler EJ, 2003, NEUROINFORMATICS, V1, P343, DOI 10.1385/NI:1:4:343; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; CHURCHILL GA, 1994, GENETICS, V138, P963; DARVASI A, 1995, GENETICS, V141, P1199; Iakoubova OA, 2001, GENOMICS, V74, P89, DOI 10.1006/geno.2000.6497; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Iraqi F, 2000, MAMM GENOME, V11, P645, DOI 10.1007/s003350010133; Iraqi F, 2000, EXP LUNG RES, V26, P641, DOI 10.1080/01902140150216729; Jagodic M, 2004, J IMMUNOL, V173, P1366, DOI 10.4049/jimmunol.173.2.1366; Korstanje R, 2002, NAT GENET, V31, P235, DOI 10.1038/ng0702-235; Lu L, 2001, J NEUROSCI, V21, P3503, DOI 10.1523/JNEUROSCI.21-10-03503.2001; Lyon ML, 1989, GENETIC VARIANTS STR, P773; Palmer AA, 2003, NEUROPSYCHOPHARMACOL, V28, P818, DOI 10.1038/sj.npp.1300064; Peirce JL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001036; Peirce JL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-7; Peirce JL, 2003, GENES BRAIN BEHAV, V2, P238, DOI 10.1034/j.1601-183X.2003.00030.x; Sen S, 2001, GENETICS, V159, P371; SHENG J, 2005, GENETICS; Silver L. M., 1995, MOUSE GENETICS; Sobel E, 2001, HUM HERED, V52, P121, DOI 10.1159/000053366; Sobel E, 1996, AM J HUM GENET, V58, P1323; Taylor BA, 1999, MAMM GENOME, V10, P335, DOI 10.1007/s003359900998; Tsaih SW, 2005, MAMM GENOME, V16, P344, DOI 10.1007/s00335-004-2466-1; Wang M, 2003, CANCER RES, V63, P3317; Wang XS, 2003, GENOME RES, V13, P1654, DOI 10.1101/gr.1185803; WELLER JI, 1990, J DAIRY SCI, V73, P2525, DOI 10.3168/jds.S0022-0302(90)78938-2; Williams RW, 2004, MAMM GENOME, V15, P637, DOI 10.1007/s00335-004-2380-6; Williams RW, 2001, GENOME BIOL, V2; Zhou G, 1999, INVEST OPHTH VIS SCI, V40, P817; ZOU F, QUANTITATIVE TRAIT L; ZOU F, 2005, GENETICS	37	28	29	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e1977	10.1371/journal.pone.0001977	http://dx.doi.org/10.1371/journal.pone.0001977			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431467	Green Submitted, Green Published, gold			2022-12-25	WOS:000261558700002
J	Caffarel, MM; Moreno-Bueno, G; Cerutti, C; Palacios, J; Guzman, M; Mechta-Grigoriou, F; Sanchez, C				Caffarel, M. M.; Moreno-Bueno, G.; Cerutti, C.; Palacios, J.; Guzman, M.; Mechta-Grigoriou, F.; Sanchez, C.			JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells	ONCOGENE			English	Article						cannabinoids; breast cancer; JunD; AP-1; p27; testin	NEUROPROTECTIVE ANTIOXIDANTS; INDUCED APOPTOSIS; TUMOR-CELLS; PROTEIN; TRANSFORMATION; CANNABINOIDS; CANNABIDIOL; STRESS; AP-1; PROLIFERATION	It has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family. THC activates JunD both by upregulating gene expression and by translocating the protein to the nuclear compartment, and these events are accompanied by a decrease in cell proliferation. Of interest, neither JunD activation nor proliferation inhibition was observed in human non-tumour mammary epithelial cells exposed to THC. We confirmed the importance of JunD in THC action by RNA interference and genetic ablation. Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized. broblasts, the antiproliferative effect exerted by THC was significantly diminished. Gene array and siRNA experiments support that the cyclin-dependent kinase inhibitor p27 and the tumour suppressor gene testin are candidate JunD targets in cannabinoid action. In addition, our data suggest that the stress-regulated protein p8 participates in THC antiproliferative action in a JunD-independent manner. In summary, this is the first report showing not only that cannabinoids regulate JunD but, more generally, that JunD activation reduces the proliferation of cancer cells, which points to a new target to inhibit breast cancer progression.	[Caffarel, M. M.; Cerutti, C.; Palacios, J.; Sanchez, C.] Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Moreno-Bueno, G.] Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Palacios, J.] Hosp Univ Virgen Rocio, Dept Pathol, Seville, Spain; [Mechta-Grigoriou, F.] Inst Curie, INSERM, U830, Paris, France	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Virgen del Rocio University Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Sanchez, C (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Cerutti, Camilla/ABC-4159-2021; Cerutti, Camilla/U-8890-2019; Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020; MECHTA-GRIGORIOU, Fatima/C-5253-2017; Sanchez, Cristina/AFQ-4745-2022; Sanchez, Cristina/H-4980-2017	Cerutti, Camilla/0000-0001-9426-686X; Moreno-Bueno, Gema/0000-0002-5030-6687; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; Sanchez, Cristina/0000-0002-1428-3078; Guzman, Manuel/0000-0001-7475-118X; Caffarel, Maria/0000-0002-7442-6827	Fondo de Investigaciones Sanitarias; Fundacion Mutua Madrilena; Spanish Ministry of Education and Science; ISCIII-RETIC; Comunidad de Madrid; Inserm Avenir; Institut Curie; Fondation de France	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Spanish Ministry of Education and Science(Spanish Government); ISCIII-RETIC(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Inserm Avenir(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Curie; Fondation de France(Fondation de France)	We are indebted to the personnel of the Genomics Unit ( Complutense University) for expert advice on RT-qPCR experiments, and to the members of our laboratories for technical support and critical discussions on this work, especially to M Salazar. C Sanchez and G Moreno-Bueno are researchers of the 'Ramon y Cajal Program' of the Spanish Ministry of Education and Science. MM Caffarel is the recipient of a fellowship from the Spanish Ministry of Education and Science. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sanchez and J Palacios), Fundacion Mutua Madrilena (C Sanchez), Spanish Ministry of Education and Science (J Palacios and M Guzman), ISCIII-RETIC (J Palacios), Comunidad de Madrid (M Guzman) and Inserm Avenir, Institut Curie and Fondation de France (F Mechta-Grigoriou).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Caffarel MM, 2006, CANCER RES, V66, P6615, DOI 10.1158/0008-5472.CAN-05-4566; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Drusco A, 2005, P NATL ACAD SCI USA, V102, P10947, DOI 10.1073/pnas.0504934102; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Giuliano M, 2006, INT J MOL MED, V17, P811; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zhao Q, 2005, J BIOL CHEM, V280, P26735, DOI 10.1074/jbc.M412828200	29	55	58	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5033	5044		10.1038/onc.2008.145	http://dx.doi.org/10.1038/onc.2008.145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454173				2022-12-25	WOS:000258914800006
J	Stemmer, V; de Craene, B; Berx, G; Behrens, J				Stemmer, V.; de Craene, B.; Berx, G.; Behrens, J.			Snail promotes Wnt target gene expression and interacts with beta-catenin	ONCOGENE			English	Article						beta-catenin; colorectal cancer; epithelial-mesenchymal transition; snail; Wnt	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; TUMOR PROGRESSION; SIGNALING PATHWAY; MODULATION; TUMORIGENESIS; CANCER; CELLS	The transcription factor snail represses epithelial gene expression and thereby promotes epithelial-mesenchymal transitions (EMT) and tumor invasion. The Wnt/beta-catenin pathway is also involved in EMT and was shown to activate snail. Here, we demonstrate that snail increases Wnt reporter gene activity induced by beta-catenin, LRP6 or dishevelled, and also promotes transcription activated by GAL4-beta-catenin fusion proteins. Snail mutants lacking the transcriptional repressor domain also stimulate beta-catenin-dependent transcription indicating that downregulation of snail target genes is not required for this activity. Snail interacts with beta-catenin in immunoprecipitation experiments at its N-terminus, which is required for activation by snail. In colorectal cancer cell lines, overexpression of snail leads to increased expression of Wnt target genes, whereas downregulation of endogenous snail by siRNA reduces target gene expression. Our data indicate a positive feedback stimulation of the Wnt pathway by activation of snail.	[Stemmer, V.; Behrens, J.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Germany; [de Craene, B.; Berx, G.] Univ Ghent VIB, Dept Mol Biomed Res Mol & Cellular Oncol, Ghent, Zwijnaarde, Belgium	University of Erlangen Nuremberg; Flanders Institute for Biotechnology (VIB); Ghent University	Behrens, J (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Glueckstr 6, D-91054 Erlangen, Germany.	jbehrens@molmed.uni-erlangen.de	De Craene, Bram/B-9373-2009	Berx, Geert/0000-0001-5770-2458				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Roy HK, 2004, MOL CANCER THER, V3, P1159; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	18	186	198	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5075	5080		10.1038/onc.2008.140	http://dx.doi.org/10.1038/onc.2008.140			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469861				2022-12-25	WOS:000258914800010
J	Buech, TRH; Biebermann, H; Kalwa, H; Pinkenburg, O; Hager, D; Barth, H; Aktories, K; Breit, A; Gudermann, T				Buech, Thomas R. H.; Biebermann, Heike; Kalwa, Hermann; Pinkenburg, Olaf; Hager, Denise; Barth, Holger; Aktories, Klaus; Breit, Andreas; Gudermann, Thomas			G(13)-dependent activation of MAPK by thyrotropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; THYROID-STIMULATING HORMONE; PROTEIN-COUPLED RECEPTORS; EPITHELIAL-CELL PROLIFERATION; BOTULINUM C2 TOXIN; GENE-EXPRESSION; ADENYLATE-CYCLASE; RNA INTERFERENCE; MAMMALIAN-CELLS; SIRNA DESIGN	Stimulation of the thyrotropin receptor (TSHR) activates G proteins of all four subfamilies (G(s), G(i/o), G(q/11), and G(12/13)). Whereas G(s)/cAMP-dependent cellular responses upon TSHR stimulation are well established, other signaling pathways are less characterized. We evaluated TSH-elicited cellular responses in human follicular thyroid carcinoma cells stably expressing the TSHR and in primary, nonneoplastic human thyrocytes. In these cellular models, stimulation with TSH caused activation of p44/42 MAPK and subsequent induction of c-Fos. MAPK stimulation occurred independently of G(s), G(i/o), and G(q/11) signaling. Dominant negative constructs of G(12) or G(13) as well as shRNA- mediated suppression of G alpha(12) or G alpha(13) revealed that MAPK activation was dependent on G(13) but not on G(12) signaling. Furthermore, G(13)-dependent transactivation of the epidermal growth factor receptor was necessary for MAPK activation in follicular carcinoma cells, whereas EGFR was not involved in MAPK activation in nonneoplastic primary thyrocytes. The use of bacterial inhibitors of monomeric GTPases revealed that MAPK activation proceeded independently of Rho proteins but was clostridial toxin B-sensitive, suggesting involvement of Cdc42 or Rac. Thus, our data shed new light on cAMP-independent TSHR signaling and identify the first G(13)-dependent TSHR signaling pathway in human thyrocytes.	[Buech, Thomas R. H.; Kalwa, Hermann; Pinkenburg, Olaf; Hager, Denise; Breit, Andreas; Gudermann, Thomas] Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; [Biebermann, Heike] Humboldt Univ, Virchow Klinikum, Klin & Poliklin Kinderheikunde, D-13353 Berlin, Germany; [Barth, Holger] Univ Ulm Klinikum, Inst Pharmakol & Toxikol, D-89081 Ulm, Germany; [Aktories, Klaus] Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; [Aktories, Klaus] Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	Philipps University Marburg; Humboldt University of Berlin; Ulm University; University of Freiburg; University of Freiburg	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl von Frisch Str 1, D-35033 Marburg, Germany.	guderman@staff.uni-marburg.de	Aktories, Klaus/CAJ-5682-2022; Kalwa, Hermann/ABG-2323-2021; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; Biebermann, Heike/0000-0002-2024-7778				Allgeier A, 1997, MOL CELL ENDOCRINOL, V127, P81, DOI 10.1016/S0303-7207(96)03996-2; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Biebermann H, 1997, J CLIN ENDOCR METAB, V82, P3471, DOI 10.1210/jc.82.10.3471; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calebiro D, 2006, MOL ENDOCRINOL, V20, P3196, DOI 10.1210/me.2005-0493; Correze C, 2000, THYROID, V10, P747, DOI 10.1089/thy.2000.10.747; Coulonval K, 2000, BIOCHEM J, V348, P351, DOI 10.1042/0264-6021:3480351; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Demeure MJ, 1997, SURGERY, V122, P1195, DOI 10.1016/S0039-6060(97)90227-0; DERWAHL M, 1993, BIOCHEM BIOPH RES CO, V191, P1131, DOI 10.1006/bbrc.1993.1334; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esapa C, 1997, J CLIN ENDOCR METAB, V82, P493, DOI 10.1210/jc.82.2.493; Gilbert JA, 2006, J IMMUNOL, V176, P5084, DOI 10.4049/jimmunol.176.8.5084; GILMAN AG, 1968, J BIOL CHEM, V243, P5872; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Gudermann T, 2001, NOVART FDN SYMP, V239, P68; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hara T, 1999, ENDOCRINOLOGY, V140, P1724, DOI 10.1210/en.140.4.1724; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Jamnongjit M, 2005, P NATL ACAD SCI USA, V102, P16257, DOI 10.1073/pnas.0508521102; Kero J, 2007, J CLIN INVEST, V117, P2399, DOI 10.1172/JCI30380; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LAMY F, 1993, J BIOL CHEM, V268, P8398; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; Ohta K, 1997, J CLIN ENDOCR METAB, V82, P2633, DOI 10.1210/jc.82.8.2633; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAPOPORT B, 1976, ENDOCRINOLOGY, V98, P1189, DOI 10.1210/endo-98-5-1189; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Shan DD, 2006, DEV CELL, V10, P707, DOI 10.1016/j.devcel.2006.03.014; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; TOURNIER C, 1995, EUR J BIOCHEM, V228, P16, DOI 10.1111/j.1432-1033.1995.0016o.x; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VONEICHELSTREIBER C, 1995, MOL MICROBIOL, V17, P313, DOI 10.1111/j.1365-2958.1995.mmi_17020313.x; Wayne CM, 2007, MOL ENDOCRINOL, V21, P1940, DOI 10.1210/me.2007-0020; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Williams ED, 1995, MUTAT RES-FUND MOL M, V333, P123, DOI 10.1016/0027-5107(95)00138-7; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Yiu SM, 2005, BIOINFORMATICS, V21, P144, DOI 10.1093/bioinformatics/bth498	62	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20330	20341		10.1074/jbc.M800211200	http://dx.doi.org/10.1074/jbc.M800211200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18445595	hybrid			2022-12-25	WOS:000257565300049
J	Lim, KB; Bu, WY; Goh, WI; Koh, E; Ong, SH; Pawson, T; Sudhaharan, T; Ahmed, S				Lim, Kim Buay; Bu, Wenyu; Goh, Wah Ing; Koh, Esther; Ong, Siew Hwa; Pawson, Tony; Sudhaharan, Thankiah; Ahmed, Sohail			The Cdc42 effector IRSp53 generates filopodia by coupling membrane protrusion with actin dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE; TYROSINE KINASE SUBSTRATE; MISSING-IN-METASTASIS; N-WASP; BAR-DOMAIN; INTRACELLULAR MOTILITY; STRUCTURAL BASIS; HOMOLOGY DOMAIN; SH3 DOMAIN; COMPLEX	The Cdc42 effector IRSp53 is a strong inducer of filopodia formation and consists of an Src homology domain 3 (SH3), a potential WW-binding motif, a partial-Cdc42/Rac interacting binding region motif, and an Inverse-Bin-Amphiphysins-Rvs (I-BAR) domain. We show that IRSp53 interacts directly with neuronal Wiskott-Aldrich syndrome protein (N-WASP) via its SH3 domain and furthermore that N-WASP is required for filopodia formation as IRSp53 failed to induce filopodia formation in N-WASP knockout (KO) fibroblasts. IRSp53-induced filopodia formation can be reconstituted in N-WASP KO fibroblasts by full-length N-WASP, by N-WASP Delta WA (a mutant unable to activate the Arp2/3 complex), and by N-WASPH208D (a mutant unable to bind Cdc42). IRSp53 failed to induce filopodia in mammalian enabled (Mena)/VASP KO cells, and N-WASP failed to induce filopodia when IRSp53 was knocked down with RNA interference. The IRSp53 I-BAR domain alone induces dynamic membrane protrusions that lack actin and are smaller than normal filopodia ("partial-filopodia") in both wild-type N-WASP and N-WASP KO cells. We propose that IRSp53 generates filopodia by coupling membrane protrusion through its I-BAR domain with actin dynamics through SH3 domain binding partners, including N-WASP and Mena.	[Lim, Kim Buay; Bu, Wenyu; Goh, Wah Ing; Koh, Esther; Sudhaharan, Thankiah; Ahmed, Sohail] Inst Med Biol, Singapore 138665, Singapore; [Ong, Siew Hwa; Pawson, Tony] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ahmed, S (corresponding author), Inst Med Biol, 8A Biomedical Grove, Singapore 138665, Singapore.	sohail.ahmed@imb.a-star.edu.sg	Koh, Esther GL/E-3921-2013; Pawson, Tony J/E-4578-2013	Goh, Wah Ing/0000-0001-6594-0640				Alvarez CE, 2002, J BIOL CHEM, V277, P24728, DOI 10.1074/jbc.M202512200; Casal E, 2006, BIOCHEMISTRY-US, V45, P12917, DOI 10.1021/bi060717k; CHIEN CB, 1993, NEURON, V11, P237, DOI 10.1016/0896-6273(93)90181-P; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Disanza A, 2006, NAT CELL BIOL, V8, P1337, DOI 10.1038/ncb1502; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Herrick-Davis K, 2006, J BIOL CHEM, V281, P27109, DOI 10.1074/jbc.M604390200; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hori K, 2003, FEBS LETT, V554, P30, DOI 10.1016/S0014-5793(03)01074-3; Hwang LC, 2004, CHEMPHYSCHEM, V5, P549, DOI 10.1002/cphc.200301057; Jacinto A, 2001, CURR BIOL, V11, pR634, DOI 10.1016/S0960-9822(01)00378-5; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 2002, BIOCHEM BIOPH RES CO, V293, P93, DOI 10.1016/S0006-291X(02)00218-8; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Miyahara A, 2003, J HUM GENET, V48, P410, DOI 10.1007/s10038-003-0047-x; Oda K, 1999, CYTOGENET CELL GENET, V84, P75, DOI 10.1159/000015219; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Okamura-Oho Y, 2001, BIOCHEM BIOPH RES CO, V289, P957, DOI 10.1006/bbrc.2001.6102; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Sekerkova G, 2003, J NEUROSCI, V23, P1310, DOI 10.1523/JNEUROSCI.23-04-01310.2003; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Soltau M, 2004, J NEUROCHEM, V90, P659, DOI 10.1111/j.1471-4159.2004.02523.x; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Suetsugu S, 2006, J BIOL CHEM, V281, P35347, DOI 10.1074/jbc.M606814200; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200	42	102	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20454	20472		10.1074/jbc.M710185200	http://dx.doi.org/10.1074/jbc.M710185200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18448434	hybrid			2022-12-25	WOS:000257565300060
J	Guerriero, CJ; Lai, YM; Weisz, OA				Guerriero, Christopher J.; Lai, Yumei; Weisz, Ora A.			Differential sorting and Golgi export requirements for raft-associated and raft-independent apical proteins along the biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; PLASMA-MEMBRANE; VESICULAR STOMATITIS; MDCK CELLS; IN-VITRO; NETWORK; TRANSPORT; TRAFFICKING; COMPARTMENTS; CARRIERS	Sorting signals for apically destined proteins are highly diverse and can be present within the luminal, membrane-associated, and cytoplasmic domains of these proteins. A subset of apical proteins partition into detergent-resistant membranes, and the association of these proteins with glycolipid-enriched microdomains or lipid rafts may be important for their proper targeting. Recently, we observed that raft-associated and raft-independent apical proteins take different routes to the apical surface of polarized Madin-Darby canine kidney cells (Cresawn, K. O., Potter, B. A., Oztan, A., Guerriero, C. J., Ihrke, G., Goldenring, J. R., Apodaca, G., and Weisz, O. A. (2007) EMBO J. 26, 3737 -3748). Here we reconstituted in vitro the export of raft-associated and raft-independent markers staged intracellularly at 19 C. Surprisingly, whereas release of the raft-associated protein influenza hemagglutinin was dependent on the addition of an ATP-regenerating system and cytosol, release of a yellow fluorescent protein (YFP)-tagged raft-independent protein (the 75-kDa neurotrophin receptor; YFP-p75) was efficient even in the absence of these constituents. Subsequent studies suggested that YFP-p75 is released from the trans-Golgi network in fragile tubules that do not withstand isolation procedures. Moreover, immunofluorescence analysis revealed that hemagglutinin and YFP-p75 segregate into distinct subdomains of the Golgi complex at 19 C. Our data suggest that raft-associated and raft-independent proteins accumulate at distinct intracellular sites upon low temperature staging, and that upon warming, they exit these compartments in transport carriers that have very different membrane characteristics and morphologies.	[Guerriero, Christopher J.; Lai, Yumei; Weisz, Ora A.] Univ Pittsburgh, Sch Med, Div Renal & Electrolyte, Dept Med, Pittsburgh, PA 15261 USA; [Weisz, Ora A.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Sch Med, Div Renal & Electrolyte, Dept Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Guerriero, Christopher/0000-0002-1046-2300	NIDDK NIH HHS [DK 054407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfalah M, 2005, J BIOL CHEM, V280, P42636, DOI 10.1074/jbc.M505924200; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; Cresawn KO, 2007, EMBO J, V26, P3737, DOI 10.1038/sj.emboj.7601813; Derby MC, 2004, J CELL SCI, V117, P5865, DOI 10.1242/jcs.01497; Derby MC, 2007, INT REV CYTOL, V261, P47, DOI 10.1016/S0074-7696(07)61002-X; Ellis MA, 2004, J BIOL CHEM, V279, P52735, DOI 10.1074/jbc.M410533200; Ellis MA, 2006, AM J PHYSIOL-RENAL, V291, pF707, DOI 10.1152/ajprenal.00161.2006; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; Gravotta D, 2007, P NATL ACAD SCI USA, V104, P1564, DOI 10.1073/pnas.0610700104; Guerriero CJ, 2006, J BIOL CHEM, V281, P15376, DOI 10.1074/jbc.M601239200; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Karaivanova VK, 1998, BIOCHEM J, V329, P511; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; Lieu ZZ, 2008, P NATL ACAD SCI USA, V105, P3351, DOI 10.1073/pnas.0800137105; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lock JG, 2005, TRAFFIC, V6, P1142, DOI 10.1111/j.1600-0854.2005.00349.x; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk RS, 2006, TRAFFIC, V7, P1092, DOI 10.1111/j.1600-0854.2006.00453.x; Potter BA, 2006, AM J PHYSIOL-CELL PH, V290, pC1, DOI 10.1152/ajpcell.00333.2005; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Wang CW, 2006, J CELL BIOL, V174, P973, DOI 10.1083/jcb.200605106; YEAMAN C, 1998, CELL BIOL LAB HDB, V2, P237	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18040	18047		10.1074/jbc.M802048200	http://dx.doi.org/10.1074/jbc.M802048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18434305	Green Published, hybrid			2022-12-25	WOS:000256949200033
J	Hogan, C; Hutchison, C; Marcar, L; Milne, D; Saville, M; Goodlad, J; Kernohan, N; Meek, D				Hogan, Carol; Hutchison, Caroline; Marcar, Lynnette; Milne, Diane; Saville, Mark; Goodlad, John; Kernohan, Neil; Meek, David			Elevated levels of oncogenic protein kinase pim-1 induce the p53 pathway in cultured cells and correlate with increased mdm2 in mantle cell lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSION; CROSS-TALK; PHOSPHORYLATION; AKT; PROTOONCOGENE; HDM2; UBIQUITINATION; DEGRADATION; APOPTOSIS; MULTIPLE	Mutation of the p53 gene is a common event during tumor pathogenesis. Other mechanisms, such as mdm2 amplification, provide alternative routes through which dysfunction of the p53 pathway is promoted. Here, we address the hypothesis that elevated expression of pim oncogenes might suppress p53 by regulating Mdm2. At a physiological level, we show that endogenous Pim-1 and Pim-2 interact with endogenous Mdm2. Additionally, the Pim kinases phosphorylate Mdm2 in vitro and in cultured cells at Ser(166) and Ser(186), two previously identified targets of other signaling pathways, including Akt. Surprisingly, at high levels of Pim expression, as would occur in tumors, active, but not inactive, Pim-1 or Pim-2 blocks the degradation of both p53 and Mdm2 in a manner that is independent of Mdm2 phosphorylation, leading to increased p53 levels and, proportionately, p53-dependent transactivation. Additionally, Pim-1 induces endogenous ARF, p53, Mdm2, and p21 in primary murine embryo fibroblasts and stimulates senescence-associated beta-galactosidase levels, consistent with the induction of senescence. Immunohistochemical analysis of a cohort of 33 human mantle cell lymphomas shows that elevated expression of Pim-1 occurs in 42% of cases, with elevated Pim-2 occurring in 9% of cases, all of which also express Pim-1. Notably, elevated Pim-1 correlates with elevated Mdm2 in MCL with a p value of 0.003. Taken together, our data are consistent with the idea that Pim normally interacts with the p53 pathway but, when expressed at pathological levels, behaves as a classic dominant oncogene that stimulates a protective response through induction of the p53 pathway.	[Hogan, Carol; Marcar, Lynnette; Milne, Diane; Meek, David] Ninewells Hosp, Biomed Res Ctr, Dundee DD1 9SY, Scotland; [Hutchison, Caroline; Goodlad, John; Kernohan, Neil] Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; [Saville, Mark] Ninewells Hosp, Div Surg & Oncol, Dundee DD1 9SY, Scotland; [Saville, Mark] Univ Dundee, Sch Med, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee; University of Dundee; University of Dundee	Meek, D (corresponding author), Ninewells Hosp, Biomed Res Ctr, Level 5, Dundee DD1 9SY, Scotland.	d.w.meek@dundee.ac.uk		Goodlad, John Robert/0000-0002-8385-8517	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Allende-Vega N, 2007, ONCOGENE, V26, P4234, DOI 10.1038/sj.onc.1210209; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; de Vos S, 2003, DIAGN MOL PATHOL, V12, P35, DOI 10.1097/00019606-200303000-00005; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ionov Y, 2003, ANTICANCER RES, V23, P167; Jackson MW, 2006, J BIOL CHEM, V281, P16814, DOI 10.1074/jbc.M511617200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; Popivanova BK, 2007, CANCER SCI, V98, P321, DOI 10.1111/j.1349-7006.2007.00390.x; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swerdlow SH, 2002, HUM PATHOL, V33, P7, DOI 10.1053/hupa.2002.30221; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang Z, 2001, J Vet Sci, V2, P167; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Webster GA, 1999, MOL CELL BIOL, V19, P3485; White E, 2003, GENE DEV, V17, P1813, DOI 10.1101/gad.1123103; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhu Y, 2002, BRIT J HAEMATOL, V119, P905, DOI 10.1046/j.1365-2141.2002.03931.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	54	61	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18012	18023		10.1074/jbc.M709695200	http://dx.doi.org/10.1074/jbc.M709695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18467333	Green Accepted, hybrid			2022-12-25	WOS:000256949200030
J	Shimamura, T; Hiraki, K; Takahashi, N; Hori, T; Ago, H; Masuda, K; Takio, K; Ishiguro, M; Miyano, M				Shimamura, Tatsuro; Hiraki, Kenji; Takahashi, Naoko; Hori, Tetsuya; Ago, Hideo; Masuda, Katsuyoshi; Takio, Koji; Ishiguro, Masaji; Miyano, Masashi			Crystal structure of squid rhodopsin with intracellularly extended cytoplasmic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; COVALENT CROSS-LINKING; COMPLEX-FORMATION; CONTACT SITES; G-PROTEINS; RECEPTOR; CRYSTALLOGRAPHY; TRANSDUCIN; SEQUENCE; HELIX-8	G-protein-coupled receptors play a key step in cellular signal transduction cascades by transducing various extracellular signals via G-proteins. Rhodopsin is a prototypical G-protein-coupled receptor involved in the retinal visual signaling cascade. We determined the structure of squid rhodopsin at 3.7 A resolution, which transduces signals through the G(q) protein to the phosphoinositol cascade. The structure showed seven transmembrane helices and an amphipathic helix H8 has similar geometry to structures from bovine rhodopsin, coupling to G(t), and human beta(2)-adrenergic receptor, coupling to G(s). Notably, squid rhodopsin contains a well structured cytoplasmic region involved in the interaction with G-proteins, and this region is flexible or disordered in bovine rhodopsin and human beta 2-adrenergicreceptor. The transmembrane helices 5 and 6 are longer and extrude into the cytoplasm. The distal C-terminal tail contains a short hydrophilic alpha-helix CH after the palmitoylated cysteine residues. The residues in the distal C-terminal tail interact with the neighboring residues in the second cytoplasmic loop, the extruded transmembrane helices 5 and 6, and the short helix H8. Additionally, the Tyr-111, Asn-87, and Asn-185 residues are located within hydrogen-bonding distances from the nitrogen atom of the Schiff base.	[Hiraki, Kenji; Masuda, Katsuyoshi; Ishiguro, Masaji] Suntory Inst Bioorgan Res, Mishima, Osaka 6188503, Japan; [Shimamura, Tatsuro; Takahashi, Naoko; Hori, Tetsuya; Ago, Hideo; Takio, Koji; Miyano, Masashi] Harima Inst, RIKEN, SPring Ctr 8, Sayo, Hyogo 6795148, Japan	Suntory Holdings Ltd; RIKEN	Ishiguro, M (corresponding author), Suntory Inst Bioorgan Res, 1-1-1 Wakayamadai,Shimamoto Cho, Mishima, Osaka 6188503, Japan.	ishiguro@sunbor.or.jp; miyano@spring8.or.jp	Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Delos Santos NM, 2006, J BIOL CHEM, V281, P12896, DOI 10.1074/jbc.M508500200; Elefsinioti AL, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-208; Go L, 2003, COMP BIOCHEM PHYS B, V135, P601, DOI 10.1016/S1096-4959(03)00140-4; HARANISHIMURA I, 1993, FEBS LETT, V317, P5, DOI 10.1016/0014-5793(93)81480-N; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITO Y, 1982, METHOD ENZYMOL, V81, P43; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kuniyeda K, 2007, J BIOL CHEM, V282, P3998, DOI 10.1074/jbc.M610540200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Murakami M, 2007, ACTA CRYSTALLOGR F, V63, P475, DOI 10.1107/S1744309107017423; Nakamura T, 2004, PROTEOMICS, V4, P2558, DOI 10.1002/pmic.200300812; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; SAIL HR, 1984, P NATL ACAD SCI USA, V81, P5111; Sgourakis NG, 2005, BIOINFORMATICS, V21, P4101, DOI 10.1093/bioinformatics/bti679; Takahashi N, 2003, EUR J BIOCHEM, V270, P2627, DOI 10.1046/j.1432-1033.2003.03636.x; Terakita A, 1998, FEBS LETT, V439, P110, DOI 10.1016/S0014-5793(98)01340-4; Terakita A, 2004, NAT STRUCT MOL BIOL, V11, P284, DOI 10.1038/nsmb731	32	105	105	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17753	17756		10.1074/jbc.C800040200	http://dx.doi.org/10.1074/jbc.C800040200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18463093	hybrid, Green Published			2022-12-25	WOS:000256949200002
J	Loyola, RD; Becker, CG; Kubota, U; Haddad, CFB; Fonseca, CR; Lewinsohn, TM				Loyola, Rafael Dias; Becker, Carlos Guilherme; Kubota, Umberto; Baptista Haddad, Celio Fernando; Fonseca, Carlos Roberto; Lewinsohn, Thomas Michael			Hung Out to Dry: Choice of Priority Ecoregions for Conserving Threatened Neotropical Anurans Depends on Life-History Traits	PLOS ONE			English	Article							IDENTIFYING CONSERVATION PRIORITIES; RESERVE SELECTION ALGORITHMS; POPULATION DECLINES; ECOLOGICAL TRAITS; SPECIES RICHNESS; INDICATOR GROUPS; BIODIVERSITY; DIVERSITY; LANDSCAPE; HABITAT	Background: In the Neotropics, nearly 35% of amphibian species are threatened by habitat loss, habitat fragmentation, and habitat split; anuran species with different developmental modes respond to habitat disturbance in different ways. This entails broad-scale strategies for conserving biodiversity and advocates for the identification of high conservation-value regions that are significant in a global or continental context and that could underpin more detailed conservation assessments towards such areas. Methodology/Principal Findings: We identified key ecoregion sets for anuran conservation using an algorithm that favors complementarity (beta-diversity) among ecoregions. Using the WWF's Wildfinder database, which encompasses 700 threatened anuran species in 119 Neotropical ecoregions, we separated species into those with aquatic larvae (AL) or terrestrial development (TD), as this life-history trait affects their response to habitat disturbance. The conservation target of 100% of species representation was attained with a set of 66 ecoregions. Among these, 30 were classified as priority both for species with AL and TD, 26 were priority exclusively for species with AL, and 10 for species with TD only. Priority ecoregions for both developmental modes are concentrated in the Andes and in Mesoamerica. Ecoregions important for conserving species with AL are widely distributed across the Neotropics. When anuran life histories were ignored, species with AL were always underrepresented in priority sets. Conclusions/Significance: The inclusion of anuran developmental modes in prioritization analyses resulted in more comprehensive coverage of priority ecoregions-especially those essential for species that require an aquatic habitat for their reproduction-when compared to usual analyses that do not consider this life-history trait. This is the first appraisal of the most important regions for conservation of threatened Neotropical anurans. It is also a first endeavor including anuran life-history traits in priority area-selection for conservation, with a clear gain in comprehensiveness of the selection process.	[Loyola, Rafael Dias] Univ Estadual Campinas, Inst Biol, Programa Posgrad Ecol, Sao Paulo, Brazil; [Loyola, Rafael Dias; Becker, Carlos Guilherme; Kubota, Umberto; Lewinsohn, Thomas Michael] Univ Estadual Campinas, Inst Biol, Dept Zool, Sao Paulo, Brazil; [Baptista Haddad, Celio Fernando] Univ Estadual Paulista, Dept Zool, Sao Paulo, Brazil; [Fonseca, Carlos Roberto] Univ Vale Rio dos Sinos, Sao Leopoldo, Sao Leopoldo, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual Paulista; Universidade do Vale do Rio dos Sinos (Unisinos)	Loyola, RD (corresponding author), Univ Estadual Campinas, Inst Biol, Programa Posgrad Ecol, Sao Paulo, Brazil.	avispa@gmail.com	Loyola, Rafael/S-3978-2019; Becker, C. Guilherme/B-9887-2014; Fonseca, Carlos Roberto/V-5869-2017; Loyola, Rafael/A-4425-2008; Haddad, Célio F. B./C-4267-2012; Lewinsohn, Thomas M/D-5880-2012; Fonseca, Carlos Roberto/A-9273-2013	Loyola, Rafael/0000-0001-5323-2735; Fonseca, Carlos Roberto/0000-0003-0292-0399; Loyola, Rafael/0000-0001-5323-2735; Haddad, Célio F. B./0000-0002-7044-5764; Lewinsohn, Thomas M/0000-0001-5950-5343; 	CNPq [140267/2005-0, 302512/2005-5, 305428/2005-5, 306049/2004-0]; FAPESP [04/13132-3]; CAPES;  [04/15482-1]	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); 	RDL, CGB and UK were supported by CNPq (140267/2005-0), FAPESP (04/13132-3) and CAPES, respectively. CFBH thanks FAPESP and CNPq (302512/2005-5) for financial support. CRF is supported by CNPq (305428/2005-5). TML was funded by FAPESP (04/15482-1) and CNPq (306049/2004-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDELMAN S, 1999, SITES V 1 0 AN TOOLB; Becker CG, 2008, BIODIVERS CONSERV, V17, P2297, DOI 10.1007/s10531-007-9298-8; Becker CG, 2007, SCIENCE, V318, P1775, DOI 10.1126/science.1149374; Bell KE, 2006, CONSERV BIOL, V20, P1750, DOI 10.1111/j.1523-1739.2006.00522.x; Bini LM, 2006, DIVERS DISTRIB, V12, P475, DOI 10.1111/j.1366-9516.2006.00286.x; BOJORQUEZTAPIA LA, 1995, ECOL APPL, V5, P215, DOI 10.2307/1942065; Brooks T, 2001, BIOSCIENCE, V51, P613, DOI 10.1641/0006-3568(2001)051[0613:TABFCI]2.0.CO;2; Cabeza M, 2001, TRENDS ECOL EVOL, V16, P242, DOI 10.1016/S0169-5347(01)02125-5; CALDERON R, 2004, NATURE CONSERVANCY; Csuti B, 1997, BIOL CONSERV, V80, P83, DOI 10.1016/S0006-3207(96)00068-7; Diniz JAF, 2006, ACTA OECOL, V29, P9, DOI 10.1016/j.actao.2005.07.004; Duellman W.E., 1979, MONOGR MUS NAT HIST, P371, DOI 10.5962/bhl.title.3207; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; Ferrier S, 2000, BIOL CONSERV, V93, P303, DOI 10.1016/S0006-3207(99)00149-4; Frost DR, 2007, AMPHIBIAN SPECIES WO; Garcia A, 2006, BIOL CONSERV, V130, P25, DOI 10.1016/j.biocon.2005.11.030; Gascon C, 1999, BIOL CONSERV, V91, P223, DOI 10.1016/S0006-3207(99)00080-4; Grenyer R, 2006, NATURE, V444, P93, DOI 10.1038/nature05237; Guerry AD, 2002, CONSERV BIOL, V16, P745, DOI 10.1046/j.1523-1739.2002.00557.x; Haddad CFB, 2005, BIOSCIENCE, V55, P724, DOI 10.1641/0006-3568(2005)055[0724:RMIFC]2.0.CO;2; Hero JM, 2005, J ZOOL, V267, P221, DOI 10.1017/S0952836905007296; Howard PC, 1998, NATURE, V394, P472, DOI 10.1038/28843; *IUCN CONS INT NAT, 2006, GLOB AMPH ASS; KIRKPATRICK JB, 1983, BIOL CONSERV, V25, P127, DOI 10.1016/0006-3207(83)90056-3; Kress WJ, 1998, BIODIVERS CONSERV, V7, P1577, DOI 10.1023/A:1008889803319; Lamoreux JF, 2006, NATURE, V440, P212, DOI 10.1038/nature04291; Lips KR, 1998, CONSERV BIOL, V12, P106, DOI 10.1046/j.1523-1739.1998.96359.x; Lips KR, 2003, CONSERV BIOL, V17, P1078, DOI 10.1046/j.1523-1739.2003.01623.x; Loyola RD, 2007, DIVERS DISTRIB, V13, P389, DOI 10.1111/j.1472-4642.2007.00345.x; LOYOLA RD, 2008, DIVERS DIST IN PRESS; Margules CR, 2000, NATURE, V405, P243, DOI 10.1038/35012251; McKnight MW, 2007, PLOS BIOL, V5, P2424, DOI 10.1371/journal.pbio.0050272; Meir E, 2004, ECOL LETT, V7, P615, DOI 10.1111/j.1461-0248.2004.00624.x; Mittermeier RA, 2004, HOTSPOTS REVISITED; Moore JL, 2003, CONSERV BIOL, V17, P207, DOI 10.1046/j.1523-1739.2003.01126.x; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; Pearman PB, 1997, CONSERV BIOL, V11, P1211, DOI 10.1046/j.1523-1739.1997.96202.x; Pimenta BVS, 2005, SCIENCE, V309, DOI 10.1126/science.1112996; Pineda E, 2004, BIOL CONSERV, V117, P499, DOI 10.1016/j.biocon.2003.08.009; Pope SE, 2000, ECOLOGY, V81, P2498; Possingham H, 1998, QUANTITATIVE METHODS FOR CONSERVATION BIOLOGY, P291; Pounds JA, 2006, NATURE, V439, P161, DOI 10.1038/nature04246; Pounds JA, 1999, NATURE, V398, P611, DOI 10.1038/19297; Pressey RL, 1996, BIOL CONSERV, V76, P259, DOI 10.1016/0006-3207(95)00120-4; Pressey RL, 1997, BIOL CONSERV, V80, P207, DOI 10.1016/S0006-3207(96)00045-6; Reyers B, 2000, P ROY SOC B-BIOL SCI, V267, P505, DOI 10.1098/rspb.2000.1029; Rittenhouse TAG, 2006, BIOL CONSERV, V131, P14, DOI 10.1016/j.biocon.2006.01.024; Sarkar S, 2002, J BIOSCIENCES, V27, P299, DOI 10.1007/BF02704961; Sierra R, 2002, LANDSCAPE URBAN PLAN, V59, P95, DOI 10.1016/S0169-2046(02)00006-3; Silvano RAM, 2005, ECOL ECON, V53, P369, DOI 10.1016/j.ecolecon.2004.12.003; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; Tocher Mandy D., 2001, P235; Urbina-Cardona JN, 2006, BIOL CONSERV, V132, P61, DOI 10.1016/j.biocon.2006.03.014; VIANA V.M., 1997, TROPICAL FOREST REMN, P347; *WORLD WILDL FUND, 2006, WILDFINDER ONL DAT S; Young BE, 2001, CONSERV BIOL, V15, P1213, DOI 10.1046/j.1523-1739.2001.00218.x	56	55	61	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2120	10.1371/journal.pone.0002120	http://dx.doi.org/10.1371/journal.pone.0002120			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461175	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400041
J	Kinkhabwala, A; Guet, CC				Kinkhabwala, Ali; Guet, Calin C.			Uncovering cis Regulatory Codes Using Synthetic Promoter Shuffling	PLOS ONE			English	Article								Revealing the spectrum of combinatorial regulation of transcription at individual promoters is essential for understanding the complex structure of biological networks. However, the computations represented by the integration of various molecular signals at complex promoters are difficult to decipher in the absence of simple cis regulatory codes. Here we synthetically shuffle the regulatory architecture-operator sequences binding activators and repressors-of a canonical bacterial promoter. The resulting library of complex promoters allows for rapid exploration of promoter encoded logic regulation. Among all possible logic functions, NOR and ANDN promoter encoded logics predominate. A simple transcriptional cis regulatory code determines both logics, establishing a straightforward map between promoter structure and logic phenotype. The regulatory code is determined solely by the type of transcriptional regulation combinations: two repressors generate a NOR: NOT (a OR b) whereas a repressor and an activator generate an ANDN: a AND NOT b. Three-input versions of both logics, having an additional repressor as an input, are also present in the library. The resulting complex promoters cover a wide dynamic range of transcriptional strengths. Synthetic promoter shuffling represents a fast and efficient method for exploring the spectrum of complex regulatory functions that can be encoded by complex promoters. From an engineering point of view, synthetic promoter shuffling enables the experimental testing of the functional properties of complex promoters that cannot necessarily be inferred ab initio from the known properties of the individual genetic components. Synthetic promoter shuffling may provide a useful experimental tool for studying naturally occurring promoter shuffling.	[Kinkhabwala, Ali; Guet, Calin C.] Rockefeller Univ, Lab Living Matter, New York, NY 10021 USA; [Kinkhabwala, Ali] Max Planck Inst Mol Physiol, Syst Cell Biol, Dortmund, Germany; [Guet, Calin C.] Univ Chicago, Inst Biophys Dynam, Chicago, IL USA	Rockefeller University; Max Planck Society; University of Chicago	Kinkhabwala, A (corresponding author), Rockefeller Univ, Lab Living Matter, 1230 York Ave, New York, NY 10021 USA.	kinkhabw@mpi-dortmund.mpg.de; calin@uchicago.edu			NIH [Ruth L. Kirschstein NRSA fellowship]; Yen Fellowship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yen Fellowship	A.K. was supported by an NIH Ruth L. Kirschstein NRSA fellowship, C.C.G. was supported by a Yen Fellowship.	Babu MM, 2003, TRENDS GENET, V19, P75, DOI 10.1016/S0168-9525(02)00039-2; Beer MA, 2004, CELL, V117, P185, DOI 10.1016/S0092-8674(04)00304-6; Brinig MM, 2006, J BACTERIOL, V188, P2375, DOI 10.1128/JB.188.7.2375-2382.2006; Buchler NE, 2003, P NATL ACAD SCI USA, V100, P5136, DOI 10.1073/pnas.0930314100; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Chuzhanova NA, 2000, GENE, V254, P9, DOI 10.1016/S0378-1119(00)00308-5; Chuzhanova NA, 2002, EVOLUTION, V56, P224; Davidson E. H., 2001, DEV EVOLUTION; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; GUET CC, 2004, THESIS PRINCETON U P; Hermsen R, 2006, PLOS COMPUT BIOL, V2, P1552, DOI 10.1371/journal.pcbi.0020164; Kauffman S. A., 1993, ORIGINS ORDER; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Morgan-Kiss RM, 2002, P NATL ACAD SCI USA, V99, P7373, DOI 10.1073/pnas.122227599; REEDER T, 1993, J MOL BIOL, V231, P205, DOI 10.1006/jmbi.1993.1276; Sanges R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r56; Schleif R, 2003, BIOESSAYS, V25, P274, DOI 10.1002/bies.10237; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Stone JR, 2001, MOL BIOL EVOL, V18, P1764, DOI 10.1093/oxfordjournals.molbev.a003964; SUGITA M, 1961, J PHYS SOC JPN, V16, P737, DOI 10.1143/JPSJ.16.737; Surguchov A, 1991, Biomed Sci, V2, P22; Tan K, 2005, GENOME RES, V15, P312, DOI 10.1101/gr.3069205; Walser JC, 2006, PLOS GENET, V2, P1541, DOI 10.1371/journal.pgen.0020165; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; ZADEH LA, 1965, INFORM CONTROL, V8, P338, DOI 10.1016/S0019-9958(65)90241-X; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	30	33	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2030	10.1371/journal.pone.0002030	http://dx.doi.org/10.1371/journal.pone.0002030			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446205	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300004
J	Michael, JB; Nigel, JB; Edward, MS; Clokie, MRJ; Mann, NH; Bryan, SJ				Bryan, Michael J.; Burroughs, Nigel J.; Spence, Edward M.; Clokie, Martha R. J.; Mann, Nicholas H.; Bryan, Samantha J.			Evidence for the Intense Exchange of MazG in Marine Cyanophages by Horizontal Gene Transfer	PLOS ONE			English	Article								Background: S-PM2 is a phage capable of infecting strains of unicellular cyanobacteria belonging to the genus Synechococcus. S-PM2, like other myoviruses infecting marine cyanobacteria, encodes a number of bacterial-like genes. Amongst these genes is one encoding a MazG homologue that is hypothesized to be involved in the adaption of the infected host for production of progeny phage. Methodology/Principal Findings: This study focuses on establishing the occurrence of mazG homologues in other cyanophages isolated from different oceanic locations. Degenerate PCR primers were designed using the mazG gene of S-PM2. The mazG gene was found to be widely distributed and highly conserved among Synechococcus myoviruses and podoviruses from diverse oceanic provinces. Conclusions/Significance: This study provides evidence of a globally connected cyanophage gene pool, the cyanophage mazG gene having a small effective population size indicative of rapid lateral gene transfer despite being present in a substantial fraction of cyanophage. The Prochlorococcus and Synechococcus phage mazG genes do not cluster with the host mazG gene, suggesting that their primary hosts are not the source of the mazG gene.	[Bryan, Michael J.; Spence, Edward M.; Mann, Nicholas H.; Bryan, Samantha J.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Burroughs, Nigel J.] Univ Warwick, Warwick Syst Biol Ctr, Coventry, W Midlands, England; [Clokie, Martha R. J.] Univ Leicester, Dept Infect, Immun & Inflammat, Leicester, Leics, England	University of Warwick; University of Warwick; University of Leicester	Michael, JB (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Samantha_bryan@hotmail.co.uk		Clokie, Martha/0000-0002-6069-8936	Warick University	Warick University	Funding was provided by the Warick University. They had no role in the design or conduct of the study.	Bailey S, 2004, RES MICROBIOL, V155, P720, DOI 10.1016/j.resmic.2004.06.002; BORBELY G, 1980, J BACTERIOL, V144, P859; Breitbart M, 2006, FEMS MICROBIOL LETT, V254, P332; Clokie MRJ, 2006, ENVIRON MICROBIOL, V8, P2074, DOI 10.1111/j.1462-2920.2006.01171.x; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; FRIGA GM, 1981, ARCH MICROBIOL, V129, P341, DOI 10.1007/BF00406458; Fuller NJ, 1998, APPL ENVIRON MICROB, V64, P2051; Galperin MY, 2006, MOL MICROBIOL, V59, P5, DOI 10.1111/j.1365-2958.2005.04950.x; Gelman A., 1992, STAT SCI, V7, P457, DOI [DOI 10.1214/SS/1177011136, 10.1214/ss/1177011136]; Gross M, 2006, MOL MICROBIOL, V59, P590, DOI 10.1111/j.1365-2958.2005.04956.x; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Magnusson LU, 2005, TRENDS MICROBIOL, V13, P236, DOI 10.1016/j.tim.2005.03.008; MANN N, 1975, BIOCHIM BIOPHYS ACTA, V402, P41, DOI 10.1016/0005-2787(75)90368-8; Mann NH, 2005, J BACTERIOL, V187, P3188, DOI 10.1128/JB.187.9.3188-3200.2005; Mann NH, 2003, FEMS MICROBIOL REV, V27, P17, DOI 10.1016/S0168-6445(03)00016-0; Morris RM, 2004, APPL ENVIRON MICROB, V70, P2836, DOI 10.1128/AEM.70.5.2836-2842.2004; Short CM, 2005, APPL ENVIRON MICROB, V71, P480, DOI 10.1128/AEM.71.1.480-486.2005; SPRAGUE SG, 1981, J BACTERIOL, V147, P1021, DOI 10.1128/JB.147.3.1021-1031.1981; Wang JD, 2007, CELL, V128, P865, DOI 10.1016/j.cell.2006.12.043	19	45	56	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2048	10.1371/journal.pone.0002048	http://dx.doi.org/10.1371/journal.pone.0002048			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431505	gold, Green Published, Green Submitted			2022-12-25	WOS:000261558700040
J	Sanchez, A; Setien, F; Martinez, N; Oliva, JL; Herranz, M; Fraga, MF; Alaminos, M; Esteller, M; Rojas, JM				Sanchez, A.; Setien, F.; Martinez, N.; Oliva, J. L.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.; Rojas, J. M.			Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas	ONCOGENE			English	Article						hSpry2; epigenetic; lymphomas; B cells; suppressor gene	SPROUTY PROTEINS; PROSTATE-CANCER; DNA METHYLATION; CPG ISLANDS; SUPPRESSOR	Spry2 has been characterized as a negative regulator of the extracellular-regulated kinase (ERK) pathway. In this study we analysed whether epigenetic alterations of hSpry2 promoter occur in human lymphoid/hematopoietic malignancies. Our results revealed that hSpry2 promoter was hypermethylated in the HT cell line derived from a B-cell diffuse lymphoma, which correlated with decreased hSpry2 expression. We detected deregulation of the ERK pathway in these cells, but not in other blood cell lines expressing hSpry2. In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK upon phorbol 12-myristate-13-acetate stimulation. Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells. We found hypermethylation of hSpry2 promoter in 37% ( 26 cases out of 71) of primary tumors from patients with B-cell diffuse lymphoma but none in normal B lymphocytes from 37 healthy individuals. Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies.	[Sanchez, A.; Martinez, N.; Oliva, J. L.; Rojas, J. M.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Madrid 28220, Spain; [Setien, F.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.] Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Centro Nacional de Investigaciones Oncologicas (CNIO)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Carretera Majadahonda Pozuelo,Km 2, Madrid 28220, Spain.	jmrojas@isciii.es	Rojas, José M/D-3718-2018; Fraga, Mario F/H-7824-2017; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Rojas, José M./AAA-3354-2021; Herranz, Michel/L-2561-2016	Rojas, José M/0000-0002-5383-3482; Fraga, Mario F/0000-0001-8450-2603; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Rojas, José M./0000-0002-7547-2825; 	Ministerio de Educacion y Ciencia, Spain [SAF2006-04247]; Fundacion Mutua Madrilena Automovilista [FMMA-2005]; Fundacio la Caixa [BM04/179-02]; Comunidad de Madrid, Spain [GR/SAL/0291/2004]; Instituto de Salud Carlos III; Spanish Association Against Cancer (AECC) [FIS01-04)]	Ministerio de Educacion y Ciencia, Spain(Spanish Government); Fundacion Mutua Madrilena Automovilista; Fundacio la Caixa(La Caixa FoundationEuropean Commission); Comunidad de Madrid, Spain(Comunidad de Madrid); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Association Against Cancer (AECC)	We thank Dr A Torano and Dr M Dominguez for the comments and help to recruit the healthy volunteers. AS was recipient of a fellowship from the Instituto de Salud Carlos III. This work was supported by grants SAF2006-04247 from the Ministerio de Educacion y Ciencia, Spain; FMMA-2005 from the Fundacion Mutua Madrilena Automovilista; BM04/179-02 from the Fundacio la Caixa'; GR/SAL/0291/2004 from the Comunidad de Madrid, Spain and RETICS from the Instituto de Salud Carlos III (Red Tematica de Investigacion Cooperativa en Cancer) to JMR; and the Health (FIS, FIS01-04) and Science (I+D+I) departments of the Spanish Government to ME and the Spanish Association Against Cancer (AECC) to JMR and ME.	Bundschu K, 2007, BIOESSAYS, V29, P897, DOI 10.1002/bies.20632; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2002, J NATL CANCER I, V94, P26; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Martinez N, 2007, CELL SIGNAL, V19, P2277, DOI 10.1016/j.cellsig.2007.07.008; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353	14	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4969	4972		10.1038/onc.2008.129	http://dx.doi.org/10.1038/onc.2008.129			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427547				2022-12-25	WOS:000258596900011
J	Metzner, C; Mostegl, MM; Gunzburg, WH; Salmons, B; Dangerfield, JA				Metzner, Christoph; Mostegl, Meike M.; Guenzburg, Walter H.; Salmons, Brian; Dangerfield, John A.			Association of glycosylphosphatidylinositol-anchored protein with retroviral particles	FASEB JOURNAL			English	Article						GPI; retrovirus; lentivirus; gene therapy; vaccine development	SIMIAN IMMUNODEFICIENCY VIRUS; MAGNETIC NANOPARTICLES; CELLS; INSERTION; ENZYME	We describe for the first time the association of glycosylphosphatidylinositol (GPI)-anchored proteins with retroviral and lentiviral particles, similar to a process well established for cells, termed "painting." The aim of the study was to assess the feasibility of modification of retroviral vectors by exogenous addition of recombinant protein, removing the need for genetic engineering of virus producer cell lines. The recombinant GPI protein CD59his was purified via fast protein liquid chromatography and associated with concentrated virus stock in a controlled incubation procedure. Reaction mixtures were purified in order to remove nonassociated GPI protein and endogenous protein. Analysis of samples by immunoblotting revealed that CD59his was only detectable in the presence of viral particles. From this, we conclude that CD59his could be stably associated with retroviral particles. In addition, we demonstrated by flow cytometry that virus particles remain infectious after these procedures. As well as suggesting a novel possibility for interaction between enveloped virus and host, we believe that the stable association of recombinant GPI proteins to retroviral particles can be developed into an important tool for both research and clinical applications, especially in the fields of gene therapy and vaccine development.	[Metzner, Christoph; Mostegl, Meike M.; Guenzburg, Walter H.; Dangerfield, John A.] Univ Vet Med, Inst Virol, A-1210 Vienna, Austria; [Metzner, Christoph; Guenzburg, Walter H.] Christian Doppler Lab Gene Therapeut Vector Dev, Vienna, Austria; [Mostegl, Meike M.; Guenzburg, Walter H.; Dangerfield, John A.] Foreign Module Retroviral Nanotechnol, Christian Doppler Lab Gene Therapeut Vector Dev, Singapore, Singapore; [Salmons, Brian; Dangerfield, John A.] Austrianova, Vienna, Austria; [Salmons, Brian] Austrianova Biomfg, Vienna, Austria	University of Veterinary Medicine Vienna	Metzner, C (corresponding author), Univ Vet Med, Inst Virol, Vet Pl 1, A-1210 Vienna, Austria.	christoph.metzner@vu-wien.ac.at	Gunzburg, Walter/ABI-6076-2020; Salmons, Brian/E-3001-2010	Gunzburg, Walter/0000-0001-8907-1021; Salmons, Brian/0000-0002-9490-9447; Metzner, Christoph/0000-0001-6036-4138				Breun S, 1999, BIOCHEM BIOPH RES CO, V264, P1, DOI 10.1006/bbrc.1999.1474; Chan L, 2005, J VIROL, V79, P13190, DOI 10.1128/JVI.79.20.13190-13194.2005; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; Hlavaty J, 2004, J VIROL, V78, P1384, DOI 10.1128/JVI.78.3.1384-1392.2004; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1; Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z; Klein D, 1997, GENE THER, V4, P1256, DOI 10.1038/sj.gt.3300519; Kueng HJ, 2007, J VIROL, V81, P8666, DOI 10.1128/JVI.00682-07; Lauc G, 2006, BBA-GEN SUBJECTS, V1760, P584, DOI 10.1016/j.bbagen.2005.11.014; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Morandat S, 2002, BBA-BIOMEMBRANES, V1564, P473, DOI 10.1016/S0005-2736(02)00497-2; Pambalk K, 2002, BIOCHEM BIOPH RES CO, V293, P239, DOI 10.1016/S0006-291X(02)00207-3; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; Ronzon F, 2004, J MEMBRANE BIOL, V197, P169, DOI 10.1007/s00232-004-0651-5; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skountzou I, 2007, J VIROL, V81, P1083, DOI 10.1128/JVI.01692-06; Sloand EM, 2004, BLOOD, V104, P3782, DOI 10.1182/blood-2004-02-0645; Steinrigl A, 2007, VIROLOGY, V362, P50, DOI 10.1016/j.virol.2006.11.037; Taraboletti G, 2006, NEOPLASIA, V8, P96, DOI 10.1593/neo.05583; Wilhelm C, 2007, J NANOSCI NANOTECHNO, V7, P2933, DOI 10.1166/jnn.2007.668; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	25	22	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2734	2739		10.1096/fj.08-108217	http://dx.doi.org/10.1096/fj.08-108217			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18477763				2022-12-25	WOS:000258089300013
J	Helmerhorst, EJ; Sun, XL; Salih, E; Oppenheim, FG				Helmerhorst, Eva J.; Sun, Xiuli; Salih, Erdjan; Oppenheim, Frank G.			Identification of Lys-Pro-Gln as a novel cleavage site specificity of saliva-associated proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEINS; HUMAN PAROTID SALIVA; ENZYMATIC CHARACTERIZATION; DISC ELECTROPHORESIS; STREPTOCOCCUS-MUTANS; NUCLEOTIDE-SEQUENCE; ENAMEL PELLICLE; GENE FAMILY; P-B; CLONING	The nonsterile environment of the oral cavity facilitates substantial proteolytic processing, not only of resident salivary proteins but also of dietary proteins. To gain insight into whole saliva enzymatic processes, the in vivo generated peptides in this oral fluid were subjected to nano-flow liquid chromatography electrospray ionization tandem mass spectrometry. The 182 peptides identified were predominantly derived from acidic and basic proline-rich proteins, statherin, and histatins. The proteolytic cleavages in the basic proline-rich proteins occurred preferentially after a Gln residue with predominant specificity for the tripeptide Xaa-Pro-Gln, where Xaa in the P-3 position was mostly represented by Lys. Using the synthetic substrates Lys-Pro-Gln-pNA and Gly-Gly-Gln-pNA, the overall K-m values were determined to be 97 +/- 7.7 and 611 +/- 28 mu M, respectively, confirming glutamine endoprotease activity in whole saliva and the influence of the amino acids in positions P-2 and P-3 on protease recognition. The pH optimum of Lys-Pro-Gln-pNA hydrolysis was 7.0, and the activity was most effectively inhibited by antipain and 4-(2-aminoethyl) benzenesulfonyl fluoride, was metal ion-dependent, and not inhibited by cysteine protease inhibitors. Asystematic evaluation of enzyme activities in various exocrine and nonexocrine contributors to whole saliva revealed that the glutamine endoprotease is derived from dental plaque and likely microbial in origin. The P-1 site being occupied by a Gln residue is a nonarchetype with respect to known proteases and indicates the presence of novel glutamine-specific endoprotease(s) in oral fluid.	[Helmerhorst, Eva J.; Sun, Xiuli; Salih, Erdjan; Oppenheim, Frank G.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Helmerhorst, EJ (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, 700 Albany St,W-201, Boston, MA 02118 USA.	helmer@bu.edu		Helmerhorst, Eva/0000-0002-4803-3018; Salih, Erdjan/0000-0003-3322-2323	NIAID NIH HHS [R01 AI087803] Funding Source: Medline; NIDCR NIH HHS [DE 07652, DE 18132, DE 05672, DE 16699] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI087803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005672, R21DE018132, R03DE016699, R01DE005672] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALHASHIMI I, 1989, ARCH ORAL BIOL, V34, P289, DOI 10.1016/0003-9969(89)90070-8; ARNEBERG P, 1971, Scandinavian Journal of Dental Research, V79, P60; Azen EA, 1996, AM J HUM GENET, V58, P143; Basak A, 1999, BIOCHEM J, V343, P29, DOI 10.1042/0264-6021:3430029; BAUM BJ, 1977, COMP BIOCHEM PHYS A, V56, P115, DOI 10.1016/0300-9629(77)90171-2; BAUM BJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P427, DOI 10.1016/0003-9861(76)90455-0; BOBEK LA, 1991, BIOCHEM J, V278, P627, DOI 10.1042/bj2780627; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Castagnola M, 2004, J BIOL CHEM, V279, P41436, DOI 10.1074/jbc.M404322200; Chan M, 2001, EUR J BIOCHEM, V268, P3423, DOI 10.1046/j.1432-1327.2001.02241.x; CHAUNCEY HH, 1961, J AM DENT ASSOC, V63, P360, DOI 10.14219/jada.archive.1961.0215; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dawes C, 2004, CARIES RES, V38, P236, DOI 10.1159/000077760; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; Flora B, 2001, PROTEIN EXPRES PURIF, V23, P198, DOI 10.1006/prep.2001.1493; HAY DI, 1988, BIOCHEM J, V255, P15, DOI 10.1042/bj2550015; Hejgaard J, 2005, BIOL CHEM, V386, P1319, DOI 10.1515/BC.2005.150; Helmerhorst EJ, 2007, J DENT RES, V86, P680, DOI 10.1177/154405910708600802; Helmerhorst EJ, 2006, ARCH ORAL BIOL, V51, P1061, DOI 10.1016/j.archoralbio.2006.06.005; Helmerhorst EJ, 2007, ANN NY ACAD SCI, V1098, P454, DOI 10.1196/annals.1384.013; Inzitari R, 2006, PROTEOMICS, V6, P6370, DOI 10.1002/pmic.200600395; Isemura S, 2000, J BIOCHEM-TOKYO, V127, P393, DOI 10.1093/oxfordjournals.jbchem.a022620; Ishihara M, 2002, MICROBIOL IMMUNOL, V46, P299, DOI 10.1111/j.1348-0421.2002.tb02699.x; Li J, 2004, ARCH ORAL BIOL, V49, P379, DOI 10.1016/j.archoralbio.2004.01.002; Li J, 2003, ORAL MICROBIOL IMMUN, V18, P183, DOI 10.1034/j.1399-302X.2003.00065.x; MAEDA N, 1985, J BIOL CHEM, V260, P1123; Makinen K K, 1966, Acta Odontol Scand, V24, P579, DOI 10.3109/00016356609028730; Merrell Karen, 2004, J Biomol Tech, V15, P238; Messana I, 2008, MOL CELL PROTEOMICS, V7, P911, DOI 10.1074/mcp.M700501-MCP200; MINAGUCHI K, 1988, BIOCHEM J, V250, P171, DOI 10.1042/bj2500171; NISHIDE T, 1986, GENE, V41, P299; OPPENHEIM FG, 1971, BIOCHEMISTRY-US, V10, P4233, DOI 10.1021/bi00799a013; Oppenheim FG, 2007, ANN NY ACAD SCI, V1098, P22, DOI 10.1196/annals.1384.030; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAYNE JB, 1991, ORAL MICROBIOL IMMUN, V6, P169, DOI 10.1111/j.1399-302X.1991.tb00472.x; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; SABATINI LM, 1989, BIOCHEM BIOPH RES CO, V160, P495, DOI 10.1016/0006-291X(89)92460-1; SABATINI LM, 1987, AM J HUM GENET, V41, P1048; SABATINI LM, 1993, MOL BIOL EVOL, V10, P497; SAITOH E, 1991, BIOMED BIOCHIM ACTA, V50, P599; Saitoh E, 1992, Agents Actions Suppl, V38 ( Pt 1), P340; Salih E, 2005, MASS SPECTROM REV, V24, P828, DOI 10.1002/mas.20042; SLOTS J, 1981, J CLIN MICROBIOL, V14, P288, DOI 10.1128/JCM.14.3.288-294.1981; Stubbs M, 1998, ARCH ORAL BIOL, V43, P753, DOI 10.1016/S0003-9969(98)00068-5; Villen J, 2007, P NATL ACAD SCI USA, V104, P1488, DOI 10.1073/pnas.0609836104; Vora H, 2007, BIOTECHNOL BIOENG, V98, P177, DOI 10.1002/bit.21423; WIKSTROM MB, 1983, APPL ENVIRON MICROB, V45, P393; WONG RSC, 1979, J BIOL CHEM, V254, P4800; WONG RSC, 1980, J BIOL CHEM, V255, P5943	50	50	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					19957	19966		10.1074/jbc.M708282200	http://dx.doi.org/10.1074/jbc.M708282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18463091	hybrid, Green Published			2022-12-25	WOS:000257565300011
J	Alam, SMK; Konno, T; Sahgal, N; Lu, L; Soares, MJ				Alam, S. M. Khorshed; Konno, Toshihiro; Sahgal, Namita; Lu, Lu; Soares, Michael J.			Decidual cells produce a heparin-binding prolactin family cytokine with putative intrauterine regulatory actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY-DEPENDENT ADAPTATIONS; PLACENTAL LACTOGEN-II; GENE FAMILY; HETEROLOGOUS EXPRESSION; ANTIPEPTIDE ANTIBODIES; PHYSIOLOGICAL STRESSOR; MOLECULAR-CLONING; HORMONE FAMILY; GROWTH-HORMONE; STROMAL CELLS	Pregnancy in mice and rats is associated with the production of a large family of hormones/cytokines related to prolactin (PRL). The hormones/cytokines are hypothesized to coordinate maternal and fetal adaptations to pregnancy. In this study, PRL-like protein-J (PLP-J, also known as PRL family 3, subfamily c, member 1 (Prl3c1)) is shown to be a product of the uterine decidua and a regulator of postimplantation intrauterine events. PLP-J-specific antibodies and a series of recombinant PLP-J proteins were generated and used to investigate PLP-J expression and as ligands for investigating biological targets. Decidual PLP-J migrates as a 29-kDa protein and localizes to a band of decidual cells surrounding the trophoblast cell layer on gestation day 8.5. PLP-J ligands specifically bound in situ to the surrounding uterine stromal cells and vasculature within the decidua of gestation day 8.5 implantation sites. We then investigated the in vitro actions of PLP-J on uterine stromal cells and endothelial cells. PLP-J specifically interacted with both cell populations. PLP-J promoted uterine stromal cell proliferation and inhibited endothelial cell proliferation. We determined that PLP-J does not interact with PRL receptors. Instead, PLP-J interacts with heparin-containing molecules, including syndecan-1, which is expressed in gestation day 8.5 pregnant uteri, as well as in uterine stromal cells and endothelial cells. The restricted expression of PLP-J and its specific interactions with uterine stromal cells and endothelial cells suggests that it acts locally and regulates decidual cell development and the endometrial vasculature.	[Soares, Michael J.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Inst Maternal Fetal Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Div Canc & Dev Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Div Canc & Dev Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Inst Maternal Fetal Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Soares, MJ (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Inst Maternal Fetal Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	msoares@kumc.edu	Konno, Toshihiro/AAH-6276-2020	Konno, Toshihiro/0000-0001-8141-6996	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD039878, R01HD055523] Funding Source: NIH RePORTER; NICHD NIH HHS [HD039878, HD055523] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ain R, 2006, METH MOLEC MED, V121, P295; Ain R, 2004, P NATL ACAD SCI USA, V101, P16543, DOI 10.1073/pnas.0406185101; Ain R, 2003, DEV BIOL, V260, P176, DOI 10.1016/S0012-1606(03)00210-0; Alam SMK, 2006, MAMM GENOME, V17, P858, DOI 10.1007/s00335-006-0010-1; Alam SMK, 2007, DEVELOPMENT, V134, P407, DOI 10.1242/dev.02743; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; [Anonymous], 2004, STAT ANAL DATA DISPL; Aplin J, 2000, SEMIN CELL DEV BIOL, V11, P115, DOI 10.1006/scdb.2000.0157; BELL SC, 1983, OXFORD REV REPRODUCT, V5, P220; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Bern H A, 1968, Recent Prog Horm Res, V24, P681; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Bittorf T, 2000, J MOL ENDOCRINOL, V25, P253, DOI 10.1677/jme.0.0250253; Brosens JJ, 2006, J MOL ENDOCRINOL, V36, P389, DOI 10.1677/jme.1.02060; Cohick CB, 1997, J ENDOCRINOL, V152, P291, DOI 10.1677/joe.0.1520291; Cooke N E, 1995, Vitam Horm, V50, P385, DOI 10.1016/S0083-6729(08)60659-7; CROZE F, 1990, ENDOCRINOLOGY, V127, P2665, DOI 10.1210/endo-127-6-2665; Dai G, 2000, J ENDOCRINOL, V166, P63, DOI 10.1677/joe.0.1660063; DEB S, 1989, J BIOL CHEM, V264, P14348; DEB S, 1989, MOL CELL ENDOCRINOL, V63, P45, DOI 10.1016/0303-7207(89)90080-4; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; FARIA TN, 1990, DEV BIOL, V141, P279, DOI 10.1016/0012-1606(90)90384-U; Greca CDS, 2000, ANAT REC, V259, P413; HAMLIN GP, 1995, ENDOCRINOLOGY, V136, P322, DOI 10.1210/en.136.1.322; Hiraoka Y, 1999, BBA-GENE STRUCT EXPR, V1447, P291, DOI 10.1016/S0167-4781(99)00160-8; Ishibashi K, 1999, BIOCHEM BIOPH RES CO, V262, P575, DOI 10.1006/bbrc.1999.1260; Jabbour HN, 2001, REPRODUCTION, V121, P197, DOI 10.1530/rep.0.1210197; Jabbour HN, 1998, J CLIN ENDOCR METAB, V83, P2545, DOI 10.1210/jc.83.7.2545; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; Khurana S, 1999, ENDOCRINOLOGY, V140, P1026, DOI 10.1210/en.140.2.1026; Kimura F, 2001, GYNECOL ENDOCRINOL, V15, P426, DOI 10.1080/713602980; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Konno T, 2007, BIOL REPROD, V76, P709, DOI 10.1095/biolreprod.106.056481; Kruse A, 2002, BIOL REPROD, V66, P333, DOI 10.1095/biolreprod66.2.333; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin JD, 1997, ENDOCRINOLOGY, V138, P5541, DOI 10.1210/en.138.12.5541; Lin JK, 1999, J BIOL CHEM, V274, P21485, DOI 10.1074/jbc.274.30.21485; Mallon AM, 2004, GENOME RES, V14, P1888, DOI 10.1101/gr.2478604; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Muller H, 2006, METH MOLEC MED, V122, P331; Muller H, 1999, ENDOCRINOLOGY, V140, P2711, DOI 10.1210/en.140.6.2711; Muller H, 1998, BIOL REPROD, V58, P45, DOI 10.1095/biolreprod58.1.45; Muller H, 1998, J HISTOCHEM CYTOCHEM, V46, P737, DOI 10.1177/002215549804600606; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; Nicoll C.S., 1972, LACTOGENIC HORMONES, P299; Orwig KE, 1997, ENDOCRINOLOGY, V138, P5511, DOI 10.1210/en.138.12.5511; Parr MB., 1989, BIOL UTERUS, P233; Piva M, 1996, BIOL REPROD, V55, P1333, DOI 10.1095/biolreprod55.6.1333; Prigent-Tessier A, 1999, J BIOL CHEM, V274, P37982, DOI 10.1074/jbc.274.53.37982; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rasmussen CA, 1996, ENDOCRINOLOGY, V137, P5558, DOI 10.1210/en.137.12.5558; Rider V, 2006, METH MOLEC MED, V121, P57; Rider V, 2005, J ENDOCRINOL, V184, P119, DOI 10.1677/joe.1.05957; ROBY KF, 1993, J BIOL CHEM, V268, P3136; Shaw-Bruha CM, 1998, BBA-GENE STRUCT EXPR, V1442, P304, DOI 10.1016/S0167-4781(98)00172-9; Soares MJ, 2007, TRENDS ENDOCRIN MET, V18, P114, DOI 10.1016/j.tem.2007.02.005; Soares Michael J, 2004, Reprod Biol Endocrinol, V2, P51, DOI 10.1186/1477-7827-2-51; SOARES MJ, 1989, BIOL REPROD, V40, P435, DOI 10.1095/biolreprod40.2.435; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; Telgmann R, 1998, HUM REPROD UPDATE, V4, P472, DOI 10.1093/humupd/4.5.472; Tessier C, 2001, ENDOCRINOLOGY, V142, P4086, DOI 10.1210/en.142.9.4086; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Toft DJ, 1999, ENDOCRINOLOGY, V140, P5095, DOI 10.1210/en.140.11.5095; Wang D, 2000, J ENDOCRINOL, V167, P15, DOI 10.1677/joe.0.1670015; Wiemers DO, 2003, ENDOCRINOLOGY, V144, P313, DOI 10.1210/en.2002-220724	68	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18957	18968		10.1074/jbc.M801826200	http://dx.doi.org/10.1074/jbc.M801826200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18467328	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000257165600052
J	Bowden, K; Ridgway, ND				Bowden, Kristin; Ridgway, Neale D.			OSBP negatively regulates ABCA1 protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; HAMSTER OVARY CELLS; CASSETTE TRANSPORTER A1; RECEPTOR LXR-ALPHA; CELLULAR CHOLESTEROL EFFLUX; APOA-I; X-RECEPTOR; ENDOPLASMIC-RETICULUM; LOADED MACROPHAGES; PLASMA-MEMBRANE	Oxysterol binding to liver X receptors (LXR) increases the transcription of genes involved in cholesterol efflux and disposal, such as ABCA1 (ATP-binding cassette transporter A1). Other cytoplasmic sterol-binding proteins could interact with this pathway by sequestering or delivering substrates and ligands. One potential regulator is OSBP (oxysterol-binding protein), which is implicated in the integration of sterol sensing/transport with sphingomyelin synthesis and cell signaling. Since these activities could impact the cholesterol efflux pathway, we examined whether OSBP was involved in LXR regulation and in expression and activity of ABCA1. Suppression of OSBP in Chinese hamster ovary cells by RNA interference resulted in increased ABCA1 protein expression and cholesterol efflux activity following induction with oxysterols or the synthetic LXR agonist TO901317. OSBP knockdown in J774 macrophages also increased ABCA1 expression in the presence and absence of LXR agonists. OSBP depletion did not affect ABCA1 mRNA levels or LXR activity. Rather, OSBP silencing increased the half-life of ABCA1 protein by 3-fold. Sphingomyelin synthesis was suppressed in OSBP-depleted cells treated with 25-hydroxycholesterol but not TO901317 or 22-hydroxycholesterol and did not correlate with ABCA1 stabilization. Moreover, cotransfection experiments revealed that reduction of ABCA1 protein by OSBP was prevented by a mutation in the sterol-binding domain but not by mutations that abrogated interaction with the Golgi apparatus or endoplasmic reticulum. Thus, OSBP opposes the activity of LXR by negatively regulating ABCA1 activity in the cytoplasm by sterol-binding domain-dependent protein destabilization.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	Ridgway, ND (corresponding author), Dalhousie Univ, Atlantic Res Ctr, 5849 Univ Ave, Halifax, NS B34 4H7, Canada.	nridgway@dal.ca		Ridgway, Neale/0000-0002-0441-6228				Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Beh CT, 2004, J CELL SCI, V117, P2983, DOI 10.1242/jcs.01157; Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012; Chen WG, 2005, J BIOL CHEM, V280, P29277, DOI 10.1074/jbc.M505566200; Costet P, 2000, J BIOL CHEM, V275, P28240; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jaworski CJ, 2001, GENOMICS, V78, P185, DOI 10.1006/geno.2001.6663; Johansson M, 2003, MOL BIOL CELL, V14, P903, DOI 10.1091/mbc.E02-08-0459; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205; Lagace TA, 1999, J LIPID RES, V40, P109; Laitinen S, 2002, J LIPID RES, V43, P245; Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200; Lehto M, 2001, J LIPID RES, V42, P1203; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Millatt LJ, 2003, BBA-MOL CELL BIOL L, V1631, P107, DOI 10.1016/S1388-1981(02)00366-9; Mohammadi A, 2001, J LIPID RES, V42, P1062; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Nagao K, 2007, J BIOL CHEM, V282, P14868, DOI 10.1074/jbc.M611230200; Nishimura T, 2005, GENES CELLS, V10, P793, DOI 10.1111/j.1365-2443.2005.00879.x; Okuhira K, 2005, J BIOL CHEM, V280, P39653, DOI 10.1074/jbc.M510187200; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Raychaudhuri S, 2006, J CELL BIOL, V173, P107, DOI 10.1083/jcb.200510084; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Suchanek M, 2007, BIOCHEM J, V405, P473, DOI 10.1042/BJ20070176; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang C, 2002, BIOCHEM J, V361, P461, DOI 10.1042/0264-6021:3610461; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Wyles JP, 2004, EXP CELL RES, V297, P533, DOI 10.1016/j.yexcr.2004.03.052; Yan D, 2008, J BIOL CHEM, V283, P332, DOI 10.1074/jbc.M705313200; Yan D, 2007, ARTERIOSCL THROM VAS, V27, P1618, DOI 10.1161/ATVBAHA.107.144121; Yan DG, 2007, ARTERIOSCL THROM VAS, V27, P1108, DOI 10.1161/ATVBAHA.106.138545; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	51	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18210	18217		10.1074/jbc.M800918200	http://dx.doi.org/10.1074/jbc.M800918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18450749	hybrid			2022-12-25	WOS:000256949200049
J	Gutti, RK; Tsai-Morris, CH; Dufau, ML				Gutti, Ravi K.; Tsai-Morris, Chon-Hwa; Dufau, Maria L.			Gonadotropin-regulated testicular helicase (DDX25), an essential regulator of spermatogenesis, prevents testicular germ cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RNA HELICASE; GENE-EXPRESSION; PROTEIN-KINASE; BCL-2 FAMILY; RAT TESTIS; PHOSPHORYLATION; SURVIVAL; DEATH; BAD	Gonadotropin-regulated testicular helicase (GRTH)/DDX25 is an essential post-transcriptional regulator of spermatogenesis. In GRTH null mice severe apoptosis was observed in spermatocytes entering the metaphase of meiosis. Pro- and antiapoptotic factors were found to be under GRTH regulation in comparative studies of spermatocytes from wild type and GRTH(-/-) knock-out (KO) mice. KO mice displayed decreased levels of Bcl-2 and Bcl-xL (anti-apoptotic factors), an increase in Bid, Bak, and Bad (pro-apoptotic), reduced phospho-Bad, and release of cytochrome c. Also, an increase on Smac, a competitor of inhibitor apoptotic proteins that release caspases, was observed. These changes caused an increase in cleavage of caspases 9 and 3, activation of caspase 3 and increases in cleavage products of PARP. The half-life of caspase 3 transcripts was markedly increased in KO, indicating that GRTH had a negative role on its mRNA stability. I kappa B alpha, which sequesters NF-kappa B from its transcriptional activation of pro-apoptotic genes, was highly elevated in KO, and its phospho-form, which promotes its dissociation, was reduced. The increase of HDAC1 and abolition of p300 expression in KO indicated a nuclear action of GRTH on the NF-kappa B-mediated transcription of anti-apoptotic genes. It also regulates the associated death domain pathway and caspase 8-mediated events. GRTH-mediated apoptotic regulation was further indicated by its selective binding to pro- and anti-apoptotic mRNAs. These studies have demonstrated that GRTH, as a component of mRNP particles, acts as a negative regulator of the tumor necrosis factor receptor 1 and caspase pathways and promotes NF-kappa B function to control apoptosis in spermatocytes of adult mice.	[Gutti, Ravi K.; Tsai-Morris, Chon-Hwa; Dufau, Maria L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Dev Endocrinol & Genet, Endocrinol & Reprod Res Branch, NIH,Sect Mol Endocrinol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Dev Endocrinol & Genet, Endocrinol & Reprod Res Branch, NIH,Sect Mol Endocrinol, Bldg 49,Rm 6A-36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	dufaum@mail.nih.gov		Gutti, Ravi Kumar/0000-0002-0912-5796; Tsai Morris, Chon Hwa/0000-0002-8113-0979	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Boekelheide K, 2000, P SOC EXP BIOL MED, V225, P105, DOI 10.1046/j.1525-1373.2000.22513.x; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Dufau ML, 2007, TRENDS ENDOCRIN MET, V18, P314, DOI 10.1016/j.tem.2007.09.001; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Fawcett D. W, 1970, Biology Reprod., V2, P129, DOI 10.1095/biolreprod2.1.129; Gu Wei, 2004, Novartis Found Symp, V259, P197; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Jahnukainen K, 2004, BIOL REPROD, V70, P290, DOI 10.1095/biolreprod.103.018390; Jeyaraj D Antony, 2003, Reprod Biol Endocrinol, V1, P48, DOI 10.1186/1477-7827-1-48; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Morales A, 2007, ANAT REC, V290, P206, DOI 10.1002/ar.20417; Mori C, 1997, DEV DYNAM, V208, P125; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Shaha Chandrima, 2007, Soc Reprod Fertil Suppl, V63, P173; Shan YX, 2003, J MOL CELL CARDIOL, V35, P1135, DOI 10.1016/S0022-2828(03)00229-3; Sheng Y, 2003, J BIOL CHEM, V278, P27796, DOI 10.1074/jbc.M302411200; Sheng Y, 2006, J BIOL CHEM, V281, P35048, DOI 10.1074/jbc.M605086200; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Suominen JS, 2004, EUR J ENDOCRINOL, V151, P629, DOI 10.1530/eje.0.1510629; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tang PZ, 1999, J BIOL CHEM, V274, P37932, DOI 10.1074/jbc.274.53.37932; Thomson M, 2002, CELL MOL LIFE SCI, V59, P213, DOI 10.1007/s00018-002-8417-7; Tsai-Morris CH, 2004, P NATL ACAD SCI USA, V101, P6373, DOI 10.1073/pnas.0401855101; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	36	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17055	17064		10.1074/jbc.M708449200	http://dx.doi.org/10.1074/jbc.M708449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18430733	Green Published, hybrid			2022-12-25	WOS:000256720600012
J	Li, CH; Nissim, I; Chen, P; Buettger, C; Najafi, H; Daikhin, Y; Nissim, I; Collins, HW; Yudkoff, M; Stanley, CA; Matschinsky, FM				Li, Changhong; Nissim, Itzhak; Chen, Pan; Buettger, Carol; Najafi, Habiba; Daikhin, Yevgeny; Nissim, Ilana; Collins, Heather W.; Yudkoff, Marc; Stanley, Charles A.; Matschinsky, Franz M.			Elimination of K-ATP channels in mouse islets results in elevated [U-C-13] glucose metabolism, glutaminolysis, and pyruvate cycling but a decreased gamma-aminobutyric acid shunt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; MALIC ENZYME; GLUTAMATE-DEHYDROGENASE; PANCREATIC-ISLETS; INDUCED GLUCAGON; BETA-CELLS; RELEASE; MECHANISM; MICE	Pancreatic beta cells are hyper-responsive to amino acids but have decreased glucose sensitivity after deletion of the sulfonylurea receptor 1 (SUR1) both in man and mouse. It was hypothesized that these defects are the consequence of impaired integration of amino acid, glucose, and energy metabolism in beta cells. We used gas chromatography-mass spectrometry methodology to study intermediary metabolism of SUR1 knock-out (SUR1(-/-)) and control mouse islets with D-[U-C-13] glucose as substrate and related the results to insulin secretion. The levels and isotope labeling of alanine, aspartate, glutamate, glutamine, and gamma-aminobutyric acid (GABA) served as indicators of intermediary metabolism. We found that the GABA shunt of SUR1(-/-) islets is blocked by about 75% and showed that this defect is due to decreased glutamate decarboxylase synthesis, probably caused by elevated free intracellular calcium. Glutaminolysis stimulated by the leucine analogue D,L-beta-2-amino-2-norbornane-carboxylic acid was, however, enhanced in SUR1(-/-) and glyburide-treated SUR1(+/+) islets. Glucose oxidation and pyruvate cycling was increased in SUR1(-/-) islets at low glucose but was the same as in controls at high glucose. Malic enzyme isoforms 1, 2, and 3, involved in pyruvate cycling, were all expressed in islets. High glucose lowered aspartate and stimulated glutamine synthesis similarly in controls and SUR1(-/-) islets. The data suggest that the interruption of the GABA shunt and the lack of glucose regulation of pyruvate cycling may cause the glucose insensitivity of the SUR1(-/-) islets but that enhanced basal pyruvate cycling, lowered GABA shunt flux, and enhanced glutaminolytic capacity may sensitize the beta cells to amino acid stimulation.	[Buettger, Carol; Najafi, Habiba; Collins, Heather W.; Matschinsky, Franz M.] Univ Penn, Sch Med, Diabetes Ctr, Philadelphia, PA 19104 USA; [Buettger, Carol; Najafi, Habiba; Collins, Heather W.; Matschinsky, Franz M.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Li, Changhong; Chen, Pan; Stanley, Charles A.] Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA; [Nissim, Itzhak; Daikhin, Yevgeny; Nissim, Ilana; Yudkoff, Marc] Childrens Hosp Philadelphia, Div Child Dev & Pediat Rehabil, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Matschinsky, FM (corresponding author), Univ Penn, Sch Med, Diabetes Ctr, Philadelphia, PA 19104 USA.	matsch@mail.med.upenn.edu		STANLEY, CHARLES/0000-0003-4881-9392	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK056268, R01DK022122, R01DK056268, R01DK053012, R56DK053761, R01DK053761, R37DK022122, P30DK019525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037915] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26979] Funding Source: Medline; NIDDK NIH HHS [DK 53012, DK22122, DK 53761, P30 DK019525, DK 56268] Funding Source: Medline; NINDS NIH HHS [NS 37915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT SJ, 1970, BIOCHEM J, V119, P5, DOI 10.1042/bj1190005; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; CHAMBERLIN ME, 1991, AM J PHYSIOL, V260, pR159, DOI 10.1152/ajpregu.1991.260.1.R159; Chang GG, 2003, BIOCHEMISTRY-US, V42, P12721, DOI 10.1021/bi035251+; Doliba NM, 2007, AM J PHYSIOL-ENDOC M, V292, pE1507, DOI 10.1152/ajpendo.00282.2006; Doliba NM, 2006, AM J PHYSIOL-ENDOC M, V291, pE525, DOI 10.1152/ajpendo.00579.2005; Doliba NM, 2004, AM J PHYSIOL-ENDOC M, V286, pE834, DOI 10.1152/ajpendo.00292.2003; Fourtner SH, 2006, J PEDIATR-US, V149, P47, DOI 10.1016/j.jpeds.2006.02.033; Frenkel R, 1975, Curr Top Cell Regul, V9, P157; Guay C, 2007, J BIOL CHEM, V282, P35657, DOI 10.1074/jbc.M707294200; HANSFORD RG, 1975, BIOCHEM J, V148, P389, DOI 10.1042/bj1480389; Heart E, 2007, BIOCHEM J, V403, P197, DOI 10.1042/BJ20061209; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HOEK JB, 1976, BIOCHEM J, V160, P253, DOI 10.1042/bj1600253; Karsten WE, 2003, BIOCHEMISTRY-US, V42, P9712, DOI 10.1021/bi034101w; Li CH, 2006, J BIOL CHEM, V281, P10214, DOI 10.1074/jbc.M512792200; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Li CH, 2006, J BIOL CHEM, V281, P15064, DOI 10.1074/jbc.M600994200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MALAISSE W J, 1986, Diabetes Metabolism Reviews, V2, P243; MANDELLA RD, 1975, J BIOL CHEM, V250, P5877; Matschinsky F.M., 2001, HDB PHYSL 7, P125; Matschinsky FM, 2006, DIABETES, V55, P1; Newgard CB, 2002, DIABETES, V51, pS389, DOI 10.2337/diabetes.51.2007.S389; Nissim I, 2006, J BIOL CHEM, V281, P8486, DOI 10.1074/jbc.M506984200; Nissim I, 2006, CANCER RES, V66, P7824, DOI 10.1158/0008-5472.CAN-06-1043; PAGLIARA AS, 1975, J CLIN INVEST, V55, P244, DOI 10.1172/JCI107928; PAGLIARA AS, 1974, J CLIN INVEST, V54, P819, DOI 10.1172/JCI107822; Pongratz RL, 2007, J BIOL CHEM, V282, P200, DOI 10.1074/jbc.M602954200; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; SENER A, 1983, ACTA DIABETOL LAT, V20, P205, DOI 10.1007/BF02581264; SENER A, 1983, BIOCHEM J, V210, P913, DOI 10.1042/bj2100913; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Simpson NE, 2006, DIABETOLOGIA, V49, P1338, DOI 10.1007/s00125-006-0216-5; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; Veech RL, 2006, BIOCHEM MOL BIOL EDU, V34, P168, DOI 10.1002/bmb.2006.49403403168; Wang C, 2005, AM J PHYSIOL-ENDOC M, V288, pE307, DOI 10.1152/ajpendo.00222.2004; Winnock F, 2002, AM J PHYSIOL-ENDOC M, V282, pE937, DOI 10.1152/ajpendo.00071.2001	45	31	31	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17238	17249		10.1074/jbc.M709235200	http://dx.doi.org/10.1074/jbc.M709235200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18445600	Green Published, hybrid			2022-12-25	WOS:000256720600033
J	Reinartz, M; Ding, ZP; Flogel, U; Godecke, A; Schrader, J				Reinartz, Michael; Ding, Zhaoping; Floegel, Ulrich; Goedecke, Axel; Schrader, Juergen			Nitrosative stress leads to protein glutathiolation, increased S-nitrosation, and up-regulation of peroxiredoxins in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; COMPLEX-I; NITROSYLATION; GLUTATHIONYLATION; ACTIN; PEROXYNITRITE; NITROSOTHIOLS; REDUCTION; MYOGLOBIN	Nitric oxide (NO) is produced by different isoforms of nitric oxide synthases (NOSs) and operates as a mediator of important cell signaling pathways, such as the cGMP signaling cascade. Another mechanism by which NO exerts biological effects is mediated through S-nitrosation of target proteins. To explore thiol-based protein modifications in a situation of defined nitrosative stress, we used a transgenic mouse model with cardiac specific overexpression of inducible nitric oxide synthase (iNOS) and concomitant myoglobin deficiency (iNOS(+)/myo(-/-)). In comparison with the wild type hearts, protein glutathiolation detected by immunoblotting was significantly enhanced in iNOS(+)/myo(-/-) hearts, whereas protein S-nitrosation as measured by the biotin switch assay and two-dimensional PAGE revealed that nearly all of the detected proteins (similar to 60) remained unchanged with the exception of three proteins. Tandem mass spectrometry revealed these proteins to be peroxiredoxins (Prxs), which are known to possess peroxidase activity, whereby hydrogen peroxide, peroxynitrite, and a wide range of organic hydroperoxides are reduced and detoxified. Immunoblotting with specific antibodies revealed up-regulation of Prx VI in the iNOS(+)/ myo(-/-) hearts, whereas expression of Prx II and Prx III remained unchanged. Furthermore, the analysis of the cardiac S-nitrososubproteome identified several new proteins possibly being involved in NO-signaling pathways. Our data indicate that S-nitrosation and glutathiolation of cardiac proteins may contribute to the phenotype of NO-induced heart failure. The up-regulation of antioxidant proteins like Prx VI appears to be an additional mechanism to antagonize an excess of reactive oxygen/nitrogen species. Furthermore, S-nitrosation of Prxs may serve a new function in the signaling cascade of nitrosative stress.	[Reinartz, Michael; Ding, Zhaoping; Floegel, Ulrich; Goedecke, Axel; Schrader, Juergen] Univ Dusseldorf, Dept Cardiovasc Physiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Reinartz, M (corresponding author), Univ Dusseldorf, Dept Cardiovasc Physiol, Univ Str 1, D-40225 Dusseldorf, Germany.	Michael.Reinartz@uni-duesseldorf.de						Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen FC, 2006, AM J PHYSIOL-CELL PH, V290, pC719, DOI 10.1152/ajpcell.00419.2005; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dahm CC, 2006, J BIOL CHEM, V281, P10056, DOI 10.1074/jbc.M512203200; Dalle-Donne I, 2000, J MUSCLE RES CELL M, V21, P171, DOI 10.1023/A:1005671319604; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; DEBELDER AJ, 1995, BRIT HEART J, V74, P426; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eaton P, 2002, J BIOL CHEM, V277, P21189, DOI 10.1074/jbc.M200591200; Flogel U, 2007, MAGN RESON MED, V57, P50, DOI 10.1002/mrm.21101; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Flogel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje; Forrester MT, 2007, J BIOL CHEM, V282, P13977, DOI 10.1074/jbc.M609684200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; Hattori F, 2003, J NEUROCHEM, V86, P860, DOI 10.1046/j.1471-4159.2003.01918.x; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hill BG, 2007, IUBMB LIFE, V59, P21, DOI 10.1080/15216540701196944; Hoppe G, 2004, EXP EYE RES, V78, P1085, DOI 10.1016/j.exer.2004.02.001; Huang B, 2006, FREE RADICAL BIO MED, V41, P562, DOI 10.1016/j.freeradbiomed.2006.03.006; Huot J, 1996, CANCER RES, V56, P273; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kan H, 1999, AM J PHYSIOL-HEART C, V277, pH1641, DOI 10.1152/ajpheart.1999.277.4.H1641; Kelm M, 1997, CARDIOVASC RES, V36, P185, DOI 10.1016/S0008-6363(97)00149-1; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kojda G, 1996, CIRC RES, V78, P91, DOI 10.1161/01.RES.78.1.91; Konorev EA, 2000, FREE RADICAL BIO MED, V28, P1671, DOI 10.1016/S0891-5849(00)00281-1; Landino LM, 2006, BIOCHEM BIOPH RES CO, V340, P347, DOI 10.1016/j.bbrc.2005.12.013; Li HM, 2005, FREE RADICAL RES, V39, P1091, DOI 10.1080/10715760500260348; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nagy N, 2006, AM J PHYSIOL-HEART C, V291, pH2636, DOI 10.1152/ajpheart.00399.2006; Padgett Christine M., 1995, Cell Biochemistry and Biophysics, V27, P157; Peltoniemi MJ, 2006, J BIOL CHEM, V281, P33107, DOI 10.1074/jbc.M605602200; Peskin AV, 2007, J BIOL CHEM, V282, P11885, DOI 10.1074/jbc.M700339200; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; RADI R, 1991, J BIOL CHEM, V266, P4244; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Saraiva RM, 2006, CURR OPIN CARDIOL, V21, P221, DOI 10.1097/01.hco.0000221584.56372.dc; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sliskovic I, 2005, J BIOL CHEM, V280, P8733, DOI 10.1074/jbc.M408080200; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Taimor G, 2001, FASEB J, V15, P2518, DOI 10.1096/fj.01-0353fje; Tao LM, 2004, BIOCHEMISTRY-US, V43, P4028, DOI 10.1021/bi035924o; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; West MB, 2006, FASEB J, V20, P1715, DOI 10.1096/fj.06-5843fje; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.jmb.2005.12.030	66	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17440	17449		10.1074/jbc.M800126200	http://dx.doi.org/10.1074/jbc.M800126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18426799	hybrid			2022-12-25	WOS:000256720600052
J	Canter, JA; Olson, LM; Spencer, K; Schnetz-Boutaud, N; Anderson, B; Hauser, MA; Schmidt, S; Postel, EA; Agarwal, A; Pericak-Vance, MA; Sternberg, P; Haines, JL				Canter, Jeffrey A.; Olson, Lana M.; Spencer, Kylee; Schnetz-Boutaud, Nathalie; Anderson, Brent; Hauser, Michael A.; Schmidt, Silke; Postel, Eric A.; Agarwal, Anita; Pericak-Vance, Margaret A.; Sternberg, Paul, Jr.; Haines, Jonathan L.			Mitochondrial DNA Polymorphism A4917G Is Independently Associated with Age-Related Macular Degeneration	PLOS ONE			English	Article								The objective of this study was to determine if MTND2* LHON4917G (4917G), a specific non-synonymous polymorphism in the mitochondrial genome previously associated with neurodegenerative phenotypes, is associated with increased risk for age-related macular degeneration (AMD). A preliminary study of 393 individuals (293 cases and 100 controls) ascertained at Vanderbilt revealed an increased occurrence of 4917G in cases compared to controls (15.4% vs. 9.0%, p = 0.11). Since there was a significant age difference between cases and controls in this initial analysis, we extended the study by selecting Caucasian pairs matched at the exact age at examination. From the 1547 individuals in the Vanderbilt/Duke AMD population association study (including 157 in the preliminary study), we were able to match 560 (280 cases and 280 unaffected) on exact age at examination. This study population was genotyped for 4917G plus specific AMD-associated nuclear genome polymorphisms in CFH, LOC387715 and ApoE. Following adjustment for the listed nuclear genome polymorphisms, 4917G independently predicts the presence of AMD (OR = 2.16, 95% CI 1.20-3.91, p = 0.01). In conclusion, a specific mitochondrial polymorphism previously implicated in other neurodegenerative phenotypes (4917G) appears to convey risk for AMD independent of recently discovered nuclear DNA polymorphisms.	[Canter, Jeffrey A.; Olson, Lana M.; Spencer, Kylee; Schnetz-Boutaud, Nathalie; Anderson, Brent; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37203 USA; [Agarwal, Anita; Sternberg, Paul, Jr.] Vanderbilt Univ, Med Ctr, Dept Ophthalmol, Nashville, TN USA; [Hauser, Michael A.; Schmidt, Silke] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA; [Postel, Eric A.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA; [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL USA	Vanderbilt University; Vanderbilt University; Duke University; Duke University; University of Miami	Canter, JA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37203 USA.	jeff.canter@vanderbilt.edu	Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	Vanderbilt University Medical Center Clinical Research Center [M01 RR00095];  [EY12118]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [U10EY012118, R01EY012118] Funding Source: NIH RePORTER	Vanderbilt University Medical Center Clinical Research Center; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This study was supported by grant EY12118 (to M. A. P.-V and J.L.H.) and by the Vanderbilt University Medical Center Clinical Research Center (grant M01 RR00095).	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; CANN RL, 1984, GENETICS, V106, P479; Canter JA, 2008, PHARMACOGENOMICS J, V8, P71, DOI 10.1038/sj.tpj.6500470; *CDCP, 2004, PREV VIS IMP SEL EY; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1; Hulgan T, 2005, AIDS, V19, P1341, DOI 10.1097/01.aids.0000180786.02930.a1; Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646; Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003; Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025; Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822; Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883; Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212; Torroni A, 1996, GENETICS, V144, P1835; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	22	79	84	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2091	10.1371/journal.pone.0002091	http://dx.doi.org/10.1371/journal.pone.0002091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461138	gold, Green Published, Green Submitted			2022-12-25	WOS:000261642400014
J	Bagramyan, K; Barash, JR; Arnon, SS; Kalkum, M				Bagramyan, Karine; Barash, Jason R.; Arnon, Stephen S.; Kalkum, Markus			Attomolar Detection of Botulinum Toxin Type A in Complex Biological Matrices	PLOS ONE			English	Article								Background: A highly sensitive, rapid and cost efficient method that can detect active botulinum neurotoxin (BoNT) in complex biological samples such as foods or serum is desired in order to 1) counter the potential bioterrorist threat 2) enhance food safety 3) enable future pharmacokinetic studies in medical applications that utilize BoNTs. Methodology/Principal Findings: Here we describe a botulinum neurotoxin serotype A assay with a large immuno-sorbent surface area (BoNT/A ALISSA) that captures a low number of toxin molecules and measures their intrinsic metalloprotease activity with a fluorogenic substrate. In direct comparison with the "gold standard'' mouse bioassay, the ALISSA is four to five orders of magnitudes more sensitive and considerably faster. Our method reaches attomolar sensitivities in serum, milk, carrot juice, and in the diluent fluid used in the mouse assay. ALISSA has high specificity for the targeted type A toxin when tested against alternative proteases including other BoNT serotypes and trypsin, and it detects the holotoxin as well as the multi-protein complex form of BoNT/A. The assay was optimized for temperature, substrate concentration, size and volume proportions of the immuno-sorbent matrix, enrichment and reaction times. Finally, a kinetic model is presented that is consistent with the observed improvement in sensitivity. Conclusions/Significance: The sensitivity, specificity, speed and simplicity of the BoNT ALISSA should make this method attractive for diagnostic, biodefense and pharmacological applications.	[Bagramyan, Karine; Kalkum, Markus] Beckman Res Inst City Hope, Div Immunol, Duarte, CA USA; [Barash, Jason R.; Arnon, Stephen S.] Calif Dept Publ Hlth, Infant Botulism Treatment & Prevent Program, Richmond, CA USA	City of Hope; Beckman Research Institute of City of Hope; California Department of Public Health	Bagramyan, K (corresponding author), Beckman Res Inst City Hope, Div Immunol, Duarte, CA USA.	mkalkum@coh.org	Taylor, Graham/A-4027-2012; Pacific-Southwest, RCE/B-6155-2009	Kalkum, Markus/0000-0002-9506-671X	Pacific South West Regional Center for Excellence; NIH [AI-65359-03]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI065359] Funding Source: NIH RePORTER	Pacific South West Regional Center for Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Pacific South West Regional Center for Excellence, NIH grant AI-65359-03 (P.I. Dr. Alan Barbour).	Ahmed SA, 2004, PROTEIN J, V23, P445; Ahmed SA, 2001, J PROTEIN CHEM, V20, P221, DOI 10.1023/A:1010952025677; Aoki KR, 2001, EUR J NEUROL, V8, P21, DOI 10.1046/j.1468-1331.2001.00035.x; Arnon SS, 2006, NEW ENGL J MED, V354, P462, DOI 10.1056/NEJMoa051926; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; Barr JR, 2005, EMERG INFECT DIS, V11, P1578, DOI 10.3201/eid1110.041279; Beseler-Soto B, 2003, REV NEUROLOGIA, V37, P444, DOI 10.33588/rn.3705.2003250; Boyer AE, 2005, ANAL CHEM, V77, P3916, DOI 10.1021/ac050485f; Cai SO, 1999, BIOCHEMISTRY-US, V38, P6903, DOI 10.1021/bi990086c; Cai SW, 2001, BIOCHEMISTRY-US, V40, P15327, DOI 10.1021/bi011350g; Centers for Disease Control Prevention, 1998, HDB EP CLIN LAB WORK, P1; Chao HY, 2004, TOXICON, V43, P27, DOI 10.1016/j.toxicon.2003.10.013; Chen F, 1998, INFECT IMMUN, V66, P2420, DOI 10.1128/IAI.66.6.2420-2425.1998; Chertow DS, 2006, JAMA-J AM MED ASSOC, V296, P2476, DOI 10.1001/jama.296.20.2476; Crowner BE, 2007, CLIN NEUROPHARMACOL, V30, P310, DOI 10.1097/WNF.0B013E31804B1A0D; EKONG TAN, 1995, J IMMUNOL METHODS, V180, P181, DOI 10.1016/0022-1759(94)00313-L; Ferreira JL, 2003, J AOAC INT, V86, P314; Garcia-Rodriguez C, 2007, NAT BIOTECHNOL, V25, P107, DOI 10.1038/nbt1269; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; Jankovic J, 2004, J NEUROL NEUROSUR PS, V75, P951, DOI 10.1136/jnnp.2003.034702; Kalb SR, 2006, ANAL BIOCHEM, V351, P84, DOI 10.1016/j.ab.2006.01.027; Kalb SR, 2005, ANAL CHEM, V77, P6140, DOI 10.1021/ac0511748; KAUTTER DA, 1977, J ASSOC OFF ANA CHEM, V60, P541; KOEPKE R, 2008, PEDIATRICS IN PRESS; Kukreja R, 2005, J BIOL CHEM, V280, P39346, DOI 10.1074/jbc.M508463200; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Liu W, 2003, P NATL ACAD SCI USA, V100, P13621, DOI 10.1073/pnas.2233819100; Long SS, 2007, PEDIATR INFECT DIS J, V26, P261, DOI 10.1097/01.inf.0000256442.06231.17; LOSIKOFF ME, 1978, APPL ENVIRON MICROB, V36, P386, DOI 10.1128/AEM.36.2.386-388.1978; Marks JD, 2004, MOVEMENT DISORD, V19, pS101, DOI 10.1002/mds.20023; Mason JT, 2006, NAT PROTOC, V1, P2003, DOI 10.1038/nprot.2006.331; Mason JT, 2006, NAT BIOTECHNOL, V24, P555, DOI 10.1038/nbt1201; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; Min D, 2004, P NATL ACAD SCI USA, V101, P14701, DOI 10.1073/pnas.0404107101; Partikian A, 2007, J CHILD NEUROL, V22, P1235, DOI 10.1177/0883073807306269; Ravichandran E, 2007, INFECT IMMUN, V75, P3043, DOI 10.1128/IAI.01893-06; Ravichandran E, 2006, J PHARMACOL EXP THER, V318, P1343, DOI 10.1124/jpet.106.104661; SAKAGUCHI G, 1982, PHARMACOL THERAPEUT, V19, P165, DOI 10.1016/0163-7258(82)90061-4; SAMSONOV V G, 1979, Biokhimiya, V44, P1192; SCHANTZ EJ, 1978, J ASSOC OFF ANA CHEM, V61, P96; SCHANTZ EJ, 1992, MICROBIOL REV, V56, P80, DOI 10.1128/MMBR.56.1.80-99.1992; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schmidt JJ, 2003, APPL ENVIRON MICROB, V69, P297, DOI 10.1128/AEM.69.1.297-303.2003; Sharma SK, 2006, APPL ENVIRON MICROB, V72, P1231, DOI 10.1128/AEM.72.2.1231-1238.2006; Sharma SK, 2003, TOXICON, V41, P321, DOI 10.1016/S0041-0101(02)00309-4; Simpson LL, 2001, J BIOL CHEM, V276, P27034, DOI 10.1074/jbc.M102172200; Sobel J, 2004, EMERG INFECT DIS, V10, P1606, DOI 10.3201/eid1009.030745; SUGIYAMA H, 1980, MICROBIOL REV, V44, P419, DOI 10.1128/MMBR.44.3.419-448.1980; Varnum SM, 2006, ANAL CHIM ACTA, V570, P137, DOI 10.1016/j.aca.2006.04.047; Wein LM, 2005, P NATL ACAD SCI USA, V102, P9984, DOI 10.1073/pnas.0408526102; Werner SB, 2000, CLIN INFECT DIS, V31, P1018, DOI 10.1086/318134; Zhang L, 2003, GENE, V315, P21, DOI 10.1016/S0378-1119(03)00792-3	56	90	101	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2041	10.1371/journal.pone.0002041	http://dx.doi.org/10.1371/journal.pone.0002041			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446228	Green Submitted, Green Published, gold			2022-12-25	WOS:000261572300013
J	Donati, G; Gatta, R; Dolfini, D; Fossati, A; Ceribelli, M; Mantovani, R				Donati, Giacomo; Gatta, Raffaella; Dolfini, Diletta; Fossati, Andrea; Ceribelli, Michele; Mantovani, Roberto			An NF-Y-Dependent Switch of Positive and Negative Histone Methyl Marks on CCAAT Promoters	PLOS ONE			English	Article							H2B UBIQUITYLATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CBF/NF-Y; BINDING; H3; UBIQUITINATION; RECRUITMENT; TRIMETHYLATION; CHROMATIN	Background: Histone tails have a plethora of different post-translational modifications, which are located differently in "open'' and "closed'' parts of genomes. H3K4me3/H3K79me2 and H4K20me3 are among the histone marks associated with the early establishment of active and inactive chromatin, respectively. One of the most widespread promoter elements is the CCAAT box, bound by the NF-Y trimer. Two of NF-Y subunits have an H2A-H2B-like structure. Principal findings: We established the causal relationship between NF-Y binding and positioning of methyl marks, by ChIP analysis of mouse and human cells infected with a dominant negative NF-YA: a parallel decrease in NF-Y binding, H3K4me3, H3K79me2 and transcription was observed in promoters that are dependent upon NF-Y. On the contrary, changes in the levels of H3K9-14ac were more subtle. Components of the H3K4 methylating MLL complex are not recruited in the absence of NF-Y. As for repressed promoters, NF-Y removal leads to a decrease in the H4K20me3 mark and deposition of H3K4me3. Conclusions: Two relevant findings are reported: (i) NF-Y gains access to its genomic locations independently from the presence of methyl histone marks, either positive or negative; (ii) NF-Y binding has profound positive or negative consequences on the deposition of histone methyl marks. Therefore NF-Y is a fundamental switch at the heart of decision between gene activation and repression in CCAAT regulated genes.	[Donati, Giacomo; Gatta, Raffaella; Dolfini, Diletta; Fossati, Andrea; Ceribelli, Michele; Mantovani, Roberto] Univ Milan, Dipartimento Sci Biomol & Biotecnol, Milan, Italy	University of Milan	Donati, G (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Milan, Italy.	mantor@unimi.it	DOLFINI, DILETTA/D-8286-2017; Fossati, Andrea/AAN-3814-2020	Fossati, Andrea/0000-0001-9368-4058; DOLFINI, DILETTA/0000-0002-5346-6096; DONATI, Giacomo/0000-0002-0370-8288	AIRC; PRIN-MIUR; CARIPLO	AIRC(Fondazione AIRC per la ricerca sul cancro); PRIN-MIUR(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); CARIPLO(Fondazione Cariplo)	This work was supported by AIRC, PRIN-MIUR and CARIPLO-Nobel grants to RM.	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bhattacharya A, 2003, CANCER RES, V63, P8167; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; CERIBELLI M, 2008, MOL CELL BI IN PRESS; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Deng HS, 2007, DEV BIOL, V308, P583, DOI 10.1016/j.ydbio.2007.05.021; Donati G, 2006, NUCLEIC ACIDS RES, V34, P3116, DOI 10.1093/nar/gkl304; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Hu QH, 2006, NUCLEIC ACIDS RES, V34, P6272, DOI 10.1093/nar/gkl801; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Kabe Y, 2005, MOL CELL BIOL, V25, P512, DOI 10.1128/MCB.25.1.512-522.2005; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Laribee RN, 2007, GENE DEV, V21, P737, DOI 10.1101/gad.1541507; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; Papp B, 2006, GENE DEV, V20, P2041, DOI 10.1101/gad.388706; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sinha S, 1996, MOL CELL BIOL, V16, P328; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suzuki Y, 2004, GENOME RES, V14, P1711, DOI 10.1101/gr.2435604; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wood A, 2005, MOL CELL, V20, P589, DOI 10.1016/j.molcel.2005.09.010; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Zhu Z, 2005, GENOME RES, V15, P848, DOI 10.1101/gr.3394405	49	24	25	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2066	10.1371/journal.pone.0002066	http://dx.doi.org/10.1371/journal.pone.0002066			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446193	Green Published, gold, Green Submitted			2022-12-25	WOS:000261572300035
J	Beretta, M; Gruber, K; Kollau, A; Russwurm, M; Koesling, D; Goessler, W; Keung, WM; Schmidt, K; Mayer, B				Beretta, Matteo; Gruber, Karl; Kollau, Alexander; Russwurm, Michael; Koesling, Doris; Goessler, Walter; Keung, Wing Ming; Schmidt, Kurt; Mayer, Bernd			Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE GUANYLYL CYCLASE; NITRIC-OXIDE; NITRATE TOLERANCE; IN-VITRO; MECHANISM; PEROXYNITRITE; OXIDATION; 1H-<1,2,4>OXADIAZOLO<4,3-A>QUINOXALIN-1-ONE; PURIFICATION; METABOLISM	Metabolism of nitroglycerin (GTN) to 1,2-glycerol dinitrate (GDN) and nitrite by mitochondrial aldehyde dehydrogenase (ALDH2) is essentially involved in GTN bioactivation resulting in cyclic GMP-mediated vascular relaxation. The link between nitrite formation and activation of soluble guanylate cyclase (sGC) is still unclear. To test the hypothesis that the ALDH2 reaction is sufficient for GTN bioactivation, we measured GTN-induced formation of cGMP by purified sGC in the presence of purified ALDH2 and used a Clark-type electrode to probe for nitric oxide ( NO) formation. In addition, we studied whether GTN bioactivation is a specific feature of ALDH2 or is also catalyzed by the cytosolic isoform ( ALDH1). Purified ALDH1 and ALDH2 metabolized GTN to 1,2- and 1,3-GDN with predominant formation of the 1,2- isomer that was inhibited by chloral hydrate ( ALDH1 and ALDH2) and daidzin ( ALDH2). GTN had no effect on sGC activity in the presence of bovine serum albumin but caused pronounced cGMP accumulation in the presence of ALDH1 or ALDH2. The effects of the ALDH isoforms were dependent on the amount of added protein and, like 1,2- GDN formation, were sensitive to ALDH inhibitors. GTN caused biphasic sGC activation with apparent EC50 values of 42 +/- 2.9 and 3.1 +/- 0.4 mu M in the presence of ALDH1 and ALDH2, respectively. Incubation of ALDH1 or ALDH2 with GTN resulted in sustained, chloral hydrate-sensitive formation of NO. These data may explain the coupling of ALDH2-catalyzed GTN metabolism to sGC activation in vascular smooth muscle.	[Beretta, Matteo; Kollau, Alexander; Schmidt, Kurt; Mayer, Bernd] Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria; [Gruber, Karl; Goessler, Walter] Karl Franzens Univ Graz, Dept Chem, A-8010 Graz, Austria; [Russwurm, Michael; Koesling, Doris] Ruhr Univ Bochum, Dept Pharmacol & Toxicol, D-44780 Bochum, Germany; [Keung, Wing Ming] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Graz; University of Graz; Ruhr University Bochum; Harvard University; Harvard Medical School	Mayer, B (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	mayer@uni-graz.at	Gruber, Karl/GPP-6706-2022; Beretta, Matteo/D-8573-2012; Mayer, Bernd/B-9391-2008; Goessler, Walter/A-1084-2016	Gruber, Karl/0000-0002-3485-9740; Goessler, Walter/0000-0002-0142-9373; Kollau, Alexander/0000-0002-3326-0517; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; Mayer, Bernd/0000-0002-2921-3494; Beretta, Matteo/0000-0001-5564-4282	Austrian Science Fund FWF [W 901, P 20669] Funding Source: Medline; Austrian Science Fund FWF [P 20669, W 901] Funding Source: Medline; Austrian Science Fund (FWF) [W 901] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		BENNETT BM, 1994, TRENDS PHARMACOL SCI, V15, P245, DOI 10.1016/0165-6147(94)90319-0; Booth BP, 2000, BIOCHEM PHARMACOL, V59, P1603, DOI 10.1016/S0006-2952(00)00290-2; Castello PR, 2006, CELL METAB, V3, P277, DOI 10.1016/j.cmet.2006.02.011; Chen ZQ, 2006, TRENDS CARDIOVAS MED, V16, P259, DOI 10.1016/j.tcm.2006.05.001; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; Difabio J, 2003, MOL PHARMACOL, V64, P1109, DOI 10.1124/mol.64.5.1109; Dikalov S, 1998, J PHARMACOL EXP THER, V286, P938; Fink B, 2000, FREE RADICAL BIO MED, V28, P121, DOI 10.1016/S0891-5849(99)00228-2; Fung HL, 2004, ANNU REV PHARMACOL, V44, P67, DOI 10.1146/annurev.pharmtox.44.101802.121646; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; Gorren ACF, 2005, BIOCHEM J, V390, P625, DOI 10.1042/BJ20050565; Ho KK, 2005, BIOCHEMISTRY-US, V44, P8022, DOI 10.1021/bi050038u; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KEUNG WM, 1993, P NATL ACAD SCI USA, V90, P1247, DOI 10.1073/pnas.90.4.1247; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4445, DOI 10.1021/bi9521093; Kollau A, 2005, BIOCHEM J, V385, P769, DOI 10.1042/BJ20041354; Kollau A, 2007, MOL PHARMACOL, V72, P191, DOI 10.1124/mol.107.035642; KOMURA S, 1974, ACTA PHARMACOL TOX, V35, P145; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Miranda KM, 2003, P NATL ACAD SCI USA, V100, P9196, DOI 10.1073/pnas.1430507100; MUKERJEE N, 1994, J BIOL CHEM, V269, P21664; Munzel T, 2005, CIRC RES, V97, P618, DOI 10.1161/01.RES.0000184694.03262.6d; Munzel T, 2000, CIRC RES, V86, pE7, DOI 10.1161/01.RES.86.1.e7; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Rocha JBT, 2005, BIOL PHARM BULL, V28, P1485, DOI 10.1248/bpb.28.1485; Russwurm M, 2005, METHOD ENZYMOL, V396, P492, DOI 10.1016/S0076-6879(05)96041-2; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Schultz G., 1984, METHOD ENZYMAT AN, P379; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; Thatcher GRJ, 2004, FREE RADICAL BIO MED, V37, P1122, DOI 10.1016/j.freeradbiomed.2004.06.013; TOWELL J, 1985, ALCOHOL CLIN EXP RES, V9, P438, DOI 10.1111/j.1530-0277.1985.tb05579.x; Wenzel P, 2007, J BIOL CHEM, V282, P792, DOI 10.1074/jbc.M606477200; Zhang J, 2004, CIRCULATION, V110, P750, DOI 10.1161/01.CIR.0000138105.17864.6B; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	40	86	87	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17873	17880		10.1074/jbc.M801182200	http://dx.doi.org/10.1074/jbc.M801182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18786921	Green Published, hybrid			2022-12-25	WOS:000256949200015
